"Rank","NCT Number","Title","Recruitment","Study Results","Conditions","Interventions","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Types","Study Designs","Other IDs","First Received","Start Date","Completion Date","Last Updated","Last Verified","Results First Received","Acronym","Primary Completion Date","Outcome Measures","URL"
1,"NCT01611727","Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients","Completed","No Results Available","BRCA1 Mutation|Metastatic Breast Cancer","Drug: Cisplatin","Pomeranian Medical University Szczecin|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","Female","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BN-001/83/07","May 31, 2012","July 2007","April 2009","July 10, 2012","July 2012","No Study Results Posted","Cisplatin","January 2009","Tumor Response Rate","https://ClinicalTrials.gov/show/NCT01611727"
2,"NCT00916500","Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer","Completed","No Results Available","CERVICAL NEOPLASMS","Drug: CONCURRENT CHEMORADIATION (CISPLATIN)","Korea Cancer Center Hospital","Female","20 Years to 75 Years   (Adult, Senior)","Phase 2","71","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KCCH GY 1001","June 7, 2009","March 2006","December 2013","April 29, 2014","April 2014","No Study Results Posted","null","December 2013","DISEASE-FREE SURVIVAL|OVERALL SURVIVAL|RECURRENCE RATE","https://ClinicalTrials.gov/show/NCT00916500"
3,"NCT00901537","Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer","Terminated","No Results Available","Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck","Drug: Azacitidine and Cisplatin","Loma Linda University","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","58358|IND 105076 (IND Exempt)","May 12, 2009","February 2009","October 2011","June 2, 2014","June 2014","No Study Results Posted","null","September 2011","Evaluate the safety and toxicity of azacitidine and cisplatin combination.|Determine the biologically effective dose of azacitidine, maximum tolerated dose of azacitidine and cisplatin combination, and tumor response","https://ClinicalTrials.gov/show/NCT00901537"
4,"NCT01561586","Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Drug: Weekly cisplatin with RT|Drug: Tri-weekly cisplatin with RT","Korea Cancer Center Hospital|Seoul National University Hospital|Asan Medical Center|Gangnam Severance Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","590","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KGOG 1027/THAI 2012","March 20, 2012","March 2012","March 2020","February 24, 2016","February 2016","No Study Results Posted","TACO","March 2017","Overall survival|Progression Free Survival|Recurrence rate|Adverse events|Compliance to radiation protocol|Quality of life","https://ClinicalTrials.gov/show/NCT01561586"
5,"NCT01149798","A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: Abraxane and Cisplatin combination","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","73","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Fudan BR2010-02","June 23, 2010","June 2010","November 2011","August 5, 2012","August 2012","No Study Results Posted","null","June 2011","Overall response rates (ORR) of abraxane and cisplatin combination therapy|Progression free Suivial (PFS)|Number of adverse event|Overrall Survival (OS)","https://ClinicalTrials.gov/show/NCT01149798"
6,"NCT00935961","RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer","Completed","No Results Available","HEAD & NECK Cancer","Drug: RAD001 + docetaxel + cisplatin","Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-028","July 7, 2009","July 2009","August 2013","August 7, 2013","August 2013","No Study Results Posted","null","August 2013","To determine the phase II recommended dose of RAD001 (everolimus) + docetaxel + cisplatin as induction chemotherapy for patients with head and neck cancer|To establish the safety and tolerability of RAD001 (everolimus) + docetaxel + cisplatin|To determine the objective response rate of all patients treated with RAD001 (everolimus) + docetaxel + cisplatin using RECIST criteria","https://ClinicalTrials.gov/show/NCT00935961"
7,"NCT00353015","Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract","Completed","No Results Available","Gastrointestinal Cancer|Carcinoma, Neuroendocrine","Drug: Cisplatin|Drug: Irinotecan","M.D. Anderson Cancer Center|Pharmacia","All","Child, Adult, Senior","Phase 2","21","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-523","July 13, 2006","March 2003","July 2009","August 1, 2012","August 2012","No Study Results Posted","null","December 2007","Participant Response Rate of Irinotecan and Cisplatin","https://ClinicalTrials.gov/show/NCT00353015"
8,"NCT00808145","Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)","Withdrawn","No Results Available","Hepatocellular Carcinoma","Drug: Gemcitabine / Cisplatin / Sorafenib","Lahey Clinic","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-108","December 11, 2008","February 2009","October 2014","October 21, 2014","October 2014","No Study Results Posted","null","October 2014","Safety of the combination of gemcitabine/cisplatin/sorafenib|Effectiveness of gemcitabine/cisplatin/sorafenib in shrinking tumors extending time to progression of disease","https://ClinicalTrials.gov/show/NCT00808145"
9,"NCT00995761","Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Docetaxel and Cisplatin","Gyeongsang National University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GNUHIRB-2009-30","October 14, 2009","October 2009","August 2012","February 9, 2014","February 2014","June 21, 2011","null","August 2012","Response Rates Confirmed With CT or MRI|We Conducted the Present Phase II Study to Investigate the Efficacy and Safety of a Biweekly Schedule of Docetaxel and Cisplatin in Patients With Unresectable NSCLC.|Time to Progression and Overall Survival Confirmed Through Follow-up and Observation Following Treatment","https://ClinicalTrials.gov/show/NCT00995761"
10,"NCT01096745","Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer","Terminated","No Results Available","Metastatic Biliary Tract Cancer|Locally Advanced Biliary Tract Cancer","Drug: Gemcitabine, Cisplatin|Drug: S-1, Cisplatin","Gyeongsang National University Hospital|Samsung Medical Center|Dong-A University|Chung-Ang University","All","20 Years and older   (Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GNUHIRB-2010-5","March 30, 2010","July 2010","September 2013","June 21, 2011","June 2011","No Study Results Posted","null","March 2013","Time to progression|Response rate Overall survival Safety profile","https://ClinicalTrials.gov/show/NCT01096745"
11,"NCT02030574","Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin","Terminated","Has Results","Invasive Bladder Cancer|Bladder Cancer","Drug: Gemcitabine and fractionated cisplatin (combination treatment)","Brown University|Lifespan","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG 300","December 20, 2013","July 2014","June 2015","July 25, 2016","July 2016","October 27, 2015","null","June 2015","Pathologic Complete Response Rate of Neoadjuvant Gemcitabine and Fractionated Cisplatin for Patients With Muscle Invasive Bladder Cancer Whom Are Not Candidates for High Dose Cisplatin.|Number of Participants Experiencing Toxicities With Neoadjuvant Gemcitabine and Fractionated Cisplatin for Patients With Bladder Cancer","https://ClinicalTrials.gov/show/NCT02030574"
12,"NCT01165385","Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors","Completed","No Results Available","Solid Tumors|Metastatic Cancer","Drug: cisplatin|Drug: Pazopanib","UNICANCER","All","18 Years and older   (Adult, Senior)","Phase 1","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEP 07/0908 - PACIFIK","June 25, 2010","June 2010","October 2014","November 14, 2014","November 2014","No Study Results Posted","PACIFIK","October 2013","Determination of the Optimal Tolerated Regimen (OTR) based on the occurrence of Dose Limiting Toxicities|Objective response - Overall Objective response rate - Clinical Benefit Rate|To characterize the pharmacokinetic (PK) profile of the combination pazopanib and cisplatin","https://ClinicalTrials.gov/show/NCT01165385"
13,"NCT00998036","Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors","Completed","No Results Available","Triple Negative Breast Cancer","Drug: Temsirolimus, cisplatin, erlotinib","Columbia University|Wyeth is now a wholly owned subsidiary of Pfizer|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 1","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AAAD8279","October 19, 2009","September 2009","October 2012","May 19, 2017","May 2017","No Study Results Posted","null","June 2012","Maximum tolerated doses of cisplatin, temsirolimus, and erlotinib","https://ClinicalTrials.gov/show/NCT00998036"
14,"NCT01114958","Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases","Unknown status","No Results Available","Lung Neoplasms|Neoplasm Metastasis","Drug: Cisplatin, Thiosulfate","University of California, San Diego","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCSD 090772","April 28, 2010","April 2010","null","May 4, 2010","April 2010","No Study Results Posted","null","October 2011","Frequency of adverse events due to intra-arterial cisplatin administration|Radiographic determination of the tumor response rate in patients with primary and metastatic lung tumors treated with intra-arterial supradose cisplatin.|Angiographic delineation of the vascular structure of primary lung tumors and lung metastases.","https://ClinicalTrials.gov/show/NCT01114958"
15,"NCT01336842","Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors","Active, not recruiting","No Results Available","Solid Tumors|Non-Small Cell Lung Cancer (NSCLC)","Drug: Panobinostat, Cisplatin, Pemetrexed","University of California, Davis|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCDCC#220","April 11, 2011","April 2011","December 2017","January 19, 2017","January 2017","No Study Results Posted","null","June 2017","Safety and feasibility of oral panobinostat in combination with cisplatin and pemetrexed|Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0|Dose-limiting toxicities and toxicity profile as assessed by NCI CTCAE, Version 4.0|Exploratory biomarker analysis|Efficacy of oral panobinostat in combination with cisplatin/pemetrexed in an expanded cohort of patients with NSCLC","https://ClinicalTrials.gov/show/NCT01336842"
16,"NCT00968435","Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma","Completed","No Results Available","Head and Neck Cancer","Other: bevacizumab, cisplatin, cetuximab, radiation therapy","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-083","August 28, 2009","August 2009","null","August 9, 2016","August 2016","No Study Results Posted","null","August 2016","To determine the 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent IMRT + cisplatin + bevacizumab + cetuximab.|To determine median overall survival for patients with locally or regionally advanced HNSCC treated with concurrent IMRT + cisplatin + bevacizumab + cetuximab.|To evaluate the safety and tolerability of concurrent IMRT + cisplatin + bevacizumab + cetuximab.|To explore the potential utility of 18F FLT PET for early response assessment.","https://ClinicalTrials.gov/show/NCT00968435"
17,"NCT02250872","Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury","Recruiting","No Results Available","Cancer|Cisplatin Adverse Reaction","Drug: Gemigliptin|Drug: Placebo|Drug: Cisplatin","Seoul National University Bundang Hospital|LG Life Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","182","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Treatment","B1408264002","September 24, 2014","December 2014","June 2018","April 18, 2016","April 2016","No Study Results Posted","null","February 2018","Incidence of acute kidney injury defined as any of the followings|delta Cr|delta eGFR","https://ClinicalTrials.gov/show/NCT02250872"
18,"NCT00148694","Preoperative Cisplatin in Early Stage Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Cisplatin","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Brigham and Women's Hospital|Breast Cancer Research Foundation","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-183","September 7, 2005","July 2004","May 2010","August 29, 2016","August 2016","No Study Results Posted","null","May 2006","To determine the clinical response after preoperative therapy with cisplatin in ER-, PR-, HER-2 negative early breast cancer patients|To determine the pathologic complete response after preoperative therapy with cisplatin in this patient population","https://ClinicalTrials.gov/show/NCT00148694"
19,"NCT02475772","A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis","Recruiting","No Results Available","Ovarian Cancer","Drug: Cisplatin and doxorubicin|Procedure: Cisplatin and doxorubicin","Clemens Tempfer|Ruhr University of Bochum","Female","18 Years to 80 Years   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PIPAC-OV2|2014-001034-28","March 27, 2014","November 2016","November 2017","November 13, 2016","November 2016","No Study Results Posted","null","November 2017","Adverse events according to CTCAE criteria|Clinical benefit according to RECIST criteria","https://ClinicalTrials.gov/show/NCT02475772"
20,"NCT01928680","Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer","Unknown status","Has Results","Metastatic Breast Cancer","Drug: Cisplatin/Capecitabine","Chinese Academy of Medical Sciences","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LQ0001|CAMS-LQ0001","May 1, 2013","November 2012","March 2016","February 4, 2015","February 2015","February 4, 2015","null","October 2015","Overall Response Rate|Progression Free Survival|Overall Survival|Number and Severity of Adverse Events of Patients Enrolled in This Trial","https://ClinicalTrials.gov/show/NCT01928680"
21,"NCT01869023","Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma","Active, not recruiting","No Results Available","Advanced Malignant Pleural Mesothelioma","Drug: Gemcitabine|Drug: Cisplatin","Instituto Nacional de Cancerologia de Mexico|National Council of Science and Technology, Mexico","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","INCANOGAR2012-JA3","April 18, 2012","November 2010","December 2017","March 1, 2017","March 2017","No Study Results Posted","null","December 2017","Evaluate adverse effects to 250 mg/m2 infusion gemcitabine|Progression Free Survival|overall survival","https://ClinicalTrials.gov/show/NCT01869023"
22,"NCT02277184","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma","Terminated","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: Ficlatuzumab|Drug: Cisplatin|Radiation: Intensity Modulated Radiotherapy (IMRT)","Julie E. Bauman, MD, MPH|AVEO Pharmaceuticals, Inc.|University of Pittsburgh","All","18 Years and older   (Adult, Senior)","Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","13-060","October 25, 2014","September 2015","September 2016","September 12, 2016","September 2016","No Study Results Posted","null","September 2016","Establish the recommended-for-phase II dose (RP2D) of the combination of ficlatuzumab, cisplatin and intensity-modulated radiotherapy (IMRT)|Evaluate the preliminary efficacy of the combination of ficlatuzumab, cisplatin and intensity-modulated radiotherapy as curative-intent treatment for patients with locally advanced HNSCC|Evaluate biomarkers of HGF/c-Met pathway activation in baseline tumor biopsies, to correlate with preliminary efficacy data|Evaluate change in biomarkers of HGF/c-Met pathway activation after a single dose of ficlatuzumab, prior to initiation of cisplatin-IMRT, to correlate with preliminary efficacy data|Evaluate pharmacodynamic plasma biomarkers of HGF/c-Met pathway activation to correlate with preliminary efficacy data.|Describe the prevalence of PIK3CA, PTEN, and HRAS mutations in patients' tumors|Describe dendritic and T cell phenotypes in pre and post ficlatuzumab biopsies|Evaluate pharmacodynamic biomarkers of peripheral T cell and natural killer cell activation","https://ClinicalTrials.gov/show/NCT02277184"
23,"NCT01854203","Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: Inductive chemotherapy + concurrent cisplatin and IMRT|Drug: Inductive chemotherapy + IMRT","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","ChiECRCT-2013003","May 10, 2013","July 2013","December 2016","July 28, 2013","July 2013","No Study Results Posted","NPC","December 2016","Overall survival|Failure-free survival|Locoregional failure-free survival|Distant failure-free survival|Difference in the complete response rates between the two treatment arms","https://ClinicalTrials.gov/show/NCT01854203"
24,"NCT01320254","PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)","Unknown status","No Results Available","Cholangiocarcinomas","Drug: Cisplatin, Gemcitabine, Panitumumab|Drug: Cisplatin, Gemcitabine","Hannover Medical School|Hannover Clinical Trial Center GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT-Nr.: 2010-018850-11","March 21, 2011","June 2011","June 2014","October 10, 2012","October 2012","No Study Results Posted","PiCCA","June 2014","progression-free survival rate|Tumor response|Progression-free survival|Overall survival|Number of Participants with Adverse Events as a Measure of Toxicity/Safety|Translational research","https://ClinicalTrials.gov/show/NCT01320254"
25,"NCT02182778","GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","Active, not recruiting","No Results Available","Biliary Tract Cancer","Drug: Gemcitabine/Cisplatin|Drug: Gemcitabine/Cisplatin /S-1","Kansai Hepatobiliary Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 3","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KHBO1401|UMIN 000014371","June 28, 2014","June 2014","May 2019","August 31, 2016","August 2016","No Study Results Posted","null","May 2017","Overall survival rate|Response rate|Progression free survival|Number of Participants with Adverse Events as a Measure of Safety","https://ClinicalTrials.gov/show/NCT02182778"
26,"NCT01872962","Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: gemcitabine and cisplatin (Induction chemotherapy)|Radiation: IMRT and concurrent cisplatin","Sun Yat-sen University|Fudan University|West China Hospital|Tongji Hospital|Peking University|Zhejiang Cancer Hospital|First People's Hospital of Foshan|Cancer Hospital of Guangxi Medical University|Jiangxi Provincial Cancer Hospital|Xijing hospital of The fourth military medical university|Cancer Hospital of Guizhou Province|Cancer Hospital of Shantou University|Fifth Affiliated Hospital, Sun Yat-Sen University|Wuhan Union Hospital, China","All","18 Years to 65 Years   (Adult)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","B2013-022-01","May 31, 2013","November 2013","November 2020","February 19, 2017","February 2017","No Study Results Posted","null","November 2018","Failure-free survival|Overall survival|Locoregional failure-free survival|Distant failure-free survival|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01872962"
27,"NCT01644994","Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma","Recruiting","No Results Available","Malignant Pleural Mesothelioma","Drug: intracavitary cisplatin-fibrin","University of Zurich|Swiss National Science Foundation|Swiss Accident Insurance Fund SUVA","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INFLuenCe - Meso","July 17, 2012","November 2012","August 2020","May 10, 2016","May 2016","No Study Results Posted","null","August 2020","number of participants with adverse events|local cisplatin concentration in the superficial chest wall tissue by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection|safety blood parameters (hematology and clinical chemistry)|overall survival|FFR freedom from recurrence = time to tumor progression by CT or PET-CT/MRI|change from baseline in SF-36 quality of life questionnaire|change from baseline in EORTC Lung Cancer Questionnaire QLQ-C15/LC13|cisplatin concentration in blood serum by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection|cisplatin concentration in urine by inductively coupled plasma sector field mass spectrometric (ICP-MS) detection|TUNEL assay (markers for apoptosis in superficial chest wall tissue)|PAI-1 and p21 markers for senescence in superficial chest wall tissue|in-treatment-field FFR freedom from recurrence = time to tumor progression by CT or PET-CT/MRI in the chest cavitiy where the IMP was applied","https://ClinicalTrials.gov/show/NCT01644994"
28,"NCT02392637","Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers","Recruiting","No Results Available","Biliary Tract Cancer","Drug: Abraxane (Nab-Paclitaxel)|Drug: Cisplatin|Drug: Gemcitabine|Behavioral: Phone Calls","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-0524|NCI-2015-00578","March 13, 2015","April 2015","null","September 23, 2016","September 2016","No Study Results Posted","null","April 2018","Progression-Free Survival (PFS) of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers|Response Rate (RR) of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers","https://ClinicalTrials.gov/show/NCT02392637"
29,"NCT00522795","Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)","Completed","Has Results","Esophageal Cancer","Drug: PPX with cisplatin and radiation","Brown University|University of Maryland Greenebaum Cancer Center","All","19 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG-E-215","August 28, 2007","August 2007","April 2010","June 26, 2014","June 2014","May 21, 2013","null","February 2010","Complete Pathologic Response","https://ClinicalTrials.gov/show/NCT00522795"
30,"NCT02994069","Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers","Recruiting","No Results Available","Carcinoma, Squamous Cell|Head and Neck Cancer","Drug: Cisplatin|Radiation: XRT","Susanne Arnold|University of Kentucky","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-16-HN-29","December 12, 2016","April 11, 2017","October 31, 2028","April 18, 2017","March 2017","No Study Results Posted","null","October 31, 2018","Adverse event rate|Local control rates|Survival","https://ClinicalTrials.gov/show/NCT02994069"
31,"NCT01312311","Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer","Unknown status","No Results Available","Nasopharyngeal Cancer","Drug: Docetaxel, Cisplatin","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-07-005","February 21, 2011","July 2006","null","March 8, 2011","March 2011","No Study Results Posted","null","May 2011","objective response rate|number of patients with adverse events","https://ClinicalTrials.gov/show/NCT01312311"
32,"NCT01650090","Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma","Active, not recruiting","No Results Available","Pulmonary Relapse of Osteosarcoma","Drug: Inhaled Lipid Cisplatin (ILC)","Eleison Pharmaceuticals LLC.","All","13 Years and older   (Child, Adult, Senior)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","EP-ILC-201","July 20, 2012","August 2012","December 2016","January 19, 2016","January 2016","No Study Results Posted","null","June 2016","Observed Relapse Free Interval (RFI)|Median, 1, 2 and 5 year Overall Survival (OS)|Median, 1, 2 and 5 year Event Free Survival (EFS)","https://ClinicalTrials.gov/show/NCT01650090"
33,"NCT02207660","Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix","Completed","No Results Available","Cervical Cancer","Drug: Cisplatin,P-HDFL","National Taiwan University Hospital","Female","20 Years to 90 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201211032RIC","July 3, 2013","July 2014","January 2015","February 3, 2015","February 2015","No Study Results Posted","null","January 2015","Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT02207660"
34,"NCT02723864","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors","Recruiting","No Results Available","Neoplasms","Drug: Veliparib + VX-970 + Cisplatin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 110 Years   (Adult, Senior)","Phase 1","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","160087|16-C-0087","March 30, 2016","March 22, 2016","December 31, 2017","May 12, 2017","March 10, 2017","No Study Results Posted","null","June 30, 2017","To establish the safety, tolerability, and MTD of the combination of VX 970 and veliparib in combination with cisplatin in patients with advanced refractory solid tumors|To assess the effect of the combination of VX-970, veliparib, and cisplatin on markers of DNA damage and apoptosis","https://ClinicalTrials.gov/show/NCT02723864"
35,"NCT00922896","Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer","Completed","No Results Available","Metastatic Pancreatic Cancer","Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)","Gyeongsang National University Hospital|Dong-A University Hospital|Chung-Ang University Hosptial, Chung-Ang University College of Medicine","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Gyeongsang-001","June 2, 2009","June 2009","May 2011","November 18, 2012","November 2012","No Study Results Posted","null","August 2010","To assess the response rate associated with gemcitabine, erlotinib and cisplatin in patients with advanced pancreatic cancer","https://ClinicalTrials.gov/show/NCT00922896"
36,"NCT01982448","Cisplatin vs Paclitaxel for Triple Neg","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Cisplatin|Drug: Paclitaxel","Dana-Farber Cancer Institute|Myriad Genetics, Inc.|Translational Breast Cancer Research Consortium","Female","18 Years and older   (Adult, Senior)","Phase 2","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13-383|TBCRC030","October 28, 2013","February 2014","June 2021","December 19, 2016","December 2016","No Study Results Posted","null","November 2017","To compare the pathologic response to neoadjuvant platinum-based chemotherapy in TNBC with and without HR-deficiency, defined as a high HRD score or a BRCA mutation|To compare the pathologic response to neoadjuvant taxane-based chemotherapy in TNBC with and without HR-deficiency, defined as a high HRD score or a BRCA mutation|To evaluate whether the positive predictive value of HR-deficiency is greater for TNBC treated with cisplatin, as compared to TNBC treated with paclitaxel.|To determine the association of HR-deficiency with pathologic complete response (pCR) to neoadjuvant platinum-based chemotherapy in TNBC.|To determine the association of HR-deficiency with pCR to neoadjuvant taxane-based therapy in TNBC.|To evaluate clinical and pathologic responses in TNBC treated with preoperative cisplatin and paclitaxel.|To evaluate the performance of the HRD-LOH assay, the HRD-TAI assay, and the HRDLST assay, to predict pathologic response to cisplatin or taxane therapy in TNBC.","https://ClinicalTrials.gov/show/NCT01982448"
37,"NCT02128906","Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design","Recruiting","No Results Available","Squamous Cell Carcinoma","Drug: Cisplatin|Radiation: IMRT|Drug: Docetaxel|Drug: Cetuximab","University of Pittsburgh","All","18 Years and older   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCI 13-056","April 29, 2014","December 2013","December 2019","November 1, 2016","November 2016","No Study Results Posted","(UPCI)13-056","December 2017","Evaluate the efficacy of radiotherapy with concurrent docetaxel-cetuximab vs. cisplatin in patients with locally advanced HNSCC and increased tumoral ERCC1 expression, as measured by time to progression (TTP)|Evaluate the efficacy of radiotherapy with concurrent docetaxel-cetuximab vs. cisplatin in patients with PULA HNSCC and decreased/normal tumoral ERCC1 expression, as measured by TTP|Evaluate the efficacy of radiotherapy with concurrent docetaxel-cetuximab vs. cisplatin in all patients irrespective of ERCC1 status, as measured by TTP|Prospectively validate the candidate cutpoint for decreased/normal vs. increased ERCC1 [4F9] expression in patients treated with cisplatin-IMRT|Prospectively investigate two sets of radiologic interpretive criteria, including RECIST 1.1 and integrated PET/CT, for the designation of complete response (CR), and to compare the ability of the two CR classifications to accurately predict 2-year TTP.","https://ClinicalTrials.gov/show/NCT02128906"
38,"NCT00528619","A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors","Completed","No Results Available","Neoplasms","Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","96","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181084","September 10, 2007","November 2006","April 2010","April 7, 2011","April 2011","No Study Results Posted","null","April 2010","To determine maximally tolerated dose of SU011248 (dosed continuously or on a 2/1 Schedule) when given in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin.|To evaluate the plasma pharmacokinetics of SU011248 and its metabolite, SU012662 in addition to pemetrexed, SU011248 and pemetrexed/cisplatin, and SU011248 and pemetrexed/carboplatin when these drugs are co-administered.|To preliminarily assess the antitumor activity of SU011248 in addition to pemetrexed, SU011248 and pemetrexed/cisplatin, and SU011248 and pemetrexed/carboplatin in patients with non-small cell lung cancer or advanced unresectable mesothelioma.","https://ClinicalTrials.gov/show/NCT00528619"
39,"NCT00443261","Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Terminated","Has Results","Squamous Cell Carcinoma","Drug: Azacitidine|Drug: Cisplatin","University of Kansas Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10498","March 2, 2007","February 2007","June 2008","January 8, 2017","January 2017","January 8, 2016","null","June 2008","Evaluate the Safety and Toxicity of Azacitidine (5-azacytidine, Vidaza®) and Cisplatin Combination","https://ClinicalTrials.gov/show/NCT00443261"
40,"NCT01674842","Cisplatin + RT for Triple Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Radiation Therapy|Drug: Cisplatin","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-283","August 23, 2012","October 2012","October 2018","August 1, 2016","August 2016","No Study Results Posted","null","January 2017","Safety of Cisplatin w/ Radiation|Local recurrence at 5 years|Long term toxicity","https://ClinicalTrials.gov/show/NCT01674842"
41,"NCT00436657","Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer","Completed","No Results Available","Peritoneal Neoplasms|Retroperitoneal Neoplasms|Gastrointestinal Neoplasms|Adenocarcinoma|Neuroblastoma|Ovarian Neoplasms|Sarcoma|Adrenocortical Carcinoma|Wilms Tumor|Rhabdomyosarcoma|Desmoplastic Small Round Cell Tumor","Drug: CHPP of Cisplatin|Procedure: Abdominal Surgery","M.D. Anderson Cancer Center","All","3 Years to 18 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0917","February 15, 2007","February 2007","April 2011","March 29, 2012","March 2012","No Study Results Posted","null","April 2011","Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer","https://ClinicalTrials.gov/show/NCT00436657"
42,"NCT00165555","Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma","Completed","No Results Available","Pleural Mesothelioma|Malignant Pleural Mesothelioma","Drug: Cisplatin|Drug: Sodium Thiosulfate","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 1","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99-124","September 12, 2005","August 1999","November 2009","March 26, 2014","March 2014","No Study Results Posted","null","April 2002","To determine the maximally tolerated dose of intracavitary cisplatin in patients with malignant pleural mesothelioma,|To quantitate the safety of intraoperative intrathoracic/intraperitoneal hyperthermic cisplatin|to study the pharmacokinetics of cisplatin administered in this way.","https://ClinicalTrials.gov/show/NCT00165555"
43,"NCT01670500","Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa","Recruiting","No Results Available","Breast Cancer","Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin","Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","12-258","August 16, 2012","October 2012","June 2018","February 4, 2017","February 2017","No Study Results Posted","null","June 2018","pCR to neoadjuvant cisplatin vs. pCR to AC|Residual Cancer Burden after neoadjuvant cisplatin or AC|Clinical response rate|Comparison of toxicities of cisplatin and AC|Collection of pre-chemotherapy biopsies","https://ClinicalTrials.gov/show/NCT01670500"
44,"NCT00858663","Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Radiation: intensity modulated radiation therapy|Drug: RAD001 (everolimus) + Cisplatin","Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-138","March 6, 2009","March 2009","July 2013","July 23, 2013","July 2013","No Study Results Posted","null","July 2013","To establish the phase II recommended dose of oral RAD001 (everolimus) tablets + weekly intravenous cisplatin given concurrently with radiation therapy.|To evaluate the safety and tolerability of oral RAD001 + radiation therapy + intravenous cisplatin.|To estimate the incidence of over-expression of eIF4E in surgical margins by immunohistochemistry (IHC).(only for those subjects who undergo primary surgery)|To describe the pharmacokinetics of RAD001 administered by PEG (percutaneous gastrostomy) tube.","https://ClinicalTrials.gov/show/NCT00858663"
45,"NCT01073839","Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.","Completed","No Results Available","Cholangiocellular Carcinoma","Drug: Cisplatin and Gemcitabine","University of Zurich","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONK USZ 001-2008","June 25, 2009","August 2008","August 2015","September 17, 2015","September 2015","No Study Results Posted","null","August 2015","Occurence of Grade 3 or 4 toxicities according to NCI-common terminology criteria for adverse events v3.0|Disease-free survival","https://ClinicalTrials.gov/show/NCT01073839"
46,"NCT03079427","Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma","Not yet recruiting","No Results Available","Cholangiocarcinoma|Biliary Tract Cancer|Adjuvant Chemotherapy|Capecitabine|Gemcitabine|Cisplatin","Drug: Gemcitabine plus cisplatin|Drug: Capecitabine","Asan Medical Center","All","19 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Asan-ONCHBP-2017-001","March 9, 2017","April 2017","April 2022","March 13, 2017","March 2017","No Study Results Posted","null","April 2021","2-year disease-free survival|Disease-free survival|Toxicities (Adverse events related with chemotherapy)|Overall survival","https://ClinicalTrials.gov/show/NCT03079427"
47,"NCT02225405","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)","Recruiting","No Results Available","Lung Cancer","Drug: Nintedanib|Drug: Cisplatin|Drug: Docetaxel","M.D. Anderson Cancer Center|Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 1","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2013-0844|NCI-2014-02091","August 22, 2014","April 2015","June 2020","March 8, 2017","March 2017","No Study Results Posted","null","June 2020","Major Pathologic Response Rate|Toxicity of Nintedanib Given With Cisplatin and Docetaxel|Recurrence-Free Survival","https://ClinicalTrials.gov/show/NCT02225405"
48,"NCT00003369","S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: tirapazamine","Southwest Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","56","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066358|SWOG-S9717|U10CA032102","November 1, 1999","August 1998","July 2004","June 13, 2012","June 2012","No Study Results Posted","null","October 2003","overall survival","https://ClinicalTrials.gov/show/NCT00003369"
49,"NCT00915382","Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer","Completed","No Results Available","Advanced Gastric Cancer","Drug: S-1 and cisplatin|Drug: S-1 and cisplatin","Asan Medical Center|Samsung Medical Center|Kyungpook National University|Seoul Veterans Hospital|National Cancer Center, Korea|Ulsan University Hospital|Inje University|Chonbuk National University Hospital|Gachon University Gil Medical Center|Korea Cancer Center Hospital|Yeungnam University College of Medicine|Hallym University Medical Center|Chonnam National University Hospital","All","18 Years to 74 Years   (Adult, Senior)","Phase 3","625","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SOS","June 5, 2009","January 2009","May 2013","January 13, 2014","January 2014","No Study Results Posted","SOS","May 2013","progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT00915382"
50,"NCT00846508","Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis","Unknown status","No Results Available","Cervical Cancer","Drug: Cisplatin","Chang Gung Memorial Hospital","Female","45 Years to 80 Years   (Adult, Senior)","Phase 3","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","97-1166A3","February 11, 2009","February 2009","January 2013","December 31, 2009","February 2009","No Study Results Posted","null","January 2012","As defined by clinical and radiological parameters, stage IB- IIB cervical cancer patients treated by cisplatin-based CCRT have greater toxicities but similar survival rate as those treated by RT alone|To conduct a translational research to find out the molecular markers associated with radiosensitivity and distant metastasis in cervical cancer patients.","https://ClinicalTrials.gov/show/NCT00846508"
51,"NCT01587820","Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer","Terminated","No Results Available","Head and Neck Cancer","Drug: Intra-arterial cisplatin|Drug: Intravenous cisplatin","Southern Illinois University","All","18 Years and older   (Adult, Senior)","Early Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ROB-SCI 12-001","March 19, 2012","June 2012","August 2014","December 4, 2014","July 2014","No Study Results Posted","null","August 2014","number of enrolled subjects|patient survival|rate of patient morbidity","https://ClinicalTrials.gov/show/NCT01587820"
52,"NCT00700336","Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)","Completed","No Results Available","Malignant Pleural Mesothelioma|Solid Tumors","Drug: pemetrexed, cisplatin and CBP501|Drug: pemetrexed and cisplatin","CanBas Co. Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CBP08-01","June 16, 2008","May 2008","November 2012","December 19, 2012","October 2011","No Study Results Posted","null","July 2012","Ph I: To determine the MTD of CBP501 + pemetrexed + cisplatin in patients with advanced solid tumors. Ph II: To evaluate the efficacy and safety profile of CBP501 + pemetrexed + cisplatin in patients with malignant pleural mesothelioma|Ph I: To determine the recommended CBP501 dose for exploration in the phase II part|Ph I: To undertake a preliminary characterization of the safety profile of the triplet combination|Ph I: Determine the pharmacokinetics of CBP501 when co-administered with cisplatin and pemetrexed and investigate any potential interactions|Ph I: To evaluate the pharmacodynamics of the triplet combination|Ph II: To characterize the efficacy according to Modified RECIST criteria, of cisplatin combined with pemetrexed in this patient population and to aid in formulation of the hypothesis for an eventual phase III trial|Ph II: To evaluate clinical benefit of patients|Ph II: To evaluate the pharmacodynamics of the combination|Ph II: Determine the pharmacokinetics of CBP501 when co-administered with cisplatin and pemetrexed and investigate any potential interactions (only in cycle 1 of the first 6 patients in each arm in the US only)","https://ClinicalTrials.gov/show/NCT00700336"
53,"NCT00582634","Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: docetaxel and cisplatin","University of Wisconsin, Madison","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-2004-0248|CO04503","December 19, 2007","September 2004","December 2007","September 30, 2015","September 2015","No Study Results Posted","null","December 2007","Time to progression|Overall survival|Incidence of adverse events|Correlate XPD and ERCC1 polymorphisms with time to progression and toxicities","https://ClinicalTrials.gov/show/NCT00582634"
54,"NCT00976976","Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer","Completed","No Results Available","Resected Advanced Gastric Cancer","Drug: docetaxel, capecitabine, cisplatin","Asan Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0604","September 14, 2009","May 2007","September 2011","January 13, 2014","January 2014","No Study Results Posted","Adjuvant DXP","September 2011","This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.|Investigate the safety profiles, patient tolerance, and overall survival in this population","https://ClinicalTrials.gov/show/NCT00976976"
55,"NCT02512692","90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma","Recruiting","No Results Available","Intrahepatic Cholangiocarcinoma","Device: SIR-Spheres microspheres (Yttrium-90 Microspheres)|Drug: Gemcitabine|Drug: Cisplatin","Medical University of South Carolina","All","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","102254","July 29, 2015","July 2015","July 2019","May 4, 2017","March 2017","No Study Results Posted","null","August 2018","Presence or absence of a dose limiting toxicity (DLT) of 90Y TARE in combination with gemcitabine and cisplatin.","https://ClinicalTrials.gov/show/NCT02512692"
56,"NCT00183885","A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma","Unknown status","No Results Available","Hepatocellular Carcinoma|Liver Cancer","Drug: mitomycin-c, cisplatin","University of Southern California","All","18 Years and older   (Adult, Senior)","Phase 2","76","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3L-03-1","September 9, 2005","October 2004","October 2015","December 17, 2014","December 2014","No Study Results Posted","null","February 2013","To assess time to progression in patients with unresectable HCC receiving intra-arterial chemotherapy with cisplatin and mitomycin-C|To assess toxicity of this treatment.|To examine associations of molecular markers that may predict response, survival and toxicity in these patients.","https://ClinicalTrials.gov/show/NCT00183885"
57,"NCT01426646","S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer","Unknown status","No Results Available","Gastric Cancer","Drug: S-1|Drug: S-1 plus cisplatin","Kyungpook National University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","218","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACSPGC-01","January 18, 2011","September 2011","September 2016","January 3, 2012","January 2012","No Study Results Posted","null","September 2014","Relapse-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01426646"
58,"NCT01345357","Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma","Completed","No Results Available","Solid Tumors or Mantle Cell Lymphoma","Drug: CEP-9722|Drug: Gemcitabine|Drug: Cisplatin","Cephalon|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","C9722/1092|2010-023658-36","April 19, 2011","May 2011","January 2013","January 17, 2013","January 2013","No Study Results Posted","null","December 2012","Determination of the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.|Evaluate the safety and tolerability of CEP-9722 in combination with gemcitabine and cisplatin|Cmax pharmacokinetics parameter|AUC pharmacokinetics parameter|Pharmacodynamics assessment|Efficacy - will be assessed by Tumor response evaluation of each patient","https://ClinicalTrials.gov/show/NCT01345357"
59,"NCT02393794","Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)","Recruiting","No Results Available","Triple-Negative Breast Cancer|Breast Cancer","Drug: Romidepsin|Drug: Cisplatin","Priyanka Sharma|Celgene Corporation|University of Kansas Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IIT-2014-PS-BRST-CISRomiTNBC|RM-CL-BRST-PI-002783","March 13, 2015","July 2015","December 2018","August 18, 2016","August 2016","No Study Results Posted","null","July 2018","Phase I: Recommended Phase II Dose of romidepsin + cisplatin to be used in combination therapy of advanced triple negative breast cancer|Phase II: Overall Response Rate of subjects treated at the recommended phase II dose.|Clinical Benefit Rate at 16 weeks of study treatment for subjects treated at the recommended phase II dose|Pharmacokinetics - romidepsin plasma concentration vs time profile when given with cisplatin|Pharmacokinetics - cisplatin plasma concentration vs time profile when given with romidepsin|Progression-Free Survival and Overall Survival","https://ClinicalTrials.gov/show/NCT02393794"
60,"NCT02351765","ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers","Recruiting","No Results Available","Biliary Tract Cancer|Gallbladder Cancer|Cholangiocarcinoma|Ampullary Cancer","Drug: Acelarin|Drug: Cisplatin","The Christie NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CFTSp096|2015-000100-26","January 27, 2015","January 2016","September 2018","December 30, 2016","December 2016","No Study Results Posted","ABC-08","September 2017","Safety profile of Acelarin in combination with Cisplatin, assessed by total incidence and rate of grade 3 and 4 adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)|Maximum Tolerated Dose (MTD) of Aclerain in combination with Cisplatin|Progression-free survival|Overall survival|Response rate|Exploration of the pharmacokinetic profile for the combination of Acelarin with Cisplatin","https://ClinicalTrials.gov/show/NCT02351765"
61,"NCT02202772","Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder","Recruiting","No Results Available","Urothelial Carcinoma of the Urinary Bladder","Drug: Cabazitaxel|Drug: Gemcitabine|Drug: Cisplatin","James M. McKiernan|Sanofi|Columbia University","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AAAM8506","July 25, 2014","December 2014","July 2017","February 17, 2017","February 2017","No Study Results Posted","CGC","July 2017","The number of serious adverse events associated with therapy of intravesically administered Cabazitaxel, Gemcitabine, and Cisplatin.|The number of complete responders after completion of six weeks of intravesically administered Cabazitaxel, Gemcitabine, and Cisplatin.","https://ClinicalTrials.gov/show/NCT02202772"
62,"NCT00714948","Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma","Terminated","Has Results","Bladder Cancer|URINARY BLADDER","Drug: gemcitabine and cisplatin plus sorafenib","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-168","July 10, 2008","July 2008","November 2011","October 18, 2015","October 2015","April 14, 2015","null","November 2011","To Determine the Progression Free Survival Rate at One Year Untreated Patients With Advanced/Metastatic Urothelial Carcinoma Treated With the Combination of Sorafenib, Gemcitabine, and Cisplatin.","https://ClinicalTrials.gov/show/NCT00714948"
63,"NCT01417390","Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: Drug: Gemcitabine and cisplatin|Drug: Cisplatin","First People's Hospital of Foshan","All","18 Years to 60 Years   (Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","FSHNG-1108","August 15, 2011","November 2011","December 2015","March 6, 2014","March 2014","No Study Results Posted","null","December 2014","Failure-free survival|Overall survival|Locoregional failure-free survival|Distant failure-free survival|The initial response rates after treatments","https://ClinicalTrials.gov/show/NCT01417390"
64,"NCT02838745","Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas","Recruiting","No Results Available","Mesothelioma","Drug: Pemetrexed|Drug: Cisplatin","Baylor College of Medicine","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other","H-36460","July 16, 2016","September 2016","August 2018","March 24, 2017","March 2017","No Study Results Posted","null","July 2018","Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma.","https://ClinicalTrials.gov/show/NCT02838745"
65,"NCT00782574","Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients","Active, not recruiting","No Results Available","Advanced Solid Tumors","Drug: AZD2281|Drug: Cisplatin","AstraZeneca","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","59","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","D0810C00021","October 29, 2008","November 12, 2008","December 29, 2017","April 3, 2017","March 2017","No Study Results Posted","null","February 1, 2012","To determine the safety and tolerability of AZD2281 in combination with Cisplatin (eg Adverse Events, Pharmacokinetic for AZD2281, overall response rate) to patients with advanced solid tumours.|To compare exposure to AZD2281 when given alone and in combination with Cisplatin (Only in patients receiving continuous dosing of AZD2281).|To make a preliminary assessment of the anti-tumour activity of AZD2281 when given in combination with Cisplatin, by measuring overall objective response rate.","https://ClinicalTrials.gov/show/NCT00782574"
66,"NCT02128282","Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma","Recruiting","No Results Available","Cholangiocarcinoma","Drug: CX-4945|Drug: Cisplatin|Drug: Gemcitabine","Senhwa Biosciences, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S4-13-001","April 28, 2014","June 2014","December 2017","October 14, 2016","October 2016","No Study Results Posted","null","June 2017","Maximum Tolerated Dose (MTD) of CX-4945 when used in combination with gemcitabine plus cisplatin|Comparison of the Objective Response Rate (ORR) between the test and the control arms using Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1","https://ClinicalTrials.gov/show/NCT02128282"
67,"NCT01182168","Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies","Completed","No Results Available","Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer","Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)","Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-106","August 11, 2010","August 2010","March 2016","March 29, 2016","March 2016","No Study Results Posted","null","March 2016","To establish the dose-limiting toxicity (DLT)|To establish the maximum tolerated dose (MTD)|To evaluate the response rate|To evaluate the time to disease progression|To assess activated mTOR pathway markers|To evaluate overall survival|To assess activated PTEN status|To assess activated Akt activation|to evaluate markers of DNA repair","https://ClinicalTrials.gov/show/NCT01182168"
68,"NCT01261728","Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma","Recruiting","No Results Available","Urothelial Carcinoma","Drug: Gemcitabine and Cisplatin","Memorial Sloan Kettering Cancer Center|Mayo Clinic|Hartford Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","10-208","December 15, 2010","December 14, 2010","December 2017","May 23, 2017","February 2017","No Study Results Posted","null","December 2017","To define the pathologic response rate (<pT2)|To determine the time to disease progression|To determine overall survival of patients|To evaluate the safety and tolerability","https://ClinicalTrials.gov/show/NCT01261728"
69,"NCT01387399","Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer","Unknown status","No Results Available","Ovarian Cancer","Procedure: Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion","University Hospital, Bonn","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT No.: 2010-024652-28","June 24, 2011","June 2011","July 2013","February 14, 2013","February 2013","No Study Results Posted","HIPEC ROC I","March 2013","Dose-limiting toxicity|Pharmacokinetics|Number of cycles of standard intravenous platinum-based systemic chemotherapy","https://ClinicalTrials.gov/show/NCT01387399"
70,"NCT01980667","Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: lurbinectedin (PM01183)|Drug: Cisplatin","PharmaMar","All","18 Years and older   (Adult, Senior)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PM1183-A-008-13","October 22, 2013","July 30, 2014","January 5, 2017","January 25, 2017","January 2017","No Study Results Posted","null","January 5, 2017","Recommended dose (RD) of the combination PM01183 and cisplatin|Pharmacokinetics (PK) characterisation of Cmax (maximum concentratio), AUC (area under the curve), CL (clearance), HL (half life) y Vss (volume of distribution)|Pharmacogenomic (PGx) analysis","https://ClinicalTrials.gov/show/NCT01980667"
71,"NCT01372904","Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment","Completed","No Results Available","Cisplatin Ototoxicity","Drug: Dexamethasone Phosphate","Meir Medical Center","All","18 Years and older   (Adult, Senior)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","CIS 4/2011","June 13, 2011","June 2011","June 2013","July 16, 2014","July 2014","No Study Results Posted","null","June 2013","Examine possible protective effect of IT dexamethasone on cisplatin-induced hearing loss. Hearing assessment would include:pure tone, speech and impedance audiometry, and Distortion Product Otoacoustic Emissions (DPOAEs) testing.","https://ClinicalTrials.gov/show/NCT01372904"
72,"NCT00076310","OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Docetaxel|Drug: OSI-774|Drug: Cisplatin","M.D. Anderson Cancer Center|Aventis Pharmaceuticals|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ID02-668","January 20, 2004","January 2004","January 2019","March 13, 2017","March 2017","No Study Results Posted","null","January 2019","Response Rate|Safety profile of OSI-774 in Conjunction with Cisplatin and Docetaxel","https://ClinicalTrials.gov/show/NCT00076310"
73,"NCT00359359","A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Small Cell","Drug: Sagopilone (BAY86-5302, ZK 219477)|Drug: Cisplatin","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","91495|2006-000067-29|310101","July 27, 2006","July 2006","August 2009","November 3, 2014","November 2014","No Study Results Posted","null","March 2009","Phase 1: Safety measure to establish the MTD or RPDII dose of Sagopilone used in combination with cisplatin|Phase 2: Efficacy measure|Phase 1: PK of Sagopilone + Cisplatin|Phase 2: Duration of CR or PR|Phase 2: TTP|Phase 2: PFS|Phase 2: OS","https://ClinicalTrials.gov/show/NCT00359359"
74,"NCT02546934","ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)","Recruiting","No Results Available","Breast Cancer","Drug: ABX, cisplatin|Drug: Gemcitabine, Cisplatin","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","254","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Fudan BR2015-18 CBCSG018","September 10, 2015","March 2016","March 2019","January 3, 2017","January 2017","No Study Results Posted","TNBC","March 2018","PFS (Progression Free Survival)|Objective Response Rate (ORR)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02546934"
75,"NCT01058408","RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer","Terminated","No Results Available","Head and Neck Cancer","Radiation: Intensity modulated radiotherapy|Drug: RAD001|Drug: cisplatin","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-342|CRAD001C4540T","January 26, 2010","February 2010","null","February 20, 2013","February 2013","No Study Results Posted","null","February 2012","To evaluate the maximum tolerated dose (MTD) and safety of the RAD001 in combination with weekly cisplatin and radiation in patients with locally advanced HNSCC.|Obtain preliminary results on efficacy of the RAD001, cisplatin and radiation therapy combination in patients with locally advanced HNSCC.","https://ClinicalTrials.gov/show/NCT01058408"
76,"NCT01110226","Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies","Unknown status","No Results Available","Non-Small Cell Lung Cancer, Small Cell Lung Cancer|Platinum Responsive Malignancies","Drug: KML-001|Drug: Cisplatin","University of Maryland","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HP-00040420|GCC 0805","December 14, 2009","May 2010","December 2015","February 23, 2015","February 2015","No Study Results Posted","0805 GCC","June 2015","To determine the maximum tolerated dose of KML001 in combination with cisplatin","https://ClinicalTrials.gov/show/NCT01110226"
77,"NCT01589094","Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer","Active, not recruiting","No Results Available","Bladder Cancer","Drug: Gemcitabine and Cisplatin (DD GC)","Memorial Sloan Kettering Cancer Center|University of North Carolina, Chapel Hill|New York University","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","12-071","April 27, 2012","April 2012","April 2018","May 5, 2017","May 2017","No Study Results Posted","null","April 2018","pathologic response rate|safety|tolerability|progression-free survival","https://ClinicalTrials.gov/show/NCT01589094"
78,"NCT02291211","S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis","Unknown status","No Results Available","Stage IV Gastric Cancer","Drug: S-1 plus cisplatin HIPEC","Tang-Du Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TDCCC006","November 11, 2014","September 2014","December 2016","November 13, 2014","September 2014","No Study Results Posted","null","October 2016","PFS: Progression Free Survival|OS: Overall Survival|Safety as measured by recording the subjects' Adverse Events from randomization to termination","https://ClinicalTrials.gov/show/NCT02291211"
79,"NCT01198392","Trial of S-1 Plus Cisplatin in Gastric Cancer","Unknown status","No Results Available","Gastric Cancer","Drug: s-1 plus cisplatin|Drug: 5-Fu plus cisplatin","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005L02859","September 1, 2010","September 2008","December 2011","July 22, 2011","August 2008","No Study Results Posted","null","December 2011","Time to progression|Response rate","https://ClinicalTrials.gov/show/NCT01198392"
80,"NCT01348009","Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer","Unknown status","No Results Available","Gastric Carcinoma","Drug: Tesetaxel-capecitabine-cisplatin","Genta Incorporated","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","63","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TOPK105","April 18, 2011","May 2011","January 2014","March 11, 2012","March 2012","No Study Results Posted","null","October 2013","Progression-free survival rate (in Phase 2 portion of study)|Recommended dose of tesetaxel for Phase 2 (in Phase 1 portion of study)|Response rate, as defined in revised RECIST (in Phase 2 portion of study)|Duration of response (in Phase 2 portion of study)|Rate of responses at least 3 months in duration (in Phase 2 portion of study)|Disease control rate, which is defined as the percentage of patients with a response of any duration or stable disease at least 6 weeks in duration (in Phase 2 portion of study)|Durable response rate, which is defined as the percentage of patients with a response at least 6 months in duration (in Phase 2 portion of study)|Progression-free survival (in Phase 2 portion of study)|Overall survival (in Phase 2 portion of study)|Percentage of patients with adverse events (in Phase 1 and Phase 2 portions)","https://ClinicalTrials.gov/show/NCT01348009"
81,"NCT00507962","Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement","Completed","No Results Available","Advanced Cancer","Drug: Cisplatin|Drug: Liposomal Doxorubicin","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 1","51","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0568","July 25, 2007","March 2005","May 2011","August 1, 2012","August 2012","No Study Results Posted","null","May 2011","Maximum tolerated dose (MTD)","https://ClinicalTrials.gov/show/NCT00507962"
82,"NCT00580333","Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Drug: cisplatin|Drug: bevacizumab|Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel","Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","06-202|AVF36335","December 20, 2007","September 2007","June 2017","March 22, 2017","March 2017","April 2, 2014","null","December 2010","Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.|Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab|Toxicity of Administering Bevacizumab in Combination With Standard Adjuvant Chemotherapy.|Patients With Miller-Payne (MP) Score 3, 4, or 5 Response","https://ClinicalTrials.gov/show/NCT00580333"
83,"NCT00388154","Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer","Completed","Has Results","Endometrial Cancer","Drug: Gemcitabine|Drug: Cisplatin","M.D. Anderson Cancer Center","Female","Child, Adult, Senior","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0823","October 12, 2006","August 2004","November 2013","November 12, 2014","November 2014","November 5, 2014","null","November 2013","Participant Responses|Overall Objective Response Rate (CR + PR)","https://ClinicalTrials.gov/show/NCT00388154"
84,"NCT00544596","R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer","Completed","No Results Available","Extensive Stage Small Cell Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: R-(-)-gossypol acetic acid|Drug: cisplatin|Drug: etoposide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","27","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00273|CO07901|2007-0145|CDR0000570006|CO 07901|8062|P30CA014520|U01CA062491","October 13, 2007","September 2007","null","April 1, 2014","June 2012","No Study Results Posted","null","July 2013","Toxicity and tolerability of R-(-)-gossypol acetic acid in combination with cisplatin and etoposide in terms of types and severities by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Response as assessed by RECIST criteria|Pharmacokinetics of R-(-)-gossypol acetic acid in combination with cisplatin and etoposide","https://ClinicalTrials.gov/show/NCT00544596"
85,"NCT00545948","Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer","Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Vinorelbine followed by Cisplatin|Drug: Pemetrexed followed by Cisplatin","Duke University|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","31","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00000657","October 16, 2007","December 2007","January 2012","June 25, 2014","June 2014","May 7, 2014","TOP0703","January 2012","2-Year Progression-Free Survival Rate in Patients With Completely Resected Stage IB, II, or IIIA NSCLC|Percentage of Patients With Completely Resected NSCLC Tumors That Can Be Analyzed and Used to Direct Adjuvant Chemotherapy|2-Year Overall Survival in Patients Treated for NSCLC|Patient Understanding and Perceptions of Participating in a Clinical Trial Evaluating Cancer Genomics for Adjuvant Treatment of Early Stage Lung Cancer|Compare Drug Sensitivity Patterns of Cisplatin and Pemetrexed in Both Treatment Arms","https://ClinicalTrials.gov/show/NCT00545948"
86,"NCT00402766","Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma","Completed","No Results Available","Mesothelioma","Drug: Cisplatin|Drug: Imatinib Mesylate|Drug: Pemetrexed|Drug: Dexamethasone","M.D. Anderson Cancer Center|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0288|NCI-2012-01381","November 20, 2006","August 2006","February 2014","November 16, 2015","November 2015","No Study Results Posted","null","February 2014","Maximum Tolerated Dose (MTD) of Cisplatin, Pemetrexed, and Imatinib Mesylate Given to Participants with Unresectable or Metastatic Malignant Mesothelioma","https://ClinicalTrials.gov/show/NCT00402766"
87,"NCT02407912","Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer","Recruiting","No Results Available","Pleural Effusion, Malignant","Drug: cisplatin","Shantou University Medical College","All","18 Years to 70 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LXY 01","March 31, 2015","March 2015","March 2020","November 18, 2015","November 2015","No Study Results Posted","null","March 2018","overall response rate","https://ClinicalTrials.gov/show/NCT02407912"
88,"NCT01384799","Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: CUDC-101|Drug: Cisplatin|Radiation: Radiation Therapy","Curis, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CUDC-101-103","June 17, 2011","November 2011","October 2013","March 12, 2015","March 2015","No Study Results Posted","null","September 2013","To establish the safety and tolerability of CUDC-101 when administered in combination with concurrent cisplatin and radiation in subjects with locally advanced head and neck cancers.|To evaluate the efficacy of CUDC-101, cisplatin and radiation combination therapy.|To assess the pharmacokinetics of CUDC-101.|To evaluate the pharmacodynamic effects of CUDC-101.","https://ClinicalTrials.gov/show/NCT01384799"
89,"NCT00632268","Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer","Completed","No Results Available","Metastatic Gastric Cancer","Drug: RAD001; Cisplatin; 5-FU; Leucovorin","National Taiwan University Hospital|National Cheng-Kung University Hospital|Taipei Veterans General Hospital, Taiwan","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200612015M","March 3, 2008","February 2008","December 2012","August 19, 2013","August 2013","No Study Results Posted","null","September 2012","To evaluate the confirmed objective response rates (complete and partial responses)|To assess the overall survival(OS), progression-free survival(PFS), treatment-related toxicities, and pharmacokinetic profile of RAD001 used in combination with 5-FU and cisplatin","https://ClinicalTrials.gov/show/NCT00632268"
90,"NCT03068936","IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Radiation: Intensity modulated radiotherapy|Drug: Cisplatin","Nanfang Hospital of Southern Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","716","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","C1033400","February 15, 2017","March 2017","September 2021","February 27, 2017","September 2016","No Study Results Posted","null","September 2019","Overall survival rate","https://ClinicalTrials.gov/show/NCT03068936"
91,"NCT01405235","Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma","Unknown status","No Results Available","Recurrent, Persistent or Metastasized Cervical Cancer","Drug: Paclitaxel|Drug: Cisplatin/Paclitaxel","Institut fuer Frauengesundheit|GlaxoSmithKline|Schantl Pharma Service, Germany","Female","18 Years and older   (Adult, Senior)","Phase 3","312","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFG-01-0106","July 27, 2011","September 2006","January 2015","April 11, 2012","September 2006","No Study Results Posted","AGO-Zervix-1","June 2012","Changes in target lesion according to RECIST 1.0","https://ClinicalTrials.gov/show/NCT01405235"
92,"NCT01285674","Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.","Unknown status","No Results Available","Cisplatin|Ototoxicity|Intratympanic Steroids","Drug: Intra-tympanic Cisplatinum","Ziv Hospital","All","18 Years to 90 Years   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","0035-10-ZIV","January 23, 2011","January 2011","January 2012","January 27, 2011","January 2011","No Study Results Posted","null","January 2012","Post-Treatment change in hearing|Tinnitus","https://ClinicalTrials.gov/show/NCT01285674"
93,"NCT00483093","Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor","Completed","No Results Available","Solid Tumors","Drug: NGR-hTNF|Drug: Cisplatin","MolMed S.p.A.","All","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NGR004|2006-006035-42","June 5, 2007","July 2007","April 2013","May 29, 2014","May 2014","No Study Results Posted","null","June 2010","To verify the safety of escalating doses of NGRhTNF (from 0.2 to 1.6 µg/m^2) in combination with cisplatin (80 mg/m^2) every 3 weeks|To document the preliminary antitumor activity of the combination in terms of objective response rate according to RECIST criteria|To evaluate the pharmacokinetic profiles of the combination of NGR-hTNF and cisplatin|To measure plasma levels of sTNFRs and anti-NGR-hTNF antibodies","https://ClinicalTrials.gov/show/NCT00483093"
94,"NCT01444521","Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: irinotecan and cisplatin","Chinese Academy of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-017","September 25, 2011","April 2011","May 2014","May 2, 2014","May 2014","No Study Results Posted","null","May 2014","Overall response rate|Time to event efficacy","https://ClinicalTrials.gov/show/NCT01444521"
95,"NCT01951482","Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer","Recruiting","No Results Available","Non Squamous Non-small Cell Lung Cancer|Brain Metastases|Bevacizumab","Drug: Pemetrexed/cisplatin|Drug: Bevacizumab and Pemetrexed/cisplatin","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSCLC brain metastasis 02","September 16, 2013","June 2013","June 2017","November 16, 2015","November 2015","No Study Results Posted","null","June 2016","Compare iPFS(intracranial progression free survival) in two arms|Response rate(CR&PR)","https://ClinicalTrials.gov/show/NCT01951482"
96,"NCT02967887","Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC","Recruiting","No Results Available","Hepatocellular Carcinoma Non-Resectable","Drug: cisplatin and 5-fluorouracil","CbsBioscience","All","20 Years and older   (Adult, Senior)","Phase 2","96","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CBS-PCT-01","November 10, 2016","November 2016","December 2018","November 16, 2016","November 2016","No Study Results Posted","SHINE","October 2018","Objective tumor response|Time-to-Progression|Progression-free-survival","https://ClinicalTrials.gov/show/NCT02967887"
97,"NCT00601159","Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC","Completed","No Results Available","Metastatic Breast Cancer","Drug: gemcitabine and cisplatin","Fudan University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200709GP","December 26, 2007","September 2007","September 2010","July 1, 2011","June 2011","No Study Results Posted","null","May 2010","PFS (progression free survival)|side effects|BRCA1 mutation realtionship with efficacy and toxicity analysis|pharmacogenetic analysis","https://ClinicalTrials.gov/show/NCT00601159"
98,"NCT00324012","Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma","Completed","No Results Available","Adrenocortical Carcinoma","Drug: cisplatin, taxotere","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Senior)","Phase 2","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02 262098","May 8, 2006","April 2006","February 2012","February 20, 2012","February 2012","No Study Results Posted","null","February 2012","response rate|Survival, time to progression, best overall response rate and duration of response","https://ClinicalTrials.gov/show/NCT00324012"
99,"NCT01554410","Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma","Unknown status","No Results Available","Cervical Carcinoma","Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Cisplatin|Drug: Gemcitabine","University of California, San Diego","Female","18 Years and older   (Adult, Senior)","Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCSD 100597","March 8, 2012","August 2010","August 2015","December 1, 2014","December 2014","No Study Results Posted","null","August 2015","Establish the maximum tolerated dose (MTD) of Gemcitabine that can be safely administered in combination with Cisplatin|Number of Participants with Acute Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Progression-Free Survival as a Measure of Response","https://ClinicalTrials.gov/show/NCT01554410"
100,"NCT01444547","A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin","Unknown status","No Results Available","Esophageal Cancer","Drug: paclitaxel and cisplatin","Chinese Academy of Medical Sciences|Beijing Municipal Science & Technology Commission","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","92","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-021|Z111107058811023","September 28, 2011","January 2007","December 2015","May 2, 2014","May 2014","No Study Results Posted","null","December 2015","Overall response rate (ORR)|Time to event efficay","https://ClinicalTrials.gov/show/NCT01444547"
101,"NCT01171781","A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasophayngeal Carcinoma Between Stage II and IVb","Drug: cisplatin (3 weekly)|Drug: cisplatin (weekly)","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-09-037","July 27, 2010","November 2009","June 2014","July 27, 2010","July 2010","No Study Results Posted","null","June 2012","progression free survival rate at 3 years|overall survival rate|objective response rate|toxicity|quality of life","https://ClinicalTrials.gov/show/NCT01171781"
102,"NCT01051765","Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial","Unknown status","No Results Available","Advanced Esophageal Squamous Carcinoma","Drug: irinotecan/cisplatin","Peking University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IP-AEC1","January 19, 2010","August 2009","August 2012","January 19, 2010","May 2009","No Study Results Posted","null","August 2011","overall survival|PFS|response rate|adverse events|polymorphism of UGT1A","https://ClinicalTrials.gov/show/NCT01051765"
103,"NCT00423865","Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: everolimus|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MSKCC 06-129|MSKCC-06129","January 16, 2007","November 2006","September 2011","May 22, 2015","September 2012","No Study Results Posted","null","September 2011","Recommended phase II dose of everolimus|Pharmacokinetic profile of cisplatin and everolimus|Pharmacodynamic profile of cisplatin and everolimus","https://ClinicalTrials.gov/show/NCT00423865"
104,"NCT00390416","Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma","Completed","Has Results","Stomach Neoplasms|Esophageal Neoplasms","Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin","Memorial Sloan Kettering Cancer Center|Sanofi|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-096","October 17, 2006","October 2006","January 2012","February 16, 2016","February 2016","December 15, 2015","null","January 2012","6 Month Progression Free Survival|1-year Survival|Patients With Measurable Disease the Confirmed Response Rate","https://ClinicalTrials.gov/show/NCT00390416"
105,"NCT02158234","Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Cisplatin|Radiation: Stereotactic Body Radiation Therapy (SBRT)","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-17799","June 4, 2014","June 3, 2014","July 2018","May 23, 2017","May 2017","No Study Results Posted","null","July 2018","Maximal Tolerated Dose (MTD) of Stereoactive Body Radiation Therapy (SBRT)|Local Control Rate|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02158234"
106,"NCT00686322","Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-small-cell Lung Cancer","Drug: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)","Taipei Veterans General Hospital, Taiwan","All","18 Years and older   (Adult, Senior)","Phase 4","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","97-02-12","May 27, 2008","April 2008","October 2009","September 13, 2011","June 2010","No Study Results Posted","null","April 2009","To determine the efficacy of this treatment modality in patients with inoperable stage III NSCLC|To determine the toxicity profiles of this treatment modality in patients with inoperable stage III NSCLC","https://ClinicalTrials.gov/show/NCT00686322"
107,"NCT02276560","Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC","Terminated","Has Results","Stage IIIA Non-Small Cell Lung Cancer","Drug: Neoadjuvant Cisplatin, nab-paclitaxel|Drug: Adjuvant Cisplatin,nab-paclitaxel|Drug: Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1407","October 21, 2014","January 2015","June 2016","March 29, 2017","March 2017","March 29, 2017","LCCC1407","June 2016","Rate of N2 Nodal Clearance","https://ClinicalTrials.gov/show/NCT02276560"
108,"NCT02194049","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer","Completed","No Results Available","Extensive Stage Small Cell Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: BKM120|Drug: cisplatin|Drug: etoposide","University of California, Davis|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCDCC#239|NCI-2014-00218|CBKM120ZUS38T","July 10, 2014","July 2014","June 2016","June 20, 2016","June 2016","No Study Results Posted","null","April 2016","Incidence of adverse events of combining daily BKM120 with cisplatin and etoposide as graded by the National Cancer Institute (NC) CTCAE version 4.0|MTD defined as the highest dose tested in which fewer than 33% of patients experience DLT attributed to the study drugs when at least 6 patients were treated at that dose, as graded by NCI CTCAE version 4.0|Response rate assessed by computed tomography (CT) scan based on Response Evaluation Criteria In Solid Tumors (RECIST)|Overall survival|Time to progression (TTP) based on RECIST|Pharmacokinetic analysis","https://ClinicalTrials.gov/show/NCT02194049"
109,"NCT00551512","Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors","Completed","No Results Available","Cancer|Solid Tumors","Drug: CBP501 and Cisplatin","CanBas Co. Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CBP 06-01","October 29, 2007","November 2006","May 2009","March 13, 2017","March 2017","No Study Results Posted","null","May 2009","Dose Limiting Toxicity (DLT) during the first two treatment cycles|Incidence and severity of adverse events and laboratory abnormalities, graded according to NCI-CTCAE version 3.0|Occurrence of Serious Adverse Events (SAEs)|Occurrence of discontinuations due to treatment-related adverse events|Serum concentrations of CBP501 and total and ultrafiltrate platinum to determine, via non-compartmental methods, Cmax, AUC, lz, t½, Cl and Vss.|Evaluation of the relationship between administered dose and plasma pharmacokinetic parameters for CBP501 and cisplatin|Objective tumor response assessed according to RECIST|Time to progression","https://ClinicalTrials.gov/show/NCT00551512"
110,"NCT01661790","Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer","Completed","Has Results","Malignant Pleural Effusion","Drug: Bevacizumab|Drug: Cisplatin","Chinese PLA General Hospital|Roche Pharma AG","All","18 Years to 85 Years   (Adult, Senior)","Phase 3","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PLA304DN-001","July 25, 2012","August 2009","October 2012","March 13, 2015","March 2015","February 16, 2015","null","June 2012","Number of Participants With ""Complete Response"" and ""Partial Response""|Median Progression Free Survival (PFS)|Overall Survival (OS)|Adverse Reactions|Qualify of Life (QoL)","https://ClinicalTrials.gov/show/NCT01661790"
111,"NCT01834963","P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.","Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Interferon Alfa、Fluorouracil|Drug: Cisplatin、Fluorouracil","Kansai Hepatobiliary Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KHBO1207|UMIN000010425","April 16, 2013","March 2013","February 2020","October 21, 2014","October 2014","No Study Results Posted","null","February 2018","Two-year overall survival rate|Progression free survival time|Overall survival time|toxicity","https://ClinicalTrials.gov/show/NCT01834963"
112,"NCT02879669","A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma","Recruiting","No Results Available","To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy","Biological: ONCOS-102|Drug: Pemetrexed/cisplatin|Drug: Cyclophosphamide","Targovax Oy|Theradex|Targovax ASA","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ONCOS C719|2015-005143-13","July 13, 2016","June 2016","null","April 28, 2017","April 2017","No Study Results Posted","null","December 2018","Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability|To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor specific CD8+ T Cells in PBMC|To determine and compare immunological activation in tumour mass in the experimental group and the control Group. Number of patients in the respective arms with infiltration of CD8+ T Cells into tumours|To determine and compare overall response rate in the experimental group and the control group by number of patients with PD, SD, PR and CR in the respective arms|To determine and compare progression-free survival (PFS) in the experimental group and the control group by median time to progression in the respective arms|To determine and compare overall survival (OS) in the experimental group and the control group|To analyse immunological activation by comparing patients with and without presence of tumour antigen recognizing CD8+ T cells|To analyse clinical outcome by time to event endpoints (OS and PFS)","https://ClinicalTrials.gov/show/NCT02879669"
113,"NCT01918306","GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer","Terminated","No Results Available","Estrogen Receptor Negative Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Triple Negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer","Drug: cisplatin|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|Drug: GDC -0941","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","11","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC BRE 1287|NCI-2013-01319","July 25, 2013","September 2013","April 2015","August 17, 2015","August 2015","No Study Results Posted","null","December 2014","Maximum Tolerated Dose(MTD) of GDC-0941 - (Phase Ib)|Percentage of Patients Achieving Overall Response Rate - (Phase II)|Number of patients with dose-limiting toxicities per grade (DLT) - (Phase Ib)|Clinical Benefit Ratio (CBR)|Time to Progression (TTP)","https://ClinicalTrials.gov/show/NCT01918306"
114,"NCT01829178","Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma","Completed","No Results Available","Upper GI Cancer|Cisplatin Adverse Reaction","Drug: Silymarin|Drug: Placebo|Drug: chemotherapy","Tehran University of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Treatment","91-03-33-18878","January 11, 2013","August 2013","September 2014","May 11, 2015","May 2015","No Study Results Posted","null","September 2014","Urine concentration of NGAL|Changes in VEGF Serum concentration|Tissue activity of caspase 3","https://ClinicalTrials.gov/show/NCT01829178"
115,"NCT00548821","Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer","Unknown status","No Results Available","Locally Advanced Cervical Cancer","Drug: Cisplatin","National University Hospital, Singapore","Female","21 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Cervix Cancer Research","October 23, 2007","null","null","May 13, 2008","May 2008","No Study Results Posted","null","null","The primary aim of this research protocol is to compare if there is a difference in progression free survival between weekly versus 5-day 3 weekly cisplatin based chemotherapy regimen in women with locally advanced cervical cancer.|The secondary aims are to compare quality of life assessment of patients and their carers as well as toxicity profiles both acute and late.","https://ClinicalTrials.gov/show/NCT00548821"
116,"NCT01188109","Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision","Terminated","Has Results","Pancreatic Neoplasms|Pancreatic Cancer","Drug: Gemcitabine|Drug: Cisplatin","Emory University","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00034258|WCI1738-09","July 23, 2010","July 2010","July 2015","August 19, 2016","August 2016","June 30, 2016","null","July 2015","Recurrence-free Survival as Measured by CT Scan|Immunohistochemistry to Determine Status of Excision Repair Cross Complementation Gene-1 (ERCC1) Expression","https://ClinicalTrials.gov/show/NCT01188109"
117,"NCT02897375","Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors","Recruiting","No Results Available","Solid Neoplasm|Stage III Pancreatic Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IVA Pancreatic Cancer|Stage IVB Pancreatic Cancer|Sarcoma|Colorectal Cancer|Head and Neck Cancer|Cancer of Unknown Primary|Bladder Cancer|Ovarian Cancer","Drug: Carboplatin|Drug: Cisplatin|Drug: Palbociclib","Emory University|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00089583|NCI-2016-01037|Winship3263-16","August 30, 2016","October 2016","February 2021","November 9, 2016","November 2016","No Study Results Posted","null","February 2019","Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Incidence of dose limiting toxicities defined as grade 3 or higher toxicity|Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin|Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria|Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax)|Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)","https://ClinicalTrials.gov/show/NCT02897375"
118,"NCT02586753","Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus","Not yet recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Other: Paclitaxel plus Cisplatin with radiotherapy|Other: S1 plus Cisplatin with radiotherapy","Mianyang Central Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MianyangCH001","October 19, 2015","December 2015","September 2016","October 23, 2015","October 2015","No Study Results Posted","null","September 2016","Overall survival (OS)|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02586753"
119,"NCT01801644","Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer","Completed","No Results Available","Bladder Cancer","Drug: gemcitabine plus cisplatin","Barmherzige Brüder Vienna","All","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Bladder Cancer-001","February 15, 2013","April 2007","February 2013","February 28, 2013","February 2013","No Study Results Posted","null","January 2013","pathologic response rate|safety, number of participants with adverse events and grade of adverse events","https://ClinicalTrials.gov/show/NCT01801644"
120,"NCT00950261","Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients","Recruiting","No Results Available","Cervical Neoplasms","Radiation: tri-weekly cisplatin","Korea Cancer Center Hospital","Female","Child, Adult, Senior","Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KCCH GY 1002","July 30, 2009","January 2009","December 2017","May 7, 2014","May 2014","No Study Results Posted","null","December 2016","disease-free survival|overall survival|all kinds of toxicity","https://ClinicalTrials.gov/show/NCT00950261"
121,"NCT02690558","Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy","Recruiting","No Results Available","Bladder Cancer","Drug: pembrolizumab, gemcitabine and cisplatin","UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1520","February 12, 2016","May 2016","May 2024","March 10, 2017","March 2017","No Study Results Posted","null","September 2019","Number of subjects that reach pathological downstaging to <pT2 defined as pT0-T1N0M0 at the time of cystectomy|Number of subjects that reach complete pathologic response (pT0) defined as pT0N0M0 at the time of cystectomy|Event Free Survival|Overall survival|Number of adverse events and severity by grade (CTCAE).","https://ClinicalTrials.gov/show/NCT02690558"
122,"NCT01630226","Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland","Unknown status","No Results Available","BRCA1 Mutation|Breast Cancer Invasive Nos","Drug: Neoadjuvant Cisplatin Chemotherapy","Pomeranian Medical University Szczecin|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Regional Oncology Hospital, Bielsko-Biala, Poland","Female","20 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BN-001/83/07-B","June 26, 2012","June 2007","null","July 10, 2012","July 2012","No Study Results Posted","null","December 2013","Pathologic Complete Response","https://ClinicalTrials.gov/show/NCT01630226"
123,"NCT00169221","Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas","Terminated","No Results Available","Head and Neck Cancer","Drug: Iressa (Gefitinib)|Radiation: chemoradiotherapy with cisplatin","Groupe Oncologie Radiotherapie Tete et Cou|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC 2004-02","September 12, 2005","September 2005","July 2011","November 14, 2011","November 2011","No Study Results Posted","null","July 2009","Disease free survival","https://ClinicalTrials.gov/show/NCT00169221"
124,"NCT01737008","Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: dacomitinib|Radiation: Radiotherapy|Drug: Cisplatin","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XDC-001","November 26, 2012","January 2013","May 2015","June 9, 2016","June 2016","No Study Results Posted","null","February 2015","Maximum Tolerated Dose (in mg) of Dacomitinib|To preliminarily evaluate the response rate of the combination of Dacomitinib, Cisplatin and Radiation|Levels of Dacomitinib in the Blood (Pharmacokinetics) in Combination with Cisplatin and Radiation|Disease free survival, overall survival and locoregional and distant metastasis free survival","https://ClinicalTrials.gov/show/NCT01737008"
125,"NCT01275183","Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck","Completed","No Results Available","Head and Neck Cancer","Drug: raltegravir and cisplatin","New Mexico Cancer Care Alliance|American Cancer Society, Inc.","All","18 Years and older   (Adult, Senior)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INST 1012|NCI-2012-00914","January 6, 2011","December 2010","April 2015","June 16, 2015","June 2015","No Study Results Posted","null","April 2015","Gene expression modification|Clinical activity|Clinical toxicity|Progression free survival and overall survival|Metnase expression","https://ClinicalTrials.gov/show/NCT01275183"
126,"NCT01623102","Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin and gemcitabine combination with Bevacizumab|Drug: Gemcitabine combined with cisplatin chemotherapy","Sichuan Cancer Hospital and Research Institute","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WJP001","June 15, 2012","February 2013","December 2014","February 11, 2013","February 2013","No Study Results Posted","null","August 2014","disease-free time to progression|quality of life","https://ClinicalTrials.gov/show/NCT01623102"
127,"NCT01216020","Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer","Terminated","No Results Available","Head and Neck Neoplasms|Laryngeal Neoplasms|Mouth Neoplasms|Pharyngeal Neoplasms","Drug: cetuximab|Drug: cisplatin (associated to radiotherapy)","Azienda USL 4 Prato|Università degli Studi di Brescia","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","eudract 2010-021552-26","October 6, 2010","October 2010","December 2019","July 16, 2015","July 2015","No Study Results Posted","CTXMAB+RT","December 2019","Compliance|event free survival|acute toxicity|Local control|cause specific survival|overall survival","https://ClinicalTrials.gov/show/NCT01216020"
128,"NCT02990468","A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer","Drug: BMX-001|Radiation: Radiation Therapy|Drug: Cisplatin","BioMimetix JV, LLC|Duke University|University of Colorado, Denver","All","18 Years and older   (Adult, Senior)","Phase 1","66","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BMX-HN-001","November 28, 2016","April 19, 2017","April 2019","April 19, 2017","April 2017","No Study Results Posted","BMX-HN","April 2019","Maximum Tolerated Dose (MTD) of BMX-001 in combination with standard radiation therapy and cisplatin, defined as the dose level that has an estimated dose limited toxicity (DLT) rate nearest to 0.25.|Reduction of radiation-induced mucositis|Reduction of radiation-induced xerostomia|Progression-free survival|Peak plasma concentrations (Cmax) for BMX-001|Area under the plasma concentration versus time curve (AUC) for BMX-001","https://ClinicalTrials.gov/show/NCT02990468"
129,"NCT00251407","Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies","Completed","No Results Available","Solid Tumor","Drug: Taxotere|Drug: Cisplatin|Drug: CPT-11","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Phase 1","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99-149","November 8, 2005","September 1999","April 2009","August 7, 2012","August 2012","No Study Results Posted","null","January 2003","To assess the maximum tolerated dose of weekly taxotere, cisplatin and CPT-11 in patients with incurable solid tumor malignancies.|To define the dose-limiting toxicities of the combination of drugs.","https://ClinicalTrials.gov/show/NCT00251407"
130,"NCT01579929","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","Active, not recruiting","No Results Available","Lung Cancer","Drug: LDE225, Etoposide and Cisplatin","Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11-206","April 16, 2012","April 2012","April 2018","February 15, 2017","February 2017","No Study Results Posted","null","April 2018","MTD|safety, tolerability|pharmacokinetic profile|efficacy|patient-reported outcomes (toxicity-related symptoms)","https://ClinicalTrials.gov/show/NCT01579929"
131,"NCT02775812","Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","56","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2016-00667|NRG-HN003|U10CA180868","May 16, 2016","November 28, 2016","null","May 24, 2017","April 2017","No Study Results Posted","null","May 15, 2018","Dose limiting toxicities in patients with high-risk head and neck squamous cell carcinoma treated with adjuvant cisplatin, intensity-modulated radiation therapy, and pembrolizumab|Change in expression of peripheral immune-inflammatory biomarkers|Disease free survival|Distant metastases|Immune-inflammatory biomarkers|Incidence of acute toxicities by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Incidence of late toxicities by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Levels of PDL1|Local-regional failure|Overall survival","https://ClinicalTrials.gov/show/NCT02775812"
132,"NCT02760901","Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity","Completed","No Results Available","Cisplatin Nephrotoxicity","Drug: Acetazolamide|Drug: Acetylcysteine|Drug: Mannitol|Drug: saline|Drug: Cisplatin","Ain Shams University","All","18 Years to 65 Years   (Adult)","Phase 2","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","master","April 1, 2016","November 2013","October 2016","January 23, 2017","January 2017","No Study Results Posted","null","October 2015","Serum Creatinine|Creatinine clearance according to Cockroft-Gault equation|Acute kidney injury|Blood urea nitrogen (BUN)|Aspartate Transaminase (AST)|hemoglo bin|adverse events|Alanine Transaminase (ALT)|platelets count|total leucocyte count","https://ClinicalTrials.gov/show/NCT02760901"
133,"NCT01258192","Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients","Completed","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: albumin-bound paclitaxel plus cisplatin","Zhejiang Cancer Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejiangCH-ESCC-01","December 3, 2010","January 2011","October 2012","July 28, 2014","July 2014","No Study Results Posted","nabPCESCC","October 2012","response to induction therapy|rate of complete pathological response|R0 resection rate.|3 years disease free and overall survival|safety and tolerability","https://ClinicalTrials.gov/show/NCT01258192"
134,"NCT01309633","Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: 12.5mg sunitinib with Cisplatin and Gemcitabine|Drug: 25mg Sunitinib alternating with Cisplatin and Gemcitabine","National University Hospital, Singapore","All","21 Years to 99 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NP01/27/10","March 3, 2011","September 2011","September 2018","June 21, 2016","June 2016","No Study Results Posted","null","September 2017","Clinical Response","https://ClinicalTrials.gov/show/NCT01309633"
135,"NCT00198172","Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors","Terminated","No Results Available","Germ Cell Tumor","Drug: Cisplatin plus Epirubicin","Indiana University School of Medicine|Indiana University","All","15 Years and older   (Child, Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0008-02","September 8, 2005","October 2000","March 2007","May 30, 2014","May 2014","No Study Results Posted","null","null","To determine the feasibility and toxicity of combining epirubicin to fixed dose cisplatin|To determine the partial and complete response rate and duration of remission","https://ClinicalTrials.gov/show/NCT00198172"
136,"NCT01097252","Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer","Completed","No Results Available","Cervical Cancers","Radiation: radiation|Drug: weekly cisplatin|Drug: tri-weekly cisplatin","Korea Cancer Center Hospital","Female","30 Years to 75 Years   (Adult, Senior)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KCCH GY 1005","March 29, 2010","January 2002","December 2009","May 7, 2014","May 2014","No Study Results Posted","null","December 2004","compliance|survival","https://ClinicalTrials.gov/show/NCT01097252"
137,"NCT00386815","Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Pleural Mesothelioma","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","20 Years to 75 Years   (Adult, Senior)","Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10512|H3E-JE-ME02","October 10, 2006","October 2006","February 2007","April 10, 2007","April 2007","No Study Results Posted","null","null","To investigate safety profile when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients|To investigate efficacy when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients","https://ClinicalTrials.gov/show/NCT00386815"
138,"NCT01228045","A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: Trastuzumab in Combination with TS-ONE and cisplatin","National University Hospital, Singapore|National Cancer Centre, Singapore","All","21 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S1/CDDP/Her","October 21, 2010","February 2011","December 2016","June 21, 2016","June 2016","No Study Results Posted","null","December 2014","Overall Response Rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Time to Treatment Failure (TTF)|Clinical Benefit Rate (CBR)|Duration of Response (DR)|Safety Evaluations","https://ClinicalTrials.gov/show/NCT01228045"
139,"NCT00703638","Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Mesothelioma|Pancreatic Cancer|Prostate Cancer|Sarcoma","Drug: cisplatin|Drug: pemetrexed disodium|Drug: sorafenib","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Senior)","Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007LS086|0712M22703","June 20, 2008","May 2008","November 2010","November 6, 2012","November 2012","No Study Results Posted","null","September 2010","Maximum tolerated dose of sorafenib tosylate|Disease Response|Maximum, Minimum and AUC Concentrations of Sorafenib","https://ClinicalTrials.gov/show/NCT00703638"
140,"NCT02989584","A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer","Recruiting","No Results Available","Bladder Cancer|Metastatic Bladder Cancer|Urothelial Carcinoma","Drug: Atezolizumab|Drug: Gemcitabine|Drug: Cisplatin","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-1428","December 2, 2016","December 20, 2016","December 2020","April 24, 2017","April 2017","No Study Results Posted","null","December 2018","Test the safety of atezolizumab in combination with gemcitabine/cisplatin as assessed by dose limiting toxicity rate.","https://ClinicalTrials.gov/show/NCT02989584"
141,"NCT01606748","A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin","Completed","Has Results","Malignant Solid Tumor","Biological: Necitumumab|Drug: Gemcitabine|Drug: Cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14473|CP11-1115|I4X-IE-JFCJ","May 24, 2012","August 2012","June 2016","April 21, 2017","April 2017","December 21, 2015","null","June 2013","Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Necitumumab|PK: Dose-Normalized Cmax of Gemcitabine|PK: Dose-Normalized Cmax of Cisplatin|PK: Area Under Concentration-Time Curve From Zero to Time 168 (AUC[-168]) of Necitumumab|PK: Dose-Normalized AUC(0-24) of Gemcitabine|PK: Dose-Normalized AUC(0-5) of Cisplatin|PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity, (AUC[0-∞]) of Necitumumab|PK: Dose Normalized AUC(0-∞) of Gemcitabine|Number of Participants With Anti-Necitumumab Antibodies|Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (Antitumor Activity of Necitumumab in Combination With Gemcitabine-cisplatin Chemotherapy)|PK: Cmax of Necitumumab After Administration of Process C and Process D Drug Product|PK: AUC(0-∞) of Necitumumab After Administration of Process C and Process D Drug Product","https://ClinicalTrials.gov/show/NCT01606748"
142,"NCT00798655","Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer","Active, not recruiting","Has Results","Cancer of Head|Cancer of Head and Neck|Cancer of Neck|Cancer of the Head|Cancer of the Head and Neck|Cancer of the Neck|Head and Neck Cancer|Head Cancer|Head Neoplasms|Head, Neck Neoplasms|Neck Cancer|Neck Neoplasms|Neoplasms, Head|Neoplasms, Head and Neck|Neoplasms, Neck|Neoplasms, Upper Aerodigestive Tract|UADT Neoplasms|Upper Aerodigestive Tract Neoplasms","Drug: Panitumumab|Drug: Cisplatin|Radiation: Radiation Therapy","Robert Ferris|Amgen|University of Pittsburgh","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-120","November 25, 2008","November 2007","June 2020","June 28, 2016","June 2016","June 28, 2016","null","June 2015","Probability of Progression-free Survival (PFS) at 2 Years|Probability of 2-year Overall Survival","https://ClinicalTrials.gov/show/NCT00798655"
143,"NCT01825603","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery","Recruiting","No Results Available","Acinar Cell Adenocarcinoma of the Pancreas|Adenocarcinoma of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Gallbladder|Duct Cell Adenocarcinoma of the Pancreas|Localized Unresectable Adult Primary Liver Cancer|Periampullary Adenocarcinoma|Recurrent Adult Primary Liver Cancer|Recurrent Gallbladder Cancer|Recurrent Pancreatic Cancer|Stage II Gallbladder Cancer|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IV Pancreatic Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer","Drug: ADH-1|Drug: cisplatin|Drug: gemcitabine hydrochloride|Other: laboratory biomarker analysis","University of Nebraska|National Cancer Institute (NCI)|Adherex Technologies, Inc.","All","19 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","470-12|NCI-2013-00406|P50CA127297","March 27, 2013","April 2013","null","May 7, 2013","May 2013","No Study Results Posted","null","December 2018","Maximum tolerated dose of ADH-1 when given in combination with gemcitabine hydrochloride and cisplatin determined by dose limiting toxicities (DLT), based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|Changes in the levels of ICAM-1|Progression-free survival|Survival|Changes in the levels of E-selectin|Changes in the levels of VEGF|Changes in the levels of soluble VEGFR|Changes in the levels of B-FGF","https://ClinicalTrials.gov/show/NCT01825603"
144,"NCT00174837","TRACE: Tirapazamine-Radiation And Cisplatin Evaluation","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Tirapazamine|Drug: Cisplatin","Sanofi|Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years and older   (Adult, Senior)","Phase 3","317","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC5512|SR259075","September 13, 2005","April 2005","January 2008","April 27, 2016","April 2016","No Study Results Posted","TRACE","January 2008","Overall survival|Failure Free Survival, Time To Loco-Regional Failure, Patterns of Failure|Initial Response Rates at 2 Months After Completion of Chemoradiation Therapy, Final complete response (CR) Rate at Six Months After Completion of Therapy|Change in QoL From Baseline, Percent of Patients Who Are Feeding Tube Dependent 12 Months After Completion of Therapy|Toxicity and Safety","https://ClinicalTrials.gov/show/NCT00174837"
145,"NCT00016367","Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Biological: Trastuzumab|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM99-015|P30CA016672|MDA-DM-99015|NCI-4450|CDR0000068626","May 6, 2001","May 2001","December 2004","July 27, 2012","July 2012","No Study Results Posted","null","December 2004","Efficacy of Cisplatin, Gemcitabine, + Trastuzumab in Untreated p185-HER2 Overexpressing Stage IIIB or IV Non-small Cell Lung Cancer","https://ClinicalTrials.gov/show/NCT00016367"
146,"NCT01574092","Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas","Completed","No Results Available","Pediatric High Risk Gliomas","Drug: Combination of two marketed drugs (irinotecan and cisplatin)","Hospital Sant Joan de Deu|Fundació Sant Joan de Déu|Spanish National Health System","All","6 Months to 18 Years   (Child, Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HSJD-GLIOMAS-IC","March 29, 2012","November 2009","March 2015","August 21, 2015","August 2015","No Study Results Posted","null","June 2014","The primary objective of this study is to determine the safety and objective response rate (ORR).|Duration of the response.|Safety of the combined Irinotecan+Cisplatin therapy|Possible associations of gene MGMT promoter and microsatellites instability with reference to response to study treatment|To assess the applicability and efficacy of volumetric measurements as a treatment tumor-response indicator.|To assess the applicability and efficacy of metabolic study by PET-methionine","https://ClinicalTrials.gov/show/NCT01574092"
147,"NCT01301248","Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck","Unknown status","No Results Available","Head and Neck Neoplasms|AJCC Stage III/IV","Other: Chemoradiation plus Cetuximab|Other: Chemoradiation","Theagenio Cancer Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EEEK2008RCT2","February 22, 2011","March 2008","June 2011","May 16, 2011","April 2011","No Study Results Posted","null","April 2011","Determine safety and toxicity of combination|Overall survival time|Progression-free survival time|Response","https://ClinicalTrials.gov/show/NCT01301248"
148,"NCT01284413","Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","Completed","No Results Available","Biliary Tract Cancer","Drug: S-1, Gemcitabine, Cisplatin","Kansai Hepatobiliary Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KHBO1002|UMIN000004468","January 3, 2011","December 2010","August 2013","June 29, 2014","June 2014","No Study Results Posted","null","August 2012","one year survival rate|Toxicity and response rate","https://ClinicalTrials.gov/show/NCT01284413"
149,"NCT00012194","7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors","Terminated","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: 7-hydroxystaurosporine|Drug: cisplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03129|DMS 9934|DMS-9934|NCI-2331","March 3, 2001","March 2001","null","July 8, 2013","July 2013","No Study Results Posted","null","January 2007","MTD of cisplatin defined as the highest dose level in which six patients have been evaluated for toxicity with no more than one patient experiencing DLT attributable to the study drugs|Toxicity observed at each dose level, graded using the NCI CTCAE|Objective tumor response|Overall survival|Time to treatment failure|Duration of response","https://ClinicalTrials.gov/show/NCT00012194"
150,"NCT02275806","Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC","Recruiting","No Results Available","Lung Neoplasms, Non-Small Cell Lung Cancer","Drug: Irinotecan|Drug: Cisplatin","Leo W. Jenkins Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LJCC 2014-01","October 22, 2014","October 2014","October 2020","October 23, 2014","October 2014","No Study Results Posted","null","October 2019","Estimate the median and three year survival rate of locally advanced NSCLC using the platinum doublet cisplatin and irinotecan|Estimate the progression-free survival|Compare the survival of patients treated with cisplatin/irinotecan with historical controls using cisplatin/etoposide.|Measure toxicities and compliance of patients on this regimen","https://ClinicalTrials.gov/show/NCT02275806"
151,"NCT01021150","Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors","Completed","No Results Available","Neoplasms, Malignant","Drug: ombrabulin (AVE8062)|Drug: cisplatin","Sanofi","All","20 Years to 75 Years   (Adult, Senior)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD11088","November 24, 2009","March 2010","May 2011","June 10, 2011","June 2011","No Study Results Posted","null","May 2011","Dose limiting toxicity|Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities|Pharmacokinetic parameters of AVE8062|Pharmacokinetic parameters of cisplatin|Pharmacokinetic parameters of AVE8062's active metabolite RPR258063|Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)","https://ClinicalTrials.gov/show/NCT01021150"
152,"NCT00571298","Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Pleural Mesothelioma","Procedure: Extrapleural pneumonectomy (EPP)|Drug: Cisplatin|Drug: gemcitabine|Drug: amifostine|Drug: sodium thiosulfate|Procedure: Pleurectomy/Decortication","Brigham and Women's Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1","141","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","07-091","December 10, 2007","November 2007","June 2015","January 19, 2017","January 2017","No Study Results Posted","null","November 2011","To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma.|To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity.|To study the pharmacokinetics of gemcitabine and cisplatin combination administered in this way.","https://ClinicalTrials.gov/show/NCT00571298"
153,"NCT01790516","Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer","Terminated","Has Results","Head and Neck Squamous Cell Cancer","Drug: Cisplatin|Drug: cetuximab|Radiation: Radiation","Georgetown University","All","18 Years and older   (Adult, Senior)","","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-439","June 21, 2012","May 2012","June 2013","September 26, 2014","October 2013","June 3, 2014","null","March 2013","Feasibility of Returning Genetic Testing Results in a Timely Manner to the Treating Physician","https://ClinicalTrials.gov/show/NCT01790516"
154,"NCT01496534","Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors","Terminated","No Results Available","Solid Tumors|Bladder Cancer","Drug: Cisplatin|Drug: Carboplatin","Matthew Galsky|Novartis|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GCO 11-0946","December 12, 2011","January 2012","September 2013","November 26, 2013","November 2013","No Study Results Posted","null","September 2013","Recommended phase II dose of combination regimen|Antitumor activity","https://ClinicalTrials.gov/show/NCT01496534"
155,"NCT01540136","Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Carcinoma","Drug: Nedaplatin|Drug: Cisplatin","Sun Yat-sen University|Guangzhou Medical University|The First Affiliated Hospital of Guangdong Pharmaceutical University|Meizhou City Hospital Of Guangdong Provience","All","18 Years to 65 Years   (Adult)","Phase 3","402","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Sun Yat-sen University","February 22, 2012","February 2012","July 2016","October 27, 2016","March 2013","No Study Results Posted","null","May 2014","Progress-free survival|Determine the toxic effects, both quantitatively and qualitatively, and quality of life (QoL) of these regimens in these patients.|Complete Response (CR)|Overall Survival(OS)|Locoregional Relapse-Free Survival(LRRFS)|Distant Metastasis-Free Survival (DMFS)|Anti-neoplasms sensitization effects of chemotherapy to radiotherapy|Cost-effectiveness analysis|Correlate effects of CCRT with biomarkers of response and predictors of long-term outcome","https://ClinicalTrials.gov/show/NCT01540136"
156,"NCT00322920","Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer","Terminated","No Results Available","Cervix Cancer","Drug: Topotecan|Drug: Cisplatin","University of Alabama at Birmingham|GlaxoSmithKline","Female","19 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","104799","May 5, 2006","July 2005","null","February 13, 2008","February 2008","No Study Results Posted","null","null","MTD of topotecan when given weekly with cisplatin|Toxicity profile in patients treated with the combination of topotecan when given weekly with cisplatin|Response rate and time to progression","https://ClinicalTrials.gov/show/NCT00322920"
157,"NCT00463788","Cetuximab and Cisplatin in the Treatment of ""Triple Negative"" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer","Completed","Has Results","Breast Neoplasm","Drug: cetuximab, cisplatin|Drug: cisplatin","Merck KGaA","Female","18 Years and older   (Adult, Senior)","Phase 2","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 200027-051","April 19, 2007","June 2007","February 2011","January 20, 2014","January 2014","June 5, 2012","BALI-1","July 2009","Best Overall Response (BOR)|Progression-Free Survival (PFS) Time|Overall Survival (OS) Time|Time to Response (TTR)|Safety- Number of Participants Experiencing Any Adverse Event (AE)","https://ClinicalTrials.gov/show/NCT00463788"
158,"NCT02254681","Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma","Terminated","No Results Available","Intrahepatic Cholangiocarcinoma","Drug: Gemcitabine|Drug: Cisplatin|Radiation: Low dose whole liver and portal lymph node basin radiotherapy","Allina Health System|Abbott Northwestern Hospital","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VPSR-1401","September 30, 2014","September 2014","September 2016","October 12, 2016","October 2016","No Study Results Posted","null","September 2016","Number of participants with radiographic disease response after combination low-dose radiotherapy and gemcitabine-cisplatin.|Number of participants with adverse events.|Number of participants with post-operative complications after partial hepatectomy after antecedent combination low-dose radiotherapy and gemcitabine-cisplatin.|Number of participants with histologic disease response after combination low-dose radiotherapy and gemcitabine-cisplatin.|Number of participants with injury to the background liver after combination low-dose radiotherapy and gemcitabine-cisplatin.|Number of participants with intrahepatic recurrence after partial hepatectomy with antecedent combination low-dose radiotherapy and gemcitabine-cisplatin.|Number of participants with intrahepatic disease progression after treatment with combination low-dose radiotherapy and gemcitabine-cisplatin.","https://ClinicalTrials.gov/show/NCT02254681"
159,"NCT01743365","Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer|Gastroesophageal Junction Cancer","Drug: Cisplatin-5FU-Afatinib","Hellenic Cooperative Oncology Group|Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HE7/12|2011-006198-25","November 28, 2012","January 2013","December 2017","February 13, 2017","August 2016","No Study Results Posted","A-GAPP","June 2017","Objective Response Rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.|Evaluation of Overall Survival (OS)|Evaluation of Progression-Free Survival (PFS)|Assessment of safety and tolerability|Value of prognostic and/or predictive biomarkers measured in tissue and blood samples","https://ClinicalTrials.gov/show/NCT01743365"
160,"NCT00337532","A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Paclitaxel|Drug: cisplatin","Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA139-384","June 14, 2006","May 2005","June 2007","February 2, 2010","June 2008","No Study Results Posted","null","June 2007","Tumor response rate of locally advanced head and neck cancer to a paclitaxel-cisplatin combination regimen in a neoadjuvant setting and administered during maximum 3 cycles.|Toxicity for maximum 3 cycles","https://ClinicalTrials.gov/show/NCT00337532"
161,"NCT00249977","Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan","Completed","No Results Available","Solid Tumors|Cancer","Drug: Capecitabine in Combination with Cisplatin and Irinotecan","University of New Mexico","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0103C","November 2, 2005","April 2003","January 2009","January 6, 2010","October 2009","No Study Results Posted","null","August 2007","To determine the safety/feasibility of Capecitabine with the combination of Cisplatin and Irinotecan. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the combination of Cisplatin and Irinotecan.|To study the biologic effect of pyrimidine inhibition on DNA repair after camptothecin therapy.","https://ClinicalTrials.gov/show/NCT00249977"
162,"NCT01485731","Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: Nelfinavir|Drug: Cisplatin|Radiation: Pelvic External Beam Radiation Therapy|Radiation: Brachytherapy|Procedure: Pharmacokinetic Sampling|Procedure: Cervical Biopsy|Procedure: Pelvic Examination|Procedure: Pap Smear|Procedure: Audiogram|Procedure: Proctoscopy|Procedure: Cytoscopy|Procedure: Renal Ultrasound|Procedure: CT Scan|Procedure: Whole Body PET/CT Scan","University of Miami","Female","18 Years and older   (Adult, Senior)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20100153","November 29, 2011","January 2012","February 2015","June 1, 2015","June 2015","No Study Results Posted","null","February 2015","Number of Patients with Adverse Events in Phase 1 Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy|The proportion of enrolled patients for whom Nelfinavir dose can be successfully administered in combination with Cisplatin and Pelvic Radiation Therapy.|Serum Levels of Nelfinavir and other Biomarker Activity|Response to protocol therapy|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01485731"
163,"NCT00531687","Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer","Suspended","No Results Available","Testicular Cancer","Drug: Paclitaxel|Drug: Cisplatin|Drug: Gemcitabine","Rigshospitalet, Denmark","Male","18 Years to 70 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Relapse testis cancer 2007","September 18, 2007","September 2007","April 2016","April 5, 2016","April 2016","No Study Results Posted","null","February 2012","Primary objective · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP. · ·|Secondary Objectives · Overall survival|Secondary Objectives · Progression free survival|Secondary Objectives · Response rates (RECIST)|Secondary Objectives · Duration of response|Secondary Objectives · To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP","https://ClinicalTrials.gov/show/NCT00531687"
164,"NCT01009346","A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck","Terminated","Has Results","Head and Neck Cancer","Drug: RAD001|Drug: Cetuximab|Drug: Cisplatin|Drug: Carboplatin","Sidney Kimmel Comprehensive Cancer Center|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0916|NA_00023951/J0916","October 21, 2009","October 2009","March 2011","January 4, 2017","January 2017","March 23, 2014","null","March 2011","Maximum Tolerated Dose (MTD) of RAD001 in Combination With Cetuximab and Cisplatin.|Progression Free Survival (PFS) of RAD001 at MTD in Combination With Weekly Cetuximab and Cisplatin.|Response Rate of RAD001 at MTD in Combination With Weekly Cetuximab & Cisplatin.|Clinical Activity of This Regimen Correlates With Markers of the EGF-R/mTOR Pathway in Tumor Tissue & the Role of FDG PET in Early Imaging.","https://ClinicalTrials.gov/show/NCT01009346"
165,"NCT03012477","CISPLATIN + AZD-1775 In Breast Cancer","Recruiting","No Results Available","Triple-negative Metastatic Breast Cancer","Drug: Cisplatin|Drug: AZD1775","Dana-Farber Cancer Institute|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-264","December 19, 2016","January 18, 2017","December 2024","March 24, 2017","March 2017","No Study Results Posted","null","September 2020","Objective response rate|Progression Free Survival","https://ClinicalTrials.gov/show/NCT03012477"
166,"NCT00191620","Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.","Completed","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: Gemcitabine|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6952|B9E-LA-S350","September 12, 2005","March 2004","May 2006","January 24, 2007","January 2007","No Study Results Posted","null","null","To evaluate the objective response rate (ORR) of the standard (30 minute infusion) versus a fixed dose rate (10 mg/m2/minute) of gemcitabine combined with cisplatin as treatment for advanced NSCLC after treatment completion.|To evaluate progression-free survival of the standard versus a fixed dose rate of gemcitabine combined with cisplatin as treatment for advanced NSCLC.|To evaluate incidence of laboratory and non laboratory adverse events by maximum Common Toxicity Criteria (CTC) toxicity grade and relationship to study drug of the standard versus a fixed dose rate of gemcitabine combined with cisplatin as treatment for","https://ClinicalTrials.gov/show/NCT00191620"
167,"NCT01412294","XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: Capecitabine, Cisplatin","Epidemiological and Clinical Research Information Network","All","20 Weeks to 74 Years   (Child, Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ECRIN-GC1106-XParTS|UMIN000005857","July 30, 2011","July 2011","December 2016","February 2, 2016","February 2016","No Study Results Posted","null","December 2016","Progression-free survival|Overall survival|Response rate|Time to treatment failure|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01412294"
168,"NCT02677597","Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Cisplatin Combined With S-1|Drug: Cisplatin Combined With Paclitaxel","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CISPEC study","February 5, 2016","January 2016","January 2019","February 8, 2016","February 2016","No Study Results Posted","null","January 2019","PFS","https://ClinicalTrials.gov/show/NCT02677597"
169,"NCT02432365","Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy","Recruiting","No Results Available","Cervical Cancer","Drug: paclitaxel|Drug: cisplatin|Procedure: Radical hysterectomy and bilateral pelvic lymphadenectomy","Chang Gung Memorial Hospital|Asian Gynecologic Oncology Group|Taiwanese Gynecologic Oncology Group","Female","35 Years to 70 Years   (Adult, Senior)","Phase 2","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGOG14-001/TGOG1008|IRB103-4781A3","February 10, 2015","February 2015","December 2019","May 1, 2015","April 2015","No Study Results Posted","null","December 2019","overall survivial|Safety (If > 6 significant G3/4 AEs occur)|Response rate (Pathological response)|Postoperative RT/CRT rate|Quality-of-life|Progression-free survival","https://ClinicalTrials.gov/show/NCT02432365"
170,"NCT02777385","Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Pembrolizumab|Drug: Cisplatin|Radiation: IMRT","University of Pittsburgh|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15-132","April 28, 2016","June 2016","April 2019","August 29, 2016","August 2016","No Study Results Posted","null","April 2019","1-year progression-free survival|1-year failure rate|acute toxicity rate|PD-L1 expression in paired tumor biopsies","https://ClinicalTrials.gov/show/NCT02777385"
171,"NCT02127372","Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571","Terminated","Has Results","Non-small Cell Lung Cancer","Drug: Docetaxel, Cisplatin and STI571|Drug: Docetaxel|Drug: Cisplatin","Duke University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00008205","April 24, 2014","November 2004","December 2010","September 12, 2014","September 2014","September 5, 2014","null","June 2010","Phase 1 - Maximum Tolerated Dose (MTD) of STI571|Phase 1 - Maximum Tolerated Dose (MTD) of Docetaxel and Cisplatin|Phase II - Radiographic Response|Phase 2: 1 Year Survival|Change in Gd-MRI Measurement","https://ClinicalTrials.gov/show/NCT02127372"
172,"NCT02845050","Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)","Not yet recruiting","No Results Available","Bladder Cancer","Drug: Vinflunine|Drug: Cisplatin|Procedure: Radical cystectomy","Association of Urogenital Oncology (AUO)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JaNEO-001|2016-000081-33","July 12, 2016","July 2016","June 2020","July 28, 2016","July 2016","No Study Results Posted","JaNEO","September 2019","Pathological Complete Response (pCR)|Overall radiological response rate before cystectomy|Progression rate|Safety of chemotherapy measured by adverse events and clavien-dindo grades|Rate of complications at cystectomy|Perioperative morbidity/mortality|Cancer-specific survival|QoL - GIQLI|QoL - QLQ-C30","https://ClinicalTrials.gov/show/NCT02845050"
173,"NCT02498860","Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung","Recruiting","No Results Available","Adenocarcinoma|Lung Neoplasm","Drug: Pemebit|Drug: Cisplatin","Chonnam National University Hospital|Kosin University Gospel Hospital|Korea University Guro Hospital|Severance Hospital|Chungnam National University Hospital|Kyungpook National University|Pusan National University Hospital","All","20 Years and older   (Adult, Senior)","Phase 2","106","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CNUHH-2015-7","July 13, 2015","July 2015","December 2018","July 19, 2015","July 2015","No Study Results Posted","APICAL","July 2018","Disease free survival rate|Overall survival|Adverse events","https://ClinicalTrials.gov/show/NCT02498860"
174,"NCT01641575","A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin","Terminated","No Results Available","Solid Tumor|Non-small-cell Lung Cancer|Lung Cancer","Drug: CO-1.01 and Cisplatin","Clovis Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CO-101-011","July 9, 2012","July 2012","June 2013","March 8, 2014","March 2014","No Study Results Posted","null","May 2013","Dose limiting toxicities (DLT)(Part 1)|Adverse events (Description of event in medical terminology, Intensity, Relationship to drug, Outcome, and/or Follow up )(Part 2)|Clinical Laboratory Abnormalities (ANC, Platelets, Hemoglobin, AST/ALT, Bilirubin, Creatinine clearance)(Part 2)|ECG Abnormalities (Part 2)|PK parameters for CO-1.01 and its metabolites in plasma and urine (AUC, Cmax, Tmax, half life, kel, Vss, Cl, and MRT) (Part 1)|Adverse events (Description of event in medical terminology, Intensity, Relationship to drug, Outcome, and/or Follow up )( (Part 1)|Clinical Laboratory Abnormalities (ANC, Platelets, Hemoglobin, AST/ALT, Bilirubin, Creatinine clearance)(Part 1)|ECG abnormalities (Part 1)|Overall response rate (ORR)(Part 2)|Duration of response (Part 2)|Progression-free survival (PFS)(Part 2)|Tumor hENT1 expression (Part 2)","https://ClinicalTrials.gov/show/NCT01641575"
175,"NCT00262769","Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors","Completed","No Results Available","Extrahepatic Bile Duct Cancer|Gallbladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","University College, London|Eli Lilly and Company","All","16 Years and older   (Child, Adult, Senior)","Phase 3","324","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000455013|CRUK-ABC-02|EU-205103|ISRCTN82956140|EUDRACT-2004-004882-14|CTA-21266/0005/001","December 6, 2005","May 2005","null","July 16, 2012","July 2012","No Study Results Posted","ABC-02","August 2008","Overall Survival|Progression-free survival|Quality of life|Toxicity","https://ClinicalTrials.gov/show/NCT00262769"
176,"NCT00006105","Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer","Completed","No Results Available","Bladder Cancer|Drug/Agent Toxicity by Tissue/Organ","Drug: amifostine trihydrate|Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: adjuvant therapy","University of Chicago|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9193|UCCRC-9193|UCCRC-CTRC-9806|NCI-G00-1831","August 3, 2000","June 2000","September 2006","September 4, 2013","September 2013","No Study Results Posted","null","November 2004","Side effects of cisplatin/gemcitabine in combination with amifostine","https://ClinicalTrials.gov/show/NCT00006105"
177,"NCT01828034","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma","Active, not recruiting","No Results Available","Advanced Biliary Tract Carcinoma","Drug: Gemcitabine|Drug: Cisplatin|Drug: MEK162","Memorial Sloan Kettering Cancer Center|Array BioPharma","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13-004","April 5, 2013","April 2013","April 2018","May 17, 2017","May 2017","No Study Results Posted","null","April 2018","MTD of MEK162 - Phase I|six-month progression free survival - phase II|objective response rate - phase II|median PFS|median overall survival|safety/toxicity profile","https://ClinicalTrials.gov/show/NCT01828034"
178,"NCT00984035","Investigation of Cisplatin-Related Kidney Toxicity","Active, not recruiting","No Results Available","Cancer","Other: urine samples (biomarkers)|Other: blood samples (biomarkers)|Other: blood sample (DNA)","University of Chicago|American Society of Clinical Oncology|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Senior)","","341","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","09-135-B","September 22, 2009","September 2009","July 2017","August 3, 2016","August 2016","No Study Results Posted","null","July 2017","Change in urine biomarker (NGAL) after cisplatin|Change in blood and urine cystatin C|Change in blood NGAL while receiving cisplatin|Genetic markers of kidney toxicity","https://ClinicalTrials.gov/show/NCT00984035"
179,"NCT01242605","ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer","Completed","No Results Available","Biliary Tract Neoplasms|Cholangiocarcinoma|Gallbladder Neoplasms","Drug: selumetinib|Drug: gemcitabine|Drug: cisplatin","University College, London|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/10/0254|2010-018522-39","July 6, 2010","February 2012","May 2016","May 11, 2016","October 2015","No Study Results Posted","ABC-04","March 2013","To investigate the safety and tolerability of the combination of cisplatin, gemcitabine and selumetinib, and to establish the recommended phase II dose of selumetinib when given in this combination.|Response rate","https://ClinicalTrials.gov/show/NCT01242605"
180,"NCT00320359","Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer, Small Cell","Drug: Intravenous topotecan/cisplatin|Drug: Intravenous etoposide/cisplatin","GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","104864-A/479","May 1, 2006","August 2002","February 2007","February 27, 2017","February 2017","No Study Results Posted","null","February 2007","Median overall survival time of participants|Number of participants with one year survival rate of the participants|Median time of disease progression|Median time to event (progressive disease or death) of participants|Median time to response to chemotherapy|Median response duration|Number of participants with objective response|Mean lung cancer symptom score (LCSS)|Mean eastern cooperative oncology group (ECOG) score|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Mean change from Baseline in hemoglobin value|Mean change from Baseline in leukocytes, neutrophils and platelets count|Mean change from Baseline in red blood cells (RBCs)|Mean change from Baseline in Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase and Lactate dehydrogenase (LDH)|Mean change from Baseline in Blood urea nitrogen (BUN), Potassium, Sodium and urea|Mean change from Baseline in Creatinine and Total bilirubin|Mean change from Baseline in Creatinine clearance|Mean change from Baseline in total protein|Number of participants with abnormal urinalysis results|Mean change from Baseline in weight|Mean change from Baseline in Body surface area","https://ClinicalTrials.gov/show/NCT00320359"
181,"NCT01410214","Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations","Recruiting","No Results Available","Non-small Cell Lung Cancer Stage IIIA","Drug: Erlotinib|Drug: vinorelbine/cisplatin","Chinese Lung Cancer Surgical Group|Tianjin Medical University Cancer Institute and Hospital|Fudan University|Zhejiang Cancer Hospital|Beijing Cancer Hospital|Sun Yat-sen University|Chinese PLA General Hospital|Qingdao University|The First Affiliated Hospital of Soochow University|Harbin Medical University|Hebei Medical University Fourth Hospital|The Second People's Hospital of Sichuan","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C-LCSG-001","August 1, 2011","May 2011","July 2017","December 21, 2011","December 2011","No Study Results Posted","null","July 2015","Disease-free survival|Number of Participants with Adverse Events|Quality of Life (QOL)|overall survival (OS)","https://ClinicalTrials.gov/show/NCT01410214"
182,"NCT00845884","Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer","Unknown status","No Results Available","Advanced Gastric Cancer","Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab","Rabin Medical Center","Male","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVDCF-2008","February 16, 2009","February 2009","December 2012","February 16, 2009","February 2009","No Study Results Posted","null","December 2012","response rate|Safety, PFS, overall survival","https://ClinicalTrials.gov/show/NCT00845884"
183,"NCT01093092","Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery","Terminated","No Results Available","Adult Solid Neoplasm","Dietary Supplement: Calcitriol|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Pharmacological Study","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 163509|NCI-2010-00263|P30CA016056","March 24, 2010","September 2011","November 2015","January 11, 2016","January 2016","No Study Results Posted","null","June 2015","MTD of oral calcitriol when combined with a standard dose of gemcitabine hydrochloride and cisplatin, determined according to incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0|Toxicity of this combination, graded according to NCI CTCAE version 4.0|Pharmacokinetic (PK) analyses of calcitriol at the MTD in an expanded cohort of 6 patients, including peak levels, area under the concentration-time curve from time 0-72 hours, terminal half-life, volume of distribution, and total body clearance|Objective tumor response, described using Response Evaluation Criteria in Solid Tumors 1.1","https://ClinicalTrials.gov/show/NCT01093092"
184,"NCT01859728","GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer","Recruiting","No Results Available","Biliary Cancer","Drug: Irinotecan|Drug: Cisplatin|Drug: Cisplatin|Drug: Gemcitabine","Hospital de Cancer de Barretos - Fundacao Pio XII|Barretos Cancer Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GAMBIT201201","May 14, 2013","January 2013","December 2018","August 5, 2015","August 2015","No Study Results Posted","GAMBIT","December 2017","Overall Response Rate|Progression-Free Survival (PFS)|Overall Survival (OS)|Disease Control Rate|Safety","https://ClinicalTrials.gov/show/NCT01859728"
185,"NCT00982436","Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Neoplasms","Drug: Docetaxel/cisplatin|Radiation: Radiotherapy|Drug: Carboplatin","University of Vermont","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VCC 0905","September 22, 2009","September 2009","December 2012","March 21, 2012","March 2012","No Study Results Posted","null","September 2012","Response rate to neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer|Response rate to neoadjuvant chemotherapy with docetaxel/cisplatin in locally advanced squamous head and neck cancer|Response rate to chemoradiotherapy in locally advanced squamous head and neck cancer|Toxicity of neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer|Progression free survival after neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer|Overall survival after neoadjuvant chemotherapy with docetaxel/cisplatin, followed by chemoradiotherapy in locally advanced squamous head and neck cancer","https://ClinicalTrials.gov/show/NCT00982436"
186,"NCT01091454","Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer","Active, not recruiting","Has Results","Triple-negative Breast Cancer","Drug: brostallicin|Drug: cisplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N0937|NCCTG-N0937|CDR0000665441|NCI-2011-02016","March 18, 2010","June 2010","null","January 31, 2017","January 2017","December 7, 2016","null","June 2012","3-month Progression-free Survival (3-mo PFS) Rate|Confirmed Response Rate|Duration of Response|6-month Progression-free Survival (6-mo PFS) Rate|Time to Disease Progression|Survival Time","https://ClinicalTrials.gov/show/NCT01091454"
187,"NCT00529100","Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Pemetrexed Phase 1|Drug: Cisplatin Phase 1|Procedure: Radiation Therapy|Drug: Pemetrexed Phase 2|Drug: Cisplatin Phase 2","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10259|H3E-CA-JMHU","September 12, 2007","December 2005","September 2012","July 3, 2013","July 2013","August 23, 2011","null","August 2010","Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy|Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year|Phase 1: Number of Participants With Adverse Events (AE; Toxicity)|Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years|Phase 2: Time to Progressive Disease (PD)|Phase 2: Percentage of Participants With Progression Free Survival (PFS)|Progression Free Survival (PFS)|Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)|Phase 2: Site of Progressive Disease (PD)","https://ClinicalTrials.gov/show/NCT00529100"
188,"NCT00047047","Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: gemcitabine hydrochloride|Drug: tanespimycin|Drug: cisplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","78","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01429|MC0111|MAYO-MC0111|CDR0000257247|NCI-5291|U01CA069912","October 3, 2002","August 2002","null","June 3, 2013","June 2013","No Study Results Posted","null","September 2007","MTD of tanespimycin, gemcitabine hydrochloride, and cisplatin, determined by incidence of dose-limiting toxicity (DLT) graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Adverse events, graded according to NCI CTCAE version 3.0|Number of responses, determined according to modified Response Evaluation Criteria in Solid Tumors (RECIST)|Heat shock protein (HSP)70 and HSP90 client protein expression","https://ClinicalTrials.gov/show/NCT00047047"
189,"NCT02875457","Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin","Not yet recruiting","No Results Available","Small Cell Lung Cancer","Drug: apatinib;etoposide and cisplatin|Drug: placebo;etoposide and cisplatin","Third Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AEP-ES-SCLC","June 11, 2016","September 2016","September 2023","August 23, 2016","August 2016","No Study Results Posted","null","September 2018","Progression-free survival|Overall survival|Tumor response rate|Treatment-related adverse events|Performance Status","https://ClinicalTrials.gov/show/NCT02875457"
190,"NCT00878449","A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer","Completed","No Results Available","Solid Tumors","Drug: ABT-263|Drug: etoposide/cisplatin","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-234","April 7, 2009","October 2009","July 2011","January 24, 2013","January 2013","No Study Results Posted","null","July 2011","Assess the safety profile of ABT-263 when administered in combination with etoposide/cisplatin in subjects with Cancer.|Characterize the pharmacokinetics of ABT-263 when administered in combination with etoposide/cisplatin .|Determine the maximum tolerable dose (MTD) of ABT-263 when administered in combination with etoposide/cisplatin.|Determine the recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with etoposide/cisplatin.|Evaluate preliminary data regarding progression free survival (PFS).|Evaluate preliminary data regarding objective response rate (ORR).|Evaluate preliminary data regarding time to tumor progression (TTP).|Evaluate preliminary data regarding overall survival (OS).|Evaluate preliminary data regarding duration of overall response.|Evaluate preliminary data regarding Eastern Cooperative Oncology Group (ECOG) performance status.|Evaluate biomarkers","https://ClinicalTrials.gov/show/NCT00878449"
191,"NCT00702299","Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer","Completed","Has Results","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: cisplatin|Drug: paclitaxel|Drug: pemetrexed disodium|Other: biologic sample preservation procedure","University of Arizona|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-0638-04|P30CA023074|UARIZ-07-0638-04|UARIZ-SRC-18183|LILLY-UARIZ-07-0638-04|UARIZ-BIO07074","June 19, 2008","September 2007","October 2012","December 2, 2015","December 2015","October 1, 2012","null","January 2012","Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)|Patients That Completed at Least 6 Courses of Therapy of Pemetrexed Along With Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)at the Determined Maximum Tolerated Dose|Patients Experienced Grade >=3 Toxicity at Dose Level 5 (1,000 mg/m2 IP Pemetrexed)|Progression-free Survival at 18 Months as Assessed by Cancer Antigen 125|Overall Survival|Pharmacokinetics (Mean Cmax, ug/mL)for Different Dosages of Pemetrexed","https://ClinicalTrials.gov/show/NCT00702299"
192,"NCT00770874","Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: S-1 + Cisplatin (arm A)|Drug: Cisplatin (arm B)","Taiho Pharmaceutical Co., Ltd.","Female","20 Years and older   (Adult, Senior)","Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","10020380","October 9, 2008","September 2008","April 2016","February 3, 2017","February 2017","No Study Results Posted","null","December 2015","Overall survival|Progression free survival, Overall response rate, safety","https://ClinicalTrials.gov/show/NCT00770874"
193,"NCT00160875","Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: Irinotecan hydrochloride trihydrate|Drug: Cisplatin","University Health Network, Toronto|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","02-0484-C","September 8, 2005","April 2009","March 2011","May 3, 2017","May 2017","No Study Results Posted","null","March 2011","pathological complete response|acute and late toxicities|postoperative mortality|disease free survival|overall survival|Quality of life (FACT-E)|clinical complete response rate|tumor microvessel density (pathological)|perfusion CT parameters (radiological)|PET scan parameters (radiological)","https://ClinicalTrials.gov/show/NCT00160875"
194,"NCT00072033","Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: Cisplatin and Docetaxel","Swiss Group for Clinical Cancer Research","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","66","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 75/02|EU-20323","November 4, 2003","March 2003","May 2010","June 2, 2012","June 2012","No Study Results Posted","null","March 2003","Feasibility of successful study therapy completion and survival after surgery|Adverse events|Overall survival|Feasibility in Switzerland after surgery","https://ClinicalTrials.gov/show/NCT00072033"
195,"NCT01910870","Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes","Terminated","No Results Available","Metastatic Breast Cancer","Drug: Cisplatin|Drug: Metronomic Cyclophosphamide","Centre Jean Perrin","Female","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","META1 - CJP4.1","May 28, 2013","July 2013","September 2016","October 10, 2016","July 2016","No Study Results Posted","null","September 2016","Response rate of cisplatin - metronomic cyclophosphamide treatment|Disease free progression|safety profile of cisplatin - metronomic cyclophosphamide association|Overall survival|Predictive factors to response and/or resistance treatment","https://ClinicalTrials.gov/show/NCT01910870"
196,"NCT02787473","A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer","Recruiting","No Results Available","Squamous Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin|Radiation: thoracic radiation therapy|Drug: docetaxel","First People's Hospital of Hangzhou","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HZCH-2016-10","April 22, 2016","October 2016","September 2020","November 23, 2016","November 2016","No Study Results Posted","null","October 2019","Overall Response Rate|Overall Survival|Local control rate|The short-term quality of life (QOL) assessed using FACT-E score|Rate of CTCAE grade 2 or higher radiation pneumonitis","https://ClinicalTrials.gov/show/NCT02787473"
197,"NCT00960349","Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients","Completed","No Results Available","Gastric Cancer","Drug: Cediranib|Drug: Cisplatin|Drug: S-1|Drug: Cisplatin|Drug: Capecitabine","AstraZeneca","All","20 Years and older   (Adult, Senior)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D8480C00066","August 11, 2009","August 2009","March 2011","June 13, 2011","June 2011","No Study Results Posted","null","January 2010","Safety of each treatment arm will be measured in terms of adverse events, vital signs, clinical chemistry, haematology, urinalysis, electrocardiogram, and physical examinations.|Pharmacokinetics will be assessed in terms of Css,max, Css,min, tmax, AUCss and AUC0-8 for cediranib, and Cmax, tmax, AUC, AUC(0-t), CL or CL/F, t½λz for capecitabine, cisplatin and TS-1. Additional PK parameters may be determined.","https://ClinicalTrials.gov/show/NCT00960349"
198,"NCT00691301","Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: pemetrexed disodium","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-0076GG|CDR0000597154|NCI-2009-00572","June 4, 2008","September 2008","null","May 27, 2015","May 2015","No Study Results Posted","null","July 2014","Frequency and duration of objective response|Frequency and severity of observed adverse effects|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00691301"
199,"NCT00716391","TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.","Unknown status","No Results Available","Head and Neck Cancer","Other: TPF, radiotherapy and cisplatin.|Other: TPF, radiotherapy and cetuximab.","Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","458","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TTCC-2007-01","July 14, 2008","July 2008","December 2013","February 12, 2011","February 2011","No Study Results Posted","null","July 2013","Global survival","https://ClinicalTrials.gov/show/NCT00716391"
200,"NCT00262821","Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Drug: cisplatin|Drug: tirapazamine","National Cancer Institute (NCI)|NCIC Clinical Trials Group","Female","18 Years and older   (Adult, Senior)","Phase 3","402","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00591|CAN-NCIC-GOG-0219|CDR0000455555|GOG-0219|U10CA027469","December 6, 2005","February 2006","null","June 18, 2014","June 2014","No Study Results Posted","null","August 2010","Progression-free survival|Frequency and severity of adverse events assessed by Common Terminology Criteria for Adverse Events version 3.0|Overall survival","https://ClinicalTrials.gov/show/NCT00262821"
201,"NCT00588237","Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","Completed","Has Results","Ovarian Cancer|Primary PERITONEUM|Fallopian Tube Cancer","Drug: Paclitaxel,Cisplatin, Bevacizumab","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-064","December 22, 2007","August 2006","November 2014","December 15, 2015","December 2015","December 15, 2015","null","November 2014","Overall Objective Response","https://ClinicalTrials.gov/show/NCT00588237"
202,"NCT01126008","Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: CCRT with weekly docetaxel & cisplatin","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-10-007","May 17, 2010","December 2009","December 2016","April 19, 2016","April 2016","No Study Results Posted","null","August 2013","Complete response rate|quality of life|overall survival rate|disease free survival rate","https://ClinicalTrials.gov/show/NCT01126008"
203,"NCT00077545","3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction","Completed","No Results Available","Adenocarcinoma of the Esophagus|Recurrent Esophageal Cancer|Stage IV Esophageal Cancer","Drug: triapine|Drug: cisplatin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","39","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02576|CDR0000352307|UCCRC-12765A|NCI-6285|12765A|6285|N01CM62201","February 10, 2004","January 2004","null","October 7, 2013","October 2013","No Study Results Posted","null","March 2007","Complete response rate|Objective response rate (CR + PR)|Overall survival|Progression-free survival|Duration of response|Number of patients with various treatment-related toxicities assessed using NCI CTCAE version 3.0|Number of patients with improvement of dysphagia|Duration of improvement of dysphagia","https://ClinicalTrials.gov/show/NCT00077545"
204,"NCT02632305","A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer","Recruiting","No Results Available","Unresectable Biliary Tract Cancer","Drug: nab-paclitaxel in combination with gemcitabine + cisplatin","AHS Cancer Control Alberta|Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AX-CSARC-PI-0001","December 14, 2015","July 2016","January 2019","February 1, 2017","February 2017","No Study Results Posted","null","January 2019","Overall response rates","https://ClinicalTrials.gov/show/NCT02632305"
205,"NCT00084812","Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: safingol","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","43","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-002|MSKCC-04002","June 10, 2004","March 2004","February 2009","March 21, 2013","March 2013","No Study Results Posted","null","February 2009","Recommended phase II dose as assessed by NCI toxicity scale during 3-4 weeks of treatment|Response as assessed by RECIST criteria during 3-6 weeks of treatment","https://ClinicalTrials.gov/show/NCT00084812"
206,"NCT01747707","Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer","Unknown status","No Results Available","Gastric Cancer|Gastroesophageal Junction Cancer","Drug: Docetaxel|Drug: Cisplatin|Drug: S-1","Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-31","December 10, 2012","September 2012","May 2014","December 10, 2012","December 2012","No Study Results Posted","null","September 2013","overall survival time (OS)|Progression free survival (PFS)|safety profile","https://ClinicalTrials.gov/show/NCT01747707"
207,"NCT00847015","Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer","Completed","Has Results","Bladder Cancer|Urinary Bladder","Drug: Sunitinib|Drug: Gemcitabine|Drug: cisplatin","Memorial Sloan Kettering Cancer Center|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-159","February 18, 2009","February 2009","November 2012","February 1, 2016","February 2016","October 19, 2015","null","November 2012","The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer.|The Pathologic Response Rate (<pT2) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer.|The Time to Disease Progression in Patients With Muscle Invasive Urothelial Carcinoma of the Bladder Treated With Neoadjuvant GCS Followed by Radical Cystectomy.","https://ClinicalTrials.gov/show/NCT00847015"
208,"NCT00346801","CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Lung Cancer","Drug: Celecoxib|Drug: Cisplatin|Drug: CPT-11|Radiation: Concurrent Thoracic Radiation Therapy","M.D. Anderson Cancer Center|National Comprehensive Cancer Network","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0352","June 28, 2006","September 2003","null","October 19, 2012","October 2012","No Study Results Posted","null","October 2012","Maximum Tolerated Dose (MTD) of Celebrex (celecoxib)","https://ClinicalTrials.gov/show/NCT00346801"
209,"NCT02607540","Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer","Recruiting","No Results Available","Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma","Other: 2 cycles cisplatin-5-fluorouracil|Other: 4 cycles cisplatin-5-fluorouracil|Radiation: Radiotherapy","The First Affiliated Hospital of Henan University of Science and Technology","All","45 Years to 75 Years   (Adult, Senior)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PF and esophageal cancer","November 16, 2015","October 2014","December 2020","January 10, 2016","January 2016","No Study Results Posted","PFCRTESC","December 2017","overall survival, OS|progression-free survival,PFS|overall remission rate, ORR|serious adverse event,SAE|quality of life, Qol|pathologic complete response rate|disease control rate,DCR","https://ClinicalTrials.gov/show/NCT02607540"
210,"NCT02585973","Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: AZD1775|Drug: Cisplatin|Radiation: Intensity Modulated Radiotherapy Treatments","UNC Lineberger Comprehensive Cancer Center|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 1430","October 22, 2015","February 2016","November 2021","July 1, 2016","July 2016","No Study Results Posted","null","November 2020","Maximum tolerated dose|Toxicity profile (Number of patients with adverse events)|Objective Response Rate","https://ClinicalTrials.gov/show/NCT02585973"
211,"NCT00118131","Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","Terminated","Has Results","Lung Cancer","Drug: cisplatin|Drug: docetaxel","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Aventis Pharmaceuticals|Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Senior)","Phase 2","49","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000433488|P30CA072720|CINJ-030302|CINJ-NJ1503","July 8, 2005","December 2003","February 2010","September 19, 2013","September 2013","September 19, 2013","null","February 2010","Overall Tumor Response Rate|Time to Progressive Disease|1-year Survival Rate|Median Survival Time","https://ClinicalTrials.gov/show/NCT00118131"
212,"NCT00826644","Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient","Unknown status","No Results Available","Carcinoma, Small Cell","Drug: Belotecan/Cisplatin|Drug: Etoposide/Cisplatin","Chonnam National University Hospital|Chong Kun Dang Pharmaceutical","All","19 Years to 80 Years   (Adult, Senior)","Phase 3","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSCLC-0810","January 21, 2009","January 2009","December 2012","January 9, 2012","January 2012","No Study Results Posted","COMBAT","June 2012","To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer|to assess the overall response duration|To assess the time to progression|to assess the overall survival","https://ClinicalTrials.gov/show/NCT00826644"
213,"NCT01126749","Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer","Unknown status","No Results Available","Bladder Cancer","Drug: gemcitabine plus cisplatin|Drug: E7389 in combination with gemcitabine plus cisplatin","Eisai Inc.|PharmaBio Development Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E7389-702|2009-015915-42","May 17, 2010","April 2010","September 2014","June 20, 2014","June 2014","No Study Results Posted","null","September 2014","Safety parameters|Efficacy Measures","https://ClinicalTrials.gov/show/NCT01126749"
214,"NCT02341911","Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)","Recruiting","No Results Available","Breast Cancer","Drug: Gemcitabine,cisplatin|Drug: Gemcitabine,carboplatin","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Fudan BR2015-16","January 13, 2015","January 2015","December 2018","January 3, 2017","January 2017","No Study Results Posted","TNBC","December 2017","PFS (Progression Free Survival)|Objective Response Rate (ORR)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02341911"
215,"NCT02381535","Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin","Active, not recruiting","No Results Available","Human Papillomavirus Infection|Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Onalespib|Other: Pharmacological Study","National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","36","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-00256|PJC-017|9874|UM1CA186644|UM1CA186709","March 5, 2015","September 21, 2015","null","May 23, 2017","May 2017","No Study Results Posted","null","May 31, 2017","Maximum tolerated dose determined by dose-limiting toxicity (DLT) of Hsp90 inhibitor AT13387 in combination with concurrent cisplatin and radiation therapy graded according to NCI CTCAE version 4.0|Pharmacokinetic (PK) profile of Hsp90 inhibitor AT13387 in combination with cisplatin and radiation therapy|PK profile of cisplatin in combination with concurrent AT13387 and radiotherapy|Antitumor activity|Incidence of non-DLT adverse events (AEs)|Predictive biomarkers for individual cancer patients utilizing biopsies and genomic sequencing technologies","https://ClinicalTrials.gov/show/NCT02381535"
216,"NCT00301808","Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: Cisplatin|Drug: Docetaxel|Drug: Pemetrexed disodium|Radiation: Radiation therapy","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000461591|P30CA022453|WSU-D-2934|WSU-0507002542","March 9, 2006","November 2005","October 2012","July 15, 2014","July 2014","April 12, 2014","null","September 2012","Probability of Overall Survival at One Year|Progression-free Survival|Overall Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00301808"
217,"NCT01356303","Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer","Suspended","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: cisplatin, docetaxel","National Guard Health Affairs","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RC08/068","March 19, 2011","March 2009","August 2016","May 12, 2016","May 2016","No Study Results Posted","TAXIS01","August 2016","Efficacy|Progression free survival, safety","https://ClinicalTrials.gov/show/NCT01356303"
218,"NCT01810367","ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: ABX Combined With Cisplatin|Drug: Gemcitabine Combined With Cisplatin","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABX-CJH","March 11, 2013","December 2011","December 2015","February 22, 2016","February 2016","No Study Results Posted","null","December 2015","PFS","https://ClinicalTrials.gov/show/NCT01810367"
219,"NCT00969761","BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour","Completed","No Results Available","Neoplasms","Drug: BI-6727|Drug: BI 6727","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 1","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1230.6|2008-003926-40","August 31, 2009","August 2009","null","July 25, 2012","July 2012","No Study Results Posted","null","February 2012","Determination of the Maximum Tolerated Dose (MTD) of the BI 6727 combination treatment with cisplatin or carboplatin.|Incidence and intensity of drug-related adverse events according to common terminology criteria for adverse events (CTCAE) v.3.0, incidence of DLT, laboratory evaluations, patient performance and vital signs.|Pharmacokinetic parameters of BI 6727 in combination with cisplatin or carboplatin.|Objective response rate and progression-free survival after BI 6727 treatment based on RECIST criteria.","https://ClinicalTrials.gov/show/NCT00969761"
220,"NCT00030576","Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: erlotinib hydrochloride","University Health Network, Toronto|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","51","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000069178 (PHL-002)|PMH-PHL-002|NCI-5380|CAN-NCIC-IND157","February 14, 2002","November 2001","December 2009","April 13, 2016","April 2016","No Study Results Posted","null","December 2009","","https://ClinicalTrials.gov/show/NCT00030576"
221,"NCT02323737","Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer","Completed","No Results Available","Extensive-stage Small Cell Lung Cancer","Drug: Irinotecan and cisplatin|Drug: Etoposide and cisplatin","Chinese Academy of Medical Sciences|China-Japan Friendship Hospital|Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-L-022","December 18, 2014","July 2010","June 2012","December 29, 2014","December 2014","No Study Results Posted","null","June 2011","progression-free survival","https://ClinicalTrials.gov/show/NCT02323737"
222,"NCT00717951","A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer","Unknown status","No Results Available","Advanced Breast Cancer","Drug: docetaxol, cisplatin, capecitabine","Academy Military Medical Science, China|Chinese Academy of Medical Sciences","Female","18 Years and older   (Adult, Senior)","Phase 2","120","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX625|CBCSG003","July 14, 2008","May 2008","May 2010","July 24, 2008","May 2008","No Study Results Posted","null","December 2009","ORR,TTP,TTF and 2 year PFS|safety and QOL","https://ClinicalTrials.gov/show/NCT00717951"
223,"NCT01282333","Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer","Terminated","No Results Available","Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer|Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Stage III Pancreatic Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Bladder Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Transitional Cell Carcinoma of the Bladder|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer","Drug: gemcitabine hydrochloride|Drug: veliparib|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study|Drug: cisplatin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","44","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02576|UPCI 10-037|CDR0000693751|PCI-10-037|U01CA099168","January 22, 2011","January 2011","null","July 1, 2013","July 2013","No Study Results Posted","null","February 2013","Maximum-tolerated dose of veliparib in combination with cisplatin and gemcitabine|Dose-limiting and other toxicities according to CTCAE v4.0|Recommended phase II dose","https://ClinicalTrials.gov/show/NCT01282333"
224,"NCT00104910","Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Radiation: Internal Radiation Therapy|Radiation: 3-Dimensional Conformal Radiation Therapy|Biological: Cetuximab|Drug: Cisplatin","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","64","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9918|NCI-2009-00621|CDR0000413880|U10CA027469","March 3, 2005","January 2005","null","December 29, 2014","December 2014","No Study Results Posted","null","January 2013","Maximum tolerated dose (MTD) or biologically effective dose (BED) of Cetuximab in combination with cisplatin and extended field radiation or whole pelvis radiation, graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)|Incidence of toxicities at the MTD, assessed by CTCAE v3.0|Progression-free survival|Site of recurrence, loco-regional vs distant, assessed by clinical and radiological evaluation|Frequency of chronic toxicities, assessed by CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00104910"
225,"NCT02639091","Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors","Recruiting","No Results Available","Medical Oncology","Drug: BAY 94-9343|Drug: Pemetrexed|Drug: Cisplatin","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","17631","November 30, 2015","February 3, 2016","July 6, 2018","May 15, 2017","May 2017","No Study Results Posted","null","March 26, 2018","Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability|Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin|Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD|Number of patients with a positive titer of anti-drug antibodies","https://ClinicalTrials.gov/show/NCT02639091"
226,"NCT01846390","Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma","Active, not recruiting","No Results Available","Peripheral T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma","Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Romidepsin","Canadian Cancer Trials Group|Celgene","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LY15","May 1, 2013","April 30, 2013","May 2017","March 22, 2017","March 2017","No Study Results Posted","null","July 6, 2016","Maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.|Efficacy of romidepsin when combined with gemcitabine, dexamethasone and cisplatin|Number of patients with adverse events","https://ClinicalTrials.gov/show/NCT01846390"
227,"NCT00754858","Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: belotecan hydrochloride|Drug: cisplatin","Yonsei University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000614308|YONSEI-4-2008-0127|CKDPC-YONSEI-4-2008-0127|YONSEI-07-YUHS-02","September 17, 2008","October 2008","June 2012","November 26, 2014","November 2014","No Study Results Posted","null","May 2010","Response rate as assessed by RECIST criteria|Overall survival|Progression-free survival|Hematologic and non-hematologic toxicity as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00754858"
228,"NCT01900158","A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas","Recruiting","No Results Available","Cholangiocarcinoma","Drug: Amphinex and Gemcitabine|Drug: Gemcitabine and Cisplatin","PCI Biotech AS","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PCI A202/12|2012-002888-10","May 15, 2013","May 2013","null","October 12, 2016","October 2016","No Study Results Posted","null","August 2019","Determine a safe and tolerable dose (Phase I)|Preliminary assessment of efficacy (Phase II)|Best Overall Response (BOR)|Pharmacokinetics (PK)|Disease Control Rate (DCR)|Overall Response Rate (ORR)|Overall Survival (OS)|Safety Profile (Phase II)|Progression Free Survival (PFS) (Phase I)","https://ClinicalTrials.gov/show/NCT01900158"
229,"NCT02113878","Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck|HPV Positive Oropharyngeal Squamous Cell Carcinoma|Hypopharyngeal Cancer|Early Invasive Cervical Squamous Cell Carcinoma|Carcinoma of Larynx|Cancer of Nasopharynx","Drug: BKM120|Drug: Cisplatin|Radiation: Intensity-modulated radiotherapy (IMRT)","Dana-Farber Cancer Institute|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14-008","April 1, 2014","October 2014","March 2020","May 19, 2017","May 2017","No Study Results Posted","null","July 2018","Determine Maximum Tolerated Dose (MTD) of BKM120/cisplatin combination with radiation therapy|Overall Response Rate|Time to Progression|Survival|Mood alteration from BKM120|Activity of BKM120 as single agent in sequential biopsies","https://ClinicalTrials.gov/show/NCT02113878"
230,"NCT02882308","Preoperative Administration of Olaparib With or Without Cisplatin in Patients Who Are Candidates for Surgery of Carcinoma of Head and Neck","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Olaparib|Drug: Cisplatin|Drug: Olaparib","Hellenic Cooperative Oncology Group|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","HE5A/15|2015-005268-41","July 20, 2016","October 2016","June 2018","February 7, 2017","February 2017","No Study Results Posted","OPHELIA","December 2017","Investigation of the change between initial and post-treatment Ki67 measured on Formalin- Fixed Parafin-Embedded collected tumour biopsy or surgical sample, before and after treatment with the combination of olaparib + cisplatin or olaparib monotherapy.|Objective response rate according to RECIST 1.1 criteria|Pathologic complete response rate|Metabolic response rate assessed by FDG-PET/CT scan (optional)|Number of participants with tolerability to the treatment.|Surgical complication rate|Mutations in genes associated with DNA repair|Expression of tissue biomarker: PARP1|Expression of tissue biomarker: BRACA1,2|Expression of tissue biomarker: ERCC1|Plasma methylation biomarker: PARP1 methylation in plasma cell-free DNA|Plasma methylation biomarker: BRCA1,2 methylation in plasma cell-free DNA|Plasma methylation biomarker: ERCC1 methylation in plasma cell-free DNA|Plasma methylation biomarker: RAD51C methylation in plasma cell-free DNA|Single-nucleotide polymorphisms: PARP-1 Val762Ala|Single-nucleotide polymorphisms: ERCC1 Asn118Asn (C/T)|Single-nucleotide polymorphisms:ERCC2 Lys751Gln (T/G)|Single-nucleotide polymorphisms: GSTP1 Ile105Val (A/G)|Single-nucleotide polymorphisms: XPD Lys751Gln (A/C, C/C)|Single-nucleotide polymorphisms: XRCC1 Arg399Gln (G/A)|Circulating tumor cells (CTCs) evaluated for DNA repair biomarkers|Circulating tumor cells (CTCs) evaluated for PD-L1","https://ClinicalTrials.gov/show/NCT02882308"
231,"NCT01088906","Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC","Terminated","No Results Available","Carcinoma, Non Small Cell Lung","Drug: Pemetrexed/Cisplatin","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 2","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GECP09-01Phalcis|2009-011327-31","March 15, 2010","January 2010","April 2014","July 3, 2015","July 2015","No Study Results Posted","Phalcis","April 2014","Objective response rate|Overall survival","https://ClinicalTrials.gov/show/NCT01088906"
232,"NCT00165191","Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus","Completed","No Results Available","Adenocarcinoma of Stomach|Adenocarcinoma of GE Junction|Adenocarcinoma of Esophagus","Drug: Doxorubicin|Drug: Cisplatin|Drug: 5-fluorouracil","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","98-048","September 9, 2005","August 1998","January 2006","April 27, 2009","April 2009","No Study Results Posted","null","January 2006","To determine the activity of doxorubicin, cisplatin and continuous infusion of 5-fluorouracil in patients with measurable, locally unresectable or metastatic adenocarcinoma of the stomach, GE junction, or esophagus.|Assess the safety of doxorubicin, cisplatin and 5-fluorouracil when given in combination to treat this patient population|evaluate the survival of this patient population.","https://ClinicalTrials.gov/show/NCT00165191"
233,"NCT01614938","Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: Cetuximab|Drug: Cisplatin|Drug: Docetaxel|Radiation: Intensity-modulated radiotherapy|Drug: Cisplatin","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HN201002","June 5, 2012","August 2010","August 2014","June 6, 2012","June 2012","No Study Results Posted","null","August 2014","Progression-free survival|Overall survival|Locoregional recurrence-free survival|Distant metastasis-free survival|Number of participants with hematologic toxicity events occurred during two cycles of neoadjuvant chemotherapy according to CTCAE v4.0|Number of participants with acute toxicities (hematologic toxicity events, oral mucositis, acne-like rash) occurred during the concurrent treatment according to CTCAE v4.0|Number of participants with late toxicities (hematologic toxicity events, dysphagia, acne-like rash) occurred from 3 months after completion of radiotherapy to last follow-up visit according to CTCAE v4.0|Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) during the concurrent treatment|Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) at 3 months after completion of radiotherapy","https://ClinicalTrials.gov/show/NCT01614938"
234,"NCT00707473","Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses","Recruiting","No Results Available","Paranasal Sinus Neoplasms|Squamous Cell Carcinoma","Drug: Docetaxel|Drug: 5-Fluorouracil|Drug: Cisplatin","M.D. Anderson Cancer Center","All","17 Years and older   (Child, Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0433|NCI-2010-01438","June 26, 2008","June 2008","null","August 22, 2016","August 2016","No Study Results Posted","null","June 2018","Number of Patients with Complete + Partial Response","https://ClinicalTrials.gov/show/NCT00707473"
235,"NCT01874171","Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC","Active, not recruiting","No Results Available","Oropharyngeal Squamous Cell Carcinoma","Drug: Cisplatin|Drug: Cetuximab","University of Warwick|Cancer Research UK|University of Birmingham|University of Oxford","All","18 Years and older   (Adult, Senior)","Phase 3","334","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RMRCT0034|2011-005165-21|ISRCTN33522080","June 6, 2013","November 15, 2012","February 2019","May 4, 2017","May 2017","No Study Results Posted","De-ESCALaTE","February 2019","Compare severe (acute and late) toxicity (Grade 3-5) caused by cetuximab and radiotherapy to that caused by cisplatin and radiotherapy.|Overall number of events of acute severe toxicity between treatment arms.|Overall number of events of late severe toxicity between treatment arms.|Quality of life outcomes assessed by EORTC QLQ C30 and HN35 between the two treatment arms.|Effect on swallowing of the two treatment arms (assessed by MDADI and by PEG or RIG utilisation rate at 1 and 2 years).|Cost-effectiveness of the two treatment arms (assessed by EuroQoL-5D).|Overall survival and recurrence between the two arms.","https://ClinicalTrials.gov/show/NCT01874171"
236,"NCT00886028","Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma","Unknown status","No Results Available","Malignant Pleural Mesothelioma","Drug: Liposomal doxorubicin|Drug: Cisplatin","National Institute of Cancerología","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CB/304/06|007/024/OMI","April 20, 2009","September 2006","June 2009","April 21, 2009","April 2009","No Study Results Posted","null","April 2009","Progression free survival|Over-all survival","https://ClinicalTrials.gov/show/NCT00886028"
237,"NCT00165503","Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate","Terminated","Has Results","Pleural Mesothelioma|Malignant Pleural Mesothelioma","Drug: Cisplatin|Drug: Sodium Thiosulfate|Drug: ALIMTA","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","04-063","September 12, 2005","April 2004","July 2010","July 25, 2016","July 2016","April 23, 2014","null","July 2010","Adjuvant Chemotherapy Completion Rate","https://ClinicalTrials.gov/show/NCT00165503"
238,"NCT02492360","Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy","Recruiting","No Results Available","Peripheral Nervous System Diseases|Testicular Neoplasms","Procedure: Blood sample collection|Behavioral: Report of peripheral neuropathy after cisplatin therapy","Costantine Albany|Indiana University","Male","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IUSCC-0516","May 13, 2015","June 2015","June 2018","August 25, 2016","August 2016","No Study Results Posted","null","June 2017","Biobank of peripheral blood mononuclear cells (PBMCs)","https://ClinicalTrials.gov/show/NCT02492360"
239,"NCT00123825","Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer","Completed","No Results Available","Gallbladder Cancer|Biliary Tract Cancer","Drug: Gemcitabine|Drug: Cisplatin","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-065","July 25, 2005","July 2002","October 2007","December 20, 2007","December 2007","No Study Results Posted","null","October 2007","To determine the response rate of the combination gemcitabine and cisplatin in patients with advanced biliary tract and gallbladder cancers|To determine the overall survival rate, progression-free survival rate, time to progression and duration of response|To determine the toxicity of gemcitabine and cisplatin|To assess the biomarker CA 19-9 response to the regimen and to correlate the CA 19-9 response with radiologic response and survival","https://ClinicalTrials.gov/show/NCT00123825"
240,"NCT02301208","Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: Nedaplatin|Drug: Cisplatin","He Xia|Jiangsu Cancer Institute & Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JiangsuCIH","November 19, 2014","December 2014","null","December 5, 2014","December 2014","No Study Results Posted","NPC-RCT-WCRT","December 2016","Response rate|Progress-free survival|Tumor response|Overall survival","https://ClinicalTrials.gov/show/NCT02301208"
241,"NCT00496275","Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Zactima (ZD6474)|Drug: Vinorelbine plus cisplatin|Drug: Gemcitabine plus cisplatin","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D4200C00054","July 3, 2007","August 2006","May 2007","August 25, 2016","August 2016","No Study Results Posted","null","null","Establish safety and tolerability of ZACTIMA in combination with vinorelbine plus cisplatin or gemcitabine plus cisplatin|Pharmacokinetics of ZACTIMA, vinorelbine or gemcitabine, plus cisplatin when co-administered|Preliminary assessment of efficacy of ZACTIMA when co-administered with vinorelbine plus cisplatin or gemcitabine plus cisplatin","https://ClinicalTrials.gov/show/NCT00496275"
242,"NCT00165464","Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer|GE Junction Cancer","Drug: Taxotere|Drug: Cisplatin|Drug: Irinotecan","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Aventis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","54","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-140","September 9, 2005","August 2001","April 2009","April 24, 2009","April 2009","No Study Results Posted","null","March 2005","To assess the response rate of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan (CPT-11).|To assess the duration of response and overall survival of patients with esophageal or gastric carcinoma to weekly Taxotere, Cisplatin, and Irinotecan.|To assess the toxicity of this combination in esophageal or gastric carcinoma.","https://ClinicalTrials.gov/show/NCT00165464"
243,"NCT00565448","Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents","Completed","Has Results","Nasopharyngeal Neoplasms|Carcinoma","Drug: docetaxel|Drug: cisplatin|Drug: 5-fluorouracil","Sanofi","All","1 Month to 21 Years   (Child, Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC10339|2007-001211-33","November 29, 2007","November 2007","January 2012","July 2, 2015","July 2015","March 5, 2010","null","March 2009","Number of Participants With Complete Response (CR)|Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group|Overall Response (OR)|Overall Survival (OS) Rate","https://ClinicalTrials.gov/show/NCT00565448"
244,"NCT00165516","Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate","Completed","No Results Available","Pleural Mesothelioma|Malignant Pleural Mesothelioma","Drug: Cisplatin|Drug: Sodium Thiosulfate","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","85","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-302","September 12, 2005","January 2004","December 2009","March 26, 2014","March 2014","No Study Results Posted","null","July 2006","To monitor tumor recurrence and patient survival, and compare those results to historic controls.|To document the morbidity and mortality of this treatment protocol in this patient population|to evaluate the pharmacokinetics of cisplatin.","https://ClinicalTrials.gov/show/NCT00165516"
245,"NCT00645593","Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer","Completed","Has Results","Bladder Cancer","Drug: Gemcitabine,|Drug: Cisplatin|Drug: Cetuximab","University of Michigan Cancer Center|National Comprehensive Cancer Network|Bristol-Myers Squibb|ImClone LLC","All","18 Years and older   (Adult, Senior)","Phase 2","89","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2007.097","March 24, 2008","March 2008","June 2015","April 14, 2016","April 2016","July 16, 2014","null","April 2014","Percentage of Participants That Respond to Treatment in Arm 1 and Arm 2|The Number of Grade 3 to 5 Adverse Events Experienced by Arm 1 and Arm 2|Median Progression-free Survival Time in Months|Median Overall Survival in Months","https://ClinicalTrials.gov/show/NCT00645593"
246,"NCT01287624","Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)","Completed","No Results Available","Breast Cancer","Drug: Gemcitabine,cisplatin|Drug: Gemcitabine, Paclitaxel","Fudan University|307 Hospital of PLA|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Sun Yat-sen University|Tianjin Medical University Cancer Institute and Hospital|Zhejiang Cancer Hospital|Changhai Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Fudan BR2010-04|CBCSG 006","January 31, 2011","January 2011","March 2014","March 19, 2015","March 2015","No Study Results Posted","TNBC","March 2014","PFS (Progression Free Survival)|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT01287624"
247,"NCT00144989","A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC","Completed","No Results Available","Small-Cell-Lung Cancer","Drug: Etoposide and cisplatin after chemoradiotherapy|Drug: Irinotecan and cisplatin after chemoradiotherapy","Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group","All","20 Years to 70 Years   (Adult, Senior)","Phase 3","281","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG0202-MF|C000000095","September 1, 2005","September 2002","September 2011","September 20, 2016","September 2016","No Study Results Posted","null","September 2011","overall survival|adverse events of induction chemoradiotherapy|chemotherapy after chemoradiotherapy|late radiation morbidity|serious adverse event|progression-free survival","https://ClinicalTrials.gov/show/NCT00144989"
248,"NCT01977235","Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer","Recruiting","No Results Available","Small Cell Lung Carcinoma","Drug: Irinotecan|Drug: Cisplatin","Third Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TDICC","October 15, 2013","September 2013","September 2017","March 31, 2016","March 2016","No Study Results Posted","TDICC","February 2017","progression-free survival|overall survival|Tumor response rate|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT01977235"
249,"NCT00049166","Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer","Completed","No Results Available","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Oropharynx","Drug: erlotinib hydrochloride|Drug: cisplatin|Radiation: intensity-modulated radiation therapy|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","48","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03155|NCI-5375|JHOC-20020723|JHOC-J0174|5375|U01CA070095","November 12, 2002","October 2002","null","September 27, 2013","September 2013","No Study Results Posted","null","July 2007","Maximum tolerated dose (MTD) of cisplatin, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0|Time to progression|Pharmacokinetics in terms of steady state concentration (Css, min)|Percent change in standardized uptake value (SUV) corrected for lean body mass|Biological response for each individual patient as defined by determination of the proportional variation of each biomarker|Relationship between time to treatment failure versus variations in the biomarkers|Effect of erlotinib hydrochloride on the EGFR activation and signaling","https://ClinicalTrials.gov/show/NCT00049166"
250,"NCT01661114","A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers","Completed","Has Results","Pancreatic Cancer|Biliary Cancer","Drug: Gemcitabine|Drug: 5-FU|Drug: Cisplatin","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2011.036|HUM 49518","July 24, 2012","July 2011","March 2016","September 1, 2016","September 2016","January 5, 2016","null","December 2014","The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment|Median Overall Survival of Previously Treated and Previously Untreated Patients","https://ClinicalTrials.gov/show/NCT01661114"
251,"NCT01187615","Determination of Safety, Efficacy, and Pharmacokinetics of ""Regorafenib"" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer","Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14458","July 16, 2010","August 2010","June 2012","July 7, 2014","July 2014","No Study Results Posted","null","June 2012","Number of participants with treatment related toxicities and adverse events and change from baseline in vitals signs and laboratory parameters|Pharmacokinetics assessments of Alimta, Cisplatin, and regorafenib in Cycle 1 and 2|Biomarkers (includes but not limited to plasma protein analysis of angiogenesis-related proteins, DNA mutational anaylsis of tumor tissue and plasma)|Tumor Assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) every second cycle","https://ClinicalTrials.gov/show/NCT01187615"
252,"NCT00191763","Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell-Lung Cancer","Drug: Gemcitabine|Drug: cisplatin","Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7138|B9E-VI-S314","September 12, 2005","November 2002","December 2005","November 5, 2007","November 2007","No Study Results Posted","null","null","To evaluate the clinical response rate of neo-adjuvant chemotherapy with gemcitabine and cisplatin in patients with operable non small cell lung cancer|To evaluate the safety of neo-adjuvant chemotherapy with gemcitabine / cisplatin|To determine the complete tumor resection rate|To evaluate overall survival and time to documented disease progression","https://ClinicalTrials.gov/show/NCT00191763"
253,"NCT00002913","Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer","Completed","No Results Available","Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer","Drug: paclitaxel|Drug: cisplatin|Drug: topotecan hydrochloride|Biological: filgrastim","National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02251|GOG-9602|U10CA027469|CDR0000065286","November 1, 1999","December 1996","null","January 23, 2013","January 2013","No Study Results Posted","null","July 2007","Maximally tolerated doses (MTDs) of the combination of paclitaxel, Topotecan, and cisplatin administered without and with G-CSF based on dose-limiting toxicities (DLT) graded according to GOG Common Toxicity Criteria|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT00002913"
254,"NCT00002998","Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","59","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-963251|CDR0000065548","November 1, 1999","August 1997","May 2006","July 12, 2016","July 2016","No Study Results Posted","null","April 2005","Response rate|time to progression|survival","https://ClinicalTrials.gov/show/NCT00002998"
255,"NCT03093922","A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer","Recruiting","No Results Available","Urothelial Carcinoma|Locally Advanced|Unresectable","Drug: Atezolizumab|Drug: Gemcitabine|Drug: Cisplatin","Memorial Sloan Kettering Cancer Center|Ohio State University|University of Chicago|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16-1621","March 23, 2017","March 22, 2017","March 2019","April 19, 2017","April 2017","No Study Results Posted","null","March 2019","Best confirmed objective response rate","https://ClinicalTrials.gov/show/NCT03093922"
256,"NCT01100944","A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies","Terminated","Has Results","Thymoma|Thymic Carcinoma","Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","100077|10-C-0077","March 18, 2010","March 2010","June 2017","November 14, 2016","November 2016","July 26, 2016","null","May 2016","Maximum Tolerated Dose (MTD) of Belinostat|Number of Participants With Grade 3 and 4 Dose Limiting Toxicity (DLT) at 2000mg/m(2) Belinostat|Objective Response Rate (Partial Response (PR) + Complete Response (CR) of Belinostat in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Patients With Advanced Thymic Malignancies|Number of Participants With Serious and Non-serious Adverse Events|Treatment-related Grade 3 and 4 Adverse Events (Highest Grade Per Event Per Patient)|Clinical Response|Disease Control Rate (DCR)|Time to Response|Duration of Response|Progression Free Survival (PFS)|Overall Survival (OS)|Time to Half Life (t1/2) of Belinostat|Total Clearance (CL) of Belinostat|Maximum Observed Plasma Concentration (Cmax) of Belinostat|Maximum Plasma Concentration (Cmax)/Dose|Time to Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF))|Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF)/Dose|Relative Change Observed in Total Protein Hyperacetylation of Cluster of Differentiation 3 (CD3)+T Cells With Belinostat|Relative Changes in the Number of Tregs With Treatment|Relative Changes in T Cell Immunoglobulin Domain and Mucin Domain-3 (TIM3)-Expressing Cluster of Differentiation 8 (CD8)+Tcells","https://ClinicalTrials.gov/show/NCT01100944"
257,"NCT01139281","The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans","Completed","No Results Available","Ototoxicity|Hearing Loss","Drug: Ginkgo Biloba Extract (GBE761)|Drug: Placebo","University of Brasilia","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","CEPSESDF-024-07","June 1, 2010","June 2007","June 2008","June 7, 2010","May 2010","No Study Results Posted","null","June 2008","the effect of GBE761 as a possible protector against cisplatin (CDDP) induced hearing loss was evaluated through the DPOAE. Comparisons were made between baseline measurements and those records after maximum cumulative CDDP dosage.","https://ClinicalTrials.gov/show/NCT01139281"
258,"NCT00064259","A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer","Terminated","Has Results","Adenocarcinoma of the Esophagus|Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Squamous Cell Carcinoma of the Esophagus|Stage III Esophageal Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer","Biological: oblimersen sodium|Drug: cisplatin|Drug: fluorouracil","National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03134|02-66|N01CM62204","July 8, 2003","June 2003","February 2010","June 10, 2015","May 2013","June 10, 2015","null","February 2010","Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU|Microarray Data","https://ClinicalTrials.gov/show/NCT00064259"
259,"NCT01297998","A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy","Completed","No Results Available","Biliary Tract Cancer","Drug: gemcitabine , cisplatin","Kansai Hepatobiliary Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KHBO1004|UMIN000004622","February 7, 2011","January 2011","June 2013","June 29, 2014","June 2014","No Study Results Posted","null","December 2012","Maximum tolerated dose|Number of Participants with dose limiting toxicity","https://ClinicalTrials.gov/show/NCT01297998"
260,"NCT02969473","Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Esophageal Neoplasm|Chemoradiation","Drug: Docetaxel|Drug: Fluorouracil","Zhu Yujia|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YP2010138","November 11, 2016","October 2010","May 2017","November 16, 2016","November 2016","No Study Results Posted","null","May 2016","Overall survival (OS)|Treatment response rate|Progress Free Survival (PFS)|Acute treatment-related toxicities","https://ClinicalTrials.gov/show/NCT02969473"
261,"NCT02199418","Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer","Completed","No Results Available","Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer","Drug: Paclitaxel|Drug: Cisplatin","RenJi Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","132","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RenJiH-BC-001","July 14, 2014","January 2013","October 2016","January 23, 2017","January 2017","No Study Results Posted","SHPD001","November 2015","Pathological complete response of breast and lymph nodes|Tolerability and Safety|Clinical and imaging response|regional recurrence free survival (RRFS)|local recurrence free survival (LRFS)|distant-disease- free survival (DDFS)|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02199418"
262,"NCT01562210","Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC","Recruiting","No Results Available","NSCLC","Drug: Olaparib|Drug: Cisplatin|Radiation: Radiation","The Netherlands Cancer Institute|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NL35195.031.11|N11ORL","March 22, 2012","April 2012","March 2020","December 7, 2016","December 2016","No Study Results Posted","olaparib","November 2017","The incidence of dose limiting toxicities (DLTs)|Additional safety variables|Objective tumor response|Locoregional control rate (LRCR)|Progression free survival|Pharmacokinetic variables|Pharmacodynamic variables|Surrogate biomarkers for antitumor response","https://ClinicalTrials.gov/show/NCT01562210"
263,"NCT01327235","Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites","Completed","No Results Available","Malignant Pleural Effusion|Malignant Ascites","Drug: Endostar|Drug: Cisplatin","Jiangsu Simcere Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","336","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SIM-90","March 28, 2011","March 2011","July 2014","July 31, 2014","July 2014","No Study Results Posted","null","April 2014","Objective Response Rate|Time to Progression|Quality of Life|Incidence of Adverse Events","https://ClinicalTrials.gov/show/NCT01327235"
264,"NCT02397928","Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)","Active, not recruiting","No Results Available","Malignant Pleural Mesothelioma","Device: NovoTTF-100L device|Drug: Pemetrexed|Drug: Cisplatin or Carboplatin","NovoCure Ltd.","All","18 Years and older   (Adult, Senior)","Phase 2","82","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","EF-23","March 19, 2015","February 2015","February 2018","May 7, 2017","March 2017","No Study Results Posted","null","February 2018","Overall Survival|Progression Free Survival|Response Rate|Toxicity","https://ClinicalTrials.gov/show/NCT02397928"
265,"NCT01689194","Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer","Active, not recruiting","No Results Available","Locally Advanced Head and Neck Squamous Cell Carcinoma","Drug: genexolPM + cisplatin","Seoul National University Hospital|Clinical Research Center for Solid Tumor, Korea","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCST-L-0007|H-1204-103-407","August 30, 2012","February 2013","December 2017","June 8, 2016","April 2016","No Study Results Posted","null","April 2016","response rate|Locoregional control rate|Quality of life|safety","https://ClinicalTrials.gov/show/NCT01689194"
266,"NCT02347917","A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma","Active, not recruiting","No Results Available","Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer","Drug: BBI608|Drug: Pemetrexed|Drug: Cisplatin","Sumitomo Dainippon Pharma Co., Ltd.","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D8807005","January 21, 2015","February 2015","null","July 19, 2016","July 2016","No Study Results Posted","null","May 2017","Phase1: Assessment of safety of BBI608 given in combination with Pemetrexed and Cisplatin by reporting the adverse events and serious adverse events.|Phase1: Assessment of dose-limiting toxicities (DLTs).|Phase1: Pharmacokinetics profile of BBI608 when administered with pemetrexed and cisplatin.|Phase2: Progression Free Survival (PFS)|Phase1: Anti-tumor activity|Phase1: Progression Free Survival(PFS)|Phase1: Overall Survival(OS)|Phase2: Overall Survival (OS)|Phase2: Response Rate(RR)|Phase2: Disease Control Rate(DCR)|Phase2: Vital Capacity(VC)|Phase2: Forced vital capacity(FVC)|Phase2: Forced Expiratory Volume in 1st second(FEV1)|Phase2: Safety by reporting the adverse events and serious adverse events.","https://ClinicalTrials.gov/show/NCT02347917"
267,"NCT01692704","Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy","Completed","No Results Available","Cholangiocellular Carcinoma","Drug: Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin","University of Zurich","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONK-USZ-003","June 6, 2012","April 2012","March 2016","March 24, 2016","March 2016","No Study Results Posted","null","March 2016","Dose limiting toxicities (DLT) of intravenous gemcitabine with concomitant administration of FUDR-HAI and intravenous cisplatin.","https://ClinicalTrials.gov/show/NCT01692704"
268,"NCT02143388","Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial","Recruiting","No Results Available","Local Advanced High Risk Nasopharyngeal Carcinoma","Drug: IMRT combine with cisplatin concurrent chemotherapy|Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy","Zhao Chong|First People's Hospital of Foshan|Guangzhou General Hospital of Guangzhou Military Command|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","258","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCRT-AC-LAHR-NPC","May 7, 2014","May 2014","December 2018","November 22, 2016","November 2016","No Study Results Posted","null","December 2017","Progression free survival|Acute Toxicity","https://ClinicalTrials.gov/show/NCT02143388"
269,"NCT00814086","Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer","Completed","No Results Available","Chemotherapeutic Agent Toxicity|Endometrial Adenocarcinoma|Fallopian Tube Carcinoma|Gastrointestinal Complication|Malignant Ovarian Mixed Epithelial Tumor|Neurotoxicity Syndrome|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage II Ovarian Cancer|Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Undifferentiated Ovarian Carcinoma","Drug: Paclitaxel|Drug: Cisplatin","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9921|NCI-2009-00624|CDR0000629746|U10CA027469","December 20, 2008","February 2009","null","December 29, 2014","December 2014","No Study Results Posted","null","July 2011","Number of patients who have at least 1 dose-limiting toxicity or delay in therapy for more than 2 weeks|Grade of toxicity as assessed by Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)|Adverse events related to the catheter or the surgical placement of the catheter|Objective tumor response (partial or complete) assessed by Response Evaluation Criteria for Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT00814086"
270,"NCT02567422","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Drug: ATR Kinase Inhibitor VX-970|Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Radiation Therapy","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","45","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-01643|9950|N01CM00100|P30CA006973|UM1CA186690|UM1CA186691","October 2, 2015","September 2, 2016","null","May 23, 2017","May 2017","No Study Results Posted","null","August 31, 2019","Frequency and grade of toxicity according to the Cancer Therapy Evaluation Program National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v. 4)|Incidence of dose limiting toxicities graded according to NCI CTCAE v. 4|RP2D as the highest doses of cisplatin and ATR kinase inhibitor VX-970 safely combined with radiation|Metabolic response rate by fluorodeoxyglucose-positron emission tomography (PET) by PET Response Evaluation Criteria in Solid Tumors|Overall response rate defined as complete response (CR) + partial response (PR) evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|PK characteristics of ATR kinase inhibitor VX-970","https://ClinicalTrials.gov/show/NCT02567422"
271,"NCT01088347","Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer","Completed","No Results Available","Advanced Cervical Cancer","Drug: mapatumumab|Drug: cisplatin|Radiation: radiotherapy","University Medical Center Groningen|Human Genome Sciences Inc.","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","24-11-2009 (versions 2.0)|2009-015941-22","March 10, 2010","March 2010","March 2014","April 21, 2015","April 2015","No Study Results Posted","null","March 2014","Phase 1b: safety and tolerability of mapatumumab in combination with cisplatin and radiotherapy Phase 2: efficacy of mapatumumab in combination with cisplatin and radiotherapy|Disease free survival, overall survival|Apoptotic pathway biomarkers, PK parameters","https://ClinicalTrials.gov/show/NCT01088347"
272,"NCT00320983","Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: Topotecan|Drug: Cisplatin","University of New Mexico","Female","Child, Adult, Senior","Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1601C","May 1, 2006","March 2002","December 2005","January 6, 2010","October 2008","No Study Results Posted","null","June 2004","disease progression","https://ClinicalTrials.gov/show/NCT00320983"
273,"NCT02300610","Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer","Recruiting","No Results Available","Bladder Cancer|Carcinoma, Transitional Cell|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer","Drug: Enzalutamide|Drug: Cisplatin|Drug: Gemcitabine","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-17924","November 21, 2014","February 11, 2015","December 2018","May 23, 2017","May 2017","No Study Results Posted","null","December 2018","Maximum Tolerated Dose (MTD)|Overall Response Rate (ORR): Complete Response (CR) + Partial Response (PR)|Progression Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02300610"
274,"NCT00253370","Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer","Completed","Has Results","Adenocarcinoma of the Gastroesophageal Junction|Metastatic Gastric Cancer|Advanced Unresectable Gastric Cancer","Drug: BAY 43-9006|Drug: docetaxel|Drug: cisplatin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","44","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02951|E5203|U10CA021115","November 11, 2005","October 2005","September 2010","November 19, 2014","December 2013","May 21, 2014","null","May 2008","The Proportion of Patients With Objective Response (Complete Response or Partial Response)|Progression-free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00253370"
275,"NCT00678132","AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers","Completed","No Results Available","Neoplasms","Drug: AZD 2281|Drug: Cisplatin|Drug: Gemcitabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1","23","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","080128|08-C-0128","May 13, 2008","April 24, 2008","November 23, 2010","May 12, 2017","September 7, 2012","No Study Results Posted","null","November 23, 2010","Establish the safety and tolerability of AZD2281 in combination with cisplatin and gemcitabine in patients with solid tumors. Establish the maximum tolerated dose (MTD) for the combination of AZD2281 with cisplation and gemcitabine.|Evaluate the effect of chemotherapy (cisplatin-gemcitabine) with or without AZD2281 on PAR levels and g-H2AX levels in tumor biopsies and peripheral blood mononuclear cells (PBMCs) pre- and post treatment. Evaluate the pharmacokinetic (PK) of A.","https://ClinicalTrials.gov/show/NCT00678132"
276,"NCT02778191","Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: cisplatin|Drug: carboplatin|Drug: 5-FU","University Medical Center Groningen|VU University Medical Center","All","18 Years to 70 Years   (Adult, Senior)","","413","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201501099","December 15, 2015","February 2016","March 2017","May 16, 2017","May 2017","No Study Results Posted","null","March 2017","Chemotherapy completion rate|Overall survival|Progression free survival|Distant metastases|Grade 3-4 acute toxicity|Late toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT02778191"
277,"NCT01281696","Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis","Completed","No Results Available","Breast Neoplasms|Leptomeningeal Metastasis|Brain Metastases","Drug: Bevacizumab, etoposide, cisplatin|Drug: Intrathecal methotrexate","National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|Taichung Veterans General Hospital|Chang Gung Memorial Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201010077M","December 24, 2010","January 2011","October 2013","October 15, 2013","October 2013","No Study Results Posted","null","July 2013","Response rate of central nervous system (CNS) metastasis|Number of participants with adverse events|To evaluate the response rate of breast cancer patients with brain parenchymal metastasis after receiving B-EP|To evaluate the response rate of breast cancer patients with leptomeningeal carcinomatosis after receiving B-EP|To evaluate the response rate of extra-CNS lesions according to RECIST|Vascular activity of brain metastatic tumors after bevacizumab treatment|Biomarkers in CSF and serum in patients with brain and/or leptomeningeal metastasis receiving B-EP|Drug concentrations of etoposide and cisplatin|Association between response of CNS metastasis and the history of prior exposure to cisplatin|Proton MR spectroscopy of metastatic brain tumor before and after B-EP treatment","https://ClinicalTrials.gov/show/NCT01281696"
278,"NCT02997189","Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss","Recruiting","No Results Available","Cisplatin Induced Hearing Loss","Drug: OTO-104","Otonomy, Inc.","All","6 Months to 21 Years   (Child, Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Outcomes Assessor|Primary Purpose: Prevention","104-201607","December 15, 2016","November 2016","June 2018","April 12, 2017","April 2017","No Study Results Posted","null","March 2018","Feasibility assessed via a questionnaire|Hearing function in each ear according to SIOP-Boston Ototoxicity Scale|Safety as assessed by adverse events|Local tolerability as assessed by otoscopic examinations","https://ClinicalTrials.gov/show/NCT02997189"
279,"NCT01951469","Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer|Brain Metastases|EGFR Mutation","Drug: Gefitinib and Pemetrexed/cisplatin|Drug: Gefitinib mono-therapy","Sun Yat-sen University|Wu Jieping Medical Foundation","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSCLC brain metastasis 01","September 16, 2013","June 2013","June 2017","November 16, 2015","November 2015","No Study Results Posted","null","June 2016","comparing the difference of iPFS(intracranial progression free survival) in two arms|comparing the difference of Response rate(CR&PR) and in two arms","https://ClinicalTrials.gov/show/NCT01951469"
280,"NCT00195078","Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer","Terminated","No Results Available","Head and Neck Cancer","Drug: ZD1839 (IRESSA)|Drug: Cisplatin|Procedure: Radiation Therapy","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","29","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0404-218","September 14, 2005","April 2004","September 2006","July 19, 2007","July 2007","No Study Results Posted","null","null","To explore whether the addition of ZD1839 to standard treatment of unresectable head and neck cancers (i.e., cisplatin and radiation therapy) improves the clinical complete response rate (as measured by RECIST criteria).|To determine the time to disease progression, duration of response, and 2?year disease-free survival in subjects with unresectable tumors of the head and neck after combined therapy with ZD1839, cisplatin, and radiation.|To determine the toxicities, and recovery from toxicities, of combined therapy with ZD1839, cisplatin, and radiation therapy.|To determine dose-limiting toxicity as well as the recommended Phase II dose of ZD1839 given concurrently with cisplatin and radiation.","https://ClinicalTrials.gov/show/NCT00195078"
281,"NCT01265147","Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin|Drug: Nedaplatin","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Daping H 001","December 3, 2010","January 2011","December 2017","January 19, 2011","November 2010","No Study Results Posted","null","December 2012","locoregionally control rate|Survival","https://ClinicalTrials.gov/show/NCT01265147"
282,"NCT00998166","A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)","Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: Pemetrexed, Cisplatin, Bevacizumab","Columbia University","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAB9652","October 14, 2009","June 2007","October 2012","September 10, 2013","September 2013","No Study Results Posted","null","October 2012","Progression free survival|Objective response rate","https://ClinicalTrials.gov/show/NCT00998166"
283,"NCT02481518","Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity","Recruiting","No Results Available","Acute Kidney Injury","Drug: Magnesium|Other: Control","Mahidol University","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator, Outcomes Assessor|Primary Purpose: Prevention","2558/172","May 17, 2015","May 2015","July 2017","March 21, 2017","March 2017","No Study Results Posted","PRAGMATIC","May 2017","Acute kidney injury|Nephrotoxicity","https://ClinicalTrials.gov/show/NCT02481518"
284,"NCT03051373","Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract","Not yet recruiting","No Results Available","Carcinoma, Transitional Cell","Drug: nanoparticle albumin-bound paclitaxel, S-1|Drug: Gemcitabine, cisplatin","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BY-001","February 9, 2017","April 1, 2017","December 31, 2020","February 10, 2017","February 2017","No Study Results Posted","null","April 30, 2019","Progression-free survival|Overall response rate|Disease control rate|Overall survival|The number of treatment-emergent adverse events (AEs) and serous adverse events (SAEs) as a measure of safety","https://ClinicalTrials.gov/show/NCT03051373"
285,"NCT02016274","Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer","Unknown status","No Results Available","Esophageal Squamous Cell Cancer","Other: Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy","Shen Lin|Peking University","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CGOG7001","December 7, 2013","December 2013","July 2016","December 13, 2013","December 2013","No Study Results Posted","null","December 2015","progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02016274"
286,"NCT02695459","Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin","Recruiting","No Results Available","Neuroendocrine Carcinomas","Drug: cisplatinum and everolimus","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","M14NEC","February 18, 2016","March 2016","January 2018","January 11, 2017","January 2017","No Study Results Posted","null","January 2018","disease control rate|time to relapse|overall survival|Effect on the markers chromogranin A (CgA) and neuron-specific enolase (NSE);|Safety of everolimus in combination with cisplatin (AEs according to CTCAE v4.0)","https://ClinicalTrials.gov/show/NCT02695459"
287,"NCT01893801","Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)","Unknown status","No Results Available","Stage IV Pancreatic Cancer","Drug: nab-paclitaxel|Drug: Cisplatin|Drug: gemcitabine","Gayle Jameson|Translational Genomics Research Institute|Translational Drug Development|Virgina G. Piper Cancer Center - Clinical Trials|Pancreatic Cancer Research Team","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCRT 12-001","July 2, 2013","May 2013","August 2014","February 27, 2014","February 2014","No Study Results Posted","null","May 2014","Complete Response Rate|Evaluate disease control rate|Evaluate treatment-related toxicities|Evaluate the change in CA 19-9 or other biomarkers","https://ClinicalTrials.gov/show/NCT01893801"
288,"NCT00909402","A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas","Completed","No Results Available","Stomach Neoplasms|Esophageal Neoplasms","Drug: BMS-833923|Drug: Cisplatin|Drug: Capecitabine","Bristol-Myers Squibb|Exelixis","All","18 Years and older   (Adult, Senior)","Phase 1","39","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA194-004|2010-018743-33","May 22, 2009","November 2009","November 2012","June 20, 2013","June 2013","No Study Results Posted","null","November 2012","Use National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) to establish the MTD, Dose Limiting Toxicity (DLT(s)) and safety profile of BMS-833923 administered in combination with Cisplatin and Capecitabine|To evaluate the safety of single-agent BMS-833923, by assessing the evaluation of number, character and duration of adverse event (AE)/serious adverse event (SAE)s|Pharmacodynamic effects of BMS-833923 will be measured in tumor biopsy samples taken prior to and during single-agent and combination treatment by evaluation of protein or mRNA of biomarkers of Hedgehog (HH) pathway activation, such as GLI-1|The pharmacokinetic parameters that will be assessed include: Cmax (Maximum observed plasma concentration)|The pharmacokinetic parameters that will be assessed include: Tmax (Time of maximum observed plasma concentration)|The pharmacokinetic parameters that will be assessed include: AUC(TAU) (Area under the concentration-time curve in one dosing interval)","https://ClinicalTrials.gov/show/NCT00909402"
289,"NCT01627379","Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer","Active, not recruiting","No Results Available","Esophageal Squamous Cell Cancer","Drug: Cisplatin, 5-FU|Drug: Panitumumab","AIO-Studien-gGmbH|Amgen|Assign Data Management and Biostatistics GmbH|Assign Clinical Research GmbH","All","18 Years and older   (Adult, Senior)","Phase 3","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","POWER / AIO-STO-0309|2010-020606-15","June 13, 2012","May 2012","May 2017","January 20, 2017","January 2017","No Study Results Posted","POWER","May 2015","Overall Survival|Progression-free survival|1-year survival|Response rate|Overall incidence of patients with adverse events|Quality of life","https://ClinicalTrials.gov/show/NCT01627379"
290,"NCT00915850","Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)","Unknown status","No Results Available","Esophageal Cancer","Drug: DCF","Wakayama Medical University","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","WMU-EC01","June 5, 2009","August 2007","August 2015","September 8, 2010","September 2010","No Study Results Posted","null","August 2010","Safety (Phase I: toxicities as assessed by NCI CTCAE version3) and efficacy (Phase II: Feasibility as evaluated by RECIST)|To determine the recommended phase II dose of docetaxel (Phase I)|To determine the clinical effectiveness in the patients with measurable disease (Phase I)|To analyze the toxicity (Phase II)|Time to progression (Phase II)|median survival time (Phase II)","https://ClinicalTrials.gov/show/NCT00915850"
291,"NCT01671449","S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: S-1|Drug: Cisplatin|Drug: Oxaliplatin","Min-Hee Ryu|Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","338","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-1202","August 17, 2012","December 2012","October 2015","November 26, 2015","November 2015","No Study Results Posted","SOPP","October 2014","Progression-free survival|Overall survival|Response rate|Quality of life|Number of Adverse Events","https://ClinicalTrials.gov/show/NCT01671449"
292,"NCT00281125","Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer","Terminated","No Results Available","Non-Small Cell Lung Cancer and Pleural Mesothelioma","Drug: PTK787 and Pemetrexed with or without Cisplatin","Nevada Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NVCI05-14","January 6, 2006","January 2006","August 2008","March 15, 2012","March 2012","No Study Results Posted","null","September 2006","To determine the Maximum tolerated dose (MTD) and Dose Limiting toxicities (DLTs) of a combination of Pemetrexed and PTK787/ZK222584 (Cohort 1) and a combination of Pemetrexed with Cisplatin and PTK787/ZK222584 (Cohort 2) in patients|To determine the preliminary evidence of safety of the above combinations in patients with non-small cell lung cancers and/or mesotheliomas (in the expansion cohorts)|To determine the pharmacokinetics of PTK787/ZK222584 in combination with Pemetrexed and Cisplatin|To determine the pharmacokinetics of Pemetrexed in combination with PTK787/ZK 222584|To determine the effect of therapy with the combination on plasma levels of VEGF A, B, C and D and on plasma levels of soluble VEGF-R2.|To determine the relationship between PTK787/ZK 222584 and Pemetrexed pharmacokinetics and plasma levels of VEGF A, B, C, D, soluble VEGF-R2, and exploratory chemotherapeutic response biomarkers.|To determine the baseline expression of VEGF-R2 by immunohistochemistry in patients where paraffin blocks/slides are available.","https://ClinicalTrials.gov/show/NCT00281125"
293,"NCT00621361","Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients","Completed","No Results Available","Lung Cancer","Drug: AZD2171|Drug: Etoposide|Drug: Cisplatin","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","62","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D8480C00054","February 12, 2008","February 2008","February 2012","December 13, 2012","December 2012","No Study Results Posted","null","August 2009","Assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171) in combination with etoposide and cisplatin (EP).|Preliminary efficacy assessment of Cediranib in combination with etoposide & cisplatin using available tumor assessment data to assess response rate,duration of response,change in tumor size(only those with measurable disease)& progression free survival","https://ClinicalTrials.gov/show/NCT00621361"
294,"NCT02537561","Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors","Withdrawn","No Results Available","Solid Tumors|Carcinoma, Non-Small Cell Lung|Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer","Drug: Cisplatin|Drug: Gemcitabine|Drug: Talazoparib","Washington University School of Medicine|BioMarin Pharmaceutical","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15-x279","August 28, 2015","December 2015","December 2018","February 10, 2016","February 2016","No Study Results Posted","null","June 2018","Safety and toxicities as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Maximum tolerated dose (MTD)|Objective response rate (ORR) in preselected patients with BRCAness tumoral genotype|Disease control rate (DCR)|Progression-free survival (PFS)|Objective response rate (ORR)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02537561"
295,"NCT00139243","Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Squamous Cell Carcinoma|Carcinoma of Head and/or Neck","Drug: Taxotere|Drug: Cisplatin|Drug: 5-Fluorouracil|Drug: Leucovorin","Dana-Farber Cancer Institute|Sanofi|Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","97-130","August 29, 2005","October 1997","January 2006","June 2, 2008","June 2008","No Study Results Posted","null","January 2006","To determine the maximum tolerated dose of taxotere, cisplatin, 5-fluorouracil and leucovorin.|To evaluate the side effects of a four day outpatient regimen with taxotere, cisplatin, 5-fluorouracil and leucovorin|to obtain preliminary information about the effectiveness of the drug combination.","https://ClinicalTrials.gov/show/NCT00139243"
296,"NCT02906800","Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients","Recruiting","No Results Available","Head and Neck Cancer","Drug: Digoxin","Assistance Publique - Hôpitaux de Paris|Cancer Research and Personalized Medicine (Carpem)|Laboratoire d’excellence en immuno-oncologie (Labex)","All","19 Years to 69 Years   (Adult, Senior)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","P150401|2015-003076-78","August 25, 2016","January 2017","May 2019","February 2, 2017","February 2017","No Study Results Posted","DIGHANC","May 2019","Appearance of the grade 3 or 4 (Adverse Events graded by NCI CTC version 4.0) clinical or biological toxicity of the combination of digoxin to cisplatin-based chemotherapy during the study|Clinical response after chemotherapy by fibroscopy (tumor seize)|Radiological response after chemotherapy|Biological efficacy: monitored by analysis of T cells recruitment|Biological efficacy: monitored by analysis of subpopulations of T cells|Biological efficacy: expression of IFN gamma assessed by quantitative RT-PCR assay|Biological efficacy: expression of IL-17 assessed by quantitative RT-PCR assay|Progression Free Survival (PFS): Death or recurrence (clinical and/or radiological analysis)","https://ClinicalTrials.gov/show/NCT02906800"
297,"NCT02643407","Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Docetaxel|Drug: Nedaplatin|Drug: Cisplatin","Guangdong Association of Clinical Trials","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","488","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTONG1501","December 29, 2015","October 2015","December 2017","December 30, 2015","December 2015","No Study Results Posted","null","December 2017","PFS","https://ClinicalTrials.gov/show/NCT02643407"
298,"NCT00794417","A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma","Completed","No Results Available","Advanced Carcinoma|Non-small Cell Lung Cancer","Biological: Aflibercept|Biological: Pemetrexed|Biological: Cisplatin","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","62","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VGFT-ST-0708|TCD10767","November 19, 2008","November 2008","June 2011","August 30, 2012","August 2012","No Study Results Posted","null","June 2011","Phase 1: Dose limiting toxicities; Phase 2: Objective Response Rate (ORR) and Progression Free Survival (PFS)|Safety, pharmacokinetic and immunogenic profile of aflibercept when given in combination with pemetrexed and cisplatin","https://ClinicalTrials.gov/show/NCT00794417"
299,"NCT01014598","Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis","Active, not recruiting","No Results Available","Metastatic Malignant Neoplasm in the Lung|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Adult Soft Tissue Sarcoma|Stage IV Non-Small Cell Lung Cancer","Drug: Cisplatin|Other: Pharmacological Study","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I 70005|NCI-2009-01604|P30CA016056","November 16, 2009","December 4, 2007","May 21, 2018","April 6, 2017","April 2017","No Study Results Posted","null","May 21, 2015","Acute toxicity assessed using CTCAE version 4.0|Frequency of patients experiencing dose limiting toxicities (DLT) as well as non-DLT|Reversibility of all toxicities from this approach.|Lung, systemic, and pulmonary artery concentrations of cisplatin|Pulmonary function test with diffusion capacity|Split lung function test","https://ClinicalTrials.gov/show/NCT01014598"
300,"NCT02308072","Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer","Drug: Olaparib|Drug: Cisplatin|Radiation: IMRT","University College, London|Cancer Research UK|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCL/13/0696|2014-002525-35","December 2, 2014","September 2015","June 2022","March 20, 2017","March 2017","No Study Results Posted","ORCA-2","June 2019","Occurrence of Dose Limiting Toxicity|Occurrence and Severity of Adverse Events|Best Overall Response|Time to Loco-Regional Progression|Time to Progression|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02308072"
301,"NCT01128387","Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer","Completed","No Results Available","Cancer","Drug: Panitumumab","University of Wisconsin, Madison|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-2009-0214|RO09211","May 17, 2010","May 2010","October 2016","November 16, 2016","November 2016","No Study Results Posted","null","October 2016","MTD of panitumumab in combination with Cisplatin/fluorouracil and radiation for locally advanced esophageal cancer|Pathologic response","https://ClinicalTrials.gov/show/NCT01128387"
302,"NCT00575952","Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer","Active, not recruiting","No Results Available","Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Mixed Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Squamous Cell Carcinoma|Endometrial Undifferentiated Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer","Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Biological: Filgrastim|Drug: Paclitaxel|Biological: Pegfilgrastim","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9920|NCI-2009-00623|CDR0000580419|U10CA180868|U10CA027469","December 15, 2007","January 2008","null","October 26, 2016","October 2016","No Study Results Posted","null","January 2016","Incidence of observed DLTs, defined as grade 3-4 hematologic or non-hematologic toxicity graded using CTCAE v3.0|Maximum tolerated dose (MTD) of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IV cisplatin, determined according to dose-limiting toxicities (DLTs) graded using CTCAE v3.0|MTD of IP paclitaxel with fixed dose IV doxorubicin hydrochloride and IP cisplatin, determined according to DLTs graded using CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00575952"
303,"NCT02485548","Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer","Recruiting","No Results Available","Head and Neck Squamous Cell Cancer","Drug: Raltitrexed|Drug: 5-fluorouracil|Drug: Cisplatin|Radiation: IMRT","Jiangsu Cancer Institute & Hospital|Wuxi Cancer Hospital|Changzhou Cancer Hospital of Soochow University|Nanjing Cancer Hospital|Northern Jiangsu Province People's Hospital|The Second Hospital of Nanjing Medical University|Nanjing BenQ Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014NL-035","June 26, 2015","June 2015","June 2018","June 29, 2015","June 2015","No Study Results Posted","null","June 2018","Progression-free survival (PFS)|Overall Survival (OS)|Locoregional and distant control rate|Percentage of participants experiencing grade 3-5 adverse events(AEs)","https://ClinicalTrials.gov/show/NCT02485548"
304,"NCT01240590","A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)","Completed","Has Results","Solid Tumor|Anaplastic Thyroid Cancer","Drug: Crolibulin|Drug: Cisplatin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","27","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","110027|11-C-0027","November 11, 2010","January 26, 2011","December 31, 2016","February 27, 2017","February 2017","October 26, 2015","null","August 31, 2015","Maximum Tolerated Dose (MTD) of Cisplatin (Phase I)|Maximum Tolerated Dose (MTD) of Crolibulin (Phase I)|Progression Free Survival (Phase II)|Number of Participants With Serious and Non-Serious Adverse Events (Phase I & II)|Number of Participants Who Underwent Medically-Necessary Interventions|Tumor Growth Rate Constant","https://ClinicalTrials.gov/show/NCT01240590"
305,"NCT02562599","Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: raltitrexed-cisplatin|Radiation: Intensity-modulated radiotherapy (IMRT)","Hubei Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Radiotherapy center-001","September 23, 2015","August 2015","August 2018","September 28, 2015","September 2015","No Study Results Posted","null","August 2016","ORR (Objective Response Rate)|OS(Overall Survival)|TTP（Time To Progression）|DCR (Disease Control Rate)|QOL（Quality Of Life）","https://ClinicalTrials.gov/show/NCT02562599"
306,"NCT02429726","Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion","Not yet recruiting","No Results Available","Malignant Pleural Effusion","Drug: rAdp53|Drug: Cisplatin|Drug: rAdp53 plus cisplatin","Shenzhen SiBiono GeneTech Co.,Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","rAd-p53-H2015002","April 24, 2015","June 2015","June 2017","April 24, 2015","April 2015","No Study Results Posted","null","June 2017","objective response rate|effusion-free survival|Karnofsky Performance Status|adverse events","https://ClinicalTrials.gov/show/NCT02429726"
307,"NCT00919061","Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy","Completed","Has Results","Extrahepatic Bile Duct Cancer|Gallbladder Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Sorafenib","Memorial Sloan Kettering Cancer Center|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-029","June 11, 2009","August 2009","March 2014","January 4, 2016","January 2016","October 19, 2015","null","March 2014","Progression-Free Survival|Median PFS","https://ClinicalTrials.gov/show/NCT00919061"
308,"NCT00882583","A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC","Terminated","Has Results","Head and Neck Cancer","Drug: Cetuximab|Drug: Dasatinib|Drug: Cisplatin|Radiation: Radiation Therapy","Sidney Kimmel Comprehensive Cancer Center|Bristol-Myers Squibb","All","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J08101|CA180123","April 15, 2009","July 2009","February 2016","January 4, 2017","January 2017","January 4, 2017","Dasatinib","February 2016","Phase I is Efficacy and Safety. Phase II Will be Tumor Response|1.Maximally Tolerated Dose (MTD) of Daily Oral Dasatinib in Combination With Cetuximab/RT in Cohort A 2. MTD of Daily Oral Dasatinib in Combination With Cisplatin/Cetuximab/RT in Cohort B","https://ClinicalTrials.gov/show/NCT00882583"
309,"NCT00349492","A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer","Drug: IP","Clinical Research Center for Solid Tumor, Korea","All","18 Years and older   (Adult, Senior)","Phase 3","372","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCST-L-0001","July 5, 2006","June 2006","October 2013","December 3, 2013","March 2012","No Study Results Posted","null","December 2011","Overall survival|Objective response rate|Progression free survival|Safety profile","https://ClinicalTrials.gov/show/NCT00349492"
310,"NCT00096174","Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck","Active, not recruiting","Has Results","Head and Neck Cancer","Biological: cetuximab C225|Drug: cisplatin|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","69","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000390923|U10CA021115|E3303","November 9, 2004","December 2004","July 2016","August 3, 2015","August 2015","February 28, 2011","null","July 2009","2-year Progression-free Survival Rate|2-year Overall Survival Rate|Overall Response Rate","https://ClinicalTrials.gov/show/NCT00096174"
311,"NCT02422498","Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy","Recruiting","No Results Available","Locally Recurrent/Metastatic Triple Negative Breast Cancer","Radiation: external beam radiation therapy|Drug: cisplatin|Procedure: Biopsy of Target Tumor","Memorial Sloan Kettering Cancer Center|Cedars-Sinai Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-032","April 14, 2015","April 2015","April 2019","January 24, 2017","January 2017","No Study Results Posted","null","April 2019","response (RECIST 1.1 vs. PET Response Criteria (PRC) as measurement tools for treatment response)","https://ClinicalTrials.gov/show/NCT02422498"
312,"NCT00081276","3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer","Completed","No Results Available","Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer","Drug: triapine|Drug: cisplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","48","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02585|GOG-0126O|U10CA027469|CDR0000360854","April 7, 2004","July 2005","null","January 23, 2013","January 2013","No Study Results Posted","null","January 2007","Frequency and duration of objective response assessed using RECIST criteria|Frequency and severity of observed adverse effects assessed using CTCAE version 3.0|Duration of progression-free survival|Duration of overall survival|Prognostic variables (e.g., initial performance status, age, and mucinous [or clear cell] histology)","https://ClinicalTrials.gov/show/NCT00081276"
313,"NCT01585805","Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","Recruiting","No Results Available","BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Metastatic Pancreatic Adenocarcinoma|PALB2 Gene Mutation|Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Veliparib","National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 2","107","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-00864|CDR0000732189|MSKCC-12-045|IRB#12-045|8993|N01CM00032|N01CM00071|P30CA008748|U01CA069856|UM1CA186705","April 25, 2012","April 18, 2012","null","May 23, 2017","May 2017","No Study Results Posted","null","July 25, 2017","Optimal dose of veliparib with gemcitabine hydrochloride and cisplatin (non-randomized part I)|Response rate of single-agent veliparib using RECIST criteria (Part II)|Response rate to gemcitabine hydrochloride and cisplatin with versus without veliparib as assessed by RECIST (randomized Part I)|Disease control rate (CR + PR + SD) and duration of response|Incidence of adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT01585805"
314,"NCT01450696","A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer","Terminated","Has Results","Gastric Cancer","Drug: Capecitabine|Drug: Cisplatin|Drug: Herceptin","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO27798|2011-001526-19","October 10, 2011","December 2011","August 2015","October 5, 2016","October 2016","October 5, 2016","HELOISE","February 2015","Percentage of Participants Who Died - FAS|Overall Survival - FAS|Percentage of Participants Who Died - Per Protocol Set (PPS)|Overall Survival - PPS|Percentage of Participants With Disease Progression or Death - PPS|Progression-Free Survival - PPS|Percentage of Participants With Objective Response - PPS|Trastuzumab Cmin on Day 21 of Cycles 1 to 11 - FAS|Trastuzumab Serum Concentration on Day 1 of Cycle 1 - FAS","https://ClinicalTrials.gov/show/NCT01450696"
315,"NCT02631590","Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma","Recruiting","No Results Available","Biliary Carcinoma|Gall Bladder Carcinoma|Cholangiocarcinoma|Gastrointestinal Tumor","Drug: Cisplatin|Drug: Gemcitabine|Drug: Copanlisib","H. Lee Moffitt Cancer Center and Research Institute|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-18435","December 14, 2015","June 28, 2016","December 2018","February 21, 2017","February 2017","No Study Results Posted","null","December 2018","Progression Free Survival (PFS)|Response Rate|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02631590"
316,"NCT01958658","AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer","Suspended","No Results Available","Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage IIIA Cervical Cancer|Stage IIIB Cervical Cancer","Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Internal Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Pulsed-Dose Rate Brachytherapy|Drug: WEE1 Inhibitor AZD1775","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","57","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-01765|PHL-087|9407|N01CM00032","October 7, 2013","September 5, 2013","null","May 23, 2017","May 2017","No Study Results Posted","null","June 30, 2021","RP2D defined as the dose level with < 1/6 patients with dose-limiting toxicity as assessed by the National Cancer Institute (NCI) Clinical Trials Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Safety profile of MK-1775 in combination with cisplatin and radiation therapy as assessed by the NCI CTCAE version 4.0 (Phase I)|Objective response to treatment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Pharmacodynamic effects of AZD1775 (MK-1775)|Pharmacokinetic (PK) parameters of AZD1775 (MK-1775)|Progression-free survival using RECIST version 1.1","https://ClinicalTrials.gov/show/NCT01958658"
317,"NCT00254904","Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cisplatin|Drug: Gemcitabine|Drug: PF-3512676|Drug: Cisplatin|Drug: Gemcitabine + Cisplatin","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","839","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A8501002","November 15, 2005","November 2005","June 2008","March 10, 2015","March 2015","No Study Results Posted","null","June 2008","Overall Survival|Patient Reported Outcomes|Overall Safety Profile|Progression Free Survival|Time to Tumor Progression|Overall Objective Response|Duration of Response","https://ClinicalTrials.gov/show/NCT00254904"
318,"NCT00818090","Paclitaxel and Cisplatin for Thymic Neoplasm","Terminated","No Results Available","Thymoma|Thymic Carcinoma","Drug: paclitaxel and cisplatin","Korean Cancer Study Group","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KCSG-LU08-03; CRCST-L-0003","January 5, 2009","September 2008","November 2011","April 11, 2013","September 2012","No Study Results Posted","null","November 2011","Response rate|toxicity|progression-free survival|duration of response|overall survival","https://ClinicalTrials.gov/show/NCT00818090"
319,"NCT01854749","S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study","Completed","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: S1 combined with cisplatin","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S1- ESCC -CJH","May 10, 2013","November 2011","null","February 22, 2016","February 2016","No Study Results Posted","null","December 2015","Progression Free Survival","https://ClinicalTrials.gov/show/NCT01854749"
320,"NCT01355302","E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer","Terminated","Has Results","Advanced or Metastatic Solid Tumors|Previously Untreated Gastric Cancer","Drug: E7050|Drug: cisplatin|Drug: capecitabine","Eisai Inc.|Quintiles, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","E7050-703|2011-000774-58","May 16, 2011","November 2011","July 2013","April 7, 2017","March 2017","January 19, 2017","null","April 2013","Area Under The Concentration-Time Curve (AUC) From 0 to 24 Hours of Golvatinib|Maximum Concentration (Cmax) of Golvatinib|Number of Participants With a Treatment-Emergent Adverse Event (TEAE)|Time to Maximum Concentration (Tmax) of Golvatinib|Overall Response Rate (ORR)|Time to Progression (TTP)","https://ClinicalTrials.gov/show/NCT01355302"
321,"NCT00608205","Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","69","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE3307|P30CA043703|NCI-2010-01197","January 30, 2008","January 2008","August 2016","September 9, 2016","September 2016","July 11, 2013","null","September 2012","Relapse Free Survival|Patterns of Failure|Overall Survival|Number of Patients With a Clinical Response-complete Disappearance of Detectable Tumor|Number of Patients With a Pathological(Final)Complete Response|Disease Recurrence|Number of Patients That Required a Feeding Tube|Nausea Level|Dry Mouth|Pain|Quality of Life|Eating|Swallowing|Alcohol Consumption|Solid Foods","https://ClinicalTrials.gov/show/NCT00608205"
322,"NCT02170090","Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer","Recruiting","No Results Available","Cholangiocarcinoma|Gall Bladder Carcinoma","Drug: Gemcitabine|Drug: Cisplatin|Other: Observation","Universitätsklinikum Hamburg-Eppendorf|Deutsche Krebshilfe e.V., Bonn (Germany)|medac GmbH|Cancer Research UK|AGITG Australasian Gastro Intestinal Trials Group|KWF Kanker Bestrijding The Netherlands","All","18 Years and older   (Adult, Senior)","Phase 3","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACTICCA-1|2012-005078-70|ACTRN12615001283561","June 18, 2014","April 2014","April 2022","March 29, 2017","March 2017","No Study Results Posted","ACTICCA-1","April 2019","Disease free survival (DFS)|Disease free survival rate at 24 months (DFSR@24)|overall survival|Safety and tolerability (assessed by the rate of patients with adverse events according to NCI CTC AE v4.03)|Quality of life|Function of biliodigestive anastomosis (in terms of surgical revision, requirement for PTCD)|Rate and severity of biliary tract infections|Patterns of disease recurrence|locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence)","https://ClinicalTrials.gov/show/NCT02170090"
323,"NCT02298595","Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma","Not yet recruiting","No Results Available","Carcinoma, Squamous|Squamous Cell Carcinoma|Oropharyngeal Neoplasms|Oropharyngeal Cancer","Drug: cisplatin|Drug: Cetuximab|Drug: BYL719","Julie E. Bauman, MD, MPH|Novartis|University of Pittsburgh","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","62","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","14-057|CBYL719XUS08T","November 11, 2014","August 2016","August 2024","July 5, 2016","July 2016","No Study Results Posted","null","August 2019","Complete clinico-radiologic response of primary tumor following induction therapy|Pathologic response of primary tumor and lymph nodes following induction therapy|2 year recurrence-free survival|Duration of survival|Proportion of patients with genomic PI3K pathway activation who have a complete clinico-radiologic and/or pathologic response to induction therapy|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02298595"
324,"NCT00527761","Taxotere/Temodar/Cisplatin Study in Melanoma Patients","Completed","No Results Available","Metastatic Melanoma","Drug: Cisplatin|Drug: Docetaxel|Drug: Temodar","M.D. Anderson Cancer Center|Aventis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","23","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-1037","September 10, 2007","August 2004","November 2007","July 26, 2012","July 2012","No Study Results Posted","null","November 2007","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT00527761"
325,"NCT00874328","A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: Irinotecan|Drug: Cisplatin|Drug: TS-1 (S-1)","National Cancer Center, Korea|Jeil Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","74","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-08-333","December 24, 2008","October 2008","December 2012","October 22, 2010","July 2010","No Study Results Posted","null","December 2011","Evaluation the Response rate IP plus TS-1(in phase 2)|To estimate the time to progression and overall survival|Determine MTD (Maximum tolerated dose) in phase I","https://ClinicalTrials.gov/show/NCT00874328"
326,"NCT00139269","Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Advanced Squamous Cell Carcinoma|Squamous Cell Carcinoma of Head and Neck|SSCHN","Drug: Docetaxel|Drug: Cisplatin|Drug: 5-Fluorouracil","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","38","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","97-199","August 29, 2005","February 1998","December 2006","June 2, 2008","June 2008","No Study Results Posted","null","December 2006","To determine whether cisplatin in combination with docetaxel and 5-fluorouracil can be given with acceptable side effects|to determine the efficacy of said combination.|To define the safety profile, the dose limiting toxicity and the recommended dose of cisplatin in combination with docetaxel and 5-fluorouracil.","https://ClinicalTrials.gov/show/NCT00139269"
327,"NCT00185835","Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck","Completed","No Results Available","Head and Neck Cancer|Carcinoma, Squamous Cell","Drug: ZD-1839|Drug: Cisplatin","Stanford University|American Society of Clinical Oncology|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ENT0012","September 12, 2005","June 2002","null","March 25, 2010","March 2010","No Study Results Posted","null","July 2006","To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD 1839 in combination with cisplatin and radiation therapy in patients with local-regional recurrent squamous cell cancer of the head and neck|To estimate the median and one-year disease-free and overall survival rates of the treated patients.|To determine the response rate, duration of response and duration of stable disease in these treated patients.|To identify and estimate the incidence rate of acute and late toxicities associated with combined ZD1839, chemotherapy and re-irradiation in patients with recurrent squamous cell cancer of the head and neck.|To determine the pattern of disease progression in recurrent disease patients treated with this regimen.|To assay EGFR pathway-related proteins by IHC and cDNA microarray, and to correlate their baseline expression, as well as changes in expression after therapy, with clinical endpoints including tumor remission and one-year survival.","https://ClinicalTrials.gov/show/NCT00185835"
328,"NCT02133612","Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma","Completed","No Results Available","Esophageal Cancer","Drug: paclitaxel; cisplatin","Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-026","May 5, 2014","December 2007","May 2014","April 13, 2015","April 2015","No Study Results Posted","null","May 2012","3 year overall survival|3 year disease-free survival","https://ClinicalTrials.gov/show/NCT02133612"
329,"NCT01874678","A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer","Completed","No Results Available","Non-small-cell Lung Cancer (NSCLC)","Drug: TS-1/Cisplatin","TTY Biopharm","All","20 Years to 74 Years   (Adult, Senior)","","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTYTG0904","June 4, 2013","March 2011","December 2015","January 10, 2016","January 2016","No Study Results Posted","null","December 2015","overall response rate|To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability","https://ClinicalTrials.gov/show/NCT01874678"
330,"NCT00515411","Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","Active, not recruiting","No Results Available","Gastroesophageal Junction Adenocarcinoma|Gastric Cancer","Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen","Memorial Sloan Kettering Cancer Center|Sanofi|Roche/Genetech|City of Hope National Medical Center|Piedmont Hospital Research Institute|Medical College of Wisconsin|Queens Health Network|Weill Medical College of Cornell University|Memorial Cancer Institute, Florida|University of Pittsburgh|Long Island Jewish Medical Center|Nebraska Cancer Specialists Methodist Estabrook Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","111","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06-103","August 10, 2007","October 2006","October 2017","November 9, 2016","November 2016","No Study Results Posted","null","October 2017","The primary endpoint for both arms is progression free survival (PFS), as measured from the start of the treatment to the date of either documentation of disease progression or death.|Secondary endpoints of efficacy are response rate, median PFS, overall, and 1 year survival.","https://ClinicalTrials.gov/show/NCT00515411"
331,"NCT01388790","Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: Cetuximab|Drug: Cisplatin|Drug: S-1","Merck KGaA","All","20 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 062202-058","June 24, 2011","June 2011","May 2013","September 9, 2013","September 2013","September 9, 2013","null","August 2012","Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments|Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments","https://ClinicalTrials.gov/show/NCT01388790"
332,"NCT00832637","Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers","Terminated","Has Results","Hepatocellular Carcinoma|Cholangiocellular Carcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct|Bile Duct Cancer|Periampullary Adenocarcinoma|Gallbladder Cancer|Extrahepatic Bile Duct Cancer","Drug: Cisplatin|Drug: Erlotinib|Drug: Gemcitabine","New Mexico Cancer Care Alliance","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INST OX-05-024|NCI-2011-02729|B9E-US-X467","January 13, 2009","August 2007","September 2016","March 15, 2016","March 2016","June 15, 2015","Gem-ox","June 2013","Tumor Control Rate|Overall Response Rate|Time to Tumor Progression (TTP)|Median Survival Time (MST)|Toxicity","https://ClinicalTrials.gov/show/NCT00832637"
333,"NCT00003928","Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer","Completed","No Results Available","Kidney Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU3897|P30CA043703|CWRU-3897|NCI-G99-1530","November 1, 1999","January 1999","April 2006","June 9, 2010","June 2010","No Study Results Posted","null","February 2005","Assess the response rate of patients with metastatic renal cell carcinoma treated with gemcitabine and cisplatin.","https://ClinicalTrials.gov/show/NCT00003928"
334,"NCT01326559","Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Docetaxel, Cisplatin, 5-FU and Cetuximab","Hong Kong Nasopharyngeal Cancer Study Group Limited|The University of Hong Kong|Sanofi|Merck Sharp & Dohme Corp.|Roche Pharma AG","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NPC-1001 trial","March 22, 2011","June 2010","March 2017","February 23, 2017","February 2017","No Study Results Posted","null","December 2016","Complete response rate|Overall response rate|Locoregional and distant control rate|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01326559"
335,"NCT00251550","Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Pleural Mesotherioma","Drug: Pemetrexed|Drug: Cisplatin","Eli Lilly and Company","All","20 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5249|H3E-JE-ME01","November 8, 2005","October 2005","August 2006","November 5, 2007","November 2007","No Study Results Posted","null","null","To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate|Duration of response|Progression free survival|Median survival time|1 year survival rate|Pulmonary function|QOL|Safety|Plasma concentration","https://ClinicalTrials.gov/show/NCT00251550"
336,"NCT01824459","S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Diffuse Gastric Adenocarcinoma Patients","Recruiting","No Results Available","Gastric Cancer","Drug: S-1|Drug: Oxaliplatin|Drug: Cisplatin","Sun Yat-sen University|Taiho Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","446","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SOX-DGCA","April 1, 2013","April 2013","March 2017","December 7, 2016","December 2016","No Study Results Posted","null","March 2017","Overall Survival|Objective response rate|time to treatment failure (TTF)|Treatment time to progression (TTP)|Adverse events (AE)","https://ClinicalTrials.gov/show/NCT01824459"
337,"NCT00371553","Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer","Completed","No Results Available","Relapsed or Cisplatin-Refractory Germ Cell Cancer","Drug: SU011248 (Sunitinib)","British Columbia Cancer Agency|Canadian Urologic Oncology Group|NCIC Testis Group|German Testicular Cancer Study Group","Male","18 Years and older   (Adult, Senior)","Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Testis protocol Version 003|CUOG-TE 05/OZM-007","September 1, 2006","November 2006","June 2009","July 7, 2009","July 2009","No Study Results Posted","null","June 2009","Response Rate|Rate and duration of stable disease|Time to progression.|Median and 1 yr survival|Safety and tolerability of SU011248","https://ClinicalTrials.gov/show/NCT00371553"
338,"NCT02639767","Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma","Withdrawn","No Results Available","Malignant Pleural Mesothelioma","Drug: Pemetrexed/Cisplatin|Radiation: Pleural Intensity Modulated Radiation Therapy|Device: MRI","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-304","December 18, 2015","December 2015","null","December 5, 2016","December 2016","No Study Results Posted","null","December 2016","Dose limiting toxicities (DLT)","https://ClinicalTrials.gov/show/NCT02639767"
339,"NCT02610556","Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin 2|Drug: Docetaxel|Drug: Cisplatin 1|Radiation: Intensity-modulated radiotherapy","Sun Yat-sen University|Affiliated Tumor Hospital of Guangzhou Medical University|The First Affiliated Hospital of Guangzhou Medical University|The First Affiliated Hospital of Guangdong Pharmaceutical University","All","18 Years to 65 Years   (Adult)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-FXY-071-Dept. of RT","November 13, 2015","January 2016","January 2022","May 25, 2016","May 2016","No Study Results Posted","null","January 2020","overall survival|failure-free survival|distant metastasis-free survival|locoregional relapse-free survival|Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02610556"
340,"NCT00388960","Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer","Drug: Amrubicin|Drug: Cisplatin|Drug: Etoposide","Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC Protocol 08062|2006-001956-11","October 13, 2006","November 2006","December 2010","November 21, 2016","November 2016","No Study Results Posted","null","April 2010","Objective tumor response rate according to RECIST criteria measured every 2 cycles (every 6 weeks)|Toxicity|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00388960"
341,"NCT01045538","Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer|Histone Deacetylase Inhibitor","Drug: Vorinostat, capecitabine, and cisplatin","Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0903","January 6, 2010","February 2010","December 2016","July 1, 2016","July 2016","No Study Results Posted","Zolinza+XP","December 2016","Phase 1 - maximum tolerated dose, Phase 2 - response rate|Toxicity profile|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01045538"
342,"NCT01095302","Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors","Completed","No Results Available","Neoplasms, Malignant","Drug: OMBRABULIN (AVE8062)|Drug: cisplatin|Drug: docetaxel","Sanofi","All","20 Years to 75 Years   (Adult, Senior)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD11089|U1111-1116-5905","March 23, 2010","May 2010","December 2011","October 12, 2013","October 2013","No Study Results Posted","null","December 2011","Dose limiting toxicity|Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities|Pharmacokinetic profiles of all study drugs and AVE8062 active metabolite based on PK parameters (Cmax, AUC, t1/2, CL, Vss).|Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)","https://ClinicalTrials.gov/show/NCT01095302"
343,"NCT00238407","Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Esophageal Cancer","Drug: Docetaxel and Cisplatin|Radiation: Radiotherapy","Swiss Group for Clinical Cancer Research","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 76/02|EU-20529","October 12, 2005","March 2004","August 2010","June 4, 2012","June 2012","No Study Results Posted","null","February 2008","Proportion of patients without local failure measured 6 months after completion of study treatment|Adverse reactions measured after completion of study treatment|Successful completion of therapy measured after completion of study treatment|Dysphagia as measured 6 months after completion of study treatment","https://ClinicalTrials.gov/show/NCT00238407"
344,"NCT01483300","Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: lobaplatin|Drug: cisplatin","Harbin Medical University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BC001","November 25, 2011","November 2011","November 2014","January 22, 2012","January 2012","No Study Results Posted","null","August 2014","Overall response rate|Time to progression|Overall Survival|Treatment related toxicity","https://ClinicalTrials.gov/show/NCT01483300"
345,"NCT00291850","Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC","Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: Paclitaxel, Cisplatin, Pegfilgrastim","Central European Cooperative Oncology Group","All","18 Years to 65 Years   (Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CECOG/NSCLC.3.2.002","February 14, 2006","June 2005","null","April 30, 2012","April 2012","No Study Results Posted","null","null","the evaluation of the clinical response rate of neo-adjuvant chemotherapy with dose-dense therapy of paclitaxel and cisplatin(PC) with peg-filgrastim in patients with operable NSCLC|>To evaluate the safety of neo-adjuvant chemotherapy with PC|- to characterize the toxicity of PC, include febrile neutropenia.|- to evaluate peri- and post-operative mortality|> to determine the pathological complete response rate|> to determine the complete tumor resection rate|> to evaluate proportion of cycle 2 and all cycles chemotherapy given with planned dose-on-time and proportion of patients receiving planned dose-on-time in cycle 2 and over all cycles.|> To evaluate the following time-to-event efficacy variables:|- disease free survival|- overall survival|> to evaluate Quality of life (EORTC QLQ-C30 and QLQ-LC13)","https://ClinicalTrials.gov/show/NCT00291850"
346,"NCT01034189","Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Drug: Cetuximab|Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiotherapy","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","62","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200803088M","December 16, 2009","October 2008","June 2012","December 16, 2009","December 2009","No Study Results Posted","null","December 2010","To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).|Pathologic complete response (pCR).|Disease-free survival.|Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery.","https://ClinicalTrials.gov/show/NCT01034189"
347,"NCT00183807","A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer","Terminated","No Results Available","Esophageal Cancer","Drug: irinotecan, cisplatin, celecoxib","University of Southern California|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3E-02-1","September 9, 2005","October 2003","March 2008","May 20, 2014","May 2014","No Study Results Posted","null","February 2006","To assess the time to progression of CPT-11 and cisplatin in combination with celebrex in patients with metastatic or unresectable carcinoma of the esophagus|To assess response rate and overall survival in these patients.|To assess the toxicity of this regimen.|To identify molecular correlates of response and survival (gene expression and genomic polymorphism of enzymes involved in drug metabolism, DNA repair, apoptosis)|To evaluate the effects of celebrex on a variety of histological and molecular biomarkers of angiogenesis, including in vitro activity assays on endothelial cell proliferation, migration and invasion.","https://ClinicalTrials.gov/show/NCT00183807"
348,"NCT00192101","Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes","Completed","No Results Available","Metastatic Breast Cancer","Drug: gemcitabine|Drug: cisplatin","Eli Lilly and Company","Female","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9590|B9E-SI-S371","September 12, 2005","October 2004","July 2005","November 16, 2007","November 2007","No Study Results Posted","null","null","Overall response rates of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer who have been previously treated with anthracycline with/without taxane based regimen|in the adjuvant/neoadjuvant or 1st line metastatic setting for each treatment arm separately.|To characterize the quantitative and qualitative toxicity of gemcitabine-cisplatin patient population for each treatment arm separately;Relative dose intensity of gemcitabine and cisplatin for each treatment arm separately|Rate of dose modifications (omissions, reductions, delays) for each treatment arm separately;Time to progression for each treatment arm separately;Duration of response for each treatment arm separately;1-year survival in each treatment arm separately|Overall survival in each treatment arm separately;To assess the medical resources utilization with the combination in each treatment arm separately","https://ClinicalTrials.gov/show/NCT00192101"
349,"NCT02322593","Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: TAS-118 plus Oxaliplatin|Drug: S-1 plus Cisplatin","Taiho Pharmaceutical Co., Ltd.|Yakult Honsha Co., LTD","All","20 Years and older   (Adult, Senior)","Phase 3","686","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","10056040","December 12, 2014","December 2014","May 2018","February 15, 2017","August 2016","No Study Results Posted","SOLAR","May 2018","Overall survival|Progression-free survival|Time to treatment failure|Overall response rate|Disease control rate|Safety monitoring including adverse events, vital signs, and laboratory assessments.","https://ClinicalTrials.gov/show/NCT02322593"
350,"NCT01445405","Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer","Completed","No Results Available","Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer","Drug: Bortezomib (Velcade, PS-341)|Drug: Cetuximab|Drug: Cisplatin|Procedure: Radiation Therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Senior)","Phase 1","3","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","080071|08-C-0071","September 30, 2011","February 5, 2008","August 27, 2010","May 12, 2017","February 8, 2013","No Study Results Posted","null","August 27, 2010","Evaluate feasibility/toxicities of combining proteasome inhibitor bortezomib with cetuximab without/with cisplatin concurrent with radiation for therapy of Pts with advanced SCCHN, and identify MTD for bortezomib for further clinical phase 2 dev...|1) Evaluate objective response rate, progression-free survival/overall survival with the above regimen. 2) Determine effects of bortezomib with cetuximab or with cetuximab/ cisplatin to inhibit activation of NF-kB, EGFR, MAPK, and STAT3 signal p...","https://ClinicalTrials.gov/show/NCT01445405"
351,"NCT02725918","Pemetrexed vs Pemetrexed Plus Cisplatin in Epidermal Growth Factor Receptor(EGFR)-Mutant NSCLC Patients After First Line EGFR Tyrosine Kinase Inhibitors (TKIs) Failure","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin","Guangdong Association of Clinical Trials","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTONG1510","March 11, 2016","April 2016","June 2020","March 28, 2016","March 2016","No Study Results Posted","null","April 2019","Progression-free survival without grade 4 (G4PFS)|Progression free survival (PFS)|Overall survival (OS)|Overall response rate (ORR)","https://ClinicalTrials.gov/show/NCT02725918"
352,"NCT02344095","A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer","Unknown status","No Results Available","Epithelial Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma","Drug: weekly paclitaxel|Drug: weekly cisplatin|Device: oncothermia","Seoul National University Hospital","Female","Child, Adult, Senior","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KGOG3030","November 1, 2014","December 2014","October 2015","January 22, 2015","January 2015","No Study Results Posted","POPOPO","October 2015","Occurrence of limiting toxicity|response rate|progression-free survival|overall-survival|quality of life, assessed with the Korean version of WHO Quality of Life-BREF (WHOQOL-BREF).|pain, assessed with the Korean version of the brief pain inventory (BPI).|fatigue, assessed with the Korean version of the Brief Fatigue Inventory (BFI).|compliance rate","https://ClinicalTrials.gov/show/NCT02344095"
353,"NCT00639769","Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC HN 0164|VU-VICC-HN-0164|VU-VICC-01-0847","March 19, 2008","February 2002","July 2008","September 7, 2012","September 2012","October 11, 2010","null","May 2007","Patient Response|Number of Patients With Each Worst-grade Toxicity","https://ClinicalTrials.gov/show/NCT00639769"
354,"NCT00747799","Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)","Completed","No Results Available","Nasopharyngeal Neoplasms","Drug: Sorafenib plus Cisplatin and 5-fluorouracil","Sun Yat-sen University","All","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BAY43-9006-2008003","September 4, 2008","January 2009","November 2011","December 8, 2013","November 2011","No Study Results Posted","null","May 2011","Objective response rate (CR+PR)|Disease control rate","https://ClinicalTrials.gov/show/NCT00747799"
355,"NCT00826891","Study of Cisplatin in Cervical Cancer Stage IVB","Unknown status","No Results Available","Cervical Cancer","Drug: Cisplatin Combined With Topotecan","Chinese Anti-Cancer Association","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CACA-2008-GSK1","January 16, 2009","February 2009","January 2010","January 20, 2009","January 2009","No Study Results Posted","null","January 2010","Response rate (CR + PR) (RECIST)|Toxicity [NCI CTCAE (Version 3.0)]","https://ClinicalTrials.gov/show/NCT00826891"
356,"NCT00232206","Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer","Terminated","No Results Available","Non-small-Cell Lung Carcinoma","Drug: Neoadjuvant Therapy with Cisplatin Plus Docetaxel","Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PPMC-EACRI-IRB-05-032|IIT #12207","September 30, 2005","May 2005","November 2007","May 17, 2011","May 2011","No Study Results Posted","null","April 2007","Primary objective: To assess the pathologic complete and partial response rate to neoadjuvant treatment with two cycles of cisplatin and docetaxel chemotherapy prior to resection of early stage NSCLC|Secondary objectives: Assessment of radiographic response rate by CT scanning, overall survival, time to progression, rate of complete surgical resection and toxicity|Evaluation of the predictive power of PET to define pathologic response","https://ClinicalTrials.gov/show/NCT00232206"
357,"NCT01453660","Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls","Active, not recruiting","No Results Available","Germ Cell Cancer","Other: Endo-PAT2000 testing|Other: Endo-PAT2000 testing","Memorial Sloan Kettering Cancer Center","Male","18 Years and older   (Adult, Senior)","","44","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","11-140","October 13, 2011","October 2011","October 2018","May 1, 2017","May 2017","No Study Results Posted","null","October 2018","Measure the endothelial reactivity (PAT-RH) in both groups|Identify sociodemographic|Identify comorbid health conditions|Measure PAT-RH index","https://ClinicalTrials.gov/show/NCT01453660"
358,"NCT03081039","A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma","Not yet recruiting","No Results Available","Intrahepatic Cholangiocarcinoma","Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine","University of Louisville","All","18 Years and older   (Adult, Senior)","Phase 3","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UL 2016.1","February 9, 2017","May 1, 2017","December 31, 2022","March 8, 2017","March 2017","No Study Results Posted","null","April 28, 2022","Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT03081039"
359,"NCT01460537","Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer","Completed","No Results Available","Neoplasms","Drug: Gemcitabine|Drug: BAY80-6946|Drug: Cisplatin|Drug: NaCl|Drug: BAY80-6964 fixed dose","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12875","September 15, 2011","November 2011","December 2015","March 7, 2016","March 2016","No Study Results Posted","null","July 2015","Adverse event collection|Maximum tolerated dose, measured by adverse event profile|Maximum drug concentration in plasma (Cmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|The time of the maximum concentration (Tmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Area under the curve (AUC) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Area under the concentration time curve (AUC (0-tn)) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Half life (t1/2) of Copanlisib with gemcitabine or cisplatin plus gemcitabine|Biomarker evaluation including analysis of pathway activation in tumor tissue and blood/plasma|Tumor Response as measured by RECIST 1.1 criteria","https://ClinicalTrials.gov/show/NCT01460537"
360,"NCT02035527","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Active, not recruiting","No Results Available","Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary","Drug: sorafenib tosylate|Drug: cisplatin|Drug: docetaxel|Other: Correlative Studies","Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","OSU-13141|NCI-2013-02086","January 10, 2014","April 14, 2014","December 31, 2018","March 1, 2017","March 2017","No Study Results Posted","null","December 31, 2017","Incidence of dose-limiting toxicity (DLT) as graded according to the NCI-CTCAE v4.0 (Phase I)|Progression-free survival (PFS) (Phase II)|Overall survival (OS)|Response rate evaluated by RECIST v1.1|Biomarker levels|Incidence of toxicities, graded according to NCI-CTCAE version 4.0","https://ClinicalTrials.gov/show/NCT02035527"
361,"NCT01616875","Bristol Bladder Trial","Recruiting","No Results Available","Infiltrating Bladder Urothelial Carcinoma","Drug: Cabazitaxel + Cisplatin chemotherapy","University Hospitals Bristol NHS Foundation Trust|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ON/2011/3775|2011-004090-82","May 17, 2012","May 2012","January 2018","April 19, 2017","April 2017","No Study Results Posted","null","September 2017","Overall pathological response rate|To record progression free survival|To assess quality of life|To record side effects and tolerability of treatment|Overall survival","https://ClinicalTrials.gov/show/NCT01616875"
362,"NCT02075112","Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck","Active, not recruiting","No Results Available","Cancer of Head and Neck","Drug: Soy isoflavone|Radiation: Radiation|Drug: Cisplatin","Emory University|Radiation Therapy Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00065591|RAD2412-13","February 12, 2014","November 2013","July 2020","July 26, 2016","July 2016","No Study Results Posted","null","July 2017","Percentage of patients with grade 2 or higher xerostomia at 1 year post-treatment|Exploratory biomarker studies: changes in interleukin 6|Exploratory biomarker studies: changes in vascular endothelial growth factor|Exploratory biomarker studies: changes in isoprostanes levels","https://ClinicalTrials.gov/show/NCT02075112"
363,"NCT01282151","TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer","Terminated","No Results Available","Carcinoma, Non Small Cell Lung","Drug: Taxotere|Drug: Pemetrexed","Chonnam National University Hospital|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","148","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_05478","January 21, 2011","July 2011","December 2014","July 13, 2015","July 2015","No Study Results Posted","TRAIL","December 2013","Progression Free Survival|Overall Survival (months from the beginning of first cycle chemotherapy)|Safety Profile|Response rate","https://ClinicalTrials.gov/show/NCT01282151"
364,"NCT00201760","Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Gemcitabine|Drug: Trastuzumab|Drug: Cisplatin","Kari Kendra|Eli Lilly and Company|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-0342","September 12, 2005","February 2005","null","November 6, 2012","November 2012","No Study Results Posted","null","December 2012","Disease free progression|Measure response rate of each drug combination|Asses the side effects of each drug combination.","https://ClinicalTrials.gov/show/NCT00201760"
365,"NCT02734537","Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Laryngeal Verrucous Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oral Cavity Verrucous Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma","Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","345","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA3132|NCI-2015-01911|U10CA180820","April 6, 2016","March 2016","null","October 4, 2016","October 2016","No Study Results Posted","null","December 2021","DFS in patients with disruptive p53 mutation|DFS in patients with non-disruptive p53 mutation|DFS in patients with wild type p53 mutation|Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4|p53 as a predictive marker of recurrence","https://ClinicalTrials.gov/show/NCT02734537"
366,"NCT00623064","Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: lapatinib ditosylate|Other: pharmacological study","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-30061|EUDRACT-2006-002976-16|GSK-EORTC-30061","February 22, 2008","November 2007","August 2012","June 30, 2014","June 2014","No Study Results Posted","null","June 2012","Maximum tolerated dose of lapatinib ditosylate in combination with cisplatin/gemcitabine hydrochloride and cisplatin/gemcitabine hydrochloride based on the documentation of the acute dose-limiting toxicity in course 1|Pharmacokinetic profile of lapatinib ditosylate in combination with cisplatin/gemcitabine hydrochloride and cisplatin/gemcitabine hydrochloride|Antitumor activity according to RECIST","https://ClinicalTrials.gov/show/NCT00623064"
367,"NCT01593306","Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix","Unknown status","No Results Available","Carcinoma Cervix","Drug: Paclitaxel, Cisplatin|Drug: Cisplatin","Indira Gandhi Medical College","Female","18 Years to 65 Years   (Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","pragyat1805","May 3, 2012","July 2011","February 2013","May 7, 2012","May 2012","No Study Results Posted","null","October 2012","clinical response of the disease|number of patients with adverse events","https://ClinicalTrials.gov/show/NCT01593306"
368,"NCT03002064","Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients","Recruiting","No Results Available","Esophagus Cancer|Chemotherapy Effects","Drug: Docetaxel|Drug: Fluorouracil|Drug: Cisplatin","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","358","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SYSUCC-ESO-01","December 16, 2016","December 2016","December 2020","December 23, 2016","December 2016","No Study Results Posted","null","December 2019","Progression free survival|Overall survival|Response rate|Grade 3 and 4 toxicities|Quality of life--Score of the questionnaire","https://ClinicalTrials.gov/show/NCT03002064"
369,"NCT01326871","A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer","Active, not recruiting","No Results Available","Transitional Cell Carcinoma of Bladder|Urethra Cancer|Ureter Cancer|Malignant Tumor of Renal Pelvis","Drug: Cisplatin|Drug: Gemcitabine|Biological: ALT-801","Altor Bioscience Corporation|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","90","Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA-ALT-801-01-10","March 30, 2011","June 2011","October 2017","April 11, 2016","April 2016","No Study Results Posted","null","July 2017","Maximum Tolerated Dose (MTD) and/or the recommended dose (RD) for dose expansion of ALT-801 in combination with cisplatin and gemcitabine or ALT-801 in combination with gemcitabine alone|Safety Profile|Clinical Benefit|Progression Free Survival|Overall survival|Pharmacokinetics and immunogenicity|Tumor Typing","https://ClinicalTrials.gov/show/NCT01326871"
370,"NCT00966914","Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel","BioNumerik Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DMS32212R","August 25, 2009","April 2010","June 2013","January 9, 2017","January 2017","No Study Results Posted","null","April 2013","Overall Survival|Progression Free Survival|Incidence of 30% or greater decrease in the calculated creatinine clearance relatively to baseline|Incidence of NCI-CTCAE grade 2,3, or 4 anemia|Proportion of patients having no impact of chemotherapy-induced emesis on daily life","https://ClinicalTrials.gov/show/NCT00966914"
371,"NCT02595905","Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer","Recruiting","No Results Available","BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma","Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Other: Placebo|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","235","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-01912|S1416|U10CA180888","November 3, 2015","July 7, 2016","null","May 24, 2017","May 2017","No Study Results Posted","null","October 31, 2021","PFS|Clinical benefit rate|Overall survival|Response rate (measurable disease only)","https://ClinicalTrials.gov/show/NCT02595905"
372,"NCT00394433","Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer","Completed","Has Results","Esophageal Cancer|Stomach Cancer","Drug: Bevacizumab|Drug: Docetaxel|Drug: Cisplatin|Drug: Irinotecan","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-100","October 31, 2006","September 2006","October 2016","November 21, 2016","September 2016","September 26, 2016","null","November 2008","10-month Progression-Free Survival Rate|Best Response|Overall Survival|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT00394433"
373,"NCT00661778","A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Bevacizumab|Drug: Cisplatin|Drug: Docetaxel","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20081|2006-005619-88","April 17, 2008","July 2007","July 2011","July 9, 2014","July 2014","May 27, 2014","null","July 2011","Progression-free Survival|Percentage of Participants With an Objective Response|Duration of the Objective Response|Overall Survival|1-year Survival","https://ClinicalTrials.gov/show/NCT00661778"
374,"NCT00942825","Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Metastatic Non-squamous Non Small Cell Lung Cancer","Drug: CBP501 + Cisplatin + Pemetrexed|Drug: Cisplatin + Pemetrexed","CanBas Co. Ltd.","All","18 Years and older   (Adult, Senior)","Phase 2","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CBP08-02","July 17, 2009","April 2009","July 2013","April 25, 2017","March 2017","March 14, 2017","CBP08-02","July 2013","The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per RECIST Criteria, or Until Death Due to Any Reason.","https://ClinicalTrials.gov/show/NCT00942825"
375,"NCT00082706","Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant","Active, not recruiting","No Results Available","Bladder Cancer|Urethral Cancer|Urachal Cancer","Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin|Drug: Cisplatin|Drug: Gemcitabine","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID03-0111|P50CA091846|P30CA016672|MDA-ID-030111|CDR0000355828|NCI-2012-01305","May 14, 2004","April 2003","null","December 19, 2016","December 2016","No Study Results Posted","null","February 2018","Number of Patients with Response|Number of Patients with Dose-Limiting Toxicity","https://ClinicalTrials.gov/show/NCT00082706"
376,"NCT01998347","Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer","Withdrawn","No Results Available","Esophageal Cancer","Drug: Paclitaxel liposome|Drug: Cisplatin|Drug: 5-fluorouracil","Shantou University Medical College","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSMECS 01|LYC01","November 17, 2013","November 2013","null","November 18, 2015","November 2015","No Study Results Posted","null","December 2017","median overall survival|median progression free survival","https://ClinicalTrials.gov/show/NCT01998347"
377,"NCT02537223","Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer","Recruiting","No Results Available","Squamous Cell Carcinoma of Head and Neck|Locoregionally Advanced","Drug: BYL719|Drug: Cisplatin|Radiation: Intensity modulated radiation therapy (IMRT)","University Health Network, Toronto|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BCX-001","August 28, 2015","September 2015","March 2019","June 21, 2016","June 2016","No Study Results Posted","null","September 2018","Number of Treatment Emergent Side Effects|Time from date of enrollment to date of relapse disease|Number of patients who do not have locoregional relapse of disease|Number of patients who do not have a distant metastatic relapse of disease|Time from date of enrolment to date of death","https://ClinicalTrials.gov/show/NCT02537223"
378,"NCT00702481","Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Nimotuzumab|Drug: Cisplatin|Radiation: Radiation","National Cancer Centre, Singapore|Innogene Kalbiotech Pte. Ltd","All","21 Years to 70 Years   (Adult, Senior)","Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IB/NCCS-01","June 19, 2008","April 2008","December 2017","March 21, 2016","March 2016","No Study Results Posted","null","December 2017","To determine the response rate of locally advanced HNSCC to treatment with Nimotuzumab and concurrent Cisplatin (CDDP) and Radiotherapy (RT).|To assess the toxicities associated with this regimen","https://ClinicalTrials.gov/show/NCT00702481"
379,"NCT01411098","Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","Terminated","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Drug: cisplatin|Drug: etoposide","University of Washington|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7506|NCI-2011-01752|P30CA015704","August 4, 2011","October 2011","null","November 3, 2015","November 2015","No Study Results Posted","null","March 2015","MTD of radiotherapy, in terms of number of daily fractions, that can be delivered using 3D-CRT or IMRT with the standard cisplatin/etoposide regimen","https://ClinicalTrials.gov/show/NCT01411098"
380,"NCT01437449","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Docetaxel|Drug: Cisplatin|Drug: Cetuximab|Drug: Carboplatin","Stanford University","All","16 Years and older   (Child, Adult, Senior)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ENT0033|SU-08222011-8290|22329|NCI-2011-03271","September 16, 2011","October 2011","January 2021","October 18, 2016","September 2016","No Study Results Posted","null","December 2018","Response rate|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01437449"
381,"NCT00006942","Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer","Drug: bryostatin 1|Drug: cisplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","32","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02831|PHII-21|T99-0039|N01CM17101","December 6, 2000","October 2000","null","August 23, 2013","August 2013","No Study Results Posted","null","March 2004","Overall survival|Progression-free survival|Time to progression|Response rate (CR or PR)|Time to treatment failure|Duration of response|Incidence by severity and type of toxicity based on the National Cancer Institute (NCI) Common Toxicity Criteria v2.0 and NCI Myalgia Toxicity Grading Scale|Association between p53, p21, bcl-2, bax, bcl-2/bax, ERCC-1, and Tdt and tumor response to chemotherapy (CR/PR vs not)","https://ClinicalTrials.gov/show/NCT00006942"
382,"NCT00982111","First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin","Active, not recruiting","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Biological: Necitumumab","Eli Lilly and Company|Quintiles, Inc.|Parexel|PPD|Medidata Solutions|Laboratory Corporation of America|University of Colorado, Denver|Thermo Fisher Scientific|Pacific Biomarkers|Intertek|Sysmex Inostics GmbH","All","18 Years and older   (Adult, Senior)","Phase 3","633","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13908|2009-012574-12|CP11-0805|I4X-IE-JFCB","September 18, 2009","November 2009","June 2017","February 15, 2017","February 2017","December 21, 2015","INSPIRE","November 2012","Overall Survival Time (OS)|Progression-Free Survival (PFS)|Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR])|Time to Treatment Failure (TTF)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab|Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity)|Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimensions (EQ-5D)|Mean Change From Baseline in PRO as Measured Using the Lung Cancer Symptom Scale (LCSS)|Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)|Percentage of Participants With EGFR Measured by IHC","https://ClinicalTrials.gov/show/NCT00982111"
383,"NCT02119650","Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer","Active, not recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Ruxolitinib|Drug: Placebo|Drug: Pemetrexed|Drug: Cisplatin","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","INCB 18424-266","April 17, 2014","March 2014","February 2017","March 3, 2016","March 2016","No Study Results Posted","null","February 2016","Part 1: Determination of the dose of ruxolitinib that is safe and tolerable in combination with pemetrexed/cisplatin as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.|Part 2: Overall Survival (OS)|Progression-free survival (PFS)|Objective Response Rate|Duration of Response|Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.","https://ClinicalTrials.gov/show/NCT02119650"
384,"NCT02657434","A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Atezolizumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Pemetrexed","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO29438|2015-003605-42","January 14, 2016","April 30, 2016","November 30, 2019","May 22, 2017","May 2017","No Study Results Posted","null","November 30, 2019","Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Overall Survival|Percentage of Participants Who Survived at Year 1|Percentage of Participants Who Survived at Year 2|Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1|Duration of Response as Determined by the Investigator Using RECIST v1.1|Time to Response as Determined by the Investigator According to RECIST v1.1|PFS as Determined by the Independent Review Facility Using RECIST V1.1|Time in Response as Determined by the Investigator Using RECIST V1.1|Time to Deterioration in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score|Time to Deterioration in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score|Time to Deterioration in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score|Minimum Observed Serum Atezolizumab Concentration (Cmin) Prior to Infusion|Maximum Observed Serum Atezolizumab Concentration (Cmax) Prior to Infusion|Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)|Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)|Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab","https://ClinicalTrials.gov/show/NCT02657434"
385,"NCT00537511","A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide","Terminated","Has Results","Carcinoma, Small Cell","Drug: Pomalidomide|Drug: Cisplatin|Drug: Etoposide","Celgene Corporation|Celgene","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC-4047-SCLC-002","September 27, 2007","February 2008","December 2010","May 7, 2013","May 2013","March 6, 2013","null","November 2010","Maximum Tolerated Dose (MTD)|Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase|Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response|Overall Survival|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase|Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase","https://ClinicalTrials.gov/show/NCT00537511"
386,"NCT00590031","Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.","Completed","Has Results","Esophageal Carcinoma","Drug: Cisplatin|Drug: Irinotecan|Radiation: External Beam Radiation Therapy","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-045|IND 65889","December 26, 2007","November 2002","December 2009","December 18, 2015","December 2015","December 18, 2015","null","December 2009","Pathologic Complete Response|Evaluate Toxicity and Tolerability Including Surgical Morbidity and Mortality","https://ClinicalTrials.gov/show/NCT00590031"
387,"NCT02196168","Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","Terminated","Has Results","Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Verrucous Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Oral Cavity Verrucous Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Verrucous Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Oral Cavity Verrucous Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue Carcinoma","Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo|Drug: WEE1 Inhibitor AZD1775","National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 2","6","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","NCI-2014-00759|PHL-088|NCI 9416|9416|N01CM00032","July 18, 2014","March 2014","April 2016","March 22, 2017","March 2017","November 18, 2016","null","April 2016","Overall Response Rate (Complete Plus Partial Response) Using RECIST Criteria v1.1|Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0|Levels of Pharmacodynamic Biomarkers|Levels of Predictive Biomarkers|Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02196168"
388,"NCT00821327","Gemzar, Cisp, Sunitinib Urothelial Ca","Completed","Has Results","Urothelial Cancer","Drug: Gemcitabine, Cisplatin, Sunitinib","US Oncology Research|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06040|WS356467","January 9, 2009","August 2008","August 2012","September 15, 2016","September 2016","January 12, 2016","null","August 2012","Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib.|Progression-free Survival|Ovarall Survival (OS)","https://ClinicalTrials.gov/show/NCT00821327"
389,"NCT00083161","Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Gundersen Lutheran Health System","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000363799|GLO-03-06-06","May 14, 2004","June 2003","May 2010","September 1, 2012","September 2012","No Study Results Posted","null","May 2010","Safety|Effect of metronomic chemotherapy on circulating endothelial cells|Progression-free survival|Response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00083161"
390,"NCT00374868","Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)","Completed","Has Results","Urologic Neoplasms","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","59","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","8679|H3E-ES-S085","September 11, 2006","August 2006","April 2008","October 20, 2010","October 2010","April 29, 2009","null","April 2008","Best Overall Tumor Response|Time to Response|Duration of Response|Duration of Stable Disease|Time to Progressive Disease|Time to Treatment Failure (TTF)|Progression-Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00374868"
391,"NCT00423930","Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: bevacizumab|Drug: cisplatin|Procedure: conventional surgery|Radiation: intensity-modulated radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-130|MSKCC-06130|PFIZER-MSKCC-06130","January 16, 2007","October 2006","July 2016","August 2, 2016","August 2016","No Study Results Posted","null","July 2016","Progression-free survival at 2 years|Median overall survival","https://ClinicalTrials.gov/show/NCT00423930"
392,"NCT00077883","TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: TLK286, cisplatin","Telik","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TLK286.2021","February 12, 2004","February 2004","March 2007","July 21, 2011","June 2005","No Study Results Posted","null","March 2007","Primary Objectives of the Study","https://ClinicalTrials.gov/show/NCT00077883"
393,"NCT00731380","A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: ABI-007","University Health Network, Toronto|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","APF-001","August 6, 2008","July 2008","June 2016","June 21, 2016","June 2016","No Study Results Posted","null","June 2016","The maximum tolerated dose of ABI-007 with Cisplatin and 5-Fluorouracil (APF)|safety and tolerability profiles for ABI-007","https://ClinicalTrials.gov/show/NCT00731380"
394,"NCT02648425","Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin With Capecitabine","Recruiting","No Results Available","Solid Tumor","Drug: ASLAN001|Drug: cisplatin + capecitabine|Drug: cisplatin + 5-fluorouracil (or+ Leucovorin)","Aslan Pharmaceuticals","All","20 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Aslan001-002","June 21, 2015","August 2014","December 2017","April 24, 2017","April 2017","No Study Results Posted","null","December 2017","Safety and Tolerability of ASALN001|Preliminary assessment of the efficacy|Pharmacokinetics profile (AUC) of ASLAN001|Pharmacokinetics profile (Cmax) of ASLAN001|Pharmacokinetics profile (Cmin) of ASLAN001|Pharmacokinetics profile (RacAUC0-6) of ASLAN001","https://ClinicalTrials.gov/show/NCT02648425"
395,"NCT00510107","Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC","Unknown status","No Results Available","Stomach Neoplasm|Stage IV|Recurrent","Drug: oxaliplatin|Drug: Cisplatin","Gachon University Gil Medical Center|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMO-GI-72","July 31, 2007","July 2007","July 2009","July 31, 2007","July 2007","No Study Results Posted","null","null","response rate|safety","https://ClinicalTrials.gov/show/NCT00510107"
396,"NCT00415168","Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10874|H3E-MW-S108","December 20, 2006","December 2006","July 2009","August 11, 2010","August 2010","July 13, 2010","null","July 2009","Percentage of Participants With Objective Response (Objective Response Rate)|Duration of Response|Progression Free Survival (PFS)|Overall Survival|Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Laboratory Toxicity Possibly Related to Study Therapy|Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Non-Laboratory Toxicity Possibly Related to Study Therapy|Number of Participants Who Died During the Study","https://ClinicalTrials.gov/show/NCT00415168"
397,"NCT03086993","Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma","Not yet recruiting","No Results Available","Bile Duct Cancer|Intrahepatic Cholangiocarcinoma","Combination Product: Melphalan/HDS|Drug: Cisplatin and Gemcitabine","Delcath Systems Inc.","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","295","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PHP-ICC-203","March 13, 2017","September 2017","May 2023","March 21, 2017","March 2017","No Study Results Posted","null","January 2023","Overall Survival|Progression-free survival, as determined by IRC|Objective response rate (CR + PR) as determined by the Investigator","https://ClinicalTrials.gov/show/NCT03086993"
398,"NCT01645748","Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: S-1|Drug: S-1|Drug: S-1","Chonnam National University Hospital|Chungbuk National University|Chonbuk National University|Chungnam National University","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CNUHH-MO-02|CNUHH","July 12, 2012","October 2008","March 2012","July 18, 2012","July 2012","No Study Results Posted","TPSHNSCC","October 2011","Response rate|Safety|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01645748"
399,"NCT00281970","Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Procedure: adjuvant therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000455112|JHOC-J0435|JHOC-WIRB-20040761|MSKCC-04039","January 24, 2006","August 2004","null","February 6, 2009","July 2007","No Study Results Posted","null","null","Total cisplatin dose|Toxicity|Overall survival|Disease-free survival","https://ClinicalTrials.gov/show/NCT00281970"
400,"NCT00678535","Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: Cetuximab|Drug: Capecitabine|Drug: Cisplatin","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","904","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 200048-052|2007-004219-75","May 13, 2008","June 2008","February 2013","July 11, 2014","July 2014","March 30, 2013","EXPAND","March 2012","Progression-free Survival (PFS) Time: Independent Review Committee (IRC) Assessments|Overall Survival (OS)|Best Overall Response (BOR) Rate: Independent Review Committee (IRC) Assessments|Quality of Life (QoL) Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Quality of Life (QoL) Assessed by EuroQol 5Dimensions (EQ-5D) Questionnaire|Safety - Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00678535"
401,"NCT00084435","S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer","Withdrawn","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000365311|S0217|U10CA032102","June 10, 2004","July 2005","January 2007","June 13, 2012","June 2012","No Study Results Posted","S0217","January 2007","Disease progression|Disease-free survival|Symptomatic deterioration|Toxicity","https://ClinicalTrials.gov/show/NCT00084435"
402,"NCT00565370","Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC)","Completed","Has Results","Advanced Gastric Cancer","Drug: Capecitabine, Cisplatin, Sorafenib","Asan Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0701","November 28, 2007","November 2007","December 2009","August 1, 2015","August 2015","December 15, 2013","XP+Sorafenib","December 2009","Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)|Progression-free Survival|Response Rate|Overall Survival|Toxicity Profile (According to National Cancer Institute Common Terminology Criteria for Adverse Event Version 3.0)","https://ClinicalTrials.gov/show/NCT00565370"
403,"NCT01076400","A Study of MK1775 in Combination With Topotecan/Cisplatin in Patients With Cervical Cancer (1775-008)","Terminated","No Results Available","Cervical Cancer","Drug: MK1775 + topotecan + cisplatin|Drug: Comparator: MK1775 + topotecan + cisplatin|Drug: Comparator: Placebo to MK1775 + topotecan + cisplatin","Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","1775-008|MK1775-008","February 24, 2010","May 2010","June 2011","February 3, 2015","February 2015","No Study Results Posted","null","June 2011","Part 1: Objective response rate|Part 1: Maximum tolerated dose as determined by the number of dose limiting toxicities (DLTs) per dose level|Part 2: Progression-free survival","https://ClinicalTrials.gov/show/NCT01076400"
404,"NCT02151084","A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","Recruiting","No Results Available","Biliary Tract Carcinoma|Gallbladder Carcinoma","Drug: Selumetinib|Drug: Cisplatin|Drug: Gemcitabine","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BIL-MEK","May 28, 2014","November 2014","May 2017","June 21, 2016","June 2016","No Study Results Posted","null","November 2016","Change in tumor size in millimetres|Number of participants with objective response and/or stable disease|Percentage of patients without progressive disease|Progression-free survival in months|Overall survival in months|Total incidence of adverse events|Total rate of grade 3 and 4 toxicities","https://ClinicalTrials.gov/show/NCT02151084"
405,"NCT01029873","QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: Cisplatin|Biological: ALT-801","Altor Bioscience Corporation|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","25","Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA-ALT-801-02-09|R44CA097550","December 9, 2009","February 2010","September 2013","October 26, 2016","October 2016","No Study Results Posted","null","November 2011","To evaluate the safety of the ALT-801-Cisplatin regimen.|To assess the objective response (OR) which includes CR and PR.|To assess the clinical benefit (CB) of the ALT-801-Cisplatin regimen which includes CR, PR and SD.|To determine the MTD of the ALT-801-Cisplatin regimen.|To assess the six-month and one-year survival rates.|To evaluate the immunogenicity and pharmacokinetic profile of ALT-801.","https://ClinicalTrials.gov/show/NCT01029873"
406,"NCT00400205","Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil","Terminated","Has Results","Squamous Cell Carcinoma|Oral Cancer","Drug: Taxotere|Drug: Cisplatin|Drug: 5-fluorouracil","Emory University|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0414-2006","November 15, 2006","August 2006","September 2009","March 30, 2011","September 2010","December 6, 2010","null","September 2009","Number of Patients Who Had Response by RECIST Criteria (Response Evaluation Criteria in Solid Tumors)|Measure the Acetylated Tubulin Expression and Correlate With Clinical Outcome.","https://ClinicalTrials.gov/show/NCT00400205"
407,"NCT00895648","Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma","Terminated","No Results Available","Mesothelioma|Pleural Mesothelioma","Drug: Pemetrexed|Drug: Cisplatin","University Health Network, Toronto|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","05-0815-C","May 6, 2009","January 2009","October 2012","May 3, 2017","May 2017","No Study Results Posted","null","October 2012","median relapse-free survival (RFS)","https://ClinicalTrials.gov/show/NCT00895648"
408,"NCT01109524","Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer","Completed","Has Results","Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma","Drug: Cetuximab|Drug: Cisplatin|Drug: Vinorelbine","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-346","April 22, 2010","July 2010","September 2012","November 24, 2015","November 2015","September 12, 2013","null","September 2012","Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population|Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population|Number of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population|Number of Participants With Hematology Laboratory Abnormalities - Treated Population|Number of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population|Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population|Number of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population","https://ClinicalTrials.gov/show/NCT01109524"
409,"NCT00949949","Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy","Completed","No Results Available","Cholangiocarcinoma of the Gallbladder|Localized Gallbladder Cancer|Unresectable Gallbladder Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: everolimus|Drug: gemcitabine hydrochloride|Drug: cisplatin","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","38","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0812|NCI-2009-01151|09-000809|P30CA015083","July 30, 2009","September 2009","July 2014","January 11, 2017","January 2017","No Study Results Posted","null","July 2014","Adverse events profile|Toxicity profile per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0|MTD of the combination of everolimus, gemcitabine hydrochloride, and cisplatin|Response profile|Timed endpoints","https://ClinicalTrials.gov/show/NCT00949949"
410,"NCT01301612","Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)","Withdrawn","No Results Available","Carcinoma|Adenocarcinoma|Uterine Cervix Adenosquamous Carcinoma","Drug: Nimotuzumab|Drug: Cisplatin|Radiation: Brachytherapy|Drug: Cisplatin|Radiation: Radiation Therapy","Eurofarma Laboratorios S.A.","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EF 110","February 21, 2011","January 2011","null","July 10, 2014","January 2012","No Study Results Posted","null","December 2017","Local control of disease|Complete clinical response rate","https://ClinicalTrials.gov/show/NCT01301612"
411,"NCT01086254","SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer Stage IV","Drug: Iniparib|Drug: gemcitabine|Drug: cisplatin","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD11420|2009-017270-21|U1111-1116-5404","March 11, 2010","May 2010","December 2011","September 23, 2013","September 2013","No Study Results Posted","null","December 2011","overall response rate (ORR) that is defined in the RECIST 1.1 version, as: complete response rate + partial response rate|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT01086254"
412,"NCT00215995","Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: Cisplatin|Drug: Irinotecan|Drug: ZD 1839","H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-13426|USFIRB#101525","September 19, 2005","July 2003","May 2007","January 12, 2012","May 2007","No Study Results Posted","null","May 2007","Number of Participants With Desired Response|Duration of Participants' Desired Response|Participants' Time to Disease Progression|Number of Participants With Overall Survival","https://ClinicalTrials.gov/show/NCT00215995"
413,"NCT00865982","Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer","Unknown status","No Results Available","Gastric Cancer|Esophageal Cancer","Drug: Docetaxel, Cisplatin, Capecitabine","Charite University, Berlin, Germany|Roche Pharma AG|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Eudract-CT-2008-001849-26","March 19, 2009","September 2008","September 2015","August 4, 2011","August 2011","No Study Results Posted","DCXAIOCHARITE","September 2014","R0-resection rate|Remission rate according to diagnostic imaging techniques|Pathological remission rate|Operative and postoperative complication rate|Resectability rate|Rate of local recurrences and metastasis|Toxicity|30-day mortality|Overall survival|Overall survival rate|Event free survival rate","https://ClinicalTrials.gov/show/NCT00865982"
414,"NCT00176813","Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Celecoxib","University of Michigan Cancer Center|Eli Lilly and Company|Barbara Ann Karmanos Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2001-071|C2442","September 9, 2005","March 2003","November 2006","April 29, 2008","April 2008","No Study Results Posted","null","November 2003","To determine the overall survival time in patients with metastatic pancreatic cancer treated with the combination of gemcitabine, cisplatin and celecoxib.|To obtain data on overall time to disease progression|To determine time to treatment failure|To determine the tolerability of celecoxib with gemcitabine and cisplatin.|To characterize the nature of the toxicity for this combination in this patient group.|To determine objective tumor response|To determine the influence of therapy on the blood levels of prostaglandins and angiogenesis","https://ClinicalTrials.gov/show/NCT00176813"
415,"NCT02768558","Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Radiation: Thoracic RT|Drug: Cisplatin|Drug: Etoposide|Drug: Nivolumab|Other: Placebo","RTOG Foundation, Inc.|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 3","660","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","RTOG 3505|RF 3505|CA209-333","May 6, 2016","October 2016","October 2024","May 18, 2017","May 2017","No Study Results Posted","null","October 2022","Overall Survival (OS)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02768558"
416,"NCT02508246","WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Cisplatin|Drug: Docetaxel|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Procedure: Therapeutic Conventional Surgery|Drug: WEE1 Inhibitor AZD1775","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9168|NCI-2015-01064|P30CA015704","July 10, 2015","July 22, 2015","null","April 28, 2017","April 2017","No Study Results Posted","null","October 2017","Incidence of adverse events graded according to the NCI CTCAE version 4.03|MTD of AZD1775, based on the incidence of dose limiting toxicity (DLT), graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Objective response (complete response, partial response, stable disease or progressive disease) according to Response Evaluation Criteria In Solid Tumors|Pharmacodynamic profile of AZD1775|PK profile of WEE1 inhibitor MK-1775 with docetaxel and cisplatin|Progression-free survival (PFS) duration","https://ClinicalTrials.gov/show/NCT02508246"
417,"NCT02944357","Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery","Not yet recruiting","No Results Available","Infiltrating Bladder Urothelial Carcinoma|Stage II Bladder Urothelial Carcinoma|Stage III Bladder Urothelial Carcinoma|Stage IV Bladder Urothelial Carcinoma","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Procedure: Radical Cystectomy|Biological: Tumor Cell-Derived Vaccine Therapy","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1452|NCI-2016-01517|P30CA015083","October 19, 2016","November 2016","null","October 24, 2016","October 2016","No Study Results Posted","null","November 2021","Change in the frequency of CD11a high PD-1+ CD8+ T cells|1-year survival rate|2-year disease-free survival rate|2-year survival rate|Disease-free survival rate|Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events|Manufacturing success rate and successful manufacture of > 5 doses and administration of 1 or more doses of AGS-003-BLD|Proportion of pathologic complete responses|Time to first metastatic lesion","https://ClinicalTrials.gov/show/NCT02944357"
418,"NCT02567409","Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer","Recruiting","No Results Available","Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Stage IV Bladder Urothelial Carcinoma","Drug: ATR Kinase Inhibitor VX-970|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","90","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-01642|PHII-135|9947|N01CM00038|P30CA033572|UM1CA186690|UM1CA186717","October 2, 2015","August 19, 2016","null","May 23, 2017","May 2017","No Study Results Posted","null","August 31, 2018","Progression-free survival|Analysis of potential predictors of response (including p53, p21, and ERCC2 mutations)|Incidence of toxicity graded according the Common Terminology Criteria for Adverse Events version 4.0|Overall response rate assessed by the Response Evaluation Criteria in Solid Tumors version 1.1|Overall survival","https://ClinicalTrials.gov/show/NCT02567409"
419,"NCT00833261","Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: cetuximab|Drug: cisplatin|Radiation: intensity-modulated radiation therapy","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000632295|SCCC-04308|CA 225314|112008-004","January 30, 2009","December 2008","December 2016","March 19, 2015","May 2014","No Study Results Posted","null","December 2016","crude survival|progression-free survival and local-regional progression|acute and late toxicities|disease progression|Response","https://ClinicalTrials.gov/show/NCT00833261"
420,"NCT02216617","Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy","Unknown status","No Results Available","HNSCC","Drug: Taxotere, Cisplatin, Afatinib","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC 2013-01|2013-002876-42","August 7, 2014","August 2014","February 2016","August 13, 2014","August 2014","No Study Results Posted","TAPIS","February 2016","Maximum Tolerated Dose (MTD)|Tolerance|Efficacy","https://ClinicalTrials.gov/show/NCT02216617"
421,"NCT02429466","Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors","Suspended","No Results Available","Germ Cell Tumor|Testis Cancer|Testicular Cancer","Drug: SGI-110","Costantine Albany|Indiana University","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IUCRO-0508","April 14, 2015","April 27, 2015","December 31, 2018","May 18, 2017","May 2017","No Study Results Posted","null","December 31, 2017","Dose limiting toxicity (DLT) of SGI-110 plus cisplatin|Maximum tolerated dose (MTD) of SGI-110 plus cisplatin|Objective response rate (ORR)|Progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT02429466"
422,"NCT00270582","A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Taxotere, Cisplatin, Gemcitabine","Far Eastern Memorial Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","58","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","FEMH-94015","December 26, 2005","November 2005","null","February 6, 2009","September 2005","No Study Results Posted","null","null","To evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens:|weekly docetaxel plus cisplatin followed by gemcitabine and|gemcitabine plus cisplatin followed by weekly docetaxel.|To evaluate the median overall time to treatment failure (TTF).|To evaluate the overall progression free survival (PFS).|To evaluate the overall survival of each arm.|To evaluate the time to treatment failure for first regimen.|To evaluate the progression free survival for first regimen.|To evaluate the response rate for each regimen.|To evaluate the toxicity of each arm.|To evaluate the duration of response.","https://ClinicalTrials.gov/show/NCT00270582"
423,"NCT00772681","Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma","Completed","No Results Available","Head and Neck Neoplasms","Drug: docetaxel and cisplatin","Sanofi","All","19 Years and older   (Adult, Senior)","Phase 4","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976F_6007","October 13, 2008","October 2004","March 2008","December 4, 2009","December 2009","No Study Results Posted","Tax-Nazo","March 2008","Complete response rate after neoadjuvant chemotherapy|Percentage of patients whose is disease controlled locally or regionally|Median length of overall survival|Median length of disease free survival|Percentage of alive patients without metastatis","https://ClinicalTrials.gov/show/NCT00772681"
424,"NCT02913066","S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma","Not yet recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Other: S-1 concurrent radiotherapy|Other: S-1 plus Cisplatin concurrent radiotherapy","Mianyang Central Hospital","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","253","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XDu","September 20, 2016","September 2016","March 2019","September 22, 2016","September 2016","No Study Results Posted","null","March 2019","Complete Remission Rate (CR)|Overall Survival (OS)|Progression-Free-Survival (PFS)","https://ClinicalTrials.gov/show/NCT02913066"
425,"NCT01595061","Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva","Recruiting","No Results Available","Stage IIIA Vulvar Cancer|Stage IIIB Vulvar Cancer|Stage IIIC Vulvar Cancer|Stage IVA Vulvar Cancer|Vulvar Squamous Cell Carcinoma","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Radiation: Intensity-Modulated Radiation Therapy|Procedure: Therapeutic Conventional Surgery","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","52","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GOG-0279|NCI-2012-01964|CDR0000732793|U10CA180868|U10CA027469","May 8, 2012","July 2012","null","May 2, 2017","May 2017","No Study Results Posted","null","September 2019","Complete pathologic response evaluated as the frequency of complete clinical and pathologic response after primary therapy|Complete clinical response, defined as no clinical/radiographic evidence of primary disease (vulvar or groin) following chemo-radiation therapy|Incidence and severity of adverse effects tabulated based on the Common Terminology Criterial for Adverse Events (CTCAE) v 4.0|Overall survival (OS)|Progression-free survival (PFS)|Site(s) of disease recurrence/relapse|Treatment compliance, including treatment span, incidence and duration of treatment delay, reasons for delays, chemotherapy dose, radiation dose and reasons for dose level reductions","https://ClinicalTrials.gov/show/NCT01595061"
426,"NCT00497315","Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: combination chemotherapy (pemetrexed + cisplatin)|Radiation: thoracic irradiation + pemetrexed","University Hospital, Antwerp|Universiteit Antwerpen|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TOGA 0502|Eudra CT 2005-004030-40","July 4, 2007","February 2006","March 2009","April 9, 2009","April 2009","No Study Results Posted","PACCORA","March 2009","Response rate|Toxicity|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT00497315"
427,"NCT01855451","Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma","Recruiting","No Results Available","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Drug: Cetuximab|Radiation: RT (70 Gy in 35 fractions)|Drug: Cisplatin","Trans-Tasman Radiation Oncology Group (TROG)","All","18 Years and older   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TROG 12.01|ACTRN12613000279729","May 13, 2013","June 2013","June 2021","February 15, 2017","February 2017","No Study Results Posted","HPVOropharynx","June 2019","Symptom Severity|Symptom severity|Interference of symptoms with daily life|Psychological distress|Impact on Health Related Quality of Life|Swallowing dysfunction|Speech and dietary function|Clinician-assessed acute and late toxicity|Rate of enteral feeding|Hearing impairment|Time to locoregional failure|Failure-free survival|Overall survival|Pattern of disease failure|Complete response rate|Cost of health resource utilisation|Work status and time to return to work|Potential prognostic markers","https://ClinicalTrials.gov/show/NCT01855451"
428,"NCT00744900","Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Lung Cancer","Drug: Pemetrexed, cisplatin","University Hospital, Brest","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GFPC 07-01|RB 07.103","August 29, 2008","September 2008","null","July 24, 2009","July 2009","No Study Results Posted","GFPC 07-01","null","Objective of this study is overall response rate on brain metastasis according to RECIST criteria.|Overall response rate, PFS after first-line CDDP plus pemetrexed, safety profile, quality of life, neurological symptoms and overall survival.","https://ClinicalTrials.gov/show/NCT00744900"
429,"NCT00885534","Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma","Completed","Has Results","Melanoma|Skin Cancer","Drug: Cisplatin, Vinblastine, Temozolomide","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-017","April 21, 2009","April 2009","October 2013","April 21, 2015","April 2015","April 7, 2015","null","October 2013","Overall Response to CVT Chemotherapy.","https://ClinicalTrials.gov/show/NCT00885534"
430,"NCT01788566","A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Necitumumab|Drug: Gemcitabine|Drug: Cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14789|I4X-MC-JFCK","February 7, 2013","March 2013","December 2015","May 20, 2016","May 2016","December 21, 2015","null","August 2014","Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)|Number of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]|Percent Change in Tumor Size (CTS)|Pharmacokinetics (PK): Minimum (Cmin) Maximum Concentration (Cmax) of Necitumumab|Number of Participants With Anti-Necitumumab Antibodies","https://ClinicalTrials.gov/show/NCT01788566"
431,"NCT00148798","Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)","Completed","Has Results","Non Small Cell Lung Cancer (NSCLC)","Drug: cetuximab + cisplatin + vinorelbine|Drug: cisplatin + vinorelbine","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","1861","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-046","September 7, 2005","October 2004","May 2012","June 13, 2014","June 2014","August 24, 2011","FLEX","July 2007","Overall Survival Time (OS)|Progression-free Survival Time|Best Overall Response Rate|Disease Control Rate|Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status|Quality of Life Assessment (EORTC QLQ-C30) Social Functioning|A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations|Safety - Number of Patients Experiencing Any Adverse Event","https://ClinicalTrials.gov/show/NCT00148798"
432,"NCT00270569","An Effective and Compliance Regimen of Paclitaxel Plus Cisplatin to Treat Metastatic Breast Cancer","Unknown status","No Results Available","Breast Neoplasms","Drug: PhyxolTM, Cisplatin","Far Eastern Memorial Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FEMH-94012","December 26, 2005","October 2005","null","February 6, 2009","August 2005","No Study Results Posted","null","February 2007","The primary objective is to determine the tumor response of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin chemotherapy for patients with metastatic breast cancer.|Toxicities of weekly low- or conventional-dose paclitaxel plus 24-hour infusion of cisplatin.|The patients'quality of life as evaluated by questionnaire interview.|Progression-free survival.|Overall survival.","https://ClinicalTrials.gov/show/NCT00270569"
433,"NCT00254384","Neoadjuvant, Tarceva, Surgery for Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting","No Results Available","Lung Cancer","Drug: Erlotinib|Drug: Cisplatin|Drug: Docetaxel","M.D. Anderson Cancer Center|Sanofi|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0221|NCI-2012-01560","November 14, 2005","October 2005","null","October 14, 2016","October 2016","No Study Results Posted","null","October 2018","Changes that occur in epidermal growth factor receptor (EGFR) and how these changes are reflected in different cells.|Safety of chemotherapy (cisplatin, docetaxel) given to patients whose lung cancer will be surgically removed, and erlotinib maintenance therapy given after surgery.","https://ClinicalTrials.gov/show/NCT00254384"
434,"NCT00318890","Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Cancer of Head and Neck|Head Cancer|Head and Neck Cancer|Neck Cancer|Neck Neoplasms","Drug: Cisplatin|Drug: Docetaxel|Procedure: Radiotherapy|Drug: Amifostine","University of Alabama at Birmingham|Aventis Pharmaceuticals","All","19 Years and older   (Adult, Senior)","Phase 1|Phase 2","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","F020522012|UAB 0210","April 25, 2006","October 2002","December 2007","February 11, 2011","February 2011","No Study Results Posted","null","April 2007","To establish the response rate to chemotherapy followed by docetaxel with radiotherapy and to assess overall survival, local-regional recurrence rate and effects on the quality of life.|To evaluate the toxicities of chemotherapy followed by concomitant docetaxel with radiotherapy in patients.|To evaluate tumor specimens for intermediary biomarkers of response or prognosis as compared to normal tissue|To assess the tolerance to subcutaneous amifostine and its effect on saliva production.","https://ClinicalTrials.gov/show/NCT00318890"
435,"NCT01611662","Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer","Terminated","Has Results","Distal Urethral Cancer|Proximal Urethral Cancer|Squamous Cell Carcinoma of the Bladder|Stage II Bladder Cancer|Stage III Bladder Cancer|Urethral Cancer Associated With Invasive Bladder Cancer","Drug: gemcitabine hydrochloride|Drug: cisplatin|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","Fox Chase Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ERP-GU-052|NCI-2012-00906|IRB#12-015","May 30, 2012","May 2012","December 2018","February 21, 2017","February 2017","December 27, 2016","null","December 2013","Pathological Complete Response Rate Following Chemotherapy Before Surgery","https://ClinicalTrials.gov/show/NCT01611662"
436,"NCT00869752","MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Biological: anti-IGF-1R recombinant monoclonal antibody MK-0646|Drug: cisplatin|Drug: etoposide","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I190|CAN-NCIC-IND190|CDR0000634447","March 25, 2009","January 2009","July 2012","March 6, 2014","July 2012","No Study Results Posted","null","March 2012","Recommended phase II dose of MK-0646 in combination with standard etoposide and cisplatin chemotherapy|Toxicity and tolerability according to NCI CTCAE v3.0|Preliminary efficacy|Objective response rate|Predictive and prognostic impact of biomarkers","https://ClinicalTrials.gov/show/NCT00869752"
437,"NCT01396681","Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: gemcitabine and cisplatin","Seoul National University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-0412-138-006","July 1, 2011","December 2004","June 2011","July 15, 2011","July 2011","No Study Results Posted","null","June 2011","recurrence/metastasis free survival|2 year survival rate|Overall survival|recurrence free survival|Safety and tolerability","https://ClinicalTrials.gov/show/NCT01396681"
438,"NCT00674167","The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma","Active, not recruiting","No Results Available","Gastric Cancer","Drug: Docetaxel|Drug: Cisplatin|Drug: Capecitabine","National University Hospital, Singapore","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GA02/33/06|2006/00462|CTC0700084","May 5, 2008","May 2007","December 2017","June 11, 2015","June 2015","No Study Results Posted","null","December 2015","Evaluation of Response and Progression using RECIST Criteria|Detection of methylated and unmethylated DNA","https://ClinicalTrials.gov/show/NCT00674167"
439,"NCT01702714","A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease","Withdrawn","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: RO5083945|Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine|Drug: paclitaxel","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BP28577|2012-003376-39","October 1, 2012","July 2014","February 2016","November 3, 2016","November 2016","No Study Results Posted","null","February 2016","Maximum tolerated dose in combination with cisplatin and gemcitabine or carboplatin and paclitaxel|Recommended phase II dose (RP2D) of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel|Safety: Incidence of adverse events|Pharmacokinetics: Serum concentrations of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel|Pharmacokinetics: Effect of RO5083945 on serum concentrations of cisplatin|Pharmacokinetics: Effect of RO5083945 on serum concentrations of gemcitabine|Pharmacokinetics: Effect of RO5083945 on serum concentrations of carboplatin|Pharmacokinetics: Effect of RO5083945 on serum concentrations of paclitaxel|Preliminary evidence of antitumor activity: Objective response rate (complete response, partial response and stable disease)|Duration of response|Biomarker assessments : Immune effector cells/EGFR markers","https://ClinicalTrials.gov/show/NCT01702714"
440,"NCT01041833","Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: atRA|Drug: Placebo","National Institute of Cancerología","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","230","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","CA/141/CB/563/09","September 7, 2009","January 2010","September 2013","December 31, 2009","September 2009","No Study Results Posted","null","September 2011","Obtain a greater response rate to chemotherapy, and an increase in PFS and the GS of patients with advanced-stage NSCLC who receive cisplatin- and paclitaxel-based chemotherapy and a 45-mg/m2 daily dose of atRA.|Demonstrate an acceptable toxicological profile of patients with advanced NSCLC who receive chemotherapy and a daily 45-mg/m2 dose of atRA.","https://ClinicalTrials.gov/show/NCT01041833"
441,"NCT01222312","Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Cisplatin|Drug: Oxaliplatin|Drug: Docetaxel|Drug: Docetaxel","Krankenhaus Nordwest","All","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S417","April 12, 2010","August 2008","November 2011","November 28, 2011","November 2011","No Study Results Posted","Taxelox","October 2011","response rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|quality of life|progression free survival PFS|overall survival OS|time to treatment failure TTF","https://ClinicalTrials.gov/show/NCT01222312"
442,"NCT01971489","Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors","Withdrawn","No Results Available","Adult Solid Neoplasm|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer","Drug: Buparlisib|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Questionnaire Administration","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 240413|NCI-2013-01941|P30CA016056","October 23, 2013","September 2015","null","August 11, 2015","August 2015","No Study Results Posted","null","August 2016","Incidence of dose limiting toxicities (DLTs) using the National Cancer Institute (NCI) CTCAE version 4.0|Maximum-tolerated dose (MTD) defined as the maximum dose level at which less than or equal to 1 out of 6 patients have DLTs using NCI CTCAE version 4.0|Disease control rate using RECIST (CR, PR, and SD)|Objective response rate (ORR) calculated as the number of patients with a confirmed complete response (CR) or partial response (PR) divided by the total number of patients using Response Evaluation Criteria in Solid Tumors (RECIST)|PIK3CA mutations|PIK3CA polymorphisms|PK effect of gemcitabine hydrochloride and cisplatin on buparlisib|Polymorphisms in buparlisib transport and metabolism|RECIST response","https://ClinicalTrials.gov/show/NCT01971489"
443,"NCT00660504","Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: Amrubicin Hydrochloride|Drug: Etoposide-Cisplatin combined chemotherapy","Sumitomo Pharmaceutical (Suzhou) Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D0750018","April 10, 2008","April 2008","August 2012","July 9, 2014","July 2014","November 21, 2013","null","February 2012","Overall Survival|Progression-Free Survival|Objective Response Rate","https://ClinicalTrials.gov/show/NCT00660504"
444,"NCT00173888","Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Docetaxel, Cisplatin|Drug: Gemcitabine, Cisplatin","National Taiwan University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","920303","September 8, 2005","July 2003","November 2012","December 4, 2012","December 2012","No Study Results Posted","null","November 2012","The primary objective of this study is to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens.|To evaluate the response rate for each regimen, the toxicity of each arm, and the duration of response","https://ClinicalTrials.gov/show/NCT00173888"
445,"NCT01821248","A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","Recruiting","No Results Available","Biliary Tract Cancer","Drug: Gemcitabine, Cisplatin, S-1","Kansai Hepatobiliary Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KHBO1201|UMIN000009831","March 22, 2013","March 2013","February 2019","August 31, 2016","August 2016","No Study Results Posted","null","February 2017","Curative resection rate|Response rate and toxicity","https://ClinicalTrials.gov/show/NCT01821248"
446,"NCT02270814","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Head and Neck","Drug: nab-paclitaxel|Drug: Cisplatin|Drug: Carboplatin|Biological: Cetuximab","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201410073","October 17, 2014","February 2, 2015","May 31, 2020","May 18, 2017","May 2017","No Study Results Posted","CACTUX","May 31, 2018","Progression-free survival (PFS) - with first line therapy|Overall survival (OS)|Overall response rate|Grade 3 and 4 adverse events|Quality of life|Progression-free survival (PFS) - with maintenance therapy|Disease control","https://ClinicalTrials.gov/show/NCT02270814"
447,"NCT01104259","Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer","Active, not recruiting","No Results Available","Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Hereditary Breast/Ovarian Cancer - BRCA1|Hereditary Breast/Ovarian Cancer - BRCA2|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer","Drug: veliparib|Drug: cisplatin|Drug: vinorelbine tartrate|Other: laboratory biomarker analysis|Other: pharmacological study","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","56","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","7161|NCI-2010-00356|P30CA015704","April 13, 2010","July 16, 2010","null","February 27, 2017","February 2017","No Study Results Posted","null","February 2015","MTD of veliparib, defined as the highest dose tested in which fewer than 33% of patients experienced dose-limiting toxicity attributable to the study regimen, when at least 6 patients were treated at that dose and were evaluable for toxicity|Toxicity profile, defined by the incidence of toxicity, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Pharmacokinetic (PK) parameters of veliparib in plasma and urine samples|Pharmacokinetic (PK) parameters of cisplatin in plasma samples|Pharmacodynamic parameters of PARP inhibition","https://ClinicalTrials.gov/show/NCT01104259"
448,"NCT01281852","Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer","Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Drug: Veliparib","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02661|GOG-0076HH|CDR0000693745|U10CA027469","January 21, 2011","March 2011","February 2017","April 11, 2017","April 2017","No Study Results Posted","null","February 2017","Dose-limiting toxicities in the first course of treatment (Phase I)|Frequency and severity of adverse effects as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events v. 4.0|Objective tumor response (complete or partial response) (Phase II)|Overall survival (Phase II)|Progression-free survival (Phase II)","https://ClinicalTrials.gov/show/NCT01281852"
449,"NCT00980603","Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer","Unknown status","No Results Available","Gastric Cancer","Drug: docetaxel|Drug: docetaxel, cisplatin|Drug: docetaxel, S-1","National Cancer Center, Korea|Seoul National University Bundang Hospital|Chungbuk National University Hospital|Gachon University Gil Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-07-296","September 18, 2009","November 2008","May 2011","September 18, 2009","September 2009","No Study Results Posted","null","November 2010","response rate|time to progression","https://ClinicalTrials.gov/show/NCT00980603"
450,"NCT01353482","A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma","Withdrawn","No Results Available","Malignant Pleural Mesothelioma","Drug: Cisplatin|Drug: Pemetrexed|Drug: Vorinostat|Drug: Placebo","University College, London|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCL/08/0359|2009-013638-26","May 11, 2011","null","null","March 21, 2012","March 2012","No Study Results Posted","MESO-02","null","Phase I only - Dose-limiting toxicities|Phase I only - Number of cycles of pemetrexed-cisplatin given|Phase II only - Progression free survival","https://ClinicalTrials.gov/show/NCT01353482"
451,"NCT00118235","Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer","Completed","No Results Available","Extensive Stage Small Cell Lung Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Biological: bevacizumab|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","72","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02815|CDR0000433341|CALGB-30306|U10CA031946|P30CA014236","July 8, 2005","December 2004","July 2011","June 16, 2014","December 2012","No Study Results Posted","null","April 2007","Survival time|Failure-free survival|Frequency of toxicity, tabulated by the most severe occurrence","https://ClinicalTrials.gov/show/NCT00118235"
452,"NCT01161498","Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer","Terminated","Has Results","Squamous Cell Carcinoma|Head and Neck Cancer","Biological: Talimogene Laherparepvec|Radiation: Radiation|Drug: Cisplatin","BioVex Limited|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","006/09|20110130","July 12, 2010","February 2011","October 2011","January 14, 2016","January 2016","November 12, 2015","null","October 2011","2-year Event-free Survival|Clinical Objective Response (cOR)|Metabolic Complete Response (mCR)|Pathologic Complete Response (mCR)|Time to Locoregional Failure|Time to Distant Failure|Time to Any Failure|Overall Survival|Disease-specific Survival|Participants With N1-2 Disease at Baseline Requiring Neck Dissection","https://ClinicalTrials.gov/show/NCT01161498"
453,"NCT01888302","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery","Completed","No Results Available","Hepatic Complication","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Quality-of-Life Assessment|Drug: Sirolimus","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","1","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1243|NCI-2013-01183|12-007515|P30CA015083","June 25, 2013","September 2013","June 2016","June 20, 2016","February 2016","No Study Results Posted","null","June 2016","Percentage of patients who are able to complete therapy","https://ClinicalTrials.gov/show/NCT01888302"
454,"NCT00678977","A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors","Completed","No Results Available","Lung Cancer, Non-Small Cell","Drug: Pazopanib (GW786034)|Drug: Gemcitabine|Drug: Cisplatin","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VEG109599","May 14, 2008","April 2008","March 2011","April 11, 2013","April 2013","No Study Results Posted","null","March 2010","Optimum tolerated regimen (OTR) for each regimen in each arm of the study. OTR determined evaluation of AEs and change in lab values. OTR defined as the highest dosing regimen that results in dose limiting toxicity in no more than 1 of 6 subjects|Anti-tumor activity evaluated using RECIST criteria (if subjects have measurable disease). Assessments of disease every 6 to 12 weeks, recorded as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD).|Pharmacokinetic parameters AUC(0-24), Cmax, and tmax of pazopanib, gemcitabine, and ultrafilterable platinum.|Levels of circulating cytokine and angiogenic factors (CAF) biomarkers (such as IL 2, IL-10, VEGF, sVEGFR2) in plasma will be determined|Genetic variants in select candidate genes in the host DNA will be evaluated","https://ClinicalTrials.gov/show/NCT00678977"
455,"NCT02560038","Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer","Recruiting","No Results Available","Urinary Bladder Neoplasms","Drug: Gemcitabine|Drug: Paclitaxel|Drug: Cisplatin","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GU-13-102|HSC-MS-13-0864","September 17, 2015","October 2015","April 2019","November 23, 2016","November 2016","No Study Results Posted","null","April 2018","Efficacy as measured by the Objective Response Rate (ORR)|Safety of drug regimen as measured by number of adverse events|Efficacy as measured by Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02560038"
456,"NCT01596868","GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China","Completed","No Results Available","Nasopharyngeal Squamous Cell Carcinoma|Toxicity Due to Radiotherapy","Drug: gemcitabine and cisplatin|Drug: docetaxel and cisplatin","Fourth Military Medical University","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Mshi","May 7, 2012","May 2012","October 2013","October 29, 2013","October 2013","No Study Results Posted","null","October 2013","overall response rate (ORR)|Overall survival|Locoregional failure-free survival|Distant failure-free survival|Number of Participants with Adverse Events|Quality of life|Acute adverse reaction","https://ClinicalTrials.gov/show/NCT01596868"
457,"NCT03092986","Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer","Not yet recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Paclitaxel|Drug: Carboplatin|Drug: Cisplatin|Drug: Vinblastine Sulfate|Radiation: three dimensional conformal radiotherapy","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","All","Child, Adult, Senior","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BangabandhuONCOLOGY","March 22, 2017","April 2017","April 2018","March 27, 2017","March 2017","No Study Results Posted","null","April 2018","tumor response","https://ClinicalTrials.gov/show/NCT03092986"
458,"NCT00477607","Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin","Completed","Has Results","Ototoxicity|Unspecified Adult Solid Tumor","Drug: alpha-lipoic acid|Behavioral: Audiology|Biological: laboratory biomarker analysis|Drug: Placebo","VA Office of Research and Development|Oregon Health and Science University","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","39","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","C4697-R|CDR0000546570|NCRAR-VA-1810|OHSU-3288","May 23, 2007","October 2007","June 2011","February 3, 2014","February 2014","October 4, 2013","null","March 2011","Ototoxicity Measurement|Malondialdehyde (MDA) Levels|Total Amount of Prescribed Cisplatin Dose Administered","https://ClinicalTrials.gov/show/NCT00477607"
459,"NCT00812266","Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)","Terminated","No Results Available","Extensive Disease|First-Line|Small Cell Lung Cancer","Drug: topotecan + cisplatin|Drug: Etoposide + carboplatin","Danish Oncological Lung Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 3","281","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DOLG7","December 19, 2008","January 2006","January 2015","January 23, 2016","January 2016","No Study Results Posted","null","December 2013","2 years survival|Response rates","https://ClinicalTrials.gov/show/NCT00812266"
460,"NCT02856568","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma","Not yet recruiting","No Results Available","Non-Resectable Cholangiocarcinoma|Recurrent Cholangiocarcinoma|Stage III Extrahepatic Bile Duct Cancer|Stage III Intrahepatic Cholangiocarcinoma|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIB Hilar Cholangiocarcinoma|Stage IVA Extrahepatic Bile Duct Cancer|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma|Stage IVB Extrahepatic Bile Duct Cancer|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Intrahepatic Cholangiocarcinoma|Unresectable Extrahepatic Bile Duct Carcinoma","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ricolinostat","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","47","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1542|NCI-2016-01057|P30CA015083","July 14, 2016","October 2016","null","August 2, 2016","July 2016","No Study Results Posted","null","October 2021","MTD of ricolinostat or a dose up to 240 mg/day whichever is lower, of ACY-1215|Best Response defined as the best objective status recorded using RECIST version 1.1|Confirmed response is defined to be a stringent complete response, complete response, very good partial response, or partial response noted as the objective status on two consecutive evaluations using RECIST version 1.1|Incidence of adverse events evaluated via the ordinal common toxicity criteria (CTC) toxicity grading of 3+|Time to any hematologic nadirs (ANC, platelets, hemoglobin)|Time to any treatment related grade 3+ toxicity|Time to any treatment related toxicity|Time to progression|Time to treatment failure","https://ClinicalTrials.gov/show/NCT02856568"
461,"NCT00369122","Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer","Completed","Has Results","Cervical Adenocarcinoma|Cervical Adenosquamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer","Radiation: external beam radiation therapy|Radiation: brachytherapy|Biological: bevacizumab|Drug: cisplatin","National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00722|CDR0000493005|RTOG 0417|RTOG-0417|U10CA021661","August 24, 2006","August 2006","June 2010","September 22, 2014","October 2013","March 5, 2013","null","June 2010","Subjects With Treatment-related Serious Adverse Events (SAEs) and Adverse Events (AEs) as Assessed by CTCAE v. 3.0 Criteria Within the First 90 Days From Treatment Start.|Treatment-related SAEs and AEs as Assessed by CTCAE v. 3.0 Criteria at Any Time.|Disease-free Survival (Failure: Local, Regional or Distant Failure, or Death Due to Any Cause)|Overall Survival (Failure: Death Due to Any Cause)","https://ClinicalTrials.gov/show/NCT00369122"
462,"NCT00603408","Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer","Terminated","Has Results","Breast Cancer","Drug: Cisplatin|Radiation: Radiation Therapy|Procedure: Mastectomy","Washington University School of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-0913","December 28, 2007","December 2007","December 2009","July 8, 2016","July 2016","July 8, 2016","null","December 2009","Overall Response|Time to Disease Progression|Overall Survival Rate (OS)|Number of Participants With Surgical Complications|Number of Participants With Medical Toxicities|Effect of Neoadjuvant Chemoradiation Therapy in Disseminated Cancer Cells in the Bone Marrow and Correlation to Tumor Response|Develop Animal Models of Triple Negative Breast Cancers|Provide Samples for the Development of the FNA Assay","https://ClinicalTrials.gov/show/NCT00603408"
463,"NCT00887822","A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: Bevacizumab|Drug: Placebo|Drug: Capecitabine|Drug: Cisplatin","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","ML22367","April 22, 2009","March 2009","August 2014","January 10, 2017","January 2017","October 31, 2016","AVATAR","May 2011","Percentage of Participants With Event (Death)|Overall Survival|Percentage of Participants With Progression-Free Survival (PFS) Events (Disease Progression/Death)|Progression-Free Survival (PFS)|Percentage of Participants With PFS Events (Disease Progression/Death) During First-line Therapy|PFS During First-line Therapy|Percentage of Participants With Disease Progression|Time to Progression|Percentage of Participants With Best Overall Response as Assessed by RECIST During First-Line Therapy|Duration of Response During First-Line Therapy|Percentage of Participants With Disease Control During First-Line Therapy|Change From Cycle 1 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 36 (QLQ-C30) Scale Over Time|Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time","https://ClinicalTrials.gov/show/NCT00887822"
464,"NCT00490399","Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas","Completed","No Results Available","Biliary Tract Carcinoma","Drug: gemcitabine|Drug: cisplatin","Eli Lilly and Company","All","20 Years to 70 Years   (Adult, Senior)","Phase 2","39","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6689|B9E-KL-S292","June 20, 2007","March 2003","September 2004","June 20, 2007","June 2007","No Study Results Posted","null","null","To evaluate the response rate|To characterize the quantitative and qualitative toxicities of gemcitabine combined with cisplatin in this patient population.|To evaluate the following time-to-event efficacy variables: Duration of response, Time to treatment failure, Time to documented disease progression, Overall survival","https://ClinicalTrials.gov/show/NCT00490399"
465,"NCT01917617","Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer","Active, not recruiting","No Results Available","Biliary Tract Cancer","Drug: Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|Drug: Gemcitabine , Cisplatin","Kansai Hepatobiliary Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KHBO1302|UMIN000010695","August 4, 2013","May 2013","March 2018","August 31, 2016","August 2016","No Study Results Posted","null","March 2016","Completion rate during the 12 weeks in the short hydration group|Rate of renal toxicity|Adverse events|Marker of renal function|Response rate|Time to treatment failure|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01917617"
466,"NCT01269255","A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: TS-1 with Cisplatin","Yonsei University","All","20 Years to 75 Years   (Adult, Senior)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","4-2009-0555","January 3, 2011","December 2009","January 2012","June 1, 2013","June 2013","No Study Results Posted","null","January 2012","maximum tolerated dose","https://ClinicalTrials.gov/show/NCT01269255"
467,"NCT00410826","Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Completed","Has Results","Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx","Drug: erlotinib hydrochloride|Drug: cisplatin|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Procedure: quality-of-life assessment","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","204","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6106|NCI-2009-01546","December 11, 2006","June 2006","null","May 8, 2013","May 2013","December 14, 2012","null","May 2012","Comparison of the Percentage of Participants With a Complete Response in Each Treatment Arm|Safety as Assessed Through Summaries of Adverse Events and Laboratory Test Results by Treatment Arm|Progression Free Survival of Patients With Locally Advanced Head and Neck Cancer Treated With Cisplatin and Radiotherapy, With and Without Erlotinib Hydrochloride","https://ClinicalTrials.gov/show/NCT00410826"
468,"NCT01554397","Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Cisplatin","University of California, San Diego|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","425","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INTERTECC|R21CA162718-01","March 8, 2012","September 2011","December 2017","December 1, 2014","December 2014","No Study Results Posted","null","December 2016","Number of Patients with Adverse Events as a Measure of Safety and Tolerability|Number of Patients with Acute and Late Adverse Events as a Measure of Safety and Tolerability|Number of Patients with Locoregional Failure as a Measure of Recurrence","https://ClinicalTrials.gov/show/NCT01554397"
469,"NCT02466971","Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer","Recruiting","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB2 Cervical Cancer|Stage II Cervical Cancer|Stage II Vaginal Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Vaginal Cancer|Stage IIIB Cervical Cancer|Stage IVA Cervical Cancer|Stage IVA Vaginal Cancer|Stage IVB Vaginal Cancer|Vaginal Adenocarcinoma|Vaginal Adenosquamous Carcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified","Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy|Radiation: Internal Radiation Therapy|Other: Laboratory Biomarker Analysis|Radiation: Radiation Therapy|Drug: Triapine","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","188","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-00835|NRG-GY006|U10CA180868","June 5, 2015","January 15, 2016","null","May 23, 2017","May 2017","No Study Results Posted","null","September 30, 2018","Progression-free survival (PFS)|Incidence of acute adverse events as assessed by CTCAE version 4.0|Incidence of chronic or late adverse events assessed by CTACE version 4|Incidence of hematologic and GI adverse events assessed by CTCAE version 4|Metabolic complete response (mCR) assessed by 18F-FDG PET/CT|Overall survival (OS)|Treatment compliance (amount of radiation, cisplatin and triapine administered, incidence and duration of treatment delays, reason for delays, and reason why off study therapy)","https://ClinicalTrials.gov/show/NCT02466971"
470,"NCT01187212","Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation","Completed","No Results Available","Malignant Neoplasm of Stomach|Effects of Chemotherapy","Drug: Capecitabine/Cisplatin + Sorafenib|Drug: Capecitabine/Cisplatin","Asan Medical Center|Bayer","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","195","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-1002","August 19, 2010","August 2010","August 2014","October 10, 2014","October 2014","No Study Results Posted","STARGATE","November 2013","Progression-free survival|Overall survival|Best tumor response|Duration of response|Disease control rate|Safety profiles|Best tumoral response of 2nd line sorafenib|Progression-free survival of 2nd line sorafenib|Biomarker for sorafenib","https://ClinicalTrials.gov/show/NCT01187212"
471,"NCT02382068","Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin","Withdrawn","No Results Available","Malignant Neoplasm|Ototoxicity","Drug: Dexamethasone|Other: Placebo|Drug: Cisplatin","Aaron Moberly|Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","OSU-12003|NCI-2014-01247","February 16, 2015","August 2014","null","July 14, 2016","July 2016","No Study Results Posted","null","July 2017","Change in score of pure tone audiometry of conventional and high-frequency ranges (hearing level decibels [dB] hearing level)|Change in score of distortion product otoacoustic emissions of conventional and high-frequency ranges (amplitude dB sound pressure level)|Presence of ototoxicity as defined by the American Speech-Language Hearing Association (ASHA)","https://ClinicalTrials.gov/show/NCT02382068"
472,"NCT01854255","Intraperitoneal Aerosol Chemotherapy in Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: doxorubicin and cisplatin","Ruhr University of Bochum","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PIPAC-GA01","May 12, 2013","November 2013","November 2016","November 13, 2016","November 2016","No Study Results Posted","PIPAC-GA01","October 2016","Clinical Benefit Rate|Observed Survival","https://ClinicalTrials.gov/show/NCT01854255"
473,"NCT01396668","Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: gemcitabine, cisplatin, capecitabine","Seoul National University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-0412-138-005","July 1, 2011","December 2004","June 2011","July 15, 2011","July 2011","No Study Results Posted","null","June 2011","Time to progression|safety|1 year survival rate|response rate|overall survival|clinical benefit rate","https://ClinicalTrials.gov/show/NCT01396668"
474,"NCT02735928","Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor","Recruiting","No Results Available","Ovarian Epithelial Cancer Recurrent|Platinum-resistant","Device: Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin","Catholic University of the Sacred Heart","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PARROT","February 8, 2016","January 2016","January 2018","October 24, 2016","October 2016","No Study Results Posted","PARROT","January 2018","Clinical Benefit Rate (CBR) according to RECIST/GCOG criteria after three cycles of PIPAC with PIPAC cisplatin and doxorubicin|The median time to progression according to RECIST criteria after three cycles of PIPAC with cisplatin|PCI, as assessed by laparoscopy|The degree of histological regression assessed by pathological review of repeated peritoneal biopsies|The proportion of women with a reduction of serum CA-125 of at least 50% after PIPAC|Evaluation of the Quality Of Life (QOL) on the basis of the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaires","https://ClinicalTrials.gov/show/NCT02735928"
475,"NCT00083122","Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer","Completed","Has Results","Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Primary Peritoneal Cavity Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Primary Peritoneal Cavity Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Primary Peritoneal Cavity Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: alvocidib|Drug: cisplatin/flavopiridol","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","45","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00029|CDR0000363562|MC0261|5876|N01CM62205|P30CA015083","May 14, 2004","April 2004","May 2012","May 6, 2014","April 2013","March 22, 2013","null","July 2010","Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR)|Overall Survival|Time to Progression","https://ClinicalTrials.gov/show/NCT00083122"
476,"NCT00658580","Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer","Completed","No Results Available","Small Cell Lung Carcinoma, Extensive Disease","Drug: Cisplatin + etoposide|Drug: Epirubicin + ifosfamide + etoposide","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","Phase 3","361","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ELCWP 01994","April 11, 2008","April 2000","February 2015","February 11, 2015","February 2015","No Study Results Posted","null","December 2013","Survival|Response rate|Toxicity","https://ClinicalTrials.gov/show/NCT00658580"
477,"NCT03095079","Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma","Recruiting","No Results Available","Melanoma","Drug: recombinant human endostatin","Beijing Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BCH-MM-","March 20, 2017","October 2016","October 2018","March 23, 2017","March 2017","No Study Results Posted","null","December 2017","progress-free survival(PFS)|Disease control rate(DCR)|adverse events","https://ClinicalTrials.gov/show/NCT03095079"
478,"NCT00889733","Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer","Terminated","No Results Available","Epithelial Ovarian Cancer","Drug: Intraperitoneal (IP) Cisplatin","University Health Network, Toronto|Princess Margaret Hospital, Canada","Female","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OVHM-01","April 27, 2009","February 2007","null","October 6, 2011","October 2011","No Study Results Posted","OVHM-01","July 2009","Safety and Dose Tolerance|Time to progression","https://ClinicalTrials.gov/show/NCT00889733"
479,"NCT00428194","Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer","Withdrawn","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: erlotinib hydrochloride|Procedure: radiation therapy","Masonic Cancer Center, University of Minnesota","Female","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006LS019|UMN-0604M84827","January 25, 2007","January 2007","March 2008","November 6, 2012","November 2012","No Study Results Posted","null","March 2008","Maximum tolerated dose of erlotinib hydrochloride|Toxicity","https://ClinicalTrials.gov/show/NCT00428194"
480,"NCT00234494","Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer","Completed","Has Results","Bladder Cancer","Drug: Cisplatin|Drug: Gemcitabine|Drug: Bevacizumab","Christopher Sweeney, MBBS|Genentech, Inc.|Eli Lilly and Company|Walther Cancer Institute|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG GU04-75","October 5, 2005","November 2005","December 2008","February 16, 2016","February 2016","January 19, 2016","null","December 2008","Progression Free Survival|Overall Survival Time|Estimate Response Rates|Duration of Response for Responding Patients","https://ClinicalTrials.gov/show/NCT00234494"
481,"NCT02061631","Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck","Completed","No Results Available","Squamous Cell Carcinoma of Head and Neck","Drug: Cisplatin|Drug: DOCETAXEL XRP6976|Drug: Dexamethasone|Drug: Dexamethasone","Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCETL06445|U1111-1131-0614","February 11, 2014","May 2014","October 2015","October 7, 2015","October 2015","No Study Results Posted","DECIDE","July 2015","Proportion of patients who achieve complete response and partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST)|Number of patients with Adverse Events (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 grade)","https://ClinicalTrials.gov/show/NCT02061631"
482,"NCT00055757","Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: tipifarnib|Drug: cisplatin|Drug: gemcitabine hydrochloride|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","48","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02808|MC0123|N01CM17104|N01CM17102","March 6, 2003","October 2003","null","June 3, 2013","June 2013","No Study Results Posted","null","April 2004","Proportion of confirmed tumor responses, defined to be either a CR or PR noted as the objective status on 2 consecutive evaluations at least 4 weeks apart|Survival time|Time to disease progression|Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented|Time to treatment failure","https://ClinicalTrials.gov/show/NCT00055757"
483,"NCT01524991","First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma","Active, not recruiting","No Results Available","Urothelial Carcinoma","Drug: Gemcitabine|Drug: Cisplatin|Drug: Ipilimumab","Hoosier Cancer Research Network|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GU10-148","January 30, 2012","January 2012","November 2017","March 8, 2017","March 2017","No Study Results Posted","null","August 2017","One-Year Overall Survival|Progression-Free Survival|Best Overall Response Rate|Number of Adverse Events Experienced by Patients","https://ClinicalTrials.gov/show/NCT01524991"
484,"NCT00265941","Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 3","720","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0522|CDR0000458049|NCI-2009-00729","December 14, 2005","November 2005","null","October 11, 2016","October 2016","No Study Results Posted","null","January 2011","Disease-free survival (DFS)|Overall survival (OS)|Local-regional control (LRC)|Mucositis toxicity ≥ grade 3|Other toxicity ≥ grade 3|Protocol treatment delivery|Death ≤ 30 days after discontinuation of protocol treatment|Quality of life as measured by Performance Status Scale for Head and Neck Cancer and the European Quality of Life questionnaire (EQ-5D)|Quality of life as measured by Functional Assessment of Cancer Therapy-General version|Correlation of expression of epidermal growth factor receptor or its down-stream molecules (e.g., MAPK, AKT, Stat-3, PKC) with DFS, OS, and LRC|Correlation of pre-treatment positron emission tomography (PET)/CT scan findings with DFS, OS, and LRC|Correlation of post-treatment PET/CT scan findings with pathologic nodal complete response and nodal relapse rate at 2 years in clinical N2-3 patients","https://ClinicalTrials.gov/show/NCT00265941"
485,"NCT01105390","AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma","Withdrawn","No Results Available","Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma","Biological: rilotumumab|Drug: cisplatin|Drug: pemetrexed disodium|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E1B09|NCI-2011-02068|U10CA021115|CDR0000670445","April 15, 2010","April 2010","null","August 1, 2013","January 2013","No Study Results Posted","null","May 2011","Progression-free survival|Toxicity defined as a grade 4 hemorrhagic event or a grade 5 event","https://ClinicalTrials.gov/show/NCT01105390"
486,"NCT00492778","Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer","Recruiting","No Results Available","Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Carcinoma","Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Radiation: Internal Radiation Therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","164","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-0238|NCI-2009-00603|CDR0000550975|U10CA180868|U10CA027469","June 25, 2007","February 2008","null","October 26, 2016","October 2016","No Study Results Posted","null","January 2017","Duration of progression-free survival|Duration of overall survival|Incidence of adverse effects graded by CTCAE version 3.0|Prognostic significance of tumor size, tumor location (vaginal only vs. all others) and histology","https://ClinicalTrials.gov/show/NCT00492778"
487,"NCT01459614","Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer","Active, not recruiting","No Results Available","Pancreatic Cancer","Drug: Gemcitabine|Drug: Taxotere|Drug: Xeloda|Drug: Cisplatin","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J11125|Swim Across America Laboratory","October 24, 2011","November 2011","November 2017","May 2, 2017","May 2017","No Study Results Posted","null","November 2015","Primary Outcome Measure|Secondary Outcome Measure: To assess safety and characterize toxicities of the combination of GTX with cisplatin in subjects with metastatic pancreatic cancer|Secondary Outcome Measure: To estimate 3, 6, 9, 12, 15, and 18 month disease control rate (DCR), PFS, and overall survival (OS).|Secondary Outcome: To estimate a PFS rate of an expansion cohort testing an alternative schedule","https://ClinicalTrials.gov/show/NCT01459614"
488,"NCT00084734","Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: capecitabine|Drug: cisplatin|Drug: docetaxel","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","61","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000365571|RPCI-RPC-0209","June 10, 2004","May 2002","December 2009","January 10, 2014","January 2014","No Study Results Posted","null","November 2009","Determine the maximum tolerated dose of docetaxel, cisplatin, and capecitabine in patients with advanced solid tumors.|Determine the non-dose-limiting toxic effects associated with this regimen in these patients","https://ClinicalTrials.gov/show/NCT00084734"
489,"NCT00069875","A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Gemcitabine|Drug: LY293111|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","4842|H6H-MC-JEAM","October 2, 2003","September 2003","December 2005","December 17, 2007","December 2007","No Study Results Posted","null","null","To determine if progression-free survival in patients with Stage IIIB or IV NSCLC receiving gemcitabine and cisplatin can be improved by adding 200 or 600 mg BID of LY293111 as compared to placebo.|time-to-event efficacy (overall survival, duration of response, time-to-response, time-to-treatment failure)|tumor response rate|toxicity rates|exposure-response relationship|quality of life","https://ClinicalTrials.gov/show/NCT00069875"
490,"NCT00004919","Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy","Completed","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: irinotecan hydrochloride|Drug: amifostine trihydrate|Other: pharmacological study","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01846|P9970|CDR0000067601|CCG-P9970|U01CA097452","March 7, 2000","December 1999","null","July 1, 2013","July 2013","No Study Results Posted","null","March 2003","MTD defined as that dose level immediately below the dose level at which 2 patients out of 3 to 6 patients experienced dose-limiting toxicity using Common Toxicity Criteria version 2.0","https://ClinicalTrials.gov/show/NCT00004919"
491,"NCT01938573","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer","Completed","No Results Available","Recurrent Bladder Carcinoma|Stage II Bladder Cancer|Stage III Bladder Cancer|Stage IV Bladder Cancer","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Sirolimus|Procedure: Therapeutic Conventional Surgery","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","8027|NCI-2013-01614|P30CA015704","September 4, 2013","October 2013","null","March 10, 2017","January 2017","No Study Results Posted","null","August 18, 2016","MTD of sirolimus based on the incidence of dose-limiting toxicity (DLT) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Percent of patients with pathologic complete response (Phase II)|DNA microenvironment damage-responsive proteins and transcripts using immunohistochemistry (IHC) assay and polymerase chain reaction|Incidence of adverse events including any unfavorable and unintended sign, symptom, diagnosis, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product (Phase I and II)","https://ClinicalTrials.gov/show/NCT01938573"
492,"NCT00436293","Taxotere + Cisplatin in Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Neoplasms","Drug: Docetaxel|Drug: Cisplatin","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976F_6002","February 16, 2007","December 2002","March 2010","November 16, 2010","November 2010","No Study Results Posted","null","March 2010","Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.|Adverse Events","https://ClinicalTrials.gov/show/NCT00436293"
493,"NCT00957411","Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer","Completed","No Results Available","Cervical Cancer","Biological: cetuximab|Drug: cisplatin","Institut Curie","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000651250|CLCC-IC-2007-04|2008-001053-18","August 11, 2009","March 2009","October 2014","April 4, 2017","April 2017","No Study Results Posted","CETUXICOL","November 2013","Recurrence-free survival at 2 years|Response as assessed by MRI after radiochemotherapy and before surgery according to RECIST criteria|Toxicity according to NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00957411"
494,"NCT01528618","Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Nasopharyngeal Neoplasms","Drug: gemcitabine and cisplatin|Drug: 5-Fluorouracil and cisplatin","Sun Yat-sen University","All","18 Years and older   (Adult, Senior)","Phase 3","362","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEM20110714","January 31, 2012","October 2015","June 2017","January 9, 2016","January 2016","No Study Results Posted","null","June 2016","Progression free survival (PFS) assessed by independent image committee and the investigators|Overall survival (OS)|Objective response rate (ORR)|Number of Participants with Adverse Events|Quality of life","https://ClinicalTrials.gov/show/NCT01528618"
495,"NCT00424853","ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Docetaxel and cisplatin followed by gemcitabine|Drug: docetaxel and cisplatin followed by gemcitabine","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_2506|EudraCT # : 2004-001044-72","January 19, 2007","May 2005","August 2008","December 4, 2009","December 2009","No Study Results Posted","null","August 2008","overall response rate assessed by RECIST criteria.|Time to progression|time to treatment failure|overall survival","https://ClinicalTrials.gov/show/NCT00424853"
496,"NCT00799240","MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Arm A: Pemetrexed Cisplatin|Drug: Arm B Pemetrexed, Cisplatin and MK-0646","University of Kansas|Merck Sharp & Dohme Corp.|University of Kansas Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11386|MK-0646","November 25, 2008","June 2009","July 2014","November 5, 2014","December 2013","No Study Results Posted","IMPACT","February 2011","Compare response rate between the two arms.|Progression-free survival, overall survival and Toxicity profile|Exploratory Objectives: Assess biomarkers of Pemetrexed, IGF-1R and immunogenicity of MK-0646.","https://ClinicalTrials.gov/show/NCT00799240"
497,"NCT02611037","Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma","Recruiting","No Results Available","Malignant Pleural Mesothelioma|Mesothelioma","Drug: Cisplatin|Drug: Methotrexate|Drug: Gemcitabine|Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-18094","November 18, 2015","January 4, 2016","February 2018","February 21, 2017","February 2017","No Study Results Posted","null","January 2018","Objective Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)|Occurrence of Treatment Related Toxicity|Quality of Life Questionnaire Scores","https://ClinicalTrials.gov/show/NCT02611037"
498,"NCT00813696","Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer","Unknown status","No Results Available","Pancreatic Cancer","Drug: gemcitabine|Drug: cisplatin","Istituti Tumori Giovanni Paolo II|Gruppo Oncologico Italia Meridionale|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Gruppo Oncologico Italiano di Ricerca Clinica|Cattedra di Endocrinochirurgia, Università di Verona","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GIP-1","December 22, 2008","April 2002","September 2009","December 22, 2008","December 2008","No Study Results Posted","GIP-1","March 2009","overall survival|clinical benefit response|quality of life|objective response|time to progression","https://ClinicalTrials.gov/show/NCT00813696"
499,"NCT02001519","Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy","Completed","No Results Available","Breast Cancer","Drug: AC4-CDDP4","Asan Medical Center","Female","20 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TNBC AC-CDDP","July 5, 2012","March 2012","July 2014","November 29, 2014","November 2013","No Study Results Posted","PACER","February 2014","pathologic complete response (pCR) rate|Overall response rate (ORR) by radiologic evaluation|Complete metabolic response (CMR) rate after 2 cycles of AC|3 year disease free survival (3yr-DFS)|Rate of breast conservation","https://ClinicalTrials.gov/show/NCT02001519"
500,"NCT00930930","Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer","Completed","Has Results","Breast Cancer","Drug: cisplatin|Drug: everolimus|Drug: paclitaxel|Other: placebo|Procedure: Venous blood draw","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","145","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VICC BRE 0904|P30CA068485|VU-VICC-BRE-0904|IRB# 090291","July 1, 2009","June 2009","October 2014","May 5, 2015","May 2015","October 30, 2014","null","October 2013","Number of Patients With Pathological Complete Response|Number of Patients That Underwent Breast Conservation Surgery|Clinical Tumor Response to Neoadjuvant Therapy as Measured by Ultrasound Immediately Before Surgery|Number of Patients With Each Worst-grade Toxicity Response","https://ClinicalTrials.gov/show/NCT00930930"
501,"NCT02409355","A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Atezolizumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO29432|2014-003106-33","April 1, 2015","May 31, 2015","September 30, 2017","April 4, 2017","April 2017","No Study Results Posted","null","September 30, 2017","Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Percentage of Participants With Adverse Events|Percentage of Participants With an Objective Response (Complete Response [CR] Plus Partial Response [PR]) as Assessed by the Investigator Using RECIST v1.1|Overall Survival (OS)|Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score|PFS as Determined by an Independent Review Facility (IRF) Using RECIST v1.1|Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1|Time in Response (TIR) as Determined by the Investigator Using RECIST v1.1|Percentage of Participants Who are Alive at Year 1 and 2|TTD in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) Questionnaire Score|TTD in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality of Life-Core Lung Cancer Module 13 (QLQ-C13) Questionnaire Score|Change From Baseline in Patient-Reported Lung Cancer Symptoms on the Symptom Severity Score of the SILC Scale|Pharmacokinetics: Minimum Observed Serum Concentration (Cmin) of Atezolizumab|Pharmacokinetics: Maximum Observed Serum Concentration (Cmax) of Atezolizumab|Percentage of Participants With Anti-Therapeutic Antibody (ATA) to Atezolizumab","https://ClinicalTrials.gov/show/NCT02409355"
502,"NCT01088620","Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer","Suspended","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Panitumumab|Drug: Pemetrexed|Drug: Cisplatin","WiSP Wissenschaftlicher Service Pharma GmbH|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH","All","18 Years and older   (Adult, Senior)","Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WISP_AG47|2009-014677-41|GMIHO-006/2008","March 16, 2010","April 2010","January 2014","March 13, 2013","March 2013","No Study Results Posted","null","January 2013","Progression free survival rate at 6 months|Determination of the tumour response|Duration of response|Overall survival|Adverse effects / toxicity|Quality of life assessment","https://ClinicalTrials.gov/show/NCT01088620"
503,"NCT02992340","Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC","Recruiting","No Results Available","Biliary Tract Cancer","Drug: Varlitinib|Drug: Cisplatin|Drug: Gemcitabine","Aslan Pharmaceuticals","All","Child, Adult, Senior","Phase 1|Phase 2","175","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ASLAN001-007","December 8, 2016","November 2016","December 2020","December 10, 2016","November 2016","No Study Results Posted","null","June 2020","Phase 1B: Maximum tolerated dose (MTD) of Varlitinib, as determined by dose-limiting toxicities (DLTs).|Phase 2: Objective Response Rate (ORR) based on RECIST v1.1|Progression Free Survival (PFS)|Disease control rate (DCR)|Duration of response (DoR)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02992340"
504,"NCT01083537","Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction","Terminated","No Results Available","Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Bowel Obstruction","Drug: Cisplatin|Drug: Paclitaxel","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MBO-CHEMO-BSC","March 1, 2010","February 2010","June 2012","June 7, 2012","June 2012","No Study Results Posted","null","June 2012","Overall Safety Profile|Quality of Life|Time to Resolution of Bowel Obstruction|Survival|Evaluation of Toxicity","https://ClinicalTrials.gov/show/NCT01083537"
505,"NCT02316327","Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab","Completed","No Results Available","Non-Small Cell Lung Cancer (NSCLC)","Drug: gemcitabine, cisplatin and bevacizumab","Fundacion Clinic per a la Recerca Biomédica","All","18 Years and older   (Adult, Senior)","Phase 4","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMPACT|2012-000459-15","December 5, 2014","July 2013","October 2016","October 4, 2016","October 2016","No Study Results Posted","null","September 2016","To evaluate blood supply, blood volume, time to peak flow increase and permeability and relation with the objective response to treatment (RC+RP)|To evaluate the response to treatment in terms of blood supply, blood volume and time to peak flow increase and permeability.|To evaluate the blood supply, blood volume, time to peak flow increase, permeability related with PFS and OS.|To evaluate the response to treatment at day +7 and +42 in terms of blood fluid, blood volume, time to peak flow increase, permeability at baseline visit related with PFS and OS.|The safety of the treatment following NCI-CTC AE (version 4.0)","https://ClinicalTrials.gov/show/NCT02316327"
506,"NCT00143455","Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer","Completed","Has Results","Small Cell Lung Carcinoma","Drug: Etoposide + cisplatin|Drug: Irinotecan + cisplatin","Pfizer","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","485","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP4174D-3001","September 1, 2005","June 2002","December 2008","February 10, 2010","February 2010","December 11, 2009","null","December 2008","Overall Survival (OS) for the Full Analysis Population (FAP)|Overall Survival for the Per Protocol (PP) Population|Number of Subjects With Overall Confirmed Response|Duration of Response (DR)|Time to Tumor Progression (TTP)|European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30)|Tumor Related Symptoms (Pain, Dyspnea, Cough, Hemoptysis, Weight, and the Use of Opioids and Non-Opioids Analgesics)","https://ClinicalTrials.gov/show/NCT00143455"
507,"NCT02535312","Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","Recruiting","No Results Available","Advanced Malignant Solid Neoplasm|Advanced Peritoneal Malignant Mesothelioma|Advanced Pleural Malignant Mesothelioma|Recurrent Malignant Solid Neoplasm|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer|Stage III Ovarian Cancer|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIC Ovarian Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Pleural Mesothelioma|Thymoma|Unresectable Solid Neoplasm","Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Drug: Methoxyamine|Drug: Pemetrexed Disodium|Other: Pharmacological Study","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","58","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-00127|PHI-76|9837|P30CA033572|UM1CA186689|UM1CA186705|UM1CA186717|ZIABC011078","August 27, 2015","August 11, 2015","null","May 23, 2017","May 2017","No Study Results Posted","null","August 31, 2017","Dose-limiting toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Arm A)|Response rate using RECIST (Arm B)|Establishment of pleural and peritoneal effluent-derived cell lines|Objective clinical response|Pharmacokinetic (PK) parameter|Response of cultured pleural and peritoneal mesothelioma cells to cisplatin, pemetrexed, and methoxyamine","https://ClinicalTrials.gov/show/NCT02535312"
508,"NCT00735904","Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer","Completed","Has Results","Carcinoma, Non-Small-Cell Lung (NSCLC)","Drug: AG-013736|Drug: gemcitabine|Drug: cisplatin","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061038","August 13, 2008","December 2008","November 2011","November 30, 2012","November 2012","November 30, 2012","null","November 2011","Percentage of Participants With Objective Response (OR)|Overall Survival (OS)|Progression Free Survival (PFS)|Duration of Response (DR)","https://ClinicalTrials.gov/show/NCT00735904"
509,"NCT01194869","Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer","Terminated","Has Results","Breast Cancer","Drug: Sorafenib|Drug: Cisplatin|Drug: Paclitaxel","Emory University|Amgen|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00019781|WCI1590-08","September 1, 2010","June 2010","June 2015","August 31, 2016","August 2016","June 17, 2016","null","June 2015","Pathologic Complete Response (pCR) at the Time of Surgery After Preoperative Treatment|Clinical Response Rate During Follow-up (Disease Recurrence)|Clinical Response Rate (Complete Pathologic Response Rate After Surgery)","https://ClinicalTrials.gov/show/NCT01194869"
510,"NCT01836341","Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation","Withdrawn","No Results Available","Non-small Cell Lung Cancer","Drug: Afatinib|Drug: Cisplatin|Drug: Carboplatin|Drug: Pemetrexed|Radiation: Radiation therapy","Memorial Sloan Kettering Cancer Center|Boehringer Ingelheim|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-279","April 17, 2013","April 2013","April 2015","December 18, 2013","December 2013","No Study Results Posted","null","April 2015","maximum tolerated dose|local control rate|tolerability of adjuvant afatinib|median progression free survival|median overall survival","https://ClinicalTrials.gov/show/NCT01836341"
511,"NCT00057850","BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: ixabepilone","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","27","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02523|UPCC-04302|NCI-5787|CDR0000276716","April 7, 2003","January 2002","null","February 8, 2013","April 2003","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00057850"
512,"NCT01591135","A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma","Active, not recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Paclitaxel plus 5-fluorouracil|Drug: Cisplatin plus 5-fluorouracil|Radiation: Radiation therapy|Radiation: Radiation therapy","Fudan University|Jiangsu Cancer Institute & Hospital|First Affiliated Hospital of Zhejiang University|The First Affiliated Hospital of Xiamen University|Fujian Cancer Hospital|Affiliated Hospital of Jiangnan University|Fudan University Shanghai Cancer Center Minhang Branch","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESO-Shanghai1","April 18, 2012","April 2012","July 2018","February 1, 2017","February 2017","No Study Results Posted","null","July 2018","3-yr overall survival|Disease progression-free survival|Local progression-free survival|Number and grade of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01591135"
513,"NCT02633176","Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cetuximab|Drug: Cisplatin|Drug: Docetaxel|Drug: Capecitabine|Radiation: Radiotherapy","Sun Yat-sen University|Chinese Southwest Oncology Group","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSWOG0103","December 10, 2015","January 2015","null","December 14, 2015","December 2015","No Study Results Posted","null","January 2023","Progression-free survival|Event-free Survival|Disease-free Survival|Overall Survival|Overall response rate","https://ClinicalTrials.gov/show/NCT02633176"
514,"NCT01000480","A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Radiation: Thoracic Radiotherapy","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13099|H3E-EW-S128","October 21, 2009","October 2009","July 2013","March 5, 2014","March 2014","November 12, 2013","null","January 2013","1 Year Progression Free Survival|Overall Survival|Number of Participants With an Objective Tumor Response","https://ClinicalTrials.gov/show/NCT01000480"
515,"NCT00079040","Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer","Completed","Has Results","Extensive Stage Small Cell Lung Cancer","Drug: cisplatin|Drug: etoposide|Biological: bevacizumab|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","65","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02944|ECOG-E3501|E3501|U10CA021115","March 8, 2004","January 2006","January 2009","April 28, 2014","December 2012","November 19, 2009","null","January 2009","Percentage of Participants Alive and Progression-free (PF) at 6 Months|Overall Survival|Best Objective Response","https://ClinicalTrials.gov/show/NCT00079040"
516,"NCT00668499","A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma","Withdrawn","No Results Available","Mesothelioma","Drug: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin","University of Southern California|Sponsor Name Pending","All","18 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","18M-07-2","April 25, 2008","April 2008","April 2011","May 19, 2014","May 2014","No Study Results Posted","null","April 2011","The primary endpoint of the phase II trial will be time to progression|Secondary endpoints are objective response rate and overall survival","https://ClinicalTrials.gov/show/NCT00668499"
517,"NCT00521521","Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Neoplasms","Drug: docetaxel and cisplatin|Drug: docetaxel","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_FR1_236","August 27, 2007","July 2001","null","December 4, 2009","December 2009","No Study Results Posted","TAX200006","May 2006","Objective response rates|Duration of the responses and overall survival","https://ClinicalTrials.gov/show/NCT00521521"
518,"NCT02016417","Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: A combination of Gemcitabine and cisplatin|Drug: A combination of Docetaxel, cisplatin and 5-Fluorouracil","Cancer Hospital of Guangxi Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CHGX20131212","December 15, 2013","May 2014","December 2020","April 15, 2014","December 2013","No Study Results Posted","null","December 2016","Failure-free survival (FFS)|Overall survival (OS)|Loco-regional failure-free survival (LFFS)|Distant metastasis failure-free survival (DMFS)|Acute induction chemotherapy toxicity","https://ClinicalTrials.gov/show/NCT02016417"
519,"NCT02608073","A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer","Completed","No Results Available","Nasopharyngeal Cancer","Drug: Capecitabine|Drug: Cisplatin","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18123","November 16, 2015","November 2004","November 2009","March 1, 2016","March 2016","No Study Results Posted","null","November 2009","Overall response rate|Overall survival|Time to disease progression|Duration of response|Complete response rate|Incidence of adverse events|Quality of life according to Visual Analog Scale (VAS) score|Treatment convenience/satisfaction according to VAS score","https://ClinicalTrials.gov/show/NCT02608073"
520,"NCT02460887","The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Gemcitabine|Drug: cisplatin|Drug: cisplatin|Radiation: Intensity-modulated Radiotherapy","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Sun Yat-sen University HPY","May 28, 2015","June 2015","June 2020","April 15, 2016","April 2016","No Study Results Posted","null","June 2017","Failure-free survival|Overall survival|Locoregional failure-free survival|Distant failure-free survival|Overall response rate|Number of participants with adverse events|Quality of life during treatment","https://ClinicalTrials.gov/show/NCT02460887"
521,"NCT02611700","Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Squamous Cell Carcinomas","Drug: Nimotuzumab|Drug: Paclitaxel|Drug: Cisplatin|Drug: Placebo","Biotech Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","504","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BPL-IST-ESO-057","November 12, 2015","November 2015","June 2019","January 29, 2016","January 2016","No Study Results Posted","null","December 2018","Median time of overall survival(OS)|Median time of progression-free survival（PFS）|Objective response rate（ORR）|Quality of life|Incidence of adverse events","https://ClinicalTrials.gov/show/NCT02611700"
522,"NCT00629226","Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: bortezomib|Drug: cisplatin|Radiation: intensity-modulated radiation therapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1","46","NIH","Interventional","Primary Purpose: Treatment","080071, CDR0000588196|NCI-08-C-0071|CCR 7205|NCI-7893","March 1, 2008","October 2007","null","September 29, 2011","September 2011","No Study Results Posted","null","December 2010","Dose-limiting toxicities and other toxicities as assessed by NCI CTCAE v3.0|Maximum tolerated dose of bortezomib when administered in combination with cetuximab and radiotherapy with and without cisplatin|Objective response rate|Progression-free survival|Overall survival|Pre-to-post-treatment changes in biomarkers","https://ClinicalTrials.gov/show/NCT00629226"
523,"NCT01471470","Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer","Active, not recruiting","No Results Available","Advanced Gastric Cancer","Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab","Asan Medical Center|Roche Pharma AG","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC ONCGI-1003","July 18, 2011","July 2010","December 2017","November 26, 2015","November 2015","No Study Results Posted","null","December 2017","R0 resection rate|Overall survival|Angiogenetic biomarkers|Progression-free survival|Toxicity","https://ClinicalTrials.gov/show/NCT01471470"
524,"NCT03101566","Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer","Not yet recruiting","No Results Available","Biliary Tract Neoplasms","Drug: Gemcitabine|Drug: Cisplatin|Drug: Ipilimumab|Drug: Nivolumab","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UMCC 2017.026|HUM00126271","March 30, 2017","May 1, 2017","November 1, 2020","March 30, 2017","March 2017","No Study Results Posted","null","November 1, 2019","The percentage of patients alive and without progression at 6 months following the initiation of treatment|The percentage of patients that respond to treatment|Median progression free survival time|Median overall survival time","https://ClinicalTrials.gov/show/NCT03101566"
525,"NCT00210041","Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma","Completed","No Results Available","Genital Neoplasms, Male","Drug: Gemcitabine|Drug: Cisplatin","Institut Claudius Regaud","Male","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03 GENH 06|02 GENM 02","September 2, 2005","February 2004","December 2012","March 26, 2015","March 2015","No Study Results Posted","null","December 2011","To evaluate objective response rate|To evaluate tolerance of the association,|time to progression,|global survival","https://ClinicalTrials.gov/show/NCT00210041"
526,"NCT03044587","Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","Not yet recruiting","No Results Available","Adenocarcinoma Metastatic|Biliary Tract Cancer|Adenocarcinoma of the Biliary Tract|Adenocarinoma Locally Advanced|Non-Resectable Hepatocellular Carcinoma|Intrahepatic Bile Duct Carcinoma|Extrahepatic Bile Duct Carcinoma","Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Drug: Arm Cisplatin + Gemcitabine (Arm B)","AIO-Studien-gGmbH|Baxalta GmbH|Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH|Shire","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AIO-YMO/HEP-0315|2016‐002467‐34|O16-33004","January 23, 2017","May 2017","January 2024","February 3, 2017","February 2017","No Study Results Posted","NIFE","October 2018","Progression-free survival [PFS]|Overall progression free survival according to RECIST 1.1|3-years overall survival|Disease control rate according to RECIST 1.1|Objective tumor response rate (ORR) according to RECIST 1.1|Toxicity/Safety according to CTC-AE-criteria|Health related quality of life|Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review|Retrospective central radiological review","https://ClinicalTrials.gov/show/NCT03044587"
527,"NCT01295502","Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer","Active, not recruiting","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage IIIA Cervical Cancer|Stage IIIB Cervical Cancer|Stage IVA Cervical Cancer","Drug: Carboplatin|Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Internal Radiation Therapy|Drug: Paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GOG-9926|NCI-2011-02665|CDR0000695304|U10CA180868|U10CA027469","February 11, 2011","April 2011","null","May 3, 2017","May 2017","No Study Results Posted","null","December 2019","MTD of adjuvant carboplatin and paclitaxel determined based on the dose-limiting toxicities assessed by NCI CTCAE version 4|Chronic toxicities experienced classified using the CTCAE version 4|Location of recurrence (loco-regional versus distant) defined as newly evident disease for patients who have no evidence of disease at baseline or progressive disease for patients who have strictly non-measurable disease at baseline|Objective tumor response rate in patients enrolled with measurable disease|Overall survival|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01295502"
528,"NCT01375972","Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma","Completed","No Results Available","Metastatic Biliary Cancer","Drug: S-1 plus cisplatin|Drug: Gemcitabine plus Cisplatin","Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC_0803","June 15, 2011","March 2008","August 2011","December 5, 2011","December 2011","No Study Results Posted","null","July 2011","Progression-free survival rate at 6 months|Response rate|Toxicities|overall survival","https://ClinicalTrials.gov/show/NCT01375972"
529,"NCT01342172","Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma","Terminated","Has Results","Urinary Bladder Neoplasms","Drug: Lenalidomide","Icahn School of Medicine at Mount Sinai|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCO 10-1339","April 21, 2011","March 2011","June 2013","November 26, 2014","November 2014","November 20, 2014","null","June 2013","Phase I: To Determine the Recommended Phase II Dose of the Combination of Gemcitabine, Cisplatin, Plus Lenalidomide|Phase II: Progression-free Survival at 1 Year|To Determine the Objective Response Rate to Treatment With Gemcitabine, Cisplatin, Plus Lenalidomide|To Determine the Safety of Combination Therapy With Gemcitabine, Cisplatin, and Lenalidomide|To Evaluate Lenalidomide as Maintenance Treatment in Patients Achieving an Objective Response or Stable Disease Following Completion of 6 Cycles of Combination Therapy.|To Determine the Impact of Treatment on Peripheral Blood Immune Cell Subsets|To Determine the Impact of Treatment on Circulating Tumor Cells","https://ClinicalTrials.gov/show/NCT01342172"
530,"NCT00530634","Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer","Terminated","Has Results","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method|Procedure: adjuvant therapy|Procedure: conventional surgery|Radiation: radiation therapy","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99077|P30CA033572|CHNMC-99077|CDR0000564760","September 13, 2007","August 1999","June 2013","October 7, 2015","October 2015","August 19, 2015","null","June 2013","Two-year Progression-free Survival From the Date of Surgery","https://ClinicalTrials.gov/show/NCT00530634"
531,"NCT01633645","Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer|Metastatic","Drug: Bortezomib|Drug: Gemcitabine|Drug: Cisplatin","University Hospital of Crete","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-LUC-2006","March 13, 2012","June 2009","April 2013","September 25, 2015","September 2015","No Study Results Posted","null","April 2013","Overall Response Rate|Progression free survival|Overall survival|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01633645"
532,"NCT01194453","Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer","Completed","Has Results","Non-small Cell Lung Cancer|Efficacy","Drug: cisplatin, dexamethasone,vitamin B12, folic acid|Drug: cisplatin, gemcitabine","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","288","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HANSOH20090601","August 25, 2010","November 2009","August 2012","May 10, 2016","May 2016","May 10, 2016","AP/GP","September 2010","Progression Free Survival (PFS)|Response Rate","https://ClinicalTrials.gov/show/NCT01194453"
533,"NCT00357149","Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)","Completed","No Results Available","Head and Neck Neoplasms","Drug: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|Drug: Concomitant cisplatin, 5-FU and radiotherapy","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976F_2501","July 26, 2006","January 2003","null","December 4, 2009","December 2009","No Study Results Posted","null","February 2008","Rate of radiologic Complete Response (CR) evaluated 6-8 weeks after the completion of treatment|Duration of response|Time to disease progression|Time to treatment failure|Median length of overall survival","https://ClinicalTrials.gov/show/NCT00357149"
534,"NCT00941070","Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer","Completed","Has Results","Recurrent Cervical Cancer|Recurrent Vaginal Cancer|Stage IB Cervical Cancer|Stage II Vaginal Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage III Vaginal Cancer|Stage IVA Cervical Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IVB Vaginal Cancer|Therapy-related Toxicity","Drug: triapine|Drug: cisplatin|Radiation: external beam radiation therapy|Procedure: quality-of-life assessment|Other: questionnaire administration|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography|Procedure: computed tomography","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02896|CDR0000647544|CASE 11808|8327|P30CA043703|U01CA062502","July 16, 2009","July 2009","July 2012","April 21, 2014","December 2012","March 20, 2013","null","April 2012","Fasting F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging Complete Metabolic Response, Reported Following National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) Guidelines.|Clinical and Objective Response Assignment|Percent of Patients With Incidence of Grade 2 or Higher Gastrointestinal and Genitourinary Toxicity, Assessed Using CTCAE v3.0 Until December 31, 2010 and CTCAE v4.0 Beginning January 1, 2011|Progression-free Survival|PET/CT Scan Metabolic Activity|Change in Sexual Function, Assessed Using the Sexual Function-Vaginal Changes Questionnaire|Change in Smoking Behavior, Assessed Using the Smoking Questionnaire and Cessation Counseling|Progression Free Survival by HPV Subtype","https://ClinicalTrials.gov/show/NCT00941070"
535,"NCT01064648","Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","Active, not recruiting","No Results Available","Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma","Drug: Cediranib Maleate|Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Drug: Pemetrexed Disodium|Other: Placebo","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","116","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2011-02015|S0905|CDR0000665415|U10CA180888|U10CA032102","February 5, 2010","March 15, 2010","null","May 23, 2017","May 2017","No Study Results Posted","null","June 1, 2017","Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I)|Progression-free survival (Phase II)|Overall survival (Phase II)|Response (Phase II)|Toxicity assessed using NCI CTCAE version 4.0 (Phase II)","https://ClinicalTrials.gov/show/NCT01064648"
536,"NCT00832117","Phase I Combination Ixabepilone + Cisplatin","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Ixabepilone|Drug: Cisplatin|Drug: Ixabepilone|Drug: Cisplatin","R-Pharm","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA163-177|2008-004909-34","January 28, 2009","May 2009","January 2011","February 9, 2016","February 2016","February 21, 2012","null","January 2011","Participants Experiencing Dose Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Cisplatin in Combination With Ixabepilone, 32 mg/m^2|Number of Participants With Best Response As Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Response|Duration of Response in Participants With Non-small Cell Lung Cancer (NSCLC)|Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Per National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE)Version 3 Criteria|Number of Participants With Laboratory Abnormalities Per National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE)Version 3 Criteria","https://ClinicalTrials.gov/show/NCT00832117"
537,"NCT02375880","Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder","Recruiting","No Results Available","Carcinoma of Intrahepatic and Extra-hepatic Biliary System|Carcinoma of Gallbladder|Bile Duct Cancer|Cholangiocarcinoma","Drug: DKN-01|Drug: gemcitabine|Drug: cisplatin","Leap Therapeutics, Inc.","All","30 Years and older   (Adult, Senior)","Phase 1","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DEK-DKK1-P103","February 18, 2015","June 2015","August 2018","February 6, 2017","February 2017","No Study Results Posted","null","August 2018","Maximum tolerated dose and dose-limiting toxicities as determined in Part A.|Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.|Pharmacokinetics - AUC|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1)","https://ClinicalTrials.gov/show/NCT02375880"
538,"NCT02370849","Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma","Completed","No Results Available","Stomach Neoplasms","Drug: nimotuzumab|Drug: cisplatin|Drug: S-1","Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20150207","February 8, 2015","October 2009","February 2015","February 19, 2015","February 2015","No Study Results Posted","null","February 2012","Objective response rate as measured by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)|Time to progression as measured by RECIST 1.1|Progression-free survival measured by RECIST 1.1|Treatment safety and toxicity as measured by Common Toxicity Criteria for Adverse Effects(CTCAE 3.0)","https://ClinicalTrials.gov/show/NCT02370849"
539,"NCT02608684","A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer","Recruiting","No Results Available","Ovarian Cancer","Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Cisplatin","Cedars-Sinai Medical Center|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IIT2015-13-Walsh-PemCiGem","November 12, 2015","February 2016","January 2020","January 31, 2017","January 2017","No Study Results Posted","PemCiGem","January 2020","Overall response rate (ORR)|Overall response rate by immune-related Response Criteria (irRC)|Progression-free survival (PFS) at 6 months and at 12 months|Time to progression|Duration of response|Overall survival (OS)|Frequency and intensity of adverse events (CTCAE v.4)","https://ClinicalTrials.gov/show/NCT02608684"
540,"NCT01206426","Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer","Active, not recruiting","No Results Available","Urothelial Cancer","","University of Chicago","All","18 Years to 89 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","09-288-B","September 13, 2010","October 2009","December 2017","April 18, 2017","April 2017","No Study Results Posted","null","December 2017","Genetic Determinants of pT0 Status|Molecular Determinants of pT0 Status","https://ClinicalTrials.gov/show/NCT01206426"
541,"NCT02240017","A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.","Recruiting","No Results Available","Urothelial Advanced or Metastatic Cancer.","Drug: Carboplatin|Drug: Fractionated Cisplatin|Drug: Gemcitabine","Institut Claudius Regaud","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13 URO 02","September 5, 2014","September 2014","September 2023","May 26, 2015","September 2014","No Study Results Posted","VEFORA","December 2017","Phase II: Efficacy - Rate of non progression at the end of treatment (C6D21).|Phase III: Overall survival (in months).|Phase II: Tolerance - Percentage of patients for whom at least one of the 3 defined tolerance criteria (see description) is observed.|Phase II and III: Objective response.|Phase II and III: Tolerance according to NCI toxicity scale (version 4.0).|Phase II and III: Geriatric evaluation using questionnaires.|Phase II and III: Quality of life using the EORTC QLQ - C30 questionnaire (European Organization for research and treatment of Cancer - Quality of life questionnaire).|Phase II and III: Pharmacokinetics - Platin concentrations|Phase II and III: Pharmacogenetics, exploration of cytidine deaminase activity and study of its genetic polymorphisms.|Phase II and III: Progression free survival.|Phase II and III: Overall survival.|Phase II and III: Time to treatment failure.","https://ClinicalTrials.gov/show/NCT02240017"
542,"NCT00101907","Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer","Terminated","Has Results","Lung Cancer|Pancreatic Cancer|Esophageal Cancer","Drug: AMG 706|Biological: Panitumumab|Drug: Gemcitabine|Drug: Cisplatin","Amgen","All","18 Years and older   (Adult, Senior)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20040206","January 18, 2005","December 2004","April 2008","February 3, 2014","February 2014","August 13, 2010","null","June 2007","Participant Incidence of Adverse Events|Number of Participants With an Objective Tumor Response|Tmax|Cmax|AUC0-24|AUC0-inf","https://ClinicalTrials.gov/show/NCT00101907"
543,"NCT00102531","Inhalation SLIT Cisplatin for the Treatment of Osteosarcoma Metastatic to the Lung","Completed","No Results Available","Osteosarcoma","Drug: SLIT Cisplatin","Insmed Incorporated","All","13 Years to 50 Years   (Child, Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TR02-2421","January 29, 2005","January 2005","March 2008","July 7, 2010","July 2010","No Study Results Posted","null","March 2008","Safety|Response|Pharmacokinetics|Duration of response","https://ClinicalTrials.gov/show/NCT00102531"
544,"NCT01973101","Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.","Unknown status","No Results Available","Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t","Drug: Cisplatin|Drug: Gemcitabine|Drug: cisplatin|Radiation: Radiotherapy|Radiation: Brachytherapy","Instituto do Cancer do Estado de São Paulo","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NP 217/2012","October 22, 2013","June 2012","April 2017","July 14, 2014","July 2014","No Study Results Posted","CIRCE","April 2017","Disease free survival|Response rate|Locoregional disease control rate|Acute and chronic toxicity in both arms|Overall survival","https://ClinicalTrials.gov/show/NCT01973101"
545,"NCT01969877","A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.","Recruiting","No Results Available","Locally Advanced Head and Neck Cancer","Drug: cetuximab|Drug: cisplatin","Lund University Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","618","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EudraCT number 2012-001879-37|2012-001879-37","October 16, 2013","November 2013","November 2024","March 6, 2017","September 2016","No Study Results Posted","ARTSCANIII","November 2024","Overall survival","https://ClinicalTrials.gov/show/NCT01969877"
546,"NCT00335998","Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies","Completed","No Results Available","Recurrent Cervical Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Vaginal Cancer|Recurrent Vulvar Cancer|Stage III Vaginal Cancer|Stage IIIA Cervical Cancer|Stage IIIA Ovarian Epithelial Cancer|Stage IIIA Vulvar Cancer|Stage IIIB Cervical Cancer|Stage IIIB Ovarian Epithelial Cancer|Stage IIIB Vulvar Cancer|Stage IIIC Ovarian Epithelial Cancer|Stage IIIC Vulvar Cancer|Stage IV Ovarian Epithelial Cancer|Stage IVA Cervical Cancer|Stage IVA Vaginal Cancer|Stage IVB Cervical Cancer|Stage IVB Vaginal Cancer","Drug: triapine|Other: laboratory biomarker analysis|Radiation: external beam radiation therapy|Radiation: brachytherapy|Drug: cisplatin|Other: pharmacological study","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","24","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03126|CASE 1805|U01CA062502","June 8, 2006","March 2006","null","January 10, 2013","January 2013","No Study Results Posted","null","October 2008","Toxicity of radiotherapy and Triapine® combination therapy as documented by dose-limiting toxicities (DLTs) using Common Terminology Criteria for Adverse Events (CTCAE) criteria, version 3.0|MTD of Triapine® when given in combination with pelvic radiotherapy with or without weekly intravenous cisplatin chemotherapy|RR R2 enzyme quantity","https://ClinicalTrials.gov/show/NCT00335998"
547,"NCT00156884","A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer","Completed","No Results Available","Hormone Refractory Prostate Cancer|Bone Metastases","Drug: strontium-89|Drug: cisplatin","Alberta Health Services|The Prostate Cancer Research Foundation of Canada|Amersham Health|AHS Cancer Control Alberta","Male","18 Years and older   (Adult, Senior)","Phase 2","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GUPPS2","September 8, 2005","August 2003","May 2008","January 18, 2012","August 2008","No Study Results Posted","null","May 2008","Palliative pain response|analgesic response","https://ClinicalTrials.gov/show/NCT00156884"
548,"NCT01873326","Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors","Recruiting","No Results Available","Germ Cell Tumors","Drug: Paclitaxel|Drug: Ifosfamide|Drug: Cisplatin|Drug: Mesna|Drug: Bleomycin|Drug: Etoposide","Memorial Sloan Kettering Cancer Center|University of Southern California|Mayo Clinic|University of Pittsburgh|University of North Carolina|University of Chicago|Stanford University|University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13-074","June 5, 2013","June 2013","June 2018","January 24, 2017","January 2017","No Study Results Posted","null","June 2018","favorable best response rate|overall best response|progression-free survival (PFS)|overall survival (OS)|toxicity","https://ClinicalTrials.gov/show/NCT01873326"
549,"NCT00680940","A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Paclitaxel & Cisplatin|Biological: Mycobacterium w.","Cadila Pharnmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","221","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR-60/7260","May 16, 2008","June 2008","December 2010","August 4, 2012","August 2012","No Study Results Posted","NSCLC","December 2010","Overall survival time of patients, quality of life|Response rate, Hematological toxicity","https://ClinicalTrials.gov/show/NCT00680940"
550,"NCT00526643","CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients","Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: gemcitabine|Drug: cisplatin","National Cancer Institute, Naples|Clinical Trials Promoting Group (APRIC/CTPG)|Gruppo Oncologico del Lazio (GOL)|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Gruppo Oncologico Italiano di Ricerca Clinica(GOIRC)|Gruppo Oncologico Italia Meridionale|Northwest Oncology Cooperative Group(GONO)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CAPPA-2|2005-005631-97","September 6, 2007","November 2007","December 2012","March 27, 2017","March 2017","No Study Results Posted","CAPPA-2","December 2012","overall survival|change in performance status|toxicity|quality of life|objective response|progression free survival","https://ClinicalTrials.gov/show/NCT00526643"
551,"NCT02478502","Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer","Recruiting","No Results Available","Testicular Cancer","Drug: cabazitaxel","Jan Oldenburg|Sanofi|University Hospital, Akershus","Male","18 Years and older   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012/1627 b|2012-004418-32","August 28, 2014","June 2015","June 2018","January 16, 2017","January 2017","No Study Results Posted","null","December 2017","Objective response rate","https://ClinicalTrials.gov/show/NCT02478502"
552,"NCT01474642","Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma","Completed","No Results Available","Advanced or Recurrent Esophageal Squamous Cell Carcinoma","Drug: Capecitabine/Cisplatin(XP)|Drug: Capecitabine/Paditaxel(XG)","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-09-10","November 10, 2011","September 2008","May 2014","December 28, 2015","December 2015","No Study Results Posted","null","September 2013","response rate|progression free survival|quality of life|Number of Adverse Event|overall survival|predictive marker","https://ClinicalTrials.gov/show/NCT01474642"
553,"NCT02573493","Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of the Head and Neck|Cancer of Head and Neck|Cancer of the Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck","Drug: nab-Paclitaxel|Drug: Cisplatin|Biological: Cetuximab|Radiation: Intensity-Modulated Radiation Therapy","Washington University School of Medicine|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","201510013","October 7, 2015","April 13, 2016","October 31, 2028","May 3, 2017","May 2017","No Study Results Posted","APA","May 31, 2018","Complete response rate as measured by clinical exam at the primary tumor site|Partial response rate as measured by clinical exam at the primary tumor site|Complete response rate as measured by clinical exam at the involved regional nodes|Partial response rate as measured by clinical exam at the involved regional nodes|Anatomic tumor response as assessed by CT using RECIST 1.0 criteria|Metabolic tumor response by Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET/CT) fusion scan|Document and quantify Ki-67 expression by IHC in primary tumor tissue and correlate with clinical primary tumor site response|Grade 3-4 adverse events as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0|Overall survival (OS)|Disease-free survival (DFS)|Progression-free survival (PFS)|Quality of life as measured by FACT-H&N and FACT/GOG-NTX-4|Overall survival (OS) rate|Disease-free survival (DFS) rate|Progression-free survival (PFS) rate","https://ClinicalTrials.gov/show/NCT02573493"
554,"NCT01281800","Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma","Unknown status","No Results Available","Mesothelioma","Procedure: Gemcitabine in long infusion","Institute of Oncology Ljubljana|Slovenian Research Agency","All","18 Years and older   (Adult, Senior)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","22k/06/08","January 17, 2011","August 2008","null","January 21, 2011","January 2011","No Study Results Posted","AGILI","August 2014","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01281800"
555,"NCT00942331","Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","Active, not recruiting","No Results Available","Bladder Urothelial Carcinoma|Distal Urethral Carcinoma|Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Proximal Urethral Carcinoma|Recurrent Bladder Carcinoma|Recurrent Prostate Carcinoma|Recurrent Urethra Carcinoma|Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter|Regional Urothelial Carcinoma of the Renal Pelvis and Ureter|Stage IV Bladder Cancer|Stage IV Prostate Cancer|Stage IV Urethral Cancer|Ureter Carcinoma","Biological: Bevacizumab|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Placebo","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","500","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2011-01952|CDR0000649174|CALGB-90601|U10CA180821|U10CA031946","July 17, 2009","July 15, 2009","null","May 24, 2017","May 2017","No Study Results Posted","null","June 30, 2019","Overall survival (OS)|Grade 3 or greater treatment-related toxicity using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Objective response rate (defined as confirmed complete and partial responses) using Response Evaluation Criteria in Solid Tumors criteria|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT00942331"
556,"NCT00573690","Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: carboplatin|Drug: cisplatin|Drug: etoposide|Drug: pemetrexed disodium|Drug: sorafenib tosylate","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","31","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 0613|CDR0000579819|UNC-LCC-07-0971","December 13, 2007","September 2007","February 2011","April 20, 2012","April 2012","No Study Results Posted","null","June 2009","Recommended phase II dose and maximum tolerated dose of sorafenib tosylate when administered in combination with cisplatin and etoposide or carboplatin and pemetrexed disodium|Toxicity|Efficacy of treatment as measured by RECIST criteria or by tumor markers|Pharmacokinetics of sorafenib tosylate in combination with etoposide (samples are no longer being collected and studies are no longer being performed as of 1/8/09)","https://ClinicalTrials.gov/show/NCT00573690"
557,"NCT00397904","Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin","Completed","Has Results","Esophageal Cancer|Gastric Cancer","Biological: cetuximab|Drug: cisplatin|Drug: irinotecan hydrochloride|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-095|P30CA008748|MSKCC-06095","November 9, 2006","October 2006","September 2010","October 22, 2015","October 2015","October 22, 2015","null","September 2010","Complete and Partial Response Rate","https://ClinicalTrials.gov/show/NCT00397904"
558,"NCT00154739","Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Epirubicin","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","46S1","September 8, 2005","October 1998","July 2005","August 1, 2008","July 2005","No Study Results Posted","null","July 2005","The primary objective of this study is to explore efficacy of gemcitabine and epirubicin in the treatment of NSCLC patients who need palliative chemotherapy.|The secondary objective of this study is to compare efficacy (response rate，overall survival) of gemcitabine/epirubicin to gemcitabine/cisplatin in the treatment of inoperable NSCLC.","https://ClinicalTrials.gov/show/NCT00154739"
559,"NCT00248482","Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: Cisplatin|Drug: Gleevec™|Drug: irinotecan","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000445222|P30CA022453|WSU-C-2461|WSU-UMCC-2001-066|CST1571B US93","November 3, 2005","February 2002","January 2008","April 25, 2013","April 2013","No Study Results Posted","null","April 2005","Progression-free survival|Overall survival|Tolerability of Gleevec maintenance therapy|Response rate as measured by RECIST at","https://ClinicalTrials.gov/show/NCT00248482"
560,"NCT01771289","Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: docetaxel/cisplatin|Radiation: Radiation","Peking University People's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PKUPH-XW1301","January 16, 2013","January 2013","null","September 25, 2016","September 2016","No Study Results Posted","null","January 2017","downstage rate of mediastinal lymph nodes|overall survival|Disease-free survival|resection rate","https://ClinicalTrials.gov/show/NCT01771289"
561,"NCT01491139","Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","Withdrawn","No Results Available","Carcinoma, Squamous Cell","Drug: olaparib|Drug: cisplatin|Radiation: Intensity Modulated Radiotherapy","University College, London|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-023599-24|62346992","December 9, 2011","null","null","May 29, 2012","May 2012","No Study Results Posted","ORCA","null","Frequency of dose limiting toxicities|Complete response rate|Time to loco-regional progression","https://ClinicalTrials.gov/show/NCT01491139"
562,"NCT01386632","Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: DCA (dichloroacetate)|Drug: Placebo","Sanford Health","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DCA 2010","May 23, 2011","May 2011","January 2019","April 28, 2014","April 2014","No Study Results Posted","null","April 2014","To evaluate the safety of delivering DCA during primary chemo-radiation.|Two-year and five-year progression-free survival rate in locally advanced head and neck squamous cell carcinoma in patients receiving concurrent cisplatin, radiation therapy, and DCA.|Relative toxicities for locally advanced head and neck squamous cell carcinoma patients receiving concurrent cisplatin, radiation therapy, and DCA.|Immune response and correlate these findings with toxicity and outcome (exploratory analysis).|Health-related quality of life among study patients by treatment arm .|Local response rate for locally advanced head and neck squamous cell carcinoma patients receiving concurrent cisplatin, radiation therapy, and DCA.|Health-related quality of life among study patients by treatment arm.|Overall survival for locally advanced head and neck squamous cell carcinoma patients receiving concurrent cisplatin, radiation therapy, and DCA.|HPV status- correlate these findings with toxicity and outcome (exploratory analysis).","https://ClinicalTrials.gov/show/NCT01386632"
563,"NCT00925743","A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer","Completed","No Results Available","Solid Cancer","Drug: cabazitaxel (XRP6258)","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD10870","June 19, 2009","June 2009","March 2013","May 15, 2013","May 2013","No Study Results Posted","null","March 2013","Dose Limiting Toxicities (DLT)'s of the combination of cabazitaxel and cisplatin (part 1)|Objective response ratio (Complete response (CR) and partial response (PR)) (part 2)|Pharmacokinetics (PK) of cabazitaxel (part 3 and 4)|Time to progression (TTP) (part 1 and 2)|Duration of response (DR) (Part 1 and 2)|Cabazitaxel pharmacokinetic (part 1 and 2)","https://ClinicalTrials.gov/show/NCT00925743"
564,"NCT00287911","Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: topotecan hydrochloride|Radiation: brachytherapy|Radiation: radiation therapy","Masonic Cancer Center, University of Minnesota|GlaxoSmithKline","Female","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000452043|UMN-2001LS041|UMN-WCC-34|104864/638","February 6, 2006","February 2005","December 2009","November 6, 2012","November 2012","No Study Results Posted","null","December 2009","Maximum tolerated dose of topotecan","https://ClinicalTrials.gov/show/NCT00287911"
565,"NCT00907504","Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer","Withdrawn","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: CP-751,871|Drug: Cisplatin|Drug: Gemcitabine|Drug: Cisplatin|Drug: Gemcitabine","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A4021017","May 20, 2009","July 2010","May 2014","June 16, 2014","June 2014","No Study Results Posted","ADVIGO1017","May 2014","Overall Survival|Progression Free survival|Objective Response|Overall Safety Profile|Patient Reported Outcome|Pharmacokinetics|Anti-drug Antibody|Biomarker Analysis","https://ClinicalTrials.gov/show/NCT00907504"
566,"NCT01283217","Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer","Unknown status","No Results Available","Gastric Adenocarcinoma","Drug: DS|Drug: SP","Yonsei University","All","20 Years and older   (Adult, Senior)","Phase 3","166","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2009-0708","January 24, 2011","March 2010","March 2016","June 1, 2013","June 2013","No Study Results Posted","null","March 2016","3-year disease free survival(DFS)","https://ClinicalTrials.gov/show/NCT01283217"
567,"NCT00226239","Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer","Completed","No Results Available","Cancer","Drug: Docetaxel|Drug: Cisplatin|Drug: Cetuximab|Procedure: Radiation Therapy","University of Pittsburgh|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-003","September 22, 2005","October 2005","July 2013","July 23, 2013","July 2013","No Study Results Posted","null","July 2013","To evaluate the objective response rate with induction with cisplatin/docetaxel/cetuximab in subjects.|To evaluate the toxicities, objective response rate post chemoradiotherapy, time to progression, overall survival, local and distant failure rates.","https://ClinicalTrials.gov/show/NCT00226239"
568,"NCT00003377","Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix","Completed","Has Results","Cervical Cancer","Drug: cisplatin|Drug: paclitaxel|Radiation: brachytherapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066371|GOG-9804","November 1, 1999","November 1999","July 2009","December 27, 2012","December 2012","November 23, 2012","null","July 2009","Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment|Disease-free Survival at 2 Years|Overall Survival at 2 Years","https://ClinicalTrials.gov/show/NCT00003377"
569,"NCT00257816","Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma","Unknown status","No Results Available","Cervical Cancer","Drug: Topotecan|Drug: Cisplatin","University of California, Irvine","Female","18 Years and older   (Adult, Senior)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 03-33","November 21, 2005","April 2004","January 2009","March 26, 2008","March 2008","No Study Results Posted","null","January 2009","To assess the feasibility and toxicity|To assess the efficacy","https://ClinicalTrials.gov/show/NCT00257816"
570,"NCT00004083","Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: cisplatin liposomal","New York University School of Medicine|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067294|P30CA016087|NYU-9871|SEQUUS-77-21|NCI-G99-1579","December 10, 1999","February 1999","null","March 25, 2011","March 2011","No Study Results Posted","null","December 1999","","https://ClinicalTrials.gov/show/NCT00004083"
571,"NCT03050437","A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cisplatin|Drug: Pemetrexed","Samsung Medical Center","All","20 Years and older   (Adult, Senior)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2012-12-035","September 22, 2015","March 2013","March 2017","February 9, 2017","February 2017","No Study Results Posted","null","February 2017","progression-free survival","https://ClinicalTrials.gov/show/NCT03050437"
572,"NCT00296322","Trial of Adjuvant Chemotherapy for Gastric Cancer","Completed","Has Results","Stomach Cancer","Drug: cisplatin, mitomycin-C, doxifluridine","Asan Medical Center|Ulsan University Hospital|Hallym University Medical Center","All","18 Years to 69 Years   (Adult, Senior)","Phase 3","528","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0102","February 24, 2006","October 2001","March 2010","August 7, 2013","August 2013","July 19, 2012","null","December 2007","Relapse-free Survival|Toxicity Profile (According to NCI CTC Version 2.0)|Overall Survival","https://ClinicalTrials.gov/show/NCT00296322"
573,"NCT02314117","A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","Active, not recruiting","No Results Available","Metastatic Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma","Drug: Ramucirumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Placebo|Drug: Fluorouracil","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","616","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","15372|I4T-MC-JVCU|2014-002240-40","December 8, 2014","January 2015","August 2018","March 8, 2017","March 2017","No Study Results Posted","RAINFALL","January 2017","Progression Free Survival (PFS)|Overall Survival (OS)|Progression Free Survival 2 (PFS2)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Time to Progression (TTP)|Duration of Response (DoR)|Change from Randomization to 30 Days After Treatment Discontinuation in Quality of Life on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)|Change from Randomization to 30 Days After Treatment Discontinuation in Health Status on the European Quality of Life 5-Dimensions 5 Level Instrument (EQ-5D- 5L)|Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)|Pharmacokinetics (PK): Minimum Ramucirumab Concentration (Cmin) and Concentration at 1-Hour Post End of Ramucirumab Infusion (Approximately Maximum Concentration [Cmax])|Number of Participants with Anti-Ramucirumab Antibodies","https://ClinicalTrials.gov/show/NCT02314117"
574,"NCT00295503","Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma","Completed","Has Results","Mesothelioma","Drug: bevacizumab|Drug: cisplatin|Drug: pemetrexed","University of Texas Southwestern Medical Center|University of Chicago|Columbia University|Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVF3442S","February 22, 2006","February 2006","August 2010","November 4, 2016","November 2016","October 18, 2013","null","June 2010","Progression Free Survival Rate at 6 Months|Response Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT00295503"
575,"NCT02325401","Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Cancer","Drug: Metformin|Drug: Cisplatin|Radiation: Radiation Therapy","University of Cincinnati","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCCI-HN-14-01","December 16, 2014","March 2015","March 2021","January 13, 2017","January 2017","No Study Results Posted","null","March 2018","Maximum tolerated dose (MTD) of metformin in combination with concurrent cisplatin and radiation|Anti-tumor effect of metformin to chemoradiation|Number of participants with adverse events|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02325401"
576,"NCT03117335","Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Advanced Non-small Cell Lung Cancer","Drug: Placebos|Drug: Sulijia","Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.|Tigermed Consulting Co., Ltd","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","560","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","TG1107RHE|BA2010071","April 10, 2017","November 10, 2011","January 17, 2017","April 12, 2017","April 2017","No Study Results Posted","null","November 14, 2016","Progression Free Survival(PFS)|Objective response rate(ORR)|Disease control rate(DCR)|Overall survival(OS)","https://ClinicalTrials.gov/show/NCT03117335"
577,"NCT00846443","Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer","Unknown status","No Results Available","Local Advanced Non-Small Cell Lung Cancer","Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy|Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy|Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy|Other: Concurrent Pemetrexed, Cisplatin and Radiotherapy","Fudan University","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSCLC2009","February 17, 2009","January 2009","null","February 17, 2009","February 2009","No Study Results Posted","null","January 2010","Dose-limiting toxicities per protocol","https://ClinicalTrials.gov/show/NCT00846443"
578,"NCT00003299","Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: paclitaxel","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Eastern Cooperative Oncology Group|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","587","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9732|U10CA031946|CLB-9732|E-C9732|NCCTG-C9732|SWOG-C9732|CDR0000066238","November 1, 1999","April 1998","January 2006","July 19, 2016","July 2016","No Study Results Posted","null","June 2005","overall survival|response rate|failure-free survival","https://ClinicalTrials.gov/show/NCT00003299"
579,"NCT00136955","Irinotecan Study For Cervical Cancer","Completed","Has Results","Uterine Cervical Neoplasms","Drug: Irinotecan","Pfizer","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP4174/2502|A5961083","August 25, 2005","June 2004","May 2008","May 22, 2015","May 2015","May 7, 2009","null","May 2008","Response to Treatment Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Evaluable Population)|Response to Treatment Based on RECIST Criteria (Intent-to-Treat [ITT] Population)|Overall Survival (OS) and Time to Tumor Progression (TTP) (Evaluable Population)|Overall Survival (OS) and Time to Tumor Progression (ITT Population)","https://ClinicalTrials.gov/show/NCT00136955"
580,"NCT01204307","Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation","Completed","No Results Available","Advanced Non-Squamous Non-Small Cell Lung Cancer","Drug: Docetaxel/cisplatin|Drug: Pemetrexed/cisplatin","Chang Gung Memorial Hospital|Taiwan Chest Disease Association","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","99-1896C","September 16, 2010","January 2010","June 2015","July 27, 2015","September 2010","No Study Results Posted","null","December 2014","Response rate to erlotinib with Docetaxel/cisplatin or Pemetrexed/cisplatin|Progression-free survival and overall survival after erlotinib treatment with 1st line Docetaxel/cisplatin or Pemetrexed/cisplatin.","https://ClinicalTrials.gov/show/NCT01204307"
581,"NCT02620839","Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies","Recruiting","No Results Available","Solid Tumors","Drug: Alpelisib|Drug: Cisplatin","Pamela Munster|University of California, San Francisco","All","18 Years and older   (Adult, Senior)","Phase 1","41","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","159516","December 1, 2015","December 1, 2016","March 2018","May 2, 2017","May 2017","No Study Results Posted","null","December 2017","Maximum Tolerated Dose|Objective Response Rate|Median Progression-Free Survival|Toxicity|Alpelisib plasma concentration","https://ClinicalTrials.gov/show/NCT02620839"
582,"NCT01360827","EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck","Terminated","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 200068-007","May 24, 2011","August 2010","null","June 16, 2014","June 2014","No Study Results Posted","null","April 2011","Maximum-tolerated-dose (MTD) at 0.16 mg/kg cohort size testing|Maximum-tolerated-dose (MTD) at 0.32 mg/kg cohort size testing|Maximum-tolerated-dose (MTD) at 0.48 mg/kg cohort size testing|Number of subjects with adverse events (AEs) and serious adverse events (SAEs)|Number of subjects with best overall response|Pharmacokinetic parameters: Cmax, Tmax and AUC (0-t)","https://ClinicalTrials.gov/show/NCT01360827"
583,"NCT00823186","Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Drug: Phyxol(Paclitaxel)","Chang Gung Memorial Hospital|Sinphar Pharmaceutical Co., Ltd","Female","35 Years to 70 Years   (Adult, Senior)","Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","97-0365A3","January 13, 2009","February 2009","January 2013","January 3, 2010","January 2009","No Study Results Posted","Chemothreapy","January 2012","to establish an optimal dose of weekly cisplatin plus paclitaxel for 3 cyclesas neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer, followed by radical hysterectomy and pelvic lymphadenectomy|to evaluate the toxicity of the study regimen and its impact to the radical hysterectomy after neoadjuvant chemotherapy|to evaluate the overall tumor response to the neoadjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT00823186"
584,"NCT00006389","Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer","Completed","Has Results","Stage III Gastric Cancer|Stage IV Gastric Cancer","Drug: bryostatin 1|Drug: cisplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02361|CHNMC-PHII-22|CDR0000068267|NCI-T99-0040|PHII-22 (USC 3S-00-1)|T99-0040|N01CM17101","October 4, 2000","October 2000","March 2010","September 26, 2014","October 2013","September 26, 2014","null","March 2010","Observed Response Rate.|Overall Survival|Progression-free Survival","https://ClinicalTrials.gov/show/NCT00006389"
585,"NCT01704690","Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer","Terminated","No Results Available","Esophageal Cancer","Drug: S-1 and Paclitaxel|Drug: Paclitaxel and Cisplatin|Drug: 5-FU and Cisplatin","Peking University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESCC001","October 4, 2012","August 2012","March 2017","April 5, 2017","April 2017","No Study Results Posted","null","March 2017","Response rate|The median overall survival time|Median progression-free time|Number of Participants with Adverse Events and the degree of each adverse event","https://ClinicalTrials.gov/show/NCT01704690"
586,"NCT00970996","Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma","Completed","No Results Available","Melanoma","Drug: Temozolomide|Drug: Abraxane|Drug: Cisplatin|Biological: Interleukin-2|Biological: Interferon alpha 2b","M.D. Anderson Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0124","September 2, 2009","September 2009","December 2012","December 31, 2012","December 2012","No Study Results Posted","BCAA","December 2012","Response Rate","https://ClinicalTrials.gov/show/NCT00970996"
587,"NCT01369641","The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy","Terminated","Has Results","Cancer","Procedure: Insertion of Pressure Equalization (PE) Tubes|Drug: Sodium Thiosulfate (STS)|Other: Saline (Placebo)|Drug: Cisplatin","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","","1","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","11D.99|2011-03","June 7, 2011","August 2011","August 2017","October 19, 2016","October 2016","January 24, 2014","null","March 2012","Efficacy of Intratympanic Sodium Thiosulfate (STS)","https://ClinicalTrials.gov/show/NCT01369641"
588,"NCT02024841","Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis","Recruiting","No Results Available","Gastric Cancer|Peritoneal Carcinomatosis","Drug: Intraperitoneal docetaxel","The University of Hong Kong|Taiho Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HKUGCDTC01","December 27, 2013","December 2013","September 2018","November 2, 2016","November 2016","No Study Results Posted","null","December 2017","Maximum tolerated dose and recommended dose|Clinical response rate|Overall survival","https://ClinicalTrials.gov/show/NCT02024841"
589,"NCT01998529","Hyperthermic Thoracic Perfusion (HITEC) for Children, Adolescents and Adults With Sarcomas","Recruiting","No Results Available","Lung Cancer","Drug: Cisplatin|Drug: Amifostine","M.D. Anderson Cancer Center","All","3 Years to 21 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0657|NCI-2014-00510","November 19, 2013","August 2014","null","October 6, 2016","October 2016","No Study Results Posted","null","August 2018","Maximum Tolerated Dose (MTD) of Hyperthermic Intrathoracic Pleural Chemotherapy (HITC)|Time to Relapse","https://ClinicalTrials.gov/show/NCT01998529"
590,"NCT01911598","A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: 5-FU|Drug: Carboplatin|Drug: Cisplatin|Drug: MEHD7945A|Drug: Paclitaxel","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO28909|2013-001285-42","July 26, 2013","September 19, 2013","April 17, 2018","May 2, 2017","May 2017","No Study Results Posted","null","April 17, 2018","Percentage of Participants With DLTs|Percentage of Participants with Adverse Events|Area Under Concentration-Time Curve From Day 1 to 21 (AUC0-21d) of MEHD7945A|Maximum Serum Concentration (Cmax) of MEHD7945A|Minimum Serum Concentration (Cmin) of MEHD7945A|Cmax of Cisplatin|Area Under Concentration-Time Curve From 0 to 6 Hours (AUC0-6h) of Cisplatin|Plasma Concentrations of 5-FU|Cmax of Carboplatin|AUC0-6h of Carboplatin|Cmax Normalized by Dose (Cmax/D) of Carboplatin|AUC0-6h Normalized by Dose (AUC0-6h/D) of Carboplatin|Cmax of Paclitaxel|Area Under Concentration-Time Curve From 0 to 24 Hours (AUC0-24h) of Paclitaxel|Plasma Half-Life (t1/2) of Paclitaxel|Percentage of Participants With Anti-Therapeutic Antibodies to MEHD7945A|Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Percentage of Participants With Disease Control (CR or PR or Stable Disease [SD]) as Assessed by Modified RECIST v1.1 Criteria|Duration of Objective Response (CR or PR) as Assessed by Modified RECIST v1.1 Criteria|Progression-Free Survival as Assessed by Modified RECIST v1.1 Criteria","https://ClinicalTrials.gov/show/NCT01911598"
591,"NCT00349089","Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Vinorelbine","Thoraxklinik am Universitätsklinikum Heidelberg","All","18 Years to 74 Years   (Adult, Senior)","Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TREAT|EudraCT Number 2005-004840-30","July 4, 2006","October 2006","December 2013","May 2, 2011","May 2011","No Study Results Posted","null","December 2013","To determine the clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin|To determine and compare the drug delivery between both treatment arms|To determine the Time to Treatment Failure (TTTF)|To determine the Distant Metastases Free Survival (DMFS)|To determine the Local Relapse Free Survival (LRFS)|To determine the Overall Survival (OS)|To determine the Localization of Relapse|To determine dose delivery|To determine the Relapse Free Survival (RFS)","https://ClinicalTrials.gov/show/NCT00349089"
592,"NCT00757172","Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction","Completed","Has Results","Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer","Biological: panitumumab|Drug: cisplatin|Drug: docetaxel|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACOSOG-Z4051|CDR0000596674|NCI-2009-00346|U10CA076001","September 22, 2008","January 2009","December 2014","February 10, 2016","February 2016","July 25, 2014","null","November 2011","Number of Participants With Pathologic Complete Response Following Surgery|Number of Participants With Near-complete Response Rate (≤ 10% Residual Cancer in Primary Tumor Viable)|Percentage of Participants With 3-year Overall Survival|Percentage of Participants With 2-year Disease-free Survival|Number of Participants With Frequent (>=15% Grade 3/4 Incidence) Adverse Events Regardless of Attribution","https://ClinicalTrials.gov/show/NCT00757172"
593,"NCT02341989","Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer","Recruiting","No Results Available","Testicular Neoplasms|Seminoma","Drug: Bleomycin Etoposide and Cisplatin|Drug: Carboplatin","St. Olavs Hospital|Skåne University Hospital|Haukeland University Hospital|University Hospital of North Norway|Sahlgrenska University Hospital, Sweden|Karolinska Institutet|Oslo University Hospital|Uppsala University Hospital|University Hospital, Linkoeping|Skane University Hospital|Norrlands University Hospital","Male","18 Years to 60 Years   (Adult)","Phase 3","348","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014/2012|2014-004075-23","January 14, 2015","April 2015","December 2020","October 13, 2016","October 2016","No Study Results Posted","SWENOTECA-ABC","December 2020","Relapse rate","https://ClinicalTrials.gov/show/NCT02341989"
594,"NCT00354679","Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer","Completed","Has Results","Esophageal Cancer","Biological: bevacizumab|Drug: cisplatin|Drug: irinotecan hydrochloride|Genetic: proteomic profiling|Other: diagnostic laboratory biomarker analysis|Other: mass spectrometry|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","34","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-013|P30CA008748|MSKCC-06013","July 19, 2006","April 2006","June 2015","April 12, 2016","April 2016","January 14, 2016","null","June 2015","Evaluation of Safety and Toxicity","https://ClinicalTrials.gov/show/NCT00354679"
595,"NCT02357147","Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).","Active, not recruiting","No Results Available","Mesothelioma, Malignant","Drug: Placebo|Drug: Amatuximab|Drug: Pemetrexed|Drug: Cisplatin","Morphotek","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","MORAb-009-201","January 14, 2015","November 4, 2015","September 2018","February 8, 2017","February 2017","No Study Results Posted","ARTEMIS","September 2017","Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate [ORR]|Duration of response (DR)|Disease control rates (DCR)|Duration of disease control (DDC)|Health related quality of life (QOL)|Duration of Performance Status Maintenance (DPSM)|Safety and tolerability as a measure of number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)|Pharmacokinetic (PK) and pharmacodynamic (PD) profile","https://ClinicalTrials.gov/show/NCT02357147"
596,"NCT01286766","Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma","Completed","No Results Available","Gastric Cancer","Drug: DCS (docetaxel with cisplatin with TS-1)|Drug: DCF (docetaxel with cisplatin with 5-FU)","Yonsei University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2009-0332","January 27, 2011","September 2009","June 2012","March 4, 2014","March 2014","No Study Results Posted","null","June 2012","RECIST(Response Evaluation Criteria in Solid Tumors)","https://ClinicalTrials.gov/show/NCT01286766"
597,"NCT01642251","Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer","Active, not recruiting","No Results Available","Extensive Stage Small Cell Lung Carcinoma|Large Cell Lung Carcinoma|Neuroendocrine Carcinoma|Small Cell Carcinoma|Stage IV Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","168","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2012-01985|ECOG-E2511|CDR0000736704|E2511|U10CA180820|U10CA021115","July 13, 2012","September 28, 2012","null","May 24, 2017","May 2017","No Study Results Posted","null","January 31, 2018","Maximum-tolerated dose of veliparib based on the incidence of dose-limiting toxicity as assessed by the Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|PFS (Phase II)|Best objective response evaluated via RECIST 1.1 (Phase II)|OS (Phase II)|Toxicity will be determined using the CTCAE version 4.0 criteria (Phase II)","https://ClinicalTrials.gov/show/NCT01642251"
598,"NCT00002583","Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: vinorelbine ditartrate","NCIC Clinical Trials Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 3","482","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BR10|CAN-NCIC-BR10|CLB-9795|E-JBR10|SWOG-JBR10|GW-565/040|NCI-V94-0492|CDR0000063698","November 1, 1999","July 1994","December 2009","September 20, 2012","March 2012","No Study Results Posted","null","December 2003","survival","https://ClinicalTrials.gov/show/NCT00002583"
599,"NCT00627835","Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)","Withdrawn","No Results Available","Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)","Drug: sorafenib|Drug: sorafenib|Drug: sorafenib and cisplatin|Drug: sorafenib and cisplatin|Drug: sorafenib and cisplatin","British Columbia Cancer Agency","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","OZM-003","February 14, 2008","null","null","July 18, 2016","November 2010","No Study Results Posted","null","null","To assess the safety of neoadjuvant BAY 43-9006 (sorafenib) and concurrent BAY 43-9006 with radiation in a cohort of SCCHN|MTD Maximal tolerated dose","https://ClinicalTrials.gov/show/NCT00627835"
600,"NCT00158678","IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC","Active, not recruiting","No Results Available","Oral Cancer|Oropharynx Cancer|Hypopharynx Cancer","Procedure: IMRT 75 Gy|Procedure: Conventional radiotherapy 70 Gy|Drug: concomitant cisplatin","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years and older   (Adult, Senior)","Phase 3","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC 2004-01","September 9, 2005","September 2005","February 2018","March 23, 2015","March 2015","No Study Results Posted","null","February 2018","Loco regional control|Survival|Xerostomia at 2 years (evaluated by parotid gland scintigraphy)|Quality of life (EORTC-QLQ-H&N35)","https://ClinicalTrials.gov/show/NCT00158678"
601,"NCT00924209","A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer","Terminated","Has Results","NSCLC|Stage IIIA (N2)","Drug: Gemcitabine|Drug: Cisplatin|Drug: Bevacizumab|Procedure: Surgery|Drug: Etoposide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","7","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","090107|09-C-0107","June 17, 2009","March 2009","September 2011","August 21, 2012","August 2012","July 19, 2012","null","September 2011","Rate of Pathologic Complete Response|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00924209"
602,"NCT00237575","Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer","Terminated","No Results Available","Bladder Cancer","Drug: gemcitabine|Drug: cisplatin|Drug: sargramostim|Drug: filgrastim","University of Kentucky|Bayer","All","18 Years and older   (Adult, Senior)","Phase 3","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","04-GU-53B","October 10, 2005","November 2005","March 2006","May 22, 2012","May 2012","No Study Results Posted","null","March 2006","Efficacy of Leukine & Neupogen to prevent grade 3 & 4 neutropenia in patients receiving cisplatin & gemcitabine: assessed before cycles 3 & 5, then at end of treatment.|Safety of Leukine & Neupogen: evaluated before each cycle & blood work is evaluated weekly throughout the study.|Reduction of grade 3 & 4 hematologic toxicities: evaluated weekly throughout the study.|Reduction of clinical hematologic toxicity including the # of: hospital days required for febrile neutropenia, transfusions & bleeding events, & days of outpatient antibiotics: evaluated throughout the study treatment and until resolved.|Reduction of non-hematologic toxicities: evaluated prior to each cycle.|Enhancement of anti-tumor effects (CR & PR, time to progression, OS & DFS): assessed before cycles 3 & 5, then on day 22 of cycle 6.|Dose intensity as planned vs administered: assessed during each treatment.|Quality of life: evaluated at baseline, pre-cylces 3 & 5, & end of treatment.","https://ClinicalTrials.gov/show/NCT00237575"
603,"NCT00816634","Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","First Line Chemotherapy|Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel|Advanced or Recurrent Esophageal Squamous Cell Carcinoma","Drug: Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2008-07-059","December 30, 2008","October 2008","December 2018","April 27, 2017","April 2017","No Study Results Posted","XP versus XT","October 2017","Response rates of both regimens|a) progression-free survival b) quality of life c) toxicity d) overall survival e) predictive markers","https://ClinicalTrials.gov/show/NCT00816634"
604,"NCT02624128","Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Valproic Acid|Drug: Cisplatin|Drug: Cetuximab","National Cancer Institute, Naples","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","V-CHANCE|2014-001523-69","November 26, 2015","February 2015","October 2019","March 28, 2017","March 2017","No Study Results Posted","V-CHANCE","February 2019","Proportion of patients with an objective response|overall survival|time to tumor progression|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02624128"
605,"NCT00084604","Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","Completed","No Results Available","Adenocarcinoma of the Gastroesophageal Junction|Diffuse Adenocarcinoma of the Stomach|Intestinal Adenocarcinoma of the Stomach|Mixed Adenocarcinoma of the Stomach|Recurrent Gastric Cancer|Stage IIIA Gastric Cancer|Stage IIIB Gastric Cancer|Stage IIIC Gastric Cancer|Stage IV Gastric Cancer","Drug: irinotecan hydrochloride|Biological: bevacizumab|Drug: cisplatin|Procedure: computed tomography|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","47","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01450|04-021|NCI-6447|MSKCC-04021|CDR0000365463|N01CM17105|U01CA099168","June 10, 2004","April 2004","null","June 3, 2013","June 2013","No Study Results Posted","null","October 2007","Time to progression, evaluated using RECIST|Overall response rate, evaluated using RECIST|Complete response rate, evaluated using RECIST|Duration of response, evaluated using RECIST|Survival|Incidence of toxicity, evaluated using CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00084604"
606,"NCT01116219","Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).","Completed","No Results Available","Lung Cancer","Biological: bevacizumab, erlotinib|Drug: bevacizumab, pemetrexed, cisplatin","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","149","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 19/09|SWS-SAKK-19-09|EU-21026","April 27, 2010","June 2010","May 2016","June 14, 2016","June 2016","No Study Results Posted","null","July 2014","Progression-free survival at 6 months in stratum wtEGFR cohort 1|Progression-free survival|Overall survival|Best response (RECIST 1.1)|Adverse events (CTCAE v4.0)|Molecular markers in tumor tissue and blood","https://ClinicalTrials.gov/show/NCT01116219"
607,"NCT00216125","Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Radiation: Radiation|Drug: Docetaxel","Nasser Hanna, M.D.|Sanofi|Walther Cancer Institute|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Senior)","Phase 3","243","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HOG LUN01-24","September 12, 2005","February 2002","March 2008","February 17, 2016","February 2016","November 23, 2015","null","June 2006","Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00216125"
608,"NCT01536223","Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma","Unknown status","No Results Available","Chemoradiation|Nasopharyngeal Carcinoma","Drug: PF (cisplatin and 5-fluorouracil) group|Drug: TPF (docetaxel plus cisplatin and 5-fluorouracil) group","Zhejiang Cancer Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University|Zhejiang University|Zhejiang Provincial People’s Hospital|Sir Run Run Shaw Hospital|Wenzhou Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejiangCH13","February 13, 2012","April 2012","February 2015","March 3, 2013","April 2012","No Study Results Posted","ESNCCT","December 2013","3-year progress free survival(PFS)|overall survival(OS)|Adverse events|local control rate (LCR)","https://ClinicalTrials.gov/show/NCT01536223"
609,"NCT00707161","Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma","Terminated","Has Results","Cancer|Melanoma","Radiation: Radiation Therapy|Drug: Cisplatin|Procedure: Surgical resection","University of Utah","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HCI15461","June 26, 2008","September 2005","February 2010","March 1, 2017","March 2017","April 20, 2011","null","February 2010","Response Rate of Melanoma Lesions","https://ClinicalTrials.gov/show/NCT00707161"
610,"NCT00859339","Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC","Terminated","Has Results","Transitional Cell Carcinoma of the Bladder","Drug: Gemcitabine|Drug: Cisplatin|Drug: Sunitinib Malate|Procedure: Radical Cystectomy","Noah Hahn, M.D.|Pfizer|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG GU07-123","March 9, 2009","March 2009","April 2011","March 15, 2016","March 2016","March 15, 2016","null","April 2011","Pathological Complete Response (pCR) Rate.|Safety Profile|Objective Response Rate|Progression Free Survival|Correlate Biomarker Expression","https://ClinicalTrials.gov/show/NCT00859339"
611,"NCT01196416","Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Skin Melanoma","Drug: Cisplatin|Drug: Gamma-Secretase Inhibitor RO4929097|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Vinblastine Sulfate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02524|CDR0000684220|10-085|8491|N01CM62206|P30CA008748|U01CA069856","September 4, 2010","August 2010","August 2015","August 27, 2015","May 2015","No Study Results Posted","null","August 2015","Maximum-tolerated dose based on the incidence of dose-limiting toxicity as assessed the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase IB)|Overall response rate (complete [CR] or partial response [PR]) according to RECIST version 1.1 (Phase II)|Overall survival (Phase II)|Change in protein levels by immunohistochemistry (Phase Ib)|Pharmacokinetics of gamma-secretase inhibitor RO4929097 in combination with temozolomide (Phase IB)|Presence or absence of markers of pathway inhibition in patient tumors (Phase Ib)|Progression-free survival (Phase II)|Toxicity as assessed by NCI CTCAE v. 4.0","https://ClinicalTrials.gov/show/NCT01196416"
612,"NCT02137343","A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer","Terminated","No Results Available","Gastric Cancer","Drug: Rilotumumab|Drug: Placebo|Drug: Cisplatin|Drug: Capecitabine","Amgen","All","20 Years to 100 Years   (Adult, Senior)","Phase 3","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20120142","April 28, 2014","July 2014","June 2015","March 4, 2016","March 2016","No Study Results Posted","RILOMET-2","June 2015","Progression-free survival|Overall Survival|TTP|ORR|DCR|TTR|Incidence of subject adverse events, laboratory abnormalities and immunogenicity","https://ClinicalTrials.gov/show/NCT02137343"
613,"NCT00147160","Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents","Completed","No Results Available","Glioma","Drug: Temozolomide, Cisplatinum","Gustave Roussy, Cancer Campus, Grand Paris","All","4 Years to 21 Years   (Child, Adult)","Phase 2","87","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CISTEM2|CSET-2002/978","September 6, 2005","October 2003","December 2007","April 10, 2012","September 2006","No Study Results Posted","null","July 2006","Radiological response after two courses of Temozolomide-Cisplatinum|Progression-free survival|Health status and quality of life|Toxicity","https://ClinicalTrials.gov/show/NCT00147160"
614,"NCT03126708","Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Recurrent and/or Metastatic Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Cancer, Squamous Cell|Cetuximab Effect|Chemotherapy Effect","Drug: cetuximab|Drug: cisplatin plus paclitaxel","Peking University","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESCC-Cetuximab-PKU","April 12, 2017","April 2017","April 2020","April 19, 2017","April 2017","No Study Results Posted","null","April 2019","Progression free survival|Overall Survival|overall response rate|Disease control rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT03126708"
615,"NCT02094625","NAC to Prevent Cisplatin-induced Hearing Loss","Recruiting","No Results Available","Neuroectodermal Tumors, Primitive|Liver Neoplasms|Neoplasms, Germ Cell and Embryonal|Osteosarcoma|Other Childhood Cancers Using Cisplatin-based Regimens","Drug: N-Acetylcysteine","Children's Hospital Los Angeles","All","1 Year to 21 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCI-14-00270","March 13, 2014","March 2016","October 2019","October 20, 2016","October 2016","No Study Results Posted","null","February 2018","Target Serum Level NAC|Adverse events during infusion of NAC|NAC Level|Hearing assessment|Renal Toxicity|Response of tumor to treatment|Effect of Genotype on Hearing Loss and Hearing Protection|Glutathione serum level","https://ClinicalTrials.gov/show/NCT02094625"
616,"NCT03028766","WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer","Not yet recruiting","No Results Available","Hypopharynx Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Larynx Cancer","Drug: AZD1775|Drug: Cisplatin|Radiation: Radiotherapy","University of Birmingham|AstraZeneca|Cancer Research UK","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RG_15-139|2015-003583-37","January 4, 2017","May 2017","December 2019","May 4, 2017","May 2017","No Study Results Posted","WISTERIA","December 2019","Recommended dose(s) of AZD1775|Safety profile of AZD1775 for Group A and Group B by reporting of all Adverse Events, Serious Adverse Events, Suspected Unexpected Adverse Reactions, deaths, deviations and withdrawal as assessed by the Safety Committee.|Disease-free survival","https://ClinicalTrials.gov/show/NCT03028766"
617,"NCT00072332","Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors","Completed","No Results Available","Esophageal Cancer|Gastric Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: edotecarin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000339607|MSKCC-03070|PHARMACIA-EDOAES-2730-001","November 4, 2003","August 2003","December 2009","December 18, 2013","December 2009","No Study Results Posted","null","December 2005","","https://ClinicalTrials.gov/show/NCT00072332"
618,"NCT01277744","Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor","Active, not recruiting","No Results Available","Advanced Cancers|Sarcoma","Procedure: Hyperthermic Peritoneal Perfusion (HIPEC)|Drug: Cisplatin","M.D. Anderson Cancer Center","All","1 Year and older   (Child, Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009-0528|NCI-2011-00245","January 12, 2011","May 9, 2011","May 1, 2019","January 26, 2017","January 2017","No Study Results Posted","null","May 1, 2019","Time to Relapse","https://ClinicalTrials.gov/show/NCT01277744"
619,"NCT01407822","Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Erlotinib|Drug: Gemcitabine/cisplatin","Guangdong Association of Clinical Trials|Guangdong General Hospital|Tianjin Medical University Cancer Institute and Hospital|Jilin Provincial Tumor Hospital|Jiangsu Cancer Institute & Hospital|Zhejiang Cancer Hospital|Beijing Cancer Hospital|Sun Yat-sen University|West China Hospital|The First Affiliated Hospital of Dalian Medical University|Peking University People's Hospital|Health Science Center of Xi’an Jiaotong University|Shanghai Zhongshan Hospital|Guangzhou General Hospital of Guangzhou Military Command|The First Affiliated Hospital of Guangzhou Medical University|Fujian Medical University Union Hospital|Linyi Tumour Hospital|Northern Jiangsu Province People's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CTONG 1103|ML25304","July 26, 2011","December 5, 2011","March 2018","February 28, 2017","February 2017","No Study Results Posted","EMERGING","June 2017","The objective response rate (ORR) in neoadjuvant treatment|Complete resection rate|Pathological complete response (pCR) rate|Progression free survival（PFS）|3 year overall survival (OS) rate|Number of Participants with Adverse Events|Quality of Life (QOL)","https://ClinicalTrials.gov/show/NCT01407822"
620,"NCT02484677","Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy","Recruiting","No Results Available","Patients With Head and Neck Cancer (ORL)","Drug: Cisplatin|Drug: Docetaxel|Drug: 5-Fluorouracile","Assistance Publique Hopitaux De Marseille","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-41|2014-005536-34|RCAPHM14_0370","June 22, 2015","June 2015","null","June 29, 2015","June 2015","No Study Results Posted","5-FU","June 2017","Determination of 5-FU (5-Fluorouracile)|Toxicities","https://ClinicalTrials.gov/show/NCT02484677"
621,"NCT00981058","First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin","Active, not recruiting","Has Results","Non Small Cell Lung Cancer","Biological: Necitumumab|Drug: Gemcitabine|Drug: Cisplatin","Eli Lilly and Company|Parexel|PPD|Medidata Solutions|Laboratory Corporation of America|University of Colorado, Denver|Thermo Fisher Scientific|ICON Clinical Research|Pacific Biomarkers|Sysmex Inostics GmbH|Intertek","All","18 Years and older   (Adult, Senior)","Phase 3","1093","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13909|CP11-0806|I4X-IE-JFCC|2009-013838-25","September 18, 2009","January 2010","June 2017","February 15, 2017","February 2017","December 21, 2015","SQUIRE","June 2013","Overall Survival Time (OS)|Progression-Free Survival (PFS)|Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR])|Time to Treatment Failure (TTF)|Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D)|Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS)|Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab|Number of Participants With a Serum Anti-Necitumumab Antibody Assessment","https://ClinicalTrials.gov/show/NCT00981058"
622,"NCT01490437","Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma","Completed","No Results Available","Urothelial Carcinoma","Drug: Pemetrexed|Drug: Cisplatin|Drug: Dexamethasone|Drug: Vitamins","Asan Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UOSG-AMC-0804","December 6, 2011","July 2008","December 2013","September 22, 2014","September 2014","No Study Results Posted","PECULIAR","December 2013","Response rate|Progression-free survival|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT01490437"
623,"NCT00895245","Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","Terminated","Has Results","Nausea and Vomiting|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx","Drug: fosaprepitant dimeglumine|Drug: cisplatin|Drug: palonosetron hydrochloride|Drug: dexamethasone|Other: Functional Living Index-Emesis Questionnaire|Behavioral: Emesis Diary|Radiation: Radiotherapy","University of Washington|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Supportive Care","6862|NCI-2009-01669","May 7, 2009","February 2009","February 2011","April 13, 2017","April 2017","January 9, 2017","null","September 2010","Proportion of Patients With a Complete Response to the Anti-emetic Medication Regimen|Rate of Complete Response to Anti-emetic Therapy in the Delayed Setting (25-120 Hours After Cisplatin Infusion)|Control of Nausea for 120 Hours Following Each Cisplatin Infusion for Multiple Cycles of Therapy as Measured by the Visual Analog Scale|Impact of Cisplatin-induced Nausea and Vomiting on Daily Life During the 5 Day Period Following Cisplatin Infusion for Multiple Cycles as Measured by the Functional Living Index-Emesis Questionnaire","https://ClinicalTrials.gov/show/NCT00895245"
624,"NCT00548418","Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer","Completed","Has Results","Cervical Cancer","Drug: Topotecan|Drug: Cisplatin|Drug: Bevacizumab","Washington University School of Medicine|GlaxoSmithKline|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-1098 / 201110266|GSK 107278","October 23, 2007","February 2007","December 2012","July 28, 2014","July 2014","June 27, 2014","null","December 2012","Anti-tumor Activity as Measured by Surviving Progression-free|Overall Survival|Frequency of Response as Measured by RECIST Criteria (Imaging)|Correlate Patterns of Gene Expression as Assessed by Microarrays|Correlate Hypoxia Inducible Factor 1 (HIF-1) and Hypoxia Induced Gene Expression as Measured by Laboratory Studies","https://ClinicalTrials.gov/show/NCT00548418"
625,"NCT00881114","Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer","Withdrawn","No Results Available","Head and Neck Cancer","Drug: Cisplatin|Drug: Cetuximab","Georgetown University","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PGx-SELECT|2008-526","April 13, 2009","April 2009","June 2013","March 26, 2015","April 2009","No Study Results Posted","PGx-SELECT","June 2009","Progression-free survival|Objective response|Overall survival|Toxicity|Quality of Life","https://ClinicalTrials.gov/show/NCT00881114"
626,"NCT00442455","Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Erlotinib chlorhydrate|Drug: Cisplatin|Procedure: Radiation therapy","Grupo de Investigación Clínica en Oncología Radioterapia","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML 18729","March 1, 2007","January 2006","August 2015","September 23, 2016","September 2016","No Study Results Posted","null","August 2015","Determinate the maximum tolerated dose (PHASE I)|Progression free survival (PHASE II)|DLT (PHASE I)|Overall survival and locoregional progression free survival (PHASE II)","https://ClinicalTrials.gov/show/NCT00442455"
627,"NCT01517009","A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: Docetaxel|Drug: cisplatin|Drug: Capecitabine|Procedure: D1extra-resection","Jeroen Bosch Ziekenhuis|Eindhoven Cancer Registry","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DoCCS|Dutch trialregister|2007-007273-23","October 21, 2011","June 2008","May 2013","June 25, 2013","June 2013","No Study Results Posted","DoCCS","November 2012","The number of patients with (serious) adverse events receiving the combination of 4 courses of docetaxel, cisplatin and capecitabine as neoadjuvant chemotherapy and standardized surgery in resectable localized or locally advanced gastric cancer.|The number of patients receiving a D1-extra-resection as protocolized surgery in resectable gastric cancer","https://ClinicalTrials.gov/show/NCT01517009"
628,"NCT00842491","Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer","Completed","No Results Available","Advanced Gastric Cancer","Drug: endostar, cisplatin, capecitabine|Drug: capecitabine|Drug: cisplatin","Peking University|Xiansheng Pharmaceutical Company","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ENDOCX","February 11, 2009","November 2008","December 2010","May 17, 2015","May 2015","No Study Results Posted","null","April 2010","Progression free survival|Tumor response rate|Disease control rate|Overall survival|adverse evens|The alteration of relative regional blood volume of the tumor","https://ClinicalTrials.gov/show/NCT00842491"
629,"NCT00553696","Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer","Completed","Has Results","Stomach Neoplasms","Drug: Cisplatin|Drug: S-1|Drug: Sunitinib","Pfizer","All","20 Years and older   (Adult, Senior)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181127","November 2, 2007","November 2007","March 2014","March 3, 2015","March 2015","March 3, 2015","null","July 2009","Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)|Maximum Observed Plasma Concentration (Cmax) of Tegafur and 5-FU|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tegafur and 5-FU|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Tegafur and 5-FU|Maximum Observed Plasma Concentration (Cmax) of Total Platinum and Free Platinum|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Total Platinum and Free Platinum|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Total Platinum and Free Platinum|Number of Participants With Objective Response|Number of Participants With Clinical Benefit Response (CBR)|Duration of Response (DR)|Progression-Free Survival (PFS)|Time to Progression (TTP)","https://ClinicalTrials.gov/show/NCT00553696"
630,"NCT01405586","MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage IIIB","Drug: Gemcitabine|Drug: Gemcitabine|Drug: Cisplatin","National Cancer Institute, Naples","All","70 Years and older   (Senior)","Phase 3","299","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MILES-3|2009-013540-36","February 26, 2010","March 2011","September 2017","March 27, 2017","March 2017","No Study Results Posted","MILES-3","June 2017","overall survival|worst grade toxicity per patient|progression free survival|quality of life|objective response","https://ClinicalTrials.gov/show/NCT01405586"
631,"NCT02185352","Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases","Recruiting","No Results Available","Breast Cancer|Brain Metastases","Drug: BEEP regimen","National Taiwan University Hospital","Female","20 Years to 75 Years   (Adult, Senior)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201402059MIPD","June 25, 2014","September 2014","July 2017","January 17, 2017","January 2017","No Study Results Posted","A-Plus","July 2017","The Brain-specific progression free survival (BS-PFS)|The 2-month brain-specific objective response rate (BS-ORR)","https://ClinicalTrials.gov/show/NCT02185352"
632,"NCT02595424","Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery","Recruiting","No Results Available","Colorectal Large Cell Neuroendocrine Carcinoma|Esophageal Large Cell Neuroendocrine Carcinoma|Gallbladder Large Cell Neuroendocrine Carcinoma|Gastric Large Cell Neuroendocrine Carcinoma|Pancreatic Large Cell Neuroendocrine Carcinoma|Small Intestinal Large Cell Neuroendocrine Carcinoma","Drug: Capecitabine|Drug: Cisplatin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Temozolomide","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","126","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA2142|NCI-2015-00547|NCI-2015-00505|U10CA180820","November 2, 2015","November 2015","null","January 5, 2016","January 2016","No Study Results Posted","null","January 2018","PFS|Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|OS|Response rate (complete response or partial response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","https://ClinicalTrials.gov/show/NCT02595424"
633,"NCT00192036","Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: gemcitabine|Drug: cisplatin|Radiation: radiation","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","8984|B9E-BX-JHSQ","September 12, 2005","August 2004","November 2009","November 22, 2010","November 2010","February 23, 2009","null","January 2008","Tumor Response at End of Treatment|Time to Progressive Disease|Overall Survival|Safety of Induction Chemotherapy|Safety of Chemo-radiotherapy","https://ClinicalTrials.gov/show/NCT00192036"
634,"NCT00482014","A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer","Completed","Has Results","Non-Small-Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin|Drug: carboplatin|Radiation: radiation therapy","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9031|H3E-US-S047","May 31, 2007","May 2007","October 2011","October 26, 2012","October 2012","October 26, 2012","null","October 2011","Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin|Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin|Phase 2 - Survival Probability at 2 Years|Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)|Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)|Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events|Phase 2 - Time to Progression|Phase 2 - Median Survival|Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)","https://ClinicalTrials.gov/show/NCT00482014"
635,"NCT00072787","Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: S-1|Drug: cisplatin","Taiho Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPU-S1101; ID02-694","November 10, 2003","October 2003","May 2006","August 6, 2009","August 2009","No Study Results Posted","null","March 2006","","https://ClinicalTrials.gov/show/NCT00072787"
636,"NCT00483223","Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response","Active, not recruiting","No Results Available","Breast Cancer","Drug: Cisplatin|Drug: carboplatin","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|North Shore Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","86","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-412|TBCRC009","June 5, 2007","June 2007","June 2017","January 9, 2017","January 2017","No Study Results Posted","null","June 2014","To determine the objective response rate in patients with ER/PgR/HER2 negative metastatic breast cancer receiving platinum as first or second-line therapy.|To evaluate the expression of p63/p73 in primary tumors from this patient cohort as a biomarker to predict response to platinum|To determine the progression free survival, clinical benefit rate, and overall survival in patients with triple-negative metastatic breast cancer receiving first line platinum therapy|To evaluate the safety and toxicity of platinum therapy in this patient population.|To conduct correlative studies to learn more about the biology of triple negative breast cancer.","https://ClinicalTrials.gov/show/NCT00483223"
637,"NCT02607592","A Prospective Multi-center Phase III Randomized Controlled Trial","Recruiting","No Results Available","Carcinoma，Non-Small-Cell Lung","Drug: cisplatin and pemetrexed|Drug: nadaplatin+pemetrexed","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","293","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201507003","November 16, 2015","August 2015","August 2018","February 17, 2016","February 2016","No Study Results Posted","NACA","August 2017","overall toxicity value|primary free-survival（PFS）|objective response rate （ORR）|overall survival（OS）","https://ClinicalTrials.gov/show/NCT02607592"
638,"NCT01939418","Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer","Terminated","No Results Available","Metastatic Breast Cancer","Drug: RAD001|Drug: Gemcitabine|Drug: Cisplatin","National Cancer Center, Korea","Female","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCCCTS-13-670|12491","August 28, 2013","August 2013","July 2017","March 28, 2017","March 2017","No Study Results Posted","null","July 2016","The recommended dose of the combination of gemcitabine, cisplatin and RAD001 (everolimus) in patients with metastatic triple-negative breast cancer|Efficacy of gemcitabine and cisplatin with or without RAD001 in patients with metastatic triple-negative breast cancer by evaluating progression free survival (PFS)|The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gemcitabine/cisplatin/RAD001|number of patients with adverse events as a measure of safety and tolerability|objective response rate|Overall survival (OS)|check biomarkers associated with the response of RAD001: angiogenesis, metabolism, immune cells profiles","https://ClinicalTrials.gov/show/NCT01939418"
639,"NCT01262482","Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment","Completed","No Results Available","Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)","Drug: Oxaliplatin|Drug: Sorafenib","Grupo Espanol Multidisciplinario del Cancer Digestivo","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCAD-0802|2008-004223-27","December 16, 2010","October 2008","December 2011","November 8, 2012","December 2010","No Study Results Posted","null","October 2011","Progression free survival|Tumoral response|Response duration|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT01262482"
640,"NCT00675194","Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: Cisplatin, Irinotecan, Capecitabine","Johannes Gutenberg University Mainz","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC-ICE-2003","May 6, 2008","October 2003","October 2007","May 16, 2008","May 2008","No Study Results Posted","null","null","response rate|safety|progression free survival|1 year survival|Quality of Life|Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients","https://ClinicalTrials.gov/show/NCT00675194"
641,"NCT00323830","Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma","Completed","No Results Available","Gastric Cancer|Surgery","Drug: Capecitabine, cisplatin, Radiotherapy (+/-)","Samsung Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","458","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-08-10","May 8, 2006","October 2004","April 2011","November 8, 2011","November 2011","No Study Results Posted","null","April 2008","disease free survival","https://ClinicalTrials.gov/show/NCT00323830"
642,"NCT02452970","RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy","Active, not recruiting","No Results Available","Cholangiocarcinoma","Drug: RRx-001|Drug: Gemcitabine and cisplatin","EpicentRx, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RRx001-27-01","May 17, 2015","May 2015","May 2018","October 29, 2016","October 2016","No Study Results Posted","EPIC","May 2017","Progression-free survival (PFS) of patients with advanced or metastatic biliary cancer after retreatment with gemcitabine and cisplatin following treatment with RRx-001|Disease control rate (DCR)|Overall Survival|Number, frequency and type of adverse events","https://ClinicalTrials.gov/show/NCT02452970"
643,"NCT02495493","S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma","Active, not recruiting","No Results Available","Gastric Adenocarcinoma","Drug: Induction DCS chemotherapy","Yonsei University","All","20 Years and older   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2013-0548","July 8, 2015","July 2013","June 2019","July 12, 2016","July 2016","No Study Results Posted","null","May 2018","pathologic response rate|overall survival","https://ClinicalTrials.gov/show/NCT02495493"
644,"NCT02743923","Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer","Recruiting","No Results Available","Carcinoma, Non-Small Cell Lung","Drug: carboplatin|Drug: paclitaxel|Drug: Bevacizumab|Drug: Pemetrexed|Drug: cisplatin","The Netherlands Cancer Institute|Dutch Society of Physicians for Pulmonology and Tuberculosis","All","18 Years and older   (Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NVALT 22","March 17, 2016","April 2016","April 2020","April 10, 2017","April 2017","No Study Results Posted","null","April 2020","progression free survival|disease control rate|overall survival|outcome between G12V versus G12C versus other subtypes of KRAS mutations (mutational analysis on plasma and blood platelets).|response by Crabb criteria (if applicable)","https://ClinicalTrials.gov/show/NCT02743923"
645,"NCT00601510","Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: capecitabine|Drug: cisplatin|Drug: imatinib mesylate","Technische Universität München","All","18 Years and older   (Adult, Senior)","Phase 1","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000581134|KRDI-TUM-STI571|KRDI-TUM-GLIVEC-CSTI571BDE54|EU-20797|NOVARTIS-KRDI-TUM-STI571|EUDRACT-2006-005792-17","January 25, 2008","November 2007","January 2012","March 18, 2013","March 2013","No Study Results Posted","null","January 2011","Safety|Tolerability|Overall tumor response as assessed by RECIST|Time to progression of disease|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00601510"
646,"NCT00116896","Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: OSI-7904L|Drug: Cisplatin","OSI Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","OSI-904-102","June 30, 2005","June 2003","December 2004","January 16, 2009","November 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00116896"
647,"NCT00510250","A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer","Completed","No Results Available","Cancer of the Cervix","Drug: Sorafenib|Drug: Cisplatin|Procedure: Radiation","University Health Network, Toronto|Bayer","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","13","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DDPDRO-002|Bayer Protocol# 12138","July 31, 2007","June 2007","July 2015","July 24, 2015","July 2015","No Study Results Posted","null","September 2010","Determine the biologic activity of sorafenib in cervix cancer.|Determine the acute and late toxicity, and effect of sorafenib in combination with radiation and chemotherapy on the disease-free survival of patients with high-risk cervix cancer.","https://ClinicalTrials.gov/show/NCT00510250"
648,"NCT01368848","Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)","Completed","No Results Available","NSCLC","Drug: Bevacizumab|Drug: Cisplatin|Drug: Docetaxel","Arbeitsgemeinschaft medikamentoese Tumortherapie|Sanofi|Roche Pharma AG","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","7","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGMT_NSCLC 1|2008-000765-33","June 7, 2011","April 2010","December 2012","August 29, 2013","August 2013","No Study Results Posted","null","December 2012","Response Rate|Progression free survival|Overall survival|Duration of response","https://ClinicalTrials.gov/show/NCT01368848"
649,"NCT02409342","A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","Recruiting","No Results Available","Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer","Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","570","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO29431|2014-003083-21","April 1, 2015","July 21, 2015","August 20, 2020","May 22, 2017","May 2017","No Study Results Posted","null","August 20, 2020","Progression-free Survival (PFS) Time as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Overall Survival (OS)|Percentage of Participants With Objective Response (ORR) as Determined by the Investigator Using RECIST v1.1|Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer Scale Symptom Score|Change From Baseline to 33 Months in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer Scale Symptom Score|PFS as Determined by an Independent Review Facility (IRF) Using RECIST v1.1|Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1|Time in Response (TIR) as Assessed by the Investigator Using RECIST v1.1|Time to Response (TTR) as Assessed by the Investigator Using RECIST v1.1|Percentage of Participants Who Were Alive at 1 and 2 Years|TTD as Assessed Using European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (EORTC QLQ-C30)|TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13)|Change From Baseline to 33 Months in EORTC QLQ-C30 Score|Change From Baseline to 33 Months in EORTC QLQ-LC13 Score","https://ClinicalTrials.gov/show/NCT02409342"
650,"NCT00448643","Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery","Completed","No Results Available","Endometrial Cancer","Radiation: Vaginal Brachytherapy|Drug: Cisplatin|Radiation: Whole Abdominal Radiation [WAR] Therapy","University of Miami","Female","18 Years to 80 Years   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20020138|SCCC-2001064|WIRB-20050721","March 15, 2007","May 2002","March 2011","December 14, 2016","December 2016","No Study Results Posted","null","March 2011","Toxicity as assessed by GOG Common Toxicity Criteria|Recommended phase II dose of whole-abdominal radiotherapy","https://ClinicalTrials.gov/show/NCT00448643"
651,"NCT00242749","IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma","Completed","No Results Available","Cancer of Head and Neck","Drug: Gefitinib, Cisplatin and Radiotherapy","AstraZeneca","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0102","October 20, 2005","December 2002","July 2007","April 22, 2009","April 2009","No Study Results Posted","null","null","Disease-free survival at 2 years|Objective tumour response (CR and PR) at 6 months after the start of treatment based on the Response Evaluation Criteria in Solid Tumours (RECIST) criteria|PFS|Nature, incidence and severity of adverse events (AEs)|Overall survival","https://ClinicalTrials.gov/show/NCT00242749"
652,"NCT00004920","Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura","Completed","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: raltitrexed","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","256","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-08983","March 7, 2000","November 1999","null","July 17, 2012","July 2012","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00004920"
653,"NCT02142010","Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: paclitaxel liposome injection plus cisplatin","Nanjing Luye Sike Pharmaceutical Co.,Ltd.","Female","18 Years to 65 Years   (Adult)","","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LY-TM-LPS-2014-01","May 9, 2014","August 2014","null","August 26, 2014","August 2014","No Study Results Posted","null","June 2015","pathological complete remission (pCR) rate|Adverse Events as a Measure of Safety and Tolerability|clinical response rate","https://ClinicalTrials.gov/show/NCT02142010"
654,"NCT01116791","Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer","Terminated","No Results Available","Peritoneal Carcinomatosis|Gastrointestinal Cancer","Procedure: Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)","Baki Topal|Universitaire Ziekenhuizen Leuven|University Hospital, Gasthuisberg","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIPCUpp-trial","May 3, 2010","July 2010","December 2015","December 1, 2015","December 2015","No Study Results Posted","null","December 2015","Overall survival time (OS) following CRS+HIPC (from surgery to cancer-related death)|In-hospital perioperative complications","https://ClinicalTrials.gov/show/NCT01116791"
655,"NCT03046862","Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer","Recruiting","No Results Available","Biliary Tract Neoplasms","Drug: Durvalumab|Drug: Tremelimumab|Drug: Gemcitabine|Drug: Cisplatin","Seoul National University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BTC-1st MEDITREME","February 6, 2017","February 25, 2017","March 2019","February 25, 2017","February 2017","No Study Results Posted","null","December 2018","Response rate|Disease control rate|Progression-free survival|Duration of response|Overall survival|Quality-of-life|Overall response rate|Toxicity","https://ClinicalTrials.gov/show/NCT03046862"
656,"NCT00191815","Combination Chemotherapy for Metastatic Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Gemcitabine|Drug: cisplatin","Eli Lilly and Company","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7311|B9E-VI-S326","September 12, 2005","October 2002","October 2007","November 9, 2009","November 2009","October 13, 2008","null","null","Objective Tumor Response|Duration of Response|Time to Progressive Disease|Time to Treatment Failure|Survival Time|Number of Participants With Maximum Common Toxicity Criteria-National Cancer Institute Toxicity (CTC-NCI) of Gemcitabine-Cisplatin Combination|Number of Participants With Hematology Maximum Common Toxicity Criteria - National Cancer Institute Grades|Number of Deaths|Number of Participants With Adverse Events Leading to Discontinuation","https://ClinicalTrials.gov/show/NCT00191815"
657,"NCT02241876","THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS","Unknown status","No Results Available","Head and Neck Neoplasms","Drug: N-acetylcysteine","University of Campinas, Brazil","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","NAC+Cisplatin2014","September 5, 2014","October 2014","null","September 13, 2014","September 2014","No Study Results Posted","null","December 2016","Hematologic, Nephro, and Hepato Toxicity - Degree of toxicity by Common Toxicity Criteria for Adverse Effects (CTCAE - version 4.0)|Gastrointestinal Toxicity - Degree of toxicity by CTCAE (version 4.0)|audiometric testing|Nephrotoxicity|Quality of Life|Cellular and plasma oxidative stress biomarkers|Effectiveness of anticancer therapy","https://ClinicalTrials.gov/show/NCT02241876"
658,"NCT00320515","Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer","Completed","Has Results","Neoplasm, Gastric","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","89","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7461|H3E-AA-S038","April 28, 2006","March 2004","July 2008","August 19, 2009","August 2009","July 9, 2009","null","July 2008","Objective Best Tumor Response|Duration of Response|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00320515"
659,"NCT00415324","Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: eribulin mesylate|Drug: cisplatin|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","36","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00168|PHI-55|CDR0000518290|7427|U01CA062505|P30CA033572","December 20, 2006","December 2006","null","May 19, 2014","April 2014","No Study Results Posted","null","May 2014","Maximum tolerated dose determined by dose-limiting toxicity graded according to the NCI CTCAE version 4.0|Survival|Time to failure","https://ClinicalTrials.gov/show/NCT00415324"
660,"NCT00126269","Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary","Unknown status","No Results Available","Carcinoma","Drug: cisplatin|Drug: gemcitabine","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Senior)","Phase 3","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEFCAPI O2","August 2, 2005","May 2003","null","September 7, 2006","September 2006","No Study Results Posted","null","null","Overall survival|Response rate|Progression-free survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT00126269"
661,"NCT00449033","A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo|Drug: Gemcitabine|Drug: Cisplatin","Bayer","All","18 Years and older   (Adult, Senior)","Phase 3","904","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12006|2006-002688-26","March 16, 2007","February 2007","June 2011","April 3, 2015","April 2015","April 20, 2011","NEXUS","April 2010","Overall Survival (OS) in the ITT (Non-squamous) Population|OS in the ITT (Both Squamous and Non-squamous) Population|OS in the ITT (Squamous) Population|Progression-free Survival (PFS) in the ITT (Non-squamous) Population|Time to Progression (TTP) in the ITT (Non-squamous) Population|Percentage of Participants With Different Tumor Response in the ITT (Non-squamous) Population|Disease Control (DC) in the ITT (Non-squamous) Population|Duration of Response in the ITT (Non-squamous) Population|Duration of Stable Disease (SD) in the ITT (Non-squamous) Population|Time to Response (TTR) in the ITT (Non-squamous) Population|Functional Assessment of Cancer Treatment-Lung (FACT-L) Scores in the ITT (Non-squamous) Population|Lung Cancer Subscale (LCS) Scores in the ITT (Non-squamous) Population|Time to Symptomatic Deterioration (TSD) in the ITT (Non-squamous) Population|Euro Quality of Life - 5D (EQ-5D) Index Scores in the ITT (Non-squamous) Population|EQ-5D Visual Analog Scale (VAS) Scores in the ITT (Non-squamous) Population","https://ClinicalTrials.gov/show/NCT00449033"
662,"NCT02017600","A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus","Terminated","No Results Available","Localized Squamous Cell Carcinoma of the Esophagus","Drug: ND-420|Procedure: Surgery|Drug: Cisplatin|Drug: fluorouracil","Nang Kuang Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Senior)","Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NKCND420/201112","December 9, 2013","August 2013","March 2017","March 28, 2017","March 2017","No Study Results Posted","null","March 2017","the R0 resection rate of participants|the response rate (RECIST) of participants|Number of participants with adverse events as a measure of safety and tolerability|the population pharmacokinetic parameters (Cmax, AUC... )of ND-420 in the participants|the correlation between clinical outcomes and the potential predictive genomic biomarkers(B-tubulin mutation, p53-Arg 72Pro, Bcl2-C938A, MDR1-C3435T polymorphism, TNFRSF1B-1466, GSTP1-l105V, CYP1B1, TS-5'UTR) for tumor response|1-year survival rate of participants|pathologic complete response rate of participants|1-year progression free survival rate of participants|1-year overall survival rate of participants","https://ClinicalTrials.gov/show/NCT02017600"
663,"NCT00458913","Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma","Completed","No Results Available","Malignant Mesothelioma","Drug: bortezomib|Drug: cisplatin","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-08052|JJPRD-26866138CAN2012|2006-000009-51","April 9, 2007","February 2007","March 2012","April 19, 2013","April 2013","No Study Results Posted","null","April 2010","Progression-free survival (PFS) rate at 18 weeks|Overall objective response rate|Symptomatic response rate|Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire|Duration of PFS|Overall survival","https://ClinicalTrials.gov/show/NCT00458913"
664,"NCT00003723","S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery","Completed","No Results Available","Malignant Mesothelioma","Drug: gemcitabine hydrochloride","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","57","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066832|SWOG-S9810|U10CA032102","November 1, 1999","February 1999","December 2007","October 5, 2012","October 2012","No Study Results Posted","null","June 2007","Estimate overall survival|qualitative and quantitative toxicities|confirmed and unconfirmed complete and partial response","https://ClinicalTrials.gov/show/NCT00003723"
665,"NCT02550327","Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer","Recruiting","No Results Available","Pancreatic Adenocarcinoma","Drug: Nab-paclitaxel|Drug: Gemcitabine|Drug: Cisplatin|Drug: Anakinra","Baylor Research Institute","All","18 Years and older   (Adult, Senior)","Early Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","015-198","September 14, 2015","January 2016","September 2018","March 16, 2016","March 2016","No Study Results Posted","null","September 2018","Disease Free Survival (DFS)|Overall Survival (OS)|Quality of Life|Toxicities and Adverse Events will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.","https://ClinicalTrials.gov/show/NCT02550327"
666,"NCT00191841","Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: gemcitabine|Drug: Cisplatin","Eli Lilly and Company","All","18 Years to 65 Years   (Adult)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7410|B9E-VI-S327","September 12, 2005","December 2002","February 2006","July 21, 2006","July 2006","No Study Results Posted","null","null","Antitumor activity|Duration of response, time to progressive disease, time to treatment failure","https://ClinicalTrials.gov/show/NCT00191841"
667,"NCT00869310","Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis","Terminated","No Results Available","Emesis","Drug: aprepitant + dexamethasone|Drug: metoclopramide + dexamethasone","S. Maria Hospital, Terni","All","18 Years and older   (Adult, Senior)","Phase 3","303","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","IGAR-01-2009|2008-001339-37","March 24, 2009","September 2009","May 2012","January 3, 2014","January 2014","No Study Results Posted","null","May 2012","Percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after cisplatin administration|Evaluation of the impact on quality of life of the two antiemetic regimens|Evaluation of the prognostic factors of delayed emesis in patients receiving a combination of aprepitant, palonosetron, dexamethasone for the prevention of acute emesis","https://ClinicalTrials.gov/show/NCT00869310"
668,"NCT01064479","Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck","Active, not recruiting","No Results Available","Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck","Drug: Cisplatin|Drug: Docetaxel|Drug: Erlotinib|Other: Placebo|Drug: Carboplatin","M.D. Anderson Cancer Center|OSI Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2009-0395|NCI-2011-03782","February 5, 2010","February 2010","null","January 13, 2017","January 2017","No Study Results Posted","null","February 2019","Median Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01064479"
669,"NCT01017874","A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Gefitinib|Drug: Gefitinib","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13021|H3E-CR-S131","November 19, 2009","November 2009","October 2014","June 9, 2015","June 2015","February 21, 2014","null","April 2013","Progression Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]|Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]|Time to Progressive Disease (TtPD)|Duration of Tumor Response|Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)","https://ClinicalTrials.gov/show/NCT01017874"
670,"NCT02348450","Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer","Recruiting","No Results Available","Small Cell Lung Cancer","Drug: Irinotecan|Drug: Etoposide|Drug: Cisplatin","Guangdong Association of Clinical Trials","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTONG1404","October 23, 2014","February 2015","December 2018","December 2, 2016","December 2016","No Study Results Posted","null","February 2017","Progression free survival of first line therapy|Overall survival|Objective Response Rate|Number of patients experience adverse events|Progression free survival of second line therapy","https://ClinicalTrials.gov/show/NCT02348450"
671,"NCT00475657","Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer","Terminated","Has Results","Small Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11473|H3E-XM-S113","May 16, 2007","October 2007","April 2008","May 22, 2009","May 2009","March 31, 2009","null","April 2008","Overall Response Rate|Overall Survival|Progression Free Survival|Duration of Response|Stable Disease Rate","https://ClinicalTrials.gov/show/NCT00475657"
672,"NCT01143974","Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer","Completed","No Results Available","Locally Advanced Malignant Neoplasm","Drug: pemetrexed plus cisplatin","Chinese Academy of Medical Sciences","Female","18 Years to 70 Years   (Adult, Senior)","Phase 4","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-BC-008","June 14, 2010","June 2010","June 2012","March 13, 2013","March 2013","No Study Results Posted","null","June 2012","PFS (progression free survival)|Safety|Response Rate","https://ClinicalTrials.gov/show/NCT01143974"
673,"NCT00269152","Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin|Drug: carboplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10105|H3E-SB-S089","December 21, 2005","December 2005","July 2013","July 28, 2015","July 2015","November 12, 2008","null","November 2007","The Feasibility of Post-Surgery Chemotherapy|Grade III/IV Adverse Events|Overall Survival at 3 Years|3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years|Overall Survival at 6 Years","https://ClinicalTrials.gov/show/NCT00269152"
674,"NCT02807181","SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma","Recruiting","No Results Available","Intrahepatic Cholangiocarcinoma","Drug: Cisplatin-gemcitabine|Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)","Sirtex Medical","All","18 Years and older   (Adult, Senior)","","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","STX0115","May 13, 2016","January 2017","December 2019","May 24, 2017","May 2017","No Study Results Posted","SIRCCA","December 2019","Survival at 18 months|Liver-specific progression free survival (PFS)|Progression free survival (PFS) at any site|Objective response rate by RECIST 1.1 and refined RECIST - liver|Objective response rate by RECIST 1.1 and refined RECIST - at any site|Overall Survival|Liver surgical resection and ablation rate|Incidence of Adverse Events (Safety and tolerability)","https://ClinicalTrials.gov/show/NCT02807181"
675,"NCT00743964","Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)","Completed","No Results Available","Advanced Gastric Cancer","Drug: Epirubicin|Drug: Cisplatin, capecitabine","Samsung Medical Center","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2008-04-027|01-9-0804027","August 27, 2008","April 2008","October 2009","January 13, 2010","January 2010","No Study Results Posted","null","October 2009","Failure-free survival|progression-free survival","https://ClinicalTrials.gov/show/NCT00743964"
676,"NCT00772863","Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasms","Drug: docetaxel and cisplatin","Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976I_6012","October 13, 2008","September 2003","null","October 28, 2009","October 2009","No Study Results Posted","Tax-Over","June 2008","Efficacy by response rate according to RECIST criteria and safety|Time to disease progression or relapse|Survival time|Quality of life based on the questionnaire EORTC QLQ-C30 filled by the patients","https://ClinicalTrials.gov/show/NCT00772863"
677,"NCT03069820","Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury","Recruiting","No Results Available","Liver Injury, Drug-Induced","Drug: docetaxel and cisplatin","Second Affiliated Hospital of Nanchang University","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Screening","HL001","February 13, 2017","February 10, 2017","January 1, 2018","February 27, 2017","February 2017","No Study Results Posted","null","January 1, 2018","Relationship of white blood cell level and chemotherapy-induced liver injury|Relationship of albumin level and chemotherapy-induced liver injury|Relationship of hemoglobin level and chemotherapy-induced liver injury|Relationship of blood platelet level and chemotherapy-induced liver injury|Relationship of age and chemotherapy-induced liver injury|Relationship of height and chemotherapy-induced liver injury","https://ClinicalTrials.gov/show/NCT03069820"
678,"NCT00005636","Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery","Completed","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: pemetrexed disodium","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","99-085|CDR0000067791|CWRU-LILY-1599|LILLY-H3E-MC-JMCH(a)|NCI-G00-1767","May 2, 2000","November 1999","November 2000","June 17, 2013","June 2013","No Study Results Posted","null","November 2000","","https://ClinicalTrials.gov/show/NCT00005636"
679,"NCT00680758","Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cisplatin|Drug: everolimus|Drug: paclitaxel","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC BRE 0770|VU-VICC-BRE-0770","May 18, 2008","May 2008","December 2010","March 7, 2013","March 2013","No Study Results Posted","null","August 2009","Safety profile and maximum tolerated dose|Antitumor activity|Response rate|Time to progression","https://ClinicalTrials.gov/show/NCT00680758"
680,"NCT01830556","Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck","Unknown status","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Cetuximab","Karolinska University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CETMET study","April 10, 2013","November 2011","November 2015","May 19, 2013","May 2013","No Study Results Posted","CETMET","November 2013","Progression free survival|Best overall response","https://ClinicalTrials.gov/show/NCT01830556"
681,"NCT00452634","Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)","Completed","No Results Available","Small Cell Lung Cancer","Drug: Irinotecan|Drug: Cisplatin|Drug: Simvastatin","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","62","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-176","March 26, 2007","April 2006","May 2010","June 17, 2013","June 2013","No Study Results Posted","null","November 2009","1-year survival & overall survival|Tumor response rate|Time to progression|Toxicity","https://ClinicalTrials.gov/show/NCT00452634"
682,"NCT00595972","Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: ECF-endostar","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ECF/endo-MGC","January 4, 2008","November 2007","December 2010","June 27, 2011","September 2010","No Study Results Posted","null","December 2010","time to progression|toxicity","https://ClinicalTrials.gov/show/NCT00595972"
683,"NCT01266512","Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer","Completed","No Results Available","Lung Neoplasms","Drug: DOCETAXEL|Radiation: Intensity Modulated Radiotherapy (IMRT)|Drug: CISPLATIN","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_05158|U1111-1115-3573","December 23, 2010","January 2011","March 2014","July 15, 2014","July 2014","No Study Results Posted","C-CRISP","March 2014","Response rate (by contrast CT scan)|Progression Free survival (PFS)|Overall survival (OS)|Adverse events (including oesophageal and pulmonary toxicities)","https://ClinicalTrials.gov/show/NCT01266512"
684,"NCT00002932","Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Primary Purpose: Treatment","RTOG-9615|CDR0000065366","November 1, 1999","May 1997","March 2005","November 19, 2014","November 2014","No Study Results Posted","null","March 2001","","https://ClinicalTrials.gov/show/NCT00002932"
685,"NCT00101192","Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","Completed","Has Results","Cervical Cancer","Biological: cetuximab|Drug: cisplatin","Gynecologic Oncology Group|National Cancer Institute (NCI)|Bristol-Myers Squibb","Female","18 Years and older   (Adult, Senior)","Phase 2","76","Other|NIH|Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","GOG-0076DD|BMS-CA225-075|CDR0000405839","January 7, 2005","September 2004","null","February 3, 2014","February 2014","February 3, 2014","null","July 2011","Tumor Response|Progression-free Survival and Overall Survival at 6 Months After Completion of Treatment","https://ClinicalTrials.gov/show/NCT00101192"
686,"NCT02034968","Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma","Withdrawn","No Results Available","Stage IV Esophageal Squamous Cell Carcinoma","Drug: Nimotuzumab","Zhejiang University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZYTOP1406","January 10, 2014","February 2014","January 2017","March 4, 2015","March 2015","No Study Results Posted","null","January 2016","Progression free survival(PFS)|Objective Response Rate","https://ClinicalTrials.gov/show/NCT02034968"
687,"NCT00400179","A Safety and Efficacy Study in Patients With Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: S-1/Cisplatin|Drug: 5-FU/cisplatin","Taiho Oncology, Inc.|Quintiles, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","1053","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TPU S-1301","June 30, 2005","May 2005","April 2008","March 28, 2012","March 2012","January 6, 2012","null","March 2008","Median Survival|Overall Response Rate (ORR)|Duration of Response (DR)|Progression-free Survival (PFS)|Time to Treatment Failure (TTF)","https://ClinicalTrials.gov/show/NCT00400179"
688,"NCT01669707","Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: Endostar -Continued Pumping into+GP|Drug: Endostar -injecting into +GP","Beijing Chest Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BeijingCH001","August 13, 2012","April 2011","August 2013","August 17, 2012","August 2012","No Study Results Posted","null","April 2013","Progression free survival (PFS)|Overall survival (OS)|Clinical benefit rate (CBR)|Number of Participants With Adverse Events(AE) as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01669707"
689,"NCT00316888","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer","Active, not recruiting","Has Results","Anal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Radiation: radiotherapy","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","E3205|U10CA023318|CDR0000470269","April 19, 2006","January 2007","May 2022","May 18, 2017","October 2016","July 18, 2016","null","November 2015","Local Failure Rate at 3 Years|3-year Overall Survival Rate|3-year Progression-free Survival Rate|Objective Response Rate|3-year Colostomy-free Survival Rate","https://ClinicalTrials.gov/show/NCT00316888"
690,"NCT00759226","Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: 5-FU|Drug: Folinic Acid","CONKO-Studiengruppe|Eli Lilly and Company|medac GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CONKO-101","September 24, 2008","July 2002","August 2007","September 25, 2008","September 2008","No Study Results Posted","CONKO-101","July 2005","Primary endpoint rate of freedom of progression (PR+CR+SD).|Secondary endpoint median survival, progression free survival and toxicity.","https://ClinicalTrials.gov/show/NCT00759226"
691,"NCT02051868","International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel","Recruiting","No Results Available","Squamous Cell Carcinoma of the Anus","Drug: Cisplatin|Drug: 5-Fluorouracil (5-FU)|Drug: Carboplatin|Drug: Paclitaxel","Royal Marsden NHS Foundation Trust|Cancer Research UK|Australasian Gastro-Intestinal Trials Group|ECOG-ACRIN Cancer Research Group|European Organisation for Research and Treatment of Cancer - EORTC|International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCR 3847 InterAACT|2013-001949-13","January 13, 2014","December 2013","February 2018","November 3, 2015","November 2015","No Study Results Posted","InterAACT","August 2017","Best overall response rate by 24 weeks post treatment|Feasibility of conducting a multicentre, international study on squamous cell carcinoma of the anus and recruiting within a reasonable time frame.|Toxicity|Progression-free survival|Overall survival|Disease control rate|Best overall response rate of non-irradiated lesions|Anti-tumour activity and magnitude of tumour response|Quality of Life|Identification of potential tumour biomarker","https://ClinicalTrials.gov/show/NCT02051868"
692,"NCT02360501","Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Neoplasms","Drug: Docetaxel|Drug: Cisplatin|Drug: Capecitabine","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DCX in NPC","February 3, 2015","January 2008","April 2016","April 18, 2016","April 2016","No Study Results Posted","null","March 2016","overall response rate|complete response rate|1 year progression free survival rate|1 year overall survival rate|safety profiles (including hematologic toxicities and non-hematologic toxicities.)","https://ClinicalTrials.gov/show/NCT02360501"
693,"NCT00154804","CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: Paclitaxel, Cisplatin,Surgery, CCRT","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","900603","September 8, 2005","August 2001","April 2004","August 22, 2007","April 2004","No Study Results Posted","null","null","Clinical and pathological response rates|Progression free survival|overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00154804"
694,"NCT01285557","Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","Active, not recruiting","No Results Available","Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm)|Drug: Fluorouracil/cisplatin (control arm)","Taiho Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TPU-S1303","January 26, 2011","February 2011","May 2017","October 19, 2016","October 2016","No Study Results Posted","DIGEST","December 2016","Outcome Measure: Overall survival (OS)|Progression-free survival (PFS)|Time to treatment failure (TTF)|Antitumor activity: Overall Response Rate (ORR), duration of response (DR), time to tumor response (TTR);|Safety and tolerability","https://ClinicalTrials.gov/show/NCT01285557"
695,"NCT01728480","Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy","Withdrawn","No Results Available","Mucositis|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer","Drug: entolimod|Radiation: intensity-modulated radiation therapy|Drug: cisplatin|Other: pharmacological study|Other: laboratory biomarker analysis","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Cleveland BioLabs, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I 209611|NCI-2012-02140","November 13, 2012","January 2014","null","December 10, 2013","December 2013","No Study Results Posted","null","October 2015","Adverse events defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related graded according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0|PK of entolimod when administered in combination with cisplatin and radiation therapy|The percentage of patients with mucositis, measured using the World Health Organization (WHO) mucositis global severity score and the oral mucositis daily questionnaire (OMDQ)","https://ClinicalTrials.gov/show/NCT01728480"
696,"NCT00320294","ILF With/Without Cisplatin for Advanced Gastric Cancer","Unknown status","No Results Available","Stomach Neoplasm","Drug: irinotecan|Drug: cisplatin","Gachon University Gil Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMO-GI-52","May 1, 2006","February 2005","March 2007","March 9, 2007","March 2007","No Study Results Posted","null","null","Objective response rate|Safety|Progression-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00320294"
697,"NCT00091377","Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: paclitaxel|Drug: phenoxodiol","MEI Pharma, Inc.","Female","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000389129|NOVOGEN-NV06-037|YALE-HIC-26423","September 7, 2004","August 2004","March 2008","July 13, 2016","July 2016","No Study Results Posted","null","December 2007","Safety and tolerability|Efficacy|Surrogate marker of tumor response in terms of plasma protein tNOX","https://ClinicalTrials.gov/show/NCT00091377"
698,"NCT01089088","Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium","Unknown status","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: sunitinib malate","Wales Cancer Trials Unit|Cardiff University","All","16 Years and older   (Child, Adult, Senior)","Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000667764|WCTU-SUCCINCT|ISRCTN54607216|EUDRACT-2007-007591-42|EU-21013|WCTU-SPON-416-07|CRUK-07/044","March 17, 2010","April 2009","February 2014","February 28, 2013","February 2013","No Study Results Posted","null","July 2013","Progression-free survival|Toxicity during and after treatment according to NCI CTCAE v 3.0|Tolerability (side effects) and feasibility of use (number of patients requiring dose delays or reduction and/or treatment withdrawal)|Overall survival|Progression-free survival (time-to-event)|Objective (radiological) response rate according to RECIST","https://ClinicalTrials.gov/show/NCT01089088"
699,"NCT01480986","IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC","Completed","No Results Available","Progression Free Survival of the Treatment","Drug: Irinotecan combined with cisplatin, octreotide lar","Peking University","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BJT-NEC-001","November 25, 2011","September 2011","December 2013","May 17, 2015","May 2015","No Study Results Posted","null","September 2012","Progression Free Survival for Irinotecan plus cisplatin and octreotide|Disease control rate|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT01480986"
700,"NCT00002659","Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin-e therapeutic implant","Matrix Pharmaceutical|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","120","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064225|MP-414-94-2|NCI-V95-0676","November 1, 1999","May 1995","null","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002659"
701,"NCT00005088","Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","RTOG-9914|CDR0000067706|RTOG-DEV-1022","April 6, 2000","April 2000","null","November 18, 2013","November 2013","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00005088"
702,"NCT01742767","Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC","Unknown status","No Results Available","NSCLC","Drug: Cisplatinum|Drug: Pemetrexed","Universität Duisburg-Essen|Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other|Industry","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","2011-001963-37","December 3, 2012","November 2012","April 2015","December 4, 2012","December 2012","No Study Results Posted","PemSplitCisp","May 2014","Response rate","https://ClinicalTrials.gov/show/NCT01742767"
703,"NCT02223611","Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer Stage Ⅱ|Non-small Cell Lung Cancer Stage ⅢA","Drug: S1 capsule|Drug: Vinorelbine","Hebei Medical University Fourth Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HBMF9990","August 14, 2014","December 2014","December 2018","August 21, 2014","August 2014","No Study Results Posted","S1VSNP","December 2016","Disease free survival rate|Disease free survival|Overall survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Quality of life (QOL)","https://ClinicalTrials.gov/show/NCT02223611"
704,"NCT02535325","Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer","Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Stage IIIA Large Cell Lung Carcinoma|Stage IIIA Lung Adenocarcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Large Cell Lung Carcinoma|Stage IIIB Lung Adenocarcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Large Cell Lung Carcinoma|Stage IV Lung Adenocarcinoma|Stage IV Non-Small Cell Lung Cancer","Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Methoxyamine|Drug: Pemetrexed Disodium","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","15","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-01408|R01CA204397|CASE 5514|9834|P30CA043703","August 27, 2015","September 30, 2015","null","May 23, 2017","May 2017","No Study Results Posted","null","October 1, 2018","Incidence of toxicity of the combination therapy, graded according to NCI CTCAE version 4.0|MTD of methoxyamine in combination with pemetrexed disodium, cisplatin and RT, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Change in lab correlative expression levels (including UNG, TS, ERCC1, Ki-67 and TopoII-alpha)|Disease-free survival|Progression-free survival (PFS)|Response rate (clinical/tumor response)","https://ClinicalTrials.gov/show/NCT02535325"
705,"NCT00536640","Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Erlotinib|Drug: Bevacizumab|Drug: Gemcitabine|Drug: Cisplatin","Aktion Bronchialkarzinom e.V.|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 2","224","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABC-2006-NSCLC-01|2006-004865-32","September 27, 2007","November 2007","May 2012","June 11, 2013","June 2013","No Study Results Posted","INNOVATIONS","August 2011","The main efficacy parameter is the progression free survival.|Overall survival|Quality of life|Response rate|Molecular investigations","https://ClinicalTrials.gov/show/NCT00536640"
706,"NCT02726399","Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer","Recruiting","No Results Available","Gastric Cancer|Gastroesophageal Junction Cancer","Drug: Ramucirumab|Drug: Trastuzumab|Drug: Capecitabine/Cisplatin","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-301","March 29, 2016","March 2016","March 2019","April 19, 2017","April 2017","No Study Results Posted","null","March 2019","progression free survival","https://ClinicalTrials.gov/show/NCT02726399"
707,"NCT00716417","Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours","Completed","Has Results","Neoplasms","Drug: BIBW 2992|Drug: BIBW 2992","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","1200.37|2008-002613-43","July 15, 2008","July 2008","null","June 3, 2014","August 2013","August 8, 2013","null","July 2010","Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)|Maximum Tolerated Dose (MTD) for Regimen A and Regimen B|Number of Patients With Objective Response|Maximum Concentration of Afatinib in Plasma at Steady State (Cmax,ss)","https://ClinicalTrials.gov/show/NCT00716417"
708,"NCT00003108","Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: bryostatin 1|Drug: cisplatin","Lombardi Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","GUMC-97166|CDR0000065849|NCI-T97-0056","November 1, 1999","October 1997","October 2007","July 17, 2013","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003108"
709,"NCT00316862","Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery","Active, not recruiting","Has Results","Esophageal Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-80302|CDR0000468495|NCI-2009-00491|U10CA180821","April 19, 2006","February 2006","null","January 26, 2017","January 2017","January 26, 2017","null","December 2012","Proportion of Patients With Adenocarcinoma Achieving a Pathologic Complete Response (CR) After Surgery|Utility of Early PET Imaging in Predicting Response to Treatment|Disease-free Survival|Overall Survival|Patterns of Failure|Proportion of Patients Experiencing Grade 3 or Greater Pneumonitis or Esophagitis|Proportion of Patients Experiencing Grade 3 or Greater Hematologic and Non-hematologic Toxicity","https://ClinicalTrials.gov/show/NCT00316862"
710,"NCT00538525","Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Doxorubicin, Docetaxel, Cisplatin","King Faisal Specialist Hospital & Research Center","All","Child, Adult, Senior","","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC#2011-022","October 1, 2007","September 2007","April 2008","May 26, 2012","May 2012","No Study Results Posted","null","April 2008","Effectiveness","https://ClinicalTrials.gov/show/NCT00538525"
711,"NCT01312324","Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer","Completed","No Results Available","Locally Advanced Stage III or IV Thymic Cancer","Drug: neoadjuvant docetaxel/cisplatin","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-01-040","March 6, 2011","February 2007","March 2016","April 19, 2016","April 2016","No Study Results Posted","null","July 2015","Complete resection rate|the number of patients with adverse events","https://ClinicalTrials.gov/show/NCT01312324"
712,"NCT00004090","Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: gemcitabine hydrochloride","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU CINJ98X1|NU-CINJ98X1|NCI-G99-1581","December 10, 1999","August 1999","August 2002","July 9, 2013","January 2011","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00004090"
713,"NCT00942357","Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer","Active, not recruiting","No Results Available","Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IA Uterine Corpus Cancer|Stage IB Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer","Drug: Carboplatin|Drug: Cisplatin|Radiation: Internal Radiation Therapy|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","804","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-0258|NCI-2011-01951|CDR0000649079|U10CA180868|U10CA027469","July 17, 2009","June 2009","null","February 9, 2016","February 2016","No Study Results Posted","null","February 2016","Recurrence-free survival (RFS)|Cumulative incidence of distant metastases (beyond the pelvis and vagina)|Cumulative incidence of grade 3 or higher bowel-related gastrointestinal adverse events graded by the NCI CTCAE version 3.0|Cumulative incidence of local recurrence (limited to the pelvis or vagina)|Incidence of acute and adverse effects as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (CTCAE) version 3.0|Incidence of late adverse events as graded by the NCI CTCAE version 3.0|Overall survival|Patient-reported quality of life (QOL)","https://ClinicalTrials.gov/show/NCT00942357"
714,"NCT01401192","Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: Gemcitabine plus cisplatin|Drug: pemetrexed plus cisplatin|Drug: pemetrexed plus cisplatin|Drug: Gemcitabine plus cisplatin","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","304","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-06-006","July 21, 2011","July 2011","null","July 22, 2011","July 2011","No Study Results Posted","null","December 2013","predictive value of TS expression|response rate","https://ClinicalTrials.gov/show/NCT01401192"
715,"NCT02560298","Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer","Recruiting","No Results Available","Anal Basaloid Carcinoma|Anal Canal Cloacogenic Carcinoma|Anal Squamous Cell Carcinoma|Metastatic Anal Canal Carcinoma|Recurrent Anal Canal Carcinoma|Stage IIIB Anal Canal Cancer|Stage IV Anal Canal Cancer","Drug: Capecitabine|Drug: Carboplatin|Drug: Cisplatin|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Quality-of-Life Assessment","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA2133|NCI-2015-00771|13/LO/1463|CCR 3847|2013-001949-13|InterAACT CCR 3847|3847|U10CA180820","September 24, 2015","January 2016","null","March 22, 2016","March 2016","No Study Results Posted","InterAACT","August 2018","Best ORR defined as the percentage of patients achieving confirmed partial (PR) or complete responses (CR) as per RECIST v1.1|Anti-tumor activity and magnitude of response|Best ORR of non-irradiated lesions defined as the percentage of patients achieving confirmed PR or CR as per RECIST v1.1 of non-irradiated sites of disease|Changes in QOL|DCR defined as CR, PR, or SD assessed according to RECIST criteria v1.1|DCR defined as CR, PR, or stable disease (SD) assessed according to RECIST criteria v1.1|Feasibility in terms of proportion of centers that successfully recruit at least one patient|Feasibility in terms of recruitment rate|OS|PFS|Proportion of patients experiencing grade 3-5 toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Sensitivity analysis of ORR","https://ClinicalTrials.gov/show/NCT02560298"
716,"NCT00489996","Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: gemcitabine|Drug: cisplatin","Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6672|B9E-GH-JHSE","June 20, 2007","January 2003","June 2005","June 20, 2007","June 2007","No Study Results Posted","null","null","Evaluate response rate|Evaluate time to progression|Evaluate toxicities|Evaluate survival","https://ClinicalTrials.gov/show/NCT00489996"
717,"NCT01015664","Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Terminated","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: temsirolimus|Drug: cisplatin|Drug: cetuximab","University of Tennessee Cancer Institute|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HN0209","November 17, 2009","February 2010","December 2012","December 13, 2012","December 2012","No Study Results Posted","null","December 2012","Phase one - the outcome measure for determining the optimal dose will be determined by whether the subjects experience a dose limiting toxicity (DLT)|Phase 2 - the outcome measure of Progression-Free Survival is defined as the time from first treatment to the documented progression of disease or death, whichever comes first.|Overall response rate is defined as the proportion of patients achieving any response (CR + PR) compared to the total patient population.|Disease control rate is defined as the proportion of patients who achieve a CR, PR, or SD (for ≥ 12 weeks) during study treatment compared to the total patient population.|Overall survival is defined as the time from first treatment to the time of death, regardless of cause.","https://ClinicalTrials.gov/show/NCT01015664"
718,"NCT02919462","Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Secondary|Advanced Stage IIIB|High Thymidylate Synthase Expression","Drug: Oral vinorelbine|Drug: Cisplatin|Drug: Maintenance with Metronomic Oral Vinorelbine|Drug: Pemetrexed|Drug: Cisplatin|Drug: Maintenance with Pemetrexed","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|Pierre Fabre Laboratories","All","18 Years and older   (Adult, Senior)","Phase 2","130","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST162.10|2015-003440-39","September 28, 2016","March 2016","March 2019","September 28, 2016","September 2016","No Study Results Posted","HighTySy","March 2019","Disease Control Rate (DCR)|Toxicity|Overall survival (OS) within th 2 arms|Progression free survival (PFS) within the two arms|optimal TS H-score cutpoint","https://ClinicalTrials.gov/show/NCT02919462"
719,"NCT01073683","Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer","Unknown status","No Results Available","Larynx Cancer","Procedure: laryngoscopy|Drug: Taxotere (Docetaxel), Cisplatin, 5FU","Rabin Medical Center|Davidoff Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RMC5476","January 12, 2010","April 2010","December 2014","March 3, 2010","February 2010","No Study Results Posted","null","December 2012","Improvement in larynx preservation free survival|Improvement in overall survival in patients treated under this regimen in comparison to historical control","https://ClinicalTrials.gov/show/NCT01073683"
720,"NCT00005868","Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: docetaxel","European Organisation for Research and Treatment of Cancer - EORTC","All","19 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Primary Purpose: Treatment","EORTC-08984","June 2, 2000","March 2000","null","July 17, 2012","July 2012","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00005868"
721,"NCT00068549","Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Drug: Gemcitabine Hydrochloride|Drug: Cisplatin|Radiation: Radiation Therapy|Radiation: Internal Radiation Therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9912|NCI-2012-02553|CDR0000327715|U10CA027469","September 10, 2003","October 2003","null","December 23, 2014","December 2014","No Study Results Posted","null","January 2008","Incidence of acute toxicity using the 21 major categories of the CTEP CTC version 2.0|Incidence of chronic toxicity using the CTC RTOG/EORTC late radiation morbidity scoring scheme|Dose of each drug|Number of cycles received|Site (local/distant) of treatment failure|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00068549"
722,"NCT00003182","Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Hope Cancer Institute, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Industry","Interventional","Primary Purpose: Treatment","CDR0000066004|HCRN-003|NCI-V98-1374","November 1, 1999","March 1997","null","December 3, 2013","July 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003182"
723,"NCT01096199","A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)","Terminated","No Results Available","Cancer","Drug: TS-ONE, Cisplatin, RAD001","National University Hospital, Singapore","All","21 Years to 80 Years   (Adult, Senior)","Phase 1","35","Other","Interventional","","PK02/12/09","March 29, 2010","null","null","January 21, 2014","January 2014","No Study Results Posted","null","September 2012","","https://ClinicalTrials.gov/show/NCT01096199"
724,"NCT00544362","Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery","Completed","No Results Available","Esophageal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery","Federation Francophone de Cancerologie Digestive","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000564075|FFCD-0505|EU-20756|EUDRACT-2006-004770-27|MERCK-FFCD-0505","October 13, 2007","July 2007","March 2013","May 27, 2016","May 2016","No Study Results Posted","null","January 2011","Complete histologic response|Tolerance to neoadjuvant therapy|Progression-free and overall survival|Mortality","https://ClinicalTrials.gov/show/NCT00544362"
725,"NCT00003264","Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066159|P30CA006927|FCCC-97021|NCI-G98-1403","November 1, 1999","October 1997","June 2002","April 16, 2013","April 2013","No Study Results Posted","null","February 2002","","https://ClinicalTrials.gov/show/NCT00003264"
726,"NCT01953952","Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer","Withdrawn","No Results Available","Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Tongue Cancer","Procedure: therapeutic conventional surgery|Radiation: intensity-modulated radiation therapy|Drug: cisplatin|Procedure: quality-of-life assessment|Other: laboratory biomarker analysis","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 1221|NCI-2013-00939|RTOG-1221|U10CA021661","September 26, 2013","December 2013","February 2015","March 18, 2015","March 2015","No Study Results Posted","null","February 2015","Progression-free survival (PFS)|Patterns of local, regional, and distant failure|Overall survival (OS)|Rate of grade 4-5 oropharyngeal hemorrhage and involved surgical margin for all patients and patients with selected T3 tumors|Objective swallowing function|Shoulder function|Short-term quality of life: head and neck-specific (swallowing domain and shoulder function) using the M. D. Anderson Dysphagia Inventory (MDADI)|Long-term quality of life: head and neck-specific (swallowing domain and shoulder function) using the MDADI","https://ClinicalTrials.gov/show/NCT01953952"
727,"NCT01630174","IMRT/Pemetrexed/Cisplatin in Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","","Shandong Cancer Hospital and Institute","All","18 Years to 75 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","phase 1 pem IMRT","June 27, 2012","October 2009","null","June 27, 2012","June 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01630174"
728,"NCT00001450","Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung|Lung Neoplasms","Drug: paclitaxel|Drug: cisplatin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","58","NIH","Interventional","Primary Purpose: Treatment","950198|95-C-0198","November 3, 1999","September 1995","June 2000","March 3, 2008","July 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001450"
729,"NCT01031446","Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Drug: cisplatin|Drug: everolimus|Drug: paclitaxel|Other: laboratory biomarker analysis","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC BRE 0949|P30CA068485|VU-VICC-BRE-0949|IRB# 090673","December 11, 2009","October 2009","July 2017","July 18, 2016","July 2016","December 6, 2012","null","December 2011","Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer|Maximum Feasible Dose in mg of RAD001 (Everolimus)for Women With Metastatic Breast Cancer|Patients With Progression-free Survival|Patients With Overall Response|Time to Progression|Time to Progression in Patients With Metastatic Basal-like Breast Cancer.","https://ClinicalTrials.gov/show/NCT01031446"
730,"NCT02703961","Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Drug: concurrent chemotherapy with cisplatin|Drug: concurrent chemotherapy with docetaxel|Radiation: pelvic radiotherapy|Radiation: brachytherapy|Drug: adjuvant chemotherapy with cisplatin and docetaxel","Fourth Military Medical University","Female","18 Years to 60 Years   (Adult)","Phase 3","598","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XJFL-2016-02-LACC-TP triweekly","March 3, 2016","February 2016","February 2021","March 15, 2016","March 2016","No Study Results Posted","null","February 2018","disease free survival|overall survival","https://ClinicalTrials.gov/show/NCT02703961"
731,"NCT02363829","A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)","Recruiting","No Results Available","Uterine Cervix Cancer","Drug: Nelfinavir|Biological: Cisplatin","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Senior)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","UPCC 32814","February 10, 2015","February 2015","February 2017","September 23, 2016","September 2016","No Study Results Posted","null","February 2017","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02363829"
732,"NCT02501954","Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol","Recruiting","No Results Available","Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer","Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Radiation Therapy","Women's Cancer Care Associates, LLC","Female","18 Years and older   (Adult, Senior)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15-07","July 9, 2015","March 2015","March 2023","October 31, 2016","October 2016","No Study Results Posted","null","March 2020","Recurrence-free survival (RFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02501954"
733,"NCT00568971","Study of Weekly DCF to Treat Advanced Gastric Cancer","Terminated","No Results Available","Gastric Cancer","Drug: Docetaxel, Cisplatin, 5-Fu","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DCF-AGC","December 5, 2007","April 2007","June 2008","January 26, 2010","August 2009","No Study Results Posted","null","June 2008","Response rate, overall survival|Side effects","https://ClinicalTrials.gov/show/NCT00568971"
734,"NCT00964626","Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer","Unknown status","No Results Available","Ovarian Cancer","Drug: cisplatin|Drug: paclitaxel","Russian Academy of Medical Sciences|National Cancer Institute (NCI)","Female","18 Years to 72 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000641288|USSR-AMS-PAC-2|EU-20937|BIOCAD-PAC-2","August 22, 2009","April 2009","null","August 23, 2013","August 2009","No Study Results Posted","null","April 2011","Progression-free survival|Overall survival|Objective response rate (complete and partial remission in patients with measurable disease)|Toxicity","https://ClinicalTrials.gov/show/NCT00964626"
735,"NCT02465736","Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma|Esophageal Cancer|Oesophageal Cancer","Drug: Docetaxel|Drug: Cisplatin|Radiation: Radiation|Procedure: Surgery|Drug: Vinorelbine|Drug: Cisplatin","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NEOCRTEC-2.0","May 30, 2015","July 2015","July 2023","February 24, 2017","February 2017","No Study Results Posted","null","July 2023","Overall survival|Toxicities of neo-adjuvant chemoradiotherapy|Disease free survival|Clinical response rate|R0 resection rate|Number of Participants who withdraw the treatment|Perioperative complication|Pathological complete response rate|Health Related Quality of Life","https://ClinicalTrials.gov/show/NCT02465736"
736,"NCT00006482","Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix","Terminated","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068313|GOG-0127Q","November 6, 2000","October 2000","null","April 10, 2013","May 2004","No Study Results Posted","null","April 2006","","https://ClinicalTrials.gov/show/NCT00006482"
737,"NCT00003132","Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: bryostatin 1|Drug: cisplatin","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065897|NYU-9709|NCI-T97-0058","November 1, 1999","January 1998","null","November 8, 2012","November 2009","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00003132"
738,"NCT02563054","A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: 5-Fluorouracil|Drug: Capecitabine|Drug: Cisplatin","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML17032","September 28, 2015","April 2003","August 2010","November 1, 2016","November 2016","No Study Results Posted","null","August 2010","Time to disease progression|Objective tumor response rate|Overall survival|Duration of response|Time to response|Incidence of adverse events","https://ClinicalTrials.gov/show/NCT02563054"
739,"NCT01374789","PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer","Terminated","No Results Available","Urinary Bladder Cancer","Drug: GemCis + Panitumumab|Drug: GemCis","WiSP Wissenschaftlicher Service Pharma GmbH|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WiSP_AG48|2009-015119-42|GMIHO-007/2008","March 30, 2011","July 2010","March 2012","June 2, 2015","June 2015","No Study Results Posted","PURO","March 2012","Primary end point: Progression-free survival rate after 12 months.|Determination of best response (CR, PR and SD) rates in accordance with the RECIST criteria|Duration of response, progression-free and overall survival time|Documentation of adverse effects in accordance with the NCI CTC criteria|Documentation of quality of life on the basis of the EORTC questionnaire","https://ClinicalTrials.gov/show/NCT01374789"
740,"NCT00003029","Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: fluorouracil","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-05962","November 1, 1999","May 1997","null","June 29, 2012","June 2012","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00003029"
741,"NCT00191100","Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix","Completed","Has Results","Cancer of Cervix","Drug: Gemcitabine|Drug: Cisplatin|Radiation: Brachytherapy|Radiation: Pelvic radiation","Eli Lilly and Company","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","515","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4015|B9E-MC-JHQS","September 12, 2005","May 2002","April 2008","August 8, 2009","August 2009","March 30, 2009","null","April 2008","Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years|Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points|Local Failure Rate|Tumor Response|Number of Participants Who Died From Any Cause at Various Time Points|Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points","https://ClinicalTrials.gov/show/NCT00191100"
742,"NCT00452881","Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC","Unknown status","No Results Available","Lung Cancer","Drug: gemcitabine|Drug: Oxaliplatin|Drug: Cisplatin","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","151","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-05-158","March 27, 2007","May 2006","December 2014","October 22, 2010","July 2010","No Study Results Posted","null","October 2009","Compare time to recurrence with these regimens|Compare to Overall survival with these regimens|Compare to Toxicities with these regimens|- To define the patient population most at risk for disease recurrence|(tissue banking and blood sampling for analysis of predictive markers)|Compare quality of life as assessed by EORTC QLQ-C30, EORTC QLQ-LC13 with these regimens","https://ClinicalTrials.gov/show/NCT00452881"
743,"NCT01160731","Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Withdrawn","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide phosphate|Drug: panobinostat|Other: laboratory biomarker analysis|Other: pharmacological study","Cancer Trials Ireland","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-09 ICORG|ICORG-07-09|EUDRACT-2008-003634-21|EU-21047","July 9, 2010","November 2009","null","December 30, 2014","October 2012","No Study Results Posted","null","October 2010","Maximum-tolerated dose (MTD) and recommended dose (RD)|Response rates and toxicity at MTD and RD|Objective response rate according to RECIST criteria|Time to progression according to RECIST criteria|Duration of response or disease stabilization according to RECIST criteria|Overall survival according to RECIST criteria|Effect of the combination regimen on drug pharmacokinetics|Adverse events|Quality of life evaluated by EQ-5D (Euro QoL)","https://ClinicalTrials.gov/show/NCT01160731"
744,"NCT00977561","A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer","Terminated","Has Results","Small Cell Lung Carcinoma","Drug: figitumumab|Drug: Cisplatin (Or Carboplatin)|Drug: Etoposide|Drug: Cisplatin (Or Carboplatin)|Drug: Etoposide","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A4021032","September 10, 2009","April 2010","October 2011","January 18, 2013","January 2013","January 18, 2013","null","October 2011","Progression-Free Survival (PFS)|Number of Participants With Objective Response|Overall Survival (OS)|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Maximum Observed Plasma Concentration (Cmax) of Figitumumab|Minimum Observed Plasma Trough Concentration (Cmin) of Figitumumab|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Etoposide|Maximum Observed Plasma Concentration (Cmax) of Etoposide|Percentage of Participants Reporting Positive Anti-Drug Antibodies (ADA) Response for Figitumumab|Cancer Dyspnea Scale (CDS) Score|Numeric Rating Scale (NRS) Score|Pre-treatment Levels of Tumor Biomarkers Involved in Insulin-Like Growth Factor 1 (IGF-I) Signaling Pathway|Levels of Serum Circulating Insulin-like Growth Factor (IGF) Pathway Related Markers|Number of Total Circulating Tumor-Related Cells (CTCs) and Insulin-Like Growth Factor 1 Receptor (IGF-IR)-Expressing CTCs","https://ClinicalTrials.gov/show/NCT00977561"
745,"NCT00603915","A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer","Completed","Has Results","Nasopharyngeal Cancer","Drug: Gemcitabine|Drug: Carboplatin/Cisplatin|Drug: erlotinib","University Health Network, Toronto|Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-774","January 17, 2008","June 2006","April 2011","October 6, 2011","October 2011","May 6, 2011","null","December 2010","Progression Free Survival.|Number of Participants With the Responses Outlined","https://ClinicalTrials.gov/show/NCT00603915"
746,"NCT02421640","Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin+TIL|Drug: Cisplatin","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 2","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC and TIL","April 11, 2015","March 2015","March 2020","October 17, 2016","September 2016","No Study Results Posted","TIL","March 2017","Progress-free survival|Overall Survival (OS)|Locoregional Relapse-Free Survival (LRRF)|Distant Metastasis-Free Survival (DMFS)|Complete Response (CR)|Determine the toxic effects in these patients.|Determine the molecular expression of EBV DNA.|Determine the quality of life (QoL) of these regimens in these patients.","https://ClinicalTrials.gov/show/NCT02421640"
747,"NCT01487915","Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma","Unknown status","No Results Available","Advanced Urothelial Carcinoma","Drug: GCb|Drug: GemOx","Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UOSG-AMC-1001|KCSG-GU10-16","December 5, 2011","October 2010","null","September 22, 2014","September 2014","No Study Results Posted","COACH","June 2015","Response rate|Safety|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01487915"
748,"NCT00004547","Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy","Completed","Has Results","Abdominal Neoplasm|Colonic Neoplasm|Mesothelioma|Peritoneal Neoplasm","Procedure: Surgery|Procedure: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|Drug: Postoperative dwell with paclitaxel and 5-FU","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","188","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","000069|00-C-0069","February 3, 2000","January 2000","August 2009","October 19, 2015","September 2015","August 30, 2011","null","August 2009","Number of Participants With Disease-free Survival|Number of Participants With a Response|Number of Participants With Adverse Events|Percentage of Participants Who Had Paclitaxel and 5-fluorouracil (5-FU) Analysis Performed|Quality of Life Questionnaire Score|Signal Transduction Pathways in Tumor Tissue Versus Normal Tissue","https://ClinicalTrials.gov/show/NCT00004547"
749,"NCT00343239","Docetaxel in Locally Advanced Gastric Adenocarcinoma","Completed","No Results Available","Stomach Neoplasms","Drug: Docetaxel|Drug: Cisplatin|Drug: Fluorouracil","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","59","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_00072","June 21, 2006","June 2006","March 2012","November 3, 2014","November 2014","No Study Results Posted","NEOTAX","March 2012","To determine the R0 resection rate for the treatment of locally advanced gastric carcinoma with Docetaxel, Cisplatin, Fluorouracil combination.","https://ClinicalTrials.gov/show/NCT00343239"
750,"NCT00127049","Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors","Unknown status","No Results Available","Germ Cell Tumor","Drug: gemcitabine, ifosfamide, cisplatin, G-CSF","Gustave Roussy, Cancer Campus, Grand Paris","Male","16 Years and older   (Child, Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIP-TG","August 3, 2005","December 2004","null","September 7, 2006","September 2006","No Study Results Posted","null","null","Complete response rate|Toxicity|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00127049"
751,"NCT00006036","Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors","Completed","No Results Available","Head and Neck Cancer|Lung Cancer|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: lurtotecan liposome","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","I133|CAN-NCIC-IND133|NEXSTAR-110-05|CDR0000068051","July 5, 2000","April 2000","December 2009","November 7, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006036"
752,"NCT00087698","Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma","Completed","Has Results","Pleural Neoplasms","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","77","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7216|H3E-US-JMGA","July 12, 2004","September 2003","February 2008","May 1, 2009","May 2009","February 16, 2009","null","February 2008","Pathological Complete Response|The 1 and 2 Year Disease-Free Survival Rate (Percentage)|Overall Tumor Response|Time to Treatment Failure|Time to Progressive Disease|Overall Survival Time","https://ClinicalTrials.gov/show/NCT00087698"
753,"NCT00063999","Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer","Active, not recruiting","No Results Available","Recurrent Uterine Corpus Carcinoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIC Uterine Corpus Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer","Drug: Carboplatin|Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Biological: Filgrastim|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Biological: Pegfilgrastim|Other: Quality-of-Life Assessment","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","1331","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-0209|NCI-2009-00584|CDR0000305940|U10CA180868|U10CA027469","July 8, 2003","August 2003","null","October 26, 2016","October 2016","No Study Results Posted","null","June 2013","Duration of overall survival|Change in functional well-being assessed using the FACT/GOG Neurotoxicity subscale|Change in physical well-being assessed using the Functional Assessment of Cancer Therapy (FACT)-Endometrial subscale|Duration of progression-free survival|Estrogen and progesterone receptor status (positive or negative)|Incidence of adverse events|Number of courses of study therapy administered (for those not completing the prescribed study therapy)|Sites of disease and tumor grade","https://ClinicalTrials.gov/show/NCT00063999"
754,"NCT00006028","Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068041|GOG-0126L","July 5, 2000","January 2001","null","May 24, 2013","March 2003","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00006028"
755,"NCT02889666","Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery for Recurrent Non-Small Cell Lung Cancer","Recruiting","No Results Available","Recurrent Non-small Cell Lung Cancer","Drug: Cisplatin|Drug: Carboplatin|Drug: Docetaxel|Drug: Gemcitabine/Carboplatin|Drug: Gemcitabine/Cisplatin|Drug: Docetaxel/Oxaliplatin|Drug: Docetaxel/Carboplatin|Drug: Placebo","Shanghai Jiao Tong University School of Medicine|Shanghai 10th People's Hospital|Jilin University|Jiangxi Provincial Cancer Hospital|Shanghai Tongji Hospital, Tongji University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LCA-81472709","August 25, 2016","January 2008","December 2018","September 2, 2016","August 2016","No Study Results Posted","CCODG-NSCLC","July 2017","5 years disease-free survival|5 years overall survival|5 years metastasis-free survival","https://ClinicalTrials.gov/show/NCT02889666"
756,"NCT00555672","Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer","Completed","Has Results","Stomach Neoplasms","Drug: 5-fluorouracil|Drug: cisplatin|Drug: sunitinib malate","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181128","November 8, 2007","August 2008","August 2010","December 12, 2011","December 2011","December 15, 2010","null","December 2009","Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration (Cmax)|Area Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)]|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Steady State Concentration (Css) of 5-Fluorouracil (5-FU)|Infusion Rate (Zero Order) (R0) of 5-FU|Clearance (CLss) of 5-FU|Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU|Number of Participants With Objective Response|Duration of Response (DR)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00555672"
757,"NCT00614965","Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Irinotecan|Drug: Cisplatin|Drug: Pemetrexed","Hellenic Oncology Research Group|University Hospital of Crete","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/06.16","February 1, 2008","November 2006","March 2010","May 20, 2011","May 2011","No Study Results Posted","null","March 2010","Overall Response Rate|Time to Tumor Progression|Overall Survival|Toxicity profile between the two treatment arms|Quality of life assessment","https://ClinicalTrials.gov/show/NCT00614965"
758,"NCT00020696","Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: tirapazamine","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068705|GOG-0146M","July 11, 2001","June 2001","null","January 7, 2012","March 2008","No Study Results Posted","null","April 2006","","https://ClinicalTrials.gov/show/NCT00020696"
759,"NCT01131429","A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations","Unknown status","No Results Available","Neoplasms, Lung|Carcinoma, Non-Small Cell Lung|Drug Therapy|Genes, EGFR","Drug: Erlotinib|Drug: Docetaxel|Drug: Cisplatin|Drug: Docetaxel|Drug: Cisplatin|Drug: Erlotinib","Chinese PLA General Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","PLAGH-TKIs","May 25, 2010","June 2010","June 2015","May 26, 2010","April 2010","No Study Results Posted","null","June 2013","Overall survival|progression-free survival during the first-line treatment|progression-free time during the second-line treatment|quality of life during the first-line therapy|quality of life during the second-line therapy|response rates during the first-line treatment|response rates during the second-line treatment|toxicity during the first-line treatment|toxicity during the second-line treatment|preditive and prognostic markers for chemotherapy or erlotinib","https://ClinicalTrials.gov/show/NCT01131429"
760,"NCT00003345","Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","35","Other|NIH","Interventional","Primary Purpose: Treatment","97-121|CDR0000066322|NCI-H98-0013","November 1, 1999","October 1997","October 2001","June 20, 2013","June 2013","No Study Results Posted","null","October 2001","","https://ClinicalTrials.gov/show/NCT00003345"
761,"NCT00655876","Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer","Active, not recruiting","No Results Available","Esophageal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: paclitaxel|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years to 74 Years   (Adult, Senior)","Phase 3","420","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RTOG 0436|CDR0000538085","April 9, 2008","June 2008","null","September 28, 2016","September 2016","No Study Results Posted","null","August 2018","Overall survival (failure: death due to any cause)|Local control (failure: residual cancer on post-treatment endoscopic biopsy or recurrent primary disease as defined in protocol)|Adverse events as assessed by NCI CTCAE v3.0|Endoscopic complete response rate|Health-related quality of life (FACT-E)|Quality-adjusted survival (using EQ-5D), if primary hypothesis is supported","https://ClinicalTrials.gov/show/NCT00655876"
762,"NCT00768755","Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","Carcinoma, Non-Small Cell Lung","Drug: axitinib|Drug: axitinib|Drug: chemotherapy|Drug: axitinib|Drug: chemotherapy","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061039","October 7, 2008","January 2009","March 2012","October 6, 2015","October 2015","March 1, 2012","null","March 2011","Progression-Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Objective Response (OR)|Duration of Response (DR)|Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score|Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score","https://ClinicalTrials.gov/show/NCT00768755"
763,"NCT00851877","Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000634258|SCCC-112008-019|ABX 236-HN08US","February 25, 2009","March 2009","December 2015","May 29, 2015","May 2015","No Study Results Posted","null","December 2015","Maximum tolerated dose of paclitaxel albumin-stabilized nanoparticle formulation|disease-free survival|Dose-limiting toxicities|Safety and tolerability|Progression-free survival|Response rates|Overall survival","https://ClinicalTrials.gov/show/NCT00851877"
764,"NCT00132639","Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Pulmonary Neoplasms","Drug: Preoperative docetaxel-cisplatin combination chemotherapy|Drug: Preoperative docetaxel monotherapy","Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group","All","20 Years to 74 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG 0204-MF|C000000032","August 19, 2005","October 2002","November 2008","September 20, 2016","September 2016","No Study Results Posted","null","November 2008","disease-free survival rate at 1 year|overall survival|disease-free survival|treatment compliance|response rate to chemotherapy|pathologic complete response (CR) rate|complete resection rate|post-surgical morbidity/mortality","https://ClinicalTrials.gov/show/NCT00132639"
765,"NCT00010023","Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","Cancer","Drug: capecitabine|Drug: cisplatin","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068434|P30CA016087|NYU-9955|ROCHE-NYU-9955|NCI-G00-1908","February 2, 2001","August 2000","null","April 4, 2011","April 2011","No Study Results Posted","null","August 2007","","https://ClinicalTrials.gov/show/NCT00010023"
766,"NCT00005965","Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix","Completed","No Results Available","Cervical Cancer","Drug: bryostatin 1|Drug: cisplatin","Icahn School of Medicine at Mount Sinai|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","MTS-99-1113-ME|CDR0000067948|NCI-T99-0082","July 5, 2000","August 2000","April 2004","July 9, 2013","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005965"
767,"NCT01165021","A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Folic Acid|Drug: Vitamin B12|Drug: Dexamethasone","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13621|H3E-EW-JMIP","July 14, 2010","November 2010","April 2016","December 21, 2016","December 2016","April 23, 2014","null","July 2013","Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]|Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)]|Percentage of Participants Who Exhibit a Downward Shift in Tumor Extent From Stage IIIAN2 to Stages IIIA, II, I, or Stage 0|Overall Survival (OS)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01165021"
768,"NCT00939848","Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers","Completed","No Results Available","Biliary Tract Neoplasms","Drug: gemcitabine|Drug: cisplatin|Drug: Placebo|Drug: cisplatin|Drug: cediranib|Drug: gemcitabine","University College, London|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","124","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ABC-03 09/0193","July 14, 2009","April 2011","September 2014","October 24, 2014","October 2012","No Study Results Posted","ABC-03","September 2012","Progression free survival|• Response Rate (RECIST) • Toxicity • Survival (as part of the follow-on phase III study) • Biomarker evaluation (inc. circulating VEGF, sVEGFR-2, bFGF, LDH and CA 19-9) • Quality of Life","https://ClinicalTrials.gov/show/NCT00939848"
769,"NCT00477711","A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: cetuximab, cisplatin, capecitabine","Peking University|Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-769","May 22, 2007","March 2007","February 2009","May 17, 2015","May 2015","No Study Results Posted","EXTRA","December 2008","Tumor response rate|Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety","https://ClinicalTrials.gov/show/NCT00477711"
770,"NCT01243632","Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment","Completed","No Results Available","Malignant Pleural Mesothelioma","Drug: Prolonged 6-hr infusion of gemcitabine","Institute of Oncology Ljubljana|Ministry of Higher Education, Science and Technology, Solvenia","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","86/12/02","November 10, 2010","December 2002","June 2010","November 17, 2010","November 2010","No Study Results Posted","null","June 2010","Response rate|Safety and tolerability","https://ClinicalTrials.gov/show/NCT01243632"
771,"NCT02641093","Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Cancer","Drug: Pembrolizumab|Procedure: Surgery|Radiation: Radiation Therapy|Drug: Cisplatin","Trisha Wise-Draper|Merck Sharp & Dohme Corp.|University of Cincinnati","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCCI-HN-15-01","December 21, 2015","January 2016","July 2021","July 29, 2016","July 2016","No Study Results Posted","null","July 2018","Number of participants with treatment related adverse effects as assessed using CTCAE v4.0 of pembrolizumab when combined with radiation alone and chemoradiation|Disease free survival in resected high risk patients treated with adjuvant pembrolizumab and chemoradiation|Disease free survival in resected intermediate risk patients treated with adjuvant pembrolizumab and radiation|Tumor immune response to pembrolizumab as measured by immunohistochemistry in tumor tissue before and after treatment","https://ClinicalTrials.gov/show/NCT02641093"
772,"NCT01861496","Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours","Recruiting","No Results Available","Advanced or Refractory Solid Tumours","Drug: LiPlaCis","Oncology Venture","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LiPlaCis/P1/002|SMR-3338","May 1, 2013","April 2013","June 2018","March 2, 2017","March 2017","No Study Results Posted","LiPlaCis","May 2018","Maximum tolerated dose (MTD) and recommended dose (RD) by evaluating the safety and tolerability|Maximum Observed Plasma Concentrations of platinum (Cmax)|Concentration of platinum (Pt-DNA)|Area Under the Plasma - Time Concentration Curve (AUC)|Elimination half-life of platinum (T½)|Total body clearance of platinum (Cl)|Volume of distribution of platinum at steady state (Vss)|Therapeutic efficacy of LiPlaCis (Efficacy Endpoint)|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01861496"
773,"NCT00763646","Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","Unknown status","No Results Available","Gastric Junction Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma","Drug: Taxotere, Cisplatin, and 5-FU","McGill University","All","19 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","McG 0620|116082","September 30, 2008","April 2007","null","October 20, 2008","September 2008","No Study Results Posted","null","December 2010","To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival.","https://ClinicalTrials.gov/show/NCT00763646"
774,"NCT02395705","Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Neoplasm","Drug: cisplatin and paclitaxel","Henan Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Beijing Cancer Hospital|Hunan Province Tumor Hospital|Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","528","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Henan CH","February 26, 2015","June 2015","July 2022","April 18, 2017","April 2017","No Study Results Posted","null","July 2022","Overall survival rate|Disease free survival|assessment in perioperation-Removal rate (R0 resection rate)|assessment in perioperation-Rate of Operative Complication|assessment in perioperation-Mortality of perioperation|assessment in perioperation-Days of Hospitalization|assessment in perioperation-Thoracic Drainage|assessment in perioperation-Quantity of bleeding|assessment in perioperation-Time of operation|Quality of life|efficacy of neo-adjuvant chemotherapy--response rate|toxicities of neo-adjuvant chemotherapy|prognostic factors|predictive factors","https://ClinicalTrials.gov/show/NCT02395705"
775,"NCT00387127","Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer","Completed","Has Results","Neoplasms, Head and Neck","Drug: Lapatinib oral tablets|Drug: radiotherapy|Drug: cisplatin chemotherapy","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","EGF105884","October 10, 2006","November 2006","January 2014","May 28, 2015","February 2015","November 6, 2014","null","June 2009","Number of Participants (Par.) With Complete Response (CR), as Assessed by Independent Radiological Review|Number of Participants With CR, as Assessed by the Investigator|Progression-Free Survival (PFS), as Assessed by the Investigator|Overall Survival (OS)|Number of Participants Who Died Due to Progressive Disease|Disease-specific Survival|Number of Participants With Loco-regional Recurrence of Initial Disease|Loco-regional Control|Number of Participants With Distant Recurrence of Initial Disease|Distant Relapse|Number of Participants With Overall Response (OR), as Assessed by the Investigator|Number of Participants Positive and Negative for the Expression of Biomarkers in Tumor Tissue: Human Epidermal Growth Factor Receptor (HER)-1, HER2, HER3, HER4, P16, and Transforming Growth Factor (TGF-alpha)|Plasma Proteome Analysis|Analysis of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) From Tumor Samples|Number of Participants Negative and Positive for Human Papilloma Virus (HPV) Infection, as Determined From Tumor Samples|Number of Participants Positive and Negative for Biomarker HER1/ErbB1 Categorized in the Indicated Independent Review Panel-assessed Tumor Responses by Expression of Biomarkers From Tumor Tissue: Sensitivity Analysis - 0 Versus (1, 2, 3)|Number of Participants Positive and Negative for Biomarker HER1/ErbB1 Categorized in the Indicated Independent Review Panel-assessed Tumor Responses by Expression of Biomarkers From Tumor Tissues: Sensitivity Analysis - 0, 1, 2 Versus 3","https://ClinicalTrials.gov/show/NCT00387127"
776,"NCT00842244","Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer","Completed","Has Results","Stomach Neoplasms|Advanced Gastric Cancer","Drug: axitinib|Drug: capecitabine|Drug: cisplatin","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061055","February 11, 2009","April 2009","October 2012","October 17, 2013","October 2013","February 25, 2012","null","December 2009","Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration (Cmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin|Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Capecitabine, Capecitabine's Metabolites and Cisplatin|Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] for Axitinib|Area Under the Curve From Time Zero Extrapolated to Infinite Time [AUC (0 - ∞)] for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin|Plasma Decay Half-Life (t1/2) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin|Apparent Oral Clearance (CL/F) for Axitinib, Capecitabine and Capecitabine's Metabolites|Clearance (CL) for Cisplatin|Apparent Volume of Distribution (Vz/F) for Axitinib, Capecitabine and Capecitabine's Metabolites|Volume of Distribution (Vz) for Cisplatin|Drug Metabolizing Enzyme Genotyping|Percentage of Participants With Objective Response (OR)|Duration of Response (DR)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00842244"
777,"NCT00012012","Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer","Completed","Has Results","Cervical Cancer|Radiation Toxicity","Drug: Amifostine trihydrate|Drug: Cisplatin|Radiation: Intracavitary brachytherapy|Radiation: External beam radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","45","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0116|CDR0000068472","March 3, 2001","August 2001","June 2010","December 24, 2014","December 2014","December 24, 2014","null","September 2007","Rate of Acute Grade 3/4 Toxicity (Excluding Grade 3 Leukopenia)|Number of Patients With Acute Grade 3/4 Toxicity (Excluding Grade 3 Leukopenia)|Pelvic Tumor Control|Distant Metastases","https://ClinicalTrials.gov/show/NCT00012012"
778,"NCT00003809","Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066954|ECOG-E5397","November 1, 1999","June 1999","null","August 22, 2013","August 2013","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00003809"
779,"NCT00006464","UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: 7-hydroxystaurosporine|Drug: cisplatin","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068274|U01CA062505|P30CA033572|CHNMC-PHI-28|NCI-T99-0065","November 6, 2000","March 2001","June 2008","January 13, 2010","January 2010","No Study Results Posted","null","January 2005","","https://ClinicalTrials.gov/show/NCT00006464"
780,"NCT00651456","Mesothelioma Avastin Plus Pemetrexed-cisplatin Study","Completed","No Results Available","Mesothelioma","Drug: Standard Chemotherapy (Pemetrexed and Cisplatin)|Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab","Intergroupe Francophone de Cancerologie Thoracique|University Hospital, Caen|Groupe Francais De Pneumo-Cancerologie","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","448","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-GFPC-0701","March 29, 2008","February 2008","September 2016","September 1, 2016","September 2016","No Study Results Posted","MAPS","January 2015","% of patients with controled disease (responder and stable patients) at 6 months|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00651456"
781,"NCT00891761","A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy","Withdrawn","No Results Available","Cancer|Chemotherapy-Induced Nausea and Vomiting|Nausea and Vomiting|Solid Tumor Cancer","Drug: Dexamethasone|Drug: Dexamethasone|Drug: IV casopitant (placebo)|Drug: IV casopitant (active)|Drug: Ondansetron","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Supportive Care","112512","April 30, 2009","September 2009","July 2010","April 15, 2015","April 2015","No Study Results Posted","null","July 2010","The proportion of subjects who achieve a complete response (defined as no vomiting/retching and no rescue therapy).|The proportion of subjects who vomit/retch|The proportion of subjects who receive anti-emetic rescue medication|Maximum nausea score (to assess the severity of nausea), assessed by a Visual Analogue Scale (VAS).|The proportion of subjects reporting significant nausea, defined as a maximum nausea score of at least 25 mm on the VAS.|The proportion of subjects who achieve a complete response|The proportion of subjects reporting nausea, defined as a maximum nausea score of at least 5 mm on the VAS.|The proportion of subjects achieving complete protection, defined as complete responders who had no significant nausea.|The proportion of subjects achieving total control, defined as complete responders who had no nausea.|Time to first anti-emetic rescue medication.|Time to first emetic event.|Time to loss of complete response.|The proportion of subjects who achieve a complete response.|The impact on subjects' daily life activities, as assessed by the FLIE questionnaire.|Assessment of the safety and tolerability of casopitant through routine physical exam, routine clinical laboratory tests, clinical monitoring and AE reporting.","https://ClinicalTrials.gov/show/NCT00891761"
782,"NCT02414685","First Line TIP in Poor Prognosis TGCTs.","Recruiting","No Results Available","Germ Cell Tumor","Drug: Paclitaxel|Drug: Ifosfamide|Drug: Cisplatin","National Cancer Institute, Slovakia","Male","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCTSK003","April 8, 2015","April 2015","June 2017","July 14, 2016","July 2016","No Study Results Posted","TIP","June 2017","Complete response rate|Response rate|Progression-free survival|Number of adverse events grade III and IV|overall survival","https://ClinicalTrials.gov/show/NCT02414685"
783,"NCT01192243","Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients","Unknown status","No Results Available","Toxicity|Non-small Cell Lung Cancer","Drug: Gefitinib|Drug: Pemetrexed|Drug: Cisplatin or carboplatin","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Iressa combined with Pem/Cis","August 4, 2010","December 2009","null","September 2, 2010","September 2010","No Study Results Posted","null","December 2011","response rate|Number of Participants with Adverse Events|Progression free survival|quality of life","https://ClinicalTrials.gov/show/NCT01192243"
784,"NCT00064077","Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Drug: Topotecan Hydrochloride|Drug: Vinorelbine Tartrate","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","513","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-0204|NCI-2012-02540|CDR0000306463|U10CA027469","July 8, 2003","May 2003","null","May 27, 2015","May 2015","No Study Results Posted","null","January 2011","Quality of life as measured by the FACT-Cervical Trial Outcome of Index and the FACT-Gynecologic Oncology Group/Neurotoxicity subscale|Survival|Frequency of response|Pain, assessed by Brief Pain Inventory|Progression-free survival","https://ClinicalTrials.gov/show/NCT00064077"
785,"NCT00248495","Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","Active, not recruiting","Has Results","Lung Cancer","Drug: cisplatin|Drug: pemetrexed disodium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Roswell Park Cancer Institute","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000441025|RPCI I-31104","November 3, 2005","June 8, 2005","April 30, 2019","April 10, 2017","April 2017","April 10, 2017","null","April 29, 2011","Pathologically Complete Response|To Document Adverse Events|Overall Survival|Disease Free Survival|To Correlate Response With Markers Such as Presence or Absence of ERCC1 and DHFR, TS, DPD and GARFT|To Correlate Pre and Post Chemotherapy Effects on FDG Uptake by the Tumor on PET Scan","https://ClinicalTrials.gov/show/NCT00248495"
786,"NCT02544243","Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Vinorelbine|Drug: Gemcitabine|Drug: Cisplatin","Shandong Cancer Hospital and Institute","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ShandongCHI-05","August 22, 2015","September 2015","null","September 5, 2015","September 2015","No Study Results Posted","null","August 2017","Progression Free Survival|Overall Survival|Clinical Benefit Rate|Duration of response|Incidence of Treatment-Emergent Adverse Events","https://ClinicalTrials.gov/show/NCT02544243"
787,"NCT01714908","Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Other: Erlotinib w Concurrent Radiotherapy|Other: etoposide/cis-platin (EP) w Concurrent Radiotherapy","Jinming Yu|Roche Pharma AG|Shandong Cancer Hospital and Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ML28545","October 23, 2012","December 14, 2012","October 20, 2018","February 4, 2017","February 2017","No Study Results Posted","RECEL","August 20, 2018","Progress Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01714908"
788,"NCT01656551","MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer Stage IIIB","Drug: Gemcitabine|Drug: Pemetrexed|Drug: Cisplatin","National Cancer Institute, Naples","All","70 Years and older   (Senior)","Phase 3","231","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","MILES-4|2012-000164-25","July 23, 2012","July 2012","September 2017","March 27, 2017","March 2017","No Study Results Posted","MILES-4","June 2017","overall survival|worst grade toxicity per patient|progression free survival|changes in quality of life|objective response","https://ClinicalTrials.gov/show/NCT01656551"
789,"NCT02121990","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer","Active, not recruiting","No Results Available","Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer","Drug: Paclitaxel,|Drug: Bevacizumab|Drug: Cisplatin|Drug: Olaparib","Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","10-220","April 22, 2014","April 21, 2014","April 2018","February 8, 2017","February 2017","No Study Results Posted","null","April 2018","maximum tolerated dose (MTD)|Toxicity","https://ClinicalTrials.gov/show/NCT02121990"
790,"NCT00911820","Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer","Active, not recruiting","No Results Available","Esophageal Cancer|Gastric Cancer|Stomach Cancer","Drug: Bevacizumab|Drug: Cisplatin|Drug: Irinotecan|Device: Docetaxel","Dana-Farber Cancer Institute|Massachusetts General Hospital|SCRI Development Innovations, LLC|Texas Oncology Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","86","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","09-039","May 29, 2009","July 2009","June 2016","May 9, 2016","May 2016","No Study Results Posted","null","June 2016","To evaluate progression-free survival for each regimen (PCA versus TPCA) at 7 months.|Evaluation of overall survival for each of the regimens.|To determine response rate (per RECIST criteria) for patients with measurable disease.|Evaluation of the type and severity of toxicities associated with each of the regimens.","https://ClinicalTrials.gov/show/NCT00911820"
791,"NCT00546130","Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer","Unknown status","No Results Available","Small Cell Lung Cancer","Drug: Irinotecan hydrochloride|Drug: Cisplatin|Drug: Krestin","University of Toyama","All","20 Years to 74 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RNCLC-01","October 17, 2007","November 2007","September 2011","September 2, 2008","August 2008","No Study Results Posted","RNCLC","September 2011","Overall survival rate|Response rate, Time to treatment failure (TTF), Time to progression (TTP), Progression free survival (PFS), Severity and frequency of toxicity","https://ClinicalTrials.gov/show/NCT00546130"
792,"NCT00003896","S9912 Combination Chemo in Stage III Ovarian Cancer,","Completed","Has Results","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: cisplatin|Drug: liposomal doxorubicin|Drug: paclitaxel","Southwest Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067066|S9912|U10CA032102","November 1, 1999","September 1999","February 2008","January 2, 2013","January 2013","October 30, 2012","null","February 2008","Progression-free Survival|Overall Survival|Adverse Events","https://ClinicalTrials.gov/show/NCT00003896"
793,"NCT00085631","Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer","Terminated","Has Results","Cervical Cancer","Drug: cisplatin|Procedure: hyperthermia treatment|Radiation: brachytherapy|Radiation: external beam radiation therapy","Mark Dewhirst|National Cancer Institute (NCI)|Northwestern University|Duke University","Female","18 Years and older   (Adult, Senior)","Phase 3","101","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00005267|DUMC-4516|CDR0000370860","June 10, 2004","March 2003","June 2009","July 10, 2013","July 2013","April 10, 2013","null","November 2008","Primary Tumor Response Rate at 4-6 Weeks Post Treatment|Five-year Failure-free Survival|Five-Year Local Recurrence-Free Survival|Five-Year Overall Survival","https://ClinicalTrials.gov/show/NCT00085631"
794,"NCT03116971","Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)","Recruiting","No Results Available","Small Cell Lung Cancer","Drug: M3814|Drug: M3814 matching placebo|Drug: Cisplatin|Drug: Etoposide|Drug: M3814|Drug: Cisplatin|Drug: Etoposide","EMD Serono Research & Development Institute, Inc.|Merck KGaA|EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","MS100036-0022","March 28, 2017","April 30, 2017","January 31, 2021","May 10, 2017","May 2017","No Study Results Posted","null","September 30, 2020","Phase Ib: Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period.|Phase Ib: Determination of Recommended Phase II dose (RP2D) of Escalating Dose of M3814 in Combination With Cisplatin and Etoposide for the Phase II Part of the Study|Phase II: Progression Free Survival (PFS) as Assessed by the Investigator according to RECIST v1.1|Phase Ib: Number of Subjects with of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths|Phase Ib: Number of Subjects with Abnormal Laboratory Values, Abnormal Vital Signs and Abnormal Electrocardiograms (ECGs)|Phase Ib: Change in Eastern Cooperative Oncology Group performance status (ECOG PS)|Phase Ib: Percentage of Subjects with Objective Response (OR) According to RECIST v1.1|Phase Ib: Duration of Response (DoR) According to RECIST v1.1|Phase Ib: Percentage of Subjects With Disease Control|Phase Ib: Progression Free Survival (PFS) According to RECIST v1.1|Phase Ib: Overall Survival (OS)|Phase Ib: Area under the concentration-time curve from 0 to 4 hours (AUC 0-4), 0 to 24 hours (AUC 0-24) for M3814, Cisplatin and Etoposide|Phase Ib: Area Under the Concentration-Time Curve From Time 0 to the Last Quantifiable Concentration (AUC 0-t ) for M3814, Cisplatin and Etoposide|Phase Ib: Maximum Observed Plasma Concentration (Cmax) for M3814, Cisplatin and Etoposide|Phase Ib: Time to Reach Maximum Plasma Concentration (Tmax) for M3814, Cisplatin and Etoposide|Phase Ib: Apparent Terminal Half-life (t1/2) for M3814|Phase Ib: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of M3814|Phase Ib: Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of M3814|Phase Ib: Intravenous (IV) Clearance (CL) of Cisplatin and Etoposide|Phase Ib: Apparent Volume of Distribution Following Extravascular Administration (Vz/f) of M3814|Phase Ib: Apparent Volume of Distribution (Vz) of Cisplatin and Etoposide|Phase Ib: Terminal rate constant (λz) for M3814, Cisplatin and Etoposide|Phase Ib: Changes in Cmax for M3814 Between Day -1 and C2D1|Phase Ib: Changes in AUC for M3814 Between Day -1 and C2D1|Phase Ib: Changes in AUC for Etoposide From C1D1 to C1D2, C1D3, and C2D1 (for the first 2 dose levels), or From C1D1 to C2D1 (other dose levels)|Phase Ib: Changes in Cmax for Etoposide From C1D1 and C2D1|Phase Ib: Changes in AUC for Cisplatin From C1D1 to C1D2, C1D3, and C2D1 (for the first 2 dose levels), or From C1D1 to C2D1 (other dose levels)|Phase Ib: Changes in Cmax for Cisplatin From C1D1 and C2D1|Phase II: Overall Survival (OS)|Phase II: Percentage of Subjects with Objective Response (OR) According to RECIST v1.1|Phase II: Duration of Response (DoR) According to RECIST v1.1|Phase II: Percentage of Subjects With Disease Control|Phase II: Percentage of Subjects Who Received Prophylactic Cranial Irradiation (PCI) and/or Thorax Irradiation After 6 Cycles of Treatment|Phase II: Tumor shrinkage From Baseline in target lesions|Phase II: Number of subjects with of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Deaths|Phase II: Number of Subjects with Abnormal Laboratory Values, Abnormal Vital Signs and Abnormal Electrocardiograms (ECGs)|Phase II: Change in Eastern Cooperative Oncology Group performance status (ECOG PS)|Phase II: Primary Health-Related Quality of Life (HRQoL) Based on Time to Definitive Deterioration (TUDD) as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)|Phase II: Primary HRQoL based on TUDD Assessed Using EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)|Phase II: Primary HRQoL based on TUDD Assessed Using European Quality of Life 5- dimensions questionnaire (EQ-5D)|Phase II: Area under the concentration-time curve from 0 to 24 hours (AUC 0-24) for M3814, Cisplatin and Etoposide|Phase II: Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-t ) for M3814, Cisplatin and Etoposide|Phase II: Maximum Observed Plasma Concentration (Cmax) for M3814, Cisplatin and Etoposide|Phase II: Time to Reach Maximum Plasma Concentration (Tmax) for M3814, Cisplatin and Etoposide|Phase II: Apparent Terminal Half-life (t1/2) for M3814|Phase II: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of M3814|Phase II: Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of M3814|Phase II: Intravenous (IV) Clearance (CL) of Cisplatin and Etoposide|Phase II: Apparent Volume of Distribution Following Extravascular Administration (Vz/f) of M3814|Phase II: Apparent Volume of Distribution (Vz) of Cisplatin and Etoposide","https://ClinicalTrials.gov/show/NCT03116971"
795,"NCT02677727","Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor","Recruiting","No Results Available","Testicular Germ Cell Tumor","Other: EORTC QLQ-CIPN20","Costantine Albany|Mayo Clinic|Indiana University","Male","15 Years and older   (Child, Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IUSCC-0502","February 5, 2016","July 1, 2015","December 31, 2019","January 27, 2017","January 2017","No Study Results Posted","null","December 31, 2018","Incidence of neuropathy|Change in neuropathy","https://ClinicalTrials.gov/show/NCT02677727"
796,"NCT01936376","A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers","Unknown status","No Results Available","Head and Neck Cancer","","Foundation for the National Institutes of Health|University of Southern California|University of Minnesota - Clinical and Translational Science Institute|M.D. Anderson Cancer Center|Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen|AstraZeneca|Eli Lilly and Company|Johnson & Johnson|Merck Sharp & Dohme Corp.|Pfizer|Critical Path Institute - Predictive Safety Testing Consortium","All","18 Years and older   (Adult, Senior)","","150","Other|NIH|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","Kidney Safety - Cisplatin","August 29, 2013","September 2012","June 2015","January 23, 2015","July 2014","No Study Results Posted","null","June 2015","biomarker change from baseline","https://ClinicalTrials.gov/show/NCT01936376"
797,"NCT02709720","Locally Advanced Trial of Tri-weekly Metronomic Oral Vinorelbine and Cisplatin as Induction Therapy and Subsequent Concomitance With Radiation Therapy in Patients With Unresectable Non Small Cell Lung Cancer (NSCLC)","Recruiting","No Results Available","Lung Cancer","Drug: Vinorelbine|Drug: Cisplatin|Drug: Vinorelbine|Drug: Cisplatin|Radiation: Radiotherapy","Spanish Lung Cancer Group","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","67","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GECP 15/02_NORA","February 2, 2016","April 2016","April 2021","October 19, 2016","October 2016","No Study Results Posted","NORA","April 2020","Efficacy (according to disease free survival of patient)|Response Rate|Overall Survival|Number of participants with treatment-related adverse events as assessed by common toxicity criteria (CTCAE) v4.0","https://ClinicalTrials.gov/show/NCT02709720"
798,"NCT00681967","Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Gefitinib|Drug: Gefitinib","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0525","May 20, 2008","February 2004","October 2009","September 21, 2010","September 2010","No Study Results Posted","IRESSA&H&N","October 2009","To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa|Both cohorts overall survival (OS) local control (LC) rate at six months and at one year|Cohort 1 only time-to-recurrence (TTR)|Cohort 2 only time-to-progression (TTP). Complete Response (CR) rate time to treatment failure (TTF)","https://ClinicalTrials.gov/show/NCT00681967"
799,"NCT02723838","Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder","Withdrawn","No Results Available","Muscle-invasive Transitional Cell Carcinoma of the Bladder","Biological: REOLYSIN®|Drug: Gemcitabine|Drug: Cisplatin","Oncolytics Biotech","All","18 Years and older   (Adult, Senior)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","REO 023","March 24, 2016","February 28, 2017","February 28, 2018","March 3, 2017","March 2017","No Study Results Posted","null","September 30, 2017","Incidence of Treatment-Emergent Adverse Events|Pre- and post-treatment biopsies will be evaluated for tumor viability, percentage of necrosis, reovirus replication and tumor infiltration of immune cells and expression of PD-1 and PD-L1|Time to Treatment Failure (TTF)|Disease Free Survival (DFS)","https://ClinicalTrials.gov/show/NCT02723838"
800,"NCT02973386","Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients","Recruiting","No Results Available","Local Advanced High Risk Nasopharyngeal Carcinoma","Drug: IMRT combine with cisplatin concurrent chemotherapy|Drug: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","278","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CCRT-AC-HRDM-NPC","November 22, 2016","January 2017","December 2024","January 19, 2017","January 2017","No Study Results Posted","null","December 2019","Five-year Distance Metastasis Free Survival|Five-year Local- Regional failure free survial|Five-year overall survival rate|Acute Toxicity|Late Toxicity","https://ClinicalTrials.gov/show/NCT02973386"
801,"NCT00102505","A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-Small-Cell Lung Carcinoma|Carcinoma, Bronchogenic","Drug: Motexafin Gadolinium Injection","Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","PCYC-0220","January 29, 2005","November 2004","null","April 2, 2009","April 2009","No Study Results Posted","null","null","Dose limiting toxicities of MGd when administered concurrently with docetaxel and cisplatin|Maximum tolerated dose of MGd when administered concurrently with docetaxel and cisplatin|Tumor response","https://ClinicalTrials.gov/show/NCT00102505"
802,"NCT00535509","Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Radiation: Cisplatin-Docetaxel ± Trastuzumab|Other: Cisplatin-Docetaxel ± Trastuzumab|Drug: Cisplatin-Docetaxel ± Trastuzumab","King Faisal Specialist Hospital & Research Center","Female","Child, Adult, Senior","","285","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC #2061-048","September 24, 2007","June 2007","June 2013","December 16, 2015","December 2015","No Study Results Posted","null","June 2013","Efficacy","https://ClinicalTrials.gov/show/NCT00535509"
803,"NCT01736410","A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer","Completed","No Results Available","HER 2 Positive Advanced Gastric Cancer","Drug: Trastuzumab, TS ONE, Cisplatin","National Cancer Centre, Singapore","All","21 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC0906","November 26, 2012","May 2010","May 2013","June 14, 2013","June 2013","No Study Results Posted","null","April 2013","Overall Response Rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Time to Treatment Failure (TTF)","https://ClinicalTrials.gov/show/NCT01736410"
804,"NCT02639650","Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor","Not yet recruiting","No Results Available","Gestational Trophoblastic Neoplasms","Drug: Etoposide|Drug: actinomycin D|Drug: methotrexate|Drug: vincristine|Drug: cyclophosphamide|Drug: Paclitaxel|Drug: Cisplatin|Drug: Carboplatin","Weiguo Lv|First Affiliated Hospital of Zhongshan Medical University|Shandong University|Huazhong University of Science and Technology|Women's Hospital School Of Medicine Zhejiang University","Female","up to 60 Years   (Child, Adult)","Phase 3","214","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","ZJHGTN1211","December 13, 2015","March 2016","March 2021","December 20, 2015","December 2015","No Study Results Posted","null","March 2019","complete remission rate in firstline treatment|Severity of adverse events as assessed by the WHO|Overall Survival Rate (OR)|Ovarian functional evaluation|The pregnancy rate","https://ClinicalTrials.gov/show/NCT02639650"
805,"NCT01042522","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors","Recruiting","No Results Available","Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor","Biological: Bleomycin Sulfate|Drug: Carboplatin|Drug: Cisplatin|Drug: Etoposide Phosphate|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","128","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GOG-0264|NCI-2011-02000|CDR0000662814|U10CA180868|U10CA027469","January 1, 2010","February 2010","null","May 2, 2017","May 2017","No Study Results Posted","null","January 2024","Progression-free survival (PFS)|Overall survival (OS)|Tumor response rate","https://ClinicalTrials.gov/show/NCT01042522"
806,"NCT01025349","Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: Bevacizumab, docetaxel, cisplatin","Taipei Medical University Hospital","Female","18 Years to 65 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TMUH-01-09-09","December 1, 2009","January 2005","September 2009","December 2, 2009","December 2009","No Study Results Posted","null","September 2009","Response Rate|Time to Progression(TTP), Progression free survival, overall survival, safety, Quality of Life","https://ClinicalTrials.gov/show/NCT01025349"
807,"NCT00093665","Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","Aichi Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","AICHI-UHA-HN03-01|CDR0000389425","October 6, 2004","November 2003","null","May 14, 2013","October 2006","No Study Results Posted","null","null","Progression-free survival at 3 years|Overall survival|Response rate|Treatment completion rate|Incidence of adverse effects","https://ClinicalTrials.gov/show/NCT00093665"
808,"NCT01461772","Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Radiation: Radiation therapy|Drug: Carboplatin|Drug: Cisplatin","Asan Medical Center|Boryung Pharmaceutical Co., Ltd","Female","20 Years to 75 Years   (Adult, Senior)","Phase 3","154","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","CCRTCICA-CXCA","October 26, 2011","December 2009","November 2015","October 27, 2011","October 2011","No Study Results Posted","null","November 2013","Response rate|Number of patients with adverse events as a measure of safety and tolerability|Disease-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT01461772"
809,"NCT01192633","Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma","Unknown status","No Results Available","Sarcoma|Chemotherapy","Drug: GVP","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","GVP-SAR","March 25, 2010","January 2009","January 2011","August 31, 2010","August 2010","No Study Results Posted","GVPS","January 2011","Progression-free Survival(Progression-free survival was evaluated for the period from the date of first treatment with this regimen to the date when disease progression was first observed or death occurred.)|Response Rate|Overall Survival|Side Effects","https://ClinicalTrials.gov/show/NCT01192633"
810,"NCT02985203","Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer","Recruiting","No Results Available","Lung Neoplasm Malignant","Drug: Vinorelbine Oral","Guangdong Association of Clinical Trials","All","18 Years and older   (Adult, Senior)","Phase 2","146","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CTONG 1512","November 29, 2016","November 2016","November 2018","February 23, 2017","February 2017","No Study Results Posted","null","April 2018","Disease control rate during maintenance|Response rate during maintenance|Duration of response|progression-free survival","https://ClinicalTrials.gov/show/NCT02985203"
811,"NCT01138137","N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer","Withdrawn","No Results Available","Ovarian Carcinoma, Stage 3 or 4|Epithelial Ovarian Carcinoma|Primary Peritoneal Carcinoma","Drug: Paclitaxel|Drug: N-acetylcysteine|Drug: Cisplatin","OHSU Knight Cancer Institute","Female","18 Years to 75 Years   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00004229|4229|SOL-08005-L|OHSU-4229","June 3, 2010","June 2010","December 2014","April 19, 2017","April 2017","No Study Results Posted","null","December 2014","To determine the MTD and assess the toxicity of IV NAC|To describe tumor response|To describe the incidence and severity of nephrotoxicity|To describe the incidence and severity of hearing loss|To describe the incidence and severity of peripheral and autonomic neuropathy","https://ClinicalTrials.gov/show/NCT01138137"
812,"NCT00293085","An Open, Randomized, Multicentre, Phase II Pilot Study","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Docetaxel|Drug: Docetaxel","Central European Cooperative Oncology Group","All","19 Years to 70 Years   (Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CECOG/ NSCLC 2.2.001","February 16, 2006","December 2001","September 2003","June 22, 2011","June 2011","No Study Results Posted","null","null","to compare the effect on disease free survival of adjuvant docetaxel and cisplatin in patients with completely resected stage I-II non-small cell lung cancer versus observation only|to determine the impact on overall survival of adjuvant docetaxel and cisplatin.|to characterise and quantitate toxicity related to this treatment regimen.|to compare quality of life of patients on both treatment arms.","https://ClinicalTrials.gov/show/NCT00293085"
813,"NCT00002717","Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","324","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064554|GOG-0162","November 1, 1999","March 1996","null","May 24, 2013","January 2010","No Study Results Posted","null","October 2007","","https://ClinicalTrials.gov/show/NCT00002717"
814,"NCT00109954","Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Liver Cancer","Drug: cisplatin|Radiation: brachytherapy|Radiation: yttrium Y 90 glass microspheres","University of Pittsburgh|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","120","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","PCI-04128|CDR0000425333|PCI-IRB-0501021","May 3, 2005","February 2005","December 2005","January 15, 2016","March 2015","No Study Results Posted","null","December 2005","Progression-free survival as assessed by tumor progression in the treated lobe of the liver|Health-related quality of life at baseline and every 3 months|Toxicity as measured by NCI CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00109954"
815,"NCT03143153","A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin","Not yet recruiting","No Results Available","Various Advanced Cancer","Biological: Nivolumab|Biological: Ipilimumab|Drug: Cisplatin|Drug: Fluorouracil","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","939","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-648|2016-001514-20","May 4, 2017","June 1, 2017","June 1, 2021","May 23, 2017","May 2017","No Study Results Posted","CheckMate 648","May 31, 2020","Overall survival (OS)|Progression-free Survival (PFS)|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT03143153"
816,"NCT00974584","A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: GDC-0941|Drug: bevacizumab|Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Drug: pemetrexed","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GDC4628g|GO01303","September 8, 2009","October 2009","March 2015","November 1, 2016","November 2016","No Study Results Posted","null","March 2015","Number of Participants with Dose Limiting Toxicities (DLTs)|Percentage of Participants with Adverse Events (AEs)|Maximum Plasma Concentration of Paclitaxel|Maximum Plasma Concentration of Carboplatin|Maximum Plasma Concentration of Pemetrexed|Maximum Plasma Concentration of Cisplatin|Percentage of Participants with Objective Response (Complete or Partial Response), as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response, as Assessed Using RECIST\n\n\n|Progression-free Survival (PFS), as Assessed Using RECIST\n|Maximum Plasma Concentration of GDC-0941","https://ClinicalTrials.gov/show/NCT00974584"
817,"NCT00967928","Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer","Withdrawn","No Results Available","Cervical Cancer","Drug: RAD001|Drug: Cisplatin|Radiation: External Beam Whole Pelvis Radiation Therapy","Accelerated Community Oncology Research Network|Novartis Pharmaceuticals","Female","18 Years and older   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ATDTCC0801","August 27, 2009","December 2009","December 2010","February 13, 2014","February 2014","No Study Results Posted","null","December 2010","To determine the maximum tolerated dose for RAD001 as adjunct therapy to standard upfront treatment of advanced stage cervical cancer in combination with weekly cisplatin and whole pelvic external beam radiation|To determine the dose limiting toxicities for RAD001 as adjunct therapy to standard upfront treatment of advanced stage cervical cancer in combination with weekly cisplatin and whole pelvic external beam radiation|To determine the pharmacokinetics of RAD001 given as adjunct therapy to standard upfront treatment of advanced stage cervical cancer|To evaluate the pharmacogenetics of RAD001 in the specified patient population|To evaluate microvessel density pre-and post-treatment with the specified treatment regimen in the specified patient population|To evaluate potential correlations between biomarkers HIF-1a, TSP-1, P53, VEGF, and VEGFR and use of the specified treatment regimen in the specified patient population|To evaluate progression free survival in the specified patient population|To assess quality of life as indicated by the Patient Care Monitor in the specified patient population","https://ClinicalTrials.gov/show/NCT00967928"
818,"NCT00268372","S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx","Terminated","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Drug: 5-fluorouracil|Procedure: surgery|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","6","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000459847|S0427|U10CA032102","December 21, 2005","December 2005","December 2007","October 3, 2012","October 2012","No Study Results Posted","null","December 2007","Survival at 2 years|Progression-free survival by FACT-HN CTCAE v 3.0 at 2 years|Toxicity by CTCAE v 3.0 after induction chemotherapy or after chemotherapy and radiotherapy|Incidence of surgical resection|Site of relapse|Quality of life by FACT-HN week 19 after first and second registration date (arm 1)","https://ClinicalTrials.gov/show/NCT00268372"
819,"NCT02439489","Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors","Active, not recruiting","No Results Available","Solid Tumors","Drug: BKM120-CIS|Drug: BKM120-CARBO","Fondazione Michelangelo","All","18 Years and older   (Adult, Senior)","Phase 1","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FM-11-F01b","April 21, 2015","December 2012","April 2017","April 7, 2016","April 2016","No Study Results Posted","null","April 2016","Number of participants with dose limiting toxicities in each of the study dose levels","https://ClinicalTrials.gov/show/NCT02439489"
820,"NCT02324543","Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer","Recruiting","No Results Available","Metastatic Pancreatic Adenocarcinoma","Drug: Gemcitabine|Drug: Taxotere|Drug: Xeloda|Drug: Cisplatin|Drug: Irinotecan","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 76 Years   (Adult, Senior)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J14161|IRB00053208","December 19, 2014","February 2015","January 2019","November 10, 2016","November 2016","No Study Results Posted","null","January 2018","Number of participants experiencing toxicities|Maximum tolerated dose (MTD) of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer|Overall survival (OS) rate at 9 months|Response rate (RR) using RECIST 1.1 criteria|Disease control rate (DCR) using RECIST 1.1 criteria|Progression-free survival (PFS) using RECIST 1.1 criteria|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02324543"
821,"NCT00220103","Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma","Completed","No Results Available","Adenocarcinoma of Oesophagus","Drug: epirubicin, capecitabine, cisplatin|Procedure: Surgical resection","Royal Marsden NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2185","September 19, 2005","November 2002","null","December 15, 2009","December 2009","No Study Results Posted","null","null","Pathological complete response rate|Progression free survival|Overall survival|Objective response rate assessed by CT and EUS|Treatment related toxicity including peri-operative complications|Time to improvement of dysphagia|Pattern of treatment failure|To assess the value of high resolution MRI to depict response to treatment and compare it with EUS and histopathology","https://ClinicalTrials.gov/show/NCT00220103"
822,"NCT00736944","Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer","Active, not recruiting","Has Results","Squamous Cell Carcinoma of the Head and Neck","Drug: Abraxane|Drug: Cetuximab|Drug: Cetuximab|Drug: Cisplatin|Drug: 5-FU|Radiation: Radiation (Post induction)|Drug: Cisplatin|Drug: Cetuximab","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","08-0911 / 201105501","August 13, 2008","December 19, 2008","August 31, 2020","January 26, 2017","January 2017","November 18, 2013","null","August 31, 2010","Clinical Complete Response Rate at the Primary Tumor|Clinical Partial Response Rate at the Primary Tumor|Clinical Complete and Partial Response Rates to the Involved Regional Nodes|Clinical Overall Complete and Partial Response Rates|Complete and Partial Response Rates of Primary Tumor by FDG Uptake on PET Scan|Complete and Partial Response Rates of Involved Lymph Nodes by FDG Uptake on PET Scan|Radiographic Complete and Partial Response Rates of Primary Tumor as Assessed by Conventional CT Scan Using RECIST Criteria|Radiographic Complete and Partial Response Rates of Involved Lymph Nodes as Assessed by Conventional CT Scan Using RECIST Criteria|Radiographic Overall Complete and Partial Response Rates as Assessed by Conventional CT Scan Using RECIST Criteria|Correlate Primary Tumor Site Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT|Correlate Nodal Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT|Correlate Overall Tumor Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT|Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy|Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy|Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy|Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy|Adverse Events Experienced During Induction Chemotherapy in the First Ten Patients for a Pre-planned Safety Analysis|Overall Survival|Disease Free Survival|Progression-free Survival","https://ClinicalTrials.gov/show/NCT00736944"
823,"NCT01217177","A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer","Completed","No Results Available","Locally Advanced Cervical Cancer","Drug: everolimus","Novartis Pharmaceuticals|Novartis","Female","Child, Adult, Senior","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C24128","October 6, 2010","December 2011","April 2014","April 1, 2015","April 2015","No Study Results Posted","PHOENIX I","April 2014","The toxicity criteria will be evaluated according to National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 3.0.|The objective response rate will be evaluated according to clinical/gynecological examination and inconformity with the RECIST criteria (Response Evaluation Criteria in Solid Tumors, version 1.1)","https://ClinicalTrials.gov/show/NCT01217177"
824,"NCT00290966","Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer","Completed","No Results Available","Stomach Neoplasm","Drug: XRP6976","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","610","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6044|XRP6976E-325","February 9, 2006","October 1998","May 2003","April 28, 2009","April 2009","No Study Results Posted","null","null","to detect a significant increase in time to progression in favor of docetaxel plus cisplatin and 5-FU compared to cisplatin plus 5-FU. Tumor assessments (assessed with WHO criteria) had to be performed every 8 weeks until progression|Patients were to be followed until death (overall survival). Clinical and laboratory were assessed with NCIC-CTG scale, before each cycle. Quality of life and clinical benefit were assessed every 2 weeks until progression and then every 3 months.","https://ClinicalTrials.gov/show/NCT00290966"
825,"NCT00548548","A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","Completed","Has Results","Adenocarcinoma","Drug: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Placebo|Drug: 5-fluorouracil","Genentech, Inc.|Hoffmann-La Roche|Chugai Pharmaceutical","All","18 Years and older   (Adult, Senior)","Phase 3","774","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","AVF4200g|BO20904","October 23, 2007","September 2007","November 2013","February 26, 2015","February 2015","December 15, 2011","AVAGAST","November 2009","Overall Survival|Progression-free Survival|Progression-free Survival During First-line Therapy|Time to Disease Progression|Participants With a Best Overall Response of Complete or Partial Response|Duration of Response|Participants With Disease Control|Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00548548"
826,"NCT02402842","Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma","Recruiting","No Results Available","Anal Canal Carcinoma","Drug: Docetaxel, Cisplatin and 5-Fluorouracil","Centre Hospitalier Universitaire de Besancon","All","18 Years and older   (Adult, Senior)","Phase 2","66","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Epitopes-HPV02|2014-001789-81","November 27, 2014","September 2014","September 2021","February 23, 2016","January 2016","No Study Results Posted","Epitopes-HPV02","September 2018","Progression-free survival rate|Overall survival|Progression free survival|response rate|Tolerance of the DCF regimen ( Common Terminology Criteria for Adverse Events version 4.03)|quality of life related to health|HPV-specific T cell responses measured by ELISPOT assay before and after DCF treatment","https://ClinicalTrials.gov/show/NCT02402842"
827,"NCT00601692","Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: docetaxel|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","27","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","02-061|P30CA008748|MSKCC-02061|SANOFI-AVENTIS-MSKCC-02061","January 17, 2008","April 2003","December 2009","March 21, 2013","March 2013","No Study Results Posted","null","December 2009","Maximum tolerated dose of docetaxel when administered together with irinotecan hydrochloride and radiotherapy|Clinical and pathological complete response rate","https://ClinicalTrials.gov/show/NCT00601692"
828,"NCT00066391","Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer","Completed","No Results Available","Penile Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC","Male","up to 75 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-30992","August 6, 2003","June 2003","null","September 20, 2012","September 2012","No Study Results Posted","null","January 2006","Objective response rate measured by RECIST at 8 weeks after completion of study treatment|Duration of response as measured by Kaplan-Meier every 8 weeks until progression, and then every 3 months thereafter|Toxicity as measured by NCI-CTC v2.0 every 8 weeks until progression","https://ClinicalTrials.gov/show/NCT00066391"
829,"NCT01910844","Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes","Terminated","No Results Available","Metastatic Breast Cancer","Drug: Cisplatin|Drug: Cyclophosphamide","Centre Jean Perrin","Female","18 Years and older   (Adult, Senior)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CJP 4.2 - META2","May 28, 2013","July 2013","September 2016","October 10, 2016","July 2016","No Study Results Posted","META2","September 2016","Response rate of cisplatine - metronomic cyclophosphamide treatment|Disease free progression|Safety profile of cisplatin - metronomic cyclophosphamide association|Overall survival|Predictive factors to response and/or resistance treatment","https://ClinicalTrials.gov/show/NCT01910844"
830,"NCT00576914","Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: recombinant human endostatin","Chinese Academy of Sciences|Chinese Academy of Medical Sciences|Shanghai Jiao Tong University School of Medicine|Beijing Chao Yang Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","1108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006 BAI02A02[1]-01","December 18, 2007","June 2007","June 2012","March 8, 2010","March 2009","No Study Results Posted","null","June 2012","overall survival|recurrence-free survival and the toxicity and safety of the regimens","https://ClinicalTrials.gov/show/NCT00576914"
831,"NCT00966706","Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: capecitabine|Drug: cisplatin|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: gemcitabine hydrochloride","IRCCS San Raffaele","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000642240|SRSI-PACT-9|2005-002586-36","August 26, 2009","June 2005","October 2009","January 31, 2012","August 2009","No Study Results Posted","PACT-9","April 2009","Progression-free survival at 6-months|Overall survival|Response rate|Toxicity","https://ClinicalTrials.gov/show/NCT00966706"
832,"NCT00220129","Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus","Completed","No Results Available","Oesophageal Carcinoma","Drug: Epirubicin, Cisplatin, Capecitabine|Procedure: Surgical Resection","Royal Marsden NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2186","September 19, 2005","November 2002","null","December 15, 2009","December 2009","No Study Results Posted","null","null","2 year overall survival|Objective clinical response rate assessed by computed tomography (CT), endoscopic ultrasound (EUS) and endoscopic biopsy|Pattern of treatment failure|Progression free survival|Proportion of patients not achieving clinical complete response and requiring surgery after chemoradiation|Treatment related toxicity|Time to improvement of dysphagia","https://ClinicalTrials.gov/show/NCT00220129"
833,"NCT01810913","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer","Active, not recruiting","No Results Available","Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Tongue Cancer","Drug: cisplatin|Drug: docetaxel|Biological: cetuximab|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment|Radiation: intensity-modulated radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","675","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RTOG 1216|NCI-2013-00500|U10CA021661","March 12, 2013","March 2013","null","May 18, 2017","May 2017","No Study Results Posted","null","May 2020","Disease-free survival (DFS) (Phase II)|Overall survival (OS) (Phase III)|Local-regional failure (LRF)|Distant metastasis (DM)|Patterns of cancer failure (local, regional, distant)|Acute toxicity profiles during and at completion of treatment, graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0|Late toxicity profiles, graded according to the NCI CTCAE version 4.0|Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N) scores|MD Anderson Symptom Inventory - Head & Neck (MDASI-HN) scores|MD Anderson Dysphagia Inventory (MDADI) scores|EuroQol (EQ-5D) scores|Quality adjusted life year (QALY)|Translational research analysis","https://ClinicalTrials.gov/show/NCT01810913"
834,"NCT02217956","Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma","Completed","No Results Available","Ovarian Adenocarcinoma|Fallopian Tube Adenocarcinoma|Primary Peritoneal Carcinoma","Drug: Cisplatin|Drug: Bevacizumab","Gustave Roussy, Cancer Campus, Grand Paris","Female","18 Years to 65 Years   (Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-024361-51|2010/1699","August 14, 2014","June 2011","June 2015","January 25, 2016","January 2016","No Study Results Posted","CHIPASTIN","June 2015","Toxicity|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02217956"
835,"NCT00997906","Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: carboplatin,|Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Radiation: intensity-modulated radiation therapy","National Cancer Centre, Singapore","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000657121|SINGAPORE-NCC0901","October 17, 2009","September 2009","July 2023","March 28, 2016","March 2016","No Study Results Posted","null","July 2018","Overall survival at 5 years|Metastases-free survival|Disease-free survival|Tumor recurrence|Toxicity according to the Common Toxicity Criteria|Quality of life as measured by the EORTC QLQ-C30","https://ClinicalTrials.gov/show/NCT00997906"
836,"NCT01342965","A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Erlotinib|Drug: Chemotherapy","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YO25121","April 26, 2011","March 2011","April 2014","February 5, 2015","February 2015","February 5, 2015","null","July 2012","Investigator-assessed Duration of Progression-free Survival|Percentage of Responders as Assessed by the Investigator|Percentage of Participants With Disease Control|Duration of Response|Overall Survival|Safety: Incidence of Adverse Events|Quality of Life: Functional Assessment of Chronic Illness Therapy - Lung (FACIT-L) Questionnaire","https://ClinicalTrials.gov/show/NCT01342965"
837,"NCT01947062","Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma","Unknown status","No Results Available","Lung Cancer|Squamous Cell Carcinoma of the Lung|Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung","Drug: Intravenous Cisplatin & etoposide|Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide","Swami Rama Cancer Hospital and Research Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MetroCyclo1","September 10, 2013","October 2013","October 2014","September 17, 2013","September 2013","No Study Results Posted","null","June 2014","Progression free survival|Response rate","https://ClinicalTrials.gov/show/NCT01947062"
838,"NCT01069081","Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Metastasis, Neoplasm","Drug: Arm C|Drug: Arm B|Drug: Arm A","Fudan University|Istituto Superiore di Sanità","Female","18 Years and older   (Adult, Senior)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Fudan BR2010-01","February 10, 2010","August 2009","February 2012","March 4, 2015","March 2015","No Study Results Posted","null","February 2012","Time to progression|Time to treatment failure,Objective response,Overall survival,Safety","https://ClinicalTrials.gov/show/NCT01069081"
839,"NCT00447421","A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy","Terminated","Has Results","Small Cell Lung Cancer|Carcinoma, Small Cell|SCLC","Drug: pemetrexed|Drug: cisplatin|Radiation: radiation","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11089|H3E-EW-S107","March 12, 2007","February 2007","May 2008","October 24, 2009","October 2009","May 28, 2009","null","May 2008","Phase 1: Maximum Tolerated Dose|Phase 2: Overall Response Rate|Phase 1: Best Overall Response|Phase 2: Complete Response Rate|Phase 2: Time to Progressive Disease|Phase 2: Duration of Response|Phase 2: Overall Survival","https://ClinicalTrials.gov/show/NCT00447421"
840,"NCT00590967","A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy","Terminated","Has Results","Cervical Cancer","Radiation: IMRT extended field external beam radiation therapy|Radiation: Brachytherapy|Drug: Cisplatin","Washington University School of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","69","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03-0300 / 201105362","December 31, 2007","May 2003","January 2013","July 18, 2016","June 2016","June 2, 2016","null","January 2013","Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity|Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher)|Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status|Efficacy of IMRT to the Para-aortic Lymph Nodes, IMRT External Beam Radiotherapy to the Pelvis, Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by the Frequency of Distant Metastasis","https://ClinicalTrials.gov/show/NCT00590967"
841,"NCT00803062","Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer","Completed","Has Results","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma|Stage IVB Cervical Cancer","Biological: Bevacizumab|Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Topotecan Hydrochloride","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","452","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01084|CDR0000628746|GOG-0240|U10CA180868|U10CA027469","December 4, 2008","April 2009","February 2013","April 15, 2016","February 2015","December 15, 2015","null","February 2013","Overall Survival|Progression-free Survival|Tumor Response|Incidence of Adverse Events Assessed by National Cancer Institute CTCAE Version 3.0.","https://ClinicalTrials.gov/show/NCT00803062"
842,"NCT00191126","Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: gemcitabine|Drug: Cisplatin|Procedure: surgery","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","263","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3532|B9E-MC-S132","September 12, 2005","September 2000","September 2007","November 21, 2016","November 2016","No Study Results Posted","null","September 2007","Progression free survival|To compare the survival and sites of relapse in the two study arms.|Pharmacology toxicity|Response rate|Pathologic response rate of tissue samples","https://ClinicalTrials.gov/show/NCT00191126"
843,"NCT00094081","Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Neoplasms","Drug: tirapazamine (SR259075)|Drug: cisplatin|Procedure: Radiation Therapy","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","861","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC4690|SR259075","October 11, 2004","October 2002","September 2006","February 12, 2010","February 2010","No Study Results Posted","null","September 2006","Overall survival.|Time to locoregional failure.","https://ClinicalTrials.gov/show/NCT00094081"
844,"NCT00380588","Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer","Completed","Has Results","Biliary Tract Cancer","Drug: gemcitabine|Drug: cisplatin","Eli Lilly and Company","All","20 Years and older   (Adult, Senior)","Phase 2","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10298|B9E-JE-BT22","September 22, 2006","September 2006","October 2008","November 18, 2009","November 2009","October 15, 2009","null","October 2008","Percentage of Patients Alive at 1 Year (1-Year Survival Rate)|Tumor Response|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00380588"
845,"NCT00820248","Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Biological: panitumumab|Drug: cisplatin|Radiation: 3-dimensional conformal radiation therapy|Radiation: accelerated radiation therapy|Radiation: intensity-modulated radiation therapy","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HN6|CAN-NCIC-HN6|CDR0000630159","January 9, 2009","December 2008","February 2017","January 17, 2017","March 2016","No Study Results Posted","null","October 2014","Progression-free survival (PFS)|Overall survival|Local and regional PFS|Distant metastasis|Adverse events, including late radiotherapy-related adverse events as assessed by NCI CTCAE v3.0|Quality of life (QOL)|Swallowing-related (QOL)|Economic evaluation, including healthcare utilization, health utilities, and indirect costs","https://ClinicalTrials.gov/show/NCT00820248"
846,"NCT01303926","Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer","Unknown status","No Results Available","Non-squamous Nonsmall Cell Neoplasm of Lung","Drug: cisplatin pemetrexed|Drug: carboplatin paclitaxel bevacizumab","Gruppo Oncologico Italia Meridionale","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Goim 2903|2009-015807-19","January 13, 2011","January 2010","June 2012","April 9, 2012","April 2012","No Study Results Posted","ERACLE","June 2012","Difference in terms of quality of life (QOL) between treatment arms|treatment activity in terms of response rate|toxicity evaluation|Evaluation of QoL across time","https://ClinicalTrials.gov/show/NCT01303926"
847,"NCT00314678","Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer","Completed","No Results Available","Epithelial Ovarian Cancer|Primary Peritoneal Cancer","Drug: Topotecan|Drug: Cisplatin|Drug: Paclitaxel","John P. Fruehauf|GlaxoSmithKline|University of California, Irvine","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 99-25","April 12, 2006","September 2005","April 2007","December 6, 2016","December 2007","No Study Results Posted","null","null","Recurrence-Free Interval|Examine the toxicity of therapy and to develop suitable strategies for dose modification.","https://ClinicalTrials.gov/show/NCT00314678"
848,"NCT03121716","A Study to Evaluate the Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC Subjects","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Biological: SHR-1210|Drug: Gemcitabine|Drug: cis-platinum","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SHR-1210-104","April 13, 2017","April 2017","April 2018","April 17, 2017","April 2017","No Study Results Posted","null","February 2018","progression of disease","https://ClinicalTrials.gov/show/NCT03121716"
849,"NCT02964689","Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.","Recruiting","No Results Available","Advanced Non-small Cell Lung Cancer|KRAS Gene Mutation|Lung Cancer","Drug: Binimetinib|Drug: Pemetrexed|Drug: Cisplatin","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SAKK 19/16","November 14, 2016","April 12, 2017","September 2020","May 1, 2017","May 2017","No Study Results Posted","null","September 2019","Dose-limiting toxicities (DLTs)|Objective response (OR)|Progression-free survival (PFS)|Overall survival (OS)|Adverse events (AEs)","https://ClinicalTrials.gov/show/NCT02964689"
850,"NCT00126633","Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Biological: bevacizumab|Drug: cisplatin|Drug: gemcitabine hydrochloride","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000437858|UCSF-04451|GENENTECH-AVF2937s","August 2, 2005","April 2004","October 2008","September 13, 2012","September 2012","No Study Results Posted","null","September 2006","Time to progression|Duration of response|Overall survival|Toxicity as measured by NCI CTC version 2.0|Micrometastases for predicting time to progression and overall survival","https://ClinicalTrials.gov/show/NCT00126633"
851,"NCT02667743","Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC","Recruiting","No Results Available","Non-Small Cell Lung Cancer(NSCLC)","Drug: Paclitaxel Micelles for Injection|Drug: Paclitaxel Injection|Drug: Cisplatin","Shanghai Yizhong Biotechnology Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","468","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PM-03-2015","January 20, 2016","March 2015","December 2019","April 26, 2017","April 2017","No Study Results Posted","null","December 2018","Objective response rate|Progression-Free-Survival|Overall survival|Incidence of Adverse Events，Serious Adverse Events.|Incidence of bone marrow suppression.|The number of patients with dose adjustment.","https://ClinicalTrials.gov/show/NCT02667743"
852,"NCT00673179","Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy","Terminated","Has Results","Osteosarcoma","Drug: Doxorubicin|Drug: Cisplatin|Drug: Methotrexate|Drug: Leucovorin|Drug: Dexrazoxane|Drug: Ifosfamide|Behavioral: Questionnaire|Drug: Gemcitabine|Drug: Sargramostim|Procedure: Surgery|Drug: Mesna","M.D. Anderson Cancer Center","All","5 Years to 40 Years   (Child, Adult)","","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0404","May 6, 2008","May 2008","November 2010","September 3, 2014","September 2014","June 12, 2013","null","November 2010","Treatment Success (6 or Fewer Hospitalizations During Front-line Chemotherapy)|Quality of Life (Ped QL) Assessment","https://ClinicalTrials.gov/show/NCT00673179"
853,"NCT01833832","Surgery and Heated Chemotherapy for Adrenocortical Carcinoma","Active, not recruiting","No Results Available","Adrenocortical Carcinoma|Peritoneal Carcinomatosis","Drug: Cisplatin|Procedure: Cytoreductive surgery|Drug: sodium thiosulfate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","11","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","130114|13-C-0114","April 12, 2013","April 4, 2013","May 1, 2019","May 12, 2017","March 24, 2017","No Study Results Posted","null","December 11, 2018","To determine intraperitoneal progression free survival after optimal debulking and heated intraperitoneal chemotherapy with cisplatin in patients with intraperitoneal spread of adrenocortical cancer.|Determine morbidity of this procedure in this patient population|Determine the impact of surgery and HIPEC on QOL|Determine the impact of surgery and HIPEC on hormone excess|Examine patterns of recurrence (local versus systemic)|Perform molecular analyses to try to discern if there are intrinsic differences between tumors that recur widely throughout the peritoneal surface and those that metastasize to other organs or are confined to a local recurrence.|Determine overall survival after optimal debulking and heated intraperitoneal chemotherapy with cisplatin in patients with intraperitoneal spread of adrenocortical cancer","https://ClinicalTrials.gov/show/NCT01833832"
854,"NCT02029690","Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin","Recruiting","No Results Available","Pleural Mesothelioma Malignant Advanced|Peritoneal Mesothelioma Malignant Advanced|Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC)|Metastatic Uveal Melanoma|Hepatocellular Carcinoma (HCC)|Glioma|Sarcomatoid Cancers","Drug: ADI-PEG 20","Polaris Group","All","18 Years and older   (Adult, Senior)","Phase 1","88","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","POLARIS2013-006","December 16, 2013","April 2014","October 2018","April 3, 2017","August 2016","No Study Results Posted","TRAP","August 2018","Define initial estimates of efficacy, measured by RECIST 1.1 criteria for non-squamous NSCLC, advanced peritoneal mesothelioma, metastatic uveal melanoma, HCC, glioma and sarcomatoid cancers for ADI-PEG 20 in combination with pemetrexed and cisplatin.|Define initial estimates of efficacy, measured by modified RECIST criteria for advanced MPM|Determine the MTD of ADI-PEG 20 in combination with pemetrexed and cisplatin","https://ClinicalTrials.gov/show/NCT02029690"
855,"NCT00683514","Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer","Completed","No Results Available","NSCLC","Drug: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|Drug: Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)","Pierre Fabre Medicament|Pierre Fabre Pharma GmbH","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PM 0259 CA 304 J1","May 21, 2008","April 2005","null","October 3, 2016","October 2016","No Study Results Posted","null","September 2011","Assessments of measurable and not measurable lesions been carried out at baseline and every 2 treatment cycles by using RECIST criteria|Assessment of measurable and not measurable lesions been carried out at baseline and every 2 treatment cycles by using RECIST criteria, LCSS QOL Questionnaire and Physical Examination","https://ClinicalTrials.gov/show/NCT00683514"
856,"NCT01232452","A Study in Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: Pemetrexed|Drug: Cisplatin|Drug: Cixutumumab","Eli Lilly and Company|ImClone LLC","All","18 Years and older   (Adult, Senior)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13973|I5A-MC-JAEM","October 28, 2010","April 2011","June 2016","July 18, 2016","July 2016","No Study Results Posted","null","January 2013","Progression-free survival (PFS)|Proportion of patients achieving an objective response (objective response rate)|Overall survival|Duration of response|Time to progressive disease|Time to worsening of symptoms as measured by Lung Cancer Symptom Scale (LCSS) score|Change in tumor size","https://ClinicalTrials.gov/show/NCT01232452"
857,"NCT02200042","Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery","Active, not recruiting","No Results Available","Stage III Intrahepatic Cholangiocarcinoma|Stage IVA Intrahepatic Cholangiocarcinoma","Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Radiation: Image Guided Radiation Therapy|Other: Laboratory Biomarker Analysis","NRG Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","182","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NRG-GI001|NCI-2014-00849|PNRG-GI001_A02PAMDREVW01|PNRG-GI001_A01PAMDREVW01|U10CA180868","July 8, 2014","September 2014","null","June 17, 2016","June 2016","No Study Results Posted","null","July 2019","OS|Distant metastases|Incidence of adverse events evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Local progression|Progression-free survival (PFS) defined as local, regional, and/or distant progression, and death due to any cause|Regional progression defined as progression or existing or appearance of new nodal disease","https://ClinicalTrials.gov/show/NCT02200042"
858,"NCT00079079","Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor","Completed","No Results Available","Head and Neck Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","34","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","HN4|CAN-NCIC-HN4|LILLY-CAN-NCIC-HN4|CDR0000353487","March 8, 2004","October 2003","February 2009","November 25, 2016","March 2010","No Study Results Posted","null","September 2008","Objective response measured by RECIST criteria after accrual of 11 evaluable patients|Toxicity assessed by NCI CTC v2.0|Overall survival","https://ClinicalTrials.gov/show/NCT00079079"
859,"NCT00072527","Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: etoposide|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","78","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-30206|U10CA031946|CDR0000339871","November 4, 2003","November 2003","January 2013","July 1, 2016","July 2016","No Study Results Posted","null","June 2007","Efficacy, in terms of survival, at 2 years after initiation of study treatment|Overall response rate as measured by RECIST at completion of study treatment|Overall survival|Failure-free survival|Response rate as measured by RECIST after completion of 2 courses of induction chemotherapy|Toxicity as measured by NCI CTCAE v.30 after completion of 2 courses of chemotherapy|Tolerability as measured by chemotherapy dose-delivered dose delays after completion of study treatment","https://ClinicalTrials.gov/show/NCT00072527"
860,"NCT01379976","Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer","Terminated","No Results Available","Non Small Cell Lung Cancer","Drug: Acetylcarnitine|Drug: Placebo","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Senior)","Phase 3","107","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2010-022021-15","June 16, 2011","April 2011","October 2014","April 23, 2015","July 2014","No Study Results Posted","null","October 2014","Toxicity Free Survival|Progression-free survival|Overall survival|Neuropathic pain","https://ClinicalTrials.gov/show/NCT01379976"
861,"NCT00122460","Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)","Completed","Has Results","Head and Neck Cancer","Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Drug: Platinum (Cisplatin or Carboplatin) + 5-FU","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","442","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62202-002","July 19, 2005","December 2004","January 2011","July 11, 2014","July 2014","August 25, 2011","null","March 2007","Overall Survival Time (OS)|Progression-free Survival Time (PFS)|Best Overall Response|Disease Control|Time to Treatment Failure|Duration of Response|Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status|Quality of Life Assessment (EORTC QLQ-C30) Social Functioning|Safety - Number of Patients Experiencing Any Adverse Event","https://ClinicalTrials.gov/show/NCT00122460"
862,"NCT00942838","Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity","Withdrawn","No Results Available","Recurrent Ovarian Carcinoma","Drug: Cisplatin|Radiation: Whole Abdomen Radiotherapy","University of Utah","Female","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI28777","July 17, 2009","July 2009","April 2010","July 23, 2013","July 2013","No Study Results Posted","WAR","April 2010","Determine the maximum tolerated dose (MTD) of whole abdomen radiation in conjunction with intraperitoneal cisplatin chemotherapy in the treatment of women with small volume (< 1 cm) recurrent ovarian cancer confined to the abdominal peritoneal cavity|Quality of Life assessment","https://ClinicalTrials.gov/show/NCT00942838"
863,"NCT00087711","A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Carcinoma","Drug: pemetrexed|Drug: gemcitabine|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","1713","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2938|H3E-MC-JMDB","July 12, 2004","July 2004","March 2008","November 21, 2016","November 2016","No Study Results Posted","null","January 2007","Overall survival|Progression free survival|Time to progressive disease|Duration of response|Time to treatment failure","https://ClinicalTrials.gov/show/NCT00087711"
864,"NCT00191308","Molecular Profiling in Lung Cancer Patients","Completed","Has Results","Non-Small Cell Lung Cancer|Carcinoma","Drug: pemetrexed|Drug: cisplatin|Procedure: Radical Non-Small Cell Lung Cancer (NSCLC) surgery","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9356|H3E-PL-S051","September 12, 2005","May 2005","December 2010","October 13, 2011","October 2011","March 16, 2010","null","July 2008","High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood|Percentage of Participants With Objective Tumor Response (Response Rate)|Duration of Response|Disease Free Survival (DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00191308"
865,"NCT00415194","A Study for Patients With Head and Neck Cancer","Completed","Has Results","Head and Neck Neoplasms","Drug: pemetrexed|Drug: cisplatin|Drug: placebo","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","795","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8431|H3E-MC-JMHR","December 20, 2006","December 2006","March 2010","June 23, 2011","June 2011","March 10, 2011","null","March 2010","Overall Survival (OS)|Progression-free Survival (PFS)|Percent of Participants With a Tumor Response (Response Rate)|Duration of Response (DoR)|Time to Treatment Worsening in Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Total Score|Correlation Between Biomarkers and Treatment Effect","https://ClinicalTrials.gov/show/NCT00415194"
866,"NCT01461759","Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer","Unknown status","No Results Available","Advanced or Recurrent Endometrial Cancer","Drug: Doctaxel|Drug: Cisplatin","Asan Medical Center|Boryung Pharmaceutical Co., Ltd","Female","20 Years to 75 Years   (Adult, Senior)","Phase 2","59","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANSGOG-002","October 25, 2011","October 2011","September 2015","October 27, 2011","October 2011","No Study Results Posted","null","September 2013","Response rate|Progression-free survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Quality of life","https://ClinicalTrials.gov/show/NCT01461759"
867,"NCT00771563","Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: cisplatin + docetaxel|Drug: cisplatin + docetaxel + enoxaparin","University Hospital, Antwerp|Universiteit Antwerpen","All","18 Years and older   (Adult, Senior)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TOGA 0601|EudraCT 2007-007696-16","October 10, 2008","June 2008","October 2012","June 27, 2013","June 2013","No Study Results Posted","SYRINGES","October 2012","Progression Free Survival|Symptom control evaluated with the Lung Cancer Symptoms Scale (LCSS)|Overall Survival|Best Overall Response|Incidence of total documented thromboembolic and hemorrhagic events|Overall safety and tolerability","https://ClinicalTrials.gov/show/NCT00771563"
868,"NCT00003358","Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: chemotherapy|Drug: cisplatin|Drug: gemcitabine hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","24","Other|NIH","Interventional","Primary Purpose: Treatment","97-129|MSKCC-97129|NCI-H98-0016","November 1, 1999","January 1998","null","January 15, 2013","January 2013","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00003358"
869,"NCT00271323","Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients","Terminated","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: docetaxel and cisplatin|Radiation: radiotherapy","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_2507|EudraCT #: 2005-001276-12","December 29, 2005","May 2005","February 2007","December 21, 2009","December 2009","No Study Results Posted","null","February 2007","overall response rate|time to progression|duration of response","https://ClinicalTrials.gov/show/NCT00271323"
870,"NCT00887159","A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage","Active, not recruiting","Has Results","Extensive Stage Small Cell Lung Carcinoma|Recurrent Small Cell Lung Carcinoma","Drug: Cisplatin|Biological: Cixutumumab|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Vismodegib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","168","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01917|ECOG-E1508|CDR0000640898|E1508|U10CA180820|U10CA021115","April 22, 2009","July 2009","null","November 4, 2016","November 2016","July 1, 2015","null","September 2014","Progression-free Survival (PFS)|Response Rate|Overall Survival (OS)|PFS","https://ClinicalTrials.gov/show/NCT00887159"
871,"NCT00215501","Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies","Active, not recruiting","No Results Available","Solid Tumor","Drug: Capecitabine|Drug: 5-Fluorouracil (5-FU)|Drug: Irinotecan|Drug: Cisplatin","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Phase 1","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-042","September 14, 2005","November 2001","September 2016","July 8, 2016","July 2016","No Study Results Posted","null","September 2005","To determine dose limiting toxicity, maximum tolerated dose and recommended Phase II dose of both capecitabine and 5-fluorouracil in this patient population.|To make a preliminary assessment of the anti-tumor activity of these combinations.","https://ClinicalTrials.gov/show/NCT00215501"
872,"NCT00160030","Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer","Completed","No Results Available","Esophageal Neoplasms","Drug: FOLFOX 4|Drug: 5-FU / Cisplatin","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L_9326","September 9, 2005","September 2004","null","December 4, 2009","December 2009","No Study Results Posted","null","October 2007","Percentage of patients having completed the full treatment and Endoscopic complete response rate|Toxicity profile (NCI-CTC).","https://ClinicalTrials.gov/show/NCT00160030"
873,"NCT02036359","Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca","Unknown status","No Results Available","Non-small Cell Lung Cancer(NSCLC)","Drug: erlotinib|Drug: docetaxel","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201203009MIB","September 24, 2013","May 2012","null","January 14, 2014","January 2014","No Study Results Posted","Oncology","June 2015","Number of Adverse Event","https://ClinicalTrials.gov/show/NCT02036359"
874,"NCT01372111","Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Cisplatin|Radiation: Elective Nodal Irradiation (ENI)","Coastal Carolina Radiation Oncology|National Cancer Institute (NCI)|New Hanover Regional Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","76","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCRO11|U54CA142152-02","June 6, 2011","March 2011","null","December 8, 2015","December 2015","No Study Results Posted","null","March 2016","To assess the actuarial elective nodal failure (ENF) rate for patients with locally advanced HNSCC treated with chemoRT including very low dose elective nodal IMRT and concurrent weekly cisplatin.|To assess actuarial LRC, DFS, and OS rates.|To evaluate patients' quality of life (QOL).|To evaluate grade 3-5 toxicity by CTCAE v4.0, with special attention to swallowing function, feeding tube dependence, and xerostomia.","https://ClinicalTrials.gov/show/NCT01372111"
875,"NCT01763788","A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting","No Results Available","Squamous Non-small Cell Lung Cancer","Drug: Necitumumab|Drug: Gemcitabine|Drug: Cisplatin","Eli Lilly and Company","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","14461|I4X-JE-JFCM","January 7, 2013","May 2013","July 2017","May 18, 2017","May 2017","No Study Results Posted","null","July 2017","Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)|Phase 2: Overall Survival (OS)|Phase 2: Progression Free Survival (PFS)|Phase 1b: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])|Phase 2: Number of Participants who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR])|Phase 2: Time to Treatment Failure (TTF)|Phase 2: Change from Baseline in EuroQol 5-Dimensional Scale (EQ-5D)|Phase 2: Change from Baseline in Lung Cancer Symptom Scale (LCSS)|Phase 1b/2: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab|Phase 1b: PK: Cmax of Gemcitabine and Cisplatin|Phase 1b: PK: Area Under the Concentration Curve (AUC) of Necitumumab|Phase 1b: PK: AUC of Gemcitabine and Cisplatin|Phase 2: PK: Minimum Concentration (Ctrough) of Necitumumab|Number of Participants with Anti Necitumumab Antibodies","https://ClinicalTrials.gov/show/NCT01763788"
876,"NCT00560573","Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: CP-751,871|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A4021015","November 15, 2007","November 2007","March 2010","March 15, 2013","March 2013","January 18, 2013","null","June 2008","Number of Participants With Dose-limiting Toxicities (DLT)|Concentration at the End of Infusion (Cinf) for Figitumumab|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Figitumumab|Minimum Observed Plasma Trough Concentration (Cmin) for Figitumumab|Maximum Observed Plasma Concentration (Cmax) for Cisplatin|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Cisplatin|Maximum Observed Plasma Concentration (Cmax) for Gemcitabine|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Gemcitabine|Maximum Observed Plasma Concentration (Cmax) for Pemetrexed|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Pemetrexed|Percentage of Participants With Objective Response or Prolonged Stabilization|Progression-Free Survival (PFS)|Duration of Response (DR)|Percentage of Participants With Blood Anti-drug Antibody (ADA) Specific for Figitumumab|Serum Total Circulating Insulin-like Growth Factor (IGF-1) Levels","https://ClinicalTrials.gov/show/NCT00560573"
877,"NCT01830270","Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer","Terminated","No Results Available","Stomach Neoplasms|Oesophageal Junction Cancer|Lower Oesophagus Cancer","Drug: Epirubicin|Drug: Cisplatin|Drug: Paclitaxel|Procedure: gastric surgery","Centre Hospitalier Universitaire de Besancon","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IPEC-GC","March 8, 2012","May 2011","May 2019","February 23, 2016","January 2016","No Study Results Posted","IPEC-GC","April 2015","curative resection rate|response rate|histologic response rate|tolerance of the therapeutic association|progression free survival|global survival","https://ClinicalTrials.gov/show/NCT01830270"
878,"NCT02899299","Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients","Recruiting","No Results Available","Mesothelioma","Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-743|2016-001859-43","August 31, 2016","October 2016","September 2021","April 17, 2017","March 2017","No Study Results Posted","CheckMate743","October 2020","Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy","https://ClinicalTrials.gov/show/NCT02899299"
879,"NCT02702700","Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies","Recruiting","No Results Available","Pleural Effusion, Malignant","Drug: Cisplatin, liposomal|Drug: Verteporfin|Device: Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry","Centre Hospitalier Universitaire Vaudois","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHUV-DO-PDT-2015","January 25, 2016","January 2016","June 2019","March 3, 2016","February 2016","No Study Results Posted","PDT-lipo","December 2016","Safety of the treatment as assessed by 30-day postoperative mortality|Tolerability of the treatment as assessed by 30-day postoperative mortality|Feasibility|Acute respiratory failure rate|Dyspnea according to CTCAE v4.0|Chest pain rate according to CTCAE v4.0|Dyspnea according to Medical Research Council (MRC) chronic dyspnea scale (5-point)|Malignant effusion recurrence-free - percentage of patients without recurrent pleural effusion at 30 days|Dyspnea reduction according to CTCAE v4.0|Tumor response|Overall survival (OS)|Overall response rate (ORR) based on investigator assessment according to Response|Progression-free survival (PFS)|Duration of Response (DOR)","https://ClinicalTrials.gov/show/NCT02702700"
880,"NCT02221999","Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Tubular Breast Cancer|Mucinous Breast Cancer|Invasive Ductal Breast Cancer|Inflammatory Breast Cancer","Drug: Paclitaxel|Drug: Cisplatin|Drug: Gonadotropin-releasing hormone agonist|Drug: Letrozole","RenJi Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RenJiH-BC-002","July 14, 2014","January 2014","October 2022","March 26, 2017","March 2017","No Study Results Posted","SHPD002","July 2017","pathological complete remission rate|Number of Participants With Drug Related Treatment Adverse Events|Clinical and imaging response|regional recurrence free survival (RRFS)|local recurrence free survival (LRFS)|overall survival (OS)|distant-disease- free survival (DDFS)|rate of tumor remission （RTR）","https://ClinicalTrials.gov/show/NCT02221999"
881,"NCT01540045","Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer","Completed","Has Results","Non-Small Cell Lung Cancer|Dysgeusia|Taste Disorders|Lung Neoplasms|Small Cell Lung Carcinoma","","Instituto Nacional de Cancerologia de Mexico","All","18 Years to 90 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECPCDLC2012","January 13, 2012","December 2010","May 2012","March 6, 2015","March 2015","July 23, 2013","null","December 2011","Dysgeusia (UMAMI Perception)|Dysgeusia (UMAMI Recognition)|Dysgeusia (SWEET Perception)|Dysgeusia (SWEET Recognition)|Dysgeusia (BITTER Perception)|Dysgeusia (BITTER Recognition)|Dysgeusia (UMAMI Dilutions Dichotomized)|Dysgeusia (SWEET Dilutions Dichotomized)|Dysgeusia (BITTER Dilutions Dichotomized)|BODY COMPOSITION|Body Mass Index|Subjective Global Assessment|PROTEIN AND FAT Consumption|IRON Consumption|Quality o f Life|Change From Baseline in Albumin After 2 Cycles of Chemotherapy|Peripheral Neuropathy (QLQ-C30 Version 3, EORTC)|Global Status of Quality of Life (C-30,LC13 EORTC)","https://ClinicalTrials.gov/show/NCT01540045"
882,"NCT01124253","Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: recombinant human endostatin","Shanghai Jiao Tong University School of Medicine|Shanghai Municipal Science and Technology Commission|Shanghai Chest Hospital|Simcere Pharmaceutical Co., Ltd","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","endo001","May 6, 2010","July 2007","October 2009","May 14, 2010","October 2009","No Study Results Posted","Dengshan","October 2009","overall survival(OS)|disease-free survival(DFS)|the toxicity and safety","https://ClinicalTrials.gov/show/NCT01124253"
883,"NCT02923258","Postoperative CCRT With Docetaxel vs Cisplatin in High Risk HNSCC","Not yet recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Docetaxel|Drug: Cisplatinum|Radiation: IMRT","Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University|Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","387","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016HNRT004","October 3, 2016","November 2016","December 2022","October 18, 2016","October 2016","No Study Results Posted","null","December 2019","Disease-free survival|Acute toxicity profiles, graded according to the NCI CTCAE version 3.0|Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) during the concurrent treatment|Late toxicity profiles, graded according to the NCI CTCAE version 3.0|overall survival rate","https://ClinicalTrials.gov/show/NCT02923258"
884,"NCT00112710","Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride","University Hospital Birmingham|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","1350","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000429610|CRUK-BTOG2-LU3005|EU-20510","June 2, 2005","March 2005","null","August 23, 2013","May 2007","No Study Results Posted","null","null","Length of survival|Symptom control and quality of life as measured by the EORTC Quality of Life Questionnaire Core 30 Items and Lung Cancer supplement 13 together with EuroQol-5 domain questionnaire|Treatment response as measured by RECIST criteria|Dose intensity of chemotherapy|Ratio of treatment courses given as in-patient versus out-patient|Toxicity as measured by CTCAE v3.0|Treatment cost","https://ClinicalTrials.gov/show/NCT00112710"
885,"NCT00933816","Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy","Completed","No Results Available","Hepatocellular Carcinoma","Drug: sorafenib, cisplatin, fluorouracil","Japan Liver Oncology Group","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JLOG0901","July 1, 2009","July 2009","October 2010","November 24, 2010","November 2010","No Study Results Posted","SILIUS","October 2010","Dose limiting toxicity in phase I and Time to progression in Phase II|Phase I and II: Overall survival (OS)|Phase I and II: Progression free survival (PFS)|Phase I: Time to progression (TTP)|Phase I and II: Response Rate (RR)|Phase I and II: Adverse effect (AE)","https://ClinicalTrials.gov/show/NCT00933816"
886,"NCT00004884","Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine hydrochloride","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","96","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-40984","March 7, 2000","July 1999","null","September 20, 2012","September 2012","No Study Results Posted","null","March 2001","","https://ClinicalTrials.gov/show/NCT00004884"
887,"NCT00077311","Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Anemia|Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Neutropenia","Biological: darbepoetin alfa|Biological: pegfilgrastim|Drug: cisplatin|Drug: docetaxel|Drug: BNP7787","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-30303|U10CA031946|CDR0000350089","February 10, 2004","August 2004","April 2009","June 28, 2016","June 2016","No Study Results Posted","null","July 2006","Toxicity|Response|Survival","https://ClinicalTrials.gov/show/NCT00077311"
888,"NCT00054444","Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Drug: Topotecan Hydrochloride Liposomes|Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Cisplatin","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9913|NCI-2009-00617|CDR0000270680|U10CA027469","February 5, 2003","September 2007","null","December 29, 2014","December 2014","No Study Results Posted","null","January 2012","Incidence of patients with acute toxicity assessed by Common Terminology Criteria for Adverse Events version 3.0|Incidence of patients with chronic toxicity assessed by Common Toxicity Criteria Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (CTC RTOG/EORTC)|Site of treatment failure","https://ClinicalTrials.gov/show/NCT00054444"
889,"NCT00054626","Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer","Unknown status","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: adjuvant therapy","Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|National Cancer Institute (NCI)","All","18 Years to 74 Years   (Adult, Senior)","Phase 3","700","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000258426|ITNRC-CU02.00447ST/97|NCI-V02-1715","February 5, 2003","September 2001","null","December 17, 2013","November 2008","No Study Results Posted","null","June 2008","Overall survival at 5 years|Disease-free survival at 5 years|Local disease-free survival at 5 years|Distant disease-free survival at 5 years|Toxicity by WHO system grading after each course|Quality of life after each course and every 6 months during follow-up|Dose intensity at the end of the treatment","https://ClinicalTrials.gov/show/NCT00054626"
890,"NCT01590017","Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer","Completed","No Results Available","Cervical Cancer|Acquired Immunodeficiency Syndrome","Drug: cisplatin|Radiation: external beam radiation therapy","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","41","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AMC-081|CDR0000732629|U01CA121947","May 1, 2012","April 2014","April 20, 2017","April 26, 2017","April 2017","No Study Results Posted","null","April 20, 2017","Treatment completion rate using the binomial proportion and its 95% confidence interval|Adverse events as graded by the National Cancer Institute Common Terminology Criteria (CTC) version 4.0 will be tabulated","https://ClinicalTrials.gov/show/NCT01590017"
891,"NCT01669226","First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer","Completed","No Results Available","Bulky Stage IIIC and IV Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma","Drug: PEip (weekly) and TCiv|Drug: TCiv","Shanghai Gynecologic Oncology Group|Fudan University|Shanghai Jiao Tong University School of Medicine|Shanghai Zhongshan Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","215","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","V01-2009-03|SGOG OV1","August 8, 2012","April 2009","July 2016","December 15, 2016","December 2016","No Study Results Posted","AICE","September 2015","12-month disease non-progression rate|Progression-free survival|Completion rate of intraperitoneal chemotherapy.|Quality of life assessments|Overall Survival|adverse effects","https://ClinicalTrials.gov/show/NCT01669226"
892,"NCT00004189","Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer","Completed","No Results Available","Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: becatecarin|Drug: cisplatin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","40","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067430|UTHSC-IDD-98-34|SACI-IDD-98-34|NCI-T98-0069","January 21, 2000","October 1999","null","February 8, 2013","September 2003","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00004189"
893,"NCT00057928","S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer","Withdrawn","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel","Southwest Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000285630|S0227|U10CA032102","April 7, 2003","April 2003","July 2003","June 11, 2012","June 2012","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00057928"
894,"NCT00273546","Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer","Completed","No Results Available","Cancer","Drug: XRP6976 (Docetaxel/Taxotere)","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6043|RP-56976-V-324","January 6, 2006","May 1999","February 2006","April 28, 2009","April 2009","No Study Results Posted","null","February 2006","Overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5-FU) or the control treatment (PF: Cisplatin plus 5-FU) followed by chemoradiotherapy.|The main secondary outcome is progression free survival (PFS).|The other secondary endpoints are improvement of local symptoms;time-to-treatment failure;quality of life;|clinical complete response rate (CR) and overall response rate(PR+CR) after chemotherapy and after locoregional therapy(chemoradiotherapy);|duration of response(CR and CR+PR); toxicity.","https://ClinicalTrials.gov/show/NCT00273546"
895,"NCT00005814","Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-095|CDR0000067817|NCI-G00-1785","June 2, 2000","December 1999","October 2005","June 17, 2013","June 2013","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00005814"
896,"NCT00625664","Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer","Completed","No Results Available","Urinary Bladder Neoplasms","Drug: larotaxel (XRP9881)|Drug: gemcitabine|Drug: cisplatin","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","337","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6668|EUDRACT: 2007-001943-23","February 19, 2008","February 2008","February 2011","April 6, 2016","April 2016","No Study Results Posted","CILAB","February 2011","Overall survival defined as the time interval from the date of randomization to the date of death due to any cause|Radiological tumor assessments (CT/MRI)|Adverse Events, laboratory assessments, vital signs, Physical Examinations, and ECOG Performance Status","https://ClinicalTrials.gov/show/NCT00625664"
897,"NCT00556621","Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer","Completed","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: biopsy|Procedure: cystoscopy|Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Institut du Cancer de Montpellier - Val d'Aurelle|Groupe D'Etude des Tumeurs Uro-Genitales","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000574107|CLCC_GEMCIRAV|INCA-RECF0285|GETUG-CLCC-GEMCIRAV","November 9, 2007","June 2005","August 2009","July 29, 2015","July 2015","No Study Results Posted","GEMCIRAV","August 2009","Incidence and nature of acute and late toxicity (Phase I)|Local tumor control (Phase II)|Maximum tolerated dose and recommended phase II dose of gemcitabine hydrochloride when administered with cisplatin and radiotherapy (Phase I)|5- and 10-year survival (Phase II)|Progression-free survival (Phase II)|Quality of life (Phase II)","https://ClinicalTrials.gov/show/NCT00556621"
898,"NCT01787006","Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Drug: Cetuximab|Drug: Cisplatin, 5-FU|Radiation: Radiotherapy","University of Schleswig-Holstein","All","18 Years and older   (Adult, Senior)","Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LEOPARD II|2010-023427-18","February 5, 2013","September 2011","null","December 19, 2014","December 2014","No Study Results Posted","null","September 2016","2-year survival|1-year survival|Progression free Survival|Overall incidence of patients with adverse events|Metastasis free survival|Response rate|Rate of local tumor control|Quality of Life","https://ClinicalTrials.gov/show/NCT01787006"
899,"NCT00017459","Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: tirapazamine|Drug: vinorelbine tartrate","Sanofi|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Primary Purpose: Treatment","SANOFI-EFC3675|CDR0000068690","June 6, 2001","July 2000","February 2004","August 1, 2013","February 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017459"
900,"NCT01640860","Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","","Chonnam National University Hospital|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","","36","Other|Industry","Observational","Time Perspective: Prospective","DCESO|CUNHH","January 7, 2008","December 2007","December 2011","July 16, 2012","July 2012","No Study Results Posted","null","December 2009","Response rate|progression free survival, overall survival and adverse events","https://ClinicalTrials.gov/show/NCT01640860"
901,"NCT01655628","GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma","Unknown status","No Results Available","Stage IV Nasopharyngeal Carcinoma","Drug: GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|Drug: GC chemotherapy (Gemcitabine, Cisplatin)","Sun Yat-sen University","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20120704","July 26, 2012","July 2012","December 2014","August 1, 2012","July 2012","No Study Results Posted","null","July 2014","Complete remission (CR)|Partial remission (PR)|Stable disease (SD)|Progressive disease (PD)|overall survival time (OS)|time to progression (TTP)|progression free survival(PFS)","https://ClinicalTrials.gov/show/NCT01655628"
902,"NCT01588431","Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer","Active, not recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery","Anand B. Karnad|The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTRC 11-36|HSC20120002H","February 29, 2012","December 2011","March 2022","January 5, 2017","January 2017","No Study Results Posted","null","December 2021","Response|Biomarkers","https://ClinicalTrials.gov/show/NCT01588431"
903,"NCT02709512","Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin","Recruiting","No Results Available","Mesothelioma","Drug: ADI-PEG 20 plus Pem Cis|Other: Placebo plus Pem Cis","Polaris Group","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","386","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","POLARIS2015-003","March 5, 2016","October 2016","June 2018","January 25, 2017","November 2016","No Study Results Posted","ATOMIC","April 2018","Response Rate|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02709512"
904,"NCT00502177","Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin","Active, not recruiting","No Results Available","Peritoneal Neoplasms","Behavioral: Questionnaire","M.D. Anderson Cancer Center","All","1 Year to 18 Years   (Child, Adult)","","48","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2006-1106","July 16, 2007","June 2007","null","January 17, 2017","January 2017","No Study Results Posted","null","December 2018","PedsQL 4.0 Generic Core Scale","https://ClinicalTrials.gov/show/NCT00502177"
905,"NCT00304135","Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: oxaliplatin","Federation Francophone de Cancerologie Digestive","All","18 Years to 120 Years   (Adult, Senior)","Phase 2|Phase 3","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000470411|FFCD-9902|SANOFI-FFCD-9902|LILLY-FFCD-9902|FFCD-FNCLCC-SFRO-9902","March 15, 2006","October 2005","December 2012","May 27, 2016","December 2006","No Study Results Posted","null","December 2012","Progression rate at 3 months|Overall survival|Toxicity|Biliary complication rate","https://ClinicalTrials.gov/show/NCT00304135"
906,"NCT00695032","Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors","Suspended","No Results Available","Chemotherapeutic Agent Toxicity|Renal Toxicity|Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: ifosfamide|Other: laboratory biomarker analysis","Institut Claudius Regaud","All","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","07GENE03|ICREGAUD-TOXIPLAT|ICREGAUD-07-GENE-03|EUDRACT-2007-004251-12|INCA-RECF0479","June 7, 2008","October 2007","null","November 4, 2014","November 2014","No Study Results Posted","null","September 2012","Evolution of different biomarkers|Sensitivity, specificity, and predictive value (positive and negative) of different markers","https://ClinicalTrials.gov/show/NCT00695032"
907,"NCT01005329","Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer","Completed","Has Results","Endometrial Adenocarcinoma|Endometrial Adenosquamous Cell Carcinoma|Endometrial Clear Cell Carcinoma|Endometrial Papillary Serous Carcinoma|Stage I Endometrial Carcinoma|Stage II Endometrial Carcinoma|Stage III Endometrial Carcinoma|Stage IV Endometrial Carcinoma","Radiation: intensity-modulated radiation therapy|Drug: cisplatin|Biological: bevacizumab|Drug: carboplatin|Drug: paclitaxel","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","34","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01982|CDR0000657979|RTOG-0921|RTOG 0921|U10CA021661","October 29, 2009","November 2009","September 2013","October 9, 2014","June 2014","January 8, 2014","null","June 2012","Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events as Assessed by NCI CTCAE v4.0|Percentage of Participants With Treatment-related Adverse Events as Assessed by NCI CTCAE v4.0|Overall Survival|Disease-free Survival|Pelvic Failure|Distant Failure","https://ClinicalTrials.gov/show/NCT01005329"
908,"NCT00242762","ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: ZD1839 (IRESSA™)|Drug: Docetaxel|Drug: Cisplatin","AstraZeneca","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0504","October 20, 2005","July 2003","March 2006","January 25, 2011","January 2011","No Study Results Posted","null","March 2006","Objective tumour response (CR and PR) at study closure based on the Response Evaluation Criteria in Solid Tumours (RECIST)|PFS|Overall survival|Incidence of DLT during the first cycle of study treatment|Nature, incidence and severity of adverse events (AEs) and serious adverse events (SAEs)","https://ClinicalTrials.gov/show/NCT00242762"
909,"NCT02365766","Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects","Recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer","Drug: Pembrolizumab|Drug: Gemcitabine|Drug: Cisplatin|Procedure: Consolidative Surgery","Christopher Hoimes, M.D.|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","81","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HCRN GU14-188","February 11, 2015","May 2015","March 2018","October 4, 2016","October 2016","No Study Results Posted","null","July 2017","Phase Ib: Number of Patients with Adverse Events as a Measure of Safety and Tolerability|Phase II: Rate of Pathologic Muscle Invasive Response (PaIR)|Relapse-Free Survival (RFS)|Overall Survival (OS)|Radical Cystectomy (RC) Rate","https://ClinicalTrials.gov/show/NCT02365766"
910,"NCT00648648","A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)","Completed","No Results Available","Solid Tumors","Drug: MK1775|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin|Drug: MK1775|Drug: MK1775|Drug: MK1775|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","203","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1775-001|2007_611","March 26, 2008","February 2008","January 2014","February 3, 2015","February 2015","No Study Results Posted","null","January 2014","Number of participants with dose limiting toxicities|Change from baseline in biomarkers PHH3, CDC2, and pCDC2|Plasma concentration of MK1775|Urine concentration of MK-1775|Number of participants with objective response","https://ClinicalTrials.gov/show/NCT00648648"
911,"NCT00005087","Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: filgrastim|Drug: cisplatin|Drug: paclitaxel|Procedure: conventional surgery|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","105","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9911|CDR0000067705","April 6, 2000","March 2000","November 2013","November 14, 2015","November 2015","No Study Results Posted","null","November 2004","Overall Survival|Disease-free Survival|Grade 4-5 toxicity|Pattern of failure (local-regional, distant, new primary, death)","https://ClinicalTrials.gov/show/NCT00005087"
912,"NCT01733823","DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole","Completed","No Results Available","HNSCC,Larynx, Pharynx and Oral Cavity","Radiation: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole","Danish Head and Neck Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAHANCA 28A","November 8, 2012","January 2013","March 2016","November 22, 2016","November 2016","No Study Results Posted","null","March 2016","Compliance|Acute toxicity|Response rate","https://ClinicalTrials.gov/show/NCT01733823"
913,"NCT01928160","Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib","Withdrawn","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: pemetrexed disodium|Drug: carboplatin|Drug: cisplatin|Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC THN 1303|NCI-2013-01385|P30CA068485","August 19, 2013","June 2014","March 2015","July 9, 2015","June 2015","No Study Results Posted","null","March 2015","Progression free survival using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1|Overall survival|Objective response rate defined as partial response (PR) and complete response (CR) using RECIST version 1.1|Number of patients with each worst grade toxicity grades 3-5 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4","https://ClinicalTrials.gov/show/NCT01928160"
914,"NCT00003690","Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Breast Cancer|Melanoma (Skin)|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: alvocidib|Drug: carboplatin|Drug: cisplatin","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","48","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066793|U01CA069912|P30CA015083|950101|276-97","November 1, 1999","December 1998","September 2003","August 2, 2011","August 2011","No Study Results Posted","null","September 2003","","https://ClinicalTrials.gov/show/NCT00003690"
915,"NCT00276796","Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: paclitaxel|Drug: topotecan hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","66","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000456248|GOG-0076EE","January 12, 2006","null","null","May 24, 2013","February 2009","No Study Results Posted","null","January 2007","The frequency and duration of objective response|The frequency and severity of observed adverse effects|Progression-free survival and overall survival|Prognostic factor: prior chemoradiation","https://ClinicalTrials.gov/show/NCT00276796"
916,"NCT00098995","Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: tirapazamine|Radiation: brachytherapy|Radiation: radiation therapy","Peter MacCallum Cancer Centre, Australia|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 1","22","Other|NIH","Interventional","Primary Purpose: Treatment","PMCC-2004/354|CDR0000393978|NCI-5485","December 8, 2004","December 2004","January 2010","June 25, 2013","November 2006","No Study Results Posted","null","January 2010","Maximum tolerated dose of tirapazamine|Safety and tolerability|Failure-free survival|Overall survival|Patterns of failure for the site of first failure (local-regional, distant, or both)|Complete response rate at 12 weeks following study completion|Hypoxia by 18F-azomycinarabinoside (FAZA) PET scan at baseline and 12 wks following completion of radiotherapy correlated w/ obj. tumor response by PET- fludeoxyglucose F 18 (FDG) and local-regional failure","https://ClinicalTrials.gov/show/NCT00098995"
917,"NCT00004264","Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer","Unknown status","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Lung Cancer","Drug: amifostine trihydrate|Drug: cisplatin|Drug: docetaxel","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067523|WCCC-CO-9653|NCI-G00-1668","January 28, 2000","July 1997","null","December 3, 2013","August 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004264"
918,"NCT00246974","Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT","Completed","No Results Available","Bladder Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Gefitinib","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0063|D7913L00063","October 31, 2005","May 2003","December 2007","October 14, 2008","October 2008","No Study Results Posted","null","October 2007","Time to progression (TTP)|1. Response rate|2. Overall survival time|3. Time to treatment failure|4. Disease control rate|5. Duration of response|6. Safety and tolerability","https://ClinicalTrials.gov/show/NCT00246974"
919,"NCT00062439","S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors","Completed","Has Results","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Drug: etoposide|Procedure: conventional surgery|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|American College of Surgeons|North Central Cancer Treatment Group|NCIC Clinical Trials Group|Cancer and Leukemia Group B","All","Child, Adult, Senior","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000304777|U10CA032102|S0220","June 5, 2003","July 2003","December 2010","October 30, 2013","October 2013","November 15, 2012","null","December 2010","Feasibility of Treating Patients With Stage IIB/IIIB Pancoast Tumors With a Regimen of Cisplatin and Etoposide Plus Concurrent Radiotherapy Followed by Surgical Resection Followed by Consolidation Therapy With Docetaxel.|Adverse Events|Overall Survival|Progression-Free Survival at 3 Years|Response","https://ClinicalTrials.gov/show/NCT00062439"
920,"NCT01077427","Hyperthermia European Adjuvant Trial","Unknown status","No Results Available","Resected Pancreatic Adenocarcinoma","Device: Gemcitabine + Cisplatin + regional hyperthermia|Drug: Gemcitabine","Klinikum der Universitaet Muenchen, Grosshadern|The European Society for Hyperthermic Oncology|Ludwig-Maximilians - University of Munich","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","115-09|2008-004802-14|AIO-PAK-0111","February 25, 2010","March 2012","March 2017","July 18, 2012","July 2012","No Study Results Posted","HEAT","March 2015","Disease-free survival (DFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT01077427"
921,"NCT01346540","A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.","Active, not recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: BIBF 1120|Drug: Placebo","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (masked roles unspecified)|Primary Purpose: Treatment","1199.82|2010-019707-32","April 19, 2011","April 14, 2011","April 1, 2018","May 16, 2017","May 2017","No Study Results Posted","null","April 1, 2018","Phase I: Determination of Maximum Tolerated Dose (MTD) of BIBF 1120 added to cisplatin/gemcitabine based on the occurrence of DLTs during treatment cycle 1.|Phase II: Progression Free Survival.|Phase II: Realtionship of tumour size to clinical response.|Phase I: Evaluation of objective response.|Phase II: Overall Survival|Phase I: Evalualuation of best overall tumour response.|Phase I: Incidence of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00","https://ClinicalTrials.gov/show/NCT01346540"
922,"NCT00003580","Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Head and Neck Cancer|Oral Complications|Radiation Toxicity","Drug: amifostine trihydrate|Drug: cisplatin|Radiation: radiation therapy","University of Tennessee|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Supportive Care","UTENN-6507|CDR0000066647|ALZA-98-066-ii|NCI-V98-1472","November 1, 1999","June 1998","May 2004","June 25, 2013","May 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003580"
923,"NCT00001569","Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis","Completed","No Results Available","Carcinoma|Peritoneal Neoplasm","Drug: Cisplatin|Drug: Paclitaxel|Drug: 5-FU","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","74","NIH","Interventional","Primary Purpose: Treatment","970072|97-C-0072","November 3, 1999","January 1997","December 2002","March 3, 2008","December 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001569"
924,"NCT01809379","Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer","Completed","No Results Available","Recurrent Ovarian Cancer","Drug: chemotherapy with doxorubicin and cisplatin","Ruhr University of Bochum","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2","69","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PIPAC-OV1","March 8, 2013","February 2013","September 2014","October 12, 2014","October 2014","No Study Results Posted","null","March 2014","Clinical Benefit Rate|safety","https://ClinicalTrials.gov/show/NCT01809379"
925,"NCT02281708","Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma","Recruiting","No Results Available","Stage Ib Lung Carcinoma","Drug: vinorelbine plus cisplatin","Seoul National University Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","1012","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRO","October 30, 2014","October 2014","September 2020","October 31, 2014","October 2014","No Study Results Posted","null","September 2018","disease-free survival (DFS)|overall survival rate (OS)|quality-of-life (QoL)","https://ClinicalTrials.gov/show/NCT02281708"
926,"NCT00875615","Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery","Completed","Has Results","Liver Cancer","Drug: Carboplatin|Drug: Cisplatin|Drug: Sorafenib","University of Miami","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20080793|SCCC-2007101|BAYER-SCCC-2007101","April 2, 2009","December 2008","June 2012","December 14, 2016","December 2016","July 18, 2013","null","June 2012","Number of Subjects Experiencing Adverse Events|Number of Patients Achieving Clinical Benefit","https://ClinicalTrials.gov/show/NCT00875615"
927,"NCT00006000","SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: irinotecan hydrochloride|Drug: semaxanib","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068008|OSU-00H0033|NCI-47","July 5, 2000","August 2000","March 2004","January 30, 2013","January 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006000"
928,"NCT00229723","IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma","Completed","Has Results","Neoplasms, Squamous Cell","Drug: gefitinib (Iressa)|Drug: cisplatin|Radiation: radiotherapy|Drug: Gefitinib (Iressa)","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","224","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1839IL/0706|EudraCT number 2004-000358-21|D7919C00706","September 28, 2005","November 2004","June 2008","June 17, 2009","June 2009","June 17, 2009","null","null","Local Disease Control Rate at 2 Years|Local Disease Control Rate at 1 Year|Complete Response|Tumour Response (Complete Response + Partial Response)|Progression Free Survival|Overall Survival|Safety and Tolerability","https://ClinicalTrials.gov/show/NCT00229723"
929,"NCT00046917","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: alvocidib|Drug: irinotecan hydrochloride|Drug: cisplatin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","13","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00023|NCI-5700|CDR0000257034|MSKCC-02043|02-043A|5700|P30CA008748|R01CA067819|U01CA069856","October 3, 2002","July 2002","null","February 21, 2014","October 2011","No Study Results Posted","null","March 2010","MTD alvocidib when administered in conjunction with irinotecan hydrochloride and cisplatin|Clinical pharmacokinetics of the regimen|Therapeutic activity of alvocidib in combination with irinotecan hydrochloride in patients with advanced solid tumors|Safety and tolerability","https://ClinicalTrials.gov/show/NCT00046917"
930,"NCT00090909","Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: dexamethasone|Drug: gemcitabine hydrochloride","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000380845|UCLA-030402301|LILLY-B9E-US-X394","September 7, 2004","June 2003","null","January 7, 2013","January 2013","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00090909"
931,"NCT01931163","NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer","Recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer","Drug: Everolimus","Jenny C. Chang, MD|The Methodist Hospital System","Female","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00008952|IRB(2)#0513-0062|CRAD001 JUST213","August 26, 2013","July 2013","August 2017","September 12, 2016","September 2016","No Study Results Posted","NECTAR","August 2017","tumor response","https://ClinicalTrials.gov/show/NCT01931163"
932,"NCT00491127","Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: gemcitabine|Drug: cisplatin|Drug: dexamethasone","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6899|B9E-XM-S315","June 21, 2007","April 2003","June 2004","June 21, 2007","June 2007","No Study Results Posted","null","null","To evaluate response rate|To assess toxicity|Overall survival|Event-free survival|Progression - free survival|Disease - free survival|Duration of response","https://ClinicalTrials.gov/show/NCT00491127"
933,"NCT02997332","Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Cancers","Drug: Durvalumab|Drug: Docetaxel|Drug: Cisplatin|Drug: 5 Fluorouracil","Gustave Roussy, Cancer Campus, Grand Paris|French National Cancer Institute","All","18 Years to 74 Years   (Adult, Senior)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015-004146-25|2015/2316","December 13, 2016","March 30, 2017","December 2019","May 10, 2017","May 2017","No Study Results Posted","MEDINDUCTION","December 2018","Recommended Phase 2 dose (RP2D)|Number of Dose Limiting Toxicity (DLT)","https://ClinicalTrials.gov/show/NCT02997332"
934,"NCT01108042","TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer","Completed","No Results Available","Oropharynx Cancer|Squamous Cell Carcinoma of the Oral Cavity","Drug: Taxotere, Cisplatin, 5-Fluorouracil (5-FU)","Orlando Guntinas-Lichius, Prof. Dr. med.|University of Jena","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","71","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TISOC-1|2009-011902-41","April 14, 2010","November 2009","February 2016","May 17, 2016","May 2016","No Study Results Posted","null","January 2016","Determination of progression-free survival after 2 years|Overall survival after 2 years|Determination of the efficacy of the induction therapy|Function of swallowing according the penetration-aspiration-scale|Adverse events as a measure of safety and tolerability|Quality of life","https://ClinicalTrials.gov/show/NCT01108042"
935,"NCT00016874","3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: paclitaxel|Drug: triapine","Vion Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Industry","Interventional","Primary Purpose: Treatment","VION-CLI-015|CDR0000068591|AECM-1200012380|NCI-V01-1658","June 6, 2001","December 2000","January 2008","July 17, 2013","December 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00016874"
936,"NCT00131586","Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins","Terminated","No Results Available","Lung Cancer|Colorectal Cancer","","AHS Cancer Control Alberta","All","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SP-11-0033/ethics 17173","August 17, 2005","April 2003","February 2009","February 24, 2016","April 2012","No Study Results Posted","null","February 2009","","https://ClinicalTrials.gov/show/NCT00131586"
937,"NCT01915134","Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma","Unknown status","No Results Available","Effects of Chemotherapy|Stage IVC Nasopharyngeal Carcinoma","Drug: Recombinant Human Endostatin plus gemcitabine and cisplatin|Drug: Gemcitabine and cisplatin","Zhejiang Cancer Hospital|Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sir Run Run Shaw Hospital","All","18 Years to 65 Years   (Adult)","Phase 3","362","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejaingCH-npc-03","July 21, 2013","August 2013","December 2016","December 30, 2014","July 2013","No Study Results Posted","null","January 2016","progress free survival(PFS)|overall survival(OS)|Adverse events","https://ClinicalTrials.gov/show/NCT01915134"
938,"NCT00062374","Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction","Completed","No Results Available","Adenocarcinoma of the Stomach|Stage II Gastric Cancer|Stage III Gastric Cancer|Stage IV Gastric Cancer","Drug: irinotecan hydrochloride|Drug: cisplatin|Procedure: conventional surgery|Procedure: positron emission tomography/computed tomography|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography/computed tomography|Other: fluorine F 18 fluorothymidine","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","40","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01438|03-032|NCI-5917|CDR0000304738|MSKCC-03032","June 5, 2003","June 2003","null","June 3, 2013","June 2013","No Study Results Posted","null","June 2011","Histological response determined by a significant drop in FDG uptake correlates","https://ClinicalTrials.gov/show/NCT00062374"
939,"NCT00696007","Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer","Withdrawn","No Results Available","Transitional Cell Carcinoma","Drug: Gemcitabine and cisplatin|Other: Retrospective comparison","Lahey Clinic","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-039","June 10, 2008","April 2008","April 2010","February 16, 2012","February 2012","No Study Results Posted","null","April 2010","Neoadjuvant chemotherapy (Gemcitabine and Cisplatin) Regime (3 cycles) before Nephroureterectomy|Overall survival compared to institutional historical cohort of subjects who have undergone a nephroureterectomy alone.","https://ClinicalTrials.gov/show/NCT00696007"
940,"NCT00001499","Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung|Lung Neoplasms","Drug: paclitaxel|Drug: cisplatin|Procedure: chest radiotherapy","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","960054|96-C-0054","November 3, 1999","March 1996","June 2000","March 3, 2008","March 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001499"
941,"NCT02967497","Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type","Enrolling by invitation","No Results Available","Epithelial Growth Factor Receptor Negative Non-small Cell Lung Cancer","Drug: YQ1","Taipei Veterans General Hospital, Taiwan|National Yang Ming University","All","20 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2016-02-003C","November 16, 2016","October 2016","September 2018","December 30, 2016","July 2016","No Study Results Posted","null","September 2017","Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02967497"
942,"NCT00005996","SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors","Unknown status","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: semaxanib","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068000|UCLA-0002046|SUGEN-ND019901/SE5416.102|NCI-G00-1805","July 5, 2000","null","null","December 18, 2013","September 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005996"
943,"NCT01158248","Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Biological: panitumumab|Drug: cisplatin|Radiation: brachytherapy|Radiation: external beam radiation therapy","Medical University Innsbruck|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","50","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000675699|MUI-AGO-20|EUDRACT-2009-012453-38|EU-21043","July 7, 2010","February 2010","null","July 8, 2010","July 2010","No Study Results Posted","null","March 2013","Progression-free survival at 4 months by MRI according to RECIST criteria|Rate of skin and/or gastrointestinal toxicity CTCAE grade 4 at 4 months|Overall response rate at 4 months according to RECIST criteria|Progression-free survival at 12 and 24 months according to RECIST criteria|Overall survival at 12 and 24 months|Rate of severe adverse events according to CTCAE at 4 months|Rate of post-treatment severe adverse events according to CTCAE at 12 and 24 months|Rate of severe adverse events according to CTCAE of panitumumab monotherapy at day 14","https://ClinicalTrials.gov/show/NCT01158248"
944,"NCT00659113","S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery","Unknown status","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: tegafur-gimeracil-oteracil potassium|Other: cytology specimen collection procedure|Procedure: endoscopic biopsy","Yonsei University|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","32","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000593402|YONSEI-4-2007-0342","April 15, 2008","March 2008","null","December 3, 2011","December 2008","No Study Results Posted","null","null","Response rate|Overall survival|Progression-free survival|Toxicity|Initial squamous cell carcinoma antigen and C-reactive protein correlation with response and survival","https://ClinicalTrials.gov/show/NCT00659113"
945,"NCT00003569","Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel","Completed","No Results Available","Head and Neck Cancer|Lung Cancer|Neurotoxicity|Ovarian Cancer","Drug: cisplatin|Drug: dimesna|Drug: paclitaxel","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","2","Other|NIH","Observational","","DS 97-39|RPCI-DS-9739|BIONUM-BNP7787IV101|NCI-G98-1478","November 1, 1999","March 1998","null","January 30, 2013","January 2013","No Study Results Posted","null","June 2003","","https://ClinicalTrials.gov/show/NCT00003569"
946,"NCT00006106","ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer","Withdrawn","No Results Available","Lip and Oral Cavity Cancer|Head and Neck Cancer|Oropharyngeal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: ONYX-015","National Cancer Institute (NCI)|Dana-Farber Cancer Institute","All","18 Years to 79 Years   (Adult, Senior)","Phase 1","0","NIH|Other","Interventional","Primary Purpose: Treatment","DFCI-98320|CDR0000068117|NCI-G00-1832","August 3, 2000","July 1999","null","July 9, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006106"
947,"NCT00632853","Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide","Recruiting","No Results Available","Lung Cancer","Radiation: Standard Radiation Dose Therapy|Drug: cisplatin|Drug: etoposide|Radiation: High Radiation Dose Therapy|Drug: carboplatin","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","729","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-30610|RTOG 0538|U10CA031946|CDR0000588879|NCI-2009-00470","March 8, 2008","March 2008","null","April 19, 2017","April 2017","No Study Results Posted","null","June 2023","Overall survival time between 3 treatment arms|Complete and partial response rates|Failure-free survival","https://ClinicalTrials.gov/show/NCT00632853"
948,"NCT03113188","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors","Not yet recruiting","No Results Available","Advanced Solid Tumors","Drug: CBP501","CanBas Co. Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CBP17-01","April 9, 2017","May 2017","March 2019","April 12, 2017","April 2017","No Study Results Posted","null","December 2018","Recommended dose","https://ClinicalTrials.gov/show/NCT03113188"
949,"NCT02254278","Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer","Active, not recruiting","No Results Available","Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue Carcinoma","Drug: Cisplatin|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","NRG Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","295","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (masked role unspecified)|Primary Purpose: Treatment","NRG-HN002|NCI-2014-01279|U10CA180868","September 29, 2014","October 2014","null","March 2, 2017","March 2017","No Study Results Posted","null","May 31, 2019","Incidence of grade >= 3 modified barium swallow (MBS) detected dysphagia assessed by Common Terminology Criteria for Adverse Events [CTCAE], version [v].4|PFS|Distant metastasis|HPV DNA copy number|HPV DNA rate decline|Human papillomavirus (HPV) deoxyribonucleic acid (DNA) detection rate|Incidence of acute toxicities (>= grade 3, CTCAE v.4)|Incidence of acute toxicities (>= grade 3, CTCAE, v.4)|Incidence of late toxicities (>= grade 3, CTCAE, v.4)|Local-regional failure|Negative predictive value (NPV) of FDG-PET/CT|Overall survival|Patient-reported swallowing outcomes as assessed by the mean individual change in total MDADI score|Patient-reported swallowing outcomes as measured by the change in total MDADI score|Variance for HPV DNA","https://ClinicalTrials.gov/show/NCT02254278"
950,"NCT02461043","Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Cancer","Drug: paclitaxel; cisplatin|Radiation: radiation","Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Senior)","Phase 3","386","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-GI-046","May 30, 2015","April 2015","December 2023","August 29, 2015","August 2015","No Study Results Posted","null","December 2020","3 year relapse free survival|3 year overall survival","https://ClinicalTrials.gov/show/NCT02461043"
951,"NCT00052312","Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: paclitaxel","European Organisation for Research and Treatment of Cancer - EORTC","Female","18 Years and older   (Adult, Senior)","Phase 2","141","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-55984","January 24, 2003","September 2002","null","September 20, 2012","September 2012","No Study Results Posted","null","September 2006","Progression-free survival as measured by Kaplan Meier and RECIST at 18 months|Overall survival as measured by Kaplan Meier after each course, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter|Toxicity as measured by NCIC Common Toxicity Criteria v2.0 after each course","https://ClinicalTrials.gov/show/NCT00052312"
952,"NCT00004201","Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067444|CPMC-IRB-9027","January 21, 2000","null","August 2004","February 1, 2013","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004201"
953,"NCT02432378","Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","Recruiting","No Results Available","Cancer of Ovary|Cancer of the Ovary|Neoplasms, Ovarian|Ovarian Cancer|Ovary Cancer|Ovary Neoplasms","Biological: Cisplatin + celecoxib + DC vaccine|Biological: Cisplatin + CKM + Celecoxib + DC Vaccine","Pawel Kalinski|Hemispherx Biopharma|National Cancer Institute (NCI)|University of Pittsburgh","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","11-128|5P01CA132714","April 8, 2015","July 2015","December 2020","January 19, 2017","January 2017","No Study Results Posted","null","July 2017","Change in the number of CD8+ tumor infiltrating T cells in the peritoneal fluid.|Number of adverse events for the different combinations|Change in the number of CD3+CD8+ T cells in the peritoneal fluid.|Change in the number of effector CD8+ T cells in the peritoneal fluid.|Change in the number of CD4+ T cells in the peritoneal fluid.|Change in the number of Tregs in the peritoneal fluid.|Change in the number of myeloid-derived suppressor cells in the peritoneal fluid.","https://ClinicalTrials.gov/show/NCT02432378"
954,"NCT02006667","A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer","Completed","Has Results","Urinary Tract Cancer","Drug: trastuzumab|Drug: gemcitabine|Drug: cisplatin","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML17600","December 5, 2013","January 2001","January 2010","February 9, 2015","February 2015","July 29, 2014","null","January 2010","Progression-Free Survival (PFS) - Percentage of Participants With an Event|Progression-Free Survival - Time to Event|Percentage of Participants Who Were Progression Free at 12 and 24 Months|Overall Survival (OS) - Percentage of Participants With an Event|Overall Survival - Time to Event|Percentage of Participants Surviving at 12 and 24 Months|Percentage of Participants Achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD)","https://ClinicalTrials.gov/show/NCT02006667"
955,"NCT00006118","Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer","Unknown status","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068131|FRE-GERCOR-U99-1|EU-20030","August 3, 2000","July 1999","null","July 23, 2008","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006118"
956,"NCT00583674","Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma","Completed","No Results Available","Gastrointestinal Cancer","Drug: AMG 386 placebo|Drug: AMG 386 10mg/kg|Drug: AMG 386 3mg/kg|Drug: Cisplatin|Drug: Capecitabine|Drug: Cisplatin|Drug: Capecitabine|Drug: Cisplatin|Drug: Capecitabine","Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060439","December 20, 2007","December 2007","June 2012","April 21, 2014","April 2014","No Study Results Posted","null","March 2010","Progression Free Survival (PFS)|Safety and Tolerability|Objective Response Rate (ORR)|Duration of Response (DOR)|Overall Survival (OS)|Time to Progression (TTP)|Time to Response|Pharmacokinetics|Patient Reported Outcomes","https://ClinicalTrials.gov/show/NCT00583674"
957,"NCT00295789","Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)","Completed","No Results Available","Uterine Cervical Neoplasms","Drug: chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Carboplatin","Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group","Female","20 Years to 75 Years   (Adult, Senior)","Phase 3","253","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG0505|C000000335","February 23, 2006","February 2006","November 2011","September 20, 2016","September 2016","No Study Results Posted","null","November 2011","overall survival|progression-free survival|response rate|adverse events|severe adverse events|proportion of periods of non-hospitalization to those of the planned treatment","https://ClinicalTrials.gov/show/NCT00295789"
958,"NCT01441349","Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer","Unknown status","No Results Available","Small Cell Lung Carcinoma","Drug: IP chemotherapy|Drug: IP chemotherapy plus simvastatin","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","192","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-11-527","September 14, 2011","August 2011","January 2015","October 18, 2012","November 2011","No Study Results Posted","null","January 2015","1-year survival rate|Tumor Response rate|Progression free survival|Toxicity","https://ClinicalTrials.gov/show/NCT01441349"
959,"NCT01663285","Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)","Terminated","Has Results","Urothelial Cancer|Bladder Cancer","Drug: Neoadjuvant Cisplatin and Gemcitabine","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2012.038|HUM00062285","July 24, 2012","September 2012","January 2014","November 4, 2015","November 2015","September 11, 2014","null","January 2014","Recurrence-free Survival Time|Number of Patients With Pathologic T0/Tis/Ta N0.|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01663285"
960,"NCT00252161","A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer","Completed","No Results Available","Gastric Neoplasm","Procedure: Gastrectomy with more than D2 dissection|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy","Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group","All","20 Years to 75 Years   (Adult, Senior)","Phase 3","316","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG0501|C000000279","November 10, 2005","November 2005","April 2015","September 20, 2016","September 2016","No Study Results Posted","null","April 2015","overall survival|progression free survival (PFS)|response rate|proportion of protocol achievement|proportion of curative resection|adverse events","https://ClinicalTrials.gov/show/NCT00252161"
961,"NCT00458887","Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin","Completed","No Results Available","Ototoxicity|Unspecified Childhood Solid Tumor, Protocol Specific","Procedure: management of therapy complications","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","","301","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ACCL05C1|COG-ACCL05C1|CDR0000538247","April 9, 2007","May 2007","February 28, 2017","March 9, 2017","March 2017","No Study Results Posted","null","January 2015","Incidence of patients with ototoxicity according to Common Toxicity Criteria, American-Speech-Language-Hearing Association, and Brock's criteria|Proportion of patients who undergo assessments using ultrahigh frequency (UHF) and evoked otoacoustic emission (OAE) testing|Proportion of patients with complete standard audiometry data (excluding UHF and OAE evaluations)","https://ClinicalTrials.gov/show/NCT00458887"
962,"NCT00022191","Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)|Groupe D'Etude des Tumeurs Uro-Genitales|Institute of Cancer Research, United Kingdom|Central European Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group|German Association of Urologic Oncology|Spanish Oncology Genito-Urinary Group|Medical Research Council","All","18 Years and older   (Adult, Senior)","Phase 3","608","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-30987|CAN-NCIC-BL7|CECOG-EORTC-30987|GAUO-EORTC-30987|GETUG-EORTC-30987|SOGUG-EORTC-30987|SWOG-30987|NCRI-CRUK-BA11|MRC-BA11","August 10, 2001","May 2001","null","June 11, 2013","June 2013","No Study Results Posted","null","June 2004","","https://ClinicalTrials.gov/show/NCT00022191"
963,"NCT00489944","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma","Unknown status","No Results Available","Intraocular Melanoma","Drug: cisplatin|Drug: sunitinib malate|Drug: tamoxifen citrate|Procedure: adjuvant therapy","San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Primary Purpose: Treatment","CDR0000551559|POHA-0604","June 20, 2007","May 2007","null","January 9, 2014","July 2009","No Study Results Posted","null","December 2012","Disease-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00489944"
964,"NCT00651833","Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: S-1","Taiho Oncology, Inc.|Quintiles, Inc.|United BioSource Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPU-S1202","March 31, 2008","February 2005","July 2007","March 17, 2011","March 2011","No Study Results Posted","null","October 2006","Overall tumor response rate (ORR - the proportion of patients with objective evidence of PR or CR)|To evaluate the safety profile of S-1|To evaluate the duration of response (DR), and progression-free survival (PFS)|To investigate the relationship of S-1 plasma levels (components and metabolites) with safety and efficacy parameters","https://ClinicalTrials.gov/show/NCT00651833"
965,"NCT00137852","Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer","Active, not recruiting","No Results Available","Esophageal Cancer","Drug: Cisplatin|Drug: Irinotecan|Drug: Celecoxib|Procedure: Radiation Therapy|Procedure: Esophagectomy","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Pharmacia","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-229","August 29, 2005","January 2002","October 2016","July 8, 2016","July 2016","No Study Results Posted","null","November 2003","Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma|Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma","https://ClinicalTrials.gov/show/NCT00137852"
966,"NCT01999933","Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer","Recruiting","No Results Available","Cervical Cancer|Toxicity Due to Radiotherapy","Radiation: Radiation|Drug: cisplatin（DDP） weekly|Drug: docetaxel plus cisplatin|Drug: docetaxel plus cisplatin","Mei Shi|Fourth Military Medical University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XJFL-201309-CCPOSTOP","November 26, 2013","November 2013","November 2018","December 2, 2013","November 2013","No Study Results Posted","null","November 2016","overall survival|disease-free survival|acute adverse events|chronic adverse events","https://ClinicalTrials.gov/show/NCT01999933"
967,"NCT01275612","Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers","Recruiting","No Results Available","Solid Tumors|Acute Kidney Injury","Biological: Mesenchymal stromal cell infusion","Mario Negri Institute for Pharmacological Research","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CIS/MSC 08|2008-007485-35","January 11, 2011","November 2010","March 2018","February 6, 2017","February 2017","No Study Results Posted","CIS/MSC08","December 2017","Serum creatinine concentration.|Neutrophil gelatinase-associated lipocalin (NGAL)|N-acetyl-p- D glucosaminidase enzyme (NAG)","https://ClinicalTrials.gov/show/NCT01275612"
968,"NCT00582205","Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","Terminated","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Uterine Cancer","Drug: Paclitaxel, Cisplatin IP","University of Oklahoma","Female","18 Years to 99 Years   (Adult, Senior)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","WalkerIP","December 19, 2007","January 2006","December 2011","April 12, 2017","April 2017","April 12, 2017","null","December 2011","To Determine the Proportion of Patients Who Are Able to Receive 6 Cycles of Intraperitoneal Cisplatin Chemotherapy.|To Determine the Frequency of Dose Reductions or Dose Delays Due to Neuropathy; To Determine the Frequency of Dose Reductions or Dose Delays Due to Metabolic, Renal, or Nausea and Vomiting Toxicity","https://ClinicalTrials.gov/show/NCT00582205"
969,"NCT01622660","Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy","Terminated","No Results Available","Bladder Cancer","Drug: Gemcitabine and Pazopanib","Memorial Sloan Kettering Cancer Center|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-191","June 15, 2012","June 2012","February 2016","February 3, 2016","February 2016","No Study Results Posted","null","February 2016","progression free survival (PFS)|safety|response rate|overall survival (OS)|Correlative studies","https://ClinicalTrials.gov/show/NCT01622660"
970,"NCT00492505","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Drug: cisplatin|Drug: sorafenib tosylate|Drug: tamoxifen citrate|Procedure: adjuvant therapy","San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Primary Purpose: Treatment","CDR0000551556|POHA-0602","June 25, 2007","April 2007","null","January 9, 2014","July 2009","No Study Results Posted","null","December 2011","Relapse-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00492505"
971,"NCT00926640","A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers","Suspended","No Results Available","Carcinoma Neuroendocrine|Small Cell Lung Carcinoma|Malignant Epithelial Neoplasms","Drug: Belinostat|Drug: Cisplatin|Drug: Etoposide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","28","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090173|09-C-0173","June 20, 2009","June 17, 2009","March 1, 2018","May 12, 2017","September 26, 2016","No Study Results Posted","null","September 1, 2017","Safety and tolerability|Markers of HDAC|Tumor response|miRNA and CGH|Increased acetylation in PBMCs","https://ClinicalTrials.gov/show/NCT00926640"
972,"NCT00995293","Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial","Active, not recruiting","No Results Available","Head and Neck Neoplasms","Drug: DOCETAXEL|Drug: CISPLATIN|Drug: 5-FLUOROURACIL","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DOCET_L_02557","September 22, 2009","August 2009","December 2017","February 13, 2017","February 2017","No Study Results Posted","null","December 2017","Progression-free survival|Overall survival|Overall response rates|Duration of response|Time to treatment failure","https://ClinicalTrials.gov/show/NCT00995293"
973,"NCT00003078","Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: brachytherapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","870","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065771|GOG-0165","November 1, 1999","October 1997","null","July 8, 2013","April 2011","No Study Results Posted","null","November 2005","","https://ClinicalTrials.gov/show/NCT00003078"
974,"NCT00326378","Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: consolidation chemotherapy with Docetaxel plus cisplatin|Drug: CCRT arm without consolidation chemotherapy","Samsung Medical Center|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","434","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-08-066","May 15, 2006","October 2005","May 2015","June 3, 2015","November 2012","No Study Results Posted","null","March 2013","Progression free survival|overall survival|response rate|patterns of failure|safety","https://ClinicalTrials.gov/show/NCT00326378"
975,"NCT00490880","Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer","Completed","No Results Available","Bladder Cancer","Drug: gemcitabine|Drug: cisplatin|Procedure: radical cystectomy|Procedure: radiotherapy","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","8193|B9E-MC-S341","June 21, 2007","November 2003","August 2004","June 21, 2007","June 2007","No Study Results Posted","null","null","To evaluate efficacy|To evaluate pathological complete responses|To evaluate progression free survival|To evaluate overall survival|To evaluate time to disease progression|To evaluate safety","https://ClinicalTrials.gov/show/NCT00490880"
976,"NCT00726986","Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Terminated","Has Results","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: sorafenib tosylate","Afshin Dowlati, MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE8507|P30CA043703|CASE-8507-CC486","July 31, 2008","July 2008","July 2012","November 5, 2014","November 2014","July 8, 2014","null","July 2012","Progression-free Survival(PFS)|Median Overall Survival|Response Rate|Safety","https://ClinicalTrials.gov/show/NCT00726986"
977,"NCT01099358","Study in Advanced Solid Tumors","Completed","Has Results","Solid Tumor","Drug: Cetuximab|Drug: Cisplatin|Drug: 5 - Fluorouracil","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","13418|I4E-MC-JXBA","March 30, 2010","April 2010","May 2016","October 20, 2016","October 2016","October 20, 2016","null","October 2015","Total Cisplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞])|Cetuximab Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC τ,ss)|Total Cisplatin Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax)|Cetuximab Pharmacokinetics: Maximum Observed Plasma Concentration at Steady State (Cmax,ss)|Total Cisplatin Pharmacokinetics: Measurement of the Time After Administration When the Maximum Plasma Concentration is Reached (Tmax)|Cetuximab Pharmacokinetics: Measurement of the Time After Administration When the Maximum Plasma Concentration is Reached (Tmax)|Cetuximab Pharmacokinetics: Confirmatory Serum Concentration","https://ClinicalTrials.gov/show/NCT01099358"
978,"NCT03067181","Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors","Recruiting","No Results Available","Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma|Stage I Testicular Embryonal Carcinoma|Stage I Testicular Yolk Sac Tumor|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma|Stage II Testicular Embryonal Carcinoma|Stage II Testicular Yolk Sac Tumor|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma|Stage III Testicular Embryonal Carcinoma|Stage III Testicular Yolk Sac Tumor|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor","Other: Best Practice|Drug: Bleomycin|Drug: Carboplatin|Drug: Cisplatin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 3","1680","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AGCT1531|NCI-2017-00178","February 14, 2017","May 2017","December 2022","May 8, 2017","May 2017","No Study Results Posted","null","December 2022","EFS|Overall survival (OS)|Content validity and understandability of AYA-Hearing Screen assessed by questionnaire|Incidence of ototoxicity|Novel genetic variants associated with an increased risk of platinum-associated ototoxicity as determined by standard audiology|Utility of the 4-miRNA panel as markers diagnostic of MGCTs","https://ClinicalTrials.gov/show/NCT03067181"
979,"NCT01682031","Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy","Terminated","Has Results","Chemotherapeutic Agent Toxicity|Mucositis|Radiation Toxicity|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Xerostomia","Dietary Supplement: selenomethionine|Other: placebo|Drug: cisplatin|Radiation: radiation therapy|Procedure: quality-of-life assessment","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Supportive Care","I 107807|NCI-2009-01503","September 5, 2012","June 2009","June 2012","August 8, 2014","August 2014","June 26, 2014","null","April 2012","Incidence of >= Grade 3 Mucositis|Tumor Complete Response Rate|Relapse-free Survival (RFS)|Overall Survival|Quality of Life|Incidence of Grade 3 or 4 Treatment-related Toxicities, Including Xerostomia|CRT Dose Delivery|Plasma Cisplatin and Selenium PK and PD Markers (NZ Only)","https://ClinicalTrials.gov/show/NCT01682031"
980,"NCT00511992","Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer","Unknown status","No Results Available","Advanced Ovarian Carcinoma|Primary Peritoneal Carcinoma|Ovarian Carcinosarcoma","Drug: Avastin","University of Oklahoma|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","22","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2674","August 3, 2007","July 2007","May 2016","May 29, 2015","May 2015","No Study Results Posted","null","May 2016","Evaluating the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.|Describe toxicities associated with intraperitoneal cisplatin with intravenous paclitaxel and Avastin.","https://ClinicalTrials.gov/show/NCT00511992"
981,"NCT01057277","RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer","Terminated","Has Results","Head and Neck Cancer","Drug: RAD001(Afinitor)","howard safran|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Roger Williams Medical Center|Brown University","All","18 Years and older   (Adult, Senior)","Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG-H&N-229","December 9, 2009","December 2009","June 2011","July 8, 2015","July 2015","July 8, 2015","null","May 2011","Response","https://ClinicalTrials.gov/show/NCT01057277"
982,"NCT00620971","Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Vinorelbine|Drug: Cisplatin|Drug: Bevacizumab|Drug: Docetaxel|Drug: Gemcitabine|Drug: Bevacizumab|Drug: Docetaxel|Drug: Cisplatin|Drug: Bevacizumab","Hellenic Oncology Research Group|University Hospital of Crete","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/07.19","January 31, 2008","January 2008","April 2010","June 24, 2014","June 2014","No Study Results Posted","null","April 2010","Overall Response Rate|Time to Tumor Progression|Overall Survival|Quality of life assessment","https://ClinicalTrials.gov/show/NCT00620971"
983,"NCT01025089","Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma","Active, not recruiting","No Results Available","Thymoma|Thymic Carcinoma|Clinical Masaoka Stage II to IVA","Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide","Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|M.D. Anderson Cancer Center|City of Hope National Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-038","December 2, 2009","December 2009","December 2018","April 4, 2017","April 2017","No Study Results Posted","null","December 2018","To determine the frequency of complete pathologic response to neo-adjuvant therapy with cisplatin, doxorubicin, cyclophosphamide (CAP) and cetuximab in patients with clinical Masaoka stage II-IVa thymoma and thymic carcinomas.|To determine the toxicity (CTCAE v.3) of neo-adjuvant therapy with CAP and cetuximab|To measure the radiographic response rate to cetuximab alone after 4 weeks|To determine the radiographic response rate to CAP and cetuximab|To determine the complete resection rate (R0) after neo-adjuvant therapy with CAP and cetuximab|To correlate percentage of pathologic response to unidimensional and volumetric radiographic response","https://ClinicalTrials.gov/show/NCT01025089"
984,"NCT00055965","Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin","Unknown status","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride","The Christie NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000271903|CHNT-GEM-HOSP|EU-20245","March 6, 2003","November 2002","null","September 19, 2013","January 2009","No Study Results Posted","null","August 2006","Rate of hospitalization due to toxicity|Need for hospitalization for chemotherapy administration|Tumor response rate|Overall survival|Relief of tumor-related symptoms|Effect on Karnofsky performance status|Toxicity as measured by NCIC CTC v2.0","https://ClinicalTrials.gov/show/NCT00055965"
985,"NCT01705184","Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Nonsquamous Nonsmall Cell Neoplasm of Lung","Drug: Cisplatin|Drug: Bevacizumab|Drug: Pemetrexed","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years and older   (Adult, Senior)","Phase 2","118","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IFCT-1102|2012-002647-18","October 5, 2012","December 2012","December 2017","March 8, 2017","March 2017","No Study Results Posted","BUCiL","January 2016","Feasibility|Control rate after the 2nd sequence|Response rate after the 1st sequence|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT01705184"
986,"NCT02797977","A Phase 1 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer","Recruiting","No Results Available","Advanced Solid Tumors","Drug: SRA737, gemcitabine, cisplatin|Drug: SRA737, gemcitabine","Sierra Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SRA737-02","May 23, 2016","July 2016","null","May 5, 2017","May 2017","No Study Results Posted","null","April 2019","Number of subjects with adverse events as assessed by CTCAE 4.03|Maximum tolerated dose of SRA737 administered in combination with gemcitabine|Recommended Phase 2 dose of SRA737 in combination with gemcitabine","https://ClinicalTrials.gov/show/NCT02797977"
987,"NCT00216008","Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.","Terminated","No Results Available","Esophageal Adenocarcinomas|Adenocarcinomas of the Gastroesophageal Junction","Drug: docetaxel|Drug: cisplatin|Procedure: radiation|Procedure: surgery","H. Lee Moffitt Cancer Center and Research Institute|Aventis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-13946|USFIRB#103493|IIT 14069","September 19, 2005","July 2005","February 2007","November 21, 2013","July 2009","No Study Results Posted","null","February 2007","response rate|toxicity and tolerability of this induction strategy|time to progression|surgical complication rate","https://ClinicalTrials.gov/show/NCT00216008"
988,"NCT02526316","Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers","Active, not recruiting","No Results Available","HPV-induced Cancers","Biological: P16_37-63 peptide combined with Montanide® ISA-51 VG|Biological: P16_37-63 peptide without Montanide® ISA-51 VG","Oryx GmbH & Co. KG","All","18 Years and older   (Adult, Senior)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICORYX-2","August 10, 2015","June 2015","September 2016","April 28, 2016","April 2016","No Study Results Posted","VICORYX-2","September 2016","Immune response against peptide P16_37-63|Tumor response as assessed by CT or MRI scans according to RECIST|Case wise listing of progression-free survival|Safety of the vaccine administration as assessed by the number and severity of adverse events categorized according to CTC criteria version 4.0.|Case wise listing of overall survival","https://ClinicalTrials.gov/show/NCT02526316"
989,"NCT01177956","A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck","Completed","Has Results","Squamous Cell Carcinoma of the Head and Neck","Biological: Cetuximab|Drug: Cisplatin|Drug: 5-Fluorouracil","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","73","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR62241_055","June 2, 2010","December 2009","November 2012","August 25, 2014","August 2014","July 3, 2012","CHANGE","January 2011","Best Overall Response (BOR) Until Cut-off Date 25 January 2011|Best Overall Response (BOR) Until Cut-off Date 15 November 2012|Overall Survival (OS) Time Until Cut-off Date 15 November 2012|Progression-free Survival (PFS) Time Until Cut-off Date 25 January 2011|Progression-free Survival (PFS) Time Until Cut-off Date 15 November 2012|Time to Progression (TTP) Until Cut-off Date 25 January 2011|Time to Progression (TTP) Until Cut-off Date 15 November 2012|Duration of Response Until Cut-off Date 25 January 2011|Duration of Response Until Cut-off Date 15 November 2012","https://ClinicalTrials.gov/show/NCT01177956"
990,"NCT01711658","TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.","Recruiting","No Results Available","Non-HPV Locally Advanced Head and Neck Cancer","Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Cisplatin|Drug: placebo|Drug: Lapatinib","Radiation Therapy Oncology Group|GlaxoSmithKline|NRG Oncology|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","142","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RF-3501|LAP116153","October 16, 2012","November 2012","November 2018","December 30, 2016","December 2016","No Study Results Posted","TRYHARD","September 2017","Progression-Free survival|Distant metastasis|Adverse Events|Compliance with planned treatment|Local-regional failure|Performance Status Scale for Head & Neck Cancer.|Functional Assessment of Cancer Therapy - Head & Neck.|University of Michigan Xerostomia-Related Quality of Life Scale.|HER2, EGFR, EMT as biomarkers of response.|Overall Survival","https://ClinicalTrials.gov/show/NCT01711658"
991,"NCT01565772","Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer","Terminated","No Results Available","Non-Small Cell Lung Cancer","Radiation: Proton Beam Radiation|Drug: Cisplatin|Drug: Etoposide","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-253","March 26, 2012","March 2012","June 2015","February 12, 2016","February 2016","No Study Results Posted","null","June 2015","MTD|Downstaging and Response|Biomarkers|Tumor Control and Survival Rates","https://ClinicalTrials.gov/show/NCT01565772"
992,"NCT01616849","Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma","Completed","No Results Available","Stage IV Nasopharyngeal Carcinoma","Drug: cisplatin and 5-Fu combined with nimotuzumab","Sun Yat-sen University|Fujian Cancer Hospital|First People's Hospital of Foshan|People's Hospital of Guangxi|Guangxi Medical University|Guangzhou Medical University|Hubei Cancer Hospital|Hunan Provincial Cancer Hospital|Hangzhou Cancer Hospital|Wuhan Union Hospital, China|Tongji Hospital|Jiangxi Provincial Cancer Hospital|Cancer Hospital of Shantou University|Wuhan University|Zhejiang Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PF-N-UMNPC","May 20, 2012","May 2012","July 2015","September 19, 2015","September 2015","No Study Results Posted","null","July 2015","Objective response rate|Progression free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT01616849"
993,"NCT01912053","Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma","Active, not recruiting","No Results Available","Cholangiocarcinoma","Radiation: Therasphere® in association with Gemcitabine and Cisplatin","Center Eugene Marquis","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-EB-CHOL-Th|2012-001213-16|A121007-71","July 17, 2013","September 2013","April 2018","December 2, 2016","December 2016","No Study Results Posted","MispheC","September 2017","Radiological response rate to the treatment with the association of chemotherapy and radioembolization|Tolerance of intra-hepatic administration of Yttrium 90-labelled microspheres in association with intravenous chemotherapy with Gemcitabine and Cisplatin assessed according NCI/CTC AE version 4.|Tumor markers changes (CA19.9, CEA and AFP)|Radiological response rate by the CHOI criteria|Change in metabolic activity measured by TEP|Changes of liver volume|Tumoral and non-tumoral dosimetric assessment of the liver","https://ClinicalTrials.gov/show/NCT01912053"
994,"NCT00445861","Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery","Completed","No Results Available","Esophageal Cancer","Biological: cetuximab + docetaxel + cisplatin|Biological: Treatment level 1|Biological: Treatment level 2|Procedure: conventional surgery","Swiss Group for Clinical Cancer Research","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 75/06|EU-20702","March 7, 2007","January 2007","November 2008","June 8, 2012","June 2012","No Study Results Posted","null","November 2008","Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin|Determine the feasibility and efficacy of the study's regimen|Determine the duration of response and patterns of failure","https://ClinicalTrials.gov/show/NCT00445861"
995,"NCT02871518","Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin combine with IMRT|Drug: Cisplatin combine with IMRT","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","cycle of CCRT and NPC","July 17, 2016","August 2016","July 2021","November 8, 2016","November 2016","No Study Results Posted","null","July 2018","Progress-free survival|The shor-term toxic effects|Complete Response (CR)|Overall Survival(OS)|Locoregional Relapse-Free Survival(LRRFS)|Distant Metastasis-Free Survival (DMFS)|Cost-effectiveness analysis|The monitoring of plasma EBV DNA|Long-term toxicities","https://ClinicalTrials.gov/show/NCT02871518"
996,"NCT00045162","S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: irinotecan hydrochloride","Southwest Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Cancer and Leukemia Group B","All","18 Years and older   (Adult, Senior)","Phase 3","671","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000256908|S0124|U10CA032102","September 6, 2002","November 2002","December 2009","July 3, 2013","July 2013","April 16, 2013","null","March 2008","Overall Survival|Progression-free Survival|Confirmed and Unconfirmed Complete and Partial Responses.|Number of Patients With a Given Type and Grade of Adverse Event.","https://ClinicalTrials.gov/show/NCT00045162"
997,"NCT01839032","Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy","Completed","No Results Available","Lung Cancer","Drug: Vinorelbine cisplatin radiotherapy","Pierre Fabre Medicament","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","041316","April 5, 2013","May 2005","October 2008","April 19, 2013","April 2013","No Study Results Posted","null","October 2008","Disease controle|- duration of response (DR)","https://ClinicalTrials.gov/show/NCT01839032"
998,"NCT00213642","Tc-99m Renography and Cisplatin-induced Nephrotoxicity","Terminated","No Results Available","Cancer|Drug Toxicity|Kidney Failure","","University Hospital, Rouen|Ligue contre le cancer, France","All","18 Years to 80 Years   (Adult, Senior)","","20","Other","Observational","Time Perspective: Prospective","2000/003/HP","September 13, 2005","July 2001","August 2004","June 17, 2013","June 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00213642"
999,"NCT01687413","Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer","Active, not recruiting","No Results Available","Oropharyngeal Neoplasms","Radiation: Intensity-modulated radiation therapy (IMRT)|Drug: Cisplatin","Washington University School of Medicine","All","21 Years and older   (Adult, Senior)","Phase 3","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","201207059","September 13, 2012","January 10, 2013","May 31, 2018","February 2, 2017","February 2017","No Study Results Posted","ADEPT","May 31, 2018","Disease-free survival (DFS)|Locoregional control|Distant metastasis rates|Disease specific survival|Cumulative incidence of complications/acute toxicity|Function and quality of life (QOL)","https://ClinicalTrials.gov/show/NCT01687413"
1000,"NCT00733889","A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma","Completed","No Results Available","Esophageal Carcinoma","Drug: cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|Merck Sharp & Dohme Corp.|Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TTD-06-02|EudraCT number:2006-001880-42","August 12, 2008","December 2006","November 2012","February 19, 2013","February 2013","No Study Results Posted","null","November 2012","• Complete clinical response rate and objective clinical response rate after the administration of 3 cycles of chemotherapy plus cetuximab and after induction chemotherapy followed by concomitant chemoradiotherapy plus cetuximab|• To determine the complete pathological response rate in the patients subject to radical surgery, according to the investigators' criteria and the policy of each centre.|Adverse events|• To study the locoregional control of the disease, the therapeutic failure patterns, specific disease-free survival, event-free survival, disease-specific survival and global survival|• To determine EGFR expression in the tumour and attempt to correlate it with efficacy","https://ClinicalTrials.gov/show/NCT00733889"
1001,"NCT00417248","Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer","Terminated","Has Results","Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Procedure: Radiotherapy|Drug: Sorafenib","Nasser Hanna, M.D.|Bayer|Amgen|Walther Cancer Institute|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG LUN06-107","December 28, 2006","June 2007","April 2008","June 13, 2016","May 2016","May 4, 2016","null","April 2008","Time to Disease Progression (TTP)|Overall Survival","https://ClinicalTrials.gov/show/NCT00417248"
1002,"NCT02107235","Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer","Completed","No Results Available","Head and Neck Neoplasms|Carcinoma, Squamous Cell","Drug: oral rigosertib|Drug: cisplatin|Radiation: Radiotherapy","Onconova Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Onconova 09-12","April 3, 2014","January 2014","January 2015","April 3, 2017","April 2017","No Study Results Posted","null","October 2014","Number of patients who experience dose limiting toxicities|Number of patients who experience adverse events|Number of patients who achieve a complete response or a partial response","https://ClinicalTrials.gov/show/NCT02107235"
1003,"NCT02256982","A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma","Terminated","Has Results","Unresectable Intrahepatic Cholangiocarcinoma|Resectable Intrahepatic Cholangiocarcinoma","Drug: Gemcitabine|Drug: Cisplatin|Procedure: Surgery|Radiation: Radiation","Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-275","September 25, 2014","October 2014","March 2016","April 11, 2016","April 2016","April 11, 2016","null","March 2016","Number of Participants Post Operative/Radiation Therapy Complications","https://ClinicalTrials.gov/show/NCT02256982"
1004,"NCT00003379","Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: paclitaxel|Radiation: brachytherapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066374|GOG-9803","November 1, 1999","November 1999","null","May 24, 2013","November 2004","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00003379"
1005,"NCT00538681","Study for Patients With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo","Completed","No Results Available","Lung Cancer","Drug: enzastaurin|Drug: pemetrexed|Drug: cisplatin|Drug: placebo","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10722|H6Q-MC-S021","October 1, 2007","September 2007","November 2008","October 16, 2009","October 2009","No Study Results Posted","null","November 2008","Part 1: evaluate safety (toxicity, serious adverse events and reasons for patient discontinuation)|Part 2: compare progression-free survival between the 2 arms through the assessment of tumor response|Part 2: to evaluate the safety and toxicity profile of study treatments|Part 2: response rate|Part 2: overall survival|Part 2: duration of disease control and response|Part 2: time to worsening of symptoms|Part 2: to assess biomarkers of the disease state and their correlation to clinical outcome","https://ClinicalTrials.gov/show/NCT00538681"
1006,"NCT00716976","Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","Active, not recruiting","No Results Available","Brain Tumor|Central Nervous System Tumor|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ototoxicity|Ovarian Cancer|Sarcoma","Drug: sodium thiosulfate|Procedure: examination","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","Phase 3","131","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","ACCL0431|COG-ACCL0431|CDR0000588655","July 15, 2008","June 2008","null","January 4, 2016","January 2016","No Study Results Posted","null","September 2012","Incidence of hearing loss|Change in hearing thresholds for key frequencies|Event-free-survival|Overall survival|Hearing loss among patients carrying/not-carrying two key gene mutations (TPMT and COMT)","https://ClinicalTrials.gov/show/NCT00716976"
1007,"NCT00178763","Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer","Unknown status","No Results Available","Pancreatic Neoplasms","Device: Heckel Infrared Radiant Heat Device|Other: cisplatin, gemcitabine, interferon-alpha|Other: thermochemotherapy","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HSC-MS-02-117","September 13, 2005","September 2003","June 2013","March 2, 2011","March 2011","No Study Results Posted","FR-WB-TT","June 2012","Tumor response, disease-free survival|Allow inoperable pancreatic cancer to be converted to operable disease","https://ClinicalTrials.gov/show/NCT00178763"
1008,"NCT00251888","CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto","Completed","No Results Available","Cervix Cancer","Drug: campto (irinotecan)|Drug: cisplatin (cisplatyl)","ARCAGY/ GINECO GROUP","Female","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CACIS","November 10, 2005","November 2002","November 2005","January 24, 2017","February 2011","No Study Results Posted","null","null","To determine the maximum tolerated dose of irinotecan associated with cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer|To evaluate :|the global response rate judged on standard clinical criteria, echography, tomodensiometry, and MRI. The histologic response rate will be appreciated in patients who had a second surgery after pelvic radiochemotherapy|local and general relapse frequency|progression free survival|global survival","https://ClinicalTrials.gov/show/NCT00251888"
1009,"NCT02325986","Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: fluorouracil|Drug: Cisplatin|Radiation: Intensity-modulated radiation therapy","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GD-B2014157","December 16, 2014","March 2015","December 2017","November 19, 2015","November 2015","No Study Results Posted","null","December 2016","overall response rate|safety: Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0).|overall survival","https://ClinicalTrials.gov/show/NCT02325986"
1010,"NCT00789373","A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer","Active, not recruiting","Has Results","Non-Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Placebo|Drug: Pemetrexed|Other: Best Supportive Care","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","939","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","12560|H3E-EW-S124|CTRI/2009/091/000113","November 10, 2008","November 2008","January 2018","January 31, 2017","January 2017","June 20, 2011","null","June 2010","Investigator-assessed Objective Progression-free Survival (PFS)|Independently-assessed Objective Progression-free Survival (PFS)|Overall Survival (OS)|Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score|Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)|Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)|Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase|Percentage of Participants With Serious Adverse Events During Maintenance Phase|Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off|Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off","https://ClinicalTrials.gov/show/NCT00789373"
1011,"NCT00004077","Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer","Completed","No Results Available","Testicular Germ Cell Tumor","Drug: cisplatin|Drug: ifosfamide|Drug: paclitaxel","Medical Research Council|National Cancer Institute (NCI)","Male","16 Years to 64 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Primary Purpose: Treatment","CDR0000067286|MRC-TIP|EU-99012","December 10, 1999","May 1996","July 2005","December 18, 2013","January 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004077"
1012,"NCT00584155","Protection From Cisplatin Ototoxicity by Lactated Ringers","Withdrawn","No Results Available","Hearing Loss","Drug: Normal Saline and 0.3% ofloxacin|Drug: Lactated Ringer's with 0.03% Ofloxacin","University of Oklahoma","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","Lactated Ringers - Berryhill","December 20, 2007","July 2006","June 2010","May 26, 2015","June 2010","No Study Results Posted","null","June 2010","Pre-treatment audiogram will be compared with the post treatment audiogram. The differences between the two will be calculated and compared to the differences in the opposite ear.","https://ClinicalTrials.gov/show/NCT00584155"
1013,"NCT02281006","Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity","Terminated","No Results Available","DDP|Head and Neck Cancer|Adverse Effect","Drug: Trans-tympanic injection of a sodium thiosulfate gel","Centre Hospitalier Universitaire de Québec, CHU de Québec","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Outcomes Assessor|Primary Purpose: Supportive Care","A13-09-985","October 30, 2014","January 1, 2015","January 20, 2017","January 26, 2017","January 2017","No Study Results Posted","STS001","January 20, 2017","Hearing loss at high frequencies|Cochlear damage|Hearing loss at lower frequencies|Adverse effects of trans-tympanic injections","https://ClinicalTrials.gov/show/NCT02281006"
1014,"NCT00077051","Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: cytochlor|Drug: tetrahydrouridine|Radiation: radiation therapy","University of Miami|National Cancer Institute (NCI)","All","21 Years to 120 Years   (Adult, Senior)","Phase 1","1","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20020154|SCCC-2002033|NCI-6301","February 10, 2004","April 2004","July 2007","December 14, 2016","December 2016","No Study Results Posted","null","July 2007","","https://ClinicalTrials.gov/show/NCT00077051"
1015,"NCT03020329","Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma|Children","Drug: Paclitaxel|Drug: Cisplatin|Drug: 5-fu|Radiation: Radical radiotherapy","Sun Yat-sen University","All","up to 18 Years   (Child, Adult)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC in Young Patients","December 14, 2016","January 2017","December 2021","January 11, 2017","January 2017","No Study Results Posted","null","December 2018","Complete Response (CR)|Overall survival(OS)|Progress-free survival(PFS)|Locoregional failure-free survival(LRFS)|Distant metastasis-free survival(DMFS)|Short-term toxic effects assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)|Long-term toxicities|Growth|Sex Development|Intelligence Development","https://ClinicalTrials.gov/show/NCT03020329"
1016,"NCT00493025","Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery","Terminated","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: gefitinib|Drug: paclitaxel|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JHOC-J0386, CDR0000549896|P30CA006973|JHOC-J0386|JHOC-04-02-20-03|ZENECA-IRUSIRES0304","June 25, 2007","April 2005","July 2011","August 15, 2011","August 2011","No Study Results Posted","null","July 2011","Pathologic complete response rate to the neoadjuvant regimen|Toxicity as assessed by NCI CTC v2.0|Safety|Time to progression|Survival|Correlation between EGFR pathway component expression and activation with pathologic complete response and survival","https://ClinicalTrials.gov/show/NCT00493025"
1017,"NCT01139775","A Study in Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: LY2603618","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13797|I2I-MC-JMMG","June 1, 2010","February 2011","August 2014","September 5, 2014","September 2014","No Study Results Posted","null","May 2013","Phase 2: Progression Free Survival Time|Phase 1: Recommended Phase 2 Dose of LY2603618|Phase 2: Overall Survival|Phase 2: Overall Tumor Response Rate: Percentage of Participants who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)|Phase 2: Change in Tumor Size|Phase 1: Pharmacokinetic: Maximum Concentration (Cmax) (Pemetrexed, Cisplatin and LY2603618)|Phase 1: Pharmacokinetic: Area Under the Curve (AUC) (Pemetrexed,Cisplatin and LY2603618)|Phase 2: Pharmacokinetic: Maximum Concentration (Cmax) (LY2603618)|Phase2: Pharmacokinetic: Area Under the Curve (AUC) (LY2603618)|Phase 2: Change from Baseline to Long Term Follow-Up in Lung Cancer Symptom Scale (LCSS)|Phase 1: Document any antitumor activity per radiological scans and/or tumor markers|Phase 2: Proportion of Participants Receiving Maintenance Therapy|Phase 2: Clinical Benefit Rate: Percentage of Participant who Achieved a Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR)","https://ClinicalTrials.gov/show/NCT01139775"
1018,"NCT00625937","Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Drug: tegafur-gimeracil-oteracil potassium|Radiation: radiation therapy","Yonsei University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000582621|YONSEI-4-2006-021-0","February 28, 2008","November 2006","null","February 25, 2011","February 2011","No Study Results Posted","null","November 2010","Objective response rate (complete or partial response) as assessed by RECIST criteria|Progression-free survival|Overall survival|Toxicity as assessed by NCI CTCAE v3.0 criteria","https://ClinicalTrials.gov/show/NCT00625937"
1019,"NCT01445392","SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma","Completed","No Results Available","Mesothelioma","Biological: Multicycle SS1P|Drug: Pemetrexed|Drug: Cisplatin|Biological: Single cycle SS1P","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 1","24","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","080026|08-C-0026","September 30, 2011","November 13, 2007","October 3, 2016","May 12, 2017","October 27, 2016","No Study Results Posted","null","January 31, 2014","Safety and MTD|Best overall response","https://ClinicalTrials.gov/show/NCT01445392"
1020,"NCT00613626","Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer","Completed","Has Results","Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Drug: Placebo|Drug: ZD6474","Hoosier Cancer Research Network|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","74","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Treatment","LUN06-113","January 31, 2008","January 2008","August 2015","October 19, 2015","October 2015","August 31, 2015","null","August 2015","Time to Disease Progression - Median Time to Progression and Log-Rank Test|Percentage of Participants With Grade 3/4 Hematologic and Non-Hematologic Toxicities|Measure the Response Rate (CR + PR) in Each Arm|Measure Disease Control Rate (CR + PR+ SD) in Each Arm|Measure Overall Survival for Each Arm|Assess VEGF Polymorphisms and Correlate Subject Response","https://ClinicalTrials.gov/show/NCT00613626"
1021,"NCT02533765","Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor","Recruiting","No Results Available","Neoplasms, Germ Cell and Embryonal","Drug: Olaparib","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","All","18 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST186.02","June 17, 2015","May 2015","December 2017","September 28, 2016","September 2016","No Study Results Posted","null","September 2017","Overall Response Rate (ORR)|Evaluation of number, type and grade of Adverse Events|Progression free survival (PFS)|Overall survival (OS)|exploratory analysis of the association between PFS or OS and biomarkers","https://ClinicalTrials.gov/show/NCT02533765"
1022,"NCT00701857","Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: Pemetrexed|Radiation: radiation therapy","University of Arizona|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-0612-04|P30CA023074|UARIZ-07-0612-04|UARIZ-BIO07067|UARIZ-SRC18084|LILLY-UARIZ-07-0612-04","June 18, 2008","February 2008","September 2015","April 19, 2016","April 2016","No Study Results Posted","null","April 2014","The maximum tolerated dose (MTD) of pemetrexed|Toxicity profile|Response (complete response, partial response, progressive disease, and stable disease) as measured by RECIST criteria","https://ClinicalTrials.gov/show/NCT00701857"
1023,"NCT00387699","Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Biological: bevacizumab|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","79","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000508653|ECOG-E1506","October 12, 2006","October 2006","April 2014","April 27, 2015","October 2008","No Study Results Posted","null","October 2007","Progression-free survival at 1 year|Response rate|Toxicity","https://ClinicalTrials.gov/show/NCT00387699"
1024,"NCT01461746","Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer","Unknown status","No Results Available","Endometrial Cancer","Drug: Docetaxel|Drug: Cisplatin|Radiation: Radiation therapy","Asan Medical Center|Boryung Pharmaceutical Co., Ltd","Female","20 Years to 75 Years   (Adult, Senior)","Phase 2","67","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANSGOG-001","October 24, 2011","October 2011","September 2015","October 27, 2011","October 2011","No Study Results Posted","null","September 2013","Progression-free survival|Overall survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Quality of life","https://ClinicalTrials.gov/show/NCT01461746"
1025,"NCT00458315","Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor","Withdrawn","No Results Available","Unknown Primary Tumors","Drug: Cisplatin|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Avastin (Bevacizumab)","Rigshospitalet, Denmark","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Cis/Gem/Tax +/- Avastin","April 6, 2007","May 2007","May 2012","May 6, 2015","September 2009","No Study Results Posted","null","August 2007","Progression Free Survival|Response|Toxicity|Response Duration","https://ClinicalTrials.gov/show/NCT00458315"
1026,"NCT01379807","Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Unknown status","No Results Available","Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma","Drug: panitumumab + docetaxel + cisplatino","Grupo Gallego de Investigaciones Oncologicas|Amgen|Trial Form Support S.L.","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GGIO-2010-01","June 22, 2011","December 2010","December 2015","March 10, 2015","April 2011","No Study Results Posted","SPIGA","December 2014","Objective response rate|Disease control rate|Duration of response|Time to response|Time to progression|Time to treatment failure|Duration of stable disease|Progression free survival|Overall survival|Safety profile|Exploratory Objectives","https://ClinicalTrials.gov/show/NCT01379807"
1027,"NCT00155259","Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel , Cisplatin , Capecitabine","National Taiwan University Hospital","Female","up to 65 Years   (Child, Adult)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","930607","September 8, 2005","October 2004","December 2006","July 23, 2007","July 2005","No Study Results Posted","null","null","The primary endpoint of this phase II trial is the objective response rate of the regimen.|The secondary endpoints include treatment-related toxicity, progression free survival and overall survival and breast conserving rate.","https://ClinicalTrials.gov/show/NCT00155259"
1028,"NCT00112697","Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","Unknown status","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000430095|FRE-FNCLCC-ACCORD-09/0201|EU-20511","June 2, 2005","December 2002","null","November 1, 2011","December 2006","No Study Results Posted","null","null","Progression-free survival rate at 6 months|Toxicity|Objective response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00112697"
1029,"NCT00259285","Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer","Terminated","Has Results","Non-Small-Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9901|H3E-XM-S092","November 28, 2005","November 2005","December 2007","April 7, 2009","April 2009","December 19, 2008","null","December 2007","Treatment Response|Pathologic Remissions After Surgery|Relapse-Free Survival","https://ClinicalTrials.gov/show/NCT00259285"
1030,"NCT01503385","Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Lung Cancer","Drug: Celecoxib","Chinese Academy of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-L-025","January 1, 2012","December 2011","December 2016","January 3, 2012","January 2012","No Study Results Posted","null","December 2014","overall survival|progression-free survival","https://ClinicalTrials.gov/show/NCT01503385"
1031,"NCT00887315","The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)","Terminated","Has Results","Non-small Cell Lung Cancer","Drug: Docetaxel and cisplatin|Radiation: Docetaxel and cisplatin Plus Hypofractionated Radiotherapy","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 2","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16574B","April 22, 2009","April 2009","June 2011","November 13, 2013","November 2013","June 24, 2013","SMART","March 2011","1-Year Overall Survival|Overall PFS and CT Rate","https://ClinicalTrials.gov/show/NCT00887315"
1032,"NCT00398385","Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","National Cancer Center, Korea|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","170","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","NCC-NCCCTS-05-122|CDR0000516823","November 9, 2006","May 2005","null","August 9, 2013","April 2008","No Study Results Posted","null","April 2010","Time to recurrence|Overall survival|Toxicity|Safety, in terms of frequency, severity, and relationship of adverse events, as assessed by NCI CTCAE v3.0|Complete resection rate|Quality of life as assessed by EORTC QLQ-C30 and EORTC QLQ-LC13 at baseline and periodically for 5 years|Patient population most at risk for disease recurrence","https://ClinicalTrials.gov/show/NCT00398385"
1033,"NCT00773188","A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: bevacizumab [Avastin]|Drug: cisplatin|Drug: vinorelbine","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BO21247","October 15, 2008","December 2008","October 2010","November 1, 2016","November 2016","No Study Results Posted","null","October 2010","Safety: Adverse events; clinical laboratory parameters; physical exam including vital signs; performance status.|Tumor response","https://ClinicalTrials.gov/show/NCT00773188"
1034,"NCT00082862","Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer","Unknown status","No Results Available","Pancreatic Cancer","Biological: recombinant interferon alfa|Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: hyperthermia treatment","The University of Texas Health Science Center, Houston|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000360863|UTHSC-MS-02117","May 14, 2004","July 2002","null","February 10, 2012","December 2008","No Study Results Posted","null","November 2012","Tumor response|Toxicity|Survival|Changes in quality of life|Conversion of inoperable tumors to operable|Changes in cellular and cytokine immune function","https://ClinicalTrials.gov/show/NCT00082862"
1035,"NCT00005060","Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: Taxotere-Cisplatin-5FU|Drug: Immediate surgery","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 43/99|SWS-SAKK-43/99|EU-99042","April 6, 2000","November 1999","March 2006","May 14, 2012","May 2012","No Study Results Posted","null","November 2005","Event-free survival|Overall survival|Time to treatment failure measured after completion of study treatment|Toxicity measured after completion of study treatment|Rate of complete resection (RO) and postoperative mortality as measured after surgery","https://ClinicalTrials.gov/show/NCT00005060"
1036,"NCT00310011","Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: conventional surgery","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","71","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CCCWFU-88197|CDR0000466059|CCCWFU-BG98-217|AMGEN-CCCWFU-88197","March 29, 2006","June 1998","August 2009","January 17, 2017","June 2013","No Study Results Posted","null","October 2005","Response|Response duration|Freedom from progression|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00310011"
1037,"NCT01735409","Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Neoplasms","Drug: ABX + DDP|Drug: ABX + DDP|Drug: ABX + DDP","Sun Yat-sen University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","69","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ABXDDP20101224","November 22, 2012","November 2012","June 2014","January 25, 2014","January 2014","No Study Results Posted","ABX-DDP-Dose","March 2014","Objective response rate (ORR)|Progression free survival (PFS)|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01735409"
1038,"NCT00959387","Induction Chemotherapy for Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Induction TP chemotherapy|Radiation: Chemoradiotherapy (CRT)","Barretos Cancer Hospital","All","18 Years to 76 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Barretos-01","August 3, 2009","August 2009","April 2013","March 22, 2014","March 2014","No Study Results Posted","null","November 2010","Tumor response rate|Overall survival|Quality of life (EORTC QLQ-C30)|Adverse Events rate|Progression-free survival.","https://ClinicalTrials.gov/show/NCT00959387"
1039,"NCT01077713","A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer","Completed","Has Results","Non-Squamous Non-Small Cell Lung Cancer","Drug: bevacizumab [Avastin]|Drug: cisplatin|Drug: gemcitabine|Drug: gemcitabine","Hoffmann-La Roche","All","70 Years and older   (Senior)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21868|2008-008739-27","February 9, 2010","February 2010","July 2014","September 9, 2015","September 2015","September 9, 2015","null","July 2014","Percentage of Participants Alive and Without Progressive Disease at Month 6|Percentage of Participants With Disease Progression or Death|Progression Free Survival (PFS)|Percentage of Participants Alive at 12 Months After Randomization|Percentage of Participants Who Died|Overall Survival (OS)|Percentage of Participants by Best Overall Response|Percentage of Participants With an Objective Response|Percentage of Participants With Disease Control|Duration of Response (DoR)","https://ClinicalTrials.gov/show/NCT01077713"
1040,"NCT01108601","Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity","Unknown status","No Results Available","Hearing Loss","Drug: Ringer's Lactate (0.03% Ciprofloxacin)","McGill University Health Center","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","GEN-07-033","April 1, 2010","April 2008","null","April 20, 2010","April 2010","No Study Results Posted","null","April 2011","Audiogram|Otoacoustic Emissions","https://ClinicalTrials.gov/show/NCT01108601"
1041,"NCT02263105","Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas","Recruiting","No Results Available","High-grade Gliomas","Drug: CDDP|Drug: Temozolomide","Huashan Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CAT001|Huashan H","September 28, 2014","October 2014","December 2017","May 12, 2017","May 2017","No Study Results Posted","null","October 2017","progression free survival (PFS)|overall survival(OS)","https://ClinicalTrials.gov/show/NCT02263105"
1042,"NCT00072215","Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors","Terminated","No Results Available","Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Drug: cisplatin|Drug: ifosfamide|Drug: paclitaxel|Drug: vinblastine","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Male","18 Years to 120 Years   (Adult, Senior)","Phase 3","1","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-90106|U10CA031946|CDR0000339340","November 4, 2003","April 2004","April 2005","July 1, 2016","July 2016","No Study Results Posted","null","April 2005","Overall survival","https://ClinicalTrials.gov/show/NCT00072215"
1043,"NCT01090466","Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: temsirolimus|Other: pharmacological study","Wales Cancer Trials Unit|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","99","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000667766|WCTU-TOTEM|ISRCTN31546330|EUDRACT-2007-007615-82|EU-21014|WCTU-SPON-417-07|CRUK-08/015","March 18, 2010","February 2008","null","August 23, 2013","September 2012","No Study Results Posted","null","January 2010","Safety (recommended phase II dose and dose-limiting toxicities) (phase I)|Progression-free survival at 6 months (phase I)|Pharmacokinetics (phase I)|Safety, including tolerability and feasibility (phase II)|Overall survival (phase II)|Progression-free survival (time-to-event) (phase II)|Objective (radiological) response rate according to RECIST criteria (phase II)|Toxicity during and after treatment according to NCI CTCAE v 3.0 (phase II)","https://ClinicalTrials.gov/show/NCT01090466"
1044,"NCT02804646","Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma","Recruiting","No Results Available","Adenocarcinoma of Lung","Drug: recombinant human endostatin|Drug: pemetrexed plus cisplatin or carboplatin","Anhui Provincial Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20160606","June 15, 2016","June 2016","December 2018","June 19, 2016","June 2016","No Study Results Posted","null","December 2017","progression free survival|objective response rate|disease control rate|overall survival","https://ClinicalTrials.gov/show/NCT02804646"
1045,"NCT01494558","Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Small Cell Lung Cancer","Other: Chemoradiotherapy Regimen between PC and PE","Chinese Academy of Medical Sciences","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006BAI02A02[1]-03","December 14, 2011","May 2007","August 2011","December 16, 2011","December 2011","No Study Results Posted","null","October 2010","Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01494558"
1046,"NCT00154882","Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Paclitaxel (Phyxol) , Cisplatin","National Taiwan University Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","920705","September 8, 2005","September 2003","July 2007","January 20, 2010","July 2005","No Study Results Posted","null","null","The primary endpoint of this phase II trial is the objective response rate of the stage I (low-dose) regimen.|The secondary endpoints include treatment-related toxicity, the change in quality of life, progression free survival and overall survival.","https://ClinicalTrials.gov/show/NCT00154882"
1047,"NCT00389688","Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery","Terminated","No Results Available","Lung Cancer","Drug: cisplatin|Drug: pemetrexed disodium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-08051|2005-003822-25","October 18, 2006","August 2006","null","July 17, 2012","July 2012","No Study Results Posted","null","July 2008","Successful treatment delivery|Toxicity (no grade 4) during chemotherapy|Overall toxicity (all grades)|Progression-free survival and overall survival|Overall clinical response rate (neoadjuvant chemotherapy arm)|Pathologic complete response (neoadjuvant chemotherapy arm)|Resectability rate (neoadjuvant chemotherapy arm)|Surgical morbidity and mortality|Fraction of patients that actually receives chemotherapy (adjuvant chemotherapy arm)","https://ClinicalTrials.gov/show/NCT00389688"
1048,"NCT01048645","Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: ATRA|Other: PLACEBO","National Institute of Cancerología|Instituto Nacional de Enfermedades Respiratorias","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","107","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","ICC/302/07","December 30, 2009","September 2007","November 2009","January 12, 2010","January 2010","No Study Results Posted","null","December 2008","The primary end-point was Response rate (RR) and Progression-free survival (PFS), as well as identifying whether expression of RAR-beta2 is a response biomarker.|Evaluate the efficiency and safety of low doses of ATRA in patients with advanced NSCLC who receive first-line CT.","https://ClinicalTrials.gov/show/NCT01048645"
1049,"NCT02657460","Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion","Recruiting","No Results Available","Malignant Pleural Effusion","Biological: tumor derived microparticles|Drug: cisplatin","Wuhan Union Hospital, China","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","v1.4","January 11, 2016","January 2016","December 2018","November 1, 2016","November 2016","No Study Results Posted","null","December 2018","Pleural effusions volume|Rivalta Test of pleural effusions|total protein level of pleural effusions|total karyocytes count of pleural effusions|lactic dehydrogenase level of pleural effusions|adenosine deaminase level of pleural effusions|the cytology test of pleural effusions|Karnofsky index|survival time|carcino embryonie antigen level in microgramme/L in serum|CYFRA21-1 level in ng/mL in serum|neuron specific annuals level in microgramme/L in serum|squamous cell carcinoma antigen level in ng/mL in serum|carcino embryonie antigen level in microgramme/L in pleural effusions","https://ClinicalTrials.gov/show/NCT02657460"
1050,"NCT00103051","Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gefitinib|Drug: gemcitabine hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-08013|2004-001332-23","February 7, 2005","December 2004","null","July 13, 2012","July 2012","No Study Results Posted","null","November 2005","Complete response rate as measured by RECIST criteria prior to surgery|Overall response rate as measured by RECIST criteria prior to surgery|Toxicity as assessed by CTC","https://ClinicalTrials.gov/show/NCT00103051"
1051,"NCT00561054","Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: CETUXIMAB","Grupo Portugues de Estudo do Cancro do Pulmao","All","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-000537-35","November 19, 2007","March 2007","null","November 19, 2007","November 2007","No Study Results Posted","Coimbra","null","oVERALL RESPONSE RATE|tIME TO PROGRESSION oVERALL SORVIVAL SAFETY","https://ClinicalTrials.gov/show/NCT00561054"
1052,"NCT00003055","Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","97-060|CDR0000065703|NCI-G97-1306","November 1, 1999","June 1997","April 2001","June 20, 2013","June 2013","No Study Results Posted","null","April 2001","","https://ClinicalTrials.gov/show/NCT00003055"
1053,"NCT02940925","TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Other: Drug: Taxol,cisplatin and capecitabine|Other: Drug: Cisplatin and 5-Fluorouracil","Sun Yat-sen University","All","18 Years to 60 Years   (Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20160049","September 21, 2016","September 2016","August 2024","October 20, 2016","October 2016","No Study Results Posted","null","August 2019","Failure-free survival calculated from randomisation to locoregional failure, distant failure, or death from any cause|Overall survival calculated from randomisation to death from any cause|Progression free survival calculated from randomisation to disease progression or death from any cause|Local-regionally relapse free survival calculated from randomisation to locoregional failure|Distant metastasis free survival calculated from randomisation to distant failure|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02940925"
1054,"NCT00003263","Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Mesothelioma","Biological: recombinant interferon alfa|Drug: cisplatin|Procedure: surgical procedure|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066157|P30CA006927|FCCC-96087|NCI-G98-1401","November 1, 1999","August 1996","November 2000","April 16, 2013","April 2013","No Study Results Posted","null","December 1999","","https://ClinicalTrials.gov/show/NCT00003263"
1055,"NCT00551122","Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor","Biological: filgrastim|Biological: lenograstim|Biological: pegfilgrastim|Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: ifosfamide|Drug: paclitaxel","University of Southampton|University Hospital Southampton NHS Foundation Trust","All","16 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000572096|USCTU-UR1002-GEM-TIP|EU-20769|EUDRACT-2004-004804-19","October 25, 2007","November 2006","null","January 22, 2013","October 2007","No Study Results Posted","GemTIP","April 2013","Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I)|Response rates (phase I)|Failure-free survival (phase I)|Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I)|Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)","https://ClinicalTrials.gov/show/NCT00551122"
1056,"NCT01302834","Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer|Precancerous Condition","Biological: cetuximab|Drug: cisplatin","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","987","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RTOG-1016|CDR0000695731|NCI-2011-02638","February 22, 2011","June 2011","null","May 18, 2017","May 2017","No Study Results Posted","null","June 2020","Overall survival|Progression-free survival|Local-regional failure|Distant metastasis|Acute toxicities (CTCAE v. 4) and overall toxicity burden at end of treatment and at 1, 3, and 6 months after completion of treatment|Late toxicities (CTCAE v. 4) at 1, 2, and 5 years|Second primary cancers|Pattern of failure|Early deaths|Feeding tube rate at 1 year|EORTC QLC-C30 at baseline, end of treatment, 3, 6, and 12 months from end of treatment.|EORTC QLQ-H&N35 at baseline, end of treatment, 3, 6, and 12 months from end of treatment.|PRO-CTCAE-H&N at baseline, end of treatment, 3, 6, and 12 months from end of treatment.|EQ-5D at baseline, end of treatment, 3, 6, and 12 months from end of treatment.|Work Status Questionnaire at baseline, end of treatment, 3, 6, and 12 months.|Dental status at baseline, 12, 24, 60 and 120 months from end of treatment.|Hearing quality of life outcomes as measured by the HHIA-S at baseline, end of treatment and at 3, 6, and 12 months from end of treatment.|Behavioral Risk Assessment Survey (BRASS) at baseline.|Translational research analysis","https://ClinicalTrials.gov/show/NCT01302834"
1057,"NCT00068744","Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer","Terminated","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","88","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-22011-40014|EORTC-22011|EORTC-40014","September 10, 2003","July 2003","null","September 20, 2012","September 2012","No Study Results Posted","null","November 2007","Response as measured by RECIST at 8 weeks after completion of study treatment (Phase II)|Event-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)|Acute toxicity and compliance to treatment as measured by CTC v 2.0 at completion of study treatment (Phase II)|Colostomy-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter (Phase III)|Overall survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter|Disease-free survival as measured by Logrank at 12 and 26 weeks, then every 6 months thereafter|Local control as measured by Gray at 12 and 26 weeks, then every 6 months thereafter|Late toxicity as measured by RTOG and EROTC every 6 months after week 26|Quality of life as measured by EORTC Quality of Life Questionnaire-C30 and ASCT at 12 and 26 weeks, then every 6 months for 2 years after entry","https://ClinicalTrials.gov/show/NCT00068744"
1058,"NCT00002876","Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: etoposide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065162|P30CA015083|907253|V96-1072|394-91","November 1, 1999","October 1991","January 2005","May 10, 2011","May 2011","No Study Results Posted","null","April 1998","","https://ClinicalTrials.gov/show/NCT00002876"
1059,"NCT00370890","A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy","Active, not recruiting","No Results Available","Nasopharyngeal Cancer","Drug: Adjuvant chemotherapy (gemcitabine and cisplatin)","Chinese University of Hong Kong|Hong Kong Nasopharyngeal Cancer Study Group Limited","All","18 Years and older   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","HKNPCSG 0502","August 30, 2006","September 2006","December 2018","January 13, 2017","January 2017","No Study Results Posted","null","December 2018","Relapse free survival|Overall survival|Loco-regional control|Metastasis-free survival|Toxicity of adjuvant chemotherapy|Correlation of plasma EBV DNA and PET/CT scan with clinical course and outcome","https://ClinicalTrials.gov/show/NCT00370890"
1060,"NCT00255476","The IRESSA Novel Head and Neck Chemotherapy Evaluation Study","Completed","No Results Available","Squamous Cell Cancer|Cancer of Head and Neck","Drug: gefitinib|Drug: cisplatin|Drug: 5-flourouracil","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0544","November 17, 2005","February 2004","July 2007","April 22, 2009","April 2009","No Study Results Posted","null","null","To compare the objective tumour response rate between cisplatin/5FU and cisplatin/5FU and ZD1839 combination in these patients|To compare safety and tolerability in these patients","https://ClinicalTrials.gov/show/NCT00255476"
1061,"NCT02633202","Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Radiation: IMRT|Drug: Cisplatin","Sun Yat-sen University|Guilin Medical University, China|First People's Hospital of Foshan","All","18 Years to 65 Years   (Adult)","Phase 3","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRNPC15","December 3, 2015","November 2015","November 2020","November 29, 2016","November 2016","No Study Results Posted","null","November 2017","Failure-free survival|Overall survival|Locoregional failure-free survival|Distant failure-free survival|Rates of participants with adverse events","https://ClinicalTrials.gov/show/NCT02633202"
1062,"NCT01504815","Adaptive Radiation Treatment for Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer","Drug: cisplatinum|Radiation: Conventional radiotherapy|Radiation: Adaptive radiotherapy","The Netherlands Cancer Institute|Karolinska Institutet|Maastricht Radiation Oncology|Institut Catala de Salut|The Christie NHS Foundation Trust|Gustave Roussy, Cancer Campus, Grand Paris|UMC Utrecht|European Union","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","268","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M11ART","December 15, 2011","March 2012","March 2020","October 25, 2016","October 2016","No Study Results Posted","ARTFORCE","November 2017","locoregional recurrence-free survival|number of patients with grade 3 toxicity or more|Quality of Life assessment|swallowing preservation|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT01504815"
1063,"NCT00055835","S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium","Completed","No Results Available","Bladder Cancer|Urethral Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000271309|S0121|U10CA032102","March 6, 2003","November 2002","June 2006","January 30, 2013","January 2013","No Study Results Posted","null","June 2006","","https://ClinicalTrials.gov/show/NCT00055835"
1064,"NCT01614132","Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults","Active, not recruiting","No Results Available","Medulloblastoma","Drug: maintenance chemotherapy (vincristin, cisplatin and CCNU)|Radiation: Radiotherapy","University of Regensburg","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NOA-07","April 26, 2012","January 2009","March 2021","October 31, 2016","October 2016","No Study Results Posted","NOA-07","September 2020","feasibility of the adjuvant chemotherapy|Number of performable cycles in chemo therapy|3 and 5 years progression-free survival|event-free survival|overall survival|course of cognitive performance/QoL","https://ClinicalTrials.gov/show/NCT01614132"
1065,"NCT01187238","The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Carcinoma","Drug: cisplatin","Chinese Academy of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-HN-001","August 18, 2010","July 2010","August 2014","September 9, 2014","September 2014","No Study Results Posted","null","May 2013","Acute toxicities|Long term treatment results","https://ClinicalTrials.gov/show/NCT01187238"
1066,"NCT00144053","A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: Cisplatin+Vindesine+MMC/ concurrent radiation|Drug: Irinotecan+Carboplatin/concurrent radiation|Drug: Paclitaxel+Carboplatin/concurrent radiation","West Japan Thoracic Oncology Group","All","20 Years to 74 Years   (Adult, Senior)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WJTOG0105","August 31, 2005","April 2001","null","January 5, 2006","August 2005","No Study Results Posted","null","null","Survival|safety","https://ClinicalTrials.gov/show/NCT00144053"
1067,"NCT00652132","Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer","Unknown status","No Results Available","Liver Cancer|Ototoxicity","Drug: cisplatin|Drug: sodium thiosulfate|Genetic: gene rearrangement analysis|Genetic: microarray analysis|Genetic: proteomic profiling|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 3","115","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CCLG-LT-2007-03|CDR0000590649|EU-20833|EUDRACT-2007-002402-21|SIOP-CCLG-LT-2007-03","April 2, 2008","December 2007","null","August 9, 2013","June 2009","No Study Results Posted","null","null","Rate of Brock grade ≥ 1 hearing loss determined after end of trial treatment or at an age of at least 3.5 years|Response to preoperative chemotherapy|Complete resection|Complete remission|Event-free survival (EFS)|Overall survival (OS)|Toxicity as graded by CTCAE v 3.0|Long-term renal clearance|Feasibility of central audiology review","https://ClinicalTrials.gov/show/NCT00652132"
1068,"NCT00022217","Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: carboplatin|Drug: cisplatin-e therapeutic implant|Drug: paclitaxel","Matrix Pharmaceutical|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000068796|MP-601-00-2|ENH-EH01-102","August 10, 2001","November 2000","null","December 17, 2013","February 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00022217"
1069,"NCT01019278","Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes","Withdrawn","No Results Available","Cervical Cancer|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Radiation: proton beam radiation therapy|Radiation: radiation therapy treatment planning/simulation|Drug: cisplatin","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 22808|NCI-2009-01350","November 18, 2009","July 2009","null","September 23, 2016","September 2016","No Study Results Posted","null","August 2011","Feasibility|Acute toxicity, as assessed by NCI CTC Version 4.0|Late toxicity, as assessed by RTOG/EORTC late morbidity scoring system|Clinical efficacy (time to local failure, time to distant failure, overall survival)","https://ClinicalTrials.gov/show/NCT01019278"
1070,"NCT00002559","Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin","Completed","No Results Available","Ovarian Cancer|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: cisplatin|Drug: ifosfamide|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","43","Other","Interventional","Primary Purpose: Treatment","94-012|CDR0000063452|NCI-V94-0408","November 1, 1999","January 1994","January 2003","July 1, 2013","July 2013","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00002559"
1071,"NCT01927744","Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection","Recruiting","No Results Available","Head and Neck Cancer","Drug: Docetaxel|Drug: Erlotinib|Other: Placebo|Behavioral: Questionnaires|Behavioral: Phone Call|Drug: Chemotherapy","M.D. Anderson Cancer Center|Astellas Pharma Inc|OSI Pharmaceuticals|Kadoorie Foundation","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","2013-0179|NCI-2014-01390","August 20, 2013","December 2013","null","September 15, 2016","September 2016","No Study Results Posted","null","December 2020","Pathological Complete Response (pCR)","https://ClinicalTrials.gov/show/NCT01927744"
1072,"NCT00259402","Oxaliplatin in Esophagus Cancer (Advanced) 1st Line","Completed","No Results Available","Esophageal Neoplasms","Drug: Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC_7127","November 28, 2005","February 2000","October 2008","December 4, 2009","December 2009","No Study Results Posted","null","October 2008","Efficacy endpoints include tumor response, progression free and overall survival.|Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations.","https://ClinicalTrials.gov/show/NCT00259402"
1073,"NCT00401323","Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","Completed","No Results Available","Head and Neck Neoplasms|Neoplasm Recurrence, Local|Neoplasm Metastasis","Drug: docetaxel (XRP6976)|Drug: cisplatin|Drug: 5-fluorouracil (5-FU)","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6051|XRP6976G-322","November 17, 2006","January 1998","June 2003","January 19, 2011","January 2011","No Study Results Posted","null","June 2003","time to progression|overall survival, overall response rate (complete response + partial response), duration of response, and time to treatment failure","https://ClinicalTrials.gov/show/NCT00401323"
1074,"NCT01414608","Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer","Recruiting","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Chemotherapeutic Agent Toxicity|Cognitive Side Effects of Cancer Therapy|Psychological Impact of Cancer|Radiation Toxicity|Sexual Dysfunction and Infertility|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage IIIB Cervical Cancer|Stage IVA Cervical Cancer","Drug: Carboplatin|Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Internal Radiation Therapy|Drug: Paclitaxel|Other: Quality-of-Life Assessment","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","900","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ANZGOG-0902-GOG-0274|NCI-2011-02978|CDR0000706698|GOG-0274|RTOG-1174|ANZGOG-0902|U10CA180868|U10CA027469","August 10, 2011","January 2012","null","May 2, 2017","May 2017","No Study Results Posted","null","July 2018","Overall survival rate|Patterns of disease recurrence|Progression-free survival rate|Quality of life including psychosexual health|Radiation protocol compliance|Rate of acute and long-term toxicities","https://ClinicalTrials.gov/show/NCT01414608"
1075,"NCT03067792","FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer","Completed","No Results Available","Inoperable Gastric Cancer","Drug: 5-fluorouracil, irinotecan and leucovorin|Drug: docetaxel and cisplatin","Yonsei University","All","19 Years to 75 Years   (Adult, Senior)","Phase 3","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","4-2014-0626","February 22, 2017","December 2014","October 17, 2016","February 28, 2017","February 2017","No Study Results Posted","null","October 17, 2016","response rate|diseases control rate|Overall survival|progression free survival","https://ClinicalTrials.gov/show/NCT03067792"
1076,"NCT01126216","Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Paclitaxel/Cisplatin|Radiation: Reduced RT|Drug: 5-FU/Cisplatin|Radiation: Standard RT","University of Erlangen-Nürnberg Medical School|Deutsche Krebshilfe e.V., Bonn (Germany)","All","18 Years and older   (Adult, Senior)","Phase 3","542","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Paccis-RCT_2005|2005-003484-23|107028","May 17, 2010","May 2010","June 2019","July 29, 2016","July 2016","No Study Results Posted","Paccis-RCT","February 2015","Disease free survival|Overall Survival|Distant metastasis free survival|Local control|Acute and Late Toxicity|Life Quality|HPV/p16-Status","https://ClinicalTrials.gov/show/NCT01126216"
1077,"NCT00059761","Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0241|CDR0000269348","May 6, 2003","March 2003","November 2013","November 14, 2015","November 2015","No Study Results Posted","null","March 2009","Maximum tolerated dose of irinotecan in combination with cisplatin and thoracic radiotherapy (45 Gy BID or 70 Gy daily) by toxicity assessment (Common Toxicity Criteria version 3.0) during acute and late toxicity|Rate of non-dose limiting toxicity","https://ClinicalTrials.gov/show/NCT00059761"
1078,"NCT02976909","Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Paclitaxel+Cisplatin+5fluorouracil","Yuhong Li|Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPF-1","November 22, 2016","November 2016","December 2017","November 28, 2016","November 2016","No Study Results Posted","null","December 2017","Progression free survival|Overall survival|Overall response rate (ORR)|Number of participants with AEs and SAEs as a measure of Safety|Quality of life using EORTC QLQ C30 - scale|Quality of life using esophageal special scale QLQ - OES18","https://ClinicalTrials.gov/show/NCT02976909"
1079,"NCT00004063","Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer","Unknown status","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Biological: recombinant interferon alfa|Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: hyperthermia treatment","The University of Texas Health Science Center, Houston|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000067264|UTHSC-MS-99116|NCI-V99-1561","December 10, 1999","August 1999","null","April 29, 2009","December 2008","No Study Results Posted","null","November 2011","Response duration|Duration of stable disease|Overall survival|Progression-free survival|Time to response","https://ClinicalTrials.gov/show/NCT00004063"
1080,"NCT00084318","Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck","Completed","Has Results","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Drug: docetaxel|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 2","238","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0234|CDR0000360850","June 10, 2004","April 2004","December 2016","December 30, 2016","December 2016","June 14, 2016","null","March 2009","Disease-free Survival|Overall Survival|Treatment Tolerance|Frequency of Toxicity (Grade 5 and Acute Non-hematologic Grade 4)|Frequency of Other Acute and Late Toxicity|Local-regional Control|Correlation of EGFR (Total and Phosphorylated) pMAPK, pAKT, Stat-3, KI-67, COX-2, and Cyclin B1 Expression With Local-regional Control, and Overall and Disease-free Survival","https://ClinicalTrials.gov/show/NCT00084318"
1081,"NCT00955240","Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer","Unknown status","No Results Available","Anal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Other: laboratory biomarker analysis|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","77","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000642638|FRE-FNCLCC-ACCORD-16-0708|EU-20941|EUDRACT-2007-0 07029-38","August 7, 2009","March 2009","null","July 8, 2011","July 2011","No Study Results Posted","null","null","Objective response (complete and partial) according to RECIST criteria at 8 weeks after completion of study treatment|Survival rate at 3 and 5 years|Colostomy-free survival at 3 and 5 years|Duration of objective response","https://ClinicalTrials.gov/show/NCT00955240"
1082,"NCT00738582","An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma","Completed","No Results Available","Malignant Pleural Mesothelioma","Drug: MORAb-009 (Amatuximab)|Drug: Pemetrexed|Drug: Cisplatin","Morphotek","All","18 Years and older   (Adult, Senior)","Phase 2","89","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MORAb-009-003 Amatuximab","August 19, 2008","December 2008","January 2014","November 13, 2015","November 2015","No Study Results Posted","Amatuximab","June 2011","Progression free survival using the EORTC modified RECIST criteria.|Overall response, duration of survival, overall survival and safety.","https://ClinicalTrials.gov/show/NCT00738582"
1083,"NCT02446574","Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Neoplasms","Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiation","Chinese Academy of Medical Sciences","All","18 Years to 68 Years   (Adult, Senior)","Phase 1|Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-27/230","April 26, 2015","July 2007","December 2016","July 30, 2016","July 2016","No Study Results Posted","null","December 2016","Maximum tolerated dose of weekly paclitaxel and cisplatin with concurrent radiation(Phase I endpoint)|Toxicities according to the Common Terminology Criteria for Adverse Events version 3.0.|Overall Survival survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)|Disease-free survival of weekly paclitaxel and cisplatin with concurrent radiation(Phase II endpoint)","https://ClinicalTrials.gov/show/NCT02446574"
1084,"NCT01216644","5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: Oxaliplatin|Drug: Docetaxel|Drug: Epirubicin|Drug: Cisplatin|Drug: 5-fluorouracil","Krankenhaus Nordwest","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","716","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","FLOT4","June 30, 2010","July 2010","June 2017","March 6, 2017","March 2017","No Study Results Posted","null","June 2017","median overall survival|histopathological regression rate|disease free survival (DFS)|correlation of pCR and DFS with survival|Perioperative Morbidity and Mortality|R0-Resection rate","https://ClinicalTrials.gov/show/NCT01216644"
1085,"NCT02879227","Radiochemotherapy in Elderly Patients With Oesophagus Cancer","Completed","No Results Available","Esophagus Cancer","Drug: Cisplatin|Drug: Oxaliplatin","Centre Hospitalier Universitaire de Besancon","All","75 Years and older   (Senior)","Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P/2009/79","August 3, 2016","January 2010","December 2014","August 22, 2016","August 2016","No Study Results Posted","Chronos","December 2014","Feasibility of treatment: Number of patients with completed treatment|Tumoral response|Quality of life","https://ClinicalTrials.gov/show/NCT02879227"
1086,"NCT00360945","Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: temozolomide|Genetic: fluorescence in situ hybridization|Genetic: loss of heterozygosity analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","4 Years to 20 Years   (Child, Adult)","Phase 2","87","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000482280|CCLG-CNS-2004-02|EU-20622","August 3, 2006","April 2004","null","September 16, 2013","November 2006","No Study Results Posted","null","null","Response rate after 2 courses|Relapse-free survival|Best response in patients receiving more than 2 courses|Rate of progression at 6 months and 1 and 2 years|Overall survival","https://ClinicalTrials.gov/show/NCT00360945"
1087,"NCT01074697","Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","Completed","No Results Available","Nausea|Vomiting|Genital Neoplasms, Female","Drug: Fosaprepitant dimeglumine|Drug: Placebo","Odense University Hospital|Helsinn Healthcare SA","Female","18 Years and older   (Adult, Senior)","Phase 3","246","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GAND-emesis|2009-014691-21","February 23, 2010","April 2010","April 2015","April 23, 2015","April 2015","No Study Results Posted","GAND-emesis","April 2015","To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.|To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the proportion of subjects with complete response in the 7 days following initiation of radiotherapy and concomitant weekly cisplatin.|To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the proportion of subjects with no significant nausea during five weeks of fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.|To compare the fosaprepitant dimeglumine regimen and the control regimen with respect to complete response in the 35 days following initiation of fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.|To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the proportion of subjects with no nausea during five weeks (35 days) of fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.|To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the number of days to first emetic episode.|To compare quality of life using the FLIE questionnaire.|To compare tolerability of both regimens.","https://ClinicalTrials.gov/show/NCT01074697"
1088,"NCT00191789","Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer","Completed","Has Results","Breast Cancer","Drug: gemcitabine|Drug: doxorubicin|Drug: cisplatin|Procedure: surgery","Eli Lilly and Company","Female","18 Years and older   (Adult, Senior)","Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7117|B9E-MC-S329","September 12, 2005","February 2003","April 2009","July 21, 2010","July 2010","April 29, 2010","null","April 2009","Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)|Summary of Deaths During Study|Progression Free Survival (PFS)|Overall Survival|Time to Treatment Failure|Number of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery","https://ClinicalTrials.gov/show/NCT00191789"
1089,"NCT00635726","Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer","Terminated","No Results Available","Bladder Cancer","Drug: Methotrexate|Drug: Vinblastine|Drug: Doxorubicin|Drug: Cisplatin|Drug: Cisplatin|Drug: Gemcitabine","Hellenic Oncology Research Group|University Hospital of Crete","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/07.16","March 11, 2008","February 2008","February 2013","October 7, 2015","October 2015","No Study Results Posted","null","February 2013","Overall response rate|Time to tumor progression|Overall survival|Toxicity profile","https://ClinicalTrials.gov/show/NCT00635726"
1090,"NCT01977209","Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: Gossypol|Drug: Placebo","Third Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GTCA","October 19, 2013","September 2013","September 2016","October 30, 2013","October 2013","No Study Results Posted","GTCA","February 2016","Progression-free survival|Overall survival|Tumor response rate|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT01977209"
1091,"NCT00453154","Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Active, not recruiting","Has Results","Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer","Drug: sunitinib malate|Drug: cisplatin|Drug: carboplatin|Drug: etoposide|Other: placebo|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","156","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","NCI-2009-00465|CDR0000538229|CALGB-30504|CALGB 30504|U10CA031946|P30CA014236","March 27, 2007","March 2007","null","November 1, 2016","November 2016","March 24, 2015","null","June 2013","Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I)|Progression-free Survival (Phase II)|Overall Survival|Number of Participants With Overall Tumor Response","https://ClinicalTrials.gov/show/NCT00453154"
1092,"NCT00106626","Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors","Completed","Has Results","Advanced Cancer","Drug: vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005_006|MK0683-012","March 28, 2005","August 2005","December 2007","March 16, 2009","March 2009","November 25, 2008","null","December 2007","Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level|Safety and Tolerability as Measured by the Number of Participants With Disease Progression","https://ClinicalTrials.gov/show/NCT00106626"
1093,"NCT00408694","Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer","Completed","Has Results","Stage II Squamous Cell Carcinoma of the Nasopharynx|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx","Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Biological: bevacizumab|Drug: cisplatin|Drug: fluorouracil","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00736|RTOG-0615|CDR0000518526|RTOG 0615|U10CA021661","December 6, 2006","December 2006","December 2011","April 21, 2014","October 2011","March 1, 2013","null","December 2011","Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the First Year.|Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment After the First Year.|Patient Tolerability to Each Component (Concurrent and Adjuvant) of the Protocol Treatment Regimen|Death During or Within 30 Days of Discontinuation of Protocol Treatment.|One- and Two-year Distant Metastases-free Rates|One- and Two-year Loco-regional Progression-free Rates|One- and Two-year Progression-free Survival Rates|One- and Two-year Overall Survival Rates","https://ClinicalTrials.gov/show/NCT00408694"
1094,"NCT02949791","HIPEC Using High Intra-abdominal Pressure","Recruiting","No Results Available","Pseudomyxoma Peritonei|Colorectal Cancer","Procedure: Cytoreductive surgery|Other: Low Intra abdominal pressure HIPEC|Other: High Intra abdominal pressure HIPEC","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Associazione Italiana per la Ricerca sul Cancro","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIRC-2013-144445","October 7, 2016","December 2014","June 2017","October 27, 2016","October 2016","No Study Results Posted","HIPEC-IAP","June 2017","Tumor tissue concentration of cisplatin|Normal tissue concentration of cisplatin|Pharmacokinetic advantage|Pharmacokinetic advantage 2|Impact of high intra-abdominal pressure on anesthesiologic parameters 1|Impact of high intra-abdominal pressure on anesthesiologic parameters 2|Impact of high intra-abdominal pressure on anesthesiologic parameters 3|Impact of high intra-abdominal pressure on anesthesiologic parameters 4|Impact of high intra-abdominal pressure on anesthesiologic parameters 5|Impact of high intra-abdominal pressure on anesthesiologic parameters 6|Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 1|Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 2|Impact of intraoperative high intra-abdominal pressure on short-term surgical outcomes 3","https://ClinicalTrials.gov/show/NCT02949791"
1095,"NCT00657423","Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Lung Neoplasms","Drug: Treated by endostar combined with docetaxel and cisplatin|Drug: Treated by docetaxel and cisplatin","Xijing Hospital|Yantai Medgenn Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","XJ-EnXS0802","April 9, 2008","April 2008","April 2009","September 15, 2010","August 2008","No Study Results Posted","null","December 2008","mean survival time|objective response rate","https://ClinicalTrials.gov/show/NCT00657423"
1096,"NCT00933387","A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma","Completed","No Results Available","Oral Cancer","Drug: Cetuximab,Paclitaxel,Cisplatin","National Health Research Institutes, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital|Chi Mei Medical Hospital|Changhua Christian Hospital|Chang Gung Memorial Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T1309|EMR62202-845","July 3, 2009","September 2009","November 2013","May 3, 2016","October 2009","No Study Results Posted","null","July 2011","The primary endpoint is the overall response rate after completion of the assigned treatment.|Secondary endpoints include the response rate after neoadjuvant therapy, progression-free survival, overall survival, biomarker prediction, and toxicity.","https://ClinicalTrials.gov/show/NCT00933387"
1097,"NCT00021333","Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer","Completed","No Results Available","Head and Neck Cancer|Lung Cancer","Biological: filgrastim|Drug: cisplatin|Drug: paclitaxel|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068770|P30CA006927|FCCC-99025|NCI-G01-1983","July 11, 2001","September 1999","May 2008","April 16, 2013","April 2013","No Study Results Posted","null","April 2006","","https://ClinicalTrials.gov/show/NCT00021333"
1098,"NCT00130780","Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Pre-surgical Treatment with Bevacizumab plus Chemotherapy|Drug: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","71","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05-052","August 12, 2005","August 2005","October 2012","December 18, 2015","December 2015","December 18, 2015","null","October 2012","The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas Improves Therapeutic Response/Outcome Assessment.","https://ClinicalTrials.gov/show/NCT00130780"
1099,"NCT02083211","Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma","Completed","No Results Available","Cervical Cancer Recurrent or Persistent|Palliative Treatment|Monoclonal Antibody in Cervical Cancer Treatment","Drug: mAb Nimotuzumab|Device: Placebo","National Institute of Cancerología|Pisa S.A de C.V|National Heart Institute, Mexico","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","NIMO 001-09 MX","February 17, 2014","July 2010","June 2014","April 13, 2015","April 2015","No Study Results Posted","null","May 2014","Overall survival|Illness free survival|Antitumoral Response|Progression free survival|Safety","https://ClinicalTrials.gov/show/NCT02083211"
1100,"NCT00174772","Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Lung Neoplasms","Drug: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|Drug: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_2505","September 12, 2005","March 2004","February 2009","February 15, 2010","February 2010","No Study Results Posted","null","February 2009","anti-tumor activity including overall response rate|all treatment related acute and chronic toxicity assessed according to the NCI-CTC scale|other adverse events not reported in the NCI-CTI scale|hematological and non-hematological toxicities","https://ClinicalTrials.gov/show/NCT00174772"
1101,"NCT00075738","Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000349275|FRE-GERCOR-D00-2|EU-20328","January 9, 2004","October 2003","null","July 23, 2008","July 2007","No Study Results Posted","null","null","Objective response rate|Clinical benefit|Tolerability|Local relapse-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00075738"
1102,"NCT00633568","Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer","Terminated","No Results Available","Non-small Cell Lung Carcinoma","Drug: Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Drug: Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","Phase 3","125","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ELCWP 01063","March 5, 2008","January 2007","February 2015","February 11, 2015","February 2015","No Study Results Posted","null","December 2014","Survival|Response rate|Toxicity|Local control rate","https://ClinicalTrials.gov/show/NCT00633568"
1103,"NCT00169247","Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation","Completed","No Results Available","Larynx Cancer|Hypopharynx Cancer","Drug: cetuximab|Drug: Cisplatin|Procedure: Radiotherapy 70 Gy, 35 fractions","Groupe Oncologie Radiotherapie Tete et Cou|Groupe d'Etude des Tumeurs de la Tête Et du Cou","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC-TREMPLIN","September 12, 2005","October 2005","null","June 23, 2011","June 2011","No Study Results Posted","null","April 2011","rate of laryngeal preservation|quality of life","https://ClinicalTrials.gov/show/NCT00169247"
1104,"NCT00431236","A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy","Completed","No Results Available","Nausea|Vomiting","Drug: Oral Casopitant (GW679769)|Drug: IV Casopitant (GW679769)|Drug: IV ondansetron hydrochloride|Drug: Oral dexamethasone","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","810","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","NKV102551","February 2, 2007","November 2006","October 2007","October 13, 2010","October 2010","No Study Results Posted","null","October 2007","To demonstrate that triple therapy casopitant, ondansetron and dexamethasone provides an improved CR rate over ZOFRAN and dexamethasone alone during the 120 hours following a cisplatin-based HEC regimen.|If a subject withdraws prematurely during the first 120 hours, then the time of withdrawal will be considered to be their time to first use of antiemetic rescue medications, and will be censored.|Time to first emetic event, defined as the time elapsed from the start of administration of HEC to the first emetic episode.|If a subject withdraws prematurely during the first 120 hours, then the time of withdrawal will be considered to be their first emetic episode, and will be censored.|The proportion of subjects who receive rescue medication.|The proportion of subjects reporting significant nausea defined as a maximum nausea score greater than or equal to 25 mm on the VAS.|The proportion of subjects reporting nausea defined as a maximum nausea score greater than or equal to 5 mm on the VAS.|The proportion of subject achieving total control, defined as complete responders who had no nausea.|The impact on subjects' daily life activities for the first 120 hours following the first cycle of chemotherapy as assessed by the FLIE questionnaire.|Subject satisfaction with the prophylactic antiemetic regimens, and the willingness of subjects to use the same treatment during future chemotherapy, as assessed by the Subject Satisfaction\Willingness Assessment in the Subject Diary.|Nausea as assessed by a categorical scale, over the first 120 hours following HEC administration.|Assessment of the safety and tolerability of casopitant through: routine physical exam, routine clinical laboratory tests, clinical monitoring and adverse events reporting.|The proportion of subjects who vomit/retch.|The proportion of subjects achieving complete protection, defined as complete responders who had no significant nausea.|Complete response over 120 hours following subsequent chemotherapy cycles Use of rescue medication over 120 hours following all chemotherapy cycles Impact on daily life activities over 120 hours, assessed using a subject diary questionnaire|The proportion of subjects who achieve a complete response during the acute (0-24 hrs.) and the delayed (24-120 hrs.) phase following the first cycle of HEC|The proportion of subjects who achieve a complete response over the first 120 hours, during the acute (0-24 hrs.), the delayed (24-120 hrs.), and the overall (0-120 hrs.) phase following subsequent cycles of HEC.|Maximum nausea score (to assess the severity of nausea), as assessed by a Visual Analogue Scale (VAS) over the first 120 hours and in the acute and delayed phases following each cycle of HEC.|Time to first antiemetic rescue medication, defined as the time elapsed from the start of the HEC regimen to the first use of antiemetic rescue medication.","https://ClinicalTrials.gov/show/NCT00431236"
1105,"NCT00555620","Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer","Completed","Has Results","Stomach Neoplasms","Drug: capecitabine|Drug: oxaliplatin|Drug: sunitinib malate|Drug: capecitabine|Drug: cisplatin|Drug: sunitinib malate","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","76","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A6181126","November 6, 2007","May 2008","December 2011","January 7, 2013","January 2013","August 4, 2011","null","August 2010","Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)|Maximum Observed Plasma Concentration (Cmax) of SU, SU012662 (Metabolite of SU), and Total Drug (SU + SU012662)|Cmax of CAP|Cmax of 5'-Deoxy-5-fluorocytidine (Metabolite of CAP, 5'DFCR)|Cmax of 5'-Deoxy-5-fluorouridine (Metabolite of CAP, 5'DFUR)|Cmax of 5-fluorouracil (Metabolite of CAP, 5-FU)|Minimum Observed Plasma Trough Concentration (Cmin) of SU, SU012662, and Total Drug (SU + SU012662)|Cmin of CAP|Cmin of 5'DFCR|Cmin of 5'DFUR|Cmin of 5-FU|Time to Reach Maximum Observed Plasma Concentration (Tmax) for SU, SU012662, and Total Drug (SU + SU012662)|Tmax for CAP|Tmax for 5'DFCR|Tmax for 5'DFUR|Tmax for 5-FU|Terminal Elimination Half-Life (t1/2) for SU, SU012662, and Total Drug (SU + SU012662)|t1/2 for CAP|t1/2 for 5'DFCR|t1/2 for 5'DFUR|t1/2 for 5-FU|Area Under the Curve From Time 0 to 24 Hours Postdose (AUC [0-24]) for SU, SU012662, and Total Drug (SU + SU012662)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: CAP, 5'DFCR, 5'DFUR, and 5-FU|Area Under the Curve From Time Zero to 12 Hours [AUC (12)] for CAP, 5'DFCR, 5'DFUR, and 5-FU|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CAP|AUClast for 5'DFCR|AUClast for 5'DFUR|AUClast for 5-FU|Percentage of Participants With Objective Response|Duration of Response (DR)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00555620"
1106,"NCT00066742","Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer","Completed","Has Results","Limited Stage Small Cell Lung Cancer","Drug: tirapazamine|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","72","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03042|U10CA032102|S0222","August 6, 2003","September 2003","August 2009","April 29, 2014","December 2012","June 14, 2012","null","August 2009","Overall Survival|Response Rate (Confirmed and Unconfirmed Complete and Partial Responses Per RECIST) in the Subset of Patients With Measurable Disease at Baseline.|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT00066742"
1107,"NCT03066778","A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)","Recruiting","No Results Available","Small Cell Lung Cancer (SCLC)","Biological: Pembrolizumab|Drug: Normal saline solution|Drug: Carboplatin|Drug: Cisplatin|Drug: Etoposide","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","430","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","3475-604|2016-004309-15","February 23, 2017","May 2, 2017","October 5, 2021","May 22, 2017","May 2017","No Study Results Posted","null","January 3, 2019","Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)|Overall Survival (OS)|Objective Response Rate (ORR) per RECIST 1.1 as Assessed by BICR|Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR|Percentage of Participants Experiencing an Adverse Event (AE)|Percentage of Participants Discontinuing Study Treatment Due to an AE|Percentage of Participants Experiencing Any Grade 3 to 5 AE as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0)|Change from Baseline at Weeks 12 and 24 in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Global Health Status/Quality of Life Scale|Time to True Deterioration in the Composite Endpoint of Cough, Chest Pain, and Dyspnea Using the EORTC Quality of Life Questionnaire and Lung Cancer Module 13 (QLQ-LC13)","https://ClinicalTrials.gov/show/NCT03066778"
1108,"NCT01234324","ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction","Active, not recruiting","No Results Available","Stomach Neoplasms|Gastroesophageal Junction Neoplasms","Drug: Epirubicin, Cisplatin, Capecitabine, Panitumumab|Drug: Epirubicin, Cisplatin, Capecitabine","AIO-Studien-gGmbH|Amgen|WiSP Wissenschaftlicher Service Pharma GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","171","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AIO/CAO-STO-0801|2008-007798-18","October 28, 2010","October 2010","March 2017","January 20, 2017","January 2017","No Study Results Posted","NEOPECX","August 2016","Frequency of pT3/T4 categories after surgery|Frequencies of pN2/N3 categories after surgery","https://ClinicalTrials.gov/show/NCT01234324"
1109,"NCT00952497","A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: Cisplatin, Capecitabine, Telatinib","ACT Biotech, Inc","All","18 Years and older   (Adult, Senior)","Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TEL0805","July 30, 2009","June 2009","January 2012","February 7, 2012","February 2012","No Study Results Posted","null","October 2011","The primary objective is to assess progression free survival (PFS). PFS will be measured from the date of first study drug administration to the date of first scan that first documents disease progression.|Other efficacy variables are overall survival, overall response rate, safety and tolerability. Exploratory analyses may be performed to investigate the correlation of biomarker status with treatment effect and response.","https://ClinicalTrials.gov/show/NCT00952497"
1110,"NCT00716560","Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin","Terminated","No Results Available","Metastatic Melanoma|Nausea","","Sidney Kimmel Cancer Center at Thomas Jefferson University|Merck Sharp & Dohme Corp.|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","","8","Other|Industry","Observational","Observational Model: Case-Only","05C.202|2004-101|0402005015","July 14, 2008","May 2005","March 2009","October 19, 2016","October 2016","No Study Results Posted","null","March 2009","Determine incidence of nausea when receiving Dartmouth regimen chemotherapy for metastatic melanoma|Assess the impact of systemic chemotherapy with Dartmouth regimen on quality of life of patients","https://ClinicalTrials.gov/show/NCT00716560"
1111,"NCT01041404","ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: Trastuzumab|Drug: Fluorouracil|Drug: Cisplatin|Drug: Capecitabine","Hoffmann-La Roche|Chugai Pharmaceutical","All","18 Years and older   (Adult, Senior)","Phase 3","584","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO18255","December 29, 2009","September 2005","June 2010","October 31, 2014","October 2014","July 22, 2014","null","June 2010","Overall Survival (OS) - Percentage of Participants With an Event|Overall Survival - Time to Event|Progression-Free Survival (PFS) - Percentage of Participants With an Event|Progression-Free Survival - Time to Event|Time to Progression (TTP) - Percentage of Participants With an Event|Time to Progression - Time to Event|Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response - Percentage of Participants With an Event|Duration of Response|Percentage of Participants With Clinical Benefit|European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores|EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores|Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)|Percentage of Participants With a Change in Analgesic Medication During the Study|Body Weight (Kilograms [kg]) at BL|Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight|Steady State Trastuzumab Area Under the Concentration (AUC)|Trastuzumab Minimum Serum Concentration (Cmin)|Trastuzumab Maximum Serum Concentration (Cmax)","https://ClinicalTrials.gov/show/NCT01041404"
1112,"NCT01245959","Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Docetaxel, cisplatin and fluorouracil|Radiation: Concurrent chemoradiotherapy","Sun Yat-sen University|Fudan University|West China Hospital|Huazhong University of Science and Technology|Beijing Cancer Hospital|Zhejiang Cancer Hospital|Central South University|Jiangsu Cancer Institute & Hospital|First People's Hospital of Foshan|The Third Affiliated Hospital of Harbin Medical University|Cancer Hospital of Guangxi Medical University|Jiangxi Provincial Cancer Hospital|Guangzhou Medical University","All","18 Years to 59 Years   (Adult)","Phase 3","476","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YP2010171","November 22, 2010","January 2011","April 2018","February 12, 2014","January 2014","No Study Results Posted","null","April 2016","Failure-free survival|Overall survival|Locoregional failure-free survival|Distant failure-free survival|The initial response rates after treatments|Toxic effects","https://ClinicalTrials.gov/show/NCT01245959"
1113,"NCT00602082","Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors","Completed","No Results Available","Gastrointestinal Carcinoid Tumor|Islet Cell Tumor","Drug: capecitabine|Drug: cisplatin|Drug: streptozocin|Genetic: DNA analysis|Genetic: RNA analysis|Genetic: protein analysis|Genetic: proteomic profiling|Other: laboratory biomarker analysis","Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","84","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CRCA-CCTC-NET-01|CDR0000582315|EUDRACT-2004-005202-71|EU-207102|ISRCTN35124268","January 25, 2008","August 2005","December 2009","August 6, 2013","June 2009","No Study Results Posted","null","December 2009","Objective response rate|Overall response rate|Functional response|Toxicity|Progression-free survival|Overall survival|Molecular markers predictive of response to chemotherapy|Quality of life","https://ClinicalTrials.gov/show/NCT00602082"
1114,"NCT01679405","BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer","Terminated","No Results Available","Metastatic Disease","Drug: BIBW 2992","Johannes Gutenberg University Mainz","All","18 Years and older   (Adult, Senior)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BIBW 2992","August 17, 2012","August 2012","December 2016","May 2, 2016","May 2016","No Study Results Posted","null","April 2016","number of adverse events|Progression free survival (PFS)|Overall survival (OS)|Objective response rate|Tumor control rate","https://ClinicalTrials.gov/show/NCT01679405"
1115,"NCT01624051","A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer","Unknown status","No Results Available","Lung Cancer","Other: Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Other: Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass","AHS Cancer Control Alberta|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Senior)","Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","Sawyer - Lung - CCI","April 26, 2012","July 2014","September 2015","September 26, 2014","September 2014","No Study Results Posted","null","September 2015","Dose limiting toxicity rates|Number of Cycles completed|Survival","https://ClinicalTrials.gov/show/NCT01624051"
1116,"NCT00952341","Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","Completed","Has Results","Chemotherapy-induced Nausea and Vomiting (CINV)","Drug: aprepitant|Drug: Comparator: Placebo to aprepitant|Drug: dexamethasone|Drug: granisetron|Drug: dexamethasone","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","421","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","0869-169|2009_626","July 31, 2009","August 2009","May 2010","March 31, 2015","March 2015","July 1, 2011","null","April 2010","Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1|Proportion of Participants With Complete Response in the Acute Phase of Cycle 1|Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1|Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1|Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1|Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1|Proportion of Participants With No Impact on Daily Life in Cycle 1|Time to First Vomiting Episode in Cycle 1","https://ClinicalTrials.gov/show/NCT00952341"
1117,"NCT00017004","Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia","Completed","No Results Available","Anemia|Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma|Drug Toxicity|Radiation Toxicity|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Radiation: External Beam Radiation Therapy|Drug: Cisplatin|Radiation: Internal Radiation Therapy|Biological: Epoetin Alfa","Gynecologic Oncology Group|NCIC Clinical Trials Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","114","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","GOG-0191|NCI-2012-02384|CAN-NCIC-CX4|CDR0000068641|U10CA027469","June 6, 2001","August 2001","null","December 29, 2014","December 2014","No Study Results Posted","null","January 2010","Progression-free survival with progression defined as a 50% or greater increase in the cross-product of the existing primary tumor relative to the smallest cross-product from all previous exams|Overall survival|Local control, coded as successful if any relapse or disease progression is is contained within the pelvic field","https://ClinicalTrials.gov/show/NCT00017004"
1118,"NCT02459457","A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer","Recruiting","No Results Available","Stage III Esophageal Squamous Cell Carcinoma","Drug: Paclitaxel and Cisplatin|Drug: Paclitaxel and Fluorouracil|Drug: Paclitaxel and Carboplatin|Radiation: Radiotherapy","Fudan University|Fudan University Shanghai Cancer Center Minhang Branch|Huadong Hospital|Wuxi No. 4 People's Hospital|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital of Xiamen University|Jiangxi Provincial Cancer Hospital|Shanxi Province Cancer Hospital|Gansu Cancer Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","321","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ESO-Shanghai 2","May 23, 2015","July 2015","December 2021","April 7, 2016","April 2016","No Study Results Posted","null","August 2019","1-yr overall survival|2-yr overall survival|3-yr overall survival|progression free survival|adverse event","https://ClinicalTrials.gov/show/NCT02459457"
1119,"NCT02776163","Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors","Recruiting","No Results Available","Salivary Gland Tumors|Head and Neck Cancer","Drug: Cisplatin|Drug: Docetaxel|Radiation: Intensity-modulated radiotherapy","Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2016HNRT002","May 12, 2016","June 2016","December 2019","September 30, 2016","September 2016","No Study Results Posted","null","December 2017","Disease-free survival|Overall survival rate|Acute toxicity profiles, graded according to the NCI CTCAE version 3.0|Late toxicity profiles, graded according to the NCI CTCAE version 3.0|Score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Core 35 (EORTC QLQ-HN35) during the concurrent treatment","https://ClinicalTrials.gov/show/NCT02776163"
1120,"NCT01230996","Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Drug: cisplatin|Radiation: intensity-modulated radiation therapy","St. Bartholomew's Hospital|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","44","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000687340|BARTS-6883|EU-21079","October 28, 2010","July 2010","null","October 28, 2010","October 2010","No Study Results Posted","null","July 2013","Grade 3 gastrointestinal toxicity at 6 months as defined by CTCAE v 3.0|Response rate assessed radiologically at 3 and 12 months|Local control of the disease at 2 years|Late toxicity at 2 years as defined by CTCAE v 3.0","https://ClinicalTrials.gov/show/NCT01230996"
1121,"NCT03058094","A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI","Not yet recruiting","No Results Available","NSCLC","Drug: Pemetrexed|Drug: Cisplatin 75mg/m2|Drug: AC0010","Hangzhou ACEA Pharmaceutical Research Co.,Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","366","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","AEGIS2:AC201602AVTN04","December 1, 2016","April 1, 2017","January 1, 2020","February 15, 2017","February 2017","No Study Results Posted","null","April 1, 2019","Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Overall Survival (OS)|Patient Reported Outcomes by EORTC QLQ-C30 Questionnaire","https://ClinicalTrials.gov/show/NCT03058094"
1122,"NCT01466244","Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Genetic: gene expression analysis|Genetic: microarray analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","42","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000715505|ECOG-E5397T3","November 2, 2011","November 11, 2011","January 11, 2012","May 16, 2017","May 2017","No Study Results Posted","null","January 11, 2012","Cetuximab activity as reflected in RR","https://ClinicalTrials.gov/show/NCT01466244"
1123,"NCT01222676","Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder","Unknown status","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: sorafenib tosylate|Other: imaging biomarker analysis|Other: laboratory biomarker analysis|Procedure: computed tomography|Procedure: neoadjuvant therapy|Radiation: fludeoxyglucose F 18","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","ITA-MIL-IRCCS-INT-52/10|CDR0000686602|EUDRACT-2010-022653-41|EU-21077","October 15, 2010","October 2010","null","August 9, 2013","October 2010","No Study Results Posted","null","October 2013","Pathological complete response|Safety and tolerability|Potential biological correlates of disease response and drug activity in tumor tissue samples before and after therapy|Correlation between 18FDG-PET and standard CT results","https://ClinicalTrials.gov/show/NCT01222676"
1124,"NCT00077103","Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer","Terminated","No Results Available","Head and Neck Cancer","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: fosbretabulin disodium|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU3302|P30CA043703|CASE-CWRU-3302|CWRU-040337|OXIGENE-CWRU-3302","February 10, 2004","November 2003","December 2007","June 9, 2010","June 2010","No Study Results Posted","null","February 2007","Median survival|Objective disease response","https://ClinicalTrials.gov/show/NCT00077103"
1125,"NCT00434668","Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: cisplatin/docetaxel|Drug: cisplatin/vinorelbine","University Hospital, Antwerp|Universiteit Antwerpen|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","99","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TOGA 0501|Eudra CT 2005-004029-24","February 12, 2007","December 2005","November 2010","November 29, 2010","November 2010","No Study Results Posted","TOLEDO","September 2010","Success of delivery treatment; data collected during chemotherapy treatment|Toxicity (occurrence of any grade 4 toxicity); data collected at the end of each cycle|Overall toxicity|Progression free survival and overall survival","https://ClinicalTrials.gov/show/NCT00434668"
1126,"NCT01762150","Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma","Active, not recruiting","No Results Available","Renal Cell Carcinoma","Drug: Sorafenib|Drug: Gemcitabine|Drug: Cisplatin","Beijing Cancer Hospital|Bayer","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BCH-RCC-120601","December 22, 2012","June 2011","June 2017","May 7, 2017","May 2017","No Study Results Posted","null","December 2016","progress-free survival,PFS|adverse event, AE","https://ClinicalTrials.gov/show/NCT01762150"
1127,"NCT00470366","Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor","Biological: pegfilgrastim|Drug: cisplatin|Drug: ifosfamide|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-044|MSKCC-07044","May 3, 2007","March 2007","June 2016","June 16, 2016","June 2016","No Study Results Posted","null","June 2016","Rate of complete response|Progression-free survival|Number of courses required to achieve maximal response|Duration of response|Safety|Toxicity","https://ClinicalTrials.gov/show/NCT00470366"
1128,"NCT00051480","Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Genetic: TNFerade","GenVec","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","GV-001.005","January 10, 2003","null","null","May 11, 2011","May 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00051480"
1129,"NCT01594099","Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women","Unknown status","No Results Available","Cervical Cancer","Radiation: irradiation|Drug: Cisplatin|Drug: liposome paclitaxel","Health Science Center of Xi’an Jiaotong University","Female","65 Years to 80 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GCR-02","March 27, 2012","April 2012","March 2014","May 6, 2012","May 2012","No Study Results Posted","null","October 2013","Objective Response Rate|Adverse Events|Local Control Rate|Tumor Free Survival Rate|Overall Survival Rate","https://ClinicalTrials.gov/show/NCT01594099"
1130,"NCT00541073","Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery","Completed","No Results Available","Malignant Mesothelioma","Dietary Supplement: vitamin B12|Drug: cisplatin|Drug: pemetrexed disodium|Genetic: gene expression analysis|Other: laboratory biomarker analysis|Other: pharmacological study","Centre Oscar Lambret|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000564058|COL-ALIMESO|INCA-RECF0441|COL-2006-04","October 5, 2007","June 2007","null","May 14, 2011","July 2009","No Study Results Posted","null","May 2011","Individual dosage-adapted protocol|Relationship between pharmacokinetic and pharmacodynamic parameters|Pharmacokinetics|Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)","https://ClinicalTrials.gov/show/NCT00541073"
1131,"NCT02236936","Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck","Recruiting","No Results Available","Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Laryngeal Squamous Cell Carcinoma Stage III|Laryngeal Squamous Cell Carcinoma Stage IV|Oropharyngeal Squamous Cell Carcinoma Stage III|Oropharyngeal Squamous Cell Carcinoma Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV|Locally Advanced Malignant Neoplasm","Dietary Supplement: Standard care of parenteral nutrition|Dietary Supplement: Parenteral over night nutrition|Biological: Cetuximab|Drug: Cisplatin|Radiation: Radiotherapy","Arbeitsgemeinschaft medikamentoese Tumortherapie|Medical University of Graz","All","18 Years and older   (Adult, Senior)","Phase 3","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AGMT_HNO_PN","September 5, 2014","February 3, 2017","September 2021","May 23, 2017","May 2017","No Study Results Posted","AGMT_HNO_PN","September 2021","Loss of body weight by more than 5% at the end of radiotherapy|Bioelectrical Impedance Analysis (BIA): reduction of phase angle by > 10% during treatment/observation","https://ClinicalTrials.gov/show/NCT02236936"
1132,"NCT01192165","Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel","Completed","No Results Available","Cancer","Drug: Trametinib (GSK1120212)|Drug: Docetaxel|Drug: Erlotinib|Drug: Pemetrexed|Drug: Carboplatin|Drug: nab-Paclitaxel|Drug: Cisplatin","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1","169","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","113486|2012-000257-32","August 30, 2010","September 2010","October 2013","November 21, 2013","November 2013","No Study Results Posted","null","October 2013","To determine the safety, tolerability, and recommended phase II dosing regimen of each GSK1120212-based treatment combination|To characterize population pharmacokinetic parameters|To evaluate the anti-tumor activity as assessed by tumor response rate according to RECIST v1.1","https://ClinicalTrials.gov/show/NCT01192165"
1133,"NCT01882621","Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Monosialoganglioside(GM1)|Drug: normal saline","Sun Yat-sen University|Southern Medical University, China","All","Child, Adult, Senior","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GM1-0324","June 17, 2013","October 2013","August 2016","May 28, 2016","May 2016","No Study Results Posted","null","August 2016","incidence rate of neurotoxicity adverse events|neurotoxicity adverse events alleviation time","https://ClinicalTrials.gov/show/NCT01882621"
1134,"NCT00619359","Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)","Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting (CINV)","Drug: Comparator: fosaprepitant dimeglumine|Drug: Comparator: Aprepitant|Drug: Dexamethasone|Drug: Dexamethasone|Drug: Ondansetron","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","2322","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Prevention","0517-017|MK0517-017|2007_594","January 28, 2008","February 2008","June 2009","February 14, 2017","February 2017","January 19, 2010","EASE","June 2009","A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin).|A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin).|No Vomiting Overall (in the 120 Hours Following Initiation of Cisplatin)","https://ClinicalTrials.gov/show/NCT00619359"
1135,"NCT00033449","Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Terminated","No Results Available","Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Oropharynx","Drug: gefitinib|Radiation: radiation therapy|Drug: cisplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02462|UCHSC-01460|CDR0000069284","April 9, 2002","February 2002","null","January 24, 2013","January 2013","No Study Results Posted","null","April 2010","Incidence of grade 4 or greater mucositis as scored by the National Cancer Institute (NCI) Common Toxicity Criteria v2.0|Incidence of grade 4 or greater skin toxicity as scored by the NCI Common Toxicity Criteria v2.0|Incidence of any other grade 4 or greater toxicity as scored by the NCI Common Toxicity Criteria v2.0|Primary tumor response rate as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)|Response rates as assessed by the RECIST|Relapse-free survival rates|Overall survival rates|Biological effects of gefitinib within the primary tumor and skin","https://ClinicalTrials.gov/show/NCT00033449"
1136,"NCT01074970","PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations","Active, not recruiting","No Results Available","Breast Cancer","Drug: Cisplatin|Drug: Rucaparib|Drug: Cisplatin","Hoosier Cancer Research Network|Clovis Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","135","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRE09-146","February 23, 2010","February 2010","August 2017","August 22, 2016","August 2016","No Study Results Posted","null","August 2017","Two-year Disease Free Survival|Side Effects and Tolerability|One-year Disease Free Survival|Overall Survival|Pharmacokinetic Data|Specimen Collection","https://ClinicalTrials.gov/show/NCT01074970"
1137,"NCT00165490","Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer","Completed","No Results Available","Adenocarcinoma of Esophagus|Squamous Cell Carcinoma of Esophagus","Drug: Cetuximab|Drug: Cisplatin|Drug: Irinotecan|Device: Radiation therapy|Procedure: Surgery","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-012","September 9, 2005","August 2004","November 2014","November 7, 2014","November 2014","No Study Results Posted","null","November 2007","To determine the response to the combination of cetuximab, cisplatin, irinotecan, and radiation therapy in resectable esophageal carcinoma.|To determine the safety of the drug combination and radiation therapy|To determine the progression-free survival of patients treated with combination chemotherapy and radiation therapy.","https://ClinicalTrials.gov/show/NCT00165490"
1138,"NCT00290719","Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery","Terminated","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: gefitinib|Drug: irinotecan hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000456200|UCSF-034510|ZENECA-1839US/0244","February 9, 2006","November 2005","June 2008","May 7, 2014","May 2014","No Study Results Posted","null","April 2008","Pathological response (complete and partial) post-operatively|Safety and toxicity post-operatively|Response rate 2 weeks into treatment, pre-operatively, and post-operatively|Completeness of resection post-operatively|Surgical morbidity and mortality post-operatively|Compare the effects of gefitinib on biomarkers that effect EGF signaling and genomic composition of tumor samples before and after treatment","https://ClinicalTrials.gov/show/NCT00290719"
1139,"NCT00916669","A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","Withdrawn","No Results Available","Small Cell Lung Cancer","Drug: Etoposide|Drug: Cisplatin|Drug: enoxaparin sodium","Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|North Shore Medical Center|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08-097","June 5, 2009","July 2008","null","May 7, 2013","July 2010","No Study Results Posted","null","July 2010","To evaluate the prophylactic and treatment doses of Enoxaparin sodium given in combination with standard chemotherapy compared to standard chemotherapy alone with respect to time to tumor progression in this patient population.|To determine the effect of 2 different doses of enoxaparin sodium in combination with chemotherapy and chemotherapy alone on biomarkers of angiogenesis and to identify if these markers correlate with overall survival and progression free survival.|To evaluate toxicity and determine the rates of bleeding complications in this patient population.","https://ClinicalTrials.gov/show/NCT00916669"
1140,"NCT00213486","Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial","Completed","No Results Available","Esophageal Neoplasms","Drug: irinotecan","University Hospital, Rouen","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2001/141/HP","September 13, 2005","June 2002","December 2004","October 27, 2005","September 2005","No Study Results Posted","null","null","clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan|toxicity profile|overall survival rate at one and two years","https://ClinicalTrials.gov/show/NCT00213486"
1141,"NCT02998385","Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors","Recruiting","No Results Available","HNSCC","Drug: Cisplatin|Radiation: radiotherapy","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years and older   (Adult, Senior)","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC 2016-02","December 15, 2016","November 2016","November 2026","December 16, 2016","December 2016","No Study Results Posted","SANTAL","November 2023","Progression-free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02998385"
1142,"NCT00842660","Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Drug: Gemzar (gemcitabine)","Chang Gung Memorial Hospital|Eli Lilly and Company","Female","35 Years to 70 Years   (Adult, Senior)","Phase 3","172","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","97-1165A3","February 8, 2009","February 2009","January 2013","January 3, 2010","February 2009","No Study Results Posted","null","January 2012","Patient survival, including overall survival and progression-free survival.|1) Acute toxicity during treatment 2) Tumor response rates 3) Sites of recurrence 4) Long-term complications and quality of life","https://ClinicalTrials.gov/show/NCT00842660"
1143,"NCT00083252","Study of Talabostat and Cisplatin in Advanced Melanoma","Completed","No Results Available","Melanoma|Skin Cancer","Drug: talabostat (PT-100) tablets|Drug: cisplatin","Point Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PTH-303","May 14, 2004","null","null","June 7, 2007","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00083252"
1144,"NCT00430313","Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin","Active, not recruiting","No Results Available","Liver Cancer|Liver Metastasis","Procedure: Electro-Stimulation of Yongquan (K1) Acupoint|Procedure: Electro-Stimulation of Yongquan (K1) Acupoint","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","2006-0735|U19 CA12150301|NCI-2012-02114","January 30, 2007","January 2007","January 2019","March 10, 2017","March 2017","No Study Results Posted","null","January 2019","Level of Patient Nausea + Vomiting","https://ClinicalTrials.gov/show/NCT00430313"
1145,"NCT00319514","Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC","Completed","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: Docetaxel","Gachon University Gil Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMO-LU-42","April 28, 2006","April 2004","October 2006","March 10, 2008","March 2008","No Study Results Posted","null","null","Objective response rate|Progression-free survival|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT00319514"
1146,"NCT02555644","A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Neoplasms","Drug: Prexasertib|Drug: Cisplatin|Drug: Cetuximab|Radiation: Intensity Modulated Radiation Therapy","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16016|I4D-MC-JTJI|2015-001215-12","September 18, 2015","February 2016","October 2018","December 23, 2016","December 2016","No Study Results Posted","null","October 2018","Part A: Maximum Tolerated Dose of Prexasertib in Combination with Cisplatin and Radiation Therapy|Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab and Radiation Therapy|Pharmacokinetics (PK): Maximum Concentration of Prexasertib, Cisplatin and Cetuximab|PK: Area Under the Concentration Curve (AUC) of Prexasertib|Locoregional Control Rate","https://ClinicalTrials.gov/show/NCT02555644"
1147,"NCT01495676","A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer","Recruiting","No Results Available","Infiltrating Bladder Urothelial Carcinoma","Other: Radiation + cisplatin|Other: Radiation + cisplatin + gemcitabine","Institut du Cancer de Montpellier - Val d'Aurelle","All","18 Years and older   (Adult, Senior)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GETUG V04|2011-000408-17","December 14, 2011","September 2011","September 2019","March 2, 2015","March 2015","No Study Results Posted","GETUGV04","September 2016","Disease-free survival|Overall survival|Acute and late toxicities|Quality of life|Correlation between lymphocyte apoptosis and severity of late toxicities.","https://ClinicalTrials.gov/show/NCT01495676"
1148,"NCT00721513","Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Procedure: computed tomography|Procedure: positron emission tomography|Procedure: quality-of-life assessment|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCWFU 60108|P30CA012197|CCCWFU-60108|CCCWFU-IRB- IRB00005784|SANOFI-AVENTIS-CCCWFU-60108","July 23, 2008","September 2008","null","October 22, 2015","October 2015","No Study Results Posted","null","September 2017","Progression-free survival|Objective response rate|Best overall response rate|Overall survival and local-regional control|Incidence of distant metastasis|Accuracy of PET/CT scan in evaluating objective response; in detecting residual disease at primary sites and nodes; in guiding the recommendation for salvage surgery or for neck dissection; and in early detection of recurrent or metastatic disease|Acute and chronic toxicities|Quality of life and swallowing","https://ClinicalTrials.gov/show/NCT00721513"
1149,"NCT00005819","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: fenretinide|Drug: paclitaxel","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU3Y99|U01CA062502|P30CA043703|CWRU-3Y99|NCI-T99-0098|CASE-3Y99","June 2, 2000","April 2000","August 2006","June 9, 2010","June 2010","No Study Results Posted","null","May 2005","Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.","https://ClinicalTrials.gov/show/NCT00005819"
1150,"NCT01336049","Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer","Unknown status","No Results Available","Esophageal Squamous Cell Cancer","Drug: Nimotuzumab","Peking University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N+TP-AEC3","March 29, 2011","March 2011","null","April 14, 2011","March 2011","No Study Results Posted","null","December 2011","Objective response rate|overall survival of all participants|progression free survival|adverse events","https://ClinicalTrials.gov/show/NCT01336049"
1151,"NCT02567253","Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer","Recruiting","No Results Available","Ovarian Cancer|Primary Peritoneal Cancer","Procedure: Cytoreductive surgery|Drug: IPEC with Cisplatin (75mg/m²)|Drug: IPEC with Cisplatin (120mg/m²)|Drug: Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Drug: HIPEC with Cisplatin (120mg/m²)","University Hospital, Ghent","Female","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Outcomes Assessor|Primary Purpose: Treatment","AGO/2015/002","September 23, 2015","March 2016","November 2018","April 14, 2017","April 2017","No Study Results Posted","OvIP1","July 2018","Tissue penetration distance of cisplatin in peritoneal tumor tissue nodules using laser-ablation inductively couples plasma mass spectrometry|Surgical morbidity and mortality will be measured using Dindo-Clavien classification|Cancer-specific Quality of Life-C30|Disease-specific Quality of Life-OV28|Maximum perfusate concentration (Cmax) of cisplatin|Maximum plasma concentration (Cmax) and Area Under The Curve (AUC) of cisplatin|Pharmacodynamics (PD) of cisplatin will be analyzed by visualizing the amount of DNA double-strand breaks (dsb) via the specific DNA-adduct immunohistochemical Liedert staining|Overall survival|Disease free survival|Peritoneal recurrence free survival|Expression analysis of selected biomarkers = Excision repair cross-complementation group 1 (ERCC1), Methylguanine methyltransferase enzyme (MGMT), Breast cancer gene 1 (BRCA1), Copper transporter 1 (CTR1) using quantitative PCR|Stromal composition and density of tumor tissues via analyzing collagen density, fibroblast Proliferation and DNA-intrastrand adduct formation of Pt-[GG]","https://ClinicalTrials.gov/show/NCT02567253"
1152,"NCT00034268","A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: LY900003","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6428|H7X-MC-JVAA","April 24, 2002","March 2002","null","July 18, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00034268"
1153,"NCT01454102","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab|Drug: Erlotinib|Biological: Ipilimumab","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-012","September 16, 2011","December 2011","November 2017","April 17, 2017","July 2016","No Study Results Posted","null","November 2017","Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of drug related adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of serious adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of clinical laboratory test by worst toxicity grade|ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of subjects treated in arms A, B, C and D|PFSR based on RECIST 1.1 of subjects treated in arms A, B, C and D|ORR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|PFSR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|ORR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N|PFSR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N","https://ClinicalTrials.gov/show/NCT01454102"
1154,"NCT00401492","MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: gemcitabine prolonged continuous infusion|Drug: cisplatin|Drug: vinorelbine","National Cancer Institute, Naples","All","70 Years and older   (Senior)","Phase 2","159","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MILES-02","November 17, 2006","June 2002","April 2007","July 12, 2012","July 2012","No Study Results Posted","null","December 2006","Activity and toxicity of monochemotherapy with gemcitabine as prolonged infusion|Toxicity and activity of 2 standard polychemotherapy cisplatin based treatments (cisplatin and vinorelbine , and cisplatin and gemcitabine|patient quality of life|the prognostic significance of the ADL and IADL scales for time to progression and survival|exploratory predictive clinical variables for chemotherapy related toxicity|exploratory predictive clinical variables for response to chemotherapy","https://ClinicalTrials.gov/show/NCT00401492"
1155,"NCT01665183","Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma","Completed","No Results Available","Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors","Drug: ADI-PEG 20","Polaris Group","All","18 Years and older   (Adult, Senior)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","POLARIS2012-005","August 8, 2012","September 2012","February 2016","February 24, 2016","February 2016","No Study Results Posted","null","February 2016","Number of participants with adverse events.|Number of participants with objective responses.","https://ClinicalTrials.gov/show/NCT01665183"
1156,"NCT00268450","Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery","Completed","No Results Available","Bladder Cancer","Biological: bevacizumab|Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Medical University of South Carolina","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000454937|MUSC-AVF-3312|MUSC-HR-15537|GENENTECH-AVF-3312|MUSC-CTO-100892","December 20, 2005","September 2005","April 2012","April 26, 2012","April 2012","No Study Results Posted","null","April 2012","Overall pT0 response rate","https://ClinicalTrials.gov/show/NCT00268450"
1157,"NCT00848783","Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers","Terminated","Has Results","Gastric Cancer|Gastric Adenocarcinoma|Esophageal Cancer","Drug: Irinotecan|Drug: Cisplatin|Procedure: Surgery|Drug: Floxuridine|Drug: Capecitabine","New York University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07-837|NYU 05-20","February 19, 2009","May 2008","September 2012","June 17, 2016","June 2016","November 9, 2012","null","August 2011","Number of Patients With One-year Recurrence-free Survival|Overall Survival Rate; Toxicity; Evaluation of Sites of Relapse of Failing Patients","https://ClinicalTrials.gov/show/NCT00848783"
1158,"NCT00660270","Chemotherapy and Radiation Following Pancreatic Surgery","Completed","No Results Available","Pancreatic Cancer","Procedure: Pancreatic Surgery|Radiation: Radiation therapy|Drug: Cisplatin|Drug: 5-FU|Drug: Alpha-interferon|Drug: Gemcitabine","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-0307","April 11, 2008","May 2002","February 2009","April 22, 2013","April 2013","No Study Results Posted","null","November 2006","To describe the overall survival and disease-free survival|To describe the toxicities associated with adjuvant chemoradiation with cisplatin, 5FU and interferon alfa followed by gemcitabine in patients with pancreatic cancers.","https://ClinicalTrials.gov/show/NCT00660270"
1159,"NCT01200797","SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin","Terminated","Has Results","Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer","Drug: SJG-136|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","19","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02519|MCC-VICC-GYN-1003|CDR0000682791|VICC GYN 1003|8489|N01CM00100","September 10, 2010","July 2010","February 2013","May 7, 2015","May 2015","October 7, 2013","null","October 2012","Overall Response (OR)|Number of Patients With Each Worst-grade Toxicity|Progression-free Survival (PFS)|Overall Survival (OS)|Time to Progression (TTP)","https://ClinicalTrials.gov/show/NCT01200797"
1160,"NCT02609503","Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin","Recruiting","No Results Available","Head and Neck Cancer","Drug: Pembrolizumab|Radiation: Intensity Modulated Radiation Theapy","UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1509","November 12, 2015","February 2016","August 2021","April 24, 2017","April 2017","No Study Results Posted","null","August 2018","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02609503"
1161,"NCT01679340","A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery","Recruiting","No Results Available","Gastric Cancer","Drug: S-1|Drug: oxaliplatin|Drug: cisplatin","Peking University|Taiho Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 2","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","SOXSP","June 13, 2012","April 2011","June 2018","May 17, 2015","May 2015","No Study Results Posted","null","March 2018","replase free survival|overall survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01679340"
1162,"NCT00066222","Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Radiation: Radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","72","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0239|CDR0000271939","August 6, 2003","June 2003","November 2013","December 10, 2014","December 2014","December 10, 2014","null","May 2012","Overall Survival at 2 Years|Overall Survival at 1 Year and Median Overall Survival|Progression-free Survival at 1 Year and Median Survival Time|Rate of Acute Treatment Related Grade 3 or 4 Esophagitis|Rate of Treatment Related Fatalities at 2 Years|Response Rates (Complete Response, Partial Response, Progressive Disease and Stable Disease)","https://ClinicalTrials.gov/show/NCT00066222"
1163,"NCT01221753","Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study","Terminated","Has Results","Squamous Cell Carcinoma of the Head and Neck|Human Papilloma Virus","Drug: docetaxel|Drug: cisplatin|Drug: 5-FU|Radiation: IMRT|Drug: cetuximab|Drug: carboplatin","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-038","September 21, 2010","July 2011","July 2017","October 13, 2016","October 2016","August 15, 2016","null","July 2012","2-Year Local-Regional Control Rate|4-y Overall Survival Rate","https://ClinicalTrials.gov/show/NCT01221753"
1164,"NCT00002654","Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: chemotherapy|Drug: cisplatin|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Swiss Group for Clinical Cancer Research","All","20 Years to 75 Years   (Adult, Senior)","Phase 3","224","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SAKK 10/94|SWS-SAKK-10/94|EU-94039|CDR0000064188","November 1, 1999","April 1994","July 2000","March 6, 2013","March 2013","No Study Results Posted","null","March 1999","","https://ClinicalTrials.gov/show/NCT00002654"
1165,"NCT01716546","Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer","Terminated","No Results Available","Gastric Cancer","Drug: Pazopanib","Hellenic Oncology Research Group","All","20 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/09.10","October 2, 2012","July 2011","January 2015","October 7, 2015","October 2015","No Study Results Posted","null","January 2015","Objective response rate|Progression Free Survival|Overall Survival|Maximum Tolerated Dose of the combination","https://ClinicalTrials.gov/show/NCT01716546"
1166,"NCT02818725","I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations","Active, not recruiting","No Results Available","Infiltrating Urothelial Carcinoma|KRAS Gene Mutation","Drug: Chemotherapy|Drug: panitumumab","UNICANCER","All","18 Years and older   (Adult, Senior)","Phase 3","93","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GETUG-AFU 19/0903","November 29, 2011","June 2010","September 2017","June 29, 2016","June 2016","No Study Results Posted","GETUG-AFU19","September 2016","Time to progression|Toxicities assessment|Evaluation of response|Evaluation of overall survival|Evaluation of time to progression","https://ClinicalTrials.gov/show/NCT02818725"
1167,"NCT02764593","Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma (HNSCC)","Drug: Nivolumab|Drug: Cisplatin|Drug: Cetuximab|Radiation: IMRT","RTOG Foundation, Inc.|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RTOG 3504|RF 3504|CA209-410","May 4, 2016","June 2016","March 2021","May 18, 2017","May 2017","No Study Results Posted","null","March 2019","Dose Limiting Toxicity (DLT)","https://ClinicalTrials.gov/show/NCT02764593"
1168,"NCT01000415","Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients","Recruiting","No Results Available","Cervical Cancer","Other: Neoadjuvant chemotherapy followed by surgery","Thai Gynecologic Oncology Collaborative Group|National Research Council of Thailand|Clinical Research Collaborative Network","Female","18 Years to 60 Years   (Adult)","Phase 3","824","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TGOC-03|ECPSU-522231012","October 21, 2009","June 2009","June 2018","June 23, 2010","March 2010","No Study Results Posted","TGOCphaseIII","September 2013","Overall survival comparison between experimental treatment group and standard treatment group|Comparing disease free survival between experimental treatment group and standard treatment group","https://ClinicalTrials.gov/show/NCT01000415"
1169,"NCT01373463","Cisplatin and Pemetrexed With Radiation Followed by Lobectomy","Terminated","No Results Available","Nonsquamous Nonsmall Cell Neoplasm of Lung|Nonsmall Cell Lung Cancer Stage III","Drug: Pemetrexed|Drug: Carboplatin|Radiation: Radiation Therapy|Drug: Pemetrexed|Drug: Cisplatin|Radiation: Radiation Therapy|Procedure: Lobectomy|Procedure: Lobectomy","Medical University of South Carolina","All","18 Years to 90 Years   (Adult, Senior)","Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","101466","June 13, 2011","May 2011","June 2012","July 24, 2012","July 2012","No Study Results Posted","CisPemXetSrg","June 2012","Safety and tolerability|Response rate, overall survival and progression free survival","https://ClinicalTrials.gov/show/NCT01373463"
1170,"NCT00705874","Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma","Completed","Has Results","Cancer","Drug: CGC-11047 and gemcitabine|Drug: CGC-11047 and docetaxel|Drug: CGC-11047 and bevacizumab|Drug: CGC-11047 and erlotinib|Drug: CGC-11047 and cisplatin|Drug: CGC-11047 and 5-flurouracil / leucovorin|Drug: CGC-11047 and sunitinib","Progen Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","172","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","47-01-002","June 23, 2008","May 2006","September 2011","June 21, 2016","June 2016","November 17, 2011","null","August 2011","Maximum Tolerated Dose (MTD)|Drug Safety|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00705874"
1171,"NCT00190801","Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma","Completed","No Results Available","Gastrointestinal Neoplasms","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6154|H3E-KL-JMFK","September 12, 2005","September 2003","September 2005","January 24, 2007","January 2007","No Study Results Posted","null","null","Response rate according to RECIST criteria|The following time to event efficacy measures:|o Duration of overall response for responding patients|o Time to documented progressive disease|o Time to treatment failure|o Overall survival|The quantitative and qualitative toxicity of pemetrexed plus cisplatin in this patient population","https://ClinicalTrials.gov/show/NCT00190801"
1172,"NCT02396498","SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy","Unknown status","No Results Available","Stage Ⅲ Gastric Cancer","Drug: HIPEC","Tang-Du Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TDCCC005","November 11, 2014","April 2014","December 2016","March 17, 2015","March 2015","No Study Results Posted","null","April 2016","DFS: Disease-Free Survival|OS: Overall Survival|The quality of life|Safety as measured by Adverse Events and Serious Adverse events In the process of the total treatment according CTCAE4.0","https://ClinicalTrials.gov/show/NCT02396498"
1173,"NCT00052494","Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: imatinib mesylate|Drug: irinotecan hydrochloride","University Health Network, Toronto|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PMH-PHL-008|CDR0000258487|NCI-5684","January 24, 2003","April 2003","null","July 22, 2015","July 2015","No Study Results Posted","null","February 2009","","https://ClinicalTrials.gov/show/NCT00052494"
1174,"NCT01211275","Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma","Completed","No Results Available","Malignant Pleural Mesothelioma","Biological: axitinib|Drug: chemotherapy","The Netherlands Cancer Institute|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NL25655.031.08","September 27, 2010","May 22, 2009","May 6, 2013","February 27, 2017","February 2017","No Study Results Posted","N08CPA","November 13, 2012","To test the impact of the addition of axitinib to standaard chemotherapy treatment on histology samples|the side effects of the standard chemotherapy and the additional risks related to axitinib use","https://ClinicalTrials.gov/show/NCT01211275"
1175,"NCT01121393","BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)","Active, not recruiting","Has Results","Carcinoma, Non-Small-Cell Lung|Adenocarcinoma","Drug: Gemcitabine+Cisplatin|Drug: BIBW 2992","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 3","364","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","1200.34","April 21, 2010","April 2010","July 2017","February 10, 2017","February 2017","December 27, 2014","null","December 2013","Progression-free Survival|Objective Response (OR)|Disease Control (DC)|Overall Survival (OS)|Time to Objective Response (OR)|Duration of Objective Response|Duration of Disease Control|Tumour Shrinkage|Change From Baseline in Body Weight|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)|Health Related Quality of Life (HRQOL): Time of Deterioration in Coughing|Health Related Quality of Life (HRQOL): Time of Deterioration in Dyspnoea|Health Related Quality of Life (HRQOL): Time of Deterioration in Pain|Pharmacokinetics of Afatinib at Day 22|Pharmacokinetics of Afatinib at Day 29|Pharmacokinetics of Afatinib at Day 43|Safety of Afatinib as Indicated by Intensity and Incidence of Adverse Events|Changes in Safety Laboratory Parameters","https://ClinicalTrials.gov/show/NCT01121393"
1176,"NCT00466466","Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients","Completed","No Results Available","Small-Cell Lung Cancer","Drug: Everolimus","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRAD001C2116","April 26, 2007","April 2007","null","November 21, 2011","November 2011","No Study Results Posted","null","November 2010","Dose limiting toxicity (DLT) rate will be measured at End-of-Cycle 1|Relative dose intensity (RDI) of carboplatin and paclitaxel will be evaluated upon completion of the dose escalation within each regimen|PK parameters derived from the PK profile of treatment drugs when administered alone or in combination will be evaluated during the first 6 cycles|Overall tumor response","https://ClinicalTrials.gov/show/NCT00466466"
1177,"NCT03117257","Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN","Recruiting","No Results Available","Locally Advanced Head and Neck Squamous Cell Carcinoma","Drug: Lobaplatin|Drug: Cisplatin","Guiyang Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","20160819","April 2, 2017","August 19, 2016","August 20, 2021","April 14, 2017","April 2017","No Study Results Posted","null","August 19, 2019","National Cancer Institute CTCAE v4.0|evaluation of immediate efficacy|overall survival|progression-free survival","https://ClinicalTrials.gov/show/NCT03117257"
1178,"NCT01593475","Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma","Active, not recruiting","No Results Available","Pancreatic Carcinoma Non-resectable","Radiation: Induction chemotherapy followed by CCRT","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-11-567","May 1, 2012","March 2012","August 2017","September 20, 2016","September 2016","No Study Results Posted","null","August 2017","feasibility and compliance|overall survival|disease-free survival.","https://ClinicalTrials.gov/show/NCT01593475"
1179,"NCT00404326","Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: Hydralazine and magnesium valproate|Procedure: Punch biopsy of the primary tumor","National Institute of Cancerología|National Council of Science and Technology, Mexico|Psicofarma S.A. de C.V.","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","005/013/ICI","November 25, 2006","May 2005","November 2006","November 27, 2006","November 2006","No Study Results Posted","null","null","Clinical Response|Safety|Gene expression profiling|Global DNA methylation|HDAC activity|Plasma levels hydralazine and valproic acid","https://ClinicalTrials.gov/show/NCT00404326"
1180,"NCT01578668","Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases","Completed","No Results Available","Lung Adenocarcinoma|Brain Metastases","Drug: erlotinib|Drug: pemetrexed|Drug: cisplatin|Drug: erlotinib","Guangzhou Medical University","All","18 Years and older   (Adult, Senior)","Phase 2","69","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GZTO1201","April 11, 2012","January 2012","January 2015","January 23, 2015","January 2015","No Study Results Posted","null","January 2015","The objective response rate of brain metastases|The disease control response rate of disease|Progression-free survival of patients|Number of participants with adverse events as a measure of safety|Overall survival of patients","https://ClinicalTrials.gov/show/NCT01578668"
1181,"NCT01038661","Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy","Completed","No Results Available","Lung Neoplasms","Drug: Docetaxel|Drug: Cisplatin|Other: Best supportive care (BSC)","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","375","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_04827","December 22, 2009","November 2009","August 2012","February 27, 2014","February 2014","No Study Results Posted","TFINE","August 2012","Progression-free survival (PFS) during the maintenance treatment phase|Disease control rate (DCR) during the first line treatment phase|Overall response rate (ORR) during the first line treatment phase|Time to disease progression (TTP) during the maintenance treatment phase|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT01038661"
1182,"NCT00296335","Trial of Adjuvant Chemotherapy for Gastric Cancer","Completed","Has Results","Stomach Cancer","Drug: Mitomycin, doxifluridine and cisplatin|Drug: Mitomycin and doxifluridine","Asan Medical Center|Ulsan University Hospital|Hallym University Medical Center","All","18 Years to 69 Years   (Adult, Senior)","Phase 3","855","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0204","February 24, 2006","February 2002","December 2009","January 13, 2014","January 2014","November 12, 2013","null","November 2007","Relapse-free Survival Rate|Overall Survival Rate|Number of Patients With Adverse Events","https://ClinicalTrials.gov/show/NCT00296335"
1183,"NCT00506155","Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer","Completed","Has Results","Bladder Cancer","Drug: Avastin|Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate|Drug: Vinblastine Sulfate","M.D. Anderson Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0620","July 23, 2007","June 2007","August 2014","March 1, 2016","March 2016","March 1, 2016","null","August 2014","Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen|5-year Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00506155"
1184,"NCT01296763","Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer","Completed","Has Results","Pancreatic Cancer","Drug: Irinotecan|Drug: Cisplatin|Drug: Olaparib (for levels 1 and 5)|Drug: Olaparib (for dose level 2)|Drug: Mitomycin-C","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1070|RC2CA148346-01|NA_00032826","January 21, 2011","January 2011","February 2016","February 19, 2016","February 2016","December 4, 2015","null","January 2014","Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD)|Number of Years From Cycle 1, Day 1 On-Study to Date of Death","https://ClinicalTrials.gov/show/NCT01296763"
1185,"NCT00898495","Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery","Completed","No Results Available","Esophageal Cancer","Genetic: loss of heterozygosity analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","118","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000551712|ECOG-E1201T1","May 9, 2009","May 11, 2007","December 31, 2008","May 17, 2017","May 2017","No Study Results Posted","null","December 31, 2008","Comparison of pretreatment clinical tumor staging vs post-treatment pathologic staging (at resection)","https://ClinicalTrials.gov/show/NCT00898495"
1186,"NCT00540280","Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer","Suspended","No Results Available","Carcinoma, Non-Small-Cell Lung","Radiation: Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin","King Faisal Specialist Hospital & Research Center","All","Child, Adult, Senior","Phase 3","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC#2031-059","October 4, 2007","October 2003","October 2013","March 6, 2011","March 2011","No Study Results Posted","null","October 2003","OS, MS, DFS","https://ClinicalTrials.gov/show/NCT00540280"
1187,"NCT01301716","A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors","Completed","No Results Available","Solid Cancers","Drug: GDC-0980|Drug: bevacizumab|Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Drug: pemetrexed","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","75","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PIM4946g|GO01336","February 18, 2011","September 2011","August 2014","November 1, 2016","November 2016","No Study Results Posted","null","August 2014","Incidence of adverse events|Incidence of dose limiting toxicities (DLTs)|Nature of adverse events|Nature of dose limiting toxicities (DLTs)|Severity of adverse events|Total exposure|Maximum plasma concentration|Time to maximum observed plasma concentration|Plasma half-life","https://ClinicalTrials.gov/show/NCT01301716"
1188,"NCT00354549","Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC","Completed","No Results Available","Lung Cancer","Drug: bevacizumab + erlotinib hydrochloride|Drug: gemcitabine hydrochloride + cisplatin or carboplatin","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","104","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 19/05|EU-20614","July 19, 2006","January 2006","September 2010","April 9, 2013","April 2013","No Study Results Posted","null","April 2009","Disease stabilization (DS) (complete response [CR], partial response [PR], or stable disease [SD]) as assessed by RECIST criteria after 12 weeks of treatment with bevacizumab and erlotinib hydrochloride|DS as assessed by RECIST criteria after 6 and 18 weeks of treatment with bevacizumab and erlotinib hydrochloride|Objective response (CR or PR) as assessed by RECIST criteria after 6, 12, and 18 weeks of treatment with bevacizumab and erlotinib hydrochloride|Best overall response when treated with bevacizumab and erlotinib hydrochloride|Adverse events (AEs) when treated with bevacizumab and erlotinib hydrochloride|Time to progression (TTP) when treated with bevacizumab and erlotinib hydrochloride|Time to treatment failure (TTF) when treated with bevacizumab and erlotinib hydrochloride|Quality of life (QOL) when treated with bevacizumab and erlotinib hydrochloride|Objective response (CR or PR) when treated with chemotherapy|Unexpected adverse drug reaction|QOL when treated with chemotherapy|Overall survival (OS) in patients treated with bevacizumab and erlotinib hydrochloride and in patients treated with subsequent chemotherapy at disease progression","https://ClinicalTrials.gov/show/NCT00354549"
1189,"NCT02201355","Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck T1/2N0-2","Radiation: Intensity Modulated Radiotherapy","University of Texas Southwestern Medical Center","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STU 112013-007","July 23, 2014","September 2014","December 2020","December 28, 2016","December 2016","No Study Results Posted","null","December 2017","Treatment completion|adverse events|progression-free survival rates|Health-related quality of life","https://ClinicalTrials.gov/show/NCT02201355"
1190,"NCT00433498","Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: etoposide phosphate|Drug: pravastatin sodium","University College, London","All","18 Years and older   (Adult, Senior)","Phase 3","846","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CDR0000531141|CRUK-LUNGSTAR|EU-20649|ISRCTN56306957|EUDRACT-2005-005821-71|UCL-BRD/05/129|MREC-06-MRE10-28|CTA-20363-0215-001|CTAAC-C1312-A5335|CTAAC-C1312-A12462","February 8, 2007","January 2007","November 2013","December 1, 2014","January 2013","No Study Results Posted","null","January 2012","Survival|Progression-free survival|Local progression-free survival (local control)|Response rate as measured by RECIST criteria after course 3|Toxicity as measured by CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00433498"
1191,"NCT00269997","A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug","Completed","No Results Available","Anemia|Neoplasms","Drug: epoetin alfa","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Senior)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","CR005839","December 22, 2005","null","July 1990","May 17, 2011","April 2010","No Study Results Posted","null","null","Number of transfusions required; Changes in hemoglobin, hematocrit, and reticulocyte (immature red blood cells) levels from before the study to the end of the study|Quality of life assessment; Physician's global evaluation; Performance score (ability to perform daily activities); Assessment of safety (laboratory tests, vital signs, and adverse events) from before the study to the end of the study","https://ClinicalTrials.gov/show/NCT00269997"
1192,"NCT00427102","MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck","Terminated","No Results Available","Squamous Cell Carcinoma|Head and Neck Cancer|Resected Head and Neck Cancer|Mucositis","Drug: Oral MRX-1024|Procedure: Standard Fractionation Radiation Therapy|Drug: High-Dose Cisplatin Chemotherapy","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J-0657|06-01","January 24, 2007","January 2007","July 2007","November 13, 2012","November 2012","No Study Results Posted","null","null","safe recommended doses and dose regimen for oral MRX-1024 with concurrent chemoradiation.|Identify toxicity profile of oral MRX-1024.|Determine pharmacokinetic parameters of oral MRX-1024.|Possibly show a trend in activity of MRX-1024 in preventing or reducing oral mucositis.","https://ClinicalTrials.gov/show/NCT00427102"
1193,"NCT00156286","Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC","Completed","No Results Available","Small Cell Lung Cancer","Drug: Gleevec","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2001-066|Legacy IRB #2002-149","September 7, 2005","March 2002","April 2006","November 12, 2010","November 2010","No Study Results Posted","null","January 2006","Tumor assessment should have been done within 28 days of starting Gleevec. Tumor assessment will be done every 8 weeks while on Gleevec.|Clinical assessment, labs, and toxicity will be done weekly from weeks 2 through 8. Evaluation may be done more frequently after the first 8 weeks if required, but should be done at least every 4 weeks.","https://ClinicalTrials.gov/show/NCT00156286"
1194,"NCT00477867","Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172","Withdrawn","No Results Available","Ovarian Cancer","Procedure: quality-of-life assessment","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","","0","Other|NIH","Interventional","Primary Purpose: Health Services Research","CDR0000078639|GOG-9905","May 23, 2007","null","null","June 7, 2013","October 2007","No Study Results Posted","null","null","Feasibility of collecting data on medical resource utilization and costs incurred in the care of patients with stage III ovarian cancer|Feasibility of collecting data on resource utilization incurred outside GOG institutions|Work load required to collect this data, in terms of mean number of hours required to complete medical resource utilization forms","https://ClinicalTrials.gov/show/NCT00477867"
1195,"NCT01608464","Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer","Terminated","No Results Available","Carcinoma of Esophagus","Drug: irinotecan and docetaxel|Drug: Cisplatin, fluorouracil and concurrent radiation therapy","King Faisal Specialist Hospital & Research Center","All","14 Years to 75 Years   (Child, Adult, Senior)","Phase 2","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2111-104","May 26, 2012","May 2012","September 2015","December 12, 2016","February 2016","No Study Results Posted","null","September 2015","Pathological Complete Response ( regression score 1a- see response assessment) in each treatment group|Rate of conversion from PET non responder to responder with each type of salvage therapy","https://ClinicalTrials.gov/show/NCT01608464"
1196,"NCT00026403","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N9942|NCI-2012-02426|CDR0000069026","November 9, 2001","September 2001","July 2009","July 12, 2016","July 2016","No Study Results Posted","null","June 2007","overall survival|quality of life","https://ClinicalTrials.gov/show/NCT00026403"
1197,"NCT01360086","Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction","Completed","No Results Available","Adenocarcinoma of the Gastroesophageal Junction|Gastric Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Procedure: therapeutic conventional surgery","Federation Francophone de Cancerologie Digestive","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000699219|FFCD-0901|EU-21111|EUDRACT-2010-023115-33|MERCK-FFCD-0901","May 20, 2011","June 2011","March 2013","May 27, 2016","May 2016","No Study Results Posted","null","March 2013","Objective response rate according to RECIST V1.1 criteria|Non-toxicity rate|Tolerance|Post-operative mortality and morbidity|Rate of recurrence at 1 and 2 years|Recurrence-free survival at 3 years|Disease-free survival at 3 years|Overall survival at 3 years|Quality of life as assessed by QLC-C30 and STO-22 questionnaires","https://ClinicalTrials.gov/show/NCT01360086"
1198,"NCT00268671","Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)","Completed","No Results Available","Head and Neck Neoplasms","Drug: Docetaxel","Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976G_2501","December 21, 2005","August 2003","April 2006","December 4, 2009","December 2009","No Study Results Posted","null","April 2006","AE SAE collection","https://ClinicalTrials.gov/show/NCT00268671"
1199,"NCT00001426","A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasm","Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Cisplatin|Drug: G-CSF","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Senior","Phase 2","47","NIH","Interventional","Primary Purpose: Treatment","950055|95-C-0055","November 3, 1999","February 3, 1995","November 7, 2013","April 19, 2017","November 7, 2013","No Study Results Posted","null","October 15, 2007","","https://ClinicalTrials.gov/show/NCT00001426"
1200,"NCT01154920","Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Paclitaxel|Drug: Carboplatin|Drug: Cetuximab|Drug: Docetaxel|Drug: Cisplatin|Drug: Fluorouracil|Radiation: Radiotherapy (RT)|Other: Chemotherapy","M.D. Anderson Cancer Center|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","128","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0885|NCI-2012-01773","June 29, 2010","July 2010","null","September 23, 2016","September 2016","No Study Results Posted","null","July 2018","Number of Patients with Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01154920"
1201,"NCT02885974","Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer","Recruiting","No Results Available","Bladder Cancer","Drug: Celecoxib|Drug: Gemcitabine|Drug: Cisplatin","Baylor College of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H-36486","May 23, 2016","December 2016","June 2020","March 10, 2017","March 2017","No Study Results Posted","BLAST","July 2018","mRNA expression in pre- and post-chemotherapy tissues|Number and severity of adverse events|Pathological disease stage at cystectomy, including the rate of pT0 and the rate of < pT2.|Two-year progression free survival|Two-year overall survival","https://ClinicalTrials.gov/show/NCT02885974"
1202,"NCT02096380","The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: One cycle TPF induction chemotherapy for NPC|Drug: Three cycles TPF induction chemotherapy for NPC","First People's Hospital of Foshan","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FSHNG-1110","November 13, 2011","May 2014","December 2018","March 22, 2014","March 2014","No Study Results Posted","null","December 2017","Failure-free survival|Locoregional failure-free survival|Overall survival|Distant failure-free survival","https://ClinicalTrials.gov/show/NCT02096380"
1203,"NCT00003157","Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach","Completed","No Results Available","Gastric Cancer|Pancreatic Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-964352|CDR0000065949","November 1, 1999","February 1998","May 2003","July 12, 2016","July 2016","No Study Results Posted","null","May 2003","Maximum tolerated dose|Survival","https://ClinicalTrials.gov/show/NCT00003157"
1204,"NCT00409006","Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Gefitinib","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10918|H3E-AA-S110","December 6, 2006","February 2007","May 2010","August 13, 2010","August 2010","August 13, 2010","null","August 2009","Progression-Free Survival (PFS)|Number of Participants With Tumor Response|Duration of Response for Responders|Overall Survival","https://ClinicalTrials.gov/show/NCT00409006"
1205,"NCT02494583","Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","Active, not recruiting","No Results Available","Gastric Adenocarcinoma","Biological: pembrolizumab|Drug: cisplatin|Drug: 5-FU|Drug: capecitabine","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","3475-062|2015-000972-88|163187","July 8, 2015","July 31, 2015","June 6, 2020","May 8, 2017","May 2017","No Study Results Posted","null","February 5, 2019","Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Blinded Independent Central Radiologists' (BICR) Review in Participants Treated with Pembrolizumab Combination Therapy Versus Chemotherapy Alone|Overall Survival (OS)|Overall Response Rate (ORR) per RECIST 1.1 by BICR Review|Duration of Response (DOR) per RECIST 1.1 by BICR Review|PFS per RECIST 1.1 by BICR Review in Participants Treated with Pembrolizumab Monotherapy|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) Core 30-question (C30) Score|Change from Baseline in EORTC QLQ Module for Gastric Cancer (STO22) Score","https://ClinicalTrials.gov/show/NCT02494583"
1206,"NCT00040625","ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.","Approved for marketing","No Results Available","Mesothelioma","Drug: Pemetrexed|Drug: Cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Expanded Access","","6093|H3E-US-JMFE","July 2, 2002","null","null","March 14, 2007","March 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040625"
1207,"NCT00109850","S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer","Terminated","Has Results","Esophageal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000426442|S0414|U10CA032102","May 3, 2005","May 2005","May 2012","November 16, 2015","November 2015","June 14, 2012","null","September 2009","Overall Survival at 2 Years|Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug|Objective Response (Confirmed and Unconfined, Complete and Partial)|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00109850"
1208,"NCT00169182","Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma","Completed","No Results Available","Larynx Cancer|Hypopharynx Cancer","Drug: DOCETAXEL","Groupe Oncologie Radiotherapie Tete et Cou|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","220","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC 2000-01","September 9, 2005","December 2000","null","September 9, 2005","September 2005","No Study Results Posted","null","null","3-years larynx preservation rate|5-years survival rate","https://ClinicalTrials.gov/show/NCT00169182"
1209,"NCT00005840","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer","Completed","No Results Available","Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer","Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiation Therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","35","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9907|NCI-2012-02334|CDR0000067856|U10CA027469","June 2, 2000","July 2000","null","December 29, 2014","December 2014","No Study Results Posted","null","July 2009","Acute toxicity for identification of MTD, using the 21 major categories of the Cancer Therapy Evaluation Program Common Toxicity Criteria (CTEP CTC) v2.0|Chronic toxicity based on the NCI CTC Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity scoring scheme|Number of dose level combinations that will have been evaluated prior to MTD establishment|Site (local/distant) of treatment failure","https://ClinicalTrials.gov/show/NCT00005840"
1210,"NCT00774319","TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Radiation: conventional radiotherapy with 'high' dose cisplatin|Radiation: accelerated radiotherapy with 'low' dose cisplatin","Radboud University|Sanofi","All","18 Years to 65 Years   (Adult)","Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NWHHT08-01","October 16, 2008","December 2008","April 2012","April 10, 2012","April 2012","No Study Results Posted","Condor","April 2012","feasibility of both study-arms|to assess the toxicity profile, tumour response, disease free survival and overall survival in both study-arms. Also QoL will be measured.","https://ClinicalTrials.gov/show/NCT00774319"
1211,"NCT03029832","A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy","Recruiting","No Results Available","Urothelial Carcinoma","Drug: MOXR0916|Drug: Atezolizumab|Drug: Placebo","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","GO39590|2016-004165-58","January 18, 2017","April 27, 2017","June 12, 2022","May 17, 2017","May 2017","No Study Results Posted","null","November 15, 2020","Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response (OR) According to RECIST v1.1|Duration of Objective Response (DOR) According to RECIST v1.1|Time to Pain Progression, Pain Palliation, and Fatigue Progression as Measured by Participant-Reported Severity According to the M. D. Anderson Symptom Inventory (MDASI)|Percentage of Participants Reporting Symptom Interference with Daily Living at the Time of Progression According to the MDASI|Percentage of Participants With Adverse Event (AEs)|Area under the plasma drug concentration-time curve (AUC) of MOXR0916 and Atezolizumab|Maximum Plasma Concentration (Cmax) of MOXR0916 and Atezolizumab|Minimum Plasma Concentration (Cmin) of MOXR0916 and Atezolizumab|Clearance of MOXR0916 and Atezolizumab|Percentage of Participants with Anti-Therapeutic antibodies (ATAs) to MOXR0916 and Atezolizumab","https://ClinicalTrials.gov/show/NCT03029832"
1212,"NCT00191139","Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Non-small Cell Lung Cancer","Drug: gemcitabine|Drug: docetaxel|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4697|B9E-US-S182","September 12, 2005","March 2003","February 2009","February 4, 2010","February 2010","November 20, 2009","null","November 2008","2-Year Survival|Number of Patients With Overall Tumor Response|Progression-Free Survival|Overall Survival|Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization","https://ClinicalTrials.gov/show/NCT00191139"
1213,"NCT01100801","A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients","Recruiting","No Results Available","Recurrent Gastric Cancer","Drug: TS-1 with cisplatin|Drug: TS-1 with oxaliplatin","National University Hospital, Singapore|National Cancer Centre, Singapore|Yonsei University","All","21 Years to 99 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GA01/01/10|2010/00064","April 7, 2010","July 2010","December 2018","June 21, 2016","June 2016","No Study Results Posted","3G","December 2017","Response Rate (RR)","https://ClinicalTrials.gov/show/NCT01100801"
1214,"NCT00290953","Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide","Completed","No Results Available","Lung Cancer|Pulmonary Neoplasms|Small Cell Lung Cancer","Drug: SR48692","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","432","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","EFC3679","February 10, 2006","October 2002","March 2006","December 22, 2008","December 2008","No Study Results Posted","SESAME","March 2006","- Overall survival (OS)|- Progression Free Survival (PFS)|- Time to Progression (TTP)|- Clinical Benefit assessed by Performance Status and body weight|- Quality of Life using the LCSS and EuroQoL validated instruments|- Toxicity and safety assessment using NCI CTC version 2.0","https://ClinicalTrials.gov/show/NCT00290953"
1215,"NCT01297101","Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy","Temporarily not available","No Results Available","Non-small Cell Lung Cancer","Drug: Erlotinib","Shanghai Chest Hospital|Guangdong General Hospital|Shanghai Pulmonary Hospital, Shanghai, China","All","18 Years and older   (Adult, Senior)","","null","Other","Expanded Access","","ML25268(C-TONG1101)","February 15, 2011","null","null","February 15, 2011","January 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01297101"
1216,"NCT00480597","Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: gemcitabine|Drug: cisplatin|Drug: vinorelbine|Drug: capecitabine","Ludwig-Maximilians - University of Munich","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Gemcitabin 02 MC","May 30, 2007","October 2002","null","October 27, 2010","May 2007","No Study Results Posted","null","null","Response rate|Time to progression|Overall Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00480597"
1217,"NCT00402545","C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Head and Neck Neoplasms","Drug: Cetuximab|Drug: Docetaxel|Drug: Cisplatin|Drug: 5-Fluorouracil","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1","29","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-128|CA225249","November 21, 2006","January 2007","July 2009","October 30, 2009","October 2009","No Study Results Posted","null","July 2009","Determine the maximum tolerated dose (MTD) of Docetaxel/Cisplatin/5-Fluorouracil (TPF) induction chemotherapy when combined with cetuximab in an induction chemotherapy setting for locally advanced squamous cell cancer of the head and neck.|To asses toxicity of this combination|To determine the response rate in this patient population.","https://ClinicalTrials.gov/show/NCT00402545"
1218,"NCT00402051","Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Non-Small-Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11077|H3E-SB-S109","November 17, 2006","November 2006","May 2009","February 1, 2010","February 2010","November 30, 2009","null","December 2008","Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)|Overall Survival|Number of Participants With Tumor Response (as Basis for Response Rate)|Time to Treatment Failure (TTF)|Pharmacology Toxicities","https://ClinicalTrials.gov/show/NCT00402051"
1219,"NCT01620242","A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes","Completed","No Results Available","Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer","Drug: Cabazitaxel","UNICANCER","All","18 Years and older   (Adult, Senior)","Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UC-0130/1106|2011-004712-32","May 24, 2012","April 2012","April 2015","June 16, 2016","June 2016","No Study Results Posted","ORL03","April 2014","non-progression at 6 weeks|progression free survival|Toxicity according to NCI-CTCAE v4.0|Quality of life evaluated by the QLQ-C30 and H&N35 questionnaire","https://ClinicalTrials.gov/show/NCT01620242"
1220,"NCT00041015","Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: topotecan hydrochloride","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","4","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SKF1501|CWRU-070144|SB-389|SB-SKF-104864A|SB-SKF-1501|NCI-G02-2092","July 8, 2002","September 2001","November 2002","January 8, 2014","January 2014","No Study Results Posted","null","November 2002","","https://ClinicalTrials.gov/show/NCT00041015"
1221,"NCT02532192","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma","Withdrawn","No Results Available","Lymphoma","Drug: Belinostat|Drug: Rituximab|Drug: Cisplatin|Drug: Cytarabine|Drug: Dexamethasone|Drug: Ciprofloxacin|Drug: Fluconazole","M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-1068|NCI-2015-01521","August 21, 2015","December 2015","null","January 5, 2016","January 2016","No Study Results Posted","null","December 2019","Maximum Tolerated Dose (MTD) of Belinostat with RDHAP Chemotherapy in Participants with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Overall response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02532192"
1222,"NCT00006096","Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva","Terminated","No Results Available","Vulvar Cancer","Drug: cisplatin|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068103|GOG-0185","August 3, 2000","March 2001","null","June 7, 2013","June 2007","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00006096"
1223,"NCT00616785","Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Yonsei University|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000584442|YONSEI-4-2007-0120","February 14, 2008","June 2007","null","February 6, 2009","September 2008","No Study Results Posted","null","November 2010","Rate of local/regional control|Rate of systemic disease control|Feasibility of radiotherapy administered concurrently with etoposide and cisplatin chemotherapy|Toxicity of irinotecan hydrochloride and cisplatin induction chemotherapy as assessed by NCI CTCAE v3.0|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00616785"
1224,"NCT02906150","Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type","Not yet recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Thymalfasin (Thymosin alpha 1, Ta1)|Drug: SoC (chemotherapy and platinum agent)","SciClone Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCI-Ta1-NSCLC-CHEMO P2-001","September 6, 2016","September 2016","July 2019","September 16, 2016","September 2016","No Study Results Posted","null","May 2019","Time to progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT02906150"
1225,"NCT02718742","Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer","Withdrawn","No Results Available","Recurrent Bladder Urothelial Carcinoma|Stage IV Bladder Urothelial Carcinoma","Other: Laboratory Biomarker Analysis|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Other: Quality-of-Life Assessment","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1551|NCI-2016-00133|P30CA015083","February 10, 2016","June 2016","null","April 14, 2016","April 2016","No Study Results Posted","null","June 2021","Proportion of progression-free survivors assessed by Response Evaluation Criteria for Solid Tumors (RECIST)|Duration of response assessed by RECIST|Frequency and severity of observed adverse effects assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)|Overall survival (OS)|Quality of life assessed using the EORTC QLQ-C30|Time to disease progression assessed by RECIST","https://ClinicalTrials.gov/show/NCT02718742"
1226,"NCT02171325","Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment","Unknown status","No Results Available","Small Cell Lung Cancer","Drug: irinotecan","Guangdong Association of Clinical Trials","All","18 Years to 65 Years   (Adult)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTONG1402","June 16, 2014","June 2014","June 2015","June 20, 2014","June 2014","No Study Results Posted","null","June 2015","Limiting Toxicity (DLT )in the irinotecan|Maximum Tolerated Dose(MTD)in the irinotecan","https://ClinicalTrials.gov/show/NCT02171325"
1227,"NCT03133390","Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients","Not yet recruiting","No Results Available","Urothelial Carcinoma","Drug: Atezolizumab 1200 mg|Drug: Bevacizumab 15 mg/kg IV","New York University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16-01918","April 17, 2017","May 2017","May 2019","April 27, 2017","April 2017","No Study Results Posted","null","May 2018","Overall Survival|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (ORR + SD)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT03133390"
1228,"NCT01258634","A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response","Terminated","No Results Available","Osteosarcoma|Lung Metastases","Drug: Dexrazoxane|Drug: Doxorubicin|Drug: Cisplatin|Drug: G-CSF|Drug: PEG-filgrastim|Drug: Etoposide|Drug: Ifosfamide|Drug: Mesna|Drug: Leucovorin","University of Chicago","All","2 Years to 35 Years   (Child, Adult)","Phase 1","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-186-B","September 30, 2010","July 2010","November 2011","December 9, 2013","December 2013","No Study Results Posted","null","November 2011","Feasibility and usefulness of measuring early changes in tumor metabolic activity.|Gather pilot data on the histological response rate|Explore whether histological response can be measured by a computer algorithm|Gather pilot data on 3-year event-free survival|Gather pilot data on toxicity","https://ClinicalTrials.gov/show/NCT01258634"
1229,"NCT00817895","Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence","Completed","No Results Available","Hepatocellular Carcinoma","Drug: sustained released 5-FU and sustained released cisplatin|Drug: sustained released 5-FU|Procedure: TACE","Eastern Hepatobiliary Surgery Hospital","All","18 Years to 75 Years   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","EHBH-RCT-2008-010","January 4, 2009","December 2008","December 2010","March 29, 2016","March 2016","No Study Results Posted","null","December 2009","disease free survival|overall survival","https://ClinicalTrials.gov/show/NCT00817895"
1230,"NCT00005830","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer","Completed","No Results Available","Endometrial Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer","Drug: Doxorubicin Hydrochloride|Drug: Cisplatin|Radiation: Radiation Therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9908|NCI-2012-02332|CDR0000067844|U10CA027469","June 2, 2000","July 2000","null","December 29, 2014","December 2014","No Study Results Posted","null","July 2009","Number of patients completing the prescribed therapy|Frequency and severity of acute adverse effects as assessed by CTEP CTC version 2.0|Frequency and severity of chronic adverse effects as assessed by CTEP CTC version 2.0|Frequency of severe and life threatening bowel, hepatic, and hematologic toxicity as assessed by CTEP CTC version 2.0|Reason for discontinuing study therapy","https://ClinicalTrials.gov/show/NCT00005830"
1231,"NCT00999700","Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: docetaxel - cisplatin - 5-fluorouracil|Radiation: radiotherapy|Drug: cetuximab|Drug: cisplatin|Radiation: radiotherapy","Gruppo Oncologico del Nord-Ovest","All","18 Years and older   (Adult, Senior)","Phase 3","282","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EUDRACT NUMBER 2009-013402-14","October 16, 2009","September 2009","December 2021","February 27, 2017","February 2017","No Study Results Posted","INTERCEPTOR","February 2017","Overall survival|Incidence of acute and late toxicities in the two arms|Progression free survival|Locoregional control|Response rate","https://ClinicalTrials.gov/show/NCT00999700"
1232,"NCT00599755","Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)","Completed","Has Results","Carcinoma|Non-small Cell Lung Cancer","Radiation: Comparator: CT or MRI and FDG-PET|Drug: Gemcitabine and Cisplatin or Gemcitabine and Carboplatin","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","68","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","0000-083|2007_662","January 7, 2008","January 2009","April 2011","October 8, 2015","October 2015","April 10, 2012","null","June 2010","Metabolic Response Conversion Rate Between 3 and 6 Weeks After Starting Chemotherapy at a Threshold of a 20% Decrease in SUVmean|Repeatability of FDG SUVmean at Baseline|Change in FDG-PET Uptake From Baseline to Week 3|Change in FDG-PET Uptake From Week 3 to Week 6|Change in FGD-PET Uptake From Baseline to Week 6","https://ClinicalTrials.gov/show/NCT00599755"
1233,"NCT00006043","Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin","Completed","No Results Available","Ovarian Cancer|Testicular Germ Cell Tumor","Drug: temozolomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","00-010|CDR0000068058|NCI-G00-1817","July 5, 2000","February 2000","November 2001","June 4, 2013","June 2013","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00006043"
1234,"NCT00068575","Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer","Completed","Has Results","Pancreatic Cancer","Biological: Recombinant Interferon Alfa|Drug: Cisplatin|Drug: Fluorouracil|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","29","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-040|P30CA016672|MDA-ID-02040|CDR0000327752","September 10, 2003","May 2002","December 2010","February 13, 2012","February 2012","January 23, 2012","null","December 2010","Median Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00068575"
1235,"NCT00940069","TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer","Completed","No Results Available","Non-small-cell Lung Cancer|Adenocarcinoma","Drug: pemetrexed","Hunan Province Tumor Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LYN-LC-001","July 14, 2009","March 2009","January 2015","February 19, 2016","February 2016","No Study Results Posted","TPEIAL","June 2013","time to progress|overall survival","https://ClinicalTrials.gov/show/NCT00940069"
1236,"NCT00082472","Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)","Unknown status","No Results Available","NSCLC","Drug: Doxorubicin HCl Inhalation Solution|Drug: Docetaxel|Drug: Cisplatin","Zivena","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Dox-2a-07","May 11, 2004","January 2004","null","April 14, 2006","April 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00082472"
1237,"NCT01192750","Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab","Completed","No Results Available","Head and Neck Cancer","Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: medical chart review","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","79","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000683281|ECOG-E5397T1","August 31, 2010","August 5, 2010","October 5, 2010","May 16, 2017","May 2017","No Study Results Posted","null","October 5, 2010","Association between ERCC1 expression (low or high) with clinical outcomes","https://ClinicalTrials.gov/show/NCT01192750"
1238,"NCT00069966","Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cisplatin|Drug: cytarabine|Drug: methylprednisolone|Drug: pixantrone dimaleate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Theradex|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000316466|THERADEX-AZA-II-02|CWRU-NOVU-1403|SUNY-HSC-4849|NOVUSPHARMA-AZA-II-02","October 3, 2003","April 2003","null","July 4, 2009","November 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00069966"
1239,"NCT00550901","Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: dexrazoxane hydrochloride|Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacological study","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","25","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000570420|P30CA033572|CHNMC-00136","October 25, 2007","February 2001","July 2007","June 3, 2015","June 2015","No Study Results Posted","null","July 2007","Toxicity|Maximum tolerated dose of dexrazoxane hydrochloride and cisplatin","https://ClinicalTrials.gov/show/NCT00550901"
1240,"NCT01611506","Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer","Terminated","No Results Available","Gastric Cancer","Biological: Cetuximab|Drug: Capecitabine|Drug: Cisplatin","Dr Anna Dorothea Wagner|Centre Hospitalier Universitaire Vaudois","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHUV-CePO-B354re (gastric)","May 15, 2012","February 2012","December 2012","January 8, 2013","January 2013","No Study Results Posted","null","December 2012","Dose limiting toxicity|Metabolic response|Secondary resectability|Major histopathological response rate|R-0 resection rate|Surgical morbidity|Overall survival|Time to local and systemic progression after R0-resection|Feasibility|Toxicity (according to NCI-CTCAE, Version 4.0)","https://ClinicalTrials.gov/show/NCT01611506"
1241,"NCT02604784","Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors","Recruiting","No Results Available","Peritoneal Carcinomatosis","Drug: Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC)","Fondazione del Piemonte per l'Oncologia","All","18 Years to 78 Years   (Adult, Senior)","Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","015-IRCCS-27F-1","November 3, 2015","October 2015","October 2018","August 19, 2016","August 2016","No Study Results Posted","PI-CaP","October 2018","Overall Response Rate (ORR) according to RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC.|The overall survival (OS)|The degree of histological regression assessed by pathological review|The median time to progression (TTP) according to RECIST criteria (version 1.1) after two or three cycles of PIPAC|Measurement of clinical tumor response to therapy using FDG- Positron Emission Tomography (PET) according to PERCIST criteria (versione 1.0).|The Peritoneal Carcinomatosis Index (PCI) before and after therapy","https://ClinicalTrials.gov/show/NCT02604784"
1242,"NCT00686114","Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Drug: Paclitaxel|Drug: Cisplatin|Drug: Tarceva|Radiation: Radiotherapy|Radiation: Radiotherapy","Wenzhou Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","344","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","Shixiu - 1","May 27, 2008","May 2008","December 2014","April 28, 2014","April 2014","No Study Results Posted","null","December 2014","overall survival|Progression-free survival|local-regional control rate|Adverse events|Health-related quality of life","https://ClinicalTrials.gov/show/NCT00686114"
1243,"NCT00868491","Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: docetaxel, cisplatin, 5-fluorouracil|Radiation: radiotherapy|Drug: cetuximab, cisplatin","Institute of Oncology Ljubljana","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR-62202-717","March 24, 2009","March 2008","October 2011","October 23, 2011","October 2011","No Study Results Posted","null","December 2009","locoregional control|feasibility (toxicity profile) of the proposed regimen|complete response rate|disease free survival|overall survival|late toxicity including thyroid function","https://ClinicalTrials.gov/show/NCT00868491"
1244,"NCT00867009","A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer","Completed","Has Results","Non-Small-Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Cetuximab","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","113","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10726|H3E-MC-S104","March 20, 2009","April 2009","September 2014","May 20, 2015","September 2014","April 10, 2012","null","May 2011","Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)|Progression-free Survival (PFS)|The Percentage of Participants Still Living at One Year (One Year Survival Rate)|The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])","https://ClinicalTrials.gov/show/NCT00867009"
1245,"NCT00757549","3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx","Unknown status","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Genetic: TdT-mediated dUTP nick end labeling assay|Other: 3'-deoxy-3'-[18F]fluorothymidine|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Early Phase 1","30","Other|NIH","Interventional","Primary Purpose: Diagnostic","MC057M|P30CA015083|08-002166|NCI-2009-01193","September 22, 2008","September 2008","null","August 25, 2014","August 2014","No Study Results Posted","null","August 2011","Percent change in the standard uptake value levels calculated for the identified volumes of interest for FLT and FDG PET scans from baseline to after 2 weeks of cetuximab therapy and from baseline to after 20-30 Gy of radiotherapy|Quantified change values (after cetuximab therapy and after 20-30 Gy of radiotherapy) for the FLT and FDG PET scan-based topographic profiles created using the ImQuant software package","https://ClinicalTrials.gov/show/NCT00757549"
1246,"NCT01697072","First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","Terminated","No Results Available","Gastric Cancer","Drug: Rilotumumab|Other: Placebo|Drug: Epirubicin|Drug: Cisplatin|Drug: Capecitabine","Amgen","All","18 Years to 99 Years   (Adult, Senior)","Phase 3","609","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20070622|2011-004923-11","September 26, 2012","October 2012","August 2015","January 18, 2016","January 2016","No Study Results Posted","RILOMET-1","November 2014","Overall Survival|PFS|TTP|ORR|DCR|TTR|Safety|Immunogenicity","https://ClinicalTrials.gov/show/NCT01697072"
1247,"NCT00003044","Chemotherapy in Treating Patients With Liver Cancer","Unknown status","No Results Available","Liver Cancer","Drug: cisplatin-e therapeutic implant","Matrix Pharmaceutical|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","55","Industry","Interventional","Primary Purpose: Treatment","CDR0000065675|MP-417-96-2|NCI-V97-1290","November 1, 1999","September 1996","null","December 18, 2013","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003044"
1248,"NCT02954536","Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer","Recruiting","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: pembrolizumab|Drug: trastuzumab|Drug: capecitabine|Drug: cisplatin|Drug: Oxaliplatin|Drug: 5-Fluorouracil","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-937","November 2, 2016","November 3, 2016","November 2019","May 12, 2017","May 2017","No Study Results Posted","null","November 2019","Progression free survival","https://ClinicalTrials.gov/show/NCT02954536"
1249,"NCT00985998","Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer","Withdrawn","No Results Available","Non-small Cell Lung Cancer","Drug: Nimotuzumab and chemotherapy","Biotech Pharmaceutical Co., Ltd.","All","18 Years to 65 Years   (Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-NSCLC-T-0902","September 27, 2009","September 2009","August 2015","August 18, 2015","August 2015","No Study Results Posted","null","August 2015","Safety and toxicity of this new treatment. Both acute and chronic toxicity will be evaluated.|To determine the complete response rate、partial rate、disease response rate、disease control rate in the patients subject to treatment","https://ClinicalTrials.gov/show/NCT00985998"
1250,"NCT00857246","Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer","Completed","Has Results","Gastric Cancer|Stomach Cancer","Drug: Cetuximab|Drug: Irinotecan|Drug: Cisplatin|Procedure: Surgery|Drug: 5-FU|Radiation: Radiation","New York University School of Medicine|Bristol-Myers Squibb|ImClone LLC","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-72 (H12637)|BMS #CA225112","March 4, 2009","July 2005","October 2015","November 6, 2015","November 2015","March 2, 2015","null","September 2011","Clinical Response Rate of an Induction Regimen Consisting of Irinotecan, Cisplatin and Cetuximab|Rate of Clearance of Nodal Involvement Among Patients Who Have Received the Induction Therapy|Rate of Potentially Curative Surgery|Rate of ""Down-staging"" From Pre-operative Clinical Staging|Safety of the Induction Regimen|Median Overall Survival (Induction Treatment and Curative Surgery)|Median Overall Survival (Adjuvant Therpary)","https://ClinicalTrials.gov/show/NCT00857246"
1251,"NCT00002774","Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Completed","No Results Available","Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)","Drug: Tirapazamine|Drug: Cisplatin|Drug: 5-fluorouracil|Radiation: Radiotherapy (RT)","Stanford University|National Cancer Institute (NCI)","All","17 Years and older   (Child, Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","IRB-12503|CA67166|NCI-T94-0119O|CDR0000064752|SQL 72951","April 6, 2000","June 1996","June 2005","June 19, 2014","June 2014","No Study Results Posted","null","June 2000","Complete response rate (CRR)|Overall survival (OS)|Cause-specific survival (CSS)|Rate of freedom from recurrence (FFR)","https://ClinicalTrials.gov/show/NCT00002774"
1252,"NCT02887248","Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma","Recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer|Transitional Cell Carcinoma","Drug: nab-paclitaxel|Drug: Gemcitabine","SCRI Development Innovations, LLC|Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SCRI GU 124","August 29, 2016","January 12, 2017","December 30, 2019","April 18, 2017","April 2017","No Study Results Posted","null","December 20, 2018","6 month progression-free survival (PFS6)|Overall Response Rate|Clinical Benefit Rate|Overall Survival|The number of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as a measure of safety.","https://ClinicalTrials.gov/show/NCT02887248"
1253,"NCT02012062","Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: TPF neoadjuvant chemotherapy|Drug: Concurrent chemotherapy with cisplatin during radiotherapy|Drug: Concurrent nimotuzumab during radiotherapy|Radiation: Radical radiotherapy","Fudan University|Fujian Province Tumor Hospital|The First Affiliated Hospital of Xiamen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-IMRT-N","December 4, 2013","July 2012","June 2018","December 10, 2013","December 2013","No Study Results Posted","null","June 2016","Number of Participants with Adverse Events (severe radiation-induced skin and mucosal toxicities)|PFS|OS","https://ClinicalTrials.gov/show/NCT02012062"
1254,"NCT02586207","Pembrolizumab in Combination With CRT for LA-SCCHN","Recruiting","No Results Available","Head and Neck Cancer|Squamous Cell Carcinoma|Oral Cavity Cancer|Oropharynx Cancer|Hypopharynx Cancer|Larynx Cancer|Laryngeal Cancer","Drug: pembrolizumab (MK-3475)|Drug: Cisplatin|Radiation: Radiation","Sanford Health|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SH MISP203","October 20, 2015","November 2015","September 2021","May 24, 2017","May 2017","No Study Results Posted","null","September 2017","CTCAE 4.0 to monitor and grade adverse events. Count and percentage of AE will be provided. Fisher's exact test will be used to compare the proportions.|The FACT-H&N questionnaire will be will be used to assess HRQOL.","https://ClinicalTrials.gov/show/NCT02586207"
1255,"NCT00033657","Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer","Completed","Has Results","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Drug: paclitaxel|Procedure: conventional surgery|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","97","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000069309|U10CA021115|E1201","April 9, 2002","May 2002","October 2009","November 30, 2012","November 2012","June 21, 2011","null","September 2009","Pathologic Complete Response Rate|Overall Survival Time|Recurrence-free Survival Time","https://ClinicalTrials.gov/show/NCT00033657"
1256,"NCT01194635","Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy","Completed","No Results Available","Head and Neck Cancer","Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: protein analysis|Genetic: protein expression analysis|Other: enzyme-linked immunosorbent assay|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","69","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000683306|ECOG-E3303T1","September 2, 2010","August 5, 2010","September 5, 2010","May 16, 2017","May 2017","No Study Results Posted","null","September 5, 2010","Correlation of biomarkers and clinical outcome","https://ClinicalTrials.gov/show/NCT01194635"
1257,"NCT00001272","A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients","Completed","No Results Available","Ovarian Neoplasms","Drug: taxol","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Senior","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","910232|91-C-0232","November 3, 1999","September 1991","May 2000","March 3, 2008","June 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001272"
1258,"NCT03071822","Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas","Recruiting","No Results Available","Peripheral T Cell Lymphoma","Drug: cisplatin|Drug: ifosfamide|Drug: gemcitabine|Drug: L-asparaginase|Drug: etoposide|Drug: dexamethasone","The University of Hong Kong","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PTCL-001","February 24, 2017","February 24, 2017","February 28, 2022","April 21, 2017","April 2017","No Study Results Posted","null","July 31, 2021","Adverse events and severe adverse events|Overall response rate (ORR)","https://ClinicalTrials.gov/show/NCT03071822"
1259,"NCT00001427","A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin","Completed","No Results Available","Ovarian Neoplasms","Drug: 9-aminocamptothecin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Senior","Phase 2","40","NIH","Interventional","Primary Purpose: Treatment","950056|95-C-0056","November 3, 1999","January 1995","April 2000","March 3, 2008","January 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001427"
1260,"NCT00677118","Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin,fluorouracil|Drug: Cisplatin","Sun Yat-sen University|Fudan University|Zhejiang Cancer Hospital|Huazhong University of Science and Technology|Fifth Affiliated Hospital, Sun Yat-Sen University|Beijing Cancer Hospital|Guangdong General Hospital","All","18 Years to 69 Years   (Adult, Senior)","Phase 3","506","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YP2008004","May 9, 2008","June 2006","March 2015","July 11, 2013","March 2010","No Study Results Posted","null","March 2015","Failure-free survival|Overall survival, distant failure-free survival and locoregional failure-free survival","https://ClinicalTrials.gov/show/NCT00677118"
1261,"NCT00418535","Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma","Completed","No Results Available","Lymphoma, T-Cell","Drug: Concurrent Radiotherapy (RT)/cisplatin, VIPD","Samsung Medical Center|Korea University Anam Hospital|Asan Medical Center|Gyeongsang National University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-10-08","January 3, 2007","April 2006","July 2009","October 20, 2009","January 2007","No Study Results Posted","null","March 2009","","https://ClinicalTrials.gov/show/NCT00418535"
1262,"NCT01215136","First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma","Active, not recruiting","No Results Available","Transitional Cell Carcinoma|Bladder Carcinoma|Urothelial Carcinoma","Drug: Everolimus|Drug: Everolimus|Drug: Paclitaxel","Matthew Galsky|Hoosier Cancer Research Network|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","HCRN GU10-147","October 4, 2010","December 2010","April 2018","February 6, 2017","February 2017","No Study Results Posted","null","June 2017","Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Progression Free Survival|Survival - 1 year","https://ClinicalTrials.gov/show/NCT01215136"
1263,"NCT02778308","Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma","Recruiting","No Results Available","Gallbladder Cancer","Drug: Gemcitabine + Cisplatin","Govind Ballabh Pant Institute of Postgraduate Medical Education and Research","All","18 Years to 75 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FI/IEC/MAMC(32)/4/2012/239","March 6, 2016","January 2012","December 2017","May 18, 2016","May 2016","No Study Results Posted","null","June 2017","Disease Free Survival|Overall Survival|Myelotoxicity|Neurotoxicity","https://ClinicalTrials.gov/show/NCT02778308"
1264,"NCT00295672","Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.","Completed","No Results Available","Lung Neoplasm","Drug: Vinorelbine","University Hospital, Brest|Fabre Clinic","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RB 05-110|VINCR - GFPC 05-03","February 23, 2006","February 2006","June 2007","July 24, 2009","July 2009","No Study Results Posted","VINCR","null","TUMORAL RESPONSE (RECIST)|TOXICITY (NCI 20)|SURVIVAL|TIME TO PROGRESSION|LATE RADIATION TOXICITY","https://ClinicalTrials.gov/show/NCT00295672"
1265,"NCT01639521","Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer","Withdrawn","No Results Available","Anterior Urethral Cancer|Localized Transitional Cell Cancer of the Renal Pelvis and Ureter|Posterior Urethral Cancer|Recurrent Bladder Cancer|Recurrent Urethral Cancer|Regional Transitional Cell Cancer of the Renal Pelvis and Ureter|Stage III Bladder Cancer|Transitional Cell Carcinoma of the Bladder|Ureter Cancer|Urethral Cancer Associated With Invasive Bladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: methotrexate|Drug: vinblastine|Drug: doxorubicin hydrochloride|Biological: pegfilgrastim|Other: laboratory biomarker analysis","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4B-10-5|NCI-2012-00961","July 10, 2012","May 2013","May 2013","January 27, 2014","January 2014","No Study Results Posted","null","May 2013","Rate of unacceptable toxicity graded according to Common Terminology Criteria (CTC) v4.0|Disease-free survival","https://ClinicalTrials.gov/show/NCT01639521"
1266,"NCT02120807","Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas","Recruiting","No Results Available","Stage IV Lung Adenocarcinoma","Drug: Certolizumab|Drug: cisplatin|Drug: pemetrexed","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","34","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-063","April 21, 2014","April 2014","null","September 12, 2016","September 2016","No Study Results Posted","null","April 2017","Maximum tolerated does (MTD)|Progression-free survival (PFS)|Immunohistochemical staining","https://ClinicalTrials.gov/show/NCT02120807"
1267,"NCT02579564","Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","Not yet recruiting","No Results Available","Malignant Hydrothorax|Non Small Cell Lung Cancer","Drug: Gemcitabine|Drug: Vinorelbine|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Oncorine|Drug: Endostar|Drug: Cisplatin","Xinqiao Hospital of Chongqing","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTAEMTF","October 12, 2015","October 2016","December 2018","October 20, 2016","October 2016","No Study Results Posted","null","June 2018","Objective response rate (ORR) of malignant pleural effusions|progression-free survival","https://ClinicalTrials.gov/show/NCT02579564"
1268,"NCT02041819","Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus","Withdrawn","No Results Available","Squamous Cell Carcinoma of Esophagus","Drug: Nimotuzumab","Zhejiang University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZYTOP1405","January 10, 2014","February 2014","January 2017","March 4, 2015","March 2015","No Study Results Posted","null","January 2016","response rate|Overall survival|Progression-free survival|Adverse events","https://ClinicalTrials.gov/show/NCT02041819"
1269,"NCT00261703","Docetaxel in Head and Neck Cancer","Completed","No Results Available","Head and Neck Neoplasms","Drug: Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Drug: Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Other: Cisplatin + radiotherapy","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","439","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976F_2503","December 2, 2005","December 2002","July 2010","May 10, 2012","May 2012","No Study Results Posted","null","July 2010","Phase II: Clinical objective response rate, at the end of inducted chemotherapy (groups A and B) and at the end of combined treatment (groups A, B and C).|Phase III: Surveillance with no progression after two years.","https://ClinicalTrials.gov/show/NCT00261703"
1270,"NCT00190476","Elderly NSCLC/D vs DP (JCOG0207)","Terminated","No Results Available","Non-small-cell Lung Cancer","Drug: Weekly docetaxel alone|Drug: Weekly docetaxel + cisplatin combination","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","All","70 Years and older   (Senior)","Phase 3","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG0207|C000000146","September 11, 2005","April 2003","April 2007","September 8, 2016","September 2016","No Study Results Posted","null","null","overall survival|Toxicity|Progression-free survival|Response rate|Symptom score","https://ClinicalTrials.gov/show/NCT00190476"
1271,"NCT02558959","Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer","Not yet recruiting","No Results Available","Biliary Tract Neoplasms","Drug: Irinotecan|Drug: Capecitabine","Zhejiang University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZYYYMedOncoBIL01","September 21, 2015","September 2015","December 2017","November 29, 2015","November 2015","No Study Results Posted","null","September 2017","Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02558959"
1272,"NCT00811447","Taxotere New Indication - Gastric Cancer Treatment Registration Trial","Completed","No Results Available","Stomach Neoplasms","Drug: 5-fluorouracil|Drug: Cisplatin|Drug: Docetaxel","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_02195","December 18, 2008","November 2008","June 2012","August 30, 2012","August 2012","No Study Results Posted","null","June 2012","Time to progression|Safety profile|Overall survival|Tumor response|Clinical toxicities/symptomatology|Laboratory toxicities/symptomatology","https://ClinicalTrials.gov/show/NCT00811447"
1273,"NCT01029678","Concomitant Radio-chemotherapy in the Elderly","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: Cisplatin IV|Drug: Vinorelbine|Radiation: Radiotherapy","University Hospital, Limoges|Pierre Fabre Laboratories","All","70 Years and older   (Senior)","Phase 2","59","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","I08011","December 9, 2009","January 2010","June 2016","March 8, 2015","March 2015","No Study Results Posted","RACCOSA","January 2015","Acute toxicity|Late toxicity|Overall response rate","https://ClinicalTrials.gov/show/NCT01029678"
1274,"NCT00588835","Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients","Terminated","No Results Available","Tumor","Drug: aprepitant|Drug: Dexamethasone and Ondansetron during CE-treatment","Radboud University|Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCN-AKF 07.02|EudraCTnr 2007-003347-73","December 24, 2007","March 2008","January 2010","March 1, 2010","February 2010","No Study Results Posted","ACE","January 2010","plasma concentrations of etoposide will be measured|Nausea and emetic episodes are recorded","https://ClinicalTrials.gov/show/NCT00588835"
1275,"NCT01755845","Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients","Recruiting","No Results Available","Cervical Cancer","Drug: paclitaxel|Drug: cisplatin|Radiation: radiotherapy","xie congying|Wenzhou Medical University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","WZMC-11256","December 19, 2012","January 2011","December 2016","April 27, 2016","April 2016","No Study Results Posted","null","December 2016","disease-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01755845"
1276,"NCT00191334","Gemcitabine in Ovarian Cancer","Completed","Has Results","Ovarian Cancer","Drug: gemcitabine|Drug: cisplatin","Eli Lilly and Company","Female","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9340|B9E-MW-S368","September 12, 2005","December 2004","December 2007","February 24, 2009","February 2009","December 17, 2008","null","December 2007","Best Overall Tumor Response|Duration of Response|Time to Progressive Disease|Time to Treatment Failure|Number of Patients With Maximum Common Toxicity Criteria - National Cancer Institute (CTC-NCI): Possibly Related to Study Drug by Grade","https://ClinicalTrials.gov/show/NCT00191334"
1277,"NCT00968799","Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study","Terminated","Has Results","Epithelial Ovarian Cancer|Fallopian Tube Carcinoma","Procedure: Hyperthermic intraoperative intraperitoneal chemotherapy|Procedure: Cytoreduction|Drug: Cisplatin","Cantonal Hospital of St. Gallen","Female","18 Years to 70 Years   (Adult, Senior)","","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SGOV01","February 12, 2008","February 2008","December 2012","May 13, 2013","May 2013","March 26, 2013","null","December 2011","Fitness for Systemic Chemotherapy|Nephrotoxicity|Surgical Complications|Overall Survival|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00968799"
1278,"NCT02705612","Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Internal Radiation Therapy|Drug: nimotuzumab","Fourth Military Medical University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XJFL-2016-02-LACC-Nimotuzumab","March 5, 2016","September 2015","September 2018","March 9, 2016","March 2016","No Study Results Posted","null","September 2016","Overall survival rate|disease free survival rate|non-distant metastasis survival rate|survival period of non-progressive.|Quality of life|Radiation protocol compliance|Rate of acute and long-term toxicities","https://ClinicalTrials.gov/show/NCT02705612"
1279,"NCT00024323","Combination Chemotherapy in Treating Patients With Advanced Cancer","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: triapine","Vion Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Industry","Interventional","Primary Purpose: Treatment","VION-CLI-021|CDR0000068918|NCI-V01-1668","September 13, 2001","March 2001","June 2003","July 17, 2013","November 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024323"
1280,"NCT01501149","Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ","Recruiting","No Results Available","Nasal and Nasal-type NK/T-cell Lymphoma","Drug: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|Drug: Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）","Mingzhi Zhang|Second Hospital of Shanxi Medical University|Shanxi Province Cancer Hospital|Wuhan University|Wuhan TongJi Hospital|Wuhan Union Hospital, China|Qingdao University|Cancer Hospital of Guizhou Province|Xinyang Central Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","hnslblzlzx2011-2","November 29, 2011","January 2011","May 2019","July 15, 2015","July 2015","No Study Results Posted","CTTNKTL-Ⅲ/Ⅳ","December 2015","Progression-free survival|response rate|overall survival|median survival time","https://ClinicalTrials.gov/show/NCT01501149"
1281,"NCT02821533","Chemoembolization for Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatocellular Carcinoma","Procedure: TACE|Drug: Cisplatin","Chinese University of Hong Kong","All","19 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VIR-13-04","June 7, 2016","February 2012","null","June 29, 2016","June 2016","No Study Results Posted","null","November 2017","Tumor response|overall survival","https://ClinicalTrials.gov/show/NCT02821533"
1282,"NCT00490659","Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: gemcitabine|Drug: cisplatin|Procedure: radical surgery|Procedure: chemoradiotherapy","Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","8191|B9E-MC-S339","June 21, 2007","September 2003","December 2004","June 21, 2007","June 2007","No Study Results Posted","null","null","2-year overall survival|Toxicity assessment|Assessment of feasibility of two treatment orders|Clinical and pathological response rate to neoadjuvant chemotherapy|Disease free survival","https://ClinicalTrials.gov/show/NCT00490659"
1283,"NCT02610010","Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin|Radiation: Intensity-modulated radiotherapy","Sun Yat-sen University|Affiliated Tumor Hospital of Guangzhou Medical University|The First Affiliated Hospital of Guangzhou Medical University|The First Affiliated Hospital of Guangdong Pharmaceutical University","All","18 Years to 65 Years   (Adult)","Phase 3","462","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-FXY-066-Dept. of RT","November 13, 2015","November 2015","November 2025","November 18, 2015","November 2015","No Study Results Posted","null","November 2022","Overall survival|failure-free survival|distant metastasis-free survival|locoregional relapse-free survival|Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0|quality of life assessing by questionnaires","https://ClinicalTrials.gov/show/NCT02610010"
1284,"NCT00042510","Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer","Completed","No Results Available","Stomach Neoplasms|Esophageal Neoplasms","Biological: Treatment group","Cancer Advances Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","103","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC4","July 31, 2002","August 2000","July 2004","August 27, 2014","August 2014","No Study Results Posted","null","February 2003","To evaluate the effects of G17DT in combination with cisplatin and 5-FU chemotherapy on tumor response assessed by radiographic means.|To evaluate the clinical efficacy of G17DT in combination with cisplatin and 5-FU chemotherapy as measured by time to disease progression, best overall response and survival.","https://ClinicalTrials.gov/show/NCT00042510"
1285,"NCT01093690","Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin","Completed","Has Results","Cancer","Drug: metoclopramide|Drug: placebo","Mahidol University|Siriraj Hospital","All","18 Years and older   (Adult, Senior)","","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Si094/2009","March 24, 2010","April 2009","October 2010","November 4, 2010","November 2010","October 10, 2010","null","June 2010","Number of Patients Who Had Complete Response|Toxicities and Severity of Nausea and Vomiting","https://ClinicalTrials.gov/show/NCT01093690"
1286,"NCT00389155","First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy","Completed","No Results Available","Bladder Cancer|Transitional Cell Carcinoma|Metastasis","Drug: Vinflunine|Drug: Gemcitabine|Other: Placebo","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","CA183-002","October 17, 2006","January 2007","January 2008","November 6, 2015","November 2015","No Study Results Posted","null","January 2008","Median Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria in Participants With Advanced Transitional Cell Carcinoma (TCC) of the Urothelium|Tumor Response Rate in Participants With A Best Response of Complete (CR) or Partial (PR) as Defined by RECIST criteria|Overall Survival of Participants With TCC of the Urothelium|Disease Control Rate in Participants With Best Response of CR, PR, or Stable Disease (SD)|Duration of Response in Participants With Best Response of CR or PR|Number of Participants With Outcome of Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Discontinuation|Number of Participants With Serum Chemistry Abnormalities by Worst Common Terminology Criteria (CTC) Grade|Number of Participants With Abnormal Laboratory Findings by Worst CTC Grade|Time to Response in Participants With Best Response of CR or PR","https://ClinicalTrials.gov/show/NCT00389155"
1287,"NCT00861094","Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: 5-FU|Drug: oxaliplatin|Radiation: radiation therapy|Drug: Folinic Acid","UNICANCER","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","266","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000595050|FRE-FNCLCC- ACCORD-17-0707|EU-20848","March 12, 2009","March 2008","December 2012","December 17, 2015","December 2015","No Study Results Posted","null","September 2011","Percentage of patients who complete the full study treatment (Phase II)|Endoscopic complete response rate (Phase II)|Progression-free survival (Phase III)|Safety profile as assessed by NCI CTC v2.0 (Phase II)|Overall survival (Phase III)|Complete response rate (Phase III)|Time to treatment failure (Phase III)|Incidence of grade 3-4 toxicities (Phase III)|Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)","https://ClinicalTrials.gov/show/NCT00861094"
1288,"NCT03100955","A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer","Recruiting","No Results Available","Progression Free Survival","Drug: cisplatin, etoposide|Drug: cisplatin, etoposide, apatinib","Qingdao University","All","18 Years and older   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","QU20170327","March 26, 2017","March 1, 2017","August 1, 2019","March 29, 2017","March 2017","No Study Results Posted","null","February 1, 2019","progression free survival","https://ClinicalTrials.gov/show/NCT03100955"
1289,"NCT01424709","Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: Gemcitabine, Docetaxel, CPT-11,Cisplatin|Drug: gemcitabine/cisplatin","Tongji University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRAVO study","May 9, 2011","December 2010","December 2014","September 23, 2014","September 2014","No Study Results Posted","BRAVO","May 2014","Overall response rate|Progression free survival|duration of response|overall survival|safety|Quality Of Life","https://ClinicalTrials.gov/show/NCT01424709"
1290,"NCT02001896","Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation","Unknown status","No Results Available","Non-Small Cell Lung Cancer","Drug: gemcitabine; cisplatin or carboplatin; erlotinib|Drug: erlotinib","Xinjiang Medical University","All","18 Years and older   (Adult, Senior)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XJTHLC001","November 21, 2013","December 2013","June 2015","November 28, 2013","November 2013","No Study Results Posted","null","June 2015","Progression-free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02001896"
1291,"NCT00072124","Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma","Completed","No Results Available","Melanoma (Skin)","Drug: cisplatin|Drug: dacarbazine|Procedure: conventional surgery","National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000335471|NCI-03-C-0279","November 4, 2003","September 2003","May 2005","June 18, 2013","January 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00072124"
1292,"NCT01848457","Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","Recruiting","No Results Available","Osteosarcoma|Nephrotoxicity|Ototoxicity","Drug: Pantoprazole|Drug: High-dose methotrexate infusion duration","Children's Hospital of Philadelphia|Gateway for Cancer Research","All","up to 30 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Supportive Care","13-009967|CHP12ST051 OS Pilot","April 29, 2013","April 2013","November 2017","December 16, 2016","December 2016","No Study Results Posted","null","May 2017","Change of urinary biomarker concentration from pre treatment and 24 hours after cisplatin or High-dose Methotrexate|Change of urinary biomarker concentration from pre treatment and 7 days after cisplatin or High-dose Methotrexate|Toxicity|Response to neoadjuvant therapy|Validating urinary biomarkers|Tissue microarray|Bone specific alkaline phosphatase (BSAP)|Nutritional status|Patient reported measure of symptoms|Ototoxicity","https://ClinicalTrials.gov/show/NCT01848457"
1293,"NCT00705016","Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Completed","Has Results","Squamous Cell Cancer","Drug: Cilengitide 2000 mg once weekly|Drug: Cilengitide 2000 mg twice weekly|Drug: Cetuximab|Drug: 5-fluorouracil (5-FU)|Drug: Cisplatin","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 200052-013|2008-000615-15","June 24, 2008","October 2008","June 2013","March 28, 2014","March 2014","March 28, 2014","ADVANTAGE","September 2011","Progression-free Survival (PFS) Time: Investigator Read|Overall Survival (OS) Time|Best Overall Response (BOR) Rate|Disease Control Rate|Time to Treatment Failure (TTF)|Duration of Response|Safety - Number of Participants Experiencing Any Adverse Event","https://ClinicalTrials.gov/show/NCT00705016"
1294,"NCT01150630","Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer","Active, not recruiting","No Results Available","Pancreatic Cancer","Drug: capecitabine|Drug: cisplatin|Drug: epirubicin|Drug: gemcitabine","IRCCS San Raffaele","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000675485|PACT-15|2010-019942-23","June 24, 2010","May 2010","June 2017","December 2, 2016","December 2016","No Study Results Posted","PACT-15","April 2017","Event-free survival at 1 year (phase II)|Radiological, biochemical, and pathological response rate (neoadjuvant arm only)|Surgical resection rate|Surgical mortality and morbidity|Tolerability|Proportion of patients with negative surgical margins|Lymph node status","https://ClinicalTrials.gov/show/NCT01150630"
1295,"NCT00547157","Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck","Completed","Has Results","Cancer|Head and Neck Cancer|Oncology|Squamous Cell Carcinoma","Drug: Panitumumab|Drug: Cisplatin","Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","20062079|CONCERT2","October 18, 2007","November 2007","March 2012","February 7, 2017","February 2017","December 16, 2013","null","December 2011","Local Regional Control Rate at 2 Years|Duration of Local Regional Control|Progression-free Survival|Overall Survival|ORR by 6 Months - Central|CRR by 6 Months - Central","https://ClinicalTrials.gov/show/NCT00547157"
1296,"NCT00154700","Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: Paclitaxel,Cisplatin,5-Fu,Folic Acid","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","159I9","September 8, 2005","January 2001","July 2005","December 19, 2005","July 2005","No Study Results Posted","null","null","Response rate|Overall survival|Progression-free survival|Toxicity","https://ClinicalTrials.gov/show/NCT00154700"
1297,"NCT01425736","Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Chemotherapy|Drug: Nimotuzumab and Chemotherapy","Wei Guo|Sun Yat-sen University|Shanghai 9th People's Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-IST-SCCHN-008","August 19, 2011","January 2009","March 2013","June 1, 2014","June 2014","No Study Results Posted","null","January 2011","Rate of Disease Control (RDC)|toxicity, progression-free survival (PFS), and overall survival (OS).","https://ClinicalTrials.gov/show/NCT01425736"
1298,"NCT00209716","Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.","Completed","No Results Available","Esophageal Cancer","Drug: Taxotere|Drug: 5-Fluorouracil|Drug: Briplatin","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","All","20 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0305-2|TPF-2","September 13, 2005","December 2003","November 2009","May 24, 2010","May 2010","No Study Results Posted","null","October 2009","Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.|Determine the clinical response rate of patients in Phase I setting.|Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.","https://ClinicalTrials.gov/show/NCT00209716"
1299,"NCT00994097","NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: NGR-hTNF|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed","MolMed S.p.A.","All","18 Years and older   (Adult, Senior)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NGR014|2008-002703-20","October 13, 2009","July 2009","June 2016","October 8, 2015","October 2015","No Study Results Posted","null","June 2016","Progression-free survival (PFS) defined as time from the randomization until to objective disease progression or death due any cause.|Safety profile of NGR-hTNF in combination with standard chemotherapy as compared to standard chemotherapy alone.|Response rate defined as the percentage of subjects achieving at a specific % tumor volume reduction in according to RECIST criteria.|Duration of response (DR) defined as the time that measurement criteria are met for complete response or partial response (whichever status is recorded first) until the progressive disease is objectively documented.|Overall survival (OS) defined as the time from the randomization until to the date of patient death from any case or discontinuation from the study.","https://ClinicalTrials.gov/show/NCT00994097"
1300,"NCT00536614","Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Genetic: cetuximab","Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Senior)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-004309-69","September 27, 2007","May 2005","September 2006","September 27, 2007","September 2007","No Study Results Posted","SPaCe-01","null","Overall survival|response to treatment, and toxicity","https://ClinicalTrials.gov/show/NCT00536614"
1301,"NCT00057837","Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","Has Results","Extensive Stage Small Cell Lung Cancer","Biological: G-CSF|Drug: Cisplatin|Drug: Etoposide|Drug: Irinotecan|Drug: Topotecan","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000276590|U10CA021115|E5501","April 7, 2003","March 2004","August 2012","January 11, 2013","January 2013","January 11, 2013","null","January 2012","Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST)|Duration of Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00057837"
1302,"NCT00662311","Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery","Terminated","No Results Available","Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Drug: vorinostat|Drug: paclitaxel|Radiation: radiation therapy","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","5","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6600|NCI-2010-00715","April 18, 2008","March 2008","September 2011","May 7, 2013","May 2013","No Study Results Posted","null","January 2010","MTD of vorinostat when administered in combination with paclitaxel and radiotherapy therapy as assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 (Phase I)|Radiological response rate as assessed by CT|Duration of response|Progression-free survival|Overall survival|Safety and toxicity of vorinostat at the MTD as assessed by NCI CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00662311"
1303,"NCT01604863","A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies","Suspended","No Results Available","Cancer","Drug: HGS1036 + Paclitaxel + Carboplatin|Drug: HGS1036 + Cisplatin + Etoposide|Drug: HGS1036 + Docetaxel","Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HGS1036-C1118","January 23, 2012","June 2012","July 2014","October 29, 2012","October 2012","No Study Results Posted","null","June 2014","Maximum Tolerated Dose (MTD)|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01604863"
1304,"NCT01405079","Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Gefitinib|Drug: Vinorelbine+Cisplatin","Guangdong Association of Clinical Trials|Guangdong General Hospital|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-sen University|Jilin Provincial Tumor Hospital|Liaoning Tumor Hospital & Institute|First Hospital of China Medical University|Chinese PLA General Hospital|Peking Union Medical College Hospital|Peking University People's Hospital|Beijing Chest Hospital|309th Hospital of Chinese People's Liberation Army|Beijing Cancer Hospital|Peking University First Hospital|Tianjin Medical University Cancer Institute and Hospital|Qingdao University|Jiangsu Cancer Institute & Hospital|The First Affiliated Hospital of Soochow University|Fudan University|Shanghai Pulmonary Hospital, Shanghai, China|Zhejiang Cancer Hospital|Zhejiang University|Wuhan Union Hospital, China|Tongji Hospital|West China Hospital|Tang-Du Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CTONG 1104","July 26, 2011","July 2011","December 2020","February 28, 2017","February 2017","No Study Results Posted","ADJUVANT","March 2017","Disease free survival|Overall survival|3 yeas DFS rate, 5 years DFS rate, 5 years OS rate|Number of Participants with Adverse Events|Quality of life","https://ClinicalTrials.gov/show/NCT01405079"
1305,"NCT00275951","Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: Cetuximab Plus P-HDFL","National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|National Health Research Institutes, Taiwan|Chang Gung Memorial Hospital|Tri-Service General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","941004","January 11, 2006","December 2005","June 2009","November 15, 2012","November 2012","No Study Results Posted","FLAG","June 2009","Confirmed objective response rates|Progression-free survival (PFS), overall survival (OS), treatment-related toxicity","https://ClinicalTrials.gov/show/NCT00275951"
1306,"NCT00313690","Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer","Withdrawn","No Results Available","Lung Cancer","Drug: Bortezomib, Docetaxel and Cisplatin","University of Southern California","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2N-05-2","April 10, 2006","April 2006","null","May 20, 2014","May 2014","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00313690"
1307,"NCT02445872","Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy","Not yet recruiting","No Results Available","Chemotherapy-Induced Nausea and Vomiting|Lung Cancer","Drug: Aprepitant|Drug: Palonosetron|Drug: Dexamethasone","Zhejiang University|Merck Sharp & Dohme Corp.","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","ZYTOP1502","April 5, 2015","December 2015","May 2016","December 8, 2015","August 2015","No Study Results Posted","null","May 2016","Complete Response|Complete Control (No emetic episode, no need for rescue medication, with a maximum grade of mild nausea)|Emesis-free|Presence of nausea|Safety and tolerability (adverse events related to study drug administration)","https://ClinicalTrials.gov/show/NCT02445872"
1308,"NCT00509366","Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer","Terminated","Has Results","Non Small Cell Lung Cancer","Drug: Cisplatin & Gemcitabine|Drug: Cisplatin & Pemetrexed|Drug: Docetaxel & Gemcitabine|Drug: Pemetrexed & Gemcitabine","Duke University|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","101","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00004599","July 30, 2007","May 2007","December 2011","August 15, 2014","August 2014","May 7, 2014","TOP0602","December 2011","1-year Progression Free Survival Rate in Chemo-naive Select Stage IIIB or Stage IV NSCLC Patients|Median Time to Progressive Disease|Mean Change From Baseline to Follow-up Cycle in Quality of Life - Functional Assessment of Cancer Therapy-Lung (FACT-L)|Drug Sensitivity Quartiles for Cisplatin and Pemetrexed","https://ClinicalTrials.gov/show/NCT00509366"
1309,"NCT01372202","CHFR Methylation Status Esophageal Cancer Study","Active, not recruiting","No Results Available","Esophageal Cancer","Drug: Paclitaxel|Drug: Cisplatin|Drug: Oxaliplatin|Drug: 5-Fluorouracil|Radiation: Radiotherapy|Procedure: Esophagectomy","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J10130|NA_00042668","June 9, 2011","June 2011","June 2019","October 12, 2016","October 2016","No Study Results Posted","J10130","June 2014","Esophageal Tumor Response|Survival|Time to disease progression|Esophageal tumor CHFR methylation and detection in plasma","https://ClinicalTrials.gov/show/NCT01372202"
1310,"NCT00209690","Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.","Completed","No Results Available","Esophageal Cancer","Drug: Taxotere|Drug: 5-FU|Drug: Briplatin","Hokkaido Gastrointestinal Cancer Study Group|Hokkaido University Hospital","All","20 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HGCSG0305-1|TPF","September 13, 2005","October 2003","April 2010","May 24, 2010","May 2010","No Study Results Posted","null","December 2009","Determine the DLT(Dose Limiting Toxicity) and MTD(Maximum Tolerated Dose) in Phase I setting. Determine the clinical response rate with Recommended dose in Phase II setting.|Determine the MST(Median Survival Time) and PFS(Progression Free Survival) in Phase II setting.","https://ClinicalTrials.gov/show/NCT00209690"
1311,"NCT00828386","Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers","Terminated","No Results Available","Nasopharyngeal Cancers","Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC-NPC2006","January 22, 2009","January 2009","August 2015","March 23, 2015","March 2015","No Study Results Posted","GORTEC-NPC2006","August 2015","Event free-survival|Survival|toxicity|Cumulative incidence of loco-regional progression|Cumulative rate of metastasis|Global response to chemo-radiotherapy|Global response to induction chemotherapy","https://ClinicalTrials.gov/show/NCT00828386"
1312,"NCT02290145","Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","Not yet recruiting","No Results Available","Mouth Neoplasms|Carcinoma, Squamous Cell","Drug: TPF group|Procedure: surgery group|Radiation: Post-operative radiotherapy","Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDSCAN2014","October 22, 2014","December 2014","December 2019","November 8, 2014","November 2014","No Study Results Posted","null","December 2016","overall survival rate as a measure by the numbers of living patients|disease free survival as a measure by the number of patients without recurrence or death|local recurrence free survival as a measure by the number of patients without recurrence|distant metastasis free survival as a measure by the number of patients without metastasis","https://ClinicalTrials.gov/show/NCT02290145"
1313,"NCT00756444","A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck","Completed","Has Results","Squamous Cell Carcinoma of Head and Neck","Drug: Panitumumab|Drug: Cisplatin|Drug: 5FU","Amgen|Takeda","All","18 Years and older   (Adult, Senior)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20080008","September 18, 2008","October 2008","May 2012","March 28, 2014","March 2014","October 23, 2013","null","May 2012","Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab|Steady-state Plasma Concentrations (Css) for 5-FU With and Without the Presence of Panitumumab","https://ClinicalTrials.gov/show/NCT00756444"
1314,"NCT00030862","Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","01-123|CDR0000069204|PHARMACIA-440E-ONC-0020-319|NCI-G01-2050","February 14, 2002","October 2001","December 2003","June 4, 2013","June 2013","No Study Results Posted","null","December 2003","","https://ClinicalTrials.gov/show/NCT00030862"
1315,"NCT00006116","Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068129|FRE-GERCOR-B98-1|EU-20026","August 3, 2000","April 1999","null","July 23, 2008","November 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006116"
1316,"NCT00002813","Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: vinorelbine tartrate","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","62","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000064956|GOG-76Z","November 1, 1999","August 1997","null","May 24, 2013","March 2008","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00002813"
1317,"NCT01573338","Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)","Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Roniciclib (BAY 1000394)|Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","43","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14858|2011-004155-39","April 5, 2012","February 25, 2013","June 23, 2016","April 25, 2017","April 2017","No Study Results Posted","null","March 25, 2016","Safety variables will be summarized using descriptive statistics based on adverse events collection|tumor response - number of subjects with best tumor response that is achieved during or within 30 days after end of therapy|Maximum Tolerated Dose (MTD) - measured by adverse event profile at the end of Cycle 1. MTD will be the highest dose level achieved during dose escalation where non or 1 of 6 subjects experience a dose limiting toxicity as defined in the protocol|Maximum drug concentration in plasma after single dose administration(Cmax) of BAY1000394|Area under the concentration versus time curve from zero to infinity after single (first) dose(AUC) of BAY1000394|Disease control rate (DCR)|Overall survival (OS)|Time to progression (TTP)|Progression-free survival (PFS)|Duration of response (DOR)|Stable disease (SD)","https://ClinicalTrials.gov/show/NCT01573338"
1318,"NCT00623558","Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)","Completed","No Results Available","Head and Neck Neoplasm","Drug: Cetuximab|Drug: Docetaxel|Drug: Cisplatin","Seoul National University Hospital|Clinical Research Center for Solid Tumor, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCST-L0002","February 17, 2008","April 2008","August 2013","December 3, 2013","April 2013","No Study Results Posted","null","November 2012","Response rate","https://ClinicalTrials.gov/show/NCT00623558"
1319,"NCT00334594","Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma","Terminated","No Results Available","Malignant Mesothelioma","Drug: Cisplatin|Drug: Pemetrexed|Procedure: Therapeutic conventional surgery|Radiation: Radiotherapy","Swiss Group for Clinical Cancer Research","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 17/04|SWS-SAKK-17/04|EU-20615|2006-000445-19|LILLY-SAKK-17/04|CDR0000481153","June 7, 2006","November 2005","June 2018","March 10, 2015","March 2015","No Study Results Posted","null","December 2013","Complete macroscopic resection (part 1)|Loco-regional relapse-free survival (part 2)|Response to neoadjuvant therapy (part 1)|Adverse drug reaction to neoadjuvant therapy (part 1)|Operability (part 1)|Surgical complications (part 1)|Reasons for non-randomization (part 1)|Relapse-free or progression-free survival (part 1)|Adverse reaction to postoperative radiotherapy (part 2)|Late toxicity (part 2)|Feasibility of postoperative radiotherapy (part 2)|Relapse-free survival (part 2)|Psychological distress (quality of life) (part 2)|Overall survival","https://ClinicalTrials.gov/show/NCT00334594"
1320,"NCT01488838","A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors","Completed","No Results Available","Malignant Salivary Gland Tumors","Drug: Cisplatin: 40 mg/m2 weekly during radiation|Radiation: Radiation: 60-66 Gy in 2 Gy daily fractions","King Faisal Specialist Hospital & Research Center|Radiation Therapy Oncology Group","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2111-096","December 7, 2011","November 2011","November 2013","February 24, 2016","December 2011","No Study Results Posted","null","November 2013","Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin.","https://ClinicalTrials.gov/show/NCT01488838"
1321,"NCT00949650","BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation","Completed","Has Results","Carcinoma, Non-Small-Cell Lung|Adenocarcinoma","Drug: Pemetrexed|Drug: BIBW 2992|Drug: Cisplatin","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 3","345","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","1200.32|2008-005615-18","July 29, 2009","August 2009","March 2017","March 27, 2017","March 2017","August 8, 2013","null","January 2012","Progression-free Survival (PFS) Time|Percentage of Patients With Objective Response (OR)|Percentage of Participants With Disease Control (DC)|Overall Survival (OS) Time|Tumour Shrinkage|Change From Baseline in Body Weight|Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)|Health Related Quality of Life (HRQOL): Time to Deterioration in Coughing|HRQOL: Time to Deterioration in Dyspnoea|HRQOL: Time to Deterioration in Pain|Trough Plasma Concentrations of Afatinib at Day 22|Trough Plasma Concentrations of Afatinib at Day 29|Trough Plasma Concentrations of Afatinib at Day 43","https://ClinicalTrials.gov/show/NCT00949650"
1322,"NCT00985855","Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","Unknown status","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: cisplatin, vinorlebine, cetuximab|Drug: cisplatine, etoposide, cetuximab","Institut de Cancérologie de la Loire","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-03|2008-005013-21","September 22, 2009","September 2009","December 2012","January 14, 2011","January 2011","No Study Results Posted","null","September 2012","rate of patients presenting at least one toxicity grade≥3 (excepted hematological toxicity and nausea-vomiting)","https://ClinicalTrials.gov/show/NCT00985855"
1323,"NCT00122746","Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients","Unknown status","No Results Available","Cancer of the Cervix","Radiation: Radiotherapy alone|Radiation: Radiotherapy with cisplatin","International Atomic Energy Agency","Female","18 Years and older   (Adult, Senior)","Phase 3","322","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E33022","July 19, 2005","December 2004","null","October 12, 2011","October 2011","No Study Results Posted","null","June 2012","3 year recurrence free survival|Incidence of Grade 3 acute toxicity|Pelvic control rates|Tumour response at 3 months.|Cancer specific survival rates.|Overall survival rates.|Acute and late toxicities after the treatment.","https://ClinicalTrials.gov/show/NCT00122746"
1324,"NCT00191854","Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line","Completed","Has Results","Breast Cancer","Drug: gemcitabine|Drug: paclitaxel|Drug: carboplatin|Drug: cisplatin","Eli Lilly and Company","Female","18 Years and older   (Adult, Senior)","Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","7451|B9E-AA-S355","September 12, 2005","March 2005","November 2009","February 24, 2010","February 2010","July 21, 2009","null","August 2008","Best Overall Response|Number of Participants With a Time to Treatment Failure (TTTF) Event|Progression Free Survival (PFS)|Duration of Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00191854"
1325,"NCT02383966","Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Subjects With Head and Neck Cancer","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: Cetuximab|Drug: Cisplatin/Carboplatin|Drug: 5-fluorouracil","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EMR062202-060","March 4, 2015","July 2015","April 2019","January 25, 2017","January 2017","No Study Results Posted","CHANGE2","August 2018","Progression-free survival (PFS) time, as assessed by an Independent Review Committee (IRC)|PFS time, as assessed by the Investigator|Overall survival (OS) time|Best overall response (BOR) rate|Disease control rate (DCR)|Duration of response|Number of Participants With Adverse Events (AEs), Serious AEs, AEs Leading to Death and AEs Leading to Discontinuation","https://ClinicalTrials.gov/show/NCT02383966"
1326,"NCT00253591","Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: vinorelbine tartrate|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000449972|MRC-LU23|EU-20535|EU-INCH-20535|EudraCT-2004-004438-15","November 11, 2005","June 2005","December 2009","December 18, 2013","July 2007","No Study Results Posted","null","December 2007","Overall survival|Progression-free survival|Toxicity|Response (complete or partial response)|Cost effectiveness","https://ClinicalTrials.gov/show/NCT00253591"
1327,"NCT01633203","Observational Study of Perioperative Chemotherapy in Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: epirubicin + cisplatin + capecitabine polychemotherapy","Grupo Oncologico Cooperativo Chileno de Investigation","All","19 Years to 80 Years   (Adult, Senior)","","61","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GOCCHI 2009-01","June 30, 2012","August 2010","September 2018","March 6, 2017","March 2017","No Study Results Posted","PRECISO","March 2018","rate of downstaging|To evaluate the rates of adverse events of ECX administered preoperatively|To evaluate clinical response after three cycles of preoperative ECX|To evaluate the surgical morbidity and mortality after three cycles of preoperative CT|progression free survival|overall survival|compliance with the planned postoperative therapy|quality of life|HER 2 expression","https://ClinicalTrials.gov/show/NCT01633203"
1328,"NCT00304278","Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)","Completed","No Results Available","Head and Neck Cancer","Drug: Erlotinib (Tarceva)|Drug: Intra-arterial Cisplatin (PLAT)|Radiation: Radiation Therapy (RAD)","Southern Illinois University|Genentech, Inc.|OSI Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAO-OSI-3601S|Genentech, Inc.","March 16, 2006","March 2006","December 2015","August 1, 2016","August 2016","No Study Results Posted","null","May 2015","Change in largest diameter of tumor lesion using RECIST criteria|Response and progression post treatment","https://ClinicalTrials.gov/show/NCT00304278"
1329,"NCT00384878","Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer","Unknown status","No Results Available","Stomach Neoplasms","Drug: Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin","Far Eastern Memorial Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FEMH-95011","October 4, 2006","June 2006","null","February 6, 2009","June 2006","No Study Results Posted","null","March 2007","The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).|The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.","https://ClinicalTrials.gov/show/NCT00384878"
1330,"NCT02795988","A Study of IMU-131 Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Advanced Cancer of the Stomach","Recruiting","No Results Available","Gastrointestinal Neoplasms|Adenocarcinoma","Biological: IMU-131|Drug: Cisplatin and either Fluorouracil (5-FU) or Capecitabine","Imugene Limited","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IMU.ACS.001","June 1, 2016","November 2016","September 2018","May 4, 2017","May 2017","No Study Results Posted","null","March 2018","Incidence of treatment-emergent adverse events|Recommended Phase 2 Dose (RP2D)","https://ClinicalTrials.gov/show/NCT02795988"
1331,"NCT00188266","Study of Adjuvant Radiochemotherapy for Gastric Cancer","Active, not recruiting","No Results Available","Stomach Neoplasms","Drug: cisplatinum combined with infusional fluorouracil (5 FU)","University Health Network, Toronto|Princess Margaret Hospital, Canada","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 02-0134-C","September 9, 2005","August 2002","August 2017","October 31, 2016","October 2016","No Study Results Posted","null","December 2013","Phase I and II: Acute toxicity: assessed according to National Cancer Institute of Canada (NCIC) and Radiation Therapy Oncology Group (RTOG) toxicity assessment criteria.|Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.|Monitor 1 and 2 year local recurrence|Survival and disease-specific survival","https://ClinicalTrials.gov/show/NCT00188266"
1332,"NCT00041106","Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer","Completed","No Results Available","Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter|Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter","Drug: gemcitabine hydrochloride|Drug: cisplatin|Drug: gefitinib|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02818|CALGB-90102|CDR0000069443|U10CA031946","July 8, 2002","May 2002","null","June 4, 2013","June 2013","No Study Results Posted","null","July 2007","Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as either a complete or partial response|Toxicity rates assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Progression-free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT00041106"
1333,"NCT00505492","Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy","Terminated","No Results Available","Uterine Neoplasms","Drug: Carboplatin|Drug: Cisplatin|Drug: Paclitaxel","M.D. Anderson Cancer Center","Female","Child, Adult, Senior","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-535","July 19, 2007","February 2002","December 2010","September 13, 2011","September 2011","No Study Results Posted","null","February 2006","Overall Survival","https://ClinicalTrials.gov/show/NCT00505492"
1334,"NCT01160744","A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting","Has Results","Carcinoma, Non-Small-Cell Lung","Biological: IMC-1121B (ramucirumab)|Drug: Pemetrexed|Drug: Carboplatin (AUC 6)|Drug: Cisplatin|Drug: Gemcitabine|Drug: Carboplatin (AUC 5)","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13916|I4T-IE-JVBL|CP12-0917|2009-016784-11","July 8, 2010","September 2010","June 2017","February 2, 2017","February 2017","December 17, 2014","null","January 2014","Progression-Free Survival (PFS)|Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]|Overall Survival (OS)|Duration of Response (DOR)|Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Who Died|Squamous Population OS","https://ClinicalTrials.gov/show/NCT01160744"
1335,"NCT01087970","A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer","Completed","Has Results","Head and Neck Neoplasms","Drug: Pemetrexed|Drug: Cetuximab|Drug: Carboplatin|Drug: Cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","69","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13491|H3E-MC-S132","March 15, 2010","August 2010","August 2013","April 18, 2014","April 2014","April 18, 2014","null","August 2013","Progression-Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)|Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)|Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)","https://ClinicalTrials.gov/show/NCT01087970"
1336,"NCT01557959","Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","Completed","Has Results","Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Non-small Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: cisplatin|Biological: pegfilgrastim|Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis|Genetic: polymorphism analysis|Other: pharmacogenomic studies|Genetic: genetic linkage analysis|Drug: docetaxel","Wake Forest University Health Sciences|National Cancer Institute (NCI)|OSI Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCWFU 62107|NCI-2009-01252","February 14, 2012","July 2007","null","January 17, 2017","November 2013","May 1, 2013","null","February 2011","Time to Progression|Response Rate Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood|Median Survival Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood","https://ClinicalTrials.gov/show/NCT01557959"
1337,"NCT01016561","Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer","Active, not recruiting","No Results Available","Cervical Cancer","Radiation: intracavitary balloon brachytherapy|Radiation: external beam radiation therapy|Radiation: intensity-modulated radiation therapy|Radiation: radiation therapy treatment planning/simulation|Radiation: 3-dimensional conformal radiation therapy|Drug: Cisplatin","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 01809","November 18, 2009","July 2009","null","December 14, 2015","December 2015","No Study Results Posted","null","July 2012","Feasibility of using MRI for intracavitary brachytherapy treatment planning.|Adverse events associated with brachytherapy delivered according to MRI-based treatment planning.|Frequency of grade 2 and higher gastrointestinal and genitourinary early event rates as compared to historical series.|True pelvis failure|Pelvis Failure|Progression-free survival|Overall survival|Toxicity as assessed by NCI CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT01016561"
1338,"NCT00423852","Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin","Completed","Has Results","Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Teratoma|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: ifosfamide|Drug: paclitaxel|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-077|MSKCC-06077","January 16, 2007","August 2006","February 2013","April 12, 2016","April 2016","December 17, 2015","null","February 2013","Response|Maximum Tolerated Dose of Ifosfamide","https://ClinicalTrials.gov/show/NCT00423852"
1339,"NCT02177695","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer","Recruiting","No Results Available","Bladder Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Methotrexate|Drug: Vinblastine|Drug: Doxorubicin|Drug: Filgrastim","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","184","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","S1314|NCI-2014-00850|U10CA180888","June 11, 2014","July 2014","October 2022","April 20, 2017","April 2017","No Study Results Posted","COXEN","February 2020","The relationship of dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)- and gemcitabine+cisplatin (GC)- specific CO-eXpression ExtrapolatioN (COXEN) scores.|Predictability of the CO-eXpression ExtrapolatioN (COXEN) score to direct which of the two regimens the patient should receive: gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)|Overall survival|Pathologic T0 rate evaluation: gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT02177695"
1340,"NCT01824004","Postoperative Chemoradiotherapy With S-1 in Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: S-1","Chonnam National University Hospital","All","19 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CNUHH-MO-03|CNUHH","March 28, 2013","April 2009","June 2012","April 3, 2013","April 2013","No Study Results Posted","null","October 2010","Disease free survival|Overall Survival|Number of participants with adverse events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT01824004"
1341,"NCT01639001","A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients","Active, not recruiting","Has Results","NSCLC (Non-small Cell Lung Cancer)","Drug: Crizotinib|Drug: Pemetrexed/Cisplatin|Drug: Pemetrexed/Carboplatin","Pfizer","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","A8081029","July 10, 2012","September 29, 2012","January 20, 2018","April 7, 2017","April 2017","June 8, 2016","null","June 30, 2015","Progression-Free Survival (PFS) Based on IRR by Treatment Arm|Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR|Overall Survival (OS)|Percentage of Participants With Disease Control at 12 Weeks Based on IRR|Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months|Duration of Response (DR) Based on IRR|Time to Tumor Response (TTR) Based on IRR|Time To Progression (TTP) Based on IRR|Intracranial Time To Progression (IC-TTP) Based on IRR|Extracranial Time To Progression (EC-TTP) Based on IRR|Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough|Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30|Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13)|Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)- Visual Analog Scale (VAS)|Change From Baseline in General Health Status as Assessed by EQ-5D- Index|Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)|Agreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable|Percentage of Participants With Treatment-emergent Adverse Events (AEs; All Causalities)|Percentage of Participants With Treatment-emergent AEs (Treatment Related)","https://ClinicalTrials.gov/show/NCT01639001"
1342,"NCT02289807","Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin|Radiation: IMRT","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SYSYCC-2014-11","November 10, 2014","March 2015","March 2020","November 10, 2014","November 2014","No Study Results Posted","null","March 2017","Failure-free survival|Overall survival|Locoregional failure-free survival|Distant failure-free survival|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02289807"
1343,"NCT01675765","Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","Active, not recruiting","No Results Available","Malignant Pleural Mesothelioma","Biological: Immunotherapy plus chemotherapy|Biological: Immunotherapy with cyclophosphamide plus chemotherapy","Aduro Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ADU-CL-02","August 23, 2012","August 2012","June 2017","January 25, 2017","January 2017","No Study Results Posted","null","June 2017","Number of subjects reporting adverse events|Induction of immune response to mesothelin by enzyme-linked immunosorbent spot (ELISPOT) assay|Objective tumor response|Time to progression|Serum mesothelin as correlate of therapeutic response","https://ClinicalTrials.gov/show/NCT01675765"
1344,"NCT03061630","A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder","Active, not recruiting","No Results Available","Urinary Bladder","Drug: Gemcitabine|Drug: Cisplatin","Samsung Medical Center","All","20 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2017-01-006","February 20, 2017","February 15, 2017","February 2020","April 25, 2017","April 2017","No Study Results Posted","null","February 2018","pathologic response|progression-free survival","https://ClinicalTrials.gov/show/NCT03061630"
1345,"NCT00385606","GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: gemcitabine|Drug: prolonged continuous infusion gemcitabine|Drug: cisplatin|Drug: rofecoxib","National Cancer Institute, Naples","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","GECO","October 10, 2006","January 2003","null","August 22, 2007","August 2007","No Study Results Posted","null","null","To evaluate the tolerability of three experimental treatment schedules|To evaluate the efficacy of the addition of rofecoxib to first-line chemotherapy|To evaluate the efficacy of prolonged continuous infusion (p.c.i.) of gemcitabine vs standard infusion, in combination with cisplatin","https://ClinicalTrials.gov/show/NCT00385606"
1346,"NCT00526396","STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study","Unknown status","No Results Available","Small Cell Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: cisplatin|Drug: etoposide","National Cancer Institute, Naples","All","up to 70 Years   (Child, Adult, Senior)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STAD-1|2006-003995-36","September 6, 2007","September 2007","July 2016","April 8, 2015","April 2015","No Study Results Posted","STAD-1","January 2016","objective response|toxicity","https://ClinicalTrials.gov/show/NCT00526396"
1347,"NCT02518802","Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma","Recruiting","No Results Available","Lung Neoplasms","Drug: Gefitinib|Drug: Pemetrexed","Tang-Du Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","W-TONG002","May 5, 2015","January 2015","January 2020","August 5, 2015","April 2015","No Study Results Posted","null","January 2018","Disease free survival|Overall survival|Number of Participants with Adverse Events|Quality of life","https://ClinicalTrials.gov/show/NCT02518802"
1348,"NCT00720083","Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer","Terminated","Has Results","Head and Neck Cancer","Drug: cisplatin|Drug: vandetanib|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0619|CDR0000599867","July 19, 2008","November 2008","August 2011","November 14, 2015","November 2015","March 22, 2013","null","August 2011","Disease-free Survival","https://ClinicalTrials.gov/show/NCT00720083"
1349,"NCT02285543","a Trial of TPF(Docetaxel, Cisplatin and 5-fluorouracil ) Induction Chemotherapy in OSCC at cN2 Stage","Not yet recruiting","No Results Available","Mouth Neoplasms|Carcinoma, Squamous Cell","Drug: TPF induction chemotherapy|Procedure: surgery|Radiation: radiotherapy","Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TOPIC2014","October 22, 2014","December 2014","December 2019","November 4, 2014","November 2014","No Study Results Posted","null","December 2016","overall survival rate as a measure by the numbers of living patients overall Survival rate|disease free survival as a measure by the number of patients without recurrence or death|local recurrence free survival as a measure by the number of patients without recurrence|distant metastasis free survival as a measure by the number of patients without metastasis","https://ClinicalTrials.gov/show/NCT02285543"
1350,"NCT00578864","Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma","Completed","Has Results","Neuroblastoma","Drug: Protracted Oral Etoposide|Drug: Adriamycin and Cyclophosphamide|Drug: IV Cisplatin and IV Bolus Etoposide","Baylor College of Medicine|Texas Children's Hospital","All","Child, Adult, Senior","Phase 2","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H20255|PEPI","December 19, 2007","March 2007","March 2015","June 25, 2015","June 2015","October 5, 2012","PEPI","July 2009","Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With High Risk Neuroblastoma Tumors.|Rate of Toxicities Associated With Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With High Risk Neuroblastoma.|Overall Survival in Children With High Risk Neuroblastoma Treated on This Regimen.|Percentage of Patients Who Have Surgery After the Second Cycle of Induction Therapy|Event Free Survival in Children With High Risk Neuroblastoma Treated on This Regimen.","https://ClinicalTrials.gov/show/NCT00578864"
1351,"NCT00006487","S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: tirapazamine|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068318|U10CA032102|S0004","November 6, 2000","October 2000","July 2004","October 3, 2012","October 2012","No Study Results Posted","null","July 2004","Feasibility and Toxicity","https://ClinicalTrials.gov/show/NCT00006487"
1352,"NCT02980991","Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma","Recruiting","No Results Available","Lung Adenocarcinoma","Drug: Pemetrexed|Drug: Cisplatin","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCPOII","December 16, 2014","December 2015","April 2018","December 1, 2016","November 2016","No Study Results Posted","null","January 2018","radiological response rate|Number of Adverse Events of chemotherapy","https://ClinicalTrials.gov/show/NCT02980991"
1353,"NCT00334815","Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","Active, not recruiting","Has Results","Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy|Biological: bevacizumab|Drug: docetaxel|Biological: filgrastim|Biological: pegfilgrastim","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","29","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01097|SWOG-S0533|CDR0000472907|S0533|U10CA180888|U10CA032102","June 7, 2006","June 2006","null","November 1, 2016","November 2016","September 22, 2015","null","July 2014","Adverse Events|Progression-free Survival|Overall Survival|Response Rate (Confirmed or Unconfirmed Partial Response)","https://ClinicalTrials.gov/show/NCT00334815"
1354,"NCT02786641","Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Docetaxel|Drug: Cisplatin 1|Drug: Xeloda|Radiation: IMRT|Drug: Cisplatin 2","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 3","235","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","2016-FXY-012-Dept. of RT","May 26, 2016","August 2016","August 2021","May 26, 2016","May 2016","No Study Results Posted","null","August 2018","FFS","https://ClinicalTrials.gov/show/NCT02786641"
1355,"NCT00331760","Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery","Completed","Has Results","Cervical Cancer|Endometrial Cancer","Drug: cisplatin|Radiation: intensity-modulated radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","Female","18 Years and older   (Adult, Senior)","Phase 2","106","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0418|CDR0000472905","May 30, 2006","March 2006","December 2016","December 30, 2016","December 2016","April 12, 2013","null","February 2009","Reproducibility of Radiation Technique (Number of Unacceptable Deviations in Central IMRT Quality Assurance Review)|Grade 2+ Bowel Adverse Events (Diarrhea, Enteritis, Fistula, Ileus; Gastrointestinal (GI), Incontinence; Anal, Necrosis; GI, Obstruction; GI, Perforation; GI, Proctitis and Stricture/Stenosis (Including Anastomotic) as Graded by CTCAE v. 3.0)|All Other Adverse Events|Chemotherapy Compliance for Cervical Carcinoma Patients|Local-regional Failure|Distant Metastases|Disease-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00331760"
1356,"NCT03071848","A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer","Not yet recruiting","No Results Available","Cervical Cancer","Other: No Intervention","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","","120","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ML39360","March 2, 2017","April 2017","September 2017","March 2, 2017","February 2017","No Study Results Posted","null","July 2017","Percentage of Participants With Gastrointestinal (GI) and Genitourinary (GU) Fistulas and GI Perforations|Percentage of Participants who Received Radiotherapy Prior to GI and GU Fistulas and GI Perforation Events|Percentage of Participants who Received Internal, External and Other Radiotherapy|Number of Doses of Prior Radiotherapy|Percentage of Participants With Selected Adverse Events of Special Interest (AESIs)|Overall Response Rate (ORR)|Progression Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT03071848"
1357,"NCT01443078","Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)","Completed","Has Results","Lung Cancer","Drug: pemetrexed plus cisplatin|Drug: vinorelbine and docetaxel","Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|United States Department of Defense","All","18 Years and older   (Adult, Senior)","Phase 2","42","Other|Industry|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","11-106","September 26, 2011","October 2011","April 2015","June 29, 2016","June 2016","June 29, 2016","null","April 2015","PERCIST Partial Metabolic Response|Overall Response Rate","https://ClinicalTrials.gov/show/NCT01443078"
1358,"NCT00217698","Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gefitinib|Drug: gemcitabine hydrochloride","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 19/03|EU-20519|ZENECA-AZ1839IL/0542","September 20, 2005","November 2003","October 2004","June 2, 2012","June 2012","No Study Results Posted","null","October 2004","Disease stabilization (complete response [CR], partial response [PR], or stable disease [SD]) after 12 weeks of study treatment|Disease stabilization (CR, PR, or SD) after 6 and 18 weeks of study treatment|Objective response (CR and PR) to gefitinib treatment after weeks 6, 12, and 18|Adverse reactions to gefitinib treatment measured after completion of study treatment|Time to progression (TTP) with gefitinib treatment after completion of study treatment|Event-free survival (EFS) with gefitinib treatment after completion of study treatment","https://ClinicalTrials.gov/show/NCT00217698"
1359,"NCT02474368","Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck","Recruiting","No Results Available","Recurrent Head and Neck Carcinoma|Head and Neck Cancer Metastatic|Head or Neck Cancer","Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Cisplatin|Radiation: Stereotactic Body Radiotherapy (SBRT)","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","15-183","June 13, 2015","November 2015","June 2021","August 5, 2016","August 2016","No Study Results Posted","null","October 2018","Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given as a boost in combination with cisplatin and intensity modulated radiation therapy (IMRT)|Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given for disease metastatic to the head and neck|Number of Participants with Adverse Events|Local Control Rate|Regional Control Rate|Progression Free Survival using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Level of circulating activated T cells as an immune correlate of stereotactic treatment|Patient reported physical function before and after treatment|Patient reported social function before and after treatment","https://ClinicalTrials.gov/show/NCT02474368"
1360,"NCT01646853","Radiation Dose Study of Concurrent Chemoradiotherapy With Cisplatin Plus Fluorouracil in Oesophageal Cancer","Unknown status","No Results Available","Esophageal Neoplasms","Radiation: Megavoltage photon beam|Drug: cisplatin-fluorouracil chemotherapy","Simcere Pharmaceutical Co., Ltd","All","18 Years and older   (Adult, Senior)","","500","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","JSNT0415","July 9, 2012","August 2012","null","July 18, 2012","July 2012","No Study Results Posted","null","December 2013","Objective Tumor Response|adverse events","https://ClinicalTrials.gov/show/NCT01646853"
1361,"NCT03047265","Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Paclitaxel|Drug: Cisplatin","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 2","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider|Primary Purpose: Treatment","308-2016-02-01","February 6, 2017","February 4, 2017","June 1, 2027","February 9, 2017","February 2017","No Study Results Posted","null","December 1, 2025","3-year progress free survival(PFS)|overall survival(OS)","https://ClinicalTrials.gov/show/NCT03047265"
1362,"NCT02309658","Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients","Completed","No Results Available","Cancer of Cervix","Drug: gemcitabine|Drug: cisplatin|Radiation: chemoradiation","Professor Fernando Figueira Integral Medicine Institute|Instituto Nacional de Cancer, Brazil","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","U1111-1156-1640","December 1, 2014","September 2013","October 2015","October 14, 2015","October 2015","No Study Results Posted","null","October 2015","Toxicity will be evaluated with Common Terminology Criteria for Adverse Events (CTCAE 4,0).|Response rate (Response Evaluation Criteria in Solid Tumors (RECIST) criteria with pelvic MRI and PET-CT)|Disease free survival|Overall Survival|hENT1 expression","https://ClinicalTrials.gov/show/NCT02309658"
1363,"NCT00309972","Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Lung Cancer","Drug: Control arm (SEQ):|Drug: Experimental arm (CON):","University College, London","All","18 Years and older   (Adult, Senior)","Phase 3","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000465629|C11922/A4558|13746987|EU-20602|2004-001920-19","March 29, 2006","December 2005","February 2012","December 1, 2014","March 2012","No Study Results Posted","SOCCAR","February 2011","Treatment related mortality (any cause)|Hematological, pulmonary, esophageal, and neurological toxicities|Quality of life|Cost effectiveness|Overall survival and progression-free survival.|Local progression-free survival (local control)|Response","https://ClinicalTrials.gov/show/NCT00309972"
1364,"NCT00051506","ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.","Completed","No Results Available","Lung Neoplasms","Drug: ALIMTA|Drug: carboplatin|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","7210|H3E-US-JMFW","January 10, 2003","null","null","July 18, 2006","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00051506"
1365,"NCT00003621","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-987251|CDR0000066700","November 1, 1999","February 1999","July 2005","July 12, 2016","July 2016","No Study Results Posted","null","February 2005","overall survival|quality of life","https://ClinicalTrials.gov/show/NCT00003621"
1366,"NCT00101842","Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer","Completed","No Results Available","Carcinoma, Transitional Cell","Drug: Pemetrexed|Drug: Gemcitabine|Drug: Platinol","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9439|H3E-US-S066","January 14, 2005","December 2004","July 2006","August 24, 2006","August 2006","No Study Results Posted","null","null","Toxicity will be measured by standard grading methods.|Response will be measured by Response Evaluation Criteria in Solid Tumors (RECIST).|Duration of response is defined as time from first objective assessment of CR or PR to first time of progression or death from any cause.|Time to progressive disease is defined as time from enrollment to first date of disease progression.|Time to treatment failure is defined as time from enrollment to first observation of disease progression, death of any cause or early discontinuation of treatment.|Survival time is defined as time from enrollment to death from any cause.","https://ClinicalTrials.gov/show/NCT00101842"
1367,"NCT01289522","Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","Completed","Has Results","Squamous Cell Head and Neck Carcinoma|Recurrent or Metastatic Disease","Biological: cetuximab IV|Other: Biopsies","Groupe Oncologie Radiotherapie Tete et Cou|Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GORTEC 2008-03 TPEx|2008-004869-25","February 1, 2011","September 2009","January 2014","April 7, 2017","October 2016","February 23, 2017","TPEx","January 2014","Objective Tumor Response Rate|Grade 1 to 5 Toxicity|Best Overall Response|Progression-free Survival|Overall Survival|Biomarkers","https://ClinicalTrials.gov/show/NCT01289522"
1368,"NCT00843934","Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma","Unknown status","No Results Available","Carcinoma, Hepatocellular","Drug: epirubicin|Drug: Cisplatin","Nihon University","All","20 Years to 79 Years   (Adult, Senior)","Phase 2|Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACE500","February 12, 2009","March 2009","February 2015","October 17, 2012","October 2012","No Study Results Posted","ACE500","December 2012","response rate","https://ClinicalTrials.gov/show/NCT00843934"
1369,"NCT00505635","Biochemotherapy With Temozolomide for Metastatic Melanoma","Terminated","Has Results","Melanoma","Drug: Temozolomide|Drug: Velban|Drug: Cisplatin|Drug: Interleukin-2|Drug: Intron-A|Drug: Thalidomide","M.D. Anderson Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM03-0218","July 20, 2007","March 2007","April 2010","May 16, 2016","March 2012","March 26, 2012","null","April 2010","Time to Progression (TTP)|Number of Participants With Response","https://ClinicalTrials.gov/show/NCT00505635"
1370,"NCT01907100","Nintedanib (BIBF 1120) in Mesothelioma","Recruiting","No Results Available","Mesothelioma","Drug: Nintedanib|Drug: Pemetrexed|Drug: Cisplatin|Drug: Cisplatin|Drug: Pemetrexed|Drug: Placebo","Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 3","537","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (masked roles unspecified)|Primary Purpose: Treatment","1199.93|2012-005201-48","July 22, 2013","September 19, 2013","October 30, 2019","May 16, 2017","May 2017","No Study Results Posted","null","October 30, 2019","Progression free survival measured from the time of randomisation to the time of disease progression or death of any cause, whichever occurs earlier|Overall survival measured from the time of randomisation to the time of death of any cause|Objective response according to modified RECIST analysed by objective response rate|Disease control according to modified RECIST analysed by disease control rate","https://ClinicalTrials.gov/show/NCT01907100"
1371,"NCT02025036","Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer","Recruiting","No Results Available","Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma","Drug: Capecitabine(Aibin)|Drug: Oxaliplatin(Aiheng)|Radiation: Radiotherapy","The First Affiliated Hospital of Henan University of Science and Technology|Luoyang Central Hospital|Military 150 Hospital|Anyang Cancer Hospital|Nanyang Central Hospital|Henan Oncology Hospital|The First Affiliated Hospital of Xinyang Medical College|Sanmenxia Central Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","630","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FirstHenanUST","November 17, 2013","October 2014","December 2020","July 2, 2016","July 2016","No Study Results Posted","CRTCOESC","December 2017","Grade 3/4 acute toxicities|PFS|overall remission rate, ORR|quality of life, Qol|pathologic complete response rate","https://ClinicalTrials.gov/show/NCT02025036"
1372,"NCT01542931","TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma","Unknown status","No Results Available","Stage III Oral Cavity Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma","Drug: TPF induction chemotherapy","Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","256","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TPF for resectable OSCC|2007BAI18B03","February 26, 2012","January 2008","December 2015","March 1, 2012","February 2012","No Study Results Posted","null","December 2015","Survival rate|local control|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01542931"
1373,"NCT01884259","Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Squamous Cell Carcinoma of the Larynx Stage III|Squamous Cell Carcinoma of the Larynx Stage IV|Squamous Cell Carcinoma of the Oropharynx Stage III|Squamous Cell Carcinoma of the Oropharynx Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV","Drug: Docetaxel|Drug: Cisplatin|Drug: 5-fluorouracil|Biological: Cetuximab Induction|Biological: Cetuximab Radioimmunotherapy|Radiation: Boost irradiation","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGMT_HNO 2","May 18, 2012","May 2013","June 2019","June 1, 2016","June 2016","No Study Results Posted","HNO-2","June 2019","Response Rate (CR, PR)|Overall Response Rate (CR, PR, PD, SD)|Locoregionally monitoring|Progression Free Survival (PFS)|Toxicity|Overall-Survival","https://ClinicalTrials.gov/show/NCT01884259"
1374,"NCT00699517","A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies","Completed","No Results Available","Sarcoma","Drug: OMBRABULIN (AVE8062)|Drug: Placebo","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","355","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10145|EudraCT 2007-003592-39","May 7, 2008","June 2008","April 2013","November 18, 2015","November 2015","No Study Results Posted","null","April 2013","Progression free survival|Overall survival|Response rate|Safety profile","https://ClinicalTrials.gov/show/NCT00699517"
1375,"NCT00425191","Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Docetaxel and Gemcitabine|Drug: Docetaxel and Gemcitabine|Drug: Gemcitabine cisplatin followed by docetaxel","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_2501","January 19, 2007","July 2002","null","December 4, 2009","December 2009","No Study Results Posted","null","April 2005","Response Rate|Time to progression.","https://ClinicalTrials.gov/show/NCT00425191"
1376,"NCT01003964","Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: Irinotecan, Cisplatin, Gemcitabine, Pemetrexed, Docetaxel","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","284","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-08-371","October 28, 2009","February 2009","December 2014","November 13, 2013","November 2013","No Study Results Posted","null","September 2014","Response Rate|Overall survival (OS)|Progression-free survival (PFS)|Toxicity|Pharmacogenomic study using tumor tissue and blood for providing rational strategy to the treatment of advanced NSCLC","https://ClinicalTrials.gov/show/NCT01003964"
1377,"NCT00095875","Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)","Completed","Has Results","Head and Neck Cancer","Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","145","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DFCI 04-006|P30CA006516|CDR0000393548","November 9, 2004","August 2004","April 2012","October 25, 2013","October 2013","May 15, 2013","null","April 2012","Overall Survival|Progression-free Survival and Disease-specific Survival as Assessed by Disease Progression or Death and Log Rank Tests at the Median, and 2, 3, and 5 Years","https://ClinicalTrials.gov/show/NCT00095875"
1378,"NCT01154140","A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung","Completed","Has Results","Non Squamous Lung Cancer","Drug: treatment|Drug: treatment","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","A8081014|2010-021336-33|XALCORI","June 29, 2010","January 13, 2011","November 30, 2016","April 13, 2017","April 2017","November 26, 2014","PROFILE 1014","November 30, 2013","Progression-Free Survival (PFS) Based on Independent Radiology Review (IRR) by Treatment Arm|Overall Survival (OS)|OS Probability at Months 12 and 18|Objective Response Rate - Percentage of Participants With Objective Response as Assessed by IRR|Duration of Response (DR) Based on IRR|Time to Tumor Response (TTR) Based on IRR|Percentage of Participants With Disease Control at Week 12 Based on IRR|Time to Progression (TTP) Based on IRR|Time to Intracranial Progression (IC-TTP) Based on IRR|Time to Extracranial Progression (EC-TTP) Based on IRR|Percentage of Participants With Treatment-emergent Adverse Events (AEs; All Causalities)|Percentage of Participants With Treatment-emergent AEs (Treatment Related)|Plasma Predose Concentration (Trough Concentration [Ctrough]) of Crizotinib and Its Metabolite|Percentage of Participants for Each Anaplastic Lymphoma Kinase (ALK) Gene Fusion Variants|ORR Between ALK Variant Groups Based on IRR|Time to Deterioration (TTD) in Pain in Chest, Dyspnea, or Cough|Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30|Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13)|Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)- Visual Analog Scale (VAS)|Percentage of Participants With Hospital Admissions-Healthcare Resource Utilization (HCRU)","https://ClinicalTrials.gov/show/NCT01154140"
1379,"NCT02161419","RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer","Terminated","No Results Available","Small Cell Lung Carcinoma","Drug: Roniciclib (BAY1000394)|Drug: Placebo","Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","14615|2013-004198-28","June 10, 2014","July 30, 2014","May 25, 2016","April 4, 2017","April 2017","No Study Results Posted","CONCEPT-SCLC","December 31, 2015","Progression free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Overall response rate (ORR)","https://ClinicalTrials.gov/show/NCT02161419"
1380,"NCT01081041","A Study in Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer","Drug: Cetuximab|Drug: Cisplatin|Drug: Carboplatin|Drug: 5-Fluorouracil","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","13611|I4E-MC-JXBD","March 3, 2010","June 2010","September 2015","March 14, 2017","March 2017","June 12, 2014","null","August 2013","Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013|Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013|Overall Survival (OS)|Progression-Free Survival (PFS)|Percentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])|Number of Participants With Anti-Cetuximab Antibodies|Percentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR)|Maximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing|Cmax of Cetuximab at Steady State|Area Under the Concentration Curve (AUC) of Cetuximab at Steady State","https://ClinicalTrials.gov/show/NCT01081041"
1381,"NCT00454519","Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis","Unknown status","No Results Available","Stomach Neoplasms|Colorectal Neoplasms|Neoplasm Metastasis|Mesothelioma","Procedure: cytoreductive surgery|Procedure: intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin","Wuhan University|NPO Organization to Support Peritoneal Dissemination Treatment|Kishiwada Tokushukai Hospital|Kusatsu General Hopital|Ikeda Hospital","All","20 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WUCC-0701","March 29, 2007","March 2007","null","February 12, 2009","February 2009","No Study Results Posted","IPHC","December 2009","overall survival time|perioperative morbidity and mortality","https://ClinicalTrials.gov/show/NCT00454519"
1382,"NCT01023347","A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Paclitaxel (Genexol®)|Drug: Paclitaxel loaded polymeric micelle (Genexol-PM®)","Samyang Biopharmaceuticals Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GPM-0801","November 30, 2009","June 2008","June 2012","May 8, 2017","May 2017","No Study Results Posted","null","December 2009","response rate|overall survival|progression-free survival|toxicity profiles","https://ClinicalTrials.gov/show/NCT01023347"
1383,"NCT03102320","Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors","Not yet recruiting","No Results Available","Neoplasms","Drug: Cisplatin|Drug: Gemcitabine|Drug: Anetumab ravtansine (BAY94-9343)","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","348","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","15834|2016-004002-33","March 30, 2017","July 31, 2017","February 11, 2020","May 19, 2017","May 2017","No Study Results Posted","ARCS-Multi","May 31, 2019","Maximum tolerated dose (MTD) of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine in patients with mesothelin-expressing cholangiocarcinoma and pancreatic adenocarcinoma|Objective response rate (ORR) of anetumab ravtansine for monotherapy and combination therapy in mesothelin expressing advanced solid tumors|Number of serious and non-serious adverse events (AEs)|Disease control rate (DCR)|Duration of response (DOR)|Durable response rate (DRR)|Progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT03102320"
1384,"NCT00239304","Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer","Completed","No Results Available","Head and Neck Neoplasms","Drug: Gefitinib|Drug: Cisplatin|Procedure: Radiotherapy","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0151","October 13, 2005","June 2003","March 2006","December 14, 2007","December 2007","No Study Results Posted","null","null","Parts 1 and 2: Safety (Incidence of DLTs)|Part 3: Safety and tolerability|Parts 2 and 3: Efficacy (Incidence of complete response at 3 months after the end of trial treatment based on RECIST criteria)|Exploratory Outcome: EGFR-1 expression, amplification and activation Serum VEGF levels","https://ClinicalTrials.gov/show/NCT00239304"
1385,"NCT02999893","A Study of APR-246 in Oesophageal Cancer","Recruiting","No Results Available","Oesophageal Carcinoma","Drug: APR-246","Peter MacCallum Cancer Centre, Australia","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16/012","December 5, 2016","April 11, 2017","April 30, 2023","May 17, 2017","May 2017","No Study Results Posted","APROC","June 30, 2019","Establish the safety profile of combined APR-246 plus cisplatin and 5FU as measured by the satisfactorily low rate of adverse events described according to NCI CTCAE v 4.03.|Evidence of clinical efficacy of a combined APR-246 and cisplatin/5FU chemotherapy regimen as confirmed by CT/PET/MRI scan.","https://ClinicalTrials.gov/show/NCT02999893"
1386,"NCT00777491","Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery","Active, not recruiting","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0712|CDR0000616858","October 21, 2008","December 2008","null","September 28, 2016","September 2016","No Study Results Posted","null","January 2018","Rate of distant metastasis at 3 years|Treatment completion rate|Grade 3 or more genitourinary, gastrointestinal, and hematologic toxicities as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0|Complete response of the primary tumor|Preservation of the native, tumor-free bladder 5 years after completion of study therapy","https://ClinicalTrials.gov/show/NCT00777491"
1387,"NCT02711553","A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","Recruiting","No Results Available","Biliary Tract Cancer|Metastatic Cancer|Advanced Cancer","Drug: Ramucirumab|Drug: Merestinib|Drug: Cisplatin|Drug: Gemcitabine|Drug: Placebo Oral|Drug: Placebo IV","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","16329|I3O-MC-JSBF|2015-004699-31","March 14, 2016","May 2016","June 2018","May 3, 2017","May 2017","No Study Results Posted","null","March 2018","Progression Free Survival (PFS)|Overall Survival (OS)|Proportion of Participants with a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)|Proportion of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)|Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab|PK: Plasma Concentration of Merestinib|Number of Participants with Treatment-Emergent Anti-Ramucirumab Antibodies|Change from Baseline in Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire (FACT-Hep)|Change from Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)","https://ClinicalTrials.gov/show/NCT02711553"
1388,"NCT00379665","Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cisplatin","Southwestern Regional Medical Center","All","20 Years to 80 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTCT 05-01","September 20, 2006","October 2005","September 2012","December 10, 2012","December 2012","No Study Results Posted","null","December 2010","To affect a faster clearing of the obstruction as compared with initial evaluation, based on the percentage of lumen opened.|Respiratory symptoms due to occlusion to be assessed both before and after the procedure.","https://ClinicalTrials.gov/show/NCT00379665"
1389,"NCT00004033","Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Mesothelioma","Drug: liposomal NDDP|Procedure: therapeutic thoracoscopy","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066141|P30CA016087|NYU-9850|MDA-FDR001234|MDA-ID-95209|NCI-G99-1575","December 10, 1999","September 1998","null","March 25, 2011","March 2011","No Study Results Posted","null","May 2001","","https://ClinicalTrials.gov/show/NCT00004033"
1390,"NCT02901301","Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer","Recruiting","No Results Available","Gastric Cancer","Drug: Pembrolizumab|Drug: Trastuzumab|Drug: Capecitabine|Drug: Cisplatin","Yonsei University","All","19 Years and older   (Adult, Senior)","Phase 1|Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2016-0190","September 11, 2016","October 2016","March 2018","January 9, 2017","January 2017","No Study Results Posted","null","March 2018","The recommended dose of phase II|The overall response rate using RECIST 1.1|Duration of response|Time to response","https://ClinicalTrials.gov/show/NCT02901301"
1391,"NCT00109928","S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma","Completed","Has Results","Lymphoma","Drug: cisplatin|Drug: etoposide|Drug: gemcitabine|Drug: methylprednisolone","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000425643|S0350|U10CA032102","May 3, 2005","September 2005","April 2014","September 18, 2014","September 2014","June 11, 2014","null","June 2012","2-year Overall Survival Rate|2-year Progression-free Survival Rate|Response Rate|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT00109928"
1392,"NCT00003930","Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer","Completed","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: conventional surgery|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","84","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9906|CDR0000067122|RTOG-DEV-14321","November 1, 1999","September 1999","November 2013","October 13, 2015","October 2015","No Study Results Posted","null","July 2003","Completion and safety of induction chemo-radiotherapy followed by definitive local therapy of either radical cystectomy or consolidation TCI, followed by four cycles of outpatient adjuvant gemcitabine-cisplatin chemotherapy.|Complete response after TCI induction|Completion and safety of the four cycles of gemcitabine-cisplatin chemotherapy|Invasive local treatment failure|Distant metastasis|To examine the value of tumor histopathology, molecular genetics and DNA flow cytometric parameters as possible significant prognostic factors for initial tumor response and recurrence-free survival.","https://ClinicalTrials.gov/show/NCT00003930"
1393,"NCT01889303","Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer","Recruiting","No Results Available","Gastric Cancer","Drug: DC|Drug: concurrent chemoradiotherapy with 5-FU/CF|Radiation: adjuvant radiation","Wuhan University","All","19 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HCCSC G-02","June 2, 2013","May 2013","December 2017","April 28, 2016","April 2016","No Study Results Posted","null","June 2017","Disease free survival|Overall survival(OS)|Local and regional control rate|feasibility (including adverse events )","https://ClinicalTrials.gov/show/NCT01889303"
1394,"NCT01902875","Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: Paclitaxel + Cisplatin|Biological: CIK cell therapy","Jinling Hospital, China","All","40 Years to 70 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","NJ0001","July 14, 2013","June 2013","null","July 16, 2013","July 2013","No Study Results Posted","null","December 2014","Disease Control Rate(DCR) and Disease Progression-Free Survival(PFS)|safety and tolerance of patient","https://ClinicalTrials.gov/show/NCT01902875"
1395,"NCT00352105","Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: Iressa|Radiation: hyperfractionated radiation therapy","David Adelstein|National Cancer Institute (NCI)|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCF5842|P30CA043703|CCF-5842|ZENECA-1839/0235","July 13, 2006","April 2006","May 2010","November 1, 2012","November 2012","November 17, 2011","null","September 2008","Number of Patients Treated With ZD1839 With Chemotherapy and Hyperfractionated Radiation That Had a 1-year Survival|Number of Participants With No Distant Metastatic Disease at 1 Year|Number of Participants With No Local Disease at 1 Year|Number of Patients With Greater Than or Equal to Mild (Grade 1) Toxicity|Number of Patients With a Complete Response Defined as Complete Disappearance of All Clinically Detectable Tumor.|Number of Participants Who Completed 2 Years of Therapy","https://ClinicalTrials.gov/show/NCT00352105"
1396,"NCT02436733","Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM","Not yet recruiting","No Results Available","Malignant Pleural Mesothelioma","Procedure: pleurectomy/decortication|Drug: Pemetrexed/Cisplatin","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-1205","April 21, 2015","September 2016","April 2020","September 19, 2016","September 2016","No Study Results Posted","null","September 2019","Rate of success to complete the full treatment|Loco-regional failure free survival|Overall survival|Treatment side-effects","https://ClinicalTrials.gov/show/NCT02436733"
1397,"NCT01088581","Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma","Completed","No Results Available","Hepatocellular Carcinoma","Drug: Adjuvant group","Yonsei University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","4-2005-0203","March 16, 2010","January 2006","December 2008","January 31, 2012","January 2012","No Study Results Posted","null","December 2007","2-year recurrence rate and adverse events|overall survival","https://ClinicalTrials.gov/show/NCT01088581"
1398,"NCT01525771","Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer","Completed","No Results Available","Stage IV Gastric Cancer With Metastasis","Other: Docetaxel","Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-XPID-1","July 18, 2011","February 2011","December 2014","June 26, 2015","June 2015","No Study Results Posted","XPID","December 2014","Maximum tolerated dose|Safety profile|Overall survival|Progression free survival|efficacy","https://ClinicalTrials.gov/show/NCT01525771"
1399,"NCT00008112","Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Drug: cisplatin|Procedure: hyperthermia treatment|Radiation: brachytherapy|Radiation: radiation therapy","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","DUT-KWF-CKVO-2000-02|CDR0000068376|EU-20036","January 6, 2001","June 2000","null","August 6, 2013","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00008112"
1400,"NCT02996214","Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung","Not yet recruiting","No Results Available","Lung Squamous Cell Carcinoma","Drug: Paclitaxel Liposome|Drug: Gemcitabine|Drug: Cisplatin","Nanjing Luye Sike Pharmaceutical Co.,Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","536","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LY-TM-LPS-2016-01","December 4, 2016","November 2016","June 2020","December 14, 2016","December 2016","No Study Results Posted","LIPUSU","December 2019","progression free survival (PFS)|Objective Response Rate (ORR)|Regional lymph node remission rate|Overall Survival (OS)|Safety Assessment|Quality of Life","https://ClinicalTrials.gov/show/NCT02996214"
1401,"NCT03114280","Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)","Not yet recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma (HNSCC)","Drug: TPF2|Other: Radiotherapy with carboplatin","Centre Antoine Lacassagne","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2017/13","April 2, 2017","June 2017","June 2021","April 10, 2017","April 2017","No Study Results Posted","PICH","June 2019","Progression-free survival|Overall survival rate|Overall response","https://ClinicalTrials.gov/show/NCT03114280"
1402,"NCT00191490","A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Gemcitabine|Drug: docetaxel|Drug: cisplatin","Eli Lilly and Company|Aventis Pharmaceuticals","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6549|B9E-IT-JHSC","September 12, 2005","July 2002","May 2005","January 24, 2007","January 2007","No Study Results Posted","null","null","To assess the antitumour activity as measured by response rate in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of two different combinations of docetaxel and gemcitabine and of a sequential treatment of|cisplatin /gemcitabine|To determine time to progression, duration of response, time to treatment failure, and overall survival in each group.|To evaluate changes from baseline in the Lung Cancer Symptom Scale of patients in each treatment arm","https://ClinicalTrials.gov/show/NCT00191490"
1403,"NCT02969083","Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma","Not yet recruiting","No Results Available","Upper Tract Urothelial Carcinoma","Procedure: RNU|Drug: Gemcitabine/Cisplatin|Drug: M-VAC Protocol","The European Uro-Oncology Group|Centre for Human Drug Research, Netherlands","All","18 Years and older   (Adult, Senior)","Phase 2","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","EudraCT 2016-004017-27","November 11, 2016","January 2017","December 2018","November 24, 2016","November 2016","No Study Results Posted","URANUS","June 2018","Proportion of UTUC patients randomized to neo- or adjuvant chemotherapy that is actually able to start and finalize three courses of planned chemotherapy|Disease Free Survival (DFS)|Overall Survival (OS)|Cancer-Specific Survival (CSS)","https://ClinicalTrials.gov/show/NCT02969083"
1404,"NCT01216111","Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer","Available","No Results Available","Triple Negative Breast Cancer","Drug: Paclitaxel Cisplatin","Fudan University|Chinese Anti-Cancer Association","Female","18 Years to 65 Years   (Adult)","","null","Other","Expanded Access","","Fudan TNBC Adjuvant CT","October 6, 2010","null","null","October 6, 2010","June 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01216111"
1405,"NCT00520091","Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: CPT- 11|Drug: Cisplatin|Drug: Celecoxib|Radiation: Radiation|Procedure: Surgery","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 0203|CDR0000561610","August 21, 2007","March 2005","September 2010","May 16, 2012","May 2012","No Study Results Posted","null","November 2006","Rates of cellular apoptosis and proliferation|Rate of pathologic complete remission in patients with resectable disease|Number of subjects experiencing adverse events|Median overall survival of patients with resectable disease|Formation of prostaglandin E2 (PGE2) in tumor tissue|Downstream effects of inhibition of cyclooxygenase 2 function|Response Rate","https://ClinicalTrials.gov/show/NCT00520091"
1406,"NCT01857726","Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion","Withdrawn","No Results Available","Hepatocellular Carcinoma","Drug: Doxorubicin|Drug: Cisplatin","Seoul National University Hospital","All","18 Years to 80 Years   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PVT_TACE/TACI","May 13, 2013","July 2013","December 2016","April 27, 2016","April 2016","No Study Results Posted","null","December 2016","Overall survival|Time-to-progression|Progression-free survival","https://ClinicalTrials.gov/show/NCT01857726"
1407,"NCT00537875","Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens","Completed","No Results Available","Nausea|Vomiting","Dietary Supplement: Ginger|Dietary Supplement: Placebo","National Research Institute of Tuberculosis and Lung Disease, Iran","All","18 Years and older   (Adult, Senior)","","36","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","5336-18-06-86","October 1, 2007","September 2007","September 2009","October 7, 2015","October 2015","No Study Results Posted","null","September 2008","Nausea, Vomiting","https://ClinicalTrials.gov/show/NCT00537875"
1408,"NCT00509561","Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Biological: cetuximab|Drug: capecitabine|Drug: cisplatin|Radiation: radiation therapy","Wales Cancer Trials Unit|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","259","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000558804|WCTU-SCOPE-1|EU-20739|EUDRACT-2006-002241-37|ISRCTN47718479|CTA-17853/0202/001-0001","July 30, 2007","February 2008","null","December 17, 2012","December 2012","No Study Results Posted","null","September 2012","Treatment-failure rate at 24 weeks|Overall survival|Feasibility|Toxicity|Quality of life|Quality of assurance|Health economics","https://ClinicalTrials.gov/show/NCT00509561"
1409,"NCT01005680","A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Gemcitabine|Drug: Cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12878|H3E-CR-JMIL","October 29, 2009","November 2009","November 2012","October 18, 2013","October 2013","October 18, 2013","null","November 2012","Overall Survival (OS)|Progression Free Survival (PFS)|Time to Progressive Disease (TtPD)|Duration of Response (DoR)|Time to Treatment Failure (TtTF)|Tumor Response Rate|Risk/Benefit Ratio","https://ClinicalTrials.gov/show/NCT01005680"
1410,"NCT02276248","Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma","Completed","No Results Available","Stage I/II Extranodal NK/T-cell Lymphoma","Radiation: Intensity-modulated radiation therapy|Drug: GDP chemotherapy","Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GREEN","October 23, 2014","June 2010","December 2014","July 25, 2016","July 2016","No Study Results Posted","null","December 2014","2-year progression-free survival|2-year overall survival|number of patients with adverse events","https://ClinicalTrials.gov/show/NCT02276248"
1411,"NCT00147147","Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)","Completed","No Results Available","Gastric Neoplasm","Procedure: Gastrectomy with D2 or greater lymph node dissection|Drug: Gastrectomy+ chemotherapy","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","All","up to 75 Years   (Child, Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG9206-2|C000000067","September 5, 2005","January 1993","March 2004","September 20, 2016","September 2016","No Study Results Posted","null","null","Overall survival|Relapse-free survival|the site of recurrence","https://ClinicalTrials.gov/show/NCT00147147"
1412,"NCT01487226","Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Drug: paclitaxel|Drug: Cisplatin 50mg/m2","Korean Gynecologic Oncology Group","Female","20 Years to 70 Years   (Adult, Senior)","Phase 2","69","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KGOG1012","December 4, 2011","January 2008","January 2015","December 6, 2011","December 2011","No Study Results Posted","null","January 2015","Kaplan-Meier|log-rank test Cox regression analysis","https://ClinicalTrials.gov/show/NCT01487226"
1413,"NCT00045617","S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer","Terminated","No Results Available","Lung Cancer","Biological: monoclonal antibody 11D10 anti-idiotype vaccine|Biological: monoclonal antibody GD2 anti-idiotype vaccine|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000256922|S0122|U10CA032102","September 6, 2002","January 2003","May 2003","June 11, 2012","June 2012","No Study Results Posted","null","May 2003","overall survival|immune response|toxicity assessment|response","https://ClinicalTrials.gov/show/NCT00045617"
1414,"NCT00324415","Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer","Completed","Has Results","Anal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","45","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-045|U01CA070019|CDR0000440065","May 10, 2006","September 2006","May 2016","June 14, 2016","June 2016","July 22, 2015","null","April 2014","Local Failure Rate at 3 Years|Progression-free Survival|Relapse-free Survival|Colostomy-free Survival at 1 Year|Overall Survival|Quality of Life|Toxicity|Changes in CD4 Counts During and for 1 Year After Completion of Study Treatment|Incidence of Opportunistic Illnesses|Anogenital Human Papilloma Virus (HPV) Infection and Anal Cytology|Objective Response Rate (Complete and Partial)","https://ClinicalTrials.gov/show/NCT00324415"
1415,"NCT00014196","S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer","Terminated","No Results Available","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068516|S0022|U10CA032102","April 10, 2001","March 2001","March 2005","February 12, 2013","February 2013","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00014196"
1416,"NCT00599131","Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)","Terminated","Has Results","Cancer of Larynx","Drug: Cisplatin|Drug: Cetuximab|Drug: 5-Fluorouracil|Drug: Docetaxel","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2007.029|HUM 11350","December 12, 2007","August 2007","October 2010","November 4, 2015","November 2015","April 16, 2014","null","July 2008","Percentage of Patients Achieving Histologic Complete Response|The Difference, From Baseline, in EGFR, for Tumor Biopsies Taken After the Administration of Cetuximab Following TPF.|The Change in Overall Quality of Life Score During Radiation Therapy and at 6, 12, and 24 Months Post Treatment.|Overall Survival Time|The Number of Patients That Experience Grade 3 and 4 Mucositis or Dysphagia","https://ClinicalTrials.gov/show/NCT00599131"
1417,"NCT02335411","A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)","Active, not recruiting","No Results Available","Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma","Biological: pembrolizumab|Drug: cisplatin|Drug: 5-FU|Drug: capecitabine","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","253","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","3475-059|2014-003574-16","January 7, 2015","February 2015","June 2018","March 7, 2017","March 2017","No Study Results Posted","null","November 2016","Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Discontinuing Study Drug Due to AEs|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02335411"
1418,"NCT00068406","Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva","Completed","No Results Available","Vulvar Cancer","Drug: cisplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","58","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000322259|GOG-0205","September 10, 2003","January 2005","null","September 2, 2012","September 2009","No Study Results Posted","null","December 2010","Complete clinical and pathologic tumor response at completion of treatment|Toxicity weekly during treatment then every 3 months after treatment","https://ClinicalTrials.gov/show/NCT00068406"
1419,"NCT00329472","Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer","Withdrawn","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: gemcitabine, cisplatin","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-09-027","May 22, 2006","April 2006","July 2010","August 26, 2010","July 2010","No Study Results Posted","null","July 2010","3-year disease-free survival|overall survival|pattern of relapse|quality of life|operative mortality and toxicity","https://ClinicalTrials.gov/show/NCT00329472"
1420,"NCT00794547","Phase I/II Calcitriol in Lung Cancer","Terminated","Has Results","Non Small Cell Lung Cancer","Drug: Calcitriol|Drug: Calcitriol","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2008.042|HUM 21242","November 19, 2008","December 2008","August 2013","August 28, 2015","August 2015","March 31, 2014","null","October 2011","MTD of Intravenous Calcitriol When Administered Prior to Fixed Dose Cisplatin 75mg/m2 and Docetaxel 75 mg/m2, Every 3 Weeks in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Number of Participants That Experience Grade 3 or Greater Neutropenia|Median Time to Progression|Median Overall Survival|To Assess Pharmacokinetics (PK) of Intravenous (IV) Calcitriol in Combination With Cisplatin and Docetaxel During Cycle 1 of the Phase II Part of the Study Using a Validated Limited Sampling Technique.|To Correlate the Pharmacokinetic Parameters of Systemic Calcitriol Exposure (AUC) With SNPs of the 24-hydroxylase (CYP24), the Major Vitamin D3 Inactivating Enzyme.","https://ClinicalTrials.gov/show/NCT00794547"
1421,"NCT00003242","Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: bryostatin 1|Drug: cisplatin|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","97-139|CDR0000066117|NCI-T97-0118","November 1, 1999","February 1998","October 2001","June 20, 2013","June 2013","No Study Results Posted","null","October 2001","","https://ClinicalTrials.gov/show/NCT00003242"
1422,"NCT01949870","Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study","Terminated","Has Results","Inoperable Locally Advanced or Metastatic Biliary Tract Cancer","Drug: Cisplatin|Drug: Gemcitabine|Drug: Selumetinib","AstraZeneca","All","20 Years to 130 Years   (Adult, Senior)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D1532C00075","September 10, 2013","October 2013","August 2014","May 5, 2016","May 2016","August 19, 2015","null","August 2014","The Number of Dose-limiting Toxicities","https://ClinicalTrials.gov/show/NCT01949870"
1423,"NCT02845323","Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder","Not yet recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer","Drug: Nivolumab in combination with Urelumab|Drug: Nivolumab monotherapy","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1682|IRB00103062","July 13, 2016","September 2016","January 2019","August 2, 2016","August 2016","No Study Results Posted","null","September 2018","Immune response to treatment with Nivolumab and Urelumab compared to Nivolumab monotherapy measured by tumor infiltrating CD8+ T cell density at cystectomy|To evaluate the number of participants with treatment-related adverse events as assessed by CTCAE v 4.0|Proportion of patients achieving pathologic response (<pT2N0) with Nivolumab and Urelumab and the use of Urelumab alone|Prognostic value of tumor biopsy PD-1 and PD-L1 expression and change in expression for pathologic tumor response as defined by cystectomy pathologic staging <pT2 N0 in patients treated with Nivolumab|Change in expression for pathologic tumor response as defined by cystectomy pathologic staging <pT2 N0 in patients treated with Nivolumab|Prognostic value of tumor bx 4-1BB (CD137)& 4-1BB ligand (CD137L) expression|Change in expression, assessed by (IHC) analysis, for tumor response, defined by cystectomy staging < pT2N0, in cisplatin-ineligible MIBC pts tx w/Urelumab.|Prognostic value of tumor biopsy 4-1BB expression|Change in expression, assessed by (IHC) analysis, for pathologic CR response, defined by cystectomy staging pT0N0, in cisplatin-ineligible MIBC pts tx w/ Urelumab.|Proportion of patients achieving pathologic complete response with neoadjuvant Nivolumab and Urelumab (Arm A) and Nivolumab monotherapy (Arm B).","https://ClinicalTrials.gov/show/NCT02845323"
1424,"NCT03015727","Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma","Recruiting","No Results Available","Locally Advanced Nasopharyngeal Carcinoma","Drug: Docetaxel|Drug: Cisplatin|Radiation: IMRT/TOMO|Drug: Chemotherapy","Zhejiang Cancer Hospital|Zhejiang Provincial People’s Hospital|The Central Hospital of Lishui City|Jinhua Central Hospital|First Affiliated Hospital of Wenzhou Medical Univeristy|Ningbo Medical Center Lihuili Eastern Hospital|People's Hospital of Quzhou","All","18 Years to 65 Years   (Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejiangCH 01536224","December 24, 2016","December 2016","December 2024","January 9, 2017","December 2016","No Study Results Posted","IRCNPC","December 2022","Progress Free Survival (PFS)|Overall Survival (OS)|Adverse Events","https://ClinicalTrials.gov/show/NCT03015727"
1425,"NCT00746655","SBRT + TACE for Primary Hepatocellular Carcinoma","Withdrawn","No Results Available","Hepatocellular Carcinoma","Radiation: Stereotactic Body Radiation Therapy (SBRT)|Procedure: Transcatheter Arterial Chemoembolization (TACE)","University of Pittsburgh","All","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-042","September 2, 2008","July 2009","December 2015","December 23, 2015","December 2015","No Study Results Posted","null","December 2015","To determine the feasibility and toxicity of combining SBRT and TACE for HCC.|To evaluate the Health Related Quality of Life (HRQL) associated with combined therapy.|To determine local response of combination therapy with PET/CT and CT only.|To evaluate the progression free interval associated with this local regional therapy.|To determine if SBRT and TACE will be able to bridge patients to transplant that were initially ineligible.","https://ClinicalTrials.gov/show/NCT00746655"
1426,"NCT01659554","A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers","Terminated","Has Results","Recurrent Ovarian Cancer|Fallopian Tube Cancer","Drug: Cisplatin|Drug: Doxorubicin","Columbia University","Female","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AAAI1246","July 10, 2012","March 2012","April 2014","January 30, 2017","January 2017","November 3, 2014","HIPEC","April 2014","Adverse Event Rate and/or Laboratory Changes|Toxicity Rating Based on NCI Common Toxicity Criteria|Time to Serum Ca-125 Nadir and/or CT Response (RECIST Criteria)|Kaplan-Meier Curves for Patient Overall Survival","https://ClinicalTrials.gov/show/NCT01659554"
1427,"NCT00003996","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carmustine|Drug: chemotherapy|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","93","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-987252|NCI-2012-02308|CDR0000067206","November 1, 1999","May 1999","May 2008","December 5, 2016","December 2016","No Study Results Posted","null","August 2001","overall survival|quality of life","https://ClinicalTrials.gov/show/NCT00003996"
1428,"NCT00047008","Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer","Active, not recruiting","Has Results","Head and Neck Cancer","Drug: cisplatin|Radiation: Standard fractionation RT|Radiation: Accelerated fractionation radiation therapy|Procedure: Conventional surgery for select patients","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 3","743","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0129|CDR0000257233|RTOG-H-0129|RTOG-DEV-1069","October 3, 2002","July 2002","null","November 11, 2015","November 2015","July 28, 2014","null","June 2010","Overall Survival (3-year Rate)|Local-regional Control|Disease-free Survival|Rate of Grade 3-5 Toxicity|Quality of Life|Correlation of Epidermal Growth Factor Receptor(EGFR) With Outcomes|Correlation of COX-2 With Outcomes","https://ClinicalTrials.gov/show/NCT00047008"
1429,"NCT02994251","A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma","Not yet recruiting","No Results Available","Unresectable Intrahepatic Cholangiocarcinoma","Drug: gemcitabine|Drug: Cisplatin|Drug: Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C","Yale University","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1603017367","December 6, 2016","December 2016","June 2020","December 14, 2016","December 2016","No Study Results Posted","null","June 2020","progression-free survival|overall survival|overall time to progression (TTP)|time to untreatable progression (TTUP)|toxicities of the gemcitabine and cisplatin regimen in combination with cTACE therapy using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.|correlation between changes in dynamic contrast-enhanced MRI of liver lesions and progression free survival|correlation between changes in dynamic contrast-enhanced MRI of liver lesions and overall survival","https://ClinicalTrials.gov/show/NCT02994251"
1430,"NCT01210131","Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)","Withdrawn","No Results Available","Small Cell Lung Cancer (SCLC)","Drug: [18F]HX4","Maastricht Radiation Oncology|Maastricht University Medical Center","All","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HX4 in small cell lung cancer|2010-023033-30","September 21, 2010","July 2013","August 2014","August 26, 2013","January 2013","No Study Results Posted","HX4 in SCLC","January 2014","Cumulative local progression 18 months post-treatment as evaluated in a chest FDG-PET-CT scan|Overall survival","https://ClinicalTrials.gov/show/NCT01210131"
1431,"NCT02429687","TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors","Enrolling by invitation","No Results Available","Ovarian Germ Cell Cancer|Ovarian Neoplasms|Ovarian Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Bleomycin|Drug: Etoposide|Drug: Cisplatin","Beihua Kong|Huazhong University of Science and Technology|Zhejiang University|Sun Yat-sen University|Shandong University","Female","14 Years to 65 Years   (Child, Adult)","Phase 3","129","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MOGCT-01","April 24, 2015","April 2015","May 2020","February 14, 2016","February 2016","No Study Results Posted","MOGCT-01","May 2018","Progression-free survival|Chemotherapy related adverse effects in two arms|Tumor response rate|Overall survival","https://ClinicalTrials.gov/show/NCT02429687"
1432,"NCT02986503","European Study in Bone Sarcoma Patients Over 40 Years","Completed","No Results Available","Spindle Cell Sarcoma of Bone|Osteosarcoma","Drug: Doxorubicin+cisplatin+ifosfamide|Drug: Doxorubicin+cisplatin+ifosfamide+methotrexate","Italian Sarcoma Group|Scandinavian Sarcoma Group|Cooperative Osteosarcoma Study Group","All","41 Years to 65 Years   (Adult)","","100","Other","Observational","Time Perspective: Prospective","EURO-B.O.S.S","November 25, 2016","January 2002","November 2016","December 5, 2016","December 2016","No Study Results Posted","EUROBOSS","December 2015","Event-free survival|Progression-free survival|Disease-free survival|Metastasis-free survival|Overall survival|Chemotherapy toxicity","https://ClinicalTrials.gov/show/NCT02986503"
1433,"NCT00292955","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma","Unknown status","No Results Available","Cancer of the Cervix","Drug: Cetuximab","University of Virginia|Bristol-Myers Squibb|ImClone LLC|Washington University School of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB-HSR#13748|CA225243|HRPO #05-0702","February 14, 2006","February 2006","null","May 26, 2011","May 2011","No Study Results Posted","null","February 2012","To identify genes that may be identified as predictive of response to cetuximab|To sequence the epidermal growth factor receptor (EGFR) to describe mutations in the receptor that may predict tumor response to cetuximab|To evaluate the validity of fluorodeoxyglucose (FDG) uptake, as determined by positron emission tomography (PET) imaging, as a surrogate marker for response to cetuximab|To determine the safety and tolerability of cetuximab with concurrent chemoradiation in women with locally advanced cervical carcinoma|To determine the progression-free and overall survival in women with locally advanced or metastatic cervical carcinoma treated with concurrent chemoradiation and cetuximab","https://ClinicalTrials.gov/show/NCT00292955"
1434,"NCT02429700","TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors","Enrolling by invitation","No Results Available","Ovarian Sex Cord Stromal Tumor|Ovarian Neoplasms|Ovarian Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Bleomycin|Drug: Etoposide|Drug: Cisplatin","Beihua Kong|Huazhong University of Science and Technology|Zhejiang University|Sun Yat-sen University|Shandong University","Female","14 Years to 65 Years   (Child, Adult)","Phase 3","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCST-01","April 24, 2015","April 2015","May 2020","February 14, 2016","February 2016","No Study Results Posted","SCST-01","May 2018","Progression-free survival|Chemotherapy related adverse effects in two arms|Tumor response rate|Overall survival","https://ClinicalTrials.gov/show/NCT02429700"
1435,"NCT01569919","A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma","Unknown status","No Results Available","Malignant|Pleural|Mesothelioma","Biological: TroVax®|Drug: Pemetrexed|Drug: Cisplatin|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid|Drug: Dexamethasone","Wales Cancer Trials Unit|Velindre NHS Trust|June Hancock Mesothelioma Research Fund|Velindre Cancer Centre Stepping Stones Appeal","All","18 Years and older   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010/VCC/0049|2010-023230-22","March 28, 2012","December 2012","December 2014","March 11, 2013","March 2013","No Study Results Posted","SKOPOS","June 2014","Immune response to 5T4 and MVA antigens as measured by intracellular cytokine staining (ICCS)|Safety and tolerability|Clinical activity in terms of PFS, ORR and OS|Relationship between immune response and clinical response|Identify potential predictors of treatment benefit","https://ClinicalTrials.gov/show/NCT01569919"
1436,"NCT00003627","Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","160","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066710|FRE-FNCLCC-96003|EU-98027","November 1, 1999","October 1998","null","February 6, 2009","January 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003627"
1437,"NCT01860040","Neoadjuvant Chemo for NSCLC","Terminated","No Results Available","Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer|Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Pemetrexed|Drug: Gemcitabine","Western Regional Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-04","May 17, 2013","April 2013","April 2016","December 8, 2014","December 2014","No Study Results Posted","null","September 2014","Rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer|Histologic response rate and correlation with disease-free survival (DFS) and overall survival (OS)|Imaging response rate and correlation with DFS and OS","https://ClinicalTrials.gov/show/NCT01860040"
1438,"NCT00003587","S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine|Drug: paclitaxel|Drug: vinorelbine","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","204","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066656|S9806|U10CA032102","November 1, 1999","October 1998","January 2007","October 5, 2012","October 2012","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00003587"
1439,"NCT00182611","S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: tegafur-gimeracil-oteracil potassium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Kyoto University|National Cancer Institute (NCI)","All","20 Years and older   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","KYUH-UHA-GC04-03|CDR0000426403","September 15, 2005","April 2004","November 2008","June 25, 2013","November 2008","No Study Results Posted","null","September 2008","Overall survival|Progression-free survival (PFS)|Postoperative PFS|Surgical/pathological curative resection|Death related to treatment|Death related to operation|Postoperative complications|Adverse events","https://ClinicalTrials.gov/show/NCT00182611"
1440,"NCT00020787","Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Biological: G17DT Immunogen|Drug: cisplatin|Drug: fluorouracil","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068713|P30CA016042|UCLA-0006040|APHTON-BB-IND-8737|NCI-G01-1959|UCLA-GC4C","July 11, 2001","July 2001","December 2002","September 30, 2015","July 2012","No Study Results Posted","null","January 2002","To determine whether a concomitant G17DT-chemotherapy regimen affects tumor response in subjects with gastric or gastroesophageal cancer.|Time to disease progression, best overall response, and survival will be evaluated in the intent-to-treat population and the evaluable population.","https://ClinicalTrials.gov/show/NCT00020787"
1441,"NCT00006011","Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer","Completed","Has Results","Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Endometrial Serous Adenocarcinoma|Stage III Uterine Corpus Cancer","Drug: Doxorubicin Hydrochloride|Drug: Cisplatin|Biological: Filgrastim|Biological: Pegfilgrastim|Drug: Paclitaxel","Gynecologic Oncology Group|Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","659","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","GOG-0184|NCI-2012-02350|ECOG-G0184|RTOG-EN0130|CDR0000068020|U10CA027469","July 5, 2000","July 2000","null","April 30, 2015","April 2015","May 20, 2014","null","March 2010","Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation.","https://ClinicalTrials.gov/show/NCT00006011"
1442,"NCT01312350","Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)","Active, not recruiting","No Results Available","Hypopharyngeal Cancer","Drug: neoadjuvant docetaxel/cisplatin/fluorouracil|Drug: No treatment before definitive CCRT","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-10-028","February 21, 2011","November 2010","December 2016","April 19, 2016","April 2016","No Study Results Posted","null","March 2016","To determine whether addition of neoadjuvant chemotherapy before definite CCRT increase progression-free survival(PFS) compared with CCRT only|To determine whether addtion of neoaduvant chemotherapy increase complete response rate compared with CCRT only|To determine whether addtion of neoaduvant chemotherapy increase organ preservation rate compared with CCRT only|To determine whether addition of neoadjuvant chemotherapy to CCRT increase the number of patients with adverse events compared with CCRT only","https://ClinicalTrials.gov/show/NCT01312350"
1443,"NCT01752023","A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.","Terminated","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: Arm A|Drug: Arm B","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1230|NA_00067809","December 14, 2012","March 2013","June 2019","October 12, 2016","October 2016","No Study Results Posted","NA_00067809","April 2014","Objective response rates|Tumor blood flow.|Median time to progression|Adverse effects|Itraconazole exposure parameters|Tumor necrosis","https://ClinicalTrials.gov/show/NCT01752023"
1444,"NCT02949700","Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Metformin","Baylor College of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H-39773","October 27, 2016","January 26, 2017","December 2021","March 28, 2017","March 2017","No Study Results Posted","null","December 2019","Phase I - toxicity|Phase II - efficacy","https://ClinicalTrials.gov/show/NCT02949700"
1445,"NCT01057589","A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer","Completed","Has Results","Head and Neck Neoplasms","Drug: Pemetrexed|Drug: Cetuximab|Drug: Cisplatin|Dietary Supplement: Folic Acid|Dietary Supplement: Vitamin B12","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","66","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12170|H3E-MC-S123","January 20, 2010","February 2010","October 2012","September 5, 2013","September 2013","February 6, 2013","null","February 2012","Progression Free Survival (PFS)|Overall Survival (OS)|Percent of Participants With a Partial Response (PR) or a Complete Response (CR)|Change From Baseline in Participant Reported European-Quality of Life 5 Dimension Instrument (EQ-5D) Visual Analog Scale (VAS) at End of Triplet Combination Therapy and End of Maintenance Therapy|Change From Baseline in Participant Reported EQ-5D Utility Score at End of Triplet Combination Therapy and End of Maintenance Therapy|Change From Baseline in Performance Status Scale for Head and Neck Cancer Patients (PSS-HNC)","https://ClinicalTrials.gov/show/NCT01057589"
1446,"NCT00088816","S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer","Unknown status","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: tegafur-gimeracil-oteracil potassium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Kyoto University|National Cancer Institute (NCI)","All","20 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000368443|KYUH-UHA-GC03-01","August 4, 2004","April 2003","null","September 16, 2013","March 2008","No Study Results Posted","null","March 2008","Overall survival|Time to progression|Tumor response|Death related to treatment|Histological response|Postoperative complications|Surgical/pathological curative resection|Types of initial recurrence|Adverse events","https://ClinicalTrials.gov/show/NCT00088816"
1447,"NCT00512096","Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis","Completed","Has Results","Penile Cancer","Drug: Ifosfamide|Drug: Paclitaxel (Taxol)|Drug: Cisplatin","M.D. Anderson Cancer Center","Male","14 Years and older   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID99-194","August 6, 2007","August 1999","August 2010","July 27, 2012","July 2012","November 3, 2010","null","August 2010","Number of Participants With Pathologic Complete Remission (pCR)","https://ClinicalTrials.gov/show/NCT00512096"
1448,"NCT03123445","Endostar First-line Treatment of Advanced NSCLC","Not yet recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Endostar|Drug: Gemcitabine|Drug: Cisplatin","China Medical University, China|The First Affiliated Hospital of Dalian Medical University|The Second Affiliated Hospital of Dalian Medical University|Liaoning Tumor Hospital & Institute|Shengjing Hospital|General Hospital of Shenyang Military Region","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CLOG1701","April 5, 2017","April 2017","September 2019","April 18, 2017","April 2017","No Study Results Posted","null","April 2019","Progression-free Survival (PFS)|ORR","https://ClinicalTrials.gov/show/NCT03123445"
1449,"NCT01064921","Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx","Drug: vorinostat|Drug: cisplatin|Radiation: radiation therapy|Procedure: Correlative Studies","Ohio State University Comprehensive Cancer Center|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 1","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-09120|NCI-2009-01606","February 5, 2010","February 2010","null","October 24, 2016","October 2016","No Study Results Posted","null","December 2016","Maximum tolerated dose of vorinostat in combination with concurrent chemoradiation therapy|The toxic effects of the combination of vorinostat and cisplatin using NCI CTCAE v. 4.0|Tumor responses to vorinostat or vorinostat combined with chemoradiation.|Complete response rate|Overall survival|Progression free survival|Relationship between Vorinostat therapy and tumor suppressor genes product assessed by Fas and FasL protein expression level in tumor and the normal mucosa|HPV-specific T-cell in patients with HPV+ tumors","https://ClinicalTrials.gov/show/NCT01064921"
1450,"NCT00009932","Combination Chemotherapy in Treating Patients With Solid Tumors","Unknown status","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: fenretinide|Drug: paclitaxel","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","OSU-00H0186|CDR0000068425|NCI-2530","February 2, 2001","January 2001","null","May 14, 2013","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00009932"
1451,"NCT02575547","Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma|Malnutrition","Drug: cisplatin and docetaxel","Zhao Chong|Wuhan University|Fudan University|Fujian Cancer Hospital|Zhejiang Cancer Hospital|First Affiliated Hospital of Guangxi Medical University|The First Affiliated Hospital of Xiamen University|Cancer Hospital of Guizhou Province|Hainan People's Hospital|First People's Hospital of Foshan|Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","","186","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2015-FXY-034-Nutrition and NPC","September 19, 2015","May 2015","December 2019","October 25, 2016","October 2016","No Study Results Posted","null","October 2016","Change in Body weight|Acute Toxicity|Number of Participants With Abnormal Laboratory Values|Adverse Events That Are Related to Treatment|Tumor regressive rate after treatment|Late toxicity|Three-year locoregional relapse free survival rate|Three-year distance metastasis free survival rate|Three-year overall survival rate|Three-year disease free survival rate","https://ClinicalTrials.gov/show/NCT02575547"
1452,"NCT00324298","Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Drug: cisplatin|Drug: etoposide|Procedure: management of therapy complications","Queen Mary University of London|National Cancer Institute (NCI)","Male","18 Years to 50 Years   (Adult)","Phase 3","210","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","BARTS-TE3|CDR0000472976|EU-20608|ISRCTN08648791","May 10, 2006","July 2003","March 2011","August 9, 2013","January 2007","No Study Results Posted","null","null","Pulmonary toxicity|Response to treatment|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00324298"
1453,"NCT01880359","AF CRT +/- Nimorazole in HNSCC","Recruiting","No Results Available","Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers","Drug: Cisplatin|Radiation: Radiotherapy|Drug: Placebo|Drug: Nimorazole","European Organisation for Research and Treatment of Cancer - EORTC|Danish Head and Neck Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 3","640","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EORTC-1219|2013-002441-12","June 12, 2013","July 2014","December 2020","October 11, 2016","October 2016","No Study Results Posted","null","May 2019","locoregional control rate|Time to distant metastasis|Time to second cancer|Overall survival|Disease-specific free survival|Acute and late morbidity","https://ClinicalTrials.gov/show/NCT01880359"
1454,"NCT02099786","Randomized Trial Comparison of Ototoxicity Monitoring Programs","Recruiting","No Results Available","Cisplatin Ototoxicity|Hearing Loss","Other: COMP-VA|Other: Standard of care|Other: Program evaluation","VA Office of Research and Development","All","18 Years to 85 Years   (Adult, Senior)","","71","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Prevention","C0239-R|3114","February 26, 2014","April 1, 2015","March 2018","April 25, 2017","April 2017","No Study Results Posted","COMP-VA","March 2018","Audiology Clinic use|Counseling tools|Hearing test and quality of life measure.","https://ClinicalTrials.gov/show/NCT02099786"
1455,"NCT01004250","A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Bevacizumab","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","109","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13034|H3E-EW-S125","October 28, 2009","October 2009","December 2013","April 23, 2014","April 2014","November 7, 2013","null","November 2012","Progression-Free Survival|Overall Survival|Percentage of Participants With Confirmed Complete Response or Partial Response During Study Treatment (Induction and Maintenance)|Percentage of Participants With Confirmed Response Complete or Partial Response During the Induction Treatment Only|Percentage of Participants With Confirmed Complete Response or Partial Response During the Maintenance Therapy Only","https://ClinicalTrials.gov/show/NCT01004250"
1456,"NCT01664975","Treatment of Peripheral T-cell Lymphoma","Completed","Has Results","Peripheral T-cell Lymphoma","Drug: GDPT regimen|Drug: CHOP regimen","Mingzhi Zhang|Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","hnslblzlzx2011-3","August 10, 2012","August 2011","April 2016","August 10, 2016","August 2016","August 10, 2016","null","April 2016","Progression-free Survival|Response Rate|Overall Survival|Median Survival Time","https://ClinicalTrials.gov/show/NCT01664975"
1457,"NCT01566435","Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer","Active, not recruiting","Has Results","Head and Neck Neoplasms","Drug: paclitaxel albumin-stabilized nanoparticle formulation|Drug: Cisplatin|Drug: Fluorouracil|Radiation: Intensity modulated radiation therapy|Drug: Cetuximab|Procedure: Quality-of-life assessment","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201202113","March 27, 2012","August 9, 2012","October 31, 2023","January 26, 2017","January 2017","September 8, 2015","null","October 31, 2013","Percentage of Participants With Complete Response (CR) by Clinical Exam at Primary Tumor Site|Percentage of Participants With Partial Response (PR) at Primary Tumor Site|Number of Participants Per Anatomic Tumor Response by CT Scan|Metabolic Tumor Responses as Measured by FDG-PET/CT|Overall Survival Rate|Adverse Events as Measured by Number of Participants That Experienced Each Common Adverse Event During ACF Induction Therapy|Changes in Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue|Quality of Life (QOL)|Complete Response (CR) or Partial Response (PR) at Regional (Neck) Nodes as Measured by Clinical Exam|Changes in Ki-67 Expression by Immunohistochemistry (IHC) in Primary Tumor Tissue|Disease-free Survival (DFS) Rate|Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01566435"
1458,"NCT00003298","Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer","Completed","Has Results","Gastric Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: leucovorin calcium|Drug: paclitaxel|Procedure: surgery|Radiation: radiation therapy","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066237|E7296|U10CA023318","November 1, 1999","February 1999","May 2011","June 22, 2015","June 2015","June 2, 2015","null","February 2010","Grade 3 or Higher Toxicity Incidence on Step 1|Best Confirmed Response to Neoadjuvant Therapy|Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00003298"
1459,"NCT00045604","Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: imatinib mesylate|Drug: irinotecan hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000256923|MSKCC-02015|NCI-5653","September 6, 2002","July 2002","null","July 23, 2008","April 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00045604"
1460,"NCT01167192","Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer","Terminated","Has Results","Breast Neoplasms","Drug: Cisplatin|Drug: Carboplatin|Radiation: Radiation therapy|Procedure: Mastectomy (recommended but not mandatory)","Washington University School of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201310089","July 14, 2010","February 2011","September 2016","November 9, 2016","November 2016","September 8, 2016","null","August 2012","Response Rate as Measured by Number of Participants Who Achieved Complete Response (CR) or Partial Response (PR)|Relationship Between Tumor Response and Deficiencies in DNA Repair Mechanisms|Time to Disease Progression|Number of Participants With Surgical Complications|Determine the Effect of Neoadjuvant Chemoradiation Therapy in Disseminated Cancer Cells in the Bone Marrow|Overall Survival Rate|Medical Toxicities as Measured by Number of Grade 3 or Higher Adverse Events|Successful Development of Animal Models of Triple Negative Breast Cancers as Measured by the Ability to Grow the Tumors in Mice.|Successful Development of Animal Models for Triple Negative Breast Cancers as Measured by the Ability to Passage the Tumors in Mice|Successful Development of Animal Models in Triple Negative Breast Cancers as Measured by the Ability of the Tumors to Metastasize to Other Organs|Successful Development of Animal Models of Triple Negative Breast Cancer as Measured by the Genetic Similarity Between the Primary Tumor and the Tumor in Animals|Determine the Effect of Neoadjuvant Chemoradiation Therapy in Disseminated Cancer Cells in the Bone Marrow and the Correlation to Tumor Response","https://ClinicalTrials.gov/show/NCT01167192"
1461,"NCT00003237","Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: surgical procedure","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066109|E-8296","November 1, 1999","March 1998","null","January 26, 2010","January 2010","No Study Results Posted","null","October 2003","","https://ClinicalTrials.gov/show/NCT00003237"
1462,"NCT00055601","Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer","Active, not recruiting","Has Results","Bladder Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Radiation: radiation therapy|Drug: Gemcitabine|Procedure: Radical cystectomy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NRG Oncology","All","up to 120 Years   (Child, Adult, Senior)","Phase 2","97","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0233|CDR0000258303|ECOG-R0233|NCI-2011-01578","March 6, 2003","December 2002","null","June 30, 2016","June 2016","June 30, 2016","null","October 2010","Treatment Completion Rate|Complete Response After Induction|Bladder-intact Survival","https://ClinicalTrials.gov/show/NCT00055601"
1463,"NCT01918124","A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer","Unknown status","No Results Available","Prosthesis Survival","Radiation: radiotherapy|Drug: Cisplatin|Drug: Cisplatin and Doxorubicin and Cyclophosphamide|Drug: Paclitaxel and Carboplatin","Fan Ming|Fudan University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070148-7","July 29, 2013","January 2008","January 2014","August 6, 2013","August 2013","No Study Results Posted","EC-0701","January 2014","Disease Free Survival(DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01918124"
1464,"NCT00003037","Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","97-040|CDR0000065659|NCI-G97-1285","November 1, 1999","April 1997","March 2002","June 25, 2013","June 2013","No Study Results Posted","null","March 2002","","https://ClinicalTrials.gov/show/NCT00003037"
1465,"NCT00450138","Open Label, Phase I ZD6474 Head and Neck Cancer Study","Completed","No Results Available","Head and Neck Cancer","Drug: ZD6474 (vandetanib)|Drug: Cisplatin|Radiation: Radiation","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D4200C00062","March 20, 2007","December 2006","November 2011","August 26, 2016","August 2016","No Study Results Posted","null","November 2009","To determine the maximum tolerated dose of vandetanib given in combination with radiation or radiation and chemotherapy in patients with late stage head and neck cancer","https://ClinicalTrials.gov/show/NCT00450138"
1466,"NCT02952586","Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Avelumab|Other: Chemoradiation","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","640","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","B9991016|2016-001456-21|LOCALLY ADVANCED HEAD AND NECK","October 31, 2016","November 28, 2016","May 18, 2022","May 18, 2017","May 2017","No Study Results Posted","null","April 8, 2021","Progression Free Survival (PFS)|Overall Survival (OS)|Trough plasma concentration (Ctrough) of avelumab|Percentage of patients with positive anti-drug antibodies (ADA) and neutralizing antibodies|Tumor tissue biomarker status|Maximum plasma concentration (Cmax) of Avelumab|Area under the concentration-time curve extrapolated to infinity (AUCinf) for cisplatin|Cmax of Cisplatin|Clearance (CL) of cisplatin|Time to maximum plasma concentration (Tmax) and elimination half-life (t1/2)for cisplatin|Volume of distribution (Vz) for cisplatin (total and free)|Change from Baseline in the EuroQoL Group 5-Dimension 5- Level Self-Report Questionnaire (EQ-5D-5L)|Change from baseline in National Cancer Comprehensive Network (NCCN) Head and Neck Symptom Index-22 items (FHNSI-22)|Rate of pathologic complete response|Locoregional tumor control|Distant metastatic failure|Objective Response Rate - Percentage of Participants With Objective Response|Duration of response|The incidence of pathologically-positive neck dissection versus the incidence of pathologically-negative neck dissection","https://ClinicalTrials.gov/show/NCT02952586"
1467,"NCT00304070","Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor","Active, not recruiting","No Results Available","Stage I Adrenocortical Carcinoma|Stage II Adrenocortical Carcinoma|Stage III Adrenocortical Carcinoma|Stage IV Adrenocortical Carcinoma","Drug: doxorubicin hydrochloride|Procedure: conventional surgery|Drug: cisplatin|Drug: mitotane|Drug: etoposide|Biological: filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","78","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARAR0332|NCI-2009-00413|CDR0000467191|COG-ARAR0332|U10CA098543","March 15, 2006","September 2006","null","March 17, 2016","March 2016","No Study Results Posted","null","December 2015","Event-free survival (EFS)|Toxicity Associated with mitotane using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Toxicity Associated with Chemotherapy using NCI CTCAE v. 4.0|Feasibility and Complications Associated with Radical Adrenalectomy and RLND|Frequency of Tumor Spillage and Lymph Node Involvement|Incidence and Type of Germline TP53 Mutations in Non-Brazilian Children and Children from Southern Brazil by deoxyribonucleic acid (DNA) sequencing and Affymetrix Gene Chip analysis|Molecular alterations and embryonal markers in children with ACT.","https://ClinicalTrials.gov/show/NCT00304070"
1468,"NCT00963807","A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC","Completed","Has Results","Recurrent Non-Small Cell Lung Carcinoma|Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer","Drug: Cisplatin|Procedure: CT|Drug: Docetaxel|Drug: FDG|Drug: FLT|Procedure: PET/CT|Procedure: Surgery","National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 2","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-02899|NA_00017885|J08134|NCI 8340|N01CM00070|P30CA006973","August 18, 2009","September 2009","November 2014","January 27, 2017","January 2017","October 17, 2016","null","August 2012","Change in 18F-Fluorothymidine (FLT) Uptake|Change in FLT Uptake|Change in FLT Uptake in Responders and Non-responders|Change in 18F-Fluorodeoxyglucose (FDG) Uptake|Overall Response Rate Reported as a Proportion of the Total Number of Patients Who Received at Least One Cycle of Therapy Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT00963807"
1469,"NCT00004199","Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: prinomastat","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","AG-3340-017|CDR0000067442","January 21, 2000","March 1999","null","August 7, 2012","August 2012","No Study Results Posted","null","July 2001","","https://ClinicalTrials.gov/show/NCT00004199"
1470,"NCT02716961","Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer","Recruiting","No Results Available","Bladder Cancer|Gemcitabine and Cisplatin Chemotherapy|Epirubicin Instillation|Recurrence|Prognosis","Drug: Gemcitabine, cisplatin","The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 70 Years   (Adult, Senior)","","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","2015-SR-193","March 14, 2016","January 2016","December 2020","March 22, 2016","November 2015","No Study Results Posted","null","December 2020","Tumor progression|Drug intervention complications|The percent of patients transferred to radical cystectomy.|The existence of circulating tumor cells.","https://ClinicalTrials.gov/show/NCT02716961"
1471,"NCT00002568","Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer","Completed","No Results Available","Ovarian Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: conventional surgery","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","470","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063600|GOG-152","November 1, 1999","June 1994","null","July 8, 2013","May 2010","No Study Results Posted","null","December 2004","","https://ClinicalTrials.gov/show/NCT00002568"
1472,"NCT02157116","Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer","Terminated","Has Results","Non-small Cell Lung Cancer","Drug: cisplatin|Drug: Docetaxel|Drug: Pegfilgrastim","Duke University|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00004682","May 29, 2014","May 2006","January 2010","June 5, 2014","June 2014","June 5, 2014","null","October 2009","Induction Response|Differential Gene Expression Between Responsive and Resistant Tumor Treated With Dose-dense Therapy|Number of Grade III/IV Hematologic Adverse Events|Number of Grade III/IV Non-hematologic Adverse Events|Number of Patients Who Were Able to Maintain Hemoglobin Between 11-13 g/dL During Induction|Overall Survival","https://ClinicalTrials.gov/show/NCT02157116"
1473,"NCT02512315","A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Docetaxel (DOC)|Drug: Cisplatin (DDP)|Radiation: Concurrent chemoradiation (CRT)","Sun Yat-sen University","All","up to 70 Years   (Child, Adult, Senior)","Phase 3","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NACT4-NPC-5010","July 24, 2015","August 2015","December 2024","April 13, 2016","April 2016","No Study Results Posted","null","December 2024","5-year overall survival (5y-OS)|5-year distant-metastasis-free survival (5y-MFS)|5-year local-relapse-free survival (5y-RFS)|5-year disease-free survival (5y-DFS)|Incidence of grade 3/4 adverse event","https://ClinicalTrials.gov/show/NCT02512315"
1474,"NCT02486718","Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Atezolizumab|Drug: Cisplatin|Drug: Vinorelbine|Drug: Docetaxel|Drug: Gemcitabine|Drug: Pemetrexed","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","1127","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO29527|2014-003205-15","June 4, 2015","October 31, 2015","September 25, 2026","May 22, 2017","May 2017","No Study Results Posted","null","September 25, 2026","DFS, Assessed Using Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)/X-Ray in in Stage IB-IIIA (Intent-to-Treat [ITT]) Population|DFS, Assessed Using CT/MRI/X-Ray in Stage II-IIIA and PD-L1-Selected Subpopulation|Overall Survival (OS)|Percentage of Participants Who are Disease-Free at Year 3, Assessed Using CT/MRI/X-Ray|Percentage of Participants Who are Disease-Free at Year 5, Assessed Using CT/MRI/X-Ray|Percentage of Participants with Adverse Events|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab|Maximum Plasma Concentration (Cmax) of Atezolizumab|Minimum Serum Concentration (Cmin) at Steady-State of Atezolizumab","https://ClinicalTrials.gov/show/NCT02486718"
1475,"NCT02879513","Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy","Recruiting","No Results Available","Invasive Ductal Breast Cancer|Tubular Breast Cancer|Mucinous Breast Cancer|Inflammatory Breast Cancer","Drug: Paclitaxel|Drug: Cisplatin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: 5-fluoruracil","RenJi Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RenJiH-BC-003","July 17, 2016","January 2014","December 2022","March 26, 2017","March 2017","No Study Results Posted","null","December 2017","Disease-free survival (DFS)|overall survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|regional recurrence free survival (RRFS)|local recurrence free survival (LRFS)|distant-disease- free survival (DDFS)","https://ClinicalTrials.gov/show/NCT02879513"
1476,"NCT02707666","A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma","Recruiting","No Results Available","Pleural Mesothelioma","Drug: Pembrolizumab|Drug: Cisplatin and Pemetrexed","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB15-1149","February 29, 2016","February 2016","null","December 28, 2016","December 2016","No Study Results Posted","null","March 2018","Gamma-Interferon Gene Expression profile (GEP) response rate defined as an increase beyond the median value of the sum of individual genes|Number of participants with adverse events as measured by CTCAEv4.0","https://ClinicalTrials.gov/show/NCT02707666"
1477,"NCT00011960","Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: adjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-G-0114|CDR0000068464","March 3, 2001","May 2001","null","November 14, 2015","November 2015","No Study Results Posted","null","May 2006","","https://ClinicalTrials.gov/show/NCT00011960"
1478,"NCT00976768","Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin","Completed","No Results Available","Advanced Gastric Cancer","Drug: oxaliplatin, 5-fluorouracil","Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0402","September 11, 2009","October 2004","December 2009","January 13, 2014","January 2014","No Study Results Posted","null","December 2009","Progression-free survival|Overall survival|Toxicity profile (according to National Cancer Institute Common Terminology Criteria for Adverse Event [NCI CTC AE] version 3.0)|Response rate","https://ClinicalTrials.gov/show/NCT00976768"
1479,"NCT03127774","Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma","Not yet recruiting","No Results Available","Adrenocortical Carcinoma|Peritoneal Carcinomatosis","Drug: Cisplatin|Drug: Sodium thiosulfate|Procedure: Cytoreductive surgery","Columbia University","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AAAQ9194","April 2, 2017","May 2017","May 2023","April 24, 2017","April 2017","No Study Results Posted","null","May 2022","Progression free survival|Morbidity rate|Quality of Life (QOL) score|Overall survival","https://ClinicalTrials.gov/show/NCT03127774"
1480,"NCT00178698","Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors","Unknown status","No Results Available","Neuroendocrine Cancer|Small Cell Lung Cancer|Non-Small Cell Lung Cancer|Gastric Cancer","Other: thermochemotherapy|Drug: Cisplatin, Gemcitabine, Interferon-a|Other: thermochemotherapy","The University of Texas Health Science Center, Houston","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HSC-MS-04-259","September 13, 2005","July 2002","June 2014","March 2, 2011","March 2011","No Study Results Posted","FR-WB-TT/che","June 2013","Tumor Response by RECIST criteria (CR+PR)|Response Duration|Survival|Toxicity|Quality of Life","https://ClinicalTrials.gov/show/NCT00178698"
1481,"NCT00961415","AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","Non-Squamous Non-Small Cell Lung Cancer","Drug: bevacizumab [Avastin]|Drug: cisplatin|Drug: pemetrexed","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO22089|2008-007008-27","August 18, 2009","August 2009","May 2011","January 24, 2016","January 2016","November 30, 2015","null","May 2011","Progression Free Survival During Maintenance Treatment Phase|Overall Survival During Maintenance Treatment Phase|Best Overall Response Rate During Maintenance Treatment Phase|Duration of Response During Maintenance Treatment Phase|Duration of Disease Control During Maintenance Treatment Phase|Incidence of Adverse Events and Serious Adverse Event|Number of Participants With Marked Laboratory Abnormalities|Quality of Life","https://ClinicalTrials.gov/show/NCT00961415"
1482,"NCT02812420","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy","Recruiting","No Results Available","Malignant Neoplasms of Urinary Tract","Drug: Durvalumab|Drug: Tremelimumab|Procedure: Cystectomy|Behavioral: Phone Calls","M.D. Anderson Cancer Center|MedImmune LLC","All","18 Years and older   (Adult, Senior)","Early Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0033|NCI-2016-01147","June 16, 2016","March 7, 2017","March 2019","April 19, 2017","April 2017","No Study Results Posted","null","March 2019","Toxicity of Durvalumab Plus Tremelimumab|Immune Changes in Peripheral Blood and Tumor Tissues|Molecular Changes in Peripheral Blood and Tumor Tissues","https://ClinicalTrials.gov/show/NCT02812420"
1483,"NCT00330499","Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.","Completed","No Results Available","Transitional Cell Carcinoma of Urinary Bladder","Drug: Cisplatin|Radiation: External beam radiation treatment","Trans-Tasman Radiation Oncology Group (TROG)|National Health and Medical Research Council, Australia","All","18 Years and older   (Adult, Senior)","Phase 3","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TROG 02.03|NHMRC 243100","May 25, 2006","October 2002","February 2010","January 22, 2017","January 2017","No Study Results Posted","null","February 2010","Invasive local failure at 3 years|Complete response (CR) rate at 3 months from randomisation|Disease-free survival|Overall survival|Cystectomy-free survival|Acute and late toxicity|Pattern of failure (local, regional, distant)|Quality of life measures","https://ClinicalTrials.gov/show/NCT00330499"
1484,"NCT02104986","A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent","Recruiting","No Results Available","Extra Cranial Non Seminomateous Malignant Germ Cell Tumour","Drug: Velbe-Bleomycin-Cisplatin|Drug: Vepeside-ifosfamide-Cisplatin","Centre Leon Berard","All","up to 18 Years   (Child, Adult)","Phase 2","94","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TGM 2013-NS","March 27, 2014","May 2014","May 2024","March 30, 2016","March 2016","No Study Results Posted","null","May 2019","Progression-free survival|Overall survival|complete remission rate after 1st line treatment (chemotherapy and surgery)","https://ClinicalTrials.gov/show/NCT02104986"
1485,"NCT01185847","A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: RO5083945|Drug: cisplatin|Drug: gemcitabine|Drug: pemetrexed","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BP22349|2010-018945-72","August 19, 2010","November 2010","September 2012","December 31, 2015","December 2015","No Study Results Posted","null","September 2012","Part 2: Progression-free survival, according to RECIST criteria by CT/MRI|Part 1: Adverse event profile: adverse events, ECG, hematology, urinalysis, human anti-human antibodies (HAHA)|Pharmacokinetics of RO5083945 (AUC, Cmax and Cmin) in combination with cisplatin and gemcitabine/pemetrexed|Duration of response, according to RECIST criteria by CT/MRI|Clinical benefit rate (complete response, partial response or stable disease for >/=6 weeks), according to RECIST criteria by CT/MRI|Overall survival|Overall response rate (ORR), according to RECIST criteria by CT/MRI","https://ClinicalTrials.gov/show/NCT01185847"
1486,"NCT00215514","Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma","Completed","No Results Available","Stomach Cancer|Gastric Cancer|Gastro-esophageal Junction Cancer","Drug: Epirubicin|Drug: Cisplatin|Drug: 5-Fluorouracil (5-FU)|Procedure: Radiation","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Early Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","00-165","September 20, 2005","September 2000","July 2014","July 28, 2014","July 2014","No Study Results Posted","null","November 2003","To assess patient tolerance and toxicity of postoperative adjuvant regimen using epirubicin, cisplatin, and infusional 5-FU before and after a course of radiotherapy among patients with curatively resected gastric or gastroesophageal adenocarcinoma.","https://ClinicalTrials.gov/show/NCT00215514"
1487,"NCT02936388","Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis","Recruiting","No Results Available","Uveal Melanoma","Procedure: SIRT|Procedure: DSM-TACE","Charite University, Berlin, Germany","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SirTac2014","September 9, 2016","January 2016","December 2018","October 14, 2016","October 2016","No Study Results Posted","SirTac","January 2018","Pregression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02936388"
1488,"NCT00002888","Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065210|E-1395|SWOG-E1395","November 1, 1999","March 1997","August 2004","June 20, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002888"
1489,"NCT00003624","Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer","Terminated","No Results Available","Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Neurotoxicity|Ovarian Cancer|Primary Peritoneal Cavity Cancer|Sarcoma","Drug: amifostine trihydrate|Drug: cisplatin|Drug: paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Supportive Care","CDR0000066705|GOG-9805","November 1, 1999","December 1998","null","April 10, 2013","May 2006","No Study Results Posted","null","January 2004","","https://ClinicalTrials.gov/show/NCT00003624"
1490,"NCT02513342","Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma","Recruiting","No Results Available","Advanced Lung Squamous Carcinoma","Biological: Endostar|Drug: Docetaxel|Drug: Cisplatin","Nanjing NingQi Medicine Science and Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JSLCG-001","July 17, 2015","March 2015","April 2018","July 30, 2015","March 2015","No Study Results Posted","null","October 2017","Progression-free Survival (PFS)|overall remission rate(ORR)|Disease control rate （DCR）|Overall survival（OS）","https://ClinicalTrials.gov/show/NCT02513342"
1491,"NCT01501136","Treatment of Natural Killer/T Cell Lymphoma-I/II","Recruiting","No Results Available","Nasal and Nasal-type NK/T-cell Lymphoma","Other: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|Other: VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|Other: gemcitabine,pegaspargase,cisplatin,dexamethasone|Other: cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiation: Radiotherapy","Mingzhi Zhang|Second Hospital of Shanxi Medical University|Shanxi Province Cancer Hospital|Wuhan University|Wuhan TongJi Hospital|Wuhan Union Hospital, China|Qingdao University|Cancer Hospital of Guizhou Province|Xinyang Central Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine|Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","hnslblzlzx2011","November 25, 2011","January 2011","May 2019","July 15, 2015","July 2015","No Study Results Posted","CTTNKTL-I/II","December 2015","Progression-free survival|Response rate|overall survival|median survival time","https://ClinicalTrials.gov/show/NCT01501136"
1492,"NCT00634595","Trial of E10A in Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Squamous Carcinoma|Nasopharyngeal Carcinoma","Drug: E10A|Drug: Cisplatin|Drug: Paclitaxel","Sun Yat-sen University|Doublle Bioproduct Inc","All","18 Years to 65 Years   (Adult)","Phase 2","116","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TG0717E10A","March 5, 2008","March 2008","December 2010","July 26, 2010","July 2010","No Study Results Posted","null","December 2010","tumor response confirmed by CT or MRI|NCI toxicity criteria (CIC 3.0)","https://ClinicalTrials.gov/show/NCT00634595"
1493,"NCT00004865","Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|ImClone LLC","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH|Industry","Interventional","Primary Purpose: Treatment","CDR0000067521|UCLA-9906095|IMCL-CP02-9816|UAB-9917|NCI-G00-1667","March 7, 2000","November 1999","null","March 6, 2009","March 2009","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00004865"
1494,"NCT00992199","Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer","Unknown status","No Results Available","Advanced Gastric Cancer","Drug: cisplatin, Fluorouracil","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","IP chemo-AGC","October 8, 2009","August 2009","December 2011","September 7, 2010","September 2010","No Study Results Posted","IPchemo-AGC","October 2011","Metastasis in Peritoneum and peritoneal cavity|Liver metastasis|Refraction-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00992199"
1495,"NCT02710734","Trimodality Bladder Preservation Therapy: Maximal Transurethral Resection Followed by Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (AMVAC) and Concurrent Chemoradiation With Intensity Modulated Radiation Therapy for Muscle Invasive Bladder Cancer","Recruiting","No Results Available","Urothelial Carcinoma of the Bladder","Drug: Methotrexate|Drug: Vinblastine|Drug: Doxorubicin|Drug: Cisplatin|Radiation: Intensity modulated radiation therapy|Procedure: Maximal Transurethral Resection|Drug: 5-FU|Drug: Mitomycin C","Fox Chase Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GU-086","February 18, 2016","February 2016","April 2018","November 22, 2016","November 2016","No Study Results Posted","null","April 2018","Number of subjects completing treatment|Time to recurrence of disease based on RECIST Criteria v 1.1|Number of subjects experiencing serious adverse events per CTCAE v4.03","https://ClinicalTrials.gov/show/NCT02710734"
1496,"NCT00002684","Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer","Completed","No Results Available","Bladder Cancer|Urethral Cancer","Drug: cisplatin|Drug: ifosfamide|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Primary Purpose: Treatment","95-031|CDR0000064373|NCI-V95-0743","November 1, 1999","May 1995","October 2007","July 2, 2013","July 2013","No Study Results Posted","null","October 2007","Efficacy","https://ClinicalTrials.gov/show/NCT00002684"
1497,"NCT00686959","Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Etoposide|Drug: Vinorelbine|Drug: Paclitaxel|Drug: Carboplatin|Radiation: Thoracic Radiation Therapy (TRT)","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","598","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11514|H3E-MC-JMIG","May 28, 2008","September 2008","November 2014","May 20, 2016","May 2016","October 22, 2015","PROCLAIM","October 2014","Overall Survival|Progression-free Survival (PFS)|Objective Response Rate (Complete Response [CR] + Partial Response [PR])|Survival Rates at 1, 2, and 3 Years|First Site of Disease Failure in Terms of Relapse|Percentage of Participants With a Post Baseline Swallowing Diary Score >=4","https://ClinicalTrials.gov/show/NCT00686959"
1498,"NCT00002488","Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy","Unknown status","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Ottawa Regional Cancer Centre|National Cancer Institute (NCI)","All","18 Years to 64 Years   (Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077375|CAN-OTT-9106|NCI-V92-0013","November 1, 1999","December 1991","null","September 16, 2013","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002488"
1499,"NCT02513355","Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research","Recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: Endostar|Drug: Changchun marina|Drug: cisplatin|Drug: Taxol|Drug: parapl","Nanjing NingQi Medicine Science and Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JS-ENDO-001","July 17, 2015","February 2015","null","July 31, 2015","February 2015","No Study Results Posted","null","November 2017","PFS（progression-free survival）|ORR（Objective Response Rate）|DCR(disease control rate)|OS（overall survival）","https://ClinicalTrials.gov/show/NCT02513355"
1500,"NCT00113386","Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer","Terminated","Has Results","Lung Cancer","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: docetaxel|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group","All","18 Years and older   (Adult, Senior)","Phase 3","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0412|CDR0000429479|SWOG-S0332|CALGB-RTOG-0412|ECOG-RTOG-0412|NCCTG-RTOG-0412","June 7, 2005","April 2005","null","June 21, 2013","June 2013","November 27, 2012","null","February 2009","Comparison of Overall Survival","https://ClinicalTrials.gov/show/NCT00113386"
1501,"NCT00470340","Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients","Terminated","No Results Available","Liver Neoplasms|Liver Cirrhosis|Carcinoma, Hepatocellular|Recurrence|Neoplasm Recurrence, Local","Drug: Oxaliplatin, gemcitabine, cisplatin, lipiodol","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","263","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","P051062","May 4, 2007","June 2007","November 2008","May 4, 2011","May 2007","No Study Results Posted","GEMOXIAL","November 2008","Survival without recurrence at 2 years|Morbidity and mortality following adjuvant treatment","https://ClinicalTrials.gov/show/NCT00470340"
1502,"NCT01345279","Indirect Comparison Topotecan Cervical Carcinoma","Completed","No Results Available","Cervical Intraepithelial Neoplasia","Drug: cisplatin|Drug: topotecan|Drug: paclitaxel","GlaxoSmithKline","Female","21 Years and older   (Adult, Senior)","","1","Industry","Observational","Time Perspective: Retrospective","114016","July 16, 2010","June 2009","July 2009","April 28, 2011","April 2011","No Study Results Posted","null","July 2009","Overall survival","https://ClinicalTrials.gov/show/NCT01345279"
1503,"NCT00002993","Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus","Terminated","No Results Available","Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: mitomycin C","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065540|GOG-87I","November 1, 1999","August 1997","null","July 8, 2013","May 2006","No Study Results Posted","null","January 2000","","https://ClinicalTrials.gov/show/NCT00002993"
1504,"NCT00066482","Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors","Completed","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: conventional surgery|Biological: MESNA","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGCT01P1|CDR0000316244","August 6, 2003","July 2004","null","October 15, 2013","October 2013","No Study Results Posted","null","April 2007","Feasibility of adding cyclophosphamide to a PEB backbone|Maximum tolerated dose|Estimate the response rate","https://ClinicalTrials.gov/show/NCT00066482"
1505,"NCT00971932","Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Completed","Has Results","Squamous Cell Carcinoma of the Head and Neck","Drug: Cetuximab|Drug: Cisplatin/Carboplatin|Drug: 5-Fluorouracil","Merck KGaA","All","20 Years and older   (Adult, Senior)","Phase 2","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62241-056","September 3, 2009","July 2009","null","March 10, 2014","March 2014","July 4, 2012","null","March 2011","Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria|Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Criteria|Disease Control Rate|Duration of Response|Progression-Free Survival (PFS) Time|Overall Survival (OS) Time|Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT00971932"
1506,"NCT00941135","Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab","Terminated","No Results Available","Laryngeal Neoplasms","Other: Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab","Fundacion Miguel Servet|Salutis Research, SL|Unidad de Genética Clínica (Clínica Universitaria de Navarra)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HN2008|EudraCT number: 2008-003365-29","July 15, 2009","May 2009","May 2013","September 28, 2011","September 2011","No Study Results Posted","null","May 2013","To evaluate progression-free time in patients with complete or partial response >30% evaluated over primary tumour(T and N) after TPF induction treated with RT + Cetuximab.","https://ClinicalTrials.gov/show/NCT00941135"
1507,"NCT00227630","Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: pemetrexed disodium|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","59","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","EORTC-08031|2004-004273-28","September 26, 2005","July 2005","null","July 17, 2012","July 2012","No Study Results Posted","null","August 2007","Feasibility in terms of 90-day progression-free survival|Toxicity|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00227630"
1508,"NCT00522886","Phase I Cetuximab and Concurrent Radio-chemotherapy","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Cetuximab","Maastricht Radiation Oncology|Academisch Ziekenhuis Maastricht|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-03-009","August 29, 2007","April 2007","null","July 18, 2011","July 2011","No Study Results Posted","null","July 2011","Maximum Tolerated Dose (MTD) 3 months after the ende of chemo-radiation|During and after chemo-radiation: (CTC 3.0) Dysphagia, Cough, Dyspnea, Skin rash, Myelitis, Neuropathy, Neutrophiles, Platelets, Hemoglobin, Diarrhea, Renal failure, Liver dysfunction, Tumour response 3 m. after end chemo-radiation and Survival","https://ClinicalTrials.gov/show/NCT00522886"
1509,"NCT00208936","Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus","Terminated","No Results Available","Esophageal Diseases","Drug: Taxol, Cisplatin, 5-Fluorouracil, G-CSF","Emory University","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0691-1995","September 13, 2005","January 1996","null","September 5, 2014","September 2014","No Study Results Posted","null","March 2006","","https://ClinicalTrials.gov/show/NCT00208936"
1510,"NCT01214343","Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC","Unknown status","No Results Available","Advanced Hepatocellular Carcinoma|Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Neoplasms","Drug: Sorafenib with Low-dose FP|Drug: Sorafenib","Ministry of Health, Labour and Welfare, Japan","All","20 Years and older   (Adult, Senior)","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SILIUS Phase III trial","October 4, 2010","October 2010","September 2013","June 14, 2011","October 2010","No Study Results Posted","null","September 2013","Overall survival|Time to progression|Progression Free Survival|Change of tumor marker|Biomarker predicting the efficacy","https://ClinicalTrials.gov/show/NCT01214343"
1511,"NCT02074189","Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer","Enrolling by invitation","No Results Available","Bladder Cancer","Drug: Gemcitabine, Cisplatin","Southwest Hospital, China","All","18 Years and older   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012XLC02-1|2012XLC02","February 26, 2014","March 2014","April 2019","February 27, 2014","February 2014","No Study Results Posted","null","April 2019","cancer progressive free survival rate|overall survival","https://ClinicalTrials.gov/show/NCT02074189"
1512,"NCT00980954","Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy","Recruiting","No Results Available","Cervical Cancer","Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 0724|CDR0000654709|NCI-2011-01973","September 18, 2009","September 2009","null","September 28, 2016","September 2016","No Study Results Posted","null","August 2021","Disease-free survival|Overall survival|Chemotherapy-induced neuropathy as measured by FACT-GOG/NTX4|Quality of life as measured by FACT-Cx and FACIT-D","https://ClinicalTrials.gov/show/NCT00980954"
1513,"NCT00816855","Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: docetaxel, cisplatin, fluorouracil","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","52","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-0702","January 2, 2009","February 2007","June 2010","January 2, 2009","January 2009","No Study Results Posted","null","December 2009","overall survival|distant metastases free survival , and disease-free survival","https://ClinicalTrials.gov/show/NCT00816855"
1514,"NCT00816816","Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: docetaxel, cisplatin, fluorouracil","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-0703","January 2, 2009","February 2007","June 2010","January 2, 2009","January 2009","No Study Results Posted","null","December 2009","overall survival|distant metastases free survival, and disease-free survival","https://ClinicalTrials.gov/show/NCT00816816"
1515,"NCT00173862","Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC","Completed","No Results Available","Transitional Cell Carcinoma","Drug: Gemcitabine, Ifosfamide","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","155I1","June 30, 2005","May 2000","June 2006","July 23, 2007","June 2005","No Study Results Posted","null","null","Response rate|Overall Survival, Safety","https://ClinicalTrials.gov/show/NCT00173862"
1516,"NCT00335543","Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","254","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","IAGTDK-70-3046-Ho2|CDR0000472206|EU-20609|ISRCTN78805636","June 8, 2006","June 2003","October 2009","August 9, 2013","August 2009","No Study Results Posted","null","June 2009","Median survival|3-year survival rate|R0 resection rate|Rate of medium and high toxicity events|Rate of complete and incomplete remission of the tumor as measured by radiographic imaging studies|Rate of different regression gradings in resected tumor specimens|Quality of life before, during, and after therapy","https://ClinicalTrials.gov/show/NCT00335543"
1517,"NCT00776698","A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: bevacizumab [Avastin]|Drug: cisplatin|Drug: etoposide","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BO21563|2008-002279-28","October 20, 2008","April 2009","February 2010","November 1, 2016","November 2016","No Study Results Posted","null","February 2010","Dose limiting toxicity|AEs, laboratory parameters|Tumor response","https://ClinicalTrials.gov/show/NCT00776698"
1518,"NCT00062322","Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000304720|P30CA006927|FCCC-02613","June 5, 2003","February 2003","October 2009","February 11, 2010","February 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00062322"
1519,"NCT01933568","Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.","Completed","No Results Available","Inoperable Locally Advanced Non Small Cell Lung Cancer","Radiation: SABR|Drug: Cisplatin","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N12HYB","August 28, 2013","February 2013","January 2017","April 4, 2017","April 2017","No Study Results Posted","N12HYB","January 2017","The mean‐lung dose that is associated with a 15% probability of dose limiting toxicity, defined according to the CTCAE v4; radiation pneumonitis ≥ grade 3 and radiation induced dyspnea ≥ grade 3.","https://ClinicalTrials.gov/show/NCT01933568"
1520,"NCT00190554","A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma","Terminated","No Results Available","Esophageal Neoplasms|Carcinoma, Squamous Cell","Drug: Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|Drug: (Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","All","up to 75 Years   (Child, Adult, Senior)","Phase 3","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG9907|C000000223","September 13, 2005","May 2000","May 2009","September 20, 2016","September 2016","No Study Results Posted","null","May 2004","Disease free survival|Overall survival|Toxicity of chemotherapy|Operative morbidity","https://ClinicalTrials.gov/show/NCT00190554"
1521,"NCT00002472","Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Pediatric Germ Cell Tumor|Extragonadal Germ Cell Tumor","Drug: cisplatin|Drug: etoposide|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Mayo Clinic|National Cancer Institute (NCI)","All","3 Years and older   (Child, Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000076756|P30CA015083|891351|T92-0208D","November 1, 1999","March 1991","August 2005","March 14, 2011","March 2011","No Study Results Posted","null","August 2005","Response rate|Survival|Endocrine and cognitive function","https://ClinicalTrials.gov/show/NCT00002472"
1522,"NCT02435186","p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer","Not yet recruiting","No Results Available","Ovarian Epithelial Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: p53 gene|Drug: Cisplatin|Drug: Paclitaxel","Shenzhen SiBiono GeneTech Co.,Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","rAd-p53-H20150111","April 28, 2015","June 2015","August 2018","April 30, 2015","April 2015","No Study Results Posted","null","August 2018","response rate|progress-free survival|overall survival|Karnofsky Performance Status score（KPS）|safety as measured by adverse events, vital signs, clinical lab tests, ECG and physical examination","https://ClinicalTrials.gov/show/NCT02435186"
1523,"NCT01262859","Pilot Study for Locally Advanced Head and Neck Cancer","Withdrawn","No Results Available","Head and Neck Neoplasms","Drug: bevacizumab","University of Pittsburgh|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-039|UPCI 09-039","December 16, 2010","December 2010","July 2011","January 10, 2014","January 2014","No Study Results Posted","null","July 2011","Response rate|Serum Correlatives|Biomarkers|Toxicity|Response rate and progression-free survival","https://ClinicalTrials.gov/show/NCT01262859"
1524,"NCT03138720","Pre-operative Treatment for Patients With Untreated Advanced Pancreatic Cancer","Recruiting","No Results Available","Resectable Pancreatic Cancer|Unresectable Pancreatic Cancer|Pancreatic Adenocarcinoma","Drug: Paclitaxel Protein Bound (Abraxane)","HonorHealth Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NABPLAGEM-NEO 2017-001","May 1, 2017","May 23, 2017","December 1, 2018","May 18, 2017","May 2017","No Study Results Posted","null","May 15, 2018","CA19-9 value|Pathologic Complete Response Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT03138720"
1525,"NCT01276730","Advanced Cervical Cancer Trial in India","Completed","No Results Available","Cervical Cancer","Drug: Interferon, Retinoic Acid and radiation|Drug: Cisplatin and radiation","James Graham Brown Cancer Center|University of Louisville","Female","18 Years and older   (Adult, Senior)","Phase 2","209","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","464.05","November 2, 2010","October 2007","August 2015","November 21, 2016","November 2016","No Study Results Posted","null","August 2015","Survival|Response rate|Overall toxicity|Determine immune response to Human Papillomavirus HPV","https://ClinicalTrials.gov/show/NCT01276730"
1526,"NCT00166881","Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin","Completed","No Results Available","Gastric Cancer","Drug: Docetaxel-Irinotecan","National Taiwan University Hospital|Far Eastern Memorial Hospital","All","16 Years to 75 Years   (Child, Adult, Senior)","Phase 2","29","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","57M9","September 12, 2005","June 2000","June 2011","July 4, 2013","November 2012","No Study Results Posted","P-HDFL-DI","December 2010","Overall survival (OS)|Objective response rates (CR, PR)","https://ClinicalTrials.gov/show/NCT00166881"
1527,"NCT00996567","A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.","Completed","No Results Available","Cancer","Drug: Cetuximab (Erbitux)","University Hospital, Ghent|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009/337","October 15, 2009","October 2009","September 2015","February 7, 2017","February 2017","No Study Results Posted","MesoMab","September 2015","Progression fee survival rate|Response rate according to modified RECIST criteria|Toxicity (CTCAE version 4)|Overall survival","https://ClinicalTrials.gov/show/NCT00996567"
1528,"NCT00003332","Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: surgical procedure|Radiation: radiation therapy","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","36","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066296|P30CA016087|NYU-9703|NCI-G98-1423","November 1, 1999","July 1997","null","March 25, 2011","March 2011","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00003332"
1529,"NCT00801736","ERCC1 Targeted Trial","Terminated","No Results Available","Lung Cancer","Drug: Cisplatin, Paclitaxel","University College, London|Eli Lilly and Company|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 3","648","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ISRCTN02370070|CRUK-UCL-ET|EUDRACT-2007-007639-17","December 2, 2008","October 2009","null","December 9, 2013","December 2012","No Study Results Posted","ET","July 2013","Overall Survival|Time to progression","https://ClinicalTrials.gov/show/NCT00801736"
1530,"NCT02278250","An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors","Recruiting","No Results Available","Solid Tumor|Advanced Solid Tumor","Drug: VX-803|Drug: Carboplatin|Drug: Gemcitabine|Drug: Cisplatin","Vertex Pharmaceuticals Incorporated","All","18 Years and older   (Adult, Senior)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","VX14-803-001","October 27, 2014","January 2015","March 2017","February 9, 2017","July 2016","No Study Results Posted","null","March 2017","Parts A, B, C: Safety parameters, including adverse events, clinical laboratory values (serum chemistry and hematology), vital signs, and electrocardiogram (ECG) assessments|Part A: Maximum tolerated dose (MTD) and/or recommended Phase 2 (RP2D) of single-agent VX-803 administered BIW|Part B: MTD and/or RP2D of VX-803 administered in combination with carboplatin (Part B1), with gemcitabine (Part B2), and with cisplatin (B3)|Part A: Pharmacokinetics (PK) parameters of single-agent VX-803 administered BIW, derived from plasma concentration-time data|Parts A, B, C: Objective tumor response (OR) and disease stabilization (SD) as evaluated by Response Criteria Evaluation (Response Evaluation Criteria in Solid Tumors [RECIST]) 1:1|Part B: PK Parameters of VX-803 administered in combination with carboplatin (Part B1), with gemcitabine (Part B2), and with cisplatin (Part B3), derived from plasma concentration-time data|Part C: Progression Free Survival (PFS) and Response Duration (RD) as evaluated by RECIST 1:1|Part C: PK parameter estimates of VX-803","https://ClinicalTrials.gov/show/NCT02278250"
1531,"NCT01820754","Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Ipilimumab|Drug: Paclitaxel, Cisplatin, Carboplatin","Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00038093","March 26, 2013","March 2013","March 2021","December 30, 2016","September 2016","No Study Results Posted","TOP1201 IPI","March 2018","Percentage of subjects with detectable circulating T cells after treatment|Feasibility and tolerability of neoadjuvant chemotherapy plus ipilimumab and surgery|Median Disease-Free Survival|Number of subjects experiencing a metastasis by site of metastasis|Patterns of pathologic response and response evaluation criteria in solid tumor (RECIST) response","https://ClinicalTrials.gov/show/NCT01820754"
1532,"NCT00227539","Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: cisplatin|Drug: pemetrexed disodium|Procedure: adjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: fludeoxyglucose F 18","University of Washington|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","6228|P30CA015704|UWCC-6228|UWCC-UW-6228|UW-04033|LILY-UW-04033|CDR0000441239","September 26, 2005","July 2005","November 2013","March 31, 2017","February 2017","February 14, 2017","null","March 2010","Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy|Safety of Neoadjuvant Chemotherapy|Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate","https://ClinicalTrials.gov/show/NCT00227539"
1533,"NCT02162537","Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases","Recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Non-small Cell Lung Cancer|Adenocarcinoma of Lung Metastatic to Brain|Cerebral Metastases","Drug: Cisplatin|Drug: Pemetrexed|Drug: Bevacizumab|Radiation: Cerebral Radiotherapy","Centre Hospitalier Intercommunal Creteil|Groupe Francais De Pneumo-Cancerologie","All","18 Years and older   (Adult, Senior)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","METAL 2","March 21, 2014","December 2013","January 2019","June 16, 2016","June 2016","No Study Results Posted","METAL2","May 2018","To compare the progression-free survival rate in both arms|Overall survival|Disease control rate (response + stability)|Toxicity|Quality of life assessment|Neurological assessment","https://ClinicalTrials.gov/show/NCT02162537"
1534,"NCT03067610","Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer|Carcinoma, Squamous Cell|Neoplasms, Oral|Neoplasms, Pharyngeal","Radiation: Intensity Modulated Radiation Therapy|Drug: chemotherapy","University of Texas Southwestern Medical Center","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","STU 052016-044","November 18, 2016","January 20, 2017","December 31, 2026","March 23, 2017","March 2017","No Study Results Posted","INFIELD","December 31, 2019","recurrence|patient-reported outcomes|toxicities|gastrostomy dependence|Patient utilities|overall survival|progression-free survival|patterns-of-failure","https://ClinicalTrials.gov/show/NCT03067610"
1535,"NCT00379717","Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: Cisplatinum|Drug: Docetaxel|Device: Tomotherapy","AZ-VUB|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VUB06-001|TomoCT","September 21, 2006","November 2006","April 2008","March 12, 2008","September 2006","No Study Results Posted","null","null","To evaluate the feasibility and toxicity of radiation dose escalation using helical tomotherapy concurrently with chemotherapy (docetaxel-cisplatin combination) in stage III locally advanced non small cell lung cancer (LA-NSCLC).|To estimate efficacy parameters in terms of overall response rate, progression free survival and overall survival. To monitor quality of life (QOL) before, during and after treatment.","https://ClinicalTrials.gov/show/NCT00379717"
1536,"NCT01797900","The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT","Completed","No Results Available","Nasopharyngeal Neoplasms","Drug: Cisplatin|Drug: Paclitaxel|Radiation: IMRT","Chinese Academy of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-HN-002","February 21, 2013","March 2013","September 2014","September 9, 2014","September 2014","No Study Results Posted","null","September 2014","Distant failure free survival|overall survival|acute treatment toxicity|late treatment toxicity|Local recurrence rate","https://ClinicalTrials.gov/show/NCT01797900"
1537,"NCT01084083","Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer","Completed","Has Results","Head and Neck Cancer|Precancerous Condition","Biological: cetuximab|Radiation: intensity-modulated radiation therapy (IMRT)|Drug: Paclitaxel|Drug: Cisplatin","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","90","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000665170|ECOG-E1308|U10CA023318","March 9, 2010","March 2010","January 2015","September 22, 2015","September 2015","August 17, 2015","null","January 2015","24-month Progression-free Survival|24-months Overall Survival|Primary Clinical Response Rate","https://ClinicalTrials.gov/show/NCT01084083"
1538,"NCT00046969","Epoetin Beta in Treating Anemia in Patients With Cervical Cancer","Completed","No Results Available","Anemia|Cervical Cancer","Biological: epoetin beta|Drug: cisplatin|Radiation: brachytherapy|Radiation: radiation therapy","AGO Study Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 4","450","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive Care","AGOSG-OVAR-MO16375-MARCH|CDR0000257189|EU-20217|ROCHE-MO16375|ROCHE-RO2053859","October 3, 2002","July 2002","June 2007","May 29, 2013","March 2007","No Study Results Posted","null","null","Number of treatment failures within 6 months after beginning radiochemotherapy (RCT) (stage I)|Overall survival after RCT (stage II)|Progression/relapse-free survival|Overall response rate to RCT|Overall survival after RCT (stage I)|Frequency and localization of relapses and/or metastases|Change in hemoglobin from baseline during therapy|Quality of life as assessed by the Functional Assessment of Cancer Therapy-Anemia|Type, frequency, and degree of adverse events|Safety|Vital signs|Number of treatment failures within 6 months after beginning RCT (stage II)","https://ClinicalTrials.gov/show/NCT00046969"
1539,"NCT02651441","D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)","Recruiting","No Results Available","Lung Cancer|Non-small Cell Lung Cancer","Drug: Gemcitabine|Drug: Cisplatin|Biological: D-CIK","Shenzhen Hornetcorn Bio-technology Company, LTD|Affiliated Tumor Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HYK-NSCLC","January 5, 2016","February 2016","August 2019","May 23, 2016","January 2016","No Study Results Posted","null","May 2019","Progress-free survival|Overall survival|Quality of life (QOL)|Phenotypic analysis of T cells|Severity of adverse events","https://ClinicalTrials.gov/show/NCT02651441"
1540,"NCT00003596","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","Completed","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Southwest Oncology Group|North Central Cancer Treatment Group","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","682","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-9811|CDR0000066667|CALGB-89808|ECOG-R9811|NCCTG-R9811|SWOG-R9811|GUMC-00125","November 1, 1999","October 1998","December 2016","December 30, 2016","December 2016","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00003596"
1541,"NCT01479504","A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: nedaplatin and docetaxel|Drug: cisplatin and docetaxel|Drug: nedaplatin and docetaxel|Drug: cisplatin and docetaxel","Guangxi Medical University|People's Hospital of Guangxi|303rd Hospital of the People's Liberation Army|Nanning Second People's Hospital|Guangxi Traditional Chinese Medical University|Guilin Medical College|Guangxi Naxishan Hospital|Liuzhou Worker's Hospital|Liuzhou People's Hospital|Liuzhou Hospital of Traditional Chinese Medicine|Liuzhou Cancer Hospital|Liuzhou Railway hospital|First People's Hospital of Yulin|The Red Cross hospital of YuLin|Guigang People's Hospital|The Red Cross hospital of Wuzhou","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GuangxiMU","November 16, 2011","November 2011","December 2017","November 24, 2011","October 2011","No Study Results Posted","null","November 2012","complete response (CR) rate|Acute toxicities|Overall Survival|cost-effectiveness ratio","https://ClinicalTrials.gov/show/NCT01479504"
1542,"NCT03040999","Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","Recruiting","No Results Available","Head and Neck Neoplasms","Biological: Pembrolizumab|Drug: Placebo|Drug: Cisplatin|Radiation: Accelerated Fractionation (AFX) Radiotherapy|Radiation: Standard Fractionation (SFX) Radiotherapy","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","780","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","3475-412|2016-003934-25|MK-3475-412","February 1, 2017","April 5, 2017","April 16, 2021","May 18, 2017","May 2017","No Study Results Posted","null","April 16, 2021","Event-free Survival (EFS)|Overall Survival (OS)|Incidence of Adverse Events (AEs)|Incidence of Discontinuations|Global Health Status/Quality of Life (GHS/QoL)|Swallowing, Speech, and Pain Symptoms","https://ClinicalTrials.gov/show/NCT03040999"
1543,"NCT01648023","Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin","Recruiting","No Results Available","Unresectable Intrahepatic Cholangiocarcinoma","Device: LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|Drug: Gem-Cis or Gem-Carbo","Robert C. Martin|University of Louisville","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","11-0181","July 17, 2012","July 2012","July 2020","April 18, 2017","August 2016","No Study Results Posted","DELTIC","July 2020","Tumor response according to modified RECIST Criteria|Hepatic Progression Free Survival","https://ClinicalTrials.gov/show/NCT01648023"
1544,"NCT00043927","Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults","Completed","No Results Available","Small Cell Lung Cancer","Drug: topotecan/cisplatin|Drug: etoposide/cisplatin","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","104864-A/389","August 14, 2002","April 2001","null","August 20, 2013","August 2013","No Study Results Posted","null","January 2004","Overall Survival|response rates, response duration, time to progression, tolerability and patient-perceived disease status and well being for patients","https://ClinicalTrials.gov/show/NCT00043927"
1545,"NCT01711515","Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer","Active, not recruiting","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Positive Para-Aortic Lymph Node|Positive Pelvic Lymph Node|Stage IB2 Cervical Cancer|Stage II Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage IIIB Cervical Cancer|Stage IVA Cervical Cancer","Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Internal Radiation Therapy|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","34","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-01733|GOG-9929|GOG-PIS1102|U10CA180868|U10CA027469","October 18, 2012","October 1, 2012","null","May 23, 2017","April 2017","No Study Results Posted","null","March 9, 2017","DLTs occurring during adjuvant ipilimumab in the dose escalation phase|DLTs occurring in the feasibility phase|Toxicities as assessed by CTCAE version 4|Chronic toxicities experienced within one year of completion of therapy|Location of recurrence (loco-regional versus distant)|Overall survival|Progression-free survival (PFS)|Response rate in patients enrolled with measurable disease assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","https://ClinicalTrials.gov/show/NCT01711515"
1546,"NCT00078949","Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","Active, not recruiting","Has Results","Lymphoma","Biological: rituximab|Drug: cisplatin|Drug: cytarabine|Drug: dexamethasone|Drug: gemcitabine hydrochloride","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","16 Years to 65 Years   (Child, Adult)","Phase 3","619","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","LY12|CAN-NCIC-LY12|CDR0000353203","March 8, 2004","August 2003","December 2017","January 23, 2017","January 2016","September 17, 2014","null","May 2013","Response Rate of Patients After 2 Courses of Chemotherapy|Transplantation Rate of Patients After 2 Courses of Chemotherapy|Event-free Survival of Patients on Maintenance Randomization (Period 2)|Mobilization Rate of Patients on Treatment Arm I Assessed by CD34 Count After 2 Courses of Therapy and Stem Cell Harvesting|Toxicity Assessed by NCI CTC v2.0 for 2 Years in Patients on Treatment Arm II","https://ClinicalTrials.gov/show/NCT00078949"
1547,"NCT02177838","Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer","Recruiting","No Results Available","Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Tongue Cancer","Biological: cetuximab|Drug: cisplatin|Radiation: external beam radiation therapy|Other: laboratory biomarker analysis","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","All","18 Years and older   (Adult, Senior)","","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","031204|NCI-2014-01303|P30CA072720","June 26, 2014","May 2015","June 2020","January 19, 2017","January 2017","No Study Results Posted","null","June 2020","Locoregional control in cetuximab responders|Percent of patients who progress during neoadjuvant cetuximab by CT RECIST 1.1 criteria|Locoregional control for non-responders to neoadjuvant cetuximab","https://ClinicalTrials.gov/show/NCT02177838"
1548,"NCT02243436","Evaluation Study of Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory HL","Active, not recruiting","No Results Available","CLASSICAL HODGKIN LYMPHOMA","Drug: Brentuximab Vedotin|Drug: Etoposide|Drug: Soludomerin|Drug: Cisplatin|Drug: Ara C","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","67","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRESHAP-GELTAMO.LH-2013|2014-000835-17","August 27, 2014","November 2014","August 2018","January 8, 2017","January 2017","No Study Results Posted","null","August 2018","Phase I: Recommended dose|Phase II: Global response rate prior to ASCT.|Phase II: Complete response rate.|Toxicity according to the CTC criteria|Stem cell mobilization capacity|Transplant-related mortality (TRM)|overall survival (OS)|progression free survival (PFS)|Event-Free Survival|Time to HL Progression|Disease-Free Survival|Response Duration|Lymphoma-Specific Survival|Time to Next Treatment","https://ClinicalTrials.gov/show/NCT02243436"
1549,"NCT00003945","Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: topotecan hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Female","18 Years and older   (Adult, Senior)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067138|GOG-0179|ECOG-G0179","November 1, 1999","June 1999","null","May 24, 2013","September 2004","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00003945"
1550,"NCT01530997","De-intensification of Radiation and Chemotherapy for Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms","Radiation: Intensity Modulated Radiotherapy (IMRT)|Drug: Cisplatin|Procedure: Limited surgical evaluation","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 1120","January 20, 2012","November 2011","January 2017","July 1, 2016","May 2016","No Study Results Posted","null","November 2014","Complete pathological response rate after de-escalated CRT in HPV-positive and/or p16 positive OPSCC.|Local control rate|Regional control rate|Local-regional control rate|Cause-specific survival rate|Overall survival rate|Head and neck quality of life assessments|Speech and swallowing function","https://ClinicalTrials.gov/show/NCT01530997"
1551,"NCT00592501","Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma","Radiation: Proton/Photon Radiotherapy|Drug: Cisplatin|Drug: Fluorouracil","Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","05-089","December 28, 2007","October 2006","December 2019","April 17, 2017","April 2017","No Study Results Posted","null","December 2019","Acute Toxicity|Health related quality-of-life outcomes using objective measurements and validated quality-of-life instruments.|Treatment Compliance|Rate and pattern of locoregional tumor recurrence","https://ClinicalTrials.gov/show/NCT00592501"
1552,"NCT02878889","A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: S-1","Zhejiang Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-16-01","August 15, 2016","August 2016","null","January 10, 2017","January 2017","No Study Results Posted","null","June 2019","Objective response rate","https://ClinicalTrials.gov/show/NCT02878889"
1553,"NCT00002608","Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors","Completed","No Results Available","Adrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy","Ottawa Regional Cancer Centre|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CAN-OTT-9401|CDR0000063892|NCI-V94-0566","November 1, 1999","May 1994","April 2005","July 9, 2013","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002608"
1554,"NCT02088515","Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma","Completed","No Results Available","Squamous Cell Carcinoma","Drug: Nedaplatin|Drug: Cisplatin|Drug: Docetaxel","Jiangsu Simcere Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","5501068","March 6, 2014","December 2013","February 2017","March 2, 2017","April 2016","No Study Results Posted","null","October 2016","progress free survival|Objective Response Rate","https://ClinicalTrials.gov/show/NCT02088515"
1555,"NCT00577707","Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)","Completed","Has Results","Non Small Cell Lung Cancer|Lung Cancer","Drug: pemetrexed, cisplatin and erlotinib before surgery then erlotinib is given to patients after surgery for 2 years","Memorial Sloan Kettering Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-103","December 18, 2007","November 2007","December 2011","October 19, 2015","October 2015","October 19, 2015","null","December 2011","To Determine the Pathologic Complete Response Rate for Patients With Stage IB-IIIA NSCLC With Tumors That Harbor an EGFR Mutation Treated With Neoadjuvant Chemotherapy + Erlotinib|To Determine the Response Rate After 21 Days of Single Agent Erlotinib for Stage IB-IIIA NSCLC With a Known EGFR Mutation.|To Determine the Response Rate, 3-year Overall Survival and Median Survival of Patients With Stage IB-IIIA NSCLC With a Known EGFR Mutation Receiving Neoadjuvant Chemotherapy and Erlotinib (and Adjuvant Erlotinib).","https://ClinicalTrials.gov/show/NCT00577707"
1556,"NCT02328716","Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma","Unknown status","No Results Available","Peritoneal Carcinomatosis From Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma","Procedure: Cytoreduction|Drug: Hipec with Cisplatin","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)","EC-GC/AD-01/11|2011-001715-31","December 5, 2014","February 2012","June 2015","March 11, 2015","March 2015","No Study Results Posted","CARCINOHIPEC","September 2014","disease-free survival period|Evaluation of overall survival.|Study of morbidity.|Evaluation of quality of life related to the procedure.|Study of Ex vivo correlation.","https://ClinicalTrials.gov/show/NCT02328716"
1557,"NCT00817258","Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: cisplatin|Radiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-0701","January 2, 2009","January 2007","December 2009","January 5, 2009","January 2009","No Study Results Posted","null","June 2009","overall survival|disease-free survival, and distant metastases free survival","https://ClinicalTrials.gov/show/NCT00817258"
1558,"NCT00002670","Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery","Completed","No Results Available","Head and Neck Cancer","Drug: chemotherapy|Drug: cisplatin|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","459","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9501|CDR0000064279|E-R9501|SWOG-9515","November 1, 1999","September 1995","November 2013","January 23, 2014","January 2014","No Study Results Posted","null","July 2002","","https://ClinicalTrials.gov/show/NCT00002670"
1559,"NCT01859741","A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)","Active, not recruiting","No Results Available","Stage IV Small Cell Lung Cancer","Drug: OMP-59R5|Drug: Etoposide|Drug: Placebo|Drug: Cisplatin or Carboplatin","OncoMed Pharmaceuticals, Inc.","All","18 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","59R5-003","May 16, 2013","May 2013","April 2018","September 16, 2016","September 2015","No Study Results Posted","PINNACLE","August 2017","Dose limiting toxicities (DLT) of OMP-59R5 in combination with Etoposide and Cisplatin|Progression-free survival|PK of OMP-59R5 when given in combination with Etoposide and Cisplatin.|Overall survival, 12 month OS and overall response rate|Number of participants with adverse events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT01859741"
1560,"NCT02092298","Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer","Active, not recruiting","No Results Available","Gastrointestinal Cancer","Drug: Mitomycin C|Drug: Cisplatin|Drug: Sodium Thiosulfate","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-0989|NCI-2014-01105","March 18, 2014","May 2014","null","January 9, 2017","January 2017","No Study Results Posted","null","May 2019","Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy|Safety of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy","https://ClinicalTrials.gov/show/NCT02092298"
1561,"NCT00887549","A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13069|H3E-BP-JMIK","April 23, 2009","April 2009","June 2011","June 7, 2012","June 2012","July 29, 2011","null","July 2010","Progression Free Survival (PFS)|Percentage of Participants With Tumor Response (Tumor Response Rate)|Percentage of Participants With Concordance Between Local and Central Histological Diagnosis|Percentage of Participants Surviving at 18 Months (Overall Survival Rate)","https://ClinicalTrials.gov/show/NCT00887549"
1562,"NCT00023660","Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: celecoxib|Drug: cisplatin|Drug: fluorouracil|Radiation: brachytherapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Female","18 Years to 85 Years   (Adult, Senior)","Phase 1|Phase 2","84","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-C-0128|CDR0000068849","September 13, 2001","August 2001","null","November 18, 2013","November 2013","No Study Results Posted","null","January 2005","","https://ClinicalTrials.gov/show/NCT00023660"
1563,"NCT00387868","Preoperative Treatment of Patients With High Risk Thymoma","Completed","No Results Available","Thymoma","Drug: cisplatin and etoposide|Procedure: Surgical Resection|Radiation: Concurrent Radiotherapy","Valley Health System","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VHS07.0006a","October 11, 2006","October 2006","November 2014","December 8, 2014","December 2014","No Study Results Posted","null","October 2014","To determine the complete pathologic response rate to peroperative cisplatin and etoposide given concurrently with radiation in patients with thymoma thought to be at high risk for recurrence|Radiographic response to preoperative chemoradiotherapy by comparing pre and post treatment CT scans.|Rate of complete resection following preoperative chemoradiotherapy as determined by pathologic examination of the specimen(s).|Toxicities throughout the study treatment.|The role of PET in predicting resectability, Masaoka stage and histologic type, as well as the response to preoperative chemoradiotherapy by comparing pre and post treatment PET scans|Immunohistochemical assessment of relevant markers before and after chemoradiation (EGFR, p53,and Ki-67).|Blood-based correlative studies: genetic polymorphisms (EGFR, DNA repair, inflammatory gene pathways) and serologic analysis (EGFR, VEGF, bFGF, pro-MMP2 levels)|Recurrence rates and failure patterns following the treatment regimen.","https://ClinicalTrials.gov/show/NCT00387868"
1564,"NCT02985658","Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer","Available","No Results Available","Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation|Triple-Negative Breast Cancer","Drug: Veliparib|Drug: Cisplatin|Drug: Vinorelbine","University of Washington|AbbVie","Female","18 Years and older   (Adult, Senior)","","null","Other|Industry","Expanded Access","","9763","December 5, 2016","null","null","December 29, 2016","December 2016","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT02985658"
1565,"NCT00566540","Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Cisplatin|Drug: Paclitaxel|Radiation: Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Procedure: Triple endoscopy and biopsy","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-06026|NCI-2011-02687","November 30, 2007","December 2007","null","October 20, 2016","October 2016","No Study Results Posted","null","February 2010","Feasibility of treatment|Disease-free interval and failure sites|Correlation of molecular markers with treatment outcome|Correlation of quality of life with treatment outcome|Frequency and severity of toxicities|Treatment completion","https://ClinicalTrials.gov/show/NCT00566540"
1566,"NCT01123473","Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer","Terminated","No Results Available","Adenocarcinoma of the Gastroesophageal Junction|Gastric Cancer","Drug: capecitabine|Drug: cisplatin|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: lapatinib ditosylate","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","EORTC-40071|EU-21036|2009-011580-36","May 13, 2010","December 2010","September 2014","October 11, 2016","October 2016","No Study Results Posted","null","August 2013","Progression-free survival|Response rate|Overall survival|Toxicity|Concordance of diagnostic tests","https://ClinicalTrials.gov/show/NCT01123473"
1567,"NCT02268695","Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Cisplatin|Drug: 5-Fluorouracile|Drug: Docetaxel|Drug: Cetuximab|Drug: granulocyte colony-stimulating factor (G-CSF)","Groupe Oncologie Radiotherapie Tete et Cou|Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|AIO-Studien-gGmbH","All","18 Years to 71 Years   (Adult, Senior)","Phase 2","416","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GORTEC 2014-01","October 13, 2014","October 2014","December 2017","February 23, 2017","February 2017","No Study Results Posted","TPExtreme","December 2017","Overall survival|Objective response rate|Best overall tumor response rate|Progression free survival|Time to Progression|Toxicity|Compliance|EORTC QLQ-C30|EuroQol-5D|Net monetary benefit","https://ClinicalTrials.gov/show/NCT02268695"
1568,"NCT02285413","Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients","Completed","No Results Available","Melanoma","Biological: DC vaccination|Biological: DC vaccination with cisplatinum","Radboud University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NL32381.000.10","May 11, 2013","February 2011","April 2016","May 3, 2016","May 2016","No Study Results Posted","null","October 2015","Immunogenicity: number of participants with KLH and/or tumor-specific antigens immune responses.|Feasibility: % of vaccines meeting the release criteria.|Toxicity: number of Participants with Adverse Events.|Progression-free survival|Overall survival|Best objective response (only in stage IV)","https://ClinicalTrials.gov/show/NCT02285413"
1569,"NCT00349219","TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: erlotinib|Drug: cisplatin|Drug: gemcitabine|Drug: cisplatin|Drug: gemcitabine|Drug: erlotinib","National Cancer Institute, Naples|San Giuseppe Moscati Hospital|Princess Margaret Hospital, Canada|University of Alberta|Second University of Naples","All","18 Years and older   (Adult, Senior)","Phase 3","760","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TORCH|2005-005968-90","July 4, 2006","December 2006","June 2012","January 14, 2016","January 2016","No Study Results Posted","TORCH","December 2011","overall survival|progression free rate of first-line treatment with erlotinib|toxicity|progression-free survival|quality of life during the first-line therapy|prognostic biologic indicators|resource utilization|response rate","https://ClinicalTrials.gov/show/NCT00349219"
1570,"NCT00154687","Weekly TP-HDFL in the Treatment of Advanced TCC","Completed","No Results Available","Transitional Cell Carcinoma","Drug: Paclitaxel, Cisplatin, 5-Fluorouracil","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","159I3","September 8, 2005","October 2000","December 2004","July 30, 2007","July 2005","No Study Results Posted","null","null","response rate|Overall Survival ,Safety","https://ClinicalTrials.gov/show/NCT00154687"
1571,"NCT02795884","Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation","Withdrawn","No Results Available","NSCLC","Drug: intercalation therapy using pemetrexed, cisplatin and erlotinib|Drug: Vinorelbine, cisplatin","Yonsei University","All","19 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2015-0926","February 24, 2016","June 2016","November 2020","December 29, 2016","December 2016","No Study Results Posted","null","November 2020","Disease-free survival (DFS)|Overall survival (OS)|Treatment-related adverse events assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02795884"
1572,"NCT01291095","Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma","Unknown status","No Results Available","HEAD AND NECK CANCER","Drug: CISPLATIN|Radiation: EXTERNAL BEAM RADIOTHERAPY","All India Institute of Medical Sciences, New Delhi","All","20 Years to 60 Years   (Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RCTOFAFRTVSCRTINHNSCCAIIMS","February 7, 2011","February 2011","December 2012","March 3, 2011","March 2011","No Study Results Posted","null","July 2012","TO COMPARE THE LOCO-REGIONAL TUMOR CONTROL RATE BETWEEN AFRT & CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS.|TO COMPARE THE TOXICITY BETWEEN AFRT AND CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS|TO COMPARE POST-THERAPY QUALITY OF LIFE BETWEEN AFRT AND CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA.","https://ClinicalTrials.gov/show/NCT01291095"
1573,"NCT00006237","S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma","Completed","Has Results","Melanoma (Skin)","Biological: interleukin-2|Biological: filgrastim|Biological: interferon alfa|Drug: cisplatin|Drug: dacarbazine|Drug: vinblastine","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Children's Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","432","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S0008|U10CA032102|CALGB-500002|ECOG-S0008|COG-S0008","September 11, 2000","August 2000","July 2012","March 5, 2015","March 2015","August 20, 2012","null","July 2012","5-year Overall Survival|5-year Relapse-Free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00006237"
1574,"NCT02983097","Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP","Terminated","No Results Available","Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma Grade III (FL III°)|Mantle Cell Lymphoma (MCL), Blastoid Variant|Burkitt Lymphoma (BL)|Aggressive Marginal Zone Lymphoma (MZL)","Drug: Rituximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Dexamethasone|Drug: Cytarabine|Drug: Lenalidomide|Drug: PegFilgrastim|Procedure: peripheral stem cell collection","Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Celgene|Amgen","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DSHNHL 2008 R6|2009-010824-25","November 14, 2013","November 2010","February 2017","December 1, 2016","December 2016","No Study Results Posted","R²-DHAP","January 2014","Overall Response Rate (ORR)|Maximum tolerated dose (MTD)|Rate of complete remission|Rate of primary progression|Rate of treatment related deaths|Relapse Rate|Overall Survival|Progression free survival|tumour control|feasibility of stem cell mobilization|incidence of non-hematological toxicities > grade 2 CTC|incidence and duration of neutropenia and thrombopenia grade 4","https://ClinicalTrials.gov/show/NCT02983097"
1575,"NCT01784549","Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Azienda Sanitaria Locale di Cagliari|Azienda Ospedaliera San Gerardo di Monza|Ospedale Santa Croce-Carle Cuneo|Azienda Ospedaliera S. Maria della Misericordia|Istituto Tumori Giovanni Paolo II, BARI|Azienda Ospedaliera dei Colli|Azienda Ospedaliera Santa Maria Degli Angeli|Azienda Ospedaliera San Camillo Forlanini|Azienda Ospedaliera San Giovanni Battista|Azienda Ospedaliera Universitaria Integrata Verona|Azienda Sanitaria Locale n.2 Savonese|ASL TO4, Chivasso|Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento|Istituto Clinico Humanitas|Azienda Ospedaliera Sant'Andrea, Roma|Azienda Ospedaliera, Ospedale Civile di Legnano|Azienda Ospedaliera Spedali Riuniti di Livorno, Livorno","All","18 Years and older   (Adult, Senior)","Phase 2","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CONTEST TRIAL RF-2009-1530324|2011-005267-24","February 2, 2013","July 2012","December 2015","November 23, 2014","November 2014","No Study Results Posted","CONTEST","October 2015","Pathologic Complete Response|Overall Survival (OS)|Disease-Free Survival (DFS)|Overall Response (OR)","https://ClinicalTrials.gov/show/NCT01784549"
1576,"NCT00455936","First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker","Completed","No Results Available","Lung Cancer","Drug: Gefitinib|Procedure: chemotherapy","National Cancer Center, Korea|AstraZeneca","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","315","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-05-126|D7913L00054","April 3, 2007","October 2005","March 2010","October 22, 2010","March 2010","No Study Results Posted","null","November 2009","overall survival|To compare Progression-Free survival|To compare the quality of life|To compare safety profile|To collect the tissue samples for the study of predictors of gefitinib (optional)|To compare the objective response rate (CR+PR)","https://ClinicalTrials.gov/show/NCT00455936"
1577,"NCT00462397","Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Procedure: neoadjuvant therapy|Radiation: brachytherapy|Radiation: radiation therapy","University College London Hospitals|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000540233|UCLCTC-BRD/05/22-CERVIX|EUDRACT-2005-000134-20|CRUK-BRD/05/22|EU-20720|UCLCTC-CERVIX","April 18, 2007","June 2005","null","August 23, 2013","April 2007","No Study Results Posted","null","null","Response rate at the end of chemoradiotherapy (i.e., 12 weeks after completion of study therapy)|Response rate at the end of neoadjuvant treatment (i.e., 6 weeks after study entry)|Toxicity as assessed by NCI CTCAE v3.0|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00462397"
1578,"NCT00758381","Metastatic Advanced Pancreas Sorafenib","Unknown status","No Results Available","Locally Advanced Pancreatic Cancer","Drug: Sorafenib 400 mg po bid, continuously|Drug: Gemcitabina, Cisplatino","Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Mario Negri Institute for Pharmacological Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-001781-32","September 22, 2008","August 2007","August 2009","October 9, 2008","October 2008","No Study Results Posted","MAPS","August 2008","Progression Free Survival|- overall Response Rate (RECIST Criteria) - duration of response - overall survival time","https://ClinicalTrials.gov/show/NCT00758381"
1579,"NCT01683864","Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer","Recruiting","No Results Available","Gastric Cancer|Peritoneal Carcinomatosis","Drug: HIPEC with mytomycin and cisplatin|Procedure: Diagnostic laparoscopy one year after gastrectomy","PD Dr. Derek Zieker|University Hospital Tuebingen","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-004405-25","September 6, 2012","September 2012","September 2020","September 11, 2012","September 2012","No Study Results Posted","HIPEC_Stomach","September 2012","Peritoneal carcinosis free survival|Disease free Survival","https://ClinicalTrials.gov/show/NCT01683864"
1580,"NCT02281955","De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study","Recruiting","No Results Available","Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms","Radiation: Intensity Modulated Radiotherapy (IMRT)|Drug: Cisplatin (or alternative)|Procedure: Assessment for surgical evaluation","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC1413","October 3, 2014","August 2014","July 2018","January 30, 2017","January 2017","No Study Results Posted","null","July 2017","2 year Progression Free Survival after de-intensified CRT in HPV-positive and/or p16 positive low-risk OPSCC|Local control rate|Regional control rate|Local-regional control rate|Distant metastasis free survival|Overall survival rate|Head and neck quality of life assessments|Speech and swallowing function","https://ClinicalTrials.gov/show/NCT02281955"
1581,"NCT00003251","Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer","Unknown status","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Head and Neck Cancer|Radiation Toxicity","Drug: amifostine trihydrate|Drug: cisplatin|Drug: paclitaxel|Radiation: radiation therapy","University of Illinois at Chicago|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","46","Other","Interventional","Primary Purpose: Supportive Care","CDR0000066133|UIC-H-97-783|ALZA-UIC-H-97-783|NCI-V98-1389","November 1, 1999","December 1997","null","December 3, 2013","June 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003251"
1582,"NCT00011999","Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: conventional surgery|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","21 Years and older   (Adult, Senior)","Phase 2","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-H-0024|CDR0000068469","March 3, 2001","March 2001","June 2010","November 14, 2015","November 2015","No Study Results Posted","null","February 2004","Patient tolerance of the treatment regimen|Frequency of grade 5 and acute non-hematologic grade 4 toxicity|Frequency of other acute and late toxicity|Local-regional control|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00011999"
1583,"NCT01019798","Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: sunitinib, docetaxel, cisplatin","Taipei Medical University Hospital|Pfizer|TTY Biopharm","All","18 Years to 59 Years   (Adult)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRC-01-08-03","November 24, 2009","January 2009","December 2011","November 24, 2009","November 2009","No Study Results Posted","null","December 2010","response rate by RECIST criteria|Time to disease progression at the end of study|Duration of survival|Safety profile: cardiac toxicity assessed in accordance with National Cancer Institute Common Toxicity Criteria. NCI-CTCAE criteria (version 3.0) will be used.","https://ClinicalTrials.gov/show/NCT01019798"
1584,"NCT00014534","Combination Chemotherapy in Treating Patients With Bladder Cancer","Completed","No Results Available","Bladder Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-90104|P30CA008748|MSKCC-00138|NCI-G01-1935|CDR0000068554","April 10, 2001","March 2004","April 2009","July 12, 2016","July 2016","No Study Results Posted","null","July 2005","Overall survival","https://ClinicalTrials.gov/show/NCT00014534"
1585,"NCT00910117","Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","Completed","No Results Available","Head and Neck Cancer","Drug: nimotuzumab|Drug: PF regimen (cisplatin and 5-FU)","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HNTG 09-01","May 28, 2009","May 2009","December 2011","February 16, 2012","February 2012","No Study Results Posted","null","December 2011","overall response rate|pathologic complete response","https://ClinicalTrials.gov/show/NCT00910117"
1586,"NCT00665392","Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: Cetuximab","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000593027|GERCOR-ECHO-07-1|EUDRACT 2007-002116-25|EU-20838|MERCK-GERCOR-ECHO-07-1","April 22, 2008","February 2008","July 2012","August 21, 2012","August 2012","No Study Results Posted","null","July 2012","Complete clinical response rate at 3 months|Rate of response (partial and complete response and stable disease)|Progression-free survival|Overall survival|Pathologic response|Tolerability","https://ClinicalTrials.gov/show/NCT00665392"
1587,"NCT00014313","Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor","Terminated","No Results Available","Sarcoma","Drug: cisplatin|Drug: etoposide","European Organisation for Research and Treatment of Cancer - EORTC","All","15 Years to 65 Years   (Child, Adult)","Phase 2","3","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-62993","April 10, 2001","January 2001","null","September 20, 2012","September 2012","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00014313"
1588,"NCT00589056","Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","Active, not recruiting","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: nelfinavir mesylate|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy|Radiation: radiation therapy","Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","55","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000582319|UPCC-806285|UPCC-04507","December 25, 2007","June 2007","null","September 23, 2016","September 2016","No Study Results Posted","null","March 2012","Dose-limiting toxicity as measured by NCI Common Toxicity Criteria|Maximum tolerated dose and recommended phase II dose of nelfinavir mesylate|Response at 3 months after completion of treatment as measured by RECIST criteria|Overall survival|Expression of molecular markers (total Akt and p-Akt) in primary tumor or pathologic lymph nodes and in peripheral blood lymphocytes","https://ClinicalTrials.gov/show/NCT00589056"
1589,"NCT00292695","A Phase II Study of Nasal NK/T-cell Lymphoma","Completed","No Results Available","Lymphoma","Other: VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT","National Health Research Institutes, Taiwan|Mackay Memorial Hospital|National Cheng-Kung University Hospital|Taichung Veterans General Hospital|Taipei Veterans General Hospital, Taiwan|Kaohsiung Veterans General Hospital.|National Taiwan University Hospital|Tri-Service General Hospital|Chi Mei Medical Hospital|Kaohsiung Medical University|Changhua Christian Hospital|Buddhist Tzu Chi General Hospital","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T1405","February 15, 2006","May 2006","December 2010","October 28, 2013","October 2013","No Study Results Posted","null","December 2009","tumor response by CT scan or MRI|EBV DNA level, AEs, Withdrawal from the study treatment","https://ClinicalTrials.gov/show/NCT00292695"
1590,"NCT01015339","Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","Unknown status","No Results Available","Advanced Gastric Cancer","Drug: Paclitaxel|Drug: capecitabine|Drug: capecitabine|Drug: cisplatin","Peking University|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 3","320","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PAC-C|ML22697","November 17, 2009","November 2009","August 2015","May 17, 2015","May 2015","No Study Results Posted","null","August 2015","Progression free survival|Tumor response rate|Disease control rate|Overall survival|adverse evens","https://ClinicalTrials.gov/show/NCT01015339"
1591,"NCT00005601","Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cisplatin|Drug: cytarabine|Drug: dexamethasone|Drug: sargramostim","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","58","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N9981|NCI-2012-02326|CDR0000067714","May 2, 2000","October 2000","February 2008","December 5, 2016","December 2016","No Study Results Posted","null","July 2003","response|percentage of patients able to proceed to transplant after two courses of this treatment regimen|duration of response|overall survival","https://ClinicalTrials.gov/show/NCT00005601"
1592,"NCT00516750","Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin","Terminated","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vinblastine|Genetic: gene expression profiling|Procedure: neoadjuvant therapy","Kyoto University|National Cancer Institute (NCI)","All","20 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","TRIC-UHA-GU-03-01|CDR0000561303","August 14, 2007","July 2007","February 2009","July 9, 2013","March 2008","No Study Results Posted","null","February 2009","Detection of genes associated with sensitivity to the chemotherapy in tumor size reduction of original bladder tumor|Safety|Overall survival rate|Size reduction of metastatic lesion","https://ClinicalTrials.gov/show/NCT00516750"
1593,"NCT00017173","S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat","Terminated","No Results Available","Head and Neck Cancer","Biological: Ad5CMV-p53 gene|Drug: cisplatin|Procedure: conventional surgery|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068658|U10CA032102|S0011","June 6, 2001","February 2003","July 2011","June 12, 2012","June 2012","No Study Results Posted","null","May 2007","Feasibility|Progression-free survival from time of registration until disease progression","https://ClinicalTrials.gov/show/NCT00017173"
1594,"NCT00737438","Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma","Completed","Has Results","Esophageal Cancer|Gastric Cancer","Drug: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Weill Medical College of Cornell University","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-081","August 15, 2008","August 2008","February 2015","January 4, 2016","January 2016","January 4, 2016","null","February 2015","Overall Response Will be Characterized by the Patient's FDG-PET Scan","https://ClinicalTrials.gov/show/NCT00737438"
1595,"NCT02497118","Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Endostatin|Drug: Vinorelbine|Drug: Cisplatin","Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TMUCIH-ENDU-S001","July 5, 2015","August 2010","June 2015","July 13, 2015","May 2014","No Study Results Posted","null","April 2015","Tumor Regression Rate|Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.|Overall Survival|Clinical Benefit Rate","https://ClinicalTrials.gov/show/NCT02497118"
1596,"NCT00400114","Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: Irinotecan|Drug: Cisplatin|Procedure: Radiation|Procedure: Surgery|Drug: sunitinib (Sutent)","University Health Network, Toronto|Pfizer","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","06-0407-C","November 15, 2006","September 25, 2006","September 19, 2016","May 3, 2017","May 2017","No Study Results Posted","null","September 19, 2016","To determine the feasibility and efficacy of adjuvant Sutent therapy after concurrent neoadjuvant therapy with Irinotecan, Cisplatin, external beam conformal radiotherapy plus surgery for potentially resectable esophageal cancer.|To assess the impact of adjuvant targeted therapy with Sutent after multimodality therapy for resected esophageal cancer stage II to III, and to compare these data to our current completed trial in the same patient population|To characterize toxicity of targeted adjuvant therapy with Sutent after multimodality therapy for resected esophageal cancer stage II to III|To measure time-to-event efficacy variables including: Time to treatment failure and Time to progressive disease|Survival of patients with esophageal cancer stage II to III with adjuvant targeted therapy added to multimodality treatment protocol|To determine the pattern of relapse (local versus distant) with the addition of adjuvant targeted therapy to esophageal cancer multimodality therapy","https://ClinicalTrials.gov/show/NCT00400114"
1597,"NCT00352118","Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","Terminated","Has Results","Head and Neck Cancer","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Procedure: conventional surgery|Radiation: radiation therapy","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005LS012|UMN-0502M67486","July 13, 2006","March 2006","April 2008","November 6, 2012","November 2012","June 2, 2009","null","April 2008","Number of Patients With Feeding Tube Dependency|Number of Days With Progression-free Survival|Number of Days - Overall Survival|Number of Days With Disease Free Survival|Time to Treatment Failure|Swallowing Ability - Quality of Life Scores|Quality of Life (QOL) by Functional Assessment of Cancer Therapy-H&N QOL Questionnaire","https://ClinicalTrials.gov/show/NCT00352118"
1598,"NCT01101451","Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery","Recruiting","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IA Cervical Cancer|Stage IB Cervical Cancer|Stage IIA Cervical Cancer","Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","534","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GOG-0263|NCI-2011-02037|CDR0000670125|U10CA180868|U10CA027469","April 9, 2010","April 2010","null","May 2, 2017","May 2017","No Study Results Posted","null","December 2020","RFS|Incidence of adverse events graded according to the active version of CTCAE|Local control|OS|Patient risk-benefit|Quality of life, assessed using the FACT-Cx TOI, FACT-GOG/neurotoxicity 4 subscale, and the Brief Pain Inventory (BPI)|Site(s) of recurrence|Treatment compliance","https://ClinicalTrials.gov/show/NCT01101451"
1599,"NCT01345084","Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab","Withdrawn","No Results Available","Carcinoma|Head and Neck Cancer","Radiation: Radiation Therapy|Drug: Nimotuzumab|Drug: Cisplatin","Eurofarma Laboratorios S.A.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EF 118","April 28, 2011","November 2013","November 2017","July 24, 2015","August 2013","No Study Results Posted","NICAP","November 2013","Overall survival|Complete clinical response rate","https://ClinicalTrials.gov/show/NCT01345084"
1600,"NCT00003691","Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: paclitaxel","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","240","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066794|GOG-0177","November 1, 1999","December 1998","null","July 8, 2013","September 2010","No Study Results Posted","null","June 2004","","https://ClinicalTrials.gov/show/NCT00003691"
1601,"NCT00871403","Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer","Completed","Has Results","Lung Cancer, Non-Small Cell","Drug: pazopanib and pemetrexed|Drug: pemetrexed and cisplatin","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","111128","March 26, 2009","July 2009","March 2011","June 12, 2013","March 2012","January 26, 2012","null","March 2011","Progression-free Survival (PFS)|Overall Survival (OS)|Best Overall Response, Assessed as the Number of Participants With the Indicated Tumor Response: Investigator Assessed Only|Percentage of Participants With a Complete Response or a Partial Response","https://ClinicalTrials.gov/show/NCT00871403"
1602,"NCT02227940","Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer","Recruiting","No Results Available","Advanced Malignant Solid Neoplasm|ALK Positive|Metastatic Pancreatic Adenocarcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer","Drug: Ceritinib|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Other: Pharmacological Study","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","96","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","I 248813|NCI-2014-01766|P30CA016056","August 26, 2014","January 8, 2015","June 11, 2018","April 24, 2017","April 2017","No Study Results Posted","null","June 11, 2017","MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride alone, defined as the highest dose level at which < 2 of 6 patients experience treatment-related dose limiting toxicity (DLT) (Arms 1 and 1E)|MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and cisplatin, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 3 and 3E)|MTD and RP2D of ceritinib in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation, defined as the highest dose level at which < 2 of 6 patients experience treatment-related DLT (Arms 2 and 2E)|Incidence of adverse events of ceritinib in combination with gemcitabine hydrochloride based chemotherapy in advanced solid malignancies according to NCI CTCAE v4.0|Pharmacokinetic parameters of ceritinib and gemcitabine hydrochloride when administered in combination in patients with advanced solid tumors (Arms 1 and 1E)|Pharmacokinetic parameters of ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation when administered in combination in patients with advanced solid tumors (Arms 2 and 2E)|Pharmacokinetic parameters of paclitaxel albumin-stabilized nanoparticle formulation, and cisplatin when administered in combination in patients with advanced solid tumors (Arms 3 and 3E)|Progression free survival|Response rate as assessed by the RECIST 1.1","https://ClinicalTrials.gov/show/NCT02227940"
1603,"NCT00578760","Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?","Unknown status","No Results Available","Hearing Loss|Ototoxicity","Drug: aspirin|Drug: placebo","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aspirin-01","December 18, 2007","February 2008","February 2010","December 19, 2007","December 2007","No Study Results Posted","null","null","hearing loss|hearing loss and tinnitus questionnaires","https://ClinicalTrials.gov/show/NCT00578760"
1604,"NCT00006260","Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cisplatin|Drug: etoposide|Drug: ifosfamide|Drug: Mesna","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU4196|P30CA043703|CWRU-4196|BMS-CRWU-4196|NCI-G00-1854","September 11, 2000","May 1997","null","June 9, 2010","June 2010","No Study Results Posted","null","January 2005","Determine the objective response rate in patients with metastatic breast cancer treated with etoposide, ifosfamide with mesna, and cisplatin.","https://ClinicalTrials.gov/show/NCT00006260"
1605,"NCT01326468","Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer","Withdrawn","No Results Available","Head and Neck Cancer","Drug: Temsirolimus|Drug: Cetuximab|Drug: Cisplatin|Device: Radiation Therapy","Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10D.133|2009-44","March 29, 2011","January 2011","null","October 19, 2016","October 2016","No Study Results Posted","null","null","Maximum Tolerated Dose (MTD) of Torisel|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT01326468"
1606,"NCT00276666","Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: lomustine|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","29","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000454549|CCLG-CNS-2001-06|EU-20577","January 12, 2006","November 2001","null","September 16, 2013","June 2009","No Study Results Posted","null","March 2010","Toxicity","https://ClinicalTrials.gov/show/NCT00276666"
1607,"NCT00454649","Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor","Completed","Has Results","Neoplasms","Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Drug: Axitinib + Paclitaxel (Cohort 4)|Drug: Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Drug: Axitinib + Docetaxel (Cohort 5)|Drug: Axitinib + Capecitabine (Cohort 6)|Drug: Axitinib + Capecitabine (Cohort 7)|Drug: Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Drug: Axitinib + Pemetrexed + Cisplatin (Cohort 9)","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A4061019","March 29, 2007","December 2005","April 2011","March 30, 2012","March 2012","February 25, 2012","null","August 2009","Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy|Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)|Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)|Minimum Observed Plasma Trough Concentration (Cmin) for Axitinib (AG-013736)|Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)|Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel|Maximum Observed Plasma Concentration (Cmax) for Paclitaxel|Minimum Observed Plasma Trough Concentration (Cmin) for Paclitaxel|Plasma Clearance (CL) for Paclitaxel|Plasma Decay Half Life (t1/2) for Paclitaxel|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel|Maximum Observed Plasma Concentration (Cmax) for Docetaxel|Minimum Observed Plasma Trough Concentration (Cmin) for Docetaxel|Plasma Clearance (CL) for Docetaxel|Plasma Decay Half Life (t1/2) for Docetaxel|Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine|Maximum Observed Plasma Concentration (Cmax) for Capecitabine|Minimum Observed Plasma Trough Concentration (Cmin) for Capecitabine|Apparent Oral Clearance (CL/F) for Capecitabine|Plasma Decay Half Life (t1/2) for Capecitabine|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine|Maximum Observed Plasma Concentration (Cmax) for Gemcitabine|Minimum Observed Plasma Trough Concentration (Cmin) for Gemcitabine|Plasma Clearance (CL) for Gemcitabine|Plasma Decay Half Life (t1/2) for Gemcitabine|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin|Maximum Observed Plasma Concentration (Cmax) for Carboplatin|Minimum Observed Plasma Trough Concentration (Cmin) for Carboplatin|Plasma Clearance (CL) for Carboplatin|Plasma Decay Half Life (t1/2) for Carboplatin|Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin|Maximum Observed Plasma Concentration (Cmax) for Cisplatin|Minimum Observed Plasma Trough Concentration (Cmin) for Cisplatin|Plasma Clearance (CL) for Cisplatin|Plasma Decay Half Life (t1/2) for Cisplatin|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed|Maximum Observed Plasma Concentration (Cmax) for Pemetrexed|Minimum Observed Plasma Trough Concentration (Cmin) for Pemetrexed|Plasma Clearance (CL) for Pemetrexed|Plasma Decay Half Life (t1/2) for Pemetrexed|Percentage of Participants With Objective Response","https://ClinicalTrials.gov/show/NCT00454649"
1608,"NCT01672671","BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy","Completed","No Results Available","Early Triple Negative Breast Cancer","Drug: Doxorubicin, Paclitaxel, Cisplatin","Russian Academy of Medical Sciences","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TNNP 001","August 16, 2012","August 2011","November 2015","November 1, 2015","November 2015","No Study Results Posted","null","June 2015","The pathological complete response rate to neoadjuvant platinum-based chemotherapy|Disease-free survival|Clinical responses to neadjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT01672671"
1609,"NCT00421096","Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer","Terminated","No Results Available","Uterine Cervical Cancer","Drug: Gemcitabine|Procedure: Radiotherapy|Drug: Cisplatin","Centre Oscar Lambret","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEMCOL 0401","January 10, 2007","May 2005","December 2011","July 23, 2012","July 2012","No Study Results Posted","GEMCOL","April 2008","Progression-free survival|Global survival|safety","https://ClinicalTrials.gov/show/NCT00421096"
1610,"NCT01086826","Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: RT+CDDP/5-FU|Drug: RT+CETUXIMAB|Drug: INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|Drug: INDUCTION CTx(TPF)+(RT+CETUXIMAB)","Associazione Volontari Pazienti Oncologici|Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","H&N07","March 12, 2010","March 2008","December 2014","January 23, 2015","June 2013","No Study Results Posted","H&N07","April 2014","overall survival|progression free survival","https://ClinicalTrials.gov/show/NCT01086826"
1611,"NCT00274911","Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: lomustine|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","3 Years to 18 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CCLG-CNS-2004-01|CDR0000454540|EU-20580","January 10, 2006","February 2004","null","August 1, 2013","June 2009","No Study Results Posted","null","March 2010","Toxicity measured by hematological, gastrointestinal, mucosal, neurological, and skin morbidity during treatment and for 6 weeks after completion of treatment|Overall and relapse free survival at follow up every 2 months for 1 year, every 3 months for 2 years, and then every 6 months for 2 years","https://ClinicalTrials.gov/show/NCT00274911"
1612,"NCT02500940","Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin|Drug: Fluorouracil|Radiation: Radiation therapy|Drug: Leucovorin","Taichung Veterans General Hospital|Fujian Cancer Hospital","All","20 Years and older   (Adult, Senior)","Phase 3","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CF15113A","June 22, 2015","May 2015","May 2021","July 14, 2015","July 2015","No Study Results Posted","null","May 2016","Tumor response by RECIST version 1.1|Overall survival|Acute toxicity by CTCAE deifnition","https://ClinicalTrials.gov/show/NCT02500940"
1613,"NCT00123318","A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: epirubicin|Drug: cisplatin|Drug: 5-fluorouracil|Radiation: Radiotherapy","Trans-Tasman Radiation Oncology Group (TROG)|The Royal Australian and New Zealand College of Radiologists","All","18 Years and older   (Adult, Senior)","Phase 3","52","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TROG 03.02","July 19, 2005","February 2003","February 2012","June 17, 2013","June 2013","No Study Results Posted","null","February 2012","The percentage of patients who develop grade 3 or grade 4 haematological and gastrointestinal acute toxicity|The percentage of patients who complete the planned chemoradiation protocol|The percentage of major radiotherapy protocol violations|Median survival and overall survival at 3 years","https://ClinicalTrials.gov/show/NCT00123318"
1614,"NCT02947113","Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC","Not yet recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Cisplatin|Radiation: hypofractionated radiotherapy|Drug: Pemetrexed|Drug: Etoposide","The Netherlands Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N16HYP|2016-003790-18|NL57625.031.16","October 14, 2016","December 2016","December 2019","October 25, 2016","October 2016","No Study Results Posted","HYPOLAN","December 2018","Incidence of treatment related Adverse events (according to CTCAE v 4.03)|safety defined by the rate of grade 3-4 treatment related adverse events|disease control rate|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02947113"
1615,"NCT00842712","Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Cilengitide|Drug: Cilengitide|Drug: Cetuximab|Drug: Cisplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Vinorelbine|Drug: Cilengitide|Drug: Cilengitide|Drug: Cetuximab|Drug: Chemotherapy","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","232","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR200037-014|EudraCT Number: 2008-004148-35","February 10, 2009","February 2009","July 2013","January 12, 2017","January 2017","July 31, 2014","CERTO","July 2013","Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)|Randomized Part: Progression Free Survival (PFS) Time - Independent Read|Randomized Part: Progression Free Survival (PFS) Time - Investigator Read|Randomized Part: Overall Survival (OS) Time|Randomized Part: Best Overall Response (BOR) Rate|Randomized Part: Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT00842712"
1616,"NCT00028743","Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Drug: topotecan hydrochloride","NCIC Clinical Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Grupo Español de Investigación en Cáncer de Ovario|Canadian Cancer Trials Group","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","819","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OV16|CAN-NCIC-OV16|EORTC-55012|GEICO-0101|CDR0000069129","January 4, 2002","August 2001","January 2013","October 31, 2013","December 2012","No Study Results Posted","null","October 2007","Progression free survival|Overall Survival|Response Rates|Toxic Effects|Quality of Life|CA125 Normalization Rates","https://ClinicalTrials.gov/show/NCT00028743"
1617,"NCT01467115","Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Radiation: Radiotherapy|Drug: Leucovorin|Biological: Cetuximab|Drug: Filgrastim|Drug: Erythropoetin|Drug: Cisplatin|Drug: Fluorouracil|Drug: Docetaxel","Drexel University College of Medicine|Drexel University","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","19834","November 4, 2011","March 2010","October 7, 2014","May 8, 2017","May 2017","No Study Results Posted","DREXNECK","June 2014","Organ Sparing Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01467115"
1618,"NCT01736917","Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors","Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting","Drug: Fosaprepitant|Drug: Dexamethasone|Drug: 5HT3","Lawrence Einhorn|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.","Male","15 Years and older   (Child, Adult, Senior)","Phase 2","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","QL12-153","November 21, 2012","January 2013","June 2015","April 18, 2016","April 2016","March 1, 2016","null","March 2015","Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting|Total Number of Emetic Episodes|Use of Rescue Medications.|Self-Reported Assessment of Nausea","https://ClinicalTrials.gov/show/NCT01736917"
1619,"NCT00407186","Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)","Unknown status","No Results Available","Gastric Cancer","Drug: cisplatin+capecitabine|Radiation: radiotherapy|Drug: epirubicin+cisplatin+capecitabine","Dutch Colorectal Cancer Group|The Netherlands Cancer Institute|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 3","788","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRITICS","December 1, 2006","December 2006","December 2013","August 27, 2011","August 2011","No Study Results Posted","null","June 2013","overall survival|disease-free survival|toxicity|health-related quality of life","https://ClinicalTrials.gov/show/NCT00407186"
1620,"NCT02754726","Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma","Recruiting","No Results Available","Untreated Metastatic Pancreatic Ductal Adenocarcinoma","Drug: Nivolumab|Drug: Albumin-bound paclitaxel|Drug: Paricalcitol|Drug: Cisplatin|Drug: Gemcitabine","HonorHealth Research Institute|Translational Genomics Research Institute|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NAPPCG-EB 2015-001","April 19, 2016","April 2016","null","May 1, 2017","May 2017","No Study Results Posted","null","December 2017","Complete response rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02754726"
1621,"NCT00817583","Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: docetaxel, cisplatin, fluorouracil|Radiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC20081|NPC20081-1","January 5, 2009","January 2009","July 2011","January 26, 2009","January 2009","No Study Results Posted","TPF for NPC","July 2010","overall survival|distant metastases free survival , and disease-free survival","https://ClinicalTrials.gov/show/NCT00817583"
1622,"NCT00490360","Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head","Completed","No Results Available","Cancer of the Pancreatic Head","Drug: Gemcitabine / Cisplatin","University of Zurich","All","18 Years and older   (Adult, Senior)","Phase 2","2007","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","21-2001","June 21, 2007","October 2001","May 2007","June 21, 2007","June 2007","No Study Results Posted","null","null","Resectability rate > 70% after restaging","https://ClinicalTrials.gov/show/NCT00490360"
1623,"NCT00122772","CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy","Completed","No Results Available","Cervix Cancer","Radiation: Radiotherapy|Radiation: Radiotherapy|Radiation: Radiotherapy/Cisplatin|Radiation: Radiotherapy/Cisplatin","International Atomic Energy Agency","Female","18 Years and older   (Adult, Senior)","Phase 3","601","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E33026","July 19, 2005","November 2005","June 2010","October 13, 2011","October 2011","No Study Results Posted","null","June 2010","Clinical Outcome|Treatment Toxicity|Molecular markers that will predict tumor control/resistance|Whether E6 and E7 viral proteins predict cellular radiosensitivity in oxic and hypoxic conditions in vitro and tumor control/resistance in vivo|Effectiveness of a questionnaire template on a computer in face-to-face interviews in a multicentre multinational study.","https://ClinicalTrials.gov/show/NCT00122772"
1624,"NCT00498979","Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers","Completed","No Results Available","Stage IV Melanoma","Biological: recombinant interferon alfa-2b|Drug: cisplatin|Drug: sodium stibogluconate|Drug: dacarbazine|Drug: vinblastine","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE3Y06|P30CA043703","July 10, 2007","May 2007","January 2012","September 29, 2015","September 2015","No Study Results Posted","null","May 2010","Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy|Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product|Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes|Pharmacokinetics of sodium stibogluconate in serum at escalating doses|Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy","https://ClinicalTrials.gov/show/NCT00498979"
1625,"NCT01519804","A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: Placebo|Drug: cisplatin/carboplatin|Drug: onartuzumab|Drug: paclitaxel","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","GO27820","December 19, 2011","April 2012","September 2015","September 1, 2016","September 2016","No Study Results Posted","null","January 2014","Progression-free survival (tumor assessments according to RECIST criteria)|Progression-free survival: Subgroup of patients with Met diagnostic-positive squamous NSCLC|Overall survival|Overall response rate (tumor assessments according to RECIST criteria)|Duration of response (time from first documented objective response to disease progression)|Disease control rate (rate of partial response plus complete response plus stable disease for at least 6 weeks)|Safety: Incidence of adverse events|Pharmacokinetics: serum concentration (Cmin/Cmax)|Plasma concentrations of paclitaxel/platinum|Serum levels of anti-therapeutic antibodies (MetMAb ATAs)","https://ClinicalTrials.gov/show/NCT01519804"
1626,"NCT01817023","The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Radiation: SIB-IMRT|Drug: Cisplatin","Chinese Academy of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","590","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-HN-003","March 20, 2013","April 2013","April 2018","September 9, 2014","September 2014","No Study Results Posted","null","April 2015","overall survival|Acute and late toxicities|3 year Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01817023"
1627,"NCT00367497","Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma","Terminated","No Results Available","Lymphoma, Non-Hodgkin","Drug: Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin","Keio University","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","17-40","August 22, 2006","August 2005","November 2007","November 19, 2007","November 2007","No Study Results Posted","null","null","Overall response|Complete response|Safety|Overall survival|Progression free survival|Effectiveness of peripheral blood stem cell collection","https://ClinicalTrials.gov/show/NCT00367497"
1628,"NCT02375204","Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors","Recruiting","No Results Available","Germ Cell Tumor|Teratoma|Choriocarcinoma|Germinoma|Mixed Germ Cell Tumor|Yolk Sac Tumor|Childhood Teratoma|Malignant Germ Cell Neoplasm|Extragonadal Seminoma|Non-seminomatous Germ Cell Tumor|Seminoma","Drug: paclitaxel|Drug: ifosfamide|Drug: cisplatin|Drug: pegylated G-CSF|Drug: G-CSF|Drug: carboplatin|Drug: etoposide phosphate|Procedure: stem cell reinfusion","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|European Organisation for Research and Treatment of Cancer - EORTC|Movember Foundation|Institute of Cancer Research (ICR), United Kingdom|Cancer Research UK (CRUK)|UNICANCER|Irish Group CTI","Male","14 Years and older   (Child, Adult, Senior)","Phase 3","420","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","A031102|U10CA180821|NCI-2014-01696","February 20, 2015","March 2015","null","April 19, 2017","April 2017","No Study Results Posted","null","March 2018","overall survival|progression free survival|proportion of patients achieving either a complete response (CR) or partial response|treatment related mortality|number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Validation of International Prognostic Factor Study Group stratification system (eg, primary site, prior response, progression free interval)","https://ClinicalTrials.gov/show/NCT02375204"
1629,"NCT02445391","Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy","Recruiting","No Results Available","Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma","Drug: Capecitabine|Drug: Carboplatin|Drug: Cisplatin|Other: Laboratory Biomarker Analysis","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","562","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA1131|NCI-2014-01820|U10CA180820","May 13, 2015","April 2015","null","September 29, 2016","September 2016","No Study Results Posted","null","May 2019","IDFS of patients with basal-like TNBC|Incidence of toxicity graded using the National Cancer Institute CTCAE v. 4.0|OS of patients with basal-like TNBC with residual disease after neoadjuvant chemotherapy|Rate of basal-like gene expression using PAM50 analysis by digital mRNA quantification|RFS","https://ClinicalTrials.gov/show/NCT02445391"
1630,"NCT00930891","Bevacizumab in Extensive Small Cell Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer","Drug: Standard Chemotherapy (PCDE or PE)|Drug: Experimental Treatment (PCDE or PE + bevacizumab)|Drug: Prerandomization Chemotherapy (PCDE or PE)","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-0802|2009-010187-42","July 1, 2009","September 2009","July 2013","March 9, 2016","March 2016","No Study Results Posted","CPC","July 2012","Response rate (complete response + partial response)|Progression-free survival|Complete response length|Quality of life|Toxicities","https://ClinicalTrials.gov/show/NCT00930891"
1631,"NCT00823719","Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)","Completed","Has Results","Lymphoma, Large-Cell, Diffuse","Drug: ofatumumab + ICE|Drug: ofatumumab + DHAP","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110927","January 8, 2009","May 2009","September 2011","March 7, 2013","February 2013","June 21, 2012","null","July 2011","Number of Participants With Overall Response (OR), as Assessed by the Investigator|Number of Participants With CR, as Assessed by the Investigator|Number of Participants With the Ability to Mobilize at Least 2 Million Cluster of Differentiation (CD)34+ Cells Per Kilogram (kg) From Peripheral Blood|Progression-free Survival (PFS)|Overall Survival|Area Under the Concentration-time Curve From Time Zero to Infinity, AUC(0-inf), of Ofatumumab at the First Infusion (Cycle 1, Day 1) and the Last Infusion (Cycle 3)|Area Under the Concentration-time Curve During the Dosing Interval (AUC(0-tau)) of Ofatumumab at the Last Infusion (Cycle 3)|Clearance (CL) of Ofatumumab|Maximum Plasma Concentration (Cmax) of Ofatumumab at the First Infusion (Cycle 1 Day 1), Second Infusion (Cycle 1 Day 8), and Last Infusion (Cycle 3)|Trough Plasma Concentration (Ctrough) of Ofatumumab Prior to Second Infusion (Cycle 1 Day 8), Third Infusion (Cycle 2), and Last Infusion (Cycle 3)|Terminal Phase Half-life (t1/2) of Ofatumumab|Volume of Distribution at Steady State (Vss) of Ofatumumab|Number of Participants Who Were Positive and Negative for Human Anti-human Antibodies (HAHA) at the Indicated Time Points|Number of Participants With the Indicated Adverse Events (AEs) Associated With Neutropenia|Number of Participants With the Indicated AEs Associated With Decreased Hemoglobin Counts|Number of Participants With the Indicated AEs Associated With Decreased Platelet Counts","https://ClinicalTrials.gov/show/NCT00823719"
1632,"NCT01670409","Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer","Completed","No Results Available","Esophageal Neoplasms","Radiation: SMART|Drug: PF","Chuangzhen Chen|Shantou University Medical College","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","85","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SUMC-ECA-001|ChiCTR-ONC-12002356","August 12, 2012","August 2012","August 2015","August 27, 2015","August 2015","No Study Results Posted","null","August 2015","Toxicities|local control rate|overall survival rate","https://ClinicalTrials.gov/show/NCT01670409"
1633,"NCT00313872","Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer","Completed","No Results Available","Gastric Cancer|Metastases","Drug: DP|Drug: FOLFIRI","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SMC IRB 2005-03-044","April 11, 2006","May 2003","January 2010","January 10, 2012","January 2012","No Study Results Posted","null","June 2009","Second progress-free survival|Toxicity, overall survival","https://ClinicalTrials.gov/show/NCT00313872"
1634,"NCT02215356","Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Icotinib with concurrent radiotherapy|Drug: Chemoradiotherapy","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BD-IC-IV66","August 11, 2014","August 2014","February 2019","August 11, 2014","August 2014","No Study Results Posted","null","August 2018","Progression-free survival|Overall survival|Objective response rate|Adverse events","https://ClinicalTrials.gov/show/NCT02215356"
1635,"NCT02624999","Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck","Not yet recruiting","No Results Available","Squamous Cell Carcinoma Head and Neck","Biological: AlloVax™|Drug: Cisplatin","Immunovative Therapies, Ltd.","All","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ITL-020-HENK-VAXPII","November 29, 2015","December 2016","May 2019","July 10, 2016","July 2016","No Study Results Posted","null","December 2018","Safety and tolerability (vital signs, physical examination, clinical laboratory profile, adverse events assessed by CTCAE v4.0 and dose limiting toxicity (DLT))|Overall Survival|Health related Quality of Life (HRQoL)","https://ClinicalTrials.gov/show/NCT02624999"
1636,"NCT00916097","NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)","Completed","No Results Available","Head and Neck Neoplasms","Drug: DOCETAXEL(XRP6976)","Sanofi","All","20 Years to 75 Years   (Adult, Senior)","Phase 2","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976F_2502","June 5, 2009","July 2002","November 2005","June 23, 2009","June 2009","No Study Results Posted","null","November 2005","Evaluation of tumor response in patients with measurable disease according to RECIST criteria|Evaluation of the radiological response after chemotherapy and radiotherapy|Evaluation of the pathological response after chemotherapy|Overall response duration|Estimation of the time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT00916097"
1637,"NCT02326285","Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB","Recruiting","No Results Available","Non-squamous Non-small Cell Lung Cancer Stage II|Non-squamous Non-small Cell Lung Cancer Stage IIIA|Non-squamous Non-small Cell Lung Cancer Stage IIIB|Activating EGFR Mutation|NSCLC","Drug: Gefitinib|Drug: docetaxel|Drug: cisplatin|Procedure: Surgery","AIO-Studien-gGmbH|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO-TRK-0214|2014-005595-28|IISR ESR-14-10598","December 18, 2014","November 2015","January 2019","July 28, 2016","July 2016","No Study Results Posted","NeoIntercal","December 2018","pathologic complete remission rate (pCR rate)|Adverse Events (AEs) / Serious adverse events (SAEs)|Surgical R0 resection rate|Response: radiologic response based on CT|progression free survival (PFS)|Overall survival (OS)|relapse pattern|quality of life|translational research|monitoring of epidermal growth factor receptor (EGFR) mutation status","https://ClinicalTrials.gov/show/NCT02326285"
1638,"NCT02409186","A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Prosthesis Survival","Drug: Nimotuzumab|Radiation: radiotherapy|Drug: chemoradiotherapy Paclitaxel|Drug: chemoradiotherapy Cisplatin|Other: placebo","Shandong Cancer Hospital and Institute","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NXCEL1311","December 3, 2014","March 2015","December 2021","April 19, 2016","April 2016","No Study Results Posted","null","December 2017","Over Survival","https://ClinicalTrials.gov/show/NCT02409186"
1639,"NCT00682383","Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Unresectable Locally Advanced NSCLC","Drug: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta","Mt. Sinai Medical Center, Miami|Amgen","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","LUN 07","May 20, 2008","September 2003","January 2010","October 29, 2012","October 2012","No Study Results Posted","null","January 2010","To determine the safety and efficacy of administering pegfilgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgramstim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.|To determine the frequency of dose reductions, dose delays, and dose omissions during chemoradiotherapy with filgrastim and consolidation therapy with pegfilgrastim.","https://ClinicalTrials.gov/show/NCT00682383"
1640,"NCT00172380","Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III","Completed","No Results Available","NSCLC","Drug: Docetaxel Plus CDDP","National Taiwan University Hospital","All","20 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","930911","September 12, 2005","February 2005","March 2010","December 19, 2012","December 2012","No Study Results Posted","null","January 2010","overall response rate|resectability|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT00172380"
1641,"NCT01502202","Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers","Unknown status","No Results Available","Non Small Cell Lung Cancer|Adenocarcinoma","Drug: Gefitinib|Drug: Placebo|Drug: Pemetrexed plusCIsplatin","National Cancer Center, Korea|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","162","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCCCTS-11-581","December 22, 2011","March 2012","February 2015","June 19, 2012","June 2012","No Study Results Posted","null","August 2014","To compare progression-free survival|To compare objective response rate (CR+PR)|To compare duration of response.|To compare non progression rate (CR+PR+SD) at 16 weeks.|To compare overall survival.|To compare number of Grade 3/4 Adverse Events|To assess biomarker","https://ClinicalTrials.gov/show/NCT01502202"
1642,"NCT01903018","A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00","Completed","No Results Available","Radiation Induced Mucositis in Head and Neck Cancer","Drug: P276-00|Radiation: Radiation Therapy|Drug: Cisplatin","Piramal Enterprises Limited","All","18 Years and older   (Adult, Senior)","Phase 2","73","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","P276-00/64/11","July 11, 2013","July 2012","September 2014","September 3, 2014","September 2014","No Study Results Posted","null","March 2014","Number of severe Radiation Induced Mucositis (WHO grade >=3)|Time to onset of severe RIM (WHO Grade ≥ 3)|Duration of severe RIM (WHO Grade>=3)|Progression-Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01903018"
1643,"NCT00003811","Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors","Completed","No Results Available","Childhood Germ Cell Tumor|Drug/Agent Toxicity by Tissue/Organ|Extragonadal Germ Cell Tumor|Ovarian Cancer","Biological: bleomycin sulfate|Drug: amifostine trihydrate|Drug: cisplatin|Drug: etoposide|Procedure: conventional surgery","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 14 Years   (Child)","Phase 2","27","Other|NIH","Interventional","Primary Purpose: Treatment","9749|POG-9749|CDR0000066956","November 1, 1999","April 2000","September 2007","July 3, 2013","July 2013","No Study Results Posted","null","October 2004","Feasibility from Efficacy Standpoint|Assessment of Reduction in Toxicity","https://ClinicalTrials.gov/show/NCT00003811"
1644,"NCT01487499","Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)","Terminated","Has Results","Small Cell Lung Cancer","Drug: Cisplatin","University of Florida","All","Child, Adult, Senior","Phase 3","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCLC","December 1, 2011","December 2011","March 2015","May 15, 2015","May 2015","March 16, 2015","SCLC","March 2015","Solid Tumor Growth After Completion of Interventional Bronchoscopies|Progression-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01487499"
1645,"NCT02429037","P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer","Not yet recruiting","No Results Available","Advanced Head and Neck Cancer","Drug: rAd-p53|Radiation: radiation|Drug: Cisplatin","Shenzhen SiBiono GeneTech Co.,Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","rAd-p53-J1002","April 20, 2015","May 2015","December 2018","April 23, 2015","March 2015","No Study Results Posted","null","December 2018","progression-free survival|Adverse events|overall survival","https://ClinicalTrials.gov/show/NCT02429037"
1646,"NCT00150670","Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: TS-1 and cisplatin|Drug: TS-1","Taiho Pharmaceutical Co., Ltd.","All","20 Years to 74 Years   (Adult, Senior)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","91023039","September 7, 2005","March 2002","December 2006","July 6, 2011","July 2011","No Study Results Posted","null","December 2006","Overall survival|Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile","https://ClinicalTrials.gov/show/NCT00150670"
1647,"NCT02000531","Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population","Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Erlotinib|Drug: Chemotherapy","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 4","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML29028","November 27, 2013","January 2014","December 2014","December 9, 2015","December 2015","December 9, 2015","null","December 2014","Progression Free Survival (PFS) Based on Well-documented and Verifiable Progression Events|Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT02000531"
1648,"NCT00004103","Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: floxuridine|Drug: irinotecan hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067322|P30CA016087|NYU-9822|P-UPJOHN-647597196|NCI-G99-1594","December 10, 1999","July 1998","June 2009","April 5, 2011","April 2011","No Study Results Posted","null","March 2007","","https://ClinicalTrials.gov/show/NCT00004103"
1649,"NCT01454089","A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer","Completed","No Results Available","Urologic Neoplasms|Metastatic Bladder Cancer|Urinary Tract Neoplasms","Drug: OGX-427 600 mg|Drug: OGX-427 1000 mg|Drug: Placebo|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin","OncoGenex Technologies|PRA Health Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OGX-427-02","October 5, 2011","October 2011","November 2014","October 6, 2016","October 2016","No Study Results Posted","null","November 2014","Overall Survival (OS)|Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, and Grade 3 or Higher AEs|Number of Participants With ≥ 1 Hematology Abnormality and ≥ 1 Grade 3 or Higher Hematology Abnormality|Number of Participants With ≥ 1 Chemistry Laboratory Abnormality and ≥ 1 Grade 3 or Higher Chemistry Laboratory Abnormality|Number of Participants With ≥ 1 Urinalysis Abnormality and ≥ 1 Grade 3 or Higher Urinalysis Abnormality|Best Objective Tumor Response|Overall Response Rate (ORR) and Disease Control Rate|Duration of Overall Response Rate|Progression-free Survival (PFS)|Change From Baseline in Serum Hsp27 levels by End of Treatment|Change From Baseline in Serum Clusterin Levels by End of Treatment|Change From Baseline in Circulating Tumor Cell (CTC) Count by End of Treatment|Serum OGX-427 Cmax and Trough Levels","https://ClinicalTrials.gov/show/NCT01454089"
1650,"NCT01046461","Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer","Unknown status","No Results Available","Solid Tumour|Postoperative Nausea and Vomiting","Drug: Ramosetron, Aprepitant, Dexamethasone","Hallym University Medical Center|Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","RAD1.0","January 8, 2010","January 2010","June 2012","February 16, 2012","February 2012","No Study Results Posted","RAD","March 2012","Complete response (CR) rate of RAD for the prevention of chemotherapy induced nausea vomiting (CINV) during overall phase (form 1 to 5 days) (overall phase is defined as acute and delayed phase)|CR rate of RAD for the prevention of acute and delayed phase of CINV (from 0 to 24 hours /from 2 to 5 days)|Severity of nausea|Time to first occurrence of vomiting|Adverse events reported using CTCAE v3.0","https://ClinicalTrials.gov/show/NCT01046461"
1651,"NCT01670890","Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas","Unknown status","No Results Available","Malignant Gliomas","Drug: TMZ|Drug: TMZ plus CDDP","Peking Union Medical College Hospital|Beijing Tiantan Hospital|Tianjin Medical University General Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","pumch-neurosurgery-01","August 19, 2012","August 2012","null","August 21, 2012","August 2012","No Study Results Posted","null","August 2014","over all survival|progression free survival","https://ClinicalTrials.gov/show/NCT01670890"
1652,"NCT00003111","Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: irinotecan hydrochloride|Drug: paclitaxel|Procedure: neoadjuvant therapy|Procedure: surgical procedure|Radiation: radiation therapy","Yale University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065855|YALE-HIC-9317|NCI-G97-1345","November 1, 1999","April 1997","April 2004","July 23, 2013","August 2009","No Study Results Posted","null","April 2004","","https://ClinicalTrials.gov/show/NCT00003111"
1653,"NCT02022098","Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Cisplatin|Radiation: Radiotherapy|Drug: Debio 1143|Drug: Placebo","Debiopharm International SA","All","18 Years to 75 Years   (Adult, Senior)","","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","Debio 1143-201","December 13, 2013","October 2013","April 2019","May 18, 2017","May 2017","No Study Results Posted","null","December 2018","Phase II: Percentage of participants achieving Locoregional Control (LRC) at 18 months from the end of chemo-radiation therapy (CRT)|Phase II: Complete Response Rate (by RECIST version 1.1) at six months after completion of chemo-radiation therapy (CRT) therapy|Phase II: Best Overall response rate, Disease Control rate and Response Rate after 10 weeks from the end of CRT|Phase II: Best Overall response rate, Disease Control rate and Response Rate after 6 months from the end of CRT|Phase II: Locoregional control rate at 6 months and one year after completion of CRT|Phase II: Progression free survival rate at one year, 18 months and at 2 years as of initiation of CRT|Phase II: Distant relapse rate at six months, one year and 18 months after completion of CRT|Phase II: Disease specific survival rate one year and at 2 years as of initiation of CRT|Phase II: Overall survival rate at one year and at 2 years as of initiation of CRT|Phase II: Number of participants with clinically significant change in vital signs during participation in the trial|Phase II: Number of participants with Serious Adverse Events|Phase II: Number of participants with Adverse Events (AEs)|Phase II: Number of participants with Laboratory Abnormalities|Phase II: Number of participants with Late Toxicity as of initiation of CRT|Phase II: Number of participants with treatment changes due to AEs","https://ClinicalTrials.gov/show/NCT02022098"
1654,"NCT02862535","Andecaliximab as Monotherapy and in Combination With Chemotherapy in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma","Recruiting","No Results Available","Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma","Drug: Andecaliximab|Drug: S-1|Drug: Cisplatin","Gilead Sciences","All","20 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GS-US-296-1884","August 8, 2016","September 20, 2016","May 2019","May 16, 2017","May 2017","No Study Results Posted","null","May 2019","Overall Safety Profile of Andecaliximab|Plasma Concentrations of Andecaliximab|PK Parameter: Cmax of Andecaliximab|PK Parameter: AUC of Andecaliximab|Incidence Rate of Positive Anti-Andecaliximab Antibodies","https://ClinicalTrials.gov/show/NCT02862535"
1655,"NCT00022308","Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068803|P30CA006927|FCCC-98020|NCI-G01-1995","August 10, 2001","January 1999","September 2006","August 30, 2013","August 2013","No Study Results Posted","null","September 2006","","https://ClinicalTrials.gov/show/NCT00022308"
1656,"NCT00005638","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: irinotecan hydrochloride|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-081|CDR0000067794|NCI-G00-1766","May 2, 2000","October 1999","April 2004","June 17, 2013","June 2013","No Study Results Posted","null","April 2004","","https://ClinicalTrials.gov/show/NCT00005638"
1657,"NCT00137358","Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer","Withdrawn","No Results Available","Cervical Cancer","Procedure: Radiation Therapy|Drug: Cisplatin|Drug: Amifostine","University of Alabama at Birmingham|MedImmune LLC","Female","19 Years and older   (Adult, Senior)","Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ETH175-04D","August 26, 2005","null","null","January 23, 2013","January 2013","No Study Results Posted","null","null","The primary objective is to determine the maximum tolerated dose (MTD) of external beam radiation to the para-aortic lymph nodes using IMRT and amifostine.|The secondary endpoints include local-regional control, overall survival and toxicity.","https://ClinicalTrials.gov/show/NCT00137358"
1658,"NCT00005850","Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","Completed","No Results Available","Anxiety Disorder|Depression|Fatigue|Lung Cancer","Drug: cisplatin|Drug: fluoxetine|Drug: gemcitabine hydrochloride","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-119802|U10CA031946|CLB-119802|CDR0000067871","June 2, 2000","August 2001","September 2003","July 1, 2016","July 2016","No Study Results Posted","null","September 2003","Change in the MHI-17 global psychological distress subscale|Overall survival|Failure-free survival","https://ClinicalTrials.gov/show/NCT00005850"
1659,"NCT00792701","S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Other: active surveillance","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000625070|S0720|U10CA032102","November 16, 2008","November 2008","null","February 5, 2015","February 2015","No Study Results Posted","null","June 2016","Feasibility of pharmacogenomics-based treatment assignment in the cooperative group setting|Two-year disease-free survival|Frequency and severity of toxicities as assessed by NCI CTCAE v3.0|Relationship between RNA and protein expression of RRM1 and ERCC1 and relationship between RRM1 and ERCC1 expression in the formalin-fixed and paraffin-embedded tumor specimens|Generation of results on in situ protein expression and other assays for genes involved in drug efficacy|Analytical performance of the biomarker assay","https://ClinicalTrials.gov/show/NCT00792701"
1660,"NCT02901483","A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer","Not yet recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: PEP503|Drug: Cisplatin|Radiation: Radiotherapy","PharmaEngine","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","42","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PEP503-HN-1002","August 31, 2016","September 2016","null","October 26, 2016","September 2016","No Study Results Posted","null","November 2018","Phase 1: Determination of the Recommended doses and the Dose Limiting Toxicities (DLT)|Phase 2: The rate of locoregional control at one year|Phase1 and 2: Evaluation of Safety profile of PEP503|Phase 1: The body kinetic profile of PEP503|Phase 2: Evaluation of objective tumor response as per Response Evaluation Criteria in Solid Tumors (RECIST)|Phase 2: Pathological response (pR)|Phase 2: Evalution of progression free survival rate at 1 year","https://ClinicalTrials.gov/show/NCT02901483"
1661,"NCT01059188","Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting","No Results Available","Lung Cancer","Drug: cetuximab|Drug: cisplatin|Drug: docetaxel|Radiation: Radiotherapy|Procedure: Surgery","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","69","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 16/08|SWS-SAKK-16/08|EU-21002|CDR0000664070","January 28, 2010","January 2010","June 2021","July 19, 2016","July 2016","No Study Results Posted","null","January 2016","Progression-free survival|Treatment-related death during chemoimmunotherapy, radioimmunotherapy, and perioperatively|Metabolic response evaluated by PET|Response status after chemoimmunotherapy and radioimmunotherapy|Complete pathological response|Overall survival|Adverse events|Operability","https://ClinicalTrials.gov/show/NCT01059188"
1662,"NCT00006374","Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Withdrawn","No Results Available","Lung Cancer","Biological: filgrastim|Drug: cisplatin|Drug: etoposide|Drug: paclitaxel|Drug: topotecan hydrochloride","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","SKF2598|CWRU-SKF-2598|CWRU-059916|SB-SKF-104864/RSD-1010P3/4|NCI-G00-1864","October 4, 2000","October 1999","June 2001","January 14, 2014","January 2014","No Study Results Posted","null","June 2001","","https://ClinicalTrials.gov/show/NCT00006374"
1663,"NCT00003803","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed","Terminated","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","158","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-08972-22973|EORTC-08972","November 1, 1999","February 1999","null","July 17, 2012","July 2012","No Study Results Posted","null","March 2003","","https://ClinicalTrials.gov/show/NCT00003803"
1664,"NCT00080795","Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: ifosfamide|Procedure: conventional surgery|Procedure: neoadjuvant therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","65","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000355361|MDA-ID-01317|ID01-317","April 7, 2004","July 2001","May 2006","October 18, 2012","October 2012","No Study Results Posted","null","May 2006","Response rate|Disease-free survival at 4 years|Comparison of perioperative treatment morbidity and mortality with historical standards","https://ClinicalTrials.gov/show/NCT00080795"
1665,"NCT01356368","Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer","Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: Cisplatin, Gemzar, Docetaxel, Alimta","National Guard Health Affairs","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RC09/095","March 19, 2011","May 2010","May 2013","January 19, 2014","January 2014","No Study Results Posted","Customizing","May 2013","Efficacy and Safety|Tumor marker","https://ClinicalTrials.gov/show/NCT01356368"
1666,"NCT00003202","Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Radiation: radiation therapy","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","Phase 1|Phase 2","40","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000066052|CCCWFU-62197|NCI-G98-1386","November 1, 1999","January 1998","July 2006","January 18, 2017","July 2012","No Study Results Posted","null","April 2002","•Determine the maximum tolerated dose of twice-weekly gemcitabine when delivered concurrently with thoracic radiotherapy|assess the efficacy of dose of twice-weekly gemcitabine when delivered concurrently with thoracic radiotherapy","https://ClinicalTrials.gov/show/NCT00003202"
1667,"NCT00622349","Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cisplatin, Ifosfamide, Gemcitabine|Drug: Ifosfamide, Gemcitabine|Drug: Cisplatin, docetaxel","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","Phase 3","707","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ELCWP-01041","February 14, 2008","February 2004","December 2009","January 29, 2013","January 2013","No Study Results Posted","null","March 2009","Survival|Response rate|Toxicity|Activity of second-line chemotherapy","https://ClinicalTrials.gov/show/NCT00622349"
1668,"NCT02891083","Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer","Recruiting","No Results Available","Esophageal Neoplasms","Drug: Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Radiation: Adjuvant radiotherapy|Other: Control group (Surgery alone)","Shanghai Chest Hospital|Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Sichuan Cancer Hospital and Research Institute|Hunan Cancer Hospital|Fujian Cancer Hospital|Fudan University|Qingdao University|Fujian Medical University|Wuhan TongJi Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","486","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016shchest","September 1, 2016","January 2016","January 2021","September 6, 2016","September 2016","No Study Results Posted","null","January 2019","Disease free survival|Overall survival|side effect of adjuvant therapy","https://ClinicalTrials.gov/show/NCT02891083"
1669,"NCT01756170","Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients","Recruiting","No Results Available","Cervical Cancer","Drug: paclitaxel|Drug: cisplatin|Radiation: Radiotherapy","xie congying|Wenzhou Medical University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","WZMC-11352","December 13, 2012","January 2011","December 2016","April 27, 2016","April 2016","No Study Results Posted","null","December 2016","disease-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01756170"
1670,"NCT02667925","Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin","Withdrawn","No Results Available","Ovarian Cancer","Drug: Intraperitoneal cisplatin with nanocis","Centre Jean Perrin","Female","18 Years to 70 Years   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-004103-12","January 19, 2016","March 2016","September 2016","October 10, 2016","September 2016","No Study Results Posted","ISOTOVE","September 2016","Quantification by visual analysis the intensity of fixation of the solvent characterized in the intraperitoneal cavity|Note adverse events assessed with CTCAE v4.0|Correlate pain intensity to fixation intensity in the peritoneal cavity|dosimetric study with peritoneal scintigraphy|Correlate site of relapse to localisation of labeled intraperitoneal solvent by nanocis in peritoneal cavity","https://ClinicalTrials.gov/show/NCT02667925"
1671,"NCT00815308","Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma","Completed","Has Results","Esophageal Cancer","Drug: cetuximab (Erbitux)|Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiation","Shandong Cancer Hospital and Institute|Chinese Academy of Medical Sciences|Beijing Cancer Hospital|Hebei Fourth Hospital|Jiangsu Cancer Institute & Hospital|RenJi Hospital|The Affiliated Cancer Hospital of Zhengzhou University|West China Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SDRTC-0901","December 29, 2008","January 2009","July 2010","February 4, 2011","July 2009","October 15, 2010","EXCEL","July 2010","Number of Participants With Overall Response Rate (RR)|Number of Participants With Toxicity|Participants With Overall Survival (OS) at 1 Year|Participants With Overall Survival (OS) at 3 Year|Participants With Progression Free Survival (PFS)|Number of Participants With K-ras Gene Mutation","https://ClinicalTrials.gov/show/NCT00815308"
1672,"NCT00004003","Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067213|P30CA022453|WSU-D-1993|WSU-04-03-99-M01-FB|NCI-G99-1553","November 1, 1999","April 1999","August 2003","April 3, 2013","April 2013","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00004003"
1673,"NCT00980759","Prophylactic Irradiation of the Para-Aortic Lymph Nodes in Locally Advanced Uterine Cervical Cancer","Active, not recruiting","No Results Available","Cervical Cancer","Radiation: EFI|Radiation: Pelvic RT","National Cancer Center, Korea","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2","312","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-209","September 18, 2009","July 2006","December 2018","July 5, 2016","July 2016","No Study Results Posted","null","December 2018","To evaluate the efficacy of the Extended-Field Irradiation on the recurrence rate in para-aortic lymph nodes and the disease-free survival rate of the patients with locally advanced uterine cervical cancer|To evaluate overall survival, toxicities and quality of life (QOL) of the patients treated by EFI compared to the control group of patients","https://ClinicalTrials.gov/show/NCT00980759"
1674,"NCT00005791","Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: fluorouracil|Drug: irinotecan hydrochloride","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067737|MSKCC-99065|NCI-G00-1743","June 2, 2000","October 1999","December 2009","December 18, 2013","December 2009","No Study Results Posted","null","July 2002","","https://ClinicalTrials.gov/show/NCT00005791"
1675,"NCT01220583","Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery","Recruiting","No Results Available","Head and Neck Cancer","Drug: cisplatin|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RTOG 1008|CDR0000686072|NCI-2013-00370","October 12, 2010","January 2011","null","April 24, 2017","April 2017","No Study Results Posted","null","October 2023","Progression-free survival (PFS), defined by the events of local-regional progression or recurrence, distant metastasis, or death from any cause, primarily at 2 years|Overall survival (OS) rate at 2 years|PFS rate at 5 years|OS rate at 5 years|Treatment-related toxicity, defined as any grade 3-4 adverse events (CTCAE v. 4) deemed to be definitely, probably, or possibly related to protocol treatment|Treatment-related mortality, defined as any death during or within 30 days of discontinuation of protocol treatment|Chemotherapy delivery as measured by percentage of protocol prescription given|Radiation delivery as measured by elapsed treatment days|Determine whether quality of life, fatigue and xerostomia differ as a function of treatment assignment at 3, 12, and 24 months after completing radiotherapy.","https://ClinicalTrials.gov/show/NCT01220583"
1676,"NCT02116231","The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Effects of Chemotherapy","Drug: Concurrent chemotherapy with cisplatin|Radiation: Intensity modulated radiotherapy","Cancer Hospital of Guangxi Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CHGX20140402","April 2, 2014","April 2014","May 2018","April 15, 2014","April 2014","No Study Results Posted","null","May 2017","Failure-free survival (FFS)|Overall survival (OS)|Loco-regional failure-free survival (LFFS)|Distant metastasis failure-free survival (DMFS)|Acute and late adverse events","https://ClinicalTrials.gov/show/NCT02116231"
1677,"NCT00989651","Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","Active, not recruiting","No Results Available","Fallopian Tube Carcinosarcoma|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Neoplasm|Fallopian Tube Transitional Cell Carcinoma|Ovarian Brenner Tumor|Ovarian Carcinosarcoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Tumor|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma","Biological: Bevacizumab|Drug: Carboplatin|Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Drug: Veliparib","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","474","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-03730|CDR0000656038|GOG-9923|U10CA180868|U10CA027469","October 2, 2009","October 28, 2009","null","May 23, 2017","May 2017","No Study Results Posted","null","September 1, 2020","Incidence of DLTs occurring in the first 4 courses of treatment (feasibility phase)|Incidence of dose-limiting toxicities (DLTs) occurring in the first or second course of treatment (dose-escalation phase)|Incidence of toxicity, graded according to National Cancer Institute CTCAE version 4.0|Objective tumor response (complete and partial response) as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)|Progression-free survival","https://ClinicalTrials.gov/show/NCT00989651"
1678,"NCT00003144","Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Unspecified Adult Solid Tumor, Protocol Specific","Drug: amifostine trihydrate|Drug: cisplatin|Drug: gemcitabine hydrochloride","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","44","Other|NIH","Interventional","Primary Purpose: Supportive Care","CDR0000065927|P30CA016087|NYU-9722|ALZA-97-011-ii|NCI-V97-1363","November 1, 1999","August 1997","null","March 25, 2011","March 2011","No Study Results Posted","null","April 2001","","https://ClinicalTrials.gov/show/NCT00003144"
1679,"NCT00198367","Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Cisplatin-Gemzar|Drug: Cisplatin-Navelbine-Radiotherapy|Drug: Carboplatin-Taxol-Radiotherapy","Hospices Civils de Lyon","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-0101","September 13, 2005","January 2003","July 2012","May 10, 2016","May 2016","No Study Results Posted","null","January 2008","percentage of patients alive and operated on without grade 4 toxicity (except for hematological and N/V toxicities)","https://ClinicalTrials.gov/show/NCT00198367"
1680,"NCT00140556","Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer|Pharynx Cancer","Radiation: Chemoradiotherapy|Drug: Cisplatin|Drug: Bevacizumab|Drug: Erlotinib","David M. Brizel, MD|Genentech, Inc.|OSI Pharmaceuticals|Duke University","All","18 Years and older   (Adult, Senior)","Early Phase 1","28","Other|Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00008840|7077","August 29, 2005","August 2005","April 2010","January 14, 2013","January 2013","August 19, 2010","null","May 2009","Tumor Resolution|Local Regional Control|Failure Free Survival","https://ClinicalTrials.gov/show/NCT00140556"
1681,"NCT00601705","Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach","Active, not recruiting","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: oxaliplatin|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","61","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE2Y07|P30CA043703|NCI-2010-01196","January 23, 2008","January 2008","null","February 4, 2016","February 2016","No Study Results Posted","null","June 2012","Feasibility of resectability rate|Response rate|Overall survival|Locoregional control and distant metastatic control|Toxicity","https://ClinicalTrials.gov/show/NCT00601705"
1682,"NCT00004100","Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: vinorelbine tartrate","Istituto Nazionale per lo Studio e la Cura dei Tumori|NCIC Clinical Trials Group|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067316|ITA-GEMVIN|CAN-NCIC-BR14|EU-99016","December 10, 1999","November 1998","null","December 17, 2013","June 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004100"
1683,"NCT01472653","Treatment Selection According to Skin Reaction to Cetuximab","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Radiation: radiotherapy|Drug: cetuximab","Institute of Oncology Ljubljana","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ORL-01-11","October 23, 2011","December 2011","December 2016","December 11, 2011","December 2011","No Study Results Posted","null","March 2014","locoregional complete response rate|feasibility (toxicity profile) of the proposed regimen|locoregional control|progression-free survival|overall survival|late toxicity including thyroid function","https://ClinicalTrials.gov/show/NCT01472653"
1684,"NCT02324296","PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases","Completed","No Results Available","Small Cell Lung Cancer","Drug: ifosfamide","Arcispedale Santa Maria Nuova-IRCCS","All","18 Years to 75 Years   (Adult, Senior)","","46","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PEI 01","December 11, 2014","December 1998","December 2010","December 19, 2014","December 2014","No Study Results Posted","null","January 2009","partial response (PR)|complete response (CR)|Median time to progression (TTP)|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02324296"
1685,"NCT00002493","Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer","Completed","No Results Available","Endometrial Cancer|Psychosocial Effects of Cancer and Its Treatment","Drug: cisplatin|Drug: doxorubicin hydrochloride|Radiation: low-LET photon therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","GOG-0122|CDR0000077572","November 1, 1999","May 1992","null","February 12, 2014","February 2014","No Study Results Posted","null","April 2001","","https://ClinicalTrials.gov/show/NCT00002493"
1686,"NCT00005086","Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer","Completed","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine hydrochloride|Drug: methotrexate","University of Chicago|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11203|UCCRC-11203|NCI-G00-1733","April 6, 2000","August 1999","April 2005","September 4, 2013","September 2013","No Study Results Posted","null","August 2002","Safety and toxic effects of giving docetaxel and methotrexate followed by gemcitabine and cisplatin","https://ClinicalTrials.gov/show/NCT00005086"
1687,"NCT00005049","Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer","Completed","No Results Available","Colorectal Cancer|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Ovarian Cancer|Peritoneal Cavity Cancer|Small Intestine Cancer","Drug: carboplatin|Drug: cisplatin|Drug: floxuridine","New York University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067641|P30CA016087|NYU-9645|NCI-G00-1717","April 6, 2000","May 1997","null","April 4, 2011","April 2011","No Study Results Posted","null","November 2006","","https://ClinicalTrials.gov/show/NCT00005049"
1688,"NCT00193882","Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.","Completed","No Results Available","Esophagus Cancer","Drug: Cisplatin|Radiation: Radiotherapy|Drug: 5-Fluorouracil","Trans-Tasman Radiation Oncology Group (TROG)|National Health and Medical Research Council, Australia|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TROG 03.01|NCIC CTG ES.2|TGA 2004/83|NHMRC 291103","September 13, 2005","July 7, 2003","June 18, 2013","January 23, 2017","January 2017","No Study Results Posted","null","March 21, 2012","Relief of dysphagia|Dysphagia progression free survival.|Quality of Life differences post treatment and at 3 months and 6 months.|Acute and late toxicity.|Survival.|Time to achieving any response in dysphagia after treatment as measured by an improvement of at least 1 point on the 5 point dysphagia scale.|Number of patients receiving secondary treatment (radiation, chemotherapy or stenting).|Time to achieving a complete response i.e. dysphagia score of 0.","https://ClinicalTrials.gov/show/NCT00193882"
1689,"NCT00002521","Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Temple University","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078282|TUHSC-2161|NCI-V93-0248","November 1, 1999","February 1993","February 2000","September 30, 2010","September 2010","No Study Results Posted","null","February 2000","","https://ClinicalTrials.gov/show/NCT00002521"
1690,"NCT01409174","IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma","Drug: Ipilimumab|Drug: Temozolomide|Drug: Cisplatin|Drug: Interferon Alfa-2b|Drug: Interleukin-2","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-0073|NCI-2011-02768","August 2, 2011","February 2013","May 2016","May 10, 2016","May 2016","No Study Results Posted","null","May 2016","Tumor Response by Participant using immune-related response criteria (irRC)","https://ClinicalTrials.gov/show/NCT01409174"
1691,"NCT00539630","TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN","Completed","No Results Available","Carcinoma, Squamous Cell","Drug: Docetaxel","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976F_3501","October 3, 2007","November 2002","null","October 3, 2007","October 2007","No Study Results Posted","null","null","Clinical response will be evaluated by modified WHO criteria. Clinical and radiological assessment of all lesions will be performed|Pathologic response if clinical response of primary tumor is CR at the end of chemotherapy and end of concurrent chemo/ radiotherapy, biopsy of primary tumor site will be performed to evaluate pathologic response rate.","https://ClinicalTrials.gov/show/NCT00539630"
1692,"NCT02934503","Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)","Not yet recruiting","No Results Available","Small Cell Lung Cancer (SCLC)","Biological: Pembrolizumab|Drug: Cisplatin|Drug: Carboplatin|Drug: Etoposide|Radiation: Radiation therapy","New York University School of Medicine|Merck Sharp & Dohme Corp.","All","19 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S16-01031","October 13, 2016","December 2016","October 2020","November 11, 2016","November 2016","No Study Results Posted","null","October 2019","Change in PD-L1 expression status as determined by immunohistochemistry in pretreatment and archival samples|Number of participants with progression-free survival (PFS)|Number of participants with overall survival|Response evaluation using Response Evaluation Criteria In Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT02934503"
1693,"NCT00002722","High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: leucovorin calcium","European Organisation for Research and Treatment of Cancer - EORTC","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","135","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-40953|GER-AIO-02/95","November 1, 1999","January 1996","null","March 2, 2012","March 2012","No Study Results Posted","null","August 1999","","https://ClinicalTrials.gov/show/NCT00002722"
1694,"NCT00003322","Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: quality-of-life assessment","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","384","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066273|GOG-0172","November 1, 1999","March 1998","null","May 24, 2013","August 2012","No Study Results Posted","null","January 2006","","https://ClinicalTrials.gov/show/NCT00003322"
1695,"NCT00191230","Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non Small Cell Lung","Drug: gemcitabine|Drug: carboplatin|Drug: cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5489|B9E-US-S236","September 12, 2005","September 2001","July 2006","January 24, 2007","January 2007","No Study Results Posted","null","null","Complete pathological response|Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.","https://ClinicalTrials.gov/show/NCT00191230"
1696,"NCT00006027","Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: adjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Gynecologic Oncology Group","Female","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-9905|CDR0000068040|GOG-0194|RTOG-DEV-1047","July 5, 2000","August 2000","null","August 9, 2013","August 2013","No Study Results Posted","null","June 2004","","https://ClinicalTrials.gov/show/NCT00006027"
1697,"NCT01181401","InductionChemo-Radio-Antibody-Treatment","Unknown status","No Results Available","Squamous Cell Carcinoma of the Head|Squamous Cell Carcinoma of the Neck","Drug: TPF induction chemotherapy|Drug: TPF experimental|Radiation: Standard Radiochemotherapy (HART)","Charite University, Berlin, Germany","All","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT No. 2010-019347-18","August 12, 2010","August 2010","December 2012","August 26, 2010","August 2010","No Study Results Posted","ICRAT","December 2012","Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.|Survival and late morbidity","https://ClinicalTrials.gov/show/NCT01181401"
1698,"NCT00006048","ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gefitinib|Drug: gemcitabine hydrochloride","AstraZeneca|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000068064|ZENECA-1839IL/0014","July 5, 2000","May 2000","null","December 18, 2013","July 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006048"
1699,"NCT00003742","Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: irinotecan hydrochloride|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","98-100|CDR0000066860|NCI-G99-1495","November 1, 1999","October 1998","August 2001","June 20, 2013","June 2013","No Study Results Posted","null","August 2001","","https://ClinicalTrials.gov/show/NCT00003742"
1700,"NCT00027703","Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma","Completed","No Results Available","Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma","Drug: gemcitabine hydrochloride|Drug: cisplatin|Biological: bevacizumab|Other: placebo|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","106","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","NCI-2012-02430|CDR0000069058|NCI-2710|UCCRC-11046A|11046A|2710|N01CM17102|P30CA014599","December 7, 2001","October 2001","null","February 10, 2014","December 2012","No Study Results Posted","null","May 2006","Time to disease progression|Complete response rate|Objective response rate (complete and partial response)|Rate of disease stabilization|Overall survival|Incidence of adverse events graded according to NCI CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00027703"
1701,"NCT01967875","A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer","Unknown status","No Results Available","Stomach Neoplasms","Drug: Capecitabine+Cisplatin|Drug: Docetaxel+Capecitabine","China Medical University, China","All","18 Years to 65 Years   (Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLOG1301","October 15, 2013","July 2013","May 2016","October 18, 2013","October 2013","No Study Results Posted","null","May 2015","Progression-Free Survival (PFS)|Overall Survival(OS)|Objective Response Rate(ORR),Including Complete Response(CR) and Partial Response(PR)|Disease Control Rate(DCR), Including Complete Response(CR) , Partial Response(PR) and Stable Disease(SD)|Duration of Response|Safety(number and degree of adverse events)|Quality of Life(QOL)","https://ClinicalTrials.gov/show/NCT01967875"
1702,"NCT00770393","Laryngeal Preservation in Pyriform Sinus Carcinoma","Completed","No Results Available","Squamous Cell Carcinoma","Procedure: induction chemotherapy|Procedure: Conventionnal chemotherapy","Centre Hospitalier Universitaire de Saint Etienne","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","71","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0201089","October 9, 2008","February 2002","June 2007","October 9, 2008","October 2008","No Study Results Posted","null","June 2005","The primary end point was to compare the two treatment arms to define the best schedule of preservation of an intact larynx.|Secondary end points analyzed causes of death, overall survival rate and event (loco-regional recurrent disease, metastases, death) free survival rate.","https://ClinicalTrials.gov/show/NCT00770393"
1703,"NCT02047201","Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Radiation: IMRT|Radiation: PET/CT|Drug: Docetaxel|Drug: Fluorouracil|Drug: Cisplatin","Lithuanian University of Health Sciences","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EHNCTE-1309","January 22, 2014","June 2013","January 2016","March 1, 2016","March 2016","No Study Results Posted","null","January 2016","Progression free survival (PFS)|Tumour metabolic response (MTV) reduction (%)|Total lesion glycolysis (TLG) reduction (%)|SUVmax reductions (%)|Number (%) of participants with adverse events|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02047201"
1704,"NCT02350712","Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer","Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Patritumab|Drug: Cetuximab|Drug: Cisplatin|Drug: Carboplatin","Daiichi Sankyo Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","U31287-A-U106","January 19, 2015","December 2014","June 2016","April 20, 2017","April 2017","No Study Results Posted","null","March 2016","Percentage of participants experiencing dose-limiting toxicities (DLTs)|Pharmacokinetic profile of serum patritumab|Pharmacokinetic profile of serum cetuximab|Percentage of participants with human anti-human antibody (HAHA) formation (anti-patritumab antibodies)|Titer of HAHA formation (anti-patritumab antibodies)","https://ClinicalTrials.gov/show/NCT02350712"
1705,"NCT00006248","S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","78","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068180|S0007|U10CA032102","September 11, 2000","November 2000","June 2005","April 8, 2013","April 2013","No Study Results Posted","null","June 2005","Overall Survival","https://ClinicalTrials.gov/show/NCT00006248"
1706,"NCT01285037","A Study of LY2801653 in Advanced Cancer","Recruiting","No Results Available","Cancer","Drug: LY2801653|Drug: Cetuximab|Drug: Cisplatin|Drug: Gemcitabine|Drug: Ramucirumab","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","190","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13008|I3O-MC-JSBA","January 26, 2011","September 9, 2009","May 17, 2018","March 27, 2017","March 2017","No Study Results Posted","null","May 17, 2018","Recommended dose for phase 2 studies: Maximum tolerated dose|Number of participants with tumor response|Clinical benefit rate (CBR)|Progression free survival (PFS)|Duration of response|Number of participants with clinically significant effects|Pharmacokinetics: Area under the concentration/time curve (AUC)|Pharmacokinetics: Maximum plasma concentration (Cmax)|Maximum tolerated dose (MTD) of LY2801653 in combination with cetuximab for phase 2 studies in HNSCC|Maximum tolerated dose (MTD) of LY2801653 in combination with cisplatin for phase 2 studies in cholangiocarcinoma|Maximum tolerated dose (MTD) of LY2801653 in combination with gemcitabine plus cisplatin for phase 2 studies in cholangiocarcinoma|Maximum tolerated dose (MTD) of LY2801653 in combination with ramucirumab for phase 2 studies in gastric carcinoma","https://ClinicalTrials.gov/show/NCT01285037"
1707,"NCT02908477","Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer","Recruiting","No Results Available","Oropharynx Cancer","Radiation: Adjuvant Radiation Therapy|Drug: Docetaxel|Drug: Cisplatin","Mayo Clinic","All","18 Years and older   (Adult, Senior)","Phase 3","214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16-004083","August 26, 2016","August 2016","August 2026","May 23, 2017","May 2017","No Study Results Posted","null","December 2021","Adverse Events Rate|Local/regional control|Quality of Life","https://ClinicalTrials.gov/show/NCT02908477"
1708,"NCT00719550","AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer","Completed","No Results Available","Esophagogastric Junction Adenocarcinoma|Gastric Cancer|Esophageal Cancer","Drug: Capecitabine|Drug: Epirubicin|Drug: AMG 102|Drug: Cisplatin|Drug: Placebo","Amgen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","20060317","July 17, 2008","February 2009","June 2013","November 13, 2013","November 2013","No Study Results Posted","null","November 2010","Progression free survival (PFS), as measured by RECIST per local review|Overall survival, objective response rate, disease control rate, time to response (for responders only), and duration of response (for responders only).|Incidence of adverse events, significant laboratory value changes form baseline and anti-AMG 102 antibody formation.|Cmax and Cmin for AMG 102; Cmax and AUC for epirubicin and cisplatin with or without AMG 102","https://ClinicalTrials.gov/show/NCT00719550"
1709,"NCT00717938","A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer","Active, not recruiting","No Results Available","Small Cell Lung Cancer","Drug: cisplatinum or carboplatin and e.g.etoposide.|Drug: cisplatinum or carboplatin and e.g.etoposide+enoxaparin","Lund University Hospital|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","390","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT number 2007-006033-14","July 16, 2008","June 2008","June 2017","September 13, 2016","September 2016","No Study Results Posted","RASTEN","June 2017","Significant increase of overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00717938"
1710,"NCT01088802","Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of Oropharynx","Radiation: IMRT|Drug: Cisplatin|Drug: Carboplatin","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","J0988, NA_00026771|NA_00026771","August 4, 2009","January 2010","February 2018","May 20, 2016","May 2016","No Study Results Posted","null","February 2018","Grade 3+ late toxicity|Quality of Life|Adverse events and their cause","https://ClinicalTrials.gov/show/NCT01088802"
1711,"NCT00907543","Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial","Recruiting","No Results Available","Esophageal Neoplasms","Other: Preoperative treatment of chemotherapy and radiation|Other: Postoperative treatment of chemotherapy and radiation","Richard Malthaner|Lawson Health Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","R-09-025","May 21, 2009","April 2009","April 2017","October 3, 2016","October 2016","No Study Results Posted","QUINTETT","April 2017","Quality of life as assessed by FACT-E|Safety and morbidity","https://ClinicalTrials.gov/show/NCT00907543"
1712,"NCT02353260","Efficacy and Safety of Ultrasound Hyperthermia Combined With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer","Device: Ultrasound Hyperthermia|Drug: Docetaxel,Cisplatin,Fluorouracil","Wei Guo|Xuzhou Central Hospital|Shanghai 9th People's Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","14-A","January 28, 2015","December 2014","September 2017","January 30, 2015","January 2015","No Study Results Posted","null","March 2016","Rate of Disease Control|Progression Free Survival|Over Survival","https://ClinicalTrials.gov/show/NCT02353260"
1713,"NCT01268878","Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol","Completed","No Results Available","Squamous Cell Head and Neck Carcinoma","","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years and older   (Adult, Senior)","","130","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GORTEC 2010-01","December 29, 2010","June 2010","November 2011","January 2, 2014","January 2014","No Study Results Posted","OTOHTPF","November 2011","biologic blood counts","https://ClinicalTrials.gov/show/NCT01268878"
1714,"NCT01551589","Elective or Prophylactic Nodal Irradiation for Esophageal Cancer","Unknown status","No Results Available","Esophageal Squamous Cell Carcinoma","Radiation: docetaxel and cisplatin concurrent chemoradiotherapy|Radiation: docetaxel and cisplatin","LANG Jin-yi|The Second People's Hospital of Sichuan","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSWOG0001|BT-IST-SCCHN-037","March 4, 2012","March 2012","September 2015","March 8, 2012","March 2012","No Study Results Posted","ENI or PNI","September 2014","Local control rate/ Inside irrational field recurrence rate|3-year Overall survival(OS)|3-year Disease-free survival|Quality of life(QoL)|Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01551589"
1715,"NCT01544179","A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","Active, not recruiting","Has Results","Non-Small Cell Lung Cancer","Drug: Gefitinib|Drug: Placebo|Drug: Pemetrexed|Drug: Cisplatin","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","D791LC00001","February 15, 2012","March 15, 2012","December 29, 2017","April 18, 2017","April 2017","April 29, 2015","IMPRESS","May 5, 2014","Progression-Free Survival (Site Read, Investigator Assessment)|Median Progression-Free Survival (Site Read, Investigator Assessment)|Overall Survival (OS)|Median Overall Survival (OS) at Time of PFS Analysis|Objective Response Rate (ORR) (Site Read Data)|Disease Control Rate (DCR)|Improvement in Trial Outcome Index|Time to Worsening in Trial Outcome Index|Improvement in FACT-L Total Score|Time to Worsening in FACT-L Total Score|Improvement in Lung Cancer Subscale|Time to Worsening in Lung Cancer Subscale","https://ClinicalTrials.gov/show/NCT01544179"
1716,"NCT01755897","A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients","Active, not recruiting","No Results Available","Uterine Cervical Neoplasms|Cervical Cancer|Uterine Cervical Cancer","Procedure: radical hysterectomy + pelvic lymph node dissection|Drug: Paclitaxel|Drug: Cisplatin|Drug: Cisplatin|Radiation: Pelvic RT","Huazhong University of Science and Technology|Zhejiang University|Shandong University","Female","up to 60 Years   (Child, Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-GYN/CC-01","December 19, 2012","November 2012","December 2017","October 7, 2016","October 2016","No Study Results Posted","CC-01","December 2015","disease-free survival (DFS) of the adjuvant chemotherapy arm (arm A)|DFS of the adjuvant CCRT arm (arm B)|3-year overall survivals (OS) of the arm A and the arm B|Quality of Life in two arms|chemotherapy- and radiotherapy- related adverse effects respectively in two arms","https://ClinicalTrials.gov/show/NCT01755897"
1717,"NCT00539669","TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian","Completed","No Results Available","Ovarian Neoplasms","Drug: Docetaxel","Sanofi","Female","18 Years and older   (Adult, Senior)","Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976I_2502","October 3, 2007","March 2003","null","October 3, 2007","October 2007","No Study Results Posted","null","null","The response rate will be determined by the number of patients with complete and partial responses according to the Modified SWOG Response Criteria. The progression free survival, duration of response and survival are evaluated.","https://ClinicalTrials.gov/show/NCT00539669"
1718,"NCT02337712","Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer","Recruiting","No Results Available","Small Cell Lung Cancer","Radiation: q.d. RT|Radiation: b.i.d.RT","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","204","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-FXY-037","January 9, 2015","January 2015","December 2020","April 15, 2017","March 2017","No Study Results Posted","null","December 2020","progression-free survival","https://ClinicalTrials.gov/show/NCT02337712"
1719,"NCT00423449","Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: vorinostat|Drug: Gemcitabine|Drug: Platinum-based agent","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0683-058|2006_528","January 17, 2007","March 2007","April 2010","February 3, 2016","February 2016","July 6, 2011","null","April 2010","Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin|Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease|Number of Participants With Clinical Adverse Experiences (Safety and Tolerability)|Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability)","https://ClinicalTrials.gov/show/NCT00423449"
1720,"NCT01512407","RCT on Adjuvant TACE After Hepatectomy for HCC","Recruiting","No Results Available","Hepatocellular Carcinoma","Procedure: Transarterial chemoembolisation using cisplatin-lipiodol mixture","Chinese University of Hong Kong","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CRE-2011.236-T","January 14, 2012","January 2012","January 2018","February 2, 2015","February 2015","No Study Results Posted","A-TECH","January 2017","1-year recurrence rate|Disease-free survival|Overall Survival|Complications of transarterial chemoembolisation|Health-related quality of life assessment","https://ClinicalTrials.gov/show/NCT01512407"
1721,"NCT00301028","Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer","Biological: Cetuximab|Drug: Carboplatin|Drug: Paclitaxel|Procedure: Conventional Surgery|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0919|P50CA097007|P30CA016672|MDA-2003-0919|BMS-CA225054|CDR0000441273","March 8, 2006","April 2006","September 2011","February 26, 2013","February 2013","February 26, 2013","null","September 2011","Number of Participants With Complete Response","https://ClinicalTrials.gov/show/NCT00301028"
1722,"NCT00193921","Chemoradiotherapy in Patients With Localised Lung Cancer","Completed","No Results Available","Non Small Cell Lung Carcinoma","Drug: Vinorelbine|Radiation: High dose Radiotherapy|Drug: Gemcitabine|Drug: Cisplatin|Radiation: High Dose Radiotherapy","Trans-Tasman Radiation Oncology Group (TROG)|Cancer Council Queensland|Victorian Cancer Council","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TROG 03.07|PMCC Protocol No. 03/85","September 13, 2005","February 2003","December 2012","July 31, 2014","July 2014","No Study Results Posted","null","December 2009","Objective response rate (RECIST criteria)|Symptomatic response rate|The feasibility (i.e. % of patients who cannot complete the planned RT dose or who require a break for toxicity) and problems encountered with protocol compliance in the setting of a multi-institutional TROG study.|Toxicity of both treatments|Progression-free survival|QOL as assessed by FACT-L version 4.","https://ClinicalTrials.gov/show/NCT00193921"
1723,"NCT01076231","Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery","Recruiting","No Results Available","Stage IIIA Non-small Cell Lung Cancer","Radiation: proton beam radiation therapy|Drug: cisplatin|Drug: etoposide|Procedure: therapeutic conventional surgery","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 25508|NCI-2010-00251","February 23, 2010","January 2010","null","April 11, 2016","April 2016","No Study Results Posted","null","July 2017","Feasibility|Dose-limiting toxicity|Pathologic CR rate|Late toxicity","https://ClinicalTrials.gov/show/NCT01076231"
1724,"NCT00310128","Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma","Withdrawn","No Results Available","AIDS-related Lymphoma|Adult Non-Hodgkin's Lymphoma|Anaplastic Large Cell Lymphoma","Drug: cisplatin|Drug: cytarabine|Drug: etoposide|Drug: methylprednisolone|Drug: rituximab|Drug: yttrium Y 90 ibritumomab tiuxetan|Procedure: antibody therapy|Procedure: biological therapy|Procedure: chemotherapy|Procedure: monoclonal antibody therapy|Procedure: radiation therapy|Procedure: radioimmunotherapy|Procedure: radioisotope therapy","AIDS Malignancy Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","AMC-044|CDR0000467797","March 29, 2006","February 2006","null","February 1, 2016","February 2016","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00310128"
1725,"NCT00550784","Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: topotecan hydrochloride|Genetic: TdT-mediated dUTP nick end labeling assay|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: pharmacological study|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","Female","up to 60 Years   (Child, Adult)","Phase 1","8","Other|NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","00067|P30CA033572|CHNMC-00067|CCC-PHI-31|CDR0000567474","October 22, 2007","January 2001","October 2014","October 3, 2014","October 2014","No Study Results Posted","null","October 2014","Toxicity|Tumor response|Reason patient is removed from study|Disease progression|Overall survival|Progression-free survival|Time to progression","https://ClinicalTrials.gov/show/NCT00550784"
1726,"NCT00003118","Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: surgical procedure|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","56","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9781|U10CA031946|CLB-C9781|E-C9781|NCCTG-C9781|RTOG-9716|CDR0000065873","November 1, 1999","October 1997","March 2000","July 1, 2016","June 2016","No Study Results Posted","null","March 2000","Overall survival","https://ClinicalTrials.gov/show/NCT00003118"
1727,"NCT00002601","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma","Completed","Has Results","Sarcoma","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","10 Years to 55 Years   (Child, Adult)","Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","94072|P30CA033572|CHNMC-IRB-94072|NCI-V94-0545|CDR0000063845","November 1, 1999","September 1994","September 2014","January 18, 2017","January 2017","November 21, 2016","null","September 2014","Number of Participants With Grade 3 Bilirubin|Toxicities Counts|5-year Progression-free Survival|5-year Overall Survival","https://ClinicalTrials.gov/show/NCT00002601"
1728,"NCT03071289","A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer","Not yet recruiting","No Results Available","Cervical Cancer|Lymphocyst|Radiation Therapy","Radiation: Radiation Method B|Drug: Cisplatin|Radiation: Radiation Method A","Sun Yat-sen University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","540","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","N2016203","March 1, 2017","April 1, 2017","March 31, 2025","March 3, 2017","March 2017","No Study Results Posted","null","March 31, 2025","5-year local-recurrence-free survival (5y-LRFS)|Incidence of grade 3/4 adverse event|5-year overall survival (5y-OS)","https://ClinicalTrials.gov/show/NCT03071289"
1729,"NCT00006111","Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract","Unknown status","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068123|FRE-FNCLCC-97015|EU-20009","August 3, 2000","April 1999","null","February 6, 2009","May 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006111"
1730,"NCT02031250","Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Cisplatin|Drug: Carboplatin|Radiation: IMRT (Intensity-Modulated Radiation Therapy)|Radiation: Boost Radiation to Hypoperfused Volumes","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2013.062|HUM00074305","December 12, 2013","February 2014","null","June 16, 2016","June 2016","No Study Results Posted","null","December 2020","Disease Free Survival (DSF) time|Local-regional control rate|Proportion of patients in which hypoperfused subvolumes overlap with recurrence volumes|Number of patients with adverse events|Correlation coefficient between continuous dose and perfusion summary measures","https://ClinicalTrials.gov/show/NCT02031250"
1731,"NCT01982955","Tepotinib With Gefitinib in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Tepotinib|Drug: Gefitinib|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EMR 200095-006|2016-001604-28","October 29, 2013","December 2013","October 2019","March 9, 2017","March 2017","No Study Results Posted","INSIGHT","September 2019","Phase 1b: Number of subjects experiencing at least one dose limiting toxicity (DLT)|Phase 1b: Percentage of subjects with adverse events (AEs)|Phase 2 (randomized): Progression free survival (PFS) time: Investigator assessments or site radiologist assessment|Phase 2 (randomized): Progression free survival (PFS) time: Independent review assessments|Phase 2 (single arm cohort): Progression free survival (PFS) time: Investigator and Independent review assessment|Overall Survival (OS) Time|Percentage of subjects with objective response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) criteria|Percentage of subjects with disease control according to RECIST version 1.1 criteria|Phase 1b: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time AUC (0-t)|Percentage of subject with treatment emergent adverse events (TEAEs), treatment related TEAEs, SAEs, treatment related SAEs, TEAEs with toxicity >= 3, treatment related TEAEs >= 3, and TEAEs leading to permanent treatment discontinuation|Phase 1b: Area Under the Plasma Concentration Versus Time Curve within 1 dosing interval (AUC 0-tau)|Phase 1b: Maximum Observed Plasma Concentration (Cmax)|Phase 1b: Average Plasma Concentration (Cavg)|Phase 1b: Minimum Concentration (Cmin)|Phase 1b:Time to Maximum Concentration (Tmax)|Phase 1b: Area Under the Curve From Time Zero to Infinity (AUC 0-inf)|Phase 1b: Apparent Body Clearance of the drug from Plasma (CL/F)|Phase 1b: Apparent Volume of Distribution (Vz/F)|Phase 1b: Volume of Distribution at Steady State (Vss/F)|Phase 1b: Apparent Terminal Rate Constant (λ z)|Phase 1b: Apparent Terminal Half-Life (t1/2)|Percentage of subjects with death with reasons within 30 (±3) days after the last dose of study drug|Percentage of subjects with abnormalities in safety laboratory tests as graded by NCI-CTCAE (Version 4.0)|Percentage of subjects with abnormalities incl. vital signs, 12-lead ECG changes, physical examination, body weight, and Eastern Cooperative Oncology Group (ECOG) PS|Health related quality of life (HRQoL)|Time-to-Symptom Progression (TTSP) measured by Lung Cancer Symptom Scale (LCSS)","https://ClinicalTrials.gov/show/NCT01982955"
1732,"NCT02187315","Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Device: Chrono-chemotherapy pump:Melodie|Device: Routine intravenous drip|Drug: induction chemotherapy|Drug: cisplatin chrono-chemotherapy|Radiation: intensity-modulated radiation therapy|Drug: cisplatin routine-chemotherapy","Feng Jing|Guiyang Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Care Provider)|Primary Purpose: Treatment","20140501","May 15, 2014","May 2014","December 2019","July 10, 2014","July 2014","No Study Results Posted","null","December 2018","Number of Participants with Adverse Events as a Measure of Safety|Number of Participants with curative effect","https://ClinicalTrials.gov/show/NCT02187315"
1733,"NCT00778908","Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Carcinoma","Radiation: Late-course accelerated hyperfractionated IMRT|Drug: Concomitant cisplatin chemotherapy|Radiation: Conventionally fractionated IMRT","Guangxi Medical University|People's Hospital of Guangxi|Guangxi Sci-Tech Office","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GUIKEGONG-0816004-40","October 22, 2008","January 2008","December 2011","August 17, 2012","August 2012","No Study Results Posted","null","January 2011","Local/regional control rate, Acute and late toxicities|Overall survival rate","https://ClinicalTrials.gov/show/NCT00778908"
1734,"NCT00474669","A Phase I Study of Intraperitoneal Hyperthermic Docetaxel","Completed","No Results Available","Ovarian Carcinoma","Drug: docetaxel","James Graham Brown Cancer Center|University of Louisville","Female","19 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BCC-GYN-07-001","May 15, 2007","June 2007","December 2009","April 22, 2013","January 2010","No Study Results Posted","IP","December 2009","Assess the MTD of docetaxel administered intraperitoneally with heat at the time of second-look surgery in patients with stage II/III ovarian carcinoma following surgery and normothermic intraperitoneal and intravenous cisplatin and paclitaxel.|To assess the quality of life of patients treated with intraperitoneal hyperthermic chemotherapy in this setting","https://ClinicalTrials.gov/show/NCT00474669"
1735,"NCT00525200","p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: 5-Fluoruracil, Cisplatinum|Drug: Docetaxel","Daniela Kandioler|Medical University of Vienna|Austrian Society Of Surgical Oncology","All","18 Years and older   (Adult, Senior)","Phase 3","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","ASSO OE-1|EudraCT 2006-006647-31","September 4, 2007","June 2007","December 2012","December 20, 2012","December 2012","No Study Results Posted","PANCHO","May 2012","Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype|Complete pathological response and relation to p53 genotype|Complete tumor resection rate|Perioperative morbidity and mortality|Disease free and overall survival and relation to p53 genotype","https://ClinicalTrials.gov/show/NCT00525200"
1736,"NCT02060656","Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Gemcitabine|Drug: Methylprednisolone|Drug: Rituximab|Drug: Cisplatin|Drug: Lenalidomide","Royal Marsden NHS Foundation Trust|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RMH CCR: 3862|2012-002620-32","January 22, 2014","September 2013","null","February 10, 2014","February 2014","No Study Results Posted","LEGEND","February 2016","Complete response rate (CRR)|Overall Response Rate|Event-free Survival|Overall Survival|Rates of successful stem cell harvest","https://ClinicalTrials.gov/show/NCT02060656"
1737,"NCT00020709","Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Drug: cisplatin|Drug: docetaxel|Drug: etoposide|Drug: gefitinib|Radiation: radiation therapy|Other: placebo","National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","840","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","NCI-2012-03041|S0023|U10CA032102|CDR0000068706","July 11, 2001","June 2001","null","February 26, 2013","February 2013","No Study Results Posted","null","February 2007","Overall Survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT00020709"
1738,"NCT02902432","A Trial of Endostar in Patients With Carcinoma of the Head and Neck","Recruiting","No Results Available","Nasopharyngeal Neoplasms","Drug: Endostar","China International Medical Foundation","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Investigator, Outcomes Assessor|Primary Purpose: Treatment","ChinaIMF","August 12, 2016","June 2016","December 2018","March 28, 2017","March 2017","No Study Results Posted","null","October 2017","Progression-Free Survival (Mon); PFS, According to RECIST v1.1|Quality of life (QOL); Scores range from 0 to 5","https://ClinicalTrials.gov/show/NCT02902432"
1739,"NCT00002536","Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer","Completed","No Results Available","Cervical Cancer","Drug: cisplatin|Drug: vincristine sulfate|Procedure: surgical procedure|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000078470|GOG-141","November 1, 1999","December 1996","null","July 8, 2013","March 2008","No Study Results Posted","null","August 2007","","https://ClinicalTrials.gov/show/NCT00002536"
1740,"NCT00014209","Combination Chemotherapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma That Has Not Responded to Previous Treatment","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: dexamethasone|Drug: gemcitabine hydrochloride","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","16 Years to 120 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","LY10|CAN-NCIC-LY10|LILLY-CAN-NCIC-LY10|CDR0000068518","April 10, 2001","December 2000","February 2009","November 25, 2016","March 2010","No Study Results Posted","null","July 2002","","https://ClinicalTrials.gov/show/NCT00014209"
1741,"NCT01125020","Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation","Unknown status","No Results Available","Liver Transplantation|Hepatocellular Carcinoma|Tumor Recurrence and Metastasis|Survival|Adjuvant Chemotherapy","Drug: gemcitabine and oxaliplatin|Drug: doxorubicin, 5-Fu and cisplatin","Shanghai Jiao Tong University School of Medicine|Shanghai Changzheng Hospital","All","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008BAI60B03","May 17, 2010","December 2008","December 2010","May 17, 2010","May 2010","No Study Results Posted","null","May 2010","tumor recurrence and metastasis|Postoperative survival","https://ClinicalTrials.gov/show/NCT01125020"
1742,"NCT01450761","Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","Active, not recruiting","Has Results","Small Cell Lung Carcinoma","Biological: Ipilimumab|Biological: Placebo matching Ipilimumab|Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 3","1414","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","CA184-156|2011-000850-48","October 10, 2011","December 2011","March 2017","February 1, 2017","June 2016","March 7, 2016","null","March 2015","Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy|Overall Survival in All Randomized Participants|Progression Free Survival (PFS) Time in Participants Who Have Received at Least One Dose of Blinded Study Therapy","https://ClinicalTrials.gov/show/NCT01450761"
1743,"NCT00411138","Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer","Active, not recruiting","No Results Available","Endometrial Cancer","Radiation: Radiation Therapy|Drug: cisplatin|Drug: carboplatin|Drug: Paclitaxel","Leiden University Medical Center|Cancer Research UK|Australia New Zealand Gynaecological Oncology Group|NCIC Clinical Trials Group|Mario Negri Institute for Pharmacological Research|UNICANCER","Female","18 Years to 90 Years   (Adult, Senior)","Phase 3","670","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000521447; P06.031|CKTO-2006-04|ISRCTN14387080|P06.031-PORTEC-3|2007-004917-33","December 11, 2006","October 2006","December 2020","April 24, 2016","April 2016","No Study Results Posted","PORTEC-3","December 2017","Overall survival|Failure-free survival|Quality of life by QLQ-C30 v3.0|Severe treatment-related morbidity|Rate of vaginal or pelvic relapse|Rate of distant metastases","https://ClinicalTrials.gov/show/NCT00411138"
1744,"NCT00002882","Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma","Completed","No Results Available","Melanoma|Skin Cancer","Biological: Aldesleukin (IL-2)|Biological: Recombinant Interferon Alfa (IFN-A)|Drug: Cisplatin|Drug: Dacarbazine|Drug: Vinblastine|Procedure: Adjuvant Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","10 Years to 70 Years   (Child, Adult, Senior)","Phase 3","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID95-196|P30CA016672|MDA-ID-95196|MDA-DM-95196|NCI-G96-1089|CDR0000065188","November 1, 1999","November 1995","April 2006","December 12, 2011","December 2011","No Study Results Posted","null","August 2003","Effectiveness of Interferon Alfa with/without Combination Chemotherapy + Interleukin-2 for Melanoma","https://ClinicalTrials.gov/show/NCT00002882"
1745,"NCT00301301","A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)","Completed","No Results Available","Non-Hodgkins Lymphoma","Drug: Gemcitabine|Drug: Cisplatinum|Drug: Rituximab","Royal Marsden NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","","39","Other","Observational","Time Perspective: Retrospective","2656","March 9, 2006","null","null","January 11, 2010","January 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00301301"
1746,"NCT01160185","Meta-analysis of Efficacy of Topotecan","Completed","No Results Available","Cervical Intraepithelial Neoplasia","Drug: paclitaxel|Drug: cisplatin|Drug: topotecan","GlaxoSmithKline","Female","21 Years and older   (Adult, Senior)","","1","Industry","Observational","Time Perspective: Retrospective","114015","July 8, 2010","June 2009","July 2009","July 8, 2010","July 2010","No Study Results Posted","null","July 2009","Survival","https://ClinicalTrials.gov/show/NCT01160185"
1747,"NCT02760667","Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer","Drug: Cisplatinum|Drug: Docetaxel|Drug: Carboplatin|Procedure: Transoral Robotic Assisted Surgery","George Washington University","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GWU-MFA Head and Neck Protocol","April 8, 2016","June 2015","June 2020","April 27, 2016","April 2016","No Study Results Posted","null","June 2017","Disease specific survival (DSS)|Relapse-free survival|Overall survival|EORTC QLQ-C30|EORTC QLQ-H&N35","https://ClinicalTrials.gov/show/NCT02760667"
1748,"NCT00113581","Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: EMD 72000 (matuzumab) + ECX","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMD 72000-024","June 9, 2005","October 2002","January 2007","February 17, 2014","February 2014","No Study Results Posted","null","May 2006","Safety and tolerability|Pharmacodynamic parameters|Pharmacokinetic parameters|Response rate","https://ClinicalTrials.gov/show/NCT00113581"
1749,"NCT00004873","Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil","Swiss Group for Clinical Cancer Research","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SAKK 42/99|SWS-SAKK-42/99|EU-99021","March 7, 2000","August 1999","July 2003","May 14, 2012","May 2012","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00004873"
1750,"NCT03147404","Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes","Not yet recruiting","No Results Available","Neuroendocrine Carcinoma, Grade 3","Drug: Avelumab","Samsung Medical Center","All","20 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2017-04-085","May 8, 2017","July 2017","February 2020","May 8, 2017","May 2017","No Study Results Posted","MS100070-0177","June 2019","BEST OF RESPONSE|OVERALL RESPONSE","https://ClinicalTrials.gov/show/NCT03147404"
1751,"NCT02603003","the""Fuzzing"" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer(NSCLC)","Drug: JinFuKang|Drug: Cisplatin|Drug: Pemetrexed","Shanghai University of Traditional Chinese Medicine","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Treatment","Longhua Hospital|TJH20151021|LB20151106","October 21, 2015","June 2015","June 2018","April 24, 2017","April 2017","No Study Results Posted","CTC-TCM-FZ","June 2017","Progression-Free Survival|Circulating Tumor Cell|Overall survival","https://ClinicalTrials.gov/show/NCT02603003"
1752,"NCT01688700","Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma Resectable","Drug: Nimotuzumab combined with paclitaxel and cisplatin","Zhejiang Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NimoESCC","September 16, 2012","September 2012","September 2017","September 19, 2012","September 2012","No Study Results Posted","null","September 2013","Pathology complete remission rate|R0 resection rate|objective response rate|overall survival|tolerability and safety|Quality of life","https://ClinicalTrials.gov/show/NCT01688700"
1753,"NCT02784171","Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma","Recruiting","No Results Available","Mesothelioma","Drug: Cisplatin|Drug: Pemetrexed|Drug: Pembrolizumab","Canadian Cancer Trials Group|National Cancer Institute, Naples|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","I227|2016-002286-60","May 24, 2016","October 7, 2016","December 2019","May 8, 2017","March 2017","No Study Results Posted","null","May 2019","Progression free survival measured as time from randomization to first observation of objective disease relapse or progression|Number and severity of adverse events|Overall Survival|Quality of Life using EORTC QLQ-C30|Response rate compared using Fisher's exact test","https://ClinicalTrials.gov/show/NCT02784171"
1754,"NCT02250404","Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide","Recruiting","No Results Available","Small Cell Lung Cancer","Other: cytology specimen collection procedure|Other: laboratory biomarker analysis","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","3","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2O-13-1|NCI-2014-01910|HS-14-00382|UL1TR000130|P30CA014089","September 23, 2014","August 22, 2014","August 22, 2019","April 11, 2017","April 2017","No Study Results Posted","null","August 22, 2018","Change in tumor tissue molecular profiles","https://ClinicalTrials.gov/show/NCT02250404"
1755,"NCT01631357","Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: Arm 1: cytokine-induced killer cell + cisplatin + paclitaxel|Drug: Arm 2: cisplatin + paclitaxel","Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CIH-RXB-201205001","May 27, 2012","November 2016","December 2016","December 21, 2015","February 2013","No Study Results Posted","CIK","November 2016","Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT01631357"
1756,"NCT00040534","Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)","Terminated","No Results Available","Neoplasms","Drug: Farnesyl Protein Transferase Inhibitor","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P01499","June 28, 2002","January 2001","July 2004","February 13, 2015","February 2015","No Study Results Posted","null","July 2004","","https://ClinicalTrials.gov/show/NCT00040534"
1757,"NCT01147809","Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag","Completed","Has Results","Thrombocytopaenia","Drug: Eltrombopag olamine|Other: Placebo","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","112765","May 20, 2010","June 2010","March 2015","March 17, 2016","March 2016","August 27, 2015","null","January 2015","Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I|Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I|Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I|Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I|Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II|Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I|Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I|Platelet Count Nadir for Each Chemotherapy Cycle in Phase I|Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I|Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count|Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts|Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I|Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts|Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I|Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II|Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II|Number of Participants Requiring a Platelet Transfusion in Phase II|Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II|Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II|Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II|Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II|Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II|Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II|Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II|Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II|Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II|Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II|Platelet Count Nadir for Each Chemotherapy Cycle in Phase II|Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II|Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II|Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II|Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II|Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II","https://ClinicalTrials.gov/show/NCT01147809"
1758,"NCT01730222","A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma","Active, not recruiting","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: capecitabine|Drug: gemcitabine|Drug: nab-paclitaxel","IRCCS San Raffaele","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","137","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PACT-19|2012-001763-75","November 4, 2012","November 2012","June 2017","April 18, 2017","April 2017","No Study Results Posted","PACT-19","February 2017","first cycle toxicity for phase I part|progression-free survival for phase II part, stage IV patients|resectability rate for phase II part, stage III patients|response rate|biochemical response rate|toxicity|overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT01730222"
1759,"NCT02158988","Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis","Recruiting","No Results Available","Malignant Neoplasm of Stomach|Secondary Malignant Neoplasm of Peritoneum|Secondary Malignant Neoplasm of Other and Unspecified Sites","Procedure: HIPEC","Charite University, Berlin, Germany|German Cancer Aid","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Gastripec I","May 4, 2014","March 2014","September 2020","February 13, 2017","February 2017","No Study Results Posted","GASTRIPEC","September 2017","The primary outcome measure is overall survival|30 days complication-rate|time to progress|time to other distant metastases|quality of life","https://ClinicalTrials.gov/show/NCT02158988"
1760,"NCT00070096","Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor","Drug: ixabepilone","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000329992|MSKCC-03041|NCI-6022","October 3, 2003","August 2003","June 2007","June 21, 2013","April 2006","No Study Results Posted","null","null","Efficacy|Safety","https://ClinicalTrials.gov/show/NCT00070096"
1761,"NCT01284335","A Safety Study in Patients With Advanced Solid Tumors","Completed","No Results Available","Advanced Solid Tumors","Drug: Gemcitabine|Drug: Docetaxel|Drug: Temozolomide|Drug: Cisplatin|Drug: Erlotinib|Drug: LY573636","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","234","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12267|H8K-MC-JZAK","January 19, 2011","July 2008","May 2016","August 25, 2016","August 2016","No Study Results Posted","null","October 2012","Recommended Phase 2 dose|Pharmacokinetic, concentration maximum (Cmax)|Number of patients with a tumor response|Number of participants with a clinically significant effects|Pharmacokinetic, area under the curve (AUC)","https://ClinicalTrials.gov/show/NCT01284335"
1762,"NCT00945451","Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer","Recruiting","No Results Available","Lung Cancer","Device: CK","Centre Antoine Lacassagne","All","18 Years to 120 Years   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000639362|CALACASS-CYBERTAXCIS|INCA-RECF0941|2008-A01104-51","July 23, 2009","January 2009","December 2021","February 21, 2017","February 2016","No Study Results Posted","null","January 2018","Maximum tolerated dose (phase I)|Overall response rate by RECIST (phase II)","https://ClinicalTrials.gov/show/NCT00945451"
1763,"NCT01558947","Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer","Unknown status","No Results Available","Gastric Cancer","Drug: Peri-operative chemotherapy of ECX|Drug: Peri-operative chemotherapy of XP","Zhejiang Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","PC-AGC-01","March 7, 2012","January 2011","June 2013","March 18, 2012","March 2012","No Study Results Posted","null","December 2012","the relapse-free survival time/rate","https://ClinicalTrials.gov/show/NCT01558947"
1764,"NCT02957266","Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy","Recruiting","No Results Available","Cervical Cancer","Radiation: Volumetric Arc Radiotherapy|Radiation: Interstitial brachytherapy|Drug: Cisplatin|Drug: Gemcitabine|Genetic: PIK3CA|Genetic: KRAS|Genetic: BRAF|Genetic: RRM1","The National Center of Oncology, Azerbaijan","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MOM-0001","November 3, 2016","March 2015","December 2020","November 14, 2016","November 2016","No Study Results Posted","CERVIPIB","December 2018","Relapse Rate (local and/or distant) and Number of Deaths Due to Any Cause|Number of Participants With Progressive Disease|Incidence of acute toxicity|Incidence of late toxicity","https://ClinicalTrials.gov/show/NCT02957266"
1765,"NCT00524498","A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma","Completed","No Results Available","Hepatocellular Carcinoma","Drug: OPC-18|Drug: cisplatin","Otsuka Pharmaceutical Co., Ltd.","All","20 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","018-06-002","August 31, 2007","September 2007","January 2010","October 13, 2015","October 2015","No Study Results Posted","null","January 2010","Antitumor effect (tumor size reduction)|Disease control rate Overall survival Progression-free survival","https://ClinicalTrials.gov/show/NCT00524498"
1766,"NCT00003087","Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: paclitaxel|Procedure: surgical procedure|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Primary Purpose: Treatment","97-088|CDR0000065787|NCI-T97-0066","November 1, 1999","August 1997","February 2005","June 24, 2013","June 2013","No Study Results Posted","null","February 2005","","https://ClinicalTrials.gov/show/NCT00003087"
1767,"NCT00630240","Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization","Completed","No Results Available","Hepatocellular Carcinoma","","Kaohsiung Medical University Chung-Ho Memorial Hospital","All","20 Years to 80 Years   (Adult, Senior)","","53","Other","Observational","Time Perspective: Prospective","KMUH-IRB-960297","February 26, 2008","February 2008","February 2009","August 30, 2009","July 2009","No Study Results Posted","null","February 2009","The blood levels of anticancer drugs (epirubicin, mitomycin C and cisplatin) will be determined within one hour and at the third day after TACE.","https://ClinicalTrials.gov/show/NCT00630240"
1768,"NCT01303978","Phase II Proof-of-concept Study of APD421","Completed","No Results Available","Chemotherapy-induced Nausea and Vomiting","Drug: APD421","Acacia Pharma Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","DN10007","February 24, 2011","February 2011","July 2012","September 21, 2012","September 2012","No Study Results Posted","null","July 2012","Complete Response","https://ClinicalTrials.gov/show/NCT01303978"
1769,"NCT00090207","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)","Completed","No Results Available","Nausea|Vomiting","Drug: MK0869, aprepitant / Duration of Treatment: 3 days|Drug: Comparator: ondansetron / Duration of Treatment: 4 days","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 4","477","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Prevention","0869-801|2004_005","August 25, 2004","January 13, 2004","September 30, 2004","April 20, 2017","April 2017","No Study Results Posted","null","September 30, 2004","Patient vomiting|Number of rescue therapies","https://ClinicalTrials.gov/show/NCT00090207"
1770,"NCT00606021","A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","Completed","Has Results","Non Small Cell Lung Cancer","Drug: pemetrexed|Drug: Best Supportive Care","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11839|H3E-EZ-S114","January 17, 2008","January 2008","December 2010","November 21, 2011","November 2011","October 3, 2011","null","December 2010","Progression Free Survival During Maintenance Phase|Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])|Overall Survival During Maintenance Phase|Overall Survival During Overall Period (IP + MP)|Number of Participants With Adverse Events (AEs) During Overall Period|Tumor Response Rate and Disease Control Rate After Induction Phase (IP)","https://ClinicalTrials.gov/show/NCT00606021"
1771,"NCT03062800","Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)","Recruiting","No Results Available","Advanced Nsclc","Drug: Thalidomide|Drug: pemetrexed|Drug: cisplatin|Drug: carboplatin","Qilu Hospital of Shandong University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","232","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Dream-003","February 7, 2017","December 2016","October 2018","February 20, 2017","February 2017","No Study Results Posted","null","October 2017","progression-free survival (PFS)|objective response rate(ORR)|weight|vascular endothelial growth factor (VEGF) VEGF","https://ClinicalTrials.gov/show/NCT03062800"
1772,"NCT00002546","Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus","Completed","No Results Available","Sarcoma","Drug: cisplatin|Drug: ifosfamide|Procedure: adjuvant therapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Female","21 Years to 120 Years   (Adult, Senior)","Phase 3","216","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GOG-0150|CDR0000063303|ECOG-G150|NCI-2012-02226","November 1, 1999","December 1993","null","February 10, 2016","February 2016","No Study Results Posted","null","September 2007","","https://ClinicalTrials.gov/show/NCT00002546"
1773,"NCT00859495","Trimodal Lung-Sparing Treatment of Pleural Mesothelioma","Unknown status","No Results Available","Pleural Mesothelioma","Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)","Columbia University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAB9658 (A6)","March 9, 2009","February 2008","December 2014","October 28, 2011","October 2011","No Study Results Posted","null","December 2013","To determine the feasibility of multimodal lung sparing regimen","https://ClinicalTrials.gov/show/NCT00859495"
1774,"NCT00003888","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","359","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-24971|RP-56976-V-323","November 1, 1999","April 1999","March 2015","July 16, 2015","July 2015","No Study Results Posted","null","March 2002","","https://ClinicalTrials.gov/show/NCT00003888"
1775,"NCT01203735","Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer","Unknown status","No Results Available","Locally Advanced Inoperable Non-small-lung Cancer","Drug: Valproic acid","Soroka University Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SOR507910CTIL","September 15, 2010","February 2011","February 2015","March 27, 2011","September 2010","No Study Results Posted","null","February 2013","Toxicity|Survival","https://ClinicalTrials.gov/show/NCT01203735"
1776,"NCT02595879","Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer","Suspended","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB Vulvar Cancer|Stage IB2 Cervical Cancer|Stage II Vulvar Cancer|Stage IIA1 Cervical Cancer|Stage IIA2 Cervical Cancer|Stage IIB Cervical Cancer|Stage IIIA Cervical Cancer|Stage IIIA Vulvar Cancer|Stage IIIB Cervical Cancer|Stage IIIB Vulvar Cancer|Stage IIIC Vulvar Cancer|Stage IVA Cervical Cancer|Stage IVA Vulvar Cancer|Vulvar Adenocarcinoma|Vulvar Squamous Cell Carcinoma","Drug: Cisplatin|Radiation: External Beam Radiation Therapy|Radiation: High-Dose Rate Brachytherapy|Radiation: Intensity-Modulated Radiation Therapy|Radiation: Internal Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Triapine","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","64","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-01907|UPCI 15-157|15-157|9892|P30CA047904|UM1CA186690","November 3, 2015","May 27, 2016","null","May 23, 2017","May 2017","No Study Results Posted","null","December 31, 2018","Incidence of dose-limiting toxicity (DLT) to determine MTD, defined as the dose level where < 2/6 DLTs are observed, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|18F-FDG-PET CT metabolic complete response (mCR) rate|Basal expression of ribonucleotide reductase (RR) subunits (RRM1, RRM2, RRM2b) by immunohistochemistry|Change in gamma-H2AX levels measured by semi-quantitative multiplexed immunoblot assay|Change in phosphorylated (p)-ATM levels measured by semi-quantitative multiplexed immunoblot assay|Incidence of toxicity, evaluated using the NCI CTCAE version 4.0|Oral bioavailability of the oral form of the triapine|PK parameters","https://ClinicalTrials.gov/show/NCT02595879"
1777,"NCT00054054","S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000269781|S0216|U10CA032102","February 5, 2003","April 2003","null","July 21, 2011","July 2011","No Study Results Posted","null","November 2007","","https://ClinicalTrials.gov/show/NCT00054054"
1778,"NCT00700440","Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy","Completed","Has Results","Nasopharyngeal Carcinoma","Drug: C225 (cetuximab)","Sun Yat-sen University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Sichuan Cancer Hospital and Research Institute|Fujian Cancer Hospital|Fudan University|Cancer Hospital of Guizhou Province|First Affiliated Hospital of Guangxi Medical University|Central South University","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR62202-770|PPRA-RTOG 0001","June 17, 2008","July 2008","April 2009","March 9, 2010","February 2009","January 11, 2010","ENCORE","April 2009","3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy|1,3,5 Year Loco-regional Control Rate, 1 Year Progression-free Survival and Metastasis-free Survival, 3 and 5 Year Overall Survival","https://ClinicalTrials.gov/show/NCT00700440"
1779,"NCT02662504","Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma","Recruiting","No Results Available","Malignant Pleural Mesothelioma","Device: photodynamic therapy (PDT)|Procedure: thoracic surgery Pleurectomy / extended Decortication|Drug: Adjuvant chemotherapy","University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France|University of Pennsylvania|Région Nord-Pas de Calais, France","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014_01|2015-001554-15","January 14, 2016","January 2016","December 2017","February 1, 2017","February 2017","No Study Results Posted","MesoPDT","November 2017","Number of Patients having the full multimodal treatment without unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0|Number of responders or stable patients after surgery|Progression-free survival (PFS)|Quality of life assessed by a specific questionnaire MPM (HCCA EORTC-30)","https://ClinicalTrials.gov/show/NCT02662504"
1780,"NCT00993655","Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","Completed","No Results Available","Fallopian Tube Cancer|Metastatic Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Procedure: quality-of-life assessment","Canadian Cancer Trials Group|National Cancer Institute (NCI)|Grupo Español de Investigación en Cáncer de Ovario|Cancer Research UK|Southwest Oncology Group","Female","18 Years and older   (Adult, Senior)","Phase 2","275","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OV21|CAN-NCIC-OV21|UCL08/0379|GEICO-0902|SWOG OV.21|CDR0000655241","October 9, 2009","September 2009","July 2016","July 11, 2016","March 2016","No Study Results Posted","null","March 2016","9-month progression rate post-randomization|Completion rate of treatment (based on toxic effects and feasibility)|Toxic effects as evaluated after each cycle and periodically after completion of therapy|Progression-free survival|Quality of life as measured by EORTC QLQ-C30, ovarian cancer module (EORTC QLQ-OV28), and FACT/GOG-Ntx questionnaires on day 1 cycle 2, day 1 cycle 3 and at end of last cycle|Progression free and Overall survival|Toxic effects|Quality of life|Correlative biological studies|Economic evaluation|Outcomes associated with variation in nursing-related practices as measured by nursing management questions worksheet for IP chemotherapy administration on day 1 and 8 of each cycle of IP treatment (Phase II)","https://ClinicalTrials.gov/show/NCT00993655"
1781,"NCT00004913","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: leucovorin calcium","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 98X2|NU-98X2|NCI-G00-1707","March 7, 2000","January 2000","May 2002","May 31, 2012","May 2012","No Study Results Posted","null","May 2002","","https://ClinicalTrials.gov/show/NCT00004913"
1782,"NCT00993616","Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin","Completed","Has Results","Brenner Tumor|Fallopian Tube Cancer|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mixed Epithelial Carcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Ovarian Undifferentiated Adenocarcinoma|Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer","Drug: belinostat|Drug: carboplatin","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","29","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2010-01663|CDR0000656707|GOG-0126T|U10CA027469","October 9, 2009","December 2009","null","June 18, 2014","June 2014","December 5, 2013","null","July 2012","Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1)|Frequency and Severity of Observed Adverse Effects Graded According to NCI CTCAE Version 4.0|Survival Time for All Patients|Duration of Progression-free Interval for All Patients","https://ClinicalTrials.gov/show/NCT00993616"
1783,"NCT02728492","Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy","Completed","No Results Available","Non-small Cell Lung Cancer|Epithelial Ovarian Cancer","Drug: Quisinostat|Drug: Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine|Drug: Cisplatin","NewVac LLC|Janssen Pharmaceutica N.V., Belgium","All","18 Years and older   (Adult, Senior)","Phase 1","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-13-NSCLC/OVA-7-QUI-1B","November 13, 2015","August 2013","January 2016","May 2, 2016","May 2016","No Study Results Posted","null","December 2015","safety and tolerability of Quisinostat based on number of patients with treatment -related AEs assessed by CTCAE v4.0, number of patients with abnormal laboratory values and instrumental tests (ECG) that are related to treatment","https://ClinicalTrials.gov/show/NCT02728492"
1784,"NCT01899989","Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer","Radiation: Stereotactic Body Radiation Therapy (SBRT)|Drug: cisplatin or carboplatin-based","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13-113","July 8, 2013","July 5, 2013","July 2017","February 22, 2017","February 2017","No Study Results Posted","null","July 2017","maximum tolerated dose (Cohort A)|≥ grade 4 or persistent ≥ grade 3 late toxicities (Cohorts A & B)|overall survival (Cohorts A & B)","https://ClinicalTrials.gov/show/NCT01899989"
1785,"NCT00436644","Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin","Completed","Has Results","Ovarian Cancer|Peritoneal Cavity Cancer","Drug: Lapatinib|Drug: Topotecan","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","18","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RC0661|P30CA015083|06-002426","February 15, 2007","March 2007","November 2012","March 20, 2014","March 2014","February 17, 2012","null","March 2009","Response Rate (Complete Response (CR) or Partial Response (PR))|Time to Progression|Adverse Event Profile|Overall Survival","https://ClinicalTrials.gov/show/NCT00436644"
1786,"NCT00508664","Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)","Completed","No Results Available","Squamous Cell Carcinoma of the Hypopharynx|Larynx Carcinoma","Radiation: Radiation|Drug: Cetuximab|Drug: Docetaxel|Drug: Cisplatin (TP)|Drug: 5-Fluorouracil (TPF) (only until Feb 2009)","ClinAssess|Merck Sharp & Dohme Corp.|Sanofi|University of Leipzig","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TP(F)+Radiation+/-Cetuximab","July 27, 2007","July 2007","February 2015","June 1, 2015","June 2015","No Study Results Posted","DeLOS II","February 2015","Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation|Descriptive analysis of the study arms concerning the secondary end criteria of the study|Explorative comparison of the study arms concerning the primary and secondary end criteria of the study","https://ClinicalTrials.gov/show/NCT00508664"
1787,"NCT02773485","Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma","Recruiting","No Results Available","Cholangiocarcinoma","Radiation: High Dose Radiation|Drug: Systemic chemotherapy","Tata Memorial Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","155","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TMC IRB 1457","March 8, 2016","May 2015","June 2022","May 17, 2016","May 2016","No Study Results Posted","null","June 2022","Overall Survival|loco-regional progression free survival|Toxicity Assessment|Quality of Life|Surgical Resectability Rates|cause specific survival","https://ClinicalTrials.gov/show/NCT02773485"
1788,"NCT00006012","Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Radiation Toxicity","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: etoposide|Drug: paclitaxel|Drug: topotecan hydrochloride|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","73","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N9923|CDR0000068021","July 5, 2000","February 2001","May 2006","July 1, 2016","July 2016","No Study Results Posted","null","May 2006","Survival at 2 years|Local progression-free survival at 2 years|Overall survival|Time to progression","https://ClinicalTrials.gov/show/NCT00006012"
1789,"NCT01565109","NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma","Recruiting","No Results Available","Gastric Adenocarcinoma","Drug: Docetaxel - Cisplatine - 5FU|Radiation: Radiation of 45 Grays on 5 weeks","Institut Sainte Catherine","All","18 Years to 65 Years   (Adult)","Phase 2","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NESC","October 13, 2010","March 2009","March 2018","December 20, 2012","December 2012","No Study Results Posted","null","March 2013","Histological response rate on surgical specimen after chemotherapy and chemoradiotherapy preoperative","https://ClinicalTrials.gov/show/NCT01565109"
1790,"NCT02344979","The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC","Unknown status","No Results Available","Thrombocytopenia","","Shenyang Sunshine Pharmaceutical Co., LTD.","All","18 Years and older   (Adult, Senior)","Phase 4","120","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","ShenyangSunshine","January 18, 2015","May 2009","June 2015","January 22, 2015","January 2015","No Study Results Posted","null","June 2015","The mean minimal and maximal platelet count after rHuTPO or rHuIL-11.|The time to achieve platelet count ≥75×109/L and ≥100×109/L after rHuTPO or rHuIL-11. The duration of platelet count <50×109/L after rHuTPO or rHuIL-11.|The number of platelet transfusions after rHuTPO or rHuIL-11.","https://ClinicalTrials.gov/show/NCT02344979"
1791,"NCT02633800","Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )","Recruiting","No Results Available","Head and Neck Neoplasms","Drug: Patritumab|Drug: Cetuximab|Drug: Cisplatin|Drug: Carboplatin|Drug: Placebo","Daiichi Sankyo Inc.|Covance","All","18 Years and older   (Adult, Senior)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","U31287-A-U203|2015-002222-40","December 15, 2015","December 2015","December 2018","April 27, 2017","April 2017","No Study Results Posted","null","July 2017","Mean Progression Free Survival|Mean Overall Survival|Percentage of Participants with Best Overall Response","https://ClinicalTrials.gov/show/NCT02633800"
1792,"NCT02933099","Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting","Not yet recruiting","No Results Available","Chemotherapy-induced Nausea and Vomiting","Drug: Aprepitant+palonosetron+dexamethasone|Drug: palonosetron+dexamethasone","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","WuhanUHC","October 7, 2016","October 2016","December 2018","October 11, 2016","October 2016","No Study Results Posted","CINV","April 2018","Complete response|Acute Phase Response|Delayed Phase Response|Functional Living Index -Emesis (FLIE)|Safety and tolerability as measured by the incidence and severity of adverse","https://ClinicalTrials.gov/show/NCT02933099"
1793,"NCT01584284","Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer","Completed","No Results Available","Cancer of Head and Neck","Biological: GL-ONC1","Genelux Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GL-ONC1-005","April 22, 2012","April 2012","July 2015","August 21, 2015","August 2015","No Study Results Posted","null","June 2015","Safety and Tolerability as measured by the number of patients with Adverse Events, as well as type of AE and frequency|Presence of Virus in Tumor|Determine Initial Susceptibility of tumor to viral infection|Anti-Tumor Activity (Early Efficacy)","https://ClinicalTrials.gov/show/NCT01584284"
1794,"NCT01714037","A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]","Terminated","No Results Available","Non-small Cell Lung Cancer","Drug: Debio 0932|Drug: Cisplatin|Drug: Pemetrexed|Drug: Gemcitabine|Drug: Docetaxel","Debiopharm International SA|INC Research","All","18 Years and older   (Adult, Senior)","Phase 1","82","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Debio 0932-201","October 3, 2012","August 2012","November 2014","April 7, 2015","April 2015","No Study Results Posted","HALO","November 2014","Occurrence of Dose Limiting Toxicities|Change in vital signs and Eastern Cooperative Oncology Group Performance Status (ECOG PS)|Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Incidence of laboratory abnormalities|Incidence of treatment discontinuations due to AEs and SAEs|Change in left ventricular ejection fraction (LVEF)|Pharmacokinetic parameters of Debio 0932 and its metabolite Debio 0932-MET1|Pharmacokinetic parameters of cisplatin/pemetrexed, cisplatin/gemcitabine, and docetaxel|Best overall tumor response|Pharmacodynamic biomarkers|Pharmacogenomic, tumour pharmacogenetic, proteomic, and pharmacogenetic factors predictive of response to Debio 0932","https://ClinicalTrials.gov/show/NCT01714037"
1795,"NCT01230476","Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma","Terminated","No Results Available","Nasopharyngeal Carcinoma","Drug: Cetuximab","University of Malaya|Merck Serono International SA","All","18 Years to 65 Years   (Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","EMR 62202-832","October 18, 2010","May 2010","May 2015","May 19, 2017","May 2017","No Study Results Posted","null","May 2013","Number of participants with adverse events as a measure of safety and tolerability|Objective response rate|Progression and overall survival","https://ClinicalTrials.gov/show/NCT01230476"
1796,"NCT01225523","Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus","Completed","No Results Available","Squamous Carcinoma of Esophagus|Esophagus Disorders","Drug: Paclitaxel; Cisplatin; 5-Fluorouracil|Drug: Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine","Health Science Center of Xi’an Jiaotong University","All","18 Years and older   (Adult, Senior)","Phase 1","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","ZY-01","October 19, 2010","January 1997","January 2010","October 20, 2010","September 2010","No Study Results Posted","null","December 2008","Overall survival rate|Progression-free survival|Pathological remission rate|Resectability rate|Operative and postoperative complication rate|30-day mortality|Toxicity of preoperative and postoperative chemotherapy|Rate of local recurrences and metastasis","https://ClinicalTrials.gov/show/NCT01225523"
1797,"NCT00001332","Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis","Completed","No Results Available","Peritoneal Neoplasms|Stomach Neoplasms","Procedure: CHPP with cisplatin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","50","NIH","Interventional","Primary Purpose: Treatment","930048|93-C-0048","November 3, 1999","December 1992","October 2000","March 3, 2008","November 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001332"
1798,"NCT00002984","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: surgical procedure|Radiation: radiation therapy","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 9622|CDR0000065519|NCI-G97-1240","November 1, 1999","March 1997","January 2007","May 22, 2012","May 2012","No Study Results Posted","null","May 2006","Maximum Tolerated Dose|Number of subjects experiencing adverse events|Efficacy of treatment","https://ClinicalTrials.gov/show/NCT00002984"
1799,"NCT02739204","Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma","Recruiting","No Results Available","Oral Squamous Cell Carcinoma","Drug: Celecoxib","China Medical University Hospital|Ministry of Health and Welfare, Taiwan","All","20 Years to 80 Years   (Adult, Senior)","Phase 2","270","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","CMUH102-REC1-071","March 22, 2016","November 2013","December 2017","April 11, 2016","April 2016","No Study Results Posted","null","December 2016","Relapse-free recurrence|Relapse-free survival","https://ClinicalTrials.gov/show/NCT02739204"
1800,"NCT02890030","The Platinum Study Comparison Group","Recruiting","No Results Available","Testicular Neoplasms","Behavioral: Questionnaire","Lawrence Einhorn|Indiana University","Male","18 Years to 55 Years   (Adult)","","109","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IUSCC-0587","June 8, 2016","May 2015","August 2019","August 31, 2016","August 2016","No Study Results Posted","null","August 2018","Proportion of patients with ototoxicity|Proportion of patients with neurotoxicity|Proportion of patients with obesity|Proportion of patients with hypertension|Proportion of patients who use antidepressants/anxiolytics","https://ClinicalTrials.gov/show/NCT02890030"
1801,"NCT00454779","PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response","Completed","Has Results","Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck","Drug: Cisplatin|Drug: Panitumumab|Drug: Docetaxel|Drug: Cisplatin|Drug: Docetaxel","Amgen","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20050236","March 29, 2007","January 2007","May 2014","December 15, 2016","December 2016","October 11, 2013","null","August 2012","Progression Free Survival (PFS) During the First-line Treatment Phase|Overall Response Rate (ORR) During the First-line Treatment Phase|Rate of Disease Control (RDC) During the First-line Treatment Phase|Duration of Response (DOR) During the First-line Treatment Phase|Time to Response (TTR) During the First-line Treatment Phase|Overall Survival (OS) for the First-line Treatment|Progression Free Survival (PFS) During the Second-line Treatment Phase|Overall Response Rate (ORR) During the Second-line Treatment Phase|Rate of Disease Control (RDC) During the Second-line Treatment Phase|Duration of Response (DOR) During the Second-line Treatment Phase|Time to Response (TTR) During the Second-line Treatment Phase|Overall Survival (OS) for the Second-line Treatment","https://ClinicalTrials.gov/show/NCT00454779"
1802,"NCT00369954","Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin","Withdrawn","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Drug: carboplatin|Drug: gemcitabine hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000496764|GOG-0102H","August 29, 2006","April 2006","null","June 7, 2013","October 2007","No Study Results Posted","null","null","Relative risk of progression-free survival|Frequency and severity of observed adverse effects by CTCAE version 3.0|Relative risk of survival","https://ClinicalTrials.gov/show/NCT00369954"
1803,"NCT02215265","Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)","Not yet recruiting","No Results Available","Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer","Drug: Cisplatin|Radiation: Postoperative radiotherapy","Lisette Nixon|Velindre NHS Trust","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","242","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014/VCC/0014","August 11, 2014","December 2014","null","August 12, 2014","August 2014","No Study Results Posted","PATHOS","December 2019","Phase II: Patient-reported swallowing outcome|Swallowing panel including qualitative and quantitative swallowing assessments|QOL (using validated EORTC QLQ C30 and HN35 questionnaires)|Acute and late toxicity using CTACE version 4.03|Overall survival|Disease Free Survival","https://ClinicalTrials.gov/show/NCT02215265"
1804,"NCT01914900","Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer","Unknown status","No Results Available","Locally Advanced Resectable Oral Cavity Squamous Cell Cancer","Drug: docetaxel, cisplatin, 5 fluorouracil","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INT40/10","July 29, 2013","June 2012","March 2015","July 31, 2013","July 2013","No Study Results Posted","null","January 2015","pathologic complete remission|Progression free survival|Overall Survival|Compliance to induction chemotherapy|Percentage of patient receiving postoperative radiotherapy and chemotherapy|Early functional response evaluation by DWI and DCE MRI|Comparison between (DWI - DCE) MRI response and pathological response","https://ClinicalTrials.gov/show/NCT01914900"
1805,"NCT01529411","Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer","Completed","No Results Available","Carcinoma, Transitional Cell","Drug: Vinflunine|Other: Undefined (standard care)","Spanish Oncology Genito-Urinary Group","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SOGUG2011/02","January 20, 2012","February 2012","December 2014","December 17, 2014","February 2012","No Study Results Posted","MAJA","February 2013","Progression Free Survival.","https://ClinicalTrials.gov/show/NCT01529411"
1806,"NCT00002883","Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus","Unknown status","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","UNICANCER|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065190|FRE-FNCLCC-94012|EU-96018","November 1, 1999","October 1996","null","February 6, 2009","April 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002883"
1807,"NCT02607631","A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor","Not yet recruiting","No Results Available","Thymic Epithelial Tumors","Drug: Pembrolizumab","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-04-132-005","October 7, 2015","November 2015","August 2018","November 17, 2015","November 2015","No Study Results Posted","null","February 2018","Response rate by RECIST 1.1|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02607631"
1808,"NCT01812369","Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer","Recruiting","No Results Available","Bladder Cancer","Drug: GEMCITABINE CISPLATINE|Drug: METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF","University Hospital, Rouen","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011/119/HP","January 22, 2013","March 2013","August 2021","December 6, 2016","December 2016","No Study Results Posted","VESPER","July 2019","Progression-free survival (PFS) at 3 years|· Toxicity (CTC AE v4.0)|· Response (RECIST criteria)|· Time to progression (TTP)|number of patients with adverse events ; type and grade of adverse events for each chemotherapy","https://ClinicalTrials.gov/show/NCT01812369"
1809,"NCT00719524","AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor","Completed","No Results Available","Neoplasms","Drug: OMBRABULIN (AVE8062)","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","71","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD10620|EudraCT: 2007-006676-11","July 17, 2008","July 2008","February 2013","March 8, 2013","March 2013","No Study Results Posted","null","February 2013","Recommended dose of the combination based on Dose Limiting Toxicities observed|Overall safety profile|Pharmacokinetic profile|Anti-tumor activity of the combination","https://ClinicalTrials.gov/show/NCT00719524"
1810,"NCT01926236","Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers","Recruiting","No Results Available","Biliary Tract Cancer|Gallbladder Cancer|Cholangiocarcinoma|Ampullary Cancer","Other: Active Symptom Control|Drug: L-folinic acid|Drug: 5 FU|Drug: Oxaliplatin","The Christie NHS Foundation Trust|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 3","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CFTSp048|A16281|2013-001812-30","August 17, 2013","February 2014","January 2018","August 3, 2016","August 2016","No Study Results Posted","ABC06","January 2018","Overall survival|Progression-free survival|Response rate (chemotherapy arm only)|Toxicity (frequency of adverse events and serious adverse events)|Quality of life|Costs of health and social care|Health status (Euroqol)|Quality adjusted life years (QALYs)","https://ClinicalTrials.gov/show/NCT01926236"
1811,"NCT00142350","A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: continuous infusion of 5-fluorouracil|Drug: combination of irinotecan and cisplatin|Drug: oral administration of S-1","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan|Taiho Pharmaceutical Co., Ltd.|Yakult Honsha Co., LTD","All","20 Years to 75 Years   (Adult, Senior)","Phase 3","690","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG9912|C000000062","September 1, 2005","November 2000","January 2007","September 8, 2016","September 2016","No Study Results Posted","null","null","overall survival|time to treatment failure|incidences of adverse events|response rate|non-hospitalized survival","https://ClinicalTrials.gov/show/NCT00142350"
1812,"NCT00612495","Endometrial Cancer - LOHP Alone and With 5FU","Completed","No Results Available","Endometrial Cancer","Drug: oxaliplatin, 5 FU","Sanofi","Female","18 Years and older   (Adult, Senior)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC_7496","January 28, 2008","January 2001","March 2005","February 8, 2008","January 2008","No Study Results Posted","null","null","Overall RR (World Health Organization [WHO]/Union Internationale Contre le Cancer [International Union Against Cancer] [UICC] criteria|Progression free-survival, duration of response and overall survival.","https://ClinicalTrials.gov/show/NCT00612495"
1813,"NCT02279576","Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)","Terminated","No Results Available","Penile Squamous Cell Carcinoma Stage IV","Drug: Pazopanib|Drug: Paclitaxel","Spanish Oncology Genito-Urinary Group","Male","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SOG-CPE-2014-03|2014-003127-22","October 27, 2014","January 2015","September 2016","October 13, 2016","November 2015","No Study Results Posted","PAZOPEN-SOGUG","September 2016","Overall response rate|Clinical benefit rate|Progression free survival|Response duration|Overall survival|Safety tolerability profile as measured by the number of events per patient","https://ClinicalTrials.gov/show/NCT02279576"
1814,"NCT03036098","Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer","Recruiting","No Results Available","Urothelial Cancer","Biological: nivolumab|Biological: ipilimumab|Drug: Gemcitabine|Drug: cisplatin|Drug: carboplatin","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","690","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-901|2016-003881-14","January 27, 2017","March 24, 2017","December 23, 2022","April 19, 2017","April 2017","No Study Results Posted","CheckMate901","April 26, 2020","Progression free survival (PFS) in cisplatin-ineligible participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) of cisplatin-ineligible participants|Progression free survival (PFS) in all participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) in all participants|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Global Health Status score","https://ClinicalTrials.gov/show/NCT03036098"
1815,"NCT00403403","A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)","Completed","Has Results","Small Cell Lung Cancer","Drug: Bevacizumab|Drug: Chemotherapy|Drug: Placebo","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","AVF3995g","November 21, 2006","March 2007","June 2009","April 27, 2011","April 2011","January 28, 2010","null","February 2009","Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With an Objective Response|Number of Participants With an Objective Response|Duration of Objective Response","https://ClinicalTrials.gov/show/NCT00403403"
1816,"NCT02951767","A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)","Active, not recruiting","Has Results","Bladder Cancer","Drug: Atezolizumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","119","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GO29293 (Cohort 1)|IMvigor 210|2013-005486-39","October 31, 2016","June 30, 2014","August 31, 2017","March 10, 2017","March 2017","February 14, 2017","null","September 30, 2015","Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to RECIST v1.1|Duration of Response as Assessed by the IRF According to RECIST v1.1|Duration of Response as Assessed by the Investigator According to RECIST v1.1|Percentage of Participants With Death or Disease Progression as Assessed by the IRF According to RECIST v1.1|Progression-Free Survival (PFS) as Assessed by the IRF According to RECIST v1.1|Percentage of Participants With Death or Disease Progression as Assessed by the Investigator According to RECIST v1.1|PFS as Assessed by the Investigator According to RECIST v1.1|Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According RECIST v1.1|Percentage of Participants Who Died|Overall Survival (OS)|Percentage of Participants Alive at 1-year|Maximum Serum Concentration (Cmax) of Atezolizumab|Minimum Serum Concentration (Cmin) of Atezolizumab|Percentage of Participants Positive for Anti-therapeutic Antibodies (ATA) to Atezolizumab","https://ClinicalTrials.gov/show/NCT02951767"
1817,"NCT02627807","Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Neoplasms","Radiation: IMRT using individualized CTV|Radiation: IMRT using traditional CTV|Drug: Gemcitabine and cisplatin (induction chemotherapy)|Drug: Docetaxel and cisplatin (induction chemotherapy)|Drug: Cisplatin 100mg/m² concurrent chemotherapy|Drug: Cisplatin 80mg/m² concurrent chemotherapy","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","","378","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012011","December 3, 2015","December 2015","December 2022","January 9, 2017","January 2017","No Study Results Posted","null","December 2020","Local-regional recurrence-free survival rate|Overall survival rate|Distant metastasis-free survival rate|Constituent ratio of local and regional recurrence pattern|Number of participants with adverse events|Quality of life score measured by EORTC QLQ-C30|Quality of life score measured by EORTC H&N35|Target volumes' dose coverage and doses irradiated to organs at risk","https://ClinicalTrials.gov/show/NCT02627807"
1818,"NCT02412670","Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer","Recruiting","No Results Available","Localized Urothelial Carcinoma of the Renal Pelvis and Ureter|Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter|Regional Urothelial Carcinoma of the Renal Pelvis and Ureter","Drug: Methotrexate|Drug: Vinblastine|Drug: Doxorubicin Hydrochloride|Drug: Cisplatin|Drug: Gemcitabine Hydrochloride|Drug: Carboplatin|Procedure: Therapeutic Conventional Surgery|Other: Laboratory Biomarker Analysis","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EA8141|NCI-2014-02267|U10CA180820","April 6, 2015","April 2015","null","August 19, 2015","August 2015","No Study Results Posted","null","February 2020","pCR rates|Recurrence-free survival|Event-free survival|Bladder cancer-free survival|Cancer-specific survival|The proportion of patients with renal insufficiency (CrCl < 60 ml/min) post chemotherapy and post nephroureterectomy|The proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study)|Distribution of changes in renal function post chemotherapy and post surgery|Incidence of toxicities","https://ClinicalTrials.gov/show/NCT02412670"
1819,"NCT03105596","Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)","Not yet recruiting","No Results Available","B-cell Non-Hodgkin's Lymphoma","Drug: Chidamide plus DICE Regimen","Peking University","All","18 Years to 65 Years   (Adult)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Chidamide plus DICE","April 4, 2017","April 11, 2017","September 30, 2019","April 9, 2017","April 2017","No Study Results Posted","null","September 30, 2018","objective response rate（ORR）|progression-free survival（PFS）|events-free survival（EFS）|overall survival（OS）","https://ClinicalTrials.gov/show/NCT03105596"
1820,"NCT02422563","NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB","Not yet recruiting","No Results Available","Cervical Cancer","Procedure: hysterectomy|Radiation: Radiation|Drug: Cisplatin|Drug: Paclitaxel|Drug: Carboplatin|Drug: Ifosfamide","Charite University, Berlin, Germany","Female","18 Years and older   (Adult, Senior)","Phase 3","534","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NACOPRAD_2015","February 11, 2015","October 2015","October 2025","April 20, 2015","April 2015","No Study Results Posted","NACOPRAD","October 2020","disease free survival|overall survival|local control|quality of life","https://ClinicalTrials.gov/show/NCT02422563"
1821,"NCT00632333","Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Biological: URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil","Teikyo University|Human Genome Center, Institute of Medical Science, University of Tokyo","All","20 Years to 80 Years   (Adult, Senior)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TPR07-079","February 29, 2008","February 2008","March 2012","July 20, 2011","September 2009","No Study Results Posted","null","December 2011","Safety(toxicities as assessed by NCI CTCAE version3)|Peptide specific CTL induction|DTH to peptide|Changes in levels of regulatory T cells|Objective response rate as assessed by RECIST criteria|Time to progression|survival","https://ClinicalTrials.gov/show/NCT00632333"
1822,"NCT00808639","Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma","Completed","Has Results","Bladder Cancer|Muscle-invasive Bladder Cancer","Drug: Methotrexate|Drug: Doxorubicin|Drug: vinblastine|Drug: cisplatin|Drug: Pegfilgrastim","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-208","December 15, 2008","December 2008","September 2016","September 9, 2016","September 2016","January 14, 2014","null","December 2013","Number of Patients Achieving Pathologic Response|Number of Patients Experiencing Febrile Neutropenia|Number of Patients Experiencing Surgery-related Toxicity","https://ClinicalTrials.gov/show/NCT00808639"
1823,"NCT01640782","Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach","Completed","No Results Available","Adenocarcinoma of the Stomach|Adenocarcinoma of the Gastroesophageal Junction","Drug: Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|Drug: Leucovorin, 5-Fluorouracil","Mario Negri Institute for Pharmacological Research|Aventis Pharmaceuticals|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Gruppo Oncologico Italiano di Ricerca Clinica|Gruppo Oncologico del Nord-Ovest|Italian Trial in Medical Oncology|Southern Italy Cooperative Oncology Group|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|Oncotech","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","1100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ITACA-S","July 9, 2012","February 2005","January 2013","July 17, 2014","December 2013","No Study Results Posted","ITACA-S","January 2013","Progression Free Survival will be defined as the time from date of randomisation to date of first appearance of local, regional or distant relapse, or death from any cause; patients alive without relapse will be censored at date last known to be alive.|OS will be defined as the time from date of randomisation to date of death by any cause, with living patients censored at date last known to be alive|Toxicity, graded according to the NCI-CTG Expanded Common Toxicity Criteria|Adverse events","https://ClinicalTrials.gov/show/NCT01640782"
1824,"NCT00446225","Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Erlotinib (Tarceva)|Drug: Carboplatin // Gemcitabine // Docetaxel //Cisplatin","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 3","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EURTAC-SLCG // GECP06/01|EudraCT:2006-003568-73","March 8, 2007","February 2007","December 2012","March 8, 2013","October 2008","No Study Results Posted","null","December 2009","Progression Free-survival|Objective Response|One year survival|Overall survival|Safety incidence|Life quality|Molecular markers related to EGFR and study pathology","https://ClinicalTrials.gov/show/NCT00446225"
1825,"NCT02404571","GDP in Frontline Chemotherapy for Patients With PTCL-NOS","Recruiting","No Results Available","Lymphoma, T-Cell, Peripheral","Drug: GDP chemotherapy","Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GiFT","March 26, 2015","January 2011","December 2016","July 25, 2016","July 2016","No Study Results Posted","null","December 2016","overall response rate|2-year progression-free survival|2-year overall survival|number of patients with adverse events","https://ClinicalTrials.gov/show/NCT02404571"
1826,"NCT01404156","Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","Recruiting","No Results Available","Esophageal Cancer|Adenocarcinoma, Esophageal|Adenocarcinoma, Gastroesophageal Junction","Drug: Epirubicin cisplatin 5-Fluorouracil|Other: Carboplatin paclitaxel plus concurrent radiotherapy","Dr. Gordon Buduhan|Nova Scotia Health Authority|CancerCare Manitoba","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CDHA 174431-7","July 26, 2011","September 2015","February 2019","April 3, 2017","April 2017","No Study Results Posted","POWERRANGER","February 2018","compliance with assigned neoadjuvant treatment|treatment response|survival|quality of life","https://ClinicalTrials.gov/show/NCT01404156"
1827,"NCT03027284","A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer","Recruiting","No Results Available","Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkin's Lymphoma","Drug: Merestinib|Drug: Cisplatin|Drug: Gemcitabine","Eli Lilly and Company","All","20 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16330|I3O-JE-JSBG","January 19, 2017","February 3, 2017","June 4, 2018","April 11, 2017","April 2017","No Study Results Posted","null","June 4, 2018","Number of Participants with Merestinib Dose-Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Merestinib and its Metabolites|PK: Area Under the Concentration Time Curve (AUC) of Merestinib and its Metabolites|Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response|Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of Complete Response, Partial Response, and Stable Disease","https://ClinicalTrials.gov/show/NCT03027284"
1828,"NCT02573584","Vascular Fingerprint Validation Study","Recruiting","No Results Available","Testicular Cancer","","University Medical Center Groningen","Male","18 Years to 50 Years   (Adult)","","178","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","201500864","October 8, 2015","October 2015","December 2017","October 21, 2016","October 2016","No Study Results Posted","null","December 2017","Development of arterial cardiovascular events|Overall survival|Response to testicular cancer treatment (no evidence of disease / relapse / no response to treatment)|Development of venous thromboembolic events (VTE) (WHO ICD-10 I26, I80-82)","https://ClinicalTrials.gov/show/NCT02573584"
1829,"NCT00006004","Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068012|E-1599","July 5, 2000","May 2000","null","August 16, 2013","August 2013","No Study Results Posted","null","January 2005","","https://ClinicalTrials.gov/show/NCT00006004"
1830,"NCT01343264","Trimodality Therapy for Malignant Pleural Mesothelioma","Unknown status","No Results Available","Malignant Pleural Mesothelioma","","HSK Wiesbaden","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RP2002-01","April 5, 2011","November 2002","null","April 26, 2011","April 2011","No Study Results Posted","null","December 2012","To determine the overall 5-year survival rate.|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with treatment related deaths as a Measure of Safety and Tolerability|Recurrence","https://ClinicalTrials.gov/show/NCT01343264"
1831,"NCT00005051","Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer","Completed","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Drug: topotecan hydrochloride","New York University School of Medicine|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067644|NYU-9913|NCI-G00-1720","April 6, 2000","August 1999","null","November 8, 2012","December 2003","No Study Results Posted","null","March 2003","","https://ClinicalTrials.gov/show/NCT00005051"
1832,"NCT01215266","Sorafenib in Urothelium Cancer of Bladder","Terminated","No Results Available","Bladder Cancer","Drug: Sorafenib|Drug: Placebo","Association of Urogenital Oncology (AUO)|University Hospital, Essen","All","18 Years and older   (Adult, Senior)","Phase 2","98","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Treatment","AB 31/05 RUTT 204|2005-006098-29","October 1, 2010","October 2006","June 2011","September 7, 2011","September 2011","No Study Results Posted","null","June 2011","Progression free survival|Response rates, time of response|Time to progression|Overall survival|Evaluation and comparison in both treatment arms","https://ClinicalTrials.gov/show/NCT01215266"
1833,"NCT02047487","After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study","Recruiting","No Results Available","Head and Neck Neoplasms","","Chinese PLA General Hospital","All","18 Years to 70 Years   (Adult, Senior)","","120","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","S2013-110-02","January 26, 2014","May 2013","August 2018","January 26, 2014","January 2014","No Study Results Posted","null","August 2014","ORR","https://ClinicalTrials.gov/show/NCT02047487"
1834,"NCT01719835","CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study","Recruiting","No Results Available","Peripheral T-cell Lymphoma NOS|Anaplastic Large Cell Lymphoma, ALK-Negative|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic Gamma/ Delta T-cell Lymphoma","Drug: Cyclophosphamide|Drug: Gemcitabine|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: methylprednisolone|Drug: Cisplatin","Royal Marsden NHS Foundation Trust|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 2","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RMH CCR: 3549|2011-004146-18","April 12, 2012","March 2012","August 2022","October 30, 2012","October 2012","No Study Results Posted","CHEMO-T","March 2017","complete response rate (CR/CRu)|Toxicity|Overall Survival|Progression Free survival|Metabolic Complete Response Rate","https://ClinicalTrials.gov/show/NCT01719835"
1835,"NCT02741856","Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation","Recruiting","No Results Available","Oesophageal Cancer","Drug: Carboplatin|Drug: Paclitaxel|Drug: Cisplatin|Drug: Capecitabine|Radiation: Radiotherapy","Lisette Nixon|Cancer Research UK|Velindre NHS Trust","All","17 Years and older   (Child, Adult, Senior)","Phase 2|Phase 3","584","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014/VCC/0015|2015-001740-11|Ethics Reference Number","April 12, 2016","June 2016","April 2023","September 20, 2016","September 2016","No Study Results Posted","SCOPE2","April 2021","Primary endpoint phase II in squamous cell carcinoma comparing standard dose radiotherapy to high dose radiotherapy|Primary endpoint phase III in squamous cell carcinoma: Overall survival (OS) comparing standard dose radiotherapy to high dose radiotherapy|Primary endpoint in squamous cell carcinoma when switching chemotherapy|Primary endpoint phase in adenocarcinoma phase II comparing standard dose radiotherapy to high dose radiotherapy|Primary endpoint in adenocarcinoma when switching chemotherapy|Overall survival|Progression free survival|Quality of Life|Toxicity|Health economics","https://ClinicalTrials.gov/show/NCT02741856"
1836,"NCT00573131","Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer","Terminated","Has Results","Esophageal Cancer|Adenocarcinoma of the Esophagus|Squamous Cell Carcinoma","Drug: OncoGel (Paclitaxel gel)|Drug: cisplatin|Drug: 5-FU|Radiation: radiation therapy|Procedure: esophageal resection","BTG International Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","154","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","PR016-CLN-pro003","December 11, 2007","January 2008","November 2010","January 12, 2016","January 2016","April 17, 2014","null","November 2010","Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT","https://ClinicalTrials.gov/show/NCT00573131"
1837,"NCT00572572","Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors","Completed","Has Results","Germ Cell Tumors","Drug: Aprepitant|Drug: Placebo","Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.","Male","15 Years and older   (Child, Adult, Senior)","Phase 3","69","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Supportive Care","QL05-37","December 11, 2007","December 2007","February 2011","March 8, 2016","March 2016","December 17, 2015","null","December 2010","Complete Response.|Proportion of Patients With no Emesis During the Acute CINV Time Period (Cycle Days 1-5)|Proportion of Patients With no Emesis During the Delayed CINV Time Period (Cycle Days 6-8)|Visual Analouge (VAS) 100mm Scale Score|MD Anderson Symptom Inventory Score|Preferred Treatment Cycle","https://ClinicalTrials.gov/show/NCT00572572"
1838,"NCT00012220","Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine hydrochloride|Drug: irinotecan hydrochloride","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","259","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-89904|U10CA031946|CDR0000068495","March 3, 2001","January 2001","April 2009","July 12, 2016","July 2016","No Study Results Posted","null","June 2004","Overall Survival|Time to disease progression|Toxicity","https://ClinicalTrials.gov/show/NCT00012220"
1839,"NCT02320448","Treating Peritoneal Carcinomatosis With PIPAC","Active, not recruiting","No Results Available","Peritoneal Carcinomatosis","Drug: PIPAC","Michael Bau Mortensen|Odense University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PIPAC","December 9, 2014","March 2015","March 2017","November 7, 2016","November 2016","No Study Results Posted","null","March 2017","Number of Patients with Adverse Events.|Occupational health.|Feasibility: Completion of procedure in 28:35","https://ClinicalTrials.gov/show/NCT02320448"
1840,"NCT01625702","Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer","Completed","No Results Available","Gastric Cancer","Device: CellSearch® CTC kit","Peking University","All","18 Years and older   (Adult, Senior)","","138","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Basic Science","CGOG5001","June 13, 2012","June 2012","December 2015","May 7, 2017","May 2017","No Study Results Posted","null","July 2014","circulating tumor cells in blood","https://ClinicalTrials.gov/show/NCT01625702"
1841,"NCT01958372","Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer","Active, not recruiting","No Results Available","Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Dietary Supplement: soy isoflavones|Drug: cisplatin|Drug: etoposide|Drug: pemetrexed disodium|Radiation: radiation therapy","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2013-021|NCI-2013-01835|1307012220|P30CA022453","October 7, 2013","August 2014","June 30, 2018","May 23, 2017","May 2017","No Study Results Posted","null","June 30, 2018","Safety, in terms of dose-limiting toxicity of adding oral soy isoflavone supplementation to concurrent chemotherapy and radiotherapy, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4|Survival proportion|Grade 3-4 toxicity rate graded according to NCI CTCAE version 4.0|Response (complete response [CR] and partial response [PR]) rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Time to tumor progression (TTP)|Overall survival (OS)|Response duration","https://ClinicalTrials.gov/show/NCT01958372"
1842,"NCT00263016","Docetaxel in Non Small Cell Lung Cancer (NSCLC)","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Docetaxel","Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XRP6976B_2503","December 6, 2005","May 2005","null","March 18, 2008","March 2008","No Study Results Posted","null","null","Tumour response rate|Survival at 1 year|Time to progression","https://ClinicalTrials.gov/show/NCT00263016"
1843,"NCT01064466","Discovery Stage IND EXEMPT Clinical Study - Etoposide and Single Nucleotide Polymorphisms","Active, not recruiting","No Results Available","Small Cell Lung Cancer","Drug: ETOPOSIDE - Usual|Drug: ETOPOSIDE - Study","Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair|Medicine Invention Design, Inc","All","22 Years to 75 Years   (Adult, Senior)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","FWA00015357|NPI - 1831468511|NPI - 1023387701|IRB00009424|IORG0007849","February 2, 2010","August 2016","August 2018","May 22, 2017","May 2017","No Study Results Posted","Drugs-SNPs","March 2018","Find Etoposide Drug Targets' SNP Genotypes which are effectiveness-associated and which are risk-associated.","https://ClinicalTrials.gov/show/NCT01064466"
1844,"NCT01055496","Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma, B-Cell","Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Senior)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3129K2-1105|B1931003","January 21, 2010","March 2010","March 2014","March 31, 2014","March 2014","No Study Results Posted","null","July 2013","To determine the tolerability, the initial safety profile, as evaluated by an analysis of laboratory results and adverse event (AE) reporting.|Determination of MTD or recommended dose of the immunochemotherapeutic regimens R-CVP or R-GDP given in combination with inotuzumab ozogamicin in subjects with CD22-positive NHL.|To obtain preliminary information on the antitumor activity of R-CVP or R-GDP in combination with inotuzumab ozogamicin as measured by ORR, progression-free survival, and overall survival data in MTD confirmation/expanded efficacy cohorts|To evaluate PK of 0.8 mg/m2 of inotuzumab ozogamicin when combined with R CVP or with R-GDP|To develop a molecular predictor of response to inotuzumab ozogamicin plus R-CVP or R-GDP.","https://ClinicalTrials.gov/show/NCT01055496"
1845,"NCT01774786","A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: 5-Fluorouracil|Drug: Capecitabine|Drug: Cisplatin|Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","780","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","BO25114|2012-003554-83","January 21, 2013","June 10, 2013","December 15, 2021","May 10, 2017","May 2017","No Study Results Posted","null","December 9, 2016","Overall Survival|Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria|Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria|Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria|Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria|Percentage of Participants With Adverse Events|Percentage of Participants With Left Ventricular Systolic Dysfunction (Symptomatic or Asymptomatic)|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) Questionnaire Score|EORTC QLQ-Gastric Cancer Module (EORTC QCQ-STO22) Questionnaire Score|European Quality of Life - 5 Dimensions (EQ-5D) Questionnaire Score|Maximum Serum Concentrations (Cmax) of Pertuzumab\n|Cmax of Trastuzumab|Minimum Serum Concentration (Cmin) of Pertuzumab|Cmin of Trastuzumab|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Pertuzumab","https://ClinicalTrials.gov/show/NCT01774786"
1846,"NCT00176137","Preoperative Twice Daily Chemoradiation in Addition to Chemotherapy Prior to Surgery in Stage III Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-Small Cell Lung Cancer","Procedure: preoperative radiochemotherapy","Heidelberg University|University Hospital Muenster|Lung Clinic Hemer|Kreiskrankenhaus Diekholzen|University Hospital, Saarland|FLT Berlin / Buch","All","18 Years to 69 Years   (Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GLCCG01/95|German Cancer Aid","September 13, 2005","October 1995","September 2005","April 21, 2008","April 2008","No Study Results Posted","null","null","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00176137"
1847,"NCT01641172","Taste, Smell and Chemotherapy (TASTY)","Completed","No Results Available","Testicular Cancer","Procedure: Dexa scan|Procedure: audiogram|Procedure: measurement of heart rate variability and baroreflex sensitivity|Procedure: Glucose tolerance assessment|Dietary Supplement: oral nutrition supplements|Behavioral: Two day food records|Behavioral: Food Frequency Questionnaire","University Medical Center Groningen","Male","18 Years to 50 Years   (Adult)","Phase 4","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","TASTY-01|NL38757.042.11","January 25, 2012","June 2012","January 2016","April 14, 2016","April 2016","No Study Results Posted","TASTY","January 2016","investigate the nature, prevalence, and duration of taste and smell changes|explore the short- and long-term consequences of taste and smell changes|investigate the appreciation of medical food products|Are changes related to metabolic syndrome?|Is chemotherapy induced neurotoxicity related to changes?","https://ClinicalTrials.gov/show/NCT01641172"
1848,"NCT02999087","Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","Not yet recruiting","No Results Available","HNSCC","Drug: Cetuximab|Drug: avelumab|Drug: Cisplatin|Radiation: IMRT","Groupe Oncologie Radiotherapie Tete et Cou|Merck KGaA|Pfizer","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","688","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GORTEC 2017-01","December 14, 2016","April 2017","January 2021","February 6, 2017","December 2016","No Study Results Posted","REACH","October 2019","Progression free survival|Overall survival|Safety: acute adverse events graded by NCI CTCAE v4.03","https://ClinicalTrials.gov/show/NCT02999087"
1849,"NCT02624531","Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)","Recruiting","No Results Available","Cervical Cancer","Drug: Taxane|Procedure: radical trachelectomy","Sun Yat-sen University","Female","18 Years to 40 Years   (Adult)","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015-FXY-070","November 9, 2015","November 2015","November 2020","April 1, 2017","April 2017","No Study Results Posted","SYSUGO-005","November 2020","pregnancy rate|overall survival rate","https://ClinicalTrials.gov/show/NCT02624531"
1850,"NCT02921984","Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors","Recruiting","No Results Available","Salivary Gland Tumors|Head and Neck Cancer","Drug: Docetaxel|Radiation: Intensity-modulated radiotherapy|Drug: Pemetrexed|Drug: Cisplatin","Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2013HNRT01","September 30, 2016","September 2013","February 2017","September 30, 2016","September 2016","No Study Results Posted","null","December 2016","Acute toxicity profiles, graded according to the NCI CTCAE version 3.0|Disease-free survival","https://ClinicalTrials.gov/show/NCT02921984"
1851,"NCT02938273","Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: avelumab|Radiation: radiotherapy|Drug: cetuximab","The Netherlands Cancer Institute|Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N16BIR","September 26, 2016","December 2, 2016","October 2018","March 7, 2017","March 2017","No Study Results Posted","null","October 2017","occurence of grade 3-5 toxicity in new combination|Overall Response Rate","https://ClinicalTrials.gov/show/NCT02938273"
1852,"NCT01014767","Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors","Suspended","No Results Available","Brain Cancer|Choroid Plexus Tumors","Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Dactinomycin|Drug: Doxorubicin|Drug: Etoposide|Drug: Irinotecan|Drug: Leucovorin|Drug: Methotrexate|Drug: Temozolomide|Drug: Vincristine","Tufts Medical Center","All","Child, Adult, Senior","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPT-SIOP-2009","November 13, 2009","November 2009","null","July 21, 2016","July 2016","No Study Results Posted","null","October 2013","Time to Disease Progression|Toxicity during first 4 months of therapy","https://ClinicalTrials.gov/show/NCT01014767"
1853,"NCT00003592","Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: methotrexate|Drug: paclitaxel","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","230","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066662|E-7397","November 1, 1999","September 1998","null","January 28, 2009","January 2009","No Study Results Posted","null","August 2000","","https://ClinicalTrials.gov/show/NCT00003592"
1854,"NCT00002711","Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: chemotherapy|Drug: cisplatin|Drug: paclitaxel|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Primary Purpose: Treatment","95-073|CDR0000064528|NCI-H95-0791","November 1, 1999","October 1995","October 2000","July 1, 2013","July 2013","No Study Results Posted","null","October 2000","","https://ClinicalTrials.gov/show/NCT00002711"
1855,"NCT01868022","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling","Active, not recruiting","No Results Available","Cancer","Drug: GSK3052230|Drug: paclitaxel|Drug: carboplatin|Drug: docetaxel|Drug: pemetrexed|Drug: cisplatin","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","117360","May 30, 2013","October 9, 2013","September 28, 2017","May 15, 2017","May 2017","No Study Results Posted","null","September 28, 2017","Rate and severity of adverse events (AEs) as a measure of safety and tolerability|Number of Participants withdrawn due to AEs as measure of safety and tolerability|Dose interruptions and reduction as a measure of safety and tolerability|Treatment duration as a measure of safety and tolerability|Dose limiting toxicity (DLT) as a measure of safety and tolerability|Change from baseline in vital sign as a measure of safety and tolerability|Change from baseline in 12-lead electrocardiogram (ECG) as a measure of safety and tolerability|Change from baseline in Echocardiogram (ECHO) as measure of safety and tolerability|Change from baseline in laboratory test as measure of safety and tolerability|Maximum tolerated dose (MTD) or maximum feasible dose (MFD) of GSK3052230 in arm A and B|Best response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Overall response rate (ORR) per RECIST 1.1 or modified RECIST|Change from baseline in physical examination parameters|Progression-free survival (PFS) by investigator assessment per RECIST 1.1 or modified RECIST|GSK3052230 population pharmacokinetic (PK) profile|Change from baseline in Forced Vital Capacity (FVC) in subjects with MPM","https://ClinicalTrials.gov/show/NCT01868022"
1856,"NCT00404703","A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer","Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: bevacizumab [Avastin]|Drug: Platinum-based chemotherapy","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","37","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BO19734","November 28, 2006","August 2006","February 2008","August 23, 2016","August 2008","No Study Results Posted","null","February 2008","Rate of grade >=3 Avastin-related pulmonary hemorrhage|Overall response, duration of response, progression-free survival.|AEs, laboratory parameters, coagulation parameters.","https://ClinicalTrials.gov/show/NCT00404703"
1857,"NCT00533299","Hydralazine Valproate for Ovarian Cancer","Unknown status","No Results Available","Ovarian Cancer","Drug: Hydralazine and magnesium valproate|Drug: Placebo","National Institute of Cancerología","Female","18 Years and older   (Adult, Senior)","Phase 3","211","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","006/028/DDI","September 19, 2007","August 2007","December 2009","September 20, 2007","August 2007","No Study Results Posted","null","null","Progression-Free Survival|Safety, response, overall survival.","https://ClinicalTrials.gov/show/NCT00533299"
1858,"NCT00300586","IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Stage IV Non-small Cell Lung Cancer","Drug: observation|Drug: gemcitabine|Drug: erlotinib","Hospices Civils de Lyon","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","842","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005.386","March 6, 2006","June 2006","March 2011","December 28, 2011","December 2011","No Study Results Posted","null","March 2011","Progression free survival since randomization|Overall survival,|toxicity (NCIC-CTC 3.0),|quality of life (as assessed by LCSS).","https://ClinicalTrials.gov/show/NCT00300586"
1859,"NCT00059826","Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Biological: interferon-alfa-2b|Drug: cisplatin|Drug: 5-fluorouracil|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","89","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACOSOG-Z05031|CDR0000298776","May 6, 2003","March 2003","February 2011","December 5, 2016","December 2016","No Study Results Posted","null","July 2007","Overall survival at 18 months|Toxicity|Disease-free survival|Local-regional disease control|Distant disease control","https://ClinicalTrials.gov/show/NCT00059826"
1860,"NCT01232374","Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Squamous Cell Carcinoma","Drug: Nimotuzumab|Drug: Placebo|Drug: cisplatin|Radiation: Radiotherapy","Biotech Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BT-ESO-1001","October 12, 2010","September 2010","January 2016","August 19, 2015","August 2015","No Study Results Posted","null","October 2015","Response rate of Nimotuzumab combined with chemo-irradiation|1-yr overall survivals|2-yr overall survival|3-yr overall survival|Local progression-free survival|Disease progression-free survival|Distant metastasis rate|Number and grade of Participants with Adverse Events|Quality of life","https://ClinicalTrials.gov/show/NCT01232374"
1861,"NCT00053105","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: cisplatin|Drug: cytarabine|Drug: methylprednisolone|Drug: pixantrone dimaleate","Theradex|National Cancer Institute (NCI)","All","18 Years to 64 Years   (Adult)","Phase 1","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000269140|THERADEX-AZA-I-05|NOVUSPHARMA-AZA-I-05|NOVUSPHARMA-AZA-1401|CWRU-050213J","January 27, 2003","February 2002","null","July 4, 2009","March 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00053105"
1862,"NCT02365935","4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery","Completed","No Results Available","Uterine Cervical Neoplasms","Procedure: Group A adjuvant chemotherapy|Procedure: Group B adjuvant chemotherapy|Drug: Cisplatin|Drug: Paclitaxel","Campus Bio-Medico University","Female","18 Years to 75 Years   (Adult, Senior)","","215","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CC/47 cbm","January 21, 2015","February 2007","September 2014","February 18, 2015","February 2015","No Study Results Posted","null","January 2013","overall survival|safety:to evaluate and compare safety, in term of toxicity profile, of the two adjuvant treatment options.|disease free interval","https://ClinicalTrials.gov/show/NCT02365935"
1863,"NCT02819999","A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer","Recruiting","No Results Available","Small Cell Lung Cancer","Drug: Rovalpituzumab Tesirine|Drug: Cisplatin|Drug: Etoposide","Stemcentrx","All","18 Years and older   (Adult, Senior)","Phase 1","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SCRX001-004","June 27, 2016","October 2016","December 2020","May 19, 2017","May 2017","No Study Results Posted","null","October 2020","Dose limiting toxicities (DLT) of rovalpituzumab tesirine when administered as monotherapy, in series or in combination with frontline chemotherapy to subjects with delta-like protein 3 (DLL3)-expressing extensive-stage small cell lung cancer (SCLC)|Treatment emergent adverse events (TEAEs)|Incidence of subjects with CTCAE Grade >2 laboratory abnormalities|Progression-Free Survival (PFS)|Best overall response rate|Duration of response (DOR)|Clinical Benefit Rate (CBR)|Overall Survival (OS)|Incidence of anti-therapeutic antibodies (ATAs) against rovalpituzumab tesirine|Progression-free survival (Phase 1a)|Pharmacokinetic parameters: Cmax (Maximum plasma concentration observed )|Pharmacokinetic parameters: AUC0-tau (Area under the plasma concentration-time curve within a dosing interval)|Pharmacokinetic parameters: AUC0-∞ (Area under the curve from time 0 extrapolated to infinity)|Pharmacokinetic parameters: Tmax (Time of Cmax)|Pharmacokinetic parameters: Ctrough (Observed plasma concentrations at trough)|Pharmacokinetic parameters: T1/2 (Terminal half-life)|Pharmacokinetic parameters: CL (Clearance)|Pharmacokinetic parameters: Vss (Volume of distribution at steady state)|Incidence of TEAEs|Changes in vital signs (Heart Rate)|Changes in vital signs (Blood pressure)|Changes in vital signs (Temperature)|Changes in vital signs (Weight)|Changes in vital signs (Respirations)|Eastern Cooperative Oncology Group (ECOG) score","https://ClinicalTrials.gov/show/NCT02819999"
1864,"NCT02161692","Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors","Completed","No Results Available","Testicular Neoplasms|Germ Cell Tumors","Drug: Cyclophosphamide|Drug: Etoposide|Drug: Cisplatin|Drug: Bleomycin|Drug: Carboplatin","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Male","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INT48/96","June 10, 2014","December 1996","April 2009","June 11, 2014","June 2014","No Study Results Posted","null","May 2007","Evidence of disease progression confirmed by computed tomography (CT) scan and/or serum tumor markers.|Overall survival","https://ClinicalTrials.gov/show/NCT02161692"
1865,"NCT00806923","A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Gemcitabine|Drug: Placebo|Drug: bevacizumab [Avastin]|Drug: bevacizumab [Avastin]","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","1044","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO17704","December 10, 2008","February 2005","February 2011","November 1, 2016","November 2016","No Study Results Posted","null","February 2011","Progression-free survival|Efficacy: Duration of overall survival, time to treatment failure, response rate, and duration of response.|Safety:AEs, laboratory tests, SAEs, coagulation parameters","https://ClinicalTrials.gov/show/NCT00806923"
1866,"NCT02915965","A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma","Not yet recruiting","No Results Available","Stage II and III Esophageal Squamous Cell Carcinoma","Drug: DCX|Procedure: surgery","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ESCC01-SUMS6","September 23, 2016","October 2016","null","September 24, 2016","September 2016","No Study Results Posted","null","October 2018","overall survival rate|Pathologic response rate|Disease-free survival|Incidence of adverse event based on CTCAE 4.0","https://ClinicalTrials.gov/show/NCT02915965"
1867,"NCT02644863","Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer","Recruiting","No Results Available","Esophageal Neoplasms|Neoplasms|Digestive System Neoplasms|Esophageal Cancer","Drug: Paclitaxel|Biological: DC-CIK|Drug: Cisplatin","Shenzhen Hornetcorn Bio-technology Company, LTD|Affiliated Tumor Hospital of Guangzhou Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HYK-esophageal cancer","December 28, 2015","December 2015","May 2019","May 23, 2016","December 2015","No Study Results Posted","null","December 2018","Overall survival|Progress-free survival|Quality of life (QOL)|Phenotypic analysis of T cells","https://ClinicalTrials.gov/show/NCT02644863"
1868,"NCT00806117","Comparison of Post-surgery Adjuvant Therapy for Cervical Carcinoma","Recruiting","No Results Available","Cervical Cancer","Radiation: Radiotherapy (RT)|Other: Concurrent chemoirradiation (CCRT)|Other: Sequence chemotherapy and radiotherapy (SCRT)","Sun Yat-sen University|Guangdong Provincial People's Hospital|First Affiliated Hospital, Sun Yat-Sen University|Shenzhen People's Hospital|Cancer Hospital of Guangxi Medical University","Female","18 Years to 65 Years   (Adult)","Phase 3","990","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","SYSU50102008049","December 8, 2008","February 2008","December 2018","March 13, 2016","March 2016","No Study Results Posted","null","December 2018","Disease Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00806117"
1869,"NCT02766348","Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients","Not yet recruiting","No Results Available","NSCLC","Drug: gemcitabine|Biological: DC-CTL|Drug: cisplatinum","Shenzhen Hornetcorn Bio-technology Company, LTD","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HYK-DC-CTL-NSCLC","May 5, 2016","May 2016","December 2018","May 6, 2016","May 2016","No Study Results Posted","null","December 2017","Progress-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02766348"
1870,"NCT00039910","Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia","Completed","No Results Available","Non-Hodgkin Lymphoma|Hodgkin Disease|Thrombocytopenia","Drug: (PN-152,243)/ PN-196,444","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","444-ONC-0003-0019","June 14, 2002","July 2000","March 2003","May 3, 2007","September 2006","No Study Results Posted","null","null","To evaluate the effectiveness of primary prophylaxis with intravenous rhTPO versus placebo in reducing the cumulative proportion of patients who experience severe chemotherapy-induced thrombocytopenia.|Identify the effect of rhTPO on the number of platelet transfusions|Evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhTPO prophylaxis|Quantify the effect of rhTPO on the occurrence of any bleeding events associated with thrombocytopenia|Assess the likelihood that patients were to have adequate hematologic recovery to allow on-time chemotherapy administration in the subsequent cycles|Assess the safety of multiple IV doses of rhTPO|Determine the occurrence and clinical implications of any anti-TPO antibodies|Assess the antitumor activity of DHAP chemotherapy|Evaluate the impact of rhTPO prophylaxis on health economics/cost effectiveness|Evaluate the impact of rhTPO prophylaxis on patient quality of life","https://ClinicalTrials.gov/show/NCT00039910"
1871,"NCT01363479","An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting","Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting","Drug: Oral palonosetron|Drug: I.V. palonosetron|Drug: Dexamethasone","Helsinn Healthcare SA|Parexel","All","18 Years and older   (Adult, Senior)","Phase 3","743","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PALO-10-01","May 30, 2011","July 2011","null","November 6, 2014","November 2014","November 6, 2014","null","November 2012","Proportion of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication|Proportion of Patients With no Emesis|Proportion of Patients With no Rescue Medication","https://ClinicalTrials.gov/show/NCT01363479"
1872,"NCT02135042","Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA","Recruiting","No Results Available","Epstein-Barr Virus Infection|Stage II Nasopharyngeal Carcinoma|Stage III Nasopharyngeal Carcinoma|Stage IVA Nasopharyngeal Carcinoma|Stage IVB Nasopharyngeal Carcinoma","Drug: Cisplatin|Other: Clinical Observation|Drug: Fluorouracil|Drug: Gemcitabine Hydrochloride|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Quality-of-Life Assessment","NRG Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","924","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NRG-HN001|NCI-2014-00635|RTOG-1305|U10CA180868|U10CA021661","May 7, 2014","April 2014","null","June 17, 2016","June 2016","No Study Results Posted","null","July 2021","Overall survival (OS) (Undetectable Plasma EBV DNA Cohort Phase III)|Progression-free survival (PFS) (Detectable Plasma EBV DNA Cohort Phase II)|Changes in pure tone audiometry (Phase II and III)|Changes in QOL (hearing) as assessed by the Hearing Handicap Inventory for the Elderly-Screening version (HHIE-S) (Phase II and III)|Changes in QOL (peripheral neuropathy) as assessed by the FACT-Taxane (Phase II and III)|Changes in quality of life (QOL) (general and physical well-being) assessed using the Functional Assessment of Cancer Therapy (FACT)-Nasopharyngeal (NP) (Phase II and III)|Cost effectiveness as assessed by the health-related QOL (HRQOL) from the EuroQol (EQ-5D) instrument (Phase II and III)|Incidence of acute grade 3-5 adverse events (Phase II and III)|Incidence of death (Phase II and III)|Incidence of late grade 3-5 adverse events (Phase II and III)|OS (Detectable Plasma EBV DNA Cohort Phase II)|PFS (Undetectable Plasma EBV DNA Cohort Phase III)|Time to distant metastasis (DM) (Phase II and III)|Time to local progression (Phase II and III)|Time to regional progression (Phase II and III)","https://ClinicalTrials.gov/show/NCT02135042"
1873,"NCT02899195","Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma","Recruiting","No Results Available","Mesothelioma|Pleural Mesothelioma","Drug: Concurrent Durvalumab|Drug: Maintenance Durvalumab","PrECOG, LLC.|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PrE0505|ESR-15-10792","September 8, 2016","May 2017","December 2020","May 17, 2017","May 2017","No Study Results Posted","PrE0505","August 2020","Overall Survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Progression-Free Survival (PFS)|Time to Progression (TTP) on Durvalumab|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02899195"
1874,"NCT02844114","Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Ganoderma lucidum spore|Drug: Placebo|Drug: Chemotherapy","Gao Yajie|The First Affiliated Hospital of Dalian Medical University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NationalHealthyFood G20090069","June 19, 2016","January 2016","January 2018","March 30, 2017","March 2017","No Study Results Posted","LCKY2015-21(x)","January 2018","The life quality of participants was assessed with use of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at the initial diagnosis (baseline) and at 42 days after the treatment.|Investigators assessed Procedural mortality factor ligand 1(PD-L1) expression prospectively on tumour cells and tumour-infiltrating immune cells with the VENTANA PD-L1 immunohistochemistry assay.","https://ClinicalTrials.gov/show/NCT02844114"
1875,"NCT00896181","Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)","Recruiting","No Results Available","Stage II Lymphoepithelioma of the Nasopharynx|Stage II Squamous Cell Carcinoma of the Nasopharynx|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx","Drug: docetaxel|Drug: cisplatin|Drug: carboplatin|Drug: fluorouracil|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Stanford University","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ENT0025-|NCI-2009-01162|CDR0000671087|8209|IRB-15411","May 7, 2009","January 2009","July 2020","December 9, 2016","December 2016","No Study Results Posted","null","July 2019","Progression free survival rate, using RECIST criteria|Overall survival|Rates of adverse events resulting in treatment discontinuation","https://ClinicalTrials.gov/show/NCT00896181"
1876,"NCT01674738","TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV","Withdrawn","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Pemetrexed|Drug: Cisplatin|Drug: Bevacizumab","Aktion Bronchialkarzinom e.V.|Roche Pharma AG|Eli Lilly and Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABC-2011-NSCLC-03|2011-002145-35","August 23, 2012","null","null","October 10, 2013","October 2013","No Study Results Posted","SELECT-A","null","Progression free survival|Overall survival|Quality of life|Response rate|Molecular investigations","https://ClinicalTrials.gov/show/NCT01674738"
1877,"NCT00779714","Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC","Unknown status","No Results Available","Melanoma","Drug: DTIC (dacarbazine)|Drug: paclitaxel + cisplatin|Drug: treosulfan + cytarabine","University of Wuerzburg|Hiege-Stiftung gegen Hautkrebs|medac GmbH|DCS Innovative Diagnostik Systeme","All","18 Years and older   (Adult, Senior)","Phase 3","360","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","101.321-13/07|EudraCT Nr. 2008-001686-28","October 22, 2008","October 2008","April 2013","October 22, 2008","October 2008","No Study Results Posted","ChemoSensMM","October 2012","Disease-specific overall survival|Objective response","https://ClinicalTrials.gov/show/NCT00779714"
1878,"NCT01843647","Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients","Recruiting","No Results Available","Non-small-cell Lung Cancer","Drug: Icotinib|Drug: Chemotherapy","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BD-IC-IV06","April 26, 2013","April 2013","February 2018","July 14, 2015","December 2014","No Study Results Posted","null","December 2016","Objective response rate|Disease free survival|The pathological complete response rate after neoadjuvant therapy with icotinib|The lymph node staging reduction rate of patients after neoadjuvant therapy with icotinib|The resection rate of patients after neoadjuvant therapy with icotinib","https://ClinicalTrials.gov/show/NCT01843647"
1879,"NCT02001168","Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Pemetrexed|Drug: Docetaxel|Drug: rh-Endostatin|Drug: Cis-platinum","Xinjiang Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","392","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","XinjiangMU","November 4, 2013","October 2013","October 2022","November 26, 2013","November 2013","No Study Results Posted","null","December 2020","Disease free survival|Adverse reactions of adjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT02001168"
1880,"NCT02582697","Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","Recruiting","No Results Available","Germ Cell Tumor","Drug: Bleomycin (active name: Bleomycin Sulfate)|Drug: Etoposide|Drug: Cisplatin|Drug: Pegylated G-CSF (Pegfilgrastim)","University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Children's Oncology Group|Dana-Farber Cancer Institute|University of Southern California","Male","16 Years to 45 Years   (Child, Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANZUP1302|ACTRN12613000496718","September 7, 2015","February 2014","July 2023","May 11, 2016","May 2016","No Study Results Posted","P3BEP","February 2022","Progression-free survival (disease progression or death)|Initial response assessment|Final response assessment|Adverse events (worst grade according to NCI CTCAE v4.03)|Health-related quality of life|Health-related quality of life for testicular cancer|Treatment preference|Delivered dose-intensity of chemotherapy (relative to standard BEP)|Overall survival","https://ClinicalTrials.gov/show/NCT02582697"
1881,"NCT01260103","Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma","Withdrawn","No Results Available","Optic Nerve Glioma","Drug: Temozolomide|Drug: ANP Therapy","Burzynski Research Institute","All","6 Months to 18 Years   (Child, Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRI-BT-54","December 13, 2010","December 2011","December 2018","December 5, 2016","December 2016","No Study Results Posted","null","December 2016","Progression free survival (PFS)|Safety Analysis","https://ClinicalTrials.gov/show/NCT01260103"
1882,"NCT00532025","Sorafenib in Resected Non-small Cell Lung Carcinoma","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Sorafenib","Johannes Gutenberg University Mainz","All","18 Years and older   (Adult, Senior)","Phase 2","134","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SIRN-TOM1 KKS 2006-010","September 18, 2007","September 2007","September 2008","July 24, 2009","July 2009","No Study Results Posted","SIRN","September 2008","Progression-free survival (PFS) clinical and radiological assessment of remission status (RECIST criteria)|Progression free survival|Overall survival|Assessment of safety and tolerability of Sorafenib when administered as adjuvant treatment following surgery for NSCLC|Assessment of biomarkers relevant to Sorafenib response and disease state, and their correlation to clinical outcome","https://ClinicalTrials.gov/show/NCT00532025"
1883,"NCT02575859","Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients","Completed","No Results Available","Colorectal Neoplasm|Metastasis","Drug: adjuvant HIPEC|Procedure: surgery","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Azienda Usl di Bologna","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","35/13","September 21, 2015","January 2006","December 2011","October 13, 2015","September 2015","No Study Results Posted","null","June 2010","Positive predictive value of preoperative/intraoperative assessment of primary tumor-related risk factors for the development of metachronous peritoneal metastases in patients undergoing curative surgery for colorectal cancer.|Number of patients with postoperative treatment-related adverse events.|Peritoneal progression-free survival","https://ClinicalTrials.gov/show/NCT02575859"
1884,"NCT01218516","A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung","Completed","No Results Available","Adenocarcinoma of the Lung","Biological: Farletuzumab|Other: Placebo|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cisplatin","Morphotek","All","18 Years and older   (Adult, Senior)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MORAb-003-009","October 7, 2010","April 2011","November 2013","June 16, 2016","June 2016","No Study Results Posted","null","December 2012","Progression-free survival (PFS)|Overall Response rate (ORR)|Duration of Response (DR)|Overall Survival (OS)|Number of participants with Treatment emergent adverse events (TEAEs) and Treatment emergent Serious adverse events (SAEs)","https://ClinicalTrials.gov/show/NCT01218516"
1885,"NCT02124148","A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer","Recruiting","No Results Available","Neoplasm Metastasis|Colorectal Neoplasms","Drug: Prexasertib|Drug: Cisplatin|Drug: Cetuximab|Drug: G-CSF|Drug: Pemetrexed|Drug: Fluorouracil|Drug: LY3023414|Drug: Leucovorin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","185","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","15295|I4D-MC-JTJF","April 24, 2014","June 18, 2014","April 27, 2019","March 8, 2017","March 2017","No Study Results Posted","null","April 27, 2019","Part A: Maximum Tolerated Dose and Schedule of Prexasertib in Combination with Cisplatin|Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab|Part C: Maximum Tolerated Dose of Prexasertib in Combination with Pemetrexed|Part D: Maximum Tolerated Dose of Prexasertib in Combination with Fluorouracil (5-FU)|Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414|Pharmacokinetics: Maximum Concentration of Prexasertib|Pharmacokinetics: Area Under the Concentration Curve of Prexasertib|Part B Dose Expansion: Overall Response Rate|Part B Dose Expansion: Disease Control Rate|Part B Dose Expansion: Progression-Free Survival|Part B Dose Expansion: Duration of Response","https://ClinicalTrials.gov/show/NCT02124148"
1886,"NCT01233843","Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.","Active, not recruiting","No Results Available","Squamous Cell Head and Neck Carcinoma","Drug: carboplatin|Drug: 5 fluorouracil|Radiation: radiation therapy","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","370","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GORTEC 2007-02","October 25, 2010","May 2009","May 2019","January 2, 2014","January 2014","No Study Results Posted","2007/02","February 2016","Complete response rate of the treatment|The second focus of this study is to compare Overall survival between the two arms . It is defined as the time from the date of randomization to the date of death from any cause.","https://ClinicalTrials.gov/show/NCT01233843"
1887,"NCT00667342","A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma","Active, not recruiting","Has Results","Osteosarcoma|Malignant Fibrous Histiocytoma (MFH) of Bone","Biological: Bevacizumab|Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate|Drug: Ifosfamide|Drug: etoposide|Procedure: Surgery|Radiation: Radiotherapy","St. Jude Children's Research Hospital|Genentech, Inc.","All","up to 30 Years   (Child, Adult)","Phase 2","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","OS2008|GENENTECH PHARM|NCI-2009-00846","April 24, 2008","June 2008","April 2018","April 17, 2017","April 2017","June 9, 2014","null","May 2014","Number of Participants With Unacceptable Toxicity|3-Year Event Free Survival|Histologic Response by Stratum|2-Year Event Free Survival (EFS) of Patients With Osteosarcoma|2-Year Overall Survival (OS) of Patients With Osteosarcoma|2-Year Event Free Survival (EFS) in Patients With Localized Resectable Disease Compared to St. Jude OS99 Protocol.|2-Year Overall Survival (OS) in Patients With Localized Resectable Disease Compared to OS99 Protocol.|Mean Ktrans|Mean Vp|Mean Ve|Histologic Response by Number of Participants|Ktrans by Good and Poor Response|P95 of Ktrans by Good and Poor Response|Difference Between Good and Poor Response by SUVmax","https://ClinicalTrials.gov/show/NCT00667342"
1888,"NCT01336192","Maintenance Gemcitabine in the Chinese Advanced Lung Cancer","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: Gemcitabine|Drug: Best supportive care","Tongji University|Shanghai Pulmonary Hospital, Shanghai, China","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SHPH-11ZL113","April 7, 2011","April 2011","April 2013","April 13, 2011","April 2011","No Study Results Posted","MAGICAL","April 2012","Progression free survival|Overall Survival|Response Rate|Time to The Progression|Health Related Quality of Life|Number of Participants with treatment-related grade III/IV adverse events","https://ClinicalTrials.gov/show/NCT01336192"
1889,"NCT00146276","Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer","Unknown status","No Results Available","Bladder Cancer|Carcinoma, Transitional Cell","Drug: gemcitabine","Association of Urogenital Oncology (AUO)|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","178","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B9E-MC-S062|AB 22/00","September 2, 2005","July 2000","null","September 26, 2006","September 2005","No Study Results Posted","null","null","progression-free survival|overall survival|toxicity and tolerability of gemcitabine|quality of life (EORTC QLQ-C30, version 2.0)","https://ClinicalTrials.gov/show/NCT00146276"
1890,"NCT01313663","A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population","Terminated","Has Results","Lung Cancer, Small Cell","Drug: pazopanib|Drug: pemetrexed","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","113758","January 27, 2011","February 2011","July 2012","October 16, 2014","October 2013","March 7, 2013","null","July 2012","Progression Free Survival (PFS)|Overall Survival|Number of Participants (Par.) With the Indicated Best Overall Response|Number of Participants With Any Non-serious On-therapy Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) and Serious Adverse Event (SAE)|Time on Study Treatment (Pazopanib), as a Measure of Extent of Exposure|Mean Daily Dose, as a Measure of Extent of Exposure|Mean Number of Pemetrexed Dosing Cycles, as a Measure of Extent of Exposure|Average Dose of Pemetrexed for All Cycles, as a Measure of Extent of Exposure|Number of Participants With Any AE (Serious or Non-serious) Leading to Withdrawal From Study Treatment|Number of Participants With Any On-therapy AE (Serious or Non-serious) Leading to Dose Reductions (DRs) or Interruptions/Delays in the Study|Number of Participants With the Indicated Worst-case Change From Baseline in Blood Pressure|Number of Participants With a Increase From Baseline in Bazett's QTc at the Indicated Time Points|Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Clinical Laboratory Parameters|Number of Participants With the Indicated Grade Changes From Baseline Grade in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk. Phos.), and Total Bilirubin (TB)|Number of Participants With the Indicated Changes From Baseline Value in Lactate Dehydrogenase (LDH)","https://ClinicalTrials.gov/show/NCT01313663"
1891,"NCT00002783","Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","50","Other|NIH","Interventional","Primary Purpose: Treatment","96-027|CDR0000064831|NCI-H96-0916","November 1, 1999","May 1996","January 2001","July 1, 2013","July 2013","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00002783"
1892,"NCT01283178","Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC","Terminated","No Results Available","Salivary Gland Squamous Cell Carcinoma|Stage II Salivary Gland Cancer|Stage II Squamous Cell Carcinoma of the Hypopharynx|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Verrucous Carcinoma of the Oral Cavity","Radiation: intensity-modulated radiation therapy|Drug: cisplatin|Radiation: image-guided adaptive radiation therapy|Other: 3'-deoxy-3'-[18F]fluorothymidine|Procedure: positron emission tomography/computed tomography|Radiation: fludeoxyglucose F 18","Virginia Commonwealth University|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 1","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC 13222|NCI-2010-02340|P30CA016059","January 24, 2011","July 2011","September 2016","October 27, 2016","October 2016","No Study Results Posted","null","March 2016","Feasibility of integrating molecular imaging (PET with FLT tracer) into current state-of-the-art image-guided adaptive radiation therapy (IGART) of head and neck cancer|Comparison of gross tumor volumes defined by FDG-PET, FLT-PET, CBCT, and regular FBCT|Impact of escalated doses to tumor sub-volumes with high FLT and FDG uptake using post-treatment FDG images as an early surrogate for sub-volume-specific local control|Development of a database consisting of all molecular and anatomic images, including daily CBCT data sets, obtained during chemo-radiation therapy to support further research|Patient long-term toxicities and survival|Impact of daily image-guided setup; off-line every other week adaptive re-planning; and molecular-image based targeting on sparing of tissues and organs responsible for late and early treatment sequelae","https://ClinicalTrials.gov/show/NCT01283178"
1893,"NCT01726374","Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours","Active, not recruiting","No Results Available","Stage I Testicular Non-Seminomatous Germ Cell Tumor","Drug: BEP(500)","Institute of Cancer Research, United Kingdom|University Hospital Birmingham NHS Foundation Trust|Cancer Research UK","Male","16 Years and older   (Child, Adult, Senior)","Phase 3","236","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ICR-CTSU/2008/10019|ISRCTN37875250|2008-006295-29|09/H1102/86|CRUK/09/011","November 9, 2012","February 2010","August 2019","September 18, 2015","September 2015","No Study Results Posted","111","August 2016","Recurrence|Immediate and delayed toxicity including long-term permanent infertility (>2 years)|Relapse free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01726374"
1894,"NCT02272699","Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma","Suspended","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: Nimotuzumab|Drug: Paclitaxel|Drug: Cisplatin|Radiation: Radiation|Procedure: Surgery","Peking University","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","195","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESCC002","October 11, 2014","November 2014","December 2018","April 5, 2017","April 2017","No Study Results Posted","null","December 2018","Disease-free survival|Overall survival|Pathological complete response of neoadjuvant treatment|The R0 resection rate|Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.","https://ClinicalTrials.gov/show/NCT02272699"
1895,"NCT02036164","Adjuvant Chemotherapy for Locally Advanced Cervical Cancer","Recruiting","No Results Available","Uterine Cervical Cancer","Radiation: Pelvic radiation|Drug: Cisplatin|Drug: Paclitaxel|Drug: Carboplatin","Siriwan Tangjitgamol, MD|National Research Council of Thailand|Navamindradhiraj University|Chiang Mai University|Prince of Songkla University|Bhumibol Adulyadej Hospital|Lopburi Cancer Hospital|Ubonratchathani Cancer Hospital|Udonthani Cancer Hospital|Chonburi Cancer Hospital|Lampang Cancer Hospital|Health Intervention and Technology Assessment Program|Rajburi Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Outcomes Assessor|Primary Purpose: Treatment","COA-CREC 002/2013|20140106001","January 8, 2014","January 2014","January 2019","April 4, 2017","April 2017","No Study Results Posted","ACT-LACC","January 2018","Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02036164"
1896,"NCT02208583","Molecular Phenotype Changes and Personalized Treatment for CRPC","Unknown status","No Results Available","Hormone Refractory Prostate Cancer","Drug: Docetaxel & Prednisone|Drug: DP & Targeted drugs|Drug: cisplatin & Etoposide|Drug: EP & Targeted drugs","Tianjin Medical University Cancer Institute and Hospital","Male","18 Years and older   (Adult, Senior)","","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","E2014064","July 29, 2014","June 2014","December 2016","August 4, 2014","June 2014","No Study Results Posted","null","December 2016","Molecular phenotypic changes after acquired resistance of hormonal therapy|clinical progression free survival(cPFS)|Overall Survival(OS)|The relationship between molecular phenotypic changes and OS","https://ClinicalTrials.gov/show/NCT02208583"
1897,"NCT01461057","A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer","Active, not recruiting","Has Results","Gastric Cancer","Drug: Capecitabine|Drug: Cisplatin|Drug: Pertuzumab|Drug: Pertuzumab|Drug: Trastuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BP27836","October 26, 2011","December 6, 2011","June 30, 2017","April 5, 2017","April 2017","May 19, 2016","null","March 1, 2015","Percentage of Participants With Day 43 Serum Pertuzumab Trough Concentrations (Cmin) Greater Than or Equal to (>=) 20 Microgram Per Milliliter (mcg/mL)|Number of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT01461057"
1898,"NCT01924819","Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","Recruiting","No Results Available","Gastric Cancer","Drug: Epirubicin + cisplatin + 5-fluorouracil|Radiation: Preoperative chemoradiotherapy|Procedure: Gastric resection","Australasian Gastro-Intestinal Trials Group|National Health and Medical Research Council, Australia|Trans-Tasman Radiation Oncology Group (TROG)|European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","752","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AG0407GR|ACTRN12609000035224|U1111-1146-0762|TROG 08.08|22114-40111|GA.1","August 14, 2013","September 2009","December 2020","July 12, 2016","July 2016","No Study Results Posted","TOPGEAR","December 2020","Overall survival|Disease free survival|Pathological response rate|Proportion of participants with given grades of toxicities|Surgical complete resection rate (R0)","https://ClinicalTrials.gov/show/NCT01924819"
1899,"NCT01406249","XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer","Active, not recruiting","No Results Available","Gastric Cancer","Drug: SP|Drug: XP","Epidemiological and Clinical Research Information Network","All","20 Years to 74 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ECRIN-GC1107-XParTS II|UMIN000006045","July 28, 2011","August 2011","December 2016","February 2, 2016","February 2016","No Study Results Posted","null","December 2016","Progression-free survival rate|Time-to treatment failure|Response rate|Overall survival|Safety","https://ClinicalTrials.gov/show/NCT01406249"
1900,"NCT01836029","Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Active, not recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: VTX-2337|Drug: Carboplatin|Drug: Cisplatin|Drug: 5-fluorouracil|Drug: Placebo","VentiRx Pharmaceuticals Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VRXP-A202","April 12, 2013","July 2013","September 2016","January 5, 2016","January 2016","No Study Results Posted","null","September 2016","To compare the efficacy of VTX-2337 plus SOC to SOC alone in prolonging the PFS of patients with recurrent or metastatic SCCHN.|To compare the safety of VTX-2337 plus SOC versus SOC alone by adverse events, including clinically significant changes in physical examination, peripheral blood hematology, serum chemistry, urinalysis, and ECG.|To compare the efficacy of VTX-2337 plus SOC versus SOC alone in prolonging the OS of patients with recurrent or metastatic SCCHN.|To compare the efficacy of VTX-2337 plus SOC to SOC alone on objective response rate.|To compare the efficacy of VTX-2337 plus SOC to SOC alone on duration of best response.|To compare the efficacy of VTX-2337 plus SOC to SOC alone on disease control rate.|To compare the efficacy of VTX-2337 plus SOC to SOC alone on duration of disease control.","https://ClinicalTrials.gov/show/NCT01836029"
1901,"NCT00705627","A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: neoadjuvant chemotherapy plus concurrent chemoradiotherapy","Sun Yat-sen University|Guangdong General Hospital|Cancer Center of Guangzhou Medical University|Cancer Hospital of Shantou University","All","18 Years to 60 Years   (Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2007047","June 24, 2008","June 2008","June 2017","May 26, 2014","May 2014","No Study Results Posted","null","February 2015","distant metastasis free survival,disease free survival|overall survival","https://ClinicalTrials.gov/show/NCT00705627"
1902,"NCT00039039","Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: carboplatin|Drug: chemotherapy|Drug: cisplatin|Drug: paclitaxel|Radiation: radiation therapy","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068846|INRC-PITCAP|EU-20202|INRC-ITA|NCI-V01-1665","June 6, 2002","February 2000","null","December 17, 2013","August 2006","No Study Results Posted","null","null","Overall survival rate|One-year survival rate and mean survival time|Objective response rate and local control|Tolerability|Safety profile, in terms of acute and delayed toxicity","https://ClinicalTrials.gov/show/NCT00039039"
1903,"NCT00085202","Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor","Active, not recruiting","Has Results","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine|Procedure: autologous hematopoietic stem cell transplantation|Radiation: radiation therapy","St. Jude Children's Research Hospital","All","3 Years to 21 Years   (Child, Adult)","Phase 3","416","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJMB03|NCI-2011-01185","June 10, 2004","August 2003","January 2023","March 31, 2017","January 2017","November 4, 2013","null","December 2016","Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors|Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.|Frequency of Mutations Associated With SHH and WNT Tumors|Reading Decoding Composite Scores in the Intervention and Standard of Care Groups|Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa|Mean RT Dose to Specified Target Tissue Volume by Rate and Pattern of Failure, e.g. Local Failure, Distant Failure, Etc.","https://ClinicalTrials.gov/show/NCT00085202"
1904,"NCT02495896","Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Metastatic Pancreatic Adenocarcinoma|Non-Resectable Cholangiocarcinoma|Pancreatic Adenocarcinoma|Recurrent Gallbladder Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage III Pancreatic Cancer|Stage IIIA Gallbladder Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Gallbladder Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Gallbladder Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pancreatic Cancer|Unresectable Gallbladder Carcinoma|Unresectable Pancreatic Cancer","Drug: Cisplatin|Drug: Docetaxel|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Other: Pharmacological Study|Biological: Recombinant EphB4-HSA Fusion Protein","University of Southern California|National Cancer Institute (NCI)|Vasgene Therapeutics, Inc","All","18 Years and older   (Adult, Senior)","Phase 1","80","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0S-15-5|NCI-2015-00987|P30CA014089","July 6, 2015","September 2015","December 2017","July 15, 2016","July 2016","No Study Results Posted","null","September 2017","Duration of overall response or SD|Incidence of toxicities, graded according to Common Terminology Criteria for Adverse Events version 4|Objective response using RECIST version 1.1|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT02495896"
1905,"NCT02577341","Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer","Recruiting","No Results Available","Non-small-cell Lung Cancer","Drug: Nimotuzumab|Drug: docetaxel and cisplatin|Radiation: daily RT (65Gy in 25 fractions) to the chest|Drug: placebo","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-FXY-061","October 12, 2015","August 2015","July 2020","April 15, 2017","March 2017","No Study Results Posted","null","July 2020","overall survival|Objective Response Rate|progression-free survival|rate of grade 3-4 radiation esophagitis|rate of grade 3-4 radiation pneumonitis","https://ClinicalTrials.gov/show/NCT02577341"
1906,"NCT01379339","Cabazitaxel - PF Induction Chemotherapy","Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Cabazitaxel 10mg/m2|Drug: Cabazitaxel 12.5mg/m2|Drug: Cabazitaxel 15mg/m2|Drug: Cabazitaxel 17.5mg/m2|Drug: Cabazitaxel 20mg/m2","Krzysztof Misiukiewicz|Sanofi|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","11-0646(0001)(01)|183133-96-2|HS#: 11-00201","June 15, 2011","April 2011","January 2015","February 9, 2015","February 2015","No Study Results Posted","null","January 2015","Maximum Tolerated Dose (MTD)|Dose-limiting toxicity (DLT)|Toxicity Profile|Overall Response Rate|Progression Free Survival/Overall Survival","https://ClinicalTrials.gov/show/NCT01379339"
1907,"NCT00005047","4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer","Unknown status","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vinblastine|Procedure: adjuvant therapy","Southwest Oncology Group|National Cancer Institute (NCI)|NCIC Clinical Trials Group|University of Southern California","All","Child, Adult, Senior","Phase 3","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067639|LAC-USC-4B951|SWOG-4B951|NCI-G00-1715|NYU-9852|CAN-NCIC-BL10|CCCWFU-88198","April 6, 2000","September 1998","null","July 21, 2011","June 2011","No Study Results Posted","null","null","Time to recurrence at 3 years|Overall survival at 3 years","https://ClinicalTrials.gov/show/NCT00005047"
1908,"NCT01791374","Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ","Completed","No Results Available","Part 1- Advanced Solid Tumors|Part 2- Advanced or Metastatic Gastric Cancer|Part 2- Advanced or Metastatic GEJ","Drug: Rilotumumab|Drug: Rilotumumab","Amgen","All","20 Years to 100 Years   (Adult, Senior)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20110251","January 4, 2013","November 2012","March 2015","February 26, 2016","February 2016","No Study Results Posted","null","August 2013","Part1: Dose-limiting toxicities (DLT) for each dose level of rilotumumab tested|Part 2: Dose-limiting toxicities (DLT) for each dose level of rilotumumab in combination with cisplatin and capecitabine (CX) chemotherapy tested|Part 1: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies.|Part 1: Pharmacokinetics parameters of rilotumumab monotherapy as measured by: Maximum concentration, time to achieve maximum concentration, observed minimum concentration, area under the concentration-time curve, terminal elimination half-life.|Part 1: Evaluate efficacy based on the treatment effects of rilotumumab monotherapy as measured by the following: Objective Response Rate, duration of response, progression-free survival.|Part 2: Incidence of AEs, clinical laboratory abnormalities and anti-rilotumumab antibodies not defined as DLTs.|Part 2: Pharmacokinetics parameters of rilotumumab in combination with cisplatin and capecitabine as measured by: Maximum concentration, observed minimum concentration, area under the concentration-time curve.|Part 2: Evaluate efficacy based on the treatment effects of rilotumumab in combination with cisplatin and capecitabine as measured by the following: Objective Response Rate, duration of response, progression-free survival, overall survival.","https://ClinicalTrials.gov/show/NCT01791374"
1909,"NCT02262325","Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery","Recruiting","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Radiation: hypofractionated radiation therapy|Drug: cisplatin|Drug: etoposide|Radiation: 3-dimensional conformal radiation therapy|Other: laboratory biomarker analysis","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-14091|NCI-2014-01663","October 7, 2014","December 2014","null","July 12, 2016","July 2016","No Study Results Posted","null","November 2017","Primary tumor control rate, as measured from the time of treatment completion until the first documented date of local failure|Frequency of all adverse events, with special attention to grade 3-5 esophagitis, pneumonitis, and cardiac adverse events as defined by the National Cancer Institution Common Terminology Criteria for Adverse Events CTCAE version 4.0|Tolerability measured by the number of patients who discontinue treatment|Regional control|Distant control|Progression-free survival (PFS)|Overall survival (OS)|Objective response rate as measured by Response Evaluation Criteria in Solid Tumors criteria|Changes in tumor perfusion measured by MR-DCE/PWI|Changes in diffusion measured by MR-diffusion|Changes in hypoxia measured by BOLD sequences","https://ClinicalTrials.gov/show/NCT02262325"
1910,"NCT00274937","Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer","Active, not recruiting","Has Results","Stage I Lymphoepithelioma of the Nasopharynx|Stage I Squamous Cell Carcinoma of the Nasopharynx|Stage II Lymphoepithelioma of the Nasopharynx|Stage II Squamous Cell Carcinoma of the Nasopharynx|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx","Drug: amifostine trihydrate|Drug: fluorouracil|Drug: cisplatin|Other: laboratory biomarker analysis|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 3","111","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARAR0331|NCI-2009-00412|COG-ARAR0331|CDR0000454849|U10CA098543","January 10, 2006","February 2006","null","November 23, 2016","November 2016","October 24, 2016","null","March 2016","Two Year Event-free Survival (EFS)|Predictive Value of Epstein-Barr Virus (EBV) DNA as Measured by Quantitative Detection at Enrollment on EFS 2 Years After Treatment|Prognostic Significance of EBV Viral Load|Predictive Value of the Detection of EBV DNA in the Peripheral Blood|Protective Effects of Amifostine Assessed Primarily by Sialometry|Protective Effects of Amifostine Assessed Primarily by Sialometry: Weight of Unstimulated Saliva Production in Grams.","https://ClinicalTrials.gov/show/NCT00274937"
1911,"NCT00003606","Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: etoposide|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","216","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066683|FRE-FNCLCC-95012|EU-98021","November 1, 1999","March 1998","null","February 6, 2009","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003606"
1912,"NCT00005834","S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma","Terminated","No Results Available","Multiple Myeloma","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: thalidomide","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S9922|U10CA032102","June 2, 2000","April 2000","November 2007","March 5, 2015","March 2015","No Study Results Posted","null","November 2003","PFS","https://ClinicalTrials.gov/show/NCT00005834"
1913,"NCT02381847","Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients","Recruiting","No Results Available","Malignant Neoplasm of Stomach","Procedure: intraperitoneal chemoperfusion","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NDTHNanjingUMS","February 28, 2015","January 2015","March 2020","March 4, 2015","February 2015","No Study Results Posted","null","March 2017","overall survival|complication rate|time to progress|time to distant metastasis","https://ClinicalTrials.gov/show/NCT02381847"
1914,"NCT01167738","Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer","Terminated","No Results Available","Pancreatic Cancer","Drug: capecitabine|Drug: cisplatin|Drug: epirubicin|Drug: gemcitabine|Drug: metformin","IRCCS San Raffaele","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000681691|PACT-17|2010-020979-23","July 21, 2010","July 2010","April 2015","April 23, 2015","April 2015","No Study Results Posted","PACT-17","December 2014","Progression-free survival at 6 months|Overall survival|Response rate|Toxicity","https://ClinicalTrials.gov/show/NCT01167738"
1915,"NCT01627288","Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)","Active, not recruiting","No Results Available","Cancer of the Cervix|Cervical Neoplasms","Radiation: Boost radiation","Duke University","Female","18 Years and older   (Adult, Senior)","","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00033820","June 21, 2012","June 2012","June 2020","January 10, 2017","January 2017","No Study Results Posted","IDEAL","August 2019","Maximum tolerated dose of integrated boost radiation therapy, administered with IMRT technique with concurrent chemotherapy (cisplatin).|Local-regional control with integrated boost radiation therapy (TTLR)|Time to distant recurrence (TTDR)|Disease free survival(DFS).|Overall survival (OS)|The number of acute dose limiting toxicities (DLT).|The number of late dose limiting toxicities (DLT)","https://ClinicalTrials.gov/show/NCT01627288"
1916,"NCT00500760","Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer|Squamous Cell Carcinoma","Drug: Cisplatin|Radiation: Standard Fractionation Radiotherapy|Drug: Panitumumab","Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20062080","July 12, 2007","October 2007","November 2011","July 10, 2014","July 2014","February 13, 2014","null","April 2011","Local Regional Control Rate at 2 Years|Local Regional Control Rate at 6 Months and 12 Months|Duration of Local-regional Control|Progression-Free Survival|Overall Survival|Percentage of Participants With an Objective Response at 6 Months|Percentage of Participants With a Complete Response at 6 Months","https://ClinicalTrials.gov/show/NCT00500760"
1917,"NCT02425397","Cancer and Hearing Loss Related in Children","Unknown status","No Results Available","Cancer in Children.|Hearing Loss","Genetic: Genetic study|Genetic: Genetic study MT-RN1","Assistance Publique - Hôpitaux de Paris","All","4 Years and older   (Child, Adult, Senior)","","103","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","2010-A00405-34","September 22, 2014","February 2011","March 2016","April 23, 2015","April 2015","No Study Results Posted","OTOPLAT","October 2015","genetic factors (drug metabolism enzymes, membrane transporters) predisposing to cisplatin and carboplatin ototoxicity in children|genetic factors predisposing to aminoglycoside ototoxicity;|To provide a rationale for prevention of ototoxicity by the use of antioxidant medications.","https://ClinicalTrials.gov/show/NCT02425397"
1918,"NCT02630264","E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck","Recruiting","No Results Available","Head and Neck Neoplasms","Drug: Endostatins|Drug: Paclitaxel injection|Drug: Cisplatin injection","Guangzhou Double Bioproducts Co., Ltd","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E10AIII","December 26, 2013","June 2013","December 2016","December 10, 2015","December 2015","No Study Results Posted","null","June 2016","Time to progression|Change in Overall response rate (CR+PR)|Chang in disease control rate (CR+PR+SD)|Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)|Overall survival","https://ClinicalTrials.gov/show/NCT02630264"
1919,"NCT02807636","Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma","Recruiting","No Results Available","Urothelial Carcinoma","Drug: Atezolizumab|Drug: Carboplatin|Drug: Gemcitabine|Other: Placebo|Drug: Cisplatin","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","WO30070|2016-000250-35","June 17, 2016","June 30, 2016","July 30, 2020","May 22, 2017","May 2017","No Study Results Posted","IMvigor130","December 31, 2018","Progression-Free Survival (PFS) Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Participants Treated with Atezolizumab Combination Therapy Compared With Placebo Arm|Overall Survival (OS)|Percentage of Participants with Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Percentage of Participants with Best Overall Response of Complete Response (CR) or Partial Response (PR) Assessed by Investigator Using RECIST v1.1|Duration of response (DOR) Assessed by Investigator Using RECIST v1.1|Percentage of Participants Who Were Alive at Year 1|Percentage of Participants Who Were Alive and Progression Free at Year 1 Using RECIST v1.1|Median Time to Deterioration in Global Health Status as Measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score|Median Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score|Maximum Atezolizumab Serum Concentration|Minimum Atezolizumab Serum Concentration|Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)|Progression-Free Survival (PFS) Assessed by Investigator Using RECIST v1.1 in Participants Treated with Atezolizumab Montotherapy Compared With Placebo Arm","https://ClinicalTrials.gov/show/NCT02807636"
1920,"NCT02516813","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy","Recruiting","No Results Available","Advanced Solid Tumors","Drug: MSC2490484A|Radiation: Fractionated RT|Drug: Cisplatin|Drug: MSC2490484A|Drug: MSC2490484A|Radiation: Fractionated RT|Radiation: Fractionated RT","EMD Serono Research & Development Institute, Inc.|Merck KGaA|EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 1","136","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","100036-002|2015-000673-12","August 4, 2015","September 2015","January 2021","February 9, 2017","February 2017","No Study Results Posted","null","January 2021","Phase Ia (Arm A): Number of Subjects Experiencing at Least one Dose-limiting Toxicity (DLT)|Phase Ib (Arm A expansion Cohort): Number of subjects experiencing at least one DLT|Phase Ia (Arm B): Number of Subjects Experiencing at Least one DLT|Phase Ib: Number of subjects experiencing treatment emergent adverse events (TEAEs)|Phase Ib: Number of Subjects With Clinically Significant Vital signs, Electrocardiogram (ECG) and Laboratory Abnormalities|Phase Ia: Number of Subjects with Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Treatment Discontinuation, and TEAEs Leading to Death|Phase Ia: Number of Subjects With Clinically Significant Vital signs, Electrocardiogram (ECG) and Laboratory Abnormalities|Best Overall Response Rate|Tumor Size Measurement|Progression-free Survival (PFS) Time|Overall Survival (OS) Time|Phase Ia: Maximum plasma concentration (Cmax) of MSC2490484A|Phase Ia: Time to reach maximum plasma concentration (tmax) of MSC2490484A|Phase Ia: Area under the plasma concentration curve from zero to last sampling time AUC (0-t) of MSC2490484A|Phase Ia: Area under the plasma concentration curve from zero to infinity AUC (0-inf) of MSC2490484A|Phase Ia: Terminal half life (t1/2) of MSC2490484A|Phase Ia: Apparent total body clearance (CL/f) of MSC2490484A|Phase Ia: Volume of distribution (Vz/F) of MSC2490484A|Phase Ia: Area under the plasma concentration-time curve over the dosing interval after multiple dosing (AUC0-tau) of MSC2490484A|Phase Ia: Oral clearance of MSC2490484A at steady state (CLss/f) in Plasma|Phase Ia: Apparent volume of distribution at steady state (Vss/f) of MSC2490484A in plasma|Phase Ia: Accumulation ratio for area under the concentration-time curve (Racc[AUC])|Phase Ia: Accumulation ratio for maximum concentration (Racc[Cmax])","https://ClinicalTrials.gov/show/NCT02516813"
1921,"NCT00057785","Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer","Completed","Has Results","Head and Neck Cancer|Oral Complications of Radiation Therapy|Radiation Toxicity","Drug: cisplatin|Drug: fluorouracil|Radiation: Intensity modulated radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0225|CDR0000269314","April 7, 2003","February 2003","December 2016","December 30, 2016","December 2016","October 8, 2014","null","February 2007","Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered|Rate of Xerostomia at 1 Year (Grade ≥ 2)|Rate of Locoregional Control at 2 Years|Whole Mouth Saliva Output Relative to Pretreatment Measurements|Other Acute and Late Toxicities|Chemotherapy Compliance","https://ClinicalTrials.gov/show/NCT00057785"
1922,"NCT00004164","Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx","Unknown status","No Results Available","Head and Neck Cancer","Biological: filgrastim|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: leucovorin calcium|Radiation: radiation therapy","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067408|DFCI-99132|RP-DFCI-99132|NCI-G99-1631","December 10, 1999","August 1999","null","February 6, 2009","September 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004164"
1923,"NCT00003269","Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors","Completed","No Results Available","Breast Cancer|Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Lymphoma|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: sargramostim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Scripps Health","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000066165|SCRF-98014|ALZA-97-49-ii|NCI-V98-1396","November 1, 1999","February 1998","January 2001","January 6, 2011","January 2011","No Study Results Posted","null","January 2001","duration of neutropenia|incidence of nephrotoxicity|incidence of ototoxicity","https://ClinicalTrials.gov/show/NCT00003269"
1924,"NCT01028729","A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Drug: Endostar|Drug: Gemcitabine-Cisplatin chemotherapy","Simcere Pharmaceutical Co., Ltd","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SIM090801","December 7, 2009","September 2009","August 2011","December 8, 2009","December 2009","No Study Results Posted","NSCLC","July 2011","Progression Free Survival (PFS)|Objective Response Rate (ORR)|Clinical Benefit Response (CBR)|Overall Survival (OS)|Survival Rate|Adverse Events","https://ClinicalTrials.gov/show/NCT01028729"
1925,"NCT00002735","SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue","Terminated","No Results Available","Head and Neck Cancer","Drug: Induction chemotherapy|Drug: cisplatin|Drug: fluorouracil|Radiation: low-LET cobalt-60 gamma ray therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000064634|SWOG-9451|U10CA032102","November 1, 1999","April 1996","March 2005","September 28, 2015","September 2015","No Study Results Posted","null","April 2004","Complete response","https://ClinicalTrials.gov/show/NCT00002735"
1926,"NCT02403531","Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer","Recruiting","No Results Available","Neoplasms","Drug: Docetaxel|Drug: Cisplatin|Radiation: Radiotherapy","Mian XI|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ICNOIC","March 19, 2015","May 2015","July 2018","October 12, 2016","October 2016","No Study Results Posted","null","April 2017","overall response rate|Overall survival|Progression-free survival|Quality of life","https://ClinicalTrials.gov/show/NCT02403531"
1927,"NCT00094497","Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)","Completed","Has Results","Carcinoma, Adrenal Cortical","Drug: Etoposide|Drug: Doxorubicin|Drug: Cisplatin|Drug: Streptozotocin|Drug: Mitotane","Collaborative Group for Adrenocortical Carcinoma Treatment|German Federal Ministry of Education and Research|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","304","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CO-ACT-001","October 19, 2004","June 2004","December 2010","September 19, 2016","September 2016","September 19, 2016","null","December 2010","Overall Survival|Progression-free Survival|Change in Quality of Life as Measured by QLQ-C30|Best Overall Response Rate|Number of Disease-free Patients","https://ClinicalTrials.gov/show/NCT00094497"
1928,"NCT03025477","Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer","Recruiting","No Results Available","Ovarian Cancer, Epithelial","Drug: CC0 - Carboplatin (IV) - Paclitaxel (IV)|Drug: CC0 - Cisplatin (IP) - Epirubicin (IV)|Drug: CC>0 - Carboplatin (IV)- Paclitaxel (IV)|Drug: CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)","Groupe Hospitalier Diaconesses Croix Saint-Simon|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RVT_2015_2","December 15, 2016","May 2016","May 2029","January 16, 2017","December 2016","No Study Results Posted","CHIMOVIP","May 2018","Pathological complete peritoneal response (pCR)|Quality of life (QLQ -C30) assessment|Quality of life (QLQ-OV28) assessment|IPSS score|Number of patients with treatment-related adverse events as assessed by CTCAE version 4.03|Event-free survival (EFS)|Objective response rate at the various surgical step|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT03025477"
1929,"NCT00617656","Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma","Terminated","No Results Available","LUNG CANCER","Drug: Cisplatin, Docetaxel|Drug: Gemcitabine, Cisplatin|Drug: Docetaxel, Cisplatin|Drug: Docetaxel","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GECP-BREC|2007-004278-20","February 5, 2008","February 2008","April 2015","July 3, 2015","July 2015","No Study Results Posted","BREC","April 2015","Time to progression|Assess Overall survival of both treatment groups.","https://ClinicalTrials.gov/show/NCT00617656"
1930,"NCT00586846","Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma","Completed","Has Results","Osteosarcoma","Drug: Cisplatin|Drug: Doxorubicin|Drug: Methotrexate","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-074","December 21, 2007","July 2003","February 2009","December 15, 2015","December 2015","December 15, 2015","null","February 2009","Radiographic Response","https://ClinicalTrials.gov/show/NCT00586846"
1931,"NCT00193791","Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix","Active, not recruiting","No Results Available","Cancer of Cervix","Other: CT + RT","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult)","Phase 3","850","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TMH/114/2003/CRACX TRIAL","September 13, 2005","July 2003","May 2018","March 26, 2017","March 2017","No Study Results Posted","CRACx","May 2018","To compare the disease free survivals.|To compare the overall survivals|To compare the distant metastasis rates|To compare the quality of life in both the groups|To compare the normal tissue toxicities (Acute & Late) of standard radiation therapy with concomitant chemo-radiation.","https://ClinicalTrials.gov/show/NCT00193791"
1932,"NCT02434614","Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Docetaxel,Cisplatin,Fluorouracil|Radiation: Intensity-modulated radiation therapy (IMRT)|Drug: Cisplatin","Wei Jiang|Wuzhou Red Cross Hospital|Guangxi Naxishan Hospital|Liuzhou People's Hospital|Guigang People's Hospital|Affiliated Hospital of Youjiang Medical University for Nationalities|Nanning Monority Hospital|Guilin Medical University, China","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GLMU-01","April 27, 2015","March 2015","March 2020","April 30, 2015","April 2015","No Study Results Posted","null","March 2017","Progression-free Survival|Overall Survival|Locoregional Failure-free Survival|Distant Failure-free Survival|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT02434614"
1933,"NCT02759575","A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma","Recruiting","No Results Available","Head and Neck Cancer","Drug: Pembrolizumab|Radiation: Radiation Therapy|Drug: Cisplatin","Nooshin Hashemi-Sadraei|Merck Sharp & Dohme Corp.|University of Cincinnati","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCCI-HN-15-02","April 26, 2016","April 2016","January 2018","April 29, 2016","April 2016","No Study Results Posted","null","January 2018","Number of participants with Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0|Laryngectomy-free survival in locally advanced laryngeal squamous cell carcinoma","https://ClinicalTrials.gov/show/NCT02759575"
1934,"NCT02349958","Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy","Recruiting","No Results Available","Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Uterine Cancer|Mesotheliomas|Gastrointestinal Cancers|Cervical Cancer","Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min|Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Device: HIPEC: CDDP 75 mg/m2 @T0|Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0","Bay Area Gynecology Oncology","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HIPEC","December 22, 2014","September 2006","January 2018","January 30, 2017","January 2017","No Study Results Posted","HIPEC/IPHC","January 2018","measure treatment response to HIPEC and tumor debulking|Toxicity Monitoring","https://ClinicalTrials.gov/show/NCT02349958"
1935,"NCT01118676","Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Locally Advanced Non Small Cell Lung Cancer (NSCLC)*","Drug: cilengitide, radiochemotherapy","Institut Claudius Regaud|Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07 POUM 01","May 5, 2010","March 2010","April 2015","September 3, 2015","September 2015","No Study Results Posted","null","April 2015","To determine the Maximum Tolerated dose (MTD) of Cilengitide administered as continuous infusion during standard radiochemotherapy|To determine the rate of objective response according to RECIST and pathological response.|To determine the survival free of metastases and the survival without local relapse at one year.|To determine the overall survival|To determine the toxicity of the combination of radiochemotherapy and continuous infusion cilengitide as well as the toxicity of the combination of chemotherapy and twice weekly cilengitide.|Ancillary studies will be undertaken to determine factors predictive of response to treatment and to characterize the anti-angiogenic effect of Cilengitide.","https://ClinicalTrials.gov/show/NCT01118676"
1936,"NCT01809210","Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIB IV;","Drug: selumetinib|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin|Drug: pemetrexed","AstraZeneca","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","76","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D1532C00070|EudraCT number: 2012-005202-22","March 8, 2013","April 2013","January 2016","March 4, 2016","March 2016","No Study Results Posted","SELECT-3","January 2016","Investigate safety, tolerability and recommended Phase Ib dose of selumetinib in combination with first line chemotherapy by assessing adverse events.|Investigate safety, tolerability and recommended Phase Ib dose of selumetinib in combination with first line chemotherapy by assessing physical examination, pulse and blood pressure|Investigate safety, tolerability and recommended Phase Ib dose of selumetinib in combination with first line chemotherapy by assessing laboratory variables|Investigate safety, tolerability and recommended Phase Ib dose of selumetinib in combination with first line chemotherapy by assessing eye examinations and ECG.|Investigate safety, tolerability and recommended Phase Ib dose of selumetinib in combination with first line chemotherapy by assessing LVEF|Rate and extent of absorption of selumetinib at steady state when administered with doublet chemotherapy, by assessment of a range of PK parameters (including AUC and Cmax) of selumetinib.|Rate and extent of absorption of chemotherapies gemcitabine or pemetrexed and cisplatin or carboplatin when infusion given in combination with selumetinib by assessment of PK parameters.|Efficacy assessed by tumour response (objective response rate) assessed using RECIST 1.1|Efficacy assessed by tumour response (best overall response) assessed using RECIST 1.1","https://ClinicalTrials.gov/show/NCT01809210"
1937,"NCT00152828","Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix","Completed","No Results Available","Cervix Neoplasms","Drug: Celecoxib","University Health Network, Toronto|NCIC Clinical Trials Group|Princess Margaret Hospital, Canada","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 00-0431-C|National Cancer Instit.Canada","September 7, 2005","February 2001","January 2011","February 8, 2016","February 2016","No Study Results Posted","null","January 2011","Safety - Tolerance of concurrent celecoxib with standard cisplatin/radiotherapy|Objective changes in tumour oxygenation and IFP|Objective molecular marker response (COX-2, PGE2, VEGF, apoptosis)","https://ClinicalTrials.gov/show/NCT00152828"
1938,"NCT00003907","Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver","Completed","Has Results","Liver Cancer|Metastatic Cancer","Drug: cisplatin|Drug: doxorubicin|Drug: mitomycin|Procedure: embolization","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067083|U10CA021115|E4298","November 1, 1999","August 1999","August 2012","February 12, 2013","February 2013","January 7, 2013","null","May 2011","Time to Progression|Tumor Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00003907"
1939,"NCT00062270","Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Drug: gefitinib|Drug: gemcitabine hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","University of Alabama at Birmingham|National Cancer Institute (NCI)","All","19 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000304674|UAB-0162|UAB-F020730006|ZENECA-ZD1839US-0207|AVENTIS-GIA-12139","June 5, 2003","May 2003","September 2004","October 6, 2015","September 2015","No Study Results Posted","null","September 2004","Determine the tolerability and toxicity of gefitinib in combination with chest radiotherapy in patients with stage IIIA or stage IIIB non-small cell lung cancer.","https://ClinicalTrials.gov/show/NCT00062270"
1940,"NCT00766480","Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus","Unknown status","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","University of Toyama|National Cancer Institute (NCI)","All","20 Years to 74 Years   (Adult, Senior)","","160","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000615602|TOYAMAU-TRIEC0601","October 3, 2008","January 2007","null","August 23, 2013","July 2009","No Study Results Posted","null","March 2010","1-year progression-free survival|1-year local progression-free survival|3-year progression-free survival|3-year overall survival|Complete histological response","https://ClinicalTrials.gov/show/NCT00766480"
1941,"NCT00003133","Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Primary Purpose: Treatment","97-106|CDR0000065899|NCI-G97-1358","November 1, 1999","September 1997","January 2003","June 26, 2013","June 2013","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00003133"
1942,"NCT00791154","QUILT-2.013: A Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer|Small Cell Lung Cancer|Solid Tumors|Extensive-stage Small Cell Lung Cancer","Drug: AMG 479|Drug: Etoposide|Drug: Placebo|Drug: AMG 102|Drug: Carboplatin|Drug: Cisplatin","NantCell, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","204","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","20060534|QUILT-2.013","October 23, 2008","December 2008","February 2013","October 26, 2016","October 2016","No Study Results Posted","null","June 2012","Part 2: To estimate the relative treatment effect of platinum-based chemotherapy and AMG 479, and of platinum-based chemotherapy and AMG 102, compared to platinum-based chemotherapy and placebo as measured by the respective HR for overall survival|Part 1: The incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicities (DLTs). Part 2: Overall survival (OS)|Incidence of adverse events and laboratory abnormalities not defined as DLTs.|Incidence of anti-AMG 479 and anti-AMG 102 antibody formation|Pharmacokinetics (Cmax and Cmin for AMG 102 and AMG 479)|ORR, DOR, TTP, PFS and OS rates at 10, 12, 24 and 36 months|EORTC QLQ-C30 and EORTC QLQ-LC13 scores","https://ClinicalTrials.gov/show/NCT00791154"
1943,"NCT00021320","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068769|P30CA006927|FCCC-00003|NCI-G01-1982","July 11, 2001","May 2000","April 2009","May 7, 2014","May 2014","No Study Results Posted","null","January 2004","","https://ClinicalTrials.gov/show/NCT00021320"
1944,"NCT02358031","A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","Active, not recruiting","No Results Available","Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer","Biological: Pembrolizumab|Drug: Cisplatin|Drug: Carboplatin|Drug: 5-FU|Biological: Cetuximab","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","825","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","3475-048|2014-003698-41","February 3, 2015","March 2015","September 2018","March 16, 2017","March 2017","No Study Results Posted","null","March 2018","Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PDL1)-Positive Expression|Overall Survival in Participants With PDL1-Postive Expression|PFS per RECIST 1.1 by BICR in All Participants|Overall Survival in All Participants|PFS at 6 Months per RECIST 1.1 by BICR|Objective Response Rate per RECIST 1.1 by BICR|PFS at 12 Months per RECIST 1.1 by BICR|Time to Deterioration in Quality of Life Global Health Status/Quality of Life Scales of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score for Items 29 and 30","https://ClinicalTrials.gov/show/NCT02358031"
1945,"NCT00951496","Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","Active, not recruiting","No Results Available","Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Undifferentiated Ovarian Carcinoma","Biological: Bevacizumab|Drug: Carboplatin|Drug: Carboplatin|Drug: Cisplatin|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Drug: Paclitaxel|Other: Quality-of-Life Assessment","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","1526","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01956|CDR0000650601|GOG-0252|U10CA180868|U10CA027469","August 1, 2009","July 2009","null","December 21, 2016","December 2016","No Study Results Posted","null","January 2016","Progression-free survival|Frequency and severity of adverse events, as defined by NCI CTCAE version 3.0|Overall survival|Quality of life and other patient-reported outcomes (e.g., neuropathy, abdominal discomfort, fatigue, and nausea) as assessed by FACT-O-TOI, FACT-GOG/NTX4, FACT-GOG/AD, FACIT-Fatigue, and FACT-Nausea questionnaires","https://ClinicalTrials.gov/show/NCT00951496"
1946,"NCT00262951","Chemoradiation in Locally Advanced Pancreatic Cancer","Terminated","Has Results","Pancreatic Cancer","Biological: recombinant interferon alfa|Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy|Procedure: Resection of tumor","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004LS060|0410M64346","December 6, 2005","January 2005","August 2011","January 3, 2012","January 2012","November 14, 2011","null","April 2011","Number of Patients in Whom Tumor Was Resectable|Overall Survival","https://ClinicalTrials.gov/show/NCT00262951"
1947,"NCT01053390","New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma","Completed","No Results Available","Gallbladder Neoplasms","Drug: Somatostatin|Drug: epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）","Shanghai Jiao Tong University School of Medicine|Xuanwu Hospital, Beijing|Capital Medical University|Peking University First Hospital|Tianjin Medical University Cancer Institute and Hospital|The First Affiliated Hospital of Dalian Medical University|China Medical University, China|The first clinical college of harbin medical university|The Second Affiliated Hospital of Harbin Medical University|Shengjing Hospital|Jilin University|The people’s hospital of Heilongjiang province|Eastern Hepatobiliary Surgery Hospital|Shanghai Changzheng Hospital|Shandong Provincial Hospital|Qilu Hospital of Shandong University|Fourth Military Medical University|Tang-Du Hospital|Qinghai People's Hospital|Affiliated Hospital of Qinghai University|First Affiliated Hospital of Chongqing Medical University|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|First People's Hospital of Kunming|LanZhou University|Xi'an Central Hospital|The first people’s hospital of Guiyang|Southwest Hospital, China|The First Affiliated Hospital of Kunming Medical College","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","xh2009-35","January 20, 2010","October 2009","December 2013","December 18, 2013","December 2013","No Study Results Posted","null","December 2013","(Response Evaluation Criteria in Solid Tumors, RECIST,2009 ), CR(complete response) and PR(partial response)|A: KPS (karnofsky performance score) B:Laboratory tests: Reexamination of CA19-9（Carbohydrate Antigen 19-9）、 CEA（ carcinoembryonic antigen）, especially for those which are abnormal prior to chemotherapy","https://ClinicalTrials.gov/show/NCT01053390"
1948,"NCT00267046","Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma","Completed","Has Results","Sarcoma|Oral Mucositis","Drug: Palifermin|Drug: Placebo|Drug: Adriamycin (Doxorubicin)|Drug: Ifosfamide|Drug: Vincristine|Drug: Cisplatin","M.D. Anderson Cancer Center","All","15 Years to 65 Years   (Child, Adult)","Phase 2","49","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","2004-0511","December 19, 2005","December 2005","July 2009","April 17, 2012","April 2012","January 18, 2012","null","July 2009","Cumulative Incidence Rate of Oral Mucositis|Median Maximum Score for Patient Reported Outcomes in 2 Blinded Cycles","https://ClinicalTrials.gov/show/NCT00267046"
1949,"NCT02394652","The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial","Recruiting","No Results Available","Uterine Cervical Neoplasms|Squamous Cell Carcinoma|Adenocarcinoma|Carcinoma, Adenosquamous","Drug: Metformin|Drug: Cisplatin|Drug: FAZA","University Health Network, Toronto","Female","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CXMET1","March 16, 2015","May 2015","May 2018","June 21, 2016","June 2016","No Study Results Posted","null","October 2017","• Change in fractional hypoxic volume of the tumor on FAZA-PET scan before and after 1 week of metformin.|Disease-free survival|Acute and late gastrointestinal and genitourinary toxicities following metformin and chemoradiation.|Effect of metformin on endogenous hypoxia and other markers.|Biomarkers of response to metformin.","https://ClinicalTrials.gov/show/NCT02394652"
1950,"NCT00463515","Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC","Completed","No Results Available","Non-Small-Cell-Lung Cancer","Drug: carboplatin/gemcitabine|Procedure: cisplatin/radiation therapy","University Hospital, Antwerp|Universiteit Antwerpen|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","77","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHER@NOS","April 18, 2007","January 2003","November 2006","July 11, 2013","July 2013","No Study Results Posted","CHER@NOS","November 2006","2-year survival rates|Response rate|Time to intrathoracic failure|Overall survival|Toxicity of induction chemotherapy|Toxicity of chemo-radiotherapy","https://ClinicalTrials.gov/show/NCT00463515"
1951,"NCT01052844","Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy","Completed","Has Results","Vomiting|Cisplatin Adverse Reaction","Drug: Placebo|Drug: Gabapentin","Faculdade de Medicina do ABC","All","18 Years and older   (Adult, Senior)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABC-2009","December 17, 2009","January 2009","July 2010","January 18, 2014","January 2014","September 24, 2010","null","July 2010","Number of Patients With Complete Response During Chemotherapy Course 1|Number of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1","https://ClinicalTrials.gov/show/NCT01052844"
1952,"NCT01715233","A Phase II Study Investigating Checkpoint With Forkhead and Ring Finger Domains (CHFR) Methylation Status In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer","Recruiting","No Results Available","Metastatic Esophageal Cancer|Gastroesophageal Cancer|Gastric Cancer","Drug: mDCF|Drug: mDCF","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","127","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1248","October 24, 2012","October 2012","November 2019","October 10, 2016","October 2016","No Study Results Posted","null","November 2017","Response|CHFR methylaton Status.|Overall survival","https://ClinicalTrials.gov/show/NCT01715233"
1953,"NCT02938546","18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study","Not yet recruiting","No Results Available","Non-small-cell Lung Cancer","Radiation: 18F-FDG","Shanghai Chest Hospital","All","18 Years to 90 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","WXIE","October 17, 2016","November 2016","January 2023","October 19, 2016","October 2016","No Study Results Posted","null","January 2023","Glucose metabolism discrepancy of different genotype NSCLC as Assessed by EORTC|Different genotype NSCLC metabolic response after treatment as Assessed by EORTC","https://ClinicalTrials.gov/show/NCT02938546"
1954,"NCT00620269","Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III","Unknown status","No Results Available","Lung Cancer|NSCLC","Drug: Erlotinib|Drug: Induction or consolidation IP chemotherapy|Drug: CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Radiation: CCRT","National Cancer Center, Korea|Roche Pharma AG|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","212","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-07-255","January 25, 2008","February 2008","March 2015","November 4, 2011","November 2011","No Study Results Posted","null","March 2015","Response rate|Time to progression|Patient's Quality of life(QOL)|Toxicity|Overall Survival","https://ClinicalTrials.gov/show/NCT00620269"
1955,"NCT02629718","Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer","Not yet recruiting","No Results Available","PFS|OS|Quality of Life","Drug: NACT (Paclitaxel + Cisplatin or carboplatin)|Procedure: radical surgery","Sun Yat-sen University","Female","18 Years to 65 Years   (Adult)","Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-FXY-069","December 10, 2015","December 2015","December 2022","December 11, 2015","December 2015","No Study Results Posted","SYSGO-003","December 2022","Disease free survival|overall survival|quality of life","https://ClinicalTrials.gov/show/NCT02629718"
1956,"NCT01599013","JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin","Completed","No Results Available","Bladder Transitional Cell Carcinoma Stage IV","Drug: Vinflunine, Gemcitabine|Drug: Vinflunine, Carboplatin","Pierre Fabre Medicament","All","18 Years to 79 Years   (Adult, Senior)","Phase 2","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L00070 IN 213 P1","April 16, 2012","February 2011","April 2014","December 7, 2015","December 2015","No Study Results Posted","JASINT1","October 2013","Disease control rate as defined by RECIST criteria (version 1.1) as a percentage of best overall responses of Complete (CR) + Partial (PR) + Stable Disease (SD) for both Vinflunine-Gemcitabine and Vinflunine-Carboplatin combinations|Tumor Response Rate as defined by RECIST criteria (version 1.1) with a best response as Complete (CR) or Partial (PR)|Duration of Disease control in Participants With Best Response of CR + PR + SD|Duration of Response in Participants With Best Response of CR or PR|Time to First Response calculated among the responders|Time to Treatment Failure|Progression Free Survival|Overall Survival|Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Discontinuation","https://ClinicalTrials.gov/show/NCT01599013"
1957,"NCT02283476","The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.","Not yet recruiting","No Results Available","Lung Cancer","Drug: Endostar continuous intravenous infusion|Drug: Endostar routine intravenous infusion|Drug: Gemcitabine|Drug: Cisplatin","Jiangsu Simcere Pharmaceutical Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SIM-ED-1302","November 3, 2014","November 2014","November 2017","November 5, 2014","October 2014","No Study Results Posted","null","November 2017","objective response rate based on Recist 1.1 edition|progress free survival|overall survival|Quality of life (QoL) Questionnaire","https://ClinicalTrials.gov/show/NCT02283476"
1958,"NCT02972216","Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy","Completed","No Results Available","Nonsmall Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck","Drug: Nolbaxol|Drug: Taxotere|Drug: cisplatin","Yung Shin Pharm. Ind. Co., Ltd.|Taichung Veterans General Hospital|National Cheng-Kung University Hospital|Tri-Service General Hospital","All","20 Years and older   (Adult, Senior)","Phase 4","40","Industry|Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","YSP RFH3001-01","November 16, 2016","November 2014","null","November 21, 2016","November 2016","No Study Results Posted","null","October 2016","Progression-Free Survival (PFS)|Overall Response Rate (ORR)|Adverse Events as a measure on safety","https://ClinicalTrials.gov/show/NCT02972216"
1959,"NCT00113399","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery","Terminated","Has Results","Head and Neck Cancer","Biological: filgrastim|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: paclitaxel|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0421|CDR0000429480|ECOG-R0421","June 7, 2005","April 2005","null","June 26, 2013","June 2013","November 27, 2012","null","February 2009","Overall Survival","https://ClinicalTrials.gov/show/NCT00113399"
1960,"NCT00002522","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Temple University","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078283|TUHSC-2162|NCI-V93-0249","November 1, 1999","February 1993","February 2002","September 30, 2010","September 2010","No Study Results Posted","null","February 2002","","https://ClinicalTrials.gov/show/NCT00002522"
1961,"NCT01970722","Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","Recruiting","No Results Available","Recurrent Uterine Corpus Cancer|Recurrent Fallopian Tube Cancer|Recurrent Ovarian Cancer|Recurrent Primary Peritoneal Cancer|Stage IIIA Uterine Corpus Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cavity Cancer|Stage IIIB Uterine Corpus Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cavity Cancer|Stage IIIC Uterine Corpus Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cavity Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cavity Cancer|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer","Procedure: therapeutic conventional surgery|Drug: cisplatin|Drug: carboplatin|Drug: paclitaxel|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Procedure: quality-of-life assessment|Other: laboratory biomarker analysis","City of Hope Medical Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12316|NCI-2013-01948","October 23, 2013","May 2014","null","October 18, 2016","October 2016","No Study Results Posted","null","May 2020","Treatment-related toxicities according to NCI CTCAE guidelines|QoL assessed by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) QoL questionnaire|PFS","https://ClinicalTrials.gov/show/NCT01970722"
1962,"NCT02621970","Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma","Not yet recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin 1|Drug: Cisplatin 2|Drug: Docetaxel|Drug: Xeloda|Radiation: Intensity-modulated radiotherapy","Sun Yat-sen University|Affiliated Tumor Hospital of Guangzhou Medical University|The First Affiliated Hospital of Guangzhou Medical University|The First Affiliated Hospital of Guangdong Pharmaceutical University","All","18 Years to 60 Years   (Adult)","Phase 3","534","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-FXY-098-Dept. of RT","December 2, 2015","January 2016","January 2024","December 2, 2015","December 2015","No Study Results Posted","null","January 2022","failure-free survival|overall survival|distant metastasis-free survival|locoregional relapse-free survival|Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02621970"
1963,"NCT00006038","Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: docetaxel|Drug: floxuridine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: conventional surgery","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-066|CDR0000068053|NCI-G00-1813","July 5, 2000","February 2000","February 2003","June 17, 2013","June 2013","No Study Results Posted","null","February 2003","","https://ClinicalTrials.gov/show/NCT00006038"
1964,"NCT01566240","Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Drug: Paclitaxel|Drug: Carboplatin|Radiation: Radiotherapy|Drug: Cisplatin","University College, London|Cancer Research UK","Female","18 Years and older   (Adult, Senior)","Phase 3","770","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UCL 11/0034|2011-001300-35|C37815/A12832","March 27, 2012","September 2012","September 2021","May 17, 2017","June 2016","No Study Results Posted","INTERLACE","December 2017","Overall Survival|Progression free survival|Adverse events (AE) as assessed by the Common Terminology Criteria for Adverse Events v4.03|Quality of Life (UK and Ireland only) as assessed by EORTC QLQ-C30, QLQ-CX24 and EQ-5D|Patterns of first relapse (local and/or systemic)","https://ClinicalTrials.gov/show/NCT01566240"
1965,"NCT00039338","Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer","Active, not recruiting","No Results Available","Cervical Cancer","Procedure: conventional surgery|Procedure: neoadjuvant chemotherapy|Radiation: brachytherapy|Radiation: radiation therapy|Drug: cisplatin","European Organisation for Research and Treatment of Cancer - EORTC","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","686","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-55994|2008-003396-52","June 6, 2002","March 2002","null","December 2, 2016","December 2016","No Study Results Posted","null","July 2019","Overall survival at 5 years","https://ClinicalTrials.gov/show/NCT00039338"
1966,"NCT02549261","Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: nimotuzumab|Drug: Cisplatin|Drug: Etoposide|Radiation: radiotherapy","Biotech Pharmaceutical Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BT-NI-LC-2","August 18, 2015","March 2011","December 2015","September 11, 2015","September 2015","No Study Results Posted","null","April 2012","Progression-free survival|Overall survival Time|Quality of life|Objective response rate|Disease controlled rate|Adverse event rate","https://ClinicalTrials.gov/show/NCT02549261"
1967,"NCT00468169","Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: Cetuximab","University of Chicago|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","110","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","14401A","April 30, 2007","July 2006","November 2012","October 5, 2012","October 2012","No Study Results Posted","EPIC","August 2012","progression free survival (PFS) and overall survival (OS)|to assess and compare the toxicity profile of both regimens; to assess best overall response rate","https://ClinicalTrials.gov/show/NCT00468169"
1968,"NCT00199758","Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer","Completed","No Results Available","Non Small Cell Lung Carcinoma","Drug: cisplatin|Drug: Gemcitabine|Drug: Taxol","University Hospital, Limoges|Groupe Français de Pneumologie Cancérologie (GFPC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","227","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","I03022","September 14, 2005","September 2003","June 2007","November 9, 2007","November 2007","No Study Results Posted","null","null","1-Complete response|2-Partial response|3-Stable disease|4-Progression|-Toxicity (NCI-CTC criteria)","https://ClinicalTrials.gov/show/NCT00199758"
1969,"NCT00003582","Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer","Completed","No Results Available","Carcinoma of Unknown Primary|Head and Neck Cancer","Drug: amifostine trihydrate|Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: quality-of-life assessment|Radiation: radiation therapy","University of Miami","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","36","Other","Interventional","Primary Purpose: Treatment","88191|SCCC-1988007|ALZA-97-052-ii|BHM-98-32|NCI-V98-1474","November 1, 1999","May 1988","December 1996","December 14, 2016","December 2016","No Study Results Posted","null","December 1996","","https://ClinicalTrials.gov/show/NCT00003582"
1970,"NCT01134861","Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: Etoposide|Drug: Vinblastine|Radiation: Radiation therapy|Drug: Cisplatin|Radiation: Radiation therapy|Radiation: Radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 3","610","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9410|U10CA021661|CDR0000063640","May 28, 2010","July 1994","March 2012","March 26, 2015","March 2015","No Study Results Posted","null","October 1998","Overall Survival","https://ClinicalTrials.gov/show/NCT01134861"
1971,"NCT02082522","Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)","Terminated","No Results Available","Hilar Cholangiocarcinoma","Drug: Photodynamic therapy-Photofrin|Procedure: Stenting procedure|Drug: Chemotherapy regimen","Concordia Laboratories Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","PIN-PHO1201","March 6, 2014","August 2014","December 2018","December 19, 2016","August 2014","No Study Results Posted","null","December 2018","Overall survival|Time-to-bilirubin response|Best overall tumor response|Time-to-tumor progression|Change from baseline in performance status on the Karnofsky Performance Scale (KPS)|Change from baseline in health-related quality of life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)|Change from baseline in health-related quality of life on the 4- and 7-point EORTC QLQ-C30","https://ClinicalTrials.gov/show/NCT02082522"
1972,"NCT00360971","Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer","Terminated","Has Results","Head and Neck Cancer|Mucositis|Pain|Radiation Toxicity","Biological: palifermin|Drug: cisplatin|Other: placebo|Procedure: neck dissection|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","21","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","RTOG-0435|CDR0000491088","August 3, 2006","July 2006","February 2009","November 14, 2015","November 2015","April 16, 2014","null","May 2008","Duration of Oral Mucositis as Measured in Terms of Days|Incidence of Mucositis as Measured by the World Heath Organization (WHO) Scale|Time to Onset of Mucositis as Measured by the World Heath Organization (WHO) Scale|Overall Survival|Progression-free Survival|Time to Second Primary Tumor","https://ClinicalTrials.gov/show/NCT00360971"
1973,"NCT00003027","Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cisplatin|Drug: dacarbazine|Drug: vinblastine","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B","All","18 Years and older   (Adult, Senior)","Phase 3","482","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065617|E3695|CLB-509802|SWOG-E3695","November 1, 1999","October 1997","null","January 28, 2010","January 2010","No Study Results Posted","null","July 2007","Overall survival|Response rate (complete and partial response)|Durable complete response rate|Response duration","https://ClinicalTrials.gov/show/NCT00003027"
1974,"NCT00460265","Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer","Completed","Has Results","Recurrent and/or Metastatic Head and Neck Cancer","Drug: ARM 2|Drug: ARM 1","Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","658","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20050251","April 12, 2007","May 2007","May 2012","February 3, 2014","February 2014","May 13, 2011","SPECTRUM","May 2010","Overall Survival|Overall Response Rate|Duration of Response|Time to Progression|Time to Response|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00460265"
1975,"NCT00394966","A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)","Completed","No Results Available","Nausea|Vomiting","Drug: SCH 619734 Dose 1|Drug: SCH 619734 Dose 2|Drug: SCH 619734 Dose 3|Drug: SCH 619734 Dose 4|Drug: Placebo","Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","P04351|Study ID: 3283299","October 31, 2006","September 2006","March 2008","October 22, 2009","October 2009","No Study Results Posted","null","March 2008","The primary efficacy endpoint is the overall complete response rate (no emesis and no use of rescue medication from 0 through 120 hours following initiation of cisplatin-based chemotherapy).|The key secondary efficacy endpoints are the complete response rates for the acute (0 through 24 hours) and delayed (>24 through 120 hours) phases of CINV.|The key secondary safety endpoints are adverse events, physical examinations, vital signs, electrocardiograms, and safety laboratory values.","https://ClinicalTrials.gov/show/NCT00394966"
1976,"NCT00808899","Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma","Terminated","Has Results","Neuroblastoma","Drug: Temsirolimus|Drug: Irinotecan|Procedure: Surgical Resection of Primary Tumor|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Etoposide|Drug: Cisplatin|Drug: Topotecan|Procedure: PBSC|Radiation: Radiation Therapy|Drug: 13-cis-retinoic acid","St. Jude Children's Research Hospital","All","up to 18 Years   (Child, Adult)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NB2008","December 11, 2008","December 2008","July 2009","May 25, 2010","May 2010","April 19, 2010","null","July 2009","Complete Response Plus Partial Response","https://ClinicalTrials.gov/show/NCT00808899"
1977,"NCT01631136","Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer","Active, not recruiting","No Results Available","Advanced Non Small Cell Lung Cancer","Drug: Cisplatin|Drug: Pemetrexed|Drug: Cisplatin|Drug: Gemcitabine","Intergroupe Francophone de Cancerologie Thoracique|Groupe Francais De Pneumo-Cancerologie","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","932","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-GFPC-1101","June 26, 2012","July 2012","December 2017","September 1, 2016","September 2016","No Study Results Posted","null","December 2017","Overall survival|Disease free survival|Control and response rate|Safety analysis|treatment exposure","https://ClinicalTrials.gov/show/NCT01631136"
1978,"NCT00003376","Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: paclitaxel|Drug: vinblastine","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B","All","18 Years and older   (Adult, Senior)","Phase 3","330","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066368|E4897|CLB-99908|GUMC-01011","November 1, 1999","September 1998","null","January 26, 2010","January 2010","No Study Results Posted","null","September 2005","","https://ClinicalTrials.gov/show/NCT00003376"
1979,"NCT02595554","Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer","Recruiting","No Results Available","Cervical Carcinoma Stage IIB","Radiation: Concurrent chemoirradiation|Drug: Paclitaxel|Procedure: Radical Surgery|Drug: Cisplatin","Sun Yat-sen University","Female","18 Years to 60 Years   (Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CSEM007","November 2, 2015","November 2015","December 2020","February 2, 2017","February 2017","No Study Results Posted","SYSGO002","December 2020","Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02595554"
1980,"NCT00069953","Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","Completed","Has Results","Esophageal Cancer","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Procedure: conventional surgery|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-0246|CDR0000306455","October 3, 2003","September 2003","December 2016","December 30, 2016","December 2016","October 14, 2014","null","March 2007","Overall Survival (1-year Rate Reported)|Frequency of Major (Grade 4) Acute Treatment-related Toxicities|Frequency of Patients With Persistent or Recurrent Disease Eligible for Surgical Salvage Resection","https://ClinicalTrials.gov/show/NCT00069953"
1981,"NCT02724579","Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","Not yet recruiting","No Results Available","Untreated Childhood Medulloblastoma","Drug: Cisplatin|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Lomustine|Radiation: Radiation Therapy|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS1422|NCI-2016-00150|U10CA180886","March 25, 2016","October 2016","null","September 23, 2016","September 2016","No Study Results Posted","null","May 2025","PFS|Change in neurocognitive function (cognitive, social, emotional and behavioral) according to Children Oncology Group Standard Neuropsychological Battery|DNA methylation profiling as real-time classification of WNT-driven medulloblastoma","https://ClinicalTrials.gov/show/NCT02724579"
1982,"NCT02076477","The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）","Recruiting","No Results Available","Oligo-metastatic Stage IV Non-small Cell Lung Cancer","Radiation: concurrent chemoradiotherapy|Drug: Docetaxel|Drug: pemetrexed|Drug: Cisplatin","Sichuan Cancer Hospital and Research Institute|Mianyang Central Hospital|Cancer Hospital of Guizhou Province","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","scch201402","February 24, 2014","January 2014","null","November 11, 2016","November 2016","No Study Results Posted","OITROLC","January 2017","short-term effects（The response rate，RR）|PFS（progression-free survival）|Quality of life (QOL)|esophagitis and pneumonitis|Other grade 3-5 adverse events","https://ClinicalTrials.gov/show/NCT02076477"
1983,"NCT00883779","A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer","Completed","Has Results","Non-Squamous Non-Small Cell Lung Cancer","Drug: Placebo|Drug: Platinum chemotherapy (cisplatin or carboplatin)|Drug: erlotinib [Tarceva]|Drug: gemcitabine","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","451","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","MO22201","April 15, 2009","April 2009","December 2014","November 10, 2015","November 2015","November 10, 2015","null","December 2014","Median Progression Free Survival (PFS) Time|Percentage of Participants Alive and Free From Disease Progression|Median PFS Time Based on Different Subgroups|Median Overall Survival (OS) Time-Overall and Among Different Subgroups|Percentage of Participants Alive at the End of Study-Overall and Among Different Subgroups|Non-Progression Rate: Percentage of Participants With a Confirmed Best Overall Response of Either Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) for At Least 16 Weeks|Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR|Duration of Response|Time to Progression|Percentage of Participants With Symptomatic Progression Assessed Using the Lung Cancer Subscale (LCS)|Time to Symptomatic Progression|Percentage of Participants With Deterioration in Trial Outcome Index (TOI) Using FACT-L Version 4.0|Time to Deterioration in TOI Using FACT-L Version 4.0|Percentage of Participants With Deterioration in Quality of Life (QOL) Using FACT-L Version 4.0|Time to Deterioration in QOL Using FACT-L Version 4.0|Median Follow-up Time During the Study","https://ClinicalTrials.gov/show/NCT00883779"
1984,"NCT00128037","Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806)","Completed","No Results Available","Pulmonary Neoplasm","Drug: mitomycin C, vindesine, cisplatin and radiotherapy","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","All","15 Years to 74 Years   (Child, Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG 9806|C000000031","August 8, 2005","May 1999","February 2006","September 20, 2016","September 2016","No Study Results Posted","null","null","3-year survival rate|complete resection rate|post-surgical morbidity/mortality|local control rate","https://ClinicalTrials.gov/show/NCT00128037"
1985,"NCT00957086","Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer","Recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: Nimotuzumab|Drug: Placebo","National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore|Innogene Kalbiotech Pte. Ltd","All","21 Years and older   (Adult, Senior)","Phase 3","710","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","IHN01","August 11, 2009","August 2009","June 2021","March 28, 2017","March 2017","No Study Results Posted","null","June 2018","To compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/RT with the control arm|To compare the overall survival between the two arms|To assess the Toxicity Profile between the 2 arms","https://ClinicalTrials.gov/show/NCT00957086"
1986,"NCT00004887","Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery","Unknown status","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: ifosfamide|Drug: mitomycin C|Drug: paclitaxel|Drug: vinblastine sulfate","The Christie NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067562|CHNT-PC/MIC|EU-99046","March 7, 2000","January 1999","null","September 19, 2013","March 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004887"
1987,"NCT01102231","Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Stage III Non-small Cell Lung Cancer","Drug: Chemotherapy|Drug: ERBITUX|Radiation: Radiotherapy","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","106","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IFCT-0803","April 10, 2010","March 2010","December 2015","March 1, 2017","March 2017","No Study Results Posted","null","January 2014","Disease-Control Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT01102231"
1988,"NCT02987998","Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC","Not yet recruiting","No Results Available","Stage IIIA Non-Small Cell Lung Cancer","Drug: Cisplatin|Drug: Etoposide|Drug: Pembrolizumab|Drug: Radiation","Nathan Pennell, MD, PhD|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE4516","December 7, 2016","January 2017","January 2020","December 12, 2016","December 2016","No Study Results Posted","null","January 2019","Number of patients with grade 3 pulmonary toxicity or grade 4 other non hematologic toxicity|Progression Free Survival|Objective Response Rate|Complete Pathologic Response Rate|Nodal Downstaging at Surgery|Overall Survival","https://ClinicalTrials.gov/show/NCT02987998"
1989,"NCT00544414","Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium|Genetic: gene expression analysis|Genetic: protein expression analysis|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Radiation: radiation therapy","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","98147|P30CA033572|CHNMC-98147|CDR0000566884","October 13, 2007","April 2000","null","January 12, 2017","January 2017","No Study Results Posted","null","January 2018","Complete and overall response rate|Feasibility|Prospective impact of neoadjuvant chemotherapy, concurrent chemoradiotherapy, and organ preservation surgery on overall survival, time to progression, and pattern of disease recurrence|Biochemical correlates|Treatment-associated morbidity|Comparison of diagnostic salivary cytology with histopathology at initial diagnosis and at follow-up|Tolerability","https://ClinicalTrials.gov/show/NCT00544414"
1990,"NCT00984997","Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors","Completed","No Results Available","Lung Cancer","Procedure: Surgery|Radiation: Chest Irradiation|Drug: Cisplatin|Drug: Etoposide|Radiation: Prophylactic Cranial Irradiation","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID92-038","September 24, 2009","October 1993","June 2015","June 29, 2016","June 2016","No Study Results Posted","null","June 2007","Rates of Locoregional control (LRC) [Response] Following Surgery and Accelerated Radiation Therapy/Chemotherapy","https://ClinicalTrials.gov/show/NCT00984997"
1991,"NCT00960284","Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: capecitabine|Drug: cisplatin|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: gemcitabine hydrochloride","IRCCS San Raffaele","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000641309|PACT-7","August 14, 2009","June 2003","June 2009","January 12, 2012","January 2012","No Study Results Posted","PACT-7","June 2009","1-year progression-free survival (Phase II)|Pattern of relapse","https://ClinicalTrials.gov/show/NCT00960284"
1992,"NCT00016341","Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer","Terminated","No Results Available","Endometrial Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: megestrol acetate|Drug: paclitaxel|Drug: tamoxifen citrate","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068624|GOG-0189","May 6, 2001","May 2001","null","April 10, 2013","June 2007","No Study Results Posted","null","October 2003","","https://ClinicalTrials.gov/show/NCT00016341"
1993,"NCT00022178","Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin","Unknown status","No Results Available","Carcinoma of Unknown Primary","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: vincristine sulfate","The Christie NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068792|CHNT-VAC-VS-ECF|EU-20041","August 10, 2001","December 1998","null","September 19, 2013","February 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00022178"
1994,"NCT00014573","Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068559|P30CA022453|WSU-D-1654|WSU-07-92-98-P04-FB|NCI-G01-1937","April 10, 2001","August 1998","October 2004","April 5, 2013","April 2013","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00014573"
1995,"NCT00981656","Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer","Recruiting","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RTOG 0926|CDR0000654727","September 19, 2009","November 2009","null","May 18, 2017","May 2017","No Study Results Posted","null","October 2018","Rate of freedom from radical cystectomy at 3 years|Rate of freedom from radical cystectomy at 5 years|Rate of freedom from the development of distant disease progression at 3 and 5 years|Rate of freedom from progression of bladder tumor to stage T2 or greater at 3 and 5 years|Disease-specific survival at 5 years|Overall survival|Incidence of adverse events as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE), v3.0|Recurrence rate of any local bladder tumor|Descriptive analysis for American Urological Association symptom score at baseline and at 3 years","https://ClinicalTrials.gov/show/NCT00981656"
1996,"NCT00003105","Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: ifosfamide|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","97-095|CDR0000065841|NCI-G97-1339","November 1, 1999","September 1997","August 2004","July 2, 2013","July 2013","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00003105"
1997,"NCT02115464","Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy","Recruiting","No Results Available","Lung Cancer","Drug: Metformin plus Chemo-radiotherapy|Radiation: Chemo-radiotherapy","Ontario Clinical Oncology Group (OCOG)|Canadian Institutes of Health Research (CIHR)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","OCOG-2014-ALMERA","April 14, 2014","September 2014","December 2018","March 6, 2017","March 2017","No Study Results Posted","ALMERA","December 2017","Progression free survival|Overall survival|Time to loco-regional progression|Distant progression-free survival|Toxicities","https://ClinicalTrials.gov/show/NCT02115464"
1998,"NCT00003240","Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: ifosfamide|Drug: mitomycin C|Drug: vinblastine sulfate|Drug: vindesine|Drug: vinorelbine tartrate|Procedure: conventional surgery|Radiation: radiation therapy","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","1800","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066115|LLCG-BLT|MRC-BLT|EU-98003","November 1, 1999","October 1995","null","December 17, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003240"
1999,"NCT02876861","Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC","Recruiting","No Results Available","High-Grade Upper Tract Urothelial Carcinoma","Procedure: Radical nephroureterectomy|Procedure: Distal ureterectomy|Drug: Neoadjuvant Chemotherapy","Xiangya Hospital of Central South University|Central South University|The Third Xiangya Hospital of Central South University|Hunan Cancer Hospital|Hunan Provincial People's Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","XYURO001","August 14, 2016","February 2014","August 2020","September 6, 2016","August 2016","No Study Results Posted","null","August 2020","Overall survival (OS)|Objective Response Rate (ORR)|Disease-free survival (DFS)|Progression-free survival (PFS)|Number of participants with chemotherapy-related adverse events as assessed by National Cancer Institute Common Toxicity Criteria version 4.0.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02876861"
2000,"NCT01828099","LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: LDK378|Drug: Pemetrexed + cisplatin or pemetrexed + carboplatin","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","374","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLDK378A2301|2013-000319-26","April 3, 2013","July 2013","June 2018","November 3, 2016","November 2016","No Study Results Posted","null","June 2018","Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Duration of Response (DOR)|Disease Control Rate (DCR)|Time to response (TTR)|Patient Reported Outcomes","https://ClinicalTrials.gov/show/NCT01828099"
2001,"NCT01336543","Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)","Withdrawn","No Results Available","Stage III Non-small Cell Lung Cancer","Drug: Chemotherapy following concurrent Chemoradiotherapy","Syed Jafri|Louisiana State University Health Sciences Center Shreveport","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H11-071","April 12, 2011","March 2011","July 2013","December 16, 2014","December 2014","No Study Results Posted","null","July 2013","Progression free survival","https://ClinicalTrials.gov/show/NCT01336543"
2002,"NCT00002642","SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|NCIC Clinical Trials Group|North Central Cancer Treatment Group","All","18 Years and older   (Adult, Senior)","Phase 2","116","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000064135|SWOG-9416|CAN-NCIC-BR11|CLB-9495|E-S9416|NCCTG-9416|INT-0160|U10CA032102","November 1, 1999","April 1995","July 2004","October 5, 2012","October 2012","No Study Results Posted","null","January 2001","Feasibility|toxicity|response rate","https://ClinicalTrials.gov/show/NCT00002642"
2003,"NCT02741570","Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Recruiting","No Results Available","Head and Neck Cancer","Biological: Nivolumab|Biological: Ipilimumab|Drug: Cetuximab/Erbitux|Drug: Cisplatin/Platinol|Drug: Carboplatin/Paraplatin|Drug: Fluorouracil/Adrucil","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 3","490","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-651|2016-000725-39","April 13, 2016","August 2016","March 2020","April 17, 2017","October 2016","No Study Results Posted","CheckMate 651","January 2019","Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Time to deterioration by using the 10-item Functional Assessment of Cancer Therapy-Head & Neck (FACT-HN) Symptom Index (FHNSI-10)|PD-L1 expression as a predictive biomarker for efficacy","https://ClinicalTrials.gov/show/NCT02741570"
2004,"NCT00201396","A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Carcinoma","Radiation: CCRT|Drug: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Tri-Service General Hospital|Chang Gung Memorial Hospital|China Medical University Hospital|Chung Shan Medical University|Changhua Christian Hospital|Chi Mei Medical Hospital|Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.|Taipei Veterans General Hospital, Taiwan","All","up to 70 Years   (Child, Adult, Senior)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1303","September 13, 2005","August 2003","December 2011","February 23, 2015","May 2006","No Study Results Posted","null","August 2009","The primary endpoint is the disease-free survival.|Secondary endpoints include overall survival and tumor response rate.","https://ClinicalTrials.gov/show/NCT00201396"
2005,"NCT00003399","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Drug: paclitaxel|Procedure: in vitro-treated peripheral blood stem cell transplantation","University of Maryland","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-9732|CDR0000066402|NCI-V98-1435","November 1, 1999","September 1998","September 2002","March 28, 2017","March 2017","No Study Results Posted","null","September 2002","","https://ClinicalTrials.gov/show/NCT00003399"
2006,"NCT01793701","Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer","Unknown status","No Results Available","Locally Advanced Cervical Cancer","Radiation: intensity modulated radiotherapy|Procedure: Intracavitary brachytherapy|Drug: Cisplatin","Queen Mary University of London|Barts & The London NHS Trust|Barts Cancer Institute","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6883|28435|09/H0706/90","February 14, 2013","July 2010","null","October 23, 2014","October 2014","No Study Results Posted","DEPICT","July 2015","severe gastrointestinal toxicity assessed according to Common Terminology for Adverse Event Criteria (CTCAE) v 3.0.|Objective tumour response rate|2 year local control rate","https://ClinicalTrials.gov/show/NCT01793701"
2007,"NCT00003211","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","3 Years to 20 Years   (Child, Adult)","Phase 2","94","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000066069|SJCRH-MB-96|SJMB-96|NCI-G98-1387","November 1, 1999","October 1996","June 2007","November 6, 2012","November 2012","No Study Results Posted","null","June 2007","","https://ClinicalTrials.gov/show/NCT00003211"
2008,"NCT01218048","ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Cetuximab|Procedure: Surgery|Radiation: Post-surgical radiation|Drug: Cisplatin or carboplatin","University of Pittsburgh|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCI 08-013","October 7, 2010","February 2011","October 2018","January 6, 2016","January 2016","No Study Results Posted","null","September 2017","To determine the extent to which immune biomarkers are modulated in peripheral blood and HNC tumors by preoperative treatment with 4 consecutive weeks of single-agent cetuximab|To assess if neoadjuvant modulation of immune and signaling (EGFR pathway blockade) biomarkers can predict antitumor response to adjuvant cetuximab therapy and clinical outcome.|To correlate biomarkers with the 2-year progression free survival and disease recurrence of HNC patients treated with surgery, postoperative chemoradiation and adjuvant cetuximab.|To determine time to progression and overall survival.","https://ClinicalTrials.gov/show/NCT01218048"
2009,"NCT00715611","Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma","Recruiting","No Results Available","Mesothelioma","Procedure: Pleurectomy/Decortication|Drug: pemetrexed and cisplatin or carboplatin|Radiation: Intensity Modulated Radiation Therapy","Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|M.D. Anderson Cancer Center|Princess Margaret Hospital, Canada|Mayo Clinic|Brigham and Women's Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","81","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","08-053","July 11, 2008","July 11, 2008","July 2017","February 22, 2017","February 2017","No Study Results Posted","null","July 2017","number of patients ≥ grade 3 pneumonitis","https://ClinicalTrials.gov/show/NCT00715611"
2010,"NCT00002854","High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer","Completed","No Results Available","Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","94098|P30CA033572|CHNMC-IRB-94098|NCI-V96-1042|CDR0000065102","November 1, 1999","December 1994","August 2015","August 24, 2015","August 2015","No Study Results Posted","null","August 2015","Feasibility of two cycles of high dose chemotherapy with stem cell reinfusion|Toxicity of two cycles of high dose chemothearpy and stem cell reinfusion|Maximum tolerated dose of two cycles of high dose chemothearpy and stem cell reinfusion","https://ClinicalTrials.gov/show/NCT00002854"
2011,"NCT01633541","Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer","Recruiting","No Results Available","Laryngeal Cancer","Drug: AT-101|Drug: Docetaxel|Drug: Cisplatin|Drug: Carboplatin","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2010.101|HUM 43975","June 29, 2012","March 2012","December 2018","September 13, 2016","September 2016","No Study Results Posted","null","December 2018","Number of patients alive and free from indication for laryngectomy three months post treatment","https://ClinicalTrials.gov/show/NCT01633541"
2012,"NCT02578680","Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)","Active, not recruiting","No Results Available","Non-Small-Cell Lung Carcinoma","Biological: Pembrolizumab 200 mg|Drug: Cisplatin|Drug: Carboplatin|Drug: Pemetrexed|Dietary Supplement: Folic acid 350-1000 μg|Dietary Supplement: Vitamin B12 1000 μg|Drug: Dexamethsone 4 mg|Drug: Saline solution","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","570","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","3475-189|2015-003694-15|163421","October 15, 2015","January 2016","March 2019","February 22, 2017","February 2017","No Study Results Posted","null","September 2017","Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging|Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging|Overall Survival (OS)|Progression Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria","https://ClinicalTrials.gov/show/NCT02578680"
2013,"NCT01047007","A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)","Terminated","No Results Available","Solid Tumors","Drug: MK1775|Drug: Comparator: MK1775 in combination with 5-FU|Drug: Comparator: MK1775 in combination with 5-FU/CDDP","Merck Sharp & Dohme Corp.","All","20 Years and older   (Adult, Senior)","Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1775-005|MK1775-005","January 11, 2010","January 2010","June 2011","February 3, 2015","February 2015","No Study Results Posted","null","June 2011","Dose limiting toxicities|Maximum Tolerated Dose of MK1775 in combination with 5-FU/CDDP, determined by number of dose limiting toxicities (DLTs) per dose level","https://ClinicalTrials.gov/show/NCT01047007"
2014,"NCT02052960","CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer","Active, not recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: CetuGEX™|Drug: Cetuximab|Drug: Combination of Cisplatin and 5-Fluorouracil","Glycotope GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEXMab52201","January 27, 2014","January 2014","July 2017","July 8, 2016","July 2016","No Study Results Posted","RESGEX","July 2017","To evaluate the efficacy of CetuGEX™ in terms of progression-free survival","https://ClinicalTrials.gov/show/NCT02052960"
2015,"NCT00049348","Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Biological: epoetin alfa|Biological: filgrastim|Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000258056|E1200","November 12, 2002","May 2003","null","November 12, 2010","June 2005","No Study Results Posted","null","October 2005","Percentage of margin-free resections produced by each program|Efficacy as measured by CT scan response|Post-treatment fibrosis in the resected specimens|Toxicity|Duration of objective response|Disease-free survival|Overall survival|Effect of therapy and recurrence on CA19-9 values","https://ClinicalTrials.gov/show/NCT00049348"
2016,"NCT02977169","To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer Stage IIIA|Radiotherapy","Radiation: PORT|Drug: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)","Shanghai Chest Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCHLC009","November 27, 2016","November 2016","December 2019","December 25, 2016","December 2016","No Study Results Posted","null","December 2019","Disease-free survival (DFS)|Overall survival (OS)|Locoregional recurrence-free survival (LRFS)|Distant metastasis-free survival (DMFS)|Treatment-related adverse event","https://ClinicalTrials.gov/show/NCT02977169"
2017,"NCT02662062","Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer","Recruiting","No Results Available","Bladder Cancer","Drug: Pembrolizumab|Drug: Cisplatin|Radiation: Radiotherapy","Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Peter MacCallum Cancer Centre, Australia","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ANZUP 1502","January 13, 2016","August 2016","January 2024","May 17, 2017","May 2017","No Study Results Posted","PCR-MIB","September 2023","Number of patients with grade 3 or 4 acute toxicities (excluding grade 3 or 4 urinary toxicities) that are related to study drug, graded according to CTCAE v4.03.|The efficacy of the addition of pembrolizumab to concurrent chemoradiation regimen using the best response achieved, as assessed by cystoscopy at weeks 19 and 31 of the trial (12 and 24 weeks post completion of chemoradiotherapy).|The number of patients to develop metastatic disease (i.e. the rate of metastatic disease), as assessed by CT scan.|The number of patients having a salvage cystectomy (i.e. the rate of salvage cystectomy), as assessed by cystoscopy.","https://ClinicalTrials.gov/show/NCT02662062"
2018,"NCT00003402","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Primary Purpose: Treatment","CDR0000066407|MSGCC-9734|NCI-V98-1439","November 1, 1999","January 1999","December 2002","September 23, 2009","September 2009","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00003402"
2019,"NCT00101582","Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","Completed","Has Results","Mucositis|Solid Tumors|Stomatitis|Head and Neck Cancer|Squamous Cell Carcinoma","Drug: Placebo|Drug: palifermin|Drug: cisplatin chemotherapy|Radiation: Radiotherapy","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20020402","January 12, 2005","August 2005","August 2016","August 19, 2016","August 2016","January 3, 2014","null","September 2007","Number of Participants With Severe (Grade 3 or 4) Oral Mucositis|Duration of Severe (WHO Grade 3 or 4) Oral Mucositis|Time to Onset of Severe (WHO Grade 3 or 4) Oral Mucositis|Number of Participants With Xerostomia at Month 4 (Grade 2 or Higher)|Patient-Reported Mouth and Throat Soreness Score|Total Dose of Opioid Analgesics Used for Mucositis Within 15 Weeks|Number of Participants With Unplanned Breaks in Cisplatin Chemotherapy Treatment|Number of Participants With Unplanned Breaks in Radiotherapy","https://ClinicalTrials.gov/show/NCT00101582"
2020,"NCT02641847","TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","Recruiting","No Results Available","Triple Negative Breast Cancer|Breast Cancer","Drug: docetaxel|Drug: doxorubicin or epirubicin|Drug: cyclophosphamide|Drug: gemcitabine|Drug: cisplatin","Fudan University","Female","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","503","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1506147-4","December 22, 2015","July 2015","null","December 24, 2015","December 2015","No Study Results Posted","null","June 2021","Recurrence free survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02641847"
2021,"NCT02520219","Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study","Recruiting","No Results Available","Peripheral T-cell Lymphomas","Drug: GDP|Biological: Endostar","Nanjing NingQi Medicine Science and Technology Co., Ltd.|Jiangsu Cancer Institute & Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Endostar-PTLC-001","July 26, 2015","December 2014","December 2015","August 6, 2015","August 2015","No Study Results Posted","null","August 2015","ORR(Overall release rate)|PFS（progression-free survival）|DCR(disease control rate)|OS（overall survival）|Adverse reaction|The quality of life（QOL） Questionnaire","https://ClinicalTrials.gov/show/NCT02520219"
2022,"NCT00003401","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-9731|CDR0000066405|NCI-V98-1437","November 1, 1999","January 1999","September 2002","March 28, 2017","March 2017","No Study Results Posted","null","September 2002","","https://ClinicalTrials.gov/show/NCT00003401"
2023,"NCT00002481","Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","St. Luke's Medical Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077128|STLMC-ABMR-9001|NCI-V91-0112","November 1, 1999","March 1990","null","December 17, 2013","May 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002481"
2024,"NCT03023436","Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis","Recruiting","No Results Available","Stomach Neoplasm","Procedure: Cytoreductive surgery|Procedure: Hyperthermic Intraperitoneal Chemotherapy|Drug: Fluoropyrimidine|Drug: Cisplatin","Nanfang Hospital of Southern Medical University","All","19 Years to 74 Years   (Adult, Senior)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CLASS - 05","January 9, 2017","January 2016","June 2022","February 4, 2017","February 2017","No Study Results Posted","null","June 2022","Median survival time|2-year overall survival rate|Progression free survival rate|Morbidity and mortality","https://ClinicalTrials.gov/show/NCT03023436"
2025,"NCT00504751","Phase II Study of ""VIPER"" Chemotherapy in Rel/Ref DLBCL","Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: bortezomib, dexamethasone, ifosfamide|Drug: mesna, cisplatin, etoposide, rituximab","Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","0701008963","July 19, 2007","May 2007","February 17, 2012","February 23, 2017","February 2017","February 23, 2017","null","December 2010","Complete Response","https://ClinicalTrials.gov/show/NCT00504751"
2026,"NCT00416507","Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Pancreatic Cancer","Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: liposomal cisplatin","Federation Francophone de Cancerologie Digestive","All","up to 120 Years   (Child, Adult, Senior)","Phase 3","190","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000453847|FFCD-2000-01|EU-20542|FFCD-SFRO-2000-01","December 27, 2006","March 2000","January 2007","May 27, 2016","May 2016","No Study Results Posted","null","July 2005","","https://ClinicalTrials.gov/show/NCT00416507"
2027,"NCT02959385","A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer","Recruiting","No Results Available","Stage II Esophageal Cancer|Stage III Esophageal Cancer","Radiation: Definitive Radiochemotherapy|Procedure: Neoadjuvant Radiochemotherapy","Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIH-PQS-2016090001","October 29, 2016","September 2016","September 2021","November 6, 2016","October 2016","No Study Results Posted","null","September 2018","Overall survival|Progression-free survival|Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment|Comparison of pathological diagnosis between specimens of endoscopic biopsy and surgically resected in esophageal cancer|Comparison between gross tumor volume (GTV) delineated with ultrasonic endoscopically placed titanium clips and GTV with conventional contouring method in thoracic esophageal cancer|Determination of internal target volume (ITV) of thoracic esophageal cancer by evaluating movement of ultrasonic endoscopically placed titanium clips, with or without swallowing, during radiotherapy simulation","https://ClinicalTrials.gov/show/NCT02959385"
2028,"NCT00201383","Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients","Completed","No Results Available","Oral Cavity|Squamous Cell Carcinoma","Drug: cisplatin","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Changhua Christian Hospital|China Medical University Hospital|Buddhist Tzu Chi General Hospital|Mackay Memorial Hospital|Sun Yat-sen University|Chi Mei Medical Hospital|Kaohsiung Veterans General Hospital.","All","Child, Adult, Senior","Phase 3","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T2399","September 13, 2005","October 1999","August 2009","September 13, 2005","January 2005","No Study Results Posted","null","null","RT versus RT plus CT in effect on local control and survival of patients of oral cavity cancer after curative operation.|the acute and chronic toxicity of RT versus RT plus CT in patients of oral cavity cancer after curative operation.","https://ClinicalTrials.gov/show/NCT00201383"
2029,"NCT02359058","A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","Completed","No Results Available","Stomach Neoplasms","Drug: Ramucirumab|Drug: Capecitabine|Drug: Cisplatin|Drug: S-1|Drug: Oxaliplatin","Eli Lilly and Company","All","20 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15532|I4T-JE-JVCX","February 4, 2015","February 2015","November 2016","December 13, 2016","December 2016","No Study Results Posted","null","July 2016","Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration|Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Ramucirumab|Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) of Ramucirumab|Percentage of Participants with a Tumor Response","https://ClinicalTrials.gov/show/NCT02359058"
2030,"NCT00002461","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: sargramostim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","15 Years to 65 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000075725|AECM-8802027|NCI-V89-0089","November 1, 1999","April 1988","null","February 6, 2009","October 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002461"
2031,"NCT02567383","Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer","Recruiting","No Results Available","Recurrent Head and Neck Cancer","Radiation: Radiation|Device: Hyperthermia; Thermotron RF-8|Drug: Cisplatin|Drug: Taxotere","Shin Kong Wu Ho-Su Memorial Hospital","All","20 Years to 85 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","20150205D","October 1, 2015","September 2015","March 2018","April 16, 2017","April 2017","No Study Results Posted","null","March 2018","Tumor response rate|Adverse events|Late adverse events","https://ClinicalTrials.gov/show/NCT02567383"
2032,"NCT00626639","A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy","Completed","Has Results","Mucositis|Head and Neck Cancer","Drug: Placebo|Drug: palifermin|Radiation: Radiotherapy|Drug: Cisplatin","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Supportive Care","20040124","February 21, 2008","July 2005","July 2015","April 12, 2016","April 2016","January 24, 2014","null","May 2007","Number of Participants With Adverse Events (AEs)|Ratio of Ki67-positive Cells Before and After Palifermin Treatment|Pharmacokinetics of Palifermin|Number of Participants With Severe Oral Mucositis (OM) (Adapted RTOG/EORTC Grade ≥3)|Patient-Reported Mouth and Throat Soreness Score|Number of Participants With Disease Progression by Week 12|Overall Survival","https://ClinicalTrials.gov/show/NCT00626639"
2033,"NCT02886195","EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC","Enrolling by invitation","No Results Available","EGFR Gene Mutation","Drug: pemetrexed|Drug: cisplatin|Drug: Erlotinib","Fujian Cancer Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","secgolc001","August 2, 2016","July 2016","July 2019","August 27, 2016","July 2016","No Study Results Posted","effect","July 2019","Progression-Free Survival (PFS)|Response Rate (RR)|Overall Survival (OS)|Adverse Event (AE)","https://ClinicalTrials.gov/show/NCT02886195"
2034,"NCT00532818","Hydralazine Valproate for Cervical Cancer","Unknown status","No Results Available","Metastatic Cervical Cancer","Drug: Hydralazine and magnesium valproate|Drug: Placebo","National Institute of Cancerología|Psicofarma S.A. de C.V.","Female","18 Years and older   (Adult, Senior)","Phase 3","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","006/027/ICI","September 18, 2007","July 2007","December 2010","March 27, 2009","March 2009","No Study Results Posted","null","September 2010","Progression-free survival|Response rate, safety, overall survival.","https://ClinicalTrials.gov/show/NCT00532818"
2035,"NCT00863512","Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer","Terminated","Has Results","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium|Drug: vinorelbine tartrate|Procedure: standard follow-up care","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","34","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-30506|CDR0000636895","March 17, 2009","March 2009","November 2012","February 7, 2017","February 2017","December 13, 2016","null","November 2011","Overall Survival","https://ClinicalTrials.gov/show/NCT00863512"
2036,"NCT01107639","Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery","Active, not recruiting","No Results Available","Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer","Biological: cetuximab|Drug: cisplatin|Drug: docetaxel|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","297","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 75/08|2009-016584-10|EU-21024|CDR0000669249","April 20, 2010","April 2010","June 2019","November 10, 2016","November 2016","No Study Results Posted","null","December 2013","Progression-free survival (PFS)|Progression-free survival after surgery|Adverse events according to CTCAE version 4.0 and major postoperative complications|Pathological remission|Overall survival|Time to locoregional failure after R0 resection|Time to systemic failure after R0 resection|In-hospital mortality|Time to progression (TTP)","https://ClinicalTrials.gov/show/NCT01107639"
2037,"NCT02891447","Study of Cytoreduction, Gastrectomy, & Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology","Recruiting","No Results Available","Gastroesophageal Cancer|Gastric Cancer|Diseases of Oesophagus Stomach and Duodenum","Procedure: Hyperthermic intraperitoneal chemoperfusion (HIPEC)|Drug: Sodium thiosulfate","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2016-0269","September 1, 2016","September 2016","null","October 5, 2016","October 2016","No Study Results Posted","null","September 2019","Overall Survival","https://ClinicalTrials.gov/show/NCT02891447"
2038,"NCT02542111","A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Bortezomib|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin","Ruijin Hospital","All","16 Years to 75 Years   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","V-GDP","August 24, 2015","May 2015","null","July 31, 2016","July 2016","No Study Results Posted","null","May 2017","Response rate|Progression free survival|Overall survival|Safety as assessed using the CTCAE","https://ClinicalTrials.gov/show/NCT02542111"
2039,"NCT02715531","A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","Recruiting","No Results Available","Solid Tumor","Drug: 5-FU|Drug: Atezolizumab|Drug: Bevacizumab|Drug: Gemcitabine|Drug: Leucovorin|Drug: Nab-Paclitaxel|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Cisplatin|Drug: Vanucizumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","291","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO30140","March 17, 2016","April 30, 2016","May 31, 2019","May 22, 2017","May 2017","No Study Results Posted","null","May 31, 2019","Number of Participants With At Least One Adverse Event|Serum Concentrations of Atezolizumab (All Arms)|Measure: Serum Concentration of Bevacizumab (Arm A, Arm B, and Group D2)|Plasma Concentration of Vanucizumab (Group D1)|Plasma Concentration of Oxaliplatin (Arm B and Group E1)|Plasma Concentration of 5-FU (Arms B and E)|Plasma Concentration of Cisplatin (Group E2)|Plasma Concentration of nab-Paclitaxel (Arm C)|Plasma Concentration of Gemcitabine (Arm C)|Percentage of Participants with Best Overall Response as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1|Percentage of Participants with Best Overall Response as Determined by Immune-Modified RECIST|Percentage of Participants with Best Overall Response as Determined by HCC-Specific Modified RECIST (Arm D only)|Percentage of Participants with Objective Response as Determined by RECIST v1.1|Percentage of Participants with Objective Response as Determined by Immune-Modified RECIST|Percentage of Participants with Objective Response as Determined by HCC-Specific Modified RECIST (Arm D only)|Duration of Objective Response as Determined by RECIST v1.1|Duration of Objective Response as Determined by Immune-Modified RECIST|Duration of Objective Response as Determined by HCC-Specific Modified RECIST (Arm D Only)|Progression Free-Survival Duration as Determined by RECIST v1.1|Progression Free-Survival Duration as Determined by Immune-Modified RECIST|Progression Free-Survival Duration as Determined by HCC-Specific Modified RECIST (Arm D Only)|Overall Survival Duration|Time to Radiological Progression as Determined by RECIST v1.1 (Arms A and D only)|Time to Radiological Progression as Determined by Immune-Modified RECIST (Arms A and D only)|Time to Radiological Progression as Determined by HCC-Specific Modified RECIST (Arm D only)|Time to Symptomatic Progression as Defined by the Assessment of Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index 8 (FHSI-8) Questionnaire (Arm D only)|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab|Percentage of Participants With ATAs to Bevacizumab|Percentage of Participants With ATAs to Vanucizumab","https://ClinicalTrials.gov/show/NCT02715531"
2040,"NCT01031420","Dose Dense MVAC for Muscle Invasive Bladder Cancer","Completed","No Results Available","Muscle Invasive Bladder Cancer|High Risk Urothelial Carcinoma of the Upper Urinary Tracts","Drug: single arm dose dense MVAC","Fox Chase Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FER-GU-026|NCI-2010-01910","December 3, 2009","December 2009","July 2013","November 3, 2015","November 2015","No Study Results Posted","null","July 2013","To assess the rate of complete response at cystectomy or ureterectomy following preoperative dose dense MVAC in patients with muscle invasive urothelial carcinoma of the bladder or high risk upper tract urothelial carcinoma.|To assess the toxicity profile of dose dense MVAC given in the neoadjuvant setting.","https://ClinicalTrials.gov/show/NCT01031420"
2041,"NCT00052429","High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer","Completed","Has Results","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-077|MSKCC-02077|NCI-H02-0101","January 24, 2003","September 2002","November 2010","January 22, 2016","January 2016","December 15, 2015","null","November 2010","Survival Rate of Patients|Local Control of Participants","https://ClinicalTrials.gov/show/NCT00052429"
2042,"NCT01459484","ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma","Recruiting","No Results Available","Osteosarcoma","Drug: Mifamurtide arm|Other: 3 drugs arm","Italian Sarcoma Group","All","up to 40 Years   (Child, Adult)","Phase 2|Phase 3","225","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ISG/OS-2|2011-001659-36","October 19, 2011","July 2011","February 2020","March 17, 2017","March 2017","No Study Results Posted","ISG/OS-2","January 2020","Overall Survival|Events free survival in patient with ABCB1/P-glycoprotein over-expression, and who do not over-express ABCB1/P-glycoprotein","https://ClinicalTrials.gov/show/NCT01459484"
2043,"NCT02072148","The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)","Recruiting","No Results Available","Human Papilloma Virus|Oropharyngeal Squamous Cell Carcinoma","Procedure: PET/CT|Radiation: Radiotherapy|Radiation: Concurrent Chemoradiation","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GCO 13-1662","February 24, 2014","March 2014","March 2019","March 6, 2017","March 2017","No Study Results Posted","null","March 2019","Disease Free Survival|Local Regional Control|Overall Survival|Toxicity Rate|Quality of Life Outcomes|Dose limiting Toxicity","https://ClinicalTrials.gov/show/NCT02072148"
2044,"NCT02899728","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer","Recruiting","No Results Available","Small Cell Lung Carcinoma","Drug: Carboplatin|Drug: Cediranib Maleate|Drug: Cisplatin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Olaparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","132","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2016-01363|9974|P30CA006516|UM1CA186709","September 13, 2016","April 7, 2017","April 7, 2020","April 23, 2017","April 2017","No Study Results Posted","null","April 7, 2020","PFS rate in patients who receive cediranib maleate/olaparib as maintenance therapy as compared to standard therapy|Incidence of adverse events assessed using CTCAE version 4.03|OS rate","https://ClinicalTrials.gov/show/NCT02899728"
2045,"NCT01993810","Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","Recruiting","No Results Available","Stage IIA Non-small Cell Lung Cancer|Stage IIB Non-small Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Radiation: photon beam radiation therapy|Radiation: proton beam radiation therapy|Drug: paclitaxel|Drug: carboplatin|Drug: etoposide|Drug: cisplatin|Procedure: quality-of-life assessment|Other: questionnaire administration","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology","All","18 Years and older   (Adult, Senior)","Phase 3","560","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG 1308|NCI-2013-01850|RTOG-1308|U10CA021661","November 12, 2013","February 2014","null","June 10, 2016","June 2016","No Study Results Posted","null","December 2020","Overall Survival|Progression-free survival|Adverse events|Quality of life (QOL)|Cost-effectiveness|Changes in pulmonary function","https://ClinicalTrials.gov/show/NCT01993810"
2046,"NCT00870870","A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Gemcitabine|Drug: Cisplatin|Biological: IMC-A12 (cixutumumab)|Biological: Cetuximab|Biological: IMC-A12 (cixutumumab)|Biological: Cetuximab|Drug: Carboplatin","ImClone LLC","All","18 Years and older   (Adult, Senior)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13930|CP02-0860|CP13-0811|I5A-IE-JAEF","March 26, 2009","March 2009","May 2012","June 12, 2012","June 2012","No Study Results Posted","null","April 2012","Objective response rate (ORR)|Overall Survival (OS)|Progression-Free Survival (PFS)|Time To Progression (TTP)|Duration of Response|Summary of Adverse Events (AEs)|Serum Anti-IMC-A12 (cixutumumab) Assessment|Maximum concentration (Cmax) at study day 1|Maximum concentration (Cmax) Cycle 1|Maximum concentration (Cmax) Cycle 3|Maximum concentration (Cmax) Cycle 5|Minimum concentration (Cmin) at study day 1|Minimum concentration (Cmin) Cycle 1|Minimum concentration (Cmin) Cycle 3|Minimum concentration (Cmin) Cycle 5","https://ClinicalTrials.gov/show/NCT00870870"
2047,"NCT01687439","Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Endostar|Drug: Vinorelbine|Drug: Cisplatin|Radiation: Radiotherapy","Fudan University","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSCLC0901","August 16, 2012","December 2008","October 2009","September 18, 2012","September 2012","No Study Results Posted","null","October 2009","Tumor blood volume|Tumor blood flow|Permeability-surface area product|18-FDG PET SUV values|The incidence of adverse events","https://ClinicalTrials.gov/show/NCT01687439"
2048,"NCT00030810","Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC","Completed","No Results Available","Lung Cancer","Radiation: Hyperfractionated|Drug: Taxotere/Cisplatin|Procedure: conventional surgery","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 16/01|EU-20137","February 14, 2002","September 2001","May 2006","May 14, 2012","May 2012","No Study Results Posted","null","May 2006","Rate of event-free survival measured 1 year after registration|Operability after chemotherapy|Postoperative mortality 30 days after surgery|Complete resection rate after surgery|Toxicity|Response rate","https://ClinicalTrials.gov/show/NCT00030810"
2049,"NCT01249352","A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer","Completed","No Results Available","Esophageal Cancer|Adenocarcinoma","Drug: Nimotuzumab|Drug: Cisplatin|Drug: Fluorouracil|Radiation: Radiotherapy","Eurofarma Laboratorios S.A.","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EF024-201","November 25, 2010","January 2009","November 2013","January 3, 2014","January 2014","No Study Results Posted","NICE","November 2013","Overall survival and assessment of the complete endoscopic response|Complete clinical response rate","https://ClinicalTrials.gov/show/NCT01249352"
2050,"NCT00588770","Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","Active, not recruiting","No Results Available","Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Major Salivary Gland Cancer AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Verrucous Carcinoma AJCC v7|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Verrucous Carcinoma AJCC v7|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Verrucous Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Verrucous Carcinoma AJCC v7|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVC Oral Cavity Verrucous Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7|Tongue Carcinoma|Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary","Biological: Bevacizumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Docetaxel|Drug: Fluorouracil|Other: Laboratory Biomarker Analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","400","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00507|CDR0000582533|E1305|U10CA180820|U10CA021115","December 28, 2007","August 8, 2008","null","May 24, 2017","May 2017","No Study Results Posted","null","December 1, 2017","Overall survival|Comorbidities|Incidence of toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Objective response rates|Progression-free survival","https://ClinicalTrials.gov/show/NCT00588770"
2051,"NCT02365805","Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Drug: Epirubicin + Cisplatin + Fluorouracil|Drug: Docetaxel + Ciclofosfamide","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2011-005843-28","December 30, 2014","April 2014","October 10, 2016","March 9, 2017","March 2017","No Study Results Posted","BERNAQ","October 10, 2016","Rate of residual tumor types RCB-0 and RCB-I (good pathological response) at the time of surgery.|Percentaje of patients candidates to conventional mastectomy as indicated by surgeon|Rates of residual tumor types RCB-0, RCB-I, RCB-II and RCB-III pathological response in surgical breast and axillary node resection specimens|Percentage of patients with negative axillary nodes|Complete tumoral response at the time of surgery (WHO criteria).|Percentaje of patients candidates to breast conserving mastectomy as indicated by surgeon|Partial tumoral response at the time of surgery (WHO criteria).","https://ClinicalTrials.gov/show/NCT02365805"
2052,"NCT01516996","Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer","Recruiting","No Results Available","Oropharyngeal Cancer|Hypopharyngeal Cancer","Drug: docetaxel and cisplatin|Radiation: IMRT|Biological: Nimotuzumab","The Second People's Hospital of Sichuan|Biotech Pharmaceutical Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BT-IST-SCCHN-036","January 11, 2012","March 2012","March 2018","March 18, 2012","March 2012","No Study Results Posted","null","September 2013","Objective response rate|The Number of Participants with Adverse Events|Overall Survival|Progression-Free Survival|Evaluate the Local control Rate in 1 to 5 years.|Tumor-Free Survival|Non-metastatic Rate","https://ClinicalTrials.gov/show/NCT01516996"
2053,"NCT02083679","Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer","Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Drug: Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Drug: Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Drug: Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel","EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR200637-003|2013-003995-11","March 7, 2014","July 2014","August 2015","August 29, 2016","August 2016","August 29, 2016","null","August 2015","Number of Subjects With Dose Limiting Toxicities (DLTs)|Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death","https://ClinicalTrials.gov/show/NCT02083679"
2054,"NCT02867865","Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers","Not yet recruiting","No Results Available","Gall Bladder Cancers","Drug: Gemcitabine|Drug: Cisplatin|Radiation: Chemoradiation|Procedure: PETCECT|Procedure: Laparoscopy","Tata Memorial Hospital","All","19 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","314","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1652","July 29, 2016","August 2016","August 2022","August 13, 2016","July 2016","No Study Results Posted","POLCAGB","August 2021","Overall Survival|Surgical resection rate|Progression free survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT02867865"
2055,"NCT00003053","Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Procedure: adjuvant therapy","European Institute of Oncology|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 3","750","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065700|CNR-NICO-01|EU-97010","November 1, 1999","January 1994","null","September 19, 2013","January 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003053"
2056,"NCT02402920","Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer","Recruiting","No Results Available","Lung Cancer","Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin|Drug: MK-3475|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-1003|NCI-2015-00598","March 25, 2015","July 2015","July 2023","April 25, 2017","April 2017","No Study Results Posted","null","July 2023","Maximum Tolerated Dose (MTD) of MK 3475|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02402920"
2057,"NCT00052962","Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis","Completed","Has Results","Gastrointestinal Neoplasm","Procedure: Cytoreductive surgery|Procedure: Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 3","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","030085|03-C-0085","January 26, 2003","January 2003","September 2008","November 16, 2012","November 2012","September 4, 2012","null","September 2008","Progression Free Survival|Number of Participants With an Adverse Event","https://ClinicalTrials.gov/show/NCT00052962"
2058,"NCT00496652","DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC","Completed","No Results Available","Cancer of the Head and Neck","Radiation: Radiotherapy|Drug: Zalutumumab","Danish Head and Neck Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 3","619","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DAHANCA 19|Ethical Comittee: 20070091|DKMA: 2612-3486","July 3, 2007","November 2007","November 2016","November 22, 2016","November 2016","No Study Results Posted","null","July 2012","Locoregional control after curative intended radiotherapy/chemoradiotherapy +/- zalutumumab|Disease-specific survival and overall control Acute and late toxicity","https://ClinicalTrials.gov/show/NCT00496652"
2059,"NCT00559351","RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus","Terminated","No Results Available","Esophageal Neoplasms|Squamous Cell Cancer","Procedure: transthoracic esophagectomy 2-field extended lymphadenectomy|Drug: neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|Radiation: neoadjuvant chemoradiotherapy","Ministry of Scientific Research and Information Technology, Poland","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6P05C01320|PL SCSR 6P05C01320","November 15, 2007","December 2001","April 2004","November 15, 2007","September 2007","No Study Results Posted","null","null","mean, median, 1-year, 3-year, 5-year overall survival|toxicity-related morbidity and mortality|postoperative morbidity and mortality|clinical and pathological response rates|curative resection rate","https://ClinicalTrials.gov/show/NCT00559351"
2060,"NCT00003642","Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer","Terminated","No Results Available","Bladder Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","43","Other","Interventional","Primary Purpose: Treatment","EORTC-22971","November 1, 1999","October 1998","null","March 5, 2012","March 2012","No Study Results Posted","null","July 2001","","https://ClinicalTrials.gov/show/NCT00003642"
2061,"NCT00003004","Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: alvocidib|Drug: cisplatin|Drug: paclitaxel","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","73","Other|NIH","Interventional","Primary Purpose: Treatment","96-077|CDR0000065571|NCI-T96-0091","November 1, 1999","July 1997","October 2001","June 20, 2013","June 2013","No Study Results Posted","null","October 2001","","https://ClinicalTrials.gov/show/NCT00003004"
2062,"NCT02788461","Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Radiation: Chemoradiotherapy|Radiation: Chemoradiotherapy with Integrated Boost Dose","Lawson Health Research Institute","All","18 Years and older   (Adult, Senior)","","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PET-BOOST NSCLC","April 28, 2016","May 2016","April 2025","January 26, 2017","January 2017","No Study Results Posted","PET-BOOST","April 2025","Reduction of local-regional failure rate|Progression-Free Survival|Overall Survival|Grade 3-5 Toxicity Rate|Quality of Life FACT-L|Quality of Life EQ-5D|Dose-Response Characterization|Dose Escalation Feasibility|Imaging Use","https://ClinicalTrials.gov/show/NCT02788461"
2063,"NCT01103544","JAVLOR® Online Non-Interventional Trial","Completed","No Results Available","Transitional Cell Carcinoma","","Pierre Fabre Pharma GmbH|DocCheck Medical Services GmbH","All","18 Years and older   (Adult, Senior)","","200","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JONAS-1","April 11, 2010","April 2010","August 2013","May 12, 2015","May 2015","No Study Results Posted","JONAS-1","September 2011","Side effects according to NCI-CTCAE v3.0 and treatment conditions in daily routine|Explorative assessment of Overall Response Rate (ORR)|Anti-emetic comedication|Anti-obstipative diet / comedication|General well-being / quality of life of the patients (patient questionnaire)|Patients' satisfaction with the treatment (patient questionnaire)|Physicians' satisfaction with the treatment|Patients' compliance with regards to the cotreatments (patient questionnaire)","https://ClinicalTrials.gov/show/NCT01103544"
2064,"NCT01743482","Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors","Unknown status","No Results Available","Germ Cell Tumors|Measurable Disease|Relapse or Progression After 2 or 3 Chemotherapy Regimens.|Relapse or Progression After High-dose Chemotherapy.","Drug: Pazopanib","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|GlaxoSmithKline","Male","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INT123/12","December 3, 2012","January 2013","April 2015","December 4, 2012","December 2012","No Study Results Posted","Pazotest-01","January 2015","Progression Free Survival|Safety and tolerability of pazopanib according to the Common Terminology Criteria for Adverse Events version 4.03|Response Rate|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT01743482"
2065,"NCT00450203","Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer","Recruiting","No Results Available","Oesophagogastric Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: cisplatin|Drug: Epirubicin|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Drug: Lapatinib","Professor David Cunningham|Cancer Research UK|Roche Pharma AG|GlaxoSmithKline|Medical Research Council","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","1103","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000536013|MRC-ST03|EU-20710|ISRCTN46020948|2006-000811-12|00316/0221/001","March 20, 2007","October 2007","December 2017","November 30, 2016","November 2016","No Study Results Posted","ST03","December 2017","Safety|Efficacy|Overall survival|Feasibility|Treatment-related morbidity|Response rates to pre-operative treatment|Surgical resection rates|Disease-free survival|Quality of life|Cost-effectiveness|HER-2 Positivity Rate|Feasibility of centralised HER-2 testing","https://ClinicalTrials.gov/show/NCT00450203"
2066,"NCT02501278","A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer","Withdrawn","No Results Available","Uterine Cervical Neoplasms","Biological: INO-3112 vaccine|Radiation: Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|Drug: Cisplatin chemotherapy","European Organisation for Research and Treatment of Cancer - EORTC|Inovio Pharmaceuticals|Centre Hospitalier Universitaire Vaudois","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-1411|2015-004602-42","July 7, 2015","May 2016","May 2021","May 12, 2016","May 2016","No Study Results Posted","null","May 2019","Occurence of Adverse Events|Progression free survival (PFS) at 18 months assessed by RECIST","https://ClinicalTrials.gov/show/NCT02501278"
2067,"NCT02194556","Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC","Active, not recruiting","No Results Available","EGFR Positive Non-small Cell Lung Cancer|Adenocarcinoma","Drug: Sequential and maintenance icotinib|Drug: Maintenance icotinib","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BD-IC-IV69","July 16, 2014","July 2014","July 2017","July 17, 2014","July 2014","No Study Results Posted","null","July 2017","Progression Free Survival|Overall survival|Objective response rate|Adverse events|Disease control rate (DCR)","https://ClinicalTrials.gov/show/NCT02194556"
2068,"NCT00875849","Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Radiation: radiation therapy","Centre Antoine Lacassagne","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000633474|CALACASS-AACER|MERCK-CALACASS-AACER|INCA-RECF0623|EUDRACT-2007-004384-22","April 2, 2009","March 2008","December 2013","November 20, 2014","August 2012","No Study Results Posted","null","February 2010","Disease-free survival at 2 years","https://ClinicalTrials.gov/show/NCT00875849"
2069,"NCT01004978","Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","Active, not recruiting","No Results Available","Hepatocellular Carcinoma|Non-Resectable Hepatocellular Carcinoma","Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Drug: Doxorubicin-Eluting Beads|Other: Laboratory Biomarker Analysis|Drug: Mitomycin|Other: Pharmacological Study|Other: Placebo|Drug: Sorafenib Tosylate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","400","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2011-01981|ECOG-E1208|CDR0000657952|E1208|U10CA180820|U10CA021115","October 29, 2009","October 28, 2009","null","May 23, 2017","May 2017","No Study Results Posted","null","February 1, 2018","PFS|Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall survival","https://ClinicalTrials.gov/show/NCT01004978"
2070,"NCT02987699","Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil","Recruiting","No Results Available","HepatoCellular Carcinoma","Drug: 5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin , leucovorin","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Unique Protocol ID: HCC-S026","December 7, 2016","November 2016","May 2017","December 27, 2016","December 2016","No Study Results Posted","null","April 2017","Tumor response|Adverse Events|Number of of Patients developed Adverse Events","https://ClinicalTrials.gov/show/NCT02987699"
2071,"NCT03042429","Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients","Completed","No Results Available","Neuroblastoma","Drug: Cycles N8, N5 and N6|Drug: Cycles N5 and N6","University of Cologne","All","6 Months to 21 Years   (Child, Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","UCologne","February 1, 2017","January 1, 2007","December 31, 2016","February 3, 2017","February 2017","No Study Results Posted","NB2004-HR","December 31, 2016","Event free survival|Overall survival|early response|late response","https://ClinicalTrials.gov/show/NCT03042429"
2072,"NCT02120118","Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors","Withdrawn","No Results Available","Solid Tumors","Radiation: Radiation|Other: Hyperthermia|Drug: Cisplatin|Drug: Taxotere","Shin Kong Wu Ho-Su Memorial Hospital","All","20 Years to 85 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20140101D","March 17, 2014","February 2014","February 2017","June 8, 2015","October 2014","No Study Results Posted","null","February 2017","Tumor response rate|Adverse events|Late adverse events|Time to Disease Progression","https://ClinicalTrials.gov/show/NCT02120118"
2073,"NCT01055301","S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","Withdrawn","No Results Available","Multiple Myeloma|Plasma Cell Myeloma","Drug: bortezomib|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: lenalidomide|Drug: melphalan|Drug: thalidomide|Genetic: gene expression analysis|Genetic: microarray analysis|Other: laboratory biomarker analysis|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0833|U10CA032102","January 22, 2010","July 2011","July 2011","March 5, 2015","March 2015","No Study Results Posted","null","July 2011","Progression-free survival at 3 years|Overall survival|Frequency and severity of toxicities|Gene expression profiling analysis of CD138+ purified plasma cells","https://ClinicalTrials.gov/show/NCT01055301"
2074,"NCT02283489","Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors","Unknown status","No Results Available","Head and Neck Neoplasms","Drug: recombinant human endostatin adenovirus|Drug: Cisplatin injection|Drug: Paclitaxel injection","Renmiao Zhang|West China Hospital|Chengdu Shi Endor Biological Engineering Technology Co., Ltd","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","180","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","ChengduShiEn_RMZ_001","October 15, 2014","October 2014","October 2016","November 3, 2014","November 2014","No Study Results Posted","null","October 2016","Change in Objective response rate (ORR) of target lesion|Change in Disease control rate of target lesion|Change in ORR of all lesions|Time to progression|Change in Immune response","https://ClinicalTrials.gov/show/NCT02283489"
2075,"NCT01993979","A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)","Recruiting","No Results Available","Transitional Cell Carcinoma of Ureter","Drug: Chemotherapy|Other: Surveillance","Institute of Cancer Research, United Kingdom|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 3","345","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ICR-CTSU/2011/10031|2011-002577-33|ISRCTN98387754|CRUK/11/027|11/NW/0782","November 19, 2013","May 2012","May 2022","November 19, 2013","November 2013","No Study Results Posted","POUT","May 2020","Disease-free survival (DFS)|Overall survival|Metastasis free survival|Incidence of bladder second primary tumours|Incidence of contralateral primary tumours|Acute and late toxicity|Quality of life (QoL)","https://ClinicalTrials.gov/show/NCT01993979"
2076,"NCT01034332","Paclitaxel/Cisplatin/Fluorouracil Followed by Paclitaxel/Cisplatin/Radiotherapy and Esophagectomy for Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Procedure: TP-HDFL,TP-CCRT, Esophagectomy","National Taiwan University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","58","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200707051M","January 7, 2008","December 2007","December 2009","December 17, 2009","December 2009","No Study Results Posted","null","December 2009","To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT","https://ClinicalTrials.gov/show/NCT01034332"
2077,"NCT00310739","Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury","Unknown status","No Results Available","Kidney Failure","","Hamamatsu University","All","Child, Adult, Senior","","null","Other","Observational","Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","16-50","April 3, 2006","null","null","November 6, 2006","April 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00310739"
2078,"NCT01133678","Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck","Active, not recruiting","No Results Available","Head and Neck Cancer","Drug: Everolimus escalating dose|Drug: Everolimus or Placebo","University of Chicago|Novartis Pharmaceuticals","All","18 Years to 89 Years   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","10-069-B","May 27, 2010","May 2010","October 2017","May 15, 2017","May 2017","No Study Results Posted","null","September 2017","Tumor Responses","https://ClinicalTrials.gov/show/NCT01133678"
2079,"NCT00433563","Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer","Active, not recruiting","No Results Available","Lung Cancer","Radiation: Once daily radiotherapy|Radiation: Twice daily radiotherapy","Sally Falk|Cancer Research UK|NCIC Clinical Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Spanish Lung Cancer Group|Groupe Francais De Pneumo-Cancerologie|Intergroupe Francophone de Cancerologie Thoracique|The Christie NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 3","547","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000531709|CHNT-CONVERT|CHNT-CTAAC-CONVERT-C17052/A815","February 8, 2007","April 2008","February 2019","December 7, 2016","December 2016","No Study Results Posted","CONVERT","February 2016","Overall survival|Local progression-free survival|Metastasis-free survival|Toxicity|Cytotoxic dose intensity|Radiotherapy dose intensity","https://ClinicalTrials.gov/show/NCT00433563"
2080,"NCT02296684","Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","Recruiting","No Results Available","Cancer of Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck|Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head and Neck","Biological: MK-3475|Procedure: Surgery|Radiation: Intensity modulated radiation therapy|Radiation: Image-guided radiation therapy|Drug: Cisplatin","Washington University School of Medicine|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201412118","November 17, 2014","March 25, 2015","March 31, 2022","February 8, 2017","February 2017","No Study Results Posted","null","March 31, 2019","Locoregional recurrence rates|Distant failure rate|Occurrence of adverse events|Surgical complications and/or delays","https://ClinicalTrials.gov/show/NCT02296684"
2081,"NCT01920061","A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents","Recruiting","No Results Available","Neoplasm","Drug: PF-05212384|Drug: Docetaxel|Drug: PF-05212384|Drug: Cisplatin|Drug: PF-05212384|Drug: Dacomitinib","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","124","Industry","Interventional","Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Basic Science","B2151002|2013-001390-24","August 7, 2013","September 10, 2013","October 14, 2019","March 7, 2017","March 2017","No Study Results Posted","null","November 25, 2018","Number of participants with Dose-limiting toxicities (DLT)|Maximum Observed Plasma Concentration (Cmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Gene sequence data|QTc interval|Objective tumor response|Levels of PI3K pathway protein biomarkers","https://ClinicalTrials.gov/show/NCT01920061"
2082,"NCT02949895","Study of BMS-986012 in Subjects With Small Cell Lung Caner","Recruiting","No Results Available","Small Cell Lung Cancer","Drug: BMS-986012|Drug: Cisplatin|Drug: Etoposide","Bristol-Myers Squibb","All","20 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA001-045","October 28, 2016","November 29, 2016","October 29, 2018","May 15, 2017","May 2017","No Study Results Posted","null","October 28, 2018","Number of participants with adverse events (AEs)|Number of participants with serious adverse events (SAEs )|Number of Discontinuations due to AEs|Number of Deaths due to AEs|Number of participants with laboratory toxicity grade shift from baseline|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration(Tmax)|Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T))|Observed serum concentration at the end of a dosing interval(Ctau)|Area under the concentration-time curve in 1 dosing interval(AUC(TAU))|Characterization of Immunogenicity as measured by Anti-Drug Antibodies (ADA)|Best overall response (BOR)|Duration of response (DOR)","https://ClinicalTrials.gov/show/NCT02949895"
2083,"NCT01040312","An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors","Unknown status","No Results Available","Small Cell Lung Cancer|Non-small Cell Lung Cancer|Cervical Cancer|Ovarian Cancer|Gastric Cancer (Inoperable and Recurrent)","Drug: CPT-11 and platinum analogues","Daiichi Sankyo Co., Ltd.","All","Child, Adult, Senior","","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TOP009-062","December 23, 2009","October 2009","March 2014","March 28, 2013","March 2013","No Study Results Posted","null","March 2013","Influence of UGT1A1 genotypes on severe toxicities (ex. neutropenia) induced by CPT-11 based regimens|Influence of UGT1A1 genotypes on response rate or disease control rate|Exploratory analysis of risk factors for severe toxicities (ex. neutropenia) induced by CPT-11 based regimens other than UGT1A1 polymorphisms.","https://ClinicalTrials.gov/show/NCT01040312"
2084,"NCT02399306","Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma|Enteral Nutrition Therapy|Chemoradiotherapy","Drug: nutrison|Radiation: radiotherapy|Drug: Docetaxel, cisplatin","Sichuan Cancer Hospital and Research Institute|Wuhan University|Xiangya Hospital of Central South University|Shanxi Province Cancer Hospital|Shandong Tumor Hospital|Henan Cancer Hospital|Beijing Cancer Hospital|Hebei Medical University Fourth Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","scch2015001","March 17, 2015","March 2015","June 2019","November 11, 2016","November 2016","No Study Results Posted","null","June 2017","Body Weight Changes|quality of life（QOL）","https://ClinicalTrials.gov/show/NCT02399306"
2085,"NCT01063478","Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC","Terminated","No Results Available","Non-Small Cell Lung Cancer","Drug: RAD001 (in addition to standard radiation and chemotherapy)","University of Chicago|Novartis Pharmaceuticals","All","18 Years to 89 Years   (Adult, Senior)","Phase 1","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-384-B","February 3, 2010","February 2010","January 2012","January 16, 2014","January 2014","No Study Results Posted","RAD001","June 2011","To evaluate the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of RAD001 when administered in combination with chemotherapy and radiation.|To evaluate the preliminary clinical benefit rate after administration of RAD001 in combination with chemotherapy and radiation.","https://ClinicalTrials.gov/show/NCT01063478"
2086,"NCT02749526","Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial","Recruiting","No Results Available","Esophageal","Drug: ""Endostar""|Drug: Liposo|Drug: cisplatin|Drug: Gimeracil and Oteracil Potassium （Tegafur）","The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JS-ENDO-003","March 28, 2016","April 2016","December 2016","April 22, 2016","April 2016","No Study Results Posted","null","December 2016","R0 Resection rate|pCR rate","https://ClinicalTrials.gov/show/NCT02749526"
2087,"NCT00478699","Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)","Completed","No Results Available","Non-small-cell Lung Cancer","Drug: Docetaxel/Cisplatin|Drug: Docetaxel|Drug: Gemcitabine/Cisplatin|Drug: Docetaxel/Cisplatin","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GECP-SCAT|EudraCT Code: 2007-000067-15","May 24, 2007","June 2007","July 2015","July 3, 2015","July 2015","No Study Results Posted","GECP-SCAT","June 2015","Evaluate overall survival|Evaluate the disease-free survival, pattern of recurrences, toxicity profile and potential genetic markers of response and/or resistance to treatment.","https://ClinicalTrials.gov/show/NCT00478699"
2088,"NCT01734798","Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer","Completed","No Results Available","Locally Advanced Bladder Cancer","Radiation: Radiation|Drug: gemcitabine and cisplatin|Other: Radiotherapy and Drug","Cairo University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Bladder-02","November 19, 2012","December 2002","November 2012","November 22, 2012","November 2012","No Study Results Posted","null","January 2008","Comparison of the disease-free survival and overall survival of post-operative radiotherapy , adjuvant chemotherapy and the combined modalities [radiotherapy and chemotherapy] after radical cystectomy|comparison of the Local recurrence rate in the three Arms","https://ClinicalTrials.gov/show/NCT01734798"
2089,"NCT02444949","A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma","Enrolling by invitation","No Results Available","Nasopharyngeal Neoplasms","Drug: endostar|Radiation: intensity modulated radiation|Drug: cisplatin","China Three Gorges University, Yichang, China","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTGU1501","April 7, 2015","June 2014","June 2017","May 14, 2015","March 2015","No Study Results Posted","null","June 2017","Progression-free Survival|Overall response rate|Adverse effects as assessed by adverse events|Overall survival|Quality of Life measured by the ECDG score","https://ClinicalTrials.gov/show/NCT02444949"
2090,"NCT01840579","Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)","Recruiting","No Results Available","Solid Tumor|Non-small Cell Lung Cancer|Small Cell Lung Cancer","Biological: Pembrolizumab 2 mg/kg|Biological: Pembrolizumab 10 mg/kg|Biological: Pembrolizumab 200 mg|Drug: Cisplatin 75 mg/m^2|Drug: Pemetrexed 500 mg/m^2|Drug: Carboplatin AUC 5 mg/mL/min|Drug: Carboplatin AUC 6 mg/mL/min|Drug: Paclitaxel 200 mg/m^2|Drug: Nab-paclitaxel 100 mg/m^2|Biological: Ipilimumab 1 mg/kg|Drug: Etoposide 100 mg/m^2","Merck Sharp & Dohme Corp.","All","20 Years and older   (Adult, Senior)","Phase 1","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","3475-011|132249","April 23, 2013","April 26, 2013","June 22, 2019","April 6, 2017","April 2017","No Study Results Posted","null","June 22, 2019","Number of participants experiencing dose-limiting toxicities (DLTs)","https://ClinicalTrials.gov/show/NCT01840579"
2091,"NCT00611962","Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin","Completed","No Results Available","Neoplasms, Germ Cell and Embryonal","Drug: Oxaliplatin, Paclitaxel","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC_7407","January 28, 2008","December 2000","March 2004","January 28, 2008","January 2008","No Study Results Posted","null","null","Evaluate efficacy of oxaliplatin-paclitaxel combination using established criteria in metastatic germ cell cancer patients|Evaluate safety, and toxicity using established criteria,specific neurotoxicity scales, serious adverse events (SAEs) and treatment withdrawals","https://ClinicalTrials.gov/show/NCT00611962"
2092,"NCT00169572","Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy","Completed","No Results Available","Nausea and Vomiting|Chemotherapy-Induced","Drug: Aprepitant|Drug: Ondansetron|Drug: GW679769|Drug: Dexamethasone","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","492","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","NKV20001","September 9, 2005","February 2005","null","May 6, 2010","May 2010","No Study Results Posted","null","null","The number of subjects who do not experience vomiting, retching or nausea over a 5 day period following the initiation of chemotherapy.|Routine physical exam findings, vital signs, routine clinical laboratory tests, clinical monitoring and/or observation, and adverse events reporting.","https://ClinicalTrials.gov/show/NCT00169572"
2093,"NCT02672865","Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer","Recruiting","No Results Available","Locally Advanced Malignant Neoplasm|Gastric Cancer","Procedure: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","Loma Linda University","All","18 Years to 75 Years   (Adult, Senior)","","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5150301","February 2, 2016","December 2015","December 2018","September 12, 2016","September 2016","No Study Results Posted","null","July 2018","Post Operative Complications","https://ClinicalTrials.gov/show/NCT02672865"
2094,"NCT00933673","New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: L-asp, DXM, IFO, VP-16, DDP","Fudan University","All","14 Years to 75 Years   (Child, Adult, Senior)","Phase 2","76","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LMTG 09-02","July 6, 2009","June 2009","June 2012","February 16, 2012","February 2012","No Study Results Posted","null","June 2012","complete response rate|Overall response rate, PFS and OS","https://ClinicalTrials.gov/show/NCT00933673"
2095,"NCT00568607","Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: IFO, VP-16, DDP, DXM","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DICE-NK/T","December 5, 2007","March 2007","December 2010","September 7, 2010","September 2010","No Study Results Posted","null","December 2010","Response rate|TTP and OS","https://ClinicalTrials.gov/show/NCT00568607"
2096,"NCT01720563","A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy","Terminated","No Results Available","Cancer-related Fatigue","Drug: Astragalus polysaccharides 500 mg|Drug: Placebo|Procedure: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks","PhytoHealth Corporation","All","20 Years to 70 Years   (Adult, Senior)","Phase 2","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PH-CP021","October 29, 2012","December 2012","April 2014","November 3, 2015","November 2015","No Study Results Posted","null","April 2014","Fatigue status by Brief Fatigue Inventory (BFI)|Symptoms/Quality of Life Assessments by EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 and H&N 35 questionnaires|Karnofsky Performance Scale (KPS)|Incidences of myelosuppression|Serum inflammatory cytokines and c-reactive protein|Weight loss|Incidence of adverse events|Tumor response","https://ClinicalTrials.gov/show/NCT01720563"
2097,"NCT01424839","Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors","Recruiting","No Results Available","Intracranial Germ Cell Tumors","Radiation: craniospinal irradiation|Drug: Carboplatin, Etoposide, Ifosfamide|Radiation: ventricular irradiation|Drug: Cisplatin, etoposide, Ifosfamide (standard)|Drug: Cisplatin, Etoposide, Ifosfamide (high dose)|Radiation: focal irradiation","University Hospital Muenster|Deutsche Kinderkrebsstiftung|Hannover Medical School|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany","All","Child, Adult, Senior","Phase 4","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UKM08_0057|2009-018072-33","August 11, 2011","October 2011","October 2018","June 3, 2015","June 2015","No Study Results Posted","SIOPCNSGCTII","October 2018","survival|short and long term toxicity|overall survival","https://ClinicalTrials.gov/show/NCT01424839"
2098,"NCT00775385","TAilored Post-Surgical Therapy in Early Stage NSCLC","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Standard Chemotherapy|Drug: Customized Treatment","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IFCT-0801|Eudract : 2008-004939-38","October 17, 2008","April 2009","January 21, 2016","March 1, 2017","March 2017","No Study Results Posted","TASTE","April 2013","Feasibility (% of patients having started the treatment before 2 months after the surgery, with the biological results EGFR and ERCC1)|Disease-free Survival","https://ClinicalTrials.gov/show/NCT00775385"
2099,"NCT00448240","Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer","Terminated","No Results Available","Head and Neck Cancer|Carcinoma, Squamous Cell","Drug: Erlotinib","Henry Ford Health System|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HFHS 05-03","March 14, 2007","February 2007","January 2015","February 1, 2010","January 2009","No Study Results Posted","null","January 2012","Response Rate|Toxicity|Median Survival|Progression-free Survival","https://ClinicalTrials.gov/show/NCT00448240"
2100,"NCT01059552","Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","Active, not recruiting","No Results Available","Locally Advanced Non-small Cell Lung Cancer","Drug: vorinostat","Fox Chase Cancer Center|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FER-TH-031|NCI-2010-01913","January 28, 2010","December 6, 2009","December 1, 2017","January 24, 2017","January 2017","No Study Results Posted","NSCLC","December 1, 2017","To assess that safety and maximally tolerated dose of vorinostat in combination with chemoradiation for unresectable locally advanced NSCLC.|To investigate progression free survival.|To evaluate response rates with this combination|To assess if pre-treatment tumor expression of TS, ERCC1 and HDAC1, 2, 3 are associated with response rate.","https://ClinicalTrials.gov/show/NCT01059552"
2101,"NCT01828736","Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma","Completed","No Results Available","Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder","Biological: Trastuzumab|Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin","Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","61","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CVH-CT 02","April 4, 2013","February 9, 2004","February 23, 2010","February 3, 2017","February 2017","No Study Results Posted","CVH-CT02","February 23, 2010","Progression Free survival|Objective response rate|Number of participants with adverse events as a measure of safety and tolerability|Quality of life|Overall survival","https://ClinicalTrials.gov/show/NCT01828736"
2102,"NCT01096368","Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma","Recruiting","No Results Available","Childhood Infratentorial Ependymoma|Childhood Supratentorial Ependymoma|Newly Diagnosed Childhood Ependymoma","Drug: liposomal vincristine sulfate|Other: clinical observation|Radiation: 3-dimensional conformal radiation therapy|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: cisplatin|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0831|NCI-2011-02029|COG-ACNS0831|CDR0000668560|U10CA098543","March 30, 2010","March 2010","null","August 30, 2016","August 2016","No Study Results Posted","null","March 2020","Event-free survival (EFS) defined as time to the first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause|Overall survival (OS)|EFS and OS of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by post-operative induction chemotherapy or by second surgery|EFS and OS of children with supratentorial classic ependymoma who achieve a complete resection at first or second surgery or children who achieve a CR after induction chemotherapy assigned to observation|Neurologic, neuropsychological, and endocrine long-term sequelae of surgery, conformal radiotherapy, and maintenance chemotherapy|Gene expression signatures and genomic alterations in pediatric ependymoma","https://ClinicalTrials.gov/show/NCT01096368"
2103,"NCT02195453","Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer","Unknown status","No Results Available","Non-Small Cell Lung Cancer","Drug: Yangzhengxiaoji Capsule|Drug: Placebo Capsule","Shandong Cancer Hospital and Institute|Beijing Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","yl-yxb08-lcsyfa-201302","July 7, 2014","August 2014","December 2016","July 17, 2014","July 2014","No Study Results Posted","null","September 2016","Functional Assessment of Cancer Therapy-Lung scale|Lung Cancer Symptom Scale|Anti-cancer drugs common grading evaluation of adverse reaction|Completion of chemotherapy|Objective response rate|Progression-free survival","https://ClinicalTrials.gov/show/NCT02195453"
2104,"NCT00697905","Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma","Completed","No Results Available","Nasopharyngeal Carcinoma","Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin|Drug: 5-fluorouracil (5-FU)","Ministry of Health, Malaysia","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT 06-01","June 12, 2008","January 2008","May 2011","November 20, 2014","April 2010","No Study Results Posted","null","May 2011","The primary efficacy variable is response to therapy. Response will be evaluated using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.|Progression free survival defined as the duration of time from start of treatment to time of disease progression or death, whichever occurs first.|Duration of response defined as the interval between the first documented response (CR or PR) and the first documented sign of disease progression or death, whichever occurs first.|Safety and tolerability assessments will consist of 1.Monitoring and recording all AE and SAE, 2.Regular monitoring of hematology, blood chemistry and urinary laboratory parameters, 3.Regular performance of physical examinations, including vital signs","https://ClinicalTrials.gov/show/NCT00697905"
2105,"NCT02937519","Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer","Recruiting","No Results Available","Esophageal Neoplasms [C06.405.117.430]","Device: Chrono-chemotherapy pump:Melodie|Device: Routine intravenous drip|Drug: induction Chrono-chemotherapy|Drug: induction Routine-chemotherapy|Drug: cisplatin chrono-chemotherapy|Drug: cisplatin routine-chemotherapy|Radiation: intensity-modulated radiation therapy","Guiyang Medical University|The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016080201","August 16, 2016","June 2015","June 2018","October 16, 2016","October 2016","No Study Results Posted","null","June 2018","Number of Participants with curative effect|Number of Participants with Adverse Events as a Measure of Safety|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02937519"
2106,"NCT01427478","Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: AFATINIB|Drug: Placebo of AFATINIB","Centre Leon Berard|Boehringer Ingelheim","All","18 Years and older   (Adult, Senior)","Phase 3","315","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","BIBW2992 ORL|2010-023265-22","August 31, 2011","September 2011","September 2021","February 22, 2017","February 2017","No Study Results Posted","BIBW2992ORL","September 2018","Disease Free Survival 2 years after the end of radiotherapy|Safety profile|Quality of life|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01427478"
2107,"NCT00398424","Evaluating Patients With Impaired Hepatic Function","Completed","No Results Available","Impaired Hepatic Function","Drug: S-1/Cisplatin","Taiho Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TPU-S1112","November 8, 2006","February 2006","March 2009","August 6, 2009","August 2009","No Study Results Posted","null","November 2008","To provide specific dosing recommendations for S-1 in patients with hepatic impairment based on the PK of S-1 and its components after single dose and during steady state condition|To assess the antitumor activity and safety profile of S-1 in patients with impaired hepatic function","https://ClinicalTrials.gov/show/NCT00398424"
2108,"NCT00398307","Evaluating Patients With Varying Degrees of Renal Function","Completed","No Results Available","Renal Impairment","Drug: S-1/Cisplatin","Taiho Oncology, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TPU-S1111","November 8, 2006","February 2006","September 2010","April 7, 2011","April 2011","No Study Results Posted","null","September 2010","To provide specific dosing recommendations for S-1 in patients with renal impairment based on the PK of S-1 and its components after single dose and steady state conditions.|Assess Anti-tumor activity, and safety profile of S-1 in patients with impaired renal function","https://ClinicalTrials.gov/show/NCT00398307"
2109,"NCT02504229","DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment","Recruiting","No Results Available","Gastric Cancer","Biological: autologous dendritic cells co-cultured with cytokine-induced killer cells|Drug: Gimeracil and Oteracil Porassium Capsules|Drug: Oxaliplatin","Beijing Biohealthcare Biotechnology Co.,Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GC-A-004","July 20, 2015","November 2014","null","July 20, 2015","July 2015","No Study Results Posted","null","July 2018","Progression free survival","https://ClinicalTrials.gov/show/NCT02504229"
2110,"NCT00785421","Chemotherapy With or Without Enoxaparin in Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: enoxaparin|Drug: chemotherapy with LMWH - enoxaparin|Drug: only chemotherapy","CONKO-Studiengruppe|Sanofi|Amgen|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","312","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CONKO 004|CCT-NAPN-16752","November 4, 2008","April 2004","June 2009","January 7, 2015","January 2015","No Study Results Posted","PROSPECT","January 2009","DVT/TVE event rate|TTP, OS, side effects","https://ClinicalTrials.gov/show/NCT00785421"
2111,"NCT00042835","Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer","Terminated","No Results Available","Adenocarcinoma of the Lung|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: erlotinib hydrochloride|Radiation: radiation therapy|Drug: docetaxel|Drug: paclitaxel|Drug: carboplatin|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","48","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","NCI-2012-02478|11432B|N01CM17102|N01CM62201|CDR0000069474","August 5, 2002","May 2002","null","January 31, 2013","January 2013","No Study Results Posted","null","December 2008","MTD defined as the dose at which at least 2 of 6 patients experience dose-limiting toxicity assessed using NCI CTCAE version 3.0|Response assessed using RECIST|Level of EGFR expression","https://ClinicalTrials.gov/show/NCT00042835"
2112,"NCT02337530","Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Selumetinib|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin","Canadian Cancer Trials Group|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","I219","January 9, 2015","February 5, 2015","February 2018","May 8, 2017","March 2017","No Study Results Posted","null","December 2017","Efficacy determined by objective response rate|Severity of adverse events in patients|Progression free survival","https://ClinicalTrials.gov/show/NCT02337530"
2113,"NCT00911092","Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Procedure: Blood sampling|Radiation: Radiation|Drug: Chemotherapy (Fluorouracil and Cisplatin)","Centre Oscar Lambret","All","18 Years and older   (Adult, Senior)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","2006-13","May 29, 2009","October 2007","December 2011","December 30, 2011","December 2011","No Study Results Posted","COL06-13","September 2011","Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry|Initial complete clinical response|Prolonged clinical response at one year","https://ClinicalTrials.gov/show/NCT00911092"
2114,"NCT02368990","T790M Mutation Positive 2nd Line STandard of cAre Registry","Withdrawn","No Results Available","Non Small Cell Lung Cancer","","AstraZeneca|Parexel","All","18 Years and older   (Adult, Senior)","","0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","D5160R00001","January 29, 2015","June 2015","June 2018","July 6, 2015","July 2015","No Study Results Posted","T-STAR","June 2018","Overall Survival|Response to Therapy as assessed by the physician|Time on treatment by line of therapy and between therapies|Admission of planned/unplanned hospitalizations, emergency department visits and outpatient/physician visits|Time to symptom deterioration|Symptom Improvement Rate|Duration of Response as defined by the physician|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02368990"
2115,"NCT00201344","A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients","Terminated","No Results Available","Nasopharyngeal Carcinoma","Drug: Cisplatin,5-FU,Leucovorin","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Tri-Service General Hospital|Kaohsiung Medical University|Kaohsiung Veterans General Hospital.|Taipei Veterans General Hospital, Taiwan|Mackay Memorial Hospital","All","up to 70 Years   (Child, Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1394","September 13, 2005","November 1994","January 2000","March 25, 2010","June 2009","No Study Results Posted","null","null","overall survival, relapse free survival,distant metastasis and local-regional control rates.|toxicities of the two treatment methods.","https://ClinicalTrials.gov/show/NCT00201344"
2116,"NCT00405405","Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer|Parotid Gland Cancer|Thyroid Gland Cancer|Melanoma|Stage IV Head and Neck Cancer","Drug: Cisplatin|Drug: Docetaxel|Drug: Bevacizumab|Drug: Erlotinib|Radiation: Radiotherapy","Sidney Kimmel Cancer Center at Thomas Jefferson University|Genentech, Inc.|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06C.46|2005-58","November 29, 2006","December 2006","June 2010","October 19, 2016","October 2016","No Study Results Posted","null","June 2010","Bevacizumab and Erlotinib Combined with Chemoradiotherapy for the Treatment of Advanced Head and Neck Cancer|Determination of Dose Limiting Toxicity (DTL)|Complete Remission Rate","https://ClinicalTrials.gov/show/NCT00405405"
2117,"NCT01693718","A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck","Drug: Hydroxyurea|Drug: 5- Fluorouracil|Drug: Cisplatin","University of Chicago","All","59 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12141B","August 20, 2010","March 2003","September 2004","September 4, 2013","September 2013","No Study Results Posted","null","September 2003","Response Rates|Feasibility of administering adjuvant CRA and interferon alfa2a|Side effects of study regimen","https://ClinicalTrials.gov/show/NCT01693718"
2118,"NCT00454636","A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.","Completed","Has Results","Gastric Cancer","Drug: Cisplatin|Drug: Capecitabine|Drug: Epirubicin|Drug: Cisplatin|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Docetaxel|Drug: Capecitabine","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","158","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20777","March 30, 2007","March 2007","July 2010","August 23, 2016","August 2016","July 12, 2016","null","July 2010","Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS)|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Duration of Response|Time to Response","https://ClinicalTrials.gov/show/NCT00454636"
2119,"NCT01579630","Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy","Unknown status","No Results Available","NSCLC","Drug: Pemetrexed 500mg/m2 iv|Drug: Pemetrexed 500mg/m2 iv and Gefitinib 250 mg","Taipei Veterans General Hospital, Taiwan|National Taiwan University Hospital|Taichung Veterans General Hospital|China Medical University Hospital|Dalin Tzu Chi General Hospital|Tri-Service General Hospital","All","20 Years and older   (Adult, Senior)","Phase 2|Phase 3","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D7913L00077","April 12, 2012","March 2011","June 2014","April 3, 2014","April 2014","No Study Results Posted","null","June 2013","Progression free survival|Overall objective tumour response","https://ClinicalTrials.gov/show/NCT01579630"
2120,"NCT02875314","HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","Recruiting","No Results Available","Medulloblastoma|Central Nervous System Embryonal Tumors","Drug: Induction|Drug: Single Cycle Intensive Chemotherapy|Drug: Tandem 3 Cycle Intensive Chemotherapy","Nationwide Children's Hospital|Children's Hospital Los Angeles","All","up to 10 Years   (Child)","Phase 4","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB15-00399","April 27, 2016","September 2015","September 2020","February 6, 2017","February 2017","No Study Results Posted","null","September 2020","Compare tandem consolidation vs. single cycle consolidation A|Compare tandem consolidation vs. single cycle consolidation B|Induction Cycle Reduction|Uniform Treatment Regimen|Therapy-Related Hearing Loss Evaluation A|Therapy-Related Hearing Loss Evaluation B|Neuropsychological effects will be evaluated using age based tests and questionnaires.|Endocrine studies will be conducted using Serum-free T4, TSH, Cortisol, IGF and IGFBP3 laboratory tests.|Physical growth will be evaluated by collecting patient's height, weight and BSA.|The development of second neoplasms will be monitored.|Neuropathology Biorepository and Clinical Database","https://ClinicalTrials.gov/show/NCT02875314"
2121,"NCT00828841","Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Cetuximab|Drug: Paclitaxel|Drug: Carboplatin|Drug: Gemcitabine|Drug: Cisplatin","Accelerated Community Oncology Research Network","All","18 Years and older   (Adult, Senior)","Phase 2","601","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AC01L08","January 23, 2009","December 2008","August 2012","October 11, 2013","October 2013","August 7, 2013","null","July 2012","Overall Survival by Treatment Arm|1-year Survival by Treatment Arm|Overall Survival by Histology","https://ClinicalTrials.gov/show/NCT00828841"
2122,"NCT02861872","Intra-peritoneal Chemotherapy in Ovarian Cancer","Recruiting","No Results Available","Ovarian Neoplasms|Immune Tolerance|Neoplasms|Effects of Chemotherapy","","Radboud University","Female","18 Years to 70 Years   (Adult, Senior)","","15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MOGYN16IP","July 20, 2016","July 2016","December 2017","August 4, 2016","July 2016","No Study Results Posted","null","December 2017","Primary immunological endpoint: study the use of aspiration fluid from the IP cavity as a biomarker for the efficacy of chemotherapy intervention, measured by decrease in tumor cell count in IP fluid.|Primary pharmacokinetic endpoint: study pharmacokinetics of cisplatin (platinum unbound fraction) when administered in the IP cavity in plasma and in the peritoneal fluid.|Primary pharmacokinetic endpoint: study pharmacokinetics of paclitaxel (plasma concentrations) when administered in the IP cavity in plasma and in the peritoneal fluid.|Secondary immunological endpoint: rise in dendritic cells|Secondary immunological endpoint: rise in tumor infiltrating lymphocytes|Secondary immunological endpoint: rise in natural killer cells|Secondary immunological endpoint: decrease in macrophages M1 type|Secondary immunological endpoint: decrease in macrophages M2 type|Secondary immunological endpoint: change in cytokine level (IL-6) measured by ELISA|Secondary immunological endpoint: change in cytokine level (IL-10) measured by ELISA|Secondary immunological endpoint: change in cytokine level (IFNg) measured by ELISA|Secondary immunological endpoint: change in cytokine level (TNFa) measured by ELISA|Secondary immunological endpoint: change in cytokine level (CCL2) measured by ELISA|Primary immunological endpoint: study the use of aspiration fluid from the IP cavity as a biomarker for the efficacy of chemotherapy intervention, measured by decrease in pSTAT in IP fluid.","https://ClinicalTrials.gov/show/NCT02861872"
2123,"NCT02812641","Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC","Recruiting","No Results Available","Stage III Esophageal Squamous Cell Carcinoma","Drug: BPF-CCRT (run-in)|Drug: BPF-CCRT (randomized)|Drug: PF-CCRT (randomized)","National Taiwan University Hospital","All","20 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201511008MINC","June 13, 2016","June 2016","December 2021","June 27, 2016","June 2016","No Study Results Posted","null","December 2019","Dose-limiting toxicity (run-in phase)|Pathological complete response rate (randomized phase)|Acute toxicity|Late toxicity|Patient reported outcome (Quality of Life questionnaire of cancer patients)|Patient reported outcome (Quality of Life questionnaire of esophageal cancer patients)|Image response|Metabolic Image response|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02812641"
2124,"NCT00226473","Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma","Unknown status","No Results Available","Metastatic Melanoma","Drug: Cisplatin, Vindesine, Dacarbazine (drugs)","Dermatologic Cooperative Oncology Group","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ADO-MM-PAL8","September 25, 2005","September 2001","September 2005","June 20, 2006","September 2005","No Study Results Posted","null","null","Overall survival|Quality of life analysis|Objective tumor response rate in study arm B|Time to tumor progression|Cost analysis","https://ClinicalTrials.gov/show/NCT00226473"
2125,"NCT00112996","Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer","Completed","No Results Available","Neurotoxicity|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: alpha-lipoic acid|Other: placebo","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","244","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","CDR0000403155|MDA-CCC-0327|MDA-2004-0728|2004-0728|NCI-2009-00636|3U10CA045809-15S1","June 2, 2005","January 2007","April 2014","April 7, 2014","April 2014","No Study Results Posted","null","April 2014","Severity of neuropathy|Group Differences in Change scores|Number of courses received|Optimal tumor response","https://ClinicalTrials.gov/show/NCT00112996"
2126,"NCT02572843","Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)","Recruiting","No Results Available","NSCLC Non-small Cell Lung Cancer","Drug: MEDI4736 (anti-PD-L1)","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","68","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SAKK 16/14|000001480","October 1, 2015","March 2016","December 2021","March 3, 2017","March 2017","No Study Results Posted","null","March 2021","Event-free survival (EFS)|Overall survival (OS)|Objective response (OR) after neoadjuvant chemotherapy|OR after neoadjuvant immunotherapy|Pathological responses (pCR)|Adverse Events (AEs) (according to NCI CTCAE v4.0)","https://ClinicalTrials.gov/show/NCT02572843"
2127,"NCT02579616","Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy","Active, not recruiting","No Results Available","Biliary Tract Cancer","Drug: Lenvatinib","Eisai Co., Ltd.|Eisai Inc.","All","20 Years and older   (Adult, Senior)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","E7080-J081-215","October 16, 2015","October 2015","October 2017","November 8, 2016","November 2016","No Study Results Posted","null","July 2017","Objective response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Disease control rate (DCR)|Clinical benefit rate (CBR)|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Blood concentration","https://ClinicalTrials.gov/show/NCT02579616"
2128,"NCT02467426","Isolated Thoracic Perfusion (ITP-F) for MPM","Completed","No Results Available","Mesothelioma","Drug: Chemotherapy","Medias Klinikum for Surgical Oncology","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","23","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","0001","May 26, 2015","September 2009","May 2015","June 9, 2015","June 2015","No Study Results Posted","null","January 2015","Survival|Toxicity","https://ClinicalTrials.gov/show/NCT02467426"
2129,"NCT00139230","Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck","Completed","No Results Available","Squamous Cell Carcinoma|Carcinoma of Head/Neck","Drug: Taxotere|Drug: Cisplatin|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: G-CSF|Drug: Ciprofloxacin","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","96-184","August 29, 2005","January 1997","December 2006","June 2, 2008","June 2008","No Study Results Posted","null","December 2006","To evaluate the safety of a four day regimen of taxotere, cisplatin, 5-fluorouracil and high-dose leucovorin with growth factor support and ciprofloxacin.|To determine the efficacy of this regimen in patients with advances, previously untreated squamous cell carcinoma of the head and neck.","https://ClinicalTrials.gov/show/NCT00139230"
2130,"NCT01969578","Androgen Deprivation Therapy in Advanced Salivary Gland Cancer","Recruiting","No Results Available","Salivary Gland Cancer","Drug: bicalutamide + triptorelin|Drug: Cisplatin + Doxorubicin|Drug: Carboplatin + Paclitaxel","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EORTC-1206|2013-000314-38","September 24, 2013","February 2015","December 2020","March 15, 2017","March 2017","No Study Results Posted","null","December 2020","Progression Free Survival (PFS)|Response rate (RR)|Response Rate (RR)","https://ClinicalTrials.gov/show/NCT01969578"
2131,"NCT00198432","Chemoradiotherapy of NSCLC Stage IIIB","Completed","No Results Available","NSCLC Stage IIIB|Concomitant Radiochemotherapy","Drug: Paclitaxel, vinorelbine, cisplatin","Intergroupe Francophone de Cancerologie Thoracique|Bristol-Myers Squibb|Pierre Fabre Laboratories|Ligue contre le cancer, France","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","130","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-0201","September 13, 2005","March 2002","December 2006","March 9, 2016","March 2016","No Study Results Posted","null","null","Objective response rate|Overall survival|Time to progression|Relapse rate (local control)|Safety","https://ClinicalTrials.gov/show/NCT00198432"
2132,"NCT00162721","The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas","Unknown status","No Results Available","Uterine Sarcoma","Drug: doxorubicin, ifosfamide, cisplatin","Gustave Roussy, Cancer Campus, Grand Paris","Female","18 Years to 65 Years   (Adult)","Phase 3","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SARC-GYN1","September 9, 2005","September 2001","null","August 9, 2007","August 2007","No Study Results Posted","null","null","Effects of the addition of an adjuvant chemotherapy to adjuvant pelvic radiotherapy on a 3 year event-free survival in the treatment of localized uterine sarcomas|Effects of the addition of an adjuvant chemotherapy to adjuvant pelvic radiotherapy on overall survival|Evaluation of global toxicity of the treatment in each arm","https://ClinicalTrials.gov/show/NCT00162721"
2133,"NCT01192230","Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Endostatins|Drug: Docetaxel","Fudan University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EndoDocNSCLC","August 4, 2010","June 2009","null","September 15, 2010","August 2010","No Study Results Posted","null","December 2011","Response rate|Progression free survival|Overall survival|Quality of Life","https://ClinicalTrials.gov/show/NCT01192230"
2134,"NCT00637624","N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Mesothelioma","Drug: N-Acetylcysteine|Drug: Placebo","Rijnstate Hospital","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","LTC-510-100108-Bahce|CCMO: NL19614.091.07|EudraCT: 2007-002787-95","March 11, 2008","March 2008","February 2012","August 8, 2011","August 2011","No Study Results Posted","NAC-PNP","December 2011","The occurrence of peripheral neuropathy: with the peripheral neuropathy score (PNP-score) and the electrophysiological measurements. If no EMG is available, then audiometric measurements will be taken into account.|haematological abnormalities|creatinine clearance.|liver chemistry abnormalities|Karnofski Performance Score|Quality of life","https://ClinicalTrials.gov/show/NCT00637624"
2135,"NCT00883480","Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Docetaxel|Drug: Docetaxel-Cisplatin|Drug: Gemcitabine-Cisplatin|Drug: Erlotinib","Spanish Lung Cancer Group","All","18 Years and older   (Adult, Senior)","","153","Other","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","SLAT","December 22, 2008","June 2005","November 2008","April 16, 2009","April 2009","No Study Results Posted","SLAT","January 2008","Tumoral Response (RECIST criteria)|Overall Survival","https://ClinicalTrials.gov/show/NCT00883480"
2136,"NCT03082586","Radiation Dose Escalation in Esophageal Cancer","Recruiting","No Results Available","Esophageal Cancer","Radiation: radiochemotherapy 1|Radiation: radiochemotherapy 2|Radiation: radiochemotherapy 3|Radiation: radiochemotherapy 4|Radiation: radiochemotherapy 5|Radiation: radiochemotherapy 6","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","SGH201705","March 13, 2017","November 20, 2016","January 20, 2019","April 10, 2017","April 2017","No Study Results Posted","null","January 20, 2018","Maximum Tolerated Dose|Time to Local Failure","https://ClinicalTrials.gov/show/NCT03082586"
2137,"NCT00312819","Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: chemotherapy +/- disulfiram","Hadassah Medical Organization|Augusta Hospital, Berlin","Female","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DVC1.03-HMO-CTIL","April 10, 2006","March 2006","December 2009","August 30, 2010","February 2009","No Study Results Posted","null","December 2009","tumor response disease free survival survival|Clinical response|treatment tolerance","https://ClinicalTrials.gov/show/NCT00312819"
2138,"NCT00070629","CPG 7909 Injection in Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small Cell Lung","Drug: CPG 7909|Drug: Chemotherapy|Drug: Chemotherapy","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","116","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C017|ProMune|CO17|A8501017","October 6, 2003","May 2003","July 2007","February 9, 2009","February 2009","No Study Results Posted","null","null","Efficacy- overall response rate (CR & PR) according to the RECIST criteria|Safety- drug exposure, adverse events, laboratory tests, vital signs, ECG, and physical examinations|Secondary Efficacy|compare number of patients who achieve complete response, partial response, or stable disease (CR, PR, SD) between the two treatment groups|duration of overall response (CR, PR), survival time, and time to disease progression.|To assess the immunopharmacodynamic response to CPG 7909 Injection plus chemotherapy in responding vs nonresponding patients receiving chemotherapy or the combination.","https://ClinicalTrials.gov/show/NCT00070629"
2139,"NCT00392327","Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma","Recruiting","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Pineoblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Radiation: Radiation Therapy|Drug: Vincristine Sulfate|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0332|NCI-2009-00336|COG-ACNS0332|CDR0000511991|R01CA114567|U10CA180886|U10CA098543","October 25, 2006","March 2007","null","August 19, 2016","August 2016","No Study Results Posted","null","June 2018","Event-free survival (EFS) percentage|Tumor response to radiation therapy with or without carboplatin|Time to death","https://ClinicalTrials.gov/show/NCT00392327"
2140,"NCT02258659","Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer","Active, not recruiting","No Results Available","Human Papilloma Virus Infection|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx","Drug: paclitaxel albumin-stabilized nanoparticle formulation|Drug: carboplatin|Radiation: radiation therapy|Drug: paclitaxel|Drug: fluorouracil|Drug: hydroxyurea|Drug: cisplatin|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment","University of Chicago|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","62","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB14-0639|NCI-2014-01867|P30CA014599","September 19, 2014","September 2014","null","May 10, 2017","May 2017","No Study Results Posted","OPTIMA","August 2017","PFS, evaluated using RECIST version (v) 1.1|Rate of pathologic complete response on post treatment biopsy/surgery, evaluated using RECIST v1.1|Clinical complete response by positron emission tomography, evaluated using RECIST v1.1|Overall survival|Cancer-specific survival|Rates of acute toxicity, determined by incidence of mucositis, xerostomia, anorexia, weight loss, dermatitis and G-tube placement|Rates of late toxicity, determined by incidence of xerostomia, dental decay, osteroradionecrosis, G-tube dependency, tracheostomy placement and dysphagia","https://ClinicalTrials.gov/show/NCT02258659"
2141,"NCT03159143","Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract","Completed","No Results Available","Metastatic Transitional Cell Cancer of the Urothelial Tract","Drug: Docetaxel|Drug: Oxaliplatin","University of Pittsburgh|Sanofi-Synthelabo","All","18 Years and older   (Adult, Senior)","Phase 2","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UPCI 04-055","May 8, 2017","December 17, 2004","December 2, 2009","May 17, 2017","May 2017","No Study Results Posted","null","June 2, 2009","Response Rate|Progression Free Survival|Disease Free Survival|Overall Survival|Incidence of Treatment-Emergent Adverse Events of IV docetaxel in combination with IV oxaliplatin","https://ClinicalTrials.gov/show/NCT03159143"
2142,"NCT02178241","Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery","Active, not recruiting","No Results Available","Metastatic Ureteral Neoplasm|Metastatic Urethral Neoplasm|Stage III Bladder Urothelial Carcinoma|Stage III Ureter Cancer|Stage III Urethral Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Ureter Cancer|Stage IV Urethral Cancer|Ureter Urothelial Carcinoma|Urethral Urothelial Carcinoma","Drug: Eribulin Mesylate|Drug: Gemcitabine Hydrochloride","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","21","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-01294|P9653_A02PAMDREVW01|PHII-130|9653|N01CM00038|P30CA093373","June 26, 2014","December 11, 2014","null","May 23, 2017","May 2017","No Study Results Posted","null","December 31, 2017","Objective response rate defined as either a confirmed complete response (CR) or a confirmed partial response (PR) based on RECIST version 1.1|Incidence of adverse events as graded by the CTCAE v. 4|Overall response rate (ORR)|Overall survival|PFS using RECIST v1.1","https://ClinicalTrials.gov/show/NCT02178241"
2143,"NCT01118039","Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer","Unknown status","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: sunitinib malate|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: quality-of-life assessment","Hospital del Mar|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","HDM-SU-011248|CDR0000671673|EUDRACT-2005-005115-16|PFIZER-HDM-SU-011248","May 5, 2010","July 2006","null","August 6, 2013","September 2012","No Study Results Posted","null","December 2010","Time to disease progression|Safety|Progression-free survival|Overall response rate|Overall survival|Time to treatment failure|Pharmacodynamic profile|Quality of life","https://ClinicalTrials.gov/show/NCT01118039"
2144,"NCT00003852","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors","Terminated","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","UNICANCER","All","15 Years to 120 Years   (Child, Adult, Senior)","Phase 2","45","Other","Interventional","Primary Purpose: Treatment","CDR0000067015|FRE-FNCLCC-GETUG-04|EU-99004","November 1, 1999","March 1998","March 2000","June 22, 2016","June 2016","No Study Results Posted","null","March 2000","","https://ClinicalTrials.gov/show/NCT00003852"
2145,"NCT01104714","Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers","Completed","No Results Available","Carcinoma, Squamous Cell|Mouth Neoplasms|Oropharyngeal Neoplasms|Laryngeal Neoplasms|Hypopharyngeal Neoplasms","","Centre Hospitalier Universitaire de Nīmes","All","30 Years to 80 Years   (Adult, Senior)","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LOCAL/2008/BL-01|2008-006874-14","April 14, 2010","April 2010","July 2014","March 25, 2015","March 2015","No Study Results Posted","APPROCHE ORL","July 2014","%change in tumor volume before and after chemotherapy (baseline versus 62 days)","https://ClinicalTrials.gov/show/NCT01104714"
2146,"NCT00502463","Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial","Unknown status","No Results Available","Head and Neck Cancer","Procedure: radio-immunotherapy","Austrian South Oncology Group|Medical University of Graz","All","18 Years to 75 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ASOG-HNO1","July 15, 2007","June 2007","December 2013","July 30, 2009","July 2009","No Study Results Posted","ASOG-HNO1","February 2009","locoregional tumour control|response rate toxicity progression free survival","https://ClinicalTrials.gov/show/NCT00502463"
2147,"NCT00616109","Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC","Completed","Has Results","Extensive-Stage Small Cell Lung Cancer","Drug: sunitinib","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2007.034|HUM12046","February 4, 2008","September 2007","January 2011","March 13, 2014","March 2014","February 7, 2013","null","December 2009","Progression Free Survival Rate|Median Overall Survival|Percent of Patients With an Objective Response|Number of Patients That Discontinue Drug Due to Toxicity","https://ClinicalTrials.gov/show/NCT00616109"
2148,"NCT00452985","Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasms","Drug: Docetaxel|Drug: Carboplatin","Sanofi","Female","15 Years to 75 Years   (Child, Adult, Senior)","","30","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TAX_BD1_601","March 27, 2007","February 2002","November 2010","August 13, 2012","August 2012","No Study Results Posted","OCSTUD","November 2010","Measurements of the disease (assessed clinically and/or by CA-125)|Response rate|Clinical examination including neurologic examination, vital signs (blood pressure, heart rate, temperature), weight, assessment of any residual toxicity due to previous therapy, assessment of performance status.|Adverse events|Progression free survival|Overall survival|Biology and Hematology laboratory determinations","https://ClinicalTrials.gov/show/NCT00452985"
2149,"NCT00429754","Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)","Withdrawn","No Results Available","Nausea|Vomiting","Drug: Aprepitant","Radboud University|Merck Sharp & Dohme Corp.","Male","18 Years to 75 Years   (Adult, Senior)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCN-AKF 06.01","January 31, 2007","null","September 2008","January 25, 2016","January 2016","No Study Results Posted","null","null","Pharmacokinetic blood samples will be taken at day 2 at pre-dose,|at 1/2 hour after intake, at 1, 4, 6, 8 and 24 hours (is day 3) after intake of medication.|Also at day 5 at the same time points blood samples will be taken.|Nausea and vomiting questionnaires will be answered at day 1,2,3,4,5,6,8 en 15.","https://ClinicalTrials.gov/show/NCT00429754"
2150,"NCT00439426","A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.","Completed","No Results Available","Nasopharyngeal Cancer","Drug: Oxaliplatin|Drug: capecitabine [Xeloda]","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20508","February 22, 2007","April 2007","September 2009","November 1, 2016","November 2016","No Study Results Posted","null","September 2009","Overall response rate|Time to disease progression or death, survival time, duration of response, complete response rate.|AEs, laboratory parameters.","https://ClinicalTrials.gov/show/NCT00439426"
2151,"NCT02985255","Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue","Recruiting","No Results Available","Tongue Neoplasms|Squamous Cell Carcinoma|Anterior Tongue Squamous Cell Carcinoma","Drug: Docetaxel|Drug: Cisplatin|Drug: 5FU|Radiation: Radiotherapy|Procedure: Glossectomy","HealthCare Global Enterprise Ltd.","All","1 Year to 99 Years   (Child, Adult, Senior)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCG/SX/001/2016","September 29, 2016","April 2016","June 2017","December 2, 2016","December 2016","No Study Results Posted","null","June 2017","Tongue Preservation Rate|Overall Survival|Progression Free Survival|Sensitivity and Specificity of PET-CT","https://ClinicalTrials.gov/show/NCT02985255"
2152,"NCT00003994","Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer","Completed","No Results Available","Childhood Hepatoblastoma|Recurrent Childhood Liver Cancer|Stage I Childhood Liver Cancer","Procedure: therapeutic conventional surgery|Drug: cisplatin|Drug: vincristine sulfate|Drug: fluorouracil|Drug: amifostine trihydrate|Drug: carboplatin","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","277","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P9645|NCI-2012-02306|COG-P9645|CCG-P9645|POG-9645|CDR0000067200|U10CA098543","November 1, 1999","March 1999","null","June 13, 2013","June 2013","No Study Results Posted","null","October 2007","Event-free survival (EFS) rates|Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC)","https://ClinicalTrials.gov/show/NCT00003994"
2153,"NCT02167711","Treatment for Bile Duct Cancer in the Liver","Recruiting","No Results Available","Cholangio Carcinoma","Drug: SIRT Yttrium-90","Chinese University of Hong Kong","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BTC001","June 17, 2014","September 2014","October 2017","February 3, 2017","February 2017","No Study Results Posted","null","October 2017","Overall survival|Progression-free survival|Radiological response|disease control rate|Duration between timing of chemotherapy and SIRT-Y90|Rate and severity of toxicities|Serological response in CA 19.9","https://ClinicalTrials.gov/show/NCT02167711"
2154,"NCT01665417","Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma","Recruiting","No Results Available","EGFR Positive Non-small Cell Lung Cancer|Adenocarcinoma","Drug: Experimental|Drug: Chemotherapy|Drug: Chemotherapy","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BD-IC-IV08","August 12, 2012","August 2012","December 2017","February 7, 2017","February 2017","No Study Results Posted","null","July 2017","Progression-free survival|Overall survival|Time to Tumor Progression|Objective response rate|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01665417"
2155,"NCT00675597","Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)","Memorial Sloan Kettering Cancer Center|Sanofi","All","18 Years and older   (Adult, Senior)","","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-178","May 7, 2008","May 2008","February 2012","October 20, 2015","October 2015","October 20, 2015","null","February 2012","To Measure the Number of Cycles","https://ClinicalTrials.gov/show/NCT00675597"
2156,"NCT02016209","Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: nanoparticle albumin-bound paclitaxel","Zhejiang University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZYTOP1402","December 7, 2013","January 2014","March 2016","December 14, 2013","December 2013","No Study Results Posted","null","December 2015","Tumor response rate and Number of Adverse Events|disease free survival","https://ClinicalTrials.gov/show/NCT02016209"
2157,"NCT01612351","Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery","Active, not recruiting","No Results Available","Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck","Drug: Carboplatin|Drug: Paclitaxel|Drug: Lapatinib|Drug: Cisplatin|Drug: Cisplatin|Radiation: Ipsilateral Radiation|Radiation: Bilateral Radiation|Procedure: Transoral Surgery","UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1125","May 31, 2012","June 2012","August 2019","April 24, 2017","April 2017","No Study Results Posted","null","November 2016","Overall Response Rate|Feasibility of 3 part therapy|Post Induction Chemotherapy Changes in Risk Level|Progression Free Survival and Overall Survival|Voice and Swallowing Function|Number of subjects who experience adverse events","https://ClinicalTrials.gov/show/NCT01612351"
2158,"NCT00965172","Caphosol in Sarcoma Patients With Mucositis","Completed","No Results Available","Sarcoma|Oral Mucositis","Other: Caphosol|Other: Baking Soda","M.D. Anderson Cancer Center","All","16 Years to 65 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0276","August 21, 2009","April 2010","February 2012","March 20, 2012","March 2012","No Study Results Posted","null","February 2012","Incidence/Severity of Oral Mucositis WHO Grades 1, 2, 3, and 4","https://ClinicalTrials.gov/show/NCT00965172"
2159,"NCT00138658","A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Non-small Cell Lung Cancer","Drug: custirsen sodium","OncoGenex Technologies","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","85","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OGX-011-05","August 26, 2005","November 2004","March 2010","February 2, 2012","February 2012","October 6, 2011","null","March 2010","Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based Regimen|Progression-free Survival|Overall Survival|Effect of OGX-011 on Serum Clusterin Levels|Cmax of OGX-011|t1/2 of OGX-011|AUC-0-last","https://ClinicalTrials.gov/show/NCT00138658"
2160,"NCT00003231","Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: docetaxel|Procedure: surgical procedure|Radiation: radiation therapy","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Primary Purpose: Treatment","SAKK 16/96|SWS-SAKK-16/96|EU-97034","November 1, 1999","April 1997","September 2000","May 14, 2012","May 2012","No Study Results Posted","null","September 2000","","https://ClinicalTrials.gov/show/NCT00003231"
2161,"NCT01191892","Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer","Unknown status","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Ureter Cancer|Urethral Cancer","Drug: carboplatin|Drug: gemcitabine hydrochloride|Drug: vandetanib|Drug: Placebo","Wales Cancer Trials Unit|Cardiff University","All","18 Years and older   (Adult, Senior)","Phase 2","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDR0000684016|WCTU-TOUCAN|ISRCTN-68146831|EUDRACT-2009-010140-33|EU-21066|CRUK-09/024|WCTU-SPON-672-09|ZENECA-WCTU-TOUCAN","August 29, 2010","June 2010","December 2014","July 30, 2012","July 2012","No Study Results Posted","null","December 2013","Progression Free Survival|Tolerability and feasibility|Objective response rate as assessed by RECIST criteria|Overall survival|Change in size of measurable lesions 9 weeks after start of chemotherapy|Toxicity during and after treatment as assessed by NCI CTCAE v 4.0","https://ClinicalTrials.gov/show/NCT01191892"
2162,"NCT02074241","Molecular Markers of Chemosensitivity for Bladder Cancer","Enrolling by invitation","No Results Available","Bladder Cancer|Effects of Chemotherapy","Other: Expression analysis","Southwest Hospital, China","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012XLC02-2|2012XLC02","February 26, 2014","March 2014","April 2019","February 27, 2014","February 2014","No Study Results Posted","null","April 2019","cancer progressive free survival rate|overall survival","https://ClinicalTrials.gov/show/NCT02074241"
2163,"NCT00303758","Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Pancreatic Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium","Federation Francophone de Cancerologie Digestive","All","18 Years and older   (Adult, Senior)","Phase 3","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000453841|FFCD-0301|EU-20543","March 15, 2006","October 2005","March 2012","March 3, 2014","December 2006","No Study Results Posted","null","March 2012","Overall survival|Progression-free survival|Toxicity|Quality of life|Percentage of patients needing second-line therapy|Duration of hospitalization","https://ClinicalTrials.gov/show/NCT00303758"
2164,"NCT00627432","Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer","Suspended","No Results Available","Bladder Cancer","Drug: gemcitabine hydrochloride|Drug: oxaliplatin","Institut du Cancer de Montpellier - Val d'Aurelle|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000574179|CLCC-VESUNFIT|RECF0368|SANOFI-AVENTIS-CLCC-VESUNFIT|LILLY-CLCC-VESUNFIT","February 29, 2008","July 2004","null","October 6, 2010","July 2009","No Study Results Posted","null","March 2009","Objective response rate|Tolerability|Overall survival|Progression-free survival|Quality of life as assessed by QLQ-C30 and QLQ-LC13|Duration of response","https://ClinicalTrials.gov/show/NCT00627432"
2165,"NCT00050973","Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: bexarotene","Eisai Inc.","All","Child, Adult, Senior","Phase 3","623","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L1069-49","December 31, 2002","null","March 2005","May 13, 2013","July 2008","No Study Results Posted","null","November 2004","","https://ClinicalTrials.gov/show/NCT00050973"
2166,"NCT00002558","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors","Completed","Has Results","Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","108","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","93-162|P30CA008748|MSKCC-93162|NCI-V94-0407","November 1, 1999","January 1994","April 2009","April 11, 2016","April 2016","December 21, 2015","null","April 2009","Overall Objective Response","https://ClinicalTrials.gov/show/NCT00002558"
2167,"NCT02240238","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer","Recruiting","No Results Available","Solid Tumors","Drug: NC-6004|Drug: Gemcitabine","NanoCarrier Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","182","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NC-6004-004A","August 19, 2014","May 2014","November 2017","April 5, 2017","April 2017","No Study Results Posted","null","November 2017","Determine the RPII dose of NC-6004 in combination with gemcitabine|Activity of NC-6004 measured by progression-free survival (PFS)|Overall response rate|Therapy-related AEs|Quality of life|Safety and tolerability as measured by severity of AEs and laboratory abnormalities","https://ClinicalTrials.gov/show/NCT02240238"
2168,"NCT01222572","Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer","Terminated","Has Results","Non-small Cell Lung Cancer|Lung Cancer|NSCLC","Radiation: Stereotactic boost|Radiation: Conventional RT|Drug: Etoposide|Drug: Cisplatin","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10-240","October 8, 2010","December 2010","October 2012","May 11, 2015","May 2015","August 25, 2014","null","March 2012","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT01222572"
2169,"NCT01857232","Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","Completed","No Results Available","CINV","Drug: Ondansetron, dexamethasone, fosaprepitant|Drug: Placebo","Acacia Pharma Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DN10016","May 16, 2013","October 2013","February 2015","July 28, 2016","July 2016","No Study Results Posted","null","February 2015","Complete Response","https://ClinicalTrials.gov/show/NCT01857232"
2170,"NCT00921635","A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix","Suspended","No Results Available","Cervical Cancer|Anemia","Procedure: Blood transfusion|Procedure: Blood transfusion","Tri-Service General Hospital|National Taiwan University Hospital","Female","18 Years and older   (Adult, Senior)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","ANZGOG0401|TSGHIRB095-05-044","June 15, 2009","April 2008","null","June 18, 2009","June 2009","No Study Results Posted","HOSTT","May 2011","The impact of maintaining hemoglobin levels above 120 g/L versus above 100 g/L","https://ClinicalTrials.gov/show/NCT00921635"
2171,"NCT00002550","Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Procedure: conventional surgery|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|North Central Cancer Treatment Group|NCIC Clinical Trials Group","All","18 Years and older   (Adult, Senior)","Phase 3","429","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9309|CDR0000063333|CAN-NCIC-BR13|CLB-9592|E-R9309|NCCTG-R9309|NCI-94-C-0043|SWOG-9336|INT-0139","November 1, 1999","March 1994","November 2013","November 14, 2015","November 2015","No Study Results Posted","null","June 2004","Median overall survival|Median Progression-free survival|Patterns of local and distant failure","https://ClinicalTrials.gov/show/NCT00002550"
2172,"NCT00014274","Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium","Completed","No Results Available","Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter|Urethral Cancer","Drug: carboplatin|Drug: gemcitabine hydrochloride|Drug: methotrexate|Drug: vinblastine sulfate","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","238","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-30986|EORTC-GU-30986","April 10, 2001","January 2001","null","June 11, 2013","June 2013","No Study Results Posted","null","March 2008","Duration of survival|Response as assessed by RECIST criteria|Toxicity as assessed by CTC v2","https://ClinicalTrials.gov/show/NCT00014274"
2173,"NCT02212574","Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma","Recruiting","No Results Available","Medulloblastoma","Drug: Lomustine|Drug: Vincristine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Mesna|Drug: Vincristine","Sidney Kimmel Comprehensive Cancer Center","All","3 Years to 18 Years   (Child, Adult)","","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1403|NA_00091840","July 7, 2014","March 2015","August 2019","April 26, 2017","April 2017","No Study Results Posted","null","August 2018","Progression Free Survival|Patterns of Failure","https://ClinicalTrials.gov/show/NCT02212574"
2174,"NCT00003912","Chemotherapy in Treating Children With Liver Cancer","Completed","No Results Available","Liver Cancer","Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Procedure: conventional surgery","Societe Internationale d'Oncologie Pediatrique|National Cancer Institute (NCI)","All","up to 16 Years   (Child)","Phase 3","260","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067091|SIOP-SIOPEL-3|EU-98067|UKCCSG-LT-1998-01","November 1, 1999","June 1998","October 2009","December 3, 2013","December 2000","No Study Results Posted","null","null","Tumor response|Complete resection rate|Overall survival|Event-free survival|Toxicity|Response rate|Resection rate","https://ClinicalTrials.gov/show/NCT00003912"
2175,"NCT00002555","High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","338","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-22931","November 1, 1999","February 1994","null","June 29, 2012","June 2012","No Study Results Posted","null","October 2000","","https://ClinicalTrials.gov/show/NCT00002555"
2176,"NCT02397486","The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients","Recruiting","No Results Available","Head and Neck Neoplasms","Drug: Pentoxifylline|Drug: Vitamin E|Drug: Cisplatin|Radiation: Radiation therapy","Ain Shams University","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","Ph.D 20","March 16, 2015","May 2015","June 2018","July 15, 2016","July 2016","No Study Results Posted","null","June 2018","Incidence and severity of radiotherapy-induced toxicity|Duration of grade 3 or 4 radiotherapy-induced toxicity|Patients' response to concurrent chemo-radiotherapy (objective response rate)|incidence and grade of pentoxifylline and vitamin E- related adverse events (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03)|Number of patients with unplanned breaks in radiotherapy|Total dose of opioid analgesics required|Functional oral intake score|Patients' quality of life assessed using the validated Arabic version of the EuroQol-5D-3L questionnaire","https://ClinicalTrials.gov/show/NCT02397486"
2177,"NCT02508389","A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer","Recruiting","No Results Available","Radiation Induced Oral Mucositis","Drug: Low Dose GC4419: 30mg/day|Drug: High Dose GC4419: 90mg/day|Drug: Placebo","Galera Therapeutics, Inc.|Clinical Assistance Programs, LLC|Novella Clinical","All","18 Years and older   (Adult, Senior)","Phase 2","200","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Supportive Care","GT-201","July 16, 2015","October 2015","June 2018","May 5, 2017","April 2017","No Study Results Posted","null","August 2017","Duration of Radiation Induced Severe Oral Mucositis per WHO Criteria, Through a Minimum of 60 Gy IMRT Delivered to the Tumor|Safety of Low Dose vs. High Dose GC4419, Using the Adverse Event Scale: National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v4.0)|Incidence of Radiation Induced Severe Oral Mucositis per WHO Criteria, Through a Minimum of 60 Gy IMRT Delivered to the Tumor|Cumulative Incidence of Severe Oral Mucositis, per WHO Criteria for Entire Course of IMRT|Time to Onset of Severe Oral Mucositis, per WHO Criteria|Cumulative Incidence of Grade 4 Oral Mucositis, per WHO Criteria|Duration of Severe Oral Mucositis, Per WHO Criteria|GC4419's Effect on Tumor Response within 1 Year of IMRT Completion.","https://ClinicalTrials.gov/show/NCT02508389"
2178,"NCT00186680","CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant","Completed","No Results Available","Breast Cancer","Procedure: high dose chemo then auto hematopoietic cell transplant","Stanford University","All","19 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","99","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT86","September 14, 2005","September 1996","June 2005","February 26, 2010","February 2010","No Study Results Posted","null","June 2005","Feasibility and safety|efficiency of mobilization|tumor contamination","https://ClinicalTrials.gov/show/NCT00186680"
2179,"NCT02665039","A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function","Recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer|Renal Pelvis Cancer|Ureter Cancer|Urethra Cancer","Drug: Vinflunine|Drug: Gemcitabine|Drug: Carboplatin","Dr Anders Ullén|Karolinska University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NUCOG I","January 18, 2016","April 2014","December 2017","January 26, 2016","January 2016","No Study Results Posted","VINGEM","December 2016","Progression-free survival (PFS)|Overall response rate (ORR = CR + PR)|Overall survival (OS)|Disease control rate, DCR (=CR + PR + SD)|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0|Quality of Life (QoL) assessed by QLQ-C30","https://ClinicalTrials.gov/show/NCT02665039"
2180,"NCT00578526","SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial","Unknown status","No Results Available","Urothelial Cancer|Bladder Cancer|Adult","Drug: SU011248|Drug: Placebo","Alberta Health Services|Pfizer|AHS Cancer Control Alberta","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","SPRUCE02","December 19, 2007","April 2008","null","January 18, 2012","September 2011","No Study Results Posted","SPRUCE","null","Progression Free Survival|objective response rate|duration of response|Quality of Life|Safety|Overall Survival","https://ClinicalTrials.gov/show/NCT00578526"
2181,"NCT02591030","Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours","Recruiting","No Results Available","Bile Duct Cancer","Drug: GEMCIS|Drug: mFolfirinox","Centre Hospitalier Universitaire de Saint Etienne|Federation Francophone de Cancerologie Digestive","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","316","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1408212|2015-002282-35","October 26, 2015","November 2015","June 2018","May 17, 2016","May 2016","No Study Results Posted","AMEBICA","June 2017","percentage of patients who are alive without radiological progession|overall survival|Tumour response|Toxicity of the treatment assessed according to NCI-CTC v 4.0|Biliary complications|quality of life (EORTC QLQ-C30 )","https://ClinicalTrials.gov/show/NCT02591030"
2182,"NCT00453232","Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors","Completed","No Results Available","Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Biological: pegfilgrastim|Drug: cisplatin|Drug: etoposide","Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI)","Male","18 Years to 40 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CRCA-CCTC-ACCELERATED-BEP|CDR0000537042|EUDRACT-2004-000847-79|EU-20713|ISRCTN18505589","March 27, 2007","August 2004","January 2009","August 6, 2013","August 2007","No Study Results Posted","null","December 2008","Toxicity|Feasibility|Response rate|Progression-free survival","https://ClinicalTrials.gov/show/NCT00453232"
2183,"NCT00174629","GILT Docetaxel - Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Neoplasms","Drug: Docetaxel/DDP|Drug: docetaxel/gemcitabine","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","449","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_ES1_302","September 9, 2005","June 2001","null","December 4, 2009","December 2009","No Study Results Posted","null","January 2007","Overall response rate (complete plus partial responses) between the genotypic group and the control group using an intent-to-treat analysis.|Time to treatment failure and survival|Clinical and laboratory toxicities graded according to NCIC-CTG Expanded Common Toxicity Criteria.|Adverse events not reported in NCIC-CTG Expanded Common Toxicity Criteria will be graded as mild, moderate, severe, and life threatening.","https://ClinicalTrials.gov/show/NCT00174629"
2184,"NCT00180791","High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood","Unknown status","No Results Available","Medulloblastoma|Brain Tumors|Neuroectodermal Tumors, Primitive","Drug: Etoposide, carboplatin, melphalan, cisplatin, thiotepa","Gustave Roussy, Cancer Campus, Grand Paris","All","up to 10 Years   (Child)","Phase 2","71","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PNET HR","September 9, 2005","July 2002","null","September 17, 2007","September 2006","No Study Results Posted","null","null","Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age|Progression-free survival of children less than 10 years of age with brain PNET|Progression-free survival of children less than 5 years of age with metastatic medulloblastoma|Toxicity|Long term sequelae","https://ClinicalTrials.gov/show/NCT00180791"
2185,"NCT03144466","A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer","Not yet recruiting","No Results Available","Cervix Cancer","Combination Product: Pembrolizumab","Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.|National Institute for Health Research, United Kingdom","Female","18 Years and older   (Adult, Senior)","Phase 1","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CCR 4268","April 12, 2017","June 2017","June 2019","May 5, 2017","May 2017","No Study Results Posted","PAPAYA","June 2019","Maximum Tolerated Dose (MTD)|Efficacy|Evaluate Toxicities of Treatment|Response Rates|Presence / Absence of HPV|Overall survival (OS)|Late Radiotherapy Toxicity|Progression Free survival (PFS)","https://ClinicalTrials.gov/show/NCT03144466"
2186,"NCT02750670","Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","Recruiting","No Results Available","Lymphoma, Non-Hodgkin's","Drug: Obinutuzumab|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin","University Health Network, Toronto|Hoffmann-La Roche|Ozmosis Research Inc.","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","OZM-073|ML29885","April 15, 2016","March 15, 2017","May 2020","May 4, 2017","May 2017","No Study Results Posted","null","May 2020","The overall response rate (ORR) of G2DP by investigator assessment based on conventional CT imaging.|The ORR rate by central review of conventional CT imaging after 2 cycles of G2DP|The Complete Response (CR) rate by FDG-PET scan|The rate of successfully proceeding to autologous stem cell transplant (ASCT)|Progression Free Survival (PFS) post ASCT (in transplanted patients) or after protocol discontinuation (in patients not transplanted).|The percentage of patients requiring dose reduction for hematologic toxicity.|Correlative studies on patient specimens markers of disease response (in tumor and blood/plasma) as well as to identify blood/plasma markers that provide additional discriminative information to FDG-PET scans|The Complete Response (CR) rate by central review of conventional CT imaging after 2 cycles of G2DP|Overall Survival (OS) post ASCT (in transplanted patients) or after protocol discontinuation (in patients not transplanted).","https://ClinicalTrials.gov/show/NCT02750670"
2187,"NCT01536392","Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation","Active, not recruiting","No Results Available","Cancer of the Cervix","Drug: Granisetron|Drug: Ondansetron|Behavioral: Questionnaires|Behavioral: Study Drug Diary","M.D. Anderson Cancer Center|Sancuso","Female","18 Years and older   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-1107|NCI-2012-00221","February 16, 2012","March 2012","null","June 22, 2016","June 2016","No Study Results Posted","null","March 2020","Response to Anti-Emetic Therapy","https://ClinicalTrials.gov/show/NCT01536392"
2188,"NCT00210171","Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Procedure: Toxicity : Time to progression, 1 and 2 years survival","Institut Bergonié|Sanofi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IB2004-20|BIB-01","September 12, 2005","May 2004","March 2007","July 25, 2013","October 2007","No Study Results Posted","BIB 01","null","Objective response|Toxicity|Time to progression|1 and 2 years survival","https://ClinicalTrials.gov/show/NCT00210171"
2189,"NCT01212354","Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT","Recruiting","No Results Available","Locally Advanced Head and Neck Cancer","Radiation: Radiotherapy","Technische Universität München","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ESC-928-MOL-0000-I","September 29, 2010","July 2015","September 2025","February 8, 2016","February 2016","No Study Results Posted","Escalox","January 2025","2 year-loco-regional control|Overall Survival (OS)|Progression-free survival (PFS)|Time to progression (TTP)|Distant metastases (DM)|Acute and late toxicity esp. concerning salivary glands|Quality of life (EORTC QoL-C30, H&N 35)|Adverse effects according to NCI CTC-AE (VERSION 4.0/ 10/1/2010) and LENT-SOMA|FMISO PET/CT: Reproducibility and correlation with treatment coutcome|Relapse free Survival (RFS)","https://ClinicalTrials.gov/show/NCT01212354"
2190,"NCT01936974","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma","Unknown status","No Results Available","Ovarian Carcinoma|Fallopian Tube Carcinoma|Peritoneal Carcinoma","Drug: Gemcitabine|Drug: Bevacizumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Oxaliplatin","Western Regional Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","13-27","September 3, 2013","September 2013","September 2016","January 19, 2015","January 2015","No Study Results Posted","PGA","September 2015","Progression-free survival","https://ClinicalTrials.gov/show/NCT01936974"
2191,"NCT01802021","Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Astagalus-based Formula: Qingshu-Yiqi-Tang","Chang Gung Memorial Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","97-1967A3","February 27, 2013","May 2009","February 2014","February 28, 2013","April 2009","No Study Results Posted","QSYQT","December 2013","overall survival|Progression-free interval","https://ClinicalTrials.gov/show/NCT01802021"
2192,"NCT00193739","Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix","Recruiting","No Results Available","Cancer of Cervix","Drug: NACT|Procedure: Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|Drug: Inj.Cisplatin|Radiation: Concurrent chemo radiotherapy","Sudeep Gupta|Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult)","Phase 3","730","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","119 of 2003","September 11, 2005","September 2003","December 2017","November 6, 2015","November 2015","No Study Results Posted","NACTcervix","December 2017","Disease Free Survival|Over all survival|Rate of Distant Metastases","https://ClinicalTrials.gov/show/NCT00193739"
2193,"NCT01534949","Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial","Terminated","No Results Available","Diffuse Large B-Cell Lymphoma","Biological: rituximab","Celltrion","All","21 Years to 70 Years   (Adult, Senior)","Phase 1","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT-P10 1.2","February 8, 2012","February 2012","February 2013","July 21, 2014","July 2014","No Study Results Posted","Triad-DLBCL","February 2013","safety","https://ClinicalTrials.gov/show/NCT01534949"
2194,"NCT02393248","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies","Recruiting","No Results Available","Malignant Solid Tumour|Carcinoma, Non-Small-Cell Lung|Stomach Neoplasms|Urothelial Carcinoma|Endometrial Neoplasms|Multiple Myeloma|MPN|Breast Cancer|Cholangiocarcinoma","Drug: INCB054828|Drug: Gemcitabine+Cisplatin|Drug: Pembrolizumab|Drug: Docetaxel","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCB 54828-101","January 30, 2015","January 2015","February 2018","December 12, 2016","December 2016","No Study Results Posted","null","February 2018","Determination of the maximum tolerated dose of INCB054828 as a monotherapy and in combination as measured by the number of participants with adverse events|Assess the pharmacodynamics of INCB054828 as a monotherapy and in combination as indicated by serum phosphorus level|Preliminary efficacy as assessed by Overall Response Rate (ORR) of INCB054828 as monotherapy and in combination in subjects with measurable disease|Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of INCB054828 as monotherapy and in combination|Minimum observed plasma concentration (Cmin) during the dosing interval of INCB054828 as monotherapy and in combination|Time to maximum plasma concentration (Tmax) of INCB054828 as monotherapy and in combination|Area under the single-dose plasma concentration-time curve (AUC0-t) of INCB054828 as monotherapy and in combination|Oral dose clearance (Cl/F) of INCB054828 as monotherapy and in combination","https://ClinicalTrials.gov/show/NCT02393248"
2195,"NCT01362127","Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia","Active, not recruiting","No Results Available","Carcinoma, Squamous Cell|Adenocarcinoma of the Esophagus and Gastric Cardia","Drug: Chemotherapy|Radiation: Radiochemotherapy","Karolinska University Hospital|University Hospital, Umeå|Region Örebro County|Sahlgrenska University Hospital, Sweden|Ullevaal University Hospital|Haukeland University Hospital|Oslo University Hospital|St. Olavs Hospital|Malarhospital Eskilstuna","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EU-nr 2006-001785-16|2006-001785-16","May 26, 2011","October 2006","June 2018","February 17, 2017","February 2017","No Study Results Posted","NeoRes","June 2013","To evaluate whether radiochemotherapy gives higher complete histological response (pCR) after resection than chemotherapy alone in patients with resectable carcinoma of the esophagus and cardia.|To evaluate the safety of respective neoadjuvant therapies.","https://ClinicalTrials.gov/show/NCT01362127"
2196,"NCT00381706","Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer","Completed","Has Results","Esophageal Cancer","Biological: cetuximab|Drug: ECF|Drug: IC|Drug: FOLFOX","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Bristol-Myers Squibb|Sanofi|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","245","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-80403|ECOG-E1206|CDR0000505535|NCI-2009-00492","September 26, 2006","September 2006","null","January 26, 2017","January 2017","January 26, 2017","null","April 2011","Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma|Tumor Response Rate (Complete and Partial) in Patients With Squamous Cell Carcinoma|Overall Survival in Patients With Adenocarcinoma|Progression-free Survival in Patients With Adenocarcinoma|Time to Treatment Failure in Patients With Adenocarcinoma","https://ClinicalTrials.gov/show/NCT00381706"
2197,"NCT00002875","Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: lomustine|Drug: mesna|Drug: vincristine sulfate|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Children's Oncology Group|National Cancer Institute (NCI)|Pediatric Oncology Group","All","3 Years to 22 Years   (Child, Adult)","Phase 3","421","Other|NIH","Interventional","Allocation: Randomized|Masking: Single Blind|Primary Purpose: Treatment","A9961|CCG-A9961|POG-A9961|CDR0000065160","November 1, 1999","December 1996","January 2011","July 31, 2014","July 2014","No Study Results Posted","null","February 2006","Event Free Survival","https://ClinicalTrials.gov/show/NCT00002875"
2198,"NCT00455572","Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer","Terminated","No Results Available","Lung Cancer, Non-Small Cell","Biological: Immunotherapeutic GSK1572932A|Drug: Cisplatin (CDDP)|Drug: Vinorelbine|Procedure: Radiotherapy","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1","71","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","107240","April 2, 2007","May 11, 2007","August 8, 2013","May 12, 2017","May 2017","No Study Results Posted","null","August 4, 2013","The anti-MAGE-A3 seroconversion|The anti-protein D seroconversion|The anti-CpG seroconversion|The MAGE-A3 cellular (T cell) response|Occurrence of adverse events, including abnormal hematological and biochemical laboratory values|Occurrence of serious adverse events","https://ClinicalTrials.gov/show/NCT00455572"
2199,"NCT00193804","A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix","Active, not recruiting","No Results Available","Cancer of Cervix","Radiation: IMRT","Tata Memorial Hospital|Varian Medical Systems","Female","18 Years to 65 Years   (Adult)","","200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TMH/158/2004/Cx_IMRT TRIAL","September 13, 2005","February 2005","May 2017","March 26, 2017","March 2017","No Study Results Posted","null","May 2017","To compare the normal tissue toxicities (Acute & Late) of standard radiation therapy with IMRT|To compare the disease free survivals|To compare the quality of life in both the groups|To compare the overall survivals","https://ClinicalTrials.gov/show/NCT00193804"
2200,"NCT00002839","Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","564","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-24954","November 1, 1999","July 1996","null","January 7, 2013","January 2013","No Study Results Posted","null","May 2004","","https://ClinicalTrials.gov/show/NCT00002839"
2201,"NCT00413283","Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Lung Cancer|Chemotherapy-Induced Thrombocytopenia|Non-Small Cell Lung Cancer|Cancer|Lung Neoplasms|Oncology|Solid Tumors|Thrombocytopenia","Biological: Romiplostim|Drug: Placebo|Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin","Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Supportive Care","20050154","December 15, 2006","December 2006","February 2009","September 18, 2013","September 2013","September 24, 2010","null","December 2008","Number of Participants With Adverse Events|Duration of Grade 3 or 4 Thrombocytopenia|Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.|Number of Participants With Platelet Transfusions|Platelet Count on Day 22|Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle","https://ClinicalTrials.gov/show/NCT00413283"
2202,"NCT02937116","First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors","Not yet recruiting","No Results Available","Cancer, Solid Tumor","Drug: IBI308|Drug: IBI308\Cisplatinum\Pemetrexed","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CIBI308A101","October 8, 2016","October 2016","December 2018","November 30, 2016","October 2016","No Study Results Posted","null","December 2018","Number of participants experiencing dose-limiting toxicities (DLTs)|Number of all study participants who demonstrate a tumor response|Number of participants experiencing clinical and laboratory adverse events (AEs)|The area under the curve (AUC) of plasma concentration of drug against time after administration of IBI308|Maximum concentration (Cmax) after first dose interval of IBI308|Time at which maximum concentration (Tmax) occurs for IBI308|The half-life (t1/2) of IBI308 in plasma after single dose administration","https://ClinicalTrials.gov/show/NCT02937116"
2203,"NCT01294280","Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy","Recruiting","No Results Available","Lung Cancer","Other: Laboratory Biomarker Analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","1606","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CALGB-150802|CDR0000600208|U10CA031946|NCI-2009-00454","February 10, 2011","July 2008","null","June 24, 2016","June 2016","No Study Results Posted","null","January 2100","Overall survival|Disease-free survival","https://ClinicalTrials.gov/show/NCT01294280"
2204,"NCT02621333","Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma","Recruiting","No Results Available","Lung Adenocarcinoma","Biological: CIK|Drug: chemotherapy","Henan Cancer Hospital|Henan Provincial Hospital|Hebei Medical University Fourth Hospital|Shanxi Dayi Hospital|Tangshan People's Hospital|150th Hospital of PLA|First Affiliated Hospital of Nanyang Medical College|Nanyang Central Hospital|First People's Hospital of Shangqiu|Anyang Regional Hospital|Puyang Oil Field General Hospital|Shenma Medical Group General Hospital|Jiaozuo Tumor Hospital|The 152th Central Hospital of PLA|Xinyang Central Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HenanCH003","November 25, 2015","October 2015","September 2018","December 2, 2015","December 2015","No Study Results Posted","null","September 2018","overall survival time|time to progression|objective response rate|quality of life","https://ClinicalTrials.gov/show/NCT02621333"
2205,"NCT00258323","Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: Iressa|Procedure: conventional surgery|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCF5848|P30CA043703|CCF-5848|ZENECA-1839/US/0233","November 22, 2005","October 2005","February 2010","September 29, 2015","September 2015","No Study Results Posted","null","July 2007","Survival at 1 year|Distant metastatic control at 1 year|Response rate at 6 weeks|Toxicity of induction chemoradiotherapy and gefitinib as measured by CTC version 2.0 at 6 weeks|Toxicity of maintenance gefitinib as measured by CTC version 2.0 every 8 weeks after the completion of radiotherapy","https://ClinicalTrials.gov/show/NCT00258323"
2206,"NCT01590160","Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma","Active, not recruiting","No Results Available","Lung Cancer - Malignant Pleural Mesothelioma","Drug: Ganetespib","University College, London|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UCL/12/0158|CMS # 1995|A15183|2012-001598-10|TBC","April 30, 2012","August 2013","October 2017","May 2, 2017","April 2017","No Study Results Posted","MESO-02","September 2017","Maximum Tolerated Dose of Ganetespib|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01590160"
2207,"NCT00401609","G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients","Completed","No Results Available","Small Cell Lung Cancer","Drug: gemcitabine|Drug: vinorelbine|Drug: cisplatin|Drug: etoposide|Drug: carboplatin","National Cancer Institute, Naples","All","70 Years and older   (Senior)","Phase 1|Phase 2","85","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","G-Step","November 17, 2006","November 2000","February 2009","January 13, 2016","January 2016","No Study Results Posted","G-Step","December 2007","to evaluate activity and toxicity of GEMVIN combination|to identify optimal dose of GEMETO, GEMCAR, and GEMCIS combinations|to evaluate activity and toxicity of GEMETO, GEMCAR, and GEMCIS combinations|treatment impact on patient quality of life|prognostic value of ADL and IADL multidimensional geriatric evaluation scales|clinical variables predictive of response to treatment","https://ClinicalTrials.gov/show/NCT00401609"
2208,"NCT02853305","Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)","Recruiting","No Results Available","Urothelial Carcinoma Associated 1 RNA, Human","Biological: Pembrolizumab|Drug: Cisplatin|Drug: Carboplatin|Drug: Gemcitabine","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","990","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","3475-361|2015-005731-41|163458","July 29, 2016","September 15, 2016","March 28, 2020","May 2, 2017","May 2017","No Study Results Posted","null","January 29, 2019","Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)|Overall Survival (OS)|Number of Participants Who Experience an Adverse Event (AE)|Number of Participants Who Discontinue Study Drug Due to an AE|Objective Response Rate (ORR) Using RECIST 1.1 as Assessed by BICR|Disease Control Rate (DCR) Using RECIST 1.1 as Assessed by BICR|PFS Using RECIST 1.1 as Assessed by BICR at Milestone Timepoints","https://ClinicalTrials.gov/show/NCT02853305"
2209,"NCT01667302","Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma","Unknown status","No Results Available","Extranodal NK/T-cell Lymphoma, Nasal Type","Drug: Radiotherapy followed by chemotherapy","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LMTG 12-02","August 13, 2012","June 2012","December 2016","March 2, 2013","March 2013","No Study Results Posted","null","December 2013","3-year Progression-free survival|Overall response rate|3-year overall survival|Safety","https://ClinicalTrials.gov/show/NCT01667302"
2210,"NCT01416961","Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)","Withdrawn","No Results Available","Lung Cancer","Radiation: Radiation Therapy|Drug: Chemotherapy - Squamous Cell Histologies|Drug: Chemotherapy - NSCLC other than squamous cell","Barbara Ann Karmanos Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-005","August 10, 2011","August 2011","December 2011","August 20, 2012","August 2012","No Study Results Posted","null","December 2011","Assess Dose levels (DLT & MTD)integrating 2 dose levels of neutron tx in 2 diff regimens of approx 12 pts/trt; If 1st dose level feasible but not 2nd dose level in either cohorts then 12 pts will be trted at 1st dose level for that particular cohort|To assess the Progression Free Survival (PFS), and response rate in these patients.|To assess the expression of p16 expression, ERCC1 and TS expression in tumors of enrolled patients and assess the correlation of these markers with response rate and progression free survival.","https://ClinicalTrials.gov/show/NCT01416961"
2211,"NCT02974426","To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer Stage IIIA|Radiotherapy","Radiation: PORT-first|Radiation: PORT-last|Drug: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)","Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|Fudan University|Shanghai Zhongshan Hospital|Ruijin Hospital|RenJi Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","1094","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DLY201619","November 20, 2016","November 2016","December 2020","December 25, 2016","December 2016","No Study Results Posted","null","December 2020","Disease-free survival (DFS)|Overall survival (OS)|Locoregional recurrence-free survival (LRFS)|Distant metastasis-free survival (DMFS)|Treatment-related adverse event","https://ClinicalTrials.gov/show/NCT02974426"
2212,"NCT02858804","EDOCH Alternating With DHAP for New Diagnosed Younger MCL","Recruiting","No Results Available","Mantle Cell Lymphoma","Drug: Etoposide|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Cisplatin|Drug: Rituximab|Drug: Thalidomide|Drug: Prednisone","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 65 Years   (Adult)","Phase 4","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIT2015007-EC-1","July 17, 2016","January 2016","June 2020","August 3, 2016","August 2016","No Study Results Posted","BDH-MCL01","December 2019","progression free survival|complete remission|overall survival","https://ClinicalTrials.gov/show/NCT02858804"
2213,"NCT02264990","Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers","Active, not recruiting","No Results Available","Non-squamous Non-small Cell Lung Cancer","Drug: Veliparib|Drug: Carboplatin|Drug: Paclitaxel|Drug: Cisplatin|Drug: Pemetrexed","AbbVie","All","18 Years to 99 Years   (Adult, Senior)","Phase 3","525","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","M14-359|2014-002565-30","October 9, 2014","October 1, 2014","July 31, 2017","April 27, 2017","April 2017","No Study Results Posted","null","July 31, 2017","Overall Survival (OS) in current smokers|Overall Survival (OS) in all participants|Progression Free Survival (PFS) in current smokers and all participants|Objective Response Rate (ORR) in current smokers and all participants","https://ClinicalTrials.gov/show/NCT02264990"
2214,"NCT03077243","P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC","Recruiting","No Results Available","Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms","Radiation: Intensity Modulated Radiotherapy (IMRT) - deintensified|Radiation: Intensity Modulated Radiotherapy (IMRT) - standard|Drug: Cisplatin (or alternative) - deintensified|Drug: Cisplatin (or alternative) - standard|Procedure: Assessment for surgical evaluation","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1612","January 30, 2017","August 2016","August 2046","March 6, 2017","March 2017","No Study Results Posted","null","April 2019","2 year Progression Free Survival after de-intensified chemoradiation therapy (CRT) in HPV-associated OPSCC|Changes in plasma circulating free HPV DNA during and after treatment as related to clinical outcomes in patients with HPV-associated OPSCC|Local control rate|Regional control rate|Local-regional control rate|Distant metastasis free survival|Overall survival rate|Head and neck quality of life assessments|Speech and swallowing function via penetration-aspiration scale (PAS) and EAT-10 survey assessments","https://ClinicalTrials.gov/show/NCT03077243"
2215,"NCT01709487","Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy","Completed","No Results Available","Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma","Procedure: HIPEC","Jules Bordet Institute","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIPEC","October 12, 2012","May 2010","October 2015","February 23, 2016","July 2014","No Study Results Posted","null","October 2015","mortality rate|progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01709487"
2216,"NCT02687958","Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin","Recruiting","No Results Available","Neuroendocrine Carcinoma","Drug: Everolimus","Gruppo Oncologico Italiano di Ricerca Clinica|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GOIRC 02/2014","February 17, 2016","May 2015","May 2017","February 7, 2017","February 2017","No Study Results Posted","null","January 2017","PFS|OS|ctDNA","https://ClinicalTrials.gov/show/NCT02687958"
2217,"NCT00030771","Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients","Active, not recruiting","No Results Available","Lung Cancer","Drug: Chemotherapy|Radiation: Radiotherapy|Procedure: Surgery","Swiss Group for Clinical Cancer Research","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","232","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","SAKK 16/00|SWS-SAKK-16/00|EU-20138","February 14, 2002","April 2001","December 2020","May 12, 2017","May 2017","No Study Results Posted","null","October 2013","Event-free survival|Postoperative mortality assessed|Toxicity|Complete resection rate after surgery|Objective response rate measured after completion of chemoradiotherapy|Operability|Overall survival|Failure pattern","https://ClinicalTrials.gov/show/NCT00030771"
2218,"NCT00379262","Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Capecitabine|Drug: Adjuvant chemotherapy using PF (5-Fluorouracil )|Drug: Induction chemotherapy using PF (5-Fluorouracil)","Hong Kong Nasopharyngeal Cancer Study Group Limited|The Hong Kong Anti-Cancer Society|hong Kong Cancer Fund","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","798","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","NPC-0501 Trial","September 20, 2006","September 2006","December 2017","August 15, 2016","August 2016","No Study Results Posted","null","May 2017","Progression-Free Survival, defined as the time to treatment failure at any site or death due to any cause, at 5-year.|Overall Survival, defined as the time to death due to any cause, at 5-year.|overall Failure-Free Rate, defined as time to failure at any site)|Loco-regional Failure-Free Rate, defined as time to local or nodal failure)|Distant Failure-Free Rate, defined as time to distant failure)|Incidence of chemotherapy toxicity and acute RT toxicity grade > 3|Time to late toxicity (From the date of randomization to the earliest date of late toxicity grade > 3)","https://ClinicalTrials.gov/show/NCT00379262"
2219,"NCT02976051","DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC","Not yet recruiting","No Results Available","Locally Advanced Head and Neck Cancer|Radiotherapy","Radiation: HART-CN","Danish Head and Neck Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAHANCA 33","November 22, 2016","January 2017","December 2021","November 28, 2016","November 2016","No Study Results Posted","null","December 2019","Loco-regional failure|Overall survival|Acute radiation related morbidity|Late radiation related morbidity|Disease-specific death","https://ClinicalTrials.gov/show/NCT02976051"
2220,"NCT00257829","Improving Tumor Oxygenation in Cervical Cancer","Withdrawn","No Results Available","Cervical Cancer","Drug: Methazolamide|Drug: Cisplatin","University of California, Irvine","Female","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 03-41","November 21, 2005","July 2004","null","February 27, 2008","February 2008","No Study Results Posted","null","null","To assess the feasibility in improving tumor oxygenation","https://ClinicalTrials.gov/show/NCT00257829"
2221,"NCT02820857","Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer","Not yet recruiting","No Results Available","Neuroendocrine Carcinomas","Drug: Folfiri-bevacizumab|Drug: Folfiri","Hospices Civils de Lyon","All","18 Years and older   (Adult, Senior)","Phase 2","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","69HCL14_0442","June 29, 2016","January 2017","January 2020","June 29, 2016","June 2016","No Study Results Posted","BEVANEC","June 2019","Proportion of patients alive","https://ClinicalTrials.gov/show/NCT02820857"
2222,"NCT01732640","A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.","Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Afatinib|Drug: Paclitaxel|Drug: Carboplatin|Drug: Cisplatin|Radiation: Intensity Modulated Radiation Therapy","Sidney Kimmel Comprehensive Cancer Center|Vanderbilt-Ingram Cancer Center|National Comprehensive Cancer Network","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1266|NA_00074085","November 12, 2012","December 2012","January 2017","January 26, 2017","January 2017","No Study Results Posted","null","November 2016","Maximum Tolerated Dose (MTD)|Objective Tumor Response|Overall Response after Chemoradiation|2 Year Progression Free Survival (PFS)|Median Overall Survival|Biological Marker Activity of Afatinib|Activity of Afatinib Based on Serial FLT-PET/CT and DW-MRI|Correlate Standard Imaging Pre and Post Treatment","https://ClinicalTrials.gov/show/NCT01732640"
2223,"NCT02489903","RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","Recruiting","No Results Available","Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Neuroendocrine Tumors|Ovarian Epithelial Cancer","Drug: RRx-001|Drug: Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane)|Drug: cisplatin/carboplatin plus etoposide|Drug: carboplatin/paclitaxel.","EpicentRx, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RRx001-211-01","June 29, 2015","June 2015","July 2019","April 3, 2017","April 2017","No Study Results Posted","null","June 2018","Overall Survival|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability of platinum doublet therapy post RRx-001|Changes in the level of serum biomarkers will be calculated and treatment samples will be compared to baseline samples using one-sample tests (e.g., paired t test or Wilcoxon signed rank test).","https://ClinicalTrials.gov/show/NCT02489903"
2224,"NCT01719926","Phase I Platinum Based Chemotherapy Plus Indomethacin","Recruiting","No Results Available","Colorectal Neoplasms|Esophageal Neoplasms|Ovarian Neoplasms","Drug: Indomethacin","UMC Utrecht","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","NL40487.041.12","October 30, 2012","September 2012","July 2019","October 25, 2016","October 2016","No Study Results Posted","PIFA","December 2018","Number of dose limiting toxicities at each dosage cohort|Pharmacodynamics|Efficacy","https://ClinicalTrials.gov/show/NCT01719926"
2225,"NCT00738452","Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy","Active, not recruiting","No Results Available","Lung Cancer","Other: high performance liquid chromatography|Other: pharmacological study|Procedure: radionuclide imaging|Procedure: single photon emission computed tomography|Radiation: radiation therapy|Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","07152|P30CA033572|CHNMC-07152|CDR0000611960|NCI-2010-01232|P01CA043904","August 19, 2008","August 6, 2008","November 2017","March 30, 2017","March 2017","No Study Results Posted","null","November 2017","Maximum tolerated dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose-limiting toxicity|Progression-free survival|Overall survival|Sites of recurrence","https://ClinicalTrials.gov/show/NCT00738452"
2226,"NCT00642824","A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.","Terminated","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: Standard chemotherapy|Drug: bevacizumab [Avastin]","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21150","March 19, 2008","May 2007","December 2009","November 1, 2016","November 2016","No Study Results Posted","null","December 2009","Progression-free survival|Overall survival; response rates|Adverse events","https://ClinicalTrials.gov/show/NCT00642824"
2227,"NCT01917695","Study on Early Stage Bulky Cervical Cancers","Recruiting","No Results Available","Carcinoma Cervix","Drug: Chemotherapy|Radiation: External Beam Radiotherapy|Radiation: Brachytherapy|Procedure: Radical Hysterectomy","Rajkumar Kottayasamy Seenivasagam|Government Royapettah Hospital","Female","18 Years to 60 Years   (Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GRHCO-01","August 3, 2013","August 2013","August 2018","August 11, 2015","August 2015","No Study Results Posted","null","August 2018","Overall and Disease free Survival|Acute Adverse reactions and complications|SubAcute Adverse reactions and complications|Chronic Adverse reactions and complications","https://ClinicalTrials.gov/show/NCT01917695"
2228,"NCT00003941","Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer","Completed","No Results Available","Mediastinal Cancer|Metastatic Cancer|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cisplatin|Drug: etoposide|Drug: ifosfamide|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","European Organisation for Research and Treatment of Cancer - EORTC","Male","16 Years to 50 Years   (Child, Adult)","Phase 3","222","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-30974","November 1, 1999","April 1999","null","September 20, 2012","September 2012","No Study Results Posted","null","June 2007","Failure-free survival as measured by Logrank at 1 year|Complete response as measured by negative tumor markers and no residual masses or viable cancer cells at the end of CT scan or debulking surgery|Overall survival as measured by Logrank at 2 years|Quality of life as measured by Quality of Life Questionnaire-Core 30 (QLQ-C30) v3.0 at baseline, at month 6, and at year 2|Toxicity as measured by NCI-CTC v2.0 after each course, every 6 months up to year 5, and yearly","https://ClinicalTrials.gov/show/NCT00003941"
2229,"NCT03092518","Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","Recruiting","No Results Available","Gastric Adenocarcinoma|Esophagogastric Junction","Procedure: Surgery|Drug: Cisplatin|Drug: Mitomycin C|Drug: Sodium Thiosulfate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","40","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","170070|17-C-0070","March 22, 2017","May 30, 2017","October 10, 2020","May 24, 2017","May 16, 2017","No Study Results Posted","null","October 1, 2020","median amount of time subject survives after therapy|median amount of time subject survives without intraperitoneal disease progression after treatment|median amount of time subject survives without extraperitoneal disease progression after treatment|list of adverse event frequency","https://ClinicalTrials.gov/show/NCT03092518"
2230,"NCT01689558","Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer","Unknown status","No Results Available","1、Enough Cases|2、Elekta Precise 1343 Digital Control Electron Linear Accelerator|Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia，|Image Department of Nose Pharynx Ministry MRI Dynamic Testing,","Drug: Recombine Endostatin","Jin Feng|Cancer Hospital of Guizhou Province","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (Care Provider)|Primary Purpose: Treatment","20111220","August 12, 2012","December 2011","January 2017","March 11, 2013","March 2013","No Study Results Posted","null","January 2015","main objective","https://ClinicalTrials.gov/show/NCT01689558"
2231,"NCT00083681","DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Dexamethasone|Drug: Cytoxan|Drug: Etoposide|Drug: Cisplatin|Drug: G-CSF","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 98-018","May 27, 2004","June 1998","May 2005","July 1, 2010","July 2010","No Study Results Posted","null","null","To evaluate the effectiveness of the DCEP chemoregimen with G-CSF support as compared to the DCEP regimen with G-CSF support in combination with thalidomide in high risk patients relapsing after autologous transplantation.|To evaluate the quantitative and qualitative toxicities associated with the regimens.","https://ClinicalTrials.gov/show/NCT00083681"
2232,"NCT01545687","CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy","Active, not recruiting","No Results Available","Head and Neck Cancer|Oral Complications of Radiation Therapy|Pain|Weight Changes","Dietary Supplement: Lactobacillus brevis CD2 lozenge|Other: placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","148","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Supportive Care","N11C5|NCCTG-N11C5|CDR0000727295|NCI-2012-00692","March 1, 2012","April 2012","null","July 12, 2016","July 2016","No Study Results Posted","null","December 2017","The AUC of the MTS score|OM measured by WHO OM scale, OMAS and CTCAE weekly during CRT|Impact of OM on the ability to swallow, drink, eat, talk, and sleep, as assessed by the MTS-AL|Quality of life as assessed by the FACT-HN|Opioid requirement (frequency, morphine equivalent dose) as measured by daily OMDQ|DFS at 12 months after treatment","https://ClinicalTrials.gov/show/NCT01545687"
2233,"NCT01151761","Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation","Terminated","Has Results","Cholangiocarcinoma|Hepatobiliary Neoplasm|Liver Cancer|Bile Duct Cancer|Cancer of Gallbladder","Procedure: Stereotactic Body Radiotherapy|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: Capecitabine|Drug: 5FU|Procedure: Liver transplantation","Stanford University","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HEP0032","June 15, 2010","January 2011","July 2012","June 30, 2016","June 2016","July 3, 2013","null","April 2012","Progression-free Survival at 12 Months|Pathologic Complete Response Rate|Serum CA 19-9 Levels|Overall Survival at 12 Months|Liver Transplant Rate|Freedom From Local Progression at 12 Months|Liver Transplant Conversion Rate|Median Time to Overall Survival","https://ClinicalTrials.gov/show/NCT01151761"
2234,"NCT01440270","Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer","Active, not recruiting","No Results Available","Locally Advanced Malignant Neoplasm|Oral Cancer|Oropharyngeal Carcinoma","Drug: Neo-adjuvant Erbitux-based chemotherapy","Shanghai Jiao Tong University School of Medicine|Fudan University|Tongji University|Second Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","145","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 622022237","September 22, 2011","July 2011","October 2019","May 12, 2014","May 2014","No Study Results Posted","null","April 2015","Pathological Complete Response|Disease Free Survival|Locoregional Control rates|Overall Survival|Toxicity","https://ClinicalTrials.gov/show/NCT01440270"
2235,"NCT02095119","A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer","Completed","No Results Available","Uterine Cervical Cancer","Drug: Nimotuzumab|Drug: Cisplatin|Drug: Gemcitabine|Procedure: CT Scan","National Institute of Cancerología","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCAN/CC/130/09","February 17, 2014","July 2008","March 2014","April 13, 2015","April 2015","No Study Results Posted","null","December 2013","Antitumoral Response|Progression Free Survival|Overall Survival|Drug Toxicity","https://ClinicalTrials.gov/show/NCT02095119"
2236,"NCT01033578","Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis","Unknown status","No Results Available","Hepatocellular Carcinoma","Other: PVIC, TACE","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","Fudan-LCI-PVTT-1","December 15, 2009","October 1999","December 2010","December 15, 2009","October 2009","No Study Results Posted","null","December 2009","Overall Survival|Time to Recurrence","https://ClinicalTrials.gov/show/NCT01033578"
2237,"NCT02801487","Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Radiation: CIRT with concurrent chemo arm","Shanghai Proton and Heavy Ion Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SPHIC-TR-HNCNS-2015-02","June 11, 2016","September 2015","March 2021","June 14, 2016","June 2016","No Study Results Posted","null","March 2020","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Overall survival of all patients|Progression-free survival of all patients","https://ClinicalTrials.gov/show/NCT02801487"
2238,"NCT02720614","Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Radiation: Hypofractionated radiation/chemotherapy","LIN QIANG|North China Petroleum Bureau General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NorthChinaPBGH","March 23, 2016","May 2012","November 2014","March 25, 2016","March 2016","No Study Results Posted","null","July 2014","Number of Participants with Severe and Life-threatening Adverse Events (AE)|Percentage of Participants with Progression Free Survival (PFS) at 1 Year","https://ClinicalTrials.gov/show/NCT02720614"
2239,"NCT02358863","Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach","Recruiting","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: Modified FOLFOX6|Drug: Docetaxel/Capecitabine|Drug: Cisplatin/Irinotecan|Drug: Cisplatin/Docetaxel|Drug: IRI/EPI|Drug: EPI/Docetaxel|Drug: Irinotecan/Docetaxel|Drug: Docetaxel","Georgetown University","All","18 Years and older   (Adult, Senior)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-0973","February 4, 2015","February 2015","December 2018","August 3, 2016","August 2016","No Study Results Posted","mEGA","December 2017","Objective response rate","https://ClinicalTrials.gov/show/NCT02358863"
2240,"NCT02738723","SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC","Recruiting","No Results Available","Small Cell Lung Cancer","Radiation: SBRT|Radiation: IMRT|Drug: EP","Third Military Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STIM","March 25, 2016","January 2016","January 2020","April 10, 2016","April 2016","No Study Results Posted","null","January 2019","progression-free survival|Overall survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Tumor response rate","https://ClinicalTrials.gov/show/NCT02738723"
2241,"NCT01278602","R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-ESHAP","Fudan University","All","18 Years to 65 Years   (Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LMTG 11-01","January 18, 2011","December 2010","February 2014","March 2, 2013","March 2013","No Study Results Posted","null","December 2013","Overall response rate|3-year progression-free survival rate|3-y overall survival rate","https://ClinicalTrials.gov/show/NCT01278602"
2242,"NCT02576574","Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)","Recruiting","No Results Available","First Line Non-Small Cell Lung Cancer","Drug: Avelumab|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Gemcitabine|Drug: Carboplatin|Drug: Cisplatin|Drug: Carboplatin|Drug: Avelumab","EMD Serono Research & Development Institute, Inc.|Merck KGaA|EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 3","1095","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EMR 100070-005|2015-001537-24","October 13, 2015","October 2015","April 2024","March 3, 2017","February 2017","No Study Results Posted","null","April 2019","Progression Free Survival (PFS) in Subjects With High PD-L1 + Tumor Expression Based on an Independent Review Committee (IRC) Assessment According to RECIST 1.1|Overall Survival (OS) in Subjects With High PD-L1 + Tumor Expression|Progression Free Survival (PFS) in Subjects With Moderate and High PD-L1 + Tumor Expression Based on an IRC Assessment According to RECIST 1.1|Overall Survival (OS) in Subjects With Moderate and High and any PD-L1 + Tumor Expression|Best Overall Response (BOR) as Adjudicated by the IRC|Duration of Response (DOR) According to RECIST 1.1|Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire|Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status|Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13)|Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03|Number of Subjects With Abnormalities in Safety Laboratory Tests as Graded by NCI-CTCAE (Version 4.03)|Number of Subjects With Abnormalities in Vital Signs, Physical Examination, and Eastern Cooperative Oncology Group (ECOG) PS.|Number of Subjects With Abnormalities in 12-lead ECG","https://ClinicalTrials.gov/show/NCT02576574"
2243,"NCT00580983","Optimized Intensity Modulated Irradiation for Head and Neck Cancer","Completed","Has Results","Head and Neck Cancer","Radiation: IMRT|Drug: Paclitaxel|Drug: Carboplatin|Drug: Cisplatin|Drug: 5-Fluorouracil","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2-21|HUM 43020 Legacy 2002-513","December 25, 2007","August 2003","June 2010","July 28, 2016","July 2016","November 5, 2014","null","June 2010","Percentage of Participants With Grade 0-1 Observer-rated Dysphagia|The Mean Esophageal Radiotherapy Dose in Patients With Strictures and Without Strictures","https://ClinicalTrials.gov/show/NCT00580983"
2244,"NCT00085735","Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma","Completed","No Results Available","Untreated Childhood Medulloblastoma","Drug: Cisplatin|Radiation: Craniospinal Irradiation|Drug: Cyclophosphamide|Radiation: Involved-Field Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Lomustine|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 3","549","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0331|NCI-2009-00335|COG-ACNS0331|CDR0000365506|U10CA098543","June 14, 2004","April 2004","March 2016","February 9, 2017","February 2017","No Study Results Posted","null","March 2016","Event-free survival (EFS)|Time to death from any cause / overall survival (OS)|Local posterior fossa (LPF) failure rate|Non-local posterior fossa (NLPF) failure rate|Non-posterior fossa (NPF) failure rate|Post-treatment endocrine function (growth hormone (GH) and thyroid stimulating hormone (TSH)) as measured by laboratory assessment) .|Post-treatment grade 3+ hearing loss as measured by CTCAE v4|Post-treatment neurocognitive function as measured by the estimated full-scale IQ (FSIQ) and also the metacognition index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF)|Incidence of grade 3+ hearing loss at 1-year post treatment as assessed by CTCAE Version 4|Incidence of endocrine dysfunction as measured by growth hormone stimulation test at the completion of therapy.|Time to death from any cause / overall survival (OS) by molecular subgroup based on methylation arrays|Time to recurrence, progression or death due to cancer / progression-free survival (PFS) by molecular subgroup based on methylation arrays|Compliance rates for all eligible and evaluable patients enrolled","https://ClinicalTrials.gov/show/NCT00085735"
2245,"NCT02280993","Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients","Recruiting","No Results Available","Hodgkin Lymphoma|Refractory|Relapse","Drug: DHAP|Drug: Brentuximab Vedotin|Other: Autologous Peripheral Blood Stem Cell Transplantation","Marjolein Spiering|Millennium: The Takeda Oncology Company|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Senior)","Phase 1","72","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Transplant BRaVE|NL40688.018.12|2012-003097-45","August 19, 2014","May 2014","May 2020","October 30, 2014","October 2014","No Study Results Posted","null","November 2016","rate of patient with grade 4 Adverse Events|(Severe) Adverse Event","https://ClinicalTrials.gov/show/NCT02280993"
2246,"NCT01843049","Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Radiation: Radiotherapy|Drug: Chemotherapy (5-FU+DDP)","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013ESO_FU_01","April 24, 2013","January 2013","null","April 26, 2013","April 2013","No Study Results Posted","null","December 2015","Dose limiting toxicity(DLT)|Overall survival (OS)|Progression-free survival (PFS)|Failure patterns|Late toxicity","https://ClinicalTrials.gov/show/NCT01843049"
2247,"NCT02116530","Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","Active, not recruiting","Has Results","Hematopoietic/Lymphoid Cancer|Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific","Drug: Olanzapine|Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|Other: Placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","401","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Supportive Care","A221301|NCI-2014-00446|U10CA031946","April 15, 2014","August 2014","null","February 27, 2017","February 2017","December 7, 2016","null","April 2015","Proportion of Patients With no Nausea|Median Nausea Scores|Proportion of Patients With Complete Response|Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire|Frequency of Rescue Medication","https://ClinicalTrials.gov/show/NCT02116530"
2248,"NCT02784795","A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Solid Tumor|Breast Cancer|Colon Cancer|Cholangiocarcinoma|Soft Tissue Sarcoma","Drug: LY3039478|Drug: Taladegib|Drug: Abemaciclib|Drug: Cisplatin|Drug: Gemcitabine|Drug: Carboplatin|Drug: LY3023414","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","163","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16209|I6F-MC-JJCD|2015-004421-14","May 25, 2016","November 2016","August 2018","May 11, 2017","May 2017","No Study Results Posted","null","August 2018","Maximum Tolerated Dose (MTD) of LY3039478|Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve (AUC) of LY3039478 in Combination with Taladegib, LY3023414, Abemaciclib, Cisplatin/Gemcitabine, and Gemcitabine/Carboplatin|PK: AUC of Taladegib and its Active Metabolite LSN3185556, in Combination with LY3039478|PK: AUC of LY3023414 in Combination with LY3039478|PK: AUC of Abemaciclib and its Major Active Metabolites LSN2839567 and LSN3106726, in Combination with LY3039478|Duration of Response (DoR)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02784795"
2249,"NCT00869232","UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","Enrolling by invitation","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Melphalan|Drug: Thalidomide|Drug: Dexamethasone|Drug: Cisplatin|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","106952","March 24, 2009","October 2008","October 2017","October 11, 2016","October 2016","No Study Results Posted","null","October 2017","Accelerate and sustain, at 2 years from starting therapy|48hrs after melphalan 10mg/m2, gene expression profiling (GEP) examinations of CD138-purified MM plasma cells (PC)and of bone marrow biopsy (BX)samples","https://ClinicalTrials.gov/show/NCT00869232"
2250,"NCT02205047","Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma","Recruiting","No Results Available","Malignant Neoplasm of Stomach|Malignant Neoplasm of Cardio-esophageal Junction of Stomach|Epidermal Growth Factor Receptor (EGFR) Protein Overexpression","Drug: Cisplatin|Drug: 5-fluorouracil or Capecitabine|Drug: Trastuzumab|Drug: Pertuzumab|Procedure: gastrectomy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-1203-GITCG|2014-000722-38|MO28922","July 10, 2014","September 2015","September 2024","October 11, 2016","October 2016","No Study Results Posted","INNOVATION","September 2020","Near Complete Pathological Response Rate|Locoregional failure|R0 resection rate|Distant failure|Progression-free survival|Recurrence-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT02205047"
2251,"NCT01108666","Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Nelfinavir","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","72","Other","Interventional","Primary Purpose: Treatment","UPCC 01510","April 12, 2010","March 2010","null","July 15, 2016","July 2016","No Study Results Posted","null","August 2014","Feasibility|Acute Toxicity (or dose limiting toxicity)|Late Toxicity|Clinical Efficacy|Biomarkers","https://ClinicalTrials.gov/show/NCT01108666"
2252,"NCT00871013","UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)","Recruiting","No Results Available","Myeloma","Drug: Melphalan|Drug: Velcade|Drug: Thalidomide|Drug: Dexamethasone|Drug: Cisplatin|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","108053","March 27, 2009","March 2009","March 2018","April 18, 2017","April 2017","No Study Results Posted","null","March 2018","The primary objective of this study is to assess the continued complete and near complete response rate (CR/nCR) at two years after initiation of therapy. .","https://ClinicalTrials.gov/show/NCT00871013"
2253,"NCT00301782","Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors","Completed","No Results Available","Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Drug: carboplatin|Drug: cisplatin|Drug: etoposide phosphate|Drug: vincristine sulfate","Medical Research Council|National Cancer Institute (NCI)","Male","16 Years and older   (Child, Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000456203|MRC-TE23|EU-205107|ISRCTN53643604|EUDRACT-2004-000405-22","March 9, 2006","June 2005","June 2010","August 23, 2013","May 2007","No Study Results Posted","null","null","Response rates to treatment|Overall survival|Progression-free survival|Toxicity","https://ClinicalTrials.gov/show/NCT00301782"
2254,"NCT01496742","A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: Placebo|Drug: RO5490258|Drug: bevacizumab [Avastin]|Drug: cisplatin/carboplatin|Drug: paclitaxel|Drug: pemetrexed","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","259","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","GO27821|2011-003719-42","December 19, 2011","April 2012","November 2015","September 21, 2016","September 2016","No Study Results Posted","null","November 2015","Progression-free survival (tumor assessments according to RECIST criteria)|Progression-free survival: Subgroup of patients with Met diagnostic positive tumors|Overall survival|Overall response rate (tumor assessments according to RECIST criteria)|Duration of response (time from first documented objective response to disease progression)|Disease control rate (rate of partial response plus complete response plus stable disease for at least 6 weeks)|Safety: Incidence of adverse events|Pharmacokinetics: serum concentration (Cmin/Cmax)|Serum concentrations of bevacizumab/paclitaxel/pemetrexed/platinum in combination with MetMAb|Serum levels of anti-therapeutic antibodies (MetMAb ATAs)","https://ClinicalTrials.gov/show/NCT01496742"
2255,"NCT00577057","Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer","Unknown status","No Results Available","Nasopharyngeal Neoplasms","Procedure: Conventional Radiotherapy|Procedure: Accelerated Radiotherapy|Drug: Cisplatin|Drug: 5-fluorouracil|Drug: Capecitabine","Hospital Authority, Hong Kong|Hong Kong Nasopharyngeal Cancer Study Group Limited","All","18 Years to 70 Years   (Adult, Senior)","","798","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","HKEC-2006-120|HARECCTR0500062|NPC-0501","December 18, 2007","September 2006","August 2013","August 21, 2013","August 2013","No Study Results Posted","null","null","Progression-free survival|Overall Survival|Overall / Locoregional / Distant Failure Free Rate|Chemotherapy and RT toxicity|Late Toxicity","https://ClinicalTrials.gov/show/NCT00577057"
2256,"NCT00053352","Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors","Active, not recruiting","No Results Available","Childhood Embryonal Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Extragonadal Germ Cell Tumor|Childhood Malignant Ovarian Germ Cell Tumor|Childhood Malignant Testicular Germ Cell Tumor|Childhood Teratoma|Ovarian Embryonal Carcinoma|Ovarian Yolk Sac Tumor|Stage II Malignant Testicular Germ Cell Tumor|Stage IIA Ovarian Germ Cell Tumor|Stage IIB Ovarian Germ Cell Tumor|Stage IIC Ovarian Germ Cell Tumor|Stage III Malignant Testicular Germ Cell Tumor|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIC Ovarian Germ Cell Tumor|Testicular Choriocarcinoma and Yolk Sac Tumor|Testicular Embryonal Carcinoma","Procedure: conventional surgery|Drug: cisplatin|Drug: etoposide|Biological: bleomycin sulfate|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","302","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGCT0132|NCI-2009-00373|CDR0000269433|COG-AGCT0132|U10CA098543","January 27, 2003","November 2003","null","May 6, 2016","May 2016","No Study Results Posted","null","October 2013","Event-free survival (EFS) of at least 92% (for intermediate-risk tumors only) defined as the first occurrence of relapse, progressive disease, second malignancy, or death after the start of protocol-specified chemotherapy|Overall survival (OS) of at least 95% (both low-risk and intermediate-risk tumors)|Days of hospitalization|Toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0","https://ClinicalTrials.gov/show/NCT00053352"
2257,"NCT02114229","Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","Recruiting","No Results Available","Malignant Rhabdoid Tumor|Atypical Teratoid Rhabdoid Tumor","Drug: alisertib|Drug: methotrexate|Drug: cisplatin|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: topotecan|Drug: vincristine|Procedure: Surgical resection|Radiation: Radiation therapy","St. Jude Children's Research Hospital|Millennium Pharmaceuticals, Inc.","All","up to 21 Years   (Child, Adult)","Phase 2","180","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ATRT|NCI-2014-00901","April 11, 2014","May 14, 2014","May 31, 2027","May 1, 2017","November 2016","No Study Results Posted","SJATRT","May 31, 2023","Sustained response rate of pediatric participants with recurrent or refractory AT/RT treated with alisertib (stratum A1)|Sustained response rate of pediatric participants with recurrent or refractory MRT treated with alisertib (stratum A2)|3-year progression free survival rate (stratum B1)|1-year progression free survival rate (stratum B2)|3-year progression free survival rate (stratum C1)|1-year progression free survival rate (stratum C2)|Single dose and steady state pharmacokinetics and pharmacodynamics of alisertib|Duration of objective response by stratum A1 and A2|1-year progression-free survival (PFS) by stratum A1 and A2|5-year Progression-free survival (PFS) rate in patients with newly diagnosed AT/RT (strata B1, B2, B3, C1, C2)|5-year Overall survival (OS) rate in patients with newly diagnosed AT/RT (strata B1, B2, B3, C1, C2)|Proportion of local and distant failure in strata B1, B2, B3, C1 and C2","https://ClinicalTrials.gov/show/NCT02114229"
2258,"NCT00025298","Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx","Terminated","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Head and Neck Cancer|Oral Complications|Radiation Toxicity","Drug: amifostine trihydrate|Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","5","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-24981","October 11, 2001","July 2001","null","September 20, 2012","September 2012","No Study Results Posted","null","October 2002","","https://ClinicalTrials.gov/show/NCT00025298"
2259,"NCT00003203","Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors|Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","168","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A9971|COG-A9971|CCG-99701|CDR0000066055","November 1, 1999","March 1998","March 2012","August 22, 2013","August 2013","No Study Results Posted","null","October 2007","Event Free Survival|Survival","https://ClinicalTrials.gov/show/NCT00003203"
2260,"NCT00354393","Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma","Unknown status","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: methotrexate|Drug: vinorelbine ditartrate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","36","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000486304|CASE-CCF-IRB-5179|CASE-CCF-0755","July 19, 2006","August 2002","null","February 6, 2009","October 2007","No Study Results Posted","null","null","Response to chemotherapy|Tolerability and toxicity|Relapse free and overall survival|Operability and surgical success|Quality of life","https://ClinicalTrials.gov/show/NCT00354393"
2261,"NCT00663741","Sorafenib Gastric Cancer Asian Phase I Study","Completed","No Results Available","Gastric Cancer","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Sorafenib (Nexavar, BAY43-9006)","Bayer","All","18 Years to 74 Years   (Adult, Senior)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12931","April 17, 2008","May 2008","April 2010","June 9, 2013","June 2013","No Study Results Posted","null","March 2010","Safety and pharmacokinetics|1 year survival rate|Overall survival|Progression free survival|Response rate|Duration of response","https://ClinicalTrials.gov/show/NCT00663741"
2262,"NCT01711541","Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Stage IVA Oropharyngeal Carcinoma AJCC v7|Stage IVB Oropharyngeal Carcinoma AJCC v7","Drug: Carboplatin|Drug: Cisplatin|Drug: Fluorouracil|Drug: Hydroxyurea|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Placebo|Radiation: Radiation Therapy|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","110","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","NCI-2012-02009|A091101|N01CM62201|U10CA180821|U10CA031946","October 18, 2012","October 22, 2012","null","May 23, 2017","May 2017","No Study Results Posted","null","October 15, 2017","MTD of veliparib, graded according to the Common Terminology Criteria for Adverse Events (Phase I)|Relative change in tumor size as measured by RECIST (Phase II)|Disease-free survival|DSS|OS|PFS|Time to local or distant progression|Toxicity rates during induction and overall","https://ClinicalTrials.gov/show/NCT01711541"
2263,"NCT02157792","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy","Recruiting","No Results Available","Advanced Solid Tumor","Drug: VX-970|Drug: Gemcitabine|Drug: Cisplatin|Drug: Etoposide|Drug: Carboplatin","Vertex Pharmaceuticals Incorporated","All","18 Years and older   (Adult, Senior)","Phase 1","205","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VX12-970-001|2012-003126-25","June 1, 2014","December 2012","July 2017","November 15, 2016","October 2016","No Study Results Posted","null","July 2017","Parts A, B, C1, C2, C3: Safety parameters, including adverse event (AEs), clinical laboratory values (serum chemistry, hematology, and urinalysis), vital signs, and electrocardiogram (ECG) assessments|Parts C1, C2, C3: Overall Response Rate (ORR) for all subjects in Part C1 (NSCLC), ORR for subjects in Part C2 (TNBC) who are basaloid subtype and BRCA1/BRCA2 germline wild-type, ORR for all subjects in Part C3 (SCLC)|Part A: Maximum tolerated dose (MTD) of VX-970 administered in combination with cisplatin and gemcitabine and in combination with gemcitabine|Part A: Pharmacokinetic (PK) parameter estimates of VX-970 in combination with cisplatin and gemcitabine and in combination with gemcitabine|Part B: Maximum tolerated dose (MTD) of VX-970 in combination with cisplatin and in combination with cisplatin and etoposide|Part B: PK parameter estimates of VX-970 in combination with cisplatin and in combination with cisplatin and etoposide|Part B: PK parameter estimates of etoposide derived from plasma concentration-time data after coadministration with VX-970 and in the absence of VX-970|Parts A, B: Objective tumor response (OR) as evaluated by Response Criteria Evaluation in Solid Tumors (RECIST) 1.1|Part C2: Overall Response Rate in all subjects in Part C2|Parts C1, C2, C3: Progression Free Survival (PFS)|Parts C1, C2, C3: Response Duration (RD)|Parts C1, C2, C3: Overall Survival (OS)|Parts C1, C2, C3: Clinical benefit (Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) of 6 months or greater)|Parts C1, C2, C3: PK parameter estimates of VX-970 including maximum concentrations (Cmax), area under the curve (AUC), apparent volume at steady state (Vss), clearance (CL) and terminal elimination half-life (t1/2)","https://ClinicalTrials.gov/show/NCT02157792"
2264,"NCT01261299","Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung|Urinary Bladder Neoplasms","Drug: Carbon-14-labeled carboplatin","University of California, Davis|Lawrence Livermore National Laboratory|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Senior)","Early Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCDCC#200","December 9, 2010","December 2010","November 2018","March 21, 2017","March 2017","No Study Results Posted","null","June 2017","Correlation of carboplatin-DNA monoadducts induced by microdoses of carboplatin with cancer response to carboplatin-based chemotherapy|Determination of the underlying chemoresistance mechanisms to carboplatin","https://ClinicalTrials.gov/show/NCT01261299"
2265,"NCT00003573","Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","53","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9631|POG-9631|CDR0000066640","November 1, 1999","November 1998","March 2008","July 24, 2014","July 2014","No Study Results Posted","null","October 2007","Assess the efficacy of oral etoposide at 50 mg/m2/day given concurrently with radiotherapy followed with dose intensive adjuvant chemotherapy in children with newly diagnosed high stage medulloblastoma","https://ClinicalTrials.gov/show/NCT00003573"
2266,"NCT00104676","Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","Unknown status","No Results Available","Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Drug: cisplatin|Drug: etoposide|Drug: ifosfamide|Drug: oxaliplatin|Drug: paclitaxel","UNICANCER|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 3","260","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000416124|FRE-FNCLCC-GETUG-13/0206|EU-20502","March 3, 2005","November 2003","null","December 13, 2009","November 2008","No Study Results Posted","null","null","Progression-free survival rate after 1 course of treatment|Overall survival","https://ClinicalTrials.gov/show/NCT00104676"
2267,"NCT02279134","Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma","Recruiting","No Results Available","Esophageal Neoplasms|Esophageal Cancer","Radiation: Adjuvant Chemoradiation|Radiation: Adjuvant Radiation|Drug: Paclitaxel|Drug: Cisplatin or Nedaplatin","Zefen Xiao|Chinese Academy of Medical Sciences","All","18 Years to 68 Years   (Adult, Senior)","Phase 2|Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","14-090/880","October 26, 2014","October 2014","October 2022","January 16, 2017","January 2017","No Study Results Posted","null","December 2018","Disease-free survival (DFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02279134"
2268,"NCT00052910","Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer","Active, not recruiting","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: leucovorin calcium|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","546","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-80101|U10CA031946|CDR0000258787","January 24, 2003","December 2002","null","June 17, 2016","June 2016","No Study Results Posted","null","June 2012","Overall survival|Disease free survival","https://ClinicalTrials.gov/show/NCT00052910"
2269,"NCT01822496","Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","Recruiting","No Results Available","Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer","Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Carboplatin|Drug: Cisplatin|Drug: Crizotinib|Drug: Erlotinib Hydrochloride|Drug: Etoposide|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","234","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-00737|RTOG-1306|U10CA180868|U10CA021661","April 1, 2013","November 4, 2013","null","May 24, 2017","May 2017","No Study Results Posted","null","December 31, 2021","Progression-free survival|Deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available|Distant progression free survival|Incidence of grade 3-5 adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0|Local-regional progression free survival|Overall survival|Proportion of patients who respond (completely or partially) to each treatment, assessed by the Response Evaluation Criteria in Solid Tumors","https://ClinicalTrials.gov/show/NCT01822496"
2270,"NCT00867178","Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System","Active, not recruiting","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Pineoblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide Phosphate|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Thiotepa|Drug: Vincristine Sulfate|Drug: Vorinostat","National Cancer Institute (NCI)","All","2 Months to 47 Months   (Child)","","62","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-03167|PBTC-026|U01CA081457|UM1CA081457","March 20, 2009","February 25, 2009","null","May 23, 2017","May 2017","No Study Results Posted","null","December 30, 2017","Dose-limiting toxicity of proposed vorinostat as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Feasibility in terms of completing 3 courses of induction therapy|Prognostic value of histopathological classification of pediatric medulloblastoma by single-nucleotide polymorphism (SNP) analysis and gene expression analysis|Overall survival (OS)|Predictive values of biological markers in CSF, plasma and urine in the context of a feasibility study|Progression-free survival (PFS)|Response rate of this approach in patients with measurable residual disease (primary site and/or metastatic sites)","https://ClinicalTrials.gov/show/NCT00867178"
2271,"NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","Not yet recruiting","No Results Available","Carcinoma，Non-Small-Cell Lung|Lung Carcinomas, Non-Small-Cell|Non-small-cell Lung Carcinoma|Nonsmall Cell Lung Cancer","Drug: Pemetrexed|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: REGN2810","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","R2810-ONC-1624|2016-004407-31|SAR439684","March 3, 2017","March 2017","November 2021","March 16, 2017","March 2017","No Study Results Posted","null","November 2021","Progression-free survival (PFS) as assessed by a blinded Independent review committee (IRC) using RECIST 1.1|Overall survival (OS)|Objective response rates (ORR)|Best overall response (BOR)|Compare the duration of response (DOR) of REGN2810 versus platinum based chemotherapies|Assess quality of life (QOL) of patients treated with REGN2810 versus patients receiving platinum-based chemotherapies as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Change From Baseline in Quality of Life as measured by the Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13)|Incidence of Adverse Events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities|Measure concentrations of REGN2810 in serum|Characterize the pharmacokinetics (PK) of REGN2810","https://ClinicalTrials.gov/show/NCT03088540"
2272,"NCT01858922","Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","Recruiting","No Results Available","Hodgkin Disease","Drug: ABVE-PC|Drug: DECA","Baylor College of Medicine|Texas Children's Hospital","All","Child, Adult, Senior","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","H-30993 TXCH-HD-12A|TXCH-HD-12A","May 17, 2013","December 2012","March 2021","April 6, 2017","April 2017","No Study Results Posted","TXCH-HD-12A","June 2019","Response to therapy from Day 1 of Treatment|Changes in Frequency of Regulatory Cell Population|Function of Regulatory Cell Population","https://ClinicalTrials.gov/show/NCT01858922"
2273,"NCT00209222","Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL","Unknown status","No Results Available","Lymphoma, Mantle-Cell","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Cisplatinum|Drug: Ara-C|Drug: Dexamethasone|Drug: BCNU|Drug: Melphalan|Drug: Etoposide|Drug: G-CSF|Procedure: chemotherapy: R-CHOP|Procedure: chemotherapy: R-DHAP|Procedure: chemotherapy: Dexa-BEAM|Procedure: stem cell harvest|Procedure: total body irradiation|Procedure: high-dose chemotherapy: Cyclophosphamide|Procedure: high-dose chemotherapy: Ara-C /Melphalan","European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association","All","18 Years to 65 Years   (Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCL2004-2","September 13, 2005","July 2004","December 2014","September 7, 2012","July 2009","No Study Results Posted","null","December 2014","time to treatment failure after start of therapy|complete remission (CR) rate|overall survival|progression-free survival|adverse events|serious infectious complications","https://ClinicalTrials.gov/show/NCT00209222"
2274,"NCT02054819","Treating NSCLC Minimal Stage IV With Curative Intent","Recruiting","No Results Available","Non-small Cell Lung Cancer","Other: Induction chemotherapy and concurrent radiation|Other: Consolidation: Radiation therapy to metastatic sites","Leo W. Jenkins Cancer Center|East Carolina University","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LJCC 2011-01","August 26, 2013","June 2013","December 2017","October 20, 2014","October 2014","No Study Results Posted","null","December 2016","Overall survival|New metastatic disease","https://ClinicalTrials.gov/show/NCT02054819"
2275,"NCT02041533","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)","Active, not recruiting","No Results Available","Stage IV or Recurrent Non-Small Cell Lung Cancer","Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","535","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-026|2012-004502-93","January 19, 2014","March 2014","January 2018","April 17, 2017","September 2016","No Study Results Posted","null","July 2016","Progression Free Survival (PFS) as assessed by independent radiology review committee (IRRC) in subjects with strongly Programmed death-ligand 1+ (PD-L1+) tumor expression|Objective response rate (ORR) as determined per IRRC in subjects with strongly PD-L1+ tumor expression|Overall survival (OS) in subjects with strongly PD-L1+ tumor expression|PFS in all subjects with any PD-L1+ tumor expression|Disease related symptom improvement in all subjects","https://ClinicalTrials.gov/show/NCT02041533"
2276,"NCT02607423","Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery","Recruiting","No Results Available","Stage IIIA Non-Small Cell Lung Cancer","Drug: Cisplatin|Procedure: Computed Tomography|Drug: Docetaxel|Radiation: Fludeoxyglucose F-18|Drug: Gemcitabine Hydrochloride|Drug: Pemetrexed Disodium|Procedure: Positron Emission Tomography","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","EA5123|NCI-2015-01054|U10CA180820","November 16, 2015","November 2015","null","January 22, 2016","January 2016","No Study Results Posted","null","December 2017","Rate of mediastinal downstaging|Change of SUVmax|Overall survival|Percent change of metabolic tumor volume|Percent change of SUVpeak|Percent change of TLG|SUVmax","https://ClinicalTrials.gov/show/NCT02607423"
2277,"NCT03043872","Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)","Recruiting","No Results Available","Small Cell Lung Carcinoma Extensive Disease","Drug: Durvalumab|Drug: Tremelimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Etoposide","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","795","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419QC00001|2016-001203-23","January 18, 2017","March 27, 2017","February 28, 2020","May 24, 2017","May 2017","No Study Results Posted","Caspian","March 29, 2019","Overall survival (OS)|Progression-free survival using BICR assessments according to RECIST 1.1|Objective response rate (ORR) using BICR assessments according to RECIST 1.1|Proportion of patients alive and progression free at 6 months from randomization (APF6) using BICR assessments according to RECIST 1.1|Proportion of patients alive and progression free at 12 months from randomization (APF12) using BICR assessments according to RECIST 1.1|Proportion of patients alive at 18 months (OS18)|Disease-related symptoms measured by EORTC QLQ-C30|Health-related QoL measured by EORTC QLQ-C30|Disease-related symptoms measured by EORTC QLQ-LC13|The immunogenicity of durvalumab and tremelimumab as assessed by frequency of patients with positive ADA titers|The pharmacokinetics (PK) of durvalumab and tremelimumab as determined by peak concentration|The pharmacokinetics (PK) of durvalumab and tremelimumab as determined by trough concentration|Changes in WHO/ECOG performance status","https://ClinicalTrials.gov/show/NCT03043872"
2278,"NCT00576056","Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC","Terminated","Has Results","Carcinoma, Hepatocellular","Drug: Sorafenib|Drug: TACE","University of Pittsburgh|Bayer","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-047","December 14, 2007","January 2008","April 2010","December 28, 2016","November 2016","May 23, 2016","null","March 2010","Determine Progression-free Survival in This Patient Population Treated With the Proposed Combination Treatment Modality|Determine the Overall Survival in Patients Treated With This Combination Regimen","https://ClinicalTrials.gov/show/NCT00576056"
2279,"NCT01672229","Bortezomib in Patients With Chronic Graft Versus Host Disease","Active, not recruiting","No Results Available","Graft Versus Host Disease","Drug: Bortezomib","University of California, Davis|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCDCC#229|X05379","August 1, 2012","July 2012","December 2017","January 19, 2017","January 2017","No Study Results Posted","null","December 2017","Safety of weekly bortezomib in patients with chronic graft versus host disease panobinostat in combination with cisplatin and pemetrexed|cGVHD Response|Role of bortezomib on induction of immune tolerance by performing correlative studies","https://ClinicalTrials.gov/show/NCT01672229"
2280,"NCT01434394","Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer","Unknown status","No Results Available","Locally Advanced Malignant Neoplasm|Oral Cancer|Oropharyngeal Carcinoma|Effects of Chemotherapy","Drug: Neo-adjuvant Erbitux-based chemotherapy","Shanghai Jiao Tong University School of Medicine|Fudan University|Tongji University|Second Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","243","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9thShanghai|10DZ1951300","September 2, 2011","August 2011","February 2017","November 30, 2011","November 2011","No Study Results Posted","EAGLE","December 2016","Pathological Complete Response|Disease Free Survival|Locoregional Control rates|Overall Survival|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01434394"
2281,"NCT02568033","Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer","Recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Carboplatin|Drug: Cisplatin|Drug: Docetaxel|Drug: Paclitaxel|Radiation: stereotactic radiosurgery","The Cooper Health System","All","18 Years and older   (Adult, Senior)","Early Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13-130","October 2, 2015","October 2013","October 2017","January 30, 2017","July 2016","No Study Results Posted","null","October 2017","Disease free progression|Toxicity (Treatment related side effects)","https://ClinicalTrials.gov/show/NCT02568033"
2282,"NCT02672254","New Strategies Against Cutaneous Squamous Cell Carcinoma","Completed","No Results Available","Cutaneous Squamous Cell Carcinoma","Radiation: Samples with 2 treatments","Corporacion Parc Tauli|Hospital Clinic of Barcelona","Female","Child, Adult, Senior","","3","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","FPT-2016.11","January 22, 2016","January 2016","January 2016","January 29, 2016","January 2016","No Study Results Posted","null","January 2016","Study of the effectiveness of each treatment by means of flow cytometry and transmission electron/photon microscopy|Study of the effectiveness of both treatments concomitantly by means of flow cytometry and transmission electron/photon microscopy","https://ClinicalTrials.gov/show/NCT02672254"
2283,"NCT01549730","Cervix Hypoxia FAZA","Recruiting","No Results Available","Cervix Cancer","Procedure: 18F-Fluoroazomycin Arabinoside (18F-FAZA)","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","UHN REB 11-0026-C","June 23, 2011","May 2011","May 2017","December 28, 2016","December 2016","No Study Results Posted","null","May 2017","Number of patients treated with the PET tracer FAZA to image primary tumor hypoxia in patients with cervix cancer prior to treatment with radiotherapy and concurrent cisplatin chemotherapy","https://ClinicalTrials.gov/show/NCT01549730"
2284,"NCT00002492","Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma","Completed","No Results Available","Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: isolated limb perfusion|Procedure: conventional surgery|Radiation: brachytherapy|Radiation: radiation therapy","University of Miami","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","89253|SCCC-1989032|NCI-V92-0066","November 1, 1999","November 1991","February 2000","December 14, 2016","December 2016","No Study Results Posted","null","February 2000","","https://ClinicalTrials.gov/show/NCT00002492"
2285,"NCT03004287","2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","Not yet recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Thalidomide|Drug: Dexamethasone|Drug: Daratumumab|Drug: Cisplatin|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Melphalan|Procedure: ASCT|Drug: Lenalidomide|Drug: Bortezomib","University of Arkansas|Janssen, LP","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","206241","December 19, 2016","June 1, 2017","January 2021","May 15, 2017","May 2017","No Study Results Posted","null","January 2021","Measure the progression-free survival in patients with high risk multiple myeloma","https://ClinicalTrials.gov/show/NCT03004287"
2286,"NCT01042041","Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer","Completed","No Results Available","Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer","Drug: sorafenib tosylate|Drug: doxorubicin hydrochloride|Drug: cisplatin|Drug: mitomycin C|Procedure: transarterial chemoembolization|Procedure: hepatic artery embolization","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 08208|NCI-2009-01488","December 10, 2009","September 2009","December 2010","February 25, 2013","February 2013","No Study Results Posted","null","December 2010","Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.|Time to Disease Progression","https://ClinicalTrials.gov/show/NCT01042041"
2287,"NCT00969306","Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients","Completed","No Results Available","Small Cell Lung Cancer","Drug: Chloroquine, A-CQ 100","Maastricht Radiation Oncology|Maastricht University Medical Center|National Cancer Institute (NCI)","All","18 Years to 100 Years   (Adult, Senior)","Phase 1","5","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Chloroquine IV","August 31, 2009","September 2013","June 2016","April 13, 2017","April 2017","No Study Results Posted","Chloroquine IV","June 2016","To determine the toxicity of adding chloroquine in escalating doses in SCLC patients: to standard dose cisplatin-etoposide in extensive disease SCLC; to standard dose concurrent radiotherapy and cisplatin-etoposide in limited disease SCLC|Tumor response (according to RECIST)|Overall survival","https://ClinicalTrials.gov/show/NCT00969306"
2288,"NCT03150628","Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study","Not yet recruiting","No Results Available","Gastric Cancer|Peritoneal Carcinomatosis|HIPEC","Drug: Perioperative chemotherapy|Procedure: Cytoreduction|Drug: HIPEC","Richard van Hillegersberg|UMC Utrecht","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NL58258.041.16|2016-002595-27|16-180/G-M","April 4, 2017","June 1, 2017","June 1, 2025","May 9, 2017","May 2017","No Study Results Posted","CISCA","June 1, 2020","Morbidity|Mortality|Survival|Recovery|Quality of Life|Readmissions","https://ClinicalTrials.gov/show/NCT03150628"
2289,"NCT00083915","DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation","Completed","Has Results","Multiple Myeloma","Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Etoposide|Drug: Melphalan|Drug: Thalidomide|Drug: Dexamethasone","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 3","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2001-12","June 3, 2004","June 2001","June 2010","July 7, 2011","July 2011","July 7, 2011","null","June 2010","Transplant With DT PACE-Melphalan Regimen of Chemotherapy vs. Transplant With Melphalan Alone.|Side Effects With DT PACE-Melphalan vs Side Effects With Melphalan Alone","https://ClinicalTrials.gov/show/NCT00083915"
2290,"NCT03107182","Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events","Not yet recruiting","No Results Available","HPV-Related Squamous Cell Carcinoma|HNSCC","Drug: nab-paclitaxel|Drug: Carboplatin|Drug: Nivolumab|Drug: Cisplatin|Drug: Hydroxyurea|Drug: 5-FU|Drug: Dexamethasone|Drug: Famotidine|Drug: Diphenhydramine|Drug: Paclitaxel|Procedure: Transoral robotic surgery (TORS)|Radiation: Adjuvant RT|Radiation: Chemoradiotherapy","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB17-0104","March 29, 2017","June 2017","June 2020","April 4, 2017","April 2017","No Study Results Posted","OPTIMA II","June 2020","Evaluate the tumor shrinkage (%) to measure the deep response rate (DRR)|number of patients with adverse events|to measure the 2 year progression-free survival (PFS)|to measure the 2 year overall survival (OS)|to measure the 2 year rates of locoregional and distant control","https://ClinicalTrials.gov/show/NCT03107182"
2291,"NCT01857934","Therapy for Children With Advanced Stage Neuroblastoma","Recruiting","No Results Available","Neuroblastoma","Drug: cyclophosphamide|Drug: topotecan|Biological: hu14.18K322A|Procedure: peripheral blood stem cell harvest|Procedure: surgical resection|Drug: cisplatin|Drug: etoposide|Drug: doxorubicin|Drug: vincristine|Drug: busulfan|Drug: melphalan|Biological: peripheral blood stem cell transplantation|Biological: natural killer cell infusion|Radiation: radiation therapy|Biological: GM-CSF|Biological: G-CSF|Drug: mesna|Drug: levetiracetam|Biological: interleukin-2|Drug: Isotretinoin|Device: CliniMACS","St. Jude Children's Research Hospital|Cookies for Kids' Cancer|CURE Childhood Cancer, Inc.","All","up to 18 Years   (Child, Adult)","Phase 2","210","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NB2012|NCI-2013-00034","May 16, 2013","July 5, 2013","July 31, 2021","April 17, 2017","September 2016","No Study Results Posted","null","January 31, 2021","Number of participants with complete or partial response|Event-free survival (EFS)|Feasibility of delivering hu14.18K322A to 6 cycles of induction therapy|Local failure rate|Dose limiting toxicity (DLT) or severe (grade 3 or 4) VoD|Dose limiting toxicity (DLT)","https://ClinicalTrials.gov/show/NCT01857934"
2292,"NCT00416858","Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Federation Francophone de Cancerologie Digestive","All","Child, Adult, Senior","Phase 3","40","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000453783|FFCD-9102|EU-20539|ESSAI-FFCD-9102","December 27, 2006","null","April 2007","March 3, 2014","April 2007","No Study Results Posted","null","April 2007","","https://ClinicalTrials.gov/show/NCT00416858"
2293,"NCT01066234","Adjuvant CCRT vs CT in Minimal N2 NSCLC","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Radiation: concurrent chemoradiotherapy|Drug: chemotherapy only","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-04-004","February 8, 2010","April 2009","March 2017","April 19, 2016","April 2016","No Study Results Posted","null","March 2014","Disease-free survival|Overall survival (OS)|Pattern of relapse|Toxicity profile|Quality of life (QOL)","https://ClinicalTrials.gov/show/NCT01066234"
2294,"NCT03086681","Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma","Not yet recruiting","No Results Available","Cervical Carcinoma","Drug: Endostar|Drug: DDP","Yong Zhang,MD|First Affiliated Hospital of Guangxi Medical University","Female","18 Years to 65 Years   (Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","FirstGuangxiMU-2016-062","March 16, 2017","March 2017","February 2020","March 16, 2017","March 2017","No Study Results Posted","ECWHCCFLACC","February 2020","short-time effect|Overall Survival|Progression-Free Survival","https://ClinicalTrials.gov/show/NCT03086681"
2295,"NCT00004188","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 3","495","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A3973|COG-A3973|CCG-A3973|POG-A3973|CCG-39703|FHCRC-1631.00|CDR0000067429","January 21, 2000","February 2001","null","May 16, 2013","May 2013","No Study Results Posted","null","October 2007","Event-free survival rate|Rate of occurrence of toxic (non disease-related) deaths where a toxic death will be ""counted"" if it occurs prior to the initiation of the immunotherapy|Time to engraftment|CD34 content|Tumor content as measured by reverse transcriptase polymerase chain reaction","https://ClinicalTrials.gov/show/NCT00004188"
2296,"NCT00085098","Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor","Completed","Has Results","Brain Tumor|Central Nervous System Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 25 Years   (Child, Adult)","Phase 3","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0232|CDR0000367294|COG-ACNS0232","June 10, 2004","January 2007","May 2009","February 7, 2017","February 2017","June 7, 2013","null","May 2009","Event-free Survival|Response|Toxicity and Safety as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0|Quality of Life (QOL) and Neurocognitive Assessment (NP)","https://ClinicalTrials.gov/show/NCT00085098"
2297,"NCT03070366","Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC","Recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Chemotherapy|Radiation: Stereotactic radiotherapy","Groupe Oncologie Radiotherapie Tete et Cou","All","18 Years to 77 Years   (Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GORTEC 2014-04","January 16, 2017","September 2016","October 2021","February 28, 2017","February 2017","No Study Results Posted","OMET","September 2020","Overall Survival without quality of life deterioration|Overall Survival|Progression free survival|Number of participants with adverse events grade 3 as assessed by CTCAE v4.0 within the first 6 months of treatment|Number of participants with treatment related adverse events as assessed by CTCAE v4.0|Overall response rate","https://ClinicalTrials.gov/show/NCT03070366"
2298,"NCT00514293","Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: bexarotene|Drug: capecitabine|Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: tretinoin","Raghu Nandan, M.D., Inc|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000561066|EISAI-2007-01-22","August 8, 2007","January 2007","null","January 9, 2014","August 2008","No Study Results Posted","null","December 2011","Response rate as measured by RECIST criteria|Time to progression|Survival|Patient-reported symptoms and side effects","https://ClinicalTrials.gov/show/NCT00514293"
2299,"NCT00003937","Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma","Completed","No Results Available","Cardiac Toxicity|Sarcoma","Drug: cisplatin|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: methotrexate|Procedure: conventional surgery","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 3","253","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P9754|COG-P9754|POG-P9754|CCG-P9754|CDR0000067129","November 1, 1999","September 1999","June 2008","August 4, 2014","August 2014","No Study Results Posted","null","March 2004","Event Free Survival","https://ClinicalTrials.gov/show/NCT00003937"
2300,"NCT01553942","Afatinib With CT and RT for EGFR-Mutant NSCLC","Recruiting","No Results Available","Lung Cancer","Drug: Afatinib|Radiation: Radiation|Drug: Cisplatin|Drug: Pemetrexed|Procedure: Surgery","Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11-464","March 5, 2012","April 2012","December 2018","March 10, 2017","March 2017","No Study Results Posted","null","December 2017","Response Rate|2 Year Progression-Free Survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Unresectable Disease Converted to Operable Cases|Locoregional Tumor Control Rates|Evaluation of EGFR Mutation Status and other genotypes","https://ClinicalTrials.gov/show/NCT01553942"
2301,"NCT00705549","Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer","Terminated","No Results Available","Non-Small-Cell Lung Cancer","Drug: Gemcitabine|Drug: Cisplatin|Drug: Docetaxel|Drug: Cisplatin|Drug: Vinorelbine|Drug: Pemetrexate","Hellenic Oncology Research Group|University Hospital of Crete","All","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/07.23","June 25, 2008","February 2008","September 2011","February 12, 2013","February 2013","No Study Results Posted","null","September 2011","Objective Response Rate (ORR) based on the pharmacogenomic profile of the ERCC1, RRM1 and BRCA1 expression|Determine the incidence of the different pharmacogenomic profiles as defined by the combined expression of ERCC1, RRM1 and BCRA1|Time to Tumor Progression|Overall Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00705549"
2302,"NCT00278278","Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: etoposide|Drug: ifosfamide|Drug: lomustine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","3 Years to 18 Years   (Child, Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000454723|GPOH-HIT-GBM-D|EU-205100","January 16, 2006","September 2003","null","December 18, 2013","November 2008","No Study Results Posted","null","March 2010","Overall survival (OS) rate at 5.5 years|Comparison of OS, progression-free survival, and event-free survival with historical control annually|Long-term sequelae annually|Tumor response|Progression-free survival|Event-free survival|Health status","https://ClinicalTrials.gov/show/NCT00278278"
2303,"NCT00931645","Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Procedure: Autologous stem cell transplantation|Procedure: DHAP rescue and Autologous stem cell transplantation|Procedure: DHAP rescue and F+C","University Hospital, Caen|Direction Générale de la Santé, France","All","18 Years to 65 Years   (Adult)","Phase 3","241","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SFGMTC|PHRC","June 29, 2009","April 2001","December 2008","July 1, 2009","July 2009","No Study Results Posted","Auto-LLC 2001","December 2007","Progression free survival|Overall survival, response after completion of scheduled treatment, tolerance and adverse events, quality of life, prognostic factors for response and survival.","https://ClinicalTrials.gov/show/NCT00931645"
2304,"NCT02124421","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer","Recruiting","No Results Available","Stage III Ovarian Cancer|Stage IV Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma","Procedure: Cytoreductive Surgery (CRS)|Drug: Adjuvant Chemotherapy|Other: Questionnaire|Procedure: Hyperthermic intraperitoneal chemotherapy|Drug: Carboplatin|Drug: Paclitaxel|Drug: Paclitaxel|Drug: Cisplatin","Mercy Medical Center","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MMC-2014-17","April 13, 2014","April 2014","April 2020","September 13, 2016","September 2016","No Study Results Posted","CRS/HIPEC","April 2018","Post-operative complication rates|Assessment of quality of life|Evaluate the rate of progression free survival|Evaluate overall survival","https://ClinicalTrials.gov/show/NCT02124421"
2305,"NCT00006461","Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor","Completed","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: etoposide|Procedure: therapeutic conventional surgery|Radiation: 3-dimensional conformal radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 3 Years   (Child)","Phase 3","82","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P9934|NCI-2012-02362|CDR0000068269|POG-P9934|COG-P9934|U10CA098543","November 6, 2000","October 2000","null","August 7, 2013","August 2013","No Study Results Posted","null","September 2007","Event-free survival rate|Acute and chronic toxicities associated with the treatment regimens|Neuropsychological and neuroendocrine effects of this systemic chemotherapy, surgery, and local, conformal radiation|Feasibility and validity of a centralized telephone interview based data collection method for neuropsychological evaluations|Incidence of atypical teratoid and/or rhabdoid tumor","https://ClinicalTrials.gov/show/NCT00006461"
2306,"NCT01111942","A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","Terminated","No Results Available","Head and Neck Cancer","Other: radiation combined with weekly carboplatin|Procedure: conservation surgery","Southern Illinois University","All","18 Years and older   (Adult, Senior)","Early Phase 1","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ROB-SCCI 10-001-1","April 26, 2010","February 2010","January 2014","August 4, 2015","August 2015","No Study Results Posted","null","January 2014","Rate of pathologic complete response|2 year overall survival|Clinical complete response|2 year disease-free survival|Quality of life|Incidence of HPV and EGFR positivity|K-ras mutational analysis","https://ClinicalTrials.gov/show/NCT01111942"
2307,"NCT02580253","Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation","Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Individualized Chemotherapy|Drug: mFOLFOX6","Zhejiang University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ZYYYMedOncoLT02","October 17, 2015","March 2017","December 2018","January 24, 2017","January 2017","No Study Results Posted","null","November 2018","Desease free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02580253"
2308,"NCT01211002","Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Non-small Cell Lung Cancer","Radiation: radiotherapy combined with EP|Drug: radiotherapy / EP combined with recombinant human endostatin","Simcere Pharmaceutical Co., Ltd|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","sim201002","September 27, 2010","October 2010","December 2012","September 28, 2010","September 2010","No Study Results Posted","null","December 2011","overall survival (OS)|quality of life|objective response rate (ORR)|disease control rate (DCR)|progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01211002"
2309,"NCT02142738","Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)","Active, not recruiting","No Results Available","Non-Small Cell Lung Carcinoma","Drug: Pembrolizumab|Drug: Paclitaxel|Drug: Carboplatin|Drug: Pemetrexed|Drug: Cisplatin|Drug: Gemcitabine","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","3475-024|2014-000323-25|142728","May 16, 2014","August 25, 2014","May 12, 2018","April 6, 2017","April 2017","No Study Results Posted","null","May 9, 2016","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02142738"
2310,"NCT00003141","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors|Neuroblastoma|Sarcoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 1","94","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99703|COG-99703|CCG-99703|CDR0000065924","November 1, 1999","March 1998","October 2011","March 27, 2014","March 2014","No Study Results Posted","null","December 2007","Feasibility|Maximal tolerated dose of thiotepa for consolidation therapy|Overall rates of significant toxicities including grade IV ototoxicity, electrolytic wasting (grade IV), and hemorrhagic cystitis (grade IV)|Event Free Survival","https://ClinicalTrials.gov/show/NCT00003141"
2311,"NCT01849783","Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","Recruiting","No Results Available","Extramedullary Plasmacytoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Primary Systemic Amyloidosis|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: dexamethasone|Drug: cisplatin|Drug: doxorubicin|Drug: cyclophosphamide|Drug: etoposide|Drug: bortezomib|Drug: thalidomide|Drug: melphalan|Procedure: autologous stem cell transplant","University of Iowa|National Cancer Institute (NCI)","All","65 Years to 85 Years   (Adult, Senior)","Phase 2","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201208755|NCI-2013-00883|10120146|P30CA086862","May 6, 2013","April 2013","December 2017","February 20, 2017","February 2017","No Study Results Posted","null","June 2017","PFS|Severe complications (ICU admission, death), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Percentage of participants able to complete full course of therapy|Complete response (CR) rate using the International Myeloma Working group uniform response criteria|Event free survival|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT01849783"
2312,"NCT00732498","Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL","Active, not recruiting","No Results Available","Lymphoma","Drug: Methylprednisolone|Drug: Etoposide|Drug: Cytarabine|Drug: Cisplatin|Drug: Rituximab|Drug: In-Zevalin|Drug: Y-Zevalin","University of Arizona|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","52","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","05-0303-04|P30CA023074|CDR0000597508|0500000303","August 9, 2008","May 15, 2006","December 31, 2018","May 9, 2017","May 2017","No Study Results Posted","ESHAP","December 31, 2017","Progression-free survival at 1 year|Median time to progression|Overall and complete response rates","https://ClinicalTrials.gov/show/NCT00732498"
2313,"NCT00911222","Epidemiological EMESIS-Registry","Completed","No Results Available","Antiemetic Therapy","Other: non-interventional","iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|ASORS|Arbeitskreis Klinische Studien|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","","1035","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOM-143","May 28, 2009","October 2008","August 2009","December 23, 2014","December 2014","No Study Results Posted","EMESIS","May 2009","Efficacy of anti-emetic therapies dependent on the rate ""complete and major control"" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.","https://ClinicalTrials.gov/show/NCT00911222"
2314,"NCT00031590","Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma","Terminated","No Results Available","Brain Tumors|Central Nervous System Tumors|Medulloblastoma|Primitive Neuroectodermal Tumor","Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Lomustine|Drug: Vincristine|Drug: Mesna|Radiation: Craniospinal Radiation","Children's Hospital of Philadelphia","All","3 Years to 30 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","00-002301|CHP-693","March 8, 2002","April 2001","May 2011","September 30, 2015","September 2015","No Study Results Posted","null","May 2011","Evaluate Rate of Late Neurotoxic Effects","https://ClinicalTrials.gov/show/NCT00031590"
2315,"NCT00186849","Therapy for Children With Advanced Stage High Risk Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|Procedure: Peripheral Blood Stem Cell Transplant","St. Jude Children's Research Hospital|National Institutes of Health (NIH)","All","up to 18 Years   (Child, Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NB-97","September 12, 2005","October 1997","April 2001","May 19, 2009","May 2009","No Study Results Posted","null","April 2001","Response rate|Feasibility/toxicity of an intensification phase of high-dose chemotherapy with topotecan and cyclophosphamide followed by autologous peripheral blood stem cell transplant","https://ClinicalTrials.gov/show/NCT00186849"
2316,"NCT01719536","Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients","Active, not recruiting","No Results Available","NSCLC","Drug: Icotinib|Drug: Chemotherapy","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BD-IC-IV36","October 29, 2012","December 2012","December 2016","September 28, 2016","September 2016","No Study Results Posted","Convince","September 2016","Progression Free Survival|Overall survival|Objective response rate","https://ClinicalTrials.gov/show/NCT01719536"
2317,"NCT00645632","Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma","Completed","No Results Available","Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: methotrexate|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery","Mayo Clinic|National Cancer Institute (NCI)","All","Child, Adult, Senior","","60","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000582263|P30CA015083|909101|549-90","March 26, 2008","November 1990","January 2008","May 13, 2011","May 2011","No Study Results Posted","null","January 1995","Histopathologic response rate|Clinical response rate|Toxicity|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00645632"
2318,"NCT01032967","Surgery or Chemoradiation for Esophageal Cancer","Completed","No Results Available","Esophageal Cancers","Procedure: Esophagectomy|Radiation: Definitive chemoradiation","Chinese University of Hong Kong","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Surgery or CRT Ca Esophagus","December 15, 2009","July 2000","June 2009","December 15, 2009","December 2009","No Study Results Posted","null","June 2009","Overall survival and disease-free survival|Quality of life and function outcomes","https://ClinicalTrials.gov/show/NCT01032967"
2319,"NCT00554463","G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Biological: Filgrastim|Biological: Pegfilgrastim|Drug: Concurrent chemotherapy|Drug: Adjuvant chemotherapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B","All","18 Years and older   (Adult, Senior)","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","RTOG 0623|CDR0000574000|NCI-2009-00742","November 6, 2007","January 2008","null","October 13, 2015","October 2015","September 23, 2014","null","August 2011","Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Concurrent Chemoradiotherapy as Assessed by NCI CTCAE v 3.0 (Common Terminology Criteria for Adverse Events)|Incidence of Grade 4 Neutropenia or Grades 3-4 Febrile Neutropenia Episodes During Adjuvant Chemotherapy as Assessed by NCI CTCAE v 3.0|Incidence of Dose Modifications or Treatment Delays|Incidence of Esophagitis, Pneumonitis, and Other Non-hematological Adverse Events as Assessed by NCI CTCAE v 3.0|Incidence of Grade 4 Thrombocytopenia|Median and 2-year Rates of Progression-free and Overall Survival","https://ClinicalTrials.gov/show/NCT00554463"
2320,"NCT00293358","Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cisplatin|Drug: etoposide phosphate|Drug: ifosfamide|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","500","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000455625|CCLG-GC-1997-01|EU-20579|SIOP-CNS-GCT-96","February 16, 2006","January 1997","December 2006","September 16, 2013","July 2008","No Study Results Posted","null","null","Survival|Event-free survival","https://ClinicalTrials.gov/show/NCT00293358"
2321,"NCT02777788","Curative Study of Chinese Traditional Medicine to Treat Lung Cancer","Active, not recruiting","No Results Available","Cancer","Drug: JinFuKang|Drug: XingZaoRuanJian|Drug: pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin","Shanghai University of Traditional Chinese Medicine|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","ZY3-CCCX-3-3023","May 9, 2016","September 2014","December 2016","May 18, 2016","May 2016","No Study Results Posted","TCM","December 2016","Progression-Free Survival|Objective response rate|Time-to-Progression|Number of participants with treatment-related quality of life as assessed by FACT－L4.0","https://ClinicalTrials.gov/show/NCT02777788"
2322,"NCT00238160","Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer","Withdrawn","No Results Available","Localized Resectable Adult Primary Liver Cancer|Stage III Childhood Liver Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: adjuvant therapy|Procedure: chemotherapy|Procedure: conventional surgery|Procedure: hepatic arterial infusion|Procedure: surgery","Kyoto University|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","0","Other","Interventional","Primary Purpose: Treatment","KYUH-UHA-HCC02-01|CDR0000363800","October 12, 2005","null","null","May 29, 2013","July 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00238160"
2323,"NCT00530179","FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma","Unknown status","No Results Available","Diffuse Large B Cell Lymphoma","Procedure: Autologous Blood Stem Transplantation|Drug: R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF","Alberta Health Services|Hoffmann-La Roche|AHS Cancer Control Alberta","All","18 Years to 65 Years   (Adult)","","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0307003","September 13, 2007","July 2007","null","December 6, 2011","August 2011","No Study Results Posted","PET Chop","August 2011","","https://ClinicalTrials.gov/show/NCT00530179"
2324,"NCT00416676","Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year and older   (Child, Adult, Senior)","Phase 3","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CCLG-NB-1993-01|CDR0000454571|EU-20594","December 27, 2006","null","null","August 1, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00416676"
2325,"NCT02099188","Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","Recruiting","No Results Available","Unresectable Sinonasal Tumors","Drug: Cisplatin|Drug: Docetaxel|Drug: 5-fluorouracil|Drug: Etoposide|Drug: Adriamycin|Drug: Ifosfamide|Drug: Leucovorin|Radiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)|Radiation: Radiotherapy - Patients not needing ENI|Radiation: Radiotherapy - Patients needing curative neck irradiation","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Regione Lombardia","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SINTART2|2013-000580-93","March 14, 2014","November 2013","January 2024","May 23, 2017","May 2017","No Study Results Posted","null","January 2020","Progression Free Survival (PFS)|Overall survival (OS)|Ocular function preservation by visual field tests.|Hearing preservation performed by audiogram test.|Overall safety profile of the whole treatment.|Objective Response Rate|Adverse events and laboratories abnormalities.","https://ClinicalTrials.gov/show/NCT02099188"
2326,"NCT02099175","Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","Recruiting","No Results Available","Sinonasal Tumors","Drug: Cisplatin|Drug: Docetaxel|Drug: 5-fluorouracil|Drug: Etoposide|Drug: Adriamycin|Drug: Ifosfamide|Drug: Leucovorin|Radiation: Radiotherapy - Patients needing Elective Nodal Volume (ENI)|Radiation: Radiotherapy - Patients not needing ENI|Radiation: Radiotherapy - Patients needing curative neck irradiation","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Regione Lombardia","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SINTART1|2013-000075-33","March 14, 2014","November 2013","January 2024","May 23, 2017","May 2017","No Study Results Posted","null","January 2020","Progression Free Survival (PFS)|Overall survival (OS)|Ocular function preservation by visual field tests.|Hearing preservation performed by audiogram test.|Overall safety profile of the whole treatment.|Objective Response Rate|Adverse events and laboratories abnormalities.","https://ClinicalTrials.gov/show/NCT02099175"
2327,"NCT02445209","Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma","Completed","No Results Available","HER2 Negative Gastric Cancer","Other: EOX|Other: mDCF","Jagiellonian University","All","18 Years and older   (Adult, Senior)","Phase 3","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JagiellonianU-01","April 30, 2015","September 2010","February 2014","May 14, 2015","May 2015","No Study Results Posted","null","February 2014","Overall Survival|Progression-free Survival|Safety as assessed by adverse events according to CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02445209"
2328,"NCT00498953","Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx","Completed","No Results Available","Head and Neck Cancer","Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: lapatinib ditosylate|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Genetic: in situ hybridization|Genetic: polymerase chain reaction|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","7","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-24051|2006-002667-33|GSK-EORTC-24051","July 10, 2007","May 2007","March 2009","January 7, 2013","January 2013","No Study Results Posted","null","November 2008","Maximum tolerated dose of lapatinib ditosylate (Phase I)|Dose-limiting toxicities of lapatinib ditosylate (Phase I)|Recommended dose of lapatinib ditosylate (Phase I)|Feasibility (Phase II)|Toxicity (Phase II)|Survival with functional larynx (i.e., alive without local progression/relapse, tracheotomy, feeding tube, gastrostomy, or laryngectomy) (Phase II)|Response rate (CR and PR) of neoadjuvant treatment (Phase II)|Overall response rate (Phase II)|Rate of local relapse (Phase II)|Distant metastasis (Phase II)|Overall survival (Phase II)|Predictive value of PET to spare neck dissection in N1-3 patients (Phase II)","https://ClinicalTrials.gov/show/NCT00498953"
2329,"NCT00276705","Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer","Unknown status","No Results Available","Liver Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: thalidomide|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 29 Years   (Child, Adult)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000454579|CCLG-LT-2005-05|CCLG-SIOPEL-HCC|CCLG-SIOPEL-5|EU-20590|EUDRACT-2005-000427-42","January 12, 2006","June 2005","null","September 16, 2013","June 2009","No Study Results Posted","null","April 2009","Event-free and overall survival following tumor resection|Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy","https://ClinicalTrials.gov/show/NCT00276705"
2330,"NCT01783197","Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Selumetinib|Drug: Pemetrexed|Drug: Cisplatin","Canadian Cancer Trials Group|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I215","January 31, 2013","January 30, 2013","December 2017","March 10, 2017","March 2017","No Study Results Posted","null","August 2017","Maximum dose tolerability of Selumetinib in patients|Pharmacokinetic response prediction to selumetinib","https://ClinicalTrials.gov/show/NCT01783197"
2331,"NCT01909856","The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy","Completed","No Results Available","Cancer","Drug: Palonosetron|Drug: Granisetron|Drug: Dexamethasone|Drug: Cisplatin","Jiangsu Simcere Pharmaceutical Co., Ltd.","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","sim-palonosetron","July 22, 2013","October 2011","June 2014","December 2, 2015","November 2015","No Study Results Posted","null","April 2014","Complete Response(CR) within 24-120 hours after chemotherapy|CR within 0-120 hours after chemotherapy|CR within 0-24 hours after chemotherapy|Incidence of Adverse events","https://ClinicalTrials.gov/show/NCT01909856"
2332,"NCT01175356","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","Completed","No Results Available","Disseminated Neuroblastoma|Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Drug: cyclophosphamide|Drug: topotecan hydrochloride|Drug: cisplatin|Drug: etoposide phosphate|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Radiation: iobenguane I 131|Procedure: therapeutic conventional surgery|Drug: busulfan|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: 3-dimensional conformal radiation therapy|Radiation: external beam radiation therapy|Radiation: intensity-modulated radiation therapy|Drug: isotretinoin|Other: pharmacological study|Other: questionnaire administration|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","","99","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL09P1|NCI-2011-01745|CDR0000682629|U10CA180886|U10CA098543","August 3, 2010","October 2010","September 28, 2016","February 7, 2017","February 2017","No Study Results Posted","null","September 28, 2016","Proportion of MIBG avid patients who are able to be treated with iobenguane I 131|Proportion of MIBG avid patients who are able to be treated with iobenguane I 131 and then Bu/Mel|Percentage of average per capita income encompassed by the total of travel + housing + lost wages|Proportion of eligible high-risk patients accrued to the study|Event-free survival rate|Response rate, defined as the proportion of evaluable patients who attain a response of partial response or better at the end of iobenguane I 131 + Bu/Mel therapy and local radiotherapy|Incidence of adverse events and SOS, assessed by Common Terminology Criteria version 4.0 for toxicity assessment and grading","https://ClinicalTrials.gov/show/NCT01175356"
2333,"NCT00135135","Therapy for Children With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|Procedure: Radiation therapy, Surgery, Peripheral Stem cell transplant","St. Jude Children's Research Hospital|AstraZeneca|National Institutes of Health (NIH)","All","up to 18 Years   (Child, Adult)","Phase 2","23","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NB2005|AstraZeneca IRUSIERS0389","August 24, 2005","August 2005","June 2007","June 2, 2008","June 2008","No Study Results Posted","null","June 2007","Response rate","https://ClinicalTrials.gov/show/NCT00135135"
2334,"NCT02339753","Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation","Unknown status","No Results Available","Pediatric Solid Tumor","Drug: Carboplatin","The Korean Society of Pediatric Hematology Oncology","All","up to 19 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SNUCH_carboplatinPK","January 2, 2015","January 2015","December 2016","January 15, 2015","January 2015","No Study Results Posted","null","December 2015","Area Under Curve (AUC) of carboplatin at the first and last administration day|Number of participants with adverse events after HSCT using carboplatin as the conditioning regimen","https://ClinicalTrials.gov/show/NCT02339753"
2335,"NCT02240771","Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma","Unknown status","No Results Available","Hepatocellular Carcinoma","Procedure: Transarterial chemotherapy|Drug: Oral chemotherapy","All India Institute of Medical Sciences, New Delhi|Indian Council of Medical Research","All","12 Years to 80 Years   (Child, Adult, Senior)","Phase 2|Phase 3","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAC-HCC","August 31, 2014","January 2006","March 2015","September 12, 2014","September 2014","No Study Results Posted","null","December 2014","Survival rate-|Tumor response","https://ClinicalTrials.gov/show/NCT02240771"
2336,"NCT01142414","Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence","Withdrawn","No Results Available","Head and Neck Cancer","Biological: panitumumab|Drug: cisplatin|Drug: fluorouracil|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: quality-of-life assessment|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-22071-24071|EORTC-22071|EU-21038|EUDRACT-2008-006180-36|AMGEN-EORTC-22071","June 10, 2010","null","null","January 13, 2012","January 2012","No Study Results Posted","null","null","Disease-free survival|Overall survival|Loco-regional control|Cumulative incidence of and time to distant metastases|Cumulative incidence of and time to second cancers (all sites)|Incidence of acute and late toxicity (CTCAE version 4.0)|Health-related quality of life","https://ClinicalTrials.gov/show/NCT01142414"
2337,"NCT00005838","Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer","Drug: shark cartilage extract AE-941|Other: placebo|Drug: cisplatin|Drug: vinorelbine tartrate|Drug: carboplatin|Drug: paclitaxel|Radiation: radiation therapy","National Cancer Institute (NCI)|Radiation Therapy Oncology Group|National Center for Complementary and Integrative Health (NCCIH)","All","18 Years and older   (Adult, Senior)","Phase 3","756","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","NCI-2012-02725|ID99-303|U10CA045809|CDR0000067853","June 2, 2000","March 2000","null","January 22, 2013","January 2013","No Study Results Posted","null","February 2007","Overall survival|Progression-free survival every 3 months|Tumor response rate|Tumor response duration|Metastasis-free survival","https://ClinicalTrials.gov/show/NCT00005838"
2338,"NCT01878617","A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","Recruiting","No Results Available","Medulloblastoma","Radiation: Craniospinal Irradiation with boost to the primary tumor site|Drug: Cyclophosphamide|Drug: Cisplatin|Drug: Vincristine|Drug: Vismodegib|Drug: Pemetrexed|Drug: Gemcitabine|Other: Aerobic Training|Other: Neurocognitive Remediation","St. Jude Children's Research Hospital|Genentech, Inc.|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","350","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJMB12|NCI-2013-01125|R01CA187079","June 10, 2013","June 23, 2013","December 31, 2026","March 30, 2017","February 2017","No Study Results Posted","null","June 30, 2023","Progression-free survival distribution (Stratum W1)|Progression free survival distribution (Stratum N1)|Change in VO2 peak values|Change in spatial span backward standard score|Compare progression-free survival by strata with prior St. Jude SJMB03 study participants|Compare overall survival by strata with prior St. Jude SJMB03 study participants|Proportion of patients able to complete protocol therapy|Number of patients who go off treatment for reasons other than progressive disease|Number of local failures|Change in hand grip strength|Change in range of motion|Change in overall flexibility|Change in motor proficiency|Change in quality of life (QOL) score|Change in fatigue score|Change in measure of memory function|Change in measure of attention|Change in executive function score|Change in sleep|Association between baseline cognitive performance and sleep quality|Association between baseline cognitive performance and sleep quantity|Association between baseline cognitive performance and fatigue|Longitudinal change in measure of intellectual function|Association of demographic and clinical factors with change in intellectual function|Longitudinal change in measure of academic ability|Association of demographic and clinical factors with change in academic ability|Longitudinal change in measure of attention|Association of demographic and clinical factors with change in attention|Longitudinal change in measure of memory|Association of demographic and clinical factors with change in memory|Longitudinal change in measure of cognitive processing speed function|Association of demographic and clinical factors with change in cognitive processing speed|Longitudinal change in measure of neurocognitive executive function|Association of demographic and clinical factors with change in neurocognitive executive function|Change in measure of processing speed|Change in measure of executive function ability|Change in measure of attention among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of processing speed among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of executive function among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of attention between participants who received computer-based intervention VS. those who did not|Change in measure of working memory between participants who received computer-based intervention VS. those who did not|Change in measure of processing speed between participants who received computer-based intervention VS. those who did not|Change in measure of executive function between participants who received computer-based intervention VS. those who did not","https://ClinicalTrials.gov/show/NCT01878617"
2339,"NCT02098954","Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers","Recruiting","No Results Available","Carcinoma, Non-Small Cell Lung|EGFR Gene Mutation","Drug: Gemcitabine platinum combined with erlotinib","Hunan Province Tumor Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TKIRR001","March 20, 2014","July 2014","December 2016","February 14, 2016","February 2016","No Study Results Posted","null","December 2016","mean progression free survival(mPFS)|mean overall survival(mOS)|8 week overall response rate(8 week ORR)","https://ClinicalTrials.gov/show/NCT02098954"
2340,"NCT00718913","Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: Docetaxel|Drug: Cisplatin|Drug: Capecitabine|Radiation: Radiation|Drug: Capecitabine","Hellenic Oncology Research Group|University Hospital of Crete","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/08.07","July 18, 2008","April 2008","September 2009","May 14, 2015","May 2015","No Study Results Posted","null","September 2009","The proportion of patients completing protocol therapy (feasibility)|Toxicity profile|Overall survival","https://ClinicalTrials.gov/show/NCT00718913"
2341,"NCT00324805","Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","Active, not recruiting","No Results Available","Stage IB Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer","Biological: Bevacizumab|Drug: Cisplatin|Drug: Docetaxel|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Pemetrexed Disodium|Other: Questionnaire Administration|Drug: Vinorelbine Tartrate","National Cancer Institute (NCI)|Cancer and Leukemia Group B|NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","1500","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00509|ECOG-E1505|E1505|CDR0000475774|U10CA180820|U10CA021115","May 10, 2006","June 1, 2007","null","May 24, 2017","May 2017","No Study Results Posted","null","January 1, 2018","Overall survival|Disease-free survival (DFS)|Expression of intracellular adhesion molecule (ICAM)|Expression of vascular endothelial growth factor (VEGF)|Toxicity rates as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","https://ClinicalTrials.gov/show/NCT00324805"
2342,"NCT02940990","SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations","Not yet recruiting","No Results Available","NSCLC|SBRT|GM-CSF","Radiation: SBRT concurrent with GM-CSF|Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel","Shanghai Chest Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCHLC007","October 18, 2016","November 2016","null","November 30, 2016","November 2016","No Study Results Posted","null","December 2019","Progress Free Survival (PFS)|Overall Survival （OS）|Incidence of treatment-related adverse events","https://ClinicalTrials.gov/show/NCT02940990"
2343,"NCT02128243","Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","Recruiting","No Results Available","Metastatic Esophagogastric Adenocarcinoma","Drug: S-1 de-escalation|Drug: Chemotherapy by Investigator's choice","AIO-Studien-gGmbH|Taiho Pharmaceutical Co., Ltd.|Nordic Pharma SAS","All","18 Years and older   (Adult, Senior)","Phase 2","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO-YMO-0111|2013-002742-37","April 29, 2014","September 2014","September 2018","March 18, 2016","March 2016","No Study Results Posted","MATEO","September 2018","Overall Survival (OS)|Progression-free survival (PFS)|Quality of Life","https://ClinicalTrials.gov/show/NCT02128243"
2344,"NCT01867086","Salvage Ovarian FANG™ Vaccine + Carboplatinum","Active, not recruiting","No Results Available","Stage III Ovarian Cancer|Stage IV Ovarian Cancer","Biological: Vigil™ Vaccine|Drug: Carboplatinum|Drug: Carboplatinum and Taxol","Gradalis, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CL-PTL 110","May 29, 2013","June 2013","July 2017","December 1, 2016","December 2016","No Study Results Posted","null","July 2016","Response Rate|Time to Progression","https://ClinicalTrials.gov/show/NCT01867086"
2345,"NCT02448797","Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Icotinib|Drug: Chemotherapy","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BD-IC-IV-61|CCTC-1501","May 15, 2015","May 2015","November 2021","October 10, 2016","October 2016","No Study Results Posted","EVIDENCE","November 2020","disease free survival|overall survival","https://ClinicalTrials.gov/show/NCT02448797"
2346,"NCT00256269","Weekly Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal Carcinoma","Completed","No Results Available","Esophageal Cancer|Gastroesophageal Cancer","Drug: Oxaliplatin|Drug: Irinotecan","University of California, Irvine","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 04-09|2004-3849","November 17, 2005","June 2005","April 2011","August 15, 2011","August 2011","No Study Results Posted","null","February 2008","To assess the overall response rate|To assess the frequency and severity of toxicities","https://ClinicalTrials.gov/show/NCT00256269"
2347,"NCT01283204","Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","Active, not recruiting","No Results Available","Recurrent or Metastatic Gastric Cancer","Drug: SP|Drug: FL/Tax|Drug: FL/Doc|Drug: FOLFOX","Yonsei University","All","20 Years and older   (Adult, Senior)","Phase 2","228","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2009-0596","January 24, 2011","February 2010","August 2016","March 3, 2016","March 2016","No Study Results Posted","null","August 2016","progression free survival(PFS)","https://ClinicalTrials.gov/show/NCT01283204"
2348,"NCT02103257","Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma","Recruiting","No Results Available","EGFR Positive Non-small Cell Lung Cancer|Adenocarcinoma","Drug: Sequential Icotinib Plus Chemotherapy|Drug: Icotinib","Betta Pharmaceuticals Co.,Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BD-IC-IV62","March 31, 2014","March 2014","September 2017","April 27, 2015","April 2015","No Study Results Posted","null","March 2016","Progression Free Survival|Overall survival|Objective response rate|Adverse events","https://ClinicalTrials.gov/show/NCT02103257"
2349,"NCT02815592","Trial of BMS-986012 in Combination With Platinum and Etoposide","Recruiting","No Results Available","Small Cell Lung Cancer","Drug: BMS-986012|Drug: Cisplatin|Drug: Etoposide|Drug: Platinum|Drug: Carboplatin","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA001-044|2016-001692-67","June 24, 2016","October 2016","August 2019","April 17, 2017","February 2017","No Study Results Posted","null","August 2019","Number of participants with adverse events (AEs)|Number of participants with serious adverse events (SAEs )|Discontinuations due to AEs|Number of participants who died due to AEs|Number of participants with laboratory toxicity grade shift from baseline|Progression Free Survival|Maximum observed serum concentration(Cmax)|Time of maximum observed serum concentration(Tmax)|Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T))|Observed serum concentration at the end of a dosing interval(Ctau)|Area under the concentration-time curve in 1 dosing interval(AUC(TAU))|Characterization of Immunogenicity","https://ClinicalTrials.gov/show/NCT02815592"
2350,"NCT02066220","International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","Recruiting","No Results Available","Brain Tumors","Radiation: Radiotherapy without Carboplatin|Drug: Reduced-intensity maintenance chemotherapy|Radiation: Radiotherapy with Carboplatin|Drug: Maintenance chemotherapy","Universitätsklinikum Hamburg-Eppendorf|Deutsche Kinderkrebsstiftung","All","3 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SIOP PNET 5 MB|2011-004868-30","February 7, 2014","June 2014","April 2024","May 5, 2017","May 2017","No Study Results Posted","null","April 2024","3-year Event-Free Survival (EFS)|Overall survival|Pattern of relapse|Late effects of therapy on endocrine function|Late effects of therapy on audiology|Late effects of therapy on neurology|Late effects of therapy on quality of survival|Progression-free survival|Feasibility of carboplatin treatment|Residual tumor|Leukoencephalopathy grading","https://ClinicalTrials.gov/show/NCT02066220"
2351,"NCT01732939","Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer","Unknown status","No Results Available","Breast Cancer","","Hospital Affiliated to Military Medical Science, Beijing","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","307BCNeo-01","October 10, 2012","May 2012","May 2014","February 17, 2014","February 2014","No Study Results Posted","null","December 2013","pathological complete response rate|clinical response rate, safety","https://ClinicalTrials.gov/show/NCT01732939"
2352,"NCT03167164","QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","Not yet recruiting","No Results Available","Merkel Cell Carcinoma","Biological: Avelumab|Biological: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: nab-Paclitaxel|Drug: omega-3-acid ethyl esters|Radiation: Stereotactic Body Radiation Therapy|Biological: ALT-803|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6301|Biological: haNK","NantCell, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","QUILT-3.045","May 23, 2017","August 2017","March 2019","May 23, 2017","May 2017","No Study Results Posted","null","January 2019","Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.|Objective response rate by RECIST Version 1.1|Objective response rate by irRC|Progression-free survival by RECIST Version 1.1|Progression-free survival by irRC|Overall survival|Duration of response|Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months)|Quality of life by patient-reported outcome using Functional Assessment of Cancer Therapy-Melanoma (FACT-M) Questionnaire|Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03","https://ClinicalTrials.gov/show/NCT03167164"
2353,"NCT00084838","Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","Completed","Has Results","Central Nervous System Tumor, Pediatric","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy|Drug: Dactinomycin","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-294 DFCI|P30CA006516","June 10, 2004","February 2003","March 2013","December 18, 2015","December 2015","December 14, 2012","null","February 2008","2-yr Overall Survival|Pre-Radiation Therapy Chemotherapeutic Response","https://ClinicalTrials.gov/show/NCT00084838"
2354,"NCT02972372","Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer","Recruiting","No Results Available","Esophagus Cancer","Procedure: CRT|Procedure: surgery","The First Affiliated Hospital of Henan University of Science and Technology|Jiangsu HengRui Medicine Co., Ltd.|Anyang Tumor Hospital|150th Hospital of PLA","All","18 Years to 75 Years   (Adult, Senior)","","196","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CRTESC6111","November 6, 2016","November 2016","June 2021","April 18, 2017","April 2017","No Study Results Posted","CELAEC","December 2020","2 year disease-free survival|Treatment-related adverse events|Quality of life|2 year overall survival","https://ClinicalTrials.gov/show/NCT02972372"
2355,"NCT03167177","QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","Not yet recruiting","No Results Available","Melanoma","Biological: Avelumab|Biological: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: nab-paclitaxel|Biological: Nivolumab|Drug: omega-3-acid ethyl esters|Radiation: Stereotactic Body Radiation Therapy|Biological: ALT-803|Biological: ETBX-011|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6207|Biological: GI-6301|Biological: haNK","NantCell, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","QUILT-3.046","May 23, 2017","August 2017","March 2019","May 24, 2017","May 2017","No Study Results Posted","null","January 2019","Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.|Objective response rate by RECIST Version 1.1|Objective response rate by irRC|Progression-free survival by irRC|Progression-free survival by RECIST Version 1.1|Overall survival|Duration of response|Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months)|Quality of life by patient-reported outcome using Functional Assessment of Cancer Therapy - Melanoma (FACT-M) Questionnaire","https://ClinicalTrials.gov/show/NCT03167177"
2356,"NCT00818350","Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer","Unknown status","No Results Available","Urinary Bladder Neoplasms","Drug: SUNITINIB","Campania Younger Oncologists Association","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","AGOC O1","January 5, 2009","January 2009","January 2011","January 6, 2009","January 2009","No Study Results Posted","null","August 2009","To determine the antitumor efficacy ( response rate) of sunitinib|QOL|TOXICITY ACCORDING NCI VERSION 3 CRITERIA","https://ClinicalTrials.gov/show/NCT00818350"
2357,"NCT02352792","Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer","Recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Radiation: radiochemotherapy with 70 Gy|Radiation: radiochemotherapy with 77 Gy","University Hospital Tuebingen","All","18 Years and older   (Adult, Senior)","","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2.0","January 28, 2015","December 2008","December 2022","January 30, 2015","January 2015","No Study Results Posted","null","December 2017","time to local recurrence","https://ClinicalTrials.gov/show/NCT02352792"
2358,"NCT02741388","A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP","Recruiting","No Results Available","B-cell Lymphoma","Drug: selinexor|Drug: Rituximab|Drug: Dexamethasone|Drug: Oxaliplatin|Drug: Cisplatin|Drug: Cytarabine|Drug: Gemcitabine","The Lymphoma Academic Research Organisation|Karyopharm Therapeutics Inc","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SELINDA","April 14, 2016","October 2016","December 2019","March 8, 2017","March 2017","No Study Results Posted","SELINDA","January 2018","Incidence rate of dose-limiting toxicities (DLTs) observed during the DLT assessment period (cycle 1) at each dose level examined|Response rates|Duration of response|Progression-free survival (PFS)|Time to next anti-lymphoma treatment (TTNLT)|Overall survival (OS)|Incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities","https://ClinicalTrials.gov/show/NCT02741388"
2359,"NCT01248299","Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of Esophagus","Drug: FU-CDDP|Drug: LV5FU2-CDDP|Drug: FOLFOX|Drug: TPF|Other: Best Supportive Care","Centre Oscar Lambret|National Cancer Institute, France","All","18 Years and older   (Adult, Senior)","Phase 2","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","E-DIS 2010-06|2010-021439-16","November 24, 2010","January 2011","September 2016","May 23, 2016","May 2016","No Study Results Posted","E-DIS","January 2015","Overall survival|Progression free survival|Tolerance|Quality of life|Cost analysis","https://ClinicalTrials.gov/show/NCT01248299"
2360,"NCT02822404","Description of the Cystatin C as an Early Nephrotoxic Bio-marker in Pediatric Oncology","Recruiting","No Results Available","Kidney Diseases","Dietary Supplement: Urinary and blood sample for Cystaine dosage","University Hospital, Toulouse","All","up to 18 Years   (Child, Adult)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","11 308 03","February 3, 2016","February 2012","September 2020","July 1, 2016","February 2016","No Study Results Posted","CysPed","September 2020","Urinary cystatin C rate|Sensibility, specificity and positive predictive value for urinary CysC|Predictive value for Glomerular Filtration Rate with blood rate of CysC (with Bouvet calculation method)","https://ClinicalTrials.gov/show/NCT02822404"
2361,"NCT00936364","Short-Term Fasting: Impact on Toxicity","Recruiting","No Results Available","Fasting in Malignant Solid Tumors","Other: Short-term fasting|Other: Modified fast|Other: Fasting|Other: Fasting|Other: Fasting|Other: Fasting","University of Southern California","All","19 Years and older   (Adult, Senior)","","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","0S-08-9","July 9, 2009","July 9, 2009","July 9, 2019","April 11, 2017","April 2017","No Study Results Posted","null","July 9, 2018","Identification of the longest duration of fasting which is safe|Significant toxicity as assessed by CTCAE v3.0|Changes in plasma insulin, glucose, IGF1 and IGF binding protein (IGFBP) levels, and GRP78 expression in WBCs|Changes in grp78 expression after fasting and after chemotherapy administration","https://ClinicalTrials.gov/show/NCT00936364"
2362,"NCT00142038","Docetaxel and Capecitabine in Advanced Gastric Cancer","Completed","No Results Available","Stomach Neoplasm|Neoplasm Metastasis","Drug: Docetaxel|Drug: Capecitabine","Charite University, Berlin, Germany","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGST-Magen-CapDoc-04","September 1, 2005","March 2004","December 2007","April 17, 2007","April 2007","No Study Results Posted","null","null","Response Rate|Median Survival|Time to Tumor Progression|Toxicity|Quality of Life","https://ClinicalTrials.gov/show/NCT00142038"
2363,"NCT00577993","Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients","Active, not recruiting","No Results Available","Lymphoma","Drug: Fludarabine|Drug: Novantrone|Drug: Decadron|Drug: Rituximab|Drug: Interferon|Drug: Doxorubicin|Drug: Vincristine|Drug: Bleomycin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Cisplatin|Drug: Ara-C|Drug: Methyl-Prednisolone|Drug: Procarbazine|Drug: Prednisone","M.D. Anderson Cancer Center|Genentech, Inc.","All","up to 76 Years   (Child, Adult, Senior)","Phase 3","210","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DM97-261|NCI-2010-01566","December 18, 2007","March 1998","null","September 12, 2016","September 2016","No Study Results Posted","null","December 2018","To study and compare molecular response rates with the FND regimen followed by rituximab (chimeric anti-CD20 antibody) and interferon versus FND plus rituximab concurrently, followed by interferon|To study the toxicity of these two regimens, including their effects on B- and T- cell subsets, immunoglobulins, and patterns of infections.|Compare failure-free and overall survival rates|To identify and treat with a separate strategy those follicular lymphoma patients without bcl-2 mbr or mcr gene rearrangement (""germline"" patients)","https://ClinicalTrials.gov/show/NCT00577993"
2364,"NCT01683175","Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer Stage III","Drug: Erlotinib|Drug: cis-platinum|Drug: Vinorelbine","Tianjin Medical University Cancer Institute and Hospital|Roche Pharma AG","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","94","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28280","August 30, 2012","August 2012","October 2020","October 19, 2016","October 2016","No Study Results Posted","null","October 2020","2-year disease free survival rate (DFSR)|disease free survival|overall survival (OS)|Quality of Life|Adverse Event (AE)|Serious Adverse Event (SAE)","https://ClinicalTrials.gov/show/NCT01683175"
2365,"NCT02031601","Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","Recruiting","No Results Available","Non-Small-Cell Lung Cancer","Drug: Erlotinib|Drug: Gefitinib|Drug: Icotinib|Drug: Docetaxel|Drug: Pemetrexed|Drug: Platinum (cisplatin or carboplatin)|Drug: Erlotinib|Drug: Gefitinib|Drug: Icotinib","Qilu Hospital of Shandong University","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","QLHX-0531","January 2, 2014","January 2014","December 2017","March 28, 2016","November 2015","No Study Results Posted","TCL-1","December 2016","Progression-free survival (PFS)|Objective response rate|Duration of response|Time to progression|Overall survival (OS)|Clinical benefit rate|Adverse Events (AEs), Serious Adverse Events (SAEs), laboratory data","https://ClinicalTrials.gov/show/NCT02031601"
2366,"NCT03053856","Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients","Not yet recruiting","No Results Available","Stage IIIA Non-small Cell Lung Cancer","Drug: Pembrolizumab|Procedure: Curative resection|Procedure: Neoadjuvant concurrent chemoradiotherapy|Drug: Cisplatin|Drug: Paclitaxel","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-09-018","February 6, 2017","February 14, 2017","August 13, 2021","February 14, 2017","February 2017","No Study Results Posted","null","May 13, 2021","Efficacy of adjuvant pembrolizumab in N2 Positive NSCLC|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT03053856"
2367,"NCT02784015","Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma","Recruiting","No Results Available","Unresectable Localized Soft Tissue Sarcoma","Drug: Cisplatin|Drug: Etoposide|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Ifosfamide|Drug: Carboplatin|Radiation: Radiotherapy|Drug: Thiotepa|Drug: Melphalan","Samsung Medical Center","All","up to 18 Years   (Child, Adult)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-07-115","May 24, 2016","May 2016","null","May 24, 2016","May 2016","No Study Results Posted","null","May 2020","Rate of event free survival|Rate of adverse events","https://ClinicalTrials.gov/show/NCT02784015"
2368,"NCT02436707","Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Mesna|Drug: Cyclophosphamide|Drug: Etoposide|Drug: G-CSF","Canadian Cancer Trials Group|Janssen, LP","All","16 Years to 65 Years   (Child, Adult)","Phase 2","320","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","LY17","May 4, 2015","May 5, 2015","December 2019","May 8, 2017","March 2017","No Study Results Posted","null","June 2019","Measure overall response rate|Number and severity of adverse events|Transplantation rate|Stem cell collection rate|Event free Survival Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT02436707"
2369,"NCT00336024","Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","Completed","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: etoposide|Drug: cyclophosphamide|Drug: cisplatin|Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Drug: methotrexate|Drug: leucovorin calcium|Drug: vincristine sulfate|Procedure: autologous hematopoietic stem cell transplantation|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 3","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0334|NCI-2009-00338|COG-ACNS0334|U10CA098543","June 8, 2006","August 2007","December 31, 2016","February 14, 2017","February 2017","No Study Results Posted","null","December 31, 2016","Complete response (CR) rate|Time to treatment failure defined as disease progression or recurrence, death from any cause, or occurrence of a second malignant neoplasm|Toxicity rates of acute, chronic, and late effects of the two intense regimens|Rates of gastrointestinal and nutritional toxicities|Quality of life and neuropsychological (NP) scores as assessed by the Children Oncology Group (COG) Standard Neuropsychological and Behavioral Battery|Gene expression profiling by northern blotting or by gel electrophoresis","https://ClinicalTrials.gov/show/NCT00336024"
2370,"NCT00960518","TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)","Unknown status","No Results Available","Hepatitis B Virus|Hepatocellular Carcinoma","Drug: adefovir|Procedure: TACE","Tongji University|Interventional Radiology Research Group, Shanghai Radiology Society","All","20 Years to 75 Years   (Adult, Senior)","Phase 2","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SHDSYY20090725","August 14, 2009","August 2009","August 2015","August 14, 2009","August 2009","No Study Results Posted","TACE","August 2012","the progression free survival (PFS)|the rate of overall survival","https://ClinicalTrials.gov/show/NCT00960518"
2371,"NCT02771743","Response-based Treatment of High-risk Neuroblastoma","Recruiting","No Results Available","Newly Diagnosed High Risk Neuroblastoma","Drug: Cisplatin|Drug: Doxorubicin|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Ifosfamide|Drug: Carboplatin|Procedure: Tandem HDCT/auto-SCT|Radiation: Radiotherapy|Drug: Interleukin-2|Drug: Isotretinoin|Radiation: MIBG","Samsung Medical Center","All","Child, Adult, Senior","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-02-064","May 12, 2016","April 2015","March 2023","May 23, 2016","May 2016","No Study Results Posted","null","March 2020","Rate of event free survival|Rate of late adverse effects","https://ClinicalTrials.gov/show/NCT02771743"
2372,"NCT02340936","Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: LR-ESHAP (lenalidomide 5 mg)|Drug: LR-ESHAP (lenalidomide 10 mg)|Drug: LR-ESHAP (lenalidomide 15 mg)|Drug: LR-ESHAP (lenalidomide 20 mg)","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Celgene Corporation|Dynamic Science S.L.|Thermo Fisher Scientific","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","53","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LR-ESHAP","January 9, 2015","January 2011","September 2019","November 18, 2016","November 2016","No Study Results Posted","null","September 2016","Phase I of the study: to evaluate the safety and the maximum-tolerated dose (MTD) of the combination R-ESHAP with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (determine maximum tolerated dose)|Phase II of the study: Phase II: to evaluate ORR of LR-ESHAP in patients with relapsed or refractory DLBCL candidates to HDT and ASCT (determine the overall response rate)|Phase I of the study: to analyze the adverse events of LR-ESHAP (frequency and severity of the adverse events)|Phase I of the study: preliminarily analyze effectiveness (response rates (CR and PR), duration of response and survival (DFS and OS)|Phase I of the study: evaluate haematopoietic progenitor cells mobilization after treatment with LR-ESHAP (Evaluate CD34+ cell count)|Phase I of the study: evaluate hematologic recovery after HSCT (recovery of blood parameters)|Phase II of the study: analyze effectiveness (Complete remission (CR) rate (determined by positron emission tomography [PET]/CT), event-free survival (EFS) and overall survival (OS)|Phase II of the study: rate of transplanted patients (number of patients that undergo HSCT)|Phase II of the study: to analyze the adverse events of LR-ESHAP and ASCT. (frequency and severity of the adverse events)|Phase II of the study: evaluate mobilization after treatment with LR-ESHAP (number of stem cells (2 x 106/Kg Hematopoietic progenitor cell antigen (CD34)+ cells) collected after the salvage therapy.)|Phase II of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological (such as cell of origin) prognostic factors on response rates and survival.)","https://ClinicalTrials.gov/show/NCT02340936"
2373,"NCT00453115","Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Lung Cancer","Drug: Oxaliplatin|Drug: Gemcitabine","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-05-157","March 27, 2007","January 2006","May 2011","October 22, 2010","July 2010","No Study Results Posted","null","May 2010","Response rate|To access the toxicity|To estimate the time to progression and overall survival|To evaluate the improvement quality of life|To estimate the overall survival","https://ClinicalTrials.gov/show/NCT00453115"
2374,"NCT00450762","Gemcitabine + Carboplatin in Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: gemcitabine|Drug: carboplatin","Ludwig-Maximilians - University of Munich|Eli Lilly and Company","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Gem/Carbo MUC01","March 20, 2007","March 2004","October 2006","March 21, 2007","March 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00450762"
2375,"NCT00186277","Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer","Completed","No Results Available","Bladder Cancer","Drug: Oxaliplatin|Drug: Taxotere","Stanford University|Sanofi-Synthelabo","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BLDR0001","September 13, 2005","December 2003","December 2006","March 28, 2011","March 2011","No Study Results Posted","null","December 2006","Tolerability of the this combination in patients with recurrent metastatic bladder cancer.","https://ClinicalTrials.gov/show/NCT00186277"
2376,"NCT01684904","Proton Therapy for Esophageal Cancer","Recruiting","No Results Available","Esophageal Cancer","Radiation: Proton radiation","Loma Linda University","All","18 Years and older   (Adult, Senior)","","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5120054","September 7, 2012","July 2012","August 2020","December 14, 2016","August 2016","No Study Results Posted","null","August 2018","To assess overall survival of patients treated with proton-chemotherapy (PCT) followed by surgery in patients with resectable primary esophageal or esophagogastric cancer|Number of participants with adverse events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT01684904"
2377,"NCT02829008","Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","Active, not recruiting","No Results Available","Metastatic Breast Cancer","Drug: low-dose-bevacizumab/pemetrexed|Drug: Treatment of physician's choice","Chinese Academy of Medical Sciences","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LQ002|CAMS-LQOO2","July 3, 2016","April 2016","April 2020","July 11, 2016","July 2016","No Study Results Posted","null","April 2018","Objective response rare (ORR)|progression free survival(PFS)|Overall survival(OS)","https://ClinicalTrials.gov/show/NCT02829008"
2378,"NCT02896582","Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","Not yet recruiting","No Results Available","Mantle Cell Lymphoma","Drug: Obinutuzumab|Drug: Dexamethasone|Drug: Aracytine|Drug: Cisplatinum|Drug: Etoposide|Drug: Melphalan|Drug: Carmustine","The Lymphoma Academic Research Organisation","All","18 Years to 65 Years   (Adult)","Phase 2","83","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LyMa101","September 6, 2016","October 2016","March 2025","September 12, 2016","September 2016","No Study Results Posted","LyMa101","March 2019","Molecular Residual Disease (MRD) in bone marrow after 4 cycles of GA-DHAP|Response according to Cheson 99|Overall response rate (ORR)|Positron Emission Tomography (PET) result|MRD|MRD and after maintenance ""on demand""|Progression Free Survival (PFS)|Overall survival (OS)|Number of patients for whom stemm cell collection will fail|Duration of MRD negativity|Treatment duration|Average dose|Number of premature treatment discontinuation|Frequency of premature treatment discontinuation|Number of study discontinuation|Frequency of study discontinuation|Number of adverse events","https://ClinicalTrials.gov/show/NCT02896582"
2379,"NCT02633514","Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma","Recruiting","No Results Available","Thymoma and Thymic Carcinoma","Drug: Cisplatin|Drug: Etoposide|Radiation: radiotherapy","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1508151-6","December 15, 2015","November 2015","null","August 11, 2016","August 2016","No Study Results Posted","null","November 2018","Progression free survival|Overall survival|Objective response rate","https://ClinicalTrials.gov/show/NCT02633514"
2380,"NCT01026467","Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","Completed","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: cisplatin|Drug: carboplatin|Other: questionnaire administration","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","Child, Adult, Senior","","45","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CCCWFU 98709|NCI-2009-01451","December 3, 2009","January 2010","May 2014","April 4, 2017","July 2015","No Study Results Posted","null","May 2014","Use of the Frailty Index and/or the geriatric assessment in prediction of toxicity","https://ClinicalTrials.gov/show/NCT01026467"
2381,"NCT00347256","Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer","Withdrawn","No Results Available","Paranasal Sinus Neoplasms","Drug: cisplatin|Procedure: targeted radiation therapy|Procedure: tumor resection","University of Tennessee|North American Skull Base Society","All","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NASBS-PNS001","June 29, 2006","null","null","December 9, 2008","December 2008","No Study Results Posted","null","null","Local control of cancer at two years post treatment|Response to preoperative chemoradiation|Estimation of the proportion of the inoperable tumors which become operable after chemoradiation|Identification of factors that are associated with inoperability|Estimation of the overall survival and cumulative incidence of death due to disease at 2 years|Determination of the acute and long-term toxicity, particularly ophthalmologic complications, and surgical morbidity associated with this regimen|Measurement of the accuracy of conventional imaging techniques (CT, MRI) compared with the addition of PET imaging in predicting the response to chemoradiation therapy.","https://ClinicalTrials.gov/show/NCT00347256"
2382,"NCT00030745","Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung","Completed","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: gemcitabine hydrochloride|Procedure: conventional surgery","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 17/00|SWS-SAKK-17-00|EU-20136","February 14, 2002","June 2000","August 2003","May 14, 2012","May 2012","No Study Results Posted","null","May 2003","","https://ClinicalTrials.gov/show/NCT00030745"
2383,"NCT00006051","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068073|FRE-FNCLCC-GORTEC98-01/98007|EU-20015","July 5, 2000","February 1999","null","February 6, 2009","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006051"
2384,"NCT00005022","Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","64","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RTOG-9712|CDR0000065797","April 6, 2000","February 1998","June 2010","October 31, 2013","October 2013","No Study Results Posted","null","October 2002","Frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to thoracic irradiation with concurrent chemotherapy|Compare baseline and follow-up Mini Mental Status Examinations","https://ClinicalTrials.gov/show/NCT00005022"
2385,"NCT00004209","Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: mitomycin C|Drug: vinblastine sulfate","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","ICRF-95.240|CDR0000067457|EU-99017","January 21, 2000","May 1998","null","August 6, 2013","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004209"
2386,"NCT00004141","Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Drug: Cisplatin|Drug: dacarbazine|Drug: Granulocyte-macrophage colony-stimulating factor","University of Chicago|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9372|UCCRC-9372|UCCRC-CTRC-9821|NCI-G99-1615","December 10, 1999","August 1998","April 2006","September 4, 2013","September 2013","No Study Results Posted","null","January 2003","Objective response rate","https://ClinicalTrials.gov/show/NCT00004141"
2387,"NCT00003637","Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","National Cancer Centre, Singapore|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","200","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066722|NMRC-SQNP01|EU-98047","November 1, 1999","September 1998","null","December 18, 2013","January 2006","No Study Results Posted","null","null","Clinical response|Distant metastases|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00003637"
2388,"NCT00003589","Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","450","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-08975","November 1, 1999","August 1998","null","March 5, 2012","March 2012","No Study Results Posted","null","July 2000","","https://ClinicalTrials.gov/show/NCT00003589"
2389,"NCT00002999","S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx","Withdrawn","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","Child, Adult, Senior","Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065552|U10CA032102|S9715","November 1, 1999","null","null","May 22, 2015","May 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002999"
2390,"NCT00002897","Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery","European Institute of Oncology|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065226|CNR-012809|EU-96038","November 1, 1999","July 1992","June 2001","September 19, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002897"
2391,"NCT02497053","Four Versus Six Cycles of Pemetrexed/Platinum for MPM","Recruiting","No Results Available","Malignant Pleural Mesothelioma","Drug: pemetrexed/platinum chemotherapy|Drug: Pemetrexed/platinum chemotherapy","Ain Shams University","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Meso-01","July 10, 2015","June 2015","null","July 13, 2015","July 2015","No Study Results Posted","null","June 2016","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02497053"
2392,"NCT00256295","Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer","Terminated","Has Results","Cancer of the Head and Neck","Drug: Gemcitabine|Drug: Oxaliplatin","Sai-Hong Ignatius Ou|Sanofi|University of California, Irvine","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 04-08|2004-3776","November 17, 2005","April 2005","October 2011","December 2, 2016","December 2016","June 21, 2013","null","February 2008","Overall Response Rate (Complete and Partial Response)|Frequency and Severity of Toxicities|Overall Survival and Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT00256295"
2393,"NCT00661011","Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy","Terminated","No Results Available","Non Small Cell Lung Carcinoma","Procedure: Lobectomy followed by concomitant mediastinal chemoradiotherapy","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ELCWP 01061","April 15, 2008","January 2007","June 2014","February 11, 2015","February 2015","No Study Results Posted","null","December 2013","Survival|Operative mortality and morbidity|Local control rate|Toxicity","https://ClinicalTrials.gov/show/NCT00661011"
2394,"NCT01898494","Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer","Recruiting","No Results Available","Human Papilloma Virus Infection|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx","Procedure: therapeutic conventional surgery|Radiation: intensity-modulated radiation therapy|Drug: cisplatin|Drug: carboplatin|Radiation: intensity-modulated radiation therapy|Other: laboratory biomarker analysis|Other: quality-of-life assessment","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","377","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","E3311|NCI-2013-00814|ECOG-E3311|U10CA180820|U10CA021115","July 10, 2013","August 2013","February 2023","April 10, 2017","April 2017","No Study Results Posted","null","February 2020","PFS rate|Accrual rate|Risk distribution|Incidence of grade 3-4 bleeding events during surgery and positive margins after surgery, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Incidence of adverse events evaluated by the CTCAE version 4.0|Overall survival|Swallowing function before and after treatment, evaluated using the modified barium swallow (MBS) ratings, performance status scale for head and neck cancer (PSS-HN) normalcy of diet scale, and the MD Anderson Dysphagia Inventory (MDADI)|Voice before and after treatment, evaluated using the Voice Handicap Index-10|Change in patient reported quality of life (QOL) as measured by Functional Assessment of Cancer Therapy-Head and Neck","https://ClinicalTrials.gov/show/NCT01898494"
2395,"NCT00600210","Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer","Withdrawn","No Results Available","Cervical Cancer","Drug: Bevacizumab|Drug: Carboplatin|Radiation: Radiation Therapy","Leo W. Jenkins Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVF3963s","January 11, 2008","January 2008","April 2011","September 23, 2013","September 2013","No Study Results Posted","null","April 2011","To determine the safety of the proposed treatment in this patient population.|Progression Free Survival","https://ClinicalTrials.gov/show/NCT00600210"
2396,"NCT02200354","The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab","Recruiting","No Results Available","Advanced Non-small Cell Lung Cancer","Drug: pemetrexed with bevacizumab","Kobe City General Hospital","All","20 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PEM-RE-2014","July 20, 2014","July 2014","null","February 22, 2016","January 2016","No Study Results Posted","null","July 2017","progression free survival|response rate|overall survival|time to treatment failure (TTF)|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT02200354"
2397,"NCT01326767","Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Paclitaxel dosing according to SmPC|Drug: Individualized pharmacokinetically driven paclitaxel dosing","Central European Society for Anticancer Drug Research|Saladax Biomedical, Inc.|Cantonal Hospital of St. Gallen|University Hospital, Basel, Switzerland|Assign Data Management and Biostatistics GmbH|Wake Forest University|University Hospital, Essen","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","366","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C-III-002|2010-023688-16","March 29, 2011","March 2011","December 2014","January 26, 2016","January 2016","No Study Results Posted","CEPAC-TDM","December 2014","Grad 4 Neutropenia|Objective tumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST v1.1)|Progression free survival|Overall survival|Overall neutropenia|Hematological / non-hematological toxicites|Cumulative dose and dose intensity of paclitaxel and platinum drug|Incidence of changes from cisplatin to carboplatin and reasons thereof|Overall rate of febrile neutropenia and hospitalization due to chemotherapy-associated adverse events|Health economic analysis using QoL Questionnaires","https://ClinicalTrials.gov/show/NCT01326767"
2398,"NCT01534585","Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: Icotinib|Radiation: intensity-modulated radiotherapy|Drug: Paclitaxel and Cisplatin|Other: Quality of life|Genetic: Epidermal growth factor receptor status","Taizhou Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","YHH-201201","February 13, 2012","February 2012","February 2015","February 16, 2012","February 2012","No Study Results Posted","null","February 2013","Phase I: the maximum tolerated dose of Icotinib in combination with IMRT for NPC|Phase II: 2 years locoregional control rate|The overall response rate (complete and partial response)|The acute and late toxicity profile associated with the study regimen|The duration of control of locoregional disease|Overall survival, disease-free survival, and distant relapse rates|EGFR status in tissue and blood before treatment","https://ClinicalTrials.gov/show/NCT01534585"
2399,"NCT02188615","Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer","Recruiting","No Results Available","Squamous Cell Esophageal Carcinoma","Procedure: Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Drug: Cisplatin|Device: Mckeown MIE","Chengchu Zhu|Sun Yat-sen University|Fudan University|Taizhou Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","BZhang|2011C13039-2","June 28, 2014","June 2011","July 2019","July 9, 2014","July 2014","No Study Results Posted","NACRFMIE","June 2015","Overall survival rate|Disease free survival|the opportunity of MIE after neo-adjuvant chemoradiotherapy|Side effects of neo-adjuvant chemoradiotherapy|Duration of surgery|Quantity of bleeding|number of lymph nodes retrieved|Days of postoperative stay|Rate of Operative Complication|Mortality of perioperation","https://ClinicalTrials.gov/show/NCT02188615"
2400,"NCT01462474","Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma","Unknown status","No Results Available","Locally Advanced Nasopharyngeal Carcinoma","Drug: Famitinib|Drug: Cisplatin|Radiation: radiation（IMRT）","Jiangsu HengRui Medicine Co., Ltd.|Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 1","21","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FMTN-I-LNPC","October 27, 2011","October 2011","null","November 14, 2011","November 2011","No Study Results Posted","FMTN-I-LNPC","July 2012","Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD)|ORR (Objective Response Rate)|OS(Overall Survival)|DFMR(Distant Free Metastases Rate)|DFSR(Disease Free Survival Rate)|LFRSR(Local Free Recurrence Survival Rate)|Quantitative evaluation of the blood perfusion of the metastatic cervical lymph nodes by dynamic contrast-enhanced ultrasonography after a loading dose of famitinib for 14 days|To identify the tumor's molecular profiles in patients with NPCs|To measure the changes of serum c-Kit，VEGF，Filt，KDR，and PDGFR","https://ClinicalTrials.gov/show/NCT01462474"
2401,"NCT00563927","Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)","Unknown status","No Results Available","Nasopharyngeal Neoplasms|Carcinoma, Squamous Cell","Procedure: Conventional RT|Drug: Cisplatin|Drug: 5-fluorouracil","Hospital Authority, Hong Kong|Hong Kong Nasopharyngeal Cancer Study Group Limited","All","up to 70 Years   (Child, Adult, Senior)","","340","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L/M-77 TO PYH08/79|HARECCTR0500023|NPC99-01","November 21, 2007","March 1999","October 2009","July 6, 2010","July 2010","No Study Results Posted","null","null","Failure free survival rate|Disease-specific survival rate|Overall survival rate|Complication-free rates","https://ClinicalTrials.gov/show/NCT00563927"
2402,"NCT00401401","Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer","Terminated","Has Results","Head and Neck Cancer|Squamous Cell Cancer","Drug: zalutumumab|Drug: cisplatin|Procedure: Radiotherapy","Genmab","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Hx-EGFr-203","November 17, 2006","December 2006","October 2010","November 21, 2011","November 2011","October 7, 2011","null","October 2010","Adverse Events|Overall Response|Time to Response|Best Overall Tumor Response","https://ClinicalTrials.gov/show/NCT00401401"
2403,"NCT00167401","Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: docetaxel|Drug: cisplatin|Procedure: radiation treatment","University of Rochester","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","URCC 1500|Aventis 12083-Chen","September 9, 2005","February 2002","null","May 15, 2009","May 2009","No Study Results Posted","null","June 2007","","https://ClinicalTrials.gov/show/NCT00167401"
2404,"NCT00006356","Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer","Terminated","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cisplatin|Procedure: conventional surgery","European Organisation for Research and Treatment of Cancer - EORTC","Female","18 Years and older   (Adult, Senior)","Phase 3","38","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-55963","October 4, 2000","August 2000","null","September 20, 2012","September 2012","No Study Results Posted","null","October 2002","","https://ClinicalTrials.gov/show/NCT00006356"
2405,"NCT00004917","Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer","Completed","No Results Available","Anemia|Head and Neck Cancer","Biological: epoetin alfa|Drug: cisplatin|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-9903|CDR0000067599|RTOG-DEV-1008","March 7, 2000","June 2000","December 2016","December 30, 2016","December 2016","No Study Results Posted","null","November 2007","","https://ClinicalTrials.gov/show/NCT00004917"
2406,"NCT00002894","Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel","Medical Research Council|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","800","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065217|MRC-ICON4|EU-96051|ISRCTN47434271","November 1, 1999","March 1996","June 2003","December 18, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002894"
2407,"NCT00554788","Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","Active, not recruiting","No Results Available","Extraocular Retinoblastoma","Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Biological: filgrastim|Drug: carboplatin|Drug: vincristine sulfate|Drug: thiotepa|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","Phase 3","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ARET0321|NCI-2009-00421|COG-ARET0321|CDR0000573987|U10CA180886|U10CA098543","November 6, 2007","February 2008","March 31, 2018","May 5, 2017","May 2017","No Study Results Posted","null","March 31, 2018","Failure-free survival (FFS)|Response rate to the induction phase of the regimen using a modified version of the international criteria for neuroblastoma response|Incidence of adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","https://ClinicalTrials.gov/show/NCT00554788"
2408,"NCT00155766","Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)","Unknown status","No Results Available","Cervical Cancer","Biological: HPV16 E7 peptide-pulsed autologous DCs","National Taiwan University Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9100205963","September 9, 2005","January 2003","March 2006","December 19, 2005","June 2002","No Study Results Posted","null","null","1. Safety issues in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy|1. Immunologic responses in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy|2. Clinical response in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy","https://ClinicalTrials.gov/show/NCT00155766"
2409,"NCT01726452","NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","Recruiting","No Results Available","Adenocarcinoma of the Oesophagus|Adenocarcinoma of the Oesophago-gastric Junction|Oesophageal Tumours|Junctional Tumours|Oesophageal Cancer","Drug: Epirubicin|Drug: Cisplatin|Drug: 5 Flourouracil/ Capecitabine|Radiation: (41.4 Gy/23 fractions)|Drug: Paclitaxel|Drug: Carboplatin","Cancer Trials Ireland|Southampton Clinical Trials Unit|Region H Rigshospitalet|Centre Hospitalier Régional, Universitaire de Lille","All","18 Years and older   (Adult, Senior)","Phase 3","366","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CTRIAL-IE (ICORG) 10-14","November 6, 2012","August 2012","null","May 23, 2017","May 2017","No Study Results Posted","null","January 2024","Overall survival","https://ClinicalTrials.gov/show/NCT01726452"
2410,"NCT01639625","Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application","Completed","No Results Available","Squamous Cell Carcinoma of the Cervix|Adenocarcinoma of the Cervix","Drug: CIGB300","Laboratorio Elea S.A.C.I.F. y A.","Female","21 Years to 70 Years   (Adult, Senior)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","300CX02AR01","June 15, 2012","May 2011","January 2016","August 1, 2016","August 2016","No Study Results Posted","null","September 2015","Number of patients with presence or absence of grade 3 or 4 adverse events related to the study drug, in each dose level|Number of patients with local relapses|Number of patients with distant relapses","https://ClinicalTrials.gov/show/NCT01639625"
2411,"NCT03163979","Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Biological: 18F-FDG PET/CT and Comet assay guide RapidArc|Biological: 18F-FDG PET/CT and Comet assay guide IMRT|Biological: RapidArc|Biological: 7f-IMRT","Nanjing Medical University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BE2015645","April 17, 2017","July 1, 2015","July 31, 2019","May 21, 2017","May 2017","No Study Results Posted","PROGRAMMA","April 30, 2019","PFS|OS|TTP","https://ClinicalTrials.gov/show/NCT03163979"
2412,"NCT02064491","Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC","Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Erlotinib|Drug: Chemotherapy","Finnish Lung Cancer Group|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ETAP|2013-002049-13","February 13, 2014","February 2014","May 2017","September 12, 2016","August 2016","No Study Results Posted","null","December 2016","Progression-free survival of the whole study population and in the strata 1-2|Overall Survival|Overall Response Rate|Rate of non-progression at 9 and 18 weeks|Safety and toxicity","https://ClinicalTrials.gov/show/NCT02064491"
2413,"NCT03061058","Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC","Recruiting","No Results Available","Stomach Neoplasms|Chemotherapy Effect|Chemotherapeutic Toxicity","Drug: Docetaxel|Drug: Oxaliplatin|Drug: Cisplatin|Drug: Irinotecan|Drug: Pemetrexed|Drug: S1","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years and older   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Treatment","AGC-PC","February 11, 2017","September 1, 2014","December 2019","February 17, 2017","February 2017","No Study Results Posted","null","December 2018","Progression-free Survival (PFS)|Overall Survival (OS)|Objective Response Rate|Adverse Events","https://ClinicalTrials.gov/show/NCT03061058"
2414,"NCT01782339","A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis","Recruiting","No Results Available","Germ Cell Tumour","Drug: Combination Chemotherapy","Barts & The London NHS Trust","All","16 Years to 65 Years   (Child, Adult)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","007755","January 31, 2013","July 2012","November 2018","October 21, 2014","September 2014","No Study Results Posted","GAMMA","November 2018","Objective response rate|Progression Free Survival|Overall Survival|Toxicity Level","https://ClinicalTrials.gov/show/NCT01782339"
2415,"NCT02662634","A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Biological: AGS-003-LNG|Drug: Carboplatin|Drug: Abraxane|Drug: Alimta|Drug: Cisplatin|Drug: Taxol|Radiation: Radiation Therapy","GU Research Network, LLC|Cancer Research Network of Nebraska/Oncology Associates","All","19 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGS-003-024","January 12, 2016","March 2016","March 2018","March 24, 2016","March 2016","No Study Results Posted","null","March 2018","Safety - Adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V4.03|Immunogenicity - Generation of Cluster of Differentiation-8 (CD8)+ Cluster of Differentiation (CD28)+ memory T-cells|Efficacy - Overall survival|Efficacy - Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.|Efficacy - Objective response rate. The number of patients with a Complete Response or Partial Response.|Feasibility - Number of patients with a success in the manufacture of AGS-003-LNG.","https://ClinicalTrials.gov/show/NCT02662634"
2416,"NCT02164942","LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer","Terminated","No Results Available","Bladder Cancer","","Earle Burgess|University of Miami|Carolinas Healthcare System","All","18 Years and older   (Adult, Senior)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LCI-GU-BLA-SPEC-001|00009729","June 13, 2014","June 2014","July 2017","February 20, 2016","February 2016","No Study Results Posted","null","July 2016","Correlation of pathologic response rate and aurora kinase expression","https://ClinicalTrials.gov/show/NCT02164942"
2417,"NCT01798004","Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","Suspended","Has Results","Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Drug: cyclophosphamide|Drug: topotecan hydrochloride|Drug: cisplatin|Drug: etoposide|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Radiation: external beam radiation therapy|Drug: busulfan|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Other: pharmacological study|Other: laboratory biomarker analysis|Biological: filgrastim|Drug: mesna","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL12P1|NCI-2012-02211|COG-ANBL12P1|U10CA098543|U10CA180886","January 6, 2013","April 2013","October 2018","February 9, 2017","November 2016","December 19, 2016","null","July 2015","The Tolerability of BuMel Regimen","https://ClinicalTrials.gov/show/NCT01798004"
2418,"NCT02880007","Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer","Recruiting","No Results Available","Cervical Adenocarcinoma|Stage IB Cervical Cancer|Stage II Cervical Cancer|Stage III Cervical Cancer","Radiation: External Beam Radiation Therapy|Radiation: PDR Brachytherapy|Drug: Cisplatin","Institut de Cancérologie de Lorraine","Female","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-A00235-34","August 10, 2016","June 2011","February 2020","August 22, 2016","August 2016","No Study Results Posted","TRIDICOL","February 2019","Increase the local control rate|Maintain the cumulative rate grade III and IV complications below 6.5%|Relationship between the doses delivered to the target volume and local control|Relationship between the doses delivered to the critical organs and rate of grade III and IV complications","https://ClinicalTrials.gov/show/NCT02880007"
2419,"NCT02635360","Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer","Recruiting","No Results Available","Cervical Cancer","Drug: Pembrolizumab|Radiation: Brachytherapy|Drug: Cisplatin","Linda R Duska|Merck Sharp & Dohme Corp.|University of Virginia","Female","18 Years and older   (Adult, Senior)","Phase 2","88","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","18472|UVA-LACC-PD201","December 4, 2015","January 2016","May 2021","May 1, 2017","May 2017","No Study Results Posted","null","May 2018","Change in immunologic markers following combination of study drug with chemoradiation|Incidence of dose limiting toxicities|Metabolic Response Rate on PET/CT imaging|Incidence of distant metastases|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02635360"
2420,"NCT01887340","Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma","Recruiting","No Results Available","Seminoma","Drug: Carboplatin|Drug: Etoposide|Drug: Cisplatin","Gustave Roussy, Cancer Campus, Grand Paris","Male","18 Years and older   (Adult, Senior)","Phase 2","271","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","2012-A01615-38|2012/1884","June 24, 2013","June 2013","June 2026","June 8, 2016","June 2016","No Study Results Posted","SEMITEP","June 2016","Rate of patients without pathological fixation|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01887340"
2421,"NCT00321334","Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC","Completed","No Results Available","Non-small Cell Lung Cancer","Procedure: Chemotherapy+Surgery","Chinese Society of Lung Cancer","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","410","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CSLC0501","May 1, 2006","March 2006","December 2013","August 4, 2014","August 2014","No Study Results Posted","null","December 2013","3 years Disease Free Survival (at end of 3 years)|3 years Overall Survival rate (at end of 3 years) and Safety data (after third cycle finish)","https://ClinicalTrials.gov/show/NCT00321334"
2422,"NCT02842307","Acupuncture for Chemical Therapy Induced Nausea and Vomiting","Completed","No Results Available","Chemotherapy-induced Nausea and Vomiting","Procedure: Manual acupuncture implemented by senior acupuncturists|Procedure: Manual acupuncture implemented by junior acupuncturists|Procedure: Manual acupuncture on P6 point","Beijing University of Chinese Medicine|Dongzhimen Hospital, Beijing|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Senior)","","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","EBM@BUCM-2|30901929","July 16, 2016","January 2010","December 2012","July 20, 2016","July 2016","No Study Results Posted","null","December 2012","NCI nausea and vomiting rating scale|Rhodes Scale|Global assessment on effectiveness by patients (a single direct question with five levels of alternatives)|Patients' confidence towards acupuncture treatment (a single direct question with five levels of alternatives)|Consumption of additional antiemetic","https://ClinicalTrials.gov/show/NCT02842307"
2423,"NCT02204306","Genotype Guided Chemotherapy in Gastric Cancer Patients","Unknown status","No Results Available","Metastatic Gastric Cancer","Genetic: TSER","Central South University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1000 Talents-CSU-GC|1000 Plan","July 21, 2014","April 2014","December 2016","August 12, 2014","August 2014","No Study Results Posted","null","March 2016","disease control rate|time to progression|median overall survival","https://ClinicalTrials.gov/show/NCT02204306"
2424,"NCT00568815","Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)","Completed","No Results Available","Lymphoma","Drug: Rituximab combined with ESHAP","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ESHAP-DLBCL","December 5, 2007","April 2007","December 2010","February 16, 2012","February 2012","No Study Results Posted","null","December 2010","Response rate|Toxicities","https://ClinicalTrials.gov/show/NCT00568815"
2425,"NCT01752517","Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer","Unknown status","No Results Available","Small Cell Lung Cancer","Drug: NI group","Peking Union Medical College Hospital","All","18 Years to 75 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PUMCH-S463","December 12, 2012","December 2012","December 2015","December 14, 2012","December 2012","No Study Results Posted","null","December 2014","the disease control rate|progression free survival|Overall survival|the score of functional assessment of cancer treatment-lung (FACT-L)|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01752517"
2426,"NCT00742924","Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma","Completed","Has Results","Sarcoma","Drug: cisplatin|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: zoledronic acid|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Biological: filgrastim|Drug: Mesna","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 40 Years   (Child, Adult)","Phase 1","24","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AOST06P1|CDR0000612613|COG-AOST06P1","August 27, 2008","August 2008","null","June 4, 2014","June 2014","June 4, 2014","null","April 2012","Limiting Toxicity|Histologic Response as Assessed in the Primary Tumor and in Resected Metastases|Event-free Survival|Secondary Limiting Toxicity|Prognostic Value of Bone Resorption Markers","https://ClinicalTrials.gov/show/NCT00742924"
2427,"NCT03101995","Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease","Not yet recruiting","No Results Available","Cervical Cancer","Drug: Gemcitabine","National Institute of Cancerología|Instituto Nacional de Cardiologia Ignacio Chavez|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NationalIC|INCAN","December 15, 2016","July 1, 2017","July 1, 2019","May 11, 2017","May 2017","No Study Results Posted","null","January 31, 2018","Glomerular Filtration Rate|Toxicity","https://ClinicalTrials.gov/show/NCT03101995"
2428,"NCT01377298","Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","Unknown status","No Results Available","Head and Neck Squamous Cell Carcinoma","Drug: Pazopanib","National Taiwan University Hospital|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201007042M","May 16, 2011","June 2011","May 2014","June 20, 2011","June 2011","No Study Results Posted","null","May 2013","Objective response rate|disease control rate (CR+PR+SD),|Tumor Necrosis Ratio|progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01377298"
2429,"NCT02128230","UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","Recruiting","No Results Available","Multiple Myeloma","Drug: MEL-CFZ-TD-PACE","University of Arkansas|Amgen","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","134668","April 29, 2014","August 2014","May 2025","October 6, 2016","October 2016","No Study Results Posted","null","May 2025","The remission rate for participants with high-risk myeloma","https://ClinicalTrials.gov/show/NCT02128230"
2430,"NCT03006432","PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA","Recruiting","No Results Available","OESOPHAGO-GASTRIC CARCINOMA","Drug: Oxaliplatin|Drug: 5Fluorouracil bolus|Drug: 5Fluorouracil continu|Drug: Docetaxel|Drug: Folinic Acid","Federation Francophone de Cancerologie Digestive|UNICANCER|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","All","18 Years and older   (Adult, Senior)","Phase 3","506","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PRODIGE 51","December 27, 2016","December 2016","August 2022","February 16, 2017","December 2016","No Study Results Posted","GASTFOX","August 2020","progression-free survival|Overall survival Toxicity events (adverse events) according to NCI-CTC v4.0|Objective response rate|Toxicity events according to NCI-CTC v4.0","https://ClinicalTrials.gov/show/NCT03006432"
2431,"NCT00080028","Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer","Terminated","No Results Available","Head and Neck Cancer|Oropharynx Cancer|Larynx Cancer|Hypopharynx Cancer","Drug: Motexafin Gadolinium Injection","Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-0210","March 22, 2004","null","null","May 4, 2007","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00080028"
2432,"NCT01326923","Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer","Terminated","No Results Available","Head and Neck Squamous Cell Cancer","Drug: Cetuximab","Louisiana State University Health Sciences Center Shreveport","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H10-109","March 24, 2011","June 2010","February 2014","April 7, 2015","April 2015","No Study Results Posted","null","February 2014","Complete Response|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01326923"
2433,"NCT00589290","Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage","Completed","Has Results","Thymoma|Thymic Carcinoma","Drug: Belinostat (PDX101)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","41","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080033|08-C-0033","December 25, 2007","December 2007","June 2014","September 29, 2015","September 2015","October 28, 2011","null","July 2013","Number of Participants With a Partial Response|Chromosomal Gains or Losses in Comparative Genomic Hydridization in Thymoma and Thymic Cancer|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00589290"
2434,"NCT00325351","ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasms","Drug: Sagopilone (ZK 219477) + carboplatin","Bayer","Female","18 Years and older   (Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","91476|307979","May 11, 2006","August 2006","March 2009","October 31, 2014","October 2014","No Study Results Posted","null","July 2008","Response to treatment with ZK-Epo after 6 cycles|Safety and tolerability of ZK-Epo given with carboplatin","https://ClinicalTrials.gov/show/NCT00325351"
2435,"NCT02492503","Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix","Active, not recruiting","No Results Available","Metastatic Carcinoma to the Uterine Cervix|Recurrent Carcinoma Cervix|Cervix Carcinoma Recurrent","Drug: Paclitaxel and carboplatin|Drug: Paclitaxel and carboplatin","All India Institute of Medical Sciences, New Delhi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA CX CHEMOTHERAPY","January 8, 2014","November 2013","August 2015","July 7, 2015","July 2015","No Study Results Posted","null","August 2015","Time to progression (length of time from start of chemotherapy to evidence of cancer progression.|Response rate|Overall survival|Quality Of Life Questionnaire","https://ClinicalTrials.gov/show/NCT02492503"
2436,"NCT00759824","A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide","Completed","No Results Available","Small Cell Lung Carcinoma","Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01081","September 24, 2008","September 2008","June 2014","February 11, 2015","February 2015","No Study Results Posted","null","December 2013","Six-months progression-free survival|Survival|Response rate|Toxicity","https://ClinicalTrials.gov/show/NCT00759824"
2437,"NCT02309242","Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study","Recruiting","No Results Available","Sarcoma, Soft Tissue|Osteosarcoma Tumor","Behavioral: Neuropsychological assessment, MRI","Universitaire Ziekenhuizen Leuven","All","7 Years to 25 Years   (Child, Adult)","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening","S57349","October 24, 2014","December 2014","October 2018","August 20, 2015","August 2015","No Study Results Posted","null","October 2018","Neuropsychological functioning","https://ClinicalTrials.gov/show/NCT02309242"
2438,"NCT00995488","Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer","Terminated","Has Results","Urothelial Cancer|Bladder Cancer","Drug: ABI-007 (Abraxane®)","University of Michigan Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009.025|HUM00029138","October 14, 2009","October 2009","November 2013","August 28, 2015","August 2015","September 10, 2014","null","November 2013","Percentage of Participants With a Partial or Complete Response|Median Overall Survival","https://ClinicalTrials.gov/show/NCT00995488"
2439,"NCT02285530","GDF15 Based TPF Induction Chemotherapy for OSCC Patients","Not yet recruiting","No Results Available","Mouth Neoplasms|Carcinoma, Squamous Cell","Drug: TPF induction chemotherapy|Procedure: surgery group|Radiation: Post-operative radiotherapy","Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOSCAN2014","October 22, 2014","December 2014","December 2019","November 4, 2014","November 2014","No Study Results Posted","null","December 2016","overall survival rate as a measure by the numbers of living patients|disease free survival as a measure by the number of patients without recurrence or death|local recurrence free survival as a measure by the number of patients without recurrence|distant metastasis free survival as a measure by the number of patients without metastasis","https://ClinicalTrials.gov/show/NCT02285530"
2440,"NCT00965250","Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy","Completed","Has Results","Thymoma|Thymic Carcinoma|Thymic Carcinoid|Thymic Neuroendocrine Tumors","Drug: IMC-12","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","49","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","090212|09-C-0212","August 24, 2009","August 2009","June 2016","October 31, 2016","October 2016","October 12, 2012","null","March 2012","Objective Response Rate (Partial Response (PR)+Complete Response (CR)) to IMC-A12 Monotherapy in Patients With Advanced or Recurrent Thymoma or Thymic Carcinoma.|Number of Participants With Adverse Events|Percentage of Participants Who Respond to Treatment|Disease Control Rate (DCR)|Time to Progression|Overall Survival|Median Number of Cycles of Therapy|Correlate Response to Therapy With Changes in FDG-PET Imaging","https://ClinicalTrials.gov/show/NCT00965250"
2441,"NCT02855944","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","Recruiting","No Results Available","Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer","Drug: Chemotherapy|Drug: Rucaparib","Clovis Oncology, Inc.|Foundation Medicine","Female","18 Years and older   (Adult, Senior)","Phase 3","345","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","CO-338-043","July 22, 2016","September 2016","June 2024","May 16, 2017","May 2017","No Study Results Posted","null","June 2022","Investigator assessed progression-free survival (invPFS) by RECIST Version 1.1 for rucaparib versus chemotherapy|Efficacy of rucaparib versus chemotherapy as measured by overall survival (OS)|Safety and tolerability of rucaparib versus chemotherapy assessed by AEs reported; clinical laboratory investigations; Vital signs; 12 lead ECGs; Physical examinations; and ECOG performance status","https://ClinicalTrials.gov/show/NCT02855944"
2442,"NCT00130520","Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer","Completed","Has Results","Ovarian Neoplasms","Drug: bevacizumab|Drug: erlotinib","University of Arizona|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HSC #05-47;AVF3117s","August 12, 2005","June 2005","May 2010","May 22, 2012","December 2010","December 13, 2010","null","January 2010","Objective Response (Complete Partial, Stable and Progression)|Median Response Duration (Weeks)|Progression Free Survival(PFS)","https://ClinicalTrials.gov/show/NCT00130520"
2443,"NCT00176735","Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer","Terminated","No Results Available","Pancreatic Cancer","Drug: Capecitabine","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2001-046","September 9, 2005","December 2001","August 2005","May 18, 2015","May 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00176735"
2444,"NCT00787488","Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca","Withdrawn","No Results Available","Ovarian Cancer","Device: Hyperthermia","Mark Dewhirst|Duke University","Female","18 Years to 72 Years   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00008510","November 6, 2008","April 2009","April 2009","November 10, 2014","November 2014","No Study Results Posted","null","April 2009","Toxicity|Clinically free of disease. Response definitions will be based on CA-125, clinical assessment, CT imaging","https://ClinicalTrials.gov/show/NCT00787488"
2445,"NCT00606502","Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment","Completed","Has Results","Non-small Cell Lung Cancer","Drug: Pralatrexate|Drug: Erlotinib|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PDX-012|2007-004673-26","January 22, 2008","January 2008","August 2011","June 2, 2015","June 2015","December 22, 2010","null","May 2010","Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib|Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib|Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib|Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib","https://ClinicalTrials.gov/show/NCT00606502"
2446,"NCT01330186","Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy","Unknown status","No Results Available","Anal Cancer","Other: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)","Copenhagen University Hospital at Herlev","All","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GI 1026","April 5, 2011","February 2011","May 2012","April 11, 2011","April 2011","No Study Results Posted","null","February 2012","Tumor response","https://ClinicalTrials.gov/show/NCT01330186"
2447,"NCT01760811","CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT","Not yet recruiting","No Results Available","Squamous Cell Carcinoma","Drug: Erbitux,merck serono","Rabin Medical Center|Kaplan Medical Center|Meir Medical Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RMC0766","January 2, 2013","January 2013","December 2017","January 2, 2013","January 2013","No Study Results Posted","null","December 2015","PROGRESSION FREE SURVIVAL|Adverse event rate|Biomarker prediction","https://ClinicalTrials.gov/show/NCT01760811"
2448,"NCT01503372","FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer","Unknown status","No Results Available","Advanced Gastric Cancer","Drug: Pazopanib|Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)","Charite University, Berlin, Germany","All","18 Years and older   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PaFLO|2010-024379-15","December 22, 2011","November 2011","May 2015","January 10, 2012","January 2012","No Study Results Posted","PaFLO","May 2014","progression-free survival rate at 6 months|progression-free survival rate at 9 and 12 months|median progression-free survival|response rate|duration of response|toxicity|tolerability|overall survival|time to treatment failure|evaluation of the predictive and prognostic relevance of biomarkers","https://ClinicalTrials.gov/show/NCT01503372"
2449,"NCT02986568","Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers","Recruiting","No Results Available","Cervical Cancer|Uterine Cancer","Drug: Cisplatin|Drug: Cisplatin|Procedure: Peritoneal mesometrial resection|Procedure: Radical hysterectomy|Radiation: Concurrent chemoradiation therapy (CCRT)|Procedure: Laterally extended endopelvic resection, Total mesometrial resection|Procedure: Total mesometrial resection|Drug: 5-fluorouracil, Cisplatin|Drug: 5-fluorouracil, Cisplatin|Drug: Doxorubicin, Cisplatin|Procedure: Staging operation|Radiation: Radiotherapy or Concurrent chemoradiation therapy (CCRT)|Radiation: Concurrent chemoradiation therapy (CCRT)","Seoul National University Hospital","Female","20 Years and older   (Adult, Senior)","","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-1616","October 16, 2016","May 2016","null","December 6, 2016","December 2016","No Study Results Posted","FUSION IV","December 2023","Intraoperative complications|Acute complications related with surgery|Chronic complications related with surgery|Time period for recovering normal voiding function|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02986568"
2450,"NCT01364493","A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: Trastuzumab+Capecitabine+Oxaliplatin","Peking University","All","18 Years and older   (Adult, Senior)","Phase 2","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CGOG1001","May 31, 2011","May 2011","February 2014","May 7, 2017","May 2017","No Study Results Posted","null","August 2012","Objective response rate|progression free survival|overall survival of participants|adverse events","https://ClinicalTrials.gov/show/NCT01364493"
2451,"NCT01998919","A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: erlotinib [Tarceva]|Drug: placebo|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","154","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","MO18633","November 25, 2013","August 2006","November 2011","December 12, 2014","December 2014","April 7, 2014","null","November 2011","Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Non-Progression at Week 16 as Assessed by RECIST|Percentage of Participants With Confirmed CR or PR as Assessed by RECIST|Duration of Response|Time to Progression|Progression-Free Survival (PFS)|Overall Survival","https://ClinicalTrials.gov/show/NCT01998919"
2452,"NCT01259479","Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors","Completed","No Results Available","Solid Tumors|Brain Tumors|Brain Metastases","Drug: Satraplatin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","3 Years to 25 Years   (Child, Adult)","Phase 1","9","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","110047|11-C-0047","December 11, 2010","December 3, 2010","May 29, 2015","May 12, 2017","May 29, 2015","No Study Results Posted","null","August 1, 2013","MTD|PKs|Definte anti-tumore activity|PGs","https://ClinicalTrials.gov/show/NCT01259479"
2453,"NCT00533533","A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: docetaxel, oxaliplatin","Samsung Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-10-047","September 19, 2007","January 2006","June 2008","January 12, 2009","November 2006","No Study Results Posted","DO for AGC","March 2008","To define the dose-limiting toxicity and maximum tolerated dose in phase I study To evaluate the overall response rate in phase II study|1) To evaluate the safety and tolerability of the treatment combination. 2) To estimate overall survival. 3) To estimate the time to progression and the duration of overall response.","https://ClinicalTrials.gov/show/NCT00533533"
2454,"NCT00130936","Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates","Terminated","No Results Available","Gastric Cancer|Esophageal Cancer|Tumors","Drug: Epirubicin|Drug: Carboplatin|Drug: Capecitabine","AHS Cancer Control Alberta","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GI-05-0046","August 15, 2005","October 2005","November 2007","February 12, 2016","September 2009","No Study Results Posted","null","null","recommended phase II dose|preliminary study of efficacy","https://ClinicalTrials.gov/show/NCT00130936"
2455,"NCT01383148","Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","Terminated","No Results Available","Non-Small-Cell Lung Carcinoma","Biological: TG4010|Drug: placebo","Transgene","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TG4010.14/TIME|8559","June 23, 2011","April 2012","July 2016","January 4, 2017","January 2017","No Study Results Posted","TIME","July 2015","Phase 2: Progression-free Survival (PFS)|Phase 3: Overall Survival (OS)|Phase 2 : Overall Survival (OS)|Phase 2 : Overall Response Rate (ORR)|Phase 3: Progression-free Survival (PFS)|Phase 3 : Overall Response Rate (ORR)|Phase 2 : Duration of response|Phase 2: Safety|Phase 3: Duration of response|Phase 3: Safety","https://ClinicalTrials.gov/show/NCT01383148"
2456,"NCT01966913","Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors","Recruiting","No Results Available","Germ Cell Tumor","Drug: Bevacizumab|Drug: ICE chemotherapy regimen","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P100135","October 11, 2013","April 2012","September 2017","June 23, 2016","June 2016","No Study Results Posted","TAXIFIII","March 2017","Response|Toxicity|complete response rate|complete pathological response (pCR) or complete surgical response (sCR)|overall survival|response duration|progression-free survival","https://ClinicalTrials.gov/show/NCT01966913"
2457,"NCT01379482","Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer","Completed","No Results Available","Peritoneal Carcinomatosis|Gastric Cancer","Drug: Multimodal treatment","Uppsala University","All","up to 80 Years   (Child, Adult, Senior)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007/073|43145","June 7, 2011","January 2005","March 2009","May 5, 2014","May 2011","No Study Results Posted","null","March 2009","Overall survival","https://ClinicalTrials.gov/show/NCT01379482"
2458,"NCT00953420","Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes","Completed","No Results Available","Nasopharyngeal Carcinoma","Drug: Docetaxel|Drug: Carboplatin|Drug: Dexamethasone|Biological: EBV-specific cytotoxic T lymphocytes|Biological: G-CSF or Peg-GCSF","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine|M.D. Anderson Cancer Center","All","10 Years and older   (Child, Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","25145-CADEN|CADEN","August 4, 2009","November 2009","July 2015","August 3, 2016","August 2016","No Study Results Posted","CADEN","June 2014","The primary endpoint of the study is to evaluate the overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy and immunotherapy.|Response to re-induction chemotherapy|Evaluation of immune response by measuring EBV-DNA levels","https://ClinicalTrials.gov/show/NCT00953420"
2459,"NCT00231842","A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus","Completed","No Results Available","Uterine Cancer","Drug: Ifosfamide|Procedure: Radiation Therapy","Montefiore Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MMC-03-02-040","October 3, 2005","February 2003","July 2011","April 22, 2012","April 2012","No Study Results Posted","null","July 2011","To evaluate the toxicity and tolerability of pelvic radiation ""sandwiched"" between cycles of chemotherapy in patients with MMT.|To define patterns of recurrence and one-year recurrence-free survival in patients with MMT treated with ""sandwich"" therapy","https://ClinicalTrials.gov/show/NCT00231842"
2460,"NCT02499367","Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients","Recruiting","No Results Available","Breast Cancer","Drug: Nivolumab|Radiation: Radiation therapy|Drug: Low dose doxorubicin|Drug: Cyclophosphamide|Drug: Cisplatin","The Netherlands Cancer Institute|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N15TON","July 6, 2015","August 2015","August 2022","August 30, 2016","August 2016","No Study Results Posted","TONIC","August 2019","Progression free survival|Overall response rate|Clinical benefit rate|Toxicity of all study regimens","https://ClinicalTrials.gov/show/NCT02499367"
2461,"NCT03006614","PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","Recruiting","No Results Available","Breast Cancer Model|Effects of Chemotherapy|Breast Cancer","Drug: NVB|Drug: EPI|Drug: DDP|Drug: CAP|Drug: GEM|Drug: H|Drug: CTX|Drug: T","Shi Yanxia|Sun Yat-sen University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-FXY-077-内科","April 28, 2016","April 2016","March 2023","January 13, 2017","January 2017","No Study Results Posted","PERS","March 2018","Surgical specimens of breast primary tumors and axillary lymph nodes as measured by Pathological examination.|Time as a measure from randomization to disease recurrence or patients died due to disease progression.","https://ClinicalTrials.gov/show/NCT03006614"
2462,"NCT01613677","Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer","Withdrawn","No Results Available","Treatment for Metastatic or Locally Advanced Cervical Cancer","Drug: BKM120","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CBKM120ZBR01","June 5, 2012","November 2015","September 2017","April 19, 2017","February 2016","No Study Results Posted","null","September 2017","Toxicity profile by recording the frequency and severity of adverse events associated to the use of daily oral BKM 120 as assessed by NCI CTCAE v. 3.0|Clinical benefit [complete response (CR), partial response (PR) rate and stable disease] according to RECIST criteria.","https://ClinicalTrials.gov/show/NCT01613677"
2463,"NCT01487720","GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: GEMOX","Asan Medical Center","Male","18 Years and older   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UOSG-AMC-0802","December 6, 2011","October 2008","October 2013","November 30, 2013","November 2013","No Study Results Posted","null","October 2013","PSA response|PSA decline|Time to PSA progression|Composite progression-free survival|RECIST Response|Safety","https://ClinicalTrials.gov/show/NCT01487720"
2464,"NCT00336583","Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)","Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: Oxaliplatin","Asan Medical Center|Boryung Pharmaceutical Co., Ltd","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC 2006-130","June 13, 2006","June 2006","January 2008","May 25, 2010","September 2009","May 5, 2009","null","December 2006","Overall Response Rate|Worst Toxicity Grade by Patient","https://ClinicalTrials.gov/show/NCT00336583"
2465,"NCT00319839","Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab","Unknown status","No Results Available","Head and Neck Cancer","Drug: Abraxane|Drug: Centuximab","University of California, Irvine","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 05-46","April 27, 2006","March 2006","December 2010","January 13, 2010","January 2010","No Study Results Posted","null","December 2009","To assess the overall response rate (complete and partial response)|To assess the frequency and severity of toxicities|To evaluate overall survival and progression-free survival in patients|To assess whether the addition of Cetuximab will re-sensitize head and neck cancer to Abraxane after progression on single agent Abraxane.","https://ClinicalTrials.gov/show/NCT00319839"
2466,"NCT00704639","Chemoradiation Treatment for Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Cetuximab|Drug: Carboplatin|Radiation: Radiotherapy","Trans-Tasman Radiation Oncology Group (TROG)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TROG 07.04","June 22, 2008","April 2008","December 2015","February 15, 2017","February 2017","No Study Results Posted","null","December 2014","Safety and Feasibility|Failure free survival (FFS)|Time to local and/or regional failure|Overall survival|Site of first failure|Acute and late treatment toxicities","https://ClinicalTrials.gov/show/NCT00704639"
2467,"NCT00256230","Disulfiram in Patients With Metastatic Melanoma","Completed","No Results Available","Stage IV Melanoma","Drug: Disulfiram (DSF)","John P. Fruehauf|University of California, Irvine","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 01-01|2001-2038","November 17, 2005","January 2002","August 2007","December 6, 2016","December 2011","No Study Results Posted","null","August 2007","Determine response rate|Evaluate the toxicity of disulfiram administration","https://ClinicalTrials.gov/show/NCT00256230"
2468,"NCT00638937","AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy","Completed","Has Results","Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: saracatinib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","37","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01053|PMH-PHLO-053|CDR0000587610|PHL-053|7555|N01CM00032|N01CM62203","March 18, 2008","February 2008","June 2013","June 22, 2015","October 2013","August 28, 2014","null","June 2013","Rate of Disease Control (Freedom From Disease Progression)|Objective Response Rate (Complete and Partial Response)|Stable Disease Rate|Duration of Response or Stable Disease|Median Progression-free Survival|Progression-free Survival|Median Overall Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00638937"
2469,"NCT01836575","Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2","Completed","No Results Available","Non Small Cell Lung Carcinoma","Drug: Pemetrexed|Drug: Carboplatin","Instituto Nacional de Cancer, Brazil|Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 3","228","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H3E-BL-O027-PS2|H3E - US -I023|INCA-Lung001","December 30, 2010","April 2008","December 2012","April 18, 2013","April 2013","No Study Results Posted","PS2","January 2012","Overall survival|Safety evaluation|Progression free survival|Response Rate","https://ClinicalTrials.gov/show/NCT01836575"
2470,"NCT00514540","Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: Docetaxel|Drug: Carboplatin","M.D. Anderson Cancer Center","Male","18 Years and older   (Adult, Senior)","Phase 2","121","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0097","August 9, 2007","May 2006","April 2013","January 16, 2014","January 2014","No Study Results Posted","null","April 2013","Response Rate|Median Overall Survival","https://ClinicalTrials.gov/show/NCT00514540"
2471,"NCT02921854","Detection of Circulating Biomarkers of Immunogenic Cell Death","Recruiting","No Results Available","Non Small Cell Lung Cancer","Other: Blood withdrawal","Maastricht Radiation Oncology|Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other","ICD","September 28, 2016","April 4, 2017","September 2017","April 13, 2017","September 2016","No Study Results Posted","ICD","September 2017","Changes of relative protein expression / derived exosomes, linked to ICD|Changes of lipid profile for plasma / plasma, linked to ICD|Changes of relative protein expression, linked to Th1/Th2 subsets","https://ClinicalTrials.gov/show/NCT02921854"
2472,"NCT00161174","Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity","Completed","No Results Available","Non-seminomatous Testicular Cancer","","University Medical Center Groningen|Dutch Cancer Society","Male","Child, Adult, Senior","","173","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KWF RUG 2004-3157","September 8, 2005","July 2005","January 2011","April 28, 2015","April 2015","No Study Results Posted","null","December 2010","","https://ClinicalTrials.gov/show/NCT00161174"
2473,"NCT01467921","Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma","Unknown status","No Results Available","Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma","Drug: oxaliplatin","Samsung Medical Center","All","20 Years and older   (Adult, Senior)","Phase 2","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-07-206","November 6, 2011","December 2010","null","November 14, 2011","November 2011","No Study Results Posted","null","February 2012","disease-free survival","https://ClinicalTrials.gov/show/NCT01467921"
2474,"NCT02229656","Olaparib and Radiotherapy in Head and Neck Cancer","Recruiting","No Results Available","Laryngeal Cancer Stage II|Laryngeal Cancer Stage III|Carcinoma, Squamous Cell|Head and Neck Neoplasms","Radiation: radiotherapy|Drug: Olaparib","The Netherlands Cancer Institute|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N13ORH|2011-002963-79","August 28, 2014","February 2014","February 2019","September 14, 2016","September 2016","No Study Results Posted","null","August 2017","The incidence of dose limiting toxicities|acute toxicity|late toxicity","https://ClinicalTrials.gov/show/NCT02229656"
2475,"NCT01963052","ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer","Recruiting","No Results Available","Metastatic Urothelial Cancer","Drug: AGS15E","Agensys, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Senior)","Phase 1","155","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AGS15E-13-1","October 7, 2013","August 2013","December 2017","March 22, 2017","March 2017","No Study Results Posted","null","December 2017","Incidence of adverse events|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)|Incidence of Anti-Drug Antibody (ADA)|Tumor response|Objective response rate|Disease control rate|Progression free survival|Overall survival|Duration of response","https://ClinicalTrials.gov/show/NCT01963052"
2476,"NCT02335424","Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)","Active, not recruiting","No Results Available","Urothelial Cancer","Biological: pembrolizumab","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","350","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","3475-052|2014-002206-20","January 7, 2015","February 24, 2015","June 21, 2018","March 22, 2017","March 2017","No Study Results Posted","null","June 21, 2018","ORR by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) for All Participants (Independent Radiology Review)|ORR by RECIST 1.1 for Participants with PD-L1-positive Tumors (Independent Radiology Review)|ORR by RECIST 1.1 for Participants with Strongly PD-L1-positive Tumors (Independent Radiology Review)|Duration of Response (DOR) by RECIST 1.1 for All Participants, Participants with PD-L1-positive Tumors and Participants with Strongly PD-L1-positive Tumors (Independent Radiology Review)|Progression-free Survival (PFS) by RECIST 1.1 for All Participants, Participants with PD-L1-positive Tumors and Participants with Strongly PD-L1-positive Tumors (Independent Radiology Review)|Overall Survival (OS) for All Participants, Participants with PD-L1-positive Tumors and Participants with Strongly PD-L1-positive Tumors","https://ClinicalTrials.gov/show/NCT02335424"
2477,"NCT02603159","Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy","Recruiting","No Results Available","Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma","Drug: Capecitabine(Aibin)|Radiation: radiotherapy","The First Affiliated Hospital of Henan University of Science and Technology","All","45 Years to 75 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Capecitabine and esophageal","November 9, 2015","October 2014","December 2019","November 9, 2015","October 2015","No Study Results Posted","DCECRT","December 2017","overall survival, OS|progression-free survival|overall remission rate, ORR|serious adverse event|quality of life, Qol|pathologic complete response rate","https://ClinicalTrials.gov/show/NCT02603159"
2478,"NCT02195973","Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer","Active, not recruiting","No Results Available","Recurrent Ovarian Cancer","Drug: LDE225","University of Alabama at Birmingham|Novartis Pharmaceuticals","Female","19 Years and older   (Adult, Senior)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","F140214007 (UAB 1357)|000505867","July 17, 2014","September 2014","August 2018","February 6, 2017","February 2017","No Study Results Posted","null","August 2017","Safety of weekly paclitaxel + LDE225 treatment|Assessment of toxicities|Optimal dose of LDE225 with paclitaxel","https://ClinicalTrials.gov/show/NCT02195973"
2479,"NCT00002565","Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: CHOP regimen|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: idarubicin|Drug: ifosfamide|Drug: mesna|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 3","61","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000063574|MDA-DM-94017|NCI-T94-0040D|DM94-017","November 1, 1999","May 1994","February 2007","October 5, 2012","October 2012","No Study Results Posted","null","February 2007","","https://ClinicalTrials.gov/show/NCT00002565"
2480,"NCT00042952","Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer","Terminated","No Results Available","Ovarian Dysgerminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Ovarian Germ Cell Tumor|Stage II Malignant Testicular Germ Cell Tumor|Stage II Ovarian Germ Cell Tumor|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Testicular Seminoma","Drug: imatinib mesylate|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 2","32","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02481|CLB-90105|U10CA031946|CDR0000069487","August 5, 2002","June 2002","null","January 15, 2013","January 2013","No Study Results Posted","null","October 2003","Response rate defined as either a complete or partial response using RECIST criteria|Grade 1 or higher toxicities assessed using CTC)version 2|Duration of response|Disease-free survival|Overall survival|Proportion of patients with mutations in the c-KIT gene","https://ClinicalTrials.gov/show/NCT00042952"
2481,"NCT00392886","Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","Phase 3","120","Other","Interventional","Primary Purpose: Treatment","CDR0000503990|CHLA-HEAD-START-III|CHLA-HSIII|CHLA-2004-020|CHLA-04.020|UMN-MT2004-06","October 25, 2006","March 2004","null","December 17, 2013","October 2010","No Study Results Posted","null","December 2010","Time to tumor progression, disease recurrence, or death of any cause|Event-free survival at 2 years|Toxicity|Response to induction as assessed by one-time tumor measurements at baseline and after completion of induction chemotherapy|Time to death|Overall survival","https://ClinicalTrials.gov/show/NCT00392886"
2482,"NCT01743157","Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: Biochemo + bevacizumab then ipilimumab","California Pacific Medical Center Research Institute","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BBI Total Therapy","April 4, 2011","December 2010","May 2013","August 28, 2013","August 2013","No Study Results Posted","BBI","May 2013","A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy and Bevacizumab followed by consolidation therapy with Ipilimumab (BBI)","https://ClinicalTrials.gov/show/NCT01743157"
2483,"NCT00930605","The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)","Completed","No Results Available","Peripheral T-cell Lymphoma","Drug: CHOP regimen alternate with ESHAP regimen|Drug: Alemtuzumab","King Chulalongkorn Memorial Hospital|Bayer","All","15 Years to 65 Years   (Child, Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TH011001","June 29, 2009","January 2005","July 2008","October 4, 2011","October 2011","No Study Results Posted","C+CHOP/ESHAP","November 2006","The response to treatment and the treatment-related toxicity.","https://ClinicalTrials.gov/show/NCT00930605"
2484,"NCT01044420","mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial","Unknown status","No Results Available","Advanced Esophageal Carcinoma","Drug: mFOLFIRI","Peking University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FOLFIRI-AEC2","January 6, 2010","May 2009","June 2012","January 6, 2010","May 2009","No Study Results Posted","null","June 2011","overall survival|adverse events|progression-free survival|response rate","https://ClinicalTrials.gov/show/NCT01044420"
2485,"NCT01486992","mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus","Unknown status","No Results Available","Advanced Esophageal Carcinoma","Drug: mFOLFIRI+Nimotuzumab","Peking University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N+FOLFIRI-AEC-4","November 22, 2011","November 2011","November 2012","January 11, 2012","November 2011","No Study Results Posted","null","November 2012","overall survival|adverse events|progression-free survival|response rate|disease control rate","https://ClinicalTrials.gov/show/NCT01486992"
2486,"NCT00200681","IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Velcade","Nantes University Hospital","All","18 Years to 65 Years   (Adult)","Phase 3","493","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","BRD 04/11-J","September 12, 2005","June 2005","June 2008","February 4, 2009","February 2009","No Study Results Posted","null","January 2008","To compare the CR rate (with negative or positive immunofixation) obtained with VAD or the Velcade®/dexamethasone combination used as induction treatment in patients up to the age of 65 with newly diagnosed MM, at the end of this induction treatment","https://ClinicalTrials.gov/show/NCT00200681"
2487,"NCT01201265","A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Bevacizumab|Drug: Carboplatin|Drug: Gemcitabine","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25420","September 6, 2010","February 2011","April 2015","April 21, 2016","April 2016","April 21, 2016","null","April 2015","Progression-free Survival (PFS)|Percentage of Participants Achieving an Overall Response|Percentage of Participants Achieving a Clinical Benefit Response (CBR)|Time to Progression (TTP)|Overall Survival (OS)|Number of Participants With an Adverse Event (AE)|Change From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)|Change From Baseline in Systolic Blood Pressure (SBP)|Change From Baseline in Diastolic Blood Pressure (DBP)","https://ClinicalTrials.gov/show/NCT01201265"
2488,"NCT01543412","Second Line Chemotherapy for Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Adenocarcinoma","Drug: FOLFIRI","Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Hospira, now a wholly owned subsidiary of Pfizer","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-004637-16","September 7, 2010","January 2010","December 2011","March 2, 2012","February 2012","No Study Results Posted","SLAP","June 2011","Overall Response Rate (RECIST Criteria)|Safety and tolerability; Safety (CTC criteria - version 3.0)|Overall survival (OS)|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01543412"
2489,"NCT02817113","Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Neoplasms","Drug: NC-6004|Drug: Cetuximab|Drug: 5-FU","Orient Europharma Co., Ltd.|NanoCarrier Co., Ltd.","All","20 Years to 75 Years   (Adult, Senior)","Phase 1","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NC-6004-006","June 6, 2016","June 2016","December 2017","June 24, 2016","June 2016","No Study Results Posted","null","December 2017","Maximum Tolerated Dose (MTD)|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)|Incidence of AE lead to treatment discontinuation|Peak Plasma Concentration (Cmax)|Time of Maximum concentration observed (Tmax)|Area under the plasma concentration-time curve from time zero to time (AUC0-t)|Area under the concentration time-curves from time zero to infinity (AUC0-∞)|Terminal Elimination Rate Constant (λz)|Elimination Half-life (t½)|Clearance (CL) of total platinum in plasma|Clearance (CL) of total platinum in plasma ultrafiltrate|Volume of Distribution (Vz) of total platinum in plasma|Volume of Distribution (Vz) of total platinum in plasma ultrafiltrate|Tumor response rate (RR)|Disease control rate (DCR)|Overall response rate (ORR)","https://ClinicalTrials.gov/show/NCT02817113"
2490,"NCT00723658","S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","Withdrawn","No Results Available","Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: thalidomide|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0629|U10CA032102","July 26, 2008","September 2008","null","March 5, 2015","March 2015","No Study Results Posted","null","May 2010","Progression-free survival at 3 years|Overall survival|Response rate (complete response, very good partial response, and partial response)|Standard prognostic factors and other potential correlates that may relate to progression, symptomatic disease, and/or survival|Toxicity","https://ClinicalTrials.gov/show/NCT00723658"
2491,"NCT02643056","Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer","Completed","No Results Available","Advanced Head and Neck Squamous Cancer","Drug: Panitumumab","Southern Europe New Drug Organization|Clinical Trial Unit Ente Ospedaliero Cantonale (CTU-EOC)","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S10PANI01","December 8, 2015","January 2011","December 2015","December 29, 2015","December 2015","No Study Results Posted","S10PANI01","December 2015","Rate of tumor response in advanced platinum-resistant head and neck cancer|Adverse Event according to CTCAE v.3|Analysis of tumor biomarkers","https://ClinicalTrials.gov/show/NCT02643056"
2492,"NCT01993966","EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells","Unknown status","No Results Available","Urothelial Carcinoma","","National Taiwan University Hospital","All","20 Years to 80 Years   (Adult, Senior)","","25","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","201308047RIN|103-002509","October 24, 2013","January 2014","December 2016","November 19, 2013","November 2013","No Study Results Posted","null","December 2016","The IHC staining score","https://ClinicalTrials.gov/show/NCT01993966"
2493,"NCT00365183","Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer","Terminated","No Results Available","Non-Small Cell Lung Carcinoma","Drug: Motexafin gadolinium and pemetrexed","Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 2","74","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-0228","August 15, 2006","June 2006","June 2008","October 29, 2013","October 2013","No Study Results Posted","null","January 2008","6 month progression free survival|Time to disease progression|Overall survival|Progression free survival|Response rate (CR+PR) by RECIST criteria|Duaration of reponse (CR+PR)|Clinical benefit rate (CR+PR+SD)|Safety and tolerability of MGd and pemetrexed","https://ClinicalTrials.gov/show/NCT00365183"
2494,"NCT00771810","Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer","Terminated","Has Results","Thrombocytopenia|Neutropenia|Lymphopenia|Anemia","Drug: TXA127|Drug: TXA127|Drug: Placebo","Tarix Pharmaceuticals","Female","18 Years and older   (Adult, Senior)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","TXA127-2007-002","October 9, 2008","October 2008","December 2011","October 11, 2016","October 2016","February 25, 2013","null","December 2011","Chemotherapy Cycles During Which the Platelet Count Measures Below 50,000/mm3|Subjects With Platelet Counts Below 50,000/mm3|Treatment Cycles With Platelets Counts Below 25,000/mm3|Chemotherapy Dose Intensity and Dose Density|Lymphopenia as Determined by Lymphocyte Count|Neutropenia|Anemia|Mucositis|Alopecia|Rescue Treatment for Hematopoiesis and Mucositis","https://ClinicalTrials.gov/show/NCT00771810"
2495,"NCT02305654","International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","Not yet recruiting","No Results Available","Squamous Cell Carcinoma of the Penis, Usual Type","Procedure: ILND - Inguinal Lymph Node Dissection|Drug: Paclitaxel|Drug: Ifosfamide|Drug: Cisplatin|Radiation: Intensity modulated radiation treatment (IMRT)|Procedure: Prophylactic PLND - pelvic lymph node dissection","Institute of Cancer Research, United Kingdom|ECOG-ACRIN Cancer Research Group|European Organisation for Research and Treatment of Cancer - EORTC","Male","Child, Adult, Senior","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ICR CTSU/2014/10048|CRUK/13/005","September 23, 2014","April 2015","null","November 27, 2014","November 2014","No Study Results Posted","InPACT","July 2018","Overall survival|Disease specific survival time|Number of patients experience a grade 3 or 4 toxicity|Disease-free survival time|Occurrence of surgical complication|Is it possible to achieve pathological nodal assessment after chemotherapy|Quality of life|Occurrence of Pathological complete remission|Operability|Occurrence of Lower limb/scrotal oedema|On-schedule delivery of neoadjuvant therapy","https://ClinicalTrials.gov/show/NCT02305654"
2496,"NCT01718327","A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma","Completed","No Results Available","Unresectable and Advanced Cholangiocarcinoma","Drug: Sunitinib","Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SUN-CK D09-2|2011-000073-30","October 22, 2012","September 1, 2011","November 17, 2016","January 30, 2017","January 2017","No Study Results Posted","SUN-CK","November 17, 2016","Overall survival|To evaluate the criteria of efficacy (PFS, ORR)|To evaluate the effects of sunitinib on tumor angiogenesis|To characterize the safety profile of sunitinib (collection of AEs)|To identify markers associated with response to sunitinib","https://ClinicalTrials.gov/show/NCT01718327"
2497,"NCT00446290","Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer","Completed","Has Results","Stomach Cancer","Drug: Docetaxel, Capecitabine and Oxaliplatin","Asan Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ONCGI-0609","March 9, 2007","March 2006","October 2007","September 2, 2015","September 2015","December 15, 2013","DXO","October 2007","Number of Participants With DLTs","https://ClinicalTrials.gov/show/NCT00446290"
2498,"NCT00066768","Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer","Completed","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: suramin|Drug: docetaxel|Drug: gemcitabine hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","24","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01440|5889|CDR0000318808|NCI-5889|OSU-0238|2003C0022|U01CA076576","August 6, 2003","July 2003","null","June 3, 2013","June 2013","No Study Results Posted","null","March 2008","Safety of suramin, graded according to the revised NCI CTC version 2.0|Recommended dose of chemotherapy, defined as the dose at which no more than 1/6 patients develop DLT graded according to the revised NCI CTC version 2.0","https://ClinicalTrials.gov/show/NCT00066768"
2499,"NCT00686985","Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer","Unknown status","No Results Available","Small Cell Lung Cancer","Drug: Carboplatin, docetaxel","Jeroen Bosch Ziekenhuis","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCAR study","May 27, 2008","September 2007","July 2010","May 29, 2008","May 2008","No Study Results Posted","DOCAR","null","Response rate|Time to progression; Response duration; Survival; Safety profile","https://ClinicalTrials.gov/show/NCT00686985"
2500,"NCT01247246","Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer","Unknown status","No Results Available","Oral Mucositis","Drug: SCV-07|Drug: Placebo","SciClone Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SCI-SCV-MUC-P2b-002","November 22, 2010","December 2010","June 2014","May 22, 2014","May 2014","No Study Results Posted","null","June 2014","Efficacy|Safety","https://ClinicalTrials.gov/show/NCT01247246"
2501,"NCT01136031","Paclitaxel and Irinotecan in Advanced Gastric Cancer","Completed","No Results Available","Advanced Gastric Cancer","Drug: Paclitaxel and irinotecan","Seoul National University Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-0703-042-201","May 31, 2010","January 2008","August 2011","May 19, 2015","May 2010","No Study Results Posted","TI-2ndAGC","June 2011","Dose-limiting toxicity (phase I part)|response rate (phase II part)|recommended phase II dose|time to progression|overall survival|toxicities","https://ClinicalTrials.gov/show/NCT01136031"
2502,"NCT02289547","Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer","Recruiting","No Results Available","Stomach Neoplasms","Drug: Capecitabine","The Catholic University of Korea","All","18 Years and older   (Adult, Senior)","Phase 3","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMCGA1 Trial","October 30, 2014","May 2015","January 2019","March 1, 2016","March 2016","No Study Results Posted","null","January 2018","Progression free survival|Overall survival|quality of life in patients measured by QLQ-c30 and STO-22|Toxicity profile of each patients measured by NCI-CTCAE ver 4.0","https://ClinicalTrials.gov/show/NCT02289547"
2503,"NCT01524575","Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1","Unknown status","No Results Available","Metastatic Pancreatic Cancer|ERCC1","Drug: gemcitabine and oxaliplatin","University of Hawaii","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRCH0904","January 26, 2012","January 2012","January 2014","January 30, 2012","January 2012","No Study Results Posted","null","July 2013","6 month overall survival|Overall survival|Progression free survival|Best confirmed response|Duration of overall response","https://ClinicalTrials.gov/show/NCT01524575"
2504,"NCT01437488","Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy","Completed","No Results Available","Urothelial Carcinoma","Drug: Cabazitaxel|Drug: Neulasta|Procedure: CT Scan|Biological: Blood Draw","Sidney Kimmel Cancer Center at Thomas Jefferson University|Sanofi|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11D.392|2011-52","August 31, 2011","February 16, 2012","March 30, 2017","May 10, 2017","May 2017","No Study Results Posted","null","August 4, 2014","Overall Response Rate|Overall Survival|Progression Free Survival|Safety and Tolerability of Cabazitaxel","https://ClinicalTrials.gov/show/NCT01437488"
2505,"NCT01070290","A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen","Withdrawn","No Results Available","Gastric Cancer","Drug: ARQ 197|Drug: Oxaliplatin, capecitabine or irinotecan","ArQule","All","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARQ 197-206","February 16, 2010","null","null","January 6, 2014","January 2014","No Study Results Posted","null","null","Compare the progression-free survival (PFS) of ARQ 197 versus investigator's choice of second-line chemotherapy in patients with advanced gastric cancer who have failed first-line treatment.|Compare overall response rate (ORR) of ARQ 197 versus investigator's choice of second-line chemotherapy|Compare 6-month and 1-year overall survival (OS) rates of ARQ 197 versus investigator's choice of second-line chemotherapy|Further characterize the safety profile of ARQ 197","https://ClinicalTrials.gov/show/NCT01070290"
2506,"NCT02665702","Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas","Recruiting","No Results Available","Esophageal Squamous Cell Carcinoma","Drug: NVB|Drug: DDP|Drug: Endostar","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","76","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ENDO-SH-001","January 19, 2016","January 2016","September 2019","January 24, 2016","January 2016","No Study Results Posted","null","September 2018","Progression Free Survival","https://ClinicalTrials.gov/show/NCT02665702"
2507,"NCT00980460","Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","Recruiting","No Results Available","PRETEXT Stage 1 Hepatoblastoma|PRETEXT Stage 2 Hepatoblastoma|PRETEXT Stage 3 Hepatoblastoma|PRETEXT Stage 4 Hepatoblastoma","Drug: Cisplatin|Drug: Doxorubicin Hydrochloride|Drug: Fluorouracil|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Procedure: Liver Transplantation|Drug: Temsirolimus|Procedure: Therapeutic Conventional Surgery|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","253","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-01975|CDR0000654889|AHEP0731|COG-AHEP0731|U10CA180886|U10CA098543","September 18, 2009","September 14, 2009","null","May 24, 2017","May 2017","No Study Results Posted","null","June 30, 2017","Disease status at the end of 2 courses of therapy|Event-free survival|Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events version 4.0|Rate of death|Feasibility of referral for liver transplantation","https://ClinicalTrials.gov/show/NCT00980460"
2508,"NCT00190840","A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small Cell Lung","Drug: pemetrexed","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","186","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","6685|H3E-AA-S037","September 12, 2005","September 2003","October 2005","January 24, 2007","January 2007","No Study Results Posted","null","null","Response rate according to RECIST criteria|To assess the following time to event efficacy variables:|o Duration of overall response for responding patients|o Time to progressive disease|o Time to treatment failure|o Survival|To characterize the quantitative and qualitative toxicity of pemetrexed when used at tailored dosing in this patient population","https://ClinicalTrials.gov/show/NCT00190840"
2509,"NCT01655823","The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment","Terminated","No Results Available","Pain|Peripheral Neuropathy|Neuropathic Pain","Drug: Placebo|Drug: Tetrodotoxin","Wex Pharmaceuticals Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TTX-CINP-201","July 19, 2012","July 2012","December 2016","June 1, 2015","June 2015","No Study Results Posted","TTX-CINP-201","January 2015","Change from Baseline in patient reported outcome for pain at Day 22 to Day 28.|Safety","https://ClinicalTrials.gov/show/NCT01655823"
2510,"NCT00511446","Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer","Completed","No Results Available","Stomach Neoplasms","Drug: docetaxel, oxaliplatin, capecitabine","Martin-Luther-Universität Halle-Wittenberg","All","18 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AIO STO-0601","August 2, 2007","August 2007","January 2013","June 25, 2013","June 2013","No Study Results Posted","null","May 2010","Progression-free survival rate|Number of Participants with Adverse Events as a Measure of Safety/toxicity|Median time to progression|Response rate|Rate of resections with curative intent|Time to treatment failure|Duration of response|Median overall survival","https://ClinicalTrials.gov/show/NCT00511446"
2511,"NCT00041626","Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone","Unknown status","No Results Available","Carcinoma, Squamous Cell","Genetic: INGN 201","Introgen Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T302","July 11, 2002","null","null","September 10, 2007","September 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00041626"
2512,"NCT02819752","PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","Not yet recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma","Drug: Pembrolizumab|Radiation: Radiotherapy|Drug: Chemotherapy","Royal Marsden NHS Foundation Trust|Institute of Cancer Research, United Kingdom|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","CCR4325","June 22, 2016","August 2016","December 2018","June 27, 2016","June 2016","No Study Results Posted","PEACH","March 2018","the maximum tolerated dose that can safely be combined with platin-based chemoradiotherapy in patients with HPV-ve and HPV+ve LA-SCCHN|Acute toxicity as measured during treatment by CTCAE v4.0|The Progression Free Survival|The Overall Survival|To measure the duration of clinical benefit using RECIST|To evaluate late radiotherapy toxicities as measured during treatment by LENT SOMA","https://ClinicalTrials.gov/show/NCT02819752"
2513,"NCT03135977","Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy","Recruiting","No Results Available","Extensive-stage Small Cell Lung Cancer|Lung Cancer","Drug: Apatinib, Etoposide","Sichuan Cancer Hospital and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Prevention","Ahead-SL-20170220","April 27, 2017","March 1, 2017","May 2018","May 9, 2017","May 2017","No Study Results Posted","null","March 2018","Progression-free survival|Overall survival|Duration of Response|Tumor response rate|Quality of Life (QoL) questionnaire","https://ClinicalTrials.gov/show/NCT03135977"
2514,"NCT02945852","Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.","Recruiting","No Results Available","Small Cell Lung Cancer","Drug: apatinib","Zhejiang Cancer Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","zjSAPA001","October 25, 2016","October 2016","December 2018","October 25, 2016","October 2016","No Study Results Posted","null","October 2018","Progression-free survival|Tumor response rate|Treatment-related adverse events","https://ClinicalTrials.gov/show/NCT02945852"
2515,"NCT00068289","Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy","Completed","No Results Available","Lung Cancer","Drug: bortezomib","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000320527|SWOG-S0327","September 10, 2003","September 2003","July 2007","June 21, 2013","August 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00068289"
2516,"NCT02557529","Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy","Recruiting","No Results Available","Head and Neck Neoplasms|Weight Loss","Behavioral: Progressive Resistance Training|Behavioral: physical activity|Behavioral: Diet diary","Herlev Hospital|Aarhus University Hospital|Odense University Hospital|Danish Head and Neck Cancer Group","All","18 Years and older   (Adult, Senior)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Supportive Care","DAHANCA 31","September 11, 2015","August 2015","May 2018","May 16, 2016","May 2016","No Study Results Posted","null","December 2017","Change in LBM (lean body mass)|Fat mass|Weight loss|pain|Quality of Life|Muscle strength|Chair rise|arm curls|Stair climb|Compliance to PRT program|Physical activity|Percent of patients with feeding tubes|Resumption of work|Percent relapses|Cytokines|Muscle biopsies|Patient satisfaction|NK-cells","https://ClinicalTrials.gov/show/NCT02557529"
2517,"NCT00659269","A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients","Completed","Has Results","Cancer","Dietary Supplement: Multivitamin (MV)|Dietary Supplement: Multivitamin + Vitamin B12 + Vitamin B6|Drug: Chemotherapy","New Mexico Cancer Care Alliance","All","18 Years and older   (Adult, Senior)","Phase 3","319","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Prevention","INST 0553C|NCI-2012-00946","April 14, 2008","July 2006","June 2015","January 27, 2016","January 2016","June 18, 2015","null","June 2013","Neurotoxicity Assessment at Baseline|Neurotoxicity Assessment at Cycle 2|Neurotoxicity Assessment at Cycle 4|Change in Neurotoxicity Assessment Between Cycle 4 and Baseline","https://ClinicalTrials.gov/show/NCT00659269"
2518,"NCT01749072","Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients","Recruiting","No Results Available","Non-small Cell Lung Cancer|Effects of Chemotherapy","Drug: Gefitinib group|Drug: Vinorelbine, Ifosfamide, Mesna","Peking Union Medical College Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PUMCH-S464","December 11, 2012","December 2012","December 2017","December 12, 2012","December 2012","No Study Results Posted","null","December 2016","Progression free survival|Overall survival|objective response rate|the score of functional assessment of cancer treatment-lung (FACT-L)|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT01749072"
2519,"NCT00183820","Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma","Unknown status","No Results Available","Testicular Cancer|Germ Cell Neoplasm","Drug: paclitaxel, gemcitabine, and oxaliplatin","University of Southern California|Sanofi","Male","16 Years and older   (Child, Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4T-03-1","September 9, 2005","November 2004","June 2016","March 25, 2015","March 2015","No Study Results Posted","null","December 2015","Tumor Response|Progression","https://ClinicalTrials.gov/show/NCT00183820"
2520,"NCT01453504","Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma","Recruiting","No Results Available","Hodgkin Lymphoma","Drug: DHAP|Drug: Everolimus","University of Cologne","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","125","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","HD-R3i","October 17, 2011","August 2012","August 2018","May 10, 2017","May 2017","No Study Results Posted","HD-R3i","August 2017","Dose Limiting Toxicity Rate (DLT)|Complete Remission Rate (CR)|Adverse event rate|Tumor status (assessed by CT) after chemotherapy|Tumor status (assessed by PET) after chemotherapy","https://ClinicalTrials.gov/show/NCT01453504"
2521,"NCT00604461","Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)","Terminated","Has Results","Mesothelioma","Drug: Carboplatin, Bevacizumab and Pemetrexed","H. Lee Moffitt Cancer Center and Research Institute|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-14896|AVF3483s","January 17, 2008","October 2007","January 2011","February 20, 2017","November 2011","November 17, 2011","null","January 2011","Number of Participants With Partial Response (PR) of Target Lesions|Number of Months of Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00604461"
2522,"NCT01207102","Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer","Terminated","Has Results","Metastatic Breast Cancer","Drug: Abraxane|Drug: Carboplatin","Duke University|Celgene Corporation","Female","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00019321","September 10, 2010","August 2011","June 2014","December 8, 2014","August 2014","December 8, 2014","null","June 2014","PFS|To Assess the Safety and Tolerability of a Combination Regimen of Weekly Abraxane® and Carboplatin to Treat Women With ""Triple Negative"" Stage IV Metastatic Breast Cancer","https://ClinicalTrials.gov/show/NCT01207102"
2523,"NCT01523574","Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis","Completed","No Results Available","Peripheral Neuropathy","Drug: Vitamin E|Drug: Placebo","Felipe Melo Cruz|Faculdade de Medicina do ABC","All","18 Years and older   (Adult, Senior)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VE01","December 19, 2011","August 2009","December 2010","January 29, 2012","January 2012","No Study Results Posted","null","November 2010","Incidence and grade of Peripheral neuropathy by common terminology criteria for adverse events v 3.0(CTCAE)and specific Ox PN gradation scales.","https://ClinicalTrials.gov/show/NCT01523574"
2524,"NCT00002487","Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer","Unknown status","No Results Available","Ovarian Cancer","Drug: dipyridamole|Drug: methotrexate","Ottawa Regional Cancer Centre|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077374|CAN-OTT-9017|NCI-V92-0012","November 1, 1999","July 1991","null","September 16, 2013","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002487"
2525,"NCT00080444","Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","Completed","No Results Available","Vomiting","Drug: aprepitant|Drug: ondansetron|Drug: dexamethasone|Drug: placebo to aprepitant|Drug: placebo to dexamethasone|Drug: rescue medication","Merck Sharp & Dohme Corp.","All","12 Years to 17 Years   (Child)","Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","0869-097|Formerly-0304AHEC|MK-0869-097|2004_099","March 31, 2004","April 2004","March 2007","August 4, 2014","August 2014","No Study Results Posted","null","September 2006","Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycle 1)|Percentage of Participants Who Experience a Complete Response (CR) to Anti-emetic Therapy (Cycle 1)|Percentage of Participants Who Experience Absence of Nausea (Cycle 1)|Percentage of Participants Who Experience Absence of Vomiting (Cycle 1)|Percentage of Participants Who Experience Serious Adverse Events (Cycles 2-10)|Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycles 2-10)|Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycles 2-10)|Percentage of Participants Who Experience Serious Adverse Events (Cycle 1)|Percentage of Participants Who Experience Serious Study-drug-related Adverse Events (Cycle 1)|Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycle 1)|Aprepitant Plasma Drug Concentration Profiles and Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00080444"
2526,"NCT00867347","Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer","Unknown status","No Results Available","Bladder Cancer","Procedure: therapeutic conventional surgery|Radiation: radiation therapy","Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","1015","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000633526|ICR-SPARE|ISRCTN61126465|EU-20907|ICR-CTSU/2006/10002","March 20, 2009","December 2006","null","July 9, 2011","March 2009","No Study Results Posted","null","March 2014","Number of patients randomized over 3 years|Proportion of patients undergoing selective bladder preservation|Proportion of patients undergoing radical cystectomy|Overall survival|Compliance with randomized treatment|Rate of salvage cystectomy after selective bladder preservation|Toxicity as assessed by NCI CTCAE v3.0|Quality of life as assessed by the QLQ-C30 v3.0 questionnaire|Locoregional progression-free, metastasis-free, and overall survival","https://ClinicalTrials.gov/show/NCT00867347"
2527,"NCT00215644","MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: ECX|Drug: Matuzumab + ECX","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMD 72000-032","September 15, 2005","August 2005","August 2008","November 4, 2016","November 2016","No Study Results Posted","null","July 2008","Response rate|Response duration|median time to tumor progression|median survival time|safety and tolerability|QoL|protein biomarkers|immunogenicity|matuzumab peak and trough values","https://ClinicalTrials.gov/show/NCT00215644"
2528,"NCT01870609","Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma","Terminated","No Results Available","Malignant Pleural Mesothelioma","Drug: defactinib (VS-6063)|Drug: Placebo","Verastem, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","344","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","VS-6063-202","May 29, 2013","September 2013","January 2016","January 26, 2017","March 2016","No Study Results Posted","COMMAND","January 2016","Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo|Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo|To assess Quality of Life (QoL) in subjects treated with defactinib (VS-6063) or placebo using the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)|To determine the objective response rate (ORR) in subjects receiving defactinib (VS-6063) or placebo.","https://ClinicalTrials.gov/show/NCT01870609"
2529,"NCT00049322","Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery","Completed","Has Results","Liver Cancer","Biological: bevacizumab","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000258045|P30CA016042|UCLA-0206060|NCI-G02-2124","November 12, 2002","June 2003","February 2012","February 17, 2016","February 2016","January 20, 2016","null","February 2012","Neovessel Formation as Measured by Angiogram at 14 Weeks|Progression Free Survival|Assess the Toxicities of Bevacizumab in Patients With Liver Function Impairment|Assess Pharmakokinetics of Bevacizumab in Liver Disease|Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab","https://ClinicalTrials.gov/show/NCT00049322"
2530,"NCT01655225","A Study of LY3023414 in Participants With Advanced Cancer","Recruiting","No Results Available","Advanced Cancer|Metastatic Cancer|Non-Hodgkin's Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer","Drug: LY3023414|Drug: Midazolam|Drug: Fulvestrant|Drug: Pemetrexed|Drug: Cisplatin","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","130","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13517|I6A-MC-CBBA","July 19, 2012","July 31, 2012","March 4, 2018","March 22, 2017","March 2017","No Study Results Posted","null","March 4, 2018","Recommended Phase 2 dose|Pharmacokinetics: Maximum concentration (Cmax)|Pharmacokinetics: Time of maximal concentration|Number of participants with tumor response|Potential of LY3023414 to inhibit CYP3A4-mediated metabolism","https://ClinicalTrials.gov/show/NCT01655225"
2531,"NCT02114359","Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer","Recruiting","No Results Available","Gastric Cancer","Drug: Capecitabine/cisplatin|Drug: S-1/cisplatin|Drug: Capecitabine/oxaliplatin|Drug: 5-fluorouracil/oxaliplatin|Drug: Capecitabine|Drug: S-1|Drug: 5-fluorouracil","Seoul National University Hospital|Ministry of Health & Welfare, Korea|Korean Cancer Study Group","All","70 Years and older   (Senior)","Phase 3","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20140113/16-2014-9/021","April 9, 2014","February 2014","February 2018","September 23, 2016","September 2016","No Study Results Posted","null","February 2017","comparison of overall survival|comparison of progression-free survival|comparison of response rate|comparison of adverse events|comparison of quality of life","https://ClinicalTrials.gov/show/NCT02114359"
2532,"NCT03017326","Paediatric Hepatic International Tumour Trial","Not yet recruiting","No Results Available","Hepatoblastoma|Carcinoma, Hepatocellular","Drug: Cisplatin|Drug: Doxorubicin|Drug: Carboplatin|Drug: 5Fluorouracil|Drug: Vincristine|Drug: Etoposide|Drug: Irinotecan|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Sorafenib","University of Birmingham|Fundació Institut Germans Trias i Pujol|University of Padua|University of Newcastle Upon-Tyne|University Hospital Munich|University Hospital, Bonn|University of Kiel|University Hospital Tuebingen|Medical University of Gdansk","All","up to 30 Years   (Child, Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","RG_15-114","December 14, 2016","May 2017","December 2022","May 5, 2017","May 2017","No Study Results Posted","PHITT","December 2022","Event-free survival (EFS)|Response in HCC is defined as complete (CR) or partial (PR) response according to RECIST version 1.1 criteria|Failure-free survival (FFS)|Overall survival (OS)|Toxicity categorized and graded using Common Terminology Criteria for Adverse Events (CTCAE)|Chemotherapy-related cardiac, nephro- and oto-toxicity using Common Terminology Criteria for Adverse Events (CTCAE)|Hearing loss according to the SIOP Boston Scale|Best Response|Surgical resectability defined as complete resection, partial resection or transplant|Adherence to surgical guidelines","https://ClinicalTrials.gov/show/NCT03017326"
2533,"NCT00794339","Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer","Active, not recruiting","No Results Available","Cervical Cancer","Drug: 64Cu-ATSM|Radiation: FDG","American College of Radiology Imaging Network|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","73","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Diagnostic","CDR0000624407|ACRIN-6682|U01CA080098|U01CA079778","November 19, 2008","July 2009","December 2017","March 16, 2017","March 2017","No Study Results Posted","ACRIN6682","June 2017","Relationship between copper Cu 64-ATSM uptake in the primary tumor and progression-free survival after chemoradiotherapy|Relationship between copper Cu 64-ATSM uptake and overall survival|Relationship between copper Cu 64-ATSM uptake and rates of local recurrence and development of distant metastasis|Relationship between copper Cu 64-ATSM uptake and frequency of complete metabolic response|Accuracy of copper Cu 64-ATSM uptake as a predictor of progression-free survival, overall survival, primary tumor recurrence, and future development of distant metastatic disease|Correlation between copper Cu 64-ATSM uptake and tumor volume at study entry and lymph node metastasis at diagnosis|Relationship of copper Cu 64-ATSM uptake and markers of tumor hypoxia, including VEGF, GLUT-1, CA-IX, and OPN","https://ClinicalTrials.gov/show/NCT00794339"
2534,"NCT00068653","Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: Celecoxib|Drug: ZD1839","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000327805|P30CA022453|WSU-C-2563|ZENECA-1839US/0252","September 10, 2003","June 2003","May 2008","April 25, 2013","April 2013","No Study Results Posted","null","October 2007","Response rate|Progression-free survival (PFS)|Overall survival|Toxicity of this drug combination","https://ClinicalTrials.gov/show/NCT00068653"
2535,"NCT02423811","To Study the Effect of Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy","Recruiting","No Results Available","Cancer Stem Cell","Dietary Supplement: Fursultiamine","National Cheng-Kung University Hospital","All","20 Years to 75 Years   (Adult, Senior)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A-BR-104-105","April 19, 2015","April 2015","null","April 21, 2015","April 2015","No Study Results Posted","null","December 2017","Progression-free survival","https://ClinicalTrials.gov/show/NCT02423811"
2536,"NCT02131480","Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma","Completed","No Results Available","Uterus Leiomyosarcoma|Soft Tissue Leiomyosarcoma","Drug: Doxorubicin|Drug: Trabectedin","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2009-012430-70|2008/1485","May 5, 2014","June 2010","October 2016","January 25, 2017","January 2017","No Study Results Posted","LMS02","January 2013","Disease control rate|Response rate|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02131480"
2537,"NCT00479674","Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Abraxane|Drug: Bevacizumab|Drug: Carboplatin","Duke University|Genentech, Inc.|Celgene Corporation","Female","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00014837|AVF3962s","May 25, 2007","May 2007","March 2014","January 29, 2015","January 2015","December 9, 2014","ABC","March 2014","Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III ""Triple Negative"" Metastatic Breast Cancer.|Median Proportion Progression-free as Estimated by Kaplan-Meier Methods|To Evaluate Sequential Plasma Samples for Presence of Selected Angiogenic Markers|to Determine if Apolipoprotein Alleles (Apo-E) Correlate With Treatment-related Neuropathy|to Determine if SPARC Expression in Breast Tumors Predicts Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00479674"
2538,"NCT01845779","Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal","Recruiting","No Results Available","Metastatic Anal Canal Cancer|Human Papillomavirus","Drug: DCF regimen","Centre Hospitalier Universitaire de Besancon","All","18 Years and older   (Adult, Senior)","","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","Epitope-HPV01","April 15, 2013","September 2012","January 2020","August 4, 2016","August 2016","No Study Results Posted","Epitopes-HPV01","January 2020","presence and characterization of anti-HPV immune responses in patients in complete remission|global survival|progression free survival","https://ClinicalTrials.gov/show/NCT01845779"
2539,"NCT00058071","Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer","Completed","No Results Available","Gestational Trophoblastic Tumor|Neurotoxicity|Peripheral Neuropathy|Unspecified Adult Solid Tumor, Protocol Specific","Drug: amifostine trihydrate","Gynecologic Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","100","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","CDR0000285700|GOG-0192","April 7, 2003","March 2003","null","July 8, 2013","July 2007","No Study Results Posted","null","December 2007","Improvement of neuropathy by WEST assessment at 6, 12, 18, and 24 weeks|Improved quality of life by Functional Assessment of Cancer Therapy-GOG/NTX (FACT-GOG/NTX) at 6, 12, 18, and 24 weeks","https://ClinicalTrials.gov/show/NCT00058071"
2540,"NCT01937208","Comparable Study of Different Radiation Dose in Esophageal Carcinoma","Recruiting","No Results Available","Esophageal Carcinoma","Radiation: intensity modulated radiation therapy in both arms|Drug: concurrent chemotherapy with radiation","Zhejiang Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ESC-130825","August 25, 2013","August 2013","July 2017","September 3, 2013","September 2013","No Study Results Posted","null","August 2015","Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01937208"
2541,"NCT00462735","Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer|Cancer of the Pharynx|Cancer of the Larynx|Nose Neoplasms|Paranasal Sinus Neoplasms|Cancer of the Oral Cavity","Drug: cetuximab|Drug: hydroxyurea|Drug: fluorouracil|Procedure: chemotherapy|Procedure: radiotherapy","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCO 06-1155","April 18, 2007","February 2007","null","October 12, 2010","June 2008","No Study Results Posted","null","October 2010","locoregional control|survival|acute and late toxicity|quality of life|distant metastases","https://ClinicalTrials.gov/show/NCT00462735"
2542,"NCT02783885","Clinical Utilization of Newly Approved Oncology Medications","Recruiting","No Results Available","Cancer","Drug: immunotherapy","National Guard Health Affairs","All","18 Years to 80 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RC15/097/R","May 12, 2016","May 2016","September 2020","May 23, 2016","May 2016","No Study Results Posted","null","September 2020","Descriptive measures of the pattern of use of the new medications in our population|Measuring the efficacy in terms of response|Measuring the efficacy in terms of progression-free survival (PFS)|Measuring the efficacy in terms of overall survival (OS)","https://ClinicalTrials.gov/show/NCT02783885"
2543,"NCT00134030","Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","Active, not recruiting","No Results Available","Localized Osteosarcoma|Metastatic Osteosarcoma","Drug: doxorubicin hydrochloride|Drug: cisplatin|Drug: methotrexate|Procedure: therapeutic conventional surgery|Biological: peginterferon alfa-2b|Drug: ifosfamide|Drug: etoposide|Procedure: quality-of-life assessment|Other: questionnaire administration","Children's Oncology Group|National Cancer Institute (NCI)|University College London Hospitals","All","5 Years to 40 Years   (Child, Adult)","Phase 3","1164","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AOST0331|NCI-2009-01066|EUDRACT-2004-000242-20|MRC-EURAMOS1|MRC-BO08|ISRCTN67613327|EU-20530|CDR0000438714|COG-AOST0331|U10CA098543","August 22, 2005","November 2005","January 2018","May 2, 2017","May 2017","No Study Results Posted","null","January 2018","Event-free survival|Overall survival|Toxicity as measured by CTCAE v3.0|Quality of life","https://ClinicalTrials.gov/show/NCT00134030"
2544,"NCT02456714","Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma","Recruiting","No Results Available","Cholangiocarcinoma","Drug: FOLFIRINOX","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","volgt","March 10, 2015","December 2015","January 2018","February 11, 2016","February 2016","No Study Results Posted","4CC","January 2018","pilot study: toxicity|phase II: the response rate|pilot study: the response rate|pilot study: time to progression.|pilot study: the overall survival|pilot study: quality of life|phase II: toxicity during the treatment period and 30 days after the treatment.|phase II: time to progression.|phase II: the overall survival.|phase II: quality of life","https://ClinicalTrials.gov/show/NCT02456714"
2545,"NCT01152853","PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer","Completed","No Results Available","Advanced Gastric Cancer|HER2","Drug: PF00299804","Seoul National University Hospital|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-1004-031-315","June 20, 2010","July 2010","September 2012","November 17, 2015","May 2015","No Study Results Posted","PF299804-AGC","July 2011","progression-free survival at 4-months (PFS4mo)|Overall Response Rate|Overall Survival (OS)|toxicity","https://ClinicalTrials.gov/show/NCT01152853"
2546,"NCT01099085","Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients","Completed","No Results Available","Gastric Cancer","Drug: Simvastatin|Drug: Placebo","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","207","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","2008-12-019","April 4, 2010","February 2009","January 2015","February 15, 2017","February 2017","No Study Results Posted","null","June 2013","Progression free survival of XP ± simvastatin","https://ClinicalTrials.gov/show/NCT01099085"
2547,"NCT02002195","Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer","Unknown status","No Results Available","Metastatic Gastric Cancer","Drug: FOLFOX|Drug: Capecitabine","International Group of Endovascular Oncology","All","65 Years and older   (Adult, Senior)","","47","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MATURE01|MATURE","November 29, 2013","November 2013","May 2016","April 16, 2015","April 2015","No Study Results Posted","MATURE","November 2015","progression-free survival|PFS on capecitabine maintenance|overall survival|number of patients with adverse events|tolerability|time to treatment failure|Quality of life","https://ClinicalTrials.gov/show/NCT02002195"
2548,"NCT00107614","DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients","Terminated","Has Results","Waldenstrom Macroglobulinemia","Drug: DT PACE + Rituxan","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2002-10","April 5, 2005","November 2002","February 2008","August 24, 2011","August 2011","April 15, 2011","null","February 2008","Response Rates to a Brief Remission Induction Treatment With One or Two Courses of Melphalan-based High-dose Treatment (HDT)","https://ClinicalTrials.gov/show/NCT00107614"
2549,"NCT01922232","MRI and Bladder Cancer Chemotherapy","Withdrawn","No Results Available","Invasive Bladder Cancer","","New York University School of Medicine","All","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","S13-00240","August 12, 2013","August 2013","July 2014","October 1, 2014","October 2014","No Study Results Posted","null","July 2014","Complete pathologic response","https://ClinicalTrials.gov/show/NCT01922232"
2550,"NCT00664105","Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)","Terminated","Has Results","Lung Cancer","Drug: Carboplatin|Drug: Docetaxel|Radiation: radiation therapy","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC THO 0319|VU-VICC-THO-0319|VU-VICC-030269","April 19, 2008","February 2004","June 2008","August 30, 2012","August 2012","September 30, 2010","null","June 2008","Overall Survival|Overall Response Rate|Time to Disease Progression|Number of Participants With Adverse Events by Grade","https://ClinicalTrials.gov/show/NCT00664105"
2551,"NCT02236195","Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes","Completed","No Results Available","Urothelial Carcinoma","Drug: Mocetinostat","Mirati Therapeutics Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","17","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0103-018","September 4, 2014","October 2014","July 2016","December 22, 2016","December 2016","No Study Results Posted","null","April 2016","Number of patients experiencing tumor size reduction|Number of patients experiencing adverse events|Peak blood plasma concentration of mocetinostat","https://ClinicalTrials.gov/show/NCT02236195"
2552,"NCT01243775","BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Belotaxel|Drug: Belloxa","Chonnam National University Hospital|Chong Kun Dang Pharmaceutical","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","m601NSC10B","November 15, 2010","November 2010","January 2013","July 20, 2015","July 2015","July 19, 2015","BELOXAN","January 2013","Response Rate|Progression Free Survival|Overall Survival|Neutropenia Grade 3-4","https://ClinicalTrials.gov/show/NCT01243775"
2553,"NCT00770588","Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)","Completed","Has Results","Non-small Cell Lung Cancer (NSCLC)","Drug: Gefitinib|Drug: Placebo","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 4","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","D7913L00071","October 9, 2008","September 2008","February 2011","January 15, 2016","August 2012","January 17, 2012","INFORM","January 2011","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Tumour Response (ORR)|Disease Control Rate (DCR)|Symptom Improvement|Adverse Event","https://ClinicalTrials.gov/show/NCT00770588"
2554,"NCT03059667","Immunotherapy as Second-line in Patient With Small Cell Lung Cancer","Recruiting","No Results Available","Small Cell Lung Cancer|Small Cell Lung Cancer Limited Stage|Small Cell Lung Cancer Extensive Stage","Drug: Atezolizumab|Drug: Topotecan|Drug: Carboplatin|Drug: Etoposide","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IFCT-1603","February 14, 2017","March 1, 2017","November 2018","March 8, 2017","March 2017","No Study Results Posted","null","October 2018","Response Rate in the experimental arm|Progression Free Survival|Overall Survival|Compliance assessed by the number of cycle received by patient|Safety assessed by the maximum grade will be summarized by frequency and proportion of total patients, by system organ class and NCI-CTC, Version 4.0 categories.|Duration of response|Quality of life assessed by scale","https://ClinicalTrials.gov/show/NCT03059667"
2555,"NCT00198393","Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Gefitinib|Drug: gemcitabine|Drug: Docetaxel","Intergroupe Francophone de Cancerologie Thoracique|AstraZeneca|Sanofi","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-0301","September 13, 2005","November 2004","December 2008","April 28, 2010","April 2010","No Study Results Posted","null","June 2008","Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00198393"
2556,"NCT00228488","Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma","Completed","No Results Available","Head and Neck Cancer","Drug: Gefitinib","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0547","September 27, 2005","June 2004","December 2005","December 16, 2007","December 2007","No Study Results Posted","null","null","To study the effect of Iressa on gene expression profiles in patients with head and neck cancer|To study the efficacy of Iressa as monotherapy as first line or after failing prior platinum-based regimen in patients with recurrent/metastatic head and neck carcinomas","https://ClinicalTrials.gov/show/NCT00228488"
2557,"NCT00469898","Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","Has Results","Lung Cancer","Drug: Carboplatin|Drug: irinotecan hydrochloride","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC THO 0321|VU-VICC-THO-0321","May 3, 2007","December 2003","July 2010","July 20, 2012","July 2012","October 11, 2010","null","July 2008","Patient Response|Number of Patients With Adverse Events|Time to Progression|Overall Survival","https://ClinicalTrials.gov/show/NCT00469898"
2558,"NCT02108652","A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)","Active, not recruiting","Has Results","Bladder Cancer","Drug: Atezolizumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","310","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GO29293 (Cohort 2)|IMvigor 210|2013-005486-39","April 7, 2014","May 31, 2014","August 31, 2017","April 20, 2017","April 2017","July 1, 2016","null","May 31, 2015","Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According Modified RECIST|Duration of Response as Assessed by the IRF According to RECIST v1.1|Duration of Response as Assessed by the Investigator According to RECIST v1.1|Duration of Response as Assessed by the Investigator According to Modified RECIST|Percentage of Participants With Death or Disease Progression as Assessed by the IRF According to RECIST v1.1|Progression-Free Survival (PFS) as Assessed by the IRF According to RECIST v1.1|Percentage of Participants With Death or Disease Progression as Assessed by the Investigator According to RECIST v1.1|PFS as Assessed by the Investigator According to RECIST v1.1|Percentage of Participants With Death or Disease Progression as Assessed by the Investigator According to Modified RECIST|PFS as Assessed by the Investigator According to Modified RECIST|Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According RECIST v1.1|Percentage of Participants Who Died|Overall Survival (OS)|Percentage of Participants Alive at 1-year|Maximum Serum Concentration (Cmax) of Atezolizumab|Minimum Serum Concentration (Cmin) of Atezolizumab|Percentage of Participants Positive for Anti-therapeutic Antibodies (ATA) to Atezolizumab","https://ClinicalTrials.gov/show/NCT02108652"
2559,"NCT02229916","Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS","Recruiting","No Results Available","Testicular Neoplasms","","Dr. med. Christian Rothermundt|German Testicular Cancer Study Group|Cantonal Hospital of St. Gallen","Male","18 Years and older   (Adult, Senior)","","6900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SG359/13","August 27, 2014","December 2013","January 2021","July 27, 2016","July 2016","No Study Results Posted","SAG TCCS","November 2016","Mode of relapse detection|Rate of relapses detected on chest x-ray in seminoma patients|Rate of false positive abnormalities on CT scan|Rate of false positive tumour marker elevations not due to seminomatous or non-seminomatous germ cell tumour relapses but due to other reasons|Patient characteristics at baseline and at the time-point of relapse detection.|Rate of stage I seminoma and non-seminoma patients undergoing active surveillance.|Overview of treatment and follow-up strategies in germ cell cancer patients in Switzerland, Austria and Germany|Treatment sequelae following testicular cancer treatment in terms of organ function, cardiovascular risk factors, sexual health and socioeconomic aspects.|Rate of intermediate and poor-prognosis disease at relapse.|Rate of offspring spontaneously conceived after testicular cancer treatment.","https://ClinicalTrials.gov/show/NCT02229916"
2560,"NCT00905983","Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Gemcitabine and Docetaxel","Hospital Arnau de Vilanova","All","70 Years and older   (Senior)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPNM-ANC-07","May 19, 2009","October 2007","September 2011","May 19, 2009","May 2009","No Study Results Posted","null","September 2009","Overall response rate = sum of complete and partial tumour responses divided by the number of included patients|Overall survival|Toxicity|Duration of response|Time to progression|Measurement of quality of life","https://ClinicalTrials.gov/show/NCT00905983"
2561,"NCT02016287","Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer","Unknown status","No Results Available","Esophageal Squamous Cell Cancer|Elderly Patients","Other: Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy","Shen Lin|Peking University","All","69 Years and older   (Senior)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CGOG7002","December 7, 2013","December 2013","July 2016","December 13, 2013","December 2013","No Study Results Posted","null","December 2015","progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02016287"
2562,"NCT01472419","Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma","Completed","No Results Available","Metastatic Esophageal Squamous Cell Carcinoma","","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","","239","Other","Observational","Time Perspective: Retrospective","SMCESOPROGNOSIS","November 11, 2011","March 2012","March 2013","April 7, 2013","April 2013","No Study Results Posted","null","December 2012","Overall Survival","https://ClinicalTrials.gov/show/NCT01472419"
2563,"NCT00580372","UARK 89-001 Phase II Study of Intensive ""TOTAL THERAPY"" For Untreated or Minimally Treated Patients With Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: VAD|Drug: High-Dose cyclophosphamide|Procedure: Hemopoietic stem cell procurement|Drug: EDAP|Procedure: Autologous Hemopoietic Stem Cell Transplant 1|Procedure: Autologous Hemopoietic Stem Cell Transplant 2|Drug: Maintenance","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","231","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01332","December 18, 2007","August 2002","October 2015","August 1, 2016","August 2016","August 1, 2016","null","October 2015","Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy","https://ClinicalTrials.gov/show/NCT00580372"
2564,"NCT02735057","Chemoradiotherapy in Elderly Patients With Oesophagus Cancer","Recruiting","No Results Available","Oesophagus Cancer|Elderly Patients","Drug: Carboplatin","Centre Hospitalier Universitaire de Besancon","All","75 Years to 100 Years   (Senior)","Phase 1|Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N/2014/68","March 18, 2016","April 2016","April 2024","April 14, 2017","April 2017","No Study Results Posted","OSAGE","April 2016","maximum tolerated dose (MTD)|Quality of life|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02735057"
2565,"NCT03079440","TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors","Not yet recruiting","No Results Available","Neuroendocrine Tumors|Neuroendocrine Carcinoma|Temozolomide|Capecitabine","Drug: TEMCAP","Asan Medical Center","All","19 Years and older   (Adult, Senior)","Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Asan-ONCHBP-2017-002","March 9, 2017","May 2017","October 2020","March 13, 2017","March 2017","No Study Results Posted","null","May 2019","Response rate|Progression-free survival|Overall survival|Toxicity (Adverse events graded by National Cancer Institute-Common Terminology Criteria version 4.03)","https://ClinicalTrials.gov/show/NCT03079440"
2566,"NCT00864266","Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer","Recruiting","No Results Available","Non Small Cell Lung Carcinoma","Drug: Chemotherapy","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","01082","March 16, 2009","March 2009","March 2021","August 9, 2016","August 2016","No Study Results Posted","null","March 2020","Response rate|Survival|Progression-free survival|Duration of response","https://ClinicalTrials.gov/show/NCT00864266"
2567,"NCT02127255","Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail","Completed","No Results Available","Chemotherapy-induced Nausea and Vomiting","Procedure: Manual acupuncture implemented by acupuncturist 1|Procedure: Manual acupuncture implemented by acupuncturist 2","Beijing University of Chinese Medicine|Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","18 Years to 75 Years   (Adult, Senior)","","39","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","EBM@BUCM-1|Z111107054511086","April 29, 2014","April 2014","December 2015","April 14, 2016","April 2016","No Study Results Posted","ACTIN","December 2015","NCI nausea and vomiting rating scale|Rhodes Scale|global assessment on effectiveness by patients (VAS)|patients' confidence towards acupuncture treatment(VAS)|global satisfaction for acupuncture treatments|Acupuncture Expectancy Scale (AES)","https://ClinicalTrials.gov/show/NCT02127255"
2568,"NCT02433639","Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer","Unknown status","No Results Available","Biliary Tract Cancer","Drug: TH-302 monotherapy","Seoul National University Hospital|Merck Serono International SA","All","20 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-1412-023-631","April 26, 2015","April 2015","June 2016","April 29, 2015","April 2015","No Study Results Posted","null","June 2016","progression-free survival at 4-months (PFS4mo)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Overall Survival (OS)|safety and tolerability as measured by number and grade of toxicity events","https://ClinicalTrials.gov/show/NCT02433639"
2569,"NCT02430298","Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients","Completed","No Results Available","Head and Neck Cancer","Drug: Melatonin|Drug: Matched Placebo","Khon Kaen University|Ubon Ratchathani Cancer Hospital, Ubon Ratchathani|General Drugs House Ltd., Bangkok","All","18 Years to 60 Years   (Adult)","Phase 2","39","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MLT-MX","January 28, 2014","July 2013","December 2015","February 22, 2016","February 2016","No Study Results Posted","null","December 2015","Percentage of occurrence of mucositis level 3 or more by using the criteria of CTCAE version 4.0, World Health Organization scale and MTSscores|Percentage of occurrence of xerostomia level 2 or more by using the criteria of CTCAE version 4.0 and the Visual Analogue Scale|Quality of Life (FACT- H&N Version 4)","https://ClinicalTrials.gov/show/NCT02430298"
2570,"NCT01222936","LBH Phase II in Small Cell Lung Cancer (SCLC)","Completed","No Results Available","Small Cell Lung Carcinoma","Drug: LBH581","Southern Europe New Drug Organization|Novartis Pharmaceuticals","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S075LBH501","October 11, 2010","May 2008","August 2010","October 14, 2010","October 2010","No Study Results Posted","null","June 2009","Objective response rate|Duration of antitumor activity|Drug safety profile","https://ClinicalTrials.gov/show/NCT01222936"
2571,"NCT00691236","Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma","Unknown status","No Results Available","Osteosarcoma","Drug: Zoledronic acid|Drug: Standard chemotherapy","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","382","May 27, 2008","May 2008","August 2013","June 22, 2011","June 2011","No Study Results Posted","ZOL","May 2013","histological response disease free interval","https://ClinicalTrials.gov/show/NCT00691236"
2572,"NCT01271322","Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)","Terminated","No Results Available","Adenocarcinomas of the Esophagogastric Junction","Radiation: neoadjuvant radiochemotherapy in metabolic non responders","National Center for Tumor Diseases, Heidelberg","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCT200811021017","December 17, 2010","October 2010","December 2012","April 10, 2013","April 2013","No Study Results Posted","HICON","December 2012","Correlation between change in tumor metabolism (detected by PET) and histopathological response|distribution of change in tumor metabolism during the treatment in histological responders and non-responders|accuracy of the binary prediction rule reduction in the tumor metabolism >65% vs. <65% in histopathological responders vs. non-responders|association between change in tumor metabolism before/after radiochemotherapy and histopathological response|association between change in tumor metabolism between PET Baseline and PET1 and overall survival as well as disease-free survival","https://ClinicalTrials.gov/show/NCT01271322"
2573,"NCT01609114","Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","","Far Eastern Memorial Hospital","All","20 Years to 80 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FEMH No.:100163-F","April 27, 2012","April 2012","null","May 8, 2013","May 2013","No Study Results Posted","null","July 2016","Area under the plasma concentration versus time curve (AUC) of'chemo-drugs""","https://ClinicalTrials.gov/show/NCT01609114"
2574,"NCT02105350","A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer","Suspended","No Results Available","Biliary Tract Carcinoma|Gallbladder Carcinoma","Drug: MEK 162|Drug: Gemcitabine|Drug: Oxaliplatin","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Biliary GEMOX / MEK","April 2, 2014","June 2015","December 2017","July 6, 2015","July 2015","No Study Results Posted","null","June 2017","Total incidence of grade 3 and 4 adverse events|Total rate of grade 3 and 4 adverse events|Maximum dose level at which 0/3 patients or 1/6 patients experience dose-limiting toxicity|Number of patients with objective response rate","https://ClinicalTrials.gov/show/NCT02105350"
2575,"NCT01209520","Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy","Completed","Has Results","Lung Cancer|Non Small Cell Lung Carcinoma|Hypermethylation","Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Vidaza|Procedure: Tumor Specimen for Methylation Analysis|Procedure: Blood Sample for Methylation Analysis|Drug: Vinorelbine|Drug: Docetaxel|Drug: Pemetrexed","University of Miami","All","18 Years and older   (Adult, Senior)","","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20080779|SCCC-2008045","September 22, 2010","July 2009","null","February 5, 2015","February 2015","January 9, 2015","null","December 2013","Percentage of Patients Showing a Presence of Methylated Tumor Suppressor Genes in Their Tumor Tissue and/or Serum Achieving Partial or Complete Response to Protocol Therapy.|Degree of Demethylation in Patient Tumor Tissue and/or Serum Induced by 5-azacitidine on Specific Tumor Specific Genes (TSGs)","https://ClinicalTrials.gov/show/NCT01209520"
2576,"NCT02353936","A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus","Recruiting","No Results Available","Squamous Cell Carcinoma of Esophagus","Drug: BIBW2992","Yonsei University","All","20 Years and older   (Adult, Senior)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2014-0432","January 23, 2015","January 2015","July 2017","September 5, 2016","September 2016","No Study Results Posted","null","March 2017","response rate|Progression free survival","https://ClinicalTrials.gov/show/NCT02353936"
2577,"NCT01253057","A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure","Unknown status","No Results Available","Sister-chromatic-exchange(SCE)|Micronuclei(MN)","","Taipei Medical University WanFang Hospital","All","Child, Adult, Senior","","200","Other","Observational","Observational Model: Case Control","99061","December 1, 2010","October 2010","December 2011","December 1, 2010","December 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01253057"
2578,"NCT01167530","Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer","Unknown status","No Results Available","Non-small Cell Lung Cancer|Locally Advanced Disease","Drug: Everolimus","Gustave Roussy, Cancer Campus, Grand Paris|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IGR 1269","July 21, 2010","March 2008","July 2014","April 3, 2012","July 2010","No Study Results Posted","RAD001","July 2014","Toxicity|Progression-free and overall survival.|Response rate","https://ClinicalTrials.gov/show/NCT01167530"
2579,"NCT00264056","Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases","Unknown status","No Results Available","Advanced Metastastic Malignant Melanoma|Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue Metastases","Device: hyperthermia","Fachklinik Hornheide an der Universität Münster","All","18 Years to 70 Years   (Adult, Senior)","","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOT-100","December 8, 2005","December 2005","June 2007","December 8, 2005","November 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00264056"
2580,"NCT01709006","Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy","Active, not recruiting","No Results Available","Head and Neck Cancer","Radiation: Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions","Centre hospitalier de l'Université de Montréal (CHUM)","All","70 Years to 80 Years   (Senior)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ORL IMRT/Elderly population","October 16, 2012","August 2012","December 2020","August 3, 2016","July 2016","No Study Results Posted","null","August 2017","Obtain a locoregional control that is similar to historical data","https://ClinicalTrials.gov/show/NCT01709006"
2581,"NCT01091636","Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer","Enrolling by invitation","No Results Available","Epithelial Ovarian Cancer","Procedure: Hyperthermic Intraperitoneal Chemotherapy","National Cancer Center, Korea|Ajou University","Female","up to 75 Years   (Child, Adult, Senior)","Phase 2|Phase 3","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","NCCCTS-06-222","March 23, 2010","March 2010","December 2017","September 24, 2014","September 2014","No Study Results Posted","null","February 2016","Progression free survival|Overall survival, quality of life","https://ClinicalTrials.gov/show/NCT01091636"
2582,"NCT00856830","Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer|Extensive Stage Lung Cancer|Chemonaive","Drug: Bendamustine, Irinotecan, Etoposide/Carboplatin (Novel drug combination)","University of Alabama at Birmingham|National Comprehensive Cancer Network","All","18 Years to 79 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","F080929010|UAB 0818","March 5, 2009","March 2009","May 2016","July 7, 2016","July 2016","No Study Results Posted","null","May 2015","Maximum tolerated dose (MTD) and safety of the combination bendamustine and irinotecan in chemotherapy-naive patients with extensive SCLC|To investigate the time to progression of bendamustine/irinotecan in sequence with etoposide/carboplatin in chemonaive extensive stage SCLC patients.","https://ClinicalTrials.gov/show/NCT00856830"
2583,"NCT01209507","Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy","Completed","No Results Available","Adrenal Suppression","Other: Chemotherapy","University of Colorado, Denver","Female","18 Years and older   (Adult, Senior)","","19","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-0190.cc","September 23, 2010","February 2010","November 2015","March 23, 2017","March 2017","No Study Results Posted","null","November 2015","Identify the level of adrenal suppression with recurrent, intermittent steroid administration during gynecologic chemotherapy regimens in all participating patients|Identify the differences in quality of life scores among patients with adrenal suppression and those with normal function","https://ClinicalTrials.gov/show/NCT01209507"
2584,"NCT01171170","Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer","Unknown status","No Results Available","Non Small Cell Lung Cancer","Drug: carboplatin paclitaxel bevacizumab|Drug: Standard treatment plus nitroglycerin","Dutch Society of Physicians for Pulmonology and Tuberculosis","All","18 Years and older   (Adult, Senior)","Phase 2","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NVALT12","July 23, 2010","September 2010","August 2014","July 26, 2011","July 2011","No Study Results Posted","NVALT12","August 2014","progression free survival|objective response rate|disease control rate|duration of response|safety|prediction of early response|decreased hypoxia","https://ClinicalTrials.gov/show/NCT01171170"
2585,"NCT00159471","Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.","Terminated","No Results Available","Pancreatic Cancer","Drug: capecitabine, gemcitabine, docetaxel","University of Southern California|Sanofi","All","18 Years and older   (Adult, Senior)","","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3P-03-2","September 9, 2005","February 2005","July 2006","May 20, 2014","May 2014","No Study Results Posted","null","June 2006","To see if patients with advanced pancreatic cancer treated with gemcitabine, docetaxel and capecitabine who bear more favorable genotypes of genes involved in drug metabolisms are more likely to have response and survive longer than those that do not.|To assess time to progression, toxicity and to identify other molecular correlates of response, toxicity, and survival.","https://ClinicalTrials.gov/show/NCT00159471"
2586,"NCT02690012","Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies","Recruiting","No Results Available","Hypomagnesemia","Other: Magnesium Oxide|Other: Magnesium Citrate","Ottawa Hospital Research Institute","All","19 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","20150853-01H","January 27, 2016","July 2016","December 2017","September 15, 2016","September 2016","No Study Results Posted","OTT 15-03","March 2017","Percentage of participants who are eligible and agree to participate in RCT.|Percentage of medical oncologists who agree to participate in the study at study commencement and approach patients for the study.|Magnesium levels|Cardiac risk|Cost factors|Rates of treatment delays|Rates of hospital admissions.","https://ClinicalTrials.gov/show/NCT02690012"
2587,"NCT02424045","Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma","Active, not recruiting","No Results Available","T-cell Lymphoma","Drug: BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)","Samsung Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-12-012","April 15, 2015","May 2015","July 2019","May 18, 2016","May 2016","No Study Results Posted","null","July 2018","Overall response rate|Toxicity profiles (Adverse Events and Laboratory Results)|Progression free survival|Overall survival|Incidence of febrile neutropenia","https://ClinicalTrials.gov/show/NCT02424045"
2588,"NCT02272816","A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT","Unknown status","No Results Available","Metastatic Seminoma","Drug: Carboplatin AUC-10","Barts & The London NHS Trust","Male","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","007065|2009-009882-33","November 6, 2012","February 2012","June 2015","October 21, 2014","October 2013","No Study Results Posted","Car-PET","June 2015","2 - year progression free survival|Metabolic response rate|Overall survival|Number of Adverse Events recorded for each patient","https://ClinicalTrials.gov/show/NCT02272816"
2589,"NCT00540735","Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas","Terminated","No Results Available","Cholangiocarcinoma","Procedure: photodynamic therapy","University Hospital, Angers","All","18 Years and older   (Adult, Senior)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PHRC 2006-01","October 5, 2007","April 2008","November 2009","February 3, 2010","October 2007","No Study Results Posted","CK/PDT","null","Patients' survival compared between both groups : PDT and non-PDT.","https://ClinicalTrials.gov/show/NCT00540735"
2590,"NCT01946867","NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx","Recruiting","No Results Available","Head and Neck Cancer","Device: NBTXR3","Nanobiotix","All","65 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NBTXR3-102|ID RCB: 2013-A00706-39","September 10, 2013","August 2013","August 2017","March 24, 2017","October 2016","No Study Results Posted","null","August 2017","Determination of the Recommended Doses and the early Dose Limiting Toxicities (DLT)|Evaluation of the safety and tolerability of NBTXR3|Evaluation of the Objective Response Rate (ORR) and the complete Response Rate as per Response Evaluation Criteria in Solid Tumors (RECIST) and the Tumor Volume estimation|Evaluation of the Local Progression Free Survival (LPFS)|Evaluation of the Progression Free Survival (PFS) of NBTXR3|Characterization of the body kinetics profile of NBTXR3|Evaluation of the feasibility of local administration either intratumor or intra-arterial route","https://ClinicalTrials.gov/show/NCT01946867"
2591,"NCT00760591","Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)","Unknown status","No Results Available","Acute Kidney Failure","","Soon Chun Hyang University","All","18 Years to 65 Years   (Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008-41","September 25, 2008","September 2008","null","September 25, 2008","September 2008","No Study Results Posted","null","null","NGAL","https://ClinicalTrials.gov/show/NCT00760591"
2592,"NCT02533700","CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL","Recruiting","No Results Available","Peripheral T-Cell Lymphoma|Angioimmunoblastic T Cell Lymphoma|ALK-negative Anaplastic Large Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma|Acute Adult T-Cell Leukemia/Lymphoma","Drug: CEOP/IVE/GDP chemotherapy regimen|Drug: CEOP chemotherapy regimen for 6 cycles","Shandong Provincial Hospital","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 4","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","WXin","July 18, 2015","September 2015","December 2017","April 18, 2016","April 2016","No Study Results Posted","null","September 2017","Percentage of patients with complete remission （CR）","https://ClinicalTrials.gov/show/NCT02533700"
2593,"NCT00301548","Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer","Completed","No Results Available","Breast Neoplasms|Carcinoma","Drug: perioperative chemotherapy","European Institute of Oncology","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IEO S31/499","March 9, 2006","February 2000","June 2005","March 9, 2006","January 2006","No Study Results Posted","null","null","Reduction in Ki-67 labeling index|Pathological complete remission rate|Disease-free survival|Toxicity and safety","https://ClinicalTrials.gov/show/NCT00301548"
2594,"NCT01612286","Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Drug: endostatin","Zhejiang Cancer Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZhejaingCH-npc-02","May 28, 2012","May 2012","May 2014","February 16, 2014","April 2013","No Study Results Posted","null","December 2013","progress free survival(PFS)|overall survival(OS)|Adverse events","https://ClinicalTrials.gov/show/NCT01612286"
2595,"NCT00003143","Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation","Completed","No Results Available","Lymphoma","Drug: Amifostine|Drug: DHAP","Jonsson Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000065926|UCLA-HSPC-970708701|ALZA-UCLA-HSPC-970708701|NCI-V97-1362","November 1, 1999","November 1997","null","October 3, 2012","October 2012","No Study Results Posted","null","December 2000","","https://ClinicalTrials.gov/show/NCT00003143"
2596,"NCT00772694","Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy","Unknown status","No Results Available","Testicular Cancer","Drug: sorafenib","Fondation Wygrajmy Zdrowie","Male","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12602|PL/ 183/UR/CEBK/04/08|EudraCT 2007-007599-40","October 14, 2008","September 2008","December 2011","October 23, 2008","October 2008","No Study Results Posted","GCT","December 2011","Progression free survival|ORR Evaluation of the usefulness the CT with vasculature visualisation option in the measurement of the objective response Evaluation of quality of life","https://ClinicalTrials.gov/show/NCT00772694"
2597,"NCT02468661","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: INC280 single agent|Drug: INC280 in combination with erlotinib|Drug: Platinum/pemetrexed","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","135","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CINC280B2201","June 1, 2015","September 23, 2015","March 31, 2020","April 5, 2017","April 2017","No Study Results Posted","null","March 31, 2020","Phase Ib: Frequency and characteristics of Dose Limiting Toxicity (DLTs) to the INC280 and erlotinib combination|Phase II: Progression-free Survival (PFS)|Phase Ib: Overall Response Rate (ORR)|Phase Ib: Overall Survival (OS)|Phase Ib: Number of patients with adverse events (AEs) as a measure of safety and tolerability|Phase Ib: Plasma concentration-time profiles of INC280 and pharmacokinetic parameters|Phase Ib: Plasma concentration-time profiles of erlotinib in the presence of INC280|Phase II: Overall Response Rate (ORR) by investigator's assessment according to RECIST v1.1|Phase II: Overall Survival (OS)|Phase II: Number of patients with AEs/serious adverse events (SAEs) as a measure of safety and tolerability (INC280 + erlotinib)|Phase II: Number of patients with AEs/SAEs as a measure of safety and tolerability (INC280 alone)|Phase II: Plasma concentration of INC280 (INC280 + erlotinib)|Phase II: Phase II: Plasma concentration of INC280 (INC280 alone)|Phase II: Plama concentrations of INC280 (erlotinib + INC280)|Phase Ib: Disease Control Rate (DCR)|Phase Ib: Duration of Response (DOR)|Phase Ib: Progression-free Survival (PFS)|Phase II: Disease Control Rate (DCR) by investigator's assessment according to RECIST v1.1|Phase II: Duration of Response (DOR) by investigator's assessment according to RECIST v1.1|Phase Ib: Number of patients with serious adverse events as a measure of safety and tolerability|Phase II: Overall Response Rate (ORR), Disease Control Rate by investigator's assessment according to RECIST v1.1","https://ClinicalTrials.gov/show/NCT02468661"
2598,"NCT03049410","Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy","Recruiting","No Results Available","Bladder Cancer","Procedure: Intracorporeal Robot Assisted Radical Cystectomy|Procedure: Open Radical Cystectomy","University College, London","All","18 Years and older   (Adult, Senior)","","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16/0584","February 2, 2017","March 1, 2017","February 15, 2020","April 12, 2017","April 2017","No Study Results Posted","iROC","November 30, 2019","Days at home within 90 days of the surgery|Difficulties due to health conditions measured using WHODAS version 2.0|Quality of Life measured using EQ-5D-5L Health Questionnaire and EORTC QLQ-C30 version 3.","https://ClinicalTrials.gov/show/NCT03049410"
2599,"NCT01216124","Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients","Available","No Results Available","Triple Negative Local Advanced Breast Cancer","Drug: docetaxel oxaliplatin","Fudan University|Chinese Anti-Cancer Association","Female","18 Years to 65 Years   (Adult)","","null","Other","Expanded Access","","Fudan TNBC Neo CT","October 6, 2010","null","null","October 6, 2010","September 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01216124"
2600,"NCT02455843","Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC","Recruiting","No Results Available","Non Small Cell Lung Cancer","Other: Microwave ablation","Shandong Provincial Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ShandongPH Jinan","May 16, 2015","May 2015","May 2018","November 30, 2016","November 2016","No Study Results Posted","null","May 2018","progression free survival","https://ClinicalTrials.gov/show/NCT02455843"
2601,"NCT03089892","A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy","Recruiting","No Results Available","Cancer-related Fatigue|Gynecologic Cancer|Chemotherapy","","Tri-Service General Hospital","Female","20 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CRF-TSGH02","March 20, 2017","October 19, 2016","September 20, 2018","March 20, 2017","March 2017","No Study Results Posted","null","September 20, 2018","Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T)|Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7)","https://ClinicalTrials.gov/show/NCT03089892"
2602,"NCT01926483","Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection","Unknown status","No Results Available","Non-small Cell Lung Cancer Stage IIIA","Other: Neoadjuvant Chemoradiotherapy","Zhejiang Cancer Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZTOG-1202","June 4, 2013","March 2013","June 2016","August 16, 2013","July 2012","No Study Results Posted","ZTOG-1202","June 2015","PFS|Adverse events|QOL|OS","https://ClinicalTrials.gov/show/NCT01926483"
2603,"NCT00127920","Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients","Completed","No Results Available","Ovarian Neoplasms","Drug: Avastin","Gynecologic Oncology Associates|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AV53206s","August 5, 2005","August 2004","October 2012","March 9, 2015","March 2015","No Study Results Posted","null","August 2006","time to tumor progression|response rate|safety|survival","https://ClinicalTrials.gov/show/NCT00127920"
2604,"NCT03134846","Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate","Not yet recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|Margin Assessment","Drug: Cetuximab-IRDye800CW","University Medical Center Groningen|UMC Utrecht|Erasmus Medical Center, Rotterdam","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","79","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Diagnostic","NL58585.042.16","April 20, 2017","May 2017","January 2021","April 25, 2017","April 2017","No Study Results Posted","ICON","January 2021","Phase 1: Determine the optimal dose of Cetuximab-IRDye800CW for imaging|Phase 2: Threshold level of fluorescence|Phase 1: Secondary outcome: Safety|Phase 1: Secondary outcome: Identification of positive margins|Phase 1: Tissue specificity of IRDye800cw|Phase 1: Histological location of IRDye800cw|Phase 2: Secondary outcome: Minimal thickness of the non-fluorescent margin","https://ClinicalTrials.gov/show/NCT03134846"
2605,"NCT01048970","Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer","Unknown status","No Results Available","Lung Cancer","Other: Nutritional Assessment|Dietary Supplement: EPA-DHA arm","National Institute of Cancerología|Abbott","All","20 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Supportive Care","INCAN/CC/330/09|CA171/CB/558/09","January 9, 2010","October 2009","December 2010","January 12, 2010","January 2010","No Study Results Posted","null","May 2010","Inflammatory response|Response rate to chemotherapy|Quality of life|Nutritional status|Overall survival","https://ClinicalTrials.gov/show/NCT01048970"
2606,"NCT00920920","An International Study on Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","Radiation: 3D MRI-guided Brachytherapy","Medical University of Vienna|Aarhus University Hospital|UMC Utrecht|Leiden University Medical Center|Katholieke Universiteit Leuven|Mount Vernon Hospital|Institute of Oncology Ljubljana","Female","Child, Adult, Senior","","600","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMBRACE 1","June 12, 2009","July 2008","null","June 15, 2009","June 2009","No Study Results Posted","EMBRACE","December 2013","local control/morbidity|regional control|disease free survival|overall survival|quality of life (QoL)","https://ClinicalTrials.gov/show/NCT00920920"
2607,"NCT03063450","CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma","Recruiting","No Results Available","Mesothelioma","Drug: Nivolumab|Other: Placebo","University of Southampton|University of Leicester|University of Sheffield|Queen Mary University of London|Queen's University, Belfast|Velindre NHS Trust|Beatson West of Scotland Cancer Centre","All","18 Years and older   (Adult, Senior)","Phase 3","336","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","22864|2016-003111-35|CA290841|A21400","February 10, 2017","March 28, 2017","July 2021","May 3, 2017","May 2017","No Study Results Posted","CONFIRM","June 2021","Overall survival|modified RECIST or RECIST 1.1 - progression free survival|modified RECIST or RECIST 1.1 - overall response rate|EQ-5D-5L|CTCAE V4.03|Health resource use questionnaire","https://ClinicalTrials.gov/show/NCT03063450"
2608,"NCT01376752","Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment","Recruiting","No Results Available","Ovarian Epithelial Cancer Recurrent","Procedure: maximal cytoreductive surgery","UNICANCER","Female","18 Years and older   (Adult, Senior)","Phase 3","444","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FEDEGYN 02 / 0410-CHIPOR|2010-023035-42","March 28, 2011","April 2011","December 2020","June 16, 2016","June 2016","No Study Results Posted","CHIPOR","April 2020","overall survival|relapse free survival","https://ClinicalTrials.gov/show/NCT01376752"
2609,"NCT00256282","Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma","Completed","No Results Available","Metastatic Melanoma","Drug: Vinorelbine|Drug: Docetaxel|Drug: Sargramostim","University of California, Irvine|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 02-23|2002-2763|NCI-2010-00217","November 17, 2005","April 2003","July 2012","March 19, 2013","March 2013","No Study Results Posted","null","July 2012","Evaluate the response rate (confirmed and unconfirmed complete and partial responses) of patients with metastatic melanoma when treated with vinorelbine and docetaxel.|Assess the qualitative and quantitative toxicities of docetaxel and vinorelbine","https://ClinicalTrials.gov/show/NCT00256282"
2610,"NCT02185768","Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II","Recruiting","No Results Available","Liver Cancer","Drug: idarubicin|Device: Dc- Beads 300-500µm","Federation Francophone de Cancerologie Digestive","All","18 Years and older   (Adult, Senior)","Phase 2","91","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FFCD 1307","July 3, 2014","December 2014","January 2020","August 10, 2016","May 2016","No Study Results Posted","IDASPHERE II","October 2016","Rate of patients in objective response (complete or partial response)|Rate of patients in objective response (complete or partial response) and assessed according to the investigator.|Treatment failure date|Best response|Survival without progression|Overall survival|Treatment tolerance|Quality of life","https://ClinicalTrials.gov/show/NCT02185768"
2611,"NCT00815945","Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors","Completed","No Results Available","Mesenchymal Tumor|Carcinosarcoma|Leiomyosarcoma","Drug: PegLiposomal Doxorubicin|Drug: Carboplatin","AGO Study Group|MSD SHARP & DOHME GmbH (formerly Essex Pharma GmbH)","Female","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AGO-GYN 7","December 30, 2008","June 2008","January 2012","February 13, 2017","March 2014","No Study Results Posted","null","November 2011","Anticancer activity in terms of progression-free survival time (PFS)|Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0)|Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria|Overall survival|Correlation of tumor marker CA-125 with imaging methods","https://ClinicalTrials.gov/show/NCT00815945"
2612,"NCT02721563","A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","Recruiting","No Results Available","Esophageal Neoplasms","Drug: Sodium Glycididazole|Drug: Placebo","Shandong Cancer Hospital and Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Treatment","CMNAER2","March 9, 2016","September 2015","December 2018","February 11, 2017","February 2017","No Study Results Posted","null","December 2018","Objective response rate|Overall survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02721563"
2613,"NCT00937612","Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk","Terminated","No Results Available","Head and Neck Neoplasms|Carcinoma, Squamous Cell","Radiation: Radiotherapy","Chang Gung Memorial Hospital","All","18 Years to 70 Years   (Adult, Senior)","","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CGHN-0801","July 9, 2009","June 2008","March 2014","February 6, 2017","February 2017","No Study Results Posted","null","March 2011","Any kind of cancer recurrence, measured by physical examination or image study. Pathologic confirmation is recommended.","https://ClinicalTrials.gov/show/NCT00937612"
2614,"NCT02178397","A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR","Terminated","No Results Available","NSCLC Patients With EGFR Activating Mutation Who Responded to Erlotinib in the First Line Treatment and Developed an Acquired Resistance.","Drug: ERLOTINIB WITH CHEMOTHERAPY|Drug: CHEMOTHERAPY ONLY","Centre Francois Baclesse|Groupe Francais De Pneumo-Cancerologie|Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","190","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FLARE /GFPC 03-2013","June 25, 2014","June 2014","September 2015","July 20, 2016","July 2016","No Study Results Posted","FLARE","September 2015","Efficacy by PFS|scores of QoL|Overall survival|Tumoral response|Toxicities|Rebound phenomenon (flare)","https://ClinicalTrials.gov/show/NCT02178397"
2615,"NCT02727868","Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans","Recruiting","No Results Available","Patient With Breast Cancer","Genetic: blood samples","Assistance Publique Hopitaux De Marseille","Female","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","2015-42|2015-A01753-46","March 30, 2016","March 2016","March 2018","March 30, 2016","March 2016","No Study Results Posted","PIG-A","March 2018","analysis of the frequency of granulocytes PIG-A mutated|analysis of the binucleated cell micronuclei frequency in culture","https://ClinicalTrials.gov/show/NCT02727868"
2616,"NCT03100409","Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients","Recruiting","No Results Available","Uterine Cervical Neoplasm|Dietary Modification|Radiation Toxicity|Gastrointestinal Complication","Other: Dietary modification","National Institute of Cancerología|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Female","18 Years and older   (Adult, Senior)","","320","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Participant|Primary Purpose: Supportive Care","CEI/1125/17|INCAN","March 24, 2017","February 1, 2017","August 2020","April 3, 2017","March 2017","No Study Results Posted","null","August 2017","Efficacy: Nutritional status evaluated by the complete nutritional assessment","https://ClinicalTrials.gov/show/NCT03100409"
2617,"NCT02721550","A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC","Recruiting","No Results Available","Esophageal Neoplasms","Drug: Sodium Glycididazole","Shandong Cancer Hospital and Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CMNAER1","March 9, 2016","September 2015","December 2018","February 11, 2017","February 2017","No Study Results Posted","null","December 2018","pathologic Complete Response|Overall Survival|Disease-Free Survival","https://ClinicalTrials.gov/show/NCT02721550"
2618,"NCT02721576","A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC","Recruiting","No Results Available","Esophageal Neoplasms","Drug: Sodium Glycididazole","Shandong Cancer Hospital and Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CMNAER3","March 9, 2016","September 2015","December 2018","February 11, 2017","February 2017","No Study Results Posted","null","December 2018","Objective response rate|Overall survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02721576"
2619,"NCT00128817","Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers","Terminated","No Results Available","Larynx Neoplasms","Radiation: Concurrent Chemoradiation|Procedure: Laryngectomy + adjuvant radiotherapy/chemoradiotherapy","Tata Memorial Hospital|Ministry of Science and Technology, India","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TMH/196/2004|DAECTC/Projno 4/2004-2005","August 9, 2005","May 2005","May 2015","January 21, 2013","January 2013","No Study Results Posted","null","May 2015","Overall survival at 3 and 5 years|Disease free survival at 3 and 5 years|Locoregional control rates at 3 and 5 years|Patterns of relapse|Salvage rates|Treatment-related adverse events|Completion of treatment|Quality of life","https://ClinicalTrials.gov/show/NCT00128817"
2620,"NCT00450502","Safety of Batracylin in Patients With Solid Tumors and Lymphomas","Completed","No Results Available","Neoplasms","Drug: Batracylin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1","33","NIH","Interventional","Primary Purpose: Treatment","070097|07-C-0097","March 20, 2007","February 24, 2007","April 24, 2011","April 19, 2017","August 14, 2013","No Study Results Posted","null","April 24, 2011","Define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator NAT2 genotype (NAT2 5, NAT2 6, NAT2 7, or NAT2 14) patients with solid tumors and lymphomas.|Obtain preliminary evidence of anti-tumor activity of batracylin in patients with solid tumors or lymphoma.","https://ClinicalTrials.gov/show/NCT00450502"
2621,"NCT01653067","STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma","Active, not recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab, Temsirolimus, DHAP, intravenous","Mathias Witzens-Harig|Johannes Gutenberg University Mainz|Technische Universität München|Ludwig-Maximilians - University of Munich|University Hospital Ulm|University Hospital Erlangen|Charite University, Berlin, Germany|University Hospital Freiburg|Johann Wolfgang Goethe University Hospital|University Hospital Heidelberg","All","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","STORM-2011|2011-001491-20","July 17, 2012","September 2012","July 2018","October 26, 2016","October 2016","No Study Results Posted","STORM","June 2018","Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)","https://ClinicalTrials.gov/show/NCT01653067"
2622,"NCT00539877","Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding","Completed","No Results Available","Stomach Neoplasms","Drug: irinotecan","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-05-017","October 3, 2007","October 2004","August 2007","June 22, 2010","June 2010","No Study Results Posted","null","December 2006","The objectives of this study are to assess the feasibility, to determine the maximum tolerated dose, and to assess the toxicities of intraperitoneally administered CPT-11 in gastric cancer patients with peritoneal seeding.","https://ClinicalTrials.gov/show/NCT00539877"
2623,"NCT02215447","A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas","Recruiting","No Results Available","Gastrointestinal Neuroendocrine Carcinomas","Drug: NAB paclitaxel|Drug: Carboplatin","Barwon Health|Specialised Therapeutics Australia|Deakin University|Australasian Gastro-Intestinal Trials Group","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ALCC 14.01","August 7, 2014","May 2015","October 2020","February 15, 2017","August 2016","No Study Results Posted","NABNEC","October 2017","Response rate|Progression free survival|Overall survival|Rates of adverse events as defined by NCI- Common Terminology Criteria for Adverse Events (CTCAE) V4.0","https://ClinicalTrials.gov/show/NCT02215447"
2624,"NCT01163552","Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity","Completed","No Results Available","Pleural Metastases|Breast Cancer|Colon Cancer|Ovarian Cancer|Uterine Cancer|Renal Cell Cancer|Thymic Cancer","Procedure: Surgical debulking and Intrathoracic Hyperthermic Chemotherapy","St. Luke's-Roosevelt Hospital Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SLR IRB#09-207","July 14, 2010","June 2010","May 2014","June 12, 2014","June 2014","No Study Results Posted","null","May 2014","Time to disease progression|Survival|Systemic drug absorption|Complications","https://ClinicalTrials.gov/show/NCT01163552"
2625,"NCT01304784","A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer","Completed","No Results Available","HER-2 Gene Amplification","Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111|Drug: Lapatinib +/- Trastuzumab and MM-111|Drug: Paclitaxel, Trastuzumab and MM-111|Drug: Lapatinib, trastuzumab, paclitaxel, and MM-111|Drug: Docetaxel, trastuzumab and MM-111","Merrimack Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-111-01-01-03","February 17, 2011","January 2011","June 2014","December 15, 2015","December 2015","No Study Results Posted","null","April 2014","Determine patient's safety (# of adverse events/serious adverse events) and tolerability of MM-111 in combination with multiple treatment regimens|To characterize the pharmacokinetics (PK) profile of MM-111 when administered in combination with multiple treatment regimens. The PK profile will help to determine the phase 2 dose|To establish the recommended Phase 2 dose(s) of MM-111 when administered in each of the combinations assessed (based on PK profile, safety data and overall patient tolerability)","https://ClinicalTrials.gov/show/NCT01304784"
2626,"NCT02644252","Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer","Recruiting","No Results Available","Lung Cancer","Drug: Day 1: Cisplatin 75 mg/m2|Drug: Day 1: Vinorelbine 25 mg/m2|Drug: Day 8: Capsule vinorelbine 50 mg/m2|Drug: Day 1: Carboplatin AUC=5|Drug: Day 1: Vinorelbine 30 mg/m2|Drug: Day 8: Capsule vinorelbine 60 mg/m2|Dietary Supplement: Tocotrienol 300 mg x 3 daily until progression|Drug: Placebo 1 capsule x 3 daily until progression","Vejle Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","Toco-Pulm","December 22, 2015","January 2016","June 2019","August 3, 2016","August 2016","No Study Results Posted","Toco-Pulm","June 2018","Progression free survival","https://ClinicalTrials.gov/show/NCT02644252"
2627,"NCT02118415","Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)","Recruiting","No Results Available","NSCLC Stage IIIA/B","Other: Hsp70-peptide TKD/IL-2 activated, autologous NK cells","Technische Universität München","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSCLC-TKD/IL-2|2008-002130-30","February 25, 2014","March 2014","February 2018","September 19, 2016","September 2016","No Study Results Posted","null","September 2017","Progress free survival|overall survival (OS)|toxicity (AE and SAE)|quality of life (QoLQ-30, LC-13)|biological parameters (NK cell activation)","https://ClinicalTrials.gov/show/NCT02118415"
2628,"NCT02817958","Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis","Active, not recruiting","No Results Available","Penile Cancer|Squamous Carcinoma","Drug: Chemotherapie TIP","UNICANCER|National Cancer Institute, France","Male","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UC-0160/1406|AFU-GETUG 25","May 24, 2016","April 2016","September 2022","June 24, 2016","June 2016","No Study Results Posted","MEGACEP","September 2021","survival without locoregional lymph node recurrence|Complete response rate for patients in neoadjuvant chemotherapy|Survival without locoregional lymph node recurrence|Survival without metastasis|Specific survival|Overall survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT02817958"
2629,"NCT00954512","Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","Terminated","Has Results","Neoplasms","Drug: Carboplatin|Drug: Epirubicin|Biological: Trastuzumab|Drug: Everolimus|Drug: Gemcitabine|Biological: Robatumumab|Biological: Cetuximab|Drug: Paclitaxel|Drug: Cisplatin|Drug: 5-FU|Drug: Erlotinib|Drug: Irinotecan|Drug: Folinic Acid","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P04722|MK-7454-004|2009-011101-16","July 23, 2009","September 2009","June 2011","January 11, 2016","January 2016","November 18, 2015","null","June 2011","Part 2: Number of Participants With Each Type of Response Evaluation Criteria in Solid Tumors (RECIST)-Determined Overall Best Response|Part 1: Number of Participants Who Experienced One or More Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT00954512"
2630,"NCT02679963","Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer","Recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Olaparib|Drug: Placebo","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years and older   (Adult, Senior)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-005586-75|2014/2204","January 26, 2016","January 2016","January 2021","June 8, 2016","June 2016","No Study Results Posted","PIPSeN","January 2020","Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02679963"
2631,"NCT00570531","Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma","Terminated","Has Results","Loco-regional Esophageal Cancer","Drug: Bevacizumab|Drug: Paclitaxel|Drug: Cisplatin|Drug: 5-Fluorouracil|Radiation: Radiation Therapy|Procedure: Esophagectomy","University of Michigan Cancer Center|Genentech, Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2006.117|HUM 8625","December 10, 2007","June 2007","June 2013","April 19, 2016","April 2016","January 5, 2015","null","October 2010","Disease Free Survival Time|The Number of Patients Cancer Free at the Time of Surgery|The Proportion of Toxicities Experienced by Participants","https://ClinicalTrials.gov/show/NCT00570531"
2632,"NCT00574080","UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","Terminated","Has Results","Multiple Myeloma","Drug: Dexamethasone|Drug: DPACE/Melphalan","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-15","December 12, 2007","July 2006","March 2011","June 1, 2011","June 2011","May 4, 2011","null","March 2011","Addition of Bortezomib, Thalidomide, and Dexamethasone to High Dose Chemotherapy Regimen Immediately Before Transplant|Side Effects With Both Transplant Regimens","https://ClinicalTrials.gov/show/NCT00574080"
2633,"NCT01553071","Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies","Recruiting","No Results Available","Solid Tumor","Drug: Fenretinide (4-HPR) plus Intravenous Safingol","South Plains Oncology Consortium","All","18 Years and older   (Adult, Senior)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SPOC-2010-002","March 7, 2012","November 2016","null","December 16, 2016","December 2016","No Study Results Posted","null","December 2018","Determine the maximum tolerated dose of an intravenous safingol in combination with fenretinide","https://ClinicalTrials.gov/show/NCT01553071"
2634,"NCT02014831","Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)","Withdrawn","No Results Available","Squamous Cell Carcinoma of the Penis","Drug: Cetuximab|Drug: TIP","Centre Leon Berard","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PENILANE","December 5, 2013","February 2016","February 2016","February 24, 2016","February 2016","No Study Results Posted","PENILANE","February 2016","Evaluation of the antitumor activity of Cetuximab treatment in terms of Objective Response Rate (ORR) at the end of treatment|Evaluation of the Safety Profile of Cetuximab treatment|Evaluation of the antitumor activity of Cetuximab treatment in terms of Overall Survival (OS) at the end of the study|Evaluation of the antitumor activity of Cetuximab treatment in terms of Progression-Free Survival (PFS) at the end of the study|Evaluation of Quality of Life during the Cetuximab treatment","https://ClinicalTrials.gov/show/NCT02014831"
2635,"NCT00666783","An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients","Completed","No Results Available","Chemotherapy-Induced Nausea and Vomiting","Drug: palonosetron|Drug: Granisetron","Xijing Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Supportive Care","2006L01595","April 23, 2008","null","null","April 24, 2008","August 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00666783"
2636,"NCT02350361","Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.","Unknown status","No Results Available","Lung Cancer","Drug: Recombinant human endostatin|Drug: Placebo","Peking University Third Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PekingUTH-LL01","January 12, 2015","January 2014","March 2016","January 25, 2015","January 2015","No Study Results Posted","null","July 2015","Objective Responese Rate|Progression Free Survival|Overall Survial|Number of Serious Adverse Events","https://ClinicalTrials.gov/show/NCT02350361"
2637,"NCT00970385","Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma","Completed","No Results Available","Peripheral T Cell Lymphoma","Drug: CHOP21|Drug: VIP/ABVD|Radiation: Radiotherapy consolidation","University Hospital, Grenoble|French Innovative Leukemia Organisation","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LTP 95","August 20, 2009","January 1995","September 2008","September 8, 2009","September 2009","No Study Results Posted","LTP","December 2002","Comparison between EFS rate of CHOP/21 versus VIP-rABVD in newly diagnosed PTCL.|Overall survival (OS)|response rate at the end of the treatment|progression free survival (PFS)|hematotoxicity","https://ClinicalTrials.gov/show/NCT00970385"
2638,"NCT01187290","Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases","Unknown status","No Results Available","Non-small Cell Lung Cancer","Radiation: neoadjuvant chemoradiotherapy","Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","chest1001","August 19, 2010","August 2010","June 2013","August 23, 2010","August 2010","No Study Results Posted","null","December 2012","Event-free survival|Operability|Postoperative 30-day mortality|Toxicity","https://ClinicalTrials.gov/show/NCT01187290"
2639,"NCT01074021","Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer","Active, not recruiting","No Results Available","Nasopharyngeal Cancer","Drug: Nimotuzumab|Drug: placebo plus chemoradiotherapy","Biotech Pharmaceutical Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BT-CT-001","February 21, 2010","October 2009","August 2016","October 28, 2015","August 2015","No Study Results Posted","null","May 2016","To determine the local-regional control rates of the disease in the advanced nasopharyngeal cancer patients subject to the treatment with Nimotuzumab in combination with chemoradiation|To determine the safety of the treatment with Nimotuzumab in combination with chemoradiation|To determine the Disease-free survival、Tumor control probability、Distant recurrence rate in the patients subject to the treatment at years 1,2,3|To determine the Progression free suivival、Diease free survival、Overall survival in the patients subject to the treatment","https://ClinicalTrials.gov/show/NCT01074021"
2640,"NCT02509806","Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer","Recruiting","No Results Available","Gastric Cancer","Drug: Apatinib","Hebei Medical University|Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Ahead-G309","July 26, 2015","July 2015","December 2016","September 20, 2016","September 2016","No Study Results Posted","null","December 2016","Progression free survival","https://ClinicalTrials.gov/show/NCT02509806"
2641,"NCT00486460","Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer","Unknown status","No Results Available","Pancreatic Cancer","Drug: Gemcitabine|Drug: Curcumin|Drug: Celebrex","Tel-Aviv Sourasky Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind","TASMC-07-NA-132-CTIL","June 13, 2007","June 2005","null","June 13, 2007","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00486460"
2642,"NCT01548573","Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","Terminated","No Results Available","Multiple Myeloma","Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide)|Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan)|Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan)|Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide)|Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12)|Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)","University of Iowa|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201202818|7R01CA115399","February 29, 2012","May 2012","March 2014","November 26, 2013","November 2013","No Study Results Posted","null","July 2013","Event-Free Survival (EFS)|Identification of Drug Resistant Genes|Number of grade 3 non-hematologic and grade 4 hematologic serious adverse events associated with the addition of bortezomib, thalidomide, and dexamethasone into autologous transplant regimens.|Overall survival","https://ClinicalTrials.gov/show/NCT01548573"
2643,"NCT01945879","Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Drug: Enoxaparine","CONKO-Studiengruppe","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CONKO-004/1","September 5, 2013","January 2003","April 2004","September 16, 2013","September 2013","No Study Results Posted","null","April 2004","Incidence of NCI CTC Toxicity III°/IV° and severe bleedings|overall survival","https://ClinicalTrials.gov/show/NCT01945879"
2644,"NCT02995850","A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis","Recruiting","No Results Available","Gastric Cancer With Peritoneal Metastasis (PCI<12)","Drug: CRS+HIPEC","Yonsei University","All","19 Years and older   (Adult, Senior)","Phase 1|Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Prevention","4-2016-0252","December 14, 2016","February 22, 2017","June 2021","March 6, 2017","March 2017","No Study Results Posted","null","November 2020","Ib: Maximum tolerate dose|II: Safety|OS (overall survival)|PFS (Progression-free survival)|RR (response rate)","https://ClinicalTrials.gov/show/NCT02995850"
2645,"NCT00112346","Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer","Completed","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: Cetuximab + platinum + gemcitabine|Drug: Platinum + Gemcitabine","Eli Lilly and Company|ImClone LLC","All","18 Years and older   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA225-100","June 1, 2005","January 2005","December 2006","October 26, 2015","October 2015","No Study Results Posted","null","December 2006","tumor response per treatment arm|disease control, symptom response, symptomatic progression, & progression free survival.","https://ClinicalTrials.gov/show/NCT00112346"
2646,"NCT02471027","The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer","Not yet recruiting","No Results Available","Cervical Cancer","Procedure: Neoadjuvant chemotherapy","Yu mei Wu|Peking University First Hospital|Peking University Third Hospital|Chinese PLA General Hospital|Beijing Chao Yang Hospital|Beijing Anzhen Hospital|Beijing Shijitan Hospital|Peking University People's Hospital|Capital Medical University","Female","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Case Control","D151100001915001","May 28, 2015","June 2015","June 2019","June 11, 2015","June 2015","No Study Results Posted","null","June 2019","overall survival|3 year disease-free survival (DFS)","https://ClinicalTrials.gov/show/NCT02471027"
2647,"NCT01692496","Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial","Active, not recruiting","No Results Available","Advanced and / or Metastatic Liposarcoma","Drug: Pazopanib","Grupo Espanol de Investigacion en Sarcomas|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEIS-30|2012-002745-38","September 14, 2012","January 2013","December 2016","February 18, 2016","February 2016","No Study Results Posted","null","December 2016","Progression-free survival (PFS) assessed 12 weeks after start of treatment|Overall progression free survival (median PFS)|Objective tumor response|Time to onset of response|Duration of response|Overall survival (OS)|Clinical benefit rate|Growth Modulation Index (GMI)|Safety profile (according CTCAE, version 4.0)","https://ClinicalTrials.gov/show/NCT01692496"
2648,"NCT01525927","Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity","Terminated","Has Results","Oropharyngeal Neoplasms","Drug: chemotherapy|Radiation: radiotherapy|Radiation: Reduced dose radiotherapy","Northwell Health","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSLIJ0844","February 1, 2012","August 2010","December 2011","January 29, 2016","January 2016","August 28, 2015","null","December 2011","Response (CR+PR) Status at 3 Months Post-therapy|To Define Objective Tumor Response Rates to Induction Chemotherapy and to Subsequent Radiation-based Treatment.|Progression-free Survival at 2 Years|Assess Overall Survival at 2 Years.|Assess Locoregional Disease Control at 2 Years|Assess Distant Disease Control at 2 Years.|Assessment of Quality of Life Outcomes|Identify Additional Toxicity of Treatment","https://ClinicalTrials.gov/show/NCT01525927"
2649,"NCT02055144","Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy","Recruiting","No Results Available","Non Small Cell Lung Cancer","","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","All","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VERISTRAT/IST","January 30, 2014","February 2011","March 2018","March 4, 2017","March 2017","No Study Results Posted","null","July 2017","Progression-free survival|Overall survival|Correlation with RECIST response|Correlation with known biomarkers|Changes of VeriStrat with disease progression|Metabolomics|Circulating tumor cells.","https://ClinicalTrials.gov/show/NCT02055144"
2650,"NCT01717924","Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma","Recruiting","No Results Available","Signet Ring Cell Gastric Adenocarcinoma","Procedure: peri-operative chemotherapy|Procedure: Surgery first","University Hospital, Lille|Federation Francophone de Cancerologie Digestive|UNICANCER|Fédération de Recherche en Chirurgie (FRENCH)","All","18 Years to 80 Years   (Adult, Senior)","","314","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2011_25|2012-000998-24","October 23, 2012","October 2012","April 2024","March 2, 2017","March 2017","No Study Results Posted","ADCI002","April 2021","Percentage of patients dead in the 2-years|Disease-free survival at 2 years|Disease-free survival at 3 years|Overall survival at 3 years|R0 resection rate|grade III/IV toxicity|post operative morbi-mortality|Average of patients who benefit from the overall treatment strategy|quality of life|emotional status","https://ClinicalTrials.gov/show/NCT01717924"
2651,"NCT02557035","An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting","Completed","No Results Available","Chemotherapy-Induced Nausea and Vomiting","Drug: Palonosetron|Drug: Dexamethasone","Helsinn Healthcare SA|PSI CRO AG","All","18 Years and older   (Adult, Senior)","Phase 3","441","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PALO-15-17","September 21, 2015","October 2015","March 2016","May 12, 2016","May 2016","No Study Results Posted","null","March 2016","Percentage of Patients With Complete Response (CR) defined as no emesis, no rescue medication, in the acute phase|Percentage of Patients With Complete Response (CR) defined as no emesis, no rescue medication, in the delayed phase|Percentage of Patients With Complete Response (CR) defined as no emesis, no rescue medication, in the overall phase|Percentage of Patients with no emetic episodes in the acute phase|Percentage of Patients with no emetic episodes in the delayed phase|Percentage of Patients with no emetic episodes in the overall phase|Percentage of Patients with no rescue medication in the acute phase|Percentage of Patients with no rescue medication in the delayed phase|Percentage of Patients with no rescue medication in the overall phase","https://ClinicalTrials.gov/show/NCT02557035"
2652,"NCT02145390","Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy","Recruiting","No Results Available","Bladder Cancer|Bladder Carcinoma|Transition Cell Cancer|Muscle Invasive Bladder Carcinoma","Procedure: Transurethral Resection of the Bladder Tumor & Cystoscopy|Radiation: Intensity Modulated Radiation Therapy|Behavioral: Expanded Prostate Cancer Index Composite Short Form 12|Behavioral: International Prostate Symptom Score","University of Miami","All","18 Years and older   (Adult, Senior)","","68","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","20130896","May 20, 2014","January 5, 2016","August 2019","April 12, 2017","April 2017","No Study Results Posted","null","August 2019","Rate of Failure-Free Survival with Intact Bladder (FFSIB) in Study Participants|Rate of Failure-Free Survival (FFS) at two years|Rate of Acute and Late Grade 2 or Higher Treatment-Related GU, GI and Hematologic Toxicity.|Rate of Overall Survival in Study Participants","https://ClinicalTrials.gov/show/NCT02145390"
2653,"NCT02765919","A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix","Recruiting","No Results Available","Squamous Cell Carcinoma of Cervix","Radiation: HDR Brachytherapy of 9 Gy in 2 fractions|Radiation: HDR Brachytherapy of 7 Gy in 3 fractions","Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","Female","18 Years to 65 Years   (Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","1356","May 5, 2016","July 2015","July 2017","December 6, 2016","December 2016","No Study Results Posted","null","December 2016","Reduction of tumor size in cervix","https://ClinicalTrials.gov/show/NCT02765919"
2654,"NCT01125995","Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer","Radiation: early CCRT|Radiation: late CCRT","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-02-016","May 17, 2010","June 2003","May 2013","May 29, 2013","May 2013","No Study Results Posted","null","July 2011","complete response rate|overall survival|objective response rate|Progression-free survival|toxicity by NCI common toxicity version 2.0","https://ClinicalTrials.gov/show/NCT01125995"
2655,"NCT00002836","Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: Filgrastim (G-CSF)|Drug: Carmustine|Drug: Cisplatin|Drug: Cyclophosphamide (CTX)|Drug: Etoposide|Drug: Thiotepa|Procedure: Peripheral Blood Stem Cell Transplantation","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","184","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM95-047|P30CA016672|MDA-DM-95047|NCI-G96-1014|CDR0000065048","November 1, 1999","May 1995","March 2006","July 27, 2012","July 2012","No Study Results Posted","null","March 2006","Compare Effectiveness of Chemotherapy + Filgrastim to Filgrastim Alone","https://ClinicalTrials.gov/show/NCT00002836"
2656,"NCT00113932","UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Procedure: High-Dose Density Therapy","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2003-41","June 10, 2005","December 2003","July 2010","September 1, 2011","September 2011","No Study Results Posted","null","February 2009","To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.|To evaluate the ability of pegfilgrastim to mobilize stem cells when administered following DTPACE in MM patients with active disease, compared to historical controls mobilized with DTPACE and either GM-CSF or G-CSF.","https://ClinicalTrials.gov/show/NCT00113932"
2657,"NCT00030459","Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma","Unknown status","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: mitomycin C|Drug: vinblastine sulfate|Drug: vinorelbine tartrate","British Thoracic Society|Medical Research Council|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","BTS-MESO-1|CDR0000069167|MRC-BTS-MESO-1|EU-20134","February 14, 2002","November 2000","null","August 6, 2013","May 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00030459"
2658,"NCT00025090","Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer","Completed","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: mitomycin C|Radiation: radiation therapy","University College London (UCL) Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","600","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000068911|NCRI-ACT-II|EU-20056|UKCCCR-ACT-II|ISRCTN26715889","October 11, 2001","March 2001","August 2007","August 23, 2013","March 2007","No Study Results Posted","null","null","Complete response rate at 6 months|Acute toxicity as measured up to 4 weeks after chemoradiation|Recurrence-free survival|Colostomy rate|In field recurrence rate as measured by confirmed disease within radiation therapy field|Cause-specific and overall survival","https://ClinicalTrials.gov/show/NCT00025090"
2659,"NCT00021112","Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer","Terminated","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Procedure: conventional surgery|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","5","Other","Interventional","Primary Purpose: Treatment","EORTC-08981","July 11, 2001","April 2001","null","July 17, 2012","July 2012","No Study Results Posted","null","October 2002","","https://ClinicalTrials.gov/show/NCT00021112"
2660,"NCT00006212","Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: vinblastine sulfate|Radiation: phosphorus P32|Radiation: radiation therapy","Center for Molecular Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067812|CMM-99003|NCI-V00-1586","September 11, 2000","November 1999","null","September 16, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006212"
2661,"NCT00005825","Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: mitomycin C|Drug: tretinoin|Drug: vinorelbine tartrate","Raghu Nandan, M.D., Inc|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067837|NANDAN-VES-024|NCI-V00-1587","June 2, 2000","September 1998","null","December 17, 2013","July 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005825"
2662,"NCT00004160","Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Radiation: radiation therapy","University of Alabama at Birmingham|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1|Phase 2","72","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067400|UAB-9718|UAB-F97073005|NCI-G99-1625","December 10, 1999","February 2000","May 2004","November 25, 2013","October 2005","No Study Results Posted","null","May 2004","Determine the maximum tolerated dose and dose limiting toxicity of gemcitabine and paclitaxel in combination with radiotherapy in patients with locally advanced stage IIIA or IIIB non-small cell lung cancer.|Assess response rate, duration of response, disease free survival and failure in this patient population on this regimen.|Determine the pharmacokinetics of gemcitabine and paclitaxel during the chemoradiotherapy phase","https://ClinicalTrials.gov/show/NCT00004160"
2663,"NCT00004099","Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer","Terminated","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 69 Years   (Adult, Senior)","Phase 3","144","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-40954","December 10, 1999","July 1999","null","September 20, 2012","September 2012","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00004099"
2664,"NCT00003652","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer","Unknown status","No Results Available","Anal Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: neoadjuvant therapy|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","up to 80 Years   (Child, Adult, Senior)","Phase 3","350","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066744|FNCLCC-FFCD-SFRO-ACCORD-3|EU-98050","November 1, 1999","January 1999","null","February 6, 2009","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003652"
2665,"NCT00003576","Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery","Completed","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: surgical procedure|Radiation: radiation therapy","National Cancer Centre, Singapore|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","200","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066643|NMRC-SHN01|EU-97015","November 1, 1999","January 1997","August 2005","December 18, 2013","April 2007","No Study Results Posted","null","null","Response at 6 weeks after completion of study treatment|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00003576"
2666,"NCT00002615","Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: epirubicin hydrochloride|Drug: fluorouracil|Procedure: conventional surgery","Medical Research Council|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","500","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063914|MRC-ST02|EU-94035","November 1, 1999","June 1994","December 2003","December 18, 2013","August 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002615"
2667,"NCT02996617","PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia","Recruiting","No Results Available","Lymphoma,Non-Hodgkin","Drug: rhG-CSF regimen|Drug: Pegylated rhG-CSF regimen","Shandong Provincial Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ShandongPH02","November 19, 2016","November 2016","December 2018","December 15, 2016","December 2016","No Study Results Posted","null","November 2018","Rate of grade 3/4 neutropenia（neutrophils≤1×10^ 9/L） in every cycle|Rate of the chemotherapy delay|Rate of the febrile neutropenia in every cycle","https://ClinicalTrials.gov/show/NCT02996617"
2668,"NCT01063946","A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor","Completed","No Results Available","Neoplasms, Malignant","Drug: Ombrabulin (AVE8062)","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BEX6587|2008-007824-24","February 4, 2010","January 2010","September 2011","December 20, 2011","December 2011","No Study Results Posted","null","March 2011","Percentage of radioactive dose excreted in urine, feces and expired air|Concentration-time profiles and pharmacokinetic (PK) parameters of total radioactivity in whole blood and plasma; blood over plasma concentration ratios; Concentration-time profile and PK parameters of AVE8062 and RPR258063 in plasma|Safety assessment based on Adverse events reporting, laboratory tests according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTC) v3.0 grade scaling","https://ClinicalTrials.gov/show/NCT01063946"
2669,"NCT01263886","Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: ombrabulin (AVE8062)|Drug: placebo","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","EFC10259|2010-019384-11|U1111-1115-3677","December 14, 2010","February 2011","October 2012","November 18, 2015","November 2015","No Study Results Posted","DISRUPT","March 2012","Progression free survival (PFS)|Overall survival (OS)|Objective response rate (OR)","https://ClinicalTrials.gov/show/NCT01263886"
2670,"NCT02132143","Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2","Unknown status","No Results Available","Lung Adenocarcinoma Patients With Postoperative in pN2","Radiation: intensity-modulated radiation|Radiation: intensity-modulated radiation","Hui Lin|People's Hospital of Guangxi","All","18 Years to 75 Years   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","LH-2014-XW","May 2, 2014","January 2014","January 2017","May 5, 2015","May 2015","No Study Results Posted","null","January 2017","progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02132143"
2671,"NCT01262183","Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus","Terminated","No Results Available","Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus","Drug: CRT + Panitumumab|Drug: Concurrent chemoradiation therapy without panitumumab","Radboud University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCNONCO200905","December 15, 2010","January 2011","October 2012","May 10, 2012","April 2012","No Study Results Posted","PANORAMIC","April 2012","1-year overall survival|toxicity|PFS|Response Rate|pharmacodynamics of panitumumab|Quantification of baseline FDG uptake (SUV) with PET, and SUV changes|CTCs and CECs","https://ClinicalTrials.gov/show/NCT01262183"
2672,"NCT01704716","High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)","Recruiting","No Results Available","Neuroblastoma","Drug: Vincristine|Drug: Aldesleukin|Drug: ch14.18/CHO|Drug: Carboplatin|Drug: Etoposide|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: G-CSF|Drug: Busulfan|Drug: Melphalan","St. Anna Kinderkrebsforschung","All","1 Month to 21 Years   (Child, Adult)","Phase 3","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HR-NBL-1.7 / SIOPEN","October 5, 2012","February 2002","September 2017","September 26, 2016","September 2016","No Study Results Posted","null","September 2017","Event Free Survival (R1: MAT therapy)|Event Free Survival (R4: immunotherapy)|Complete metastatic response (R3: Induction therapy)|Event free survival (R3: Induction therapy)","https://ClinicalTrials.gov/show/NCT01704716"
2673,"NCT00559156","Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","Completed","No Results Available","Head and Neck Cancer","Dietary Supplement: arginine/omega-3 fatty acids/nucleotides oral supplement|Drug: cisplatin|Procedure: adjuvant therapy|Radiation: radiation therapy","Institut du Cancer de Montpellier - Val d'Aurelle|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000574125|CLCC-IMPACT-RT|INCA-RECF0286","November 15, 2007","June 2005","null","May 13, 2011","May 2011","No Study Results Posted","null","May 2011","Effects of immunomodulator arginine/omega-3 fatty acids/nucleotides oral supplement (Oral IMPACT®) administered via percutaneous gastrostomy during adjuvant chemoradiotherapy","https://ClinicalTrials.gov/show/NCT00559156"
2674,"NCT00004176","Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Radiation Toxicity","Drug: amifostine trihydrate|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","Washington University School of Medicine|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067202|WU-98-0206|ALZA-WU-98-0206|NCI-V99-1559","January 21, 2000","October 1998","February 2001","May 14, 2013","May 2013","No Study Results Posted","null","February 2001","","https://ClinicalTrials.gov/show/NCT00004176"
2675,"NCT00003636","Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Drug: carboplatin|Drug: cisplatin|Procedure: conventional surgery|Procedure: neoadjuvant therapy","European Organisation for Research and Treatment of Cancer - EORTC","Female","Child, Adult, Senior","Phase 3","704","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-55971","November 1, 1999","September 1998","null","August 4, 2015","August 2013","No Study Results Posted","null","January 2009","Overall survival as measured by Kaplan Meier every 3 months for 2 years, every 6 months for 3 years, and then annually|Progression-free survival as measured by Kaplan Meier and RECIST every 3 months for 2 years, every 6 months for 3 years, and then annually|Health-related quality of life as measured by Quality of Life Questionnaire-C30 after courses 1, 3 and 6, then at 6 and 12 months|Toxicity as measured by NCIC Common Toxicity Criteria v2.0 within 4 weeks of surgery","https://ClinicalTrials.gov/show/NCT00003636"
2676,"NCT00003583","Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer","Unknown status","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Radiation Toxicity","Drug: amifostine trihydrate|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy","University of Florida|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Primary Purpose: Supportive Care","CDR0000066651|UF-G-97120405|ALZA-97-033-ii|NCI-V98-1475","November 1, 1999","June 1997","null","December 3, 2013","May 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003583"
2677,"NCT00002623","Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Procedure: conventional surgery|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","640","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-08941","November 1, 1999","December 1994","null","June 29, 2012","June 2012","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00002623"
2678,"NCT00002539","Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma","Completed","No Results Available","Sarcoma","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Procedure: conventional surgery","European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council","All","up to 40 Years   (Child, Adult)","Phase 3","214","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-80931|EOI-80931|MRC-BO06|EU-93024","November 1, 1999","August 1993","null","September 20, 2012","September 2012","No Study Results Posted","null","October 2002","","https://ClinicalTrials.gov/show/NCT00002539"
2679,"NCT00002477","Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer","Unknown status","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride","Medical Research Council|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077026|MRC-ICON1|EU-91002","November 1, 1999","April 1991","null","December 17, 2013","July 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002477"
2680,"NCT00791141","Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Cetuximab","Heinrich-Heine University, Duesseldorf","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACCRA-HN","November 13, 2008","August 2008","September 2013","January 22, 2014","January 2014","No Study Results Posted","ACCRA-HN","April 2013","Rate of patients experiencing grade 3/4 acute toxicities not considering grade 3/4 skin tox. outside the radiation portals combined with 2-years disease-free survival rate.|Incidence of Loco-regional relapse|Disease-free survival|Progression-free survival|Overall survival|The rate of patients with secondary primary neoplasm|The incidence of late toxicity","https://ClinicalTrials.gov/show/NCT00791141"
2681,"NCT01391572","A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer","Unknown status","No Results Available","Esophageal Squamous Cell Carcinoma","Radiation: enlarge irradiation volume|Radiation: Small volume radiation|Drug: cisplatin|Drug: fluorouracil","Fudan University|The First Affiliated Hospital of Soochow University|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China|Jiangsu Cancer Institute & Hospital|Affiliated Hospital of Jiangsu University|Zhejiang Cancer Hospital|First Affiliated Hospital of Wenzhou Medical Univeristy|Zhejiang University|The First Affiliated Hospital of Anhui Medical University|Anhui Provincial Hospital|Fujian Cancer Hospital|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|RenJi Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011ESO_FU_01","July 8, 2011","April 2011","null","July 20, 2011","March 2011","No Study Results Posted","null","December 2013","Survival|Safety and Tolerability|Failure pattern","https://ClinicalTrials.gov/show/NCT01391572"
2682,"NCT00563862","Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)","Terminated","No Results Available","Nasopharyngeal Neoplasms|Carcinoma, Squamous Cell","Procedure: Conventional RT|Procedure: Accelerated RT|Drug: Cisplatin|Drug: 5-fluorouracil","Hospital Authority, Hong Kong|The Hong Kong Nasopharyngeal Cancer Study Group","All","up to 70 Years   (Child, Adult, Senior)","","465","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","L/M-78 to PYH 08/79|HARECCTR0500024|NPC99-02","November 21, 2007","July 1999","June 2007","June 14, 2011","June 2011","No Study Results Posted","null","null","Failure free survival rate|Overall survival rate|Disease-specific survival rate|Complication-free rates","https://ClinicalTrials.gov/show/NCT00563862"
2683,"NCT00333294","Phase II Iressa + Irradiation Followed by Chemo in NSCLC","Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Gefitinib|Procedure: Radiation therapy|Drug: Cisplatin|Drug: Vinorelbine","AstraZeneca","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1839IL/0530","June 2, 2006","September 2004","January 2006","December 16, 2007","December 2007","No Study Results Posted","null","null","To estimate the objective response rate in patients treated with this drug|Determine the safety and toxicity of this drug in these patients","https://ClinicalTrials.gov/show/NCT00333294"
2684,"NCT00230451","Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma","Completed","No Results Available","Esophageal Cancer","Procedure: Radiation|Drug: Paclitaxel|Drug: Cisplatin|Drug: 5-Fluorouracil","University of Michigan Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 9740","September 28, 2005","November 1997","July 2008","January 14, 2010","January 2010","No Study Results Posted","null","December 1999","To determine the rate of complete histologic response induced by this neoadjuvant chemotherapy and radiation therapy regimen.|To determine the overall survival and time to relapse in patients treated with preoperative chemotherapy and radiation therapy followed by adjuvant combination chemotherapy.|To assess the qualitative and quantitative toxicities of this regimen.","https://ClinicalTrials.gov/show/NCT00230451"
2685,"NCT00002669","Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: recombinant interferon alfa|Drug: cisplatin|Drug: dacarbazine","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-18951","June 2, 2000","June 1995","null","June 29, 2012","June 2012","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00002669"
2686,"NCT02636556","Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma","Recruiting","No Results Available","Thymoma and Thymic Carcinoma","Radiation: concurrent chemoradiation","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1508151-5","December 15, 2015","January 2013","December 2017","February 28, 2017","February 2017","No Study Results Posted","null","June 2017","Progression free survival|Overall survival|Objective response rate|chemotherapy and radiation-induced toxicity assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02636556"
2687,"NCT02976142","The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer","Not yet recruiting","No Results Available","Gastric Cancer, Metastatic","Procedure: neoadjuvant chemoimmunotherapy","Moscow Clinical Scientific Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MKNC02/2016","November 24, 2016","December 2016","December 2020","December 12, 2016","December 2016","No Study Results Posted","null","November 2018","Overall 2-year survival|Portability of the systemic therapy methods|Mortality|Downstaging tumor|Morbidity|Quality of life","https://ClinicalTrials.gov/show/NCT02976142"
2688,"NCT02009449","A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors","Active, not recruiting","No Results Available","Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer","Drug: AM0010|Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Drug: gemcitabine/nab-paclitaxel|Drug: Capecitabine|Drug: Pazopanib|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: nivolumab|Drug: Gemcitabine/carboplatin","ARMO BioSciences","All","18 Years and older   (Adult, Senior)","Phase 1","350","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AM0010-001","December 2, 2013","November 2013","March 2018","March 13, 2017","February 2017","No Study Results Posted","null","February 2018","Safety and tolerability as measured by incidence of adverse events|Pharmacokinetic (PK) parameters|Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)|Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for patients with metastatic castration resistant prostate cancer (CRPC)|Anti-AM0010 antibody formation","https://ClinicalTrials.gov/show/NCT02009449"
2689,"NCT00718354","Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT","Completed","No Results Available","Gastric Cancer|Gastroesophageal Cancer","Drug: Enoxaparin|Drug: Standard Chemotherapy","Thrombosis Research Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","740","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","TRI0702","July 16, 2008","July 2008","August 2010","May 12, 2015","May 2015","No Study Results Posted","GASTRANOX","January 2010","Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .|Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT","https://ClinicalTrials.gov/show/NCT00718354"
2690,"NCT02753140","Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy","Not yet recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: Cetuximab|Radiation: radiation|Drug: Docetaxel|Drug: Cisplatin","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YangZZ-2016","April 18, 2016","April 2016","September 2018","April 24, 2016","April 2016","No Study Results Posted","null","March 2018","Progression-free survival|incidence of oral mucositis|Overall survival|Overall response rate after induction chemotherapy","https://ClinicalTrials.gov/show/NCT02753140"
2691,"NCT03161548","A Study of Tongue Conservation Surgery for Oral Tongue Cancer","Terminated","No Results Available","Tongue Cancer|Chemotherapy Effect|Surgery","Drug: Induction chemotherapy","Taipei Veterans General Hospital, Taiwan","All","20 Years to 70 Years   (Adult, Senior)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201009018MB","May 17, 2017","July 18, 2011","January 4, 2017","May 18, 2017","March 2017","No Study Results Posted","null","January 27, 2016","Objective response rate|Tongue conservation surgery feasibility rates|Pathological response of induction chemotherapy|Longitudinal quality of life (QOL)|Oncologic results","https://ClinicalTrials.gov/show/NCT03161548"
2692,"NCT00921739","Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer|Small Cell Lung Cancer|Thymoma|Thymus Neoplasms","Radiation: Esophageal sparing IMRT","Duke University","All","18 Years and older   (Adult, Senior)","Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00017361","June 15, 2009","August 2009","June 2019","August 10, 2016","August 2016","No Study Results Posted","ESIMRT","December 2014","Maximum tolerated dose (MTD) of IMRT|The occurrence of RT-induced acute esophagitis|To determine if biological predictors of esophagitis can identify patients who develop severe esophageal toxicity during radiation therapy","https://ClinicalTrials.gov/show/NCT00921739"
2693,"NCT03100708","Register Study of Patients With Peritoneal Carcinomatosis Treated With PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy)","Recruiting","No Results Available","Peritoneal Carcinomatosis","Procedure: PIPAC","University of Leipzig","All","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PIPAC_01","November 15, 2016","April 2016","April 2021","March 28, 2017","March 2017","No Study Results Posted","PIPAC_01","April 2021","Overall Survival (years)|The Peritoneal Carcinomatosis Index (PCI) before and after repeated PIPAC treatments|Overall Response Rate (CT RESIST criteria)|Quality of lfe questionnaire (EORTC QLQ-C15-PAL)","https://ClinicalTrials.gov/show/NCT03100708"
2694,"NCT00113919","UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","Terminated","Has Results","Multiple Myeloma","Drug: Busulfan","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-25","June 10, 2005","June 2004","October 2009","April 10, 2015","April 2015","April 14, 2011","null","October 2009","Maximal Dose of Busulfex® Given in a 2, 3, or 4 Day Period With Acceptable Toxicity to Myeloma Patients|Response Rate (CR, NCR) and Overall Survival of Patients on Busulfex Treatment","https://ClinicalTrials.gov/show/NCT00113919"
2695,"NCT01472250","A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China","Completed","No Results Available","Advanced Gastric Cancer","Drug: Clinical chemo-drugs","Peking University","All","18 Years to 85 Years   (Adult, Senior)","","498","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGOG1002","October 28, 2011","November 2011","July 2016","May 7, 2017","May 2017","No Study Results Posted","null","July 2016","chemotherapy regimen|overall survival|quality of life|treatment expense","https://ClinicalTrials.gov/show/NCT01472250"
2696,"NCT00620139","Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma","Completed","No Results Available","Head and Neck Squamous Cell Carcinoma","Biological: the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Early Phase 1","17","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","05-016","January 25, 2008","March 2005","October 2013","October 23, 2013","October 2013","No Study Results Posted","null","October 2013","To evaluate the proximal effects of concurrent chemoradiotherapy (CRT) on the expression of potential therapeutic molecular targets along the arachidonic acid and epidermal growth factor receptor (EGFR) signaling pathways in HNSCC.","https://ClinicalTrials.gov/show/NCT00620139"
2697,"NCT00083551","UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","Completed","Has Results","Multiple Myeloma","Drug: Thalidomide|Drug: Ara-C|Drug: BCNU|Drug: Cisplatin|Drug: Cytoxan|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Filgrastim|Drug: Recombinant GM-CSF|Drug: Interferon-alpha-2b|Drug: Melphalan|Drug: Vincristine","University of Arkansas|Celgene Corporation","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","668","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5226","May 25, 2004","August 1998","August 2014","October 21, 2015","October 2015","August 24, 2015","null","August 2014","Overall Survival","https://ClinicalTrials.gov/show/NCT00083551"
2698,"NCT01664663","Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy","Terminated","No Results Available","Non Small Cell Lung Cancer|Locally Advanced Disease","Radiation: Standard radiochemotherapy to 68 Gy|Radiation: Dose escalated radiochemotherapy up to 84 Gy","Ass. Prof. Jan Nyman|Swedish Lung Cancer Study Group","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PLANET","August 10, 2012","September 2011","October 2015","December 8, 2014","December 2014","No Study Results Posted","PLANET","November 2013","Progression free survival|Numbers of patients without progression of locoregional disease","https://ClinicalTrials.gov/show/NCT01664663"
2699,"NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","Completed","Has Results","Lymphoma, Large-Cell, Diffuse","Drug: OFATUMUMAB + DHAP|Drug: RITUXIMAB + DHAP","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110928","November 4, 2009","March 2010","November 2014","July 9, 2015","February 2015","October 9, 2014","ORCHARRD","February 2014","Progression-free Survival as Assessed by Independent Reviewers|Number of Participants With Overall Response (OR) and Complete Response (CR) After Salvage Chemoimmunotherapy|Number of Participants With Overall Response (OR) and Complete Response (CR) Three Months After Autologous Stem Cell Transplant|Event-free Survival|Overall Survival (OS)|Number of Participants With the Ability to Mobilize at Least 2 Million Cluster of Differentiation (CD)34+ Cells Per Kilogram From Peripheral Blood|Number of Participants Completing Autologous Stem Cell Transplant (ASCT)|Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) During Treatment|Change From Baseline in the Functional Assessment of Cancer Therapy Lymphoma Trial Outcome Index (FACT-Lym TOI) Total Score During Treatment|Time to Neutrophil and Platelet Recovery After Each Cycle of Salvage Chemotherapy|Time to Engraftment After High-dose Therapy (HDT)/ASCT","https://ClinicalTrials.gov/show/NCT01014208"
2700,"NCT00959582","Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer","Procedure: Comparator: 18-F-FDG PET/CT and Volumetric CT","Merck Sharp & Dohme Corp.","Female","35 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","0000-143|2009_632","August 12, 2009","September 2009","October 2011","January 21, 2015","January 2015","No Study Results Posted","null","October 2011","Proportion of patients with metabolic non-response assessed by FDG-PET standardized uptake value (SUV) 3 weeks and 6 weeks after starting platinum-based therapy|Progression free proportion","https://ClinicalTrials.gov/show/NCT00959582"
2701,"NCT01627197","Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer","Enrolling by invitation","No Results Available","Bladder Cancer","Procedure: Surgery of percutaneous catheter system","Sun Yat-sen University","All","18 Years and older   (Adult, Senior)","Phase 3","212","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012009","June 13, 2012","June 2012","December 2021","May 10, 2016","May 2016","No Study Results Posted","null","April 2019","cancer progressive free survival rate|overall survival|Cancer specific survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01627197"
2702,"NCT02786719","A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors","Recruiting","No Results Available","Neuroblastoma","Drug: Topotecan|Drug: Cyclophosphamide|Drug: Cisplatin|Drug: Etoposide|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Sargramostim","Baylor College of Medicine|Texas Children's Hospital","All","12 Months to 18 Years   (Child, Adult)","","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-38179 (SPRING)|SPRING","May 23, 2016","June 2016","June 2019","July 18, 2016","June 2016","No Study Results Posted","SPRING","December 2018","the incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors|incidence of delay in chemotherapy administration due to prolonged neutrophil recovery|the number of antibiotic days and hospital days due to fever and/or infection|number of platelet transfusions in in patients undergoing induction chemotherapy|the response rate following induction chemotherapy without prophylactic granulocyte colony stimulating factor (G-CSF)","https://ClinicalTrials.gov/show/NCT02786719"
2703,"NCT01733589","Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC","Unknown status","No Results Available","Stage III Non-small-Cell Lung Cancer","Drug: Recombinant human endostatin","Zhejiang Cancer Hospital|Chinese Academy of Medical Sciences|Fudan University|Beijing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Shandong Cancer Hospital and Institute|Jiangsu Cancer Institute & Hospital|Fujian Cancer Hospital|The First People's Hospital of Lianyungang","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","[2012]-10-24","November 2, 2012","November 2012","May 2014","December 23, 2012","December 2012","No Study Results Posted","null","November 2013","progression-free survival|Response rate|overall survival|treatment related toxicities","https://ClinicalTrials.gov/show/NCT01733589"
2704,"NCT01540058","Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP","Recruiting","No Results Available","Neoplasms, Unknown Primary","Other: Cancer Type ID test|Other: No test Empiric strategy","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France","All","18 Years and older   (Adult, Senior)","Phase 3","223","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","2011-A01202-39|2011/1751","February 13, 2012","March 2012","October 2017","February 9, 2016","February 2016","No Study Results Posted","GEFCAPI04","March 2016","Progression free survival|Response rate|Tolerance (Toxicity grade III and IV, toxic death)|Overall survival","https://ClinicalTrials.gov/show/NCT01540058"
2705,"NCT00577512","UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","Completed","Has Results","Multiple Myeloma","Drug: DTPACE","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-32","December 18, 2007","April 2007","April 2009","April 19, 2011","April 2011","April 19, 2011","null","April 2009","Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer.|In Subjects Achieving a Response, to Find Out How Long the Response Will Last.","https://ClinicalTrials.gov/show/NCT00577512"
2706,"NCT01805557","Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma Refractory|Diffuse Large B-cell Lymphoma Recurrent","Drug: R-DHAP|Drug: BR-DHAP","Fondazione Italiana Linfomi ONLUS|Janssen Pharmaceutica|Janssen-Cilag Ltd.|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","108","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FIL_VERAL12","March 5, 2013","February 2013","February 2018","February 29, 2016","February 2016","No Study Results Posted","FIL_VERAL12","September 2017","Complete Response (CR) Rate|Overall Response Rate (ORR)|Overall Survival (OS|Toxicity|Mobilizing potential|Feasibility","https://ClinicalTrials.gov/show/NCT01805557"
2707,"NCT01020864","Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Neoplasms","Drug: Cetuximab|Drug: Carboplatin|Drug: Vinorelbine","Per Pfeiffer|Odense University Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09.08","November 25, 2009","January 2010","January 2018","January 20, 2015","January 2015","No Study Results Posted","CECAVI","September 2012","Progression-free survival|Response rate|Toxicity|Median survival|Correlation between response and evolvement in tumor biology markers.","https://ClinicalTrials.gov/show/NCT01020864"
2708,"NCT00424255","Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery","Completed","Has Results","Neoplasms, Head and Neck","Drug: Lapatinib|Radiation: Chemoradiation|Other: Placebo","GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","688","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","EGF102988","January 17, 2007","December 2006","November 2013","July 10, 2014","June 2014","November 27, 2013","null","March 2013","Disease Free Survival (DFS)|Overall Survival (OS)|Disease Specific Survival (DSS)|Time to Locoregional Recurrence (TTLR)|Time to Distant Relapse (TTDR)|Number of Participants With a Second Primary Tumor|Extent of Exposure|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Number of Participants With the Indicated Chemistry Toxicities by Maximum Toxicity Grade (G3 and G4) at the Worst-case On-therapy Visit|Number of Participants With the Indicated Hematological Toxicities by Maximum Toxicity Grade (G3 and G4) at the Worst-case On-therapy Visit|Number of Participants With On-therapy and Follow-up Late Radiation Morbidity Events|Change From Baseline in Blood Pressure at the Indicated Time Points|Change From Baseline in Heart Rate at the Indicated Time Points|Change From Baseline in Body Temperature at the Indicated Time Points|Change From Baseline in Body Weight at the Indicated Time Points|Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points|Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value|Change From Baseline in Quality of Life Status as Assessed by the Functional Assessement of Cancer Therapy-Head and Neck (FACT-H&N) Questionnaire|Change From Baseline in Quality of Life Status as Assessed by the EuroQol-5D (EQ-5D) Scale|Number of Participants With the Indicated Biomarker Expression Status|Number of Participants With the Indicated Worst-case On-therapy Left Ventricular Ejection Fraction (LVEF) Change From Baseline","https://ClinicalTrials.gov/show/NCT00424255"
2709,"NCT00464893","Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection","Completed","No Results Available","Gastric Cancer|Gastric Adenocarcinoma","Drug: Catumaxomab|Drug: catumaxomab","Neovii Biotech","All","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IP-CAT-GC-03|EudraCT-Nr.:2006-002727-16","April 23, 2007","April 2007","April 2013","December 3, 2013","December 2013","No Study Results Posted","null","April 2009","rate of all specific postoperative complications newly observed during a period of 30 days after surgery in those study patients who received at least the first 3 doses of catumaxomab|frequency, relationship and seriousness of adverse events|surgical resection rate|chemotherapeutic response rate|overall survival at 3, 6, 9, 12 and 24 month after EOT, defined as the time from study enrolment until death|disease-free survival at 3, 6, 9, 12 18 and 24 months after EOT, defined as the time from study enrolment to the point of diagnosis of recurrent disease or death, whichever occurred first","https://ClinicalTrials.gov/show/NCT00464893"
2710,"NCT01731548","A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer","Unknown status","No Results Available","Carcinoma of Lung|Small Cell|Limited Stage","Radiation: hyperfractionated radiation therapy for both arms","Zhejiang Cancer Hospital|Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-10-25","November 14, 2012","June 2002","December 2016","January 21, 2013","January 2013","No Study Results Posted","null","December 2014","local-regional progression|overall survival","https://ClinicalTrials.gov/show/NCT01731548"
2711,"NCT02145078","Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer","Terminated","No Results Available","Recurrent Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer","Drug: docetaxel|Drug: pemetrexed disodium|Drug: gemcitabine hydrochloride|Other: laboratory biomarker analysis","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2013-177|NCI-2014-01023|1402012854|P30CA022453","May 20, 2014","June 2014","April 2018","March 29, 2017","March 2017","No Study Results Posted","null","April 2018","Baseline marker measurement|Change in biomarker expression levels|Overall survival (OS)|Progression-free survival (PFS)|Expression levels of biomarkers and other molecules","https://ClinicalTrials.gov/show/NCT02145078"
2712,"NCT01806272","Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis","Unknown status","No Results Available","Nasopharyngeal Cancers","Drug: rhGM-CSF|Drug: Compound Vitamin B12","Wei LUO|Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L-12-01","March 4, 2013","March 2013","August 2014","March 27, 2013","March 2013","No Study Results Posted","null","June 2014","The incidence of grade II and less oral mucositis at the end of treatment|Pain|Cumulative incidence and time of grade III and more oral mucositis|Dysphagia|Tumor response to chemoradiotherapy","https://ClinicalTrials.gov/show/NCT01806272"
2713,"NCT01745445","Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)","Recruiting","No Results Available","Small Cell Lung Cancer","Other: concurrent chemo-radiotherapy arm","Tianjin Medical University Cancer Institute and Hospital","All","17 Years to 75 Years   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CIH-PQS-201205001","December 6, 2012","January 2012","December 2016","May 15, 2016","April 2016","No Study Results Posted","SCLC","November 2016","disease free survival|overall survival|acute and late toxic effects","https://ClinicalTrials.gov/show/NCT01745445"
2714,"NCT00415818","Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer","Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Biological: MVA-MUC1-IL2|Drug: 1st line Chemotherapy","Transgene","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TG4010.09","December 22, 2006","December 2005","March 2010","July 15, 2014","July 2014","No Study Results Posted","null","March 2010","Progression free survival at 6 months|Response Rate according to WHO criteria|Time to progression|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT00415818"
2715,"NCT02944708","Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Drug: Conventional chemotherapy|Drug: Maintenance chemotherapy 1|Drug: Maintenance chemotherapy 2","Shanghai Proton and Heavy Ion Center|Fudan University|Eye & ENT Hospital of Fudan University|The First Affiliated Hospital of Xiamen University|Jiangxi Provincial Cancer Hospital|Taichung Veterans General Hospital|First Affiliated Hospital of Fujian Medical University|Cancer Hospital of Guangxi Medical University|National Cancer Centre, Singapore|West China Hospital|Beijing Cancer Hospital|Tongji Hospital|People's Hospital of Guangxi","All","18 Years to 65 Years   (Adult)","Phase 3","384","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SPHIC-TR-HNCNS-2015-04","October 24, 2016","October 2015","October 2018","October 26, 2016","October 2016","No Study Results Posted","null","October 2018","Progression-free survival|Overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","https://ClinicalTrials.gov/show/NCT02944708"
2716,"NCT00670631","Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","Completed","No Results Available","Multiple Myeloma","Combination Product: tandem autologous transplantation","Guido Tricot|National Cancer Institute (NCI)|University of Iowa","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","25009|7R01CA115399","April 3, 2008","February 2008","April 2014","April 4, 2017","April 2017","No Study Results Posted","null","May 2012","To determine whether, in comparison to TT II, the median EFS can be increased from 4.8 years to 6.2 years, which represents an increase in median EFS of approximately 30%|In assessing patient safety, we will examine treatment toxicity related mortality and SAEs. Historical study results indicate that a mortality rate of greater than 10% is not acceptable in this population, nor is an SAE rate of greater than 15%.|Overall survival will be compared to a historical control (UARK 98-026, TT2)as a secondary outcome.","https://ClinicalTrials.gov/show/NCT00670631"
2717,"NCT02649829","Autologous Dendritic Cell Vaccination in Mesothelioma","Recruiting","No Results Available","Malignant Pleural Mesothelioma","Biological: dendritic cell vaccination plus chemotherapy","University Hospital, Antwerp","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CCRG13-002","December 7, 2015","October 2015","November 2021","January 24, 2017","January 2017","No Study Results Posted","MESODEC","October 2020","Number of MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicity","https://ClinicalTrials.gov/show/NCT02649829"
2718,"NCT01837381","Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)","Active, not recruiting","No Results Available","Hepatocellular Carcinoma","Procedure: TEA","Chinese University of Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong","All","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VIR-13-03","April 15, 2013","February 2007","null","June 29, 2016","April 2016","No Study Results Posted","null","February 2017","overall survival and treatment-related toxicity|Time to progression(TTP)|Progression free survival(PFS)|Tumor response","https://ClinicalTrials.gov/show/NCT01837381"
2719,"NCT02879214","Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer","Recruiting","No Results Available","Squamous Cell Carcinoma of Cervix","Radiation: Simultaneous boost along with chemo","Sichuan Provincial People's Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201604","August 10, 2016","December 2015","February 2020","August 24, 2016","August 2016","No Study Results Posted","Side","December 2019","To observe the efficacy from radiation therapy dose escalation|To evaluate the chemoradiation in Stage IIB~ III carcinoma cervix|Disease free survival(DFS)","https://ClinicalTrials.gov/show/NCT02879214"
2720,"NCT01997775","Metformin in Stage IV Lung Adenocarcinoma","Terminated","No Results Available","Non-small Cell Lung Cancer","Drug: METFORMIN","National Cheng-Kung University Hospital","All","20 Years to 80 Years   (Adult, Senior)","Phase 2","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B-BR-102-039","November 17, 2013","August 2013","June 2016","September 29, 2016","September 2016","No Study Results Posted","null","June 2016","The change of plasma IL-6 level after the treatment with metformin|The objective response rate (RR)|The progression free survival|The overall survival|Number of participants with adverse events|Changes of quality of life","https://ClinicalTrials.gov/show/NCT01997775"
2721,"NCT02299999","SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: AZD2014|Drug: AZD4547|Drug: AZD5363|Drug: AZD8931|Drug: Selumetinib|Drug: Vandetanib|Drug: Bicalutamide|Drug: Olaparib|Drug: Anthracyclines|Drug: Taxanes|Drug: cyclophosphamide|Drug: DNA intercalators|Drug: Methotrexate|Drug: vinca alkaloids|Drug: Platinum based chemotherapies|Drug: Bevacizumab|Drug: Mitomycine C|Drug: Eribuline|Drug: MEDI4736","UNICANCER|Fondation ARC|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","1460","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UC-0105/1304|2013-001652-36","October 1, 2014","April 7, 2014","June 2021","May 2, 2017","May 2017","No Study Results Posted","SAFIR02_Breast","June 2019","Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm|progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm|overall survival in each substudy|overall response rates and changes in tumor size in each substudy|evaluate safety, in each substudy|efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1)|correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy","https://ClinicalTrials.gov/show/NCT02299999"
2722,"NCT00797719","Short Neoadjuvant Hemithoracic IMRT for MPM","Recruiting","No Results Available","Malignant Pleural Mesothelioma","Other: Pre-op RT +/- chemotherapy","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UHN REB 08-0106-C","November 21, 2008","October 2008","July 2017","August 30, 2016","August 2016","No Study Results Posted","null","July 2017","The primary outcome for the study will be the proportion of patients treated as per protocol without treatment related mortality.|To evaluate: acute and late morbidity related to treatment; local & distant recurrence, disease free & overall survival; identify factors/parameters associated with increased risk of treatment morbidity","https://ClinicalTrials.gov/show/NCT00797719"
2723,"NCT03003962","A Study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung Cancer","Recruiting","No Results Available","Non Small Cell Lung Carcinoma NSCLC","Biological: Durvalumab (MEDI4736)|Drug: Paclitaxel + carboplatin|Drug: Gemcitabine + cisplatin|Drug: Gemcitabine + carboplatin|Drug: Pemetrexed + cisplatin|Drug: Pemetrexed + carboplatin","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","440","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419AC00002","December 15, 2016","January 2, 2017","June 12, 2020","April 25, 2017","April 2017","No Study Results Posted","null","October 22, 2018","The efficacy of Durvalumab therapy compared to SoC in terms of progression-free survival (PFS) in patients with NSCLC|The efficacy of Durvalumab therapy compared to SoC in terms of Overall Survival (OS) in patients with NSCLC|The efficacy of Durvalumab compared to SoC in terms of Objective response rate (ORR)|The efficacy of Durvalumab compared to SoC in terms of Duration of response (DoR)|The efficacy of Durvalumab compared to SoC in terms of A Proportion of patients alive and progression free at 12 months from randomization (APF12)|The efficacy of Durvalumab compared to SoC in terms of Progression-free survival after subsequent anticancer therapy (PFS2)|Disease-related symptoms in subjects treated with durvalumab compared to SoC using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-LC13)|Health-related quality of life in subjects treated with durvalumab compared to SoC using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|The immunogenicity of durvalumab by measuring the presence of Anti-drug Antibodies","https://ClinicalTrials.gov/show/NCT03003962"
2724,"NCT02873520","Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer","Recruiting","No Results Available","Precision Cell Immunotherapy|Chemotherapy|Advanced Gastric Cancer","Drug: Chemotherapy|Biological: Precision Cell Immunotherapy","Ningbo Cancer Hospital","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NBWYKY2016-06-006","August 15, 2016","August 2016","August 2018","October 6, 2016","August 2016","No Study Results Posted","null","March 2018","Overall survival|Progress-free survival|Quality of life","https://ClinicalTrials.gov/show/NCT02873520"
2725,"NCT02862561","Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer","Recruiting","No Results Available","Precision Cell Immunotherapy|Chemotherapy|Advanced Malignancies","Drug: Chemotherapy|Biological: Precision Cells","Shanghai International Medical Center","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SIMC-20160105","August 8, 2016","August 2016","July 2018","September 1, 2016","August 2016","No Study Results Posted","null","March 2018","Overall survival|Progress-free survival|Quality of life","https://ClinicalTrials.gov/show/NCT02862561"
2726,"NCT02862587","Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer","Recruiting","No Results Available","Precision Cells|Chemotherapy|Advanced Lung Cancer","Drug: Chemotherapy|Biological: precision cells","Shanghai International Medical Center","All","18 Years to 25 Years   (Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SIMC-20160104","August 8, 2016","August 2016","August 2018","August 31, 2016","August 2016","No Study Results Posted","null","March 2018","Overall survival|Progress-free survival|Quality of life","https://ClinicalTrials.gov/show/NCT02862587"
2727,"NCT02873416","Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer","Recruiting","No Results Available","Precision Cell Immunotherapy|Chemotherapy|Advanced Lung Cancer","Drug: Chemotherapy|Biological: Precision Cells","Ningbo Cancer Hospital","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NBWYKY2016-06-004","August 15, 2016","August 2016","August 2018","October 6, 2016","August 2016","No Study Results Posted","null","March 2018","Overall survival|Progress-free survival|Quality of life","https://ClinicalTrials.gov/show/NCT02873416"
2728,"NCT00083538","Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally","Completed","No Results Available","Multiple Myeloma","Drug: Dexamethasone|Drug: Thalidomide|Drug: Cisplatinum|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2000-46","May 25, 2004","February 2001","December 2007","July 6, 2010","July 2010","No Study Results Posted","null","December 2007","To determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.","https://ClinicalTrials.gov/show/NCT00083538"
2729,"NCT00602667","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: Induction Chemotherapy|Drug: Low-Risk Therapy|Drug: High-Risk Therapy|Drug: Intermediate-Risk Therapy","St. Jude Children's Research Hospital|University of Florida|National Cancer Institute (NCI)|The Pew Charitable Trusts","All","up to 5 Years   (Child)","Phase 2","293","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJYC07|R01CA154619|NCI-2011-01193","January 10, 2008","December 17, 2007","April 30, 2023","May 22, 2017","May 2017","No Study Results Posted","null","April 30, 2018","Progression-free survival|DNA methylation in peripheral blood or tissue|Event-free survival|Chromosomal abnormalities|Gene expression patterns|Molecular abnormalities by tumor type|Number of successful collections for frozen and fixed tumor samples|Event free survival compared to historical controls|Overall survival compared to historical controls|Rate of disease progression|Objective response rate|Number of participants who successfully complete induction therapy|Number of participants who successfully complete consolidation therapy|Sustained objective response rate|Percent of total scheduled doses received during oral maintenance therapy|Change in neurostructure, especially white matter volume and integrity|Percent of PET scans with loss of signal intensity|Pharmacokinetic variables of methotrexate|Pharmacokinetic variables of intravenous and oral cyclophosphamide and its metabolites by age, gender, race, and weight|Number of participants who successfully achieve target systemic exposure of intravenous topotecan|Pharmacokinetic variables of intravenous and oral topotecan by age, gender, race and weight|Pharmacokinetic variables of oral erlotinib by age, gender, race and weight|Change in concentration of cerebrospinal fluid (CSF) neurotransmitters|Change in neurocognitive performance|Number and type of genetic polymorphisms|Pharmacogenetic variation on CNS transmitters|Change in neuropsychological performance|Change in quantitative magnetic resonance (MR) measures in the frontal lobe|Change in neurocognitive performance in attention, working memory, and fluency|Change in quantitative MR measures in the right frontal-parietal regions|Change in neurocognitive performance in visual-spatial reasoning and processing speed|Number of participants with endocrinopathy|Longitudinal change in growth hormone secretion","https://ClinicalTrials.gov/show/NCT00602667"
2730,"NCT02918955","Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection","Recruiting","No Results Available","Head and Neck Neoplasms","Procedure: up-front neck dissection|Radiation: radiotherapy|Drug: Chemotherapy (Cisplatin)|Procedure: Early Salvage Neck Dissection in case of less than cCR (Arm A only)","University Hospital Inselspital, Berne|University of Bern","All","18 Years and older   (Adult, Senior)","Phase 3","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BE 00733/16","September 21, 2016","October 2016","June 2022","November 15, 2016","November 2016","No Study Results Posted","UPFRONT-NECK","March 2020","Number of patients with acute & subacute toxicity based on CTCAE scoring system v4.03|Number of patients with late Toxicity based on CTCAE scoring system v4.03|Change from baseline quality of life(QoL)using EORTC QLQ-C30 v3&EORTC QLQ-H&N43 modules(Health related QoL specific for Head&Neck ca.)scores at end of RT, 3,12&24 months after RT.Swallowing (H&N43:4-item scale)3 months after RT is the primary QoL domain|Loco-regional control|Progression-free survival|Overall survival|Distant metastasis-free survival|Disease-specific survival|QoL comparison between the patients who accepted to be randomized (into rA and rB) and not (into oA and oB: in other words, patients who chose their own treatment strategy)","https://ClinicalTrials.gov/show/NCT02918955"
2731,"NCT01124812","131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)","Terminated","No Results Available","Non Small Cell Lung Cancer","Other: 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy","Philogen S.p.A.","All","18 Years and older   (Adult, Senior)","Phase 1","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PH-L19SIPI131-04/09|2009-017072-24","May 12, 2010","May 2010","October 2012","October 25, 2012","June 2012","No Study Results Posted","null","August 2011","Uptake of 131I-L19SIP or 124I-L19SIP|Safety and tolerability of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose/Recommended Dose (MTD/RD) for the combination treatment|Overall response rate|Overall survival","https://ClinicalTrials.gov/show/NCT01124812"
2732,"NCT03058289","A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6","Recruiting","No Results Available","Melanoma|Head and Neck Cancer|Lymphoma|Breast Cancer|Pancreatic Cancer|Liver Cancer|Colon Cancer|Lung Cancer|Glioblastoma","Drug: INT230-6|Biological: anti-PD-1|Biological: anti-PD-1 antibody","Intensity Therapeutics, Inc.|University of Southern California|University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","IT-01","February 10, 2017","February 9, 2017","January 2020","April 10, 2017","April 2017","No Study Results Posted","IT-01","July 2018","Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5)|Preliminary Efficacy: Control or Regression of Injected Tumors by Measurement of Length, Width and Height (in centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging to Calculate Tumor Volumes (cubic centimeters) Over Time.|Determine pharmacokinetic parameter Peak Plasma (Cmax in ng/mL) of each of the 3 main components of INT230-6.|Determine key pharmacokinetic parameter, Area Under the Curve (AUC) (ng*hr/mL) of each of the 3 main components of INT230-6.|Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6.","https://ClinicalTrials.gov/show/NCT03058289"
2733,"NCT01770418","A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer","Recruiting","No Results Available","Lung Neoplasms","Radiation: Radiation Concurrent Chemotherapy","Proton Collaborative Group","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LUN005-12","January 11, 2013","March 2013","null","December 14, 2016","December 2016","No Study Results Posted","null","January 2038","Phase I: Establish the maximum tolerated dose of radiotherapy in terms of Gy (RBE)/fraction using hypofractionated proton therapy concurrently with chemotherapy.|Phase II: Determine the percentage of patients that survive at least 12 months|Assess acute and late adverse events of concurrent chemotherapy with hypofractionated proton therapy.|Analyze for disease control and overall survival.","https://ClinicalTrials.gov/show/NCT01770418"
2734,"NCT02580994","Pembrolizumab in Untreated Extensive SCLC","Not yet recruiting","No Results Available","Small Cell Lung Cancer (SCLC)","Drug: Pembrolizumab|Drug: cis/carboplatin and etoposide","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","118","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-1417-LCG|2014-003090-42","October 19, 2015","January 2017","June 2020","October 11, 2016","October 2016","No Study Results Posted","REACTION","October 2019","Increase in Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02580994"
2735,"NCT00593723","IMRT Tomotherapy for Esophagus Cancer","Completed","No Results Available","Esophagus Cancer","Radiation: IMRT","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-1070 / 201105499","January 2, 2008","December 2006","December 2015","April 3, 2016","April 2016","No Study Results Posted","IMRT","January 2014","The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.|Evaluate local recurrence rates|Evaluate disease-free survival rates|Evaluate regional recurrence rates|Evaluate distant recurrence rates|Evaluate overall survival rates","https://ClinicalTrials.gov/show/NCT00593723"
2736,"NCT03058432","Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","Recruiting","No Results Available","Nasopharyngeal Carcinoma","Radiation: Radiotherapy alone|Radiation: Concurrent chemoradiotherapy","Zhejiang Cancer Hospital","All","65 Years and older   (Adult, Senior)","Phase 2","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ZJCH-2016-HN03","February 16, 2017","January 2017","December 2019","February 16, 2017","February 2017","No Study Results Posted","null","December 2019","therapeutic success","https://ClinicalTrials.gov/show/NCT03058432"
2737,"NCT01117402","Tomotherapy in Postsurgery Recurrent Carcinoma Cervix","Unknown status","No Results Available","Postsurgery Recurrent Carcinoma Cervix","Radiation: Radiotherapy","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult)","Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB 588","May 4, 2010","December 2008","December 2014","May 4, 2010","May 2010","No Study Results Posted","null","December 2013","To evaluate the utility of intensity-modulated radiotherapy (IMRT) in delivering dose escalated radiotherapy in postoperative recurrent cases of carcinoma cervix, in terms of local control|To study the late toxicities associated with this treatment","https://ClinicalTrials.gov/show/NCT01117402"
2738,"NCT02374424","Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients","Recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: GA101_DHAP","Fondazione Italiana Linfomi ONLUS","All","18 Years to 65 Years   (Adult)","Phase 2","78","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FIL_GA101_DHAP","February 17, 2015","June 2014","October 2021","December 5, 2016","December 2016","No Study Results Posted","GIOTTO","October 2018","Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.|Overall Response Rate (ORR) prior to consolidation with BEAM and ASCT|Progression free survival (PFS) at 6 month after the end of treatment (EOT)|Overall Survival (OS) at 2 years after the EOT|Toxicity: Severe, life-threatening, fatal (grade 3, 4 and 5) and/or serious adverse events|The hematopoietic cell mobilization|Feasibility: the rate of patients actually proceeding to ASCT","https://ClinicalTrials.gov/show/NCT02374424"
2739,"NCT03007212","Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis","Completed","No Results Available","Hepatocellular Carcinoma (HCC)","Procedure: transarterial chemoembolization versus the standard treatment with sorafinib","Ain Shams University","All","18 Years to 65 Years   (Adult)","Phase 4","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Hepatocellular Carcinoma","December 24, 2016","September 2014","September 2015","December 29, 2016","December 2016","No Study Results Posted","null","September 2015","changes in Radiological Response in the (CT/ MRI) after the intervention","https://ClinicalTrials.gov/show/NCT03007212"
2740,"NCT00807300","Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma","Completed","No Results Available","Hepatocellular Carcinoma","Radiation: CT-guided brachytherapy|Procedure: transarterial chemoembolization","University of Magdeburg","All","18 Years and older   (Adult, Senior)","Phase 2","77","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-000569-21","December 9, 2008","October 2006","December 2015","December 2, 2015","December 2015","No Study Results Posted","CEAL","December 2015","Time to untreatable progression|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT00807300"
2741,"NCT00522405","Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma","Unknown status","No Results Available","Hepatocellular Carcinoma","Procedure: TACE","All India Institute of Medical Sciences, New Delhi|Indian Council of Medical Research","All","12 Years to 80 Years   (Child, Adult, Senior)","Phase 2|Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A-39/29.1.2007|ICMR No-5/8/7/26/99-ECD-I","August 27, 2007","October 2007","October 2014","July 13, 2012","August 2007","No Study Results Posted","null","August 2014","Survival rate- calculated from the start of TACE|a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C","https://ClinicalTrials.gov/show/NCT00522405"
2742,"NCT01091168","Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Metastases","Drug: vinflunine|Drug: alkylating agent of physician choice registered in cancer","Pierre Fabre Medicament","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","594","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L00070 IN 308 B0","February 3, 2010","September 2009","January 2013","October 12, 2016","October 2016","No Study Results Posted","null","January 2013","Overall survival|Quality of life questionnaire|Adverse event profile|Tumour response rate|Progression free survival","https://ClinicalTrials.gov/show/NCT01091168"
2743,"NCT01510990","First Line Gefitinib by FDG-PET Metabolic Response","Unknown status","No Results Available","Non-small Cell Lung Cancer","Drug: Gefitinib","Asan Medical Center|AstraZeneca","All","19 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC 2011-0858","January 10, 2012","April 2012","November 2015","January 26, 2013","January 2013","No Study Results Posted","null","June 2013","Objective Response rate|Objective response rate by EGFR mutational status","https://ClinicalTrials.gov/show/NCT01510990"
2744,"NCT01538641","Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas","Completed","No Results Available","Refractory Aggressive Non-Hodgkin's Lymphoma|Relapsing Aggressive Non-Hodgkin's Lymphoma","Drug: Rituximab, Gemcitabine, Oxaliplatin","Auxilio Mutuo Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCAM-03-01","February 21, 2012","October 2003","December 2008","July 11, 2012","July 2012","No Study Results Posted","null","August 2007","The response rate of the combination of Gemcitabine-Oxaliplatin-Rituximab.","https://ClinicalTrials.gov/show/NCT01538641"
2745,"NCT02734524","A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer","Recruiting","No Results Available","Non-small Cell Lung Cancer","Biological: NK cells|Drug: Taxol|Drug: Carboplatin","Southwest Hospital, China","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TMMU-BTC-004","November 8, 2015","March 2016","March 2019","October 16, 2016","October 2016","No Study Results Posted","null","March 2018","Number of participants responding to treatment|Progress free survival(PFS) time|Overall survival time","https://ClinicalTrials.gov/show/NCT02734524"
2746,"NCT00391586","Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Erlotinib|Drug: Platinum-based chemotherapy","New Mexico Cancer Care Alliance|Genentech, Inc.","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INST 0601C|NCI-2012-01264","October 23, 2006","July 2006","May 2012","August 14, 2015","August 2015","June 15, 2015","null","May 2011","Progression-free Survival (PFS)|Toxicity Profile","https://ClinicalTrials.gov/show/NCT00391586"
2747,"NCT00856791","Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients","Completed","Has Results","Ovarian Cancer","Drug: ON 01910.Na","Onconova Therapeutics, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Onconova 04-12","March 4, 2009","March 2009","July 2011","January 7, 2013","January 2013","November 27, 2012","null","July 2011","Progression Free Survival|Number of Adverse Events","https://ClinicalTrials.gov/show/NCT00856791"
2748,"NCT00176800","Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma","Completed","Has Results","Esophageal Carcinoma","Drug: Tetrathiomolybdate (TM)|Procedure: Radiation|Procedure: Surgery","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","69","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2001-007|HUM 49005 Legacy 2001-0623","September 12, 2005","November 2001","May 2013","July 12, 2016","July 2016","April 14, 2016","null","February 2006","Median Recurrence Free Survival Time|Median Overall Survival Time|Percentage of Patients That Require Dose Modification Due to Toxicity","https://ClinicalTrials.gov/show/NCT00176800"
2749,"NCT02363400","A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","Enrolling by invitation","No Results Available","Nasopharyngeal Carcinoma","Drug: MEP","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Mackay Memorial Hospital|China Medical University Hospital|National Cheng-Kung University Hospital|Kaohsiung Veterans General Hospital.|Taichung Veterans General Hospital","All","20 Years and older   (Adult, Senior)","Phase 3","147","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1313","December 4, 2014","November 2014","December 2022","February 9, 2015","November 2014","No Study Results Posted","null","December 2019","Time to progression|Progression-free survival and relapse rate|Overall survival|Toxicity profile and tolerance, according to CTCAE 4.1|Predicting value of plasma EBV DNA","https://ClinicalTrials.gov/show/NCT02363400"
2750,"NCT03141359","Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","Recruiting","No Results Available","Lung","Radiation: SBRT|Drug: Carboplatin|Drug: Paclitaxel|Drug: cis Platinum|Drug: Etoposide|Radiation: IMRT","Carolinas Healthcare System","All","18 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCI-LUN-NSC-SBRT-001|00021247","May 3, 2017","May 12, 2017","June 2020","May 12, 2017","May 2017","No Study Results Posted","null","June 2020","progression free survival","https://ClinicalTrials.gov/show/NCT03141359"
2751,"NCT02560441","Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type","Active, not recruiting","No Results Available","Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type","Other: chemotherapy followed by radiotherapy|Other: radiotherapy followed by chemotherapy|Drug: IPGDP regimen chemotherapy","Chinese Academy of Medical Sciences|307 Hospital of PLA|Tianjin Medical University Cancer Institute and Hospital|First Hospital of China Medical University|The Second Affiliated Hospital of Dalian Medical University|Hebei Medical University Fourth Hospital|Qilu Hospital of Shandong University|Shandong Cancer Hospital and Institute|Nanfang Hospital of Southern Medical University|Guangdong General Hospital|People's Hospital of Guangxi|Xuzhou Medical University|Shanxi Province Cancer Hospital|Shanxi Dayi Hospital|Zhangzhou Municipal Hospital of Fujian Province","All","18 Years to 65 Years   (Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-LYM-005","September 11, 2015","September 2015","null","September 24, 2015","September 2015","No Study Results Posted","null","September 2017","progression-free survival","https://ClinicalTrials.gov/show/NCT02560441"
2752,"NCT00202969","Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer","Completed","No Results Available","Gastric Cancer","Drug: S-1|Drug: S-1 plus CDDP|Drug: 5-FU plus CDDP","Taiho Pharmaceutical Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SC101","September 12, 2005","July 2005","June 2007","July 6, 2011","July 2011","No Study Results Posted","null","January 2007","Response rate|Safety profile, time to treatment failure","https://ClinicalTrials.gov/show/NCT00202969"
2753,"NCT01365156","Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix","Active, not recruiting","No Results Available","Cervical Squamous Cell Carcinoma|Adenosquamous Carcinoma|Adenocarcinoma|Locally Advanced Malignant Neoplasm|Cervical Cancer","Procedure: Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Radiation: Chemoradiation","M.D. Anderson Cancer Center","Female","18 Years and older   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2010-0952|NCI-2011-02400","June 1, 2011","August 2011","September 2019","March 21, 2017","March 2017","No Study Results Posted","null","September 2019","Three Year Overall Survival Rate","https://ClinicalTrials.gov/show/NCT01365156"
2754,"NCT00452803","Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)","Unknown status","No Results Available","Lung Cancer","Drug: chemotherapy|Drug: Concurrent chemoradiation therapy|Radiation: Concurrent chemoradiation therapy","National Cancer Center, Korea","All","18 Years and older   (Adult, Senior)","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-06-164","March 27, 2007","April 2006","December 2012","July 9, 2010","July 2010","No Study Results Posted","null","December 2011","To estimate the time to recurrence|To estimate the overall survival|To assess the pathologic complete response rate and the complete resection rate|To estimate toxicities","https://ClinicalTrials.gov/show/NCT00452803"
2755,"NCT02151981","AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Active, not recruiting","No Results Available","Anticancer Treatment","Drug: Chemotherapy|Drug: Cross-over to AZD9291","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 3","1104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D5160C00003","May 15, 2014","August 2014","January 2018","January 23, 2017","January 2017","No Study Results Posted","AURA3","April 2016","Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Overall Survival (OS)|Tumour shrinkage according to RECIST 1.1|Patient Reported Outcomes by EORTC QLQ-C30 questionnaire|Patient Reported Outcomes by EORTC QLQ-LC13 questionnaire|Patient Reported Outcomes by EQ-5D-5L questionnaire","https://ClinicalTrials.gov/show/NCT02151981"
2756,"NCT01560195","A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy","Unknown status","No Results Available","NSCLC|Neutropenia|Febrile Neutropenia","Drug: Pegylated rhG-CSF: 100µg/kg|Drug: Pegylated rhG-CSF: 6mg|Drug: placebo and rhG-CSF 5ug/kg/d","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HHPG-19K -III-02","March 8, 2012","April 2012","null","November 4, 2012","November 2012","No Study Results Posted","null","January 2013","Rate of grade 3/4 neutropenia in cycle 1|Incidence of febrile neutropenia in cycle 1|Rate of grade 3/4 neutropenia and incidence of febrile neutropenia in cycle 2 to 4|Time to neutrophil recovery in the 4 chemotherapy cycles|Duration of 3/4 neutropenia in the 4 chemotherapy cycles|Objective response rate|Progress free survival|Overall survival|Exploratory biomarkers research","https://ClinicalTrials.gov/show/NCT01560195"
2757,"NCT00576199","A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer","Completed","Has Results","Liver Cancer","Drug: Bevacizumab|Procedure: Transarterial chemoembolisation (TACE)","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21358","December 18, 2007","February 2008","May 2011","August 18, 2014","August 2014","August 18, 2014","null","May 2011","Progression-free Survival|Percentage of Participants With an Objective Response|Time to Progression|Overall Survival|Percentage of Participants With a Best Overall Response of Complete Response, Partial Response, or Stable Disease|Tumor Necrosis","https://ClinicalTrials.gov/show/NCT00576199"
2758,"NCT00765011","TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: TPF, radiotherapy and cetuximab|Procedure: H&N surgery","Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","92","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","TTCC-2007-02","October 1, 2008","October 2008","May 2014","February 12, 2011","February 2011","No Study Results Posted","null","February 2014","Specific survival","https://ClinicalTrials.gov/show/NCT00765011"
2759,"NCT00025259","Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease","Completed","Has Results","Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma|Childhood Mixed Cellularity Classical Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Classical Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma","Biological: Bleomycin Sulfate|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Filgrastim|Radiation: Involved-Field Radiation Therapy|Drug: Prednisone|Drug: Vincristine Sulfate Liposome","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","1734","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AHOD0031|NCI-2011-02069|CDR0000068943|COG-AHOD0031|U10CA098543","October 11, 2001","September 2002","null","March 15, 2017","May 2016","October 19, 2016","null","August 2012","Event-free Survival|Disease Response Assessed by Modified RECIST Criteria|Grade 3 or 4 Non-hematologic Toxicity|Overall Survival","https://ClinicalTrials.gov/show/NCT00025259"
2760,"NCT02367443","Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC","Recruiting","No Results Available","Non-small Cell Lung Cancer","Radiation: Radiation","Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CentralHMIA","February 12, 2015","March 2014","December 2016","November 5, 2016","November 2016","No Study Results Posted","null","December 2016","Toxicity|Survival","https://ClinicalTrials.gov/show/NCT02367443"
2761,"NCT00231582","High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II","Completed","No Results Available","Testicular Neoplasms","Drug: epirubicin|Procedure: high-dose and autologous stem cell transplantation|Drug: paclitaxel|Drug: etoposide|Drug: ifosfamide|Drug: carboplatin","Assistance Publique - Hôpitaux de Paris|Ministry of Health, France|Amgen|Baxter Healthcare Corporation","Male","18 Years to 65 Years   (Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P031101","October 3, 2005","September 2004","January 2010","February 24, 2011","March 2007","No Study Results Posted","null","January 2010","Complete response rate|Survival (overall and progression-free), toxicity, toxic-death rate.","https://ClinicalTrials.gov/show/NCT00231582"
2762,"NCT01093066","Prospective Multicentric Evaluation of a Bladder Preservation Strategy","Recruiting","No Results Available","Urothelial Carcinoma","Procedure: optimal TURB","Centre Hospitalier Universitaire de Saint Etienne","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","77","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0908038|2009-014264-19","March 24, 2010","September 2010","December 2022","September 19, 2016","September 2016","No Study Results Posted","ReChiVe","December 2022","the 5 years bladder preservation rate (with or without intravesical non muscle infiltrative recurrences, treated by TURB only or intravesical instillations of either BCG or mytomicin C).|proportion of complete response|Chemotherapy tolerance in a neoadjuvant setting using the intensified MVAC|Secondary cystectomy rate|Progression free survival (either infiltrative [≥ T2] or metastatic)|Overall bladder preservation rate|Overall survival","https://ClinicalTrials.gov/show/NCT01093066"
2763,"NCT00956930","Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery","Completed","No Results Available","Liver Cancer","Radiation: yttrium Y 90 glass microspheres|Drug: Doxorubicin","Northwestern University|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STU 12339|P30CA060553|STU# 00012339|CDR0000651416","August 8, 2009","August 2009","August 2016","September 7, 2016","September 2016","No Study Results Posted","null","August 2016","Time to progression in patients treated with TACE and Y90|Characterize the safety and toxicity profile of these regimens|Determine tumor response and the need for subsequent treatment in these patients|Characterize change in quality of life and performance status in these patients","https://ClinicalTrials.gov/show/NCT00956930"
2764,"NCT00002835","Combination Chemotherapy in Treating Patients With Lymphoma","Completed","No Results Available","Lymphoma","Biological: Bleomycin Sulfate (BLM)|Biological: Filgrastim (G-CSF)|Biological: Recombinant Interferon Alfa|Drug: Carmustine|Drug: Cisplatin (CDDP)|Drug: Cyclophosphamide|Drug: Cytarabine (ARA-C)|Drug: Etoposide (VP-16)|Drug: Idarubicin|Drug: Ifosfamide|Drug: Leucovorin Calcium|Drug: Melphalan|Drug: Methotrexate|Drug: Methylprednisolone|Drug: mitoxantrone hydrochloride (DHAD)|Drug: Vincristine Sulfate|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years to 59 Years   (Child, Adult)","Phase 3","116","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MDA DM95-121|P30CA016672|MDA-DM-95121|NCI-V96-1010|CDR0000065044","November 1, 1999","July 1995","February 2004","July 27, 2012","July 2012","No Study Results Posted","null","February 2004","Efficacy of Early Intensification vs. Alternating Triple Chemotherapy","https://ClinicalTrials.gov/show/NCT00002835"
2765,"NCT02542293","Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).","Recruiting","No Results Available","Non Small Cell Lung Carcinoma NSCLC","Biological: Durvalumab +Tremelimumab|Drug: Paclitaxel + carboplatin|Drug: Gemcitabine + cisplatin|Drug: Gemcitabine + carboplatin|Drug: Pemetrexed + cisplatin|Drug: Pemetrexed + carboplatin","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","960","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419AC00003","August 26, 2015","November 3, 2015","October 4, 2018","May 18, 2017","May 2017","No Study Results Posted","NEPTUNE","October 4, 2018","To assess the efficacy of durvalumab + tremelimumab combintion therapy compared to Standard of Care (SoC) in terms of Overall Survival (OS) in patients with Non-small-cell lung cancer (NSCLC)|To assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of OS in patients with PD-L1-negative NSCLC|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Progression-free survival (PFS).|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Objective response rate (ORR).|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Duration of response (DoR).|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Proportion of patients alive at 18 months (OS18).|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Proportion of patients alive and progression free at 12 months (APF12).|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Progression-free survival after subsequent anticancer therapy (PFS2).|To assess the PK paramenters of durvalumab + tremelimumab combination therapy by measuring the concentration in blood and non compartmental PK parameters such as peak concentration and trough|To investigate the immunogenicity of durvalumab and tremelimumab by measuring the presence of Anti-drug Antibodies (confirmatory results: positive and negative; titers)|To further assess the efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Proportion of patients alive at 12 months (OS12).","https://ClinicalTrials.gov/show/NCT02542293"
2766,"NCT00572169","UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Thalidomide|Drug: Dexamethasone|Drug: Adriamycin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 3","177","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","72023","December 11, 2007","November 2006","August 2017","October 11, 2016","October 2016","No Study Results Posted","null","August 2017","To find out if outcomes of participants in this study will be better when compared to individuals who participated in Total Therapy II, especially those with chromosome abnormalities.|To find out if outcomes and incidence of toxicities of participants in this study will be better when compared to individuals who participated in Total Therapy III.","https://ClinicalTrials.gov/show/NCT00572169"
2767,"NCT00411151","Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer","Completed","Has Results","Gastric Adenocarcinoma|Barrett Esophagus","Drug: Sunitinib-Malate","Johannes Gutenberg University Mainz|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","52","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GC-SU-2006|KKS 2005-015","December 11, 2006","December 2006","August 2009","January 19, 2011","January 2011","November 29, 2010","null","July 2009","Objective Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)|One-Year Survival|Adverse Events|Safety and Tolerability: Serious Adverse Events|Safety and Tolerability: Adverse Events in ≥10% of Patients","https://ClinicalTrials.gov/show/NCT00411151"
2768,"NCT01626664","KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)","Active, not recruiting","No Results Available","Adult T-cell Leukemia-Lymphoma","Biological: KW-0761|Drug: Pralatrexate|Drug: gemcitabine plus oxaliplatin|Drug: DHAP","Kyowa Hakko Kirin Pharma, Inc.|Kyowa Kirin Pharmaceutical Development, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PROTOCOL 0761-009","June 19, 2012","June 2012","December 2017","January 26, 2017","January 2017","No Study Results Posted","null","August 2015","Overall Response Rate|progression free survival|overall survival|Quality of Life assessments","https://ClinicalTrials.gov/show/NCT01626664"
2769,"NCT01838538","Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy","Unknown status","No Results Available","Ovarian Cancer With Malignant Ascites","Drug: Bevacizumab|Drug: TC:paclitaxel + carboplatin","Chinese PLA General Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25396","April 19, 2013","June 2011","null","April 19, 2013","April 2013","No Study Results Posted","null","June 2013","objective response rate","https://ClinicalTrials.gov/show/NCT01838538"
2770,"NCT02265770","An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma","Recruiting","No Results Available","Childhood Ependymoma","Drug: 16 weeks of VEC + CDDP|Drug: VEC + HD-MTX|Drug: Chemotherapy + Valproate|Radiation: Conformal radiotherapy|Drug: VEC|Drug: Chemotherapy|Radiation: conformal radiotherapy +/- boost","Centre Leon Berard","All","up to 22 Years   (Child, Adult)","Phase 2|Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SIOP Ependymoma II (ET-13-002)|2013-002766-39|VHP358","September 29, 2014","April 2015","August 2026","August 18, 2016","August 2016","No Study Results Posted","SIOP-EP-II","June 2023","Gross Total Resection rate|Progression-Free Survival|Number of treatment responders|Number of participants undergoing a second-look surgery|Overall Survival|Quality of Survival|Evaluation of neuropsychological morbidity|Comparison of neuroendocrine morbidity|Number of participants with adverse events as a measure of safety and tolerability|Radiotherapy-free survival rate","https://ClinicalTrials.gov/show/NCT02265770"
2771,"NCT02788201","Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","Recruiting","No Results Available","Urothelial Carcinoma|Bladder Cancer|Urinary Bladder Neoplasms","Drug: 75 approved agents|Other: COXEN","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","20","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other","160121|16-C-0121","May 28, 2016","May 20, 2016","June 29, 2019","May 12, 2017","May 2, 2017","No Study Results Posted","null","June 29, 2017","Percentage of patients success assigned a treatment within 3 weeks|Time to disease progression|Objective Response Rate|average time that patients survive after COXEN intervention|Summary of Adverse events","https://ClinicalTrials.gov/show/NCT02788201"
2772,"NCT00028665","Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","12 Years to 65 Years   (Child, Adult)","Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1499|P30CA043703|CWRU-030040|NCI-G01-2040","January 4, 2002","June 2000","null","June 9, 2010","June 2010","No Study Results Posted","null","March 2005","Total CD34 cells|T and B lymphocyte counts|Disease response|Engraftment","https://ClinicalTrials.gov/show/NCT00028665"
2773,"NCT00355199","Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab-HDS|Drug: Rituximab-CHOP","Gruppo Italiano Terapie Innovative nei Linfomi","All","18 Years to 65 Years   (Adult)","Phase 3","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EUDRACT: 2005-00700-14","July 20, 2006","May 2005","March 2013","March 10, 2017","March 2017","No Study Results Posted","null","March 2013","Event free survival|Complete Remission|Disease Free Survival|Overall Survival|Toxicity|Efficacy of R-HDS conditioning as salvage therapy in patients non-responders after four cycles of R-CHOP 14","https://ClinicalTrials.gov/show/NCT00355199"
2774,"NCT02640898","Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer","Recruiting","No Results Available","Gastric Cancer","Radiation: docetaxel-based chemoradiotherapy|Radiation: FU-based chemoradiotherapy","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","20 Years to 75 Years   (Adult, Senior)","","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Treatment","SGH201510","December 19, 2015","December 2015","December 2018","March 13, 2017","March 2017","No Study Results Posted","null","October 2018","overall survival rate|progression free survival rate","https://ClinicalTrials.gov/show/NCT02640898"
2775,"NCT00825669","Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection","Completed","No Results Available","Hepatocellular Carcinoma","Drug: TACE|Procedure: Laser ablation","Eastern Hepatobiliary Surgery Hospital","All","18 Years to 70 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EHBH-RCT-2008-015","January 16, 2009","December 2008","December 2010","March 30, 2016","March 2016","No Study Results Posted","null","December 2009","overall survival|the changes of the PVTT","https://ClinicalTrials.gov/show/NCT00825669"
2776,"NCT02938195","Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer","Recruiting","No Results Available","Esophageal Cancer|Chemoradiation|Surgery","Radiation: radiotherapy|Procedure: Surgery","Shanghai Chest Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCHEC001","October 15, 2016","January 2016","January 2018","October 18, 2016","October 2016","No Study Results Posted","null","January 2018","Percentage of patients completing adjuvant chemoradiotherapy and surgery|Percentage of R0 resection|Percentage of pathological complete response","https://ClinicalTrials.gov/show/NCT02938195"
2777,"NCT01265849","Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity","Recruiting","No Results Available","Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Soft Palate","Biological: LI plus CIZ|Other: Standard of Care (SOC)|Biological: LI + SOC","CEL-SCI Corporation|Teva Pharmaceutical Industries|Orient Europharma Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","880","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CS001P3|2010-019952-35","December 22, 2010","December 2010","December 2017","August 11, 2016","August 2016","No Study Results Posted","IT-MATTERS","December 2017","Overall Survival (OS) in LI + CIZ + SOC vs. SOC|Progression Free Survival (PFS) in LI + CIZ + SOC vs.SOC|Local regional control (LRC) in LI + CIZ + SOC vs. SOC|Quality of Life (QOL) in LI + CIZ + SOC vs. SOC","https://ClinicalTrials.gov/show/NCT01265849"
2778,"NCT01480817","Sorafenib VS TACE in HCC Patients With Portal Vein Invasion","Terminated","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib|Procedure: TACE for HCC with portal vein invasion","Seoul National University Hospital","All","18 Years to 79 Years   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STAP","November 20, 2011","June 2012","December 2015","April 28, 2016","December 2013","No Study Results Posted","null","December 2015","Time to Progression (Efficacy)|overall survival|objective tumor response rate|objective tumor control rate|progression-free survival|the adverse event rate and examine the toxicities|Change of perfusion parameter|Alpha feto protein (AFP) responsiveness","https://ClinicalTrials.gov/show/NCT01480817"
2779,"NCT02129699","Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","Recruiting","No Results Available","Lung Cancer Non-small Cell Stage IV","Drug: Denosumab|Other: None, standard chemotherapy only","European Thoracic Oncology Platform|European Organisation for Research and Treatment of Cancer - EORTC|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","1000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ETOP 5-12 / EORTC 08111|2013-003156-21|20080166|SNCTP000000954","April 30, 2014","January 6, 2015","September 2020","April 24, 2017","April 2017","No Study Results Posted","SPLENDOUR","September 2019","Overall survival|Progression-free survival (PFS) based on RECIST 1.1|Response based on RECIST 1.1|Toxicity profile of denosumab|Evaluation of potential predictive biomarkers for denosumab activity","https://ClinicalTrials.gov/show/NCT02129699"
2780,"NCT01349647","Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid","Completed","No Results Available","Lung Cancer","Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Biological: Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-095","May 5, 2011","May 2011","July 2015","January 4, 2016","January 2016","No Study Results Posted","null","July 2015","Confirm the safety of the pentavalent vaccine in this patient population|Confirm the immunogenicity of the pentavalent vaccine in this patient population|To measure the B-cell response at the cellular level|To evaluate the use of a circulating tumor cell (CTC) assay in this patient population.","https://ClinicalTrials.gov/show/NCT01349647"
2781,"NCT00967499","Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)","Completed","No Results Available","Postoperative Nausea and Vomiting","Drug: ondansetron|Drug: palonosetron","Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PALO-08-11","August 27, 2009","July 2009","April 2010","May 6, 2010","May 2010","No Study Results Posted","null","April 2010","Proportion of subjects with Complete Control (CC)|Proportion of subjects with a Complete Response (CR)|Proportion of subjects with no emesis|Proportion of subjects with no rescue medication","https://ClinicalTrials.gov/show/NCT00967499"
2782,"NCT02755311","Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatocellular Carcinoma","Procedure: liver resection|Procedure: transarterial chemoembolization|Drug: carboplatin|Drug: lipiodol|Drug: epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|Other: absorbable gelatin sponge particles","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","198","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HCC 006","April 3, 2016","March 2014","June 2016","April 27, 2016","April 2016","No Study Results Posted","null","June 2016","Overall survival|Mortality","https://ClinicalTrials.gov/show/NCT02755311"
2783,"NCT02089204","Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma","Unknown status","No Results Available","Nasopharyngeal Carcinoma","Radiation: FMISO-PET/CT|Radiation: FDG-PET/CT|Radiation: contrast-enhanced CT","Xuzhou Medical University|University of North Carolina, Chapel Hill","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","300","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","H201021","March 9, 2014","June 2010","December 2015","March 13, 2014","March 2014","No Study Results Posted","null","February 2014","local progression-free (LPF) survival rates|disease-free survival (DFS)|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02089204"
2784,"NCT00054067","Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix","Terminated","No Results Available","Cervical Cancer","Drug: cisplatin|Procedure: adjuvant therapy|Procedure: conventional surgery|Radiation: brachytherapy|Radiation: radiation therapy","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000269821|GOG-0201","February 5, 2003","February 2003","null","April 10, 2013","April 2013","No Study Results Posted","null","April 2005","","https://ClinicalTrials.gov/show/NCT00054067"
2785,"NCT00053872","Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: lomustine|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","University of Leicester|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 3","316","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000269521|SIOP-PNET-4|EU-20244|UKCCSG-CNS-2003-05","February 5, 2003","February 2003","null","June 23, 2014","February 2007","No Study Results Posted","null","null","Comparison of event-free survival at 3 years|Comparison of overall survival|Comparison of the pattern of relapse (i.e., local relapse [tumor bed and posterior fossa outside tumor bed])|Comparison of late sequelae, in terms of health status, quality of life, hearing loss, and endocrine deficiencies|Toxicity of neurosurgery","https://ClinicalTrials.gov/show/NCT00053872"
2786,"NCT00047112","Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer","Completed","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Federation Francophone de Cancerologie Digestive|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|European Organisation for Research and Treatment of Cancer - EORTC|UNICANCER|Societe Francaise de Radiotherapie Oncologique","All","up to 74 Years   (Child, Adult, Senior)","Phase 3","195","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000257600|FFCD-9901|EORTC-22001|EORTC-40001|FRE-FNCLCC-FFCD-9901|FRE-GERCOR-FFCD-9901|SFRO-FFCD-9901|EU-20215","October 3, 2002","May 2002","September 2010","May 27, 2016","May 2016","No Study Results Posted","null","September 2010","overal survival|recurrence free survival","https://ClinicalTrials.gov/show/NCT00047112"
2787,"NCT00041262","Combination Chemotherapy in Treating Patients With Esophageal Cancer","Unknown status","No Results Available","Esophageal Cancer","Drug: cisplatin|Drug: epirubicin hydrochloride|Drug: fluorouracil|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Medical Research Council|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","1300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","MRC-OE05|CDR0000069457|EU-20204","July 8, 2002","November 2004","null","August 9, 2013","March 2007","No Study Results Posted","null","null","Survival|Disease-free survival|Local control|Morbidity from surgery and chemotherapy|Quality of life","https://ClinicalTrials.gov/show/NCT00041262"
2788,"NCT00002858","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Radiation: radiation therapy","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065122|FRE-CPC014|EU-96009","November 1, 1999","March 1993","null","February 6, 2009","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002858"
2789,"NCT00002747","Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","European Institute of Oncology|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 3","240","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064678|CNR-012309","November 1, 1999","September 1992","null","September 19, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002747"
2790,"NCT01432314","Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)","Withdrawn","No Results Available","Hepatocellular Carcinoma","Other: Radiation therapy|Other: Transarterial chemoembolization","Asan Medical Center","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCLee3915","September 7, 2011","October 2011","June 2014","June 24, 2014","June 2014","No Study Results Posted","RTANDTACE","June 2014","Time to tumor progression|Progression-free survival of HCC patients|safety of RT followed by TACE|Overall survival of HCC patients|Time to TACE discontinuation|Best tumor response by modified RECIST (mRECIST) and RECIST criteria","https://ClinicalTrials.gov/show/NCT01432314"
2791,"NCT01628380","Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer","Recruiting","No Results Available","Ovarian Neoplasms","Procedure: Cytoreductive Surgery and HIPEC|Procedure: CRS alone","A.O. Ospedale Papa Giovanni XXIII|Clinical Organization for Strategies & Solutions (CLIOSS), former Nerviano Medical Sciences (http://www.nervianoms.com/en/)|Onlus Cancro Primo Aiuto (http://www.cpaonlus.it/)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CHORINE 2012-002616-22","June 22, 2012","June 2012","July 2018","August 27, 2014","August 2014","No Study Results Posted","CHORINE","June 2018","Disease free survival|postoperative morbidity and mortality|Time to Chemotherapy|Overall Survival","https://ClinicalTrials.gov/show/NCT01628380"
2792,"NCT00735345","Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma","Terminated","No Results Available","Esophageal Cancer","Drug: 5-FU|Drug: Cisplatin|Drug: Taxotere|Biological: Cetuximab|Radiation: Radiation during chemoradio-immunotherapy","Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme Corp.|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGMT_ECa|EudraCT Nr. 2008-001016-21","August 13, 2008","August 2008","December 2012","March 6, 2015","March 2015","No Study Results Posted","null","December 2012","Response rate|Percentage of complete remissions and resection rate|Occurrence of toxicities|Evaluation of Quality of Life","https://ClinicalTrials.gov/show/NCT00735345"
2793,"NCT00033644","Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus","Terminated","No Results Available","Sarcoma","Biological: sargramostim|Drug: cisplatin|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: mitomycin C","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069308|GOG-0087K","April 9, 2002","March 2002","null","April 10, 2013","September 2004","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00033644"
2794,"NCT00009880","Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Biological: filgrastim|Drug: cisplatin|Drug: fluorouracil|Drug: paclitaxel|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","RTOG-0113|CDR0000068420","February 2, 2001","April 2001","null","July 17, 2013","July 2004","No Study Results Posted","null","July 2006","","https://ClinicalTrials.gov/show/NCT00009880"
2795,"NCT00003777","Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer","Unknown status","No Results Available","Head and Neck Cancer","Drug: amifostine trihydrate|Drug: cisplatin|Drug: fluorouracil|Procedure: surgical procedure|Radiation: radiation therapy","University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Primary Purpose: Treatment","CDR0000066906|UPCC-6398|ALZA-98-023-ii|NCI-V99-1518","November 1, 1999","December 1998","null","February 6, 2009","November 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003777"
2796,"NCT00003032","High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: tamoxifen citrate","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Female","16 Years to 60 Years   (Child, Adult)","Phase 3","192","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","MA16|CAN-NCIC-MA16|CDR0000065634","November 1, 1999","April 1997","December 2008","November 7, 2010","November 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003032"
2797,"NCT00002884","Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus","Unknown status","No Results Available","Esophageal Cancer","Drug: chemotherapy|Drug: cisplatin|Drug: fluorouracil|Radiation: brachytherapy|Radiation: radiation therapy","Centre Hospitalier Lyon Sud|National Cancer Institute (NCI)","All","18 Years to 74 Years   (Adult, Senior)","Phase 3","326","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","FRE-CURIE-HDD|CDR0000065193|EU-96013","November 1, 1999","March 1996","null","August 6, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002884"
2798,"NCT00002631","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus","Completed","No Results Available","Esophageal Cancer","Drug: chemotherapy|Drug: cisplatin|Drug: fluorouracil|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group","All","18 Years and older   (Adult, Senior)","Phase 3","298","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","RTOG-9405|CDR0000064043|E-R9405|NCCTG-914051|INT-0123","November 1, 1999","June 1995","null","November 18, 2013","November 2013","No Study Results Posted","null","September 1999","","https://ClinicalTrials.gov/show/NCT00002631"
2799,"NCT00673361","Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma","Terminated","Has Results","Melanoma","Drug: Concurrent decrescendo biochemotherapy regimen|Drug: Low-dose Temozolomide plus Sorafenib","Duke University|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9361|SR05-888","May 4, 2008","March 2007","January 2009","January 11, 2016","December 2012","March 20, 2013","null","January 2009","Progression Free Survival (PFS)|Response Rate as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria","https://ClinicalTrials.gov/show/NCT00673361"
2800,"NCT03001596","Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC","Not yet recruiting","No Results Available","Esophageal Squamous Cell Carcinoma Stage cT3-4aN0-1M0","Procedure: Neoadjuvant Chemoradiotherapy|Procedure: Neoadjuvant Chemotherapy|Procedure: Minimally Invasive Esophagectomy","Shanghai Zhongshan Hospital|Fujian Medical University Union Hospital|Tianjin Medical University Cancer Institute and Hospital|Ruijin Hospital|Shanghai Chest Hospital|First Affiliated Hospital of Chongqing Medical University|People's Hospital Affiliated to Jiangsu University|Peace Hospital of Changzhi Medical College|First Affiliated Hospital of Wenzhou Medical Univeristy","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMISG1701","December 17, 2016","January 2017","December 2023","January 17, 2017","January 2017","No Study Results Posted","ESCCNCRTvNCT","December 2021","Overall survival(OS)|Progression-free survival(PFS)|Pathological response rate(pCR)|R0 resection rate|Positive lymph nodes' number|Treatment related complications|Quality of life(QOL)|Recurrence-free survival (RFS)","https://ClinicalTrials.gov/show/NCT03001596"
2801,"NCT01346267","Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy","Active, not recruiting","No Results Available","Central Nervous System Tumor, Pediatric|Chemotherapy-induced Nausea and Vomiting|Unspecified Childhood Solid Tumor, Protocol Specific","Procedure: Real Acupressure Band|Procedure: Placebo Acupressure Band","University of South Florida|National Cancer Institute (NCI)","All","4 Years to 18 Years   (Child, Adult)","Phase 3","187","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Supportive Care","SCUSF 1202|SCUSF-1202|Previously COG-ACCL1032|5U10CA081920","April 29, 2011","May 2011","May 2017","March 24, 2017","March 2017","No Study Results Posted","SCUSF1202","May 2017","Control of CIN during acute phase of chemotherapy|Control of CIN during delayed phase of chemotherapy|Comparison of CIN during acute and delayed phase of chemotherapy","https://ClinicalTrials.gov/show/NCT01346267"
2802,"NCT02516241","Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","Recruiting","No Results Available","Urothelial Cancer","Drug: MEDI4736|Drug: Tremelimumab|Drug: Cisplatin|Drug: Carboplatin|Drug: Gemcitabine","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","1005","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419BC00001","July 13, 2015","November 2, 2015","July 15, 2019","March 27, 2017","March 2017","No Study Results Posted","null","April 2, 2018","The efficacy of MEDI4736 + tremelimumab combination therapy compared to Standard of Care (SoC) in terms of Progression-Free Survival (PFS) and Overall Survival (OS) in patients with Urothelial Cancer (UC)|The efficacy of MEDI4736 monotherapy compared to SoC in terms of PFS and OS in patients with UC|Health related quality of life (HRQoL) in patients treated with MEDI4736 + tremelimumab or MEDI4736 compared to SoC using the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-BL) questionnaire|The pharmacokinetics (PK) - Peak concentration (Cmax) of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy|The pharmacokinetics (PK) - Trough concentration (Ctrough) of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy|The immunogenicity of MEDI4736 and tremelimumab combination therapy and MEDI4736 monotherapy|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Objective Response Rate (ORR)|The efficacy of MEDI4736 monotherapy compared to SoC in terms of ORR","https://ClinicalTrials.gov/show/NCT02516241"
2803,"NCT00003643","Combination Chemotherapy in Treating Men With Germ Cell Cancer","Unknown status","No Results Available","Extragonadal Germ Cell Tumor|Teratoma|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cisplatin|Drug: etoposide|Drug: paclitaxel","European Organisation for Research and Treatment of Cancer - EORTC","Male","16 Years to 50 Years   (Child, Adult)","Phase 2|Phase 3","498","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-30983","November 1, 1999","October 1998","null","March 5, 2012","March 2012","No Study Results Posted","null","null","Failure-free survival as measured by Logrank|Response to treatment as measured by normalized markers without residual viable cancer after CT scan or surgery|Overall survival as measured by Logrank at end of each course, at 6 weeks after completion of study treatment, every 6 months up to year 5, and then annually thereafter|Disease-free survival as measured by Logrank at end of each course, at 6 weeks after completion of study treatment, every 6 months up to year 5, and then annually thereafter|Toxicity as measured by NCI-CTC v2.0 at end of each course, at 6 weeks after completion of study treatment, every 6 months up to year 5, and then annually thereafter|Quality of life as measured by Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline, during treatment, and at years 1 and 2","https://ClinicalTrials.gov/show/NCT00003643"
2804,"NCT01539785","Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence","Recruiting","No Results Available","First Recurrence of Ovarian Cancer","Procedure: Secondary citoreduction|Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)","Catholic University of the Sacred Heart","Female","18 Years to 70 Years   (Adult, Senior)","","158","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","138/12","February 20, 2012","September 2012","null","August 21, 2014","August 2014","No Study Results Posted","HORSE","September 2018","Estimate of progression free interval (PFI) in the two trial arms.|Estimate of overall survival (OS)in the two trial arms.|Evaluation of the morbidity and mortality in the two trial arms.","https://ClinicalTrials.gov/show/NCT01539785"
2805,"NCT01216527","Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer","Active, not recruiting","No Results Available","Squamous Cell Esophageal Carcinoma","Procedure: Neo-adjuvant Chemoradiotherapy followed by Surgery|Procedure: surgery","Sun Yat-sen University|Cancer Hospital of Shantou University|Shanghai Chest Hospital|Fudan University|Zhejiang Cancer Hospital|Taizhou Hospital|The Second People's Hospital of Sichuan|Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","430","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Outcomes Assessor|Primary Purpose: Treatment","2007048","October 6, 2010","June 2007","December 2019","February 24, 2017","February 2017","No Study Results Posted","null","December 2019","Overall survival rate|toxicities of neo-adjuvant chemoradiotherapy|assessment in perioperation|efficacy of neo-adjuvant chemoradiotherapy|Disease free survival rate","https://ClinicalTrials.gov/show/NCT01216527"
2806,"NCT01680523","Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)","Recruiting","No Results Available","Cervical Cancer","Procedure: Radical hysterectomy|Radiation: Tailored adjuvant therapy|Radiation: Primary chemoradiation therapy","Asan Medical Center","Female","20 Years to 75 Years   (Adult, Senior)","","409","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KGOG 1029","September 4, 2012","September 2012","null","September 8, 2012","September 2012","No Study Results Posted","null","July 2020","5-year overall survival|5-year progression-free survival|Pattern of disease recurrence|Treatment-related toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT01680523"
2807,"NCT02864251","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy","Recruiting","No Results Available","Non-Small-Cell Lung Carcinoma","Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-722","August 9, 2016","October 31, 2016","December 31, 2023","May 10, 2017","May 2017","No Study Results Posted","CheckMate722","September 30, 2019","Progression free survival (PFS) in subjects with epidermal growth factor receptor (EGFR) mutation, T790M negative non-small cell lung carcinoma (NSCLC)|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS) rate","https://ClinicalTrials.gov/show/NCT02864251"
2808,"NCT00531960","A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Erlotinib|Drug: Bevacizumab|Drug: Standard platinum-based chemotherapy","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO20571","September 18, 2007","January 2008","January 2010","November 4, 2014","November 2014","November 4, 2014","null","January 2010","Percentage of Participants With Disease Progression or Death|PFS|Percentage of Participants Who Died|OS|Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST V 1.0|Percentage of Participants With Disease Control According to RECIST V 1.0","https://ClinicalTrials.gov/show/NCT00531960"
2809,"NCT01327521","Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma","Withdrawn","No Results Available","Carcinoma, Hepatocellular","Device: CyberKnife|Procedure: TACE|Drug: CT Contrast|Drug: doxorubicin|Drug: Epirubicin|Drug: 5-fluorouracil|Drug: Mitomycin C|Drug: Gemcitabine|Drug: Cisplatin|Device: SMANCS","Albert Koong|Accuray Incorporated|Stanford University","All","18 Years and older   (Adult, Senior)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HEP0030|ACCH001.0|SU-05052010-5862","March 30, 2011","February 2011","null","June 7, 2012","June 2012","No Study Results Posted","null","February 2014","Freedom from local progression at 6 months and 12 months|Progression-free survival|Overall survival|Serum AFP levels","https://ClinicalTrials.gov/show/NCT01327521"
2810,"NCT01691625","Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","Recruiting","No Results Available","Esophageal Carcinoma","Other: concurrent chemoradiotherapy plus DC-CIK immunotherapy|Other: Concurrent chemoradiation only","Capital Medical University","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","JR-01","September 17, 2012","September 2012","September 2019","February 3, 2017","February 2017","No Study Results Posted","null","September 2018","the quality of life|progression-free survival","https://ClinicalTrials.gov/show/NCT01691625"
2811,"NCT02453282","Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).","Active, not recruiting","No Results Available","Non-Small-Cell Lung Carcinoma NSCLC","Biological: MEDI4736 (Durvalumab)|Biological: MEDI4736 (Durvalumab)+Tremelimumab|Drug: Paclitaxel + Carboplatin|Drug: Gemcitabine + Cisplatin|Drug: Gemcitabine + Carboplatin|Drug: Pemetrexed + Cisplatin|Drug: Pemetrexed + Carboplatin|Biological: Tremelimumab","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","1118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419AC00001","May 20, 2015","July 21, 2015","June 14, 2018","May 1, 2017","April 2017","No Study Results Posted","MYSTIC","June 15, 2017","The efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Progression-Free Survival (PFS) and Overall Survival (OS) in patients with NSCLC|The efficacy of durvalumab therapy compared to SoC in terms of Overall Survival (OS) in patients with NSCLC|The efficacy of durvalumab monotherapy compared to SoC in terms of Objective Response Rate (ORR) or Progression-Free Survival (PFS)|The efficacy of durvalumab + tremelimumab combination therapy compared to SoC in terms of Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02453282"
2812,"NCT03164616","Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","Not yet recruiting","No Results Available","Non Small Cell Lung Cancer (NSCLC)","Drug: Durvalumab|Drug: Tremelimumab|Drug: Abraxane + carboplatin|Drug: Gemcitabine + cisplatin|Drug: Gemcitabine + carboplatin|Drug: Pemetrexed + carboplatin|Drug: Pemetrexed + cisplatin","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 3","801","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419MC00004","May 22, 2017","June 30, 2017","August 2, 2021","May 22, 2017","May 2017","No Study Results Posted","POSEIDON","July 31, 2019","Progression-free survival (PFS) using Blinded Independent Central Review (BICR) assessments according to RECIST 1.1|Progression-free survival (PFS) using BICR assessments according to RECIST 1.1|Overall survival (OS)|Objective response rate (ORR) using BICR assessments according to RECIST 1.1|Duration of response (DoR) using BICR assessments according to RECIST 1.1|Time from randomization to second progression (PFS2)|Proportion of patients alive and progression free at 12 months from randomization (APF12) using BICR assessments according to RECIST 1.1|Best objective response (BoR) using BICR assessments according to RECIST 1.1|The pharmacokinetics (PK) of durvalumab and tremelimumab as determined by concentration|The immunogenicity of durvalumab and tremelimumab as assessed by presence of anti-drug antibodies (ADAs)|Health-related QoL measured by EORTC QLQ-C30 v3|Disease-related symptoms measured by EORTC QLQ-LC13|Changes in WHO/ECOG performance status","https://ClinicalTrials.gov/show/NCT03164616"
2813,"NCT00696735","High-Dose Therapy Treatment in Patients With Follicular Lymphoma","Completed","No Results Available","Follicular Lymphoma","Procedure: chemotherapy|Procedure: high dose therapy and autologous stem cell transplantation","French Innovative Leukemia Organisation","All","18 Years to 60 Years   (Adult)","Phase 3","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOELAMS 064","June 11, 2008","June 1994","May 2006","October 23, 2008","September 2006","No Study Results Posted","null","May 2003","event free survival|safety","https://ClinicalTrials.gov/show/NCT00696735"
2814,"NCT01275664","Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer","Suspended","No Results Available","Nausea and Vomiting|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Cystadenocarcinoma|Stage II Ovarian Cancer|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer|Undifferentiated Ovarian Carcinoma","Procedure: Adjuvant Therapy|Drug: Aprepitant|Drug: Carboplatin|Drug: Cisplatin|Drug: Dexamethasone|Drug: Granisetron Transdermal Patch|Procedure: Management of Therapy Complications|Other: Questionnaire Administration","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Supportive Care","GOG-0272|NCI-2011-02660|CDR0000692516|U10CA101165","January 11, 2011","June 2011","null","May 2, 2017","May 2017","No Study Results Posted","null","May 2014","Frequency of complete control defined as no vomiting and no use of rescue medications (for nausea or emesis) based on the patient-completed symptom diary|Change in vomiting, nausea and total FLIE scores|Frequency and severity of adverse effects as assessed by the NCI CTCAE v 4.0|Mean and standard deviation of vomiting, nausea, and total FLIE scores|Percentages of patients with NIDL based on FLIE","https://ClinicalTrials.gov/show/NCT01275664"
2815,"NCT02716896","Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer","Enrolling by invitation","No Results Available","Muscle Invasive Bladder Cancer","Radiation: Radiation and chemotherapy|Procedure: Radical cystectomy","The University of Texas Health Science Center at San Antonio","All","18 Years to 89 Years   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HSC2015-620H","October 15, 2015","May 2016","December 2017","July 5, 2016","June 2016","No Study Results Posted","null","April 2017","Total number of participants adhere to the assigned treatment|Total number of participants withdraw from the study|Total number of participants completed the study|Change from baseline and year 1 in health related quality of life measures|Total number of participants who are able to keep their bladder within the time frame of the study|Total number of participants who remained progression-free within the time frame of the study|Change from baseline level to year 1 on genomic markers after chemoradiation","https://ClinicalTrials.gov/show/NCT02716896"
2816,"NCT02883543","First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: icotinib|Drug: Chemotherapy|Radiation: Radiotherapy","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RILI2016","August 8, 2016","June 2016","June 2019","August 29, 2016","August 2016","No Study Results Posted","null","June 2018","Progression-free survival|Incidence of radiation injure of the lungs|Overall survival|Tumor response after icotinib induction|Quality of life","https://ClinicalTrials.gov/show/NCT02883543"
2817,"NCT00567567","Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","Active, not recruiting","No Results Available","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Radiation: External Beam Radiation Therapy|Biological: Filgrastim|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacological Study|Drug: Thiotepa|Drug: Topotecan Hydrochloride|Drug: Vincristine Sulfate Liposome","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 3","665","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL0532|NCI-2009-01065|CDR0000576571|COG-ANBL0532|U10CA098543","December 4, 2007","November 2007","null","January 13, 2017","January 2017","No Study Results Posted","null","February 2015","Event-free survival rate|Incidence rate of local recurrence|Response after induction therapy|Duration of greater than or equal to grade 3 neutropenia|Duration of greater than or equal to grade 3 thrombocytopenia|EFS in patients 12-18 months, stage 4, MYCN nonamplified tumor/unfavorable histopathology/diploid DNA content/indeterminant histology/ploidy and patients > 547 days, stage 3, MYCN nonamplified tumor AND unfavorable histopathology/indeterminant histology|Enumeration of peripheral blood cluster of differentiation (CD)3, CD4, and CD8 cells|Neurologic symptom resolution in patients with primary tumors with intraspinal extension|OS in patients 12-18 months, stage 4, MYCN nonamplified tumor/unfavorable histopathology/diploid DNA content/indeterminant histology/ploidy and patients > 547 days, stage 3, MYCN nonamplified tumor AND unfavorable histopathology/indeterminant histology|Peak serum concentration of isotretinoin in patients enrolled on either A3973, ANBL0032, ANBL0931, ANBL0532 and future high risk studies|Pharmacogenetic variants in patients enrolled on either A3973, ANBL0032, ANBL0931, ANBL0532 and future high risk studies|Presence and function of T cells capable of recognizing neuroblastoma|Proportion of patients with neuroblastoma detected in bone marrow and peripheral blood using RT-PCR technique|Response rate|Surgical response|Topotecan systemic clearance|Type of radiotherapy complication|Type of surgical complication","https://ClinicalTrials.gov/show/NCT00567567"
2818,"NCT01418859","Clinical Study in Post-operation Treatment of Cervical Cancer","Unknown status","No Results Available","Cervical Cancer","","Health Science Center of Xi’an Jiaotong University","Female","20 Years to 70 Years   (Adult, Senior)","","183","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GCR-01","August 16, 2011","August 2011","December 2015","March 19, 2012","March 2012","No Study Results Posted","null","December 2012","","https://ClinicalTrials.gov/show/NCT01418859"
2819,"NCT02556762","Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer","Recruiting","No Results Available","Esophageal Cancer","Radiation: Radiotherapy with simultaneous modulated accelerated boost|Radiation: Standard dose radiotherapy|Drug: PF","Chuangzhen Chen|Shantou University Medical College","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","SUMC-EC-002","September 17, 2015","August 2015","August 2021","April 19, 2016","April 2016","No Study Results Posted","SUMC-EC-002","August 2021","Overall survival|Local-regional control|Distant metastasis-free survival|Disease-free survival|Acute and late toxicities using CTCAE v4.0|Quality of life as assessed with FACT-E|Quality of life as measured with EQ-5D|Biomarkers","https://ClinicalTrials.gov/show/NCT02556762"
2820,"NCT02371161","Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy","Recruiting","No Results Available","Non Hodgkin Lymphoma","Drug: R-DHAP/R-ICE","Fondazione Italiana Linfomi ONLUS","All","65 Years to 75 Years   (Adult, Senior)","Phase 2","135","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FIL_RecAnz","February 11, 2015","February 2014","February 2023","March 16, 2017","March 2017","No Study Results Posted","null","February 2018","Event free survival EFS|Treatment related mortality TRM|Complete Remission (CR) rate|Overall Survival (OS)|Adverse events incidence evaluation (grade III or IV)|Quality of Life (QoL)|Immunologic evaluation","https://ClinicalTrials.gov/show/NCT02371161"
2821,"NCT03126916","Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma","Not yet recruiting","No Results Available","Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|NMYC Gene Amplification|Recurrent Neuroblastoma","Biological: Aldesleukin|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Busulfan|Drug: Carboplatin|Drug: Cisplatin|Drug: Crizotinib|Drug: Cyclophosphamide|Drug: Dexrazoxane Hydrochloride|Biological: Dinutuximab|Drug: Doxorubicin Hydrochloride|Drug: Etoposide Phosphate|Radiation: External Beam Radiation Therapy|Radiation: Iobenguane I-131|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Other: Pharmacological Study|Biological: Sargramostim|Procedure: Therapeutic Conventional Surgery|Drug: Thiotepa|Drug: Topotecan Hydrochloride|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","365 Days to 30 Years   (Child, Adult)","Phase 3","774","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL1531|NCI-2016-01734|U10CA180886","April 17, 2017","August 2017","March 2022","April 24, 2017","April 2017","No Study Results Posted","null","March 2022","EFS rate|Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria version 4.0|Non-inferiority of 131I-MIBG plus BuMel and 131I-MIBG plus tandem transplant","https://ClinicalTrials.gov/show/NCT03126916"
2822,"NCT03057106","Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC","Recruiting","No Results Available","Lung Cancer Metastatic","Drug: Durvalumab|Drug: Tremelimumab|Drug: Platinum-Based Drug","Canadian Cancer Trials Group|AstraZeneca|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Health and Medical Research Council, Australia","All","18 Years and older   (Adult, Senior)","Phase 2","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BR34","February 15, 2017","February 15, 2017","December 2019","May 8, 2017","March 2017","No Study Results Posted","null","August 2019","Overall Survival|Progression-free Survival using RECIST 1.1|Objective Response Rate using RECIST 1.1 and iRECIST|Number and Severity of Adverse Events|Cost Effectiveness of Durvalumab and Tremelimumab concurrently with combination chemotherapy|Correlate the expression of correlative markers with outcomes and response","https://ClinicalTrials.gov/show/NCT03057106"
2823,"NCT00432315","Docetaxel in Non Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Carcinoma, Squamous Cell","Drug: Docetaxel + CDDP|Drug: docetaxel + CDDP","Sanofi","All","19 Years to 75 Years   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_AT1_203","February 6, 2007","May 2001","October 2009","September 13, 2010","September 2010","No Study Results Posted","null","October 2009","To assess the response rate to induction therapy with docetaxel in combination with CDDP|Resectability after induction therapy|Time to progression|Overall survival|Safety profile|Quality of life","https://ClinicalTrials.gov/show/NCT00432315"
2824,"NCT01989858","ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)","Terminated","No Results Available","Gastric Adenocarcinoma","Other: peri-operative cht|Other: post-operative CHT|Other: peri-operative cht + post-operative cht-rtx|Other: post-operative cht + post-operative cht-rtx","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Senior)","Phase 3","1180","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-021052-25","June 16, 2011","November 2010","December 2013","January 28, 2015","July 2010","No Study Results Posted","ITACA-S2","December 2013","Overall survival (OS)- Timing Study|Dose-intensity|Maximum toxicity grade|Disease Free Survival (DFS) - Timing Study|Relapse Free Survival (l-RFS)- RTX Study","https://ClinicalTrials.gov/show/NCT01989858"
2825,"NCT00460551","Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer","Terminated","Has Results","Non Small Cell Lung Cancer","Biological: Zalutumumab|Drug: Induction chemotherapy|Radiation: Radiotherapy","Genmab","All","18 Years and older   (Adult, Senior)","Phase 2","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEN204","April 12, 2007","April 2007","October 2008","December 5, 2011","December 2011","September 12, 2011","null","October 2008","Progression Free Survival Verified by Imaging Techniques.|Adverse Events","https://ClinicalTrials.gov/show/NCT00460551"
2826,"NCT02469493","The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting","Recruiting","No Results Available","Lung Neoplasms","Device: acupuncture (Huatuo)","Xidian University","All","18 Years to 75 Years   (Adult, Senior)","","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","2014CB543203","June 8, 2015","January 2015","null","June 18, 2015","June 2015","No Study Results Posted","null","July 2017","The scores of Rhodes Index of Nausea, Vomiting and Retching.|Content of 5-hiaa in urine|Heart Rate Variability|Tachygastria percentage|Dosage of antiemetic drugs","https://ClinicalTrials.gov/show/NCT02469493"
2827,"NCT02431403","ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: ESHAP-Imatinib","Pusan National University Hospital","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","94","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMACEL","April 21, 2015","February 2015","null","May 3, 2015","May 2015","No Study Results Posted","null","February 2020","Number of Adverse Events|Phase I/II Overall Response Rate (ORR)|Phase II Event-Free Survival|Phase II Overall Survival","https://ClinicalTrials.gov/show/NCT02431403"
2828,"NCT02063412","Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens","Withdrawn","No Results Available","Gastric Cancer","","Vivian Wing Yan Lee|Hoffmann-La Roche|Queen Elizabeth Hospital, Hong Kong|Princess Margaret Hospital, Hong Kong|Chinese University of Hong Kong","All","18 Years to 85 Years   (Adult, Senior)","","0","Other|Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","Roche-TR116583|TR116583VLKZ003","February 13, 2014","August 2013","April 2014","February 1, 2017","February 2017","No Study Results Posted","null","April 2014","Composite preparation, dispensing, and administration time","https://ClinicalTrials.gov/show/NCT02063412"
2829,"NCT01755585","Irradiation Modulates the Pharmacokinetics of Anticancer Drugs","Unknown status","No Results Available","Rectal Cancer|Cervical Cancer","","Far Eastern Memorial Hospital","All","18 Years to 80 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FEMH No. 099148-F","December 19, 2012","July 2011","null","January 19, 2014","January 2014","No Study Results Posted","null","December 2015","all cause mortality","https://ClinicalTrials.gov/show/NCT01755585"
2830,"NCT02701231","Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","Recruiting","No Results Available","Lung Neoplasms","Device: Low-frequency Rotating Magnetic Therapy System|Drug: Systemic anti-tumor therapy|Device: Sham Low-frequency Rotating Magnetic Therapy System","Chinese PLA General Hospital|Xijing Hospital|Shandong University of Traditional Chinese Medicine|Shandong Provincial Hospital","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S2015-093-01","January 20, 2016","November 2015","December 2020","March 8, 2016","March 2016","No Study Results Posted","null","December 2020","Functional Assessment of Cancer Therapy-Lung Questionaire（FACT-L）|Number of Participants With Adverse Events That Are Related to Treatment|Duration of response according to standard RECIST v1.1|Objective Response Rate (ORR)|Progression Free Survival（PFS）","https://ClinicalTrials.gov/show/NCT02701231"
2831,"NCT02951897","Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma","Recruiting","No Results Available","Lung Adenocarcinoma, Stage I|Diagnoses Diseases|Circulating Tumor Cells|Treatment","Procedure: lobectomy|Procedure: segmentecomy|Drug: chemotherapy（pemetrexed+CISPLATIN）|Procedure: Lymphadenectomy|Other: CanPatrolTM to detect CTCs","Third Military Medical University","All","45 Years to 70 Years   (Adult, Senior)","","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TMMU-DP-2016-4-25","October 25, 2016","April 2016","December 2019","October 31, 2016","October 2016","No Study Results Posted","CTCs detection","December 2019","Disease free survival","https://ClinicalTrials.gov/show/NCT02951897"
2832,"NCT01975766","Ketogenic Diet Phase 1 for Head & Neck Cancer","Terminated","No Results Available","Head and Neck Neoplasms","Dietary Supplement: Ketogenic diet","University of Iowa|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Nutricia North America|Holden Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","","14","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201309759|3P30CA086862","October 29, 2013","January 2014","November 2018","February 10, 2017","February 2017","No Study Results Posted","null","November 2016","Frequency of adverse events (safety)|Ketone levels|Blood glucose levels|Oxidative stress parameters|Progression Free Survival (months)","https://ClinicalTrials.gov/show/NCT01975766"
2833,"NCT00002524","Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","Completed","No Results Available","Lymphoma","Biological: Bleomycin Sulfate|Biological: Filgrastim|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin Hydrochloride (DOX)|Drug: Etoposide|Drug: Fluorouracil|Drug: Ifosfamide|Drug: Leucovorin calcium|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Pentamidine|Drug: Prednisone|Drug: Trimethoprim-Sulfamethoxazole|Drug: Vincristine Sulfate|Drug: Zidovudine (AZT)|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM93-058|P30CA016672|MDA-DM-93058|NCI-T93-0088D|CDR0000078316","November 1, 1999","June 1993","October 2005","July 27, 2012","July 2012","No Study Results Posted","null","October 2005","Number of Patients with Clinical Response","https://ClinicalTrials.gov/show/NCT00002524"
2834,"NCT02249013","Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer","Enrolling by invitation","No Results Available","Ovarian Cancer","Procedure: Cytoreductive Surgery (CRS)|Procedure: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Drug: combination of carboplatin and paclitaxel","Professor Fernando Figueira Integral Medicine Institute|Hospital de Câncer de Pernambuco|AC Camargo Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","U1111-1158-0472|18388113.4.0000.5201","September 22, 2014","February 2015","December 2017","August 22, 2016","August 2016","No Study Results Posted","null","December 2017","Progression-free survival|Postoperative 30-day mortality rate|Postoperative complication rates|Assessment of quality of life (QLQ-C30/EORTC)|Overall survival","https://ClinicalTrials.gov/show/NCT02249013"
2835,"NCT02805530","Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Synchronous Neoplasms","Other: First line systemic treatment|Other: Radical treatment|Radiation: radiation therapy|Other: Chemoradiotherapy","Instituto Nacional de Cancerologia de Mexico","All","18 Years and older   (Adult, Senior)","","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","015/023/ICI","May 23, 2016","June 2015","December 2017","March 1, 2017","March 2017","No Study Results Posted","null","July 2017","Overall survival","https://ClinicalTrials.gov/show/NCT02805530"
2836,"NCT01305772","Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN","Terminated","Has Results","Squamous Cell Carcinoma of the Head and Neck","Drug: Panitumumab|Procedure: Surgery|Procedure: Radiation Therapy","Neal Ready|Amgen|Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00023859|20080645","February 14, 2011","January 2011","May 2012","August 19, 2014","August 2014","September 10, 2013","TOP0901","March 2012","Change in Tumor (Primary Tumor and Lymph Node) Response and Progression Between Pre- and Post- Panitumumab Therapy|Nine (9) Month Progression Free Survival (PFS)|Nine (9) Month Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01305772"
2837,"NCT02644408","Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma","Recruiting","No Results Available","Stage III Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma","Drug: Megestrol（Yining）|Radiation: radiotherapy|Other: chemotherapy","The First Affiliated Hospital of Henan University of Science and Technology","All","45 Years to 75 Years   (Adult, Senior)","Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","megestrol and cancer","November 27, 2015","October 2014","December 2020","July 2, 2016","July 2016","No Study Results Posted","null","December 2017","overall survival, OS|Number of participants with gastrointestinal reaction|body weight change|ECOG score","https://ClinicalTrials.gov/show/NCT02644408"
2838,"NCT00938145","3 Tesla MRI in Patients With Bladder Cancer","Unknown status","No Results Available","Bladder Cancer","Procedure: Specimen Ultra-High field MRI|Drug: chemotherapy|Procedure: Cystectomy and Lymphadenectomy","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","OSU-08063|NCI-2012-00937","July 10, 2009","May 2009","null","September 25, 2014","September 2014","No Study Results Posted","null","May 2016","Agreement in tumor staging between pathology and 3 Tesla MRI|Agreement in lymph node staging between pathology and 3 Tesla MRI","https://ClinicalTrials.gov/show/NCT00938145"
2839,"NCT03032614","Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation","Drug: Carboplatin|Drug: Eribulin|Drug: Veliparib","The University of Texas Health Science Center at San Antonio","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CTMS#16-0133","January 23, 2017","May 31, 2017","April 30, 2020","April 22, 2017","April 2017","No Study Results Posted","null","March 31, 2019","Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03)|Tumor response assessed using RECIST 1.1 guidelines","https://ClinicalTrials.gov/show/NCT03032614"
2840,"NCT01703910","Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","Completed","No Results Available","Adenocarcinoma of Colon|Adenocarcinoma of Rectum|Metastatic Disease","Drug: Arm A chemotherapy|Drug: arm B chemotherapy","Centro Nacional de Investigaciones Oncologicas CARLOS III|Hospital Universitario de Fuenlabrada|Grupo Hospital de Madrid|Apices Soluciones S.L.","All","18 Years to 76 Years   (Adult, Senior)","Phase 2","29","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CNIO-GI-01-2012","October 8, 2012","November 2012","December 2014","October 8, 2015","October 2015","No Study Results Posted","null","November 2012","Overall survival|gene expression profiles","https://ClinicalTrials.gov/show/NCT01703910"
2841,"NCT00734877","UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: M-VTD-PACE|Drug: TT3-LITE Regimen (L-TT3)","University of Arkansas|Millennium Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","103668","August 12, 2008","July 2008","September 2017","October 6, 2016","October 2016","No Study Results Posted","TT4B","September 2017","Progression-free survival rate","https://ClinicalTrials.gov/show/NCT00734877"
2842,"NCT02759250","A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)","Active, not recruiting","No Results Available","Cancer","Drug: ARGX-110","arGEN-X BVBA","All","18 Years and older   (Adult, Senior)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ARGX-110-1401","April 22, 2016","February 2015","July 2017","April 20, 2017","April 2017","No Study Results Posted","null","April 2017","Incidence and grading of AEs|Pharmacokinetic profile of ARGX110 by Cmax|Pharmacokinetic profile of ARGX110 by AUC|Biomarkers CD70 immunohistochemistry (IHC)","https://ClinicalTrials.gov/show/NCT02759250"
2843,"NCT00820755","Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)","Completed","Has Results","Non-Small Cell Lung Cancer (NSCLC)","Drug: Cetuximab plus Platinum-based Doublet Chemotherapy|Drug: Cetuximab 500 mg/m^2|Drug: Cetuximab 250 mg/m^2","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","583","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62240-506","January 9, 2009","January 2009","June 2013","April 4, 2014","April 2014","July 1, 2013","NEXT","December 2011","Overall Survival (OS) Time|Percentage of Participants With 1-year Overall Survival|Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)|Time to Treatment Failure|Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)|Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase|Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period|Percentage of Participants With Disease Control in the Combination Therapy Phase|Percentage of Participants With Disease Control for the Whole Study Period","https://ClinicalTrials.gov/show/NCT00820755"
2844,"NCT00312728","A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","Completed","Has Results","Non-Small Cell Lung Cancer|Brain Neoplasms","Drug: bevacizumab|Drug: First-Line Chemotherapy Agents|Drug: Second-Line Chemotherapy Agents","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","115","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVF3752g","April 7, 2006","March 2006","null","August 3, 2011","August 2011","March 18, 2011","null","June 2009","Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage|Overall Survival (OS) in First-line Setting|Number of Participants With Overall Survival (OS) in First-line Setting [1−Year or More Survival]|OS in First-line and Second-line Settings|Number of Participants With OS in First-line and Second-line Settings [1−Year or More Survival]|Number of Participants With Selected Adverse Events","https://ClinicalTrials.gov/show/NCT00312728"
2845,"NCT00058370","Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: cisplatin|Drug: lomustine|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: iodine I 131 monoclonal antibody 3F8|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","3 Years and older   (Child, Adult, Senior)","","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","02-088|MSKCC-02088","April 7, 2003","February 2003","February 2018","March 13, 2017","March 2017","No Study Results Posted","null","February 2018","Feasibility|Progression-free survival|Morbidity","https://ClinicalTrials.gov/show/NCT00058370"
2846,"NCT00005583","Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer","Completed","No Results Available","Endometrial Cancer","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Radiation: radiation therapy","Nordic Society for Gynaecologic Oncology|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","400","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","NSGO-EC9501|CDR0000067646|EORTC-55991","May 2, 2000","January 2000","July 2010","August 1, 2013","November 2006","No Study Results Posted","null","null","Progression-free survival|Relapse-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00005583"
2847,"NCT00003364","Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Radiation: radiation therapy","London Lung Cancer Group|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","Phase 3","398","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066349|LLCG-TR8SCLC|EU-98011","November 1, 1999","January 1993","August 2006","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003364"
2848,"NCT00002823","Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: vinblastine sulfate|Drug: vindesine|Drug: vinorelbine tartrate|Radiation: radiation therapy","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","3300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065002|FRE-IALT|EU-96010","November 1, 1999","February 1995","null","March 26, 2013","April 2011","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00002823"
2849,"NCT03064854","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: PDR001|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed|Drug: Carboplatin|Drug: Paclitaxel","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CPDR001C2101","February 6, 2017","May 8, 2017","October 23, 2019","April 21, 2017","April 2017","No Study Results Posted","null","October 23, 2019","Dose Limiting Toxicities (DLTs) during the first 6 weeks of therapy|Overall response rate (ORR)|Progression Free Survival (PFS) per Investigator|Disease Control Rate (DCR) per Investigator|Duration of Response (DOR) per Investigator|Time to Response (TTR) per Investigator|Overall survival (OS)|Peak Serum Concentration (Cmax) (PDR001)|Peak Plasma Concentration (Cmax) (chemotherapy)|Antidrug antibodies (ADA) prevalence at baseline|ADA incidence on treatment|Trough Serum Concentration (Cmin) (PDR001)|Trough PlasmaConcentration (Cmin) (chemotherapy)","https://ClinicalTrials.gov/show/NCT03064854"
2850,"NCT01466257","Biomarkers in Patients With Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: cisplatin|Genetic: DNA analysis|Genetic: gene expression analysis|Genetic: mutation analysis|Other: laboratory biomarker analysis","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","70","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000715520|ECOG-E5397T2","November 2, 2011","November 21, 2011","January 1, 2012","May 17, 2017","May 2017","No Study Results Posted","null","January 1, 2012","Mutation rates of HRAS and PIK3CA","https://ClinicalTrials.gov/show/NCT01466257"
2851,"NCT00343408","AZD2171 and Standard Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer or Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Lung Cancer","Drug: cediranib maleate|Drug: cisplatin|Drug: fluorouracil|Drug: gemcitabine hydrochloride|Drug: leucovorin calcium|Drug: oxaliplatin","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","I175|CAN-NCIC-IND175|CDR0000481443","June 22, 2006","August 2005","September 2008","November 7, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00343408"
2852,"NCT00281905","Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: methotrexate|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 3 Years   (Child)","Phase 2","50","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000454575|CCLG-CNS-9204|EU-20574|CCLG-CNS-1992-04","January 24, 2006","June 1992","null","September 19, 2013","June 2007","No Study Results Posted","null","null","Response rate|Event-free survival|Local recurrence or occurrence of CNS metastases|Quality of survival|Tolerance|Long-term toxicity|Proportion of patients requiring radiotherapy|Prognosis of children who receive both chemotherapy and radiotherapy|Nature and behavior of brain tumors","https://ClinicalTrials.gov/show/NCT00281905"
2853,"NCT00117572","Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)","Unknown status","No Results Available","Cancer of the Pharynx|Cancer of the Larynx|Cancer of the Nasal Cavity|Paranasal Sinus Neoplasms|Cancer of the Oral Cavity","Drug: docetaxel|Drug: cisplatin|Drug: hydroxyurea|Drug: fluorouracil|Procedure: chemotherapy|Procedure: radiotherapy","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13362B","June 30, 2005","November 2004","August 2013","October 9, 2012","October 2012","No Study Results Posted","null","May 2009","Overall survival|Distant failure-free survival (DFFS)|failure pattern|progression free survival|quality of life (QOL)","https://ClinicalTrials.gov/show/NCT00117572"
2854,"NCT00077389","Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma","Unknown status","No Results Available","Liver Cancer","Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","University of Leicester|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 2","57","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000350221|SIOP-SIOPEL-4|EU-20336|CCLG-LT-2004-09","February 10, 2004","January 2004","null","June 23, 2014","December 2009","No Study Results Posted","null","null","Rate of complete remission after completion of study therapy|Complete resection rate|Response rate to preoperative chemotherapy|Rate of grade 2 cardiac and renal, grade 3 otological, and grade 4 nonhematological toxicity as assessed during and after completion of study therapy|Overall survival|Event-free survival","https://ClinicalTrials.gov/show/NCT00077389"
2855,"NCT00003701","Combination Chemotherapy in Treating Patients With Bladder Cancer","Completed","No Results Available","Bladder Cancer|Urethral Cancer","Drug: carboplatin|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: paclitaxel|Drug: vinblastine sulfate","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","490","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066808|E-1897","November 1, 1999","March 1999","null","November 2, 2010","February 2009","No Study Results Posted","null","August 2001","","https://ClinicalTrials.gov/show/NCT00003701"
2856,"NCT00003214","Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: in vitro sensitivity-directed chemotherapy|Drug: paclitaxel","Swiss Group for Clinical Cancer Research","Female","up to 80 Years   (Child, Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SAKK 45/94|SWS-SAKK-45/94|EU-97036","November 1, 1999","July 1996","April 2000","May 14, 2012","May 2012","No Study Results Posted","null","April 2000","","https://ClinicalTrials.gov/show/NCT00003214"
2857,"NCT00002919","Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer","Completed","No Results Available","Bladder Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vinblastine sulfate|Procedure: conventional surgery","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","96-066|CDR0000065305|NCI-H97-1118","November 1, 1999","November 1996","January 2003","July 1, 2013","July 2013","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00002919"
2858,"NCT00004192","Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma|Neutropenia","Biological: filgrastim|Biological: pegfilgrastim|Drug: cisplatin|Drug: cytarabine|Drug: etoposide|Drug: methylprednisolone","University of Nebraska|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","272-99|P30CA036727|UNMC-272-99|AMGEN-990117|CWRU-AMGN-1499|UCLA-9906080|NCI-G99-1648","January 21, 2000","May 2000","March 2001","June 23, 2010","June 2010","No Study Results Posted","null","February 2001","","https://ClinicalTrials.gov/show/NCT00004192"
2859,"NCT00003400","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer","Completed","No Results Available","Prostate Cancer","Biological: filgrastim|Drug: carmustine|Drug: cisplatin|Drug: melphalan|Drug: vinorelbine tartrate|Procedure: peripheral blood stem cell transplantation","University of Maryland","Male","18 Years to 70 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Primary Purpose: Treatment","MSGCC-9748|CDR0000066404|NCI-V98-1436","November 1, 1999","September 1998","March 2000","March 28, 2017","March 2017","No Study Results Posted","null","March 2000","","https://ClinicalTrials.gov/show/NCT00003400"
2860,"NCT00148395","Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.","Completed","No Results Available","Non-Small-Cell Lung Carcinoma","Drug: Gemcitabine|Drug: Navelbine|Drug: Carboplatin|Drug: Cisplatin|Drug: Mitomycin|Drug: Ifosfamide","Aktion Bronchialkarzinom e.V.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSCLC 06/2001","September 7, 2005","June 2002","April 2008","April 21, 2008","April 2008","No Study Results Posted","null","null","Overall survival|Event-free survival|Quality of live","https://ClinicalTrials.gov/show/NCT00148395"
2861,"NCT00028756","Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium","Completed","No Results Available","Stage III Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder","Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: vinblastine sulfate|Drug: methotrexate|Drug: cisplatin|Biological: filgrastim","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)|Groupe D'Etude des Tumeurs Uro-Genitales|Institute of Cancer Research, United Kingdom|NCIC Clinical Trials Group|Arbeitsgemeinschaft Urologische Onkologie","All","Child, Adult, Senior","Phase 3","285","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC 30994|EORTC-30994|CDR0000069130|CAN-NCIC-EORTC-30994|ACOSOG-EORTC-30994|NCRI-BLADDER-EORTC-30994|UKCCCR-EORTC-30994|FNCLCC-GETUG-EORTC-30994|N02CM62212|2005-003741-13","January 4, 2002","October 2001","July 2014","August 1, 2016","August 2016","No Study Results Posted","null","January 2014","Duration of survival|Duration of progression-free survival","https://ClinicalTrials.gov/show/NCT00028756"
2862,"NCT00436774","Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01","Unknown status","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Gastrointestinal Complications|Infertility|Long-term Effects Secondary to Cancer Therapy in Children|Neurotoxicity|Ovarian Cancer|Pulmonary Complications|Sexual Dysfunction|Urinary Complications","Procedure: assessment of therapy complications|Procedure: quality-of-life assessment","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","5 Years and older   (Child, Adult, Senior)","","60","Other","Observational","","CCLG-GC-2006-06|CDR0000531140|EU-20642","February 15, 2007","June 2006","null","August 9, 2013","June 2009","No Study Results Posted","null","September 2010","Ototoxicity as measured by audiogram and Health Utilities Index in patients previously treated with cisplatin or carboplatin|Nephrotoxicity as measured by serum magnesium, calcium, and creatinine and glomerular filtration rate in patients previously treated with cisplatin or carboplatin|Myelodysplasia and second malignancies in patients previously treated with etoposide|Pulmonary toxicity as measured by lung function test and respiratory symptom questionnaire in patients previously treated with bleomycin|Bladder and bowel dysfunction, sexual function, and fertility as measured by patient-completed questionnaires and lower limb and neurological dysfunction as measured by clinician-completed questionnaires in patients with pelvic or sacrococcygeal tumors|Quality of life (QOL) as measured by pediatric cancer quality-of-life inventory or Short Form 36 questionnaires","https://ClinicalTrials.gov/show/NCT00436774"
2863,"NCT00983541","Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma","Terminated","Has Results","Cancer","Drug: Fluorouracil (5-FU)|Radiation: Brachytherapy or SBRT (Stereotactic body radiation therapy)|Drug: Gemcitabine","University of Utah","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCI35306","September 22, 2009","September 2009","March 2012","July 23, 2015","July 2015","June 21, 2013","null","March 2012","Number of Participants Experiencing Toxicity Treated With Gemcitabine Every Two Weeks & 5-FU Given Concurrently With External Beam Radiation Therapy , Followed by Brachytherapy or SBRT Boost.|Evaluate Overall Survival Ratefollowing Gemcitabine and 5-FU With Radiation Therapy in Patients With HCC|Evaluate the Rate at Which Patients With Unresectable Extrahepatic Cholangiocarcinoma Become Resectable Following Gemcitabine and Radiation Therapy.|Evaluate Progression Free Survival Rate Following Gemcitabine and 5-FU With Radiation Therapy in Patients With HCC|Evaluate Tumor Response Rate Following Gemcitabine and 5-FU With Radiation Therapy in Patients With HCC|Evaluate Local Control Rate Following Gemcitabine and 5-FU With Radiation Therapy in Patients With HCC|Evaluate Rate of Distant Mets Following Gemcitabine and 5-FU With Radiation Therapy in Patients With HCC","https://ClinicalTrials.gov/show/NCT00983541"
2864,"NCT02816931","Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations","Recruiting","No Results Available","Tuberculosis, Multidrug Resistant","","Karolinska Institutet|Fudan University|University Medical Center Groningen","All","18 Years and older   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","540-2013-8797|D0879701","April 14, 2016","March 2016","June 2020","June 24, 2016","June 2016","No Study Results Posted","TDM-MDR-TB","June 2018","Sputum culture conversion|Time to sputum culture positivity (TTP)|Change in TB score 2 during the first 3 months of treatment|Changes in drug resistance|Time to sputum culture conversion|Length of treatment|Treatment outcome","https://ClinicalTrials.gov/show/NCT02816931"
2865,"NCT02005159","Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae","Completed","No Results Available","Bacteremia by Enterobacteriaceae","Other: Microbiological studies","Fundación Pública Andaluza Progreso y Salud|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","All","17 Years and older   (Child, Adult, Senior)","","1064","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FPS-ANT-2011-01","November 14, 2013","March 2011","December 2014","August 4, 2015","August 2015","No Study Results Posted","BACTERIEMIA","December 2014","Correlation between the MIC of different antibiotics and the prognosis in patients with bacteremia.|Correlation between CLSI and EUCAST cut-off points, FC/FD cut-off points with clinical prognosis and of the microbiological response in patients with bacteremia.|Correlation between piperacillin/tazobactam serum concentrations and clinical prognosis","https://ClinicalTrials.gov/show/NCT02005159"
2866,"NCT01836458","A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection","Completed","Has Results","Malaria","Drug: KAE609","Novartis Pharmaceuticals|Novartis","All","20 Years to 60 Years   (Adult)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CKAE609A2201","April 17, 2013","January 2014","March 2015","September 14, 2016","September 2016","March 8, 2016","null","March 2015","Minimum Inhibitory Concentration (MIC) of KAE609|Median Time to Parasite Clearance|Median Time to Fever Clearance|Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 & Day 42","https://ClinicalTrials.gov/show/NCT01836458"
2867,"NCT00190528","A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer","Terminated","No Results Available","Cervical Neoplasms","Drug: neoadjuvant chemotherapy + radical hysterectomy|Procedure: radical hysterectomy","Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group","Female","20 Years to 70 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","JCOG0102|C000000194","September 13, 2005","February 2002","February 2009","September 20, 2016","September 2016","No Study Results Posted","null","December 2004","overall survival|progression-free survival|complication of surgery|completeness of radical hysterectomy|omission of postsurgical irradiation|completeness of postsurgical irradiation|response rate|adverse events","https://ClinicalTrials.gov/show/NCT00190528"
2868,"NCT03161522","Chemoradiation +/- Surgery Versus Systemic Therapy for Esophageal or Gastric Cancer With Oligometastases","Not yet recruiting","No Results Available","Malignant Neoplasms of Digestive Organs|Esophageal Cancer|Gastric Cancer","Drug: Chemotherapy|Radiation: Radiation|Procedure: Surgery|Behavioral: Symptom Questionnaires","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0972","May 18, 2017","July 2017","July 2023","May 18, 2017","May 2017","No Study Results Posted","null","July 2023","Overall Survival (OS)|Progression-Free Survival (PFS)|Quality of Life measured by the MDASI|Toxicity assessed by CTCAE v4 criteria","https://ClinicalTrials.gov/show/NCT03161522"
2869,"NCT02772107","Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer","Recruiting","No Results Available","Extensive-stage Small Cell Lung Cancer","Drug: Temozolomide|Drug: first-line chemotherapy|Radiation: Prophylactic cranial irradiation|Radiation: thoracic radiotherapy","Chinese PLA General Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","132","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","301PLAGH","May 7, 2016","December 2015","January 2018","May 15, 2016","May 2016","No Study Results Posted","null","June 2017","PFS of the maintenance therapy|PFS|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02772107"
2870,"NCT00629863","Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer","Completed","No Results Available","Esophageal Cancer|Gastric Cancer","Drug: cisplatin|Drug: fluorouracil|Other: questionnaire administration|Procedure: diagnostic endoscopic procedure|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Procedure: therapeutic conventional surgery|Procedure: therapeutic endoscopic surgery|Procedure: ultrasound imaging|Radiation: radiation therapy|Radiation: radioisotope therapy","North Wales Organisation for Randomised Trials in Health|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","700","Other","Interventional","Allocation: Randomized|Primary Purpose: Diagnostic","NWORTH-COGNATE|CDR0000584174|ISRCTN01444215|NWORTH-04/MRE10/10","March 5, 2008","September 2004","January 2010","August 6, 2013","January 2009","No Study Results Posted","null","September 2009","Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized|Complete resection rate|Quality of survival in the different treatments selected on the basis of staging at 1, 3, 6, 12, 18, and 24 months by EuroQol EQ-5D, EORTC core module QLQ-C30, EORTC esophageal module QLQ-OES24, and EORTC gastric module QLQ-STO22|Health resource utilization, including the selection of treatments and subsequent use of health service resources","https://ClinicalTrials.gov/show/NCT00629863"
2871,"NCT00470223","Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma","Terminated","No Results Available","Sarcoma","Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: methotrexate|Drug: zoledronic acid|Procedure: conventional surgery","UNICANCER|Novartis|Chugai Pharmaceutical|National Cancer Institute, France|SFCE|Ligue contre le cancer, France","All","5 Years to 50 Years   (Child, Adult)","Phase 3","318","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Sarcome 09/0603|UNICANCER-SARCOME-09-0603|2006-003377-27","May 3, 2007","March 2007","April 2025","June 21, 2016","June 2016","No Study Results Posted","OS2006","December 2015","Event-free survival|Overall survival|Percentage of good responders|Short term and long term toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT00470223"
2872,"NCT00075699","Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma","Completed","No Results Available","Malignant Mesothelioma","Drug: cisplatin|Drug: mitomycin C|Drug: vincristine sulfate|Drug: vinorelbine tartrate|Procedure: pain therapy|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Medical Research Council|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","840","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","BTS-MRC-MS01|CDR0000347461|ISRCTN54469112|EU-20349","January 9, 2004","September 2003","null","August 6, 2013","June 2008","No Study Results Posted","null","null","Overall survival|Palliation of chest pain, breathlessness, malaise (e.g., feeling weak, tiredness, anorexia), and sweating attacks|Performance status as measured by WHO grade|Analgesic usage|Toxicity as measured by the NCIC CTC|Quality of life as assessed by the European Organization for Research and Treatment of Cancer|Tumor response as measured by the RECIST criteria|Progression-free survival as measured by CT scan","https://ClinicalTrials.gov/show/NCT00075699"
2873,"NCT00003862","Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer","Completed","No Results Available","Gastric Cancer","Drug: cisplatin|Drug: fluorouracil|Drug: leucovorin calcium|Drug: paclitaxel|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","RTOG-9904|CDR0000067026|RTOG-DEV-1046","November 1, 1999","November 1999","null","July 17, 2013","September 2003","No Study Results Posted","null","November 2004","","https://ClinicalTrials.gov/show/NCT00003862"
2874,"NCT00002887","Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: etoposide|Drug: hydroxyurea|Drug: vinblastine sulfate|Drug: vindesine|Drug: vinorelbine tartrate|Procedure: drug resistance inhibition treatment","Ottawa Regional Cancer Centre|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Primary Purpose: Treatment","CDR0000065207|CAN-OTT-9501|NCI-V96-1099","November 1, 1999","July 1995","null","September 16, 2013","October 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002887"
2875,"NCT00683319","Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors|Cognitive/Functional Effects|Long-term Effects Secondary to Cancer Therapy in Children|Ototoxicity","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: methotrexate|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: cognitive assessment|Procedure: magnetic resonance imaging|Procedure: magnetic resonance spectroscopic imaging|Procedure: quality-of-life assessment","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 3","50","Other","Observational","","CDR0000590666|CCLG-CNS-2007-09|EU-20835","May 21, 2008","April 2008","null","September 19, 2013","June 2009","No Study Results Posted","null","March 2034","Overall survival|Event-free survival|Response to chemotherapy, if there is residual disease|Requirement for radiotherapy (i.e., residual disease at the completion of chemotherapy, progressive disease during chemotherapy, or recurrent disease during or after completion chemotherapy)|Late effects of treatment (i.e., ototoxicity and nephrotoxicity at the completion of chemotherapy and neurocognitive outcomes at 5, 7, 11, and 16 years of age)","https://ClinicalTrials.gov/show/NCT00683319"
2876,"NCT00365755","Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CCLG-ENSG-5|CDR0000454576|EU-20592|CCLG-NB-1990-11","August 16, 2006","null","March 2008","August 1, 2013","March 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00365755"
2877,"NCT00303810","Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide phosphate|Drug: high-dose chemotherapy|Drug: lomustine|Drug: methotrexate|Drug: thiotepa|Drug: vincristine sulfate|Radiation: radiation therapy","Universitätsklinikum Hamburg-Eppendorf","All","up to 21 Years   (Child, Adult)","","567","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000455572|GPOH-HIT-2000|EU-205105","March 15, 2006","January 2001","null","January 27, 2014","July 2009","No Study Results Posted","null","December 2013","","https://ClinicalTrials.gov/show/NCT00303810"
2878,"NCT00287950","Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","","120","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000454726|CCLG-1992-05|EU-20593|CCLG-9205","February 6, 2006","September 1992","null","September 16, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00287950"
2879,"NCT00276731","Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year and older   (Child, Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000454725|CCLG-NB-1995-02|EU-20595|UKCCSG-ENSG-9","January 12, 2006","March 1995","null","September 16, 2013","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00276731"
2880,"NCT00083083","Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: etoposide|Drug: paclitaxel|Drug: vinblastine sulfate|Drug: vinorelbine tartrate|Genetic: gene expression analysis|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","American College of Radiology Imaging Network|National Cancer Institute (NCI)|Radiation Therapy Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","250","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Diagnostic","CDR0000362061|ACRIN-6668|RTOG-0235","May 14, 2004","March 2005","null","February 26, 2011","October 2007","No Study Results Posted","null","June 2006","Relationship of survival to post-treatment peak standardized uptake value (SUV) as determined by the imaging institution|Relationship of survival to post-treatment max SUV as determined by the imaging institute|Relationship of local control to post-treatment peak and max SUV as determined by the imaging institution|Relationship of survival and of local control to pre-treatment peak and max SUV as determined by the imaging institution|Reliability between peak and max SUV measurements both pre- and post-treatment|Proportion of participants who are either upstaged or downstaged by positron emission tomography scan|Reliability between PET scan-defined response to therapy measurements|Correlation of Ki-67 expression with peak and max pre-treatment SUV|Association between Ki-67 expression and overall survival at 2 years","https://ClinicalTrials.gov/show/NCT00083083"
2881,"NCT00070200","Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 1","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL02P1|CDR0000330140|COG-ANBL02P1","October 3, 2003","March 2004","December 2013","February 12, 2014","February 2014","No Study Results Posted","null","September 2006","Proportion of patients who are classified as a ""success""|Number of toxic deaths|Proportion of patients with dose limiting toxicities during induction cycle 1 and 2|Tumor contamination of PBSCs|Inability to adequately mobilize PBSCs|Assessment of response","https://ClinicalTrials.gov/show/NCT00070200"
2882,"NCT00055887","Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer","Withdrawn","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: efaproxiral|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Drug: vinorelbine ditartrate|Procedure: radiation therapy","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000271438|ALLOS-RSR13RT-013ELITE","March 6, 2003","November 2002","null","May 8, 2013","May 2013","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00055887"
2883,"NCT00024271","Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer","Unknown status","No Results Available","Malignant Mesothelioma","Biological: recombinant interferon gamma|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: mitomycin C|Procedure: conventional surgery|Procedure: hyperthermia treatment|Radiation: radiation therapy","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068907|CPMC-IRB-13799|NCI-G01-2015","September 13, 2001","May 2001","null","January 3, 2014","January 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024271"
2884,"NCT00023998","Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma","Completed","No Results Available","Metastatic Osteosarcoma","Drug: doxorubicin hydrochloride|Drug: cisplatin|Drug: methotrexate|Drug: leucovorin calcium|Biological: filgrastim|Procedure: therapeutic conventional surgery|Radiation: radiation therapy|Drug: etoposide|Drug: ifosfamide|Biological: trastuzumab|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 2","80","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01863|AOST0121|U10CA098543|CDR0000068882","September 13, 2001","July 2001","May 2007","February 1, 2013","January 2013","No Study Results Posted","null","November 2005","Feasibility and safety of treatment assessed using CTC version 2.0|Response rate|Event free survival (EFS)","https://ClinicalTrials.gov/show/NCT00023998"
2885,"NCT00023868","Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver","Completed","No Results Available","Colorectal Cancer|Metastatic Cancer","Drug: FOLFIRI regimen|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: irinotecan hydrochloride|Drug: leucovorin calcium|Drug: mitomycin C","American College of Radiology Imaging Network|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068871|ACRIN-6655","September 13, 2001","November 2001","null","January 3, 2009","December 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00023868"
2886,"NCT00019864","Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma","Terminated","No Results Available","Cardiac Toxicity|Sarcoma","Biological: filgrastim|Drug: cisplatin|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: methotrexate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","National Cancer Institute (NCI)","All","up to 25 Years   (Child, Adult)","Phase 2","100","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000067263|NCI-99-C-0125I","July 11, 2001","March 2000","October 2011","June 4, 2015","October 2007","No Study Results Posted","null","December 2006","Rate of in vivo histologic response|Event-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00019864"
2887,"NCT00006258","Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: methotrexate|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","10 Years to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CHLA-NYU-0002H|CDR0000068192|NYU-0027H|NCI-G00-1852","September 11, 2000","November 1997","January 2005","July 17, 2013","December 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006258"
2888,"NCT00004897","Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","Terminated","No Results Available","Esophageal Cancer","Biological: recombinant interferon alfa|Drug: cisplatin|Drug: fluorouracil|Drug: hydroxyurea|Drug: leucovorin calcium|Procedure: conventional surgery|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 94I1|NU-94I1|NCI-G00-1679","March 7, 2000","October 1999","November 2007","June 8, 2012","June 2012","No Study Results Posted","null","July 2007","","https://ClinicalTrials.gov/show/NCT00004897"
2889,"NCT00004086","Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer","Unknown status","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cisplatin|Drug: cytarabine|Drug: etoposide|Drug: ifosfamide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 LL2 IgG|Radiation: yttrium Y 90 epratuzumab","Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067298|CMMI-C-037C-97|NCI-V99-1569","December 10, 1999","June 1997","null","June 6, 2009","December 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004086"
2890,"NCT00003776","Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma","Completed","No Results Available","Sarcoma","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: trimetrexate glucuronate|Procedure: surgical procedure","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","98-102|CDR0000066905|NCI-G99-1507","November 1, 1999","December 1998","March 2000","June 20, 2013","June 2013","No Study Results Posted","null","March 2000","","https://ClinicalTrials.gov/show/NCT00003776"
2891,"NCT00003640","Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer","Terminated","No Results Available","Bladder Cancer","Biological: filgrastim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vinblastine sulfate|Procedure: surgical procedure|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","Child, Adult, Senior","Phase 2","73","Other","Interventional","Primary Purpose: Treatment","EORTC-30971","November 1, 1999","September 1998","null","March 5, 2012","March 2012","No Study Results Posted","null","November 2000","","https://ClinicalTrials.gov/show/NCT00003640"
2892,"NCT00003309","Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066256|E4397|SWOG-E4397","November 1, 1999","July 1998","null","January 26, 2010","January 2010","No Study Results Posted","null","March 2004","","https://ClinicalTrials.gov/show/NCT00003309"
2893,"NCT00003209","Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer","Completed","No Results Available","Cervical Cancer","Biological: bleomycin sulfate|Drug: cisplatin|Drug: fluorouracil|Drug: ifosfamide|Drug: methotrexate|Drug: mitomycin C|Drug: vinblastine sulfate|Drug: vindesine|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council","Female","18 Years and older   (Adult, Senior)","Phase 3","700","Other","Interventional","Primary Purpose: Treatment","EORTC-55954|MRC-CE04|COSA|EU-98061|NSGO-CC-9502","November 1, 1999","December 1997","null","July 10, 2012","July 2012","No Study Results Posted","null","December 1999","","https://ClinicalTrials.gov/show/NCT00003209"
2894,"NCT00003159","Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: gemcitabine hydrochloride|Drug: ifosfamide|Drug: mitomycin C|Drug: paclitaxel|Drug: vinblastine sulfate|Drug: vinorelbine tartrate|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Medical Research Council|European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","600","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065952|MRC-LU22|EORTC-08012|EU-97016|ISRCTN25582437","November 1, 1999","August 1997","June 2007","December 3, 2013","May 2005","No Study Results Posted","null","null","Survival|Quality of life as measured by SF-36 questionnaire at baseline, 6 months, 12 months, and then annually thereafter|Clinical and post-surgery pathological staging at pre-randomization|Resectability rates|Extent of surgery|Time to and site of relapse|Tumor response to chemotherapy|Adverse effects of chemotherapy","https://ClinicalTrials.gov/show/NCT00003159"
2895,"NCT00003042","Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: melphalan|Drug: mesna|Drug: paclitaxel|Drug: tamoxifen citrate|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","96139|P30CA033572|CHNMC-96139|NCI-G97-1288|CDR0000065672","November 1, 1999","May 1997","null","September 16, 2016","September 2016","No Study Results Posted","null","September 2017","Time to progression at year 5|Feasibility at year 5|Overall survival at year 5","https://ClinicalTrials.gov/show/NCT00003042"
2896,"NCT00002822","Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: vincristine sulfate|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064998|MRC-LU21|EU-96019","November 1, 1999","March 1996","November 2005","December 18, 2013","December 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002822"
2897,"NCT00002802","Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: mesna|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy|Radiation: radioisotope therapy","Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 3","500","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000064902|GER-NB90|EU-96004","November 1, 1999","July 1990","September 2003","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002802"
2898,"NCT00002566","Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors","Unknown status","No Results Available","Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: vinblastine sulfate|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","UNICANCER|National Cancer Institute (NCI)","Male","16 Years and older   (Child, Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063579|FRE-IT94|FRE-FNCLCC-IT94|NCI-F94-0019","November 1, 1999","February 1994","null","November 2, 2010","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002566"
2899,"NCT00002496","Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx","Completed","No Results Available","Head and Neck Cancer","Drug: chemotherapy|Drug: cisplatin|Drug: fluorouracil|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","RTOG-9111|CDR0000077756|EST-R9111|SWOG-9201","November 1, 1999","August 1992","November 2013","January 23, 2014","January 2014","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00002496"
2900,"NCT00577096","Effects of Exercise in Combination With Epoetin Alfa","Completed","Has Results","Multiple Myeloma","Drug: Epoetin Alfa|Behavioral: Exercise|Biological: Autologous Peripheral Blood Stem Cell Transplantation|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan|Drug: Epoetin Alfa|Drug: Total Therapy II|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan","University of Arkansas|National Institutes of Health (NIH)|Ortho Biotech Clinical Affairs, L.L.C.","All","Child, Adult, Senior","","120","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","IRB # 29287|R01NR008937|Ortho Biotech Clinical Affairs","December 17, 2007","October 2001","June 2004","April 2, 2015","April 2015","March 17, 2011","null","June 2004","Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)|Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)|Number of Stem Cell Collection Attempts (Short Term)|Number of Stem Cell Collection Attempts (Long Term)|Total Number of Days of Stem Cell Collection (Short Term)|Total Number of Days of Stem Cell Collection (Long Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)","https://ClinicalTrials.gov/show/NCT00577096"
2901,"NCT02998528","A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC)","Recruiting","No Results Available","Non Small Cell Lung Cancer","Biological: Nivolumab|Biological: ipilimumab|Drug: cisplatin|Drug: vinorelbine|Drug: gemcitabine|Drug: docetaxel|Drug: pemetrexed|Drug: carboplatin","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 3","326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-816|2016-003536-21","December 16, 2016","January 2017","March 2024","April 17, 2017","April 2017","No Study Results Posted","CheckMate 816","September 2019","Major Pathological Response (MPR) rate|Event free survival (EFS)|Overall survival (OS)|Complete pathological response (pCR)","https://ClinicalTrials.gov/show/NCT02998528"
2902,"NCT00652860","Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery","Completed","No Results Available","Metastatic Cancer|Sarcoma","Biological: aerosol sargramostim|Biological: sargramostim|Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: mitomycin C|Other: flow cytometry|Other: immunological diagnostic method|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: multimodality therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: intraoperative radiation therapy|Radiation: selective external radiation therapy","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000582297|P30CA015083|MC0072|1021-01","April 3, 2008","August 2001","null","May 13, 2011","May 2011","No Study Results Posted","null","November 2006","Pulmonary metastatic progression-free rate at 2 years|Survival|Time to progression|Toxicity as per NCI CTC Version 2.0|Tumor response every 4 weeks during treatment","https://ClinicalTrials.gov/show/NCT00652860"
2903,"NCT00646659","Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery","Terminated","No Results Available","Head and Neck Cancer","Biological: cetuximab|Drug: carboplatin|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Genetic: fluorescence in situ hybridization|Genetic: molecular genetic technique|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-24061|MERCK-EORTC-24061|SANOFI-AVENTIS-EORTC-24061|2006-004189-14","March 27, 2008","February 2008","April 2011","January 7, 2013","January 2013","No Study Results Posted","null","May 2010","Feasibility of the chemoradiotherapy part of the treatment, assessed as at least 80% dose intensity of any of the radiotherapy, the platinum, and cetuximab during the chemoradiotherapy part of the treatment|Toxicity as assessed by NCI CTCAE v3.0|Dose modifications|Response rate (complete or partial response)|EGFR expression and downstream signaling in primary tumor and in skin samples","https://ClinicalTrials.gov/show/NCT00646659"
2904,"NCT00526318","Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma","Recruiting","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous hematopoietic stem cell transplantation|Radiation: iobenguane I 131|Radiation: radiation therapy","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","360","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GPOH-NB2004-HR|CDR0000564820|UNI-KOELN-161|EU-20661","September 5, 2007","January 2007","null","July 15, 2015","July 2015","No Study Results Posted","null","December 2016","Event-free survival (EFS)|Overall survival (OS)|Impact of well established clinical and molecular risk factors on EFS and OS|Early response, measured after 2 courses of induction chemotherapy|Response to induction therapy, measured before autologous stem cell transplantation|Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy|Impact of the extent of initial and best surgery on outcome and frequency of complications|Acute and late toxicity of radiotherapy|Correlation of MIBG activity with whole-body radiation dose|Molecular markers (MYCN and status of chromosome 1p and 11q)","https://ClinicalTrials.gov/show/NCT00526318"
2905,"NCT00410631","Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous hematopoietic stem cell transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: iobenguane I 131|Radiation: radiation therapy","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","642","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","GPOH-NB2004|CDR0000517312|EU-20661","December 11, 2006","October 2004","null","August 6, 2013","January 2008","No Study Results Posted","null","December 2010","Event-free survival (EFS)|Locoregional EFS|Time from diagnosis to transition to stage 4 disease, to death from disease, or to the last follow-up (if no transition to stage 4 disease is observed)|Overall survival|Time to the beginning of primary tumor regression (in patients in the low-risk group [LRG])|Time to the normalization of tumor markers HVA and VMA in urine|Time to no evidence of disease (in patients in the LRG with stage 4S disease)|Status of the primary tumor 12 months after diagnosis (LRG)|Best status of the primary tumor within the first 12 months (LRG)|Status of chromosome 1p (unblinded) and status of chromosome 11q (blinded)|Comparison of the extent of initial surgery (incomplete resection vs macroscopic complete resection) (LRG)|Comparison of the extent of best surgery during protocol treatment (incomplete resection vs macroscopic complete resection)|Surgery-related complications (i.e., bleeding, infection, intestinal obstruction, or other)|Disease progression and symptoms controlled after the first, second, third, and fourth N4 course (LRG)|Disease progression and symptoms not controlled after four N4 courses (LRG)|Transition to stage 4 disease at any time (LRG)|Acute and late side effects of external-beam radiotherapy (medium-risk group [MRG] and high-risk group [HRG])|Early response after 2 courses of induction therapy (N5 and N6 or two courses of N8) (HRG)|Response to induction therapy prior to conditioning therapy or after 280 days (HRG)|Grade of toxicity observed during induction therapy course 1 (N5 or N8) (HRG)|Grade of toxicity observed during induction therapy course 2 (N6 or N8) (HRG)|Frequency of grade 3 or 4 toxicity observed during the last 6 courses of induction therapy (3 courses of N5 and N6) (HRG)|Activity and whole body dose of radiotherapy","https://ClinicalTrials.gov/show/NCT00410631"
2906,"NCT00274950","Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors","Unknown status","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer","Biological: bleomycin sulfate|Drug: carboplatin|Drug: cisplatin|Drug: etoposide|Drug: ifosfamide|Drug: vinblastine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 3","105","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000454553|CCLG-GC-2005-04|EUDRACT-2004-002503-33|EU-20584","January 10, 2006","May 2005","null","September 16, 2013","June 2009","No Study Results Posted","null","May 2010","Event-free survival|Continuation of treatment|Development of common and follow-up strategies|Registration of all cases of mature and immature teratoma","https://ClinicalTrials.gov/show/NCT00274950"
2907,"NCT00025636","Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Drug: methotrexate|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","German Hodgkin's Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|EBMT Solid Tumors Working Party|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068981|GHSG-HD-R2|EBMT-GHSG-HD-R2|EORTC-20011","October 11, 2001","July 2001","null","September 16, 2013","June 2007","No Study Results Posted","null","null","Efficacy at 3 months|Toxicity at 3 months|Complete remission at 3 months|Relapse-free survival at 3 months|Overall survival at 3 months","https://ClinicalTrials.gov/show/NCT00025636"
2908,"NCT00025064","Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: chlorambucil|Drug: cisplatin|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: prednisolone|Drug: procarbazine hydrochloride|Drug: vinblastine sulfate|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 2","260","Other","Interventional","Primary Purpose: Treatment","CCLG-HD-2000-02|CDR0000068901|EU-20108","October 11, 2001","January 2000","null","August 6, 2013","December 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025064"
2909,"NCT00024193","Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: busulfan|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Children's Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI)","All","1 Year and older   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CCLG-NB-1999-02|CDR0000068899|SFOP-NB97|EU-20106","September 13, 2001","April 1999","null","August 6, 2013","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024193"
2910,"NCT00017225","Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: tretinoin|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","GPOH-GERMANY-NB97|CDR0000068664|EU-20102|GER-GPOH-NB97","June 6, 2001","May 1997","February 2002","August 1, 2013","August 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017225"
2911,"NCT00007982","Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors|Head and Neck Cancer|Lymphoma","Biological: filgrastim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Procedure: adjuvant therapy|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068360|CPMC-IRB-8445|CPMC-CAMP-004A|NCI-G00-1881","January 6, 2001","April 1999","May 2008","February 1, 2013","July 2007","No Study Results Posted","null","February 2005","Response rate|Disease-free suvival|Overall survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT00007982"
2912,"NCT00004903","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","Robert H. Lurie Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067582|NU-C94H1|NU-94H1|UCCRC-7071|NCI-G00-1690","March 7, 2000","October 1999","null","January 3, 2014","June 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004903"
2913,"NCT00003413","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer","Completed","No Results Available","Ovarian Cancer","Biological: filgrastim|Drug: carmustine|Drug: cisplatin|Drug: melphalan|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation|Procedure: surgical procedure","University of Maryland|University of Maryland Greenebaum Cancer Center","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","32","Other","Interventional","Primary Purpose: Treatment","CDR0000066426|MSGCC-9749|NCI-V98-1452","November 1, 1999","September 1998","February 2001","September 23, 2009","September 2009","No Study Results Posted","null","February 2001","","https://ClinicalTrials.gov/show/NCT00003413"
2914,"NCT00003273","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor","Withdrawn","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma|Retinoblastoma|Sarcoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","New York University School of Medicine","All","up to 10 Years   (Child)","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","CDR0000066174|NYU-P9712|NCI-V98-1400","November 1, 1999","November 1997","null","November 30, 2015","November 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003273"
2915,"NCT00002675","Chemotherapy in Treating Patients With Retinoblastoma","Completed","No Results Available","Retinoblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Drug: vincristine sulfate","Memorial Sloan Kettering Cancer Center","All","up to 17 Years   (Child)","Phase 2","50","Other","Interventional","Primary Purpose: Treatment","95-040|CDR0000064317|NCI-V95-0710","November 1, 1999","May 1995","January 2001","June 26, 2013","June 2013","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00002675"
2916,"NCT00002634","Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: monoclonal antibody 3F8|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mesna|Drug: perfosfamide|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy|Radiation: radioisotope therapy","Memorial Sloan Kettering Cancer Center","All","1 Year and older   (Child, Adult, Senior)","Phase 2","45","Other","Interventional","Primary Purpose: Treatment","94-011|CDR0000064084|MSKCC-FDR001041|NCI-V95-0622","November 1, 1999","February 1995","September 2004","July 1, 2013","July 2013","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00002634"
2917,"NCT02477826","An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Nivolumab|Drug: Ipilimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed|Drug: Paclitaxel","Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 3","2220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CA209-227|2014-003630-23","June 18, 2015","August 2015","December 2020","April 18, 2017","March 2017","No Study Results Posted","CheckMate 227","January 2018","Overall survival (OS)|Progression-free Survival (PFS) as determined by blinded independent central review (BICR)|Objective response rate (ORR)|Disease related symptom improvement as measured by the Lung Cancer Symptom Score (LCSS) in all subjects","https://ClinicalTrials.gov/show/NCT02477826"
2918,"NCT01172912","High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Biological: filgrastim|Biological: pegfilgrastim|Drug: carboplatin|Drug: cisplatin|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Other: high-dose chemotherapy with autologous stem cell rescue|Other: laboratory biomarker analysis|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","ITA-MIL-INT-38-10|CDR0000682204|EUDRACT-2010-021898-36|EU-21054","July 29, 2010","October 2010","null","August 9, 2013","August 2011","No Study Results Posted","null","October 2012","Efficacy|Toxicity|Biological correlates of outcome","https://ClinicalTrials.gov/show/NCT01172912"
2919,"NCT00920153","Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","Terminated","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: ABVD regimen|Drug: carmustine|Drug: cisplatin|Drug: cytarabine|Drug: dacarbazine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: ifosfamide|Drug: melphalan|Drug: methylprednisolone|Drug: mitoguazone|Drug: vincristine sulfate|Drug: vindesine|Drug: vinorelbine tartrate|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: autologous hematopoietic stem cell transplantation","French Innovative Leukemia Organisation","All","18 Years to 65 Years   (Adult)","Phase 3","442","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LH 2007","June 12, 2009","May 2008","March 2016","September 15, 2016","July 2016","No Study Results Posted","null","March 2016","Event-free survival","https://ClinicalTrials.gov/show/NCT00920153"
2920,"NCT00238368","Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: busulfan|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methylprednisolone|Drug: prednisone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","59","Other|NIH","Interventional","Primary Purpose: Diagnostic","J0348 CDR0000445618|P30CA006973|JHOC-J0348|JHOC-03082605","October 12, 2005","February 2004","February 2009","April 16, 2014","April 2014","No Study Results Posted","null","February 2009","2-year event free survival|Overall survival|Predictive value of early negative fludeoxyglucose F 18 positron emission tomography (FDG-PET)|Correlation of International Prognostic Index risk category with FDG-PET results and overall outcome","https://ClinicalTrials.gov/show/NCT00238368"
2921,"NCT00017368","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: sargramostim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: etoposide phosphate|Drug: ifosfamide|Drug: isotretinoin|Drug: melphalan|Drug: thiotepa|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL00P1|COG-ANBL00P1|CDR0000068681","June 6, 2001","April 2001","January 2012","February 12, 2014","February 2014","No Study Results Posted","null","September 2005","Transplant-related mortality|Incidence of symptomatic CMV, disseminated adenovirus infection, or EBV-LPD|Event-free Survival","https://ClinicalTrials.gov/show/NCT00017368"
2922,"NCT00012051","Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cisplatin|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: methotrexate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","340","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CKTO-2000-06|CDR0000068476|HOVON-44|HOVON-44/CKVO-2000-06|EU-20042|ISRCTN95614846","March 3, 2001","September 2000","October 2007","August 9, 2013","March 2007","No Study Results Posted","null","null","Overall survival|Response rate|Event-free survival","https://ClinicalTrials.gov/show/NCT00012051"
2923,"NCT00006123","Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: carboplatin|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","Beth Israel Deaconess Medical Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068138|BIH-99-12|BIH-W-99-0053-FB|NCI-V00-1610","August 3, 2000","July 2000","null","February 6, 2009","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006123"
2924,"NCT00004906","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: anastrozole|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: pamidronate disodium|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","Hackensack University Medical Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU-H97B1|CDR0000067586|NCI-G00-1682","March 7, 2000","October 1999","June 2001","May 29, 2013","November 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004906"
2925,"NCT00004900","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: anastrozole|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Hackensack University Medical Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU-HAC98B2|CDR0000067579|NCI-G00-1689","March 7, 2000","October 1999","August 2004","May 29, 2013","October 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004900"
2926,"NCT00003386","Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer","Terminated","No Results Available","Ovarian Cancer","Biological: BCG vaccine|Biological: autologous tumor cell vaccine|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Other: dinitrophenyl|Procedure: surgical procedure","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066382|GOG-9802","November 1, 1999","July 1999","null","April 10, 2013","December 2008","No Study Results Posted","null","April 2001","","https://ClinicalTrials.gov/show/NCT00003386"
2927,"NCT00003086","Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CAF regimen|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: ifosfamide|Drug: melphalan|Drug: paclitaxel|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: samarium Sm 153 lexidronam pentasodium","Feist-Weiller Cancer Center at Louisiana State University Health Sciences|National Cancer Institute (NCI)","Female","21 Years to 65 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Primary Purpose: Treatment","CDR0000065786|LSU-97447|NCI-V97-1341","November 1, 1999","March 1997","null","February 6, 2009","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003086"
2928,"NCT00002772","S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","Terminated","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B","Female","18 Years and older   (Adult, Senior)","Phase 3","602","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000064747|S9623|U10CA032102","November 1, 1999","July 1996","February 2004","January 22, 2013","January 2013","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00002772"
2929,"NCT00002596","Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors","Completed","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|Cancer and Leukemia Group B","Male","12 Years and older   (Child, Adult, Senior)","Phase 3","270","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SWOG-9442|MSKCC-94076|CLB-99812|E-3894|CDR0000063820|NCI-T94-0086D","November 1, 1999","September 1994","July 2006","June 25, 2013","October 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002596"
2930,"NCT00165139","Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas","Completed","No Results Available","Neuroblastoma|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma","Drug: Vincristine|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Etoposide (VP-16)|Drug: Cisplatin|Drug: Carboplatin|Drug: Melphalan|Drug: Ifosfamide|Drug: G-CSF (granulocyte-colony stimulating factor)|Drug: Mesna","Dana-Farber Cancer Institute|Boston Children’s Hospital|Children's Hospital of Philadelphia","All","up to 19 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","94-131","September 9, 2005","January 1996","February 2009","October 30, 2009","October 2009","No Study Results Posted","null","November 2000","To determine the toxicity and feasibility of double dose chemo-radiotherapy with blood progenitor cell rescue in this patient population.","https://ClinicalTrials.gov/show/NCT00165139"
2931,"NCT00040872","Multiple Therapies in Treating Patients With Advanced Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: monoclonal antibody 3F8|Biological: sargramostim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: thiotepa|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: drug resistance inhibition treatment|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","00-065|P30CA008748|MSKCC-00065|NCI-G02-2083","July 8, 2002","June 2000","January 2007","March 6, 2013","March 2013","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00040872"
2932,"NCT00003397","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Primary Purpose: Treatment","CDR0000066399|MSGCC-9740|NCI-V98-1432","November 1, 1999","September 1998","December 2002","September 23, 2009","September 2009","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00003397"
2933,"NCT02551159","Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","Active, not recruiting","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Biological: MEDI4736|Biological: Tremelimumab|Biological: MEDI4736+Tremelimumab|Biological: Cetuximab|Drug: 5-fluorouracil (5FU)|Drug: Cisplatin|Drug: Carboplatin","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 3","823","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","D419LC00001","September 9, 2015","October 15, 2015","October 2, 2018","May 8, 2017","April 2017","No Study Results Posted","KESTREL","March 1, 2018","The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of progression-free survival (PFS).|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Overall survival (OS).|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Objective Response Rate (ORR).|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Second Progression (PFS2).|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Duration of Response (DoR).|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of alive and progression free at 12 months (APF12).|The efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of overall survival at 24 months (OS24).|The efficacy of MEDI4736 monotherapy compared to SoC in terms of progression-free survival (PFS).|The efficacy of MEDI4736 monotherapy compared to SoC in terms of Overall survival (OS).|The efficacy of MEDI4736 monotherapy compared to SoC in terms of Objective Response Rate (ORR).|The efficacy of MEDI4736 monotherapy compared to SoC in terms of Second Progression (PFS2).|The efficacy of MEDI4736 monotherapy compared to SoC in terms of overall survival at 24 months (OS24).|the efficacy of MEDI4736 + tremelimumab combination therapy compared to MEDI4736 monotherapy in terms of Progression Free Survival (PFS).|the efficacy of MEDI4736 + tremelimumab combination therapy compared to MEDI4736 monotherapy in terms of Objective Response Rate (ORR).|the efficacy of MEDI4736 + tremelimumab combination therapy compared to MEDI4736 monotherapy in terms of Overall Survival (OS)|The pharmacokinetics (PK) analysis of MEDI4736 and Tremelimumab using Area Under the Curve (AUC)|The immunogenicity of MEDI4736 and tremelimumab|Health related quality of life (HRQoL) in patients treated with MEDI4736 + tremelimumab or MEDI4736 compared to SoC using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30)|HRQoL in patients treated with MEDI4736 + tremelimumab or MEDI4736 compared to SoC using the EORTC- 35-item Head and Neck Quality of Life Questionnaire (QLQ H&N35) module|The pharmacokinetics (PK) analysis of MEDI4736 and Tremelimumab using Maximum Plasma Concentration (Cmax)","https://ClinicalTrials.gov/show/NCT02551159"
2934,"NCT00653068","Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","Active, not recruiting","Has Results","Childhood Atypical Teratoid/Rhabdoid Tumor","Procedure: autologous hematopoietic stem cell transplantation|Radiation: 3-dimensional conformal radiation therapy|Drug: methotrexate|Drug: leucovorin calcium|Drug: etoposide|Drug: cyclophosphamide|Drug: cisplatin|Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Drug: vincristine sulfate|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0333|NCI-2009-00337|COG-ACNS0333|U10CA098543","April 3, 2008","December 2008","null","February 13, 2017","February 2017","December 20, 2016","null","April 2015","Event-free Survival|Overall Survival (OS)|Toxic Death|Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy","https://ClinicalTrials.gov/show/NCT00653068"
2935,"NCT00513383","Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck","Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Panitumumab|Drug: Carboplatin|Drug: Paclitaxel|Radiation: Intensity Modulated Radiation Therapy|Drug: 5-Fluorouracil|Drug: Docetaxel|Drug: Cisplatin","Massachusetts General Hospital|Brigham and Women's Hospital|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1","34","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","05-401","August 7, 2007","April 2006","October 2012","February 27, 2017","February 2017","No Study Results Posted","null","October 2010","To identify the maximally tolerated dose of paclitaxel given with panitumumab plus carboplatin chemoradiotherapy.|To identify the maximally tolerated dose or biologically acceptable dose of TPF, varying the 5-FU dose, given with a fixed dose of panitumumab, prior to concurrent carboplatin, paclitaxel, panitumumab chemoradiotherapy.|To evaluate the safety and tolerability of the combination of Pan-CRT and Pan-TPF.|To estimate the overall response rate to Pan-TPF.|To estimate the overall response rate of sequential therapy.|To estimate the rate of pathologic complete response of primary tumor biopsy, to estimate 2-year disease free survival and overall survival.|To evaluate functional outcome at 2 years with respect to speech, swallowing and overall quality of life.","https://ClinicalTrials.gov/show/NCT00513383"
2936,"NCT00302003","Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","Active, not recruiting","Has Results","Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma","Radiation: radiation therapy|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: cyclophosphamide|Drug: ifosfamide|Drug: vinorelbine tartrate|Drug: dexamethasone|Drug: etoposide phosphate|Drug: cisplatin|Drug: cytarabine|Biological: filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","287","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AHOD0431|NCI-2009-00377|CDR0000459962|U10CA098543|COG-AHOD0431","March 9, 2006","February 2006","null","December 16, 2016","August 2016","June 29, 2016","null","March 2012","Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).|Intensive Therapy Free Survival (ITFS).|Event Free Survival (EFS)|Overall Survival","https://ClinicalTrials.gov/show/NCT00302003"
2937,"NCT01336270","Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients","Completed","No Results Available","Melanoma","Other: biological collection","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","","217","Other","Observational","Observational Model: Cohort","P090405","April 14, 2011","May 2011","March 2014","August 25, 2014","August 2014","No Study Results Posted","IMMUMELA","November 2013","Impact of cellular infiltrate - Group 1|Impact of NK cell infiltrate - Group 2 and 3|Modifications of cellular infiltrate - Group 4","https://ClinicalTrials.gov/show/NCT01336270"
2938,"NCT02381782","Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment","Completed","No Results Available","Hearing Loss|Cancer","","General Hospital Groeninge","All","70 Years and older   (Senior)","","33","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AZGS2014125","March 5, 2015","December 2014","June 2015","July 28, 2015","July 2015","No Study Results Posted","UHEAR","June 2015","Validation of uHear™ as a screening tool to detect hearing loss in elderly cancer patients|To determine the prevalence of presbyacusis in an elderly cancer population|To compare objective and subjective hearing screening measures|To measure hearing impairment in G8 positive patients compared with G8 negative patients|To compare uHear™ with the Whispered Voice Test|To evaluate the use of uHear™ as a measure to determine eligibility for cisplatin treatment in elderly cancer patients","https://ClinicalTrials.gov/show/NCT02381782"
2939,"NCT01941680","High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant","Recruiting","No Results Available","T-cell Lymphoma|Leukaemia","","University Hospital Center of Martinique","All","18 Years to 75 Years   (Adult, Senior)","","20","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","13/B/04|2013-A00327-38","September 3, 2013","October 31, 2013","October 2018","April 25, 2017","April 2017","No Study Results Posted","ATLL-HR-01","September 2018","Number of patients with relapse|Evidence of presence of gene expression of Tax and HBZ confirmed by Rt-PCR","https://ClinicalTrials.gov/show/NCT01941680"
2940,"NCT02091999","A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","Recruiting","No Results Available","Metastatic Urothelial Cancer and Other Malignant Solid Tumors","Drug: ASG-22CE","Agensys, Inc.|Seattle Genetics, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Senior)","Phase 1","200","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ASG-22CE-13-2","March 18, 2014","June 4, 2014","December 30, 2018","May 23, 2017","May 2017","No Study Results Posted","null","September 30, 2018","Incidence of adverse events|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Concentration at the end of infusion (CEOI)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Terminal or apparent terminal half-life (t1/2)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Systemic clearance (CL)|Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Volume of distribution at steady state (Vss)|Incidence of Anti-Drug Antibody (ADA)|Tumor response|Objective response rate|Disease control rate|Progression Free Survival (PFS)|Overall Survival|Duration of Response","https://ClinicalTrials.gov/show/NCT02091999"
2941,"NCT01887314","Efficacy Study of Ginger (Zingiber Officinale) Extract ""Ginpax"" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy","Completed","No Results Available","Cancer|Nausea|Vomiting","Dietary Supplement: Standardized Ginger extract","Helsinn Healthcare SA","All","18 Years and older   (Adult, Senior)","","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","HF01-12-69","June 24, 2013","June 2013","October 2015","January 26, 2016","January 2016","No Study Results Posted","null","September 2015","To evaluate the efficacy of Ginger in protecting patients from delayed nausea (incidence of no delayed nausea and non-significant delayed nausea)|Protection from delayed vomiting (number of emetic episodes in delayed phase)|Use of antiemetic rescue medication.|Overall fatigue assessment (BFI questionnaire)","https://ClinicalTrials.gov/show/NCT01887314"
2942,"NCT00412425","Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting","Completed","Has Results","Melanoma","Drug: Palonosetron","M.D. Anderson Cancer Center|Eisai Inc.","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0506","December 14, 2006","November 2006","May 2009","April 9, 2012","April 2012","February 7, 2012","null","May 2009","Cumulative Participants Response to Palonosetron","https://ClinicalTrials.gov/show/NCT00412425"
2943,"NCT01921426","A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck","Completed","No Results Available","Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Oropharynx","Drug: GC4419","Galera Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","GT-001","August 8, 2013","August 2013","August 2016","September 21, 2016","September 2016","No Study Results Posted","null","July 2015","Frequency and Severity of Adverse Events Resulting from GC4419|Rate and Extent of Exposure to GC4419 (Pharmacokinetic Profile)|Oral Mucositis|Antitumor Effect","https://ClinicalTrials.gov/show/NCT01921426"
2944,"NCT02783794","BP-C1 Monotherapy in Patients With Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer|Stage IV Breast Cancer","Drug: BP-C1|Drug: Placebo","Meabco A/S|Meddoc AS|Norwegian University of Life Sciences","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BMC2011-1|2011-005963-25","May 18, 2016","December 2012","February 2014","May 27, 2016","May 2016","No Study Results Posted","null","February 2014","Change (%) in the sum of diameters of target lesions|Number of target lesions|Number of non-target lesions|Treatment response|Karnofsky Performance Status (KPS) score|Scores of the general questionnaire EORTC QLQ-C30 (""Physical activity problem last week"", ""Discomfort last week"", ""Health and quality of life"")|Changes in three separate scores of the specific questionnaire EORTC QLQ-BR23 (""Breast cancer treatment problem last week"", ""Sexual interest and activity last four weeks"", ""Breast cancer related pain and discomfort last week"")|Change in Maximum Common Toxicity Criteria (CTC) score|Sum CTC score|Number of registered adverse events","https://ClinicalTrials.gov/show/NCT02783794"
2945,"NCT02082886","HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry","Recruiting","No Results Available","Peritoneal Neoplasms|Neoplasm Metastasis|Adenocarcinoma|Sarcoma","","Edward Hospital|Edward-Elmhurst Health System","All","Child, Adult, Senior","","500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EDW120613A","March 5, 2014","February 2014","January 2034","February 6, 2017","February 2017","No Study Results Posted","null","January 2034","Overall survival rate|Progression-free survival rate|Rates of complications","https://ClinicalTrials.gov/show/NCT02082886"
2946,"NCT01861509","BP-C1 in Metastatic Breast Cancer Patients","Completed","No Results Available","Metastatic Breast Cancer|Stage IV Breast Cancer","Drug: BP-C1","Meabco A/S","Female","18 Years to 80 Years   (Adult, Senior)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Basic Science","BMC 2012-4|2011-006316-31","May 13, 2013","June 2013","August 2016","February 12, 2017","February 2017","No Study Results Posted","null","August 2016","Single-dose PK: Maximum Observed Serum Concentration (Cmax) for Platinum|Single-dose PK: Time to Reach Maximum Observed Serum Concentration (Tmax) for Platinum|Single-dose PK: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC(0-t)) for Platinum|Single-dose PK: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC(0-∞))|Single-dose PK: Serum Decay Half-Life (T1/2) for Platinum|Multiple-dose PK: Maximum Observed Serum Concentration at Steady State (Css,max) for Platinum|Multiple-dose PK: Time to Reach Maximum Observed Serum Concentration at steady state (Tss,max) for Platinum|Multiple-dose PK: Minimum Observed Serum Concentration at Steady State (Css,min) for Platinum|Multiple-dose PK: Average Serum concentration at steady state (Css,av) for Platinum|Multiple-dose PK: Area Under the Curve within a dosing interval of tau (=24 hr) at steady state (AUCss,tau) for Platinum|Multiple-dose PK: Serum Decay Half-Life (T1/2) for Platinum|Interleukin Serum levels (Interferon γ and β, Tumour Necrosis Factor (TNF-α), IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-21 and IL-25)|Change (%) in the sum of diameters of target lesions|Number of target lesions|Treatment response","https://ClinicalTrials.gov/show/NCT01861509"
2947,"NCT01543620","Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis","Unknown status","No Results Available","Cystic Fibrosis","","Foundation for the National Institutes of Health|University of Southern California|University of Minnesota - Clinical and Translational Science Institute|M.D. Anderson Cancer Center|Dana-Farber Cancer Institute|Brigham and Women's Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Amgen|AstraZeneca|Eli Lilly and Company|Johnson & Johnson|Merck Sharp & Dohme Corp.|Pfizer|Critical Path Institute|Predictive Safety Testing Consortium","All","18 Years and older   (Adult, Senior)","","150","Other|NIH|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","Kidney Safety - Aminoglycoside","February 28, 2012","February 2012","June 2015","December 8, 2014","July 2014","No Study Results Posted","null","June 2015","","https://ClinicalTrials.gov/show/NCT01543620"
2948,"NCT01451853","SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss","Not yet recruiting","No Results Available","Lung Cancer|Head and Neck Cancer|Hearing Loss|Ototoxicity|Tinnitus|Neuropathy","Drug: SPI-1005 Low Dose|Drug: SPI-1005 Middle Dose|Drug: SPI-1005 High Dose|Drug: Placebo","Sound Pharmaceuticals, Incorporated|VA Puget Sound Health Care System","All","19 Years to 80 Years   (Adult, Senior)","Phase 2","80","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPI-3005-201","October 7, 2011","August 2016","February 2018","June 2, 2016","June 2016","No Study Results Posted","null","January 2018","Number of participants with adverse events|Reduction of hearing loss incidence and severity|Reduction of tinnitus incidence and severity.","https://ClinicalTrials.gov/show/NCT01451853"
2949,"NCT01016028","Chemotherapy-Induced Peripheral Neuropathy Survey","Withdrawn","No Results Available","Breast Cancer|Colorectal Cancer|Myeloma|Chemotherapy-induced Peripheral Neuropathy","Behavioral: Questionnaire|Behavioral: Sensory Tests|Behavioral: Interview","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2009-0439","November 17, 2009","November 2009","February 2013","April 29, 2016","February 2013","No Study Results Posted","null","February 2013","Assessment of Patient's Symptoms (Questionnaire)","https://ClinicalTrials.gov/show/NCT01016028"
2950,"NCT00119613","A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa","Completed","No Results Available","Small Cell Lung Cancer","Drug: placebo|Drug: darbepoetin alfa","Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20010145","July 7, 2005","December 2002","April 2007","August 7, 2008","August 2008","No Study Results Posted","null","January 2007","Change in hemoglobin concentration from baseline to the end of the chemotherapy treatment period|Survival time|Change in FACT-fatigue subscale scores from baseline to the end of study treatment|Incidence of Adverse Events (including serious and treatment related)|Changes in laboratory values, changes in vital signs and incidence of concomitant medications","https://ClinicalTrials.gov/show/NCT00119613"
2951,"NCT00089453","Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant","Completed","No Results Available","Multiple Myeloma","Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Melphalan|Drug: Fludarabine|Drug: Bortezomide|Procedure: Leukapheresis|Drug: Interleukin|Procedure: Infusion #1|Procedure: Leukapheresis #2|Procedure: Infusion #2|Procedure: Auto Graft","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2003-18","August 5, 2004","September 2003","May 2010","April 17, 2012","April 2012","No Study Results Posted","null","May 2010","To induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially.|To establish the response rate, disease free survival , overall survival , and toxicity of regimen.","https://ClinicalTrials.gov/show/NCT00089453"
2952,"NCT00083876","D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide","University of Arkansas|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 98-035","June 2, 2004","September 1998","November 2007","July 1, 2010","July 2010","No Study Results Posted","null","null","1.1 To evaluate, in a randomized phase III clinical trial in previously treated multiple myeloma patients whether angio-chemotherapy with D.T. PACE may be equivalent or superior to tandem transplant.","https://ClinicalTrials.gov/show/NCT00083876"
2953,"NCT00827424","The Impact of the PACE Program Implementation on Health Services Utilization by Obese Arab Women","Completed","No Results Available","Obesity","Behavioral: Lifestyle counseling by applying a modified PACE protocol","Clalit Health Services","Female","35 Years to 64 Years   (Adult)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMC-07-0054CTIL","January 21, 2009","December 2008","July 2010","August 23, 2010","August 2010","No Study Results Posted","AWESOME","May 2010","A significant change in BMI|Patient's lifestyle habits: physical activity, eating habits|Patient's clinical measures: BP, Waist Circumference|Patient's metabolic measure: HbA1c, lipid profile, fasting plasma glucose (FPG)|Patient's readiness for change: Determined by the PACE score","https://ClinicalTrials.gov/show/NCT00827424"
2954,"NCT01995760","The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?","Completed","No Results Available","Methicillin-resistant Staphylococcus Aureus Septicemia","","National Taiwan University Hospital","All","20 Years and older   (Adult, Senior)","","123","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","201310037RINA","November 10, 2013","November 2013","June 2014","September 2, 2014","September 2014","No Study Results Posted","null","June 2014","30-day mortality|90-day mortality|In-hospital mortality","https://ClinicalTrials.gov/show/NCT01995760"
2955,"NCT02750657","Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection","Recruiting","No Results Available","Carcinoma, Pancreatic Ductal","Genetic: Molecular Profiling","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","","180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COMPASS-001","January 19, 2016","February 2016","December 2021","April 20, 2016","April 2016","No Study Results Posted","COMPASS","February 2021","The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing.|Disease control rate achieved by m-FOLFIRINOX|Disease control rate achieved by nab-paclitaxel|Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to m-FOLFIRINOX|Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to nab-paclitaxel.|Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with m-FOLFIRINOX.|Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with nab-paclitaxel.|Overall survival defined as the interval between the date of registration and the date of death of patients treated with m-FOLFIRINOX|Overall survival defined as the interval between the date of registration and the date of death of patients treated with nab-paclitaxel.|Correlation between tumor genomic characteristics and m-FOLFIRINOX response using next generation sequencing.|Correlation between tumor genomic characteristics and nab-paclitaxel response using the next generation sequencing.|Percentage of patients with germline BRCA, PALB2 and ATM mutations who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibition.|Percentage of patients with somatic DSBR deficiency who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibitor.|Percentage of patients who might benefit from immunotherapy (patients with smoking genomic signatures, patients with a hypermutated phenotype, patients with mismatch repair deficiency and patients with tumor neo-antigen expression).|Percentage of patients with rare but targetable somatic mutations.|Difference in disease control rate between patients with tumor smoking signature and those without.|Difference in overall survival between patients with tumor smoking signature and those without.|Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing.","https://ClinicalTrials.gov/show/NCT02750657"
2956,"NCT01037790","PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER","Recruiting","No Results Available","Adult Solid Tumor|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Adult Central Nervous System Germ Cell Tumor|Adult Teratoma|Benign Teratoma|Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Familial Testicular Germ Cell Tumor|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Male Breast Cancer|Ovarian Immature Teratoma|Ovarian Mature Teratoma|Ovarian Monodermal and Highly Specialized Teratoma|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Extragonadal Germ Cell Tumor|Recurrent Extragonadal Non-seminomatous Germ Cell Tumor|Recurrent Extragonadal Seminoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Melanoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Rectal Cancer|Stage III Extragonadal Non-seminomatous Germ Cell Tumor|Stage III Extragonadal Seminoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Extragonadal Non-seminomatous Germ Cell Tumor|Stage IV Extragonadal Seminoma|Stage IV Melanoma|Stage IV Ovarian Germ Cell Tumor|Stage IV Rectal Cancer|Testicular Immature Teratoma|Testicular Mature Teratoma","Drug: PD-0332991|Other: pharmacological study","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 2","205","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 03909|NCI-2009-01467","December 10, 2009","October 2009","null","August 24, 2016","July 2016","No Study Results Posted","null","October 2016","Response rates|Safety and tolerability|Pharmacodynamic effects on tumor and non-tumor tissue|Relationship between selected biomarkers, pharmacokinetics, and/or efficacy and safety outcomes|Population pharmacokinetic for PD 0332991 and correlation with efficacy outcomes","https://ClinicalTrials.gov/show/NCT01037790"
2957,"NCT03034850","Thrombin Generation and Platelet Activation in CRS/HIPEC","Completed","No Results Available","Mesothelioma; Peritoneum|Pseudomyxoma Peritonei|Peritoneal Carcinomatosis","Procedure: CRS/HIPEC","Ziekenhuis Oost-Limburg","All","up to 80 Years   (Child, Adult, Senior)","","27","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B37120154199","January 12, 2017","April 2015","July 2016","January 24, 2017","January 2017","No Study Results Posted","null","July 2016","Blood loss|Red blood cell count|White blood cell count|Platelet count|Fibrinogen levels|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (aPTT)|Endogenous Thrombin Potential (Thrombin generation assay (CAT))|Lag Time (Thrombin generation assay (CAT))|Time-to-Thrombin Peak (Thrombin generation assay (CAT))|Thrombin Peak (TP) (Thrombin generation assay (CAT))|P-selectin expression (Platelet activation test (PACT))|αIIbβ3 activation (Platelet activation test (PACT))|A5 EXTEM (Rotational thromboelastometry (ROTEM))|A5 FIBTEM (Rotational thromboelastometry (ROTEM))|A5 HEPTEM (Rotational thromboelastometry (ROTEM))|A30 EXTEM (Rotational thromboelastometry (ROTEM))|A30 FIBTEM (Rotational thromboelastometry (ROTEM))|A30 HEPTEM (Rotational thromboelastometry (ROTEM))|Alpha EXTEM (Rotational thromboelastometry (ROTEM))|Alpha FIBTEM (Rotational thromboelastometry (ROTEM))|Alpha HEPTEM (Rotational thromboelastometry (ROTEM))|Coagulation Time CT EXTEM (Rotational thromboelastometry (ROTEM))|Coagulation Time CT FIBTEM (Rotational thromboelastometry (ROTEM))|Coagulation Time CT HEPTEM (Rotational thromboelastometry (ROTEM))|Clot Formation Time CFT EXTEM (Rotational thromboelastometry (ROTEM)|Clot Formation Time CFT FIBTEM (Rotational thromboelastometry (ROTEM)|Clot Formation Time CFT HEPTEM (Rotational thromboelastometry (ROTEM)|Maximum Lysis (ML) EXTEM Rotational thromboelastometry (ROTEM)|Maximum Lysis (ML) FIBTEM Rotational thromboelastometry (ROTEM)|Maximum Lysis (ML) HEPTEM Rotational thromboelastometry (ROTEM)","https://ClinicalTrials.gov/show/NCT03034850"
2958,"NCT01453205","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","Completed","No Results Available","Diffuse Large B-Cell Lymphoma (DLBCL)","Drug: MEDI-551|Drug: Rituximab|Drug: ICE|Drug: DHAP|Procedure: Autologous Stem Cell Transplant (ASCT)","MedImmune LLC","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CD-ON-MEDI-551-1088","October 3, 2011","February 2012","July 2016","August 4, 2016","August 2016","No Study Results Posted","null","July 2016","Overall Response Rate (ORR)|Antitumor Activity|Acceptable Dose|Safety and Tolerability|Immunogenicity (IM)|Pharmacokinetics (PK)","https://ClinicalTrials.gov/show/NCT01453205"
2959,"NCT00558220","R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas","Completed","No Results Available","Diffuse Large B-Cell Lymphoma.|Primary Mediastinal B-Cell Lymphoma|Follicular Lymphoma Grade III","Procedure: immunotherapy|Procedure: Induction treatment part 1|Procedure: Induction treatment part 2 with PBPC collection|Procedure: Induction treatment part 3|Procedure: Consolidation treatment part 1: HD-chemotherapy with ASCT|Radiation: Consolidation treatment part 2: Radiotherapy","Czech Lymphoma Study Group|Ministry of Health, Czech Republic|Hoffmann-La Roche","All","18 Years to 65 Years   (Adult)","Phase 2","106","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLSG 5_02|NR-8231/3","February 12, 2007","May 2002","October 2006","November 10, 2007","November 2007","No Study Results Posted","R-MCEB","null","Progression-free survival|Complete remission and overall response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00558220"
2960,"NCT00131638","A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer","Completed","No Results Available","Head and Neck Cancer","Drug: Placebo|Drug: Palifermin","Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","241","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20040118","July 26, 2005","January 2005","July 2016","December 14, 2016","December 2016","No Study Results Posted","null","November 2007","Incidence percentage of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale)|Average patient-reported mouth and throat soreness score (as reported on Question 3 of the Oral Mucositis Weekly Questionnaire for patients with Head and Neck cancer [OMWQ-HN]|Time to onset of severe oral mucositis (WHO Grades 3 or 4)|Total dose of opioid analgesics used (mg of morphine equivalents)|Incidence of unplanned delays in CT for cisplatin administration on Day 22 (to include discontinuations of CT)|Incidence of xerostomia (CTCAE v3.0 Dry Mouth/Xerostomia scale Grade 2 or higher)|Duration of severe oral mucositis (WHO Grades 3 or 4)|Incidence of >/equal to 5 missed consecutive fractions of scheduled RT (to include discontinuations of RT)","https://ClinicalTrials.gov/show/NCT00131638"
2961,"NCT02577172","Testicular Cancer and Aerobic and Strength Training","Terminated","No Results Available","Testicular Neoplasms","Behavioral: Exercise group|Behavioral: Control group","Oslo University Hospital|Norwegian School of Sport Sciences","Male","18 Years to 60 Years   (Adult)","","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","REK - 2014/1169","October 8, 2015","November 2015","November 2016","January 25, 2017","January 2017","No Study Results Posted","TAST","November 2016","VO2peak (directly by modified Balke protocol on a treadmill)|Spirometry|One-repetition maximum muscle strength test (1RM)|Dual-energy X-ray absorptiometry (DXA)|Body mass index (BMI)|Hip- and Waist circumferences|Godin Leisure Time Exercise Questionnaire (GLTEQ)|Sick leave and Work Ability Index (WAI)|The European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) C-30|Fatigue questionnaire|Hospital and Anxiety and Depression Scale (HADS)|Markers for inflammation, endothelia dysfunction, thrombosis and cardiovascular diseases and cisplatin|Safety and tolerability","https://ClinicalTrials.gov/show/NCT02577172"
2962,"NCT02630004","Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation","Recruiting","No Results Available","Oral Mucositis","Drug: Melatonin oral gel 3%|Drug: Placebo oral gel","Spherium Biomed|Institut Català d'Oncologia L'Hospitalet|Hospital Universitari de la Vall de Hebron|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Institut Català d'Oncologia ICO Girona|Institut Català d'Oncologia ICO Badalona|Hospital Miguel Servet|Hospital Universitario La Paz|Hospital Universitario Marqués de Valdecilla|Hospital Universitario Virgen de la Victoria|Hospital San Carlos, Madrid|Hospital Clinico Universitario de Santiago","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","84","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Prevention","JAN13004-30","December 3, 2015","November 2015","March 2018","May 2, 2017","September 2016","No Study Results Posted","MUCOMEL","November 2017","Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale)|Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to NCI-CTCAE)|Number of days with mucositis of any grade according to the RTOG scale|Number of days with grade 3-4 mucositis according to the RTOG scale|Time to onset of grade 3-4 mucositis according to the RTOG scale from starting systemic antineoplastic treatment|Change from baseline in EORTC QLQ-C30 and EORTC QLQ-H&N35 scores at 4w after RT start|Change from baseline in EORTC QLQ-C30 and EORTC QLQ-H&N35 scores at one week after completion of RT|Change from baseline in EORTC QLQ-C30 and EORTC QLQ-H&N35 scores at 3 months after completion of RT or before surgery - if it is required post-chemoradiation due persistent or recurrent disease|Change from baseline in ECOG-Performance status score at different time points along the study|Number (percentage) of patients with grade 1-4 NCI-CTCAE adverse events related to IMP (melatonin oral gel 3%)|Number (percentage) of patients who develop cisplatin or cetuximab-associated grade 1-4 adverse events according to the NCI-CTCAE scale|Number (percentage) of patients who develop radiation-associated adverse events different from oral mucositis according to the RTOG scale|Pharmacokinetics evaluation [Cmax]|Pharmacokinetics evaluation [Tmax]|Pharmacokinetics evaluation [AUC]|Pharmacokinetics evaluation [T1/2]|Pharmacokinetics evaluation [Vd]|Pharmacokinetics evaluation [Clearance]","https://ClinicalTrials.gov/show/NCT02630004"
2963,"NCT02863003","Multicenter Database of Patients With Germ Cell Tumor","Not yet recruiting","No Results Available","Neoplasms, Germ Cell and Embryonal","","Latin American Cooperative Oncology Group","Male","18 Years and older   (Adult, Senior)","","1500","Other","Observational","Observational Model: Cohort","LACOG 0515","July 7, 2016","September 2016","December 2020","August 8, 2016","June 2016","No Study Results Posted","null","December 2020","Brazilian multicenter database in order to collect and analyze data from diagnosis and treatment of patients with germ cell tumor|Description of demographic characteristics of testicular germ cell tumor patients in Brazil|The clinical and pathological characteristics of testicular germ cell tumor patients in Brazil.|Treatment according to staging and relapse of patients diagnosed with testicular germ cell tumor in Brazil|Disease free survival of patients diagnosed with germ cell tumor stage 1.|Overall survival of patients diagnosed with germ cell tumor stage 1.|Disease free survival of patients diagnosed with germ cell tumor stages 2 and 3.|Overall survival of patients diagnosed with germ cell tumor stages 2 and 3.|International prognostic factors in patients with advanced germ cell tumor (stages 2 and 3) stablished by the International Germ Cell Cancer Collaborative Group in brazilian patients.|Treatment outcome in different populations: in patients with brain metastasis, patients with germinative tumor extragonodal, surgery outcome in patients with nonseminomous tumor and ressection of residual lesion after chemotherapy|Disease free survival of patients diagnosed with disease relapse after first line chemotherapy|Overall survival of patients diagnosed with disease relapse after first line chemotherapy|Prognostic model after first line treatment failure with cisplatin, stablished by the International Prognostic Factors Study Group in brazilian patients.","https://ClinicalTrials.gov/show/NCT02863003"
2964,"NCT01726582","Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (""Personalized Medicine"")","Active, not recruiting","No Results Available","Pancreatic Adenocarcinoma","Drug: Targeted chemotherapy prior to surgery|Drug: standard FOLFIRINOX chemotherapy prior to surgery|Drug: Gemcitabine after surgery|Other: No additional therapy after surgery|Drug: Targeted chemotherapy after surgery|Radiation: Chemoradiotherapy (cXRT)","Medical College of Wisconsin|University of Cincinnati","All","18 Years and older   (Adult, Senior)","Phase 2","130","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCW 15565|Advancing a Healthier WI|FP 7718","December 28, 2011","November 2011","December 2018","April 28, 2017","April 2017","No Study Results Posted","null","June 2018","Resectability Rate|Overall Survival|Progression-free Survival|Frequency with which biomarkers can be utilized to determine treatment.|To compare the molecular profile of pretreatment biopsies and resected tumors.|To determine the the histologic treatment response to targeted chemotherapeutic regimens in resected tumors.|To determine the prognostic relevance of radiological response among patients undergoing neoadjuvant therapy.|To determine the ability to generate primary xenografts of pancreatic cancer from resected tumors.","https://ClinicalTrials.gov/show/NCT01726582"
2965,"NCT01362530","A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","Completed","Has Results","Chemotherapy Induced Nausea and Vomiting","Drug: Aprepitant 125 mg|Drug: Aprepitant 80 mg|Drug: Aprepitant powder for suspension (PFS)|Drug: Ondansetron|Drug: Placebo for Aprepitant 125 mg|Drug: Placebo for Aprepitant 80 mg|Drug: Placebo for Aprepitant PFS|Drug: Emetogenic chemotherapy","Merck Sharp & Dohme Corp.","All","6 Months to 17 Years   (Child)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","0869-208","May 26, 2011","September 2011","August 2013","April 17, 2015","April 2015","February 24, 2014","null","March 2013","Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1|Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1|Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1|Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1","https://ClinicalTrials.gov/show/NCT01362530"
2966,"NCT00042367","Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors","Completed","No Results Available","Brain Tumors","Drug: Induction therapy (Regimen 1, Course 1, Cycle A1|Drug: Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drug: Cycle B|Drug: Regimen 1, Course 2|Drug: Intrathecal Mafosfamide|Drug: Regimen 1 Course 2, IT mafosfamide|Drug: Regimen 2, Course 1|Drug: Regimen 2, Course, 1, Cycle C1|Drug: Regimen 2, Course 2|Radiation: radiation therapy","Baylor College of Medicine|Texas Children's Hospital|Duke University|St. Jude Children's Research Hospital|Children's Research Institute|Seattle Children's Hospital|Children's Hospital of Philadelphia|Children's Hospital of Pittsburgh|Dana-Farber Cancer Institute|University of California, San Francisco","All","up to 36 Months   (Child)","","119","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H8619|BB'98","July 26, 2002","April 2000","June 2006","February 10, 2012","February 2012","No Study Results Posted","BB'98","December 2005","To evaluate the feasibility, including expected disease progression, of delivering 20 weeks of systemic chemotherapy plus (IT) mafosfamide.|To evaluate the safety and feasibility of a limited dose escalation schedule of IT mafosfamide in children < 3 years of age.","https://ClinicalTrials.gov/show/NCT00042367"
2967,"NCT02762266","Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","Recruiting","No Results Available","Child-Pugh Class A|Child-Pugh Class B|Recurrent Hepatocellular Carcinoma","Procedure: Computed Tomography|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Stereotactic Body Radiation Therapy|Procedure: Transarterial Chemoembolization|Drug: Chemotherapy agent|Drug: embolic agent|Drug: lipiodol","Stanford University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","HEP0052|NCI-2016-00418|35937|P30CA124435","April 5, 2016","February 27, 2016","February 27, 2021","March 1, 2017","March 2017","No Study Results Posted","null","February 27, 2019","Median FFLP|Comparison of median freedom from extra hepatic progression|Median extra hepatic PFS for patients with tumors smaller than 3 cm and greater than 3 cm per treatment group|Median FFLP for patients with tumors smaller than 3 cm and with tumors greater than 3 cm per treatment group|Median OS|Median OS for patients with tumors smaller than 3 cm and greater than 3 cm per treatment group|Median PFS|Median PFS for patients with tumors smaller than 3 cm and greater than 3 cm per treatment group|Serum Alpha-Fetoprotein level (AFP)","https://ClinicalTrials.gov/show/NCT02762266"
